



United States  
Environmental Protection  
Agency

EPA/600/R-15/068 | January 2016 | [www.epa.gov/isa](http://www.epa.gov/isa)

# Integrated Science Assessment for Oxides of Nitrogen – Health Criteria



Office of Research and Development  
National Center for Environmental Assessment, Research Triangle Park, NC

# **Integrated Science Assessment for Oxides of Nitrogen— Health Criteria**

January 2016

National Center for Environmental Assessment-RTP Division  
Office of Research and Development  
U.S. Environmental Protection Agency  
Research Triangle Park, NC

---

## **DISCLAIMER**

This document has been reviewed in accordance with the U.S. Environmental Protection Agency policy and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.

---

# CONTENTS

<b>INTEGRATED SCIENCE ASSESSMENT TEAM FOR OXIDES OF NITROGEN</b>	<b>xvi</b>
<b>AUTHORS, CONTRIBUTORS, AND REVIEWERS</b>	<b>xx</b>
<b>CLEAN AIR SCIENTIFIC ADVISORY COMMITTEE OXIDES OF NITROGEN NAAQS REVIEW PANEL</b>	<b>xxv</b>
<b>ACRONYMS AND ABBREVIATIONS</b>	<b>xxvi</b>
<b>PREAMBLE</b>	<b>xxxviii</b>
1. Process of Integrated Science Assessment Development	xxxviii
Figure I Schematic of the key steps in the review of National Ambient Air Quality Standards.	xxxix
Figure II Characterization of the general process for developing an Integrated Science Assessment.	xl
2. Literature Search	xli
Figure III Illustration of literature search and study selection process used for developing Integrated Science Assessments.	xlili
3. Study Selection	xlili
4. Evaluation of Individual Study Quality	xliv
a. Atmospheric Science and Exposure Assessment	xlv
b. Epidemiology	xlvi
c. Controlled Human Exposure and Animal Toxicology	xlviii
d. Ecological and Other Welfare Effects	xliv
5. Evaluation, Synthesis, and Integration of Evidence across Disciplines and Development of Scientific Conclusions and Causal Determinations	l
a. Evaluation, Synthesis, and Integration of Evidence across Disciplines	l
b. Considerations in Developing Scientific Conclusions and Causal Determinations	lv
Table I Aspects to aid in judging causality.	lvii
c. Framework for Causal Determinations	lix
Table II Weight of evidence for causal determination.	lx
6. Public Health Impact	lxii
a. Approach to Identifying, Evaluating, and Characterizing At-Risk Factors	lxiii
Table III Characterization of evidence for potential at-risk factors.	lxv
b. Evaluating Adversity of Human Health Effects	lxv
c. Concentration-Response Relationships	lxvi
7. Public Welfare Impact	lxvii
a. Evaluating Adversity of Ecological and Other Welfare Effects	lxviii
b. Quantitative Relationships: Effects on Welfare	lxx
<b>PREFACE</b>	<b>lxxi</b>
Legislative Requirements for the Review of the National Ambient Air Quality Standards	lxxi
Overview and History of the Review of the Primary National Ambient Air Quality Standards for Nitrogen Dioxide	lxxiii
Table I History of the primary National Ambient Air Quality Standards for nitrogen dioxide since 1971.	lxxiv

# CONTENTS (Continued)

<b>EXECUTIVE SUMMARY</b>	<b>lxxviii</b>
Purpose and Scope of the Integrated Science Assessment	lxxviii
Sources and Human Exposure to Nitrogen Dioxide	lxxix
Health Effects of Nitrogen Dioxide Exposure	lxxxii
Table ES-1 Causal determinations for relationships between nitrogen dioxide exposure and health effects from the 2008 and 2016 Integrated Science Assessment for Oxides of Nitrogen.	lxxxii
Short-Term Nitrogen Dioxide Exposure and Respiratory Effects	lxxxiii
Figure ES-1 Evidence for relationships of short-term and long-term nitrogen dioxide exposure with asthma presented as biological pathways.	lxxxiv
Long-Term Nitrogen Dioxide Exposure and Respiratory Effects	lxxxiv
Nitrogen Dioxide Exposure and Other Health Effects	lxxxv
Policy-Relevant Considerations for Health Effects Associated with Nitrogen Dioxide Exposure	lxxxvi
Summary of Major Findings	lxxxvii

## **CHAPTER 1 INTEGRATED SUMMARY 1-1**

1.1 Purpose and Overview of the Integrated Science Assessment	1-1
1.2 Process for Developing Integrated Science Assessments	1-3
1.3 Content of the Integrated Science Assessment	1-5
1.4 From Emissions Sources to Exposure to Nitrogen Dioxide	1-6
1.4.1 Emission Sources and Distribution of Ambient Concentrations	1-6
Figure 1-1 Reactions of oxides of nitrogen species in the ambient air.	1-8
1.4.2 Assessment of Nitrogen Dioxide Exposure in Health Effect Studies	1-9
1.4.3 Factors Potentially Correlated with Nitrogen Dioxide Exposure to Consider in Evaluating Relationships with Health Effects	1-12
1.5 Health Effects of Nitrogen Dioxide Exposure	1-15
1.5.1 Respiratory Effects	1-16
Figure 1-2 Characterization of the evidence for health effects related to nitrogen dioxide exposure in a mode of action framework.	1-17
1.5.2 Health Effects beyond the Respiratory System	1-22
Table 1-1 Key evidence contributing to causal determinations for nitrogen dioxide exposure and health effects evaluated in the Integrated Science Assessment for Oxides of Nitrogen.	1-31
1.6 Policy-Relevant Considerations	1-37
1.6.1 Durations of Nitrogen Dioxide Exposure Associated with Health Effects	1-37
1.6.2 Lag Structure of Relationships between Nitrogen Dioxide Exposure and Health Effects	1-39
1.6.3 Concentration-Response Relationships and Thresholds	1-40
1.6.4 Regional Heterogeneity in Effect Estimates	1-42
1.6.5 Public Health Impact	1-44
1.7 Conclusions	1-48

## **CHAPTER 2 ATMOSPHERIC CHEMISTRY AND AMBIENT CONCENTRATIONS OF OXIDES OF NITROGEN 2-1**

2.1 Introduction	2-1
2.2 Atmospheric Chemistry and Fate	2-1
Figure 2-1 Schematic diagram of the cycle of reactive, oxidized nitrogen species in the atmosphere.	2-3
2.3 Sources	2-8
2.3.1 Overview	2-8
Figure 2-2 U.S. national average NO <sub>x</sub> (sum of nitrogen dioxide and nitric oxide) emissions from 1990 to 2013.	2-9

# CONTENTS (Continued)

Figure 2-3	Major sources of NO <sub>x</sub> (sum of nitrogen dioxide and nitric oxide) emissions averaged over the U.S. from the 2008 and 2011 National Emissions Inventories.	2-11
Figure 2-4	Percentage contributions from major sources of the annual NO <sub>x</sub> (sum of nitrogen dioxide and nitric oxide) emissions averaged over the 21 largest U.S. core-based statistical areas with populations greater than 2.5 million compared to the national average.	2-13
Table 2-1	Source distribution of the annual NO <sub>x</sub> (sum of nitrogen dioxide and nitric oxide) emissions in the 21 largest U.S. core-based statistical areas with populations greater than 2.5 million—2011 National Emissions Inventory.	2-14
2.3.2	Highway Vehicles	2-15
2.3.3	Off-Highway Vehicles and Engines	2-16
2.3.4	Fuel Combustion—Utilities and Other	2-18
Figure 2-5	Fuel Combustion-Other emissions of NO <sub>x</sub> (sum of nitrogen dioxide and nitric oxide) versus average ambient January temperature for the 21 largest U.S. core-based statistical areas with populations greater than 2.5 million.	2-19
2.3.5	Other Anthropogenic Sources	2-19
Table 2-2	Relative contributions to Other Anthropogenic NO <sub>x</sub> (sum of nitrogen dioxide and nitric oxide) sources in selected U.S. cities. <sup>a</sup>	2-21
2.3.6	Biogenics and Wildfires	2-22
2.3.7	Emissions Summary	2-23
2.4	Measurement Methods	2-23
2.4.1	Federal Reference and Equivalent Methods	2-23
2.4.2	Other Methods for Measuring Nitrogen Dioxide	2-26
Figure 2-6	Comparison of nitrogen dioxide measured by cavity attenuated phase shift spectroscopy to nitrogen dioxide measured by chemiluminescence/molybdenum oxide catalytic converter for 4 days in October 2007 in Billerica, MA.	2-28
Figure 2-7	Comparison of nitrogen dioxide measured by quantum cascade-tunable infrared differential absorption spectroscopy to nitrogen dioxide measured by chemiluminescence with photolytic converter during April and May 2009 in Houston, TX.	2-29
2.4.3	Satellite Measurements of Nitrogen Dioxide	2-30
Figure 2-8	Seasonal average tropospheric column abundances for nitrogen dioxide (10 <sup>15</sup> molecules/cm <sup>2</sup> ) derived by ozone monitoring instrument for winter (upper panel) and summer (lower panel) for 2005 to 2007.	2-31
Figure 2-9	Seasonal average tropospheric column abundances for nitrogen dioxide (10 <sup>15</sup> molecules/cm <sup>2</sup> ) derived by ozone monitoring instrument for winter (upper panel) and summer (lower panel) for 2010 to 2012.	2-32
2.4.4	Measurements of Total Oxides of Nitrogen in the Atmosphere	2-33
2.4.5	Ambient Sampling Network Design	2-34
Figure 2-10	Map of monitoring sites for oxides of nitrogen in the U.S. from four networks.	2-35
2.5	Ambient Concentrations of Oxides of Nitrogen	2-36
2.5.1	National-Scale Spatial Variability	2-36
Figure 2-11	U.S. 98th percentiles of 1-hour daily maximum nitrogen dioxide concentrations for 2011–2013.	2-38
Figure 2-12	U.S. annual average nitrogen dioxide concentrations for 2013.	2-39
Table 2-3	Summary statistics for 1-hour daily maximum nitrogen dioxide concentrations (ppb) based on state and local air monitoring stations.	2-40
Table 2-4	Summary statistics for nitrogen dioxide, nitric oxide, and sum of nitrogen dioxide and nitric oxide annual average concentrations (ppb) based on state and local air monitoring stations.	2-41
Figure 2-13	Seasonal average surface nitrogen dioxide concentrations in ppb for winter (upper panel) and summer (lower panel) derived by ozone monitoring instrument/Goddard Earth Observing System-Chem for 2009–2011.	2-43

# CONTENTS (Continued)

2.5.2 Urban-Scale Spatial Variability	2-44
Figure 2-14 Coefficient of divergence for ambient nitrogen dioxide concentrations between monitor pairs in four U.S. cities.	2-45
Figure 2-15 Coefficient of divergence for ambient nitrogen dioxide concentrations among a subset of five Los Angeles, California monitors.	2-46
Table 2-5A Percent difference in annual average nitrogen dioxide concentration between monitors in Boston, Massachusetts.	2-47
Table 2-5B Percent difference in annual average nitrogen dioxide concentration between monitors in Los Angeles, California for 2011.	2-48
2.5.3 Microscale to Neighborhood-Scale Spatial Variability, Including near Roads	2-49
Table 2-6 Summary of near-road nitrogen dioxide concentration gradients from studies with passive samplers and averaging times of 12 hours to 1 month.	2-50
Table 2-7 Summary of near-road nitrogen dioxide concentration gradients from studies with averaging times of 1 hour or less.	2-52
Table 2-8 Distribution of differences in higher 1-hour nitrogen dioxide concentrations 10–15 m and lower 1-hour nitrogen dioxide concentrations at 80–100 m from the road at two locations with heavy traffic.	2-56
Table 2-9 Seasonal and diurnal variation of differences in 1-hour nitrogen dioxide concentrations 10–15 m and 80–100 m from the road at two locations with heavy traffic.	2-58
Figure 2-16 Diurnal variation of differences in 1-hour nitrogen dioxide concentrations 10–15 m and 80–100 m from the road in Los Angeles, CA and Detroit, MI.	2-60
Figure 2-17 Absolute difference in 1-hour nitrogen dioxide concentrations 10–15 m and 80–100 m from the road in Los Angeles, CA and Detroit, MI.	2-61
Figure 2-18 Influence of nitrogen dioxide concentration magnitude on the ratio of nitrogen dioxide concentrations at <1 m from the road (nearest concentration) to concentrations at 200–350 m (farthest concentration) for 1-week averaging times in rural Wales.	2-63
Figure 2-19 Percentage difference in 1-hour nitrogen dioxide concentration between 10–15 m distance and 80–100 m distance from a road with heavy traffic in two U.S. cities.	2-65
Table 2-10 Comparison of nitrogen dioxide concentrations at U.S. near-road and non-near-road monitors for 2014.	2-67
Table 2-11A Roadside and urban background nitrogen dioxide concentrations in London, U.K. 2010–2012.	2-73
Table 2-11B Roadside and urban background nitrogen dioxide concentrations in London, U.K. 2004–2006.	2-74
Table 2-12 Selected nitrogen dioxide measurements with potential nonhighway source influences for 2014.	2-79
2.5.4 Seasonal, Weekday/Weekend, and Diurnal Trends	2-82
Figure 2-20 January and July hourly profiles of nitric oxide and nitrogen dioxide (ppb) for the site in Atlanta, GA with the highest 1-hour nitrogen dioxide concentrations.	2-82
Figure 2-21 Weekend/weekday hourly profiles of nitric oxide and nitrogen dioxide (ppb) for the site in Atlanta, GA with the highest nitrogen dioxide concentrations.	2-84
2.5.5 Multiyear Trends in Ambient Measurements of Oxides of Nitrogen	2-84
Figure 2-22 U.S. national average of annual 98th percentile of 1-hour daily maximum nitrogen dioxide concentration at 24 sites, 1980–2012.	2-85
Figure 2-23 Trend in nitrogen dioxide concentrations at Elizabeth Lab monitoring site near New Jersey Turnpike 1980–2014.	2-86
2.5.6 Background Concentrations	2-86
2.6 Conclusions	2-88

# CONTENTS (Continued)

<b>CHAPTER 3</b>	<b>EXPOSURE TO OXIDES OF NITROGEN</b>	<b>3-1</b>
3.1	Introduction	3-1
3.2	Methodological Considerations for Use of Exposure Data	3-2
3.2.1	Measurement	3-2
3.2.2	Modeling	3-5
3.2.3	Choice of Exposure Metrics in Epidemiologic Studies	3-19
Table 3-1	Summary of exposure estimation methods, their typical use in nitrogen dioxide epidemiologic studies, and related errors and uncertainties.	3-20
Figure 3-1	Average nitrogen dioxide concentrations measured in studies using different monitor siting.	3-22
3.3	Characterization of Nitrogen Dioxide Exposures	3-24
3.3.1	Nitrogen Dioxide Concentration as an Indicator of Source-Based Mixtures	3-24
Figure 3-2	Spatial variability in concentrations of near-road nitrogen dioxide, nitric oxide, the sum of nitric oxide and nitrogen dioxide, carbon monoxide, and other near-road pollutants.	3-27
Table 3-2	Near- and on-road measurements of nitrogen dioxide, nitric oxide, and the sum of nitric oxide and nitrogen dioxide.	3-29
Table 3-3	Summary (mean, range) within 300 m of monitoring sites, by site type, in a spatially dense monitoring campaign in New York City, NY, based on 2-week integrated samples per season.	3-34
3.3.2	Indoor Dynamics	3-36
Table 3-4	Indoor nitrogen dioxide and nitrous acid concentrations in the presence and absence of combustion.	3-37
3.4	Exposure Assessment and Epidemiologic Inference	3-40
3.4.1	Conceptual Model of Total Personal Exposure	3-41
3.4.2	Personal-Ambient Relationships and Nonambient Exposures	3-43
Table 3-5	Ambient, outdoor, transport, indoor, and personal nitrogen dioxide measurements (ppb) across studies.	3-45
Table 3-6	Correlations between measured nitrogen dioxide concentrations from personal, outdoor, indoor, and ambient monitors.	3-52
Table 3-7	Metaregression results from 15 studies examining the relationship between personal nitrogen dioxide exposure measurements and ambient concentrations.	3-55
3.4.3	Factors Contributing to Error in Estimating Exposure to Ambient Nitrogen Dioxide	3-55
Figure 3-3	Distribution of time sample population spends in various environments, from the U.S. National Human Activity Pattern Survey (all ages).	3-56
Table 3-8	Mean fraction of time spent in outdoor locations by various age groups in the National Human Activity Pattern Survey study.	3-58
Table 3-9	Mean ventilation rates (L/min) at different activity levels for different age groups.	3-59
Figure 3-4	Regional-scale variability in nitrogen dioxide for urban and rural area data across the United Kingdom.	3-61
Figure 3-5	Urban-scale variability in nitrogen dioxide and the sum of nitric oxide and nitrogen dioxide in Atlanta, GA.	3-62
3.4.4	Confounding	3-63
Table 3-10	Synthesis of nitrogen dioxide ambient-ambient copollutant correlations from measurements reported in the literature.	3-67
Figure 3-6	Summary of temporal nitrogen dioxide-copollutant correlation coefficients from measurements reported in studies listed in Table 3-10, sorted by temporal averaging period.	3-80
Table 3-11	Pearson correlation coefficients between ambient nitrogen dioxide and personal copollutants.	3-86
Table 3-12	Pearson correlation coefficients between personal nitrogen dioxide and ambient copollutants.	3-86

# CONTENTS (Continued)

Table 3-13	Pearson correlation coefficients between personal nitrogen dioxide and personal copollutants.	3-87
Table 3-14	Correlation coefficients between indoor nitrogen dioxide and indoor copollutants.	3-88
3.4.5	Implications for Epidemiologic Studies of Different Designs	3-93
Table 3-15	The influence of exposure metrics on error in health effect estimates.	3-97
3.5	Conclusions	3-106

## CHAPTER 4 DOSIMETRY AND MODES OF ACTION FOR INHALED OXIDES OF NITROGEN 4-1

4.1	Introduction	4-1
4.2	Dosimetry of Inhaled Oxides of Nitrogen	4-2
4.2.1	Introduction	4-2
4.2.2	Dosimetry of Nitrogen Dioxide	4-3
Table 4-1	Small molecular weight antioxidant concentrations in epithelial lining fluid and predicted penetration distances for nitrogen dioxide.	4-10
4.2.3	Dosimetry of Nitric Oxide	4-22
4.2.4	Summary of Dosimetry	4-25
4.3	Modes of Action for Inhaled Oxides of Nitrogen	4-27
4.3.1	Introduction	4-27
Table 4-2	Chemical properties of nitrogen dioxide and nitric oxide that contribute to proposed modes of action.	4-28
4.3.2	Nitrogen Dioxide	4-30
4.3.3	Nitric Oxide	4-54
4.3.4	Metabolites of Nitric Oxide and Nitrogen Dioxide	4-58
4.3.5	Mode of Action Framework	4-61
Figure 4-1	Summary of evidence for the mode of action linking short-term exposure to nitrogen dioxide and respiratory effects.	4-62
Figure 4-2	Summary of evidence for the mode of action linking long-term exposure to nitrogen dioxide and respiratory effects.	4-64
Figure 4-3	Summary of evidence for the mode of action linking exposure to nitrogen dioxide with extrapulmonary effects.	4-66
Figure 4-4	Summary of evidence for the mode of action linking exposure to nitric oxide with extrapulmonary effects.	4-68
4.4	Summary	4-68

## CHAPTER 5 INTEGRATED HEALTH EFFECTS OF SHORT-TERM EXPOSURE TO OXIDES OF NITROGEN 5-1

5.1	Introduction	5-1
5.1.1	Scope of Chapter	5-1
5.1.2	Evidence Evaluation and Integration to Form Causal Determinations	5-2
5.2	Respiratory Effects	5-6
5.2.1	Introduction	5-6
5.2.2	Asthma Exacerbation	5-7
Table 5-1	Resting exposures to nitrogen dioxide and airway responsiveness in individuals with asthma.	5-14
Table 5-2	Exercising exposures to nitrogen dioxide and airway responsiveness in individuals with asthma.	5-15
Table 5-3	Fraction of individuals with asthma having nitrogen dioxide-induced increase in airway responsiveness to a nonspecific challenge.	5-18
Figure 5-1	Change in provocative dose due to exposure to nitrogen dioxide in resting individuals with asthma.	5-20
Figure 5-2	Log-normal distribution of change in provocative dose due to exposure to nitrogen dioxide in resting individuals with asthma.	5-22

## CONTENTS (Continued)

Table 5-4	Mean and upper percentile concentrations of nitrogen dioxide in epidemiologic studies of lung function in populations with asthma. _____	5-29
Figure 5-3	Associations of nitrogen dioxide ambient concentrations or personal exposure with percentage change in forced expiratory volume in 1 second (top plot) and change in percent predicted forced expiratory volume in 1 second (bottom plot) in children and adults with asthma. _____	5-33
Table 5-5	Epidemiologic studies of lung function in children and adults with asthma. _____	5-34
Table 5-6	Characteristics of controlled human exposure studies of lung function in individuals with asthma. _____	5-49
Table 5-7	Mean and upper percentile concentrations of nitrogen dioxide in epidemiologic studies of respiratory symptoms in populations with asthma. _____	5-51
Figure 5-4	Associations of ambient nitrogen dioxide concentrations with respiratory symptoms and asthma medication use in children with asthma. _____	5-56
Table 5-8	Epidemiologic studies of respiratory symptoms and asthma medication use in children with asthma. _____	5-57
Table 5-9	Characteristics of controlled human exposure studies of respiratory symptoms in individuals with asthma. _____	5-70
Table 5-10	Mean and upper percentile concentrations of oxides of nitrogen in studies of asthma hospital admissions and emergency department visits. _____	5-72
Table 5-11	Copollutant model results from Iskandar et al. (2012) for a 20-ppb increase in 24-h average nitrogen dioxide (NO <sub>2</sub> ) concentrations and a 40-ppb increase in 24-h average NO <sub>x</sub> (sum of NO and NO <sub>2</sub> ) concentrations. _____	5-81
Figure 5-5	Concentration-response function for the association between 3-day average (lag 0–2) nitrogen dioxide concentrations and emergency department visits for pediatric asthma in the Atlanta, GA area. _____	5-87
Figure 5-6	Rate ratio and 95% confidence intervals for asthma-related emergency department visits in single-pollutant and joint effect models for each pollutant at lag 0–2 days. _____	5-90
Figure 5-7	Percentage increase in asthma hospital admissions and emergency department visits in relation to short-term increases in ambient nitrogen dioxide concentrations. _____	5-93
Table 5-12	Corresponding risk estimates for studies presented in Figure 5-7. _____	5-94
Table 5-13	Characteristics of controlled human exposure studies of pulmonary inflammation in populations with asthma. _____	5-98
Table 5-14	Characteristics of animal toxicological studies of pulmonary inflammation. _____	5-103
Table 5-15	Mean and upper percentile concentrations of nitrogen dioxide in epidemiologic studies of pulmonary inflammation and oxidative stress in populations with asthma. _____	5-105
Figure 5-8	Associations of personal or ambient nitrogen dioxide with exhaled nitric oxide in populations with asthma. _____	5-107
Table 5-16	Epidemiologic studies of pulmonary inflammation and oxidative stress in children and adults with asthma. _____	5-108
5.2.3	Allergy Exacerbation _____	5-123
Table 5-17	Epidemiologic studies of allergy exacerbation. _____	5-125
5.2.4	Exacerbation of Chronic Obstructive Pulmonary Disease _____	5-127
Table 5-18	Epidemiologic panel studies of adults with chronic obstructive pulmonary disease. _____	5-129
Table 5-19	Characteristics of controlled human exposure studies of adults with chronic obstructive pulmonary disease. _____	5-132
Table 5-20	Mean and upper percentile concentrations of nitrogen dioxide in studies of hospital admission and emergency department visits for chronic obstructive pulmonary disease. _____	5-134
Figure 5-9	Percentage increase in chronic obstructive pulmonary disease hospital admissions and emergency department visits in relation to nitrogen dioxide concentrations. _____	5-139
Table 5-21	Corresponding risk estimate for studies presented in Figure 5-9. _____	5-140

# CONTENTS (Continued)

5.2.5 Respiratory Infection _____	5-142
Table 5-22 Characteristics of experimental studies of susceptibility to infection. _____	5-143
Table 5-23 Epidemiologic studies of respiratory infections reported or diagnosed in children. _____	5-149
Table 5-24 Mean and upper percentile concentrations of nitrogen dioxide in studies of hospital admissions and emergency department visits for respiratory infection. _	5-153
Figure 5-10 Percentage increase in respiratory infection-related hospital admissions and emergency department visits in relation to nitrogen dioxide concentrations. ____	5-160
Table 5-25 Corresponding risk estimate for studies presented in Figure 5-10. _____	5-161
Table 5-26 Characteristics of experimental studies of subclinical lung host defense effects. _____	5-164
5.2.6 Aggregated Respiratory Conditions _____	5-169
Table 5-27 Mean and upper percentile concentrations of nitrogen dioxide in studies of hospital admissions and emergency department visits for aggregated respiratory conditions. _____	5-171
Figure 5-11 Risk ratio and 95% confidence intervals for associations between various lag 1 day nitrogen dioxide metrics and respiratory emergency department visits. ____	5-179
Figure 5-12 Spatial correlations for nitrogen dioxide metrics in the Atlanta, GA area. _____	5-180
Figure 5-13 Percentage increase in all respiratory disease hospital admissions and emergency department visits in relation to nitrogen dioxide concentrations. ____	5-181
Table 5-28 Corresponding risk estimate for studies presented in Figure 5-13. _____	5-182
5.2.7 Respiratory Effects in Healthy Populations _____	5-184
Table 5-29 Mean and upper percentile oxides of nitrogen concentrations in epidemiologic studies of lung function in the general population. _____	5-186
Table 5-30 Epidemiologic studies of lung function in children and adults in the general population. _____	5-190
Table 5-31 Characteristics of controlled human exposure studies of lung function and respiratory symptoms in healthy adults. _____	5-203
Table 5-32 Mean and upper percentile concentrations of nitrogen dioxide in epidemiologic studies of respiratory symptoms in children in the general population. _____	5-207
Table 5-33 Epidemiologic studies of respiratory symptoms in children in the general population. _____	5-209
Table 5-34 Mean and upper percentile concentrations of oxides of nitrogen in epidemiologic studies of pulmonary inflammation and oxidative stress in the general population. _____	5-214
Figure 5-14 Associations between ambient nitrogen dioxide concentrations and exhaled nitric oxide among children and adults in the general population. _____	5-217
Table 5-35 Epidemiologic studies of pulmonary inflammation, injury, and oxidative stress in children and adults in the general population. _____	5-218
Table 5-36 Characteristics of controlled human exposure studies of pulmonary inflammation, injury, and oxidative stress in healthy adults. _____	5-230
Table 5-37 Characteristics of animal toxicological studies of pulmonary inflammation, injury, and oxidative stress. _____	5-232
5.2.8 Respiratory Mortality _____	5-236
Figure 5-15 City-specific concentration-response curves of nitrogen dioxide and daily chronic obstructive pulmonary disease mortality in four Chinese cities. _____	5-239
5.2.9 Summary and Causal Determination _____	5-239
Figure 5-16 Associations of ambient or personal nitrogen dioxide with respiratory effects adjusted for fine particulate matter, elemental/black carbon, or particle number concentration/ultrafine particles. _____	5-248
Figure 5-17 Associations of ambient nitrogen dioxide with respiratory effects adjusted for a volatile organic compound or carbon monoxide. _____	5-249
Table 5-38 Corresponding effect estimates for nitrogen dioxide-associated respiratory effects in single- and copollutant models presented in Figures 5-16 and 5-17. _	5-250
Table 5-39 Summary of evidence for a causal relationship between short-term nitrogen dioxide exposure and respiratory effects. _____	5-253

# CONTENTS (Continued)

5.3 Cardiovascular Effects	5-258
5.3.1 Introduction	5-258
5.3.2 Myocardial Infarction	5-259
Figure 5-18 Associations between short-term exposure to oxides of nitrogen and hospital admissions for ischemic heart disease.	5-261
Table 5-40 Corresponding risk estimates for hospital admissions for ischemic heart disease for studies presented in Figure 5-18.	5-262
Table 5-41 Epidemiologic studies of ST-segment amplitude.	5-271
5.3.3 Arrhythmia and Cardiac Arrest	5-273
Table 5-42 Epidemiologic studies of arrhythmia and cardiac arrest.	5-274
Table 5-43 Epidemiologic studies of out-of-hospital cardiac arrest.	5-276
5.3.4 Cerebrovascular Disease and Stroke	5-278
Figure 5-19 Associations between short-term exposure to oxides of nitrogen and hospital admissions for cerebrovascular disease and stroke.	5-280
Table 5-44 Corresponding risk estimates for hospital admissions for cerebrovascular disease and stroke for studies presented in Figure 5-19.	5-281
5.3.5 Decompensation of Heart Failure	5-287
5.3.6 Increased Blood Pressure and Hypertension	5-287
Table 5-45 Epidemiologic studies of blood pressure.	5-288
5.3.7 Venous Thromboembolism	5-292
5.3.8 Aggregated Cardiovascular Effects	5-292
Figure 5-20 Associations between short-term exposure to oxides of nitrogen and hospital admissions for all cardiovascular disease.	5-295
Table 5-46 Corresponding effect estimates for hospital admissions for all cardiovascular disease studies presented in Figure 5-20.	5-296
5.3.9 Cardiovascular Mortality	5-299
Figure 5-21 Pooled concentration-response curve for nitrogen dioxide and daily stroke mortality in eight Chinese cities for lag 0–1 day.	5-302
5.3.10 Subclinical Effects Underlying Cardiovascular Effects	5-302
Table 5-47 Epidemiologic studies of heart rate/heart rate variability.	5-304
Table 5-48 Epidemiologic studies of QT-interval duration.	5-314
Table 5-49 Epidemiologic studies of biomarkers of cardiovascular effects.	5-317
Table 5-50 Characteristics of controlled human exposure studies of cardiovascular effects.	5-328
Table 5-51 Characteristics of animal toxicological studies of cardiovascular effects.	5-332
5.3.11 Summary and Causal Determination	5-334
Table 5-52 Summary of evidence, which is suggestive of, but not sufficient to infer, a causal relationship between short-term nitrogen dioxide exposure and cardiovascular effects.	5-339
5.4 Total Mortality	5-342
5.4.1 Introduction and Summary of the 2008 Integrated Science Assessment for Oxides of Nitrogen	5-342
5.4.2 Associations between Short-Term Nitrogen Dioxide Exposure and Mortality	5-343
5.4.3 Associations between Short-term Nitrogen Dioxide Exposure and Mortality in All-Year Analyses	5-344
Table 5-53 Air quality characteristics of studies evaluated in the 2008 Integrated Science Assessment for Oxides of Nitrogen and recently published multicity and select single-city studies.	5-345
Figure 5-22 Summary of multicity studies that examined the association between short-term nitrogen dioxide exposure and total mortality.	5-348
Table 5-54 Corresponding percentage increase in total mortality for Figure 5-22.	5-349
Figure 5-23 Percentage increase in total, cardiovascular, and respiratory mortality from multicity studies in relation to ambient nitrogen dioxide concentrations.	5-350
Table 5-55 Corresponding percentage increase for Figure 5-23.	5-351

# CONTENTS (Continued)

5.4.4	Potential Confounding of the Nitrogen Dioxide-Mortality Relationship	5-352
Table 5-56	Percentage increase in total and cause-specific mortality for a 20-ppb increase in 24-hour average nitrogen dioxide concentrations in single- and copollutant models with particulate matter in all-year analyses or ozone in summer season analyses.	5-354
5.4.5	Modification of the Nitrogen Dioxide-Mortality Relationship	5-356
5.4.6	Potential Seasonal Differences in the Nitrogen Dioxide-Mortality Relationship	5-357
5.4.7	Nitrogen Dioxide-Mortality Concentration-Response Relationship and Related Issues	5-359
Figure 5-24	Percentage increase in total and cause-specific mortality associated with short-term increases in ambient nitrogen dioxide concentration at single day lags, individual lag days of a constrained polynomial distributed lag model, and multiday lags of an unconstrained distributed lag model.	5-360
Figure 5-25	Percentage increase in total and cause-specific mortality associated with short-term increases in ambient nitrogen dioxide concentration in single- and multi-day lag models in a multicity study in China.	5-361
Figure 5-26	Flexible ambient concentration-response relationship between short-term nitrogen dioxide concentrations and mortality at Lag Day 1.	5-363
Figure 5-27	China Air Pollution and Health Effects Study concentration-response curve for the association between total and cause-specific mortality and 24-hour average nitrogen dioxide concentrations at lag 0–1 days.	5-364
Figure 5-28	Concentration-response curve for association between total mortality and 24-hour average nitrogen dioxide concentrations at lag 0–1 days in the four cities of the Public Health and Air Pollution in Asia study.	5-366
5.4.8	Summary and Causal Determination	5-367
Table 5-57	Summary of evidence, which is suggestive of, but not sufficient to infer, a causal relationship between short-term nitrogen dioxide exposure and total mortality.	5-369

## CHAPTER 6 INTEGRATED HEALTH EFFECTS OF LONG-TERM EXPOSURE TO OXIDES OF NITROGEN 6-1

6.1	Scope and Issues Considered in Health Effects Assessment	6-1
6.1.1	Scope of Chapter	6-1
6.1.2	Evidence Evaluation and Integration to Form Causal Determinations	6-2
6.2	Respiratory Effects	6-4
6.2.1	Introduction	6-4
6.2.2	Development of Asthma or Chronic Bronchitis	6-5
Figure 6-1	Associations of long-term exposure to oxides of nitrogen with asthma incidence in longitudinal cohort studies of children.	6-6
Table 6-1	Longitudinal studies of long-term exposure to oxides of nitrogen and asthma incidence in children.	6-7
Figure 6-2	Overall and age-specific associations between annual average air pollutant concentrations at the birth residence and asthma during the first 8 years of life.	6-15
Table 6-2	Characteristics of animal toxicological studies of long-term nitrogen dioxide exposure and respiratory effects.	6-27
6.2.3	Severity of Asthma, Chronic Bronchitis, and Chronic Obstructive Pulmonary Disease: Respiratory Symptoms and Hospital Admissions	6-30
Figure 6-3	Concentration–response relationships between asthma-related effects and indoor nitrogen dioxide illustrated with constrained, natural spline and threshold functions in hierarchical ordered logistic regression models.	6-32
Table 6-3	Longitudinal studies of long-term nitrogen dioxide exposure and respiratory symptoms in children.	6-33
Figure 6-4	Within-community odds ratios for bronchitis symptoms associated with nitrogen dioxide adjusted for a copollutant in the 12 communities of the Children’s Health Study.	6-37
6.2.4	Development of Allergic Disease	6-40

# CONTENTS (Continued)

6.2.5	Lung Function and Lung Development	6-42
Figure 6-5	Associations of oxides of nitrogen with lung function or lung development from longitudinal studies of children.	6-43
Table 6-4	Longitudinal studies of long-term nitrogen dioxide exposure and lung function and lung development in children.	6-44
Figure 6-6	Community-specific average growth in forced expiratory volume in 1 second (mL) among girls and boys from 1993 to 2001, plotted against average nitrogen dioxide concentrations from 1994 through 2000.	6-50
Figure 6-7	Community-specific proportion of 18-year-olds with a forced expiratory volume in 1 second below 80% of the predicted value, plotted against the average concentrations of nitrogen dioxide from 1994 through 2000.	6-51
6.2.6	Changes in Lung Morphology	6-56
6.2.7	Respiratory Infection	6-58
6.2.8	Chronic Obstructive Pulmonary Disease	6-61
6.2.9	Summary and Causal Determination	6-62
Table 6-5	Summary of key evidence for a likely to be a causal relationship between long-term nitrogen dioxide exposure and respiratory effects.	6-68
6.3	Cardiovascular Effects and Diabetes	6-72
6.3.1	Introduction	6-72
6.3.2	Heart Disease	6-73
Table 6-6	Epidemiologic studies of long-term exposure to oxides of nitrogen and heart disease.	6-75
6.3.3	Cerebrovascular Disease and Stroke	6-79
Table 6-7	Epidemiologic studies of long-term exposure to oxides of nitrogen and cerebrovascular disease or stroke.	6-80
6.3.4	Hypertension	6-83
Table 6-8	Epidemiologic studies of long-term exposure to oxides of nitrogen and hypertension and blood pressure.	6-85
6.3.5	Cardiovascular Mortality	6-88
6.3.6	Markers of Cardiovascular Disease or Mortality	6-88
Table 6-9	Characteristics of toxicological studies of long-term nitrogen dioxide exposure and cardiovascular effects.	6-90
6.3.7	Diabetes	6-91
Table 6-10	Epidemiologic studies of long-term exposure to oxides of nitrogen and diabetes or diabetes-related effects.	6-92
6.3.8	Subclinical Effects Underlying Cardiovascular Disease and Diabetes	6-96
6.3.9	Summary and Causal Determination	6-97
Table 6-11	Summary of evidence, which is suggestive of, but not sufficient to infer, a causal relationship between long-term nitrogen dioxide exposure and cardiovascular effects and diabetes.	6-100
6.4	Reproductive and Developmental Effects	6-103
6.4.1	Introduction	6-103
6.4.2	Fertility, Reproduction, and Pregnancy	6-105
Table 6-12	Key epidemiologic studies of oxides of nitrogen and reproductive and developmental effects.	6-110
6.4.3	Birth Outcomes	6-116
6.4.4	Postnatal Development	6-127
Table 6-13	Characteristics of toxicological studies of nitrogen dioxide exposure and reproductive and developmental effects.	6-134
6.4.5	Summary and Causal Determination	6-135
Table 6-14	Summary of evidence supporting the causal determinations for relationships between long-term nitrogen dioxide exposure and reproductive and developmental effects.	6-137

# CONTENTS (Continued)

6.5	Total Mortality	6-140
6.5.1	Introduction and Review of Evidence from 2008 Integrated Science Assessment for Oxides of Nitrogen	6-140
6.5.2	Recent Evidence for Mortality from Long-Term Exposure to Oxides of Nitrogen	6-142
	Figure 6-8 Association between long-term exposure to oxides of nitrogen and total mortality.	6-147
	Table 6-15 Corresponding risk estimates for Figure 6-8.	6-148
	Figure 6-9 Associations between long-term exposure to oxides of nitrogen and cardiovascular mortality.	6-150
	Table 6-16 Corresponding risk estimates for Figure 6-9.	6-151
	Figure 6-10 Associations between long-term exposure to oxides of nitrogen and respiratory mortality.	6-154
	Table 6-17 Corresponding risk estimates for Figure 6-10.	6-155
6.5.3	Summary and Causal Determination	6-157
	Table 6-18 Summary of evidence, which is suggestive of, but not sufficient to infer, a causal relationship between long-term nitrogen dioxide exposure and total mortality.	6-159
6.6	Cancer	6-160
6.6.1	Introduction	6-160
6.6.2	Lung Cancer	6-161
	Table 6-19 Characteristics of toxicological studies of carcinogenicity and genotoxicity with exposure to nitrogen dioxide.	6-167
6.6.3	Leukemia Incidence and Mortality	6-169
6.6.4	Bladder Cancer Incidence and Mortality	6-170
6.6.5	Breast Cancer Incidence	6-171
6.6.6	Prostate Cancer Incidence	6-171
6.6.7	Other Cancer Incidences and Mortality	6-172
6.6.8	Genotoxicity	6-172
6.6.9	Summary and Causal Determination	6-174
	Table 6-20 Summary of evidence, which is suggestive of, but not sufficient to infer, a causal relationship between long-term nitrogen dioxide exposure and cancer.	6-176

## **CHAPTER 7 POPULATIONS AND LIFESTAGES POTENTIALLY AT RISK FOR HEALTH EFFECTS RELATED TO NITROGEN DIOXIDE EXPOSURE 7-1**

7.1	Introduction	7-1
7.2	Approach to Evaluating and Characterizing the Evidence for At-Risk Factors	7-2
	Table 7-1 Characterization of evidence for factors potentially increasing the risk for nitrogen dioxide-related health effects.	7-3
7.3	Pre-Existing Disease/Conditions	7-4
	Table 7-2 Prevalence of selected respiratory, cardiovascular, and metabolic diseases and disorders among adults by age and region in the United States in 2012.	7-5
7.3.1	Asthma	7-5
	Table 7-3 Controlled human exposure studies evaluating pre-existing asthma.	7-8
	Table 7-4 Epidemiologic studies evaluating pre-existing asthma.	7-9
7.3.2	Chronic Obstructive Pulmonary Disease	7-9
	Table 7-5 Controlled human exposure studies evaluating pre-existing chronic obstructive pulmonary disease.	7-11
	Table 7-6 Epidemiologic studies evaluating pre-existing chronic obstructive pulmonary disease.	7-12
7.3.3	Cardiovascular Disease	7-12
	Table 7-7 Epidemiologic studies evaluating pre-existing cardiovascular disease.	7-14
	Table 7-8 Controlled human exposure and toxicological studies informing risk due to pre-existing cardiovascular disease.	7-16

# CONTENTS (Continued)

7.3.4	Diabetes	7-16
Table 7-9	Epidemiologic studies evaluating pre-existing diabetes.	7-18
7.3.5	Obesity	7-19
Table 7-10	Toxicological study evaluating pre-existing obesity.	7-20
Table 7-11	Epidemiologic studies evaluating pre-existing obesity.	7-21
7.4	Genetic Factors	7-23
Table 7-12	Epidemiologic studies evaluating genetic factors.	7-26
7.5	Sociodemographic Factors	7-29
7.5.1	Lifestage	7-29
Table 7-13	Epidemiologic studies evaluating childhood lifestage.	7-33
Table 7-14	Toxicological studies evaluating childhood lifestage.	7-35
Table 7-15	Epidemiologic studies evaluating older adult lifestage.	7-38
Table 7-16	Controlled human exposure studies informing risk for older adult lifestage.	7-42
7.5.2	Socioeconomic Status	7-43
Table 7-17	Epidemiologic studies evaluating socioeconomic status.	7-46
7.5.3	Race/Ethnicity	7-50
Table 7-18	Epidemiologic studies evaluating race/ethnicity.	7-52
7.5.4	Sex	7-53
Table 7-19	Epidemiologic studies evaluating sex.	7-55
7.5.5	Residence in Urban Areas	7-61
Table 7-20	Epidemiologic studies evaluating urban residence.	7-62
7.5.6	Proximity to Roadways	7-62
Figure 7-1	Map of population density in Los Angeles, CA, in relation to primary and secondary roads.	7-64
Table 7-21	Epidemiologic studies evaluating proximity to roadways.	7-67
7.6	Behavioral and Other Factors	7-68
7.6.1	Diet	7-68
Table 7-22	Controlled human exposure and toxicological studies evaluating diet.	7-70
Table 7-23	Epidemiologic studies evaluating diet.	7-71
7.6.2	Smoking	7-71
Table 7-24	Controlled human exposure study evaluating smoking.	7-72
Table 7-25	Epidemiologic studies evaluating smoking status.	7-73
7.6.3	Physical Activity	7-76
Table 7-26	Epidemiologic studies evaluating physical activity.	7-77
7.7	Conclusions	7-77
Table 7-27	Summary of evidence for potential increased nitrogen dioxide exposure and increased risk of nitrogen dioxide-related health effects.	7-79

## APPENDIX: EVALUATION OF STUDIES ON HEALTH EFFECTS OF OXIDES OF NITROGEN A-1

Table A-1	Scientific considerations for evaluating the strength of inference from studies on the health effects of oxides of nitrogen.	A-2
-----------	--	-----

## REFERENCES R-1

---

# INTEGRATED SCIENCE ASSESSMENT TEAM FOR OXIDES OF NITROGEN

---

## Executive Direction

- Dr. John Vandenberg (Director)—National Center for Environmental Assessment-RTP Division, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Ms. Debra Walsh (Deputy Director)—National Center for Environmental Assessment-RTP Division, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Reeder Sams II (Acting Deputy Director)—National Center for Environmental Assessment-RTP Division, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Mary Ross (Branch Chief)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Steven J. Dutton (Acting Branch Chief)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Ellen Kirrane (Acting Branch Chief)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

---

## Scientific Staff

- Dr. Molini M. Patel (Team Leader, Integrated Science Assessment for Oxides of Nitrogen)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Ms. Breanna Alman—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. James Brown—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Barbara Buckley—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Mr. Evan Coffman—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Ms. Laura Datko-Williams—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Erin Hines—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Ellen Kirrane—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Dennis Kotchmar—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Thomas Long—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Thomas Luben—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Stephen McDow—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Connie Meacham—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Jennifer Nichols—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Michelle Oakes—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Elizabeth Oesterling Owens—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Joseph P. Pinto—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Kristen Rappazzo—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Jennifer Richmond-Bryant—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. Jason Sacks—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Tina Stevens—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. David Svendsgaard—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Lisa Vinikoor-Imler—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Brianna Young—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

---

### **Technical Support Staff**

Ms. Marieka Boyd—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. Kenneth J. Breito—Senior Environmental Employment Program, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. Nathan Ellenfield—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Charlene Finley—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Carolyn Gatling—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. William Griffin—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. Gerald Gurevich—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. Saturo Ito—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Katie Jelen—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. Ryan Jones—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Emily Lau—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Diane LeBlond Cummings—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Danielle Moore—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

- Ms. Candis O'Neal Edwards—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Mr. Kyle Painter—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Ms. Sandy Pham—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Ms. Olivia Philpott—Senior Environmental Employment Program, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Mr. Richard N. Wilson—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Ms. Barbara Wright—Senior Environmental Employment Program, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

---

# AUTHORS, CONTRIBUTORS, AND REVIEWERS

---

## Authors

- Dr. Molini M. Patel (Team Leader, Integrated Science Assessment for Oxides of Nitrogen)—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Ms. Breanna Alman—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. James Brown—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Barbara Buckley—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Mr. Evan Coffman—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Ms. Laura Datko-Williams—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Rachelle Duvall—National Exposure Research Laboratory, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Erin Hines—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Ellen Kirrane—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Dennis Kotchmar—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Thomas Long—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Thomas Luben—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Stephen McDow—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Jennifer Nichols—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Michelle Oakes—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Elizabeth Oesterling Owens—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Cincinnati, Ohio

- Dr. Jennifer Peel—Department of Environmental and Radiological Health Sciences, Colorado School of Public Health, Colorado State University, Fort Collins, CO
- Dr. Joseph P. Pinto—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Edward Postlethwait—Department of Environmental Health Sciences, Ryals School for Public Health, University of Alabama at Birmingham, Birmingham, AL
- Dr. Kristen Rappazzo—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Jennifer Richmond-Bryant—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Mr. Jason Sacks—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Giuseppe Squadrito—Department of Environmental Health Sciences, Ryals School for Public Health, University of Alabama at Birmingham, Birmingham, AL
- Dr. Tina Stevens—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. David Svendsgaard—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. George Thurston—Department of Environmental Medicine, New York University School of Medicine, Tuxedo, NY
- Dr. Lisa Vinikoor-Imler—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Dr. Gregory Wellenius—Department of Community Health (Epidemiology Section), Brown University, Providence, RI
- Ms. Brianna Young—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

---

## Contributors

- Mr. Adam Benson—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Ms. Rachel Housego—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC
- Ms. Meagan Madden—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. April Maxwell—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. Ihab Mikati—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Lok Namsal—Universities Space Research Association, NASA Goddard Space Flight Center, Greenbelt, MD

Dr. Havalala Pye—National Exposure Research Laboratory, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Adrien Wilkie—Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

---

## Reviewers

Mr. Chad Bailey—Office of Transportation and Air Quality, Office of Air and Radiation, U.S. Environmental Protection Agency, Ann Arbor, MI

Dr. Lisa Baxter—National Exposure Research Laboratory, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Melinda Beaver—National Exposure Research Laboratory, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. Roger Brode—Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Philip Bromberg—School of Medicine, University of North Carolina, Chapel Hill, NC

Mr. Matthew Davis—Office of Children’s Health Protection, U.S. Environmental Protection Agency, Washington, DC

Ms. Laurel Driver—Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Steven J. Dutton—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Mark Frampton—Pulmonary and Critical Care Division, Department of Medicine, University of Rochester School of Medicine, Rochester, NY

Dr. Terry Gordon—Department of Environmental Medicine, New York University School of Medicine, Tuxedo, NY

Dr. Stephen Graham—Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Beth Hassett-Sipple—Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Gary Hatch—National Health and Environmental Effects Research Laboratory, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. Marc Houyoux—Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Scott Jenkins—Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Deborah Luecken—National Exposure Research Laboratory, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. Joseph McDonald—Office of Transportation and Air Quality and National Risk Management Research Laboratory, Office of Research and Development, U.S. Environmental Protection Agency, Cincinnati, OH

Ms. Connie Meacham—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Deirdre Murphy—Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. David Orlin—Air and Radiation Law Office, Office of General Counsel, U.S. Environmental Protection Agency, Washington, DC

Mr. Chris Owen—Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Jennifer Peel—Department of Environmental and Radiological Health Sciences, Colorado School of Public Health, Colorado State University, Fort Collins, CO

Dr. Edward Postlethwait—Department of Environmental Health Sciences, Ryals School for Public Health, University of Alabama at Birmingham, Birmingham, AL

Dr. Havala Pye—National Exposure Research Laboratory, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. Venkatesh Rao—Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Elise Richman—Office of Children’s Health Protection, U.S. Environmental Protection Agency, Washington, DC

Dr. Mary Ross—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Reeder Sams II—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Stephanie Sarnat—Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA

Dr. Matthew Strickland—Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA

Dr. John Vandenberg—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Debra Walsh—National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC

Mr. Nealson Watkins—Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. Environmental Protection Agency, Research Triangle Park, NC

Ms. Larke Williams—Office of Science Policy, Office of Research and Development,  
U.S. Environmental Protection Agency, Research Triangle Park, NC

Dr. Margaret Zawacki—Office of Transportation and Air Quality, Office of Air and  
Radiation, U.S. Environmental Protection Agency, Ann Arbor, MI

---

# CLEAN AIR SCIENTIFIC ADVISORY COMMITTEE OXIDES OF NITROGEN NAAQS REVIEW PANEL

---

## Chair of the Statutory Clean Air Scientific Advisory Committee Appointed by the Environmental Protection Agency's Administrator

Dr. Ana Diez Roux—Drexel University, Philadelphia, PA

---

## Oxides of Nitrogen Review Panel Members

Dr. H. Christopher Frey (Panel Chair)\*—North Carolina State University, Raleigh, NC

Mr. George A. Allen\*\*—Northeast States for Coordinated Air Use Management  
(NESCAUM), Boston, MA

Dr. Matthew Campen—University of New Mexico, Albuquerque, NM

Dr. Ronald Cohen—University of California, Berkeley, Berkeley, CA

Dr. Douglas Dockery—Harvard University, Boston, MA

Dr. Philip Fine—South Coast Air Quality Management District, Diamond Bar, CA

Dr. Panos Georgopoulos—Rutgers University, Piscataway, NJ

Dr. Jack Harkema\*\*—Michigan State University, East Lansing, MI

Dr. Michael Jerrett—University of California, Los Angeles, Los Angeles, CA

Dr. Joel Kaufman—University of Washington, Seattle, WA

Dr. Michael T. Kleinman—University of California, Irvine, Irvine, CA

Dr. Timothy V. Larson—University of Washington, Seattle, WA

Dr. Jeremy Sarnat—Emory University, Atlanta, GA

Dr. Richard Schlesinger—Pace University, New York, NY

Dr. Elizabeth A. (Lianne) Sheppard—University of Washington, Seattle, WA

Dr. Helen Suh\*\*—Northeastern University, Boston, MA

Dr. Ronald Wyzga\*\*—Electric Power Research Institute, Palo Alto, CA

Dr. Junfeng (Jim) Zhang—Duke University, Durham, NC

\*Immediate Past statutory CASAC Chair appointed by the EPA Administrator

\*\*Members of the statutory CASAC appointed by the EPA Administrator

---

## Science Advisory Board Staff

Mr. Aaron Yeow (Designated Federal Officer)—U.S. Environmental Protection Agency,  
Science Advisory Board (1400R), 1200 Pennsylvania Avenue, NW, Washington, DC  
20460-0001, Phone: 202-564-2050, Fax: 202-565-2098, yeow.aaron@epa.gov

# ACRONYMS AND ABBREVIATIONS

Acronym/ Abbreviation	Meaning	Acronym/ Abbreviation	Meaning
•	radical species	ANPR	advanced notice of public rulemaking
8-OhdG	urinary 8-hydroxy-29-deoxyguanosine	APEX	air pollution exposure model
$\alpha$	alpha, exposure factor	APHEA	Air Pollution and Health: A European Approach study
$\alpha$ -ATD	alpha 1-antitrypsin deficiency	AQCD	air quality criteria document
A4	not classifiable for humans or animals	AQI	air quality index
AADT	annual average daily traffic	AQS	air quality system
AB	Alberta	AR	airway responsiveness
ABI	ankle brachial index	AT	Atascadero
Abs	absorbance coefficient	ATS	American Thoracic Society
ABTS <sup>•-</sup>	2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) radical	ATSDR	Agency for Toxic Substances and Disease Registry
ABTS <sup>2-</sup>	2,2'-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid)	Aug	August
ACS	American Cancer Society	avg	average
ADRB2	beta-2-adrenergic receptor	AW	area wide
AER	air exchange rate	AZ	Arizona
AERMOD	American Meteorological Society/Environmental Protection Agency Regulatory Model	$\beta$	beta
AHR	airway hyperresponsiveness	BAL	bronchoalveolar lavage
AHSMOG	California Seventh-Day Adventists cohort	BAMSE	Children, Allergy, Milieu, Stockholm, Epidemiology Survey
a <sub>j</sub>	air exchange rate	BC	black carbon, British Columbia
AIRES	Aerosol Research Inhalation Epidemiology Study	BC/EC	black carbon/elemental carbon
AK	Alaska	BD	bronchodilator
AL	Alabama; alpine	BEIS	Biogenic Emission Inventory System
ALKP	alkaline phosphatase	BHPN	N-bis (2-hydroxy-propyl) nitrosamine
ALRI	acute lower respiratory infection	BIR	birch
a.m.	ante meridiem (before noon)	bkg	background
AM	alveolar macrophages	BL	bronchial lavage
		BMI	body mass index
		BP	blood pressure

<b>Acronym/ Abbreviation</b>	<b>Meaning</b>	<b>Acronym/ Abbreviation</b>	<b>Meaning</b>
Br <sup>-</sup>	bromide	CBV	cerebrovascular
BS	black smoke	CBVD	cerebrovascular disease
BSA	body surface area	CC16	club cell protein
BTEX	sum of the VOCs benzene, toluene, ethylbenzene, xylene	CDC	Centers for Disease Control and Prevention
BW	body weight; bronchial wash	C <sub>far</sub>	farthest concentration
BWHS	Black Women's Health Study	CFD	computational fluid dynamics
C <sub>6</sub> H <sub>6</sub>	benzene	CFR	Code of Federal Regulations
C	degrees Celsius; the product of microenvironmental concentration; carbon;	cGMP	cyclic guanosine monophosphate
C&RT	classification and regression tree	CHAD	Consolidated Human Activity Database
Ca <sup>2+</sup>	calcium	CHD	coronary heart disease
CA	California; cat allergen	Chemilum	chemiluminescence
C <sub>a</sub>	ambient NO <sub>2</sub> concentration	CHS	Children's Health Study
C <sub>a,esm</sub>	ambient concentration at a central site monitor	C <sub>i</sub>	average NO <sub>2</sub> concentration in the <i>i</i> th microenvironment; substrate concentrations
CAA	Clean Air Act	CI(s)	confidence interval(s)
CalNex	California Research at the Nexus of Air Quality and Climate Change	cIMT	carotid intima-media thickness
CAMP	Childhood Asthma Management Program	C <sub>j</sub>	average NO <sub>2</sub> concentration in the <i>j</i> th microenvironment
CAMx	Comprehensive Air Quality Model with Extensions	CJ-A	Ciudad Juarez—Site A
CAN	Canada	CJ-B	Ciudad Juarez—Site B
CAP	concentrated ambient particle	Cl <sup>-</sup>	chloride
CAPES	China Air Pollution and Health Effects Study	CL/MC	chemiluminescence analyzer with a MoO <sub>x</sub> catalytic converter
CAPS	cavity attenuated phase shift	CL/PC	chemiluminescence analyzer with measurements from a photolytic converter
CARB	carbachol	CINO	nitrosyl chloride
CASAC	Clean Air Scientific Advisory Committee	CINO <sub>2</sub>	nitryl chloride
CASNET	Clean Air Status and Trends Network	cm	centimeter
C <sub>b</sub>	NO <sub>2</sub> concentration contribution away from the influence of the road	CMAQ	Community Multiscale Air Quality
CBSA	core-based statistical area	C <sub>near</sub>	nearest concentration
		CO	carbon monoxide; Colorado
		C <sub>o,j</sub>	ambient exposure to NO <sub>2</sub> outdoor concentration

<b>Acronym/ Abbreviation</b>	<b>Meaning</b>	<b>Acronym/ Abbreviation</b>	<b>Meaning</b>
CO <sub>2</sub>	carbon dioxide	DL	distributed lag
COD	coefficient of divergence	DLM	Polynomial distributed lag model
CoH	coefficient of haze	DNA	deoxyribonucleic acid
COLD	cold-dry air	DNC	Democratic National Convention
COPD	chronic obstructive pulmonary disease	DOAS	differential optical absorption spectroscopy
C-R	concentration-response (relationship)	DOCs	diesel oxidation catalysts
CRDS	cavity ring down spectroscopy	dPD	change in provocative dose
CRP	C-reactive protein	DPF	diesel particulate filter
CS	central site	DPPC	dipalmitoyl phosphatidylcholine
CT	Connecticut	DVT	deep vein thrombosis
CTM	chemical transport models	e.g.	exempli gratia (for example)
CTS	California Teachers Study	E <sub>a</sub>	the sum of an individual's ambient NO <sub>2</sub> exposure
Cu	copper	E <sub>na,j</sub>	indoor exposures from nonambient sources
C <sub>v</sub>	NO <sub>2</sub> concentration contribution from vehicles on a roadway	EBC	exhaled breath condensate
CV	coefficient of variation	EC	elemental carbon
CVD	cardiovascular disease	ECG	electrocardiographic
C <sub>x</sub>	NO <sub>2</sub> concentration at a distance x from a road	ECP	eosinophil cationic protein
D	molecular diffusion coefficient of NO <sub>2</sub>	ECRHS	European Community Respiratory Health Survey
d	distance	ED	emergency department
D	distance in kilometers, day	EGU	electric power generating unit
D.C. Cir	District of Columbia Circuit	E <sub>i,j</sub>	indoor NO <sub>2</sub> exposure in the jth microenvironment
DBP	diastolic blood pressure	ELF	epithelial lining fluid
DC	District of Columbia	E <sub>na</sub>	the sum of an individual's nonambient NO <sub>2</sub> exposure
DEARS	Detroit Exposure and Aerosol Research Study	eNO	exhaled nitric oxide
Dec	December	eNOS	endothelial nitric oxide synthase
DEP	diesel exhaust particles	E <sub>o</sub>	outdoor microenvironmental NO <sub>2</sub> exposures
DEPcCBP	diesel exhaust particle extract-coated carbon black particles	E <sub>o,j</sub>	outdoor NO <sub>2</sub> exposure in the jth microenvironment
<i>df</i>	degrees of freedom	EP	entire pregnancy
DHA	dehydroascorbate		
DJF	December, January, February		

<b>Acronym/ Abbreviation</b>	<b>Meaning</b>	<b>Acronym/ Abbreviation</b>	<b>Meaning</b>
EPA	U.S. Environmental Protection Agency	GCLM	gene that encodes the regulatory subunit for the human enzyme glutamate-cysteine ligase
EP-A	El Paso—Site A		
EP-B	El Paso—Site B	GD	gestation day
ESCAPE	European Study of Cohorts for Air Pollution Effects	GEE	generalized estimating equations
ESR	erythrocyte sedimentation rate	GEOS	Goddard Earth Observing System
E <sub>T</sub>	total personal exposure	GINI	German Infant Nutritional Intervention
ET-1	vasoconstrictor endothelin-1		
ETS	environmental tobacco smoke	GINI SOUTH	German Infant Nutritional Intervention covers the urban city of Munich, Germany, and its surrounding areas (approximately 28,000 km <sup>2</sup> )
Exp	exposure		
F	female		
FE-AADT	Fleet equivalent annual average daily traffic	GINIplus	German Infant Nutritional Intervention plus environmental and genetic influences
Feb	February		
FEF	forced expiratory flow		
FEF <sub>25–75%</sub>	forced expiratory flow at 25–75% of exhaled volume	GIS	geographic information systems
FEF <sub>50%</sub>	forced expiratory flow at 50% of forced vital capacity	GLM	generalized linear model
FEM	federal equivalent method	GLMM	generalized linear mixed model
FEV <sub>1</sub>	forced expiratory volume in 1 second	GM-CSF	granulocyte macrophage-colony stimulating factor
FL	Florida		
FR	Federal Register	GPS	global positioning system
FRM	federal reference method	GPx	glutathione peroxidase
FVC	forced vital capacity	GS*	glutathione radical
γ	gamma; uptake coefficients	GSD	geometric standard deviation
γ'	semivariogram	GSH	glutathione
g	gram	GSNOR	nitrosoglutathione reductase
g/bhp-h	grams per brake horsepower-hour	GSR	glutathione reductase
GA	Georgia	GSS	glutathione synthetase
GAM	generalized additive models	GST	glutathione S-transferase
GASPII	Gene and Environmental Prospective Study in Italy	GSTM1	glutathione S-transferase Mu 1
GCLC	gene that encodes the catalytic subunit for the human enzyme glutamate-cysteine ligase	GSTP1	glutathione S-transferase Pi 1
		GSTT1	glutathione S-transferase theta 1

<b>Acronym/ Abbreviation</b>	<b>Meaning</b>	<b>Acronym/ Abbreviation</b>	<b>Meaning</b>
GW	gestational week	I ACID	inorganic acid
h	hour(s)	i.e.	id est (that is)
H <sup>+</sup>	hydrogen ion	I.V.	intravenously
H <sub>2</sub> SO <sub>4</sub>	sulfuric acid	ICAM-1	intercellular adhesion molecule 1
HC	hydrocarbon(s)	ICAS	Inner-City Asthma Study
hCAEC	human coronary artery endothelial cell	ICD	International Classification of Diseases; implantable cardioverter defibrillators
HCl	hydrochloric acid	ICS	inhaled corticosteroids
HDL	high-density lipoprotein	ID	Idaho
HDM	house dust mite; house dust mite allergen	IDW	inverse distance weighting
HERO	Health and Environmental Research Online	IFN- $\gamma$	interferon gamma
HEV	hold-out evaluation	IgE	immunoglobulin E
HF	high frequency; high frequency component of HRV	IGM	impaired glucose metabolism
HFE	human hemochromatosis protein	IHD	ischemic heart disease
HF <sub>n</sub>	high frequency domain normalized for heart rate	IL	interleukin; Illinois
HGF	hepatocyte growth factor	IL-6	interleukin-6
HI	Hawaii	IL-8	interleukin-8
HIST	histamine	Ile	isoleucine
HMOX	heme oxygenase	IM	immediately after exposure
HNO <sub>2</sub>	nitrous acid	IMSI	Integrated Mobile Source Indicator
HNO <sub>3</sub>	nitric acid	IMT <sub>6seg</sub>	intima-media thickness of the left and right common carotid arteries, internal carotid arteries, and carotid bulbs
HNO <sub>4</sub>	peroxynitric acid	IMT <sub>cca</sub>	intima-media thickness of the common carotid artery
HO-1	heme oxygenase-1	IN	Indiana; isoprene nitrate
HO <sub>2</sub>	hydroperoxyl radical	INDAIR	probabilistic model for indoor pollution exposures
HO <sub>2</sub> NO <sub>2</sub>	peroxynitric acid	INF <sub>j</sub>	infiltration of outdoor NO <sub>2</sub>
HONO	nitrous acid	iNOS	inducible nitric oxide synthase
HOONO	pernitrous acid	IOM	Institute of Medicine
HR	hazard ratio(s); heart rate	IQR	interquartile range
HRV	heart rate variability	IRP	Integrated Review Plan
HS	hemorrhagic stroke	IRR	incidence rate ratios
HSC	Harvard Six Cities	IS	ischemic stroke
hs-CRP	high sensitivity C-reactive protein		
IA	Iowa		

<b>Acronym/ Abbreviation</b>	<b>Meaning</b>	<b>Acronym/ Abbreviation</b>	<b>Meaning</b>
ISA	Integrated Science Assessment	LISAplus	Lifestyle-Related factors on the Immune System and the Development of Allergies in Childhood plus the influence of traffic emissions and genetics
IT	intratracheal		
IUGR	intrauterine growth restriction		
IVF	in vitro fertilization	LM	Lompoc
<i>j</i>	microenvironment	LN	Lancaster
JE	joint model estimate	LOESS	locally weighted scatterplot smoothing
<i>k</i>	reaction rate; decay constant derived from empirical data	LOOCV	leave-one-out cross-validation
kcal	kilocalorie(s)	LOPAP	long path absorption photometer
kg	kilogram(s)	LOX-1	lectin-like oxidized low density lipoprotein receptor
<i>k<sub>i</sub></i>	second-order rate constant(s)	Lp-PLA <sub>2</sub>	lipoprotein-associated phospholipase A2
<i>k<sub>j</sub></i>	decay rate	LRTI	lower respiratory tract infection
km	kilometer(s)	LUR	land use regression
kPa	kilopascal(s)	μ	mu; micro
KS	Kansas	μg/m <sup>3</sup>	micrograms per cubic meter
KY	Kentucky	m	meter
L	liter(s)	M	male
LA	Louisiana; Los Angeles; Lake Arrowhead	MA	Massachusetts
LAT	L-type amino acid transporter	M1	Month 1
LB	Long Beach	M2	Month 2
LBW	low birth weight	M3	Month 3
LDH	lactate dehydrogenase	M4	Month 4
LE	Lake Elsinore	MAAS	Manchester Asthma and Allergy Study
LETO	Long-Evans Tokushima	max	maximum
LF	low-frequency component of HRV	MCP-1	monocyte chemoattractant protein-1
LF/HF	ratio of LF and HF components of HRV	MD	Maryland
LIE	Long Island Expressway	MDA	malondialdehyde
LIF	laser induced fluorescence	ME	Maine
LISA	Lifestyle-Related factors on the Immune System and the Development of Allergies in Childhood	MESA-Air	Multi-Ethnic Study of Atherosclerosis and Air Pollution
		MET	MET receptor tyrosine kinase gene

<b>Acronym/ Abbreviation</b>	<b>Meaning</b>	<b>Acronym/ Abbreviation</b>	<b>Meaning</b>
METH	methacholine	NADPH	reduced nicotinamide adenine dinucleotide phosphate
METS	metabolic equivalents		
MI	myocardial infarction (“heart attack”); myocardial ischemia; Michigan	NAL	nasal lavage
min	minimum	NAMS	National Air Monitoring Stations
ML	Mira Loma	NAS	National Academy of Sciences
mL	milliliter(s)	NC	North Carolina
MLI	mean linear intercept	NCEA	National Center for Environmental Assessment
MMEF	maximum (or maximal) midexpiratory flow	NCICAS	National Cooperative Inner-City Asthma Study
mm Hg	millimeters of mercury	NCORE	National Core network
MMP	matrix metalloproteinase	ND	North Dakota
MMP-3	matrix metalloproteinase-3	NDMA	N-nitrosodimethylamine
MMP-7	matrix metalloproteinase-7	NE	Nebraska
MMP-9	matrix metalloproteinase-9	NEI	National Emissions Inventory
MN	Minnesota	NFκB	nuclear factor kappa-light-chain-enhancer of activated B cells
mo	month(s)		
MO	Missouri	NH	New Hampshire
MOA	mode(s) of action	NH <sub>3</sub>	ammonia
mol	mole	(NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub>	ammonium sulfate
MoO <sub>x</sub>	molybdenum oxide	NHAPS	National Human Activity Pattern Survey
MPO	myeloperoxidase	NHS	Nurses Health Study
mRNA	messenger ribonucleic acid	NJ	New Jersey
MS	Mississippi	NLCS	Netherlands Cohort Study on Diet and Cancer
MT	Montana	nm	nanometer
n	sample size; total number of microenvironments that the individual has encountered	NM	New Mexico
N	nitrogen; population number	NMMAPS	The National Morbidity Mortality Air Pollution Study
N <sub>2</sub> O <sub>3</sub>	dinitrogen trioxide	NMOR	N-nitrosomorpholine
N <sub>2</sub> O <sub>4</sub>	dinitrogen tetroxide	NO	nitric oxide
N <sub>2</sub> O <sub>5</sub>	dinitrogen pentoxide	NO <sub>2</sub>	nitrogen dioxide
NA	not available	NO <sub>2</sub> <sup>-</sup>	nitrite
Na <sup>+</sup>	sodium ion	NO <sub>3</sub> <sup>-</sup>	nitrate
NAAQS	National Ambient Air Quality Standards	NO <sub>3</sub> •	nitrate radical
NAB	North American Background		
NaCl	sodium chloride		

<b>Acronym/ Abbreviation</b>	<b>Meaning</b>	<b>Acronym/ Abbreviation</b>	<b>Meaning</b>
nonHS	nonhemorrhagic stroke	PAH(s)	polycyclic aromatic hydrocarbon(s)
NOS	nitric oxide synthase	PAMS	photochemical monitoring stations
NO <sub>x</sub>	the sum of NO and NO <sub>2</sub>	PAN	peroxyacetyl nitrate; peroxyacetyl nitrate
NO <sub>y</sub>	oxides of nitrogen	PAPA	Public Health and Air Pollution in Asia
NO <sub>z</sub>	reactive oxides of nitrogen (e.g., HNO <sub>3</sub> , HONO, PAN, particulate nitrates)	Pb	lead
NQO1	NADPH-quinone oxidoreductase (genotype)	PBL	planetary boundary layer
NR	not reported; no quantitative results reported; near road	PC	provocative concentration
NS	not statistically significant	PCA	principal component analysis
NV	Nevada	PCO	protein carbonyl
NY	New York	PD	provocative dose
O ACID	organic acid	PE	pulmonary embolism
O <sub>3</sub>	ozone	PEF	peak expiratory flow
OAQPS	Office of Air Quality Planning & Standards	PFK	phosphofructokinase
OC	organic carbon	PIAMA	prevention and incidence of asthma and mite allergy
OH	hydroxide; Ohio	PiZZ	severe alpha-1 antitrypsin deficiency
8-OHdG	8-hydroxy-2'-deoxyguanosine	P <sub>j</sub>	air pollutant penetration
OK	Oklahoma	PK	pyruvate kinase
OLETF	Otsuka Long-Evans Tokushima Fatty	p.m.	post meridiem (after noon)
OLM	ozone limiting method	PM	particulate matter
OMI	ozone monitoring instrument		
OR	odds ratio(s); Oregon		
OVA	ovalbumin		
<i>p</i>	p-value, probability of obtaining a result equal to or "more extreme" than what was actually observed, assuming that the null hypothesis is true		
P	Pearson correlation		
Pa	pascal(s)		
PA	policy assessment; Pennsylvania		
PAARC	air pollution and chronic respiratory diseases		

<b>Acronym/ Abbreviation</b>	<b>Meaning</b>	<b>Acronym/ Abbreviation</b>	<b>Meaning</b>
PM <sub>10</sub>	In general terms, particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm; a measurement of thoracic particles (i.e., that subset of inhalable particles thought small enough to penetrate beyond the larynx into the thoracic region of the respiratory tract). In regulatory terms, particles with an upper 50% cut-point of 10 ± 0.5 µm aerodynamic diameter (the 50% cut point diameter is the diameter at which the sampler collects 50% of the particles and rejects 50% of the particles) and a penetration curve as measured by a reference method based on Appendix J of 40 CFR Part 50 and designated in accordance with 40 CFR Part 53 or by an equivalent method designated in accordance with 40 CFR Part 53.	PM <sub>2.5</sub>	In general terms, particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm; a measurement of fine particles. In regulatory terms, particles with an upper 50% cut-point of 2.5 µm aerodynamic diameter (the 50% cut point diameter is the diameter at which the sampler collects 50% of the particles and rejects 50% of the particles) and a penetration curve as measured by a reference method based on Appendix L of 40 CFR Part 50 and designated in accordance with 40 CFR Part 53, by an equivalent method designated in accordance with 40 CFR Part 53, or by an approved regional method designated in accordance with Appendix C of 40 CFR Part 58.
PM <sub>10-2.5</sub>	In general terms, particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm and greater than 2.5 µm; a measurement of thoracic coarse particulate matter or the coarse fraction of PM <sub>10</sub> . In regulatory terms, particles with an upper 50% cut-point of 10 µm aerodynamic diameter and a lower 50% cut-point of 2.5 µm aerodynamic diameter (the 50% cut point diameter is the diameter at which the sampler collects 50% of the particles and rejects 50% of the particles) as measured by a reference method based on Appendix O of 40 CFR Part 50 and designated in accordance with 40 CFR Part 53 or by an equivalent method designated in accordance with 40 CFR Part 53.	PMA	phorbol myristate acetate
		PMN(s)	polymorphonuclear cell(s), polymorphonuclear leukocyte
		PNC	particle number concentration
		PND	postnatal day
		pNN50	Proportion of pairs of successive normal sinus intervals exceeds 50 milliseconds divided by the total number of successive pairs of normal sinus intervals
		pNO	particulate nitrogen species
		pNO <sub>3</sub>	particulate nitrate
		PPAR <sub>γ</sub>	peroxisome proliferator activated receptor gamma
		ppb	parts per billion
		ppm	parts per million
		PROtEuS	Prostate Cancer and Environment Study
		PTB	preterm birth

<b>Acronym/ Abbreviation</b>	<b>Meaning</b>	<b>Acronym/ Abbreviation</b>	<b>Meaning</b>
PVMRM	plume volume molar ratio method	ROS	reactive oxygen species
Q1	1st quartile or quintile	RR	risk ratio(s), relative risk
Q2	2nd quartile or quintile	RSNO	S-nitrosothiols
Q3	3rd quartile or quintile	RSV	respiratory syncytial virus
Q4	4th quartile or quintile	RV	Riverside
Q5	5th quintile	$\epsilon$	Sigma, random error
QC-TILDAS	quantum cascade—tunable infrared laser differential absorption spectrometer	sec	second(s)
QT interval	time between start of Q wave and end of T wave in ECG	S. Rep.	Senate Report
QTc	corrected QT interval	s/L	seconds per liter
QTVI	QT variable index	S/N	Signal-to-noise ratio
QUIC	Quick Urban and Industrial Complex	SALIA	Study on the Influence of Air Pollution on Lung, Inflammation, and Aging
<i>r</i>	Pearson correlation coefficient; Spearman correlation coefficient	SA-LUR	source-area land use regression
$R^2$	square of the correlation coefficient	SAPALDIA	Swiss Study on Air Pollution and Lung Disease in Adults
RAG	ragweed	SAT	switching attention test
RANCH	road traffic and aircraft noise exposure and children's cognition and health	SBP	systolic blood pressure
RBC	red blood cells	SC	South Carolina
RC(=O)	acyl group	SCR	selective catalytic reduction
RC(=O)OONO <sub>2</sub>	peroxyacylnitrates	SD	standard deviation; South Dakota; San Dimas
REA	Risk and Exposure Assessment	SDNN	standard deviation of all normal-to-normal intervals, an index of total HRV
REGICOR	Registre Gironi del Cor	SE	standard error
RH	relative humidity	Se	selenium
RI	Rhode Island	SEARCH	Southeast Aerosol Research Characterization
RIVM	National Air Quality Monitoring Network of the National Institute of Public Health and the Environment	sec	second(s)
rMSSD	root mean square of successive differences; a measure of HRV	SEI	socio-economic index
RNS	reactive nitrogen species	Se-L	low selenium
RONO <sub>2</sub>	organic nitrates	SES	socioeconomic status
		Se-S	supplemented selenium
		Sess.	session
		SF <sub>6</sub>	sulfur hexafluoride
		SGA	small for gestational age
		sGaw	specific airway conductance

<b>Acronym/ Abbreviation</b>	<b>Meaning</b>	<b>Acronym/ Abbreviation</b>	<b>Meaning</b>
SHARP	Study of Houston Atmospheric Radical Precursors	TEA	triethanolamine
SHEDS	Stochastic Human Exposure and Dose Simulation	Th17	T helper cell 17
SHEEP	Stockholm Heart Epidemiology Program	Th2	T-derived lymphocyte helper 2
sICAM-1	soluble intercellular adhesion molecule-1	TIA	transient ischemic attack
SLAMS	state and local air monitoring stations	TIM	timothy
SM	Santa Maria	TIMP-2	tissue inhibitor of matrix metalloproteinase-2
SNP	single nucleotide polymorphism	t <sub>j</sub>	fraction of total time spent in the j <sup>th</sup> microenvironment
SO <sub>2</sub>	sulfur dioxide	TLR	Toll-like receptor
SO <sub>4</sub>	sulfate	TN	Tennessee
SOA	secondary organic aerosols	TNF	tumor necrosis factor
SOD	superoxide dismutase	TNF- $\alpha$	tumor necrosis factor alpha
SP-D	surfactant protein D	TSP	total suspended solids
SPE	single-pollutant model estimate	TWA	time-weighted average
sRaw	specific airway resistance	TX	Texas
SRTT	simple reaction time test	U.S.C.	U.S. Code
ST segment	segment of the electrocardiograph between the end of the S wave and beginning of the T wave	UCD	University of California, Davis
sVCAM-1	soluble vascular adhesion molecule-1	UF1	ultrafine particle number beginning at 3 nanometers
$\tau$	tau, half-time	UF2	ultrafine particle number beginning at 15 nanometers
t	fraction of time spent in a microenvironment across an individual's microenvironmental exposures, time	UFP	ultrafine particle(s)
TBARS	thiobarbituric acid reactive substances (species)	UK	universal kriging
T1	first trimester	U.K.	United Kingdom
T2	second trimester	ULTRA	The Exposure and Risk Assessment for Fine and Ultrafine Particles in Ambient Air Study conducted in Europe
T3	third trimester	UP	Upland
TBARS	thiobarbituric acid reactive substances	URI	upper respiratory infection
TCHS	Taiwan Children Health Study	U.S.	United States of America
		UT	Utah
		VA	Virginia
		Val	valine
		VCAM-1	vascular adhesion molecule-1
		$\dot{V}_E$	minute volume

<b>Acronym/ Abbreviation</b>	<b>Meaning</b>	<b>Acronym/ Abbreviation</b>	<b>Meaning</b>
VEGF	vascular endothelial growth factor	$y_i$	fraction of time spent indoors
VOC	volatile organic compound	$y_{i,j}$	fraction of a day spent in each indoor microenvironment
VPTB	very preterm birth		
$V_T$	tidal volume	$y_o$	fraction of all time spent outdoors
VT	ventricular tachyarrhythmias; Vermont	$y_{o,j}$	fraction of a day spent in each outdoor microenvironment
vWF	von Willebrand factor		
WBC	white blood cell	yr	year(s)
WHI	Women's Health Initiative	Z	covariate vector; the measured concentration; standard normal deviate
WHO	World Health Organization		
WI	Wisconsin		
WV	West Virginia	$Z^*$	the true concentration
WY	Wyoming	Zn	zinc
X	distance from the road		
Y	health effect of interest		

---

# PREAMBLE

## 1. Process of Integrated Science Assessment Development


This [Preamble](#) outlines the general process the United States Environmental Protection Agency (U.S. EPA) uses to develop an Integrated Science Assessment (ISA), including the framework for evaluating weight of evidence and drawing scientific conclusions and causal judgments. The ISA provides a concise review, synthesis, and evaluation of the most policy-relevant science to serve as a scientific foundation for the review of the National Ambient Air Quality Standards (NAAQS).<sup>1</sup> The NAAQS are established based on consideration of the air quality criteria (represented by the ISA) for the pollutants identified by the Administrator using Section 108 of the Clean Air Act (CAA). The pollutants currently identified are carbon monoxide (CO), lead (Pb), oxides of nitrogen, photochemical oxidants, particulate matter (PM), and sulfur oxides ([CAA, 1990a, b](#)). [Figure I](#) depicts the general NAAQS review process. Information for individual NAAQS reviews is available online.<sup>2</sup>

The development of the ISA is preceded by the release of an Integrated Review Plan (IRP) that discusses the planned scope of the NAAQS review; the planned approaches for developing the key assessment documents [e.g., ISA, Risk and Exposure Assessment (if warranted), Policy Assessment]; and the schedule for release and review of the documents and subsequent rulemaking notices. The key policy-relevant questions included in the IRP serve to clarify and focus the NAAQS review on the critical scientific and policy issues, including addressing uncertainties discussed during the previous review and newly emerging literature. The IRP is informed by a U.S. EPA-hosted public science and policy issue workshop that “kicks off” the review of the NAAQS for a given criteria pollutant by seeking input on the current state of the science and engaging stakeholders and experts in discussion of the policy-relevant questions that will frame the review.

---

<sup>1</sup> The general process for NAAQS reviews is described at <http://www.epa.gov/ttn/naaqs/review.html>.

<sup>2</sup> Information for individual NAAQS reviews is available at [www.epa.gov/ttn/naaqs](http://www.epa.gov/ttn/naaqs).




**Figure I Schematic of the key steps in the review of National Ambient Air Quality Standards.**

This [Preamble](#) is a general discussion of the basic steps and criteria used in developing an ISA. Details and considerations specific to an individual ISA are included in the IRP as well as the [Preface](#) and other introductory materials for that assessment. The general process for ISA development is illustrated in [Figure II](#). An initial step (not shown) is publication of a call for information in the *Federal Register* that invites the public to provide information relevant to the assessment, such as new or recent publications on health or welfare effects of the pollutant or data from the fields of atmospheric and exposure science.

The fundamental process for developing an ISA includes:

- Literature searches;
- Study selection;
- Evaluation of individual study quality;
- Evaluation, synthesis, and integration of the evidence; and
- Development of scientific conclusions and causal determinations.



Note: U.S. EPA = United States Environmental Protection Agency.

**Figure II Characterization of the general process for developing an Integrated Science Assessment.**

In developing an ISA, the U.S. EPA reviews and summarizes the evidence from studies on atmospheric sciences, human exposure, animal toxicology, controlled human exposure, epidemiology, and/or ecology and other welfare<sup>1</sup> effects. In the process of developing the first draft ISA, the U.S. EPA may convene a peer input meeting in which the scientific content of preliminary draft materials is reviewed by subject-matter experts to ensure that the ISA is up-to-date and is focused on the most policy-relevant findings. This input also assists the U.S. EPA with the integration of evidence within and across disciplines.

The U.S. EPA integrates the evidence across scientific disciplines or study types and characterizes the weight of evidence for relationships between the pollutant(s) being evaluated and various outcomes. Integrating evidence on health or welfare effects involves collaboration among scientists from various disciplines. For example, an evaluation of health effects evidence would generally include integrating the results from epidemiologic, controlled human exposure, and toxicological studies; considering exposure assessment; and applying the causal framework (described below) to draw conclusions.

Integration of results on health or welfare effects that are logically or mechanistically connected (e.g., respiratory symptoms, asthma exacerbation) informs judgments of causality on a broader health effect category (e.g., effects on the respiratory system). Using the causal framework described in this [Preamble](#), U.S. EPA scientists consider aspects, such as strength, consistency, coherence, and biological plausibility of the evidence, and develop causal determinations on the nature of the relationships with the pollutant(s) being evaluated. Causal determinations often entail an iterative process of review and evaluation of the evidence. One or more drafts of the ISA are released for review by the Clean Air Scientific Advisory Committee (CASAC) and the public, and comments received on the characterization of the science as well as the implementation of the causal framework are carefully considered in revising the draft ISA and completing the ISA.

## 2. Literature Search

In addition to the call for information in the *Federal Register* referenced above, the U.S. EPA maintains an ongoing literature search process to identify relevant scientific studies published since the last ISA for a given criteria pollutant. Search strategies are

---


<sup>1</sup> Under CAA Section 302(h) [42 U.S.C. 7602(h)], language referring to “effects on welfare” includes, but is not limited to, “effects on soil, water, crops, vegetation, man-made materials, animals, wildlife, weather, visibility, and climate, damage to and deterioration of property, and hazards to transportation, as well as effects on economic values and on personal comfort and well-being.”

designed a priori for pollutants and scientific disciplines and iteratively modified to optimize identification of pertinent publications. Papers are identified for inclusion in several additional ways: specialized searches on specific topics, identification of new publications by relational searches conducted using citations from previous assessments, review of tables of contents for journals in which relevant papers may be published, identification of relevant literature by expert scientists, review of citations in previous assessments, and recommendations by the public and CASAC during the call for information and external review processes. This multipronged search strategy aims to identify all relevant epidemiologic, controlled human exposure, toxicological, ecological, and welfare effects studies published since the last ISA as well as studies related to exposure-response relationships, mode(s) of action, and populations and lifestages at increased risk of air pollution-related health effects. Also relevant to the ISA are studies and data analyses on atmospheric chemistry, air quality and emissions, environmental fate and transport, dosimetry, toxicokinetics, and exposure.

References identified through the multipronged search strategy are then “screened” by title and abstract. References that are judged to be potentially relevant based on review beyond the title are “considered” for inclusion in the ISA and are added to the Health and Environmental Research Online (HERO) database developed by the U.S. EPA.<sup>1</sup> These “considered” references can be found on the HERO project page for the particular ISA. Studies and reports that have undergone scientific peer review and have been published (or accepted for publication) are eligible for review in the ISA. Further, only studies that have been ethically conducted (e.g., approval by an Institutional Review Board or Institutional Animal Care and Use Committee) are eligible for review in the ISA. Each “included” reference is cited in the ISA as a hyperlink to the ISA project page in the HERO database. Additional review steps (described in [Section 3](#) below) precede a decision on whether a study will be “included” in the ISA. This literature search and study selection process, including identification of “screened,” “considered,” and “included” references, is depicted in [Figure III](#).

---

<sup>1</sup> The list of “considered” and “cited” references and bibliographic information is accessible to the public through HERO (<http://hero.epa.gov>).



**Figure III** Illustration of literature search and study selection process used for developing Integrated Science Assessments.

Each ISA builds upon the conclusions of previous assessments for the pollutant under review. The U.S. EPA focuses on peer-reviewed literature published since the completion of the previous ISA and on any new interpretations of previous literature, integrating the results of recent scientific studies with previous findings. Important earlier studies may be discussed in detail to reinforce key concepts and conclusions or for reinterpretation in light of newer data. Earlier studies also are the primary focus for some topics covered in the ISA where research efforts have subsided, or if these earlier studies remain the definitive works available in the literature.

### 3. Study Selection

References considered for inclusion in the ISA undergo abstract and full-text review to determine whether they will be included in the ISA. The selection process is based on the extent to which the study is informative, pertinent, and policy relevant. Informative, pertinent, and policy-relevant studies include those that describe or provide a basis for characterizing the relationship between the criteria pollutant and health or welfare effects, including studies that offer innovation in method or design and studies that reduce uncertainty on critical issues. Emphasis is placed on studies that examine effects

associated with pollutant concentrations and exposure conditions relevant to current human population and ecosystem exposures, and particularly those pertaining to concentrations currently found in ambient air. Other studies are included if they contain unique data, such as a previously unreported effect or mode of action for an observed effect, or examine multiple concentrations to elucidate exposure-response relationships.

#### **4. Evaluation of Individual Study Quality**

After studies are selected for inclusion, individual study quality is evaluated by reviewing the design, methods, conduct, and documentation of each study, but not the study results. This uniform approach aims to assess the strengths, limitations, and possible roles of chance, confounding, and other biases that may affect the interpretation of individual studies and the strength of inference from the results of the study. Particular aspects or the absence of some features in a study do not necessarily define a less informative study or exclude a study from consideration in an ISA. As stated initially, the intent of the ISA is to provide a concise review, synthesis, and evaluation of the most policy-relevant science to serve as a scientific foundation for the review of the NAAQS, not extensive summaries of all health, ecological, and other welfare effects studies for a pollutant. A primary issue in the decision to include a study is whether it provides useful qualitative or quantitative information on exposure-response relationships for effects associated with pollutant exposures at doses or concentrations relevant to ambient conditions that can inform decisions on whether to retain or revise the standards.

Generally, in assessing the scientific quality of studies on health and welfare effects, the following considerations are taken into account.

- Were study design, study groups, methods, data, and results clearly presented in relation to the study objectives to allow for study evaluation? Were limitations and any underlying assumptions of the design and other aspects of the study stated?
- Were the ecosystems, study site(s), study populations, subjects, or organism models adequately selected, and are they sufficiently well defined to allow for meaningful comparisons between study or exposure groups?
- Are the air quality data, exposure, or dose metrics of adequate quality and sufficiently representative of information regarding ambient conditions?
- Are the health, ecological, or other welfare effect measurements meaningful, valid, and reliable?
- Were likely covariates or modifying factors adequately controlled or taken into account in the study design and statistical analysis?
- Do the analytical methods provide adequate sensitivity and precision to support conclusions?

- Were the statistical analyses appropriate, properly performed, and properly interpreted?

Additional study quality considerations specific to particular disciplines are discussed below.

## **a. Atmospheric Science and Exposure Assessment**

Atmospheric science and exposure assessment studies that are considered for inclusion in the ISA focus on measurement of, behavior of, and exposure to ambient air pollution using quality-assured field, experimental, and/or modeling techniques. The most informative measurement-based studies will include detailed descriptive statistics for measurements taken at varying spatial and temporal scales. These studies will also include a clear and comprehensive description of measurement techniques and quality-control procedures used. Quality-control metrics (e.g., method detection limits) and quantitative relationships between and within pollutant measurements (e.g., regression slopes, intercepts, fit statistics) should be provided when appropriate. Measurements that include contrasting conditions for various time periods (e.g., weekday/weekend, season), populations, regions, and categories (e.g., urban/rural) are particularly useful. The most informative modeling-based studies will incorporate appropriate chemistry, transport, dispersion, and/or exposure modeling techniques with a clear and comprehensive description of model evaluation procedures, metrics, and technique strengths and limitations. The ISA also may include analyses of data pertinent to characterizing air quality or exposure, such as emissions sources and ambient air pollutant concentrations. Sources of monitoring and modeling data should be clearly referenced and described to foster transparency and reproducibility of any analysis. In general, atmospheric science studies and data analyses focusing on locations pertinent to the U.S. will have maximum value in informing review of the NAAQS.

Exposure measurement error, which refers to inaccuracies in the characterization of the exposures of study participants, can be an important contributor to uncertainty in air pollution epidemiologic study results. Exposure measurement error can influence observed epidemiologic associations between ambient pollutant concentrations and health outcomes by biasing effect estimates toward or away from the null and/or widening confidence intervals around those estimates ([Zeger et al., 2000](#)). Factors that could influence exposure estimates include, but are not limited to: choice of exposure metric, spatial variability of the pollutant concentration, nonambient sources of exposure, topography of the natural and built environment, meteorology, instrument errors, time-activity patterns, and differential infiltration of air pollutants into indoor environments. The influence of these factors on effect estimates also depends on

epidemiologic study design. For example, when longitudinal studies depend on spatial contrasts in exposure estimates, it is important that the exposure estimates correspond in space to the population of interest. Likewise for time-series studies, the temporal variability of the exposure estimate must correspond temporally to the true exposures of the study population.

## **b. Epidemiology**

In addition to the general study quality considerations discussed above, the U.S. EPA evaluates quality of individual epidemiologic studies for inference about health effects by considering whether a given study: (1) presents information on associations with short- or long-term pollutant exposures at or near conditions relevant to ambient exposures; (2) addresses potential confounding, particularly by other pollutants; (3) assesses potential effect modifiers; (4) evaluates health endpoints and populations, groups, or lifestages not previously extensively researched; and (5) evaluates important methodological issues related to interpretation of the health evidence (e.g., lag or time period between exposure and effects, model specifications, thresholds).

In evaluating epidemiologic evidence, one important consideration is potential confounding. Confounding is "... a confusion of effects. Specifically, the apparent effect of the exposure of interest is distorted because the effect of an extraneous factor is mistaken for or mixed with the actual exposure effect (which may be null)" ([Rothman and Greenland, 1998](#)). A confounder is associated with both the exposure and the effect; for example, confounding can occur between correlated pollutants that are associated with the same effect. One approach to remove spurious associations due to possible confounders is to control for characteristics that may differ between exposed and unexposed persons; this is frequently termed "adjustment." Scientific judgment is needed to evaluate likely sources and extent of confounding, together with consideration of how well the existing constellation of study designs, results, and analyses address the potential for erroneous inferences.

Several statistical methods are available to detect and control for potential confounders; however, none of these methods is completely satisfactory. Multivariable regression models constitute one tool for estimating the association between exposure and outcome after adjusting for characteristics of participants that might confound the results. Because much of the uncertainty in inferring causality may be due to potential confounding by copollutants, evaluation of copollutant confounding in individual studies is of particular importance. The use of copollutant regression models has been the prevailing approach for controlling for potential confounding by copollutants in air pollution health effects

studies. Trying to determine whether an individual pollutant is independently associated with the health outcome of interest from copollutant regression models is made difficult by the possibility that one or more air pollutants is acting as a surrogate for an unmeasured or poorly measured pollutant or for a particular mixture of pollutants. In addition, pollutants may independently exert effects on the same system; for example, several pollutants may be associated with a respiratory effect through either the same or different modes of action. Despite these limitations, the use of copollutant models is still the prevailing approach employed in most air pollution epidemiologic studies and can provide some insight into the potential for confounding or interaction among pollutants.

Confidence that unmeasured confounders are not producing the findings is increased when multiple studies are conducted in various settings using different subjects or exposures, each of which might eliminate another source of confounding from consideration. For example, multicity studies can provide insight on potential confounding through the use of a consistent method to analyze data from across locations with different concentrations of copollutants and other covariates. Intervention studies, because of their quasi-experimental nature, can be particularly useful in characterizing causation.

Another important consideration in the evaluation of epidemiologic studies is effect-measure modification, which occurs when the effect differs between subgroups or strata; for example, effect estimates that vary by age group or a potential risk factor. As stated by [Rothman and Greenland \(1998\)](#):

“Effect-measure modification differs from confounding in several ways. The main difference is that, whereas confounding is a bias that the investigator hopes to prevent or remove from the effect estimate, effect-measure modification is a property of the effect under study .... In epidemiologic analysis one tries to eliminate confounding but one tries to detect and estimate effect-measure modification.”

When a risk factor is a confounder, it is the true cause of the association observed between the exposure and the outcome; when a risk factor is an effect modifier, it changes the magnitude of the association between the exposure and the outcome in stratified analyses. For example, the presence of a pre-existing disease or indicator of low socioeconomic status (SES) may act as an effect modifier if it is associated with increased risk of effects related to air pollution exposure. It is often possible to stratify the relationship between health outcome and exposure by one or more of these potential effect modifiers. For variables that modify the association, effect estimates in each stratum will be different from one another and different from the overall estimate,

indicating a different exposure-response relationship may exist in populations represented by these variables.

### **c.           Controlled Human Exposure and Animal Toxicology**

Controlled human exposure and animal toxicological studies experimentally evaluate the health effects of administered exposures in human volunteers and animal models under highly controlled laboratory conditions. Controlled human exposure studies are also referred to as human clinical studies. In controlled human exposure and animal toxicological experiments, investigators expose subjects or animals to known concentrations of air pollutants under carefully regulated environmental conditions and activity levels. In addition to the general quality considerations discussed previously, evaluation of controlled human exposure and animal toxicological studies includes assessing the design and methodology of each study with focus on (1) characterization of the intake dose, dosing regimen, and exposure route; (2) characterization of the pollutant(s); (3) sample size and statistical power to detect differences; and (4) control of other variables that could influence the occurrence of effects. The evaluation of study design generally includes consideration of factors that minimize bias in results, such as randomization, blinding, and allocation concealment of study subjects, investigators, and research staff, and unexplained loss of animals or withdrawal/exclusion of subjects. Additionally, studies must include appropriate control groups to allow for accurate interpretation of results relative to exposure. Emphasis is placed on studies that address concentration-dependent responses or time-course of responses and studies that investigate potentially at-risk lifestages or populations (e.g., older adults, groups with pre-existing disease).

Controlled human exposure or animal toxicological studies that approximate expected human exposures in terms of concentration, duration, and route of exposure are of particular interest. Relevant pollutant exposures are considered to be those generally within two orders of magnitude of recent ambient concentrations. This range in relevant exposures is intended to account for differences in dosimetry, toxicokinetics, and biological sensitivity of various species, strains, or potentially at-risk populations. Studies using higher concentration exposures or doses will be considered to the extent that they provide information relevant to understanding mode of action or mechanisms, inter-species variation, or at-risk human populations. In vitro studies may provide mechanistic insight for effects examined in vivo or in epidemiologic studies.

#### **d. Ecological and Other Welfare Effects**

Ecological effects evaluated in the ISAs typically include several of the topics given as examples by the CAA definition in Section 302(h) related to effects on welfare, including soils, water, vegetation, animals, and wildlife. Additional topic areas that may be evaluated in an ISA include visibility, weather, and climate, as well as materials damage, economic values, and impacts to personal comfort and well-being. In evaluating studies that consider welfare effects, in addition to assessing the general quality considerations discussed previously, emphasis is placed on studies that evaluate effects at or near ambient concentrations of the air pollutant(s). Studies conducted in any country that contribute meaningfully to the general understanding of air pollutant effects may be evaluated for relevancy to U.S. air quality considerations and inclusion in the ISA.

Studies at higher pollutant concentrations are used to evaluate ecological effects only when they are part of a range of concentrations that also include more typical values, or when they inform understanding of modes of action and illustrate the wide range of sensitivity to air pollutants across taxa or across biomes and ecoregions. In evaluating quantitative exposure-response relationships, emphasis is placed on findings from studies conducted in the U.S. and Canada as having ecological and climatic conditions most relevant for review of the NAAQS. The type of experimental approach used in the study (e.g., controlled laboratory exposure, growth chamber, open-top chamber, mesocosm, gradient, field study) is also evaluated when considering the applicability of the results to the review of criteria air pollutant effects.

In evaluating studies on climate and visibility, emphasis is placed on studies that use well-established measurement and modeling techniques, especially those that report uncertainty or compare results from an ensemble of techniques. Novel methods may also be informative in addressing knowledge gaps not well characterized by existing techniques. Relevant climate studies include those evaluating direct and indirect climate impacts of criteria air pollutants at a global scale, while for visibility, studies conducted in the U.S. and Canada provide information more applicable for review of the NAAQS. In both cases, studies that evaluate effects by source sector or region, such as regional climate modeling studies, are particularly informative. Studies that report impacts of multiple PM components for visibility and multiple criteria pollutants for climate are useful in evaluating interactions and the relative contributions of atmospheric constituents. For example, in evaluating the climate forcing effects of ozone (O<sub>3</sub>), it is useful to understand the atmospheric chemistry involving CO and NO<sub>x</sub> (the sum of nitric oxide and nitrogen dioxide) that affects atmospheric concentrations of O<sub>3</sub>. Visibility preference and valuation studies that explicitly separate preferences for visibility from

concerns about health risks of air pollution are particularly relevant in considering a welfare-based secondary NAAQS for pollutants that affect visibility.

## **5. Evaluation, Synthesis, and Integration of Evidence across Disciplines and Development of Scientific Conclusions and Causal Determinations**

The U.S. EPA has developed an approach for integrating the scientific evidence gained from the array of study types discussed above in order to draw conclusions regarding the causal nature of ambient air pollutant-related health or welfare effects. Evidence from all disciplines is integrated to evaluate consistency and inconsistency in the pattern of effects as well as strengths and limitations of the evidence across disciplines. Part of this approach includes a framework for making determinations regarding the extent to which a causal relationship exists between the pollutant in ambient air, and health or welfare effects (described in [Section 5.b](#)). This framework establishes a uniform approach and language to characterizing causality and brings specificity to the conclusions.

### **a. Evaluation, Synthesis, and Integration of Evidence across Disciplines**

The ISA focuses on evaluation of the findings from the body of evidence across disciplines, drawing upon the results of all studies judged of adequate quality and relevance per the considerations described previously. Evidence across scientific disciplines for related and similar health or welfare effects is evaluated, synthesized, and integrated to develop conclusions and causal determinations. This process includes evaluating strengths and weaknesses in the overall collection of studies across disciplines. Confidence in the collective body of evidence is based on evaluation of study design and quality. The roles of different types of evidence in drawing the conclusions varies by pollutant or assessment, as does the availability of different types of evidence for causal determination. Conclusions on health effects are informed largely by controlled human exposure, epidemiologic, and toxicological studies. Evidence on ecological and other welfare effects may be drawn from a variety of experimental approaches (e.g., greenhouse, laboratory, field) and numerous disciplines (e.g., community ecology, biogeochemistry, paleontological/historical reconstructions). Other evidence, including mechanistic, toxicokinetics, and exposure assessment, may be highlighted if it is relevant to the evaluation of health and welfare effects and is of sufficient importance to affect the overall evaluation. Causal inference can be strengthened by integrating evidence across disciplines. A weak inference from one line of evidence can be addressed by other lines

of evidence, and coherence of these lines of evidence can add support to a cause-effect interpretation of the association. Interpretation of the body of epidemiologic associations as evidence of causal relationships involves assessing the full evidence base with regard to elimination of alternative explanations for the association.

Evaluation and integration of evidence must also include consideration of uncertainty, which is inherent in scientific findings. “Uncertainty” can be defined as a deficit of knowledge to describe the existing state or future outcome with accuracy and precision (e.g., the lack of knowledge about the correct value for a specific measure or estimate). Uncertainty analysis may be qualitative or quantitative in nature. In many cases, the analysis is qualitative and can include professional judgment or inferences based on analogy with similar situations. Quantitative uncertainty analysis may include use of simple measures (e.g., ranges) and analytical techniques. Quantitative uncertainty analysis might progress to more complex measures and techniques, if needed for decision support. Various approaches to evaluating uncertainty include classical statistical methods, sensitivity analysis, or probabilistic uncertainty analysis, in order of increasing complexity and data requirements. However, data may not be available for all aspects of an assessment, and those data that are available may be of questionable or unknown quality. Ultimately, the assessment is based on a number of assumptions with varying degrees of uncertainty. While the ISA may include quantitative analysis approaches such as meta-regression in some situations, generally qualitative evaluation of uncertainties is used to assess the evidence across studies.

Publication bias is another source of uncertainty that can impact the magnitude of estimated health or welfare effects. It is well understood that studies reporting non-null findings are more likely to be published than reports of null findings. Publication bias can result in overestimation of effect estimate sizes ([Ioannidis, 2008](#)). For example, effect estimates from single-city epidemiologic studies have been found to be generally larger than those from multicity studies. This is an indication of publication bias because null or negative single-city results may be reported in multicity analyses but might not be published independently ([Bell et al., 2005](#)).

### **Health-specific Considerations**

Potential strengths and limitations of the body of studies can vary across disciplines and are evaluated during data synthesis and integration. Direct evidence of a relationship between pollutant exposures and health effects may come from controlled human exposure studies. These studies can also provide important information on the biological plausibility of associations observed in epidemiologic studies and inform determinations of factors that may increase or decrease the risk of health effects in certain populations. In

some instances, controlled human exposure studies can be used to characterize concentration-response relationships at pollutant concentrations relevant to ambient conditions. Controlled human exposures are typically conducted using a randomized crossover design, with subjects exposed both to the pollutant and a clean air control. In this way, subjects serve as their own experimental controls, effectively limiting the variance associated with potential interindividual confounders. Limitations that must be considered in evaluating controlled human study findings include the generally small sample size and short exposure time used, and that severe health outcomes are not assessed. By experimental design, controlled human exposure studies are structured to evaluate physiological or biomolecular outcomes in response to exposure to a specific air pollutant and/or combination of pollutants. In addition, the study design generally precludes inclusion of subjects with serious health conditions or heightened risks of exposure, and therefore, the results often cannot be generalized to an entire population, which includes populations or lifestages at potentially increased risk of air pollutant-induced effects. Although some controlled human exposure studies have included health-compromised individuals, such as those with mild or moderate respiratory or cardiovascular disease, these individuals may also be relatively healthy and may not represent the most sensitive individuals in the population. Thus, observed effects in these studies may underestimate the response in certain populations. In addition, the study design is limited to exposures and endpoints that are not expected to result in severe health outcomes.

Epidemiologic studies provide important information on the associations between health effects and exposure of human populations to ambient air pollution. In epidemiologic or observational studies of humans, the investigator tends not to control exposures or intervene with the study population. Broadly, observational studies can describe associations between exposures and effects. These studies fall into several categories and include, for example, cross-sectional, prospective cohort, time-series, and panel studies. Each type of study has various strengths and limitations. Cross-sectional ecologic studies use health outcome, exposure, and covariate data available at the community level (e.g., annual mortality rates and pollutant concentrations), but do not have individual-level data. Cross-sectional studies may have limited power to evaluate an extensive set of confounding factors because these studies examine between-subject or between-location comparisons. Prospective cohort studies include some data collected at the individual level, typically health outcome data, and in some cases, individual-level data on exposure and covariates are collected. Time-series and case-crossover studies are often used to evaluate the relationship between day-to-day changes in air pollution exposures and a specific health outcome at the population-level (i.e., mortality, hospital admissions, or emergency department visits). Panel studies may include repeated measurements of health outcomes (e.g., respiratory symptoms, heart rate variability) at

the individual level and include exposure data at the individual- or group-level. “Natural experiments” offer the opportunity to investigate changes in health related to a change in exposure, such as closure of a pollution source.

When evaluating the collective body of epidemiologic studies, many study design factors and limitations must be considered to properly inform their interpretation. One key consideration is the evaluation of the potential independent contribution of the criteria pollutant to a health outcome when the criteria pollutant is a component of a complex air pollutant mixture. Reported effect estimates in epidemiologic studies may reflect (1) independent effects on health outcomes, (2) effects of the pollutant acting as an indicator of a copollutant or a complex ambient air pollution mixture, and (3) effects resulting from interactions between that pollutant and copollutants.

The third main type of health effects evidence, animal toxicological studies, provides information on the biological action of a pollutant under controlled and monitored exposure circumstances. Although biological differences among species must be taken into account, animal toxicological studies contribute to our understanding of potential health effects, exposure-response relationships, and modes of action. Further, animal models can inform determinations of factors that may increase or decrease the risk of health effects in certain populations. These studies evaluate the effects of exposures to a variety of pollutants in a highly controlled laboratory setting and allow exploration of toxicological pathways or mechanisms by which a pollutant may cause effects. Understanding the biological mechanisms underlying various health outcomes can be crucial in establishing or negating causality. In the absence of human studies data, extensive, well-conducted animal toxicological studies can support determinations of causality, if the evidence base indicates that similar responses are expected in humans under ambient exposure conditions.

Interpretations of animal toxicological studies are affected by limitations associated with extrapolation between animal and human responses. The differences between humans and other species have to be considered, including metabolism, hormonal regulation, breathing pattern, and differences in lung structure and anatomy. Also, in spite of a high degree of homology and the existence of a high percentage of orthologous genes across humans and rodents (particularly mice), extrapolation of molecular alterations at the gene or protein level is complicated by species-specific differences in transcriptional regulation and/or signaling. Given these differences, uncertainties are associated with quantitative extrapolations of observed pollutant-induced pathophysiological alterations between laboratory animals and humans, as those alterations are under the control of widely varying biochemical, endocrine, and neuronal factors.

## **Ecological- and Welfare-specific Considerations**

For ecological effects assessment, both laboratory and field studies (including field experiments and observational studies) can provide useful data for causal determination. Because conditions can be controlled in laboratory studies, responses may be less variable and smaller effects may be easier to detect. However, the control conditions may limit the range of responses (e.g., animals may not be able to seek alternative food sources) or incompletely reflect pollutant bioavailability, so the responses under controlled conditions may not reflect responses that would occur in the natural environment. In addition, larger scale processes are difficult to reproduce in the laboratory.

Field observational studies measure biological changes in uncontrolled situations with high natural variability (in organismal genetics or in abiotic seasonal, climatic, or soil-related factors) and describe an association between a disturbance and an ecological effect. Field data can provide important information to assess multiple stressors or circumstances where site-specific factors significantly influence exposure. Field data are also often useful for analyzing pollutant effects at larger geographic scales and higher levels of biological organization. However, because conditions are not controlled, variability of the response is expected to be higher and may mask effects. Field surveys are most useful for linking stressors with effects when stressor and effect levels are measured concurrently. The presence of confounding factors can make it difficult to attribute observed effects to specific stressors.

Ecological impacts of pollutants are also evaluated in studies “intermediate” between the lower variability typically associated with laboratory exposures and high natural variability usually found in field studies. Some studies use environmental media collected from the field to examine the biological responses under controlled laboratory conditions. Other studies are experiments performed in the natural environment that control for some, but not all, of the environmental or genetic variability (e.g., mesocosm studies). This type of study in manipulated natural environments can be considered a hybrid between a field experiment and laboratory study because some sources of response variation are removed through use of control conditions, while others are included to mimic natural variation. Such studies make it possible to observe community and/or ecosystem dynamics and provide strong evidence for causality when combined with findings of studies that have been made under more controlled conditions.

## **b. Considerations in Developing Scientific Conclusions and Causal Determinations**

In its evaluation and integration of the scientific evidence on health or welfare effects of criteria pollutants, the U.S. EPA determines the weight of evidence in support of causation and characterizes the strength of any resulting causal classification. The U.S. EPA also evaluates the quantitative evidence and draws scientific conclusions, to the extent possible, regarding the concentration-response relationships and the loads to ecosystems, exposures, doses or concentrations, exposure duration, and pattern of exposures at which effects are observed.

Approaches to assessing the separate and combined lines of human health evidence (e.g., epidemiologic, controlled human exposure, animal toxicological studies) have been formulated by a number of regulatory and science agencies, including the National Academy of Sciences (NAS) Institute of Medicine ([IOM, 2008](#)), the International Agency for Research on Cancer ([IARC, 2006](#)), the [U.S. EPA \(2005\)](#), and the Centers for Disease Control and Prevention; ([CDC, 2004](#)). Causal inference criteria have also been described for ecological effects evidence ([U.S. EPA, 1998a](#); [Fox, 1991](#)). These formalized approaches offer guidance for assessing causality. The frameworks of each are similar in nature, although adapted to different purposes, and have proven effective in providing a uniform structure and language for causal determinations.

The 1964 Surgeon General's report on tobacco smoking defined "cause" as a "significant, effectual relationship between an agent and an associated disorder or disease in the host" ([HEW, 1964](#)). More generally, a cause is defined as an agent that brings about an effect or a result. An association is the statistical relationship among variables, but alone, it is insufficient proof of a causal relationship between an exposure and a health outcome. Unlike an association, a causal claim supports the creation of counterfactual claims; that is, a claim about what the world would have been like under different or changed circumstances ([IOM, 2008](#)).

Many of the health and environmental outcomes reported in studies have complex etiologies. Diseases such as asthma, coronary heart disease, or cancer are typically initiated by multiple agents. Outcomes depend on a variety of factors, such as age, genetic background, nutritional status, immune competence, and social factors ([IOM, 2008](#); [Gee and Payne-Sturges, 2004](#)). Effects on ecosystems are also often multifactorial with a complex web of causation. Further, exposure to a combination of agents could cause synergistic or antagonistic effects. Thus, the observed risk may represent the net effect of many actions and counteractions.

To aid judgment, various “aspects”<sup>1</sup> of causality have been discussed by many philosophers and scientists. The 1964 Surgeon General’s report on tobacco smoking discussed criteria for the evaluation of epidemiologic studies, focusing on consistency, strength, specificity, temporal relationship, and coherence ([HEW, 1964](#)). Sir Austin Bradford Hill ([Hill, 1965](#)) articulated aspects of causality in epidemiology and public health that have been widely used ([IOM, 2008](#); [IARC, 2006](#); [U.S. EPA, 2005](#); [CDC, 2004](#)). These aspects ([Hill, 1965](#)) have been modified ([Table I](#)) for use in causal determinations specific to health and welfare effects for pollutant exposures ([U.S. EPA, 2009a](#)).<sup>2</sup> Although these aspects provide a framework for assessing the evidence, they do not lend themselves to being considered in terms of simple formulas or fixed rules of evidence leading to conclusions about causality ([Hill, 1965](#)). For example, one cannot simply count the number of studies reporting statistically significant results or statistically nonsignificant results and reach credible conclusions about the relative weight of evidence and the likelihood of causality. Rather, these aspects provide a framework for systematic appraisal of the body of evidence, informed by peer and public comment and advice, which includes weighing alternative views on controversial issues. In addition, it is important to note that the aspects in [Table I](#) cannot be used as a strict checklist, but rather to determine the weight of evidence for inferring causality. In particular, not meeting one or more of the principles does not automatically preclude a determination of causality [see discussion in ([CDC, 2004](#))].

---

<sup>1</sup> The “aspects” described by Sir Austin Bradford Hill ([Hill, 1965](#)) have become, in the subsequent literature, more commonly described as “criteria.” The original term “aspects” is used here to avoid confusion with “criteria” as it is used, with different meaning, in the Clean Air Act.

<sup>2</sup> The Hill aspects were developed for interpretation of epidemiologic results. They have been modified here for use with a broader array of data (i.e., epidemiologic, controlled human exposure, ecological, animal toxicological studies, in vitro data) and to be more consistent with the EPA Guidelines for Carcinogen Risk Assessment.

---

**Table I Aspects to aid in judging causality.**

---

<b>Aspect</b>	<b>Description</b>
Consistency	An inference of causality is strengthened when a pattern of elevated risks is observed across several independent studies. The reproducibility of findings constitutes one of the strongest arguments for causality. Statistical significance is not the sole criterion by which the presence or absence of an effect is determined. If there are discordant results among investigations, possible reasons such as differences in exposure, confounding factors, and the power of the study are considered.
Coherence	An inference of causality from one line of evidence (e.g., epidemiologic, controlled human exposure, animal, welfare studies) may be strengthened by other lines of evidence that support a cause-and-effect interpretation of the association. There may be coherence in demonstrating effects from evidence across various fields and/or across multiple study designs or related health endpoints within one scientific line of evidence. For example, evidence on welfare effects may be drawn from a variety of experimental approaches (e.g., greenhouse, laboratory, field) and subdisciplines of ecology (e.g., community ecology, biogeochemistry, paleontological/historical reconstructions).
Biological plausibility	An inference of causality is strengthened by results from experimental studies or other sources demonstrating biologically plausible mechanisms. A proposed mechanism, which is based on experimental evidence and which links exposure to an agent to a given effect, is an important source of support for causality.
Biological gradient (exposure-response relationship)	A well-characterized exposure-response relationship (e.g., increasing effects associated with greater exposure) strongly suggests cause and effect, especially when such relationships are also observed for duration of exposure (e.g., increasing effects observed following longer exposure times).
Strength of the observed association	The finding of large, precise risks increases confidence that the association is not likely due to chance, bias, or other factors. However, it is noted that a small magnitude in an effect estimate may or may not represent a substantial effect in a population.
Experimental evidence	Strong evidence for causality can be provided through “natural experiments” when a change in exposure is found to result in a change in occurrence or frequency of health or welfare effects.
Temporality of the observed association	Evidence of a temporal sequence between the introduction of an agent and appearance of the effect constitutes another argument in favor of causality.
Specificity of the observed association	Evidence linking a specific outcome to an exposure can provide a strong argument for causation. However, it must be recognized that rarely, if ever, does exposure to a pollutant invariably predict the occurrence of an outcome, and that a given outcome may have multiple causes.
Analogy	Structure activity relationships and information on the agent's structural analogs can provide insight into whether an association is causal. Similarly, information on mode of action for a chemical, as one of many structural analogs, can inform decisions regarding likely causality.

---

Consistency of findings across studies is informed by the repeated observation of effects or associations across multiple independent studies. Further strength is provided by reproducibility of findings in different populations under different circumstances. However, discordant results among independent investigations may be explained by differences in study methods, random errors, exposure, confounding factors, or study power, and thus may not be used to rule out a causal connection.

In evaluating the consistency of findings across studies, the U.S. EPA emphasizes examination of the pattern of results across various studies and does not focus solely on statistical significance or the magnitude of the direction of the association as criteria of study reliability. Statistical significance is influenced by a variety of factors including, but not limited to, the size of the study, exposure and outcome measurement error, and statistical model specifications. Statistical significance may be informative; however, it is just one of the means of evaluating confidence in the observed relationship and assessing the probability of chance as an explanation. Other indicators of reliability such as the consistency and coherence of a body of studies as well as other confirming data may be used to justify reliance on the results of a body of epidemiologic studies, even if results in individual studies lack statistical significance. Traditionally, statistical significance is used to a larger extent to evaluate the findings of controlled human exposure and animal toxicology studies. Understanding that statistical inferences may result in both false positives and false negatives, the U.S. EPA considers both trends in data and reproducibility of results. Thus, in drawing judgments regarding causality, the U.S. EPA emphasizes statistically significant findings from experimental studies but does not limit its focus or consideration to statistically significant results in epidemiologic studies.

In evaluating the strength of the observed association, the U.S. EPA considers both the magnitude and statistical precision (i.e., width of confidence interval) of the association in epidemiologic studies. In a large study that accounts for several potential confounding factors, a strong association can serve to increase confidence that a finding is not due to a weak unmeasured confounder, chance, or other biases. However, in a study that accounts for several potential confounding factors and other sources of bias, a weak association does not rule out a causal connection. The health effects evaluated in the ISAs tend to have multiple risk factors that likely vary in strength of effect, and the magnitude of effect of air pollution exposure will depend on the prevalence of other risk factors in the study population. Further, a small effect size can be important from a public health impact perspective. The air pollution-related change in a health effect observed in a study can represent a shift in the distribution of responses in the study population and potentially an increase in the proportion of individuals with clinically important effects.

In making judgments regarding causality, the U.S. EPA considers biological plausibility of effects resulting from air pollutant exposure. Experimental results from in vivo studies involving animal models and humans, as well as from in vitro studies when appropriate, may be used to establish biological plausibility and to interpret other lines of evidence (e.g., health effects from epidemiologic studies). Biological plausibility is often provided from understanding the mode of action by which exposure to a pollutant leads to health effects. This understanding may encompass several different levels of biological organization including, but not limited to, molecular and cellular events in the pathways leading to disease. While a complete understanding of the mode of action is not considered necessary for making causal determinations within the ISA, biological plausibility plays a key role.

### **c. Framework for Causal Determinations**

In the ISA, the U.S. EPA assesses the body of relevant literature, building upon evidence available during previous NAAQS reviews, to draw conclusions on the causal relationships between relevant pollutant exposures and health or environmental effects. ISAs use a five-level hierarchy that classifies the weight of evidence for causation.<sup>1</sup> This weight-of-evidence evaluation is based on the integration of findings from various lines of evidence across health and environmental effect disciplines that are integrated into a qualitative statement about the overall weight of the evidence and causality. The five descriptors for causal determination are described in [Table II](#).

---

<sup>1</sup> The CDC and IOM frameworks use a four-category hierarchy for the strength of the evidence. A five-level hierarchy is used here to be consistent with the five-level hierarchy used in the U.S. EPA *Guidelines for Carcinogen Risk Assessment* and to provide a more nuanced set of categories.

**Table II Weight of evidence for causal determination.**

	<b>Health Effects</b>	<b>Ecological and Welfare Effects</b>
<b>Causal relationship</b>	Evidence is sufficient to conclude that there is a causal relationship with relevant pollutant exposures (e.g., doses or exposures generally within one to two orders of magnitude of recent concentrations). That is, the pollutant has been shown to result in health effects in studies in which chance, confounding, and other biases could be ruled out with reasonable confidence. For example: (1) controlled human exposure studies that demonstrate consistent effects, or (2) observational studies that cannot be explained by plausible alternatives or that are supported by other lines of evidence (e.g., animal studies or mode of action information). Generally, the determination is based on multiple high-quality studies conducted by multiple research groups.	Evidence is sufficient to conclude that there is a causal relationship with relevant pollutant exposures. That is, the pollutant has been shown to result in effects in studies in which chance, confounding, and other biases could be ruled out with reasonable confidence. Controlled exposure studies (laboratory or small- to medium-scale field studies) provide the strongest evidence for causality, but the scope of inference may be limited. Generally, the determination is based on multiple studies conducted by multiple research groups, and evidence that is considered sufficient to infer a causal relationship is usually obtained from the joint consideration of many lines of evidence that reinforce each other.
<b>Likely to be a causal relationship</b>	Evidence is sufficient to conclude that a causal relationship is likely to exist with relevant pollutant exposures. That is, the pollutant has been shown to result in health effects in studies where results are not explained by chance, confounding, and other biases, but uncertainties remain in the evidence overall. For example: (1) observational studies show an association, but copollutant exposures are difficult to address and/or other lines of evidence (controlled human exposure, animal, or mode of action information) are limited or inconsistent, or (2) animal toxicological evidence from multiple studies from different laboratories demonstrate effects, but limited or no human data are available. Generally, the determination is based on multiple high-quality studies.	Evidence is sufficient to conclude that there is a likely causal association with relevant pollutant exposures. That is, an association has been observed between the pollutant and the outcome in studies in which chance, confounding, and other biases are minimized but uncertainties remain. For example, field studies show a relationship, but suspected interacting factors cannot be controlled, and other lines of evidence are limited or inconsistent. Generally, the determination is based on multiple studies by multiple research groups.
<b>Suggestive of, but not sufficient to infer, a causal relationship</b>	Evidence is suggestive of a causal relationship with relevant pollutant exposures but is limited, and chance, confounding, and other biases cannot be ruled out. For example: (1) when the body of evidence is relatively small, at least one high-quality epidemiologic study shows an association with a given health outcome and/or at least one high-quality toxicological study shows effects relevant to humans in animal species, or (2) when the body of evidence is relatively large, evidence from studies of varying quality is generally supportive but not entirely consistent, and there may be coherence across lines of evidence (e.g., animal studies or mode of action information) to support the determination.	Evidence is suggestive of a causal relationship with relevant pollutant exposures, but chance, confounding, and other biases cannot be ruled out. For example, at least one high-quality study shows an effect, but the results of other studies are inconsistent.
<b>Inadequate to infer a causal relationship</b>	Evidence is inadequate to determine that a causal relationship exists with relevant pollutant exposures. The available studies are of insufficient quantity, quality, consistency, or statistical power to permit a conclusion regarding the presence or absence of an effect.	Evidence is inadequate to determine that a causal relationship exists with relevant pollutant exposures. The available studies are of insufficient quality, consistency, or statistical power to permit a conclusion regarding the presence or absence of an effect.
<b>Not likely to be a causal relationship</b>	Evidence indicates there is no causal relationship with relevant pollutant exposures. Several adequate studies, covering the full range of levels of exposure that human beings are known to encounter and considering at-risk populations and lifestages, are mutually consistent in not showing an effect at any level of exposure.	Evidence indicates there is no causal relationship with relevant pollutant exposures. Several adequate studies examining relationships with relevant exposures are consistent in not showing an effect at any level of exposure.

This standardized language was drawn from sources across the federal government and wider scientific community, especially the U.S. EPA *Guidelines for Carcinogen Risk Assessment* ([U.S. EPA, 2005](#)), U.S. Surgeon General's report, *The Health Consequences of Smoking* ([CDC, 2004](#)), and NAS IOM document, *Improving the Presumptive Disability Decision-Making Process for Veterans* ([IOM, 2008](#)), a comprehensive report on evaluating causality.

This framework:

- describes the kinds of scientific evidence used in making determinations on causal relationships between exposure and health or welfare effects,
- summarizes the key aspects of the evaluation of evidence necessary to reach a conclusion about the existence of a causal relationship,
- identifies issues and approaches related to uncertainty, and
- classifies and characterizes the weight of evidence in support of a general causal determination.

Determination of causality involves evaluating and integrating evidence for different types of health, ecological, or welfare effects associated with short- and long-term exposure periods. In drawing conclusions regarding causality, evidence is evaluated for major outcome categories or groups of related endpoints (e.g., respiratory effects, vegetation growth), integrating evidence from across disciplines, and evaluating the coherence of evidence across a spectrum of related endpoints. In discussing the causal determination, the U.S. EPA characterizes the evidence on which the judgment is based, including strength of evidence for individual endpoints within the outcome category or group of related endpoints.

In drawing judgments regarding causality for the criteria air pollutants, the ISA focuses on evidence of effects in the range of relevant pollutant exposures or doses and not on determination of causality at any particular dose. Emphasis is placed on evidence of effects at doses (e.g., blood Pb concentration) or exposures (e.g., air concentrations) that are relevant to, or somewhat above, those currently experienced by the population or that exist in the environment. The extent to which studies of higher concentrations are considered varies by pollutant and major outcome category, but generally includes those with doses or exposures in the range of one to two orders of magnitude above current or ambient conditions to account for intraspecies variability and toxicokinetic or toxicodynamics differences between experimental animals and humans. Studies that use higher doses or exposures may also be considered to the extent that they provide useful information to inform understanding of mode of action, interspecies differences, or factors that may increase risk of effects for a population and if biological mechanisms have not been demonstrated to differ based on exposure concentration. Thus, a causal

determination is based on weight-of-evidence evaluation for health or welfare effects, focusing on the evidence from exposures or doses generally ranging from recent ambient concentrations to one or two orders of magnitude above recent ambient concentrations.

In addition, the U.S. EPA evaluates evidence relevant to understanding the quantitative relationships between pollutant exposures and health or welfare effects. This includes evaluating the form of concentration-response or dose-response relationships and, to the extent possible, drawing conclusions on the concentrations at which effects are observed. The ISA also draws scientific conclusions regarding important exposure conditions for effects and populations and lifestages that may be at greater risk for effects, as described in the following two sections on public health and public welfare impacts.

## **6. Public Health Impact**

Once a determination is made regarding the causality of relationship between the pollutant and outcome category, the public health impact of exposure to the pollutant is evaluated. Important questions regarding the public health impact include:

- What populations and lifestages appear to be differentially affected (i.e., at greater or less risk of experiencing effects)?
- What exposure conditions (dose or exposure, duration, and pattern) are important?
- What is the severity of the effect (e.g., clinical relevance)?
- What is the concentration-response, exposure-response, or dose-response relationship in the human population?
- What is the interrelationship between incidence and severity of effect?

To address these questions, the entirety of quantitative evidence is evaluated to characterize pollutant concentrations and exposure durations at which effects were observed for exposed populations, including populations and lifestages potentially at increased risk. To accomplish this, evidence is considered from multiple and diverse types of studies, and a study or set of studies that best approximates the concentration-response relationships between health outcomes and the pollutant may be identified. Controlled human exposure studies provide the most direct and quantifiable exposure-response data on the human health effects of pollutant exposures, although they tend to examine potential at-risk populations and lifestages to a limited extent and tend to have small sample sizes for between-group comparisons. To the extent available, the ISA evaluates results from epidemiologic studies that characterize the shape of the relationship between a pollutant and a health outcome. Animal data may also inform evaluation of concentration-response relationships, particularly relative to modes of action and characteristics of at-risk populations.

## **a. Approach to Identifying, Evaluating, and Characterizing At-Risk Factors**

A critical part of assessing the public health impact of an air pollutant is the identification, evaluation, and characterization of populations potentially at greater risk of an air pollutant-related health effect. Under the CAA, the primary NAAQS are intended to protect public health with an adequate margin of safety. In doing so, protection is provided for both the population as a whole and those groups potentially at increased risk for health effects from exposure to a criteria air pollutant. To inform decisions on the NAAQS, the ISA evaluates the currently available information regarding those factors (e.g., lifestage, pre-existing disease) that could contribute to portions of the population being at greater risk for an air pollutant-related health effect.

Studies often use a variety of terms to classify factors and subsequently populations that may be at increased risk of an air pollutant-related health effect, including “susceptible,” “vulnerable,” “sensitive,” and “at-risk,” with recent literature introducing the term “response-modifying factor” ([Vinikoor-Imler et al., 2014](#); [Sacks et al., 2011](#); [U.S. EPA, 2010b, 2009a](#)). The inconsistency in the definitions for each of these terms across the scientific literature has shifted the focus away from answering the key questions: Which populations are at increased risk and what evidence forms the basis of this conclusion ([Vinikoor-Imler et al., 2014](#))? Due to the lack of a consensus on terminology in the scientific community, the term “susceptible populations” was used in reviews and previous ISAs ([Sacks et al., 2011](#); [U.S. EPA, 2010b, 2009a](#)) to encompass these various factors. However, it was recognized that even using the term “susceptible populations” was problematic because it often refers to populations at increased risk specifically due to biological or intrinsic factors such as pre-existing disease or lifestage. As such, starting with the ISA for Ozone and Related Photochemical Oxidants ([U.S. EPA, 2013d](#)), the terminology “at-risk” was introduced to define populations and lifestages potentially at increased risk of an air pollutant-related health effect. In assessing the overall public health impact of an air pollutant, the ISA focuses on identifying, evaluating, and characterizing “at-risk” factors to address the main question of what populations and lifestages are at increased risk of an air pollutant-related health effect. Each “at-risk” factor is evaluated with a focus on identifying whether the factor contributes to a population at increased risk of an air pollutant-related health effect. Some factors may lead to a reduction in risk, and these are acknowledged during the evaluation process. However, for the purposes of identifying those populations or lifestages at increased risk to inform decisions on the NAAQS, the ISA focuses on characterizing those factors that may increase risk.

A population or lifestage may be at increased risk for various reasons, which generally are grouped into four broad categories. The first category of factors often is referred to as intrinsic. Intrinsic factors can increase risk for an effect through a biological mechanism and include genetic or developmental factors, race, sex, lifestage, or the presence of pre-existing diseases. For example, people in this category would have a steeper concentration-risk relationship and a greater or more severe effect at a given pollutant concentration compared to those not in the category. The second category often is referred to as extrinsic or nonbiological. These factors include SES (e.g., educational attainment, income, access to healthcare), activity pattern, and exercise level. The third category includes factors that can increase risk by increasing internal dose at a given exposure concentration. Individuals in this category could have a greater dose of delivered pollutant because of breathing patterns and could include children who are typically more active outdoors. In addition, some groups could have greater exposure (concentration  $\times$  time) regardless of the delivered dose, such as outdoor workers. The final category encompasses factors that may increase risk for experiencing a greater exposure based on exposure to a higher concentration. For example, populations that live near roadways could be exposed to higher pollutant concentrations. Some factors described above are multifaceted and may influence the risk of an air pollutant-related health effect through a combination of ways (e.g., SES). Additionally, it is recognized that some portions of the population or lifestages may be at increased risk of an air pollutant-related health effect because they experience insults from a combination of factors. The emphasis is to identify and understand the factors that potentially increase the risk of air pollutant-related health effects, regardless of whether the increased risk is due to intrinsic factors, extrinsic factors, increased dose/exposure, or a combination due to the often interconnectedness of factors.

To identify at-risk factors that potentially lead to some portions of the population being at increased risk of air pollution-related health effects, the evidence is systematically evaluated across relevant scientific disciplines (i.e., exposure sciences, dosimetry, toxicology, epidemiology). The evaluation process consists of evaluating studies that conduct stratified analyses (i.e., epidemiologic, controlled human exposure) to compare populations or lifestages exposed to similar air pollutant concentrations within the same study design. Experimental studies also provide an important line of evidence in evaluating factors that can lead to increased risk of an air pollutant-related health effect. Specifically, toxicological studies conducted using animal models of disease and controlled human exposure studies that examine individuals with underlying disease or genetic polymorphisms can provide coherence with the health effects observed in epidemiologic studies as well as an understanding of biological plausibility. The potential increased risk of an air pollutant-related health effect may also be determined from studies that examine factors that result in differential air pollutant exposures. The

characterization of each at-risk factor consists of evaluating the evidence across scientific disciplines and assessing the overall confidence that a specific factor may result in a population or lifestage being at increased risk of an air pollutant-related health effect. The categories considered for describing the potential increased risk of an air pollutant-related health effect are “adequate evidence,” “suggestive evidence,” “inadequate evidence,” and “evidence of no effect.” They are described in more detail in [Table III](#).

**Table III Characterization of evidence for potential at-risk factors.**

<b>Classification</b>	<b>Health Effects</b>
Adequate evidence	There is substantial, consistent evidence within a discipline to conclude that a factor results in a population or lifestage being at increased risk of air pollutant-related health effect(s) relative to some reference population or lifestage. Where applicable, this evidence includes coherence across disciplines. Evidence includes multiple high-quality studies.
Suggestive evidence	The collective evidence suggests that a factor results in a population or lifestage being at increased risk of air pollutant-related health effect(s) relative to some reference population or lifestage, but the evidence is limited due to some inconsistency within a discipline or, where applicable, a lack of coherence across disciplines.
Inadequate evidence	The collective evidence is inadequate to determine whether a factor results in a population or lifestage being at increased risk of air pollutant-related health effect(s) relative to some reference population or lifestage. The available studies are of insufficient quantity, quality, consistency, and/or statistical power to permit a conclusion to be drawn.
Evidence of no effect	There is substantial, consistent evidence within a discipline to conclude that a factor does not result in a population or lifestage being at increased risk of air pollutant-related health effect(s) relative to some reference population or lifestage. Where applicable, the evidence includes coherence across disciplines. Evidence includes multiple high-quality studies.

## **b. Evaluating Adversity of Human Health Effects**

In evaluating health evidence, a number of factors can be considered in delineating between adverse and nonadverse health effects resulting from exposure to air pollution. Some health outcomes, such as hospitalization for respiratory or cardiovascular diseases, are clearly adverse. It is more difficult to determine the extent of change that constitutes adversity in more subtle health measures. These more subtle health effects include a wide variety of responses, such as alterations in markers of inflammation or oxidative stress, changes in pulmonary function or heart rate variability, or alterations in neurocognitive function measures. The challenge is to determine the magnitude of change in these measures when there is no clear point at which a change becomes adverse. The extent to which a change in health measure constitutes an adverse health effect may vary between

populations and lifestages. Some changes that may not be considered adverse in healthy individuals would be potentially adverse in more at-risk individuals.

Professional scientific societies may evaluate the magnitude of change in an outcome or event that is considered adverse. For example, in an official statement titled *What Constitutes an Adverse Health Effect of Air Pollution?* ([ATS, 2000b](#)), the American Thoracic Society described transient decrements in lung function as adverse when accompanied by clinical symptoms. Additionally, an air pollution-induced shift in the population distribution of a given risk factor for a health outcome was viewed as adverse, even though it may not increase the risk of any one individual to an unacceptable level. For example, a population with asthma could have a distribution of lung function such that no identifiable individual has a level associated with significant impairment. Exposure to air pollution could shift the distribution such that no identifiable individual experiences clinically relevant effects. This shift toward decreased lung function, however, could be considered adverse because individuals within the population would have diminished reserve function and therefore would be at increased risk to further environmental insult. The committee also observed that elevations of biomarkers, such as cell number and types, cytokines, and reactive oxygen species, may signal risk for ongoing injury and clinical effects or may simply indicate transient responses that can provide insights into mechanisms of injury, thus illustrating the lack of clear boundaries that separate adverse from nonadverse effects.

The more subtle health outcomes may be connected mechanistically to health events that are clearly adverse. For example, air pollution may affect markers of transient myocardial ischemia such as ST-segment (segment of the electrocardiograph between the end of the S wave and beginning of the T wave) abnormalities or onset of exertional angina. These effects may not be apparent to the individual, yet may still increase the risk of a number of cardiac events, including myocardial infarction and sudden death. Thus, small changes in physiological measures may not appear to be clearly adverse when considered alone, but may be a part of a coherent and biologically plausible chain of related health outcomes that range up to responses that are very clearly adverse, such as hospitalization or mortality.

### **c. Concentration-Response Relationships**

An important consideration in characterizing the public health impacts associated with exposure to a pollutant is whether the concentration-response relationship is linear across the range of concentrations or if nonlinear relationships exist along any part of this range. The shape of the concentration-response curve at and below the level of the current

NAAQS is of particular interest. Various sources of variability and uncertainty, such as low data density in the lower concentration range, possible influence of exposure measurement error, and variability among individuals with respect to air pollution health effects, tend to smooth and “linearize” the concentration-response function and thus can obscure the existence of a threshold or nonlinear relationship. Because individual thresholds vary from person-to-person due to individual differences such as genetic differences or pre-existing disease conditions (and even can vary from one time to another for a given person), it can be difficult to demonstrate that a threshold exists in a population study. These sources of variability and uncertainty may explain why the available human data at ambient concentrations for some environmental pollutants (e.g., PM, O<sub>3</sub>, Pb, environmental tobacco smoke, radiation) do not exhibit population-level thresholds for cancer or noncancer health effects, even though likely mechanisms include nonlinear processes for some key events.

## **7. Public Welfare Impact**

Once a determination is made regarding the causality of relationships between the pollutant and outcome category, important questions regarding the public welfare impact include:

- What endpoints or services appear to be differentially affected (i.e., at greater or less risk of experiencing effects)? What elements of the ecosystem (e.g., types, regions, taxonomic groups, populations, functions) appear to be affected, or are more sensitive to effects? Are there differences between locations or materials in welfare effects responses, such as impaired visibility or materials damage?
- What is concluded from the evidence with regard to other types of welfare effects?
- Under what exposure conditions (amount deposited or concentration, duration, and pattern) are effects seen?
- What is the shape of the concentration-response, exposure-response, or dose-response relationship?

To address these questions, the entirety of quantitative evidence is evaluated to characterize pollutant concentrations and exposure durations at which effects were observed. To accomplish this, evidence is considered from multiple and diverse types of studies, and a study or set of studies that best approximates the concentration-response relationships between welfare outcomes and the pollutant may be identified. Controlled experimental studies provide the most direct and quantifiable exposure-response data on the effects of pollutant exposures. To the extent available, the ISA also evaluates results from less controlled field studies that characterize the shape of the relationship between a pollutant and an outcome. Other types of data may also inform evaluation of

concentration-response relationships, particularly relative to modes of action and characteristics of at-risk ecosystems.

### **a. Evaluating Adversity of Ecological and Other Welfare Effects**

The final step in assessing the public welfare impact of an air pollutant is the evaluation of the level considered to be adverse. A secondary standard, as defined in Section 109(b)(2) of the CAA must “specify a level of air quality the attainment and maintenance of which, in the judgment of the Administrator, based on such criteria, is requisite to protect the public welfare from any known or anticipated adverse effects associated with the presence of such air pollutant in the ambient air.” In setting standards that are “requisite” to protect public health and welfare, as provided in Section 109(b), the U.S. EPA’s task is to establish standards that are neither more nor less stringent than necessary for these purposes.

Adversity of ecological effects can be understood in terms ranging in biological level of organization from the cellular level to the individual organism and to the population, community, and ecosystem levels. In the context of ecology, a population is a group of individuals of the same species, and a community is an assemblage of populations of different species that inhabit an area and interact with one another. An ecosystem is the interactive system formed from all living organisms and their abiotic (physical and chemical) environment within a given area ([IPCC, 2007](#)). The boundaries of what could be called an ecosystem are somewhat arbitrary, depending on the focus of interest or study. Thus, the extent of an ecosystem may range from very small spatial scales to, ultimately, the entire Earth ([IPCC, 2007](#)).

Effects on an individual organism are generally not considered to be adverse to public welfare. However if effects occur to enough individuals within a population, then communities and ecosystems may be disrupted. Changes to populations, communities, and ecosystems can in turn result in an alteration of ecosystem processes. Ecosystem processes are defined as the metabolic functions of ecosystems, including energy flow, elemental cycling, and the production, consumption, and decomposition of organic matter ([U.S. EPA, 2002](#)). Growth, reproduction, and mortality are species-level endpoints that may be clearly linked to community and ecosystem effects and are considered to be adverse when negatively affected. Other endpoints, such as changes in behavior and physiological stress, can decrease ecological fitness of an organism but are harder to link unequivocally to effects at the population, community, and ecosystem level. Support for consideration of adversity beyond the species level by making explicit the linkages

between stress-related effects at the species and effects at the ecosystem level is found in *A Framework for Assessing and Reporting on Ecological Condition: an SAB report* ([U.S. EPA, 2002](#)). Additionally, the National Acid Precipitation Assessment Program ([NAPAP, 1991](#)) uses the following working definition of “adverse ecological effects” in the preparation of reports to Congress mandated by the CAA: “any injury (i.e., loss of chemical or physical quality or viability) to any ecological or ecosystem component, up to and including the regional level, over both long and short terms.”

Beyond species-level impacts, consideration of ecosystem services allows for evaluation of how pollutant exposure may adversely impact species or processes of particular economic or cultural importance to humans. On a broader scale, ecosystem services may provide indicators for ecological impacts. Ecosystem services are the benefits that people obtain from ecosystems ([UNEP, 2003](#)). According to the *Millennium Ecosystem Assessment*, ecosystem services include “provisioning services such as food and water; regulating services such as regulation of floods, drought, land degradation, and disease; supporting services such as soil formation and nutrient cycling; and cultural services such as recreational, spiritual, religious, and other nonmaterial benefits” ([UNEP, 2003](#)). For example, a more subtle ecological effect of pollution exposure may result in a clearly adverse impact on ecosystem services if it results in a population decline in a species that is recreationally or culturally important.

A consideration in evaluating adversity of climate-related effects is that criteria air pollutants have both direct and indirect effects on radiative forcing. For example, CO has a relatively small direct forcing effect, but it influences the concentrations of other atmospheric species, such as O<sub>3</sub> and methane (CH<sub>4</sub>), which are important contributors to climate forcing. PM has both direct and indirect effects. For example, black carbon and sulfate contribute directly to warming and cooling, respectively, while aerosols are involved in cloud formation, which affect climate indirectly. Thus, it is crucial to consider the role of multiple pollutants together in evaluating the climate impact of criteria pollutants. Although climate effects of criteria air pollutants impact terrestrial and aquatic environments in diverse ways over multiple time scales, their effect on temperature is the main metric of adversity, with some consideration of proximate effects such as precipitation and relatively rapid feedbacks impacting the composition of the troposphere. Downstream effects such as land use changes are more difficult to link back to changes in concentrations of individual pollutants regulated under the NAAQS. The relative adversity of U.S. versus global emissions and concentrations is informed by regional climate modeling studies, including consideration of uncertainty and spatial and temporal variability.

The adversity of visibility impacts may be expressed in terms of psychological stress, such as impairment of aesthetic quality or enjoyment of the environment, or in monetary terms, such as willingness to pay to improve air quality. Understanding the relationship between pollutant concentration and perception of visibility, including distinguishing between concerns about health risks due to air pollution and perceived visibility impairment, can be crucial in evaluating the level of protection provided by a welfare-based secondary NAAQS when impacts on visibility are among the welfare effects that are potentially relevant for a pollutant.

Adversity of materials damage is evaluated considering the impact to human and economic well-being. Physical damage and soiling impair aesthetic qualities and function of materials. Additionally, damage to property and cultural heritage sites due to pollutant deposition may be considered adverse.

## **b. Quantitative Relationships: Effects on Welfare**

Evaluations of causality generally consider the probability of quantitative changes in welfare effects in response to exposure. A challenge to the quantification of exposure-response relationships for ecological effects is the great regional and local spatial variability, as well as temporal variability, in ecosystems. Thus, exposure-response relationships are often determined for a specific ecological system and scale, rather than at the national or even regional scale. Quantitative relationships, therefore, are estimated site by site and may differ greatly between ecosystems.

---

# PREFACE

## Legislative Requirements for the Review of the National Ambient Air Quality Standards

Two sections of the Clean Air Act (CAA) govern the establishment, review, and revision of the National Ambient Air Quality Standards (NAAQS). Section 108 [42 U.S. Code (U.S.C.) 7408] directs the Administrator of the United States Environmental Protection Agency (U.S. EPA) to identify and list certain air pollutants and then to issue air quality criteria for those pollutants. The Administrator is to list those air pollutants that in her “judgment, cause or contribute to air pollution which may reasonably be anticipated to endanger public health or welfare;” “the presence of which in the ambient air results from numerous or diverse mobile or stationary sources;” and “for which ... [the Administrator] plans to issue air quality criteria ...” [42 U.S.C. 7408(a)(1); [CAA, 1990a](#)]. Air quality criteria are intended to “accurately reflect the latest scientific knowledge useful in indicating the kind and extent of all identifiable effects on public health or welfare, which may be expected from the presence of [a] pollutant in the ambient air ...” [42 U.S.C. 7408(b)]. Section 109 [42 U.S.C. 7409; [CAA, 1990b](#)] directs the Administrator to propose and promulgate “primary” and “secondary” NAAQS for pollutants for which air quality criteria are issued. Section 109(b)(1) defines a primary standard as one “the attainment and maintenance of which in the judgment of the Administrator, based on such criteria and allowing an adequate margin of safety, are requisite to protect the public health.”<sup>1</sup> A secondary standard, as defined in Section 109(b)(2), must “specify a level of air quality the attainment and maintenance of which, in the judgment of the Administrator, based on such criteria, is requisite to protect the public welfare from any known or anticipated adverse effects associated with the presence of [the] air pollutant in the ambient air.”<sup>2</sup>

The requirement that primary standards provide an adequate margin of safety was intended to address uncertainties associated with inconclusive scientific and technical information available at the time of standard setting. It was also intended to provide a

---

<sup>1</sup> The legislative history of Section 109 indicates that a primary standard is to be set at “...the maximum permissible ambient air level... which will protect the health of any [sensitive] group of the population,” and that for this purpose “reference should be made to a representative sample of persons comprising the sensitive group rather than to a single person in such a group” S. Rep. No. 91:1196, 91st Cong., 2d Sess. 10 (1970).

<sup>2</sup> Under CAA Section 302(h) [42 U.S.C. 7602(h)], language referring to “effects on welfare” includes, but is not limited to, “effects on soils, water, crops, vegetation, man-made materials, animals, wildlife, weather, visibility and climate, damage to and deterioration of property, and hazards to transportation, as well as effects on economic values and on personal comfort and well-being” ([CAA, 2005](#)).

reasonable degree of protection against hazards that research has not yet identified.<sup>1</sup> Both kinds of uncertainty are components of the risk associated with pollution at levels below those at which human health effects can be said to occur with reasonable scientific certainty. Thus, in selecting primary standards that provide an adequate margin of safety, the Administrator is seeking not only to prevent pollution levels that have been demonstrated to be harmful but also to prevent lower pollutant levels that may pose an unacceptable risk of harm, even if the risk is not precisely identified as to nature or degree. The CAA does not require the Administrator to establish a primary NAAQS at a zero-risk level or at background concentration levels, but rather at a level that reduces risk sufficiently so as to protect public health with an adequate margin of safety.<sup>2</sup> In so doing, protection is provided for both the population as a whole and those groups potentially at increased risk for health effects from exposure to the air pollutant for which each NAAQS is set.

In addressing the requirement for an adequate margin of safety, the U.S. EPA considers such factors as the nature and severity of the health effects involved, the size of the sensitive group(s), and the kind and degree of the uncertainties. The selection of any particular approach to providing an adequate margin of safety is a policy choice left specifically to the Administrator's judgment.<sup>3</sup>

In setting standards that are "requisite" to protect public health and welfare as provided in Section 109(b), the U.S. EPA's task is to establish standards that are neither more nor less stringent than necessary for these purposes. In so doing, the U.S. EPA may not consider the costs of implementing the standards.<sup>4</sup> Likewise, "[a]ttainability and technological feasibility are not relevant considerations in the promulgation of national ambient air quality standards."<sup>5</sup>

Section 109(d)(1) requires that "not later than December 31, 1980, and at 5-year intervals thereafter, the Administrator shall complete a thorough review of the criteria published under Section 108 and the national ambient air quality standards...and shall make such revisions in such criteria and standards and promulgate such new standards as may be

---

<sup>1</sup> See *Lead Industries Association v. EPA*, 647 F.2d 1130, 1154 [(District of Columbia Circuit (D.C. Cir) 1980)]; *American Petroleum Institute v. Costle*, 665 F.2d 1176, 1186 (D.C. Cir. 1981); *American Farm Bureau Federation v. EPA*, 559 F. 3d 512, 533 (D.C. Cir. 2009); *Association of Battery Recyclers v. EPA*, 604 F. 3d 613, 617–18 (D.C. Cir. 2010).

<sup>2</sup> See *Lead Industries v. EPA*, 647 F.2d at 1156 n.51; *Mississippi v. EPA*, 723 F. 3d 246, 255, 262–63 (D.C. Cir. 2013).

<sup>3</sup> See *Lead Industries Association v. EPA*, 647 F.2d at 1161–62; *Mississippi v. EPA*, 723 F. 3d at 265.

<sup>4</sup> See generally, *Whitman v. American Trucking Associations*, 531 U.S. 457, 465–472, 475–476 (2001).

<sup>5</sup> See *American Petroleum Institute v. Costle*, 665 F. 2d at 1185.

appropriate...” Section 109(d)(2) requires that an independent scientific review committee “shall complete a review of the criteria...and the national primary and secondary ambient air quality standards...and shall recommend to the Administrator any new...standards and revisions of existing criteria and standards as may be appropriate...” Since the early 1980s, this independent review function has been performed by the Clean Air Scientific Advisory Committee (CASAC).<sup>1</sup>

## **Overview and History of the Review of the Primary National Ambient Air Quality Standards for Nitrogen Dioxide**

Nitrogen dioxide (NO<sub>2</sub>) is the indicator for gaseous oxides of nitrogen [e.g., NO<sub>2</sub>, nitric oxide (NO)]. Consistent with Section 108(c) of the CAA (42 U.S.C.21 7408), the U.S. EPA considers the term oxides of nitrogen to refer to all forms of oxidized nitrogen, including multiple gaseous species (e.g., NO<sub>2</sub>, NO) and particulate species (e.g., nitrates). The review of the primary NO<sub>2</sub> NAAQS focuses on evaluating the health effects associated with exposure to the gaseous oxides of nitrogen. The atmospheric chemistry, exposure, and health effects associated with nitrogen compounds present in particulate matter (PM) were most recently considered in the U.S. EPA’s review of the NAAQS for PM. The welfare effects associated with oxides of nitrogen are being considered in a separate assessment as part of the review of the secondary NAAQS for NO<sub>2</sub> and sulfur dioxide [SO<sub>2</sub>; (U.S. EPA, 2013f)].

NAAQS are defined by four basic elements: indicator, averaging time, level, and form. The indicator defines the pollutant to be measured in the ambient air for the purpose of determining compliance with the standard. The averaging time defines the time period over which air quality measurements are to be obtained and averaged or cumulated, considering evidence of effects associated with various time periods of exposure. The level of a standard defines the air quality concentration (i.e., an ambient concentration of the indicator pollutant) used in determining whether the standard is achieved. The form of the standard defines the air quality statistic that is compared to the level of the standard in determining whether an area attains the standard. For example, the form of the current primary 1-hour NO<sub>2</sub> standard is the 3-year average of the 98th percentile of the annual distribution of 1-hour daily maximum NO<sub>2</sub> concentrations. The Administrator considers these four elements collectively in evaluating the protection to public health provided by the primary NAAQS.

In 1971, the U.S. EPA added nitrogen oxides to the list of criteria pollutants under Section 108(a)(1) of the CAA and issued the initial air quality criteria [36 Federal

---

<sup>1</sup> Lists of CASAC members and of members of the CASAC Oxides of Nitrogen Primary NAAQS Review Panel are available at: <http://yosemite.epa.gov/sab/sabproduct.nsf/WebCASAC/CommitteesandMembership?OpenDocument>.

Register (FR) 1515, January 30, 1971]. Based on these air quality criteria, the U.S. EPA promulgated NAAQS for nitrogen oxides using NO<sub>2</sub> as the indicator (36 FR 8186, April 30, 1971). Both primary and secondary standards were set at 100 µg/m<sup>3</sup> [equal to 0.053 parts per million (ppm)], annual average. The standards were based on scientific information contained in the 1971 Air Quality Criteria Document for Nitrogen Oxides ([U.S. EPA, 1971](#)). Since then, the Agency has completed multiple reviews of the air quality criteria upon which the primary NO<sub>2</sub> NAAQS are set and the primary standards themselves. [Table I](#) provides a brief summary of these reviews.

**Table I History of the primary National Ambient Air Quality Standards for nitrogen dioxide since 1971.**

Final Rule/Decisions	Indicator	Averaging Time	Level	Form
1971 36 FR 8186 April 30, 1971	NO <sub>2</sub>	1 year	53 ppb <sup>a</sup>	Annual arithmetic average
1985 50 FR 25532 June 19, 1985	Primary NO <sub>2</sub> standard retained, without revision.			
1996 61 FR 52852 October 8, 1996	Primary NO <sub>2</sub> standard retained, without revision.			
2010 75 FR 6474 February 9, 2010	NO <sub>2</sub>	1 hour	100 ppb	3-year average of the 98th percentile of the annual distribution of daily maximum 1-hour concentrations
Primary annual NO <sub>2</sub> standard retained, without revision.				

FR = Federal Register, NO<sub>2</sub> = nitrogen dioxide, ppb = parts per billion.

<sup>a</sup>The initial standard level of the annual NO<sub>2</sub> standard was 100 µg/m<sup>3</sup> which is equal to 0.053 parts per million or 53 ppb. The units for the standard level were officially changed to ppb in the final rule issued in 2010 (75 FR 6531, February 9, 2010).

The U.S. EPA retained the primary and secondary NO<sub>2</sub> standards, without revision, in reviews completed in 1985 and 1996 (50 FR 25532, June 19, 1985; 61 FR 52852, October 8, 1996). These decisions were informed, respectively, by scientific information contained in the 1982 Air Quality Criteria Document for Oxides of Nitrogen [([U.S. EPA, 1982](#))] which updated the scientific criteria upon which the initial NO<sub>2</sub> standards were based] and the 1993 Air Quality Criteria Document for Oxides of Nitrogen ([U.S. EPA,](#)

[1993a](#)). In the latter of the two decisions, the U.S. EPA concluded that “the existing annual primary standard appears to be both adequate and necessary to protect human health against both long- and short-term NO<sub>2</sub> exposures” and that retaining the existing annual standard is consistent with the scientific data assessed in the 1993 Air Quality Criteria Document ([U.S. EPA, 1993a](#)) and the Staff Paper ([U.S. EPA, 1995a](#)) and with the advice and recommendations of CASAC” (61 FR 52854, October 8, 1996).<sup>1</sup>

The last review of the air quality criteria for oxides of nitrogen (health criteria) and the primary NO<sub>2</sub> standard was initiated in December 2005 (70 FR 73236, December 9, 2005).<sup>2,3</sup> The Agency’s plans for conducting the review were presented in the Integrated Review Plan (IRP) for the Primary National Ambient Air Quality Standard for NO<sub>2</sub> ([U.S. EPA, 2007a](#)), which included consideration of comments received during a CASAC consultation as well as public comment on a draft IRP. The science assessment for the review was described in the 2008 Integrated Science Assessment (ISA) for Oxides of Nitrogen—Health Criteria ([U.S. EPA, 2008c](#)), multiple drafts of which received review by CASAC and the public. The U.S. EPA also conducted quantitative human risk and exposure assessments, after consultation with CASAC and receiving public comment on a draft analysis plan ([U.S. EPA, 2007b](#)). These technical analyses were presented in the Risk and Exposure Assessment (REA) to Support the Review of the NO<sub>2</sub> Primary National Ambient Air Quality Standard ([U.S. EPA, 2008e](#)), multiple drafts of which received CASAC and public review.

Over the course of the last review, the U.S. EPA made several changes to the NAAQS review process. An important change was the discontinuation of the Staff Paper, which traditionally contained staff evaluations to bridge the gap between the Agency’s science assessments and the judgments required of the U.S. EPA Administrator in determining whether it was appropriate to retain or revise the NAAQS.<sup>4</sup> In the course of reviewing the second draft REA, however, CASAC expressed the view that the document would be

---

<sup>1</sup> In presenting rationale for the final decision, the U.S. EPA noted that “a 0.053 ppm annual standard would keep annual NO<sub>2</sub> concentrations considerably below the long-term levels for which serious chronic effects have been observed in animals” and that “[r]etaining the existing standard would also provide protection against short-term peak NO<sub>2</sub> concentrations at the levels associated with mild changes in pulmonary function and airway responsiveness observed in controlled human [exposure] studies” (61 FR 52854, October 8, 1996; 60 FR 52874, 52880, October 11, 1995).

<sup>2</sup> Documents related to reviews completed in 2010 and 1996 are available at: [http://www.epa.gov/ttn/naaqs/standards/nox/s\\_nox\\_index.html](http://www.epa.gov/ttn/naaqs/standards/nox/s_nox_index.html).

<sup>3</sup> The U.S. EPA conducted a separate review of the secondary NO<sub>2</sub> NAAQS jointly with a review of the secondary SO<sub>2</sub> NAAQS. The Agency retained those secondary standards, without revision, to address the direct effects on vegetation of exposure to oxides of nitrogen and sulfur (77 FR 20218, April 3, 2012).

<sup>4</sup> Initial changes to the NAAQS review process included a policy assessment document reflecting Agency (rather than staff) views published as an advanced notice of public rulemaking (ANPR). Under this process, the ANPR would have been reviewed by CASAC ([Peacock, 2006](#)).

incomplete without the addition of a policy assessment chapter presenting an integration of evidence-based considerations and risk and exposure assessment results. CASAC stated that such a chapter would be “critical for considering options for the NAAQS for NO<sub>2</sub>” s. In addition, within the period of CASAC’s review of the second draft REA, the U.S. EPA’s Deputy Administrator indicated in a letter to the CASAC chair, addressing earlier CASAC comments on the NAAQS review process, that the risk and exposure assessment will include “a broader discussion of the science and how uncertainties may effect decisions on the standard” and “all analyses and approaches for considering the level of the standard under review, including risk assessment and weight of evidence methodologies” (Peacock, 2008). Accordingly, the final 2008 REA included a policy assessment chapter that considered the scientific evidence in the 2008 ISA and the exposure and risk results presented in other chapters of the 2008 REA as they related to the adequacy of the then-current primary NO<sub>2</sub> standard and potential alternative standards for consideration (U.S. EPA, 2008e).<sup>1</sup> CASAC discussed the final version of the 2008 REA, with an emphasis on the policy assessment chapter during a public teleconference on December 5, 2008 (73 FR 66895, November 12, 2008). Following that teleconference, CASAC offered comments and advice on the primary NO<sub>2</sub> standard in a letter to the Administrator (Samet, 2008).

After considering an integrative synthesis of the body of evidence on human health effects associated with the presence of NO<sub>2</sub> in the air and the exposure and risk information, the Administrator determined that the then-existing primary NO<sub>2</sub> NAAQS, based on an annual arithmetic average, was not sufficient to protect public health from the array of effects that could occur following short-term exposures to ambient NO<sub>2</sub>. In so doing, the Administrator particularly noted the potential for adverse health effects to occur following exposures to elevated NO<sub>2</sub> concentrations that can occur around major roads (75 FR 6482). In a notice published in the Federal Register on July 15, 2009, the U.S. EPA proposed to supplement the existing primary annual NO<sub>2</sub> standard by establishing a new short-term standard (74 FR 34404). In a notice published in the Federal Register on February 9, 2010, the U.S. EPA finalized a new short-term standard with a level of 100 ppb, based on the 3-year average of the 98th percentile of the annual distribution of daily maximum 1-hour concentrations. The U.S. EPA also retained the existing primary annual NO<sub>2</sub> standard with a level of 53 ppb, annual average (75 FR 6474). The U.S. EPA’s final decision included consideration of CASAC (2009) and

---

<sup>1</sup> Subsequent to the completion of the 2008 REA, the U.S. EPA Administrator Jackson called for additional key changes to the NAAQS review process including reinstating a policy assessment document that contains staff analysis of the scientific bases for alternative policy options for consideration by senior Agency management prior to rulemaking (Jackson, 2009). A Policy Assessment will be developed for the current review as discussed in Chapter 7 of the 2014 Integrated Review Plan for the Primary National Ambient Air Quality Standards for Nitrogen Dioxide (U.S. EPA, 2014b).

public comments on the proposed rule. The U.S. EPA's final rule was upheld against challenges in a decision issued by the U.S. Court of Appeals for the District of Columbia Circuit on July 17, 2012.<sup>1</sup>

Revisions to the NAAQS were accompanied by revisions to the data handling procedures, the ambient air monitoring and reporting requirements, and the Air Quality Index (AQI).<sup>2</sup> One aspect of the new monitoring network requirements included requirements for states to locate monitors near high-traffic roadways in large urban areas and in other locations where maximum NO<sub>2</sub> concentrations can occur. Subsequent to the 2010 rulemaking, the U.S. EPA revised the deadlines by which the near-road monitors are to be operational in order to implement a phased deployment approach (78 FR 16184, March 14, 2013). The near-road NO<sub>2</sub> monitors will become operational between January 1, 2014 and January 1, 2017.

---

<sup>1</sup> See *American Petroleum Institute v. EPA*, 684 F. 3d 1342 (D.C. Cir. 2012).

<sup>2</sup> The current federal regulatory measurement methods for NO<sub>2</sub> are specified in 40 Code of Federal Regulations (CFR) part 50, Appendix F and 40 CFR part 53. Consideration of ambient air measurements with regard to judging attainment of the standards is specified in 40 CFR part 50, Appendix S. The NO<sub>2</sub> monitoring network requirements are specified in 40 CFR part 58, Appendix D, Section 4.3. The U.S. EPA revised the Air Quality Index for NO<sub>2</sub> to be consistent with the revised primary NO<sub>2</sub> NAAQS as specified in 40 CFR part 58, Appendix G. Guidance on the approach for implementation of the new standards was described in the Federal Register notices for the proposed and final rules (74 FR 34404; 75 FR 6474).

---

# EXECUTIVE SUMMARY

## Purpose and Scope of the Integrated Science Assessment

This Integrated Science Assessment (ISA) is a thorough evaluation and synthesis of the policy-relevant science aimed at characterizing exposures to ambient oxides of nitrogen and relationships with health effects. As such, this ISA serves as the scientific foundation for the review of the primary (health-based) National Ambient Air Quality Standards (NAAQS) for nitrogen dioxide (NO<sub>2</sub>).<sup>1</sup> NO<sub>2</sub> is the indicator for gaseous oxides of nitrogen (i.e., oxidized nitrogen compounds), which also include nitric oxide and gases produced from reactions involving NO<sub>2</sub> and nitric oxide ([Section 2.2](#), [Figure 2-1](#)).<sup>2,3</sup> In 2010, the U.S. Environmental Protection Agency (EPA) retained the NAAQS of 53 parts per billion (ppb) annual average concentration to protect against health effects potentially related to long-term NO<sub>2</sub> exposures. In addition, the U.S. EPA set a new 1-hour NAAQS at a level of 100 ppb, based on the 3-year average of each year's 98th percentile of the highest daily 1-hour concentration. The 1-hour NAAQS was set to protect against respiratory effects related to short-term NO<sub>2</sub> exposures in populations potentially at increased risk, such as people with asthma or people who spend time on or near high-traffic roads. The U.S. EPA also set requirements for a network of monitors to measure NO<sub>2</sub> near high-traffic roads, one of the places where the highest concentrations are expected to occur.

This ISA updates the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) with studies and reports published from January 2008 through August 2014. The U.S. EPA conducted searches to identify peer-reviewed literature on relevant topics such as health effects, ambient concentrations, and exposure. The Clean Air Scientific Advisory Committee (a formal independent panel of scientific experts) and the public also recommended studies and reports. To fully describe the state of the science, the U.S. EPA also identified relevant studies from previous assessments to include in this ISA.

As in the 2008 ISA, this ISA determines the causality of relationships with health effects only for NO<sub>2</sub> ([Chapter 5](#) and [Chapter 6](#)). Key to interpreting the health effects evidence is understanding the sources, chemistry, and distribution of NO<sub>2</sub> in the ambient air ([Chapter 2](#)) that influence exposure ([Chapter 3](#)), the uptake of inhaled NO<sub>2</sub> in the

---

<sup>1</sup> The ecological effects of oxides of nitrogen are being considered in a separate assessment as part of the review of the secondary (welfare-based) NAAQS for NO<sub>2</sub> and sulfur dioxide ([U.S. EPA, 2013f](#)).

<sup>2</sup> Total oxides of nitrogen also include several particulate species such as nitrates. Section 108(c) of the Clean Air Act, 42 U.S.C. § 7408(c) specifies that criteria for oxides of nitrogen include consideration of nitric and nitrous acids, nitrites, nitrates, nitrosamines, and other derivatives of oxides of nitrogen. Health effects associated with the particulate species are addressed in the review of the NAAQS for particulate matter ([U.S. EPA, 2014c](#)).

<sup>3</sup> The blue electronic links can be used to navigate to other parts of this ISA and to information on cited references.

respiratory tract, and subsequent biological mechanisms that may be affected ([Chapter 4](#)). Further, the ISA aims to characterize the independent effect of NO<sub>2</sub> exposure on health rather than its role as just a marker for other air pollutants. The ISA also provides understanding of policy-relevant issues ([Section 1.6](#)), such as (1) exposure durations and patterns associated with health effects; (2) concentration-response relationship(s), including evidence of potential thresholds for effects; and (3) populations or lifestyles at increased risk for health effects related to NO<sub>2</sub> exposure ([Chapter 7](#)).

## Sources and Human Exposure to Nitrogen Dioxide

A main objective of the ISA is to characterize health effects related to ambient NO<sub>2</sub> exposure. This requires understanding what factors affect exposure to ambient NO<sub>2</sub> and the ability to estimate that exposure well. It also requires accounting for the influence of factors that are related to NO<sub>2</sub> exposure, such as other pollutants and demographic characteristics. For the U.S. as a whole and for major cities, motor vehicle emissions are the largest single contributor to NO<sub>2</sub> in the ambient air ([Section 2.3.1](#), [Figure 2-3](#)). Electric power plants, industrial facilities, other forms of transportation, soil, and wildfires also can contribute considerably to ambient NO<sub>2</sub> concentrations on a national scale and to differences in concentrations and population exposures among locations.

Because many sources of NO<sub>2</sub> are ubiquitous, the potential for exposure to NO<sub>2</sub> is widespread. However, given that motor vehicles are a major source, air concentrations of NO<sub>2</sub> can be highly variable within neighborhoods ([Section 2.5.2](#)), depending on distance to roads. NO<sub>2</sub> concentrations tend to decrease over a distance of 200–500 m from the road ([Section 2.5.3](#)). The first year of data from the U.S. near-road monitoring network show that annual average NO<sub>2</sub> concentrations range from 9 to 27 ppb at near-road sites and 1 to 25 ppb at other sites, but concentrations are higher near roads than at most other sites within a given urban area ([Section 2.5.3.2](#), [Table 2-10](#)). The range in the day's highest 1-hour NO<sub>2</sub> concentration is 35–90 ppb at near-road sites and 12–73 ppb at other sites, and concentrations are not always higher at the near-road sites. This is because in addition to distance from road, local sources besides traffic, chemical reactions with ozone in the air ([Figure 2-1](#)), season, wind direction, and physical features of the environment ([Sections 2.2](#) and [2.5.3](#)) affect the distribution of NO<sub>2</sub> concentrations.

Because ambient NO<sub>2</sub> concentrations show variability among geographic regions, within communities, and over time, ambient NO<sub>2</sub> exposure can vary considerably among people. Differences in the outdoor and indoor locations where people spend time and the amount of time spent in those locations also contribute to variation in ambient NO<sub>2</sub> exposure ([Sections 3.4.1](#) and [3.4.3](#), [Figure 3-3](#)). NO<sub>2</sub> concentrations vary by the type of location, including inside vehicles and buildings ([Figure 3-1](#)), and the ventilation of buildings can

affect the amount of NO<sub>2</sub> that penetrates indoors ([Section 3.4.3.3](#)). And so, understanding the extent to which the methods used to estimate exposure adequately account for variation in ambient concentrations across locations and people's activity patterns is essential to characterize relationships between ambient NO<sub>2</sub> exposure and health effects. In this ISA, many health effects are examined in relation to ambient NO<sub>2</sub> concentrations measured at community monitoring sites. These monitors do not cover all locations where people live or spend their time and are not sited to capture the variability in NO<sub>2</sub> concentrations observed within cities, including near roads. Thus, NO<sub>2</sub> measurements at these sites have some error in representing people's actual exposures. This error may be reflected in the wide range of relationships observed between total personal NO<sub>2</sub> exposure and ambient concentrations averaged over periods up to 1 week ([Section 3.4.2](#)). Such relationships are not well characterized for exposure periods of months to years. Although these uncertainties exist, one cannot necessarily conclude that ambient NO<sub>2</sub> concentrations are poor measures of the ambient portion of personal exposure because variation among people in indoor or in-vehicle exposures and activity patterns may obscure relationships between ambient concentrations and ambient exposure.

Error in estimating exposure can impact associations observed between ambient NO<sub>2</sub> concentrations and health effects. In studies of short-term exposure that examine changes in NO<sub>2</sub> over time (e.g., day to day), NO<sub>2</sub> from community monitors has shown lower magnitude and/or more uncertain associations with health effects ([Section 3.4.5](#)) compared with NO<sub>2</sub> measured at people's locations. In studies of long-term exposure that compare people in locations that vary in ambient NO<sub>2</sub> concentrations, NO<sub>2</sub> from community monitors has shown both smaller and larger associations with health effects compared with NO<sub>2</sub> concentrations estimated for people's locations. The impact on health effect associations of using NO<sub>2</sub> concentrations at community sites to represent near-road exposures is not clear. Given the impact of exposure error, this ISA draws conclusions about health effects related to NO<sub>2</sub> exposure by considering the availability of results for NO<sub>2</sub> measured at community monitoring sites versus other locations where people live or spend time and by considering how well the method of a particular study represented differences in exposure over time or across locations. For example, there is more confidence in the evidence for respiratory effects because many studies examined exposure metrics that accounted for local variability in NO<sub>2</sub> concentrations and people's activity patterns. These metrics included short-term personal, home, and school NO<sub>2</sub> measurements and long-term average concentrations estimated at people's homes with models that well captured the spatial pattern in ambient concentrations in the study areas.

The important contribution of motor vehicles to ambient NO<sub>2</sub> concentrations not only has implications for estimating NO<sub>2</sub> exposure but also indicates the need to consider other pollutants emitted from vehicles. For example, NO<sub>2</sub> concentrations often are moderately

to highly correlated with pollutants such as elemental or black carbon, carbon monoxide, PM<sub>2.5</sub>, and ultrafine particles<sup>1</sup> ([Section 3.4.4.1](#), [Figure 3-6](#)). These pollutants show effects on many of the same biological processes and health outcomes as NO<sub>2</sub> ([Appendix](#) to the ISA). Thus, in characterizing relationships of NO<sub>2</sub> with health effects, this ISA evaluates the extent to which an effect of NO<sub>2</sub> can be separated from that of other traffic-related pollutants and PM<sub>2.5</sub>. Experimental studies are key because they can indicate whether NO<sub>2</sub> exposure has a direct effect on health outcomes and biological processes. Though epidemiologic studies that statistically adjust the NO<sub>2</sub> association for another pollutant cannot conclusively show an independent effect, some provided supporting evidence.

## Health Effects of Nitrogen Dioxide Exposure

In this ISA, information on NO<sub>2</sub> exposure, the potential influence of other traffic-related pollutants, and health effects from epidemiologic, controlled human exposure, and toxicological studies is integrated to form conclusions about the causal nature of relationships between NO<sub>2</sub> exposure and health effects. Health effects examined in relation to the full range of NO<sub>2</sub> concentrations relevant to ambient conditions are considered. Based on peak concentrations ([Section 2.5](#)) and the ISA definition that ambient-relevant exposures be within one to two orders of magnitude of current conditions ([Preamble, Section 5.c](#)), NO<sub>2</sub> concentrations up to 5,000 ppb<sup>2</sup> are defined to be ambient relevant. A consistent and transparent framework ([Preamble, Table II](#)) is applied to classify the health effects evidence according to a five-level hierarchy:

- 1) Causal relationship
- 2) Likely to be a causal relationship
- 3) Suggestive of, but not sufficient to infer, a causal relationship
- 4) Inadequate to infer a causal relationship
- 5) Not likely to be a causal relationship

The conclusions presented in [Table ES-1](#) are informed by recent findings and whether recent findings integrated with information from the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) support a change in conclusion. Important considerations include judgments of error and uncertainty in the collective body of available studies; the consistency of findings integrated across epidemiologic, controlled human exposure, and toxicological studies to inform understanding about an independent effect of NO<sub>2</sub>

---

<sup>1</sup> PM<sub>2.5</sub>: In general terms, particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm, a measure of fine particles. UFP: Definitions vary but often refer to particles with a nominal mean aerodynamic diameter less or equal to 0.1 µm.

<sup>2</sup> The 5,000-ppb upper limit applies mostly to animal toxicological studies and also a few controlled human exposure studies. Experimental studies examining NO<sub>2</sub> exposures greater than 5,000 ppb were included if they provided information on the uptake of NO<sub>2</sub> in the respiratory tract or on potential biological mechanisms.

exposure and potential biological pathways; the extent to which epidemiologic studies adequately represented NO<sub>2</sub> exposure; and examination in epidemiologic studies of the potential influence of other traffic-related pollutants and other factors that could bias associations observed with NO<sub>2</sub> exposure (described in the [Appendix](#) to the ISA).

**Table ES-1 Causal determinations for relationships between nitrogen dioxide exposure and health effects from the 2008 and 2016 Integrated Science Assessment for Oxides of Nitrogen.**

Exposure Duration and Health Effects Category <sup>a</sup>	Causal Determination <sup>b</sup>	
	2008 Integrated Science Assessment	2016 Integrated Science Assessment
<b>Short-Term Nitrogen Dioxide Exposure (minutes up to 1 month)</b>		
Respiratory effects <a href="#">Section 5.2, Table 5-39</a>	Sufficient to infer a likely causal relationship	Causal relationship
Cardiovascular effects <a href="#">Section 5.3, Table 5-52</a>	Inadequate to infer the presence or absence of a causal relationship	Suggestive of, but not sufficient to infer, a causal relationship
Total mortality <a href="#">Section 5.4, Table 5-57</a>	Suggestive of, but not sufficient to infer, a causal relationship	Suggestive of, but not sufficient to infer, a causal relationship
<b>Long-Term Nitrogen Dioxide Exposure (more than 1 month to years)</b>		
Respiratory effects <a href="#">Section 6.2, Table 6-5</a>	Suggestive of, but not sufficient to infer, a causal relationship	Likely to be a causal relationship
Cardiovascular effects and diabetes <sup>c</sup> <a href="#">Section 6.3, Table 6-11</a>	Inadequate to infer the presence or absence of a causal relationship	Suggestive of, but not sufficient to infer, a causal relationship
Reproductive and developmental effects <sup>c</sup> <a href="#">Sections 6.4.2, 6.4.3, and 6.4.4, Table 6-14</a>	Inadequate to infer the presence or absence of a causal relationship	Fertility, reproduction, and pregnancy: Inadequate to infer a causal relationship
		Birth outcomes: Suggestive of, but not sufficient to infer, a causal relationship
		Postnatal development: Inadequate to infer a causal relationship
Total mortality <a href="#">Section 6.5, Table 6-18</a>	Inadequate to infer the presence or absence of a causal relationship	Suggestive of, but not sufficient to infer, a causal relationship
Cancer <a href="#">Section 6.6, Table 6-20</a>	Inadequate to infer the presence or absence of a causal relationship	Suggestive of, but not sufficient to infer, a causal relationship

<sup>a</sup>An array of outcomes is evaluated as part of a broad health effects category: physiological measures (e.g., airway responsiveness), clinical outcomes (e.g., hospital admissions), cause-specific mortality. Total mortality includes all nonaccidental causes of mortality, and conclusions are informed by findings for the spectrum of morbidity effects (e.g., respiratory, cardiovascular) that can lead to mortality. The sections and tables referenced include a detailed discussion of the evidence that supports the causal determinations and the NO<sub>2</sub> concentrations with which health effects have been associated.

<sup>b</sup>Since the 2008 ISA for Oxides of Nitrogen, the phrasing of causal determinations has changed slightly, and the weight of evidence that describes each level in the hierarchy of the causal framework has been more explicitly characterized.

<sup>c</sup>In this ISA, the conclusion is based on cardiovascular effects and diabetes, which are related and share risk factors. Reproductive and developmental effects are separated into smaller subcategories of outcomes based on varied underlying biological processes and exposure patterns over different lifestages.


## Short-Term Nitrogen Dioxide Exposure and Respiratory Effects

A causal relationship is determined for short-term NO<sub>2</sub> exposure and respiratory effects. The conclusion is strengthened from the 2008 ISA for Oxides of Nitrogen from likely to be a causal relationship ([Table ES-1](#)) based on the evidence indicating that NO<sub>2</sub> exposure can trigger asthma attacks. There is some evidence relating short-term NO<sub>2</sub> exposure to chronic obstructive pulmonary disease, respiratory infection, respiratory effects in healthy populations, and respiratory mortality but uncertainty as to whether the effects of NO<sub>2</sub> exposure are independent of other traffic-related pollutants ([Table 5-39](#)).

The key evidence that short-term NO<sub>2</sub> exposure independently can trigger an asthma attack is the increased airway responsiveness and allergic inflammation induced by NO<sub>2</sub> exposure in controlled human exposures studies. Although reactions with antioxidants typically are beneficial, such reactions for inhaled NO<sub>2</sub> can form reactive species in the fluid lining the lung ([Section 4.2.2](#)). These reactive species can enhance allergic inflammation and airway responsiveness ([Figure ES-1](#)), so this evidence further links NO<sub>2</sub> exposure to asthma attacks. Allergic inflammation and airway responsiveness are hallmarks of asthma attacks; thus, this evidence supports epidemiologic results, which consistently link short-term increases in ambient NO<sub>2</sub> concentration with increases in hospital admissions and emergency department visits for asthma, increases in respiratory symptoms and airway inflammation in people with asthma, and decreases in lung function in children with asthma ([Section 5.2.9](#)). These associations exist not only with community-average ambient NO<sub>2</sub> concentrations but also with personal NO<sub>2</sub> and NO<sub>2</sub> measured outside children's schools and inside their homes ([Sections 5.2.9.3](#) and [5.2.9.6](#)). Because outdoor and indoor sources (e.g., vehicles, gas stoves) emit a different mix of pollutants, NO<sub>2</sub> is more weakly related to other traffic-related pollutants for total personal exposures than for ambient concentrations. The same may be true for indoor exposures. So, associations with personal and indoor NO<sub>2</sub> may be less influenced by pollutants that are related to outdoor NO<sub>2</sub>. Further, studies that measured pollutants at people's locations tend to show that NO<sub>2</sub> remains associated with asthma-related effects after accounting for PM<sub>2.5</sub> or, as examined in fewer studies, a traffic-related pollutant such as elemental or black carbon, metals, or ultrafine particles ([Figures 5-16](#) and [5-17](#)).

The 2008 ISA described much of the same evidence and determined a likely to be causal relationship, citing uncertainty as to whether the epidemiologic results for NO<sub>2</sub> reflected the effects of other traffic-related pollutants. The 2008 ISA did not explicitly evaluate the extent to which various lines of evidence supported effects on asthma attacks. In this ISA, the determination of a causal relationship is not based on new evidence as much as it is on the integrated findings for asthma attacks with due weight given to experimental studies. The epidemiologic evidence for asthma attacks and controlled human exposure study findings for increased airway responsiveness and allergic inflammation together

demonstrate that short-term NO<sub>2</sub> exposure has an independent relationship with respiratory effects and is not just an indicator for other traffic-related pollutants.



Note: NO<sub>2</sub> = nitrogen dioxide. Adapted from [Figures 4-1 and 4-2 \(Section 4.3.5\)](#). White boxes and solid arrows describe pathways well supported by available evidence. Gray boxes and dotted arrows describe potential pathways for which evidence is limited or inconsistent.

**Figure ES-1 Evidence for relationships of short-term and long-term nitrogen dioxide exposure with asthma presented as biological pathways.**

## Long-Term Nitrogen Dioxide Exposure and Respiratory Effects

There is likely to be a causal relationship between long-term NO<sub>2</sub> exposure and respiratory effects based on the evidence for development of asthma ([Section 6.2.9, Table 6-5](#)). The conclusion is strengthened from the 2008 ISA ([Table ES-1](#)) because where previous epidemiologic findings were inconsistent, recent studies consistently observe NO<sub>2</sub>-related increases in asthma development in children who are followed over time and are supported by previous experimental studies. A key strength is that asthma development is linked to ambient NO<sub>2</sub> concentrations measured near children's homes or schools or estimated at homes with models that well predicted the concentration pattern

within the community. Associations between NO<sub>2</sub> and asthma development are independent of factors such as socioeconomic status and exposure to smoking, but the influence of other traffic-related pollutants is not well studied. There is some support for an independent effect of long-term NO<sub>2</sub> exposure on asthma development provided by findings of increased airway responsiveness in rodents ([Figure ES-1](#)). Also, evidence relating short-term NO<sub>2</sub> exposure to airway inflammation in epidemiologic studies of healthy people and allergic responses in experimental studies of rodents and healthy people indicates that repeated short-term NO<sub>2</sub> exposure could lead to the development of asthma. Together, the epidemiologic and experimental evidence for asthma development supports a relationship between long-term NO<sub>2</sub> exposure and respiratory effects, but because experimental evidence is limited, there remains some uncertainty about the potential influence of other traffic-related pollutants in the epidemiologic evidence.

## **Nitrogen Dioxide Exposure and Other Health Effects**

There is more uncertainty about relationships of NO<sub>2</sub> exposure with health effects outside of the respiratory system. NO<sub>2</sub> itself is unlikely to enter the bloodstream, and reactions caused by ambient-relevant concentrations of NO<sub>2</sub> in the airways do not clearly affect concentrations of reaction products, such as nitrite, in the blood. Some but not all results suggest that substances that can cause inflammation or oxidative stress may enter the blood from the respiratory tract in response to NO<sub>2</sub> exposure ([Section 4.3.2.9](#)). This uncertainty about the effects of NO<sub>2</sub> exposure on underlying biological mechanisms is common to nonrespiratory health effects.

For short-term and/or long-term NO<sub>2</sub> exposure, evidence is suggestive of, but not sufficient to infer, a causal relationship with cardiovascular effects and diabetes, total mortality, birth outcomes, and cancer ([Table ES-1](#)). For short-term NO<sub>2</sub> exposure, recent epidemiologic studies continue to show associations with total mortality and add support for cardiovascular effects by indicating a possible effect on triggering heart attacks. Where there was little previous support, increases in recent epidemiologic evidence led to strengthening conclusions for total mortality and cancer related to long-term NO<sub>2</sub> exposure. New epidemiologic findings for heart disease and diabetes and reduced fetal growth point to possible relationships of long-term NO<sub>2</sub> exposure with health effects categories new to this ISA. For fertility, reproduction, and pregnancy, as well as postnatal development, evidence is inadequate to infer a causal relationship with long-term NO<sub>2</sub> exposure ([Table ES-1](#)) because neither epidemiologic nor toxicological studies clearly show effects. For all nonrespiratory effects, epidemiologic studies do not adequately account for the potential influence of other traffic-related pollutants, which combined with the few or inconclusive results from controlled human exposure or toxicological

studies, produces large uncertainty as to whether short-term or long-term NO<sub>2</sub> exposure has independent relationships with health effects outside of the respiratory system.

## **Policy-Relevant Considerations for Health Effects Associated with Nitrogen Dioxide Exposure**

Multiple durations of short-term and long-term NO<sub>2</sub> exposure are observed to be associated with health effects ([Section 1.6.1](#)). For short-term exposure, asthma-related effects are associated with total personal NO<sub>2</sub> exposure and NO<sub>2</sub> measured at children's schools or community monitors averaged over 1 to 5 days. These associations are observed with both daily average and the daily highest 1-hour NO<sub>2</sub> concentration. No particular duration of exposure shows a stronger effect. Controlled human studies demonstrate increased airway inflammation and airway responsiveness in adults with asthma following NO<sub>2</sub> exposures of 15 to 60 minutes. These results support the epidemiologic evidence showing that NO<sub>2</sub> exposures of 2 or 5 hours near high-traffic roads are associated with similar respiratory effects in adults with and without asthma.

For long-term exposure, asthma development in children is associated with NO<sub>2</sub> exposure estimates for homes or schools that are averaged over 1 to 10 years, representing various time periods, such as infancy, childhood, and lifetime. It is not clear what pattern of NO<sub>2</sub> exposure in time may underlie these associations, but some evidence from experimental studies in humans and rodents suggests that repeated exposure over many days or weeks can induce allergic responses that are involved in asthma development.

Information on the shape of the NO<sub>2</sub> concentration-health effects relationship is provided mostly by epidemiologic studies. Based on the few results that are available, asthma emergency department visits increase with increasing short-term average ambient NO<sub>2</sub> concentrations ([Section 1.6.3](#)). In Atlanta, GA, an association is present with daily highest 1-hour NO<sub>2</sub> concentrations from 37 to 11 ppb but is uncertain at lower concentrations. The lower bound of NO<sub>2</sub> concentrations where an association is present also is uncertain because concentrations were averaged across sites in Atlanta, GA, which may not reflect the range of concentrations in the city or range of exposures among individuals.

Health effects related to NO<sub>2</sub> exposure potentially have a large public health impact. Many people in the U.S. live, work, or spend time near roads and may have higher exposures to NO<sub>2</sub>. Higher NO<sub>2</sub> exposure also is suggested for urban, low socioeconomic status, and nonwhite populations. Further, people with asthma, children (especially ages 0–14 years), and older adults (especially ages 65 years and older) are identified as being at increased risk of NO<sub>2</sub>-related health effects ([Chapter 7](#)). Evidence does not clearly identify other at-risk populations in terms of other diseases or behavioral, genetic, or

sociodemographic factors. Short-term and long-term NO<sub>2</sub> exposure is linked to clinically relevant increases in airway responsiveness, emergency department visits and hospital admissions for asthma, and development of asthma, which can have a large impact on public health. Given that asthma is the leading chronic illness and the leading cause of missed school days and hospital admissions among U.S. children, NO<sub>2</sub>-related asthma attacks and asthma development have the potential to affect children's overall well-being.

## Summary of Major Findings

Expanding on findings from the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), recent epidemiologic studies show associations of short-term and long-term NO<sub>2</sub> exposure with an array of health effects. However, except for respiratory effects, there remains large uncertainty about whether NO<sub>2</sub> exposure has an effect that is independent of other traffic-related pollutants. As in the 2008 ISA, recent information shows that motor vehicle emissions are the largest single source of NO<sub>2</sub> in the air and that NO<sub>2</sub> concentrations tend to be variable within communities, decreasing with increasing distance from roads. Information to assess whether NO<sub>2</sub> exposure estimates adequately represent the variability in ambient NO<sub>2</sub> concentrations and people's activity patterns varies among the health effects evaluated in this ISA. The major findings from this ISA about NO<sub>2</sub> exposure and health effects and related uncertainties are summarized below.

- Evidence for asthma attacks supports a causal relationship between short-term NO<sub>2</sub> exposure and respiratory effects. Evidence for development of asthma supports a likely to be causal relationship between long-term NO<sub>2</sub> exposure and respiratory effects. These are stronger conclusions than those determined in the 2008 ISA for Oxides of Nitrogen.
- There is more uncertainty as to whether short-term or long-term NO<sub>2</sub> exposure is related to cardiovascular effects, diabetes, reproductive and developmental effects, total mortality, and cancer.
- People with asthma, children, and older adults are at increased risk for NO<sub>2</sub>-related health effects.
- People living or spending time near or on roads, low socioeconomic status populations, and nonwhite populations may have increased NO<sub>2</sub> exposure.
- The first year of data from the U.S. near-road monitoring network indicate that near-road sites tend to have higher NO<sub>2</sub> concentrations on average but do not always have the highest 1-hour NO<sub>2</sub> concentration within an urban area.
- Epidemiologic studies link asthma attacks and asthma development to NO<sub>2</sub> measures that appeared to well represent exposure, including personal measures and concentrations where participants live or spend a lot of time.
- No specific NO<sub>2</sub> averaging time, duration, or age of exposure is more strongly associated with asthma attacks or asthma development. It is not clear whether there is an exposure concentration below which effects do not occur.

---

# CHAPTER 1 INTEGRATED SUMMARY

---

## 1.1 Purpose and Overview of the Integrated Science Assessment

The Integrated Science Assessment (ISA) is a comprehensive evaluation and synthesis of the policy-relevant science “useful in indicating the kind and extent of identifiable effects on public health or welfare which may be expected from the presence of [a] pollutant in ambient air” ([CAA, 1990a](#)). This ISA communicates critical science judgments of the health criteria for a broad category of gaseous oxides of nitrogen (i.e., oxidized nitrogen compounds) for which nitrogen dioxide (NO<sub>2</sub>) is the indicator. As such, this ISA serves as the scientific foundation for the review of the current primary (health-based) National Ambient Air Quality Standards (NAAQS) for NO<sub>2</sub>. Gaseous oxides of nitrogen include NO<sub>2</sub>, nitric oxide (NO), and their various reaction products ([Section 2.2, Figure 1-1](#)).<sup>1</sup> There also are particulate oxides of nitrogen (e.g., nitrates, nitro-polycyclic aromatic hydrocarbons),<sup>2</sup> which are being considered in the review of the NAAQS for particulate matter (PM) ([U.S. EPA, 2014c](#)). The welfare effects of oxides of nitrogen are being evaluated separately as part of the review of the secondary (welfare-based) NAAQS for NO<sub>2</sub> and sulfur dioxide [SO<sub>2</sub>; ([U.S. EPA, 2013f](#))].

This ISA evaluates relevant scientific literature published since the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), integrating key information and judgments contained in the 2008 ISA and the 1993 Air Quality Criteria Document for Oxides of Nitrogen ([U.S. EPA, 1993a](#)). Thus, this ISA updates the state of the science that was available for the 2008 ISA, which informed decisions on the primary NO<sub>2</sub> NAAQS in the review completed in 2010. In 2010, the U.S. Environmental Protection Agency (EPA) retained the existing annual average (avg) NO<sub>2</sub> NAAQS with a level of 53 parts per billion (ppb) to protect against health effects potentially associated with long-term exposure. The U.S. EPA established a new 1-hour (h) NAAQS at a level of 100 ppb NO<sub>2</sub> based on the 3-year (yr) avg of each year’s 98th percentile of 1-h daily maximum (max) concentrations.<sup>3</sup> The 1-h standard was established to protect against a broad range of respiratory effects associated with short-term exposures in potential at-risk populations such as people with asthma and people who spend time on or near high-traffic roads. In 2010, the U.S. EPA also set requirements for a monitoring network in urban areas that

---

<sup>1</sup> The blue electronic links can be used to navigate to other parts of this ISA and to information on cited references.

<sup>2</sup> Section 108(c) of the Clean Air Act, 42 U.S.C. § 7408(c) specifies that criteria for oxides of nitrogen include consideration of nitric and nitrous acids, nitrites, nitrates, nitrosamines, and other derivatives of oxides of nitrogen, including multiple gaseous and particulate species.

<sup>3</sup> The legislative requirements and history of the NO<sub>2</sub> NAAQS are described in detail in the [Preface](#) to this ISA.

include placing monitors near [within 50 meters (m)] high-traffic roads, one of the locations where the highest NO<sub>2</sub> concentrations are expected to occur ([U.S. EPA, 2010c](#)).

This review of the primary NO<sub>2</sub> NAAQS is guided by several policy-relevant questions that have been identified in *The Integrated Review Plan for the Primary National Ambient Air Quality Standard for Nitrogen Dioxide* ([U.S. EPA, 2014b](#)). To address these questions and update the scientific judgments in the 2008 ISA, this ISA aims to:

- Characterize the evidence for health effects associated with short-term (minutes up to 1 month) and long-term (more than 1 month to years) exposure to oxides of nitrogen by integrating findings across scientific disciplines and across related health outcomes and by considering important uncertainties identified in the interpretation of the scientific evidence, including the role of NO<sub>2</sub> within the broader ambient mixture of pollutants.
- Inform understanding of policy-relevant issues related to quantifying health risks, such as exposure concentrations, durations, and patterns associated with health effects; concentration-response relationships and evidence of thresholds below which effects do not occur; and populations and lifestyles with increased risk of health effects related to NO<sub>2</sub> exposure.

Although the scope of the ISA includes all gaseous oxides of nitrogen, much of the information on the distribution of oxides of nitrogen in the air, human exposure and dose, impact of errors associated with exposure assessment methods, and health effects is for NO<sub>2</sub>. There is limited information for NO and the sum of NO and NO<sub>2</sub> (NO<sub>x</sub>) as well as large uncertainty in relating health effects to NO or NO<sub>x</sub> exposure. In the body, NO is produced from nitrates and nitrites derived from diet and through enzymatic pathways that are enhanced during inflammation. Ambient NO concentrations generally are in the range of endogenous NO concentrations exhaled from the respiratory tract. It is not clear whether ambient-relevant NO exposures substantially alter endogenous NO production in the respiratory tract or pathways affected by endogenous NO ([Section 4.2.3](#)). Thus, the potential for detrimental health effects occurring from ambient-relevant NO exposure is unclear. This lack of evidence leaves NO<sub>2</sub> as the component of NO<sub>x</sub> to consider in evaluating health effects in relation to NO<sub>x</sub> exposure. Because the ratio of NO<sub>2</sub> to NO<sub>x</sub> varies across locations, time of day, and season ([Section 2.5](#)), NO<sub>x</sub> may not represent NO<sub>2</sub> exposure consistently. The lack of evidence that ambient-relevant NO exposure can lead to detrimental health effects and the measurement error related to using NO<sub>x</sub> to represent NO<sub>2</sub> exposure are the rationale for determining the causal nature of health effects only for NO<sub>2</sub> exposure.

In addressing policy-relevant questions, this ISA aims to characterize the independent health effects of NO<sub>2</sub> exposure, not the role of NO<sub>2</sub> as just a marker for a broader mixture of pollutants in the ambient air. The potential influence of other traffic-related pollutants was the main uncertainty in the conclusions drawn in the 2008 ISA Oxides of Nitrogen

([U.S. EPA, 2008c](#)). As discussed in this ISA, evidence combined from controlled human exposure and epidemiologic studies sufficiently describes a coherent, biologically plausible relationship between short-term NO<sub>2</sub> exposure and respiratory effects indicative of asthma exacerbation. These effects include increased airway responsiveness as well as increased symptoms, emergency department (ED) visits, and hospital admissions. New epidemiologic evidence supports a relationship of long-term NO<sub>2</sub> exposure with respiratory effects, specifically, the development of asthma in children, and a small body of previous experimental studies provide some indication that NO<sub>2</sub> exposure may have an independent effect. Recent epidemiologic studies continue to suggest that short-term NO<sub>2</sub> exposure may be associated with cardiovascular effects and mortality, and new findings potentially link long-term NO<sub>2</sub> exposure to cardiovascular effects, diabetes, poorer birth outcomes, mortality, and cancer. However, for nonrespiratory effects, epidemiologic studies have not adequately accounted for effects of other traffic-related pollutants, and findings from experimental studies continue to be limited. The information in the ISA forming the basis for these judgments will serve as the scientific foundation for the review of the current primary 1-hour and annual NO<sub>2</sub> NAAQS.

---

## 1.2 Process for Developing Integrated Science Assessments

The U.S. EPA uses a structured and transparent process for evaluating scientific information and determining the causality of relationships between air pollution exposures and health effects ([Preamble](#)). This process includes approaches for literature searches, guidelines for selecting and evaluating relevant studies, and a framework for evaluating the weight of evidence and determining causality. As part of this process, the ISA is reviewed by the Clean Air Scientific Advisory Committee (CASAC), a formal independent panel of scientific experts, and the public. As this ISA informs the review of the primary NO<sub>2</sub> NAAQS, it assesses information relevant to characterizing exposure to gaseous oxides of nitrogen and potential effects on health. Studies on atmospheric chemistry, spatial and temporal trends, and exposure assessment are relevant, as are analyses by the U.S. EPA of air quality and emissions data. Also relevant are epidemiologic, controlled human exposure, and toxicological studies on health effects, as well as studies on dosimetry and modes of action.

The U.S. EPA initiated the current review of the primary NAAQS for NO<sub>2</sub> in February 2012 with a call for information from the public ([U.S. EPA, 2012c](#)). Thereafter, the U.S. EPA routinely conducted literature searches to identify relevant peer-reviewed studies published since the previous ISA (i.e., from January 2008 through August 2014). Multiple search methods were used ([Preamble, Section 2](#)) including searches in databases such as PubMed and Web of Science. Also, CASAC and the public recommended

studies. The U.S. EPA identified additional studies considered to be the definitive work on particular topics from previous assessments to include in this ISA. Some studies were judged to be irrelevant (i.e., did not address a topic described in the preceding paragraph) based on title and were excluded. Studies judged to be potentially relevant based on review of the abstract or full text and considered for inclusion in the ISA are documented and can be found at the Health and Environmental Research Online (HERO) website. The HERO project page for this ISA (<http://hero.epa.gov/oxides-of-nitrogen>) contains the references that are cited in the ISA, the references that were considered for inclusion but not cited, and electronic links to bibliographic information and abstracts.

Health effects were considered for evaluation in this ISA if they were examined in previous assessments by the U.S. EPA for oxides of nitrogen or multiple recent studies (e.g., neurodevelopment). Literature searches identified one or two recent epidemiologic studies each on outcomes such as gastrointestinal effects, bone density, headache, and depression [Supplemental Table S1-1; (U.S. EPA, 2015f)]. A review of these studies indicated they are similar in design and conducted in areas and populations for which associations between ambient NO<sub>2</sub> concentrations and other health effects have been documented. These few studies were excluded from this ISA because they do not provide new information on particular geographic locations, potential at-risk populations or lifestages, or range of ambient NO<sub>2</sub> concentrations. These studies also are more likely to be subject to publication bias.

The [Preamble](#) describes the general framework for evaluating scientific information, including criteria for assessing the strength of inference of a study and developing scientific conclusions. Aspects specific to evaluating studies of NO<sub>2</sub> are described in the [Appendix](#). For epidemiologic studies, emphasis is placed on studies that characterize quantitative relationships between NO<sub>2</sub> and health effects, examine exposure metrics that well represent the variability in concentrations in the study area, consider the potential influence of other air pollutants and factors correlated with NO<sub>2</sub>, examine potential at-risk populations and lifestages, or combine information across multiple cities. With respect to the evaluation of controlled human exposure and toxicological studies, emphasis is placed on studies that examine effects relevant to humans and NO<sub>2</sub> concentrations that are defined in this ISA to be relevant to ambient exposures. Based on peak ambient concentrations ([Section 2.5](#)) and the ISA definition that ambient-relevant exposures be within one to two orders of magnitude of current levels, NO<sub>2</sub> concentrations of 5,000 ppb<sup>1</sup> or less are defined to be ambient relevant. Experimental studies with higher exposure concentrations were considered if they examined dosimetry or potential modes of action. For the evaluation of human exposure to ambient NO<sub>2</sub>, emphasis is placed on

---

<sup>1</sup> The 5,000-ppb upper limit applies largely to animal toxicological studies but also a few controlled human exposure studies.

studies that examine the adequacy of methods used to assess exposures, such as central site monitors, land use regression (LUR) models, and personal exposure monitors. The ISA also emphasizes studies that examine factors that influence exposure, such as time-activity patterns and building ventilation characteristics.

Integrating information across scientific disciplines and related health outcomes and synthesizing evidence from previous and recent studies, the ISA draws conclusions about relationships between NO<sub>2</sub> exposure and health effects. Determinations are made about causation not just association and are based on judgments of aspects such as the consistency, coherence, and biological plausibility of observed effects (i.e., evidence for effects that can be linked in a mode of action) as well as related uncertainties. As such, determinations of causation are made not on evidence for individual disciplines or individual outcomes but on the integrated body of evidence. The ISA uses a formal causal framework ([Table II](#) of the [Preamble](#)) to classify the weight of evidence according to the five-level hierarchy summarized below.

- **Causal relationship:** the consistency and coherence of evidence integrated across scientific disciplines and related health outcomes are sufficient to rule out chance, confounding, and other biases with reasonable confidence.
- **Likely to be a causal relationship:** there are studies where results are not explained by chance, confounding, or other biases, but uncertainties remain in the evidence overall. For example, the influence of other pollutants is difficult to address, or evidence among scientific disciplines may be limited or inconsistent.
- **Suggestive of, but not sufficient to infer, a causal relationship:** evidence is generally supportive but not entirely consistent or overall is limited. Chance, confounding, and other biases cannot be ruled out.
- **Inadequate to infer a causal relationship:** there is insufficient quantity, quality, consistency, or statistical power of results from studies.
- **Not likely to be a causal relationship:** several adequate studies, examining the full range of human exposure concentrations and potential at-risk populations and lifestages, consistently show no effect.

---

## 1.3 Content of the Integrated Science Assessment

The ISA consists of the [Preamble](#), [Preface](#) (legislative requirements and history of the primary NO<sub>2</sub> NAAQS), [Executive Summary](#), and seven chapters. [Chapter 1](#) synthesizes the scientific evidence that best informs policy-relevant questions that frame this review of the primary NO<sub>2</sub> NAAQS. [Chapter 2](#) characterizes the sources, atmospheric processes of oxides of nitrogen, and trends in ambient concentrations. [Chapter 3](#) describes methods to estimate human exposure to oxides of nitrogen and the impact of error in exposure estimates on associations with health effects. [Chapter 4](#) describes the dosimetry and

potential modes of action for NO<sub>2</sub> and NO. [Chapter 5](#) and [Chapter 6](#) evaluate and integrate epidemiologic, controlled human exposure, and toxicological evidence for health effects related to short-term and long-term exposure to oxides of nitrogen, respectively. [Chapter 7](#) evaluates information on potential at-risk populations and lifestyles.

The purpose of this chapter is not to summarize each of the aforementioned chapters but to synthesize the key findings on each topic that are considered in characterizing NO<sub>2</sub> exposure and relationships with health effects. This chapter also integrates information across the ISA to address policy-relevant issues such as NO<sub>2</sub> exposure durations and patterns associated with health effects, concentration-response relationships, and the public health impact of NO<sub>2</sub>-related health effects ([Section 1.6](#)). A key consideration in the health effects assessment is the extent to which evidence indicates that NO<sub>2</sub> exposure independently causes health effects versus indicating that NO<sub>2</sub> may be serving just as a marker for a broader mixture of air pollutants, especially those related to traffic. To that end, this chapter draws upon information about the sources, distribution, and exposure to ambient NO<sub>2</sub> and identifies pollutants and other factors correlated with the distribution of or exposure to ambient NO<sub>2</sub> that can potentially influence epidemiologic associations observed between health effects and NO<sub>2</sub> exposure ([Section 1.4.3](#)). The discussions of the health effects evidence and causal determinations ([Section 1.5](#)) describe the extent to which epidemiologic studies accounted for these factors and the extent to which findings from controlled human exposure and animal toxicological studies support independent relationships between NO<sub>2</sub> exposure and health effects.

---

## **1.4 From Emissions Sources to Exposure to Nitrogen Dioxide**

Characterizing human exposure is key to understanding the relationships between ambient NO<sub>2</sub> exposure and health effects. The sources of oxides of nitrogen and the transformations that occur in ambient air influence the spatial and temporal pattern of NO<sub>2</sub> concentrations in the air. These patterns have implications for variation in exposure in the population, the adequacy of methods used to estimate exposure, and in turn, the strength of inferences that can be drawn from associations observed in epidemiologic studies between NO<sub>2</sub> exposure and health effects.

---

### **1.4.1 Emission Sources and Distribution of Ambient Concentrations**


The strength and distribution of emissions sources are important determinants of the distribution of NO<sub>2</sub> in the ambient air, and in turn, human exposure. Information on

emissions is available for NO<sub>x</sub>, which is emitted primarily as NO. NO rapidly reacts with radicals and ozone (O<sub>3</sub>) to form NO<sub>2</sub> in the air. Based on the 2011 National Emissions Inventory, the largest single source of NO<sub>x</sub> emissions in the U.S. overall and in major population centers (city and surrounding communities) is highway vehicles (40–67%; [Section 2.3](#), [Table 2-1](#)). Sources such as electric utilities, commercial and residential boilers, and industrial facilities are more variable across locations but can be important contributors to ambient NO<sub>2</sub> concentrations for the U.S. as a whole and in certain populated areas. Some of these smaller sources can affect local air quality with large, transient emissions of NO<sub>x</sub>. Natural sources such as microbial processes in soil and wildfires contribute 2% of emissions in U.S. population centers, and emissions from natural and anthropogenic sources from continents other than North America (i.e., North American Background) account for less than 1% (typically 0.3 ppb) of ambient concentrations ([Section 2.5.6](#)). Although highway vehicles are a large, ubiquitous source of NO<sub>x</sub>, the varying presence and mix of specific emissions sources across locations can contribute to heterogeneity in ambient NO<sub>2</sub> concentrations regionally and locally, which has implications for variation in exposure to ambient NO<sub>2</sub> within the population.

In addition to emissions sources, factors that influence NO<sub>2</sub> ambient concentrations include chemical transformations, transport to other locations, meteorology, and deposition to surfaces ([Figure 1-1](#) and in more detail, [Figure 2-1](#)). NO and NO<sub>2</sub> react with gas phase radicals and O<sub>3</sub> to form other oxides of nitrogen such as peroxyacetyl nitrate (PAN) and nitric acid (HNO<sub>3</sub>; [Section 2.2](#)). NO and NO<sub>2</sub> also are involved in reaction cycles with radicals produced from volatile organic compounds (VOCs) to form O<sub>3</sub>. The reactions of NO and NO<sub>2</sub> into other oxides of nitrogen typically occur more slowly than the interconversion between NO<sub>2</sub> and NO does, and NO and NO<sub>2</sub> are the most prevalent oxides of nitrogen in populated areas. HNO<sub>3</sub> and PAN can make up a large fraction of ambient oxides of nitrogen downwind of major emission sources.

Sources, atmospheric transformations, and meteorology contribute to the temporal trends observed in ambient NO<sub>2</sub> concentrations. As a result of pollution control technologies on vehicles and electric utilities ([Section 2.3.2](#)), NO<sub>x</sub> emissions from highway vehicles and fuel combustion decreased by 49% in the U.S. from 1990 to 2013 ([Figure 2-2](#)). During that time (1990–2012), U.S.-wide annual average NO<sub>2</sub> concentrations decreased by 48% ([Figure 2-22](#)). In addition to long-term trends, ambient NO<sub>2</sub> concentrations show seasonal trends, with higher concentrations measured in the winter than summer. Reflecting trends in traffic, ambient concentrations at most urban sites are higher on weekdays than weekends, and within a day, concentrations peak in early mornings, decrease until late afternoon, then increase again in early evening corresponding with morning and evening commutes. Diurnal trends in ambient NO<sub>2</sub> also are affected by meteorology, with

concentrations rising during the night when atmospheric mixing is reduced because of low wind speeds and low mixing layer heights.



Note: The inner shaded box depicts  $\text{NO}_x$  [sum of nitric oxide ( $\text{NO}$ ) and nitrogen dioxide ( $\text{NO}_2$ )]. The outer box contains oxides of nitrogen formed from reactions of  $\text{NO}_x$  ( $\text{NO}_2$ ). Oxides of nitrogen in the outer and inner boxes ( $\text{NO}_x + \text{NO}_2$ ) are collectively referred to as  $\text{NO}_y$  by the atmospheric sciences community.

Source: National Center for Environmental Assessment. For more details on the various reactions, see [Figure 2-1](#).

**Figure 1-1 Reactions of oxides of nitrogen species in the ambient air.**

The spatial variation in emissions sources and chemical transformation of oxides of nitrogen likely contribute to the variability in ambient  $\text{NO}_2$  concentrations observed at regional, urban, neighborhood, and near-road scales ([Section 2.5](#)). Measurements from U.S. air monitoring networks<sup>1</sup> of several hundred sites ([Section 2.5.1](#)) show wide variation in ambient  $\text{NO}_2$  concentrations across the U.S. Across central site monitors, the mean 1-h daily maximum ambient  $\text{NO}_2$  concentration for 2011–2013 was 19 ppb, and the

<sup>1</sup> The air monitoring networks serve many objectives: determining compliance with the NAAQS, providing the public with air pollution data in a timely manner, and providing estimates of ambient exposure for research studies.

5th to 99th percentile range was 2–55 ppb ([Table 2-3](#)). The mean annual average NO<sub>2</sub> concentration was 8.6 ppb, and the 5th to 99th percentile range was 1.4–22.5 ppb ([Table 2-4](#)). Ambient NO<sub>2</sub> concentrations are higher in large cities than in less populated areas ([Figures 2-11](#) and [2-12](#)). Ambient NO<sub>2</sub> concentrations also can vary widely across sites within cities where vehicle emissions are the major source ([Figure 2-14](#), [Table 2-5](#)). Some sites agree well with each other in terms of temporal correlations or magnitude of concentration. However, the siting of most monitors away from sources likely means that the monitors do not capture the extent of variability in ambient NO<sub>2</sub> in a city. Preliminary data from the first year of the near-road network for 41 U.S. cities show that near-road (within 50 m) sites have higher mean NO<sub>2</sub> concentrations than many other sites within an urban area but not always the highest 1-hour concentrations ([Table 2-10](#)). Across near-road sites, means for 1-h daily maximum NO<sub>2</sub> concentrations were 9–27 ppb, and 98th percentiles were 35–74 ppb. For durations of 1 hour or less, studies measured NO<sub>2</sub> concentrations of 5.8 to 120 ppb within 20 m of a road, which are up to 100% higher than concentrations 80 to 400 m from the same road ([Section 2.5.3](#), [Table 2-8](#)). The wide variation in ambient NO<sub>2</sub> concentrations across spatial and temporal scales, largely influenced by vehicle emissions, can contribute to variation in NO<sub>2</sub> exposure within the population and has important implications for adequately characterizing exposure.

---

#### **1.4.2 Assessment of Nitrogen Dioxide Exposure in Health Effect Studies**

Characterizing the adequacy of various exposure assessment methods to represent the variability in ambient concentrations in a location is key in drawing inferences from epidemiologic associations with health effects. Exposure is determined by concentrations in specific ambient, indoor, and in-vehicle locations and time spent in those locations ([Section 3.4.1](#)). People vary in the locations where they spend time and time spent in those locations ([Section 3.4.3.1](#)), and NO<sub>2</sub> concentrations can vary widely across outdoor, indoor, and in-vehicle locations ([Figure 3-1](#)). Measures of NO<sub>2</sub> exposure that do not fully account for the variability in ambient concentrations and people's activity patterns have some amount of error, and this error can impact the characterization of relationships between NO<sub>2</sub> exposure and health effects. The extent and impact of error can differ by exposure assessment method and by study design. Errors in representing the temporal and spatial variability in short-term and long-term averages, respectively, of ambient NO<sub>2</sub> concentrations in a given area and exposures of the population can attenuate relationships between NO<sub>2</sub> exposure and health effects. For some long-term NO<sub>2</sub> exposure estimates, the mismatch in where NO<sub>2</sub> is measured and where people are located can inflate health effect estimates. Exposure error also can impact the precision [i.e., 95% confidence interval (CI)] of health effect estimates due to variable relationships between personal

and ambient NO<sub>2</sub> across people and time and differences in nonambient exposures. Thus, for short-term exposure, this ISA emphasizes studies indicating that exposure metrics well captured temporal (e.g., day to day) changes in NO<sub>2</sub>. For long-term exposure, this ISA emphasizes studies that well captured variability among people living in locations that differ in ambient NO<sub>2</sub> concentrations ([Section 3.4.5](#)).

Ambient NO<sub>2</sub> concentrations at central site monitors represent both short-term and long-term exposure with some amount of error. Central site monitors do not cover all locations where people live or spend their time and also are not likely to capture the temporal or spatial variability in ambient NO<sub>2</sub> concentrations in a given area. Long-term personal NO<sub>2</sub> exposures and their relationships with ambient NO<sub>2</sub> concentrations are not well characterized. A wide range of correlations (0.12 to 0.43; [Table 3-6](#)) is observed between short-term total (ambient plus nonambient components) personal and ambient NO<sub>2</sub> concentrations and in ambient NO<sub>2</sub> concentrations across sites within some cities ([Section 2.5.2](#)). On one hand, poor correlations do not necessarily mean that concentrations at central sites are inadequate exposure metrics because the data may not reflect relationships between ambient NO<sub>2</sub> concentrations and the ambient component of personal exposure ([Section 3.4.2](#)). On the other hand, the correlations could mean that there is variation among individuals in how well short-term temporal changes in NO<sub>2</sub> concentrations at central site monitors represent temporal changes in ambient exposure.

Proximity to roads may contribute substantially to short-term and long-term ambient NO<sub>2</sub> exposure among people living or working near roads or commuting on roads, and the 2008 ISA for Oxides of Nitrogen cited the potential for in-vehicle exposures to dominate short-term personal exposure ([U.S. EPA, 2008c](#)). Data from the U.S. near-road monitoring network are too preliminary to allow for meaningful comparisons of the temporal or spatial patterns in NO<sub>2</sub> near and away from roads. However, annual avg NO<sub>2</sub> concentrations often are higher at near-road sites than other sites within an urban area, which is consistent with NO<sub>2</sub> being formed from NO emitted by vehicles on the road. These data indicate that central site monitors may not represent the magnitude of long-term average NO<sub>2</sub> concentrations near roads. Whether NO<sub>2</sub> concentrations at central sites and near-road sites differ with respect to correlations with personal exposures is unknown. Thus, it is unclear how error produced from using ambient NO<sub>2</sub> concentrations at central site monitors to represent near-road exposures impacts health effect associations. Another issue in estimating exposure from central site monitors is that the chemiluminescence measurement method tends to overestimate ambient NO<sub>2</sub> concentrations because of interference from other oxides of nitrogen. However, interference generally is less than 10% in urban areas ([Section 2.4.1](#)) and may not vary widely day to day ([Section 3.4.3.4](#)) to produce substantial error in characterizing daily changes in NO<sub>2</sub> concentration. It is not clear how interference compares among locations

and what impact interference may have on comparisons of long-term average NO<sub>2</sub> concentrations among locations.

Given the aforementioned sources of uncertainty, there is confidence in some results relating asthma exacerbation ([Sections 5.2.2.2](#) and [5.2.2.5](#)) to NO<sub>2</sub> measured at central site monitors based on demonstrations of good correlation in short-term NO<sub>2</sub> averages among sites within a city or with total personal exposure. Results for short-term averages of NO<sub>2</sub> measured at people's locations ([Sections 5.2.2.2](#) and [5.2.2.5](#)) also are a source of confidence. Such metrics include total NO<sub>2</sub> exposure as well as NO<sub>2</sub> measured outdoors at schools and indoors at homes and schools. Further, personal ambient NO<sub>2</sub> was examined in natural experiments in which people spent well-defined periods of time in outdoor locations ([Section 5.2.2.2](#)). A time-weighted average of NO<sub>2</sub> concentrations in people's locations correlated well with total personal short-term NO<sub>2</sub> exposures ([Section 3.4.3.1](#)). Thus, although NO<sub>2</sub> concentrations in a specific location may not represent potentially important exposures across the range of locations where people spend time, they can represent a component of personal exposure and aid in inference about NO<sub>2</sub>-related health effects. Spatially resolved exposure metrics also have shown larger magnitude associations with health effects compared to NO<sub>2</sub> measured at a single central site monitor or averaged over multiple monitors in a city ([Section 3.4.3.1](#)). Inference for results relating asthma exacerbation to short-term total personal or indoor NO<sub>2</sub> concentrations also is strong because these metrics can help distinguish NO<sub>2</sub>-related effects from the potential influence of other traffic-related pollutants. Because the mix of sources differs indoors and outdoors, correlations between NO<sub>2</sub> and some copollutants are lower for total personal or indoor metrics than ambient metrics ([Section 3.4.4.3](#), [Table 3-13](#)). Results for total personal and indoor NO<sub>2</sub> concentrations also can aid understanding of health effects related to ambient exposure for populations whose indoor exposures are affected by the penetration of ambient NO<sub>2</sub> from open windows or other factors that increase building air exchange rate ([Section 3.4.3.3](#)). In the case of asthma exacerbation, one study indicated a good personal-ambient NO<sub>2</sub> correlations.

As with short-term exposure, many studies indicate that their long term NO<sub>2</sub> exposure metrics adequately capture the variation in ambient NO<sub>2</sub> exposures among people. For example, asthma development is associated with long-term average ambient NO<sub>2</sub> concentrations measured at central site monitors 1 km from children's homes or schools ([Section 6.2.2.1](#)). For asthma development and other health effects, there is an increase in recent studies that use LUR models to estimate long-term NO<sub>2</sub> exposures at the neighborhood scale or at an individual's residence. Compared with NO<sub>2</sub> estimated by LUR, long-term average NO<sub>2</sub> concentrations at central site monitors often show smaller associations with a health effect but larger associations in some studies ([Section 3.4.5.2](#)). Many epidemiologic studies in this ISA demonstrated their models to predict well the

patterns in long-term average ambient NO<sub>2</sub> concentrations in the study areas. In these studies, LUR models appear to account for differences among people in distance between home and sources of NO<sub>2</sub> ([Section 3.5](#)).

For short-term and long-term exposure, evaluating how well NO<sub>2</sub> metrics capture the variability in ambient concentrations or exposure and the potential impact of exposure error is a key consideration in drawing inferences about NO<sub>2</sub>-related health effects from epidemiologic studies. Particularly for asthma exacerbation and asthma development, associations are observed with personal, central site, location-specific, or LUR NO<sub>2</sub> metrics that are indicated to well represent temporal and spatial variability in short-term and long-term NO<sub>2</sub> exposure, respectively.

---

### **1.4.3 Factors Potentially Correlated with Nitrogen Dioxide Exposure to Consider in Evaluating Relationships with Health Effects**

The large influence of motor vehicle emissions on the distribution of ambient NO<sub>2</sub> concentrations not only affects the assessment of NO<sub>2</sub> exposure but also has implications for co-exposure to other traffic-related pollutants. NO<sub>2</sub> concentrations are higher near roads as are concentrations of elemental or black carbon (EC/BC), ultrafine particles (UFP), carbon monoxide (CO), and VOCs ([Section 3.3.1](#)). The exact nature of gradients varies among pollutants, but concentrations of traffic-related pollutants, including NO<sub>2</sub>, decrease with increasing distance from the road. PM<sub>2.5</sub><sup>1</sup> and organic carbon (OC) do not show clear gradients; however, a portion of PM<sub>2.5</sub> and OC comes from vehicle emissions. These correlations and evidence that the copollutants show relationships with many of the same health effects as NO<sub>2</sub> and have similar modes of action ([Appendix](#) to this ISA) point to the importance of evaluating the potential for NO<sub>2</sub>-related health effects to be confounded (i.e., biased) by PM<sub>2.5</sub> or traffic-related pollutants or for NO<sub>2</sub> to represent a mixture of such pollutants. Common sources, atmospheric reactions, or similar trends due to meteorologic conditions extend the potential for co-exposures to pollutants beyond those emitted from vehicles. Factors such as socioeconomic status (SES), season, and temperature also show correlations with NO<sub>2</sub> concentrations and relationships with similar health effects. The potential for a particular factor to confound NO<sub>2</sub>-health effect associations varies depending on the extent of correlation with NO<sub>2</sub> concentrations, the nature of the relationship with the health effect, and study design (i.e., whether temporal variation in short-term exposure or spatial variation in long-term exposure is examined).

---

<sup>1</sup> In general terms, particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm, a measure of fine particles.

Short-term average NO<sub>2</sub> concentrations show a range of correlations with PM<sub>2.5</sub> and traffic-related copollutants ([Figure 3-6](#), [Table 3-10](#)), but high correlations are observed often. For example, for averaging times of 1 to 24 hours, the 25th to 75th percentile ranges of correlation coefficients are 0.41–0.61 for PM<sub>2.5</sub>, 0.58–0.67 for EC, and 0.59–0.96 for CO. Limited data indicate similar correlations with short-term averages of VOCs, and lower correlations with OC. Long-term average ambient NO<sub>2</sub> concentrations show correlations with PM<sub>2.5</sub> and CO similar to short-term averages, but the distribution of correlations is shifted to higher values. Correlations of long-term averages of NO<sub>2</sub> with EC/BC, VOCs, OC, and UFP are not well characterized ([Figure 3-6](#)). Information on seasonal correlations between ambient concentrations of NO<sub>2</sub> and key copollutants is sparse, but there is some indication of lower NO<sub>2</sub>–PM<sub>2.5</sub> correlations for short-term averages in the warm season ([Section 3.4.4.1](#)). These data point to potentially lower confounding by PM<sub>2.5</sub> in the warm season. Although traffic-related copollutants and PM<sub>2.5</sub> have been associated with many of the same health effects as NO<sub>2</sub> ([Appendix to this ISA](#)), the wide range of correlations with short-term and long-term average NO<sub>2</sub> concentrations indicates variation among locations in confounding potential.

Much of the data characterizing correlations of NO<sub>2</sub> with PM<sub>2.5</sub> and traffic-related copollutants are based on measurements at central site monitors. The varying spatial patterns among pollutants may obscure true correlations across study areas or correlations in personal exposure. Except for UFP, the few available data do not show systematically higher correlations near roads ([Figure 3-6](#)). However, compared with ambient concentrations, correlations can be weaker for short-term average personal exposures of NO<sub>2</sub> with PM<sub>2.5</sub> ( $r = 0.06$  to  $0.38$ ), EC ( $r = 0.22$  to  $0.49$ ), and VOCs ( $r = -0.42$  to  $0.14$ ) ([Table 3-13](#), [Section 3.4.4.3](#)). Correlations of short-term averages of NO<sub>2</sub> with PM<sub>2.5</sub> and BC sometimes can be lower indoors than outdoors ([Table 3-12](#) and [Table 3-14](#)). These limited data indicate that associations of short-term personal or indoor NO<sub>2</sub> exposures with health effects may be less subject to confounding by PM<sub>2.5</sub> or certain traffic-related copollutants. In some locations, short-term average ambient NO<sub>2</sub> concentrations are related more strongly to personal PM than personal NO<sub>2</sub> exposure. However, recent data show negative to moderate correlations between ambient NO<sub>2</sub> concentrations and personal PM<sub>2.5</sub> or EC ( $r = -0.19$  to  $0.44$ ; [Table 3-11](#)), suggesting that ambient NO<sub>2</sub> concentrations are not necessarily just a surrogate for personal PM exposure. The varying correlations for short-term average concentrations of NO<sub>2</sub> with other traffic-related pollutants and PM<sub>2.5</sub> across various microenvironments indicate that the potential for confounding by the copollutants of primary concern varies by the exposure assessment method. Similar information to compare copollutant correlations among microenvironments is not available for long-term average NO<sub>2</sub> concentrations.

Other potential confounding factors to consider for long-term NO<sub>2</sub> exposure are measures of traffic proximity or intensity, which could represent exposure to other pollutants that display gradients with distance to road. Although NO<sub>2</sub> is not unique to vehicle emissions and can indicate sources such as off-highway vehicles and electric utilities (Section 2.3), distance to roads, the length of nearby roads, and vehicle counts are predictors of ambient NO<sub>2</sub> concentrations in LUR models (Section 3.2.2.1). Given recent findings linking residential proximity to roads with respiratory effects and possibly with cardiovascular effects and mortality (HEI, 2010), roadway proximity could confound NO<sub>2</sub>-health effect associations by indicating exposure to traffic pollution. Studies considering the influence of exposure to traffic, including residential proximity to roads, are another line of evidence used to assess whether long-term NO<sub>2</sub> exposure independently affects health.

Short-term and long-term averages of NO<sub>2</sub> also show a range of correlations with the copollutants PM<sub>10</sub>,<sup>1</sup> SO<sub>2</sub>, and O<sub>3</sub>. Short-term and long-term average NO<sub>2</sub> concentrations tend to be moderately correlated with PM<sub>10</sub> ( $r$  for 25th–75th percentiles = 0.40–0.66 for short-term averages, 0.44–0.75 for long-term averages) and SO<sub>2</sub> (Figure 3-6, Table 3-10). Short-term averages of O<sub>3</sub> often are inversely correlated with NO<sub>2</sub>, and peak correlations are moderate ( $r$  for 25th–75th percentile = –0.51 to 0.32) even in the summer, when O<sub>3</sub> concentrations are higher (Table 3-10). Higher correlations are observed between long-term averages of NO<sub>2</sub> and O<sub>3</sub> ( $r$  for 25th–75th percentiles = 0.26–0.63). The wide range of correlations observed for short-term and long-term average concentrations of NO<sub>2</sub> with PM<sub>10</sub>, SO<sub>2</sub>, and O<sub>3</sub> indicates the variable potential for these pollutants to confound health effect associations for NO<sub>2</sub>. For short-term average NO<sub>2</sub> concentrations, the distributions of correlations with PM<sub>10</sub> and SO<sub>2</sub> are shifted to lower values compared to correlations with most traffic-related pollutants, indicating the lower potential for confounding. Specific to long-term exposure, relationships of long-term SO<sub>2</sub> and O<sub>3</sub> exposure with many of the health effects evaluated in this ISA are uncertain (Appendix to this ISA) as is their potential to confound NO<sub>2</sub>-health effect associations.

Residence near traffic has been linked to higher noise or stress levels, but information on whether noise or stress confounds health effect associations with short-term or long-term NO<sub>2</sub> exposure is limited. Weak to moderate correlations tend to be reported between noise and short-term ( $r$  = 0.14–0.62) and long-term ( $r$  = 0.22–0.46) average ambient NO<sub>2</sub> concentrations, but high correlations have been observed for short-term NO<sub>2</sub> averages ( $r$  = 0.83; Section 3.4.4.4). The impact of short-term changes in noise or stress on health effects is not well characterized, but some data link long-term noise exposure and stress to cardiovascular effects (Section 6.3.2) and decreases in cognitive function

---

<sup>1</sup> In general terms, particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 μm, a measure of thoracic particles.

([Section 6.4.4](#)). Thus, the potential for stress or noise to confound NO<sub>2</sub>-health effect associations is uncertain for short-term exposure but may exist for long-term exposure.

Other potential confounding factors to consider include temperature and humidity for associations of health effects with short-term NO<sub>2</sub> exposure because of similar time-varying patterns as ambient NO<sub>2</sub> concentrations and health effects. Also, similar to many health effects, short-term averages of ambient NO<sub>2</sub> concentration vary by day of the week and season and exhibit long-term time trends. For studies of long-term NO<sub>2</sub> exposure that compare individuals living in different locations, it is important to evaluate confounding by factors such as SES, race ([Sections 7.5.2](#) and [7.5.3](#)), and age, all of which can covary with long-term NO<sub>2</sub> exposures among individuals and spatially with long-term ambient NO<sub>2</sub> concentrations among communities.

For studies reviewed in this ISA, the main method to account for potential confounding is multivariable models that include NO<sub>2</sub> concentrations and the putative confounder. The NO<sub>2</sub> effect estimate represents the effect of NO<sub>2</sub>, keeping the level of the covariate constant. Confounding is assessed by examining the change in the magnitude of the effect estimate and width of the 95% CI, not a change in statistical significance. There are limitations to multivariable models, and correlations between variables and the exposure assessment method are important considerations in drawing inferences about confounding ([Section 5.1.2.1](#)). High correlations between NO<sub>2</sub> concentrations and the potential confounder can misleadingly decrease or increase the magnitude or precision of the effect estimate for NO<sub>2</sub> or the covariate and are a particular concern for models that include a traffic-related copollutant or include three or more pollutants in the same model. Potential differences in exposure measurement error between NO<sub>2</sub> and the copollutant also limit inferences from copollutant models about an independent NO<sub>2</sub> association. Inference from copollutant models may be stronger for pollutants measured at people's locations and for personal exposure than for pollutants measured at central site monitors. As in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), a key issue in this ISA is the adequacy in which epidemiologic studies examined potential confounding by traffic-related copollutants and the extent to which other lines of evidence support independent relationships between NO<sub>2</sub> exposure and health effects.

---

## 1.5 Health Effects of Nitrogen Dioxide Exposure


This ISA evaluates relationships between an array of health effects and short-term ([Chapter 5](#)) and long-term ([Chapter 6](#)) exposures to NO<sub>2</sub> as examined in epidemiologic, controlled human exposure, and animal toxicological studies. Short-term exposures are defined as those with durations of minutes up to 1 month, with most studies examining

effects related to exposures in the range of 1 hour to 1 week. Long-term exposures are defined as those with durations of more than 1 month to years. Drawing from the health effects evidence described in detail in [Chapter 5](#) and [Chapter 6](#) information on dosimetry and modes of action presented in [Chapter 4](#), as well as issues regarding exposure assessment and potential confounding described in [Chapter 3](#) and [Section 1.4](#), the subsequent sections and [Table 1-1](#) present the key evidence that informs the causal determinations for relationships between NO<sub>2</sub> exposure and health effects.

---

### 1.5.1 Respiratory Effects

The strongest evidence for relationships of short-term and long-term NO<sub>2</sub> exposure with respiratory effects is that for asthma exacerbation and asthma development, respectively. Such relationships also are supported by information on the dosimetry for inhaled NO<sub>2</sub> and by evidence for effects that can be linked together in a mode of action. Although it is unclear how ambient-relevant NO<sub>2</sub> exposures compare with NO<sub>2</sub> produced endogenously in the lung during inflammation and other immune responses ([Section 4.2.2.4](#)), ambient-relevant concentrations of inhaled NO<sub>2</sub> are absorbed throughout the respiratory tract. The conducting airways have the primary role in asthma, and dosimetry models predict that total NO<sub>2</sub> dose is relatively constant across the tracheobronchial region ([Section 4.2.2.3](#)). NO<sub>2</sub> is a reactive gas that rapidly reacts with antioxidants and other constituents of the epithelial lining fluid of the respiratory tract. While antioxidant reactions often are thought to reduce oxidant species, reactions with NO<sub>2</sub> lead to the formation of secondary oxidation products ([Section 4.2.2.1](#)). Antioxidant levels vary across regions of the respiratory tract, and the variable physical and chemical nature of the respiratory tract may influence the site in the respiratory tract of NO<sub>2</sub> uptake and NO<sub>2</sub>-induced effects. The formation of secondary oxidation products likely is the initiating event in the mode of action proposed for NO<sub>2</sub> ([Section 4.3.2.1](#)). These products can induce oxidative stress, inflammation, allergic responses, and altered immune function, all of which are events in the mode of action proposed for NO<sub>2</sub>-related asthma exacerbation and asthma development ([Figures 1-2](#) and [4-1](#)) as described in the sections that follow.



Note: NO<sub>2</sub> = nitrogen dioxide. Modified from [Figures 4-1, 4-2, and 4-3](#) in [Section 4.3.5](#) to depict the strength of evidence for effects occurring at ambient-relevant concentrations. Solid arrows and dark boxes represent pathways for which there is consistent evidence. Dotted lines and white boxes represent uncertain pathways because evidence is limited or inconsistent.

**Figure 1-2 Characterization of the evidence for health effects related to nitrogen dioxide exposure in a mode of action framework.**

### Respiratory Effects and Short-Term Exposure to Nitrogen Dioxide

A causal relationship exists between short-term NO<sub>2</sub> exposure and respiratory effects based on evidence for asthma exacerbation. The conclusion is strengthened from the likely to be a causal relationship determined in the 2008 ISA for Oxides of Nitrogen because the combined controlled human exposure and epidemiologic evidence can be linked in a coherent and biologically plausible pathway to explain how NO<sub>2</sub> exposure can trigger an asthma exacerbation ([Table 1-1](#)). There is some evidence indicating that short-term NO<sub>2</sub> exposure may be related to other respiratory effects, such as exacerbation of allergy or chronic obstructive pulmonary disease (COPD), respiratory infection, respiratory mortality, and respiratory effects in healthy people. However, because of inconsistency across disciplines and/or limited information to support biological plausibility, there is uncertainty whether short-term NO<sub>2</sub> exposure has independent relationships with nonasthma respiratory effects ([Section 5.2.9, Table 5-39](#)).

Although indicating NO<sub>2</sub>-associated asthma exacerbation, epidemiologic evidence on its own does not rule out the influence of other traffic-related pollutants ([Section 1.4.3](#)). The key evidence that NO<sub>2</sub> exposure can independently exacerbate asthma are the findings from previous controlled human exposure studies for increases in airway responsiveness in adults with asthma following NO<sub>2</sub> exposures of 200 to 300 ppb for 30 minutes and 100 ppb for 1 hour. Airway hyperresponsiveness can lead to poorer control of symptoms and is a hallmark of asthma. A recent meta-analysis shows that NO<sub>2</sub> exposure reduced by one-half the dose of a challenge agent required to increase airway responsiveness, which is a measure of a clinically relevant change. This evidence for clinically relevant increases in airway responsiveness induced by NO<sub>2</sub> exposures that are not much higher than peak ambient concentrations ([Section 2.5](#)) provides plausibility that asthma can be exacerbated by ambient NO<sub>2</sub> exposures. Biological plausibility also is supported by experimental studies of adults with asthma showing NO<sub>2</sub> exposures of 260 ppb for 15 or 30 minutes to enhance allergic inflammation, which by increasing airway responsiveness, is a key event in the mode of action proposed for asthma exacerbation ([Figure 1-2](#)).

The NO<sub>2</sub>-induced increases observed in airway responsiveness and allergic inflammation indicate that the epidemiologic evidence for increases in hospital admissions, ED visits, and symptoms for asthma, as well as decreases in lung function in children with asthma in association with short-term increases in NO<sub>2</sub> concentration, can plausibly be attributed to NO<sub>2</sub> exposure. As uncontrolled symptoms are the major reason for seeking medical treatment, coherence also is demonstrated among the various asthma-related outcomes examined in epidemiologic studies. Associations are observed in studies with maximum concentrations of 48–106 ppb for 24-h avg NO<sub>2</sub> and 59–306 ppb for daily 1-h max NO<sub>2</sub>. Epidemiologic evidence is consistent across the methods used to estimate NO<sub>2</sub> exposure and include personal ambient and total NO<sub>2</sub> measurements, NO<sub>2</sub> measured outside children's schools, NO<sub>2</sub> measured inside children's schools and homes, and ambient NO<sub>2</sub> concentrations averaged across central site monitors in a city. NO<sub>2</sub> measured at people's locations, whether outdoors, indoors, or all locations combined, likely represent exposure better than NO<sub>2</sub> measured at central site monitors and lend confidence in epidemiologic evidence base relating short-term NO<sub>2</sub> exposure to asthma exacerbation. Further, the results for airway responsiveness and allergic inflammation increasing after NO<sub>2</sub> exposures of 100–300 ppb for up to 1 hour support the few epidemiologic results of increased respiratory effects in adults with asthma and healthy adults associated with NO<sub>2</sub> exposure (range 5.7–154 ppb) occurring over 2 or 5 hours at locations near roads.

Not all evidence supports NO<sub>2</sub>-related respiratory effects. NO<sub>2</sub> exposure has variable effects on oxidative stress in experimental studies. NO<sub>2</sub>-related decreases in lung function are observed in epidemiologic but not controlled human exposure studies. In this ISA, lung function is distinguished from airway responsiveness assessments by co-exposure to

a bronchoconstrictor in the latter but not the former. Neural reflexes do not appear to be involved ([Figure 1-2](#), [Section 4.3.2.2](#)), but NO<sub>2</sub>-induced (500 ppb) mast cell degranulation in rats suggests airway obstruction, which could lead to decreases in lung function. Thus, additional coherence can be drawn among these results, evidence for allergic inflammation, and the epidemiologic findings for NO<sub>2</sub>-related respiratory effects in populations with asthma that also had high prevalence of allergy.

NO<sub>2</sub> associations with asthma-related effects persist with adjustment for temperature, humidity, season, long-term time trends, as well as PM<sub>10</sub>, SO<sub>2</sub>, or O<sub>3</sub>. Recent studies add findings for NO<sub>2</sub> associations that persist with adjustment for a key copollutant such as PM<sub>2.5</sub> or those from traffic such as EC/BC, UFP, or CO (examined in few studies). Only in a few studies are NO<sub>2</sub> associations eliminated with adjustment for EC/BC, UFP, or a VOC. Confounding by OC, PM metal species, or VOCs is poorly studied, but NO<sub>2</sub> associations with asthma exacerbation tend to persist in the few available copollutant models. In some cases, single-pollutant models indicate asthma-related effects in association with NO<sub>2</sub> but not PM<sub>2.5</sub> or EC/BC, which were moderately correlated with NO<sub>2</sub> ( $r = 0.22-0.57$ ). Recent epidemiologic results also suggest asthma exacerbation in relation to indices that combine NO<sub>2</sub> with EC, PM<sub>2.5</sub>, O<sub>3</sub>, and/or SO<sub>2</sub> concentrations, but neither epidemiologic nor experimental studies strongly indicate synergistic effects between NO<sub>2</sub> and copollutants. Although causality cannot be confirmed from copollutant models, results based on personal exposure or pollutants measured at people's locations provide support for NO<sub>2</sub> associations that are independent of PM<sub>2.5</sub>, EC/BC, OC, or UFP because of comparable measurement error among pollutants. Associations with personal total and indoor NO<sub>2</sub> measurements also support an independent effect of NO<sub>2</sub> exposure because the lower (e.g.,  $r = -0.37$  to  $0.31$ ) correlations observed with many traffic-related copollutants compared to ambient NO<sub>2</sub> concentrations indicate that the findings for personal and indoor NO<sub>2</sub> may be less prone to confounding by the same traffic-related copollutants than findings for ambient NO<sub>2</sub> concentrations ([Section 1.4.3](#)). In the indoor studies, the relative contribution of indoor and outdoor sources to indoor NO<sub>2</sub> concentrations are unknown. And, while associations of outdoor school NO<sub>2</sub> with asthma-related effects persist with adjustment for indoor NO<sub>2</sub> in one group of children, it is unclear whether indoor exposure alters responses of people to outdoor NO<sub>2</sub> exposure.

The nature of the evidence from epidemiologic and experimental studies largely was similar in the 2008 ISA. However, the 2008 ISA did not explicitly evaluate the coherence and biological plausibility for specific respiratory outcome groups. Rather than new evidence, the integrated experimental and epidemiologic evidence for asthma exacerbation, with due weight to controlled human exposure studies, supports a causal relationship between short-term NO<sub>2</sub> exposure and respiratory effects. This includes the uptake of NO<sub>2</sub> in the respiratory tract and formation of reactive oxidation products.

Further, the allergic inflammation and airway responsiveness shown in controlled human exposure studies, asthma symptoms, hospital admissions, and ED visits, associations with NO<sub>2</sub> measured in people's locations (which may better represent exposure), and results from copollutant models with a traffic-related copollutant describe a coherent, biologically plausible pathway linking short-term NO<sub>2</sub> exposure to asthma exacerbation.

### **Respiratory Effects and Long-Term Exposure to Nitrogen Dioxide**

There is likely to be a causal relationship between long-term NO<sub>2</sub> exposure and respiratory effects based on evidence for the development of asthma. The conclusion is strengthened from that determined in the 2008 ISA for Oxides of Nitrogen because whereas previous epidemiologic findings were limited and inconsistent, recent evidence consistently indicates associations between ambient NO<sub>2</sub> concentrations and asthma incidence in children and is supported by experimental studies that characterize a potential mode of action for NO<sub>2</sub> (Table 1-1). As with short-term NO<sub>2</sub> exposure, the evidence base varies across respiratory outcomes, and there is more uncertainty as to whether long-term NO<sub>2</sub> exposure decreases lung function or lung development or increases risk of COPD, respiratory infection, or respiratory mortality.

Providing a strong basis for relating long-term NO<sub>2</sub> exposure to asthma development, many studies estimated NO<sub>2</sub> exposures at or near children's homes or schools. Asthma incidence is associated with NO<sub>2</sub> measured at sites 1 km from schools or homes and with NO<sub>2</sub> exposures estimated from LUR models that were shown to well predict measured concentrations in the communities studied ( $R^2 = 0.68$  or  $0.69$ ; Section 6.2.9, Table 6-5). Results also are consistent for less spatially resolved ambient NO<sub>2</sub> concentrations at central site monitors. Another strength of the recent epidemiologic studies is their aim to isolate the development of asthma from the exacerbation of pre-existing asthma by following children over time, in several cases from birth, and examining NO<sub>2</sub> exposure for periods preceding asthma diagnosis. Asthma incidence is associated with the average NO<sub>2</sub> concentration for the first year of life and NO<sub>2</sub> averaged over multiple years (study means: 14 to 28 ppb), and no single critical exposure period is identified.

Associations with asthma are found with adjustment for SES, smoking exposure, gas stove use, community of residence, and in one study, psychosocial stress. However, potential confounding by traffic-related pollutants or proximity to roads is not examined. The uncertainty in the epidemiologic evidence as to whether NO<sub>2</sub> exposure has an independent effect on asthma development is reduced partly by the biological plausibility provided by a small body of previous experimental studies that characterize a potential mode of action linking NO<sub>2</sub> exposure with asthma development. NO<sub>2</sub> exposure (1,000 to 4,000 ppb) for 6–12 weeks increased airway responsiveness and allergic responses in

rodents. Also lending support is the coherent mode of action information between studies of short-term and long-term NO<sub>2</sub> exposure ([Figure 1-2](#)). Long-term NO<sub>2</sub> exposure also is shown to increase oxidative stress and inflammation but not consistently across studies. The temporal pattern of NO<sub>2</sub> exposure underlying the epidemiologic associations with asthma is not well delineated. However, a few experimental studies show that repeated short-term NO<sub>2</sub> exposures over 4 to 14 days led to the development of allergic responses in healthy adults and healthy rodent models (2,000–4,000 ppb) and to increased airway responsiveness in rodents (4,000 ppb). This evidence for short-term NO<sub>2</sub> exposure supports a relationship between long-term NO<sub>2</sub> exposure and asthma development because it demonstrates the development of asthma-related effects in healthy humans and animal models and indicates that repeated increases in exposure may be important. NO<sub>2</sub> exposures that induce effects related to asthma development are higher than those that induce effects related to asthma exacerbation as described in the preceding section but are within the range of exposures considered to be ambient relevant ([Section 1.2](#)).

Epidemiologic studies continue to show associations of long-term NO<sub>2</sub> exposure with decreases in lung function and development and increased respiratory disease severity in children. These outcomes are associated with similar NO<sub>2</sub> concentrations, durations, and exposure assessment methods as asthma development ([Table 6-5](#)). However, there is more uncertainty whether long-term NO<sub>2</sub> exposure independently can decrease lung function or development or increase respiratory disease severity. Associations of long-term NO<sub>2</sub> exposure with bronchitic symptoms or lung function persisted when adjusted for PM<sub>2.5</sub>, EC, OC, or distance to freeway, but such findings are few in number and inconsistent. Further, NO<sub>2</sub> exposure does not alter lung function in animal models, and the hyperproliferation of lung epithelial cells and fibrosis in adult animals are not related to the lung function changes described in children. While associations of lung function with long-term NO<sub>2</sub> persist after adjustment for short-term NO<sub>2</sub> exposure, most studies of symptoms do not assess the potential influence of short-term NO<sub>2</sub> exposure.

Together, evidence from recent epidemiologic studies and previous experimental studies supporting effects on the development of asthma indicates there is likely to be a causal relationship between long-term NO<sub>2</sub> exposure and respiratory effects. Epidemiologic studies observe associations with NO<sub>2</sub> exposure estimated at or near children's homes or schools, which may better represent differences in ambient NO<sub>2</sub> exposure among subjects compared with less spatially resolved NO<sub>2</sub> measurements from central site monitors. Potential confounding by traffic-related copollutants largely is unexamined for asthma development. However, findings from experimental studies for increased airway responsiveness and allergic responses, which are part of the mode of action proposed for asthma development, are considered to provide some support for an independent effect of long-term NO<sub>2</sub> exposure. Because such evidence is limited, some uncertainty remains in

attributing epidemiologic associations between long-term NO<sub>2</sub> exposure and asthma development specifically to NO<sub>2</sub> among the array of traffic-related pollutants.

---

## 1.5.2 Health Effects beyond the Respiratory System

Epidemiologic studies show associations between NO<sub>2</sub> exposure and health effects in various organ systems, and associations are observed with a similar range of short-term and long-term NO<sub>2</sub> concentrations as respiratory effects ([Table 1-1](#)). However, compared to respiratory effects, there is more uncertainty in relationships with NO<sub>2</sub> exposure, largely in identifying an independent effect from other traffic-related pollutants. For some health effects, epidemiologic findings also are inconsistent. A common source of uncertainty across nonrespiratory health effects is the limited availability of controlled human exposure and/or toxicological studies to inform understanding of how ambient-relevant exposures to NO<sub>2</sub> may affect biological processes that underlie the health effects observed beyond the respiratory system. NO<sub>2</sub> itself is not likely to enter the blood ([Section 4.2.2](#)). Among the various products of NO<sub>2</sub> reactions that occur in the epithelial lining fluid of the respiratory tract, nitrite has been identified in the blood. However, nitrite produced from inhaled NO<sub>2</sub> may not appreciably alter levels derived from diet or induce potentially detrimental health effects ([Section 4.2.3](#)). Nitrite can react with red blood cell hemoglobin to form methemoglobin. Methemoglobin has been linked with health effects but has not been found with ambient-relevant NO<sub>2</sub> exposure concentrations ([Section 4.3.4.1](#)). A recent controlled human exposure study suggests that mediators from the respiratory tract may migrate into the blood. This migration could lead to systemic inflammation and oxidative stress ([Figure 1-2](#), [Section 4.3.5](#)), providing a potential mechanism by which NO<sub>2</sub> exposure could lead to health effects beyond the respiratory system.

### Cardiovascular Effects and Diabetes

Although it is not clear how inhaled NO<sub>2</sub> affects underlying biological pathways, epidemiologic evidence indicates associations of short-term NO<sub>2</sub> exposure with cardiovascular effects and long-term exposure with cardiovascular effects and diabetes. For both short-term and long-term NO<sub>2</sub> exposure, the 2008 ISA for Oxides of Nitrogen concluded that evidence was inadequate to infer a causal relationship with cardiovascular effects ([U.S. EPA, 2008c](#)). There was supporting evidence for short-term NO<sub>2</sub> exposure but uncertainty about potential confounding by traffic-related copollutants. Additional findings relating short-term NO<sub>2</sub> exposure to the triggering of myocardial infarction support a suggestive of, but not sufficient to infer, a causal relationship with

cardiovascular effects ([Table 1-1](#)). A similar determination is made for long-term NO<sub>2</sub> exposure, but the health effect category is expanded to include diabetes. Supporting evidence previously was lacking, but new findings relate long-term NO<sub>2</sub> exposure to the development of diabetes and heart disease. Evidence is inconsistent for the effects of short-term and long-term NO<sub>2</sub> exposure on cardiovascular effects, such as arrhythmia, cerebrovascular diseases, and hypertension. There still is uncertainty whether NO<sub>2</sub> exposure has effects that are independent of other traffic-related pollutants.

Recent epidemiologic studies continue to indicate that short-term NO<sub>2</sub> exposure may trigger a myocardial infarction. There are consistent findings for associations between short-term increases in ambient NO<sub>2</sub> concentration and hospital admissions or ED visits for myocardial infarction, angina, and their underlying cause, ischemic heart disease ([Section 5.3.11.1](#), [Table 5-52](#)). Coherence is found with epidemiologic evidence for NO<sub>2</sub>-related ST segment changes, a nonspecific marker of myocardial ischemia, and increases in cardiovascular mortality, of which ischemic heart disease is the leading cause ([Finegold et al., 2013](#)). The robustness of epidemiologic findings is demonstrated by the fact that associations are consistently observed in studies conducted over several years, in diverse geographic locations, and with data pooled from multiple cities. Also, as with findings for asthma exacerbation ([Section 1.5.1](#)), associations of short-term NO<sub>2</sub> exposure with effects related to myocardial infarction persist with adjustment for meteorology, long-term time trends, and a copollutant such as PM<sub>10</sub>, SO<sub>2</sub>, or O<sub>3</sub>. ([Section 5.3.11.1](#)). Most of the epidemiologic evidence is based on NO<sub>2</sub> exposures assigned as the average ambient concentration across multiple monitors within a city; however, ST segment changes are associated with outdoor residential NO<sub>2</sub>, which may better represent temporal changes in subjects' personal exposures.

New epidemiologic evidence for increases in diabetes and heart disease in relation to long-term NO<sub>2</sub> exposure is suggestive of, but not sufficient to infer, a causal relationship ([Section 6.3.9](#), [Table 6-11](#)). The study reviewed in the 2008 ISA observed a weak association with cardiovascular events. The most consistent recent findings are for diabetes. Similar to asthma development, diabetes is associated with ambient NO<sub>2</sub> estimated at subjects' homes using LUR models that were demonstrated to well predict ambient NO<sub>2</sub> concentrations in the study areas. Most studies examine concurrent 1-yr avg NO<sub>2</sub> concentrations, but some aim to represent longer exposures more relevant to disease development by examining people who did not change residence. There is also some support for heart disease and mortality from ischemic heart disease related to long-term NO<sub>2</sub> exposure. Heart disease is associated with 1- or 2-yr avg NO<sub>2</sub> concentrations estimated at a neighborhood scale from central site monitors or dispersion models or at subjects' homes with LUR. Most studies assess heart disease by acute cardiovascular events such as myocardial infarction or hospital admissions without considering the

potential influence of short-term NO<sub>2</sub> exposure. Some studies assess exposures for periods after the cardiovascular event, and it is uncertain the extent to which these periods represent exposures during disease development. In addition to assessing residential NO<sub>2</sub> exposures, many studies of heart disease and diabetes are noteworthy for their large sample sizes, prospective follow-up of subjects (up to 20 years), and adjustment for potential confounding by age, sex, SES, and comorbid conditions.

Despite the epidemiologic evidence relating cardiovascular effects and diabetes to short-term and/or long-term NO<sub>2</sub> exposure, studies do not adequately account for potential confounding by PM<sub>2.5</sub> or traffic-related copollutants, as was the case in the 2008 ISA. In limited examination of copollutant models with PM<sub>2.5</sub>, UFP, or CO, associations of short-term NO<sub>2</sub> exposure with effects related to myocardial infarction are not consistently observed. Confounding by other traffic-related pollutants has not been examined. Also in contrast with findings for asthma exacerbation ([Section 1.5.1](#)), copollutant model results are based on NO<sub>2</sub> and copollutant concentrations measured at central site monitors. Differential exposure measurement error may limit the reliability of copollutant model results. Studies of long-term NO<sub>2</sub> exposure and heart disease and diabetes do not examine potential confounding by stress, PM<sub>2.5</sub>, or traffic-related copollutants. Evidence for NO<sub>2</sub> associations that are independent of noise also is limited.

New findings from experimental studies point to the potential for NO<sub>2</sub> exposure to induce cardiovascular effects and diabetes but are not sufficient to address the uncertainties in the epidemiologic evidence. Consistent with findings that reactive products of inhaled NO<sub>2</sub> or mediators of inflammation may migrate from the respiratory tract to the blood ([Figure 1-2](#)), some recent experimental studies find increases in mediators of inflammation and oxidative stress in the blood or heart tissue of healthy humans and rodent models in response to short-term NO<sub>2</sub> exposure ([Section 5.3.11.1](#)). Evidence does not strongly support the involvement of neural reflexes as examined by decreases in heart rate variability or indirectly by changes in respiratory rate ([Figure 1-2](#), [Sections 4.3.2.2](#) and [5.3.11.2](#)). Findings for increases in inflammation and oxidative stress describe early, nonspecific changes induced by NO<sub>2</sub> exposure that have the potential to lead to myocardial infarction. Although the findings are mostly for single-day exposures, they also may describe a possible way for recurrent NO<sub>2</sub> exposures to lead to the development of heart disease or diabetes. Limited findings of dyslipidemia in rats and epidemiologic findings of vascular damage in adults in relation to long-term NO<sub>2</sub> exposure also describe potential pathways for NO<sub>2</sub> exposure to lead to heart disease. The limited extent and consistency of findings from experimental studies and nonspecific nature of most of the evidence is not sufficient to demonstrate an independent effect of NO<sub>2</sub> exposure.

In conclusion, evidence is suggestive of, but not sufficient to infer, causal relationships for cardiovascular effects and diabetes with short-term and/or long-term NO<sub>2</sub> exposure. Conclusions were changed from the 2008 ISA based on more epidemiologic evidence linking myocardial infarction to short-term exposure and new evidence linking heart disease and diabetes to long-term exposure. However, an independent effect of NO<sub>2</sub> exposure is not clearly demonstrated. Examination of confounding by PM<sub>2.5</sub> and traffic-related copollutants is absent for long-term NO<sub>2</sub> exposure and gives inconsistent results for short-term NO<sub>2</sub> exposure. Some but not all recent experimental studies show that short-term NO<sub>2</sub> exposure increases inflammation and oxidative stress in the blood or heart tissue. Increases in inflammation and oxidative stress describe a potential way for short-term or long-term NO<sub>2</sub> exposure to lead to cardiovascular effects and diabetes, but because the findings are not linked to any specific health effect, unlike the mode of action information for asthma exacerbation or development ([Section 1.5.1](#)), they do not rule out chance, confounding, and other biases in the epidemiologic evidence.

### **Total Mortality**

Similar to the evidence described above for cardiovascular effects and diabetes, epidemiologic evidence supports associations of both short-term and long-term NO<sub>2</sub> exposure with total mortality from all nonaccidental causes. However, potential confounding by PM<sub>2.5</sub> and traffic-related copollutants remains largely unresolved, and it is not clear what biological processes NO<sub>2</sub> exposure may affect to lead to mortality. This uncertainty weighed with the supporting epidemiologic evidence is the basis for concluding that evidence is suggestive of, but not sufficient to infer, a causal relationship for both short-term and long-term NO<sub>2</sub> exposure with total mortality ([Table 1-1](#)). For short-term exposure, the nature of the evidence has not changed substantively, resulting in the same conclusion as the 2008 ISA. For long-term NO<sub>2</sub> exposure, whereas evidence in the 2008 ISA was limited, inconsistent, and inadequate to infer a causal relationship, several recent epidemiologic studies report associations with total mortality, supporting a stronger causal determination.

Evidence is suggestive of, but not sufficient to infer, a causal relationship between short-term NO<sub>2</sub> exposure and total mortality based on consistent epidemiologic findings across geographic locations, including several studies pooling data across cities ([Section 5.4.8](#), [Table 5-57](#)). Ambient NO<sub>2</sub> exposures were assessed as the average concentration across central site monitors within a city, which has uncertainty in adequately representing the temporal pattern in personal NO<sub>2</sub> exposures. Similar to findings for asthma exacerbation ([Section 1.5.1](#)), associations with mortality persist with adjustment for meteorological factors, long-term time trends, and a copollutant among PM<sub>10</sub>, SO<sub>2</sub>, or O<sub>3</sub>. A multicontinent study suggests interaction between NO<sub>2</sub> and PM<sub>10</sub>,

with higher PM<sub>10</sub>-mortality associations observed for periods of higher ambient NO<sub>2</sub> concentrations. However, in contrast with asthma exacerbation, potential confounding of associations between short-term NO<sub>2</sub> exposure and total mortality by PM<sub>2.5</sub> or traffic-related copollutants remains unexamined.

The generally supportive evidence from the large number of recent epidemiologic studies is suggestive of, but not sufficient to infer, a causal relationship between long-term NO<sub>2</sub> exposure and total mortality (Section 6.5.3, Table 6-18). Epidemiologic associations are observed in large cohorts in diverse locations followed for long durations up to 26 years. Increases in total mortality are found in association with NO<sub>2</sub> concentrations averaged over 1 to 16 years and assessed for the year of death and for periods up to 20 years before death. Not all studies observe associations, but the inconsistency does not appear to be due to differences among studies in long-term average ambient NO<sub>2</sub> concentrations or the exposure period examined. Total mortality is associated with long-term NO<sub>2</sub> exposure assigned from central site monitors and exposures estimated at people's homes by LUR models that well represented the spatial variability in ambient NO<sub>2</sub> concentrations in the study areas ( $R^2 = 0.61$  and  $0.71$ ). NO<sub>2</sub> associations persist with adjustment for potential confounding by age, sex, smoking, education, and comorbid conditions. In a few studies, associations between long-term NO<sub>2</sub> exposure and mortality persist with adjustment for traffic density or proximity, but confounding remains a concern because NO<sub>2</sub> associations are inconsistently observed with adjustment for PM<sub>2.5</sub> or BC exposures estimated from central site monitors or LUR models.

Evidence relating NO<sub>2</sub> exposure to cardiovascular and respiratory effects can provide understanding of whether NO<sub>2</sub> exposure has an independent effect on mortality by indicating whether NO<sub>2</sub> exposure affects the underlying causes of mortality. In the U.S., cardiovascular disease, namely ischemic heart disease, is the leading cause of death [35% as cited in (Hoyert and Xu, 2012)]. Respiratory causes comprise a smaller fraction of mortality (9% in the U.S.), but COPD and respiratory infections are among the leading causes of all mortality in the world. As described in the preceding sections, independent effects of short-term and long-term ambient NO<sub>2</sub> exposure on myocardial infarction, heart disease, diabetes, COPD, and respiratory infection are uncertain. Strong evidence demonstrates NO<sub>2</sub>-related asthma exacerbation, but asthma is not a leading cause of mortality. Thus, it is not clear what spectrum of cardiovascular and respiratory effects NO<sub>2</sub> exposure may induce to lead to mortality and by what biological processes short-term or long-term NO<sub>2</sub> exposure may lead to mortality.

In conclusion, evidence is suggestive of, but not sufficient to infer, a causal relationship for total mortality with both short-term and long-term NO<sub>2</sub> exposure based on supporting epidemiologic evidence. The evidence bases for total mortality related to short-term and

long-term NO<sub>2</sub> exposure share many characteristics. Although there is supporting epidemiologic evidence, studies do not adequately account for potential confounding by PM<sub>2.5</sub> or traffic-related copollutants. Thus, it is uncertain the extent to which epidemiologic findings for total mortality can be attributed specifically to short-term or long-term NO<sub>2</sub> exposure. Also uncertain are the independent effects of NO<sub>2</sub> exposure on the cardiovascular and respiratory morbidity conditions that make up the leading causes of mortality. Because potential confounding by traffic-related copollutants is largely unaddressed and the biological processes underlying the effects of NO<sub>2</sub> exposure on mortality are unclear, chance, confounding, and other biases cannot be ruled out in the epidemiologic evidence for short-term and long-term NO<sub>2</sub> exposure with total mortality.

### **Reproductive and Developmental Effects**

The 2008 ISA for Oxides of Nitrogen concluded that evidence was inadequate to infer a causal relationship between NO<sub>2</sub> exposure and a heterogeneous group of reproductive and developmental effects based on limited and inconsistent epidemiologic and animal toxicological evidence for effects on birth outcomes. This ISA presents separate conclusions for more defined categories of outcomes that are likely to occur by different biological processes and exposure patterns over different stages of development: (1) fertility, reproduction, and pregnancy ([Section 6.4.2](#)); (2) birth outcomes ([Section 6.4.3](#)); and (3) postnatal development ([Section 6.4.4](#)). For all three categories, there is a recent increase in epidemiologic studies. However, there is reasonable consistency only in the finding for birth outcomes to support strengthening the causal determination to suggestive of, but not sufficient to infer, a causal relationship with long-term NO<sub>2</sub> exposure ([Table 1-1](#)). For all three categories of reproductive and developmental effects, there is large uncertainty in identifying an independent effect of NO<sub>2</sub> exposure. In particular, animal toxicological evidence to support biological plausibility remains limited and inconclusive.

#### ***Fertility, Reproduction, and Pregnancy***

Evidence is inadequate to infer a causal relationship between long-term NO<sub>2</sub> exposure and effects on fertility, reproduction, and pregnancy ([Section 6.4.5](#), [Table 6-14](#)). This conclusion is based heavily on findings from the epidemiologic studies of pre-eclampsia, a pregnancy complication related to hypertension and protein in the urine ([Table 1-1](#)). Associations are inconsistently observed with ambient NO<sub>2</sub> exposures estimated at homes by LUR models that well predicted ambient NO<sub>2</sub> concentrations in the study areas ( $R^2 = 0.59$  to  $0.86$ ). Studies that observe associations considered confounding by maternal age, smoking, SES, diabetes, and parity, but few examine other traffic-related pollutants to assess the potential for confounding. Other lines of evidence to inform biological

plausibility are not available. Toxicological studies have not examined effects related to pre-eclampsia, and there is a lack of coherence with epidemiologic findings for conditions that contribute to pre-eclampsia, such as gestational hypertension and placental function. Inconsistent and limited findings from animal toxicological and/or epidemiologic studies for detrimental effects on sperm quantity and quality, fertility, maternal weight gain in pregnancy, and litter size add to the uncertainty regarding a relationship of NO<sub>2</sub> exposure with fertility, reproduction, and pregnancy.

### ***Birth Outcomes***

Evidence is suggestive of, but not sufficient to infer, a causal relationship between NO<sub>2</sub> exposure and effects on birth outcomes based primarily on recent epidemiologic associations with fetal growth restriction ([Section 6.4.5](#), [Table 6-14](#)). The combined epidemiologic and toxicological findings for effects on birth weight and infant mortality are inconsistent as are epidemiologic findings for preterm birth and birth defects. Evidence for NO<sub>2</sub>-related decreases in fetal growth is not entirely consistent, but many studies observe associations with ambient NO<sub>2</sub> concentrations at homes estimated by LUR models that well predict NO<sub>2</sub> concentrations in the study areas ( $R^2 = 0.68$  to  $0.91$ ; [Table 1-1](#)). A few studies observe stronger associations for children whose mothers spent more time at home and less time outdoors in locations other than home, which may be due to stronger correlations between residential ambient NO<sub>2</sub> and personal exposures. Other strengths of recent studies include fetal or neonatal physical measurements and analysis of confounding by season of conception, maternal age, smoking, SES, and in one study, noise. However, epidemiologic studies do not examine potential confounding by traffic-related copollutants. Further, toxicological studies have not examined fetal growth, and a potential mode of action for NO<sub>2</sub> cannot be proposed ([Figure 1-2](#)). Prenatal ambient NO<sub>2</sub> exposure is associated with a marker of inflammation in fetal cord blood but not maternal blood. The role of inflammation in affecting birth outcomes is not clearly established, and epidemiologic findings do not rule out effects of other pollutants. Thus, despite the supporting evidence for fetal growth restriction, there is considerable uncertainty in attributing epidemiologic findings specifically to NO<sub>2</sub> exposure.

### ***Postnatal Development***

Evidence is inadequate to infer a causal relationship between NO<sub>2</sub> exposure and effects on postnatal development based largely on the inconclusive findings across several recent epidemiologic studies of cognitive function in children ([Section 6.4.5](#), [Table 6-14](#)). Associations are inconsistently found for concurrent, infancy, or prenatal NO<sub>2</sub> exposure estimated at children's homes or schools with LUR models that well represent the variability in ambient NO<sub>2</sub> concentrations in the study areas ( $R^2 = 0.64$  to  $0.85$ ; [Table 1-1](#)). Further, confounding by traffic-related copollutants or stress is unexamined,

although one study shows an association with decreases in memory, adjusting for noise. The recent study indicating that short-term NO<sub>2</sub> exposure of adult rats induced oxidative stress and neuronal degeneration, which potentially could lead to impaired cognitive function, is not sufficient to address the uncertainties in epidemiologic findings. Findings for other effects on postnatal development are both limited and inconsistent. Specifically, evidence integrated from epidemiologic and toxicological studies is inconclusive for motor function and psychological or emotional distress. Evidence is inconsistent for decrements in attention and limited for autism as examined in epidemiologic studies and for physical development as examined in toxicological studies.

## **Cancer**

The best evidence base pointing to a possible relationship between NO<sub>2</sub> exposure and cancer is that for lung cancer ([Table 1-1](#)). A few recent epidemiologic studies indicate associations between NO<sub>2</sub> exposure and leukemia, bladder cancer, and prostate cancer, but findings for NO<sub>2</sub> exposure inducing carcinogenicity or mutagenicity in bone marrow, spermatocytes, and lymphocytes is inconsistent and based on higher than ambient-relevant NO<sub>2</sub> exposures. The findings for associations of NO<sub>2</sub> exposure with lung cancer incidence and mortality from some recent epidemiologic studies combined with some previous findings in rodents that NO<sub>2</sub> exposure may be involved in lung tumor promotion is the basis for strengthening the causal determination from inadequate to infer a causal relationship in the 2008 ISA for Oxides of Nitrogen to suggestive of, but not sufficient to infer, a causal relationship ([Section 6.6.9](#), [Table 6-20](#)).

Among the many recent epidemiologic studies, some report associations for NO<sub>2</sub> with lung cancer incidence or mortality, but others do not. Findings are inconsistent for NO<sub>2</sub> exposure assessed from central site monitors and estimated at subjects' homes with well-validated LUR models. In studies observing associations, NO<sub>2</sub> concentrations were averaged over 1 year at the beginning of the study up to 30 years before the outcome. Thus, there is evidence for associations with exposure durations considered to be relevant for cancer. However, it is not clear whether LUR or dispersion models predicting concentrations for periods a few years before cancer or mortality adequately account for decreases in ambient NO<sub>2</sub> concentration over years or represent longer duration exposures because most studies do not report on changes in residence. Studies not finding associations do not differ in mean NO<sub>2</sub> concentrations or exposure duration examined. Many studies examined large numbers of cancer cases, followed adults for 7–30 years, and adjusted for potential confounding by SES, smoking, diet, and occupational exposures. One study observes an association of residential NO<sub>2</sub> exposure with lung cancer mortality that persists with adjustment for PM<sub>2.5</sub>. But, examination of confounding by diesel exhaust and other traffic-related pollutants is absent.

NO<sub>2</sub> exposure does not independently induce lung tumor formation in various animal models or transform other chemicals in the body into carcinogens at ambient-relevant concentrations. However, some findings indicate a potential role for NO<sub>2</sub> in tumor promotion. In some but not all studies, ambient-relevant NO<sub>2</sub> exposures increased lung tumors incidence in rodents with spontaneously high tumor rates, with co-exposure to a carcinogen, or injection with metastatic cancer cells. Increases in secondary oxidation products in the respiratory tract ([Section 1.5.1](#)) and limited evidence for NO<sub>2</sub>-induced increases in hyperplasia of the lung epithelium of rodents are early events that have the potential to mediate NO<sub>2</sub>-related lung cancer. While NO<sub>2</sub> exposure impairs host defense in animal models ([Section 5.2.9](#)), parameters more directly linked to antitumor immunity, such as cytotoxic or regulatory T cells and interferon-gamma, have not been studied.

In conclusion, evidence is suggestive of, but not sufficient to infer, a causal relationship between long-term NO<sub>2</sub> exposure and cancer based on findings for lung cancer. Associations between ambient NO<sub>2</sub> concentrations and lung cancer incidence and mortality are found in some but not all epidemiologic studies. NO<sub>2</sub> exposures, some at higher than ambient-relevant concentrations, show an effect on lung tumor promotion in rodents but do not directly induce carcinogenesis. Potential confounding by diesel exhaust particles and other traffic-related copollutants is unaddressed and information to support biological plausibility is limited. Therefore, chance, confounding, and other biases cannot be ruled out based on the associations of long-term NO<sub>2</sub> exposure with lung cancer incidence and mortality observed in some epidemiologic studies.

**Table 1-1 Key evidence contributing to causal determinations for nitrogen dioxide exposure and health effects evaluated in the Integrated Science Assessment for Oxides of Nitrogen.**

Health Effect Category <sup>a</sup> and Causal Determination <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects
<p><b>Respiratory Effects and Short-Term Exposure (Section 5.2)</b>            2016 ISA—Causal relationship. 2008 ISA—Sufficient to infer a likely causal relationship.</p>	
<p><b>Key evidence (Table 5-39)</b></p> <p>Strongest evidence is for effects on asthma exacerbation. Controlled human exposure studies demonstrate independent effect of NO<sub>2</sub>. In adults with asthma, NO<sub>2</sub> exposures not much higher than peak ambient concentrations induce clinically relevant increases in airway responsiveness and increases in allergic responses, which are part of the proposed mode of action linking NO<sub>2</sub> and asthma exacerbation. Inconsistent experimental results for effects on lung function and respiratory symptoms in absence of challenge agent.</p> <p>Evidence from controlled human exposures provides plausibility for consistent epidemiologic evidence for decreases in lung function and increases in respiratory symptoms in children with asthma and increases in asthma hospital admissions and ED visits. Associations observed with NO<sub>2</sub> measured at central site monitors and at subjects' locations (i.e., personal ambient, outdoor school). Copollutant models, based on pollutants measured at subjects' locations, show NO<sub>2</sub> associations that are independent of PM<sub>2.5</sub> or, as examined in fewer studies, EC/BC, OC, UFP, VOCs, PM metals. NO<sub>2</sub> associations persist with adjustment for meteorology, medication use, PM<sub>10</sub>, SO<sub>2</sub>, or O<sub>3</sub>. Coherent findings available for total personal and indoor NO<sub>2</sub> with lower potential for copollutant confounding.</p> <p>Uncertainty in the independent effect of NO<sub>2</sub> on other respiratory effects (i.e., allergy exacerbation, COPD exacerbation, respiratory infection, respiratory effects in healthy populations) due to limited coherence among findings from epidemiologic and experimental studies.</p>	<p>Airway responsiveness: 200 to 300 ppb for 30 min, 100 ppb for 1 h</p> <p>Allergic inflammation: 260 for 15 min and 581 ppb for 30 min</p> <p>Overall study ambient maximums</p> <p>Central site monitors:            24-h avg: 55 to 80 ppb            1-h max: 59 to 306 ppb</p> <p>Outdoor school:            24-h avg: 7.5 and 16.2 ppb</p> <p>Personal ambient:            2-h avg: 77.7 and 154 ppb</p> <p>Total personal:            24-h avg: 48 and 106 ppb</p>
<p><b>Reason for change in causal determination</b></p>	<p>Evidence from controlled human exposure studies plus epidemiologic evidence for NO<sub>2</sub> exposures assessed for subjects' locations and in copollutant models with PM<sub>2.5</sub> or a traffic-related copollutant demonstrate consistency, coherence, and biological plausibility for effect of NO<sub>2</sub> exposure on asthma exacerbation to rule out chance, confounding, and other biases with reasonable confidence.</p>
<p><b>Uncertainty remaining</b></p>	<p>Strength of inference from copollutant models about independent associations of NO<sub>2</sub>, especially with pollutants measured at central site monitors. Potential exists for NO<sub>2</sub>-copollutant mixture effects.</p>

**Table 1-1 (Continued): Key evidence contributing to causal determinations for nitrogen dioxide exposure and health effects evaluated in the Integrated Science Assessment for Oxides of Nitrogen.**

<b>Health Effect Category<sup>a</sup> and Causal Determination<sup>b</sup></b>		<b>NO<sub>2</sub> Concentrations Associated with Effects</b>
<b>Respiratory Effects and Long-Term Exposure (Section 6.2)</b>		
2016 ISA—Likely to be a causal relationship. 2008 ISA—Suggestive of, but not sufficient to infer, a causal relationship.		
Key evidence (Table 6-5)	<p>Strongest evidence is for effects on asthma development. Consistent epidemiologic evidence from recent cohort studies for associations of ambient NO<sub>2</sub> averaged over 1–10 years with asthma incidence in children. Associations found with NO<sub>2</sub> estimated at homes and measured at central site monitors 1 km from homes or schools. NO<sub>2</sub> associations persist with adjustment for SES and smoking exposure. Potential confounding by traffic-related copollutants or proximity to roads not examined.</p> <p>Small body of experimental studies show NO<sub>2</sub> effects on hallmarks of asthma. Long-term exposure increases allergic responses and airway responsiveness in rodents. Short-term exposure induces development of allergic responses in humans and rodents. Inconsistent epidemiologic associations between long-term NO<sub>2</sub> exposure and development of allergic responses in children.</p> <p>More uncertainty in relationships with other respiratory effects because of limited coherence among disciplines. Epidemiologic evidence for increased severity of respiratory disease and decreased lung function and lung development in children. Animal toxicological evidence for respiratory infection.</p>	<p>Overall study ambient means: 14 to 28 ppb for residential annual avg estimates</p> <p>Individual city ambient means: 9.6 to 51.3 ppb for annual avg; 7.3 to 31.4 ppb for 10-yr avg</p> <p>Allergic responses: 2,000 ppb for 4 days in humans; 3,000 ppb for 2 weeks and 4,000 ppb for 12 weeks in rodents</p>
Reason for change in causal determination	New epidemiologic evidence for associations of ambient NO <sub>2</sub> exposure estimated at/near homes or schools with asthma development and biological plausibility from a small body of experimental studies.	Airway responsiveness: 1,000 to 4,000 ppb in rodents for 6 or 12 weeks
Uncertainty remaining	Some uncertainty remains in identifying an independent effect of NO <sub>2</sub> exposure from traffic-related copollutants because evidence from experimental studies for effects related to asthma development is limited, and epidemiologic analysis of confounding is lacking.	
<b>Cardiovascular Effects and Short-Term Exposure (Section 5.3)</b>		
2016 ISA—Suggestive of, but not sufficient to infer, a causal relationship. 2008 ISA—Inadequate to infer a causal relationship.		
Key evidence (Table 5-52)	<p>Strongest evidence is for effects related to triggering myocardial infarction. Consistent epidemiologic evidence for ST segment changes, increases in hospital admissions and ED visits for myocardial infarction and ischemic heart disease, and cardiovascular mortality. Most evidence is based on NO<sub>2</sub> averaged across central site monitors in a city. Associations persist with adjustment for meteorology, PM<sub>10</sub>, SO<sub>2</sub>, or O<sub>3</sub>. NO<sub>2</sub> associations inconsistent in copollutant models with PM<sub>2.5</sub> or CO.</p> <p>Some, but not entirely consistent, findings from experimental studies for early, nonspecific effects with the potential to lead to myocardial infarction: increases in markers of inflammation and oxidative stress in plasma of humans and heart tissue of rats. Inconsistent epidemiologic findings for inflammation.</p> <p>Inconsistent evidence for cerebrovascular effects, arrhythmia, and hypertension.</p>	<p>Individual city ambient 24-h avg: 90th: 22 to 53 ppb; maximums: 58 to 135 ppb</p> <p>Overall study ambient 1-h max: 90th: 68 ppb</p> <p>Oxidative stress in rats: 5,320 ppb for 6 h/day, 7 days; inflammation in rats: 2,660 and 5,320 ppb for 6 h/day, 7 days</p>
Reason for change in causal determination	Additional epidemiologic evidence for array of effects related to the triggering of myocardial infarction.	Inflammation in human cells exposed to human plasma; oxidative stress in human plasma: 500 ppb for 2 h
Uncertainty remaining	Effect of NO <sub>2</sub> independent from traffic-related copollutants is uncertain because experimental evidence is limited and not specific to myocardial infarction, and epidemiologic analysis of confounding is limited. Potential exposure error associated with NO <sub>2</sub> measured at central site monitors not well characterized.	

**Table 1-1 (Continued): Key evidence contributing to causal determinations for nitrogen dioxide exposure and health effects evaluated in the Integrated Science Assessment for Oxides of Nitrogen.**

Health Effect Category <sup>a</sup> and Causal Determination <sup>b</sup>		NO <sub>2</sub> Concentrations Associated with Effects
<b>Cardiovascular Effects and Diabetes and Long-Term Exposure (Section 6.3)</b>		
2016 ISA— Suggestive of, but not sufficient to infer, a causal relationship. 2008 ISA—Inadequate to infer a causal relationship.		
Key evidence: (Table 6-11)	<p>Strongest evidence is for development of diabetes and heart disease. Generally supportive, but not entirely consistent, epidemiologic evidence from recent cohort studies for associations of diabetes, myocardial infarction, and heart failure with ambient NO<sub>2</sub> averaged over 1–2 year periods around time of outcome assessment. Coherence with evidence for cardiovascular mortality. Associations found with NO<sub>2</sub> estimated at homes and measured at central site monitors. NO<sub>2</sub> associations persist with adjustment for age, sex, SES, comorbid conditions, and in a few cases, noise. Potential confounding by traffic-related copollutants, proximity to roads, or stress not examined.</p> <p>Some, but not entirely consistent, findings from experimental studies for early, nonspecific effects with the potential to lead to heart disease or diabetes: dyslipidemia in rats with long-term NO<sub>2</sub> exposure, increases in markers of inflammation and oxidative stress in plasma of humans and heart tissue of rats with short-term NO<sub>2</sub> exposure. Inconsistent epidemiologic associations between long-term NO<sub>2</sub> exposure and inflammation.</p>	<p>Overall study ambient means: 4.2 to 31.9 ppb for residential annual avg estimates; 34 ppb for 9.5-yr avg at central site monitors</p> <p>Dyslipidemia in rats: 160 ppb for 32 weeks</p> <p>Oxidative stress in rats: 5,320 ppb for 6 h/day, 7 days; inflammation in rats: 2,660 and 5,320 ppb for 6 h/day, 7 days</p>
Reason for change in causal determination	Large increase in recent epidemiologic studies of heart disease and diabetes, with generally supportive, but not entirely consistent evidence. New evidence for estimates of residential NO <sub>2</sub> exposure.	Inflammation in human cells exposed to human plasma; oxidative stress in human plasma: 500 ppb for 2 h
Uncertainty remaining	Effect of NO <sub>2</sub> independent from traffic-related copollutants is uncertain because experimental evidence is limited and not specific to heart disease or diabetes, and epidemiologic analysis of confounding is lacking.	
<b>Total Mortality and Short-Term Exposure (Section 5.4)</b>		
2016 ISA and 2008 ISA—Suggestive of, but not sufficient to infer, a causal relationship.		
Key evidence: (Table 5-57)	<p>Consistent epidemiologic evidence for increases in total mortality in association with NO<sub>2</sub> averaged across central site monitors in a city. Associations persist with adjustment for meteorology, long-term time trends, PM<sub>10</sub>, SO<sub>2</sub>, or O<sub>3</sub>. Potential confounding by traffic-related copollutants not examined.</p> <p>Evidence does not clearly describe independent NO<sub>2</sub> effects on biological processes leading to mortality. Large percentage of mortality is due to cardiovascular causes, for which independent effect of NO<sub>2</sub> is uncertain. The strongest evidence for respiratory morbidity is for asthma and is more limited or inconsistent for COPD and respiratory infection, which are larger causes of mortality in adults.</p>	<p>Individual city ambient 24-h avg maximums: 55 to 135 ppb</p> <p>Individual city ambient 1-h max: 90th: 33 to 133 ppb Maximums: 96 to 147 ppb</p>
Reason for no change in causal determination	Effect of NO <sub>2</sub> independent from traffic-related copollutants is uncertain because epidemiologic analysis of confounding is lacking, and the independent effect of NO <sub>2</sub> on biological processes (i.e., effects on morbidity) that lead to mortality not clearly demonstrated. Potential exposure error associated with NO <sub>2</sub> measured at central site monitors not well characterized.	
Uncertainty remaining		

**Table 1-1 (Continued): Key evidence contributing to causal determinations for nitrogen dioxide exposure and health effects evaluated in the Integrated Science Assessment for Oxides of Nitrogen.**

<b>Health Effect Category<sup>a</sup> and Causal Determination<sup>b</sup></b>		<b>NO<sub>2</sub> Concentrations Associated with Effects</b>
<b>Total Mortality and Long-Term Exposure (Section 6.5)</b>		
2016 ISA— Suggestive of, but not sufficient to infer, a causal relationship. 2008 ISA—Inadequate to infer a causal relationship.		
Key evidence: (Table 6-18)	<p>Generally supportive, but not entirely consistent, epidemiologic evidence from recent cohort studies, including those with extended follow-up (up to 26 years) of existing cohorts. Associations found with NO<sub>2</sub> averaged over 1 to 16 years for periods 0 to 20 years before death. Most evidence is based on NO<sub>2</sub> measured at central site monitors, but associations also observed with NO<sub>2</sub> estimated at homes. Associations found with adjustment for age, sex, smoking, education, comorbid conditions, and in some cases, neighborhood-level SES. In limited analysis, NO<sub>2</sub> associations persist with adjustment for traffic proximity or density but mostly are attenuated in copollutant models with PM<sub>2.5</sub> or BC.</p> <p>Evidence does not clearly describe independent NO<sub>2</sub> effects on biological processes leading to mortality. Large percentage of mortality is due to cardiovascular causes, for which independent effect of NO<sub>2</sub> is uncertain. The strongest evidence for respiratory morbidity is for asthma and is more limited or inconsistent for COPD and respiratory infection, which are larger causes of mortality in adults.</p>	<p>Overall study ambient means:</p> <p>12.1 to 21.7 ppb for residential annual avg estimates</p> <p>13.9 to 33.6 ppb for 1-yr to 15-yr avg at central site monitors</p>
Reason for change in causal determination	Large increase in recent epidemiologic studies, with generally supportive, but not entirely consistent, evidence. New evidence for estimates of residential NO <sub>2</sub> exposure in some but not all recent studies.	
Uncertainty remaining	Effect of NO <sub>2</sub> independent from traffic-related copollutants is uncertain because epidemiologic analysis of confounding is limited and inconclusive, and the independent effect of NO <sub>2</sub> on biological processes (i.e., effects on morbidity) that lead to mortality not clearly demonstrated. Potential exposure error associated with NO <sub>2</sub> measured at central site monitors not well characterized.	
<b>Reproductive and Developmental Effects Long-Term Exposure<sup>c</sup></b>		
2008 ISA—Inadequate to infer a causal relationship for broad category.		
<b>Fertility, Reproduction, and Pregnancy (Section 6.4.2)</b>		
2016 ISA—Inadequate to infer a causal relationship.		
Key evidence (Table 6-14)	<p>Heterogeneous group of indicators of a successful pregnancy with little support for relationship with NO<sub>2</sub> exposure. Inconsistent epidemiologic evidence among several recent studies for associations of pre-eclampsia, increases in blood pressure, and systemic inflammation in pregnancy with NO<sub>2</sub> estimated at homes with LUR or measured at central site monitors. Studies adjust for maternal age, smoking, SES, diabetes, and parity. Lack of toxicological studies to inform a potential effect of NO<sub>2</sub>.</p> <p>More limited and inconsistent epidemiologic evidence for effects on fertility. No effect on fertility in rodents, but change in reproductive cycle found. No epidemiologic or toxicological evidence for effects on sperm count or quality. Limited, inconclusive evidence in rodents for changes in pregnancy weight.</p>	<p>Overall study ambient mean for pre-eclampsia:</p> <p>31 ppb for residential 3rd trimester avg estimate</p>
Reason for no change in causal determination	Increase in recent epidemiologic studies, but results lack sufficient consistency, including those for residential estimates of NO <sub>2</sub> exposure. Limited and inconclusive toxicological evidence does not provide insight on a potential effect of NO <sub>2</sub> .	
Uncertainty remaining		

**Table 1-1 (Continued): Key evidence contributing to causal determinations for nitrogen dioxide exposure and health effects evaluated in the Integrated Science Assessment for Oxides of Nitrogen.**

Health Effect Category <sup>a</sup> and Causal Determination <sup>b</sup>		NO <sub>2</sub> Concentrations Associated with Effects
<b>Birth Outcomes (Section 6.4.3)</b>		
2016 ISA— Suggestive of, but not sufficient to infer, a causal relationship.		
Key evidence (Table 6-14)	<p>Strongest evidence is for fetal growth restriction. Generally supportive but not entirely consistent recent epidemiologic evidence for decreased head circumference and fetal or birth length, particularly as assessed with fetal or neonatal physical measurements. Associations found with NO<sub>2</sub> estimated at homes and measured at central site monitors. NO<sub>2</sub> associations persist with adjustment for maternal age, SES, smoking, alcohol use, and season of conception. Potential confounding by traffic-related copollutants not examined, and no available toxicological studies to inform a potential effect of NO<sub>2</sub>.</p> <p>Evidence for decreased birth weight in a study of rats, but large epidemiologic evidence base is inconsistent. Inconsistent epidemiologic evidence for associations with preterm birth, birth defects, early life mortality, and no or inconclusive toxicological evidence to inform a potential effect of NO<sub>2</sub>.</p>	<p>Overall study ambient means:</p> <p>Entire pregnancy: 15.5 to 20 ppb</p> <p>Specific trimesters: 7.8 to 36 ppb</p> <p>Decreased birth weight in rats: 1,300 ppb for 3 mo</p>
Reason for change in causal determination	Large increase in epidemiologic studies, with generally supportive, but not entirely consistent, evidence for associations between residential ambient NO <sub>2</sub> exposure and fetal growth restriction.	
Uncertainty remaining	Effect of NO <sub>2</sub> independent from traffic-related copollutants is uncertain because evidence from experimental studies and epidemiologic analysis of confounding are lacking.	
<b>Postnatal Development (Section 6.4.4)</b>		
2016 ISA—Inadequate to infer a causal relationship.		
Key evidence (Table 6-14)	<p>Inconsistent recent epidemiologic evidence for associations with neurodevelopmental effects, such as cognitive function, attention, motor function, and emotional responses. Association found with indoor NO<sub>2</sub>, but not consistently with ambient NO<sub>2</sub> exposure estimated at home or school by LUR. Associations found with adjustment for SES and, in one study, noise. Potential confounding inconsistently examined for smoking and not examined for stress or traffic-related copollutants.</p> <p>Limited and inconclusive toxicological evidence for effects on motor function and emotional responses. In a study of adult rats, short-term NO<sub>2</sub> exposure induced neurodegeneration and oxidative stress, which have the potential to lead to neurodevelopmental effects.</p> <p>Limited and inconclusive toxicological evidence for impaired physical development in rats and no analogous epidemiologic investigation.</p>	<p>Overall study ambient means for cognitive function:</p> <p>16.5 ppb for concurrent school annual avg estimate</p> <p>15.7 ppb for prenatal home annual avg estimate</p> <p>Neurodegeneration in rat brains: 2,500 ppb for 7 days</p> <p>Oxidative stress in rat brains: 5,320 ppb for 7 days</p>
Reason for no change in causal determination	Large increase in epidemiologic studies of cognitive function, but results lack sufficient consistency, including those for residential or school estimates of NO <sub>2</sub> exposure. Limited and inconclusive toxicological evidence does not provide insight on a potential effect of NO <sub>2</sub> .	
Uncertainty remaining		

**Table 1-1 (Continued): Key evidence contributing to causal determinations for nitrogen dioxide exposure and health effects evaluated in the Integrated Science Assessment for Oxides of Nitrogen.**

Health Effect Category <sup>a</sup> and Causal Determination <sup>b</sup>		NO <sub>2</sub> Concentrations Associated with Effects
<b>Cancer and Long-Term Exposure (Section 6.6)</b>		
2016 ISA— Suggestive of, but not sufficient to infer, a causal relationship. 2008 ISA—Inadequate to infer a causal relationship.		
Key evidence (Table 6-20)	<p>Best evidence is for lung cancer. Some, but not consistent, recent epidemiologic evidence from cohorts followed for 7–30 years for associations of lung cancer incidence and mortality with NO<sub>2</sub> exposures averaged over 1 to 30 years. Inconsistency observed for NO<sub>2</sub> estimated at homes and measured at central site monitors. Associations persist with adjustment for smoking, diet, SES, and occupational exposures, but confounding by diesel exhaust or other traffic-related copollutants largely not examined.</p> <p>Lack of toxicological evidence for direct effect of NO<sub>2</sub> in lung tumor induction, but findings in some studies suggest a possible role for NO<sub>2</sub> in lung tumor promotion with carcinogen co-exposure or with metastatic cancer. Evidence for formation of secondary oxidation products in the respiratory tract and limited evidence for hyperplasia of lung epithelium, which have the potential to lead to carcinogenicity.</p> <p>Limited epidemiologic evidence for associations with cancers of other sites, but inconsistent findings for mutagenic and genotoxic effects in experimental animals to support an independent effect of NO<sub>2</sub>.</p>	<p>Overall study ambient means: 12.1 to 23.2 ppb for residential annual avg estimates</p> <p>Individual city ambient means: 6.4 to 32.4 ppb for 10-yr avg at central site monitors 6.4 to 32.4 ppb for 3-yr avg at central site monitors</p>
Reason for change in causal determination	Evidence in some, but not all, epidemiologic studies for lung cancer incidence and mortality, including associations with residential estimates of NO <sub>2</sub> exposure. Some, not entirely consistent, toxicological evidence for role of NO <sub>2</sub> in lung tumor promotion.	Lung tumor promotion in rodents: inconsistent 250 to 5,000 ppb for 6 to 17 months
Uncertainty remaining	Effect of NO <sub>2</sub> independent from traffic-related copollutants is uncertain because epidemiologic analysis of confounding and results from experimental studies that NO <sub>2</sub> acts as a direct carcinogen are lacking.	

Avg = average; BC = black carbon; CO = carbon monoxide; COPD = chronic obstructive pulmonary disease; EC = elemental carbon; ED = emergency department; h = hour; ISA = Integrated Science Assessment; km = kilometer; min = minutes; max = maximum; mo = months; NO<sub>2</sub> = nitrogen dioxide; O<sub>3</sub> = ozone; OC = organic carbon; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 μm; ppb = parts per billion; SES = socioeconomic status; SO<sub>2</sub> = sulfur dioxide; UFP = ultrafine particles; VOC = volatile organic compound; yr = year.

<sup>a</sup>A large spectrum of outcomes is evaluated as part of a broad health effect category including physiological measures (e.g., airway responsiveness, lung function), clinical outcomes (e.g., respiratory symptoms, hospital admissions), and cause-specific mortality. Total mortality includes all nonaccidental causes of mortality and conclusions are informed by the nature of the evidence for the spectrum of morbidity effects (e.g., respiratory, cardiovascular) that can lead to mortality. The sections and tables referenced include a detailed discussion of the available evidence that informed the causal determinations.

<sup>b</sup>Since the completion of the 2008 ISA for Oxides of Nitrogen, the phrasing of causal determinations has changed slightly, and the weight of evidence that describes each level in the hierarchy of the causal framework has been more explicitly characterized.

<sup>c</sup>In the 2008 ISA, a single causal determination was made for the broad category of reproductive and developmental effects. In this ISA, separate causal determinations are made for smaller subcategories of reproductive and developmental effects based on varying underlying biological processes and exposure patterns over different lifestages.

---

## 1.6 Policy-Relevant Considerations

As described in the [Preamble](#) and [Section 1.1](#), this ISA addresses policy-relevant issues that are aimed at characterizing quantitative aspects of relationships between ambient NO<sub>2</sub> exposure and health effects and the impact of these relationships on public health. To that end, this section integrates information from the ISA to describe NO<sub>2</sub> exposure durations and patterns related to health effects, the shape of the concentration-response relationship, regional heterogeneity in relationships, the adverse nature of health effects, and at-risk populations and lifestyles. In addressing these policy-relevant issues, this section focuses on respiratory effects, for which the evidence indicates there is a causal and likely to be a causal relationship, respectively, with short-term and long-term NO<sub>2</sub> exposure. Because of uncertainty in the independent effects of NO<sub>2</sub> exposure, other health effects are discussed if they potentially provide new insight on a particular issue.

---

### 1.6.1 Durations of Nitrogen Dioxide Exposure Associated with Health Effects

The primary NO<sub>2</sub> NAAQS are based on 1-h daily max concentrations (3-yr avg of each year's 98th percentile) and annual average concentrations. These NAAQS were set to protect against an array of respiratory effects associated with short-term NO<sub>2</sub> exposures and various health effects potentially associated with long-term exposure ([Section 1.1](#)). Thus, an important consideration in the review of the primary NO<sub>2</sub> NAAQS is whether the nature of the health effects evidence varies by NO<sub>2</sub> exposure duration.

For short-term exposure, the majority of previous and recent evidence associates health effects with 24-h avg ambient NO<sub>2</sub>, but the small body of evidence is equally consistent for subdaily averages, such as 1 or 8-h max NO<sub>2</sub> and NO<sub>2</sub> averaged over periods of 2 or 5 hours. The 24-h avg and 1-h max ambient NO<sub>2</sub> metrics, assessed primarily from concentrations averaged across multiple monitors within a city, are associated with a spectrum of effects related to asthma exacerbation. In the few within-study comparisons and based on typical increases in 24-h avg and 1-h max ambient NO<sub>2</sub> concentrations (20 and 30 ppb, respectively; [Section 5.1.2.2](#)), effect estimates for the two highly correlated NO<sub>2</sub> metrics did not clearly differ ([Sections 5.2.2](#) and [5.2.7](#)). A study of asthma-related ED visits in Atlanta, GA observed similar associations for 1-h max and 24-h avg NO<sub>2</sub> with a 1-day lag, and a slightly larger association for 6-h nighttime avg NO<sub>2</sub> [12:00 ante meridiem (a.m.)–6:00 a.m.; [Section 5.2.2.4](#)]. Based on measurements from central site monitors, the distribution of concentrations and spatial heterogeneity varied among the array of NO<sub>2</sub> averaging times, which may account for differences in associations with asthma ED visits. For example, nighttime avg NO<sub>2</sub> had a wider range of concentrations

than 24-h avg NO<sub>2</sub>. Nighttime avg NO<sub>2</sub> was similar to 1-h max NO<sub>2</sub> in spatial heterogeneity but lower in concentration. The spatial heterogeneity in ambient NO<sub>2</sub> concentrations within urban areas and with distance to roads ([Sections 2.5.2](#) and [2.5.3](#)) and diurnal trends with higher concentrations measured during morning commute hours ([Section 2.5.4](#)) are not unique to Atlanta, GA. This heterogeneity in ambient NO<sub>2</sub> concentrations, along with diurnal variation in people's time-activity patterns, suggest that the array of NO<sub>2</sub> averaging times vary in the extent to which they represent people's exposures, which could obscure true differences in association with health effects.

NO<sub>2</sub> measurements aligned with subjects' locations, including total and ambient personal, outdoor and indoor school, and indoor home NO<sub>2</sub>, are associated with asthma-related effects ([Sections 5.2.2.2](#) and [5.2.2.5](#)) and mostly are integrated over 1 or multiple days. These results do not necessarily mean that continuous exposure is required, as any diurnal pattern of NO<sub>2</sub> exposure that may underlie associations with asthma-related effects cannot be discerned. The relative importance of daily average exposures or acute peaks in exposure occurring as a result of diurnal variation in ambient concentrations is not clear. Any contribution of acute peaks in indoor NO<sub>2</sub> exposures ([Table 3-4](#)) to associations observed between 3-day or 4-week avg indoor NO<sub>2</sub> and asthma-related effects also is not known. However, NO<sub>2</sub> exposures of 2 or 5 hours during time spent outdoors are related to pulmonary inflammation and lung function decrements in adults ([Section 5.2.9.3](#)). Inference from these results is strong because they are based on personal ambient NO<sub>2</sub> measurements or NO<sub>2</sub> measured at the locations of outdoor exposures. Controlled human exposure studies showing clinically relevant increases in airway responsiveness ([Section 5.2.2.1](#)) and allergic inflammation ([Section 5.2.2.5](#)) in adults with asthma in response to 100–400 ppb NO<sub>2</sub> exposures in the range of 30 minutes to 6 hours provides biological plausibility for subdaily ambient NO<sub>2</sub> exposures inducing asthma exacerbation.

With respect to long-term ambient NO<sub>2</sub> exposure, asthma development in children is associated with 1-yr avg concentrations estimated at homes by LUR models with good predictive accuracy and 10-yr avg concentrations measured at central site monitors 1 km from homes or schools ([Section 6.2.2.1](#)). The NO<sub>2</sub> concentrations averaged over 1 year during prenatal or infancy periods could represent critical time windows of exposure for asthma development or represent longer durations of NO<sub>2</sub> exposure for subjects who remain in the same home or neighborhood. Experimental studies do not provide direct insight into what the epidemiologic findings may be indicating are important periods of long-term NO<sub>2</sub> exposure for asthma development because experimental studies examined NO<sub>2</sub> exposures of less than one year in adulthood. However, findings for increased allergic responses and airway responsiveness in humans or rodents indicate that repeated increases in NO<sub>2</sub> exposure over multiple days or exposures over 1 to 3 months may play a role in asthma development ([Section 6.2.2.3](#)).

Overall, asthma exacerbation and asthma development are linked to a range of short-term and long-term durations of NO<sub>2</sub> exposure, respectively. There is no indication of a stronger association for any particular short-term or long-term duration of NO<sub>2</sub> exposure.

---

## 1.6.2 Lag Structure of Relationships between Nitrogen Dioxide Exposure and Health Effects

Characterizing the NO<sub>2</sub> exposure lags (i.e., time between exposure and effect) associated with health effects can aid in understanding the nature of relationships between NO<sub>2</sub> exposure and health effects. The lag structure for associations with NO<sub>2</sub> exposure may vary among health effects depending on differences in the time course by which underlying biological processes occur. Identifying important lag structures can depend on whether the lag structure varies within the population according to differences among individuals in time-activity patterns, pre-existing disease, or other factors that influence exposure and responses to exposure. Another consideration in drawing inferences about important lag structures is that differences in associations among exposure lags, particularly single-day and multiday average NO<sub>2</sub> concentrations, may not only have a biological basis but may be influenced by differences in the extent to which single-day and multiday average ambient NO<sub>2</sub> concentrations represent people's actual exposures.

Epidemiologic panel studies of children with asthma observed increases in pulmonary inflammation and respiratory symptoms and decreases in lung function in association with increases in NO<sub>2</sub> concentration lagged 0 day (same day as outcome) or 1 day and multiday averages of 2 to 7 days ([Section 5.2.2](#)). Consistent with these findings, increases in asthma-related hospital admissions and ED visits were observed in association with NO<sub>2</sub> concentrations lagged 0 or 1 day or averaged over 2 to 5 days. Whereas no particular lag of NO<sub>2</sub> exposure was more strongly associated with decreases in lung function, several studies indicate larger increases in pulmonary inflammation, respiratory symptoms, and asthma-related hospital admissions and ED visits for increases in multiday averages of NO<sub>2</sub> than single-day lags. Asthma-related effects also were associated with multiday average NO<sub>2</sub> concentrations (i.e., 2 to 4 days) for measures of personal ambient and total NO<sub>2</sub>, outdoor school NO<sub>2</sub>, and indoor NO<sub>2</sub>, which may better represent exposure compared with measurements from central site monitors.

Studies in which adults with asthma and healthy adults were exposed for 2 or 5 hours in outdoor traffic and nontraffic locations indicate decreases in lung function and increases in pulmonary inflammation immediately or 2 hours after exposures ([Sections 5.2.2](#) and [5.2.7](#)). In both populations, decreases in lung function also were found the day after exposures. In healthy adults, increases in pulmonary inflammation did not persist the day

after outdoor exposure ([Section 5.2.7.4](#)). These data based on personal ambient exposure assessment or NO<sub>2</sub> measured at the locations of people's outdoor exposures support other epidemiologic findings showing increases in respiratory effects at lag 0 or 1 day of NO<sub>2</sub> exposure and also indicate a similar lag structure for respiratory effects in people with and without asthma. Experimental studies show that NO<sub>2</sub> exposure affects the biological processes underlying the asthma-related effects observed in epidemiologic studies on a similar time frame. Controlled human exposure studies found airway responsiveness in adults with asthma to increase immediately after or 20 minutes to 4 hours after a single NO<sub>2</sub> exposure and over 4 days of repeated exposure ([Section 5.2.2.1](#)). In experimental studies, NO<sub>2</sub> exposure enhanced allergic inflammation 30 minutes up to 19 hours after a single- or 2-day exposure in humans and 7 days after exposure in rats ([Section 5.2.2.5](#)). Thus, the findings from experimental studies provide biological plausibility for the asthma-related effects observed in epidemiologic studies in association with 2- or 5-hour exposures, same-day NO<sub>2</sub> exposures, as well as exposures averaged over multiple days.

---

### 1.6.3 Concentration-Response Relationships and Thresholds

Characterizing the shape of the concentration-response relationship aids in quantifying the public health impact of NO<sub>2</sub> exposure. A key issue is whether the relationship is linear across the full range of ambient concentrations or whether there are deviations from linearity at and below the levels of the current 1-h NAAQS of 100 ppb and annual NAAQS of 53 ppb. Also important for the review of the primary NO<sub>2</sub> NAAQS is identifying ambient NO<sub>2</sub> concentrations below which there is uncertainty in the relationship with health effects. Characterization of the concentration-response relationship in epidemiologic studies is complicated by fewer observations in the low range of ambient concentrations, the influence of other pollutants or risk factors for the health effects, and variability among individuals in the population in their response to air pollution exposures. The shape of the concentration-response relationship for health effects related to short-term NO<sub>2</sub> exposure is examined in a limited number of epidemiologic studies and for respiratory hospital admissions and ED visits and total mortality rather than for other health effects.

Recent U.S. studies suggest a linear relationship between short-term NO<sub>2</sub> exposure and asthma ED visits in children ([Section 5.2.2.4](#)). In Atlanta, GA during 1993–2004, a linear association was observed for 1-h max NO<sub>2</sub> concentrations (lag 0–2 day avg) combined across urban monitors by placing more weight on concentrations in more populated areas. Risk estimates increased across quintiles of NO<sub>2</sub> between 28 and 181 ppb (with NO<sub>2</sub> less than 28 ppb as the reference). Also, in nonparametric models, asthma ED visits in the warm season (May–October) increased with increasing 1-h max NO<sub>2</sub> concentrations

between 11 and 37 ppb (5th to 95th percentiles). There is similar confidence in the relationship throughout this range of concentrations; the 95% CI is relatively narrow even at 11 ppb NO<sub>2</sub>. A relationship is uncertain at 1-h max NO<sub>2</sub> concentrations less than 11 ppb because effect estimates were reported to be unstable. In Atlanta, GA, the distribution of 1-h max NO<sub>2</sub> varied across monitors, with higher concentrations at the downtown site (mean 42 ppb). Thus, while a population-weighted average of NO<sub>2</sub> may better represent concentrations where people live and spend time, they may not clearly indicate concentrations at which an association is not present. Analysis of 24-h avg NO<sub>2</sub> in Detroit, MI during 2004–2006 does not indicate deviation from a linear relationship. Risk estimated assuming linearity across the range of concentrations did not differ from risk estimated for 24-h avg NO<sub>2</sub> concentrations above 23 ppb (point of deviation from linearity, between the 82nd and 85th percentiles) in the nonlinear model. NO<sub>2</sub> concentrations were averaged between two Detroit, MI sites, and comparisons of ambient NO<sub>2</sub> concentrations between sites were not reported. These limited findings from U.S. cities suggest that the association between short-term NO<sub>2</sub> exposure and asthma ED visits in children is present at NO<sub>2</sub> concentrations typical of U.S. urban areas ([Section 2.5.1](#)).

The concentration-response relationship for short-term NO<sub>2</sub> exposure and asthma-related effects is not well examined in controlled human exposure or animal toxicological studies. Combining data across multiple studies, a recent meta-analysis observed that NO<sub>2</sub> exposure cut in half the dose of the challenge agent required to induce an increase in airway responsiveness (i.e., provocative dose) in adults with asthma, but the provocative dose did not change with increasing NO<sub>2</sub> concentration in the range of 100–500 ppb ([Figure 5-1](#)). Experimental studies do not provide insight on whether asthma responses increase with increasing NO<sub>2</sub> concentration because few studies examined multiple NO<sub>2</sub> exposure concentrations, and the range of these NO<sub>2</sub> concentrations (greater than 100 ppb) exceed those examined in epidemiologic studies of concentration-response.

Linear concentration-response relationships also are observed for mortality associated with short-term NO<sub>2</sub> averages in the U.S., Canada, and Asia based on comparisons of linear and various nonlinear models with natural and cubic splines or quadratic and cubic terms for NO<sub>2</sub> ([Section 5.4.7](#)). A few previous results point to nonlinear associations but for health effects for which the concentration-response relationship has not been widely examined, including cough in children in the general population or cardiovascular hospital admissions in adults. These studies tend to find NO<sub>2</sub>-related increases in effects that are larger in magnitude per increment in NO<sub>2</sub> concentration in the lower range of NO<sub>2</sub> concentrations than in the upper range of concentrations. The implications of results for these nonasthma health effects is less clear given the uncertainty as to whether NO<sub>2</sub> exposure has independent relationships with nonasthma health effects.

For long-term NO<sub>2</sub> exposure, information on the shape of the concentration-response relationship with asthma development is too limited to draw inferences. In analyses of tertiles or quartiles of estimates of residential NO<sub>2</sub> exposure (Section 6.2.2.2), a linear concentration-response is indicated in one study but not another. In the study observing a linear relationship, annual average NO<sub>2</sub> concentrations ranged from 1.8 to 24 ppb, but because tertiles of NO<sub>2</sub> concentration were not reported, the range of NO<sub>2</sub> concentrations where there may be more or less uncertainty in the relationship with asthma development cannot be assessed. Also based on categories of NO<sub>2</sub> concentration or splines, linear associations are observed for long-term averages of NO<sub>2</sub> with asthma symptoms in children, chronic bronchitis in adults, and asthma hospital admissions in adults (Section 6.2.3). These findings may not be attributable specifically to long-term NO<sub>2</sub> exposure but rather, reflect associations with short-term NO<sub>2</sub> exposure. Analysis of the concentration-response with categories of long-term average NO<sub>2</sub> concentrations does not provide a strong basis for assessing whether there is a threshold for respiratory effects.

In summary, the shape of the concentration-response relationship is better characterized in epidemiologic studies and for short-term NO<sub>2</sub> exposure than long-term exposure. Few controlled human exposure or toxicological studies of asthma-related effects examined multiple NO<sub>2</sub> exposure concentrations; therefore, that evidence lacks strong insight into the concentration-response relationship. Based on an array of methods, including analysis of splines, higher order terms for NO<sub>2</sub> (e.g., quadratic, cubic), and categories of NO<sub>2</sub> concentration, previous and recent evidence indicates a linear relationship between short-term NO<sub>2</sub> exposure and hospital admissions or ED visits for asthma and multiple respiratory conditions combined. In Atlanta, GA, a linear relationship with asthma ED visits is indicated for 1-h max NO<sub>2</sub> concentrations averaged over 3 days, with similar confidence in the relationship across the range of 11 to 37 ppb. There is uncertainty in the relationship at concentrations less than 11 ppb. Another source of uncertainty is that 24-h avg or 1-h max NO<sub>2</sub> concentrations were averaged across multiple central site monitors within a city, which may not reflect varying distributions of concentrations within the city or population exposures.

---

#### 1.6.4 Regional Heterogeneity in Effect Estimates

In addition to examining the shape of the concentration-response relationship for NO<sub>2</sub>-related health effects across the distribution of concentrations, studies have examined whether associations vary across geographical regions. In one study, heterogeneity was noted among Asian cities in the shape of the NO<sub>2</sub>-mortality relationship. Information on regional heterogeneity is limited, particularly for the U.S. and for relationships of NO<sub>2</sub> exposure with asthma exacerbation or development. There is

no strong indication of heterogeneity in associations of short-term NO<sub>2</sub> exposure with respiratory symptoms in children in the general population among Korean cities (Section 5.2.7.3). A few studies observe regional heterogeneity in associations between short-term NO<sub>2</sub> exposure and total mortality among European and Asian cities (Section 5.4.7). A nonlinear concentration-response relationship observed in one of four Asian cities was hypothesized to be due to differences among cities in mortality from infection, air conditioning use, time spent by the population outdoors, or temperature. On a smaller geographic scale, NO<sub>2</sub>-related respiratory effects do not clearly differ between two cities in Ohio with similar ambient NO<sub>2</sub> concentrations (Section 5.2.2.4) or neighboring urban and suburban communities in Europe that differed in ambient NO<sub>2</sub> concentrations (Section 7.5.5). Limited results point to potential within-city differences in asthma exacerbation in relation to short-term NO<sub>2</sub> exposure. NO<sub>2</sub>-related asthma ED visits were larger in Bronx than Manhattan, NY (Section 5.2.2.4), and NO<sub>2</sub>-related lung function and pulmonary inflammation among children with asthma differed between two El Paso, TX schools (Sections 5.2.2.2 and 5.2.2.5). The reasons for the heterogeneity were not explicitly analyzed. In the El Paso study, the schools differed in proximity to road, ambient NO<sub>2</sub> concentrations, racial composition, and asthma medication use.

For long-term NO<sub>2</sub> exposure, differences are observed between Chicago, IL; Houston, TX; San Francisco, CA; New York, NY; and Puerto Rico in the association with asthma prevalence among Latino and African American individuals ages 8–21 years (Section 6.2.2.1). A test for heterogeneity was not statistically significant, but associations are observed only in the San Francisco, CA and New York, NY cohorts. Odds ratios for the average ambient NO<sub>2</sub> concentration for the first year or first 3 years of life are largest in the San Francisco, CA cohort, which comprised only African American individuals. The reasons for heterogeneity among the locations were not explicitly analyzed, but the locations differed in the distribution of ambient NO<sub>2</sub>, SO<sub>2</sub>, and PM<sub>2.5</sub> concentrations, which may indicate varying air pollution mixtures among locations. San Francisco, CA had lower ambient NO<sub>2</sub> and SO<sub>2</sub> concentrations than New York, NY. PM<sub>2.5</sub> and SO<sub>2</sub> were associated with asthma prevalence in Houston, TX but not in New York, NY or San Francisco, CA.

In summary, with limited available information, including one U.S. study of asthma prevalence, it is not clear whether there is regional heterogeneity in the relationship between short-term or long-term NO<sub>2</sub> exposure and respiratory effects. There is some evidence of heterogeneity in associations of short-term NO<sub>2</sub> exposure with mortality among cities in Europe and Asia. Given the uncertainty as to whether NO<sub>2</sub> exposure has an independent relationship with mortality, the extent to which the regional heterogeneity in risk is applicable specifically to NO<sub>2</sub> exposure is uncertain.

---

## 1.6.5 Public Health Impact

The public health impact of air pollution-related health effects is determined by the adverse nature of the health effects that are observed, the size of the population exposed to the air pollutant or affected by the health outcome, and the presence of populations or lifestyles with higher exposure or increased risk of air pollution-related health effects.

### Characterizing Adversity of Health Effects

Both the World Health Organization (WHO) and the American Thoracic Society (ATS) have provided guidance in describing what health effects may be considered adverse. WHO defines health as “the state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity” ([WHO, 1948](#)). By this definition, changes in health outcomes that are not severe enough to result in a diagnosis of a clinical effect or condition can be considered adverse if they affect the well-being of an individual. ATS also has considered a wide range of health outcomes in defining adverse effects. Distinguishing between individual and population risk, ATS described its view that small air pollution-related changes in an outcome observed in individuals might be considered adverse on a population level. This is because a shift in the distribution of population responses resulting from an increase in air pollution exposure might increase the proportion of the population with clinically important effects or at those at increased risk of a clinically important effect that could be caused by another risk factor ([ATS, 2000b](#)).

Increases in ambient NO<sub>2</sub> concentrations are associated with a broad spectrum of health effects related to asthma, including those characterized as adverse by ATS such as ED visits and hospital admissions ([ATS, 2000b](#)). ATS also describes lung function changes occurring with symptoms as adverse, but experimental studies do not show symptoms increasing after NO<sub>2</sub> exposures of a few hours. NO<sub>2</sub> exposure also is associated with more subtle effects such as increases in airway responsiveness and pulmonary inflammation and decreases in lung function ([Section 1.5.1](#)). Increases in airway responsiveness and pulmonary inflammation are proposed as part of mode of action linking NO<sub>2</sub> exposure to asthma exacerbation and asthma development ([Figure 1-2](#)) and show a distribution within populations. Based on ATS guidance, NO<sub>2</sub>-associated changes in airway responsiveness or pulmonary inflammation may be considered adverse on a population level because they can increase the proportion of the population with clinically important changes that can lead to exacerbation or development of asthma. A meta-analysis of controlled human exposure studies demonstrates that NO<sub>2</sub> exposures of 140–200 ppb for 1–2 hours reduces by one-half the dose of a challenge agent required to increase airway responsiveness in adults with asthma ([Section 5.2.2.1](#)). Such observations that NO<sub>2</sub> concentrations not much higher than peak ambient concentrations can induce

clinically relevant effects related to asthma exacerbation further support a role for ambient NO<sub>2</sub> exposures in inducing adverse health effects.

### **At-Risk Populations and Lifestages for Health Effects Related to Nitrogen Dioxide Exposure**

The primary NAAQS are intended to protect public health with an adequate margin of safety. In so doing, protection is provided for both the population as a whole and those groups potentially at increased risk for health effects from exposure to the air pollutant for which each NAAQS is set ([Preface](#) to the ISA). Hence, the public health impact of NO<sub>2</sub> exposure also is determined by whether specific lifestages or population groups are identified as being at increased risk of NO<sub>2</sub>-related health effects. The large proportion of the U.S. population living near roads, where ambient NO<sub>2</sub> concentrations are higher compared to many other locations ([Section 2.5.3](#)), indicates the widespread potential for elevated ambient NO<sub>2</sub> exposures. In 2009, 17% of U.S. homes were estimated to be within 91 m of sources of ambient NO<sub>2</sub> such as a four-lane highway, railroad, or airport ([Section 7.5.6](#)). The percentage of the population with elevated NO<sub>2</sub> exposures may be greater in cities. For example, 40% of the Los Angeles, CA population was estimated to live within 100 m of a major road ([Section 7.5.6](#)). People spending time near roads and commuting or working on roads also have the potential for elevated NO<sub>2</sub> exposure, and in turn, potential for increased risk of NO<sub>2</sub>-related health effects.

At-risk populations or lifestages also can be characterized by specific biological, sociodemographic, or behavioral factors, among others. Since the 2008 ISA for Oxides of Nitrogen and as used in the recent ISAs for Ozone ([U.S. EPA, 2013e](#)) and Lead ([U.S. EPA, 2013c](#)), the U.S. EPA has developed a framework for drawing conclusions about the role of such factors in modifying risk of air pollutant-related health effects ([Table III](#) of the [Preamble](#)). Conclusions describe the confidence in the evidence based on judgments of consistency and coherence within and across disciplines ([Chapter 7](#)). Briefly, the evaluation is based primarily on studies that compare exposure or health effect relationships among groups that differ according to a particular factor (e.g., people with and without asthma). Where available, information on exposure, dosimetry, and modes of action is evaluated to assess coherence with health effects evidence and provide understanding of how a particular factor may increase risk of NO<sub>2</sub>-related health effects (e.g., by increasing exposure, increasing biological effect for a given dose).

There is adequate evidence that people with asthma, children, and older adults are at increased risk for NO<sub>2</sub>-related health effects, specifically effects indicative of asthma exacerbation ([Table 7-27](#)). These conclusions are substantiated by the clear evidence of an independent relationship of asthma exacerbation with short-term NO<sub>2</sub> exposure

(Section 1.5.1). Limited, supporting evidence suggests that females, people of low SES, and people with low antioxidant diets have increased risk for NO<sub>2</sub>-related health effects. The inconsistent evidence is inadequate to determine whether genetic variants, COPD, cardiovascular disease, diabetes, obesity, race/ethnicity, smoking, urban residence, or proximity to roads increase NO<sub>2</sub>-related health effects. For many of these factors, the common uncertainty is that the evidence is for cardiovascular effects, diabetes, or mortality, which are not clearly related to NO<sub>2</sub> exposure.

A causal relationship between short-term NO<sub>2</sub> exposure and respiratory effects is based on the evidence for asthma exacerbation (Section 1.5.1). The increased risk for people with asthma is supported further by controlled human exposure studies demonstrating increased airway responsiveness at lower NO<sub>2</sub> concentrations in adults with asthma than in healthy adults (Section 7.3.1). Differences in NO<sub>2</sub> dosimetry (Section 4.2.2) or exposure among people with asthma are not well described. Epidemiologic evidence does not consistently indicate differences in NO<sub>2</sub>-related respiratory effects between children with asthma and without asthma. However, because asthma is a heterogeneous disease and the populations examined varied in prevalence of asthma medication use and atopy, the inconsistent epidemiologic results are not considered to be in conflict with controlled human exposure studies, which examined primarily adults with mild, atopic asthma.

The increased risk of NO<sub>2</sub>-related asthma hospital admissions and ED visits for children (Section 7.5.1.1) and older adults (Section 7.5.1.2) suggests that among people with asthma the effects of NO<sub>2</sub> exposure may vary by lifestage. Although not clearly delineated for NO<sub>2</sub>, several physiological and behavioral traits may contribute to the increased risk for children. Compared with adults, children have developing respiratory systems and increased oronasal breathing and ventilation rates (Section 4.2.2.3). Limited data do not clearly indicate higher personal NO<sub>2</sub> exposures in children (Table 3-5) but do indicate more time and vigorous activity outdoors (Section 7.5.1.1). Thus, children may have greater NO<sub>2</sub> uptake in the respiratory tract and/or less exposure measurement error. Many studies reported a higher proportion of asthma ED visits or hospital admissions among children than other lifestages. Thus, higher incidence of asthma exacerbation in children may be a reason for their increased risk.

Because the respiratory system continues to develop throughout childhood, it is possible that critical time windows of exposure exist for NO<sub>2</sub>-related asthma development. However, the evidence shows that asthma development in children is associated with several different time windows of long-term NO<sub>2</sub> exposure: the prenatal period, infancy, year of diagnosis, or lifetime exposure (Section 7.5.1.1). Studies do not consistently identify a specific time window of long-term NO<sub>2</sub> exposure more strongly associated with the development of asthma as ascertained in children ages 4–18 years.

Children not only comprise a large proportion of the U.S. population (24% in the 2010 U.S. census) but also have a higher rate of asthma health care encounters than adults (e.g., 10.7 vs. 7.0 per 100 persons with asthma).<sup>1</sup> Further, asthma is the leading chronic illness (9.5% prevalence) and reason for missed school days in children in the U.S. Many U.S. schools are located near high-traffic roads (7% within 250 m; [Section 7.5.6](#)). NO<sub>2</sub> concentrations outside schools are associated with asthma-related effects in children ([Sections 5.2.2.2](#) and [5.2.2.5](#)), and school could be an important source of NO<sub>2</sub> exposure. Based on the large number of children in the U.S., the high prevalence of asthma morbidity among children, and potential for high NO<sub>2</sub> exposures, higher risks of asthma exacerbation for children compared with adults can translate into large numbers of people affected, magnifying the potential public health impact of NO<sub>2</sub> exposure.

The public health impact of NO<sub>2</sub>-related health effects also is magnified by the growing proportion of older adults in the U.S. As with children, it is not well understood why older adults have increased risk for NO<sub>2</sub>-related hospital admissions for asthma. Older adults did not consistently have a higher proportion of asthma hospital admissions compared with younger adults, so higher incidence of asthma exacerbation does not seem to explain their higher NO<sub>2</sub>-related risk estimates. Differences in NO<sub>2</sub> dosimetry also are not described for older adults ([Section 4.2.2.3](#)). Time-activity patterns have been shown to differ between older and younger adults, but there is not a clear difference in time spent in a particular location that could explain differential exposure to NO<sub>2</sub> in older adults ([Section 7.5.1.2](#)). Older adults have higher prevalence of many chronic diseases compared to younger adults ([Table 7-2](#)). COPD, cardiovascular diseases, and diabetes did not consistently modify NO<sub>2</sub>-related health effects, but studies have not examined whether co-occurring morbidity contributes to the increased risk of NO<sub>2</sub>-related asthma exacerbation among older adults or whether age alone influences risk.

Although evidence does not clearly identify increased NO<sub>2</sub>-related health effects in populations of low SES or nonwhite race or populations living near roads or in urban areas, there is an indication of higher NO<sub>2</sub> exposure among these groups. In particular, some communities are characterized as having both higher ambient NO<sub>2</sub> concentrations and higher proportions of nonwhite and low SES populations ([Section 7.5.2](#)). Further, a few studies characterize schools located near high-traffic roads as having high nonwhite and low SES populations compared to schools located farther away from roads ([Section 7.5.6](#)). Nonwhite and low SES populations also are recognized to have higher risks of certain illnesses or diseases, including asthma, although it is not clear whether higher NO<sub>2</sub> exposure and higher risk of negative health effects interact to influence NO<sub>2</sub>-related health effects in these groups. A recent study observed higher risk of

---

<sup>1</sup>National Center for Health Care Statistics Data Brief. Available: <http://www.cdc.gov/nchs/data/databriefs/db94.htm>.

NO<sub>2</sub>-related asthma hospital admissions among Hispanic children compared with white children only in the low SES group (Section 7.5.2). While these findings suggest that co-occurring risk factors in a population could influence the risk of NO<sub>2</sub>-related health effects, information at present is too limited to draw firm conclusions.

In summary, the public health impact of NO<sub>2</sub> exposure is supported by many lines of evidence. A large proportion of the U.S. population lives near roads or spends time near or on roads, resulting in a large number of people potentially with elevated ambient NO<sub>2</sub> exposure. NO<sub>2</sub> exposure is linked to health effects that are clearly adverse, such as ED visits and hospital admissions for asthma and development of asthma. NO<sub>2</sub>-related increases in airway responsiveness can be considered adverse at a population level because an increase in NO<sub>2</sub> exposure can lead to an increase in the number of people with clinically important effects. The public health impact of NO<sub>2</sub> exposure also is supported by the increased risk for people with asthma, children, and older adults. The roles of co-occurring risk factors or combined higher NO<sub>2</sub> exposure and health risk within a population in influencing risk of NO<sub>2</sub>-related health effects is not well understood. The large proportions of children and older adults in the U.S. population and the high prevalence of asthma in children can translate into a large number of people affected by NO<sub>2</sub> and thus magnify the public health impact of ambient NO<sub>2</sub> exposure.

---

## 1.7 Conclusions

There is a causal relationship between short-term NO<sub>2</sub> exposure and respiratory effects. This conclusion is stronger than that determined in the 2008 ISA for Oxides of Nitrogen and is supported by the evidence integrated from controlled human exposure and epidemiologic studies for asthma exacerbation. Asthma-related effects continue to be associated with NO<sub>2</sub> concentrations at central site monitors, but recent epidemiologic studies add evidence for associations with personal ambient and total NO<sub>2</sub> measurements as well as NO<sub>2</sub> concentrations outside schools and inside homes. Epidemiologic evidence continues to show independent associations of NO<sub>2</sub> exposure with asthma-related effects in copollutant models with PM<sub>2.5</sub> or a traffic-related pollutant such as EC/BC, OC, UFP, CO, or a VOC. The potential influence of the full array of traffic-related pollutants or mixtures has not been examined. Thus, the key evidence for an independent effect of NO<sub>2</sub> are the findings from previous controlled human exposure studies that NO<sub>2</sub> exposure not much higher than peak ambient concentrations enhances allergic inflammation and induces clinically relevant increases in airway responsiveness. These effects are hallmarks of asthma exacerbation and suggest a mode of action linking NO<sub>2</sub> exposure to asthma exacerbation.

There is likely to be a causal relationship between long-term NO<sub>2</sub> exposure and respiratory effects. The conclusion is strengthened from the 2008 ISA based on new epidemiologic evidence for associations of asthma development in children combined with biological plausibility from experimental studies. Epidemiologic studies did not examine confounding by traffic-related copollutants. However, a small body of previous experimental studies, which show that long-term and short-term NO<sub>2</sub> exposure increases airway responsiveness and allergic responses in healthy humans and rodent models, provide some indication that long-term NO<sub>2</sub> exposure may have an independent effect on asthma development. For both short-term and long-term exposure, results for NO<sub>2</sub> measured or estimated in subjects' locations that were shown to well represent exposure, provide a stronger basis for inferring relationships with respiratory effects.

Evidence is suggestive of, but not sufficient to infer, a causal relationship for short-term NO<sub>2</sub> exposure with cardiovascular effects and total mortality and for long-term NO<sub>2</sub> exposure with cardiovascular effects and diabetes, poorer birth outcomes, and cancer. While there is continued or new supporting epidemiologic evidence, a large uncertainty remains whether NO<sub>2</sub> exposure has an effect independent of traffic-related copollutants. Epidemiologic studies have not adequately accounted for confounding, and there is a paucity of support from experimental studies. Some recent experimental studies show NO<sub>2</sub>-induced increases in systemic inflammation or oxidative stress. Such changes are not consistently observed or necessarily linked to any health effect, unlike the mode of action information available for asthma. The insufficient consistency of epidemiologic and toxicological evidence is inadequate to infer a causal relationship for long-term NO<sub>2</sub> exposure with fertility, reproduction, and pregnancy, as well as postnatal development.

As described above, key considerations in drawing conclusions about relationships between ambient NO<sub>2</sub> exposure and health effects include evaluating the adequacy of NO<sub>2</sub> exposure estimates to represent the temporal or spatial patterns in ambient NO<sub>2</sub> concentrations in a given study and separating the effect of NO<sub>2</sub> from that of other traffic-related pollutants. Although motor vehicle emissions in the U.S. have decreased greatly over the last few decades, vehicles still are the largest single source of ambient NO<sub>2</sub> in U.S. population centers and can contribute to spatial and temporal heterogeneity in ambient NO<sub>2</sub> concentrations. Recent information combined with that in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) shows that ambient NO<sub>2</sub> concentrations can be higher at locations within 200–500 m of a road compared with locations farther away. Additionally, the first year of data from the U.S. near-road monitoring network show that near-road sites on average have higher NO<sub>2</sub> concentrations at than most other sites within a given urban area but not always the day's highest 1-hour NO<sub>2</sub> concentration.

As in the 2008 ISA, many studies assess exposure with ambient NO<sub>2</sub> concentrations measured at monitors whose siting away from sources likely does not capture the variability in ambient NO<sub>2</sub> concentrations within an area. The resulting error in representing temporal variation in short-term exposure and spatial variation in long-term exposure can produce smaller magnitude or less precise associations with health effects. Such findings are similar to those reported in the 2008 ISA ([U.S. EPA, 2008c](#)). This ISA additionally indicates that error produced from using NO<sub>2</sub> concentrations at central site monitors to represent long-term exposure in some cases can increase health effect estimates compared with residential NO<sub>2</sub> exposure metrics from LUR models. Thus, spatial misalignment of study subjects and ambient NO<sub>2</sub> concentrations potentially can overestimate health effect associations with long-term NO<sub>2</sub> exposure if the difference in exposure between groups that differ in the health effect systematically is underestimated. Given the potential impact of exposure measurement error, the additional epidemiologic findings for exposures assessed for people's locations (e.g., ambient or total personal, outdoor or indoor home or school) increases confidence in inferences about relationships between ambient NO<sub>2</sub> exposure with asthma exacerbation or asthma development. There is confidence in this evidence also because relationships between personal and ambient NO<sub>2</sub> concentrations are variable for short-term averages and largely uncharacterized for long-term averages. Data from the near-road monitoring network may help address gaps in the understanding of the variability in ambient NO<sub>2</sub> concentrations and people's exposures within urban areas and the potential importance of the near-road environment as a source of NO<sub>2</sub> exposure contributing to health effects.

In addition to determining causality, characterizing quantitative aspects of NO<sub>2</sub>-related health effects is key to the review of the primary NO<sub>2</sub> NAAQS. Limited investigation suggests a linear association for short-term ambient NO<sub>2</sub> exposure with asthma ED visits. The association is present at 1-h max NO<sub>2</sub> concentrations frequently observed in U.S. urban areas but uncertain at the lowest end of the concentration distribution. Recent evidence continues to indicate that people with asthma, children, and older adults are at increased risk for NO<sub>2</sub>-related health effects. While recent evidence points to higher NO<sub>2</sub> exposure among people of low SES or nonwhite race or people living in urban areas or close to roads, it is not clear whether this higher NO<sub>2</sub> exposure leads to increased health effects. Large numbers of people in the U.S. live near (e.g., within 100 m) or travel on major roads and potentially have elevated exposures to ambient NO<sub>2</sub> compared with people away from roads. The large numbers of children and older adults in the U.S. population and the high prevalence of asthma in children can translate into a large number of people potentially affected by NO<sub>2</sub> exposure and thus magnify the public health impact of ambient NO<sub>2</sub> exposure.

---

# CHAPTER 2    ATMOSPHERIC CHEMISTRY AND                   AMBIENT CONCENTRATIONS OF                   OXIDES OF NITROGEN

---

## 2.1    Introduction

This chapter presents concepts and findings relating to emissions sources, atmospheric science, and spatial and temporal concentration patterns for oxides of nitrogen. It is intended as a prologue for detailed discussions on the evidence for human exposure to and health effects of oxides of nitrogen that follow in the subsequent chapters, and as a source of information to help interpret those effects in the context of data about atmospheric concentrations.

In this Integrated Science Assessment (ISA), the term “oxides of nitrogen” (NO<sub>y</sub>) refers to all forms of oxidized nitrogen (N) compounds, including nitric oxide (NO), nitrogen dioxide (NO<sub>2</sub>), and all other oxidized N-containing compounds formed from NO and NO<sub>2</sub>. NO and NO<sub>2</sub>, along with volatile organic compounds (VOCs), are precursors in the formation of ozone (O<sub>3</sub>) and photochemical smog. NO<sub>2</sub> is an oxidant and can react to form other photochemical oxidants such as peroxyacyl nitrates (PANs) and toxic compounds such as nitro-substituted polycyclic aromatic hydrocarbons (nitro-PAHs). NO<sub>2</sub> can also react with a variety of atmospheric species to produce organic and inorganic nitrates, which make substantial contributions to the mass of atmospheric particulate matter (PM) and the acidity of clouds, fog, and rainwater. The abbreviation NO<sub>x</sub> refers specifically to the sum of NO and NO<sub>2</sub>. This chapter describes the origins, distribution, and fate of gaseous oxides of nitrogen. Aspects of particulate nitrogen species [such as particulate nitrate (pNO<sub>3</sub>)] are addressed in the review of the National Ambient Air Quality Standards (NAAQS) for PM [see 2009 ISA for Particulate Matter ([U.S. EPA, 2009a](#))] and 2014 Call for Information ([U.S. EPA, 2014c](#)).

---

## 2.2    Atmospheric Chemistry and Fate

The chemistry of oxidized nitrogen compounds in the atmosphere was reviewed in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)). The role of NO<sub>x</sub> in O<sub>3</sub> formation was reviewed in Chapter 3 of the 2013 ISA for Ozone ([U.S. EPA, 2013e](#)) and has been discussed in numerous texts [e.g., ([Jacobson, 2002](#); [Jacob, 1999](#); [Seinfeld and Pandis, 1998](#))]. The main points from the 2008 ISA for Oxides of Nitrogen will be presented here along with updates based on recent material.

The overall chemistry of reactive, oxidized nitrogen compounds in the atmosphere is summarized in [Figure 2-1](#). Sources include naturally occurring processes associated with wildfires, lightning, and microbial activity in soils. Anthropogenic sources are dominated by emissions from motor vehicles and electricity generating units. Oxidized nitrogen compounds are emitted into the atmosphere mainly as NO, with only 10% or less emitted as NO<sub>2</sub>. Further details about the composition of sources is given in [Section 2.3](#). Freshly emitted NO is primarily converted to NO<sub>2</sub> by reacting with O<sub>3</sub>, and NO is recycled during the day by photolysis of NO<sub>2</sub>. Thus, NO and NO<sub>2</sub> are often grouped together into their own group or family, which the atmospheric sciences community refers to as NO<sub>x</sub> (shown in the inner box in [Figure 2-1](#)). A large number of oxidized nitrogen species in the atmosphere are formed from the oxidation of NO and NO<sub>2</sub>. These include nitrate radicals (NO<sub>3</sub>), nitrous acid (HONO), nitric acid (HNO<sub>3</sub>), dinitrogen pentoxide (N<sub>2</sub>O<sub>5</sub>), nitryl chloride (ClNO<sub>2</sub>), peroxyxynitric acid (HNO<sub>4</sub>), PAN and its homologues (PANs), other organic nitrates like alkyl nitrates [including isoprene nitrates(IN)], and pNO<sub>3</sub>. These reactive oxidation products are referred to collectively as NO<sub>z</sub>. All of the species shown within the dashed lines of [Figure 2-1](#) constitute NO<sub>y</sub> (NO<sub>y</sub> = NO<sub>x</sub> + NO<sub>z</sub>). The boxes labeled “inorganic” and “organic” in [Figure 1-1](#) ([Chapter 1](#)) contain the species shown in the left and right halves of [Figure 2-1](#).



result in shorter times, while dispersion and depletion of reactants increase this time. A rough estimate of the time for transport away from a broad boulevard is about a minute ([Düring et al., 2011](#)); this time is shorter for more open conditions and ranges up to about an hour in midtown Manhattan street canyons ([Richmond-Bryant and Reff, 2012](#)). The time for reaction must be compared to the time for mixing away from the road and for replenishment of O<sub>3</sub> because the interplay between these factors determines how far NO will travel downwind before it is oxidized. These dependencies imply seasonal variability and geographic variability in the time scale for the reaction. In general, cooler months present the most favorable conditions for NO to travel further before it is oxidized (lower temperature, decreased vertical mixing of O<sub>3</sub> to the surface, generally lower O<sub>3</sub>). At any time of the year, if loss of O<sub>3</sub> has been extensive near the surface as happens in many locations at night, then NO could travel a kilometer or more before being oxidized, resulting in a more uniform downwind distribution of NO<sub>2</sub> than if NO were being oxidized right at its source. The NO<sub>2</sub> that is formed depletes hydroxyl radicals (OH) so that they cannot oxidize hydrocarbons to continue the cycle of new O<sub>3</sub> formation. During the day, NO<sub>2</sub> photolyzes back to NO within a few minutes, setting up the cycle shown in [Figure 2-1](#). Although the assumption of a photostationary state to describe the relations in the NO/NO<sub>2</sub>/O<sub>3</sub> triad might not be strictly valid, several studies [e.g., [Düring et al. \(2011\)](#); [Clapp and Jenkin \(2001\)](#)] have shown the assumption of a photostationary state can provide a useful approximation of the relationship among these species. Once the sun sets, NO<sub>2</sub> no longer photolyzes to reform NO. If very little or no O<sub>3</sub> is present due to titration in a statically stable, near-surface boundary layer, then NO<sub>2</sub> accumulates through the night solely from direct emissions.

Because of the interplay between dispersion and chemical reaction, the distribution of NO<sub>2</sub> downwind of roads would likely differ from that of a traffic pollutant that is present in ambient air mainly as the result of direct emissions, such as ultrafine particles (UFP) or carbon monoxide (CO) ([Section 2.5.3](#)). In addition, day-night differences in both transport and chemistry will also result in day-night differences in the patterns of spatial and temporal variability of NO<sub>2</sub>. Examples of the behavior of NO<sub>2</sub> and NO<sub>x</sub> downwind of streets and highways are examined in [Section 2.5.3](#). In summary, the major influences on NO<sub>2</sub> concentrations within and downwind of urban centers are the fraction of emissions of NO<sub>x</sub> as NO<sub>2</sub>, dispersion, and the NO/NO<sub>2</sub>/O<sub>3</sub> equilibrium, which is established on a time scale of a few minutes during daylight.

All the other species mentioned above in the definition of NO<sub>Y</sub> (i.e., NO<sub>Z</sub>) are products of reactions of NO or NO<sub>2</sub>. Inorganic NO<sub>Z</sub> species are shown on the left side of the outer box, and organic species are shown on the right side of the outer box in [Figure 2-1](#). Ammonium nitrate and other inorganic particulate species [e.g., sodium (Na<sup>+</sup>), calcium (Ca<sup>2+</sup>) nitrates] are formed from species shown on the left side of the figure; organic

nitrates are formed from species shown on the right side of [Figure 2-1](#). The conversion of  $\text{NO}_x$  into the inorganic and organic species in the outer box (collectively referred to as  $\text{NO}_z$ ) typically takes place on much longer time scales than do interconversions between  $\text{NO}$  and  $\text{NO}_2$ , which occur on timescales of seconds to minutes. For example, conversion of  $\text{NO}_x$  to  $\text{NO}_z$  takes about an hour for conditions in Houston, TX, in April–May of 2009 ([Ren et al., 2013](#)) but it likely takes longer in many other areas, especially those at higher latitudes and generally during the cold season. As a result,  $\text{NO}_x$  emitted during morning rush hour by vehicles can be converted almost completely to products by late afternoon during warm, sunny conditions. However, note the conversion of  $\text{NO}_2$  to  $\text{HNO}_3$  and hence the atmospheric lifetime of  $\text{NO}_x$  depends on the concentration of OH radicals, which in turn depends on the concentration of  $\text{NO}_2$  [e.g., [Valin et al. \(2013\)](#); [Hameed et al. \(1979\)](#)].

Inorganic  $\text{NO}_z$  species shown on the left side of the outer box of [Figure 2-1](#) include  $\text{HONO}$ ,  $\text{HNO}_3$ ,  $\text{ClNO}_2$ ,  $\text{HNO}_4$ , and  $\text{pNO}_3$ . Pernitric acid ( $\text{HNO}_4$ ) is unlikely to represent an important reservoir for  $\text{NO}_x$  except perhaps under extremely cold conditions. [Mollner et al. \(2010\)](#) identified pernitrous acid ( $\text{HOONO}$ ), an unstable isomer of nitric acid, as a product of the major gas-phase reaction forming  $\text{HNO}_3$ . However, because  $\text{HOONO}$  is unstable, it is also not a substantial reservoir for  $\text{NO}_x$ . With consideration of the troposphere as a whole, most of the mass of products shown in the outer box of [Figure 2-1](#) is in the form of PAN and  $\text{HNO}_3$ . The stability of PAN at low temperatures allows its transport to remote regions where it has been shown to exert strong influence on the local production of  $\text{O}_3$  [see [Fischer et al. \(2014\)](#) and references therein]. Other organic nitrates (e.g., alkyl nitrates, isoprene nitrates) increase in importance in the planetary boundary layer (PBL), particularly at locations closer to sources ([Perring et al., 2013](#); [Horowitz et al., 2007](#); [Singh et al., 2007](#)).

In addition to the above compounds, there is a broad range of gas-phase organic nitrogen compounds that are not shown in [Figure 2-1](#). They are emitted by combustion sources and formed in the atmosphere from reactions of  $\text{NO}$ ,  $\text{NO}_2$ , and  $\text{NO}_3$ . These compounds include nitro-aromatics (e.g., nitrotoluene), nitro-PAHs [e.g., nitro-naphthalene; ([Nishino et al., 2008](#))], nitrophenols [e.g., ([Harrison et al., 2005](#))], nitriles [e.g., ethane-nitrile; ([de Gouw et al., 2003](#))], and isocyanic acid ([Roberts et al., 2014](#)).

Sources of  $\text{NO}_x$  are distributed with height, with some occurring at or near ground level and others aloft as indicated in [Figure 2-1](#).  $\text{NO}_x$  emitted by elevated sources can be oxidized to  $\text{NO}_z$  products and/or be transported to the surface, depending on time of day, abundance of oxidants, and strength of vertical mixing. During times of rapid convection, typically in the afternoon on hot sunny days, vertical mixing through the PBL can take place in about 1 hour [e.g., [Stull \(2000\)](#)], and fresh emissions can be brought rapidly to

the surface. After sunset, turbulence subsides, and emissions entrained into the nocturnal residual boundary layer are not mixed downward to the surface. Also, because the prevailing winds aloft are generally stronger than those at the surface, emissions from elevated sources (e.g., the stacks of electrical utilities) can be distributed over a wider area than those emitted at the surface (e.g., motor vehicles). Emissions from elevated sources entrained into the nocturnal residual boundary layer can be transported over long distances, up to a few hundred kilometers overnight depending on location [e.g., [Husar et al. \(1978\)](#)]. Oxidation of  $\text{NO}_x$  can occur during the night and in the morning in the residual layer before it breaks up. Turbulence then mixes  $\text{NO}_x$  and its oxidation products downward. Emissions directly into the free troposphere are unlikely except in areas such as the Intermountain West where PBL heights can be  $<200$  m during winter, or even  $<100$  m in some locations. Because people live closer to surface sources, such as motor vehicles, they are more likely to be exposed to  $\text{NO}$  and  $\text{NO}_2$  from these sources. Thus, atmospheric chemical reactions determine the partitioning of a person's exposure to  $\text{NO}_2$  and its reaction products from different sources, and the sources of a person's exposure cannot be judged solely by the source strengths given in the National Emissions Inventory (NEI). Issues related to the transport and dispersion of  $\text{NO}_x$  emitted by traffic are discussed in depth in [Section 2.5.3](#).

Oxidized nitrogen compounds are ultimately lost from the atmosphere by wet and dry deposition to the Earth's surface. Soluble species are taken up by aqueous aerosols and cloud droplets and are removed by wet deposition by rainout (i.e., incorporation into cloud droplets that eventually coagulate into falling raindrops). Both soluble and insoluble species are removed by washout (i.e., impaction with falling raindrops, another component of wet deposition), and by dry deposition (i.e., impaction with the surface and gas exchange with plants).  $\text{NO}$  and  $\text{NO}_2$  are not very soluble, and therefore wet deposition is not a major removal process for them. However, a major  $\text{NO}_x$  reservoir species,  $\text{HNO}_3$ , is extremely soluble, and its deposition (both wet and dry) represents a major sink for  $\text{NO}_y$ .

Many of the species shown in [Figure 2-1](#), including  $\text{pNO}_3$  and gas-phase  $\text{HONO}$ , are formed by multiphase processes. Data collected in Houston, TX as part of TexAQS-II summarized by [Olague et al. \(2009\)](#) indicate that concentrations of  $\text{HONO}$  are much higher than can be explained by gas-phase chemistry and by tailpipe emissions.

$\text{N}_2\text{O}_5$  is the acid anhydride of  $\text{HNO}_3$ , and its uptake on aqueous aerosol represents a major sink for  $\text{NO}_x$ . The uptake of  $\text{N}_2\text{O}_5$  by atmospheric aerosols or cloud droplets leads to the loss of  $\text{O}_3$  and  $\text{NO}_x$  and the production of aqueous-phase nitric acid, aerosol nitrate, and gaseous halogen nitrites. [MacIntyre and Evans \(2010\)](#) showed that the sensitivity of key tropospheric species, such as  $\text{O}_3$ , varies from very small to high over the range of uptake

coefficients ( $\gamma$ ) for  $\text{N}_2\text{O}_5$  obtained in laboratory studies. For example, global  $\text{O}_3$  loss ranges from 0 to over 10%, with large regional variability over the range of reported  $\text{N}_2\text{O}_5$  uptake coefficients. However, uptake coefficients for  $\text{N}_2\text{O}_5$  [ $\gamma(\text{N}_2\text{O}_5)$ ] on atmospheric particles are not well defined, largely due to uncertainty and variability in aerosol composition. As noted by [Brown and Stutz \(2012\)](#),  $\gamma(\text{N}_2\text{O}_5)$  is largest ( $\approx 0.02$ ) for aqueous inorganic aerosols and water droplets, except for nitrate in aerosol, which can reduce  $\gamma(\text{N}_2\text{O}_5)$  by up to an order of magnitude. The uptake of  $\text{N}_2\text{O}_5$  by mineral particles could also represent an important removal process. For example, values of  $\gamma(\text{N}_2\text{O}_5)$  for calcite and Saharan dust are about 0.03. However, as noted by [Tang et al. \(2014\)](#) not enough is known to permit a global assessment of the importance of  $\text{N}_2\text{O}_5$  uptake on mineral surfaces. Organic aerosol and soot can reduce  $\gamma(\text{N}_2\text{O}_5)$  by two orders of magnitude or more, further complicating the task of assessing the importance of uptake of  $\text{N}_2\text{O}_5$  on aerosol surfaces.

The uptake of  $\text{N}_2\text{O}_5$  by aqueous aerosols containing chloride ( $\text{Cl}^-$ ) and bromide ( $\text{Br}^-$ ) has been associated with the release of gaseous  $\text{ClNO}_2$  from marine aerosol [sea-spray; [Osthoff et al., 2008](#)].  $\text{ClNO}_2$  has been found not only in coastal and marine environments, but also well inland. For example, [Thornton et al. \(2010\)](#) found production rates of gaseous  $\text{ClNO}_2$  near Boulder, CO from reaction of  $\text{N}_2\text{O}_5$  with particulate  $\text{Cl}^-$  at levels similar to those found in coastal and marine environments. They also found that substantial quantities of  $\text{N}_2\text{O}_5$  are recycled through  $\text{ClNO}_2$  back into  $\text{NO}_x$  instead of forming  $\text{HNO}_3$ .  $\text{ClNO}_2$  readily photolyzes to yield  $\text{Cl}$  and  $\text{NO}_2$  and can represent a significant source of reactive  $\text{Cl}$ , capable of initiating the oxidation of hydrocarbons (generally with much higher rate coefficients than  $\text{OH}$  radicals). [Riedel et al. \(2014\)](#) found increases in the production of radicals by 27% and of  $\text{O}_3$  by 15% during the 2010 CalNex [California Research at the Nexus of Air Quality and Climate Change in May to June 2010 in Southern California; [Ryerson et al., 2013](#)] field study. However,  $\text{ClNO}_2$  was found to cause only modest  $\text{O}_3$  increases (e.g.,  $\sim 1$  to 1.5 ppb for nominal  $\text{O}_3$  concentrations between 60 and 85 ppb) in a model study of the Houston, TX airshed ([Simon et al., 2009](#)). Differences are likely related to differences in the  $\text{NO}_x$  sensitivity of the two airsheds. Therefore, caution is advised in extrapolating results obtained in one airshed to another.

As mentioned earlier,  $\text{NO}$  and  $\text{NO}_2$  are important precursors of  $\text{O}_3$  formation. However, because  $\text{O}_3$  changes in a nonlinear way with changes in the concentrations of its precursors ( $\text{NO}_x$  and  $\text{VOCs}$ ),  $\text{O}_3$  is unlike many other atmospheric species with rates of formation that vary directly with emissions of their precursors. At the low  $\text{NO}_x$  concentrations found in environments ranging from remote continental areas to rural and suburban areas downwind of urban centers, the net production of  $\text{O}_3$  typically increases with increasing  $\text{NO}_x$ . In this low- $\text{NO}_x$  regime, the overall effect of the oxidation of

VOCs is to generate (or at least not consume) radicals, and O<sub>3</sub> production varies directly with NO<sub>x</sub>. In the high-NO<sub>x</sub> regime, NO<sub>2</sub> reacts with OH radicals to form HNO<sub>3</sub> [e.g., [Hameed et al. \(1979\)](#)]. Otherwise, these OH radicals would oxidize VOCs to produce peroxy radicals, which in turn would oxidize NO to NO<sub>2</sub>. In this regime, O<sub>3</sub> production is limited by the availability of radicals ([Tonnesen and Jeffries, 1994](#)), and O<sub>3</sub> shows only a weak dependence on NO<sub>x</sub> concentrations. Reaction of O<sub>3</sub> with NO in fresh motor vehicle exhaust depletes O<sub>3</sub> in urban cores, but O<sub>3</sub> can be regenerated during transport downwind of urban source areas, and additional chemical production of O<sub>3</sub> can occur, resulting in higher O<sub>3</sub> concentrations than found upwind of the urban center. Similar depletion of O<sub>3</sub> can occur in power plant plumes with subsequent O<sub>3</sub> regeneration downwind.

[Brown et al. \(2012\)](#) conducted a field study comparing nighttime chemistry in the plumes of two power plants in Texas, one with selective catalytic reduction (SCR) NO<sub>x</sub> emissions controls and the other without these controls. They noted that the plume from the power plant with SCR controls did not have enough NO<sub>x</sub> to deplete all of the O<sub>3</sub> present in background air. As a result, almost all of the NO<sub>x</sub> in the plume was oxidized to NO<sub>z</sub> species. This situation contrasts with that in the plume from the power plant without controls. In that plume, there was minimal formation of NO<sub>z</sub> species. Instead, NO<sub>x</sub> was more nearly conserved.


---

## 2.3 Sources

---

### 2.3.1 Overview

Estimated total NO<sub>x</sub> emissions in the United States (U.S.) from all sources decreased by 49% over the period from 1990 to 2013, as shown in [Figure 2-2](#). The NEI is a national compilation of emissions sources collected from state, local, and tribal air agencies as well as emission estimates developed by the U.S. Environmental Protection Agency (EPA) from collected or estimated data by source sector. Emissions after 2011 for mobile sources and electric utilities are regularly added to the 2011 NEI, but emissions for the other sectors are based on 2011 estimates. Through this process, some of the major sectors in the 2011 NEI have emission estimates more recent than 2011, while emissions from other source sectors are based on 2011 data. When emissions from these sources are added for later years, the inventory is still referred to as a version of the 2011 NEI.




Source: National Center for Environmental Assessment 2014 analysis of 2011 National Emissions Inventory data ([U.S. EPA, 2013a](#)).

**Figure 2-2 U.S. national average NO<sub>x</sub> (sum of nitrogen dioxide and nitric oxide) emissions from 1990 to 2013.**

The NEI program develops data sets, blends data from multiple sources, and performs quality assurance steps that further enhance and augment the compiled data. The inventory database does not include sector emissions uncertainty estimates. The accuracy of individual emission estimates may vary from facility to facility or county to county, and for some sources, data may be incomplete or lacking. For example, there is no lightning data in the NEI, and the 2008 NEI for oil and gas was incomplete, although an oil and gas production estimation tool was developed for subsequent inventories. While uncertainties are difficult to predict, the NEI undergoes continuous improvement by the U.S. EPA with the assistance of state, local, and tribal agencies by their reporting emissions information for facilities, other stationary sources, and mobile sources. Each 3-year cycle of NEI development incorporates improvements based on lessons learned from the previous cycles, and estimation procedures for emissions sectors typically

evolve over time in response to identified deficiencies as the data are used. As a result, in spite of inexact and potentially unknown uncertainties, the NEI largely meets the needs for general emissions assessments and national trends reporting. For example, NO<sub>x</sub> data from the NEI has done a reasonable job of predicting ozone concentrations, resulting in decision making that has significantly improved air quality over the years.

The major sources of NO<sub>x</sub> in the U.S. identified from the 2008 and 2011 NEI ([U.S. EPA, 2013a, 2011a](#)) are described in [Figure 2-3](#). The values shown are U.S. nationwide averages and may not reflect the mix of sources relevant to individual exposure in populated areas. For most sources, data are generally available for all 50 states and the District of Columbia (in some cases, such as agricultural burning, data available in the NEI exclude Alaska and Hawaii). Biogenic emissions were estimated using 2011 meteorology and land use information using the Biogenic Emission Inventory System, version 3.14 [BEIS (Biogenic Emission Inventory System)3.14] model. Although the BEIS domain includes Canada and Mexico, the NEI uses BEIS estimates from counties that make up the contiguous 48 states.



Source: National Center for Environmental Assessment 2014 analysis of 2011 National Emissions Inventory data ([U.S. EPA, 2013a, 2011a](#)).


**Figure 2-3 Major sources of NO<sub>x</sub> (sum of nitrogen dioxide and nitric oxide) emissions averaged over the U.S. from the 2008 and 2011 National Emissions Inventories.**

The source categories displayed in [Figure 2-3](#) represent groups of similar NEI source sectors. Highway Vehicles include all on-road vehicles, including light-duty as well as heavy-duty vehicles, both gasoline- and diesel-powered. Off-Highway Vehicles and Engines include aircraft, commercial marine vessels, locomotives, and nonroad equipment. Fuel Combustion-Utilities includes electric power generating units (EGUs). It includes all types of fuels, but is dominated by coal combustion, which accounts for 85%

of all NO<sub>x</sub> emissions from utilities in the 2011 NEI. Fuel Combustion-Other includes commercial/institutional, industrial, and residential combustion of biomass, coal, natural gas, oil, and other fuels. Other Anthropogenic sources include field burning, prescribed fires, and various industrial processes (e.g., cement manufacturing, oil and gas production). On a national scale, field burning and prescribed fires are the greatest contributors to the Other Anthropogenic sources category. Biogenics and Wildfires include NEI emission estimates for biogenic (plant and soil) emissions and wildfires. For NO<sub>x</sub>, biogenic emissions are dominated by soil emissions, which are one to two orders of magnitude greater than vegetation emissions.

Highway Vehicles are the largest source in the 2011 NEI, contributing 37% of the total NO<sub>x</sub> emissions. Off-Highway Vehicles and Engines account for 20% of emissions, Fuel Combustion-Utilities (by EGUs) for 14%, Fuel Combustion-Other for 11%, Other Anthropogenic sources for 10%, and Biogenics and Wildfires for 8% of 2011 NEI national emissions of NO<sub>x</sub>. Nationwide estimates of total NO<sub>x</sub> emissions in the 2011 NEI are 13% lower than 2008 NEI estimates, decreasing from 18.0 megatons to 15.6 megatons. This decrease reflects lower emission estimates in the 2011 NEI than in the 2008 NEI for the four largest categories in [Figure 2-3](#): 17% lower for Highway Vehicles, 10% lower for Off-Highway Vehicles and Engines, 33% lower for Fuel Combustion-Utilities, and 6% lower for Fuel Combustion-Other. However, estimated emissions were 17% higher for Other Anthropogenic sources, with the greatest increases observed for oil and gas production, agricultural field burning, prescribed fires, and mining. Although Biogenics and Wildfire emissions have increased as a proportion of total national emissions, Anthropogenic sources (i.e., the other categories) still account for more than 90% of emissions in the 2011 NEI.

A somewhat different source mixture than the U.S. national average occurs in the most populated areas. [Figure 2-4](#) compares contributions from different groups of sources in the 21 core-based statistical areas (CBSAs) of the U.S. with populations greater than 2.5 million, where 39% of the U.S. population lives. Relative to the national average, the urban areas have greater contributions to total NO<sub>x</sub> emissions from both Highway Vehicle emissions and Off-Highway Vehicle and Engine emissions, and smaller contributions from Fuel Combustion-Utilities (EGUs), Other Anthropogenic emissions, and Biogenics and Wildfires. [Table 2-1](#) provides details on source distributions for individual CBSAs.



Source: National Center for Environmental Assessment 2014 analysis of 2011 National Emissions Inventory data ([U.S. EPA, 2013a](#)).

**Figure 2-4** Percentage contributions from major sources of the annual NO<sub>x</sub> (sum of nitrogen dioxide and nitric oxide) emissions averaged over the 21 largest U.S. core-based statistical areas with populations greater than 2.5 million compared to the national average.

**Table 2-1 Source distribution of the annual NO<sub>x</sub> (sum of nitrogen dioxide and nitric oxide) emissions in the 21 largest U.S. core-based statistical areas with populations greater than 2.5 million—2011 National Emissions Inventory.**

	Highway Vehicles (%)	Off-Highway Vehicles and Engines (%)	Utilities (%)	Fuel Combustion-Other (%)	Other Anthropogenic (%)	Biogenics and Wildfires (%)
New York, NY	44.3	27.6	4.4	21.6	1.8	0.4
Los Angeles, CA	59.6	26.2	0.6	10.4	2.5	0.7
Chicago, IL	40.1	27.1	11.1	14.8	5.4	1.4
Dallas, TX	53.9	21.5	1.2	9.2	9.5	4.7
Houston, TX	46.0	25.6	3.0	9.5	11.4	4.5
Philadelphia, PA	51.2	22.5	4.0	14.7	6.7	0.9
Washington, DC	55.2	23.4	7.8	10.9	1.5	1.3
Miami, FL	50.5	32.2	7.6	4.8	2.7	2.2
Atlanta, GA	57.7	19.6	15.1	5.7	1.1	0.9
Boston, MA	46.4	27.3	2.7	18.7	4.6	0.4
San Francisco, CA	52.8	30.6	0.8	9.7	4.9	1.2
Riverside, CA	53.0	20.8	1.6	8.5	12.4	3.7
Phoenix, AZ	64.0	25.9	1.7	5.2	0.6	2.7
Detroit, MI	52.5	19.4	8.4	14.4	4.1	1.2
Seattle, WA	66.5	25.7	0.1	5.1	2.3	0.4
Minneapolis, MN	50.2	19.4	11.3	13.9	3.3	2.0
San Diego, CA	64.3	25.5	0.6	4.3	0.8	4.6
Tampa, FL	52.7	23.2	13.5	5.6	2.1	2.9
St. Louis, MO	56.9	13.6	15.3	6.7	5.2	2.4
Baltimore, MD	48.5	21.4	11.5	11.0	6.6	1.0
Denver, CO	55.6	22.5	3.2	12.2	2.9	3.6
Urban Average	51.9	23.8	6.4	11.6	4.6	1.8

NY = New York; CA = California; IL = Illinois; TX = Texas; PA = Pennsylvania; FL = Florida; GA = Georgia; MA = Massachusetts; AZ = Arizona; MI = Michigan; WA = Washington; MN = Minnesota; MO = Missouri; MD = Maryland; CO = Colorado.

Source: National Center for Environmental Assessment 2014 analysis of 2011 National Emissions Inventory data ([U.S. EPA, 2013a](#)).

---

## 2.3.2 Highway Vehicles

Nationally, Highway Vehicles account for about 37% of NO<sub>x</sub> emissions, according to the 2011 NEI. In the 21 largest CBSAs in the U.S. represented in [Figure 2-4](#), more than half of the urban NO<sub>x</sub> emissions are from Highway Vehicles, ranging from 40% in Chicago, IL to 67% in Seattle, WA. Together, Highway Vehicles and Off-Highway Vehicles and Engines account for more than three-quarters of total emissions. Other estimates of high contributions from Highway Vehicles have also been reported. For example, on-road vehicles were estimated to account for about 80% of anthropogenic NO<sub>x</sub> concentrations in the Los Angeles, CA area ([McDonald et al., 2012](#)) and 72% in the Atlanta, GA area ([Pachon et al., 2012](#)). Highway Vehicle NO<sub>x</sub> emissions nationwide are roughly equally split between light-duty gasoline engines (48%) and heavy-duty diesel engines (46%), according to the 2011 NEI. This is in spite of a national vehicle fleet distribution of more than 230 million mostly gasoline-powered light-duty vehicles compared to only 10 million mostly diesel-powered heavy-duty vehicles.<sup>1</sup> [McDonald et al. \(2012\)](#) estimated that diesel engines were the dominant on-road NO<sub>x</sub> sources in the San Joaquin Valley, CA, accounting for up to 70% of on-road NO<sub>x</sub> emissions. In contrast in Fulton County, GA it was estimated that 60% of on-road NO<sub>x</sub> emissions were from gasoline vehicles and 40% from diesel ([Pachon et al., 2012](#)). [McDonald et al. \(2012\)](#) estimated that in California, gasoline engine-related NO<sub>x</sub> emissions steadily decreased by 65% over the period from 1990 to 2010. The study authors also found that the ratio of NO<sub>x</sub> emission factors for heavy-duty diesel versus light-duty gasoline engines grew from ~3 to ~8 between 1990 and 2010 due to improved effectiveness of catalytic converters on gasoline engines.

However, NO<sub>x</sub> emissions from on-road diesel engines in the U.S. have also decreased substantially due to stricter emission standards, and emissions continue to decline ([McDonald et al., 2012](#)). Emission standards for heavy-duty diesel trucks were first established at 10.7 g/bhp-h in 1988, and the current standard of 0.20 g/bhp-h was gradually phased in for model years 2007 through 2010 ([U.S. EPA, 2001](#)), so that emission standards from heavy-duty diesel trucks were reduced by more than a factor of 50 between 1988 and 2010. The current standard is achieved using a urea-based SCR catalyst in engine exhaust placed downstream of a diesel oxidation catalyst (DOC) and a catalyzed diesel particulate filter (DPF) used for PM emissions control. In extensive testing of diesel engines, substantial reductions in NO<sub>x</sub> were observed, averaging 61% relative to the 2010 standard requirements and 97% relative to the 2004 standard requirements ([Southwest Research Institute, 2013](#)). However, while total diesel NO<sub>x</sub> emissions have substantially decreased because of urea-based SCR control, the NO<sub>2</sub>/NO<sub>x</sub>

---

<sup>1</sup> <https://www.fhwa.dot.gov/policyinformation/statistics/2010/vm1.cfm>.

ratio has increased. But these reductions for diesel emissions together with the recent final Tier 3 rule for gasoline engine emissions and lower S 41 gasoline ([U.S. EPA, 2014a](#)) are likely to result in a substantial decline in NO<sub>x</sub> emissions as newer vehicles penetrate into the on-road fleet over the next several years.

---

### 2.3.3 Off-Highway Vehicles and Engines

Off-Highway Vehicles and Engines constitute the next largest group of NO<sub>x</sub> emission sources after Highway Vehicles, both on a nationwide basis and in large U.S. urban CBSAs as shown in [Figure 2-4](#) and [Table 2-1](#). Emissions from the nonroad source sector can also significantly contribute to local and national air quality. The 2011 NEI estimated that approximately 20% of nationwide NO<sub>x</sub> was from Off-Highway Vehicles and Engines. [Zhu et al. \(2011\)](#) estimated that nonroad diesel engines contribute 12% of total nationwide NO<sub>x</sub> emissions from mobile sources. Off-Highway Vehicle and Engine sources include aviation, marine, and railroad engines, as well as nonroad agricultural and industrial equipment, all of which emit NO<sub>x</sub> through combustion processes.

Examples of nonroad equipment include farm tractors, excavators, bulldozers, and wheel loaders. Nationally, agricultural and industrial equipment accounts for more than half of Off-Highway Vehicle and Engine NO<sub>x</sub> emissions, mostly from diesel-powered equipment ([U.S. EPA, 2013a](#)). The U.S. EPA has set a series of standards to reduce NO<sub>x</sub> emissions from nonroad diesel, referred to as Tier 1–4 standards. The most recent standard, Tier 4, was introduced in May 2004, and the phase-in is currently underway, covering a time period between 2008 and 2015. In most cases, advanced diesel engine design, exhaust gas recirculation, and/or SCR have been used to comply with these standards, with DOC/DPFs used in several engine categories.

Although Fuel Combustion-Utilities is generally a smaller contributor to total NO<sub>x</sub> in urban areas than it is nationally, emergency generators are an emerging concern. In urban areas, emissions of NO<sub>x</sub> have been observed to increase substantially on days of near peak electricity demand because of small natural gas- and petroleum-powered steam turbines used to generate additional electrical power to meet demand. These generators are classified in the NEI as nonroad equipment that fall into the category of Off-Highway Vehicles and Engines. They are typically operated in densely populated areas. They are usually older units with higher emissions and lower stack heights than larger generators and are often located close to residential neighborhoods. Because of these factors, emergency generators can have substantial impacts on local air quality. For example, [Gilbraith and Powers \(2013\)](#) estimated that reducing emissions from emergency generators could decrease NO<sub>x</sub> emissions in New York, NY alone by 70 tons per year.

Aircraft, commercial marine transport, and locomotive emissions account for the remaining 40% of Off-Highway Vehicle and Engine emissions, nationally. Aircraft includes all aircraft types used for public, private, and military purposes, classified into four types: commercial, air taxis, general aviation, and military. Airport-related NO<sub>x</sub> emissions can significantly impact local and regional air quality. In the U.K., within a 2–3-km radius of London Heathrow Airport, [Carslaw et al. \(2006\)](#) reported that airport emissions can comprise up to 15% of total ambient NO<sub>x</sub>. In Atlanta, GA, [Unal et al. \(2005\)](#) showed that roughly 2.6% of regional NO<sub>x</sub> concentrations can be attributed to emissions from activities at Hartfield-Jackson International Airport. Compared to airport-related emissions of other gaseous pollutants [e.g., ammonia (NH<sub>3</sub>), CO, sulfur dioxide (SO<sub>2</sub>), VOCs], airport NO<sub>x</sub> emissions had the largest contribution to decreased regional air quality in Atlanta, GA.

Commercial marine vessels include boats and ships used either directly or indirectly in the conduct of commerce or military activity. Globally, marine transport is a significant source of NO<sub>x</sub> emissions, accounting for more than 14% of all global nitrogen emissions from fossil fuel combustion [mostly NO<sub>x</sub>; ([Corbett et al., 1999](#))]. On a regional scale, the contribution of shipping emissions to total NO<sub>x</sub> emissions is variable and can be a substantial fraction near port cities ([Kim et al., 2011](#); [Williams et al., 2009](#); [Vutukuru and Dabdub, 2008](#)). In Los Angeles, CA, [Vutukuru and Dabdub \(2008\)](#) estimated that commercial shipping contributed 4.2% to total NO<sub>x</sub> emissions in 2002. Using the NEI-05, [Kim et al. \(2011\)](#) estimated that roughly 50% of NO<sub>x</sub> concentration near the Houston Ship Channel is associated with commercial shipping emissions. However, this estimation is much higher than observed in satellite and aircraft measurements.

Locomotives powered by diesel engines are a source of NO<sub>x</sub> emissions. Using a fuel-based approach to quantify emissions, [Dallmann and Harley \(2010\)](#) estimated that diesel locomotives emitted on average 50% of total NO<sub>x</sub> from all nonroad mobile sources and roughly 10% of total NO<sub>x</sub> from all mobile sources in the U.S. during 1996–2006 ([Dallmann and Harley, 2010](#)). Locomotives can comprise a much larger fraction of NO<sub>x</sub> emissions for areas in or near large rail yard facilities (>90% of emissions), including NO<sub>2</sub> nonattainment areas ([U.S. EPA, 2010a](#)). In a year-long study at the Rougemere Rail Yard facility near Dearborn, MI, 98% of NO<sub>x</sub> emissions was attributed to locomotive operation, with only minimal impacts from other sources such as on-road mobile sources and stationary sources ([U.S. EPA, 2009a](#)). [Cahill et al. \(2011\)](#) measured gaseous and PM pollutants during a 5-week period near the Roseville Rail Yard in Placer County, CA. They observed several transient NO<sub>x</sub> emission events, where NO levels between 200 ppb and 500 ppb, or roughly seven times larger than the observed urban background NO, were observed downwind of the Roseville Rail Yard.


---

### 2.3.4 Fuel Combustion—Utilities and Other

Fuel combustion for electric power generation and for industrial, residential, commercial, and institutional purposes (excluding motor vehicles and nonroad equipment) accounts for about 25% of NO<sub>x</sub> emissions nationwide. As indicated in [Figure 2-3](#), Fuel Combustion-Utilities accounts for about 14% of total NO<sub>x</sub> emissions nationally. Nationally, about 85% of the NO<sub>x</sub> emissions from power generation is from coal combustion. In urban areas, as shown in [Figure 2-4](#), and fuel combustion for purposes other than electric power generation (Fuel Combustion-Other) appears to be a greater source of emissions than Fuel Combustion-Utilities.

In contrast to Fuel Combustion-Utilities, coal accounts for only about 1% of Fuel Combustion-Other emissions. However, Fuel Combustion-Other is still dominated by fossil fuels, with natural gas contributing about 68% and oil combustion contributing about 14% of other fuel combustion emissions. Although biofuels are an important NO<sub>x</sub> source globally ([Jaegle et al., 2005](#)), only about 10% of Fuel Combustion-Other emissions in the U.S. are due to biomass burning. For Fuel Combustion-Utilities and Fuel Combustion-Other combined, fossil fuels account for more than 90% of U.S. stationary source fuel combustion, and biomass only 4%. Combustion of biofuels accounts for only about 1% of total NO<sub>x</sub> emissions nationwide.

Fuel Combustion-Other accounts for an additional 12% of urban NO<sub>x</sub> emissions, but ranges as high as 22% in New York, NY and 19% in Boston, MA as shown in [Table 2-1](#). [Figure 2-5](#) shows that the contribution of Fuel Combustion-Other to overall urban NO<sub>x</sub> emissions varies with average January temperatures. This trend suggests that winter heating is the driving factor for Fuel Combustion-Other emissions, and that in winter the Fuel Combustion-Other contribution is likely to be considerably greater than the contribution presented on an annual basis in [Table 2-1](#), possibly rivaling Highway Vehicle emissions in winter.



Source: National Center for Environmental Assessment 2014 analysis of 2011 National Emissions Inventory data ([U.S. EPA, 2013a](#)).

**Figure 2-5 Fuel Combustion-Other emissions of NO<sub>x</sub> (sum of nitrogen dioxide and nitric oxide) versus average ambient January temperature for the 21 largest U.S. core-based statistical areas with populations greater than 2.5 million.**

### 2.3.5 Other Anthropogenic Sources

Other Anthropogenic sources include prescribed and agricultural fires as well as industrial operations such as oil and gas production and mining. As emissions estimates from other major source categories have decreased in the U.S. between 2008 and 2011, emissions from these sources have increased by 17%, from about 1.4 megatons in 2008 to more than 1.6 megatons in 2011. On a national scale, agricultural burning and prescribed fires are responsible for a large fraction of the Other Anthropogenic sources category and the increase in national emissions for Other Anthropogenic sources between 2008 and 2011. However, in urban areas, fires are less of a contributor, and Other Anthropogenic sources are mainly industrial. Other Anthropogenic sources vary considerably among the

21 largest U.S. CBSAs with populations greater than 2.5 million. In three CBSAs as described below, NO<sub>x</sub> emissions from Other Anthropogenic sources exceed 10,000 tons per year. Emissions in these three CBSAs are separated by industrial sector in [Table 2-2](#).

In Chicago, IL, emissions from several different sources contribute to Other Anthropogenic emissions. In contrast, Other Anthropogenic NO<sub>x</sub> emissions in Dallas, TX are dominated by oil and gas production, which is not an important source in Chicago, IL. The oil and gas production sector is an increasing source of NO<sub>x</sub>, with a 2011 emission estimate of more than 600,000 tons, compared to slightly more than 400,000 tons in 2008. [Pacsi et al. \(2013\)](#) estimated that routine operating activities from the Barnett Shale production facility near Dallas, TX can emit roughly 30 to 46 tons NO<sub>x</sub>/day, depending on the demand for natural gas electricity generation. Nonroutine gas flares can also result in episodic peaks of large NO<sub>x</sub> emissions, affecting local air quality ([Olague, 2012](#)). Houston, TX presents yet another variation, with anthropogenic emissions mainly coming from petroleum refining and chemical manufacturing. These data demonstrate that sources with relatively small nationwide or annual emissions may contribute substantially to emissions on a local scale. For example, cement manufacturing, which is listed in [Table 2-2](#) as an important source in the local Dallas, TX, airshed, accounts for less than 1% of annual national emissions, but has been characterized by variable emissions with high peaks ([Walters et al., 1999](#)).

**Table 2-2 Relative contributions to Other Anthropogenic NO<sub>x</sub> (sum of nitrogen dioxide and nitric oxide) sources in selected U.S. cities.<sup>a</sup>**

	Chicago, IL %	Dallas, TX %	Houston, TX %
Bulk gasoline terminals	<1	<1	<1
Fires—agricultural field burning	<1	1	3
Fires—prescribed fires	1	NR <sup>b</sup>	1
Fires—wildfires	<1	4	<1
Gas stations	NR <sup>b</sup>	<1	<1
Industrial processes—cement manufacturing	NR <sup>b</sup>	19	NR <sup>b</sup>
Industrial processes—chemical manufacturing	8	<1	43
Industrial processes—ferrous metals	9	2	<1
Industrial processes—not elsewhere classified	35	6	3
Industrial processes—nonferrous metals	21	<1	<1
Industrial processes—oil & gas production	0	66	9
Industrial processes—petroleum refineries	13	<1	37
Industrial processes—pulp & paper	<1	<1	NR <sup>b</sup>
Industrial processes—storage and transfer	<1	<1	<1
Miscellaneous nonindustrial not elsewhere classified	<1	<1	<1
Solvent—degreasing	NR <sup>b</sup>	<1	<1
Solvent—graphic arts	<1	<1	<1
Industrial surface coating & solvent use	1	<1	1
Waste disposal	11	1	4
Total	100	100	100

<sup>a</sup>NO<sub>x</sub> (sum of NO and NO<sub>2</sub>) emissions as percent of “Other Anthropogenic sources” emissions in the Core-Based Statistical Area.

<sup>b</sup>NR indicates that no emissions were reported for this sector (i.e., there were no sources with emissions above the reporting threshold).

Source: National Center for Environmental Assessment 2014 analysis of 2011 National Emissions Inventory data ([U.S. EPA, 2013a](#)).

---

### 2.3.6 Biogenics and Wildfires

The NEI's Biogenics sector includes emissions from plants and soil. In the case of NO<sub>x</sub>, biogenic emissions are dominated by emissions from soil. Biogenic emissions account for about 6% of total NO<sub>x</sub> emissions in the 2011 NEI. However, spatial and temporal variability in NO<sub>x</sub> emissions from soil leads to considerable variability in biogenic emission estimates. For example, estimates obtained from satellite observations indicated that 15–40% of the total NO<sub>2</sub> column in various locations over the Great Plains region can be attributed to soil emissions in spring and summer months ([Hudman et al., 2010](#)). This is consistent with geographic differences in soil contributions described in the 2011 NEI, in which soil contributions accounted for 13–34% of NO<sub>x</sub> emissions in Iowa, Kansas, Nebraska, North Dakota, and South Dakota. About 60% of the total NO<sub>x</sub> emitted from soils is estimated to occur in the central corn belt of the U.S. Because of low population density and the wide area over which emissions are distributed, soil emissions are a less important concern for exposure than more concentrated sources in more highly populated areas.

Biogenic emissions for the 2011 NEI were computed based on the BEIS model. The BEIS modeling domain includes the contiguous 48 states in the U.S., parts of Mexico, and Canada. The NEI uses the biogenic emissions from counties from the contiguous 48 states and DC. Both nitrifying and denitrifying organisms in the soil can produce NO<sub>x</sub>, mainly in the form of NO. Emission rates depend mainly on the amount of applied fertilizer, soil temperature, and soil moisture. As a result, a high degree of uncertainty is associated with soil emissions, and estimates obtained from satellite observations can be greater than source-based estimates ([Jaegle et al., 2005](#)).

Emissions from wildfires can produce enough NO<sub>x</sub> to cause local and regional degradation of air quality in some regions ([Pfister et al., 2008](#)). Roughly 15% of global NO<sub>x</sub> emissions are from biomass burning ([Denman et al., 2007](#)). [Burling et al. \(2010\)](#) reported that NO<sub>x</sub> emissions from southwestern U.S. vegetation ranged from 2.3 to 5.1 g/kg, with the majority of the NO<sub>x</sub> present as NO. Emissions vary considerably among different species of biota, making it difficult to estimate emissions for key ecosystems, such as extratropical forests ([McMeeking et al., 2009](#)). Emissions from forest wildfires can be more than double per amount of energy released than for shrub wildfires ([Mebust et al., 2011](#)).

---

### 2.3.7 Emissions Summary

Major categories of NO<sub>x</sub> emissions in the U.S. are Highway Vehicles, Off-Highway Vehicles and Engines, Fuel Combustion-Utilities, Fuel Combustion-Other, Other Anthropogenic emissions, and Biogenics and Wildfire emissions. Of these, Fuel-Combustion-Utilities and Biogenics and Wildfire emissions are less important in populated U.S. urban areas with the highest NO<sub>2</sub> concentrations, and thus, potentially have less impact on human exposure to NO<sub>2</sub>. Instead, in urban areas, emissions are generally dominated by Highway Vehicles and Off-Highway Vehicles and Engines, which make up more than three-quarters of emissions in the 21 largest CBSAs with populations greater than 2.5 million. Other sources can make important contributions. For example, in cities with average January temperatures below freezing, NO<sub>x</sub> emissions from Fuel Combustion-Other can also be important, and episodic emissions from Other Anthropogenic sources can be important locally. Advances in emission control standards and technology have led to substantial reduction in NO<sub>x</sub> emissions from Highway Vehicles, and hold promise for further reductions. However, Highway Vehicles is generally the greatest source of NO<sub>x</sub> emissions in urban areas.

---

## 2.4 Measurement Methods

---

### 2.4.1 Federal Reference and Equivalent Methods

This discussion focuses on current methods and on promising new technologies for measuring oxides of nitrogen. No attempt is made here to cover in detail the development of these methods, or of methods such as wet chemical techniques, which are no longer in use. More detailed discussions of the histories of these methods can be found elsewhere ([U.S. EPA, 1996a](#), [1993a](#)).

NO is routinely measured using the chemiluminescence induced by its reaction with O<sub>3</sub> at low pressure. The Federal Reference Method (FRM) for NO<sub>2</sub> makes use of this technique of NO detection with a prerequisite step that is meant to reduce NO<sub>2</sub> to NO on the surface of a molybdenum oxide (MoO<sub>x</sub>) substrate heated to between 300 and 400°C. On June 1, 2012, an automated Federal Equivalent Method (FEM) for measuring NO<sub>2</sub> using a photolytic convertor to reduce NO<sub>2</sub> to NO met the equivalency specifications outlined in 40 Code of Federal Regulations (CFR) Part 53 and was approved by the [U.S. EPA \(2012a\)](#). Although photolytic convertors have lower conversion efficiencies than FRM-based analyzers, they have been found to be stable over a period of at least two

months ([Pollack et al., 2011](#)). In addition, two monitors using cavity attenuated phase shift (CAPS) spectroscopy have been approved more recently as FEMs ([U.S. EPA, 2014d, 2013b](#)). These techniques are described below.

Because the chemiluminescence based FRM cannot detect NO<sub>2</sub> specifically, the concentration of NO<sub>2</sub> is determined as the difference between the NO in the air stream passed over the heated MoO<sub>x</sub> substrate and the NO in the air stream that has not passed over the substrate.

However, the reduction of NO<sub>2</sub> to NO on the MoO<sub>x</sub> catalyst substrate also reduces other oxidized nitrogen compounds that are present in the sample (i.e., NO<sub>z</sub> compounds shown in the outer box of [Figure 2-1](#)) to NO. This interference by NO<sub>z</sub> compounds has long been recognized following [Winer et al. \(1974\)](#) who found over 90% conversion of PAN, ethyl nitrate, ethyl nitrite, and n-propyl nitrate and 6–7% conversion of nitroethane to NO with a MoO<sub>x</sub> converter. HNO<sub>3</sub> produced a response, but its form could not be determined. As a result of their experiments, [Winer et al. \(1974\)](#) concluded that “the NO<sub>x</sub> mode of commercial chemiluminescent analyzers must be viewed to a good approximation as measuring *total* gas phase ‘oxides of nitrogen,’ not simply the sum of NO and NO<sub>2</sub>.” Numerous later studies have confirmed these results ([Dunlea et al., 2007](#); [Steinbacher et al., 2007](#); [U.S. EPA, 2006](#); [McClenny et al., 2002](#); [Parrish and Fehsenfeld, 2000](#); [Nummermacker et al., 1998](#); [Crosley, 1996](#); [U.S. EPA, 1993a](#); [Rodgers and Davis, 1989](#); [Fehsenfeld et al., 1987](#)). The sensitivity of the FRM to potential interference by individual NO<sub>z</sub> compounds was found to be variable, depending on characteristics of individual monitors, such as the design of the instrument inlet, the temperature and composition of the reducing substrate, and on the interactions of atmospheric species with the reducing substrate.

Only recently have attempts been made to systematically quantify the magnitude and variability of the interference by NO<sub>z</sub> species in ambient measurements of NO<sub>2</sub>. [Dunlea et al. \(2007\)](#) found an average of about 22% of ambient NO<sub>2</sub> (~9 to 50 ppb), measured in Mexico City over a 5-week period during the spring of 2004, was due to interference from NO<sub>z</sub> compounds. However, similar comparisons have not been carried out under conditions typical for State and Local Air Monitoring Stations (SLAMS) monitoring sites in the U.S. [Dunlea et al. \(2007\)](#) compared NO<sub>2</sub> measured using the conventional chemiluminescent instrument with other (optical) techniques. The main sources of interference were HNO<sub>3</sub> and various organic nitrates. Efficiency of conversion was estimated to be ~38% for HNO<sub>3</sub> and ~95% for PAN and other organic nitrates. Peak interference of up to 50% was found during afternoon hours and was associated with O<sub>3</sub> and NO<sub>z</sub> compounds, such as HNO<sub>3</sub> and the alkyl and multifunctional alkyl nitrates.

[Lamsal et al. \(2008\)](#) used data for the efficiency of reduction of NO<sub>z</sub> species on the MoO<sub>x</sub> catalytic converters to estimate seasonal correction factors for NO<sub>2</sub> measurements across the entire U.S. These factors range from <10% in winter to >80%, with the highest values found during summer in relatively unpopulated areas. In general, interference by NO<sub>z</sub> species in the measurement of NO<sub>2</sub> is expected to be larger downwind of urban source areas and in relatively remote areas due to the conversion of NO<sub>2</sub> to NO<sub>z</sub> during transport downwind of source areas.

In a study in rural Switzerland, [Steinbacher et al. \(2007\)](#) compared continuous measurements of NO<sub>2</sub> from a chemiluminescence analyzer with a MoO<sub>x</sub> catalytic converter (CL/MC) with measurements from a chemiluminescence analyzer with a photolytic converter (CL/PC) that reduces NO<sub>2</sub> to NO. They found the conventional technique using catalytic reduction (as in the FRM) overestimated the measured NO<sub>2</sub> compared to the photolytic technique on average by 10% during winter and 50% during summer.

[Villena et al. \(2012\)](#) and [Kleffmann et al. \(2013\)](#) suggested that negative interference in the chemiluminescent method using the photolytic converter could occur from production of HO<sub>2</sub> and RO<sub>2</sub> radicals by the photolysis of VOCs (e.g., glyoxal) in the photolytic converter. Subsequent to photolysis and prior to detection, these radicals react with NO that is produced either by the photolytic converter or already in the sampling stream. Because the chemiluminescent techniques rely on detection of NO, a negative artifact results. The most direct evidence for this artifact was found at high concentrations in a smog chamber containing 1 ppm glyoxal, a concentration more than a thousand times higher than typically found in ambient air. Similar indications were also found by [Kleffmann et al. \(2013\)](#) in a street canyon (at the University of Wuppertal, Germany) and in an urban background environment (University of Santiago, Chile). However, [Kleffmann et al. \(2013\)](#) also found that the magnitude of the negative artifact is smaller when a light source with a smaller spectral range is used and that this artifact is expected to be most apparent under high VOC conditions, such as in street canyons.

Within the urban core of metropolitan areas, where many of the ambient monitors are sited in areas influenced by strong NO<sub>x</sub> sources such as motor vehicles on busy streets and highways (i.e., where NO<sub>2</sub> concentrations are highest), the positive artifacts due to the NO<sub>2</sub> oxidation products are much smaller on a relative basis. Conversely, the positive artifacts are larger on a relative basis away from NO<sub>x</sub> sources. Data for PAN and HNO<sub>3</sub> were collected in Houston, TX in April and May of 2009 during the Study of Houston Atmospheric Radical Precursors (SHARP) campaign ([Olague et al., 2014](#)). Median concentrations of PAN and HNO<sub>3</sub> during the afternoon were 181 [interquartile range (IQR) 94] parts per trillion (ppt) and 164 (IQR 158) ppt, respectively, for NO<sub>2</sub> <1 ppb

measured by CL/PC during SHARP and 157 (IQR 54) ppt and 146 (IQR 402) ppt, respectively, for  $\text{NO}_2 > 10$  ppb. These results suggest that potential interference in CL/MC caused by  $\text{HNO}_3$  and PAN is estimated to be  $< 1$  ppb using the conversion efficiencies obtained by [Dunlea et al. \(2007\)](#) and concentrations of  $\text{HNO}_3$  and PAN obtained during SHARP. However, the extent of interference could be expected to be most problematic for  $\text{NO}_2 < \sim 1$  ppb.

In summary, the current FRM for determining ambient  $\text{NO}_x$  concentrations and then reporting  $\text{NO}_2$  concentrations by subtraction of NO is subject to a consistently positive interference by  $\text{NO}_x$  oxidation products, including  $\text{HNO}_3$ , PAN and its analogues, and total organic nitrates ( $\text{RONO}_2$ ). The magnitude of this positive bias is largely unknown as measurements of these oxidation products in urban areas are sparse. However, it is likely to be less important in urban areas influenced by fresh  $\text{NO}_x$  combustion emissions than in remote areas where  $\text{NO}_x$  oxidation has had more time to proceed.


---

## 2.4.2 Other Methods for Measuring Nitrogen Dioxide

Optical methods such as those using differential optical absorption spectroscopy (DOAS) or laser-induced fluorescence (LIF) are available for use in ambient monitoring. However, these particular methods, even those that have been commercialized (e.g., DOAS), can be more expensive than either the FRM monitors or photolytic reduction technique and require specialized expertise to operate; moreover, the DOAS obtains a path-integrated rather than a point measurement. Cavity attenuated phase shift (CAPS) monitors are an alternative optical approach requiring much less user intervention and expense than either DOAS or LIF ([Kebabian et al., 2008](#)). At first glance, it might appear that this technique is not highly specific to  $\text{NO}_2$ , as it is subject to interference by species that absorb at 440 nm such as 1,2-dicarbonyl compounds. However, this source of interference is expected to be small ( $\sim 1\%$ ), and if necessary, the extent of this interference can be limited by shifting the detection to longer wavelengths and adjusting the lower edge of the detection band to 455 nm. In principle,  $\text{NO}_2$  detection limits could be  $< 30$  ppt for a 60-second time scale.


[Lee et al. \(2011a\)](#) describe the development of a dual continuous-wave mode quantum cascade-tunable infrared laser differential absorption spectrometer (QC-TILDAS) to measure  $\text{NO}_2$  and HONO simultaneously. The one-second detection limit [signal-to-noise ratio ( $S/N$ ) = 3] for  $\text{NO}_2$  is 30 ppt. A field comparison of measurements of  $\text{NO}_2$  between CAPS and CL/MC is shown in [Figure 2-6](#). The CAPS—CL/MC (Thermo Electron 42I) data were obtained over 4 days in a parking lot located  $\sim 200$  m from a major arterial highway (Route 3 in Billerica, MA) in October 2007. [Figure 2-7](#) shows the results of a

comparison of NO<sub>2</sub> measured by QC-TILDAS to NO<sub>2</sub> measured by CL/PC. The QC-TILDAS-CL/PC data were collected in Houston, TX in April and May of 2009 during the SHARP campaign ([Olague et al., 2014](#)). Both comparisons show very high  $R^2$  (>0.99) and close agreement over concentrations ranging from <1 ppb to >30 ppb, and both comparisons are characterized by small nonzero intercepts. For the CAPS instrument ([Figure 2-6](#)), slightly higher values than those reported by the CL/MC monitor are seen at concentrations <~2 ppb. [Figure 2-7](#) shows that the QC-TILDAS obtains slightly lower concentrations than reported by CL/PC for NO<sub>2</sub> concentrations <~1 ppb. Although CAPS presents a practical alternative to chemiluminescence for NO<sub>2</sub> measurements, an important consideration in routine network deployment of CAPS or any other method that only measures NO<sub>2</sub> (e.g., does not measure NO) is the potential loss of NO and NO<sub>x</sub> data, which has been used as an indicator for traffic- or other combustion-related pollution.



Note: CAPS = cavity attenuated phase shift, CL/MC = chemiluminescence/MoO<sub>x</sub> catalytic converter, NO<sub>2</sub> = nitrogen dioxide.  
Source: National Center for Environmental Assessment 2013 analysis of data from [Kebabian et al. \(2008\)](#).

**Figure 2-6 Comparison of nitrogen dioxide measured by cavity attenuated phase shift spectroscopy to nitrogen dioxide measured by chemiluminescence/molybdenum oxide catalytic converter for 4 days in October 2007 in Billerica, MA.**



Note: NO<sub>2</sub> = nitrogen dioxide, PC = photolytic converter, QC-TILDAS = quantum cascade-tunable infrared differential absorption spectroscopy.

Source: National Center for Environmental Assessment 2013 analysis of data from [Lee et al. \(2013\)](#).

**Figure 2-7 Comparison of nitrogen dioxide measured by quantum cascade-tunable infrared differential absorption spectroscopy to nitrogen dioxide measured by chemiluminescence with photolytic converter during April and May 2009 in Houston, TX.**

[Villena et al. \(2011\)](#) describe the development of a long path absorption photometer (LOPAP) to measure NO<sub>2</sub>. In this technique, NO<sub>2</sub> is sampled in a stripping coil using a modified Griess-Saltzman reagent with the production of an azo dye whose visible absorption is measured by long-path photometry. This reaction was the basis for a much earlier manual method for measuring NO<sub>2</sub> ([Saltzman, 1954](#)). Interference, which can be minimized by additional stripping coils, could be caused by HONO, O<sub>3</sub>, and PAN. In an intercomparison with a CL/PC carried out over four days in March 2007 on the fifth floor balcony of a building at the University of Wuppertal in Germany, very good agreement (mean deviation of 2%) was obtained. Interestingly, in the entire range of NO<sub>2</sub> measurements (~0.5 ppb to ~40 ppb), the relation between LOPAP and CL/PC can be characterized by  $\text{LOPAP (ppb)} = 0.984 \times \text{CL/PC} - 0.42$  (ppb). However, if the range

<6 ppb only is considered, the relation becomes LOPAP (ppb) =  $0.998 \times \text{CL/PC} + 0.19$  (ppb).

Diode laser-based cavity ring-down spectroscopy (CRDS) has also been used to detect NO<sub>2</sub>. [Fuchs et al. \(2009\)](#) developed a portable instrument that relies on NO<sub>2</sub> absorption at 404 nm, with 22 ppt detection limit at 1 second (S/N = 2). As opposed to chemiluminescence monitors that measure NO<sub>2</sub> indirectly based on direct measurement of NO, NO<sub>2</sub> (formed by reaction of NO with excess O<sub>3</sub>) is directly measured in CRDS. NO is then determined by subtracting NO<sub>2</sub> measured in the first cavity from the sum of NO<sub>2</sub> and NO (i.e., NO<sub>x</sub>) measured in the second cavity. The O<sub>3</sub> is generated by photolysis of O<sub>2</sub> in the Schumann-Runge bands at 185 nm. This conversion should be much more complete than relying on the reduction of NO<sub>2</sub> and NO<sub>z</sub> species with variable efficiency on a MoO<sub>x</sub> converter. Note that the optical methods relying on NO<sub>2</sub> absorption at ~400 nm described above (i.e., CAPS, CRDS) might be subject to positive interference from absorption by trace components (e.g., glyoxal and methyl glyoxal). However, absorption cross sections for these dicarbonyls are much lower than for NO<sub>2</sub> at this wavelength, and concentrations for these potentially interfering species are generally lower than those for NO<sub>2</sub>. Furthermore, it is possible that thermal decomposition of NO<sub>z</sub> species, such as PAN, in inlets or their reduction on inlet surfaces or in optical cavities can be a source of NO<sub>2</sub> in these or other instruments requiring an inlet.

---


### 2.4.3 Satellite Measurements of Nitrogen Dioxide

Remote sensing by satellites is an approach that could be especially useful in areas where surface monitors are sparse. Retrieving NO<sub>2</sub> column abundances from satellite data involves three steps: (1) determining the total NO<sub>2</sub> integrated line-of-sight (slant) abundance by spectral fitting of solar backscatter measurements; (2) removing the stratospheric contribution by using data from remote regions where the tropospheric column abundance<sup>1</sup> is small; and (3) applying an air mass factor to convert tropospheric slant columns into vertical columns. The retrieval uncertainty is largely determined by Steps 1 and 2 over remote regions where there is little tropospheric NO<sub>2</sub>, and by Step 3, over regions of elevated tropospheric NO<sub>2</sub> ([Boersma et al., 2004](#); [Martin et al., 2002](#)). Satellite retrievals are largely limited to cloud fractions <20%. The algorithm used here to derive the tropospheric column of NO<sub>2</sub> is given in [Bucsela et al. \(2013\)](#). This algorithm was used to generate the maps in [Figure 2-8](#) for 2005 to 2007 and in [Figure 2-9](#) for 2010 to 2012 showing seasonal average NO<sub>2</sub> columns obtained by the Ozone Monitoring Instrument (OMI) on the AURA satellite. Other algorithms, for example the Berkeley

---

<sup>1</sup> Column refers to the integrated line-of-sight abundance in a unit cross section, such that its units are molecules/cm<sup>2</sup>.


High-Resolution product ([Russell et al., 2011](#)), which is based on higher resolution input fields (topography, albedo, and NO<sub>2</sub> vertical profile shape) in the retrievals, can reduce the uncertainty in the measurements.



Note: Images shown were constructed by Dr. Lok Lamsal of Universities Space Research Association from data obtained by the Ozone Monitoring Instrument (OMI) on the AURA satellite (<http://aura.gsfc.nasa.gov/scinst/omi.html>) using the algorithm described in [Bucsela et al. \(2013\)](#). Top panel (winter; DJF: December, January, February). Lower panel (summer; JJA: June, July, August).

**Figure 2-8** Seasonal average tropospheric column abundances for nitrogen dioxide ( $10^{15}$  molecules/cm<sup>2</sup>) derived by ozone monitoring instrument for winter (upper panel) and summer (lower panel) for 2005 to 2007.

OMI Tropospheric NO<sub>2</sub> ( $10^{15}$  molec. cm<sup>-2</sup>)



Note: Images shown were constructed by Dr. Lok Lamsal of Universities Space Research Association from data obtained by the Ozone Monitoring Instrument (OMI) on the AURA satellite (<http://aura.gsfc.nasa.gov/scinst/omi.html>) using the algorithm described in [Bucsela et al. \(2013\)](#). Top panel (winter; DJF: December, January, February). Lower panel (summer; JJA: June, July, August).

**Figure 2-9** Seasonal average tropospheric column abundances for nitrogen dioxide ( $10^{15}$  molecules/cm<sup>2</sup>) derived by ozone monitoring instrument for winter (upper panel) and summer (lower panel) for 2010 to 2012.

Areas of high column NO<sub>2</sub> abundance are found over major source areas during both 2-year periods shown in [Figures 2-8](#) and [2-9](#). High column abundances are found over many major urban areas, such as Los Angeles, CA; Houston, TX; Chicago, IL; and New York, NY; and over major power plant complexes such as the Four Corners (Colorado, New Mexico, Arizona, and Utah) and the Ohio River Valley. A diffuse area with column abundances above background is found over the Bakken Shale fields in northwestern North Dakota in winter. However, in general, the area of high column abundance of NO<sub>2</sub>

(shown in orange and red) is smaller in the 2010 to 2012 composite than from 2005 to 2007. The photochemical lifetime of NO<sub>2</sub> is longer in winter than in summer resulting in lower column abundances of NO<sub>2</sub> in summer than in winter during the two 3-year periods shown in [Figures 2-8](#) and [2-9](#).

Because satellite instruments do not return surface concentrations directly, information on NO<sub>2</sub> surface concentrations must be inferred from the column measurements. [Lamsal et al. \(2008\)](#) and [Lamsal et al. \(2010\)](#) combined satellite data for column NO<sub>2</sub> from OMI with results from the Goddard Earth Observing System (GEOS)-Chem global scale chemistry-transport model to derive surface concentrations of NO<sub>2</sub> (see [Figure 2-13](#) for an example of seasonally averaged surface NO<sub>2</sub> concentrations derived by this method). This method accounts for the feedback from the abundance of NO<sub>2</sub> on the lifetime of NO<sub>2</sub>. Note, however, that data are collected only during the daily satellite overpass in early afternoon and this method has only been applied for the time of satellite overpass. Some other means must be used to extend the time period of applicability, for example by scaling the afternoon value by the diel variation in a model, provided the model bias in simulating NO<sub>2</sub> has been characterized over the times of interest in a 24-hour cycle ([Stavrakou et al., 2008](#); [Kim et al., 2006b](#)).

---

#### 2.4.4 Measurements of Total Oxides of Nitrogen in the Atmosphere

Commercially available NO<sub>x</sub> monitors have been converted to NO<sub>y</sub> monitors by moving the MoO<sub>x</sub> convertor to interface directly with the sample inlet. Because of losses on inlet surfaces and differences in the efficiency of reduction of NO<sub>z</sub> compounds on the heated MoO<sub>x</sub> substrate, NO<sub>x</sub> concentrations cannot be considered as a universal surrogate for NO<sub>y</sub>. However, most of the NO<sub>y</sub> is present as NO<sub>x</sub> close to sources of fresh combustion emissions, such as highways during rush hour. To the extent that all the major oxidized nitrogen species can be reduced quantitatively to NO, measurements of NO<sub>y</sub> concentrations should be more reliable than those for NO<sub>x</sub> concentrations, particularly at typical ambient levels of NO<sub>2</sub>. Exceptions might apply in locations near NO<sub>x</sub> sources, where NO<sub>x</sub> measurements are likely to be less biased and confidence in measurement accuracy increases.


Alternatively, multiple methods for observing components of NO<sub>y</sub> have been developed and evaluated in some detail. As a result of these methods, as applied in the field and the laboratory, knowledge of the chemistry of odd-N species has evolved rapidly. Recent evaluations of methods can be found in [Arnold et al. \(2007\)](#) for HNO<sub>3</sub>, [Wooldridge et al. \(2010\)](#) for speciated PANs, and [Pinto et al. \(2014\)](#) for HONO. However, it is worth reiterating that the direct measurements of NO are still the most reliable method. Reliable

measurements of  $\text{NO}_Y$  and  $\text{NO}_2$  concentrations, especially at the low concentrations observed in many areas remote from sources, are also crucial for evaluating the performance of three-dimensional, chemical transport models of oxidant and acid production in the atmosphere.

---

#### 2.4.5 Ambient Sampling Network Design

[Figure 2-10](#) shows that approximately 500 monitoring sites operate routinely across the U.S. for oxidized nitrogen in ambient air. Four networks are highlighted: (1) regulatory-based SLAMS designed to determine NAAQS compliance; (2) Clean Air Status and Trends Network (CASTNET), which provides weekly averaged values of total nitrate ( $\text{HNO}_3$  and  $\text{pNO}_3$ ) in rural locations; (3) the National Core (NCore) Network, a subset of SLAMS comprised of approximately 70 stations designed to capture area-representative multiple-pollutant concentrations that provides routinely measured  $\text{NO}_Y$ ; and (4) the Southeast Aerosol Research Characterization (SEARCH), a privately funded network of 6–10 sites including direct measurements of true  $\text{NO}_2$  as well as  $\text{NO}_Y$  and other nitrogen species (oxidized and reduced forms). Relative to the  $\text{O}_3$  and PM monitoring networks, the ambient  $\text{NO}_2$  monitor density is significantly lower.



Note: SLAMS = State and Local Air Monitoring Stations, CASTNET = Clean Air Status and Trends Network, NCORE = National Core Network, SEARCH = Southeast Aerosol Research Characterization.

Source: U.S. Environmental Protection Agency 2013 analysis of data from monitoring networks.

**Figure 2-10 Map of monitoring sites for oxides of nitrogen in the U.S. from four networks.**

Currently, with the exception of 4–6 sites in the SEARCH network ([Hansen et al., 2003](#)), direct or true NO<sub>2</sub> is sparingly measured on a routine basis. The regulatory networks rely mainly on chemiluminescence difference techniques that provide NO concentration directly and report a calculated NO<sub>2</sub> concentration as the difference between NO<sub>x</sub> concentration and NO concentration as discussed in [Section 2.4.1](#). Criteria for siting ambient NO<sub>2</sub> and NO<sub>y</sub> monitors are laid out in 40 CFR Part 58, Appendix D. NO<sub>2</sub> monitors are meant to be representative of several scales: microscale (in close proximity, up to 100 m from the source), middle (several city blocks, 100 to 500 m), neighborhood (0.5 to 4 km), and urban (4 to 50 km). Microscale to neighborhood-scale monitors are used to determine the highest concentrations and source impacts, while neighborhood- and urban-scale monitors are used for relatively wider area concentrations.

The U.S. EPA promulgated new minimum monitoring requirements in February 2010, mandating that state and local air monitoring agencies install near-road NO<sub>2</sub> monitoring

stations within the near-road environment in larger urban areas, and other monitoring stations including area-wide measurements, and measurements in areas having vulnerable and susceptible populations. With regard to the near-road monitors, under these new requirements, state and local air agencies will operate one near-road NO<sub>2</sub> monitor in any CBSA with a population of 500,000 or more, and two near-road NO<sub>2</sub> monitors in CBSAs with 2,500,000 or more persons or roadway segments carrying traffic volumes of 250,000 or more vehicles. These monitoring data are intended to represent the highest population exposures that may be occurring in the near-road environment throughout an urban area over the averaging times of interest. The near-road NO<sub>2</sub> network is intended to focus monitoring resources on near-road locations where peak ambient NO<sub>2</sub> concentrations are expected to occur because of on-road mobile source emissions and to provide a clear means to determine whether the NAAQS is being met within the near-road environment throughout a particular urban area. The network is now being phased in, and the first phase became operational in January of 2014.

---

## 2.5 Ambient Concentrations of Oxides of Nitrogen

This section provides a brief overview of ambient concentrations of NO<sub>2</sub> and associated oxidized N compounds in the U.S.; it also provides estimates of background concentrations used to inform risk and policy assessments for the review of the NAAQS.

In the 2008 ISA for Oxides of Nitrogen, NO<sub>2</sub> concentrations were summarized with an explanation that the annual average NO<sub>2</sub> concentrations of ~15 ppb reported by the regulatory monitoring networks were well below the level of the NAAQS (53 ppb), but that the 1-hour daily maximum concentrations can be much greater in some locations, especially in areas with heavy traffic ([U.S. EPA, 2008c](#)).

---


### 2.5.1 National-Scale Spatial Variability

In the 2008 ISA for Oxides of Nitrogen, data were analyzed for NO<sub>2</sub> measured at monitoring sites located within urbanized areas in the U.S. ([U.S. EPA, 2008c](#)). NO<sub>2</sub> concentrations were ~15 ppb for averaging periods ranging from a day to a year, and the 1-hour daily maximum NO<sub>2</sub> concentration was ~30 ppb, about twice as high as the 24-h avg. Data on NO<sub>z</sub> concentrations were very limited but indicated that HNO<sub>3</sub> and HONO concentrations were considerably lower than NO<sub>2</sub> concentrations. HNO<sub>3</sub> concentrations ranged from <1 to >10 ppb, and HONO concentrations were reported as <1 ppb even under heavily polluted conditions. HNO<sub>3</sub> concentrations were highest downwind of an urban center. HONO was present in areas with traffic, at concentrations

several percent of NO<sub>2</sub> concentrations ([U.S. EPA, 2008c](#)). Field study results indicating much higher NO<sub>z</sub> concentrations than NO<sub>x</sub> concentrations in relatively unpolluted rural air were also described ([U.S. EPA, 2008c](#)).

[Figure 2-11](#) presents a national map of the U.S. 98th percentile of 1-hour daily maximum concentrations based on 2011–2013 data, and [Figure 2-12](#) presents annual average NO<sub>2</sub> concentrations based on 2013 calendar year data. In both figures, data are included only for monitors with 75% of days reported for each calendar quarter over the 3-year period and only for days with 75% of all hours reported. Because of the completeness requirements, there are cases where sites have valid annual average data but not valid 1-hour daily maximum concentrations. The highest concentrations are in the Northeast Corridor, California, and other urbanized regions, and the lowest concentrations are in sparsely populated regions, most notably in the West. These observations are consistent with those described in the 2008 ISA ([U.S. EPA, 2008c](#)).


[Table 2-3](#) presents summary data on 1-hour daily maximum NO<sub>2</sub> concentrations and [Table 2-4](#) presents annual average NO, NO<sub>2</sub> and NO<sub>x</sub> concentrations for the period 2011–2013. [Table 2-3](#) also includes summary data by individual years and by quarters averaged over the 3 years, as well as summary data for selected urban areas that are examined in recent U.S. epidemiologic studies on the health effects of NO<sub>2</sub> ([Chapters 5 and 6](#)). Nationally, 1-hour daily maximum concentrations rarely exceeded 60 ppb for the 3-year period, but 99th percentile concentrations were greater than 60 ppb in New York, NY; Los Angeles, CA; and Denver, CO. The 50th percentile 1-hour daily maximum concentration nationwide was 16 ppb, but varied among cities in [Table 2-3](#), ranging from 8 ppb in Atlanta to near 40 ppb in Denver, CO. Annual average NO<sub>2</sub> concentrations from [Table 2-4](#) were mostly less than 10 ppb, and the highest concentrations never exceeded 26 ppb. The 50th percentile annual average NO concentrations were less than those for NO<sub>2</sub> but the ratio of NO concentration to NO<sub>2</sub> concentration increased with increasing NO<sub>x</sub> concentration. For 99th percentile and maximum, annual NO concentrations were higher than those for NO<sub>2</sub>, indicating that on the most polluted days, the ratio of NO to NO<sub>2</sub> is higher, consistent with fresh combustion emissions. Annual average NO<sub>x</sub> concentrations for a given location were usually under 20 ppb and never exceeded 70 ppb.



Note: NO<sub>2</sub> = nitrogen dioxide. Concentrations indicated are the highest concentration in the county and do not represent countywide concentrations.

Source: U.S. Environmental Protection Agency 2014 analysis of data from state and local air monitoring stations.

**Figure 2-11 U.S. 98th percentiles of 1-hour daily maximum nitrogen dioxide concentrations for 2011–2013.**



Note: NO<sub>2</sub> = nitrogen dioxide. Concentrations indicated are the highest concentration in the county and do not represent countywide concentrations.

Source: U.S. Environmental Protection Agency 2014 analysis of data from state and local air monitoring stations.

**Figure 2-12 U.S. annual average nitrogen dioxide concentrations for 2013.**

**Table 2-3 Summary statistics for 1-hour daily maximum nitrogen dioxide concentrations (ppb) based on state and local air monitoring stations.**

	Year	n	Mean	Percentiles								
				1	5	10	25	50	75	90	95	99
NO <sub>2</sub>	2011–2013	390,713	19	1	2	3	8	16	27	38	44	55
NO <sub>2</sub>	2011	127,610	19	1	2	4	8	16	28	39	45	57
NO <sub>2</sub>	2012	130,170	18	1	2	3	8	16	27	37	43	55
NO <sub>2</sub>	2013	132,933	18	1	2	3	7	15	26	37	43	54
NO <sub>2</sub>	1st Quarter	94,612	22	1	2	4	10	20	32	41	47	58
NO <sub>2</sub>	2nd Quarter	96,962	16	1	2	3	6	12	22	33	40	52
NO <sub>2</sub>	3rd Quarter	99,125	16	1	2	3	7	13	22	32	38	50
NO <sub>2</sub>	4th Quarter	100,101	21	1	2	4	10	20	31	40	46	58
Atlanta, GA <sup>a</sup>	2011–2013	3,215	13	2	2	3	4	8	18	34	41	52
Atlanta, GA—all <sup>b</sup>	2011–2013	3,215	13	2	2	3	4	8	18	34	41	52
Boston, MA <sup>a</sup>	2011–2013	6,246	25	5	8	11	16	24	32	39	44	52
Boston, MA—all <sup>b</sup>	2011–2013	10,986	19	1	3	4	9	17	28	36	41	49
Denver, CO <sup>a</sup>	2011–2013	966	38	6	14	22	30	39	46	53	58	68
Denver, CO—all <sup>b</sup>	2011–2013	2,184	41	9	21	26	33	41	48	55	61	73
Houston, TX <sup>a</sup>	2011–2013	9,525	21	1	3	5	10	18	29	45	45	56
Houston, TX—all <sup>b</sup>	2011–2013	16,610	18	1	3	4	8	15	26	36	43	54
Los Angeles, CA <sup>a</sup>	2011–2013	8,328	27	4	7	10	16	26	36	44	49	60
Los Angeles, CA—all <sup>b</sup>	2011–2013	30,612	28	4	7	10	17	28	38	47	52	63
New York, NY <sup>a</sup>	2011–2013	9,469	27	1	3	5	13	27	38	47	52	64
New York, NY—all <sup>b</sup>	2011–2013	11,803	27	1	3	5	15	27	38	47	52	63
Seattle, WA <sup>a</sup>	2011–2013	none										
Seattle, WA—all <sup>b</sup>	2011–2013	1,649	13	3	4	5	7	11	17	24	31	46

NO<sub>2</sub> = nitrogen dioxide; GA = Georgia; MA = Massachusetts; CO = Colorado; TX = Texas; CA = California; NY = New York; WA = Washington.

<sup>a</sup>City name only rows contain hourly data that meet 75% completeness criteria.

<sup>b</sup>City—all rows report data regardless of whether completeness criteria are met.

Source: Office of Air Quality Planning and Standards and National Center for Environmental Assessment 2014 analysis of Air Quality System network data 2011–2013.

**Table 2-4 Summary statistics for nitrogen dioxide, nitric oxide, and sum of nitrogen dioxide and nitric oxide annual average concentrations (ppb) based on state and local air monitoring stations.**


Pollutant	Year	n	Mean	Percentiles								
				5	10	25	50	75	90	95	99	Max
NO <sub>2</sub>												
	2011-2013	1,041	8.6	1.4	2.2	4.3	8.1	11.8	16.2	18.6	22.5	26.0
	2011	338	9.0	1.5	2.5	4.7	8.4	12.3	16.8	19.6	23.9	25.3
	2012	347	8.5	1.4	2.2	4.2	8.1	11.6	15.9	18.6	22.1	26.0
	2013	356	8.3	1.3	2.1	4.2	7.7	11.6	15.8	18.1	21.8	24.6
NO												
	2011-2013	1,127	4.8	0.1	0.3	1.0	2.9	6.8	11.3	15.3	25.3	48.8
	2011	363	5.0	0.1	0.3	1.1	3.1	7.4	12.7	15.1	23.9	46.9
	2012	377	4.8	0.1	0.2	1.0	2.9	6.6	10.9	15.0	27.7	48.8
	2013	387	4.6	0.1	0.2	1.0	2.6	6.5	11.0	15.7	21.5	36.2
NO <sub>x</sub>												
	2011-2013	1,011	13.4	1.5	2.6	5.4	11.3	18.6	28.1	31.8	45.4	68.4
	2011	320	13.7	1.5	2.6	5.8	11.8	19.3	28.9	31.7	44.8	68.4
	2012	342	13.2	1.3	2.6	5.2	11.2	18.5	26.8	31.3	48.9	61.0
	2013	349	13.3	1.7	2.6	5.4	10.9	18.3	28.0	32.7	44.1	61.7

Max = maximum, Min = minimum; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO<sub>2</sub> and NO.

Source: Office of Air Quality Planning and Standards and National Center for Environmental Assessment 2014 analysis of Air Quality System network data 2011-2013.

As described in [Section 2.2](#), the lifetime of NO<sub>2</sub> with respect to conversion to NO<sub>z</sub> species can be as short as an hour. This relatively short NO<sub>2</sub> lifetime results in gradients and low concentrations away from major sources that are not adequately captured by the existing monitoring networks (see [Figure 2-10](#) for location of monitoring sites). Satellite data coupled with model simulations might be more useful for showing large-scale features in the distribution of NO<sub>2</sub>. Winter and summer seasonal average NO<sub>2</sub> concentrations for 2009–2011 derived from the OMI on the AURA satellite and the GEOS-Chem global, three-dimensional chemistry-transport model are shown in [Figure 2-13](#). In this method, integrated vertical column abundances of NO<sub>2</sub> derived from the OMI instrument are scaled to surface mixing ratios using scaling factors derived from GEOS-Chem [see ([Lamsal et al., 2010](#); [Lamsal et al., 2008](#)); also see [Section 2.4](#) for more complete descriptions of the method]. A nested version of GEOS-Chem at 50 km × 50 km horizontal resolution is used in this method. A description of the capabilities of GEOS-Chem and other three-dimensional chemistry transport models is given in the 2013 ISA for Ozone ([U.S. EPA, 2013e](#)).

Large variability in NO<sub>2</sub> concentrations is apparent in [Figure 2-13](#). As expected, the highest NO<sub>2</sub> concentrations are seen in large urban regions, such as in the Northeast Corridor, and lowest values are found in sparsely populated regions located mainly in the West. Minimum hourly values can be less than ~10 ppt, leading to a large range between maximum and minimum concentrations. Although overall patterns of spatial variability are consistent with the current understanding of the behavior of NO<sub>2</sub>, not much confidence should be placed on values <~100 ppt due to limitations in the satellite retrievals. NO<sub>2</sub> concentrations tend to be higher in January than in July, largely reflecting lower planetary boundary layer heights in winter. Such seasonal variability is also evident on a local scale, as measured by surface monitors. For example, in Atlanta, GA, NO<sub>x</sub> measurements also exhibited higher concentrations in winter and lower concentrations in summer, when NO<sub>x</sub> is more rapidly removed by photochemical reactions ([Pachon et al., 2012](#)).



Note: NO<sub>2</sub> = nitrogen dioxide, OMI = Ozone Monitoring Instrument. Images shown were constructed by Dr. Lok Lamsal of Universities Space Research Association from data obtained by the OMI instrument on the AURA satellite (<http://aura.gsfc.nasa.gov/scinst/omi.html>) using the algorithm described in [Bucsela et al. \(2013\)](#). Output from the GEOS-Chem, global-scale, three-dimensional, chemistry-transport model is used to derive surface concentration fields from the satellite data as described in [Lamsal et al. \(2008\)](#) and [Lamsal et al. \(2010\)](#).


Top panel (winter; DJF: December, January, February). Lower panel (summer; JJA: June, July, August).

**Figure 2-13 Seasonal average surface nitrogen dioxide concentrations in ppb for winter (upper panel) and summer (lower panel) derived by ozone monitoring instrument/Goddard Earth Observing System-Chem for 2009–2011.**

---

## 2.5.2 Urban-Scale Spatial Variability

[Figure 2-14](#) describes 1-hour daily maximum concentration agreement between pairs of SLAM monitors from 2011–2013 for selected U.S. CBSAs with more than one monitor. Agreement is expressed as coefficient of divergence (COD), which has been widely used to assess spatial variability of air pollutant concentrations ([U.S. EPA, 2008c](#); [Wilson et al., 2005](#); [Pinto et al., 2004](#)). In practical terms, a COD = 0 indicates perfect agreement, and COD values increase as spatial variability increases. COD values in [Figure 2-14](#) generally range from about 0.1 to 0.4, with a few higher values. This indicates a range of variability across CBSAs from fairly uniform to a moderate degree of variability ([Wilson et al., 2005](#)). At first glance, distance between sites does not appear to be an important factor for explaining variability between site pairs on an urban scale. However, for extremely short distances, a trend with distance is observed, especially for data within the same city. For example, for Boston, MA, the six observations with the shortest distances between them exhibit a trend of increasing COD with distance, from about 3 km to about 10 km. These data are for the four sites closest to the city center. As indicated by the COD values, there is a substantial degree of variability for all but the closest sites, with CODs ranging above 0.4 even for comparison between site pairs near the city center.




Source: National Center for Environmental Assessment 2014 analysis of Air Quality System network data.

**Figure 2-14 Coefficient of divergence for ambient nitrogen dioxide concentrations between monitor pairs in four U.S. cities.**

A similar trend is observed for Los Angeles, CA but over a broader scale. In Los Angeles, CA, the highest observed COD at a given distance increases regularly with distance up to about 40 km, but at distances greater than 40 km it appears to level off with distance at about 0.4. In addition, for all sites within 15 km of each other, a high degree of agreement is observed. The difference between Boston, MA and Los Angeles, CA in how much COD changes with distance is consistent with their different extents. Boston, MA has a much smaller land surface area than Los Angeles, CA. Another major difference between Boston, MA and Los Angeles, CA is that good agreement (COD ~0.1) is often observed between sites up to 50 km or more apart in Los Angeles, CA, suggesting that other factors besides distance are important. Five of the Los Angeles, CA monitors (Main Street Los Angeles, Burbank, Pasadena, Pomona, and Long Beach North) form a subset of monitors with distinctly lower variability than the area as a

whole, with low CODs for each possible combination of monitors within this group, as shown in [Figure 2-15](#). Other monitors near the ocean or mountains exhibit poorer agreement with these five monitors, even if the distances between monitors are shorter.



Source: National Center for Environmental Assessment 2014 analysis of Air Quality System network data.

**Figure 2-15** Coefficient of divergence for ambient nitrogen dioxide concentrations among a subset of five Los Angeles, California monitors.

Yet another pattern is observed for Phoenix, Arizona (AZ) and Philadelphia, PA. For these cities, low COD values are observed for all sites except rural locations outside of the urbanized area. The Phoenix, AZ data in [Figure 2-14](#) fall into two clusters: one for urban site pairs ranging up to 10 km distance from each other and one for urban-rural site pairs 40 to 60 km from each other. All of the comparisons between urban sites exhibit a  $COD < 0.2$ , but poorer agreement is observed between urban and rural site pairs. Similarly, good agreement ( $COD \sim 0.1$ ) is observed between two monitoring sites operating within the city of Philadelphia, PA about 10 km apart, but poorer agreement is observed for more distant suburban sites. This result is consistent with observations of [Sarnat et al. \(2010\)](#), who observed that using monitors in rural areas of counties considered part of the Atlanta, GA metropolitan area affected relative risk estimates for

associations with health effects, but that using different urban monitors within approximately 15 to 30 km of a study subject did not.

To summarize urban-scale spatial variability for NO<sub>2</sub>, good agreement among nearby sites in city cores is common and was observed for 2011 to 2013 data for all sites in Philadelphia, PA and Phoenix, AZ. In Los Angeles, CA good agreement was also usually observed over similar distances to those compared in Philadelphia, PA and Phoenix, AZ (i.e., among sites separated by less than 15 km). In contrast, agreement among monitors in Boston, MA became poorer over a shorter distance. NO<sub>2</sub> concentrations followed a trend of increasing variability with distance among sites over 3 to 10 km, a smaller spatial scale than the other cities.

Similar results are observed for annual averages. [Tables 2-5A](#) and [2-5B](#) present the difference in annual average NO<sub>2</sub> concentrations between pairs of sites divided by the average between the two sites for that year as a measure of the percent difference in concentration for Boston, MA and Los Angeles, CA. The CODs of annual average NO<sub>2</sub> concentrations show wide ranges in agreement similar to those reported for 1-hour daily maximum NO<sub>2</sub> concentrations measured in both Boston, MA and Los Angeles, CA. The nearest site pairings in Boston, MA agree within 3 to 20%, while the other two site pairings exhibit poorer agreement ranging from 38 to 65% and 31 to 90%.

The 14 sites in Los Angeles County that reported data for 2011 are shown in [Table 2-5B](#). A number of site pairings agree within 10 to 15%. For example, concentrations at the Pico Rivera (1602 in [Table 2-5B](#)), Pomona (1701 in [Table 2-5B](#)), and Long Beach Hudson (4006 in [Table 2-5B](#)) sites all agree within 10% of the concentrations reported at the Los Angeles Main Street site.

**Table 2-5A Percent difference in annual average nitrogen dioxide concentration between monitors in Boston, Massachusetts.**

	ID's of Monitors Compared		
	0002 vs. 0040 %	0002 vs. 0042 %	0040 vs. 0042 %
2011	41	10	31
2012	65	20	47
2013	38	3	90

Source: National Center for Environmental Assessment 2014 analysis of Air Quality System network data 2011–2013.

**Table 2-5B Percent difference in annual average nitrogen dioxide concentration between monitors in Los Angeles, California for 2011.**

Monitor ID	Monitor ID												
	0002 %	0016 %	0113 %	1103 %	1201 %	1302 %	1602 %	1701 %	2005 %	4002 %	4006 %	5005 %	6012 %
0016	7												
0113	17	20											
1103	21	57	38										
1201	16	22	2	36									
1302	3	35	15	23	13								
1602	22	58	39	1	37	25							
1701	26	62	43	5	41	28	4						
2005	7	44	24	14	23	10	15	19					
4002	7	31	10	28	9	4	29	33	14				
4006	12	49	29	9	28	15	10	14	5	19			
5005	32	5	15	52	17	30	53	57	39	25	44		
6012	35	3	18	55	20	32	56	60	42	28	47	3	
9033	47	10	30	66	32	45	67	71	54	40	58	4	13

Source: National Center for Environmental Assessment 2014 analysis of Air Quality System network data 2011.

While these results indicate that relatively good agreement in 1-hour daily maximum and annual average NO<sub>2</sub> concentrations between pairs of nearby urban monitors in the same metropolitan area occurs in some cases, they do not rule out the possibility of greater variability on a smaller spatial scale. [Vardoulakis et al. \(2011\)](#) described a distinction between “intra-urban” and “street-scale” variability, explaining that long-term monitoring sites tend to be situated away from sources and hot spots that can strongly influence variability. They compared results from long-term monitoring sites to short-term networks of passive samplers. The passive samplers were placed in areas among the long-term monitors at varying distances from key roads and intersections. Results indicated that “street-level” variability determined from the passive sampler measurements placed between long-term monitors exhibited greater variability than

“intra-urban” variability based on long-term monitors themselves. Spatial variability near roads is described in detail in [Section 2.5.3](#).

---

## 2.5.3 Microscale to Neighborhood-Scale Spatial Variability, Including near Roads

---

### 2.5.3.1 Near-Road Gradient Observations

#### General Observations

The spatial trends described in this section provide a background for understanding the traffic-related NO<sub>2</sub> exposure on and near roads described in [Section 3.3.1.1](#). Numerous observations have been summarized in several recent reviews, each of which concluded that a zone of elevated NO<sub>2</sub> concentration typically extends from 200 to 500 m from roads with heavy traffic ([HEI, 2010](#); [Karner et al., 2010](#); [Zhou and Levy, 2007](#)). [Tables 2-6](#) and [2-7](#) describe observations from studies that were included in these reviews and/or in the 2008 Risk and Exposure Assessment for the review of the primary NO<sub>2</sub> NAAQS ([U.S. EPA, 2008e](#)) to estimate on-road concentrations, as well as more recent observations. Concentrations measured relatively near the road ( $C_{\text{near}}$ ), concentrations measured relatively farther from the road ( $C_{\text{far}}$ ), and the difference between them in concentration units ( $C_{\text{near}} - C_{\text{far}}$ ) and as a fraction of the concentration measured farthest from the road ( $[C_{\text{near}} - C_{\text{far}}]/C_{\text{far}}$ ) are summarized in [Tables 2-6](#) and [2-7](#).  $C_{\text{near}}$  was measured from 0 to 60 m from the road, and  $C_{\text{far}}$  was measured at distances from 80 m to more than 350 m, depending on the study. [Table 2-6](#) describes observations based on averaging times of a half day or longer and includes important early studies based on passive sampling methods that typically require sampling periods of 1 to 2 weeks to collect a sufficient amount of sample. [Table 2-7](#) describes observations based on averaging times of 1 hour or shorter, and includes several recent studies with shorter time resolution. A direct comparison of the observations included in these tables is not appropriate because experimental designs, measurement methods, averaging times, distances from the road, time of year, and other important factors vary among studies. However, [Tables 2-6](#) and [2-7](#) provide a broad overview of the magnitudes of NO<sub>2</sub> concentration differences observed with distance from road and the spatial extent over which differences in concentration have been observed.

**Table 2-6 Summary of near-road nitrogen dioxide concentration gradients from studies with passive samplers and averaging times of 12 hours to 1 month.**

Author	Location	Traffic Count (vehicles/day)	Method/Averaging Time	Time of Year	C <sub>near</sub> Average or Range (distance from road)	C <sub>far</sub> Average or Range (distance from road)	Spatial Extent (m)	% Difference <sup>a</sup> in C <sub>near</sub> and C <sub>far</sub> Average or Range	ppb Difference <sup>a</sup> in C <sub>near</sub> and C <sub>far</sub> Average or Range
<a href="#">Gilbert et al. (2003)</a>	Montreal, Canada	185,000	Passive/1 week	September	29 ppb <sup>b</sup> (0 m)	18 ppb <sup>b</sup> (200 m)	200	60 <sup>b</sup>	11 <sup>b</sup>
<a href="#">Monn et al. (1997)</a>	Zurich, Switzerland	NA	Passive/1 week	Summer	20 ppb <sup>c</sup> (15 m)	12 ppb <sup>c</sup> (80 m)	>80	>30 <sup>c</sup>	~8 <sup>c</sup>
				Winter	25 ppb <sup>c</sup> (15 m)	25 ppb <sup>c</sup> (80 m)	None	~0 <sup>c</sup>	~0 <sup>c</sup>
<a href="#">Pleijel et al. (2004)</a>	Rural Sweden	18,900–32,500 <sup>d</sup>	Passive/1 month	Not reported	8–18 ppb <sup>d</sup> (10 m)	4–10 ppb <sup>d</sup> (100 m)	500	80–100 <sup>d</sup>	2–8 <sup>d</sup>
<a href="#">Roorda-Knape et al. (1998)</a>	the Netherlands	80,000–152,000 <sup>e</sup>	Passive/2 weeks	Spring/Summer	24–25 ppb <sup>e</sup> (15–32 m)	16–17 ppb <sup>e</sup> (260–305 m)	>300	45–50 <sup>e</sup>	8 <sup>e</sup>
<a href="#">Singer et al. (2004)</a>	Oakland, CA	90,000–210,000 <sup>f</sup>	Passive/1 week	Fall/spring	30 ppb <sup>f</sup> (60 m)	20 ppb <sup>f</sup> (>350 m)	350	60 <sup>f</sup>	11 <sup>f</sup>
<a href="#">Smargiassi et al. (2005)</a>	Montreal, Canada	>150,000	Passive/1 day	May–June	33 ppb <sup>g</sup> (<10 m)	20 ppb <sup>g</sup> (>1,000 m)	NA	70 <sup>g</sup>	13 <sup>g</sup>
<a href="#">†Beckerman et al. (2008)</a>	Toronto, Canada	349,100 & 395,400 <sup>h</sup>	Passive/1 week	August	19 & 28 ppb <sup>h</sup> (4 & 47 m)	14 & 15 ppb <sup>h</sup> (>380 m)	300	30 & 100 <sup>h</sup>	4 & 15 <sup>h</sup>
<a href="#">Zou et al. (2006)</a>	Shanghai, China	NA	Passive/2 weeks	All year	50–65 ppb <sup>i</sup> (0 m)	39–48 ppb <sup>i</sup> (350 m)	>350	30–40 <sup>i</sup>	12–18 <sup>i</sup>
<a href="#">Gonzales et al. (2005)</a>	El Paso, TX	NA	Passive/1 week	Winter	25 ppb <sup>j</sup> (0.25 m)	15 ppb <sup>j</sup>	>3,750	~70 <sup>j</sup>	10 <sup>j</sup>
<a href="#">Cape et al. (2004)</a>	Scotland, U.K.	240–85,000 <sup>k</sup>	Passive/1 week	April–May	3–50 ppb <sup>k</sup> (1 m)	3–40 ppb <sup>k</sup> (10 m)	>10	<0–70 <sup>k</sup>	0–11 <sup>k</sup>
<a href="#">Bell and Ashenden (1997)</a>	Rural Wales, U.K.	2,000–6,000 <sup>l</sup>	Passive/1 week	All year	8–28 ppb <sup>l</sup> (<1 m)	2–14 ppb <sup>l</sup> (200–350 m)	100	20–660 <sup>l</sup>	3–20 <sup>l</sup>

**Table 2-6 (Continued): Summary of near-road nitrogen dioxide concentration gradients from studies with passive samplers and averaging times of 12 hours to 1 month.**

Author	Location	Traffic Count (vehicles/day)	Method/Averaging Time	Time of Year	C <sub>near</sub> Average or Range (distance from road)	C <sub>far</sub> Average or Range (distance from road)	Spatial Extent (m)	% Difference <sup>a</sup> in C <sub>near</sub> and C <sub>far</sub> Average or Range	ppb Difference <sup>a</sup> in C <sub>near</sub> and C <sub>far</sub> Average or Range
<a href="#">Signal et al. (2007)</a>	Rural England, U.K.	74,000–94,000 <sup>m</sup>	Passive/ 11–17 days	NA	25 ppb <sup>m</sup>	10–20 ppb <sup>m</sup> (250 m)	100	25–150 <sup>m</sup>	5–15 <sup>m</sup>
<a href="#">Kodama et al. (2002)</a>	Tokyo, Japan	50,000–60,000 <sup>n</sup>	Passive/ 48 h	All year	25–50 ppb <sup>n</sup> (<50 m)	20–45 ppb <sup>n</sup> (>200 m)	>200	NA	<10 <sup>n</sup>
<a href="#">Maruo et al. (2003)</a>	Sapporo, Japan	NA	Sensor/ ½ day	July	32 ppb <sup>o</sup>	22 ppb <sup>o</sup> (150 m)	150	45 <sup>o</sup>	10 <sup>o</sup>
<a href="#">Nitta et al. (1993)</a>	Tokyo, Japan	>30,000	Colorimetry/ 1 week	NA	34–57 ppb <sup>p</sup> (0 m)	24–42 ppb <sup>p</sup> (150 m)	150	10–50 <sup>p</sup>	8–17 <sup>p</sup>

C<sub>far</sub> = concentrations measured at the farthest distance; C<sub>near</sub> = concentrations measured at the nearest distance; NA = not available.

<sup>a</sup>% Difference refers to (C<sub>near</sub> – C<sub>far</sub>)/C<sub>far</sub>; ppb Difference refers to C<sub>near</sub> – C<sub>far</sub>.

<sup>b</sup>Based on a single set of samples.

<sup>c</sup>Average for nine winter and eight summer sets of samples.

<sup>d</sup>Range for five sets of samples at two different roads (three at one road, two at the other).

<sup>e</sup>Averages for two different roads based on eight sets of samples at one road and nine at the other.

<sup>f</sup>Average for 14 spring and 8 fall sets of samples with distance measured to different roads for different samples.

<sup>g</sup>Average for 15 sets of samples.

<sup>h</sup>Low and high values from single experiments at two different roads.

<sup>i</sup>Range for 12 sets of samples with 3 from each of four seasons.

<sup>j</sup>Based on a single set of samples with distance measured to different roads for different samples.

<sup>k</sup>Range of annual average concentrations at 14 locations; annual average concentrations based on six bimonthly sets of samples.

<sup>l</sup>Range of concentrations for 26 sets of samples from two different road segments of the same road.

<sup>m</sup>Range of averages for three different road segments (two on the same road); averages are for eight sets of samples for each segment.

<sup>n</sup>Range of average concentrations from each of 10 sets of samples simultaneously measured outside homes at varying distances from the road. Number of samples in each set of samples ranged 34–103.

<sup>o</sup>Average for 28 sets of samples.

<sup>p</sup>Average of single measurements at seven locations.

†Study published since the 2008 ISA for Oxides of Nitrogen.

**Table 2-7 Summary of near-road nitrogen dioxide concentration gradients from studies with averaging times of 1 hour or less.**

Author	Location	Traffic Count (vehicles/day)	Method/Averaging Time	Time of Year	C <sub>near</sub> Average or Range (distance from road)	C <sub>far</sub> Average or Range (distance from road)	Spatial Extent (m)	% Difference <sup>a</sup> in C <sub>near</sub> & C <sub>far</sub> Average or Range	ppb Difference <sup>a</sup> in C <sub>near</sub> & C <sub>far</sub> Average or Range
<a href="#">Rodes and Holland (1981)</a>	Los Angeles, CA—high O <sub>3</sub>	200,000	Chemilum /1 h	July–August	~120 ppb <sup>b</sup> (8 m)	~40 ppb <sup>b</sup> (388 m)	>400	~200 <sup>b</sup>	80 <sup>b</sup>
	Los Angeles, CA—medium O <sub>3</sub>				~80 ppb <sup>b</sup> (8 m)	~40 ppb <sup>b</sup> (388 m)	>400	~100 <sup>b</sup>	40 <sup>b</sup>
	Los Angeles, CA—low O <sub>3</sub>				~70 ppb <sup>b</sup> (8 m)	~40 ppb <sup>b</sup> (388 m)	>400	~80 <sup>b</sup>	30 <sup>b</sup>
<a href="#">†Massoli et al. (2012)</a>	New York, NY	210,000	Chemilum/real-time <sup>c</sup>	July	25–40 ppb <sup>d</sup> (10 m)	25–40 ppb <sup>d</sup> (500 m)	None	~0 <sup>d</sup>	~0 <sup>d</sup>
<a href="#">†Polidori and Fine (2012b)</a>	Los Angeles, CA	NR <sup>e</sup>	Chemilum/1 h	Summer	28 ppb <sup>f</sup> (15 m)	18 ppb <sup>f</sup> (80 m)	>80	56 <sup>f</sup>	10 <sup>f</sup>
				Winter	37 ppb <sup>g</sup> (15 m)	32 ppb <sup>g</sup> (80 m)	>80	15 <sup>g</sup>	5 <sup>g</sup>
<a href="#">†Kimbrough et al. (2013)</a>	Las Vegas, NV	161,500	Chemilum/1 h	All year	25 ppb <sup>h</sup> (20 m)	20 ppb <sup>h</sup> (300 m)	>100	30 <sup>h</sup>	5 <sup>h</sup>
	Downwind only				28 ppb <sup>i</sup> (20 m)	23 ppb <sup>i</sup> (300 m)	>100	20 <sup>i</sup>	5 <sup>i</sup>
<a href="#">†McAdam et al. (2011)</a>	Ontario, Canada	34,000	Chemilum /1 h	Summer	5.8 ppb <sup>j</sup> (10 m)	4.5 ppb <sup>j</sup> (60 m)	None	~25 <sup>j</sup>	1 <sup>j</sup>
<a href="#">†Durant et al. (2010)</a>	Somerville, MA	>150,000	TILDAS/real-time <sup>c</sup>	January	~15–35 ppb <sup>k</sup> (<50 m)	~10–30 ppb <sup>k</sup> (400 m)	100–250	>0 <sup>k</sup>	<10 <sup>k</sup>

C<sub>far</sub> = concentrations measured at the farthest distance; C<sub>near</sub> = concentrations measured at the nearest distance; Chemilum = chemiluminescence; NR = not reported; O<sub>3</sub> = ozone; TILDAS = tunable infrared differential absorption spectroscopy.

<sup>a</sup>% Difference refers to (C<sub>near</sub> - C<sub>far</sub>)/C<sub>far</sub>; ppb Difference refers to C<sub>near</sub> - C<sub>far</sub>.

<sup>b</sup>Average of at least 27 hourly measurements for each category.

<sup>c</sup>Described by authors as real-time monitoring with a mobile platform.

<sup>d</sup>Range for five time periods from early to late morning with each time period averaged over two samples from different days.

<sup>e</sup>Total daily traffic count not reported, truck traffic at maximum count (10:00 a.m.–2:00 p.m.) >600 vehicles/hour winter and >400 vehicles/hour summer. 20% of vehicles were heavy-duty diesel trucks.

<sup>f</sup>Seasonal average of more than 900 hourly measurements for each season.

<sup>g</sup>Average of 7,390 hourly measurements.

<sup>h</sup>Average of 2,913 hourly measurements.

<sup>i</sup>Average of 231 hourly measurements at both 10 m and 30 m, 281 measurements at both 30 m and 60 m.

<sup>j</sup>Range for five sets of samples at different times of day on the same day.

<sup>†</sup>Studies published since the 2008 ISA for Oxides of Nitrogen.

If sufficient detail is given on individual experiments, ranges for  $C_{\text{near}}$ ,  $C_{\text{far}}$ , and differences between them are provided in [Tables 2-6](#) and [2-7](#). Otherwise, averages over the entire study or over various categories such as season, wind direction, location, or  $\text{O}_3$  concentration are given. Earlier studies, including some of the studies in [Table 2-6](#), were mainly limited to passive samplers that required collection for 1 or 2 weeks, making it difficult to explore effects of time of day or wind direction, which typically shifts on shorter time scales. Several recent studies, summarized in [Table 2-6](#), have used chemiluminescence, QC-TILDAS, and other methods that not only provide greater time resolution, but also result in the collection of larger numbers of samples. Both are useful for better understanding the factors influencing near-road concentration patterns. There are essentially three types of experimental designs used in the studies listed in [Tables 2-6](#) and [2-7](#), (1) samples are collected simultaneously at varying distance from the same road; (2) samples are collected by a mobile laboratory with high time resolution (samples are collected at different distances from a road, not simultaneously, but with minimal elapsed time between sampling at different distances from the road); or (3) samples are collected over a wider spatial scale at varying distances from a number of heavily trafficked roads and distance parameters are not linked to the same road for all samples.

Most of the studies listed in [Tables 2-6](#) and [2-7](#) conclude that the spatial extent of elevated  $\text{NO}_2$  concentrations is within the range of 200 to 500 m from the road as described by [HEI \(2010\)](#) or [Zhou and Levy \(2007\)](#). Some recent studies concluded that the influence of the road on  $\text{NO}_2$  concentrations can extend even farther, up to several kilometers, but with smaller differences in concentration ([Gilbert et al., 2007](#); [Gonzales et al., 2005](#)). [Bell and Ashenden \(1997\)](#) and [Cape et al. \(2004\)](#) also observed remarkably greater differences in  $\text{NO}_2$  concentration with distance within the first 10 to 20 m from road than at further distances from the road, suggesting the possibility of an exponential relationship of decreasing concentration with distance from the road with a steeper decrease right next to the road.

Several investigators have attempted to fit NO<sub>2</sub> concentration data as a function of distance from the road. NO<sub>2</sub> concentrations followed a logarithmic function with distance from a road over a range of 100 m ([Pleijel et al., 2004](#)), more than 300 m ([Roorda-Knappe et al., 1998](#)), and more than 1,000 m ([Gilbert et al., 2003](#)):

$$C_x = C_b + C_v - k \log x$$

**Equation 2-1**

where

$x$  = distance from the road

$k$  = decay constant derived from empirical data

$C_x$  = NO<sub>2</sub> concentration at a distance  $x$  from a road

$C_b$  = NO<sub>2</sub> concentration contribution away from the influence of the road

$C_v$  = NO<sub>2</sub> concentration contribution from vehicles on a roadway

[Cape et al. \(2004\)](#) used an exponential decay function to fit NO<sub>2</sub> concentrations measured from 1 to 10 m from the road:

$$C_x = C_b + C_v e^{-kx}$$

**Equation 2-2**

A shifted power law model has also been used ([Zou et al., 2006](#)):

$$C_x = C_b(x + 1)^{-k}$$

**Equation 2-3**

Compared to NO, UFP, and other traffic-related pollutants, NO<sub>2</sub> concentrations decrease less rapidly with distance from the road over a range of about 200 to 500 m, and exhibit a somewhat greater spatial extent of elevated concentration ([Section 3.3.1.1](#)). This has been attributed to chemical production occurring downwind of roads ([Section 2.2](#)) and to other nontraffic-related sources of NO<sub>2</sub> ([Chaney et al., 2011](#); [Zhou and Levy, 2007](#); [Rodes and Holland, 1981](#)). Because of the interaction between dispersion and chemical reaction described in [Section 2.2](#), the distribution of NO<sub>2</sub> downwind of roads would likely differ from that of a strictly primary traffic pollutant. For example, [Massoli et al. \(2012\)](#) found that the concentrations of carbon dioxide [CO<sub>2</sub>] and NO<sub>x</sub> decreased by approximately

50% within 150 m downwind of the LIE, but that the concentration of NO<sub>2</sub> was nearly constant over this distance from the road.

A slight effect of wind conditions has also been observed. NO<sub>2</sub> concentration varies with distance from the road under all wind conditions, but is more pronounced downwind from the road ([Kimbrough et al., 2013](#); [McAdam et al., 2011](#); [Beckerman et al., 2008](#); [Roorda-Knape et al., 1998](#)). When air is sampled both upwind and downwind of the road, more gradual gradients are observed on the downwind side of the roadway ([Durant et al., 2010](#); [Clements et al., 2009](#); [Hu et al., 2009](#); [Beckerman et al., 2008](#)). Also, higher concentrations are observed at low wind speeds, especially for winds blowing from the road ([Kimbrough et al., 2013](#)).

Because of the long sampling duration required for passive monitors, earlier studies in [Table 2-6](#) were limited to a few samples and it was not possible to focus on spatial differences over short time periods. In many early studies using passive monitors with usual sampling periods of 1 to 2 weeks, C<sub>near</sub> ranged from 30 to 100% higher than C<sub>far</sub>. These results are consistent with more recent observations of an approximately 40% decrease in NO<sub>2</sub> concentration due to road closures in Boston, also measured by passive sampling for 1 week ([Levy et al., 2006](#)).

Thousands of hourly chemiluminescence measurements from two recent studies ([Kimbrough et al., 2013](#); [Polidori and Fine, 2012b](#)) support observations from the earlier passive sampling studies in [Table 2-6](#). As described in [Table 2-7](#), [Kimbrough et al. \(2013\)](#) reported average concentrations of more than 7,000 hourly measurements, and showed that NO<sub>2</sub> concentrations 20 m from the road were an average of 27% higher than at 300 m from the road in Las Vegas, NV. In Los Angeles, CA, [Polidori and Fine \(2012b\)](#) reported that the average of hourly NO<sub>2</sub> concentrations at 15 m was 56% higher in summer and 15% higher in winter than at 80 m. Averaging over the two seasons gives an NO<sub>2</sub> concentration 34% higher at 15 m than at 80 m, which is remarkably similar to the observation of [Kimbrough et al. \(2013\)](#). [Table 2-8](#) summarizes hourly NO<sub>2</sub> data from two field studies for which samples were collected 10–15 m from a major road and simultaneously 80–100 m from the road. In Los Angeles, CA, samples were collected as part of a near-road monitoring study by the South Coast Air Quality Management District on the I-710 freeway, on which heavy-duty diesel trucks account for about 20% of the total number of vehicles ([Polidori and Fine, 2012b](#)). Samples in Detroit, MI were collected at the Eliza Howell Park monitoring sites (140,500 vehicles per day) at 10 m and 100 m from the road, and 26,000 hours of data were available 2011–2014. On average over the entire data set including both seasons, hourly concentrations were 34% higher at 15 m than at 80 m from the road in Los Angeles, CA and 70% higher at 10 m than at 100 m from the road in Detroit, MI. The largest differences were 40 ppb in Los

Angeles, CA and 52 ppb in Detroit, MI. However, the 99th percentile differences were less than 30 ppb, 98th percentile differences were less than 25 ppb, and 95th percentile differences were less than 20 ppb in both locations.

**Table 2-8 Distribution of differences in higher 1-hour nitrogen dioxide concentrations 10–15 m and lower 1-hour nitrogen dioxide concentrations at 80–100 m from the road at two locations with heavy traffic.**

Location	Parameter	Mean <sup>a</sup>	Percentiles					Maximum <sup>a</sup>
			50th	90th	95th	98th	99th	
Los Angeles, CA I-710 freeway with heavy diesel traffic <sup>b</sup>	Difference (ppb) <sup>c</sup>	7.0	5.9	16	19	24	27	40
	Percentage difference <sup>d</sup>	34%	30%	72%	86%	99%	116%	170%
Detroit, MI Eliza Howell Park near I-96, 140,500 vehicles/day <sup>b</sup>	Difference (ppb) <sup>c</sup>	5.3	4.0	12	16	20	23	52
	Percentage difference <sup>d</sup>	70%	45%	167%	233%	350%	450%	<sup>e</sup>

<sup>a</sup>Mean and maximum concentrations all of concentrations for the entire data set, including all seasons and years.

<sup>b</sup>Los Angeles, CA data were collected 1/29/2009 to 3/11/2009 and 6/30/2009 to 8/19/09. Detroit, MI data were collected 10/1/2011 to 12/31/2014.

<sup>c</sup>Difference in concentration between monitors at 15 and 80 m from the road in Los Angeles, CA and 10 and 100 m in Detroit, MI.

<sup>d</sup>Percentage difference in concentration relative to the concentration farthest from the road ( $C_{15} - C_{80}$ )/ $C_{80}$  in Los Angeles, CA and ( $C_{10} - C_{100}$ )/ $C_{100}$  in Detroit, MI.

<sup>e</sup>Maximum is infinite because some concentrations at 100 m ( $C_{100}$ ) are below detection limit.

Source: National Center for Environmental Assessment 2015 analysis of Los Angeles, CA data obtained from [Polidori and Fine \(2012b\)](#) and Detroit, MI data obtained from Air Quality System database.

In Los Angeles, CA, near-road hourly NO<sub>2</sub> concentrations were rarely more than 100% higher than hourly concentrations farther from the road. Such large differences in concentration occurred more frequently in Detroit, MI. On average, the difference in concentration at 10 and 100 m of the road was 70%, and the 90th percentile was 167%. This is probably due in part to the lower concentrations observed in Detroit, MI ([Section 2.5.3.1](#)).

The magnitude of the difference in 1-hour NO<sub>2</sub> concentrations near and farther away from the road are not directly comparable to earlier studies based on passive sampling ([Beckerman et al., 2008](#); [Singer et al., 2004](#); [Gilbert et al., 2003](#); [Roorda-Knape et al., 1998](#)) because the passive sampling results are for longer averaging times of 1 week or

longer. However, the hourly data presented in [Table 2-8](#) averaged over several months or years and the passive sampling data presented in [Table 2-6](#) both indicate that NO<sub>2</sub> concentrations are consistently higher near the road than at a greater distance from the road.

The absolute differences in measured NO<sub>2</sub> concentrations between the nearest and farthest locations ( $C_{\text{near}} - C_{\text{far}}$ ) in [Tables 2-6](#) and [2-7](#) are also consistent across most studies, with concentration differences rarely exceeding 20 ppb, regardless of averaging time. The exception is the [Rodes and Holland \(1981\)](#) study from Los Angeles, CA in the early 1980s. Because this is an older study than the others, the vehicle fleet was not strictly regulated for NO<sub>x</sub> emissions. As a result, the concentrations observed may not be relevant to current conditions. With this study excluded, the range in  $C_{\text{near}} - C_{\text{far}}$  is somewhat smaller than the range for  $C_{\text{far}}$  across all of the studies, which implies that a ratio of concentrations at different distances from the road could be more strongly influenced by the concentration away from the road than by the concentration nearest the road.

### **Seasonal and Diurnal Patterns**

It is worth noting that in most of the earlier passive sampling studies in [Table 2-6](#), samples were collected mostly in warmer months, between May and September, depending on the study ([Beckerman et al., 2008](#); [Singer et al., 2004](#); [Gilbert et al., 2003](#); [Roorda-Knape et al., 1998](#)). In a comparison between seasons by [Monn et al. \(1997\)](#) presented in [Table 2-6](#), similar results were observed in summer, but very little difference in NO<sub>2</sub> concentration was observed in winter. More recently, a number of field studies based on hourly measurements using the chemiluminescence Federal Reference Method ([Section 2.4](#)) have been conducted. Based on these measurements it is possible to evaluate concentration trends over shorter time periods, to examine seasonal and diurnal patterns, and to determine concentration averages and distributions of hourly data over thousands of hours. From [Table 2-6](#), it is evident that in studies with finer time resolution, more observations of a lack of any difference between concentrations nearest the road and farther from the road ( $C_{\text{near}} - C_{\text{far}} = \sim 0$ ) are reported. The lack of a near-road NO<sub>2</sub> concentration gradient appears to be especially common in early morning measurements ([Massoli et al., 2012](#); [McAdam et al., 2011](#)).

[Table 2-9](#) shows how NO<sub>2</sub> concentration differences near and far away from the road are influenced by season and time of day. Data are divided into a warm season and a cold season at each location. Averages of hourly concentrations are higher 10–15 m from the road than 80–100 m regardless of location, season, or time of day. The near-road influence is greater during the day in the warmer months and smallest at night in the

winter. On summer days, near-road concentrations are on average 8.5 ppb and 133% higher in Detroit, MI and 10.1 ppb and 54% higher in Los Angeles, CA than concentrations farther from the road. In contrast, average concentration differences on winter nights are less than 3 ppb in both locations. In Los Angeles, CA this corresponds to a less than 10% higher concentration near the road than at the 80-m distance. For individual nighttime hours in winter, there was frequently little or no difference in 1-hour NO<sub>2</sub> concentration between the near-road measurement and measurements farther from the road, similar to results reported in other studies focused on early morning measurements ([Massoli et al., 2012](#); [McAdam et al., 2011](#)).

**Table 2-9 Seasonal and diurnal variation of differences in 1-hour nitrogen dioxide concentrations 10–15 m and 80–100 m from the road at two locations with heavy traffic.**

Location	Season	Time of Day	Mean Concentration 80–100 m of road <sup>a</sup> (ppb)	Mean Difference <sup>b</sup> (ppb)	Mean Percentage Difference <sup>c</sup> (%)
Los Angeles, CA <sup>d</sup> I-710 freeway with heavy diesel traffic <sup>b</sup>	Warm Jun–Aug	7:00 a.m. to 6:00 p.m.	19.2	10.1	54
		7:00 p.m. to 6:00 a.m.	20.4	8.0	41
	Cold Feb–Mar	7:00 a.m. to 6:00 p.m.	28.8	6.6	27
		7:00 p.m. to 6:00 a.m.	35.9	2.8	9
Detroit, MI <sup>d</sup> Eliza Howell Park near I-96, 140,500 vehicles/day <sup>b</sup>	Warm Apr–Sep	7:00 a.m. to 6:00 p.m.	9.1	8.5	133
		7:00 p.m. to 6:00 a.m.	12.3	3.8	48
	Cold Oct–Mar	7:00 a.m. to 6:00 p.m.	13.4	6.7	73
		7:00 p.m. to 6:00 a.m.	15.0	2.7	32

Aug = August; a.m. = ante meridiem; Feb = February.

<sup>a</sup>Mean concentration 80 m from the road in Los Angeles, CA and 100 m from the road in Detroit, MI. Mean of all hourly concentrations in time of day and season specified.

<sup>b</sup>Mean difference in concentration between monitors at 15 m and 80 m from the road in Los Angeles, CA and 10 m and 100 m in Detroit, MI. Mean of all hourly concentrations in time of day and season specified.


<sup>c</sup>Mean percentage difference in concentration relative to the concentration farthest from the road ( $C_{15} - C_{80}$ )/ $C_{80}$  in Los Angeles, CA and ( $C_{10} - C_{100}$ )/ $C_{100}$  in Detroit, MI. Mean of all hourly concentrations in time of day and season specified.

<sup>d</sup>Los Angeles, CA data were collected 1/29/2009 to 3/11/2009 and 6/30/2009 to 8/19/09. Detroit, MI data were collected 10/1/2011 to 12/31/2014.

Source: National Center for Environmental Assessment 2015 analysis of Los Angeles, CA data obtained from [Polidori and Fine \(2012b\)](#) and Detroit, MI data obtained from Air Quality System database.

[Figure 2-16](#) describes the evolving nature of NO<sub>2</sub> concentrations and roadway gradients during different seasons and hours of the day. NO<sub>2</sub> roadway concentrations typically increase during morning rush hour (6:00–10:00 a.m.) then gradually decrease from late morning to mid-afternoon as the atmospheric mixing layer expands. Roadway NO<sub>2</sub> concentrations begin to increase again during afternoon rush hour and nighttime, and are generally similar to or slightly lower than NO<sub>2</sub> concentrations during morning rush hour. This diurnal profile is more evident in the winter compared to the summer.


Notably, while maximum concentrations tend to occur during morning rush hour and nighttime, especially during the winter, the NO<sub>2</sub> roadway gradient is largest during afternoon hours (10:00 a.m.–5:00 p.m.). This trend is further demonstrated in [Figure 2-17](#), which shows the absolute difference in NO<sub>2</sub> concentrations between near-road and downwind sites during winter and summer for Los Angeles, CA and Detroit, MI. In both cities, the absolute difference between sites is below 15 ppb during morning rush hour and nighttime, whereas a somewhat larger difference is observed during mid-afternoon hours (12:00 p.m.–5:00 p.m.).



Note: NO<sub>2</sub> = nitrogen dioxide. The box represents the interquartile range of concentrations observed during a given hour, with the 10th and 90th percentiles of concentrations shown by bottom and top whiskers, respectively. Red: within 15 m of a major interstate. Gray: within 100 m of a major interstate.

Source: National Center for Environmental Assessment 2014 analysis of data obtained from [Polidori and Fine \(2012b\)](#) and [Vette et al. \(2013\)](#).

**Figure 2-16 Diurnal variation of differences in 1-hour nitrogen dioxide concentrations 10–15 m and 80–100 m from the road in Los Angeles, CA and Detroit, MI.**



Note: NO<sub>2</sub> = nitrogen dioxide. The box represents the interquartile range of concentrations observed during a given hour, with the 10th and 90th percentiles of concentrations shown by bottom and top whiskers, respectively. Red: winter. Gray: summer.

Source: National Center for Environmental Assessment 2014 analysis of data obtained from [Polidori and Fine \(2012b\)](#) and [Vette et al. \(2013\)](#).


**Figure 2-17 Absolute difference in 1-hour nitrogen dioxide concentrations 10–15 m and 80–100 m from the road in Los Angeles, CA and Detroit, MI.**

The results for seasonal differences in 1-hour NO<sub>2</sub> concentration near and farther away from the road are an important new contribution provided by the hourly data. A similar seasonal pattern has also been observed in a few other studies using passive samplers ([Bell and Ashenden, 1997](#); [Monn et al., 1997](#)), but the hourly data summarized in [Table 2-9](#) and in [Figures 2-16](#) and [2-17](#) provides a more complete description of seasonal and diurnal behavior. There have been a few recent observations of little or no variation of NO<sub>2</sub> concentration with distance to the road for short time intervals before sunrise ([Gordon et al., 2012](#); [Massoli et al., 2012](#)). The data presented here based on more than 27,000 hours of NO<sub>2</sub> measurements in two cities build on these early studies to indicate a clear trend of greater concentration differences between samples collected 10–15 m from the road and those collected 80–100 m from the road during daytime than during nighttime hours.

### Concentration Dependence

The absolute concentration of NO<sub>2</sub> also influences the magnitude of the road impact. In studies with both one week or longer averaging times ([Table 2-6](#)), and one hour or shorter

averaging times ([Table 2-7](#)); a few observations of NO<sub>2</sub> concentrations more than 100% higher at the location nearest the road than at the location farthest from the road were reported, mostly when C<sub>far</sub> was much lower than usual. This is illustrated in [Figure 2-18](#), which shows that on a major road in a rural area of Great Britain ([Bell and Ashenden, 1997](#)), percentage differences in NO<sub>2</sub> concentrations ranged up to 600%, but the greatest differences were observed when C<sub>far</sub> was lower than usual. Differences were consistently greater than 200% when C<sub>far</sub> was less than 4 ppb, but less than 100% when C<sub>far</sub> exceeded 10 ppb. Because C<sub>far</sub> was so low, even for the greatest differences in concentrations observed by [Bell and Ashenden \(1997\)](#), the absolute difference in concentration between distances of <1 m and 200 m never exceeded 20 ppb. Differences of similar magnitude were observed by [Bignal et al. \(2007\)](#) for a British rural area where C<sub>far</sub> ranged from 5 to 10 ppb. Because data were collected in a rural area, the differences observed by [Bignal et al. \(2007\)](#) would not necessarily be applicable for absolute differences that might be observed in urban areas where NO<sub>2</sub> concentrations are typically higher. Thus, [Figure 2-18](#) clearly demonstrates that C<sub>near</sub>/C<sub>far</sub> at a lower concentration could be greater than C<sub>near</sub>/C<sub>far</sub> observed at higher concentrations.



Source: National Center for Environmental Assessment 2014 analysis of data from [Bell and Ashenden \(1997\)](#).

**Figure 2-18** Influence of nitrogen dioxide concentration magnitude on the ratio of nitrogen dioxide concentrations at <1 m from the road (nearest concentration) to concentrations at 200–350 m (farthest concentration) for 1-week averaging times in rural Wales.


This concentration effect is also evident for short averaging times presented in [Table 2-7](#). In [Table 2-7](#), the greatest percentage differences in concentration between 10–15 m and 80–100 m distance from the road tend to occur at the times during which all sites experience the generally lowest concentrations. For example, the greatest percentage difference occurs April–September and 7:00 a.m. to 6:00 p.m. in Detroit, MI, the period and location with the lowest concentration of all locations and time periods in [Table 2-9](#). In fact, Detroit, MI consistently had both the lowest concentrations and a greater percentage difference than Los Angeles, CA at all time periods. Similarly, summer days have the greatest percentage difference but lowest concentrations in both Los Angeles, CA and Detroit MI, while winter nights have the highest concentrations and smallest percentage differences. All of these observations concerning differences with location, season, and time of day are also consistent with an inverse relationship between

concentration and percentage difference in concentration with distance to road. This relationship is clearly illustrated in [Figure 2-19](#).

In [Figure 2-19](#) the percentage difference in concentrations between measurements 10–15 m from the road and measurements 80–100 m from the road is plotted as a function of concentration at 80–100 m at both Los Angeles, CA and Detroit, MI for the same data summarized in [Tables 2-8](#) and [2-9](#). Hourly near-road NO<sub>2</sub> concentrations are sometimes several times higher than concentrations 80–100 m from the road, but only when NO<sub>2</sub> concentrations at 80–100 m are below about 30 ppb. At 80–100 m NO<sub>2</sub> concentrations greater than 33 ppb, near road concentrations are always less than 100% higher than 80–100 m NO<sub>2</sub> concentrations, and when 80–100 m NO<sub>2</sub> concentrations are greater than 50 ppb, near road NO<sub>2</sub> concentrations are always less than 50% higher than 80–100 m NO<sub>2</sub> concentrations. A smooth decrease of the upper limit of the percentage difference in NO<sub>2</sub> concentration is evident in [Figure 2-19](#). This pattern is consistent with the concentration differences described in [Table 2-7](#) and with earlier studies based on passive sampling with longer averaging times described in [Table 2-6](#) and [Figure 2-18](#).

Low C<sub>far</sub> measurements do not explain all of the high ratios of (C<sub>near</sub> – C<sub>far</sub>)/C<sub>far</sub> in [Tables 2-6](#) and [2-7](#). In [Table 2-6](#), [Rodes and Holland \(1981\)](#) observed percent differences for (C<sub>near</sub> – C<sub>far</sub>)/C<sub>far</sub> ranging from 100 to 200% for averaging times of 1 h for average C<sub>far</sub> concentrations of about 40 ppb, and attributed this to rapid formation of NO<sub>2</sub> between the road and monitor because of high O<sub>3</sub> concentrations. Most of the NO<sub>x</sub> emitted from vehicles is emitted as NO, which can be rapidly converted into NO<sub>2</sub> in the presence of O<sub>3</sub> as described in [Section 2.2](#). However, differences this large are not likely to be representative of today's near road environment because at the time of the study, the vehicle fleet was not strictly regulated for NO<sub>x</sub> emissions. In general, the observations in [Tables 2-6](#) and [2-7](#) indicate that NO<sub>2</sub> concentrations nearest the road rarely appear to be more than 100% higher than concentrations 80 to 400 m from the road for either 1-hour or 1-week averaging times, except at very low concentrations.

To summarize, a zone of elevated NO<sub>2</sub> concentration typically extends up to a distance of 200 to 500 m from roadways. NO<sub>2</sub> concentrations for averaging times from 1 hour to 1 month measured 0–20 m from the road range up to 30 ppb higher or up to 100% higher than concentrations measured at 80–400 m from a road, with greater differences during daylight hours, in the summer, and at low concentrations. The difference in concentration could be more strongly influenced by concentrations farther from the road than by concentration nearest the road.



Note: NO<sub>2</sub> = nitrogen dioxide. <sup>a</sup>Percentage difference in concentration relative to the concentration farthest from the road ( $(C_{15} - C_{80})/C_{80}$  in Los Angeles, CA and  $(C_{10} - C_{100})/C_{100}$  in Detroit, MI, where  $C_n$  = concentration at n meters from the road. <sup>b</sup>Concentration at 80 m from the road in Los Angeles, CA 100 m from the road in Detroit, MI. Los Angeles, CA data collected from 1/29/2009 to 3/11/2009 and 6/30/2009 to 8/19/09 next to I-710 freeway with heavy diesel traffic. Detroit, MI data collected from 10/1/2011 to 12/31/2014 at Eliza Howell Park near-road monitoring site, 140,500 vehicles/day. Source: National Center for Environmental Assessment 2015 analysis of Los Angeles, CA data obtained from [Polidori and Fine \(2012b\)](#) and Detroit, MI data obtained from Air Quality System database.

**Figure 2-19 Percentage difference in 1-hour nitrogen dioxide concentration between 10–15 m distance and 80–100 m distance from a road with heavy traffic in two U.S. cities.**

### 2.5.3.2 Near-Road Monitoring

The near-road monitoring network described in [Section 2.4.5](#) was scheduled to be implemented in three phases, with monitors in the first phase to become operational January 1, 2014. As of July 2015, 56 monitoring sites were operational. Of these, certified data for 2014 were available for 41 monitors in the Air Quality System database. NO<sub>2</sub> concentrations from this first year of near-road monitoring at these 41 sites are

summarized and compared to concentrations at nonnear-road monitors in the same city in [Table 2-10](#). All near-road monitoring sites are within 50 m of a road with fleet equivalent annual average daily traffic (FE-AADT) greater than 100,000 vehicles per day, and 57% of them are within 20 m of the road. Many sites became operational after January 1, 2014 and did not accumulate a complete year of certified data. The number of days of available data is also noted in [Table 2-10](#). Because data presented here are for only a single year or less, concentration trends and patterns should be considered very preliminary.

During 2014, 98th percentile daily 1-hour maximum NO<sub>2</sub> concentrations at all near-road monitors in [Table 2-10](#) were below the 1-hour daily maximum NAAQS of 100 ppb. No near-road monitoring site had a 98th percentile 1-hour daily maximum NO<sub>2</sub> concentration greater than 90 ppb or an estimated annual average concentration based on available data of greater than 27 ppb. The highest 98th percentile 1-hour daily maximum concentrations were observed for New York, NY; Denver, CO; Seattle, WA; and Los Angeles, CA, each of which had concentrations greater than 65 ppb. At all other near-road monitors, 98th percentile 1-hour daily maximum concentrations were less than 60 ppb.

High NO<sub>2</sub> concentrations were observed for near-road monitors with the highest traffic counts. The three near-road monitors with target roads having FE-AADT of greater than 600,000 vehicles per day (New York, NY; Los Angeles, CA; and Phoenix, AZ) also had among the six highest 98th percentile 1-hour daily maximum concentrations. The Seattle, WA near-road monitor is targeting one of the highest FE-AADT counts in the network and measured one of the highest 98th percentile 1-hour daily maximum concentrations. Denver, CO and Houston, TX are important exceptions to this trend. In Denver, CO, the second-highest 98th percentile daily 1-hour maximum concentration of all near-road monitors was observed, but the target road FE-AADT was lower than that for most other CBSAs in [Table 2-10](#). In contrast, the Houston, TX near road site targets one of the highest FE-AADT counts among all near-road sites, but measured a 98th percentile 1-hour daily maximum concentration that was lower than that for most other CBSAs in [Table 2-10](#). Overall, the very highest 98th percentile 1-hour maximum concentrations were generally observed at the monitors adjacent to roads with the highest traffic counts.

**Table 2-10 Comparison of nitrogen dioxide concentrations at U.S. near-road and non-near-road monitors for 2014.**

CBSA <sup>a</sup>	Number of Days	Annual Average (ppb)		1-h Maximum 98th Percentile (ppb)		Highest 1-h Maximum (ppb)		Near-Road AADT	Near-Road FE-AADT <sup>c</sup>
		Near-Road	Nonnear-Road <sup>b</sup>	Near-Road	Nonnear-Road <sup>b</sup>	Near-Road	Nonnear-Road <sup>b</sup>		
New York, NY	268	19	4-22	90	41-70	258	51-90	311,234	612,212
Denver, CO	354	25	18-23	70	64-73	97	71-136	249,000	263,118
Seattle, WA	236	24	12	69	47	91	60	237,000	471,630
Los Angeles, CA	355	27	8-22	66	40-85	79	52-136	272,000	695,776
Cincinnati, OH	356	23	4-11	59	31-45	68	40-50	163,000	386,380
Phoenix, AZ	321	21	9-25	59	37-64	62	57-102	320,138	624,315
Indianapolis, IN	318	17	9-14	58	46-49	64	54-58	189,760	362,110
Boston, MA	351	17	4-17	53	25-62	64	31-68	198,239	251,761
Milwaukee, WI	359	16	10	53	43	62	62	133,000	133,000
San Jose, CA	122	20	13	52	55	65	58	191,000	294,140
San Francisco, CA	330	17	3-14	52	17-58	65	21-84	216,000	424,008
Providence, RI	271	20	1-10	51	12-44	56	22-50	186,300	416,790
Baltimore, MD	275	18	11-16	51	47-52	56	54-62	186,750	452,309
Philadelphia, PA	353	16	6-18	51	34-59	65	43-73	124,610	257,460
Detroit, MI	357	16	12	51	49-52	62	65-66	140,500	188,200
Nashville, TN	166	15	10	51	40	63	43	144,204	338,879
Birmingham, AL	358	14	9	51	41	67	83	141,190	215,527
St. Louis, MO	355	14	5-12	50	34-45	72	41-54	159,326	360,077
Atlanta, GA	199	20	3-11	50	17-53	58	23-58	284,920	406,256
Hartford, CT	354	14	9	49	45	80	60	159,900	231,855
Minneapolis, MN	362	16	5-9	48	28-50	53	43-70	277,000	387,250
Austin, TX	247	14	5	48	31	57	37	188,150	350,712
Houston, TX	331	13	2-13	48	18-52	55	23-98	324,119	496,226
New Orleans, LA	283	12	7	48	42	64	56	68,015	129,229
Columbus, OH	365	12	10	47	51	53	63	142,361	286,050
Kansas City, MO	357	12	11-13	46	51-53	52	63-78	114,495	347,582
San Antonio, TX	345	11	5-6	46	31-37	51	38-48	201,840	405,295

**Table 2-10 (Continued): Comparison of nitrogen dioxide concentrations at U.S. near-road and nonnear-road monitors for 2014.**

CBSA <sup>a</sup>	Number of Days	Annual Average (ppb)		1-h Maximum 98th Percentile (ppb)		Highest 1-h Maximum (ppb)		Near-Road AADT	Near-Road FE-AADT <sup>c</sup>
		Near-Road	Nonnear-Road <sup>b</sup>	Near-Road	Nonnear-Road <sup>b</sup>	Near-Road	Nonnear-Road <sup>b</sup>		
Richmond, VA	262	14	5–8	45	37–44	54	47–56	151,000	259,720
Louisville, KY	226	13	11	45	49	70	75	163,000	247,600
Tampa, FL	258	12	5	45	30	59	36–79	190,500	327,660
Boise, ID	239	12	NA <sup>d</sup>	43	NA <sup>d</sup>	48	NA <sup>d</sup>	103,000	162,000
Jacksonville, FL	267	12	8	44	40	70	47	139,000	304,062
Memphis, TN	183	12	8	44	42	48	53	140,850	292,968
Pittsburgh, PA	121	13	3–11	40	21–45	42	24–56	87,534	148,248
Dallas, TX	273	10	3–10	40	24–28	58	29–63	235,790	431,027
Buffalo, NY	268	10	9	40	55	50	71	131,019	NA <sup>d</sup>
Portland, OR	225	12	8	38	35	49	40	156,000	289,052
Charlotte, NC	121	11	9	38	41	44	51	153,000	260,830
Cleveland, OH	152	10	12	36	48	45	66	153,660	287,580
Raleigh, NC	313	10	12	36	48	45	66	141,000	203,280
Des Moines, IA	349	9	6	35	35	41	47	110,000	150,140

AADT = annual average daily traffic; CBSA = core-based statistical area; FE-AADT = fleet-equivalent annual average daily traffic; NA = not available; NY = New York; CO = Colorado; WA = Washington; CA = California; OH = Ohio; AZ = Arizona; IN = Indiana; MA = Massachusetts; WI = Wisconsin; RI = Rhode Island; MD = Maryland; PA = Pennsylvania; MI = Michigan; TN = Tennessee; AL = Alabama; MO = Missouri; GA = Georgia; CT = Connecticut; MN = Minnesota; TX = Texas; LA = Louisiana; VA = Virginia; KY = Kentucky; FL = Florida; ID = Idaho; OR = Oregon; NC = North Carolina; IA = Iowa.

<sup>a</sup>A core-based statistical area is a U.S. geographic area that centers on an urban center and adjacent areas that are socioeconomically tied to the urban center by commuting. For CBSAs that are identified by more than one urban center, only the first city used to identify the CBSA is used, without regard to monitor location. For example, the San Francisco-Oakland-Hayward CBSA is identified in the table as San Francisco, CA even though the near-road monitor is in Oakland, CA. CBSAs are listed in decreasing order of 98th percentile daily 1-hour maximum concentration.

<sup>b</sup>Nonnear-road monitors are all monitors that report data to the Air Quality System database that do not meet criteria for near-road monitors. These can be intended to be representative of area wide (AW), near source, or background concentrations. Data are reported for the range of concentrations across nonnear-road monitors in a city or the concentration at the single nonnear-road monitor.

<sup>c</sup>FE-AADT = (AADT – HD<sub>c</sub>) + (HD<sub>m</sub> × HD<sub>c</sub>) where AADT is annual average daily traffic, HD<sub>c</sub> is total number of heavy-duty vehicles on a road segment, HD<sub>m</sub> is a multiplier [estimated as 10; (U.S. EPA, 2012b)] that represents heavy-duty to light-duty emission ratios on the road segment.

<sup>d</sup>Boise, ID does not have a nonnear-road monitor. Buffalo, NY does not have fleet equivalent annual average daily traffic count. Source: National Center for Environmental Assessment and Office of Air Quality Planning and Standards 2014 analysis of Air Quality System network data.

The highest near-road annual average NO<sub>2</sub> concentrations were observed at Los Angeles, CA (27 ppb); Denver, CO (25 ppb); and Seattle, WA (24 ppb). In New York, NY, the annual average concentration was considerably lower (19 ppb), but winter concentrations were not included because the site was not operational until April 1. Annual average concentrations of 20 ppb or greater were also observed at Cincinnati, OH; Phoenix, AZ;

San Jose, CA; Providence, RI; and Atlanta, GA. At all other near-road monitors, annual average concentrations were less than 20 ppb. For context, the only other monitors in the national network with annual average NO<sub>2</sub> concentrations greater than 20 ppb in 2014 were two other sites within 200 m of highways with more than 200,000 vehicles per day (Greenwood in Phoenix, AZ and Elizabeth Lab in Elizabeth, NJ), and several nonnear-road monitors in Los Angeles, CA and Denver, CO. Because annual average concentrations greater than 20 ppb were only observed at either near-road network monitors (or other monitors strongly influenced by heavy traffic) or in the Denver, CO and Los Angeles, CA CBSAs, it is interesting that the very highest annual average NO<sub>2</sub> concentrations observed nationwide in 2014 were at the Los Angeles, CA and Denver, CO near-road monitors.

For those CBSAs that have a near-road monitor and at least one nonnear-road monitor, annual average concentrations were usually higher at near-road sites than at nonnear-road counterparts within the same CBSA. This was the case even though approximately half of the near road sites (i.e., those sites in [Table 2-10](#) that operated for less than approximately 270 days) were not yet operational during the winter months, when concentrations are likely to be highest (see [Table 2-9](#)).

In almost half of the CBSAs in [Table 2-10](#), both the highest 98th percentile 1-hour daily maximum concentration in the CBSA and the highest annual average concentration in the CBSA were observed at the near-road monitoring site. In most of the remaining CBSAs, the highest annual average concentration was observed at the near-road site, but not for the highest 98th percentile 1-hour daily maximum concentration value of the available data. The highest estimated annual average concentration was observed at the near-road monitor in more than 80% of the CBSAs.

The differences between near-road and nonnear-road concentrations in [Table 2-10](#) are not directly comparable to the differences observed in the near-road gradient studies discussed in [Section 2.5.3.1](#). The range of nonnear-road concentrations in [Table 2-10](#) includes observations not only from monitors sited to measure typical concentrations in areas of high population, but also monitors sited to determine the highest concentration expected to occur in the area, or to determine the impact of other significant sources. An analysis of monitor siting prior to implementation of near-road monitoring requirements indicated that across the entire network 177 monitors were sited for general population exposure, 58 to measure the highest concentration in the area, 69 to measure general or upwind background concentrations, and 19 for source-oriented measurements ([U.S. EPA, 2010a](#)). It should be noted that any monitoring site can have multiple of these monitoring objectives, as they are not mutually exclusive. In that context, [Table 2-10](#) indicates how

near-road concentrations fit into a wider range of urban concentrations rather than how they compare to an urban background with less traffic influence.

The Los Angeles, CA CBSA provides an example. It contains one of the busiest ports as well as one of the busiest airports in the U.S. ([Section 2.5.3.3](#)). Out of 18 monitors in the Los Angeles, CA CBSA, three of the five highest 98th percentile 1-hour maximum concentrations were observed at the near-road site, the site nearest the port, and the site adjacent to the airport. At the LAX Hastings monitoring site adjacent to Los Angeles International Airport, the 98th percentile 1-hour daily maximum NO<sub>2</sub> concentration for 2014 was 66 ppb, identical to the concentration at the Los Angeles, CA near-road site, although the annual average concentration of 12 ppb was much lower. The highest 1-hour NO<sub>2</sub> concentration in the Los Angeles, CA CBSA in 2014 (136 ppb) was observed at Long Beach North monitor, the site closest to the port of Long Beach, CA. The 98th percentile 1-hour daily maximum concentration at the site was also the highest in the Los Angeles, CA CBSA (85 ppb), and far exceeded the 98th percentile 1-hour daily maximum concentration at the near-road site. However, in Los Angeles, CA as in most of the CBSAs with near-road monitors, the annual average concentration was highest at the near-road monitor.

Many of the nonnear-road concentration ranges in [Table 2-10](#) also include concentrations that are unusually low for urban areas. The lowest values of the range are more indicative of whether the CBSA contains monitors sited for background measurements than how concentrations compare among CBSAs. For example, in New York, NY, annual average nonnear-road NO<sub>2</sub> concentrations range from 4 to 22 ppb, while in Denver, CO they range from 18 to 23 ppb. This is not an indication that concentrations are much lower in New York, NY than those in Denver, CO. Rather, the Chester monitoring site is in a rural area of New Jersey upwind of the New York, NY CBSA and is identified as a background site, and its annual average NO<sub>2</sub> concentration in 2014 was 4 ppb. This concentration is much lower than the near-road concentration of 19 ppb for the New York, NY CBSA, but also much lower than the concentration ranges for many other CBSAs in the U.S. in [Table 2-10](#). Without the two designated background sites for the New York, NY CBSA, the range of nonnear-road concentrations would be 16 to 22 ppb, more similar to Denver, CO, which does not have a background monitor.

Nonnear-road monitors can also be influenced by traffic. One of the highest 1-hour daily maximum NO<sub>2</sub> concentrations was 136 ppb, which was observed at a Denver, CO nonnear-road site. As indicated in [Table 2-10](#), this is much higher than the maximum 1-hour concentration of 97 ppb observed at the Denver, CO near-road monitor. The 136-ppb concentration was observed at the Childhood Asthma Management Program (CAMP) monitor located approximately 3 km downwind of the near-road monitor, but

one block from high-rise buildings that form the edge of the high-density central business district (which lies between the two monitors). At the CAMP monitor, local traffic is also a likely source, in addition to commercial heating and other activities. Recent traffic counts on the nearest streets to the CAMP monitor, Broadway and 22nd Street, were 44,850 (in 2014) and 23,389 (in 2013) vehicles per day, respectively. Traffic counts on other streets within one block were 22,000 (20th St.), 13,000 (Park Ave.), 5,000 (Champa St.), and 2,490 (Curtis St.) vehicles per day according to the Denver Regional Council of Governments data.<sup>1</sup> This adds up to more than 100,000 vehicles per day on streets within one block of this nonnear-road monitor.

While the near-road network has not been operating long enough to evaluate long-term trends in near-road concentrations, there are older monitors in the U.S. that are informative, even though they do not strictly meet new requirements for near-road monitoring. The Elizabeth Lab site in Elizabeth, NJ does not meet near-road monitoring requirements because it is more than 50 m from the road. Some of the highest NO<sub>2</sub> concentrations in the U.S. have been observed at this site, and long-term NO<sub>2</sub> concentration trends are described in [Section 2.5.5](#).

Outside of the U.S. (e.g., London, U.K.), routine near-road monitoring has been conducted for a longer time. The preliminary results from the U.S. near-road network are similar to data from the London, U.K. network, despite potential differences from the U.S. in fleet mix (including fraction of vehicles with diesel engines), distance from road, traffic mitigation policies, and small geographic scope that may limit generalizability. London, U.K. data were analyzed because the city has a well-established system of roadside and urban background monitors. Air quality data were obtained from the Airbase database ([EIONET, 2014](#)) for 2004 to 2006 and 2010 to 2012 in the form of hourly NO<sub>2</sub> measurements, and monitors of interest were those whose city was listed as London and were within 10 m of the roadway to capture NO<sub>2</sub> primarily derived from mobile sources. The site with the highest concentration, Marylebone Road, had a traffic count of 70,000 vehicles per day ([Dall'Osto et al., 2011](#)), and was within 2 m of a road, or close enough to approximate on-road conditions. Overall, there were large differences in NO<sub>2</sub> concentrations between roadside and urban background monitors, which ranged from 2.4 to 9.8 km apart as shown in [Tables 2-11A](#) and [2-11B](#). The differences in 24-h avg NO<sub>2</sub> concentrations ranged from approximately 24% lower to 170% higher at the roadside than urban background site. The largest relative differences in 24-h avg NO<sub>2</sub> concentrations were observed when the ambient urban background concentrations were less than 20 ppb. NO<sub>2</sub> concentrations at all roadside monitors were positively correlated with concentrations at the overall urban background monitors. Interquartile ranges were

---

<sup>1</sup> <http://gis.drcog.org/trafficcounts/>.

generally similar between roadside monitor-urban background monitor pairs, indicating that while in the majority of cases roadside monitors had higher NO<sub>2</sub> concentrations than urban background monitors, temporal variability was similar between the two monitors. As with the preliminary results from the U.S. near-road network, the results for London, U.K. suggest that while NO<sub>2</sub> concentrations measured at roadside monitors were generally higher than those measured at urban background monitors, there was a wide range in mean differences between roadside and background.

**Table 2-11A Roadside and urban background nitrogen dioxide concentrations in London, U.K. 2010–2012.**

Monitor Pairs		Distance between Monitors (km)	Mean Concentration <sup>a</sup> (ppb)	Δ Mean (%)	98th Percentile of 1-Hour Daily Maximum (ppb)	Δ 98th Percentile (%)	24-Hour Avg IQR (ppb)	1-Hour Max IQR (ppb)	24-Hour Avg Correlation with Urban Background Monitors (95% CI)
Roadside	London Marylebone Rd	2.4	52.3	68	140.5	102	25.7	59.6	0.30
Urban bkg	London Bloomsbury		31.2		69.7		12.0	14.4	(0.25, 0.36)
Roadside	Camden Kerbside	2.8	43.8	124	132.0	108	16.9	32.4	0.74
Urban bkg	London N. Kensington		19.6		63.6		12.6	16.0	(0.71, 0.77)
Roadside	Haringey Roadside	9.8	23.8	-24	64.2	-7.9	12.0	18.6	0.84
Urban bkg	London Bloomsbury		31.2		69.7		12.0	14.4	(0.83, 0.86)

Δ = difference between roadside and urban background monitors; avg = average; bkg = background; CI = confidence interval; IQR = interquartile range.  
<sup>a</sup>3-year average.

Source: National Center for Environmental Assessment 2014 analysis of European Air Quality Database data from 2010–2012.

**Table 2-11B Roadside and urban background nitrogen dioxide concentrations in London, U.K. 2004–2006.**

Monitor Pairs		Distance between Monitors (km)	Mean 1-Hour Concentration (ppb)	$\Delta$ Mean <sup>a</sup> (%)	98th Percentile of 1-Hour Daily Maximum <sup>b</sup> (ppb)	$\Delta$ 98th Percentile (%)	24-Hour Avg IQR (ppb)	1-Hour Max IQR (ppb)	24-Hour Avg Correlation with Urban Background Monitors (95% CI)
Roadside	London Marylebone Rd	2.4	58.3	88	163.5	132	28.6	45.5	0.24
Urban bkg	London Bloomsbury		31.1		70.6		13.1	16.0	(0.18, 0.29)
Roadside	Southwark Roadside	3.3	33.0	96	80.7	50	11.1	13.3	0.86
Urban bkg	London Eltham		16.84		53.7		10.7	16.5	(0.84, 0.88)
Roadside	London Cromwell Rd 2	3.4	42.7	131	97.7	51	12.1	21.0	0.63
Urban bkg	London Bexley		18.5		64.5		11.9	16.0	(0.59, 0.66)
Roadside	Camden Kerbside	3.8	37.0	74	116.3	62	15.7	26.9	0.78
Urban bkg	London N. Kensington		21.2		71.8		12.7	17.0	(0.75, 0.80)
Roadside	Tower Hamlets Roadside	4.1	32.3	26	80.1	-12	15.2	19.2	0.81
Urban bkg	London Hackney		25.7		91.2		14.3	19.7	(0.79, 0.83)
Roadside	Haringey Roadside	4.5	24.4	-5	66.1	-28	12.0	16.5	0.80
Urban bkg	London Hackney		25.7		91.2		14.3	19.7	(0.78, 0.82)
Roadside	London Bromley	5.2	24.7	-5	80.4	-8	12.4	17.6	0.70
Urban bkg	London Lewisham		26.0		87.4		12.6	17.0	(0.67, 0.73)
Roadside	London A3 Roadside	6.2	35.3	170	93.0	74	14.7	19.2	0.64
Urban bkg	London Teddington		13.1		53.5		11.2	19.2	(0.77, 0.81)

$\Delta$  = difference between roadside and urban background monitors; avg = average; bkg = background; CI = confidence interval; IQR = interquartile range.

<sup>a</sup>Roadside vs. urban background comparison.

<sup>b</sup>3-year average.

Source: National Center for Environmental Assessment 2014 analysis of European Air Quality Database data from 2004–2006.

While NO<sub>2</sub> measurements are more widely used than NO<sub>x</sub> for exposure estimates in epidemiologic studies, NO<sub>2</sub> accounts for only a fraction of NO<sub>x</sub> near roads with heavy traffic. For example, [Clements et al. \(2009\)](#) measured concentrations of NO, NO<sub>2</sub>, and NO<sub>x</sub>, 5 m downwind from a state road in Austin, TX, and observed NO<sub>x</sub> concentrations of approximately 40–50 ppb, NO concentrations of approximately 15–40 ppb, and NO<sub>2</sub> concentrations of approximately 5–15 ppb under downwind conditions. NO<sub>2</sub> accounted for 10–38% of the NO<sub>x</sub>.

It follows that NO is often a greater contributor to NO<sub>x</sub> near roads. [Baldauf et al. \(2008a\)](#) presented a time series of pollutants that were measured 5 m from I-40 in Raleigh, NC, and reported that NO concentrations reached near 250 ppb between 8:00 a.m. and 9:00 a.m., with minimum NO concentrations around 50 ppb during that time period. The predominance of NO (rather than NO<sub>2</sub>) in the near-road environment contrasts with nationwide annual average concentrations in [Table 2-4](#), for which NO<sub>2</sub> (rather than NO) accounts for more than 60% of the annual average ambient concentration of NO<sub>x</sub>.

Wind speed and atmospheric stability also impact roadway NO<sub>x</sub> concentrations. Peak roadway concentrations are often observed during presunrise hours when winds are weak and atmospheric inversions are present ([Gordon et al., 2012](#); [Durant et al., 2010](#); [Hu et al., 2009](#)). During these presunrise hours, the NO<sub>x</sub> concentrations exhibit a more gradual decay from the roadway than after sunrise. [Hu et al. \(2009\)](#) observed this effect for NO during a near-road field campaign in Santa Monica, CA. They observed elevated NO concentrations (90–160 ppb) as far as 1,200 m downwind of the roadway during presunrise hours, which is much larger than the expected spatial extent of NO (100–300 m; [Section 3.3.1.1](#)). NO<sub>x</sub> concentration gradients continue to change throughout the day as atmospheric stability evolves. After sunrise, near-road NO<sub>x</sub> concentrations drop as vertical mixing increases ([Gordon et al., 2012](#); [Durant et al., 2010](#)) until concentrations reach a minimum during the late afternoon ([Gordon et al., 2012](#)). In some studies, no clear gradient is observed in NO<sub>x</sub> concentrations (or other traffic-related species) during mid-morning or early evening hours ([Gordon et al., 2012](#); [Durant et al., 2010](#)). However, the exact response of the horizontal concentration gradient to changes in boundary layer height is unresolved to some extent.

Dispersion of NO<sub>x</sub> in the near-road environment is influenced by several factors: atmospheric turbulence, vehicle-induced turbulence, and roadway-induced turbulence ([Baldauf et al., 2009](#); [Wang and Zhang, 2009](#)). Atmospheric turbulence occurs because of meteorological factors within the urban boundary layer. Vehicle-induced turbulence results from the air disturbances caused by the direction and speed of vehicle motion. Roadway-induced turbulence happens when wind-driven air masses undergo separation following impact with a roadway structure in the built environment. These sources of

turbulence interact with each other to create complex, unique dispersion profiles at a given road segment to influence NO<sub>x</sub> concentrations. This discussion addresses the physical factors influencing dispersion of NO<sub>x</sub>.

Several atmospheric conditions affect regional or urban airflow profiles and potentially can impact the dispersion profile of NO<sub>x</sub> even in the absence of adjacent buildings, roadway structures, or traffic-related turbulence. In urban areas, effects of the built environment can be seen at regional-, urban-, neighborhood-, and street-level scales ([Fernando, 2010](#); [Britter and Hanna, 2003](#)). Roughness created by upstream buildings contributes to local turbulence levels, even in the absence of adjacent buildings. Land forms such as slopes and valleys can affect the atmospheric turbulence level because they interact with atmospheric stability conditions to restrict air movement. [Finn et al. \(2010\)](#) observed that tracer gas concentration increased with increasing atmospheric stability. This finding is consistent with results with other studies ([Gordon et al., 2012](#); [Durant et al., 2010](#); [Hu et al., 2009](#)) that observed the highest concentrations of NO, NO<sub>2</sub>, and NO<sub>x</sub> before sunrise when traffic levels and atmospheric stability are high. [Hu et al. \(2009\)](#) also argued that atmospheric stability potentially extends the decay profile of near-roadway pollutants. Additionally, the presence of slopes and valleys can cause spots where airflow converges or diverges ([Fernando, 2010](#)). Heat flux can be sizeable in urban areas where the “heat island” effect from roadways and buildings can raise local temperatures by several degrees ([Britter and Hanna, 2003](#)); heat flux potentially contributes to convection near roadways and other structures in the built environment. Underscoring the dominant role of local turbulence on dispersion patterns, [Venkatram et al. \(2007\)](#) measured meteorological factors potentially affecting NO concentrations near a road segment in Raleigh, NC and found that among meteorological variables, vertical velocity fluctuations had the largest effect on NO concentration.

Vehicle motion creating high levels of turbulence on and near roads can contribute to the dispersion of traffic-related air pollution in the vicinity of a roadway ([Baldauf et al., 2008a](#)). An early description of this was provided by [Sedefian et al. \(1981\)](#) for the General Motors experiments, in which groups of vehicles were driven along a test track while towers with mounted anemometers measured mean and fluctuating velocities. It was observed that vehicle-induced turbulence dissipates slowly under low mean wind conditions and vice versa. Vehicle-induced turbulence was found in that study to contribute to vertical dispersion of emitted pollutants. Computational fluid dynamics (CFD) simulations by [Wang and Zhang \(2009\)](#) also found that vehicle-induced turbulence contributed to vertical dispersion. [Rao et al. \(2002\)](#) observed large measurements of turbulence kinetic energy in the wake of a vehicle outfitted with a trailer carrying sonic anemometers driving along a runway. [Sedefian et al. \(1981\)](#) found that advection of vehicle-induced turbulence away from the roadway was related to the speed

and direction of mean winds. [di Sabatino et al. \(2003\)](#) showed that vehicle-induced turbulence is related to traffic levels. In light traffic, the wake behind a vehicle is isolated, but for increasing traffic, the wakes interact and turbulence is a function of the number of vehicles and vehicle length scale. At congested traffic levels, the vehicle-induced turbulence becomes independent of the number of vehicles. For street canyon simulations and measurements, [Kastner-Klein et al. \(2003\)](#) observed that predictions of tracer concentrations were overestimated when vehicle-induced turbulence was not considered; this implies additional dispersion related to vehicle-induced turbulence. Traffic directionality was investigated by [He and Dhaniyala \(2011\)](#) and [Kastner-Klein et al. \(2001\)](#). [He and Dhaniyala \(2011\)](#) observed that turbulent kinetic energy from two-way traffic was roughly 20% higher than that for one-way traffic, and increased with decreasing distance among the traffic lanes. [Kastner-Klein et al. \(2001\)](#) observed that two-way traffic suppresses the mean flow of vehicle-induced air motion along a street canyon, whereas one-way traffic produces a piston-like effect [note that the [Kastner-Klein et al. \(2001\)](#) study was for the geometrical case of a street canyon]. Substantially higher turbulence levels were produced with two-way traffic compared with one-way traffic for the [Kastner-Klein et al. \(2001\)](#) study as well.

The presence of near-road structures results in recirculating airflow regions that may trap air pollutants on one side and disperse them on another side, depending on wind conditions ([Baldauf et al., 2008b](#)). [Finn et al. \(2010\)](#) simulated transport from a roadway using a point source tracer gas with barrier and open terrain conditions. With airflow from the simulated roadway and high atmospheric stability, high concentrations were trapped in the roadway region with a negligible tracer gas in the wake downstream of the barrier with considerable lateral and vertical plume dispersion. For open terrain, transport of the tracer was characterized by a narrow plume. [Hagler et al. \(2011\)](#) used CFD to model airflow and concentrations around barriers of different heights and similarly found reductions in inert tracer concentration downwind of the barrier compared with the open terrain case with trapping of air pollutants upstream of the barrier. With the barrier in place, downwind tracer concentrations were observed at elevations of twice the barrier height. Mean airflow vectors also illustrate a wind disturbance at elevations of twice the barrier height. Even for the open terrain case, vertical dispersion occurs. In additional simulations involving a service road just downstream of the barrier, [Hagler et al. \(2011\)](#) observed entrainment of tracer in the wake downstream of the barrier. [Tokairin and Kitada \(2005\)](#) used CFD to investigate the effect of porous fences on contaminant transport near roads and observed tracer gas retention and airflow recirculation when the fences were designed with less than 40–50% porosity. [Heist et al. \(2009b\)](#) investigated the effect of geometry of road cuts and noise barriers in wind tunnel tracer gas experiments. They observed that elevated roadways, depressed roadways, and noise barriers all resulted in lower downwind concentrations compared with the open terrain

case with elevated roadways producing the least reduction in concentration. As in [Hagler et al. \(2011\)](#), [Heist et al. \(2009b\)](#) observed measurable concentrations at elevations that resulted from Gaussian dispersion for all geometries of the road cut or barrier, but vertical dispersion was enhanced or dampened depending on the specific geometry. Similarly, for wind tunnel simulations of a single tower above a matrix of street canyons, the tower was shown to induce both airflow and tracer concentration along the leeward edge of the building to a height exceeding the tower height ([Brixey et al., 2009](#); [Heist et al., 2009a](#)).

For the special case of street canyons, retention time for traffic-based pollution increases on the roadway with increasing building height-to-road-width ratio because recirculating airflow forms closed streamlines within the canyon ([Li et al., 2005](#); [Liu et al., 2005](#)). For wind tunnel simulations of tracer emission at street level with and without traffic, [Kastner-Klein et al. \(2001\)](#) observed measurable tracer concentrations near the top of the street canyon but with some dispersion from maximum tracer levels at the canyon floor. Dilution of NO<sub>x</sub> concentrations through these recirculating air structures leads to a steep decrease in concentration with increasing distance from the ground ([Lee et al., 2012a](#)). For low-aspect-ratio street canyons, secondary recirculating structures can arise; while contaminant retention still occurs in this case, ventilation occurs more readily than for the high-aspect-ratio case ([Simoëns and Wallace, 2008](#); [Simoëns et al., 2007](#)). [Cheng et al. \(2008\)](#) used CFD to evaluate factors leading to contaminant retention in street canyons and observed that the exchange rate for air and a tracer gas was driven by the turbulent component of airflow at the roof-level interface of the street canyon. Subsequent simulations showed that exchange rate was also aided by unstable atmospheric conditions ([Cheng et al., 2009b](#)). CFD simulations by [Gu et al. \(2010\)](#) of transport within a street canyon with and without vegetation suggested that the recirculating flow is dampened by the presence of vegetation.

---

### 2.5.3.3 Monitoring Near Nonroad Sources

Compared to near-road monitors, fewer monitors are located near other major sources. In rare cases, monitors are adjacent to or within hundreds of meters of a major source, and additional monitors are located within a few kilometers. [Table 2-12](#) summarizes NO<sub>2</sub> concentrations at selected monitoring sites that are likely to be influenced by nearby ports, airports, border crossings, petroleum refining, or oil and gas drilling.

**Table 2-12 Selected nitrogen dioxide measurements with potential nonhighway source influences for 2014.**

Monitoring Site	Potential Influence(s)	CBSA	Annual Average (ppb)		98th Percentile of 1-Hour Daily Maximum (ppb)		Highest 1-Hour Daily Maximum (ppb)	
			Site	Range across CBSA	Site	Range across CBSA	Site	Range across CBSA
Hudson	Port	Los Angeles, CA	20.7	8–27	85	40–85	136	52–136
Bayonne, NJ	Port (Newark)	New York, NY	17.1	4–22	61	41–70	75	51–90
NOAA Storage Facility	Port (Norfolk) rail yard	Norfolk, VA	8.3	NA	42	NA	56	NA
LAX Hastings	Airport	Los Angeles, CA	11.9	8–27	66	40–85	87	52–136
Schiller Park, IL	Airport (O'Hare) rail yard	Chicago, IL	19.0	10–21	58	50–67	105	66–105
Otay Mesa	Border crossing	San Diego, CA	17.8	5–20	70	25–70	87	48–87
Calexico, CA	Border crossing	None	12.3	NA	62	NA	94	NA
Chamizal	Border crossing	El Paso, TX	14.0	12–14	60	54–60	71	69–79
Fairbanks, AK	Wood burning	None	10.7	NA	75	NA	108	NA
Capitol	Petroleum refinery	Baton Rouge, LA	10.5	2–11	46	13–49	59	20–93
Roosevelt National Park, ND	Oil and gas drilling	None	1.6	NA	14	NA	89	NA
Vernal, UT	Oil and gas drilling	None	7.3	NA	88 <sup>a</sup>	NA	88 <sup>a</sup>	NA

AK = Alaska; CBSA = core-based statistical area; IEPA = Illinois Environmental Protection Agency; LAX = Los Angeles Airport; Max = maximum; NA = None available; NOAA = National Oceanic and Atmospheric Administration.

<sup>a</sup>For Vernal, UT, maximum and 98th percentile concentrations are the same because there are so few measurements.

Source: National Center for Environmental Assessment 2015 analysis of Air Quality System network data.

Three of the sites in [Table 2-12](#) are near major ports for commercial shipping. The ports of Long Beach, CA (in the Los Angeles, CA CBSA); New York-Newark, NY-NJ (in the New York CBSA); and Norfolk, VA are among the busiest ports in the U.S. The Long Beach-Hudson monitor is approximately 3 km from the port of Long Beach, CA. This monitor had the highest nationwide 98th percentile 1-hour daily maximum NO<sub>2</sub>

concentration in 2014 (85 ppb) among sites that met completeness criteria and the highest hourly NO<sub>2</sub> concentration in the Los Angeles, CA CBSA (136 ppb). However, other sources, including the I-710 freeway with heavy diesel traffic are also nearby. The Bayonne, NJ monitor is approximately 1 km directly across Newark Bay from the Port of Newark. At Bayonne, NJ, NO<sub>2</sub> concentrations were higher than those at most near-road monitors listed in [Table 2-10](#) but similar to other sites in the New York, NY CBSA. The Norfolk NOAA Storage Facility monitor, VA is located approximately 1 km across the Elizabeth River from the Portsmouth Marine Terminals and approximately 1 km from the Norfolk Southern rail yard. Here, NO<sub>2</sub> concentrations were substantially lower than those at most near-road monitors in [Table 2-10](#). Altogether, a wide range of NO<sub>2</sub> concentrations was observed for three sites near major ports, and it is difficult to generalize the impact of port emissions on concentrations at nearby monitors.

There are two NO<sub>2</sub> monitoring sites in [Table 2-12](#) located within 1 km of two of the busiest airports in the U.S., Los Angeles International Airport (LAX) and O'Hare International Airport in Chicago, IL. The 98th percentile 1-hour daily maximum concentration at LAX was identical to that at the near-road monitor, although annual average concentration was much lower. The highest hourly concentration in the Chicago, IL CBSA in 2014 (105 ppb) was observed at the Schiller Park, IL monitoring site located adjacent to the airport. However, this is also very close to a major rail yard, the Bedford Park Rail Yard. As with ports, it is difficult to isolate the impact of airports on NO<sub>2</sub> concentrations at nearby monitors.

From [Table 2-12](#), three of the highest 98th percentile 1-hour daily maximum NO<sub>2</sub> concentrations in the U.S. were observed at monitors near the U.S.-Mexico border at Otay Mesa in the San Diego, CA CBSA (70 ppb); Chamizal, in the El Paso, TX CBSA (60 ppb); and Calexico, CA (62 ppb). Each of these sites are within 4 km of one of the five busiest ports of entry to the U.S. for international truck traffic in 2014.<sup>1</sup> Data from the Otay Mesa site were instrumental in demonstrating that concentrations of traffic pollutants in the San Ysidro community surrounding the Otay Mesa border crossing are related to wind direction and border crossing wait times ([Quintana et al., 2014](#)). The Chamizal site is only 0.2 km from the principle border crossing in El Paso, TX, a city where 81% of the variance in NO<sub>2</sub> concentration has been attributed to elevation, distance from highways and ports of entry ([Gonzales et al., 2005](#)). Idling vehicles at the Calexico,

---

<sup>1</sup> Otay Mesa 810,193 trucks in 2014; El Paso 759,125 trucks in 2014; Calexico East 325,243 trucks in 2014; from U.S. Department of Transportation, Bureau of Transportation Statistics, accessed October 13, 2015. [http://transborder.bts.gov/programs/international/transborder/TBDR\\_BC/TBDR\\_BC\\_Index.html](http://transborder.bts.gov/programs/international/transborder/TBDR_BC/TBDR_BC_Index.html)

CA border crossing have been proposed as a potentially important source of NO<sub>2</sub> in that community<sup>1</sup> and efforts are underway to quantify their contribution to local pollution.<sup>2</sup>

The only other monitoring site in the U.S. with 98th percentile 1-hour daily maximum NO<sub>2</sub> concentrations greater than 60 ppb that is not in a large urban area is the Fairbanks, Alaska (AK) Ncore site. PM<sub>2.5</sub> in Fairbanks, AK is primarily due to wood smoke,<sup>3</sup> which can also be an important local NO<sub>x</sub> source ([U.S. EPA, 2013a](#)). However, Fairbanks is also impacted by coal-fired power generation, motor vehicles, and oil-fired heating systems,<sup>4</sup> and the high concentrations are enhanced by reduced reactivity of NO<sub>x</sub> in the darkness and extremely cold temperatures characteristic of Fairbanks in winter ([Joyce et al., 2014](#)).

Monitoring data from near a major petroleum refinery and in areas with oil and gas drilling activities are also included in [Table 2-12](#). These NO<sub>2</sub> concentrations are generally lower than those influenced by other sources in [Table 2-12](#). There are occasional high hourly concentrations but 98th percentile and annual average concentrations are generally not as high as those observed near roads in [Table 2-10](#) or at sites influenced by other sources in [Table 2-12](#). For example, at Theodore Roosevelt National Park, ND, a maximum NO<sub>2</sub> concentration of 89 ppb was observed, but the 98th percentile 1-hour daily maximum concentration was only 14 ppb. The Vernal, UT monitor in [Table 2-12](#) was only operated for 27 days in 2014, and the 98th percentile/highest daily 1-hour maximum concentration was 88 ppb. However, the next highest 1-hour daily maximum concentration at this site was only 47 ppb.

In general, it is more difficult to assess the impact of nontraffic sources using the national monitoring network because there are few monitors near major sources and they are located at a greater distance from sources than near-road monitors. However, 98th percentile 1-hour daily maximum concentrations at monitoring network sites near ports, airports, and border crossings have been observed to be among the higher concentrations measured in the U.S. nationwide network.

---

<sup>1</sup> Imperial County Air Pollution Control District. (2012) Annual Network Plan for Ambient Air Monitoring Imperial County Air Pollution Control District. Available online at <http://www3.epa.gov/ttn/amtic/files/networkplans/CAImperialPlan2012.pdf>.

<sup>2</sup> Imperial County Air Pollution Control District. (2014) Imperial County 2013 State Implementation Plan for the 2006 24-Hour PM<sub>2.5</sub> Moderate Nonattainment Area. Available online at [http://www.arb.ca.gov/planning/sip/planarea/imperial/Final\\_PM2.5\\_SIP\\_\(Dec\\_2,\\_2014\)\\_Approved.pdf](http://www.arb.ca.gov/planning/sip/planarea/imperial/Final_PM2.5_SIP_(Dec_2,_2014)_Approved.pdf).

<sup>3</sup> Alaska Department of Environmental Conservation. (2014) Alaska Department of Environmental Conservation Annual Air Quality Monitoring Network Plan 2014–2015. Available online at <http://dec.alaska.gov/air/am/2014-15%20Monitoring%20Plan%20Final%208-29-14.pdf>.


<sup>4</sup> Alaska Department of Environmental Conservation. (2014) Alaska Department of Environmental Conservation Annual Air Quality Monitoring Network Plan 2014–2015. Available online at <http://dec.alaska.gov/air/am/2014-15%20Monitoring%20Plan%20Final%208-29-14.pdf>.

---

## 2.5.4 Seasonal, Weekday/Weekend, and Diurnal Trends

Month-to-month variability in 24-h avg NO<sub>2</sub> concentrations was described in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)). Strong seasonal variability in NO<sub>2</sub> was reported, with higher concentrations in winter and lower concentrations in summer. Monthly maxima varied regionally. Day-to-day variability in NO<sub>2</sub> concentration was generally larger during the winter.

Recent data presented in [Table 2-3](#) continue to show similar seasonal trends for average seasonal NO<sub>2</sub> concentrations across the 2011 to 2013 3-year period. Mean and 99th percentile concentrations are highest in the first and fourth quarters. Concentration patterns of NO and NO<sub>2</sub> are affected strongly by emissions and meteorology, as concentrations peak during early morning hours and in winter when PBL heights are lowest ([Figure 2-20](#)). NO<sub>2</sub> exhibits flatter profiles relative to NO as secondary formation processes influence concentration patterns.



Note: NO = nitric oxide, NO<sub>2</sub> = nitrogen dioxide.


Source: National Center for Environmental Assessment 2013 analysis of Air Quality System network data.

**Figure 2-20** January and July hourly profiles of nitric oxide and nitrogen dioxide (ppb) for the site in Atlanta, GA with the highest 1-hour nitrogen dioxide concentrations.

[Figure 2-20](#) shows a typical diurnal cycle for a nonnear-road site for NO and NO<sub>2</sub>. As described in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), the NO<sub>2</sub>

concentration typically exhibits a daily maximum during morning rush hour, although the concentration maximum can also occur at other times of day. This pattern in [Figure 2-20](#) is shown for Atlanta, GA, but it is also typical for other urban sites. Although the concentration trends shown in [Figure 2-20](#) are for a nonnear-road monitoring site, they are similar to trends observed for the Los Angeles, CA and Detroit, MI near-road concentration patterns in [Figure 2-16](#). NO levels well above zero at night imply that O<sub>3</sub> has been completely titrated.

Typically, weekday concentrations of NO<sub>x</sub> and particularly NO exceed weekend concentrations, and diurnal cycles are more compressed on weekends. This pattern is demonstrated for NO<sub>2</sub> and NO concentrations at the same monitor in [Figure 2-21](#). In Atlanta, GA, NO<sub>x</sub> concentrations were 24% higher on weekdays than on weekends ([Pachon et al., 2012](#)). The weekend effect for NO was first observed by [Cleveland et al. \(1974\)](#) and is a general characteristic of urban NO and NO<sub>x</sub> concentrations observed in many locations ([Tonse et al., 2008](#); [Pun et al., 2003](#); [Marr and Harley, 2002](#)). Differences between weekdays and weekends were also noted in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), with more pronounced differences at sites more influenced by traffic. Modeling simulations of weekly cycles of NO<sub>x</sub> based on summer satellite column data also indicate higher concentrations on weekdays than on weekends ([Choi et al., 2012](#)). The satellite column data is converted to concentrations using a chemistry transport model of the vertical NO<sub>2</sub> distribution (see [Section 2.4.5](#)). Predicted concentrations agree with empirical observations and higher concentrations on weekdays than on weekends are observed regardless of land coverage, for urban, forest, and other regions ([Choi et al., 2012](#)). In southern California, NO<sub>x</sub> concentrations were an average of 46% lower on weekends than on weekdays in ground-based measurements, and 34% lower in airborne measurements ([Pollack et al., 2012](#)).



Note: NO = nitric oxide, NO<sub>2</sub> = nitrogen dioxide.


Source: National Center for Environmental Assessment 2013 analysis of Air Quality System network data.

**Figure 2-21** Weekend/weekday hourly profiles of nitric oxide and nitrogen dioxide (ppb) for the site in Atlanta, GA with the highest nitrogen dioxide concentrations.

### 2.5.5 Multiyear Trends in Ambient Measurements of Oxides of Nitrogen

From 1990 to 2012, the annual average NO<sub>2</sub> concentration across the U.S. based on concentrations from 135 monitoring sites in the national air quality monitoring network decreased by 48%, and from 1990 to 2014, the U.S. average annual 98th percentile of 1-hour daily maximum concentrations from 91 monitoring sites decreased by 45% (<http://www3.epa.gov/airtrends/nitrogen.html>). The steady decline in NO<sub>2</sub> concentrations over the years can be attributed mainly to reductions in emissions from mobile and stationary sources (see [Figure 2-2](#)). Considerably fewer monitoring sites were operational before 1990. However, if the 98th percentile of 1-hour daily maximum NO<sub>2</sub> concentrations were extended as far back as 1980, average U.S. concentrations would have exceeded the current NAAQS for part of the period. [Figure 2-22](#) shows the decrease in average annual 98th percentile 1-hour daily maximum NO<sub>2</sub> concentrations for 24 sites for which NO<sub>2</sub> concentration data are available from 1980 to 2014. Over this period the concentration decreased by 57%, from 111 ppb in 1980 to 47 ppb in 2014. However, it was greater than 100 ppb in 1980, 1981, 1982 and 1988, and greater than 90 ppb every year from 1980 to 1991. Since 1990, concentrations decreased steadily, and by 2014,

90% of 98th percentile 1-hour daily maximum NO<sub>2</sub> concentrations at these 24 sites were less than about 60 ppb.




Source: National Center for Environmental Assessment 2014 analysis of Air Trends data (<http://www.epa.gov/airtrends/nitrogen.html>).

**Figure 2-22 U.S. national average of annual 98th percentile of 1-hour daily maximum nitrogen dioxide concentration at 24 sites, 1980–2012.**

Information on trends on a regional basis and at individual, local air monitoring sites can be found at <http://www.epa.gov/air/airtrends/nitrogen.html> (National Trends in Nitrogen Dioxide Levels). One example of particular relevance to the near-road environment is The Elizabeth Lab site in Elizabeth, NJ. It is situated at the Interchange 13 tollbooth of the New Jersey Turnpike, within 200 m of a segment of the Turnpike with more than 250,000 vehicles per day. The Elizabeth Lab site is also within 200 m of Interstate 278, with 126,000 vehicles per day. In 2014, both the highest 98th percentile 1-hour daily maximum NO<sub>2</sub> concentration (90 ppb) and the highest nonnear-road annual average NO<sub>2</sub>

concentration (22 ppb) in the New York, NY CBSA were observed at the Elizabeth Lab monitor. [Figure 2-23](#) shows annual average, maximum, and 98th percentile 1-hour daily maximum concentrations from 1980 to 2014 at the Elizabeth Lab monitor.



Note: Average = Annual average; 98% = 98th percentile of daily 1-h maximum concentration; max = highest daily 1-h maximum concentration. Years 1981–1984 and 1996 are less than 75% complete.

Source: National Center for Environmental Assessment 2015 analysis of Air Quality System network data from 1980–2014.

**Figure 2-23 Trend in nitrogen dioxide concentrations at Elizabeth Lab monitoring site near New Jersey Turnpike 1980–2014.**

### 2.5.6 Background Concentrations

In the context of the review of a NAAQS, the U.S. EPA generally defines “background concentrations” in a way that distinguishes among concentrations that result from precursor emissions that are relatively less controllable from those that are relatively

more controllable through U.S. policies or through international agreements. The most commonly used form in the past and in this document is North American Background (NAB), which refers to simulated NO<sub>2</sub> concentrations that would exist in the absence of anthropogenic emissions from the U.S., Canada, and Mexico. This definition of background includes contributions resulting from emissions from natural sources (e.g., soils, wildfires, lightning) around the world. Other definitions can also be used. For example, in the 2013 ISA for Ozone ([U.S. EPA, 2013e](#)), a U.S. background, which includes emissions from Canada and Mexico in addition to those in the definition of a North American background, and a natural background, which includes only emissions from natural sources globally, were used. Background is used to inform policy considerations regarding the current or potential alternative standards.

As can be seen from [Figure 2-13](#), maximum seasonally averaged concentrations of NO<sub>2</sub> occur along the Northeast Corridor, the Ohio River Valley, and in the Los Angeles, CA basin. While NO<sub>2</sub> concentrations are often above 5 ppb, NAB is less than 300 ppt over most of the continental U.S., and less than 100 ppt in the eastern U.S. [see [Figure 2.4-18](#) of the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#))]. The distribution of background concentrations in the 2008 ISA was shown to reflect the distribution of soil NO emissions and lightning, with some local increases due to biomass burning, mainly in the western U.S. In the northeastern U.S., where present-day NO<sub>2</sub> concentrations are highest, NAB contributes <1% to the total.

The only updates to the results given in the 2008 ISA ([U.S. EPA, 2008c](#)) are the global-scale model calculations of [Lin et al. \(2012\)](#). In addition to U.S. and other North American sources, various NO<sub>y</sub> species from sources outside North America have long enough residence times in the atmosphere enabling them to be transported to the U.S. ([Lin et al., 2012](#)). As noted in the 2013 ISA for Ozone ([U.S. EPA, 2013e](#)), spring is the dominant season for effects of intercontinental transport of pollution to be detected in the U.S. [Lin et al. \(2012\)](#) calculated that transport of NO<sub>x</sub> from other continents contributes less than 10 ppt to the regional background in the western U.S., but concentrations of PAN could range from 50 to 80 ppt.

The annual median NO<sub>2</sub> concentration of ~8 ppb reported by the SLAMS monitoring network is well below the level of the current annual NAAQS (53 ppb) and the hourly NAAQS (100 ppb). Background concentrations of NO<sub>2</sub> are much lower than average ambient concentrations and are typically less than 0.1 ppb over most of the U.S., with the highest values found in agricultural areas. All of these values indicate that background concentrations of NO<sub>2</sub> are well beneath the level of the current NO<sub>2</sub> NAAQS.

---

## 2.6 Conclusions

A large number of oxidized nitrogen species occur in the atmosphere. They are emitted to the atmosphere mainly as NO, which interconverts with NO<sub>2</sub>. Thus, NO and NO<sub>2</sub> are often combined into their own group and referred to as NO<sub>x</sub>. NO<sub>x</sub> plays an important role in the formation of atmospheric O<sub>3</sub> and PM. The conversion of NO<sub>x</sub> into other oxides of nitrogen, such as PAN, HNO<sub>3</sub>, or particulate nitrate typically takes place on much longer time scales than does interconversion between NO and NO<sub>2</sub>. As a result, near sources, such as in heavily populated areas or busy roads with heavy traffic, oxides of nitrogen are mainly present as NO<sub>x</sub>. However, in remote areas downwind of major sources, more oxidized species account for a greater fraction of oxides of nitrogen than in populated areas.

NO<sub>x</sub> emissions in the U.S. have been roughly cut in half since 1990. In most of the largest urban areas in the U.S., motor vehicle traffic accounts for 40–67% of emissions and Off-Highway diesel and gasoline engines contribute an additional 20–30%. Mobile sources, electric power generation, other stationary fuel combustion, industrial and agricultural process, and fires are all important NO<sub>x</sub> sources on a national scale, with Highway Vehicles, Off-Highway Vehicles and Engines, and stationary fuel combustion especially important in urban areas. Urban stationary fuel combustion emissions account for a greater fraction of NO<sub>x</sub> emissions in colder climates. In some cities, specific industrial sources like oil and gas production, petroleum refining, or cement manufacturing account for a greater fraction of NO<sub>x</sub> emissions locally than they do nationally. However, traffic emissions are generally responsible for the greatest share of NO<sub>x</sub> in the U.S., especially in populated areas.

NO and NO<sub>2</sub> are most commonly measured by a Federal Reference Method based on chemiluminescence of NO induced by its reaction with O<sub>3</sub>. NO<sub>2</sub> is measured by first reducing it to NO, and then measuring the chemiluminescence of NO. Recent advancements in NO<sub>2</sub> measurements include improved methods of conversion of NO<sub>2</sub> to NO, development of optical methods to measure NO<sub>2</sub> directly, and development of satellite measurement methods. NO<sub>2</sub> is measured at hundreds of monitors in several national monitoring networks. The new near-road monitoring network was initiated in recognition that millions of people live within a few hundred meters of a major roadway, and that concentrations of NO<sub>2</sub> typically decrease with increasing distance from a major road.

If annual average NO<sub>2</sub> concentrations for individual monitoring sites are averaged over all monitoring sites in the U.S., the overall average is about 15 ppb. Similarly, the average daily 1-hour maximum NO<sub>2</sub> concentration over all U.S. monitoring sites is about

30 ppb. Average NO<sub>2</sub> concentrations are usually somewhat higher in winter than in summer. Concentrations are highest in populated urban areas where sources are dominated by vehicle emissions. Near roads with heavy traffic annual average concentrations exceeded 20 ppb and 98th percentile 1-hour daily maximum concentrations exceeded 60 ppb at several sites in 2014. Within urban areas, COD's typically range from near 0.1 to as high as 0.6, but with a large fraction below 0.2, indicating that there can be a high degree of spatial variability in some locations, but that concentrations can be fairly uniform in others. Concentrations within urban areas are usually highest near major roadways and major stationary sources. Near roadways, there is often a NO<sub>2</sub> concentration gradient, which is strongest in the summer and during daylight hours. NO<sub>2</sub> concentrations are typically up to 20 ppb higher within 20 m of a major road than at a distance a few hundred meters from the road, and the spatial extent of elevated concentration typically ranges from 200 to 500 m. Preliminary results from the U.S. EPA's new near-road monitoring network indicate that 98th percentile 1-hour daily maximum NO<sub>2</sub> concentrations at all near-road monitors were usually below 60 ppb, and always below the 1-hour daily maximum NAAQS of 100 ppb at all sites. However, annual average NO<sub>2</sub> concentrations for 2014 were usually higher at near road monitoring sites than in other locations in the same city.

Much of the most recent research on atmospheric NO<sub>2</sub> and NO<sub>x</sub> has focused on their role as a traffic pollutants and their spatial variability, especially in proximity to major roads. Because traffic is the largest source of NO<sub>x</sub> in the U.S., especially in populated areas, this research is highly relevant to human exposure, and the results described in this chapter provide a useful context for characterization of NO<sub>2</sub> exposures and associated health effects.

---

# CHAPTER 3    EXPOSURE TO OXIDES OF NITROGEN

---

## 3.1    Introduction

Assessment of exposure to ambient oxides of nitrogen builds from the characterization of concentrations and atmospheric chemistry presented in [Chapter 2](#). The primary conclusions from [Chapter 2](#) were that NO<sub>2</sub> concentrations have declined over the past 20 years, but concentrations are still elevated near roads and in urban areas, with vehicular traffic and off-highway vehicles contributing the majority of NO<sub>2</sub> emissions. For this reason, NO<sub>2</sub> exposure assessment focuses predominantly on urban and near-road settings.

Total personal exposure to ambient oxides of nitrogen is given by the concentration of oxides of nitrogen emitted from ambient sources and encountered by an individual over a given time. Personal exposure to ambient oxides of nitrogen is influenced by a number of factors, including:

- time-activity in different microenvironments (e.g., vehicle, residence, workplace, outdoor);
- climate (e.g., weather, season);
- characteristics of indoor microenvironments (e.g., window openings, draftiness, air conditioning); and
- microenvironmental emission sources (e.g., roadways, construction equipment, indoor gas stoves) and concentrations.

Surrogates for personal exposure to ambient oxides of nitrogen include ambient NO<sub>2</sub> concentrations measured at a central site monitor or modeled using spatial techniques such as land use regression (LUR), Gaussian dispersion models, or chemical transport models (CTM). All exposure surrogates are subject to measurement errors related to spatial and temporal variability of the ambient concentration field, quality of additional input data, representativeness of predictor variables, and accuracy of the monitoring or modeling methodology. The following sections describe methodological considerations for use of exposure data, characterization of NO<sub>2</sub> exposures, and exposure assessment and epidemiologic inference. This chapter focuses on the ambient component of personal exposure to NO<sub>2</sub>, because the NAAQS regulates ambient oxides of nitrogen, for which NO<sub>2</sub> is the indicator. However, studies using total personal NO<sub>2</sub> measurements and indoor NO<sub>2</sub> concentrations to represent exposure can also inform the understanding of exposure and related health effects and so are included as supporting evidence where appropriate. This chapter focuses on studies of exposure among the general population.

Exposure of at-risk groups, based for example on socioeconomic status, race, and proximity to roadways, is addressed in [Chapter 7](#); occupational exposures to ambient NO<sub>2</sub> are discussed in [Chapter 7](#) within the subsections for socioeconomic status and proximity to roadways. The information provided in this chapter will be used to help interpret the health effects studies of NO<sub>2</sub> exposure presented in [Chapter 5](#), [Chapter 6](#), and [Chapter 7](#).

---

## 3.2 Methodological Considerations for Use of Exposure Data

The following sections outline various facets of NO<sub>2</sub> measurement and estimation, including FRMs (i.e., central site monitors) and personal NO<sub>2</sub> exposure sampling techniques and NO<sub>2</sub> exposure modeling. The section ends with a discussion of the application of measurement and modeling techniques in epidemiologic studies of different designs.

---

### 3.2.1 Measurement

#### 3.2.1.1 Central Site and Near-Road Monitoring

Monitoring of NO<sub>2</sub> concentrations by chemiluminescent sampling is described in detail in [Section 2.4.1](#) along with limitations of the monitoring methodology. In summary, NO<sub>2</sub> concentrations are calculated by FRM as the difference between NO concentration measured in the air stream that has passed over a heated MoO<sub>x</sub> substrate (measuring total oxides of nitrogen) and NO concentration in the air stream that was diverted away from the substrate. FRMs are subject to positive bias because oxidized nitrogen compounds other than NO<sub>2</sub> are often detected by the MoO<sub>x</sub> substrate. A FEM is also available to measure NO<sub>2</sub> concentration directly using a photolytic converter to reduce NO<sub>2</sub> to NO. Evaluation of the chemiluminescent method is provided in [Section 2.4.1](#) along with a description of the measuring technique. Monitors set up by state agencies as part of the SLAMS network that report to the air quality system (AQS) are typically centrally sited, although the same monitors are used in select cases for near-road monitoring. See [Section 2.4.5](#) for more details.

In addition to judging compliance with the NAAQS, NO<sub>2</sub> concentrations measured by centrally sited or near-road FRMs and FEMs are frequently used by epidemiologic researchers as surrogates for exposure in studies of the health effects of exposure to oxides of nitrogen, as described further in [Section 3.4](#). Central site monitoring data can be

used in epidemiologic studies of short-term exposure to NO<sub>2</sub> when focused on the time series of exposure or in epidemiologic studies of long-term exposure when comparing average NO<sub>2</sub> concentrations from different geographic areas. [Section 3.4.3](#) explores the factors causing errors associated with siting central site or near-road monitors at a single location, and [Section 3.4.5](#) considers the influence of those errors on health effect estimates. Briefly, with respect to time-series exposure estimation for epidemiologic studies of short-term exposure, correlation decreases as distance increases between two monitors. For epidemiologic studies of long-term exposure to NO<sub>2</sub>, difference between the measured concentration and the true exposure would result in exposure error. The limited number of samplers in the network could potentially increase exposure error further.

---

### 3.2.1.2 Personal and Area Sampling

Personal sampling for NO<sub>2</sub> exposure is most commonly used in epidemiologic panel studies. Personal sampling for NO<sub>2</sub> was described in detail in Annex 3.3 to the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008a](#)) and is briefly summarized here. Active sampling systems typically involve air pumped past a chemiluminescent device; they enable measurements of NO<sub>2</sub> over short time periods to produce near real-time data. Given the weight of most active sampling systems, they are not used extensively for personal sampling. Passive samplers based on Fick's first law of diffusion are more commonly deployed for personal or area NO<sub>2</sub> sampling in a badge, tube, or radial manifold. These are typically deployed over periods ranging from a few days to several weeks. Passive sampling results are integrated over the time period during which the sorbent material is exposed, which is selected by the user and usually spans days to weeks. The 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) reported that, depending on the sorbent material, personal NO<sub>2</sub> samplers may be subject to biases related to interferences from HONO, PAN, HNO<sub>3</sub> ([Gair et al., 1991](#)), and high relative humidity (RH) ([Centro di Ricerche Ambientali, 2006](#)). These biases also depend on ambient temperature and atmospheric levels of the copollutants.

Recent work has been performed to evaluate passive sampling device performance. [Sather et al. \(2007\)](#) compared Ogawa passive samplers with a collocated NO<sub>2</sub> FRM monitor over a 4-week field study in El Paso, TX and observed good agreement between the techniques, with an average absolute difference of 1.2 ppb and  $R^2 = 0.95$ . For measurements in Umeå, Sweden, [Hagenbjork-Gustafsson et al. \(2009\)](#) observed that, when using the manufacturer's recommended uptake rates to calculate concentration, passive NO<sub>2</sub> measurements were negatively biased by 9.1%, and NO<sub>x</sub> concentration measurements were positively biased by 15% compared with an FRM. When uptake rates

were derived in the field based on the chemiluminescent FRM, NO<sub>2</sub> measurements were positively biased by 2%, and NO<sub>x</sub> concentration measurements were unbiased compared with the FRM. These results suggest that deviation from temperature conditions under which the samplers were laboratory tested may lead to biased results. [Sánchez Jiménez et al. \(2011\)](#) used Palmes-type passive diffusion tubes to measure both NO<sub>2</sub> and NO<sub>x</sub> concentrations and investigated specific sources of biases in their measurements. They found that, within the passive diffusion tubes, NO and O<sub>3</sub> were reacting to form NO<sub>2</sub>, causing NO measurements to be negatively biased while NO<sub>2</sub> measurements were positively biased. Wind was also a source of positive bias in the NO<sub>2</sub> and NO<sub>x</sub> concentration measurements because increased airflow effectively reduced the diffusion lengths of the gas collection tubes. In laboratory and field evaluation of NO<sub>2</sub> passive diffusion tubes, [Buzica et al. \(2008\)](#) observed negligible difference between the diffusion tubes and FRM measurements; however, uncertainty increased with decreasing concentration. When comparing biases among samplers, note that the FRM is subject to positive biases related to sensitivity to PAN, RONO<sub>2</sub>, and HNO<sub>3</sub> ([Sections 2.4.1](#) and [3.2.1.1](#)).

Triethanolamine (TEA) is often employed as a sorbent material in denuders used for capturing NO<sub>2</sub> during active sampling and in passive sampling because it can be applied in an even coating. However, sampling efficiency is sensitive to sampler flow rate ([Vichi and De Santis, 2012](#)), relative humidity ([Poddubny and Yushketova, 2013](#); [Šerevičienė and Paliulis, 2012](#); [Vardoulakis et al., 2009](#)), averaging time ([Vardoulakis et al., 2009](#)), and ambient temperature ([Poddubny and Yushketova, 2013](#)). [Heal \(2008\)](#) found that NO<sub>2</sub> bias was sensitive to the method of application of the TEA to the substrate. [Sekine et al. \(2008\)](#) and [Nishikawa et al. \(2009\)](#) experimented with size and number of filters, respectively, in a passive sampler and found minimal effect on NO<sub>2</sub> or NO<sub>x</sub> concentration. [Ozden and Dogeroglu \(2008\)](#) observed that TEA-complexed NO<sub>2</sub> was sensitive to photodegradation if not stored in a dark glass tube, resulting in underprediction of NO<sub>2</sub> exposure.

Recent attention has been given to using passive or miniature active monitors for saturation sampling, i.e., siting monitors over a dense grid. This is typically done in urban areas. For example, [Ross et al. \(2013\)](#) sited roughly 25 passive NO<sub>2</sub> monitors during six two-week periods at a total of 150 locations across the five boroughs of New York City, NY to create a dense concentration map for exposure estimates and to provide training and validation data for LUR. Saturation sampling was also conducted in nine MESA-Air communities with up to 105 Ogawa passive badges deployed to measure NO<sub>2</sub> during three two-week sampling periods; noise was also measured at two monitoring stations in Chicago, IL and one in Riverside, CA ([Section 3.4.4.4](#)). Similarly, [Shmool et al. \(2014\)](#) deployed Ogawa passive badges for NO<sub>2</sub> sampling, along with measuring PM<sub>2.5</sub>, BC,

relative humidity, and barometric pressure across metropolitan Pittsburgh, PA. The monitoring boxes were sited to capture air pollution gradients along the urban-to-suburban land use gradient and included areas influenced by industrial sources and highways. [Skouloudis and Kassomenos \(2014\)](#) deployed sensors for NO<sub>2</sub>, NO<sub>x</sub>, CO, O<sub>3</sub>, and benzene (C<sub>6</sub>H<sub>6</sub>) to correspond to the population distribution on the island of Malta. Active samplers were used in this scheme, with a global positioning system (GPS) and data transmission capabilities for near real-time analysis. [Skouloudis and Kassomenos \(2014\)](#) proposed that data from these dense area samplers could also be assimilated with satellite measurements to improve the accuracy of the exposure estimates.

---

### 3.2.2 Modeling

Computational models can be used in epidemiologic studies to estimate exposure when measurements are not available at locations and/or times needed to estimate spatial and temporal variability in NO<sub>2</sub> concentration. These methods can sometimes account for complex urban morphometry and meteorology, which can interact to cause turbulence that may affect pollutant residence times ([Fernando, 2010](#)) or incorporate localized sources that might not otherwise be detected by central site monitoring ([Goldman et al., 2012](#)). Such estimates can then be used as inputs to exposure models described in [Section 3.4](#). These modeling approaches produce data at times and/or locations where exposures are uncharacterized, but each method carries its own uncertainty ([Fuentes, 2009](#)). Detailed descriptions of computational models used for predicting spatially resolved concentration profiles for exposure assessment have been provided in Section AX 3.6 of the 2008 ISA for Oxides of Nitrogen Annex ([U.S. EPA, 2008a](#)) and Section 3.8 of the 2009 ISA for Particulate Matter ([U.S. EPA, 2009a](#)). Methods include LUR models, spatial interpolation through statistical techniques, CTM, and dispersion models.

---

#### 3.2.2.1 Statistical Modeling

##### Land Use Regression Models

LUR modeling has been applied extensively to estimate the spatial distribution of ambient NO<sub>2</sub> or NO concentration for neighborhood or urban-scale exposure assessment in epidemiologic studies of long-term exposure ([Clougherty et al., 2013](#); [Hatzopoulou et al., 2013](#); [Cesaroni et al., 2012](#); [Gonzales et al., 2012](#); [Mukerjee et al., 2012a](#); [Mukerjee et al., 2012b](#); [Oiamo et al., 2012](#); [Esplugues et al., 2011](#); [Fernández-Somoano et al., 2011](#);

[Hystad et al., 2011](#); [Oiamo et al., 2011](#); [Rose et al., 2011](#); [Smith et al., 2011](#); [Szpiro et al., 2011a](#); [Adamkiewicz et al., 2010](#); [Aguilera et al., 2009](#); [Cohen et al., 2009](#); [Hart et al., 2009](#); [Iniguez et al., 2009](#); [Karr et al., 2009](#); [Mukerjee et al., 2009](#); [Su et al., 2009b](#); [Aguilera et al., 2008](#); [Atari et al., 2008](#); [Cesaroni et al., 2008](#); [Rosenlund et al., 2008a](#); [Jerrett et al., 2007](#)). LUR fits a multiple linear regression model of concentration data as a function of land use data and then applies that model to locations without monitors to increase the spatial resolution of the concentration field ([Marshall et al., 2008](#)). LUR models for NO<sub>2</sub> are typically calibrated using data from passive sampler measurements. Given that most passive measurement methods are not designed for short-term sampling, LUR models are typically based on several days, weeks, or years of data and hence do not account for short-term temporal variability well. Hence, LUR is commonly used to estimate air pollution exposure in epidemiologic studies of long-term NO<sub>2</sub> exposure ([Chapter 6](#)).

Finer spatial resolution of calibration points can improve goodness of fit and representativeness of the model. Using 155 monitoring sites throughout New York City, NY, [Clougherty et al. \(2013\)](#) ran an LUR with resolutions down to 50 m with in-sample sequential  $R^2 = 0.67^1$ . [Parenteau and Sawada \(2012\)](#) examined LUR model performance when basing the model on successively finer spatial resolution from 2 km down to 50 m, with the geographic borders of the finely resolved regions tied to population groupings based on population density mapping. The two finer resolution approaches yielded better agreement with measured NO<sub>2</sub> data (in-sample  $R^2 = 0.80-0.81$ ) than the less spatially resolved approach (in-sample  $R^2 = 0.70$ ). Root mean squared error (RMSE) was computed for a cross-validation data set, and RMSE = 1.05 ppb. [Basagaña et al. \(2012\)](#) evaluated LUR models for 24 to 120 NO<sub>2</sub> measurement sites in Girona, Spain. [Basagaña et al. \(2012\)](#) observed that leave one out cross-validation (LOOCV) resulted in a higher  $R^2$  compared with out-of-sample  $R^2$  computed using distinct validation sites. At the same time, LOOCV  $R^2$  declined with increasing number of training sites, while out-of-sample validation  $R^2$  increased within increasing number of training sites. [Johnson et al. \(2010b\)](#) evaluated LUR performance in New Haven, CT when the LUR model was fit with NO<sub>2</sub> data from 25 to 285 measurement sites and found that the LOOCV sites produced  $R^2$  much smaller than in-sample  $R^2$ . The LOOCV  $R^2$  increased with increasing number of training sites. [Wang et al. \(2012\)](#) also evaluated LUR performance when fit with 24 to 120 NO<sub>2</sub> monitors distributed across the Netherlands. They compared LOOCV  $R^2$  with external validation  $R^2$ . Qualitatively, their results were the same as those of [Basagaña et al. \(2012\)](#).

---

<sup>1</sup>“Out-of-sample” refers to validation of the model with a data set not used to fit the model; in this case, the neighborhood-level simulations were cross validated against the whole-city measurements and vice versa. “In-sample” refers to a comparison between the model and measurements used to fit the model.

Recent studies have applied an LUR model among multiple cities. Recently, LUR has been implemented to examine local-scale concentration estimates across the contiguous U.S. ([Beckerman et al., 2013b](#); [Novotny et al., 2011](#); [Hart et al., 2009](#)) and Canada ([Hystad et al., 2011](#)). [Allen et al. \(2011\)](#) developed separate LUR models for two Canadian cities (Winnipeg, Manitoba and Edmonton, Alberta) with 50 calibration points each and then applied the models to the other city to compare performance. As anticipated, locally generated model performance ( $\text{NO}_2$ : in-sample  $R^2 = 0.81\text{--}0.84$ ; out-of-sample  $R^2 = 0.75\text{--}0.77$ ) was superior to performance of the model applied to the other city ( $\text{NO}_2$ :  $R^2 = 0.37\text{--}0.52$ ) and to bivariate local models using only road proximity (in-sample  $R^2 \leq 0.16$ ).  $\text{NO}_2$  models consistently performed better than NO models. [Wang et al. \(2014\)](#) developed a LUR model for  $\text{NO}_2$  based on data from 23 European study areas (containing 20–40 sites within each study area) with  $\text{NO}_2$ ,  $\text{PM}_{2.5}$ , land use, and traffic data. Given the continental design of the study, a regional background concentration variable was also imposed on the model. The in-sample LUR model fit was  $R^2 = 0.59$  for all of the urban areas combined. After fitting the LUR model, [Wang et al. \(2014\)](#) tested the LUR model's ability to predict concentrations for different configurations of cities by LOOCV. They found comparable results (LOOCV  $R^2 = 0.50$ ). Generally, both in-sample and out-of-sample  $R^2$  for multiple city studies were either comparable or lower than the respective  $R^2$  for single city studies. This would be expected given the smoothing effect of fitting a model over a large geographic area.

Selection of predictor variables, such as meteorology, traffic, land use, and population density, influences the ability of the LUR model to predict concentrations of oxides of nitrogen and depends on the specific city for which the model is fit. [Su et al. \(2008a\)](#) and [Ainslie et al. \(2008\)](#) developed the Source Area-LUR (SA-LUR) to incorporate the effects of meteorology (and hence to incorporate the effects of temporal variability) on the model results. The SA-LUR integrates data for wind speed, wind direction, and cloud cover variables in estimates for NO and  $\text{NO}_2$ . It was found to perform better when seasonal variability in concentrations was high. [Su et al. \(2008b\)](#) included a street canyon aspect ratio as a LUR predictor variable to account for retention of pollutants in street canyons. They observed that, upon adding the aspect ratio to the LUR model, in-sample  $R^2$  increased from 0.56 to 0.67 for  $\text{NO}_2$ . Similarly, when [Clougherty et al. \(2013\)](#) added “built space within 1 km” to their LUR model of  $\text{NO}_2$ , in-sample  $R^2$  increased by 0.41. [Franklin et al. \(2012\)](#) explored bivariate correlations between  $\text{NO}_2$  concentrations and several predictors reflecting traffic, population, elevation, and land use in twelve southern California communities. Pearson correlations of  $\text{NO}_2$  concentration with distance to road were  $r = -0.42$  and  $-0.35$  for freeway and nonfreeway roads, respectively. Their model produced a  $-8.2\%$  change in concentration per IQR increase in distance in the LUR model. Correlations with traffic volume within a 300-m buffer were  $r = 0.41$ , and traffic volume within a 300-m buffer produced a  $2.4\%$  change in the LUR prediction per IQR.

Correlation with neighborhood elevation was  $r = -0.50$ , and neighborhood elevation produced a  $-6.7\%$  change in LUR-modeled concentration per IQR increase in elevation. [Su et al. \(2009a\)](#) developed a method to optimize the SA-LUR variable selection process in which correlations between several land use variables and  $\text{NO}_2$  concentrations were computed across a 3-km buffer of the  $\text{NO}_2$  measurement (1.5-km buffer for traffic-related variables), and the data for correlation versus distance were fit to a curve describing that relationship. The variable with highest correlation at the optimum buffer distance was added to the model if its addition produced a statistically significant change ( $p < 0.1$ ) in the model. [Su et al. \(2009a\)](#) found the important variables to be distance from monitor, 24-hour traffic levels, expressway casement, open land use, railway, major road, land grade, population density, and distance to coast. [Beckerman et al. \(2013a\)](#) adopted an addition\substitution\deletion machine learning approach to variable selection. This method employs a  $\nu$ -fold cross-correlation and computes the least-square error for each model having different numbers and combinations of predictor variables. The algorithm selects the model that optimally minimizes both the least-square error and the size of the model. The minimum out-of-sample  $R^2 = 0.83$ , and the minimum least-square error was 0.118. This analysis of cross-validation statistics showed the point where inclusion of more variables produced relatively small gains in cross-validation so that model parsimony could be maintained.

Several studies of LUR have considered seasonality in the model. [Crouse et al. \(2009a\)](#) and [Dons et al. \(2014\)](#) evaluated LUR across seasons and found that spatial variability in the  $\text{NO}_2$  concentration profile did not change substantially with season. Therefore, the authors concluded that an annual average would be acceptable for LUR simulations. However, [Arain et al. \(2009\)](#) observed seasonal changes in the spatial distribution of  $\text{NO}_2$  concentration in a study of  $\text{NO}_2$  concentrations over the greater Toronto-Hamilton airshed. Seasonal deviations in observed spatial  $\text{NO}_2$  concentration patterns would imply that an LUR model fit would also need to account for seasonality either through a variable or through stratification.

LUR models applied several years after model development have demonstrated predictive ability in a few studies. [Eeftens et al. \(2011\)](#) compared LUR obtained from  $\text{NO}_2$  concentration measurements at 35 locations in the Netherlands over the years 1999–2000 with LUR developed from  $\text{NO}_2$  concentration measurements at 144 locations in the Netherlands during 2007. Both the  $\text{NO}_2$  concentration measurements and the LUR models agreed well for the two time periods studied; the comparison between models from the different time periods produced  $\beta = 0.9998$  and  $R^2 = 0.89$ . [Wang et al. \(2013b\)](#) tested stability of an LUR model for Vancouver, Canada between 2003 (based on 116 sites) and 2010 (based on 116 sites, with 73 from the 2003 study). [Wang et al. \(2013b\)](#) evaluated the model by testing how much variability in the measurements was

predicted by models from the other year. Linear regression for comparison of the 2003 model with 2010 measurements produced  $R^2 = 0.52\text{--}0.61$  for  $\text{NO}_2$ , while comparison of the 2010 model with 2003 measurements produced  $R^2 = 0.44\text{--}0.49$  for  $\text{NO}_2$ . [Wang et al. \(2013b\)](#) attributed the diminished performance for the 2003 model using 2010 data (compared with using the 2010 model for 2003 data) to reductions in  $\text{NO}$  and  $\text{NO}_2$  concentrations over the 7-year time period. Visual inspection of the  $\text{NO}$  and  $\text{NO}_2$  concentration maps from the [Wang et al. \(2013b\)](#) study suggests that changes in spatial correlation over time may have contributed to reduced model performance in comparison with the [Eeftens et al. \(2011\)](#) study.

LUR evaluation depends on the validation algorithm, model conditions, and basis for validation (i.e., to what the modeling results are compared when computing out-of-sample  $R^2$ ). In a recent study of LUR application in 20 European study areas, [Wang et al. \(2013a\)](#) found that LOOCV produced higher  $R^2$  for  $\text{NO}_2$  concentration compared with hold-out evaluation (HEV) (LOOCV:  $R^2 = 0.83$ ; HEV:  $R^2 = 0.52$ ). LOOCV involves repeatedly withholding a fraction of the monitoring sites from the fitting process for performance evaluation and then computing an ensemble  $R^2$ , whereas HEV entails prediction with the LUR at locations not fit by the model. Therefore, HEV provides a more independent data set for validation. [Mercer et al. \(2011\)](#) compared 10-fold cross-validated LUR with universal kriging (UK), in which a surface of concentrations was built based on measured values for three seasons in Los Angeles, CA with roughly 150 measurement sites. UK performance was slightly better than LUR for all seasons, and model performance did not vary much among the seasons (UK: 10-fold cross-validation out-of-sample  $R^2 = 0.75, 0.72, \text{ and } 0.74$ ; LUR:  $R^2 = 0.74, 0.60, 0.67$ ). [Li et al. \(2012b\)](#) developed a new formulation for LUR using generalized additive models (GAM) and cokriging to boost the performance of LUR. They evaluated this approach for Los Angeles, CA. GAM allowed localized nonlinear effects to be incorporated among the prediction covariates, while cokriging was intended to improve spatial smoothing. The LUR using GAM and cokriging had the highest LOOCV ( $R^2 = 0.88\text{--}0.92$ ), compared with universal kriging ( $R^2 = 0.68\text{--}0.75$ ) and multiple linear LUR ( $R^2 = 0.42\text{--}0.64$ ).

LUR comparison with other models has produced variable results, in part because the comparison data do not always have the same spatial resolution or account for the same physical phenomena. [Beelen et al. \(2010\)](#) compared LUR with a dispersion model incorporating a near-road module for modeling  $\text{NO}_2$  concentrations in a Rotterdam, Netherlands neighborhood. The dispersion model agreed better with  $\text{NO}_2$  measurements (out-of-sample Pearson  $r = 0.77$ ) compared with the agreement between LUR and measurements (out-of-sample  $r = 0.47$ ) from 18 evaluation sites. [Dijkema et al. \(2011a\)](#) also compared LUR for the city of Amsterdam and a larger geographic portion of northwest Netherlands with a dispersion model and found better agreement of the

dispersion models with observations for both the citywide model (dispersion:  $R^2 = 0.58$ <sup>1</sup>; LUR: out-of-sample  $R^2 = 0.48$ ) and the large-area model (dispersion:  $R^2 = 0.74$ ; LUR: out-of-sample  $R^2 = 0.57$ ). [Marshall et al. \(2008\)](#) compared LUR with inverse distance-weighted (IDW) spatial interpolation of NO and NO<sub>2</sub> measurements, nearest NO and NO<sub>2</sub> measurements, and a Community Multiscale Air Quality (CMAQ) model run for Vancouver, Canada. The LUR location was matched to each CMAQ grid cell centroid and compared with the grid cell concentration. LUR and CMAQ produced similar average absolute difference in the concentration compared with measured central site concentrations for NO (LUR: 42%, CMAQ: 47%) and NO<sub>2</sub> (LUR: 17%, CMAQ: 17%), while nearest monitor and spatial interpolation methods produced less than 5% difference for both pollutants and methods. However, it is important to recognize that these methods were compared to a central site monitor, which cannot capture the spatial variability of the NO<sub>2</sub> concentration distribution. Specifically, IDW, central site monitoring of NO<sub>2</sub> concentration, and nearest monitor NO<sub>2</sub> concentration estimation approaches do not account well for localized sources unless the sources are close to the monitors. Therefore, to inform inference for epidemiological studies, the comparison of the modeled estimates to measured values should be at locations that are relevant to the intended epidemiologic study.

Recent studies have explored combination of LUR and other models. For example, [Wilton et al. \(2010\)](#) added a covariate for concentrations computed with the CALINE3 dispersion model in their LUR to estimate NO<sub>x</sub> and NO<sub>2</sub> concentrations in Los Angeles, CA and Seattle, WA. They observed modest improvements in model  $R^2$  (Los Angeles, NO<sub>2</sub>: LOOCV  $R^2 = 0.77$  vs.  $R^2 = 0.71$ – $0.73$ ; Seattle, NO<sub>2</sub>: LOOCV  $R^2 = 0.67$  vs.  $R^2 = 0.53$ – $0.63$ ) when CALINE3-computed concentration was included as one variable along with land use, roadway length, and traffic density variables. [Möller et al. \(2010a\)](#) also used dispersion modeling data in lieu of measurement data when fitting an LUR for Greater Manchester, U.K. and found reasonable agreement of LUR-predicted NO<sub>2</sub> concentrations with a separate monitoring data set where 25% of the data were set aside for cross-validation (out-of-sample  $R^2 = 0.62$ ). Note that the nature of the monitoring data (i.e., central site or other) was not explicitly stated in the [Möller et al. \(2010a\)](#) study. [Janssen et al. \(2012\)](#) proposed using LUR to improve performance of a CTM by downscaling the CTM to the LUR. Downscaling entails a redistribution of the CTM-modeled concentrations through a statistical model that conforms to measured concentrations at points in space where measurements are available using the LUR-derived regression parameters. [Janssen et al. \(2012\)](#) found that the spatial representativeness of the CTM for NO<sub>2</sub> improved by roughly 20% when incorporating

---

<sup>1</sup>“In-sample” and “out-of-sample” terminology is not used for dispersion, chemical transport, or scale models, because those models do not require input concentration data. All comparisons with monitoring data are therefore out-of-sample.

the LUR downscaler, based on a comparison of the CTM and downscaled CTM with central site monitor measurements. It is worth noting that any errors and uncertainties associated with a particular LUR run would transfer to the downscaled result if LUR were used as a basis for downscaling CTM results. [Beckerman et al. \(2013b\)](#) had improved results when combining LUR with a Bayesian maximum entropy model to capture PM<sub>2.5</sub> concentration across the contiguous U.S., with fivefold cross-validation producing  $R^2 = 0.79$ . It is not clear whether NO<sub>2</sub> would produce as good of a validation, because NO<sub>2</sub> is more spatially variable.

### **Spatiotemporal Modeling**

Spatiotemporal modeling uses advanced statistical techniques to model concentration variation over space and time. These models decompose the concentration at each study location into a trend and a residual component ([Sampson et al., 2011](#); [Szpiro et al., 2010](#)). The mean trend was modeled at each location in the study domain as a linear combination of time-series basis functions of spatial covariates and kriging, and the basis functions were selected using singular value decomposition. Examples of spatial covariates included distance to major road, population density, and land use categories. [Sampson et al. \(2011\)](#) showed good validation, with no outliers and RMSE = 0.88–2.42 ppb (depending on site) using LOOCV across the six MESA Air cities. In [Szpiro et al. \(2010\)](#), cross-validation produced an out-of-sample  $R^2 = 0.67$  with RMSE = 4.21 ppb. ([Li et al., 2013](#)) adopted this approach to model NO<sub>2</sub> and NO<sub>x</sub> for both time-series and long-term average exposures in southern California and found that out-of-sample  $R^2$  was high for both temporal treatments (NO<sub>2</sub>: time series:  $R^2 = 0.84$ , long-term average  $R^2 = 0.89$ ; NO<sub>x</sub>: time series  $R^2 = 0.81$ , long-term average  $R^2 = 0.77$ ). Across the six MESA Air cities, [Keller et al. \(2015\)](#) observed a 10-fold LOOCV  $R^2 = 0.85$ – $0.96$  for NO<sub>2</sub> and  $R^2 = 0.00$ – $0.98$  for NO<sub>x</sub>. [Lindström et al. \(2013\)](#) adapted this spatiotemporal model by replacing the land use variables with dispersion model output. [Lindström et al. \(2013\)](#) compared their results to the spatiotemporal model employing land use covariates and found no appreciable improvement ( $R^2$  within  $\pm 0.04$ ) in model performance for a variety of averaging times (daily “snap shot,” 2-week, 10-year).

**Chemical Transport Models**

CTMs can be used to develop estimates of NO, NO<sub>2</sub>, or NO<sub>x</sub> concentrations. CTMs, such as CMAQ, are deterministic models of chemical transport that account for physical processes including advection, dispersion, diffusion, gas-phase reaction, and mixing while following the constraint of mass conservation ([Byun and Schere, 2006](#)). Temporal resolution of CTMs can be as fine as 1 hour, although larger temporal aggregation is often used to maintain reasonable data file size. These models provide regional concentration estimates and are typically run with surface grid resolutions of 4, 12, or 36 km. No studies of CMAQ grid size convergence have been found, and [U.S. EPA \(1999\)](#) points out that testing for convergence properties is prohibitive due to the large computational demands of the CMAQ program. [Shao et al. \(2007\)](#) compared simulation results among 12-km, 4-km, and 1.33-km resolutions and found that discontinuities at the grid cell boundaries increased with increasing grid size.

CTMs can be applied in epidemiologic studies of either short- or long-term exposure to NO<sub>2</sub> or NO<sub>x</sub> but are more commonly used in long-term exposure studies. These models are used to compute interactions among atmospheric pollutants and their transformation products, the production of secondary aerosols, the evolution of particle size distribution, and transport and deposition of pollutants. CTMs are driven by emissions inventories for primary species such as NO<sub>2</sub>, SO<sub>2</sub>, NH<sub>3</sub>, VOCs, and primary PM, and by meteorological fields produced by other numerical prediction models. Given observed biases in the CTMs [e.g., [Shi and Zhang \(2008\)](#) for NO<sub>2</sub>, and larger biases in organic carbon, PM<sub>2.5</sub>, nitrate, and other compounds ([Foley et al., 2010](#); [Eder and Yu, 2005](#))], much attention has been given recently to bias correction of these models for application in exposure assessment, as detailed below in the Subgrid Scale and Data Fusion Models section.

**Dispersion Models**

Dispersion models, or Gaussian plume models, estimate the transport and dispersion of ambient air pollutants emanating from a point or line source by solving for an equation that estimates the spread of the pollutant to follow a Gaussian curve that is a function of distance from the source. Given that dispersion models typically capture average concentrations, they are most commonly used in epidemiologic studies of long-term exposure. Several studies of health effects related to NO<sub>x</sub> exposure employ dispersion models to estimate NO<sub>x</sub> concentrations [e.g., [Gruzieva et al. \(2013\)](#), [McConnell et al. \(2010a\)](#), and [Oftedal et al. \(2009a\)](#)] because NO<sub>2</sub> has high local spatial variability ([Section 2.5.3](#)). The grid spacing in regional CTMs, usually between 1 and 12 km<sup>2</sup>, is too

coarse to resolve spatial variations on the neighborhood scale. More finely resolved spatial scales that better represent human exposure scales are provided by local-scale dispersion models. Several dispersion models are available to simulate concentration fields near roads, and each has its own set of strengths and weaknesses.

Several line-source Gaussian dispersion models are available to simulate the dispersion of emissions from a roadway. The CALINE family of models does not include NO<sub>x</sub> transformation chemistry. [Benson \(1992\)](#) validated the CALINE3 and CALINE4 model versions using data from field studies at U.S. Highway 99 in Sacramento, CA and a General Motors test track in Michigan. [Benson \(1992\)](#) found that more than 85% of model predictions fell within a factor of two of measured observations for sulfur hexafluoride (SF<sub>6</sub>) (an inert tracer gas). Among those that fell outside the factor of two envelope, 85% were positively biased and mostly occurred when wind speeds were below 1 m/s. Additionally, [Benson \(1992\)](#) tested the NO<sub>2</sub> module of CALINE4 under a limited set of conditions and recommended that CALINE4 not be used to predict NO<sub>2</sub> dispersion under parallel wind conditions without ample data to calibrate the model predictions.

The University of California, Davis (UCD) 2001 model was designed to improve upon the design of CALINE by using an array of point sources to represent a three-dimensional highway source of emissions and by using power law functions for wind speed and vertical eddy diffusivity ([Held et al., 2003](#)). UCD 2001 exhibited improved performance for parallel, low-speed winds (<0.5 m/s), with 87% and 83% reduction in error compared with CALINE3 and CALINE4, respectively, for the General Motors SF<sub>6</sub> evaluation data set. [Snyder et al. \(2013\)](#) recently released a Research Line-source (RLINE) dispersion model that incorporates improved formulations of horizontal and vertical dispersion and found that the predictions were within a factor of two of the observations for neutral, convective, and weakly stable atmospheric conditions, but negative bias was observed for stable conditions based on a line source SF<sub>6</sub> experiment in Idaho Falls, ID. During comparison with the U.S. 99 data set, 81% of data were within a factor of two for downwind measurements, but only 19% for upwind measurements when winds were within 30° of perpendicular to the road. Seventy-five percent of downwind predictions were within a factor of two of observations when winds were less than 1.5 m/s, and 88% were within a factor of two for wind speeds greater than 1.5 m/s. Only 51% were within a factor of two when winds were within 30° of parallel to the road. Additionally, an optimization model fitting CALINE3 line-dispersion calculations for concentration to observations of NO<sub>2</sub> was developed and applied in the greater Tel Aviv, Israel area ([Yuval et al., 2013](#)). Cross-validation was reported to have negligible bias in the model predictions with 36% error; the authors did not clearly distinguish bias and error in this manuscript.

The American Meteorological Society/Environmental Protection Agency Regulatory Model (AERMOD; [http://www.epa.gov/scram001/dispersion\\_prefrec.htm](http://www.epa.gov/scram001/dispersion_prefrec.htm)) is a steady-state point source plume model formulated as a replacement to the Industrial Source Complex (ISC3) dispersion model (Cimorelli et al., 2005). In the stable boundary layer, the model assumes the concentration distribution to be Gaussian in both the vertical and horizontal dimensions. In the convective boundary layer, the horizontal distribution is also assumed to be Gaussian, but the vertical distribution is described with a bi-Gaussian probability density function. AERMOD has provisions that can be applied to flat and complex terrain and multiple source types (including point, area, and volume sources) in both urban and rural areas. It incorporates air dispersion based on the structure of turbulence in the planetary boundary layer and scaling concepts and is meant to treat surface and elevated sources, in both simple and complex terrain in rural and urban areas. The dispersion of emissions from line sources like highways in AERMOD is handled as a source with dimensions set using an area or volume source algorithm in the model; however, actual emissions usually are not in a steady state.

Most simple dispersion models, including AERMOD, are designed without explicit chemical mechanisms but have nondefault options to estimate conversion of NO to NO<sub>2</sub> based on a NO<sub>x</sub>/O<sub>3</sub> titration model. Hendrick et al. (2013) evaluated two modules used with AERMOD to compute NO<sub>2</sub> concentrations: the plume volume molar ratio method (PVMRM) and the ozone limiting method (OLM). Both methods assume ratios of NO<sub>2</sub>-to-NO<sub>x</sub> that are based on the concentration of co-occurring O<sub>3</sub>. Hendrick et al. (2013) validated the models against more than 12 months of hourly observations taken near a small power plant in Wainwright, AK, and they observed that the PVMRM overpredicted NO<sub>2</sub> at low concentrations and underpredicted at high concentrations, although the average bias was small; the OLM also overpredicted NO<sub>2</sub> concentrations at high observed NO<sub>2</sub>.

AERMOD results have been compared with measurements and other models to evaluate relative performance. Gibson et al. (2013) found poor agreement with respect to magnitude of NO<sub>x</sub> concentrations and correlations ( $R^2 = 0.001-0.003$ ) at hourly, monthly, and annual timescales when comparing AERMOD results with observations in Halifax, Canada where several industrial facilities emit NO<sub>x</sub>. Cohan et al. (2011) compared AERMOD output with 24-hour central site monitoring observations averaged over August 2005 from San Jose, CA, where there are combined emissions from a port, rail yard, and roadways. They observed that the AERMOD model consistently underpredicted the observations; negative bias was more pronounced for simulations from January compared with August. Misra et al. (2013) compared AERMOD with the Quick Urban and Industrial Complex (QUIC) model. QUIC approximates average airflow around buildings in urban environments then models pollution parcels based on

Lagrangian particle dispersion. In this case, AERMOD underpredicted NO<sub>x</sub> concentrations in an urban street canyon, while most QUIC predictions were within a factor of two of the observed NO<sub>x</sub> concentrations.

There are also nonsteady state models for different types of sources. For example, CALPUFF (<http://www.src.com/calpuff/calpuff1.htm>), which is the U.S. Environmental Protection Agency's (EPA's) recommended dispersion model for transport in ranges >50 km, is a nonsteady state puff dispersion model that simulates the effects of time- and space-varying meteorological conditions on pollution transport, transformation, and removal and has provisions for calculating dispersion from surface sources ([U.S. EPA, 1995b](#)). However, CALPUFF was not designed to treat the dispersion of emissions from roads, and like AERMOD, it has some limited chemistry options to estimate production of secondary pollutants. The distinction between a steady state and time-varying model may not be important for studying health effects for which long-exposure timescales are relevant; however, when short-exposure timescales are of interest (e.g., 1-hour), it would be more important to approximate the short-term variability in concentrations. CALPUFF was validated against SF<sub>6</sub> data at two military test sites in Nevada ([Chang et al., 2003](#)), where it was shown that 52% of CALPUFF predictions were within a factor of two of SF<sub>6</sub> observations for one site and 29% of predictions were within a factor two of the observations at a second site. The second test site had surrounding mountains which increased vertical dispersion; CALPUFF did not account well for vertical dispersion. [Cui et al. \(2011\)](#) evaluated CALPUFF by releasing SF<sub>6</sub> from a weather tower at the bank of the Gan Jiang River in China, an area that has a combination of open field, agricultural land, and forest. CALPUFF was found to be negatively biased with only 25–27% of data within a factor of two of the observations. The authors concluded that CALPUFF did not predict hourly dispersion well. Similarly, [Ghannam and El-Fadel \(2013\)](#) compared NO<sub>2</sub> concentrations calculated using CALPUFF with NO<sub>2</sub> measurements and observed that the model severely underpredicted the measurements, sometimes by up to three orders of magnitude. It was stated to have captured the temporal variability, although correlations were not reported. [Ghannam and El-Fadel \(2013\)](#) attributed this underprediction to underestimation of the emissions input to the model. The results of [Cui et al. \(2011\)](#) and [Ghannam and El-Fadel \(2013\)](#), which indicated negative bias, are consistent with those of [Chang et al. \(2003\)](#) for the sites where vertical dispersion may have played a larger role in the airflow characteristics.

An example of where AERMOD has been used to better understand the relationship between ambient concentrations and health risks is found in [Maantay et al. \(2009\)](#). These researchers coupled AERMOD with geographic information system proximity buffers around a stationary point source in Bronx, NY. They observed that buffers based on the predicted plume shape for concentrations of NO<sub>x</sub>, PM<sub>10</sub>, PM<sub>2.5</sub>, CO, and SO<sub>2</sub>

corresponded better with asthma hospitalization rates compared with circular buffers centered around the emissions source.

### **Subgrid Scale and Data Fusion Models**

Substantial uncertainties at the subgrid scale remain when using CTM to model concentrations at resolutions of 4–36 km ([U.S. EPA, 2008c](#)). In densely populated regions of the country, monitor density may be finer than CTM surface grid resolution. Moreover, CMAQ and other CTMs suffer from pollutant-specific concentration biases, such as underestimation of total nitrate ([Fuentes and Raftery, 2005](#)), that require correction prior to interpretation for exposure assessment. Bayesian Maximum Entropy models for merging CMAQ and concentration data ([Fuentes and Raftery, 2005](#)) and downscaling ([Berrocal et al., 2010a, b](#)) have recently been developed to improve spatial resolution and provide bias correction for the modeled concentration used as an exposure surrogate, but such methods must be used with caution. For instance, [Chen et al. \(2014b\)](#) ran a 36-km resolution CMAQ simulation for NO<sub>2</sub>, NO<sub>x</sub>, and other copollutants, fused the CMAQ results with monitor observations, and compared both the raw and fused model results with monitor observation data. The raw CMAQ simulations overpredicted NO<sub>2</sub> and NO<sub>x</sub> concentrations, particularly in the winter. These overpredictions were substantially reduced (and in some cases the model slightly underpredicted concentrations) for the fused model. [Isakov et al. \(2009\)](#) modeled subgrid spatial variability within CMAQ using the AERMOD dispersion model prior to linking the modeled results with microenvironmental exposure models to predict annual and seasonal variation in urban population exposure within urban microenvironments. In each case, these papers have referred to other air pollutants, but the methodology is still applicable for NO<sub>2</sub> exposure prediction.

[Berrocal et al. \(2010b\)](#) proposed a downscaling approach combining monitoring and CMAQ modeling data to improve the accuracy of spatially resolved O<sub>3</sub> model data. Specifically, a Bayesian model was developed to regress CMAQ model estimates of O<sub>3</sub> concentration on monitoring data, and then the regression model was used to predict concentrations using the CMAQ model results as an input field. [Berrocal et al. \(2010a\)](#) extended the approach to include two pollutants (ozone and PM<sub>2.5</sub>) in a single modeling framework, and [Berrocal et al. \(2012\)](#) added smoothing processes that incorporate spatial autocorrelation and correction for spatial misalignment between monitoring and modeled data. Although these papers did not specifically use NO<sub>2</sub> concentration data, the methods can be applied for NO<sub>2</sub> as they have been for O<sub>3</sub> and PM<sub>2.5</sub>. [Bentayeb et al. \(2014\)](#) applied a similar data assimilation method in which local measurements and elevation data were combined with CTM output in a geostatistical forecasting model. This algorithm was applied for NO<sub>2</sub>, PM<sub>10</sub>, PM<sub>2.5</sub>, SO<sub>2</sub>, C<sub>6</sub>H<sub>6</sub>, and O<sub>3</sub>. Correlations between

assimilated values and measurements ranged from Pearson  $r = 0.75-0.90$ . [Deby and Mallet \(2014\)](#) also employed data assimilation for forecasting but combines three CTMs in an ensemble average to minimize the influence of their errors in conjunction with assimilation of observation data. The method of [Deby and Mallet \(2014\)](#) reduced error in hourly, daily, and peak NO<sub>2</sub> concentrations by 19, 26, and 20%, respectively.

In a slightly different approach, [Crooks and Isakov \(2013\)](#) blended CMAQ, AERMOD, and monitoring data for NO<sub>x</sub>, PM<sub>2.5</sub>, and CO using a Bayesian model based on a wavelet basis series. In this method, the true exposure is represented by the B-spline wavelet series, and then the CMAQ grid cell concentrations, AERMOD receptor concentrations, and measurement points are represented by the wavelet field modified by some assumed error. These components each comprise linear contributions to a Gaussian likelihood model. For NO<sub>x</sub>, the model was found to favor CMAQ data when modeling background and monitor data in dense urban areas where spatial variability is higher. The blended model results had lower prediction error and bias compared with kriging when smaller numbers of points were used for the kriging surface, although the blended model did not perform as well as kriging when densely gridded data were available for that purpose. Similarly, [Robinson et al. \(2013\)](#) used geographically weighted regression, which used a combination of dispersion model results and monitoring data as input for a regression model, to compute concentrations in local population centers. The authors then used kriging to fill in gaps between those population centers. When compared with other kriging methods, the geographically weighted regression approach produced the smallest residual mean squared errors when modeling average NO<sub>2</sub> concentrations across the U.K. for the year 2004. [Beevers et al. \(2012\)](#) also blended CMAQ with a near-road dispersion model and applied the blended model to estimate NO<sub>x</sub> concentrations in London, U.K. ([Beevers et al., 2013](#)). Predicted peak rush hour (6:00 a.m.–9:00 a.m.) NO<sub>x</sub> concentrations exceeded observed NO<sub>x</sub> concentrations by roughly 25% at a heavily trafficked road.

## Scale Models

Scale models characterize relationships between parameters to create a simplified relationship that can be applied despite the physical scale of the setting. For example in atmospheric science, scale models may be used to compare parameters of mean and turbulent air velocity or inertial and viscous forces to understand the relative influence of each. Although scale models are not currently used for exposure assessment in epidemiologic studies, they are described briefly here as emerging methods for potential use in exposure assessment. Existing wind tunnel and observational data have been used in scale models of wind movement that support NO<sub>x</sub> fate and transport modeling in the presence of built structures. For example, the Operational Street Pollution Model

(OSPM) uses scale modeling but is developed specifically to capture street canyon recirculation. [Berkowicz et al. \(2008\)](#) developed a model that includes a turbulent mixing velocity in the street canyon and free convection. Monthly and 6-month avg NO<sub>2</sub> concentrations were calculated using a turbulent plume model. Modeled concentrations were compared with NO<sub>2</sub> concentration measurements from a 1995 panel study and found to agree reasonably well (6–12% negative bias;  $R^2 = 0.75–0.81$ ). However, [Jensen et al. \(2009\)](#) made a more recent comparison of OSPM to NO<sub>2</sub> and NO<sub>x</sub> concentration data from a two-week passive sampling campaign in New York City as part of the MESA Air study (obtained in 2005–6). Regression of the OSPM results against the passive sampler data showed that the model underestimated NO<sub>2</sub> and NO<sub>x</sub> concentrations by 56% and 47%, respectively, with  $R^2 = 0.28$  and  $0.51$ .

---

### 3.2.2.3 Microenvironmental Exposure Models

Microenvironmental models are not used for exposure assessment in epidemiologic modeling because the stochastic component of the model can add measurement error to the health effect estimate. However, microenvironmental exposure models inform the risk assessment performed as part of the NAAQS review process. The state of the science for microenvironmental exposure models has not changed substantially since the 2008 ISA for Oxides of Nitrogen, as described in detail in Annex 3.6 ([U.S. EPA, 2008a](#)). Examples of microenvironmental exposure models include Air Pollution Exposure (APEX), Stochastic Human Exposure and Dose Simulation (SHEDS), and Exposure in Polis (or cities) (EXPOLIS), which involve stochastic treatment of the model input factors ([Kruize et al., 2003](#); [Burke et al., 2001](#)). [Dionisio et al. \(2013\)](#) compared estimates of NO<sub>x</sub> concentration from a central site monitor and AERMOD with estimates from the APEX and SHEDS models. They observed that the microenvironmental models captured the spatial variability of the concentration distribution well, but temporal variability produced by the models differed from other concentration estimation methods.

#### Hybrid Microenvironmental Models

Hybrid microenvironmental exposure models use ambient air quality input from either dispersion models or CTMs rather than from central site monitoring data. For example, in a hybrid microenvironmental model developed by [Isakov et al. \(2009\)](#), the CMAQ model is used to simulate concentrations for a coarse discrete grid. Next, local-scale concentrations from point and mobile sources are estimated using Gaussian dispersion modeling through AERMOD. In combination, these models produce an ambient air quality estimate at the location of the receptor that is then input into APEX or SHEDS to

estimate total human exposure. [Isakov et al. \(2009\)](#) observed that the omission of specific point and traffic sources led to an underestimate in median concentration by up to a factor of two, depending on location; these simulations were for benzene and PM<sub>2.5</sub>; NO<sub>x</sub> tends to be comparable in spatial variability with benzene and more spatially variable compared with PM<sub>2.5</sub> ([Beckerman et al., 2008](#)).

Recent studies have considered the variability and uncertainty associated with hybrid microenvironmental exposure modeling. [Ozkaynak et al. \(2009\)](#) considered uncertainty and variability in simulations that involved estimating concentration, exposure, and dose in separate compartments of a model. They found that uncertainty and variability propagated from one compartment to the next. [Zidek et al. \(2007\)](#) addressed uncertainty and variability in hybrid microenvironmental exposure modeling by using distributions of input parameters in the exposure model framework rather than point estimates. These models estimate time-weighted exposure for modeled individuals by summing exposure in each microenvironment visited during the exposure period. [Zidek et al. \(2007\)](#) found that use of distributions of input data allowed them to examine cases for potential subpopulations with common characteristics. Note that both of these studies model PM concentrations, but the findings are applicable to NO<sub>x</sub> concentrations.

[Sarnat et al. \(2013b\)](#) compared risks of cardiovascular and respiratory morbidity with 24-hour NO<sub>x</sub> concentrations and those of other primary and secondary air pollutants in Atlanta, GA using various exposure metrics and models. Epidemiologic results based on the mean, median, and 95th percentile of the estimated exposure distributions from APEX were compared with measures from a central site monitor, regional background, AERMOD, and a hybrid model that merged AERMOD output with regional background data. NO<sub>x</sub> concentrations modeled with APEX were generally higher than those obtained with the hybrid model, likely because the APEX model incorporates road activity levels in their exposure estimates. Epidemiologic analyses for asthma/wheeze produced statistically significant risk ratios for the APEX mean, median, and 95th percentile, but these risk ratios were not statistically significantly higher compared with those computed using alternate exposure assignment approaches.

---

### 3.2.3 Choice of Exposure Metrics in Epidemiologic Studies

Appropriateness of the exposure metric for a given study depends in part on epidemiologic study design and spatial variability of the pollutant concentration. [Table 3-1](#) summarizes the methods described in [Sections 3.2.1](#) and [3.2.2](#). Based on epidemiologic studies using various methods for exposure assessment, [Figure 3-1](#) illustrates the range of NO<sub>2</sub> concentrations to which people may be exposed in different

locations ([HEI, 2010](#)). Because this figure is the result of the [HEI \(2010\)](#) review, the data points included were sampled over different temporal scales and using different sampler types. The figure illustrates variability in concentrations across locations and also the variability measured within a type of location. Given the natural variability of concentrations over space and time, and given nuances of the specific exposure assessment techniques, it is important to recognize the specific applicability and limitations of each approach, as summarized in [Table 3-1](#). Differences in sampling methodologies may cause some of the variability observed in the figure.

**Table 3-1 Summary of exposure estimation methods, their typical use in nitrogen dioxide epidemiologic studies, and related errors and uncertainties.**


Method	Epidemiologic Application	Errors and Uncertainties in Exposure Estimates
Central site monitors	Short-term community time-series exposure of a population within a city	Correlation between true outdoor concentrations and outdoor measurements typically decreases with increasing distance from the monitor ( <a href="#">Sections 3.4.3</a> and <a href="#">3.4.5</a> ), potentially leading to reduced precision and exposure bias towards the null
	Long-term exposure to compare populations among different cities	Potential for exposure bias and reduced precision if the monitor site does not correspond to the exposed population ( <a href="#">Section 3.4.5</a> )
		Positive instrument bias in the central site monitor from other ambient oxidized nitrogen products may lead to exposure bias and reduced precision ( <a href="#">Section 3.2.1.1</a> )
Passive monitors	Short-term panel (personal monitoring or fixed local site, e.g., residence, school, work)	Positive instrument bias in the passive monitor from other ambient oxidized nitrogen products or internal reaction of NO and O <sub>3</sub> to produce additional NO <sub>2</sub> within the passive sampler body may lead to exposure bias and reduced precision ( <a href="#">Section 3.2.1.2</a> )
	Long-term exposure characterization or LUR model fit (monitors distributed across a city or at fixed local sites)	Positive instrument bias as described for the short-term panel studies above may add exposure bias and reduced precision when LUR models are fit to passive sampler data ( <a href="#">Section 3.2.1.2</a> )
		Potential for exposure bias and reduced precision for monitors sited at fixed locations ( <a href="#">Section 3.4.5</a> )

**Table 3-1 (Continued): Summary of exposure estimation methods, their typical use in nitrogen dioxide epidemiologic studies, and related errors and uncertainties.**

Method	Epidemiologic Application	Errors and Uncertainties in Exposure Estimates
LUR	Long-term exposure, usually across a city but sometimes fit among multiple cities	Potential for exposure bias and reduced precision if the solution grid is not finely resolved ( <a href="#">Section 3.2.2.1</a> ) Potential for bias and reduced precision if the model is misspecified or applied to a location different from where the model was fit ( <a href="#">Section 3.4.5</a> )
IDW and kriging	Long-term exposure across a city	Potential for negative bias and reduced precision if sources are not captured or overly smoothed ( <a href="#">Section 3.2.2.1</a> )
Spatiotemporal modeling	Not reported	Not yet well understood ( <a href="#">Section 3.2.2.1</a> )
CTM	Long-term exposure, sometimes within a city but more typically across a larger region	Potential for exposure error and reduced precision when grid cells are too large to capture spatial variability of exposures ( <a href="#">Section 3.2.2.2</a> )
Gaussian plume dispersion modeling	Long-term exposure within a city	Potential for bias and reduced precision where the dispersion model does not capture boundary conditions and resulting fluid dynamics well (e.g., in large cities with urban topography affecting dispersion) ( <a href="#">Section 3.2.2.2</a> )
Scale modeling	Not reported	Not yet well understood ( <a href="#">Section 3.2.2.2</a> )

CTM = chemical transport model; IDW = inverse distance weighting; LUR = land use regression; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; O<sub>3</sub> = ozone

Source: National Center for Environmental Assessment.



Note: hr = hour;  $\mu\text{g}/\text{m}^3$  = micrograms per cubic meters. Data presented in this figure were obtained using different types of samplers and over different averaging periods.

Source: Reprinted with the permission of the Health Effects Institute, [HEI \(2010\)](#).

**Figure 3-1 Average nitrogen dioxide concentrations measured in studies using different monitor siting.**

Concentrations measured by central site or near-road monitors are commonly used as surrogates for human exposure in studies of both short- and long-term exposure to  $\text{NO}_2$  (Section 3.2.1.1). Central site measurements are subject to positive bias from instrument error. Correlation between measured central site concentration and concentration at some distant point decreases with distance. Therefore, reductions in correlation between measurements at a central site monitor and the true exposure at the location of individuals in an epidemiologic study, caused by human activity and variation in sources over space and time, can lead to bias towards the null and loss of precision in the exposure estimate for studies of short-term exposure to ambient  $\text{NO}_2$ . For epidemiologic studies of

long-term exposure to ambient NO<sub>2</sub>, the difference between the measured concentration and the true exposure would result in exposure error.

Passive sampling can be used for panel studies, or when samples are integrated or averaged over several weeks or months, as input for long-term studies ([Section 3.2.1.2](#)). The integrated nature of the passive samples limits their application in time-resolved studies. Passive sampling techniques such as Palmes tube measurements are subject to positive instrumentation biases. Additionally, passive monitors left in place for sampling durations of weeks may produce data having errors and uncertainties that are similar to those associated with using a fixed-site monitor to capture exposures for a population that is dispersed over space and moving in time. The influence of exposure error in passive sampling methods is discussed in more detail in [Sections 3.4.5.2](#) and [3.4.5.3](#). Passively sampled concentrations are also used commonly as input for LUR model fitting ([Section 3.2.2.1](#)).

LUR is often employed to estimate NO<sub>2</sub> concentrations for use in long-term exposure studies. The quality of the exposure metric provided by the model depends on several factors, including spatial resolution of the model, the number of model training sites, the selection of predictor variables, consideration of seasonality, and model validation. IDW is also used for exposure estimation between spatially distributed NO<sub>2</sub> concentration measurements ([Section 3.2.2.1](#)). However, if too few monitors are used, then the IDW might not capture the spatial variability of the true exposures.

CTMs and dispersion models are based on physics of air flow and contaminant transport ([Section 3.2.2.2](#)). Like central site monitors, CTMs can be used to compare NO<sub>2</sub> concentrations among different cities for long-term exposure studies. However, coarse spatial resolution of CTMs limits their applicability within cities. Dispersion models are frequently used for within-city NO<sub>2</sub> concentration estimation in long-term exposure studies, but the simplifying assumption of Gaussian dispersion can add error to the concentration estimate if meteorology or topography of the built environment are complex. Given this complexity, the direction of exposure error is not predictable. Biases in dispersion model output can occur in either direction, and they depend strongly on the specific environment (i.e., topography, meteorology, source representation) being modeled. Correction methods may sometimes be applied to minimize such error for a given location, but the effectiveness of error minimization must be determined on a case-by-case basis. Subsequent sections will describe characterization of NO<sub>2</sub> concentrations, a conceptual model of exposure, relationships among exposure metrics, sources of exposure error, confounding, and implications of exposure error for epidemiologic studies of different designs.

---

## 3.3 Characterization of Nitrogen Dioxide Exposures

[Chapter 2](#) presents detailed data on NO<sub>2</sub> sources and concentrations. The purpose of this section is to present NO<sub>2</sub> concentration data used as surrogates for human exposure to NO<sub>2</sub>. It is broken into two parts: NO<sub>2</sub> concentration as an indicator of source-based mixtures and indoor dynamics. The section on NO<sub>2</sub> concentration as an indicator of source-based mixtures presents ambient NO<sub>2</sub> concentration data reported in studies of human exposure to mobile source emissions and other outdoor sources. The section on indoor dynamics describes sources, sinks, and penetration of ambient NO<sub>2</sub> into indoor environments and the chemistry influencing indoor concentrations of NO<sub>2</sub>. This section provides context for the discussion of exposure assessment and factors influencing epidemiologic inference in [Section 3.4](#).

---

### 3.3.1 Nitrogen Dioxide Concentration as an Indicator of Source-Based Mixtures

#### 3.3.1.1 Mobile Source Emissions

Seventeen percent of U.S. homes, or 22,064,000 homes, are located within 91 m of a highway with four or more lanes, a railroad, or an airport ([U.S. Census Bureau, 2009](#)). Moreover, 7% of U.S. schools serving 3,152,000 school children are located within 100 m of a major roadway, and 15% of U.S. schools serving 6,357,000 school children are located within 250 m of a major roadway based on data from the National Center for Education Statistics (NCES) ([Kingsley et al., 2014](#)). The NCES did not specifically define traffic in terms of annual average daily traffic [AADT], predominant fuel type used on the roadway, or other criteria besides number of lanes. Average one-way commuting times for the U.S. labor force working outside the home are 19.3 minutes for bicyclists, 11.5 minutes for walkers, and 25.9 minutes for all other modes of transportation. Among the populace working outside the home, 15.6% spend 45 minutes or more commuting to work each day ([U.S. Census Bureau, 2007](#)). Based on [Figure 2-4](#), the proportion of NO<sub>x</sub> emissions from mobile sources in the 21 CBSAs with at least 2.5 million residents is 16% higher than it is among the general population. Hence, a large share of the U.S. population is exposed to the on- and near-road environment on a regular basis, and those exposures are likely to be higher for the 38% of the population living in urban areas ([U.S. Census Bureau, 2013b](#)). This has implications for potential NO<sub>2</sub> exposure. [Section 2.5.3](#) describes spatial patterns of NO<sub>2</sub> concentrations near roads as a background for understanding traffic-related NO<sub>2</sub> exposure. This section builds on

the observations of NO<sub>2</sub> concentration gradients described in [Chapter 2](#) to consider how near-road concentrations influence traffic-related NO<sub>2</sub> and NO<sub>x</sub> exposure.


Time spent in traffic can be an important determinant of personal NO<sub>2</sub> exposure. [Möller et al. \(2012\)](#) calculated associations with time spent in several home, transit, and school microenvironments for a cohort of 12–13-year-old children from Greater Manchester, U.K. based on 2-day sampling periods per season; traffic data were not provided. They observed that time spent in transit was positively associated with both NO<sub>2</sub> exposure and mean prediction error of a microenvironmental model of personal NO<sub>2</sub> exposure, where mean prediction error compares the microenvironmental model with NO<sub>2</sub> measurements. Together, these findings suggest that exposures are higher on roads and consequently that time spent in transit may comprise a larger share of daily NO<sub>2</sub> exposure compared with the proportion of time in a day that is spent in transit. [Ragetti et al. \(2014\)](#) estimated the exposures of commuters who reported the times and routes of their commutes and modes of transport to the 2010 Swiss Mobility and Transport Microcensus in Basel, Switzerland. The authors used concentration estimates from a combination of dispersion modeling and LUR. Traffic data were not provided. [Ragetti et al. \(2014\)](#) found that travel in motor vehicles on highways and class 1 roads (AADT limits not defined for these road types) produced the highest exposure (reported as the product of concentration and time), followed closely by bicyclists and those taking public transit. Pedestrians had measurably lower exposures.

Health studies often focus on the independent effects of NO<sub>2</sub> exposure or use NO<sub>2</sub> concentration as a surrogate for exposure to traffic pollution mixtures when measurements of other pollutants are unavailable. NO<sub>2</sub> concentration is routinely measured at sampling sites nationwide, and NO<sub>2</sub> is a prevalent reaction product of NO, which is a component of vehicle exhaust ([Section 2.2](#)). Correlation data from several studies presented in [Section 3.4.4](#) illustrate that NO<sub>2</sub> concentration generally correlates with concentrations of other traffic-related pollutants in urban areas. NO<sub>2</sub> concentration has also been observed in at least one study to correlate with nonconcentration measures of traffic. With respect to exposure, these observations make it hard to distinguish NO<sub>2</sub> from other pollutants when considering the health impacts potentially attributable to each.

As a surrogate for traffic-related exposure, NO<sub>2</sub> concentration may do an adequate job of capturing spatial and temporal trends of traffic pollution. Microscale spatial variability of NO<sub>2</sub> concentrations near roads has been studied extensively, and NO<sub>2</sub> concentration gradients from a number of studies are summarized and compared in [Section 2.5.3](#). Based on 1–2 weeks of passive sampling measurements for NO<sub>2</sub>, [Wheeler et al. \(2008\)](#) and [Beckerman et al. \(2008\)](#) reported correlations among NO<sub>2</sub> and several traffic-related air pollutants, including benzene (Pearson  $r = 0.85$ ) and toluene ( $r = 0.63$ ). [Beckerman et al.](#)

(2008) reported that 349,100 to 395,400 vehicles traveled daily on the highways studied; Wheeler et al. (2008) did not report traffic data. The near-road air pollutant gradients displayed in the review by Karner et al. (2010) suggested that NO<sub>2</sub> concentration is correlated with concentrations of traffic-related air pollutants across various distances from a roadway. McCreanor et al. (2007) similarly found much higher personal exposure measurements of NO<sub>2</sub> when subjects in a scripted exposure study walked alongside a heavily trafficked (traffic data not provided) road in London that is limited to diesel truck and bus traffic compared with personal exposure measurements of NO<sub>2</sub> when walking in a park (road: median NO<sub>2</sub> = 75.5 ppb; park: median NO<sub>2</sub> = 18.4 ppb). These studies concluded that gradients in NO<sub>2</sub> concentrations were spatially correlated with gradients in traffic-related pollution.

The size and shape of the near-road gradient for NO<sub>2</sub> concentration determines the spatial zone where near-road exposures are most likely. Observations of the structure of the NO<sub>2</sub> near-road concentration gradient are summarized in Tables 2-6 and 2-7 in Section 2.5.3. Although NO<sub>2</sub> concentration tends to correlate with most roadway pollutants in a near-road environment, the NO<sub>2</sub> concentration gradient tends to be shallower than gradients for other primary traffic-related pollutants (e.g., CO, UFP). These gradients influence how exposure and copollutant correlations change spatially across the near-road environment. Karner et al. (2010) performed an analysis of 125 near-road NO<sub>2</sub> concentration studies and observed a concentration reduction of 42% from the edge of the roadway, in line with values presented in Tables 2-6 and 2-7. The review of Karner et al. (2010) also showed that the NO<sub>2</sub> concentration gradient was much less steep compared with the concentration gradients for NO and NO<sub>x</sub>, with decay to background levels within 550 m. In contrast, Karner et al. (2010) reported a 79–86% reduction in UFP concentration and a 90% reduction in CO concentration from the roadway edge. These results suggest that, although NO<sub>2</sub> concentration may capture many aspects of pollutant gradients from the roadway, NO<sub>2</sub> concentration used as a marker for traffic may underestimate the magnitude of the concentration gradient for other near-road pollutants, such as UFP and CO. Figure 3-2 presents the spatial variability of NO<sub>2</sub> and copollutants at various gradients from the roadway reported in the Karner et al. (2010) paper to illustrate the comparison of the spatial near-road gradient of NO<sub>2</sub>, NO, and NO<sub>x</sub> concentrations with those of other traffic-related pollutants. In a later study of near-road concentrations in Medford, MA, Padró-Martínez et al. (2012) used continuous instrumentation mounted on a mobile sampling unit operated over the course of a year, to illustrate a similar gradient; traffic levels were not provided, but heavy-duty vehicles comprised nearly 20% of total traffic.



Note: Concentrations are normalized by measurements at the edge of the road. NO<sub>2</sub>, NO, and NO<sub>x</sub> concentration gradients are presented in the center panel. NO<sub>2</sub> = nitrogen dioxide, NO = nitric oxide, NO<sub>x</sub> = sum of NO<sub>2</sub> and NO; CO = carbon monoxide; m = meter; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 μm; EC = elemental carbon; VOC1 = volatile organic compounds whose concentrations varied with distance from the road; VOC2 = volatile organic compounds whose concentrations did not vary with distance from the road; UF1 = ultrafine particles larger than 3 nm; UF2 = ultrafine particles larger than 15 nm.

Data presented from [Karner et al. \(2010\)](#) were synthesized from 41 peer-reviewed references, 11 of which reported data for NO<sub>2</sub>, 5 of which reported data for NO, and 6 of which reported data for NO<sub>x</sub>. The number in parentheses refers to regression sample size. UF1 and UF2 are measures of ultrafine particle number.

Source: Reprinted with permission of the American Chemical Society, [Karner et al. \(2010\)](#);

**Figure 3-2 Spatial variability in concentrations of near-road nitrogen dioxide, nitric oxide, the sum of nitric oxide and nitrogen dioxide, carbon monoxide, and other near-road pollutants.**

As pointed out in [Section 2.5.2](#), near road NO concentrations are typically much higher than near road NO<sub>2</sub> concentrations; [Table 2-6](#) describes the near road concentration gradient for NO<sub>2</sub> only. [Table 3-2](#) expands on these observations to consider on-road concentrations of NO<sub>2</sub> and NO while in transit. Recent on-road and near-road measurements of both NO and NO<sub>2</sub> concentrations indicate that on-road NO exposures can be much higher than on-road NO<sub>2</sub> exposures immediately upon their emission. In particular, the Los Angeles, CA data for NO<sub>x</sub> and NO concentrations suggest that rush hour NO<sub>2</sub> concentrations are roughly 50–60 ppb, but NO concentrations reach roughly 200–360 ppb in the morning and 95–260 ppb in the afternoon, based on 2-hour avg of 1-minute data ([Fujita et al., 2011](#)). These studies were conducted on four Los Angeles, CA highways with traffic levels ranging from approximately 190,571 to 289,167 vehicles per day with roughly 4–15% of traffic comprised of heavy-duty diesel traffic. [Beckerman et al. \(2008\)](#) measured 1-week integrated NO and NO<sub>2</sub> concentration samples next to two highways in Toronto, Canada and also observed that mean NO concentrations were 3–4 times higher than mean NO<sub>2</sub> concentrations.

The relationship between NO<sub>2</sub> concentration and traffic metrics informs exposure assessment because it establishes potential for exposure among those commuting or living in the near-road environment. In Minneapolis, MN, [Pratt et al. \(2014\)](#) compared direct traffic metrics, such as traffic volume, with LUR-computed NO<sub>2</sub> concentrations (which were not estimated from traffic volume although road length was included in the model). They observed a correlation (type unstated) of 0.58 between NO<sub>2</sub> concentration and traffic density (AADT per km<sup>2</sup>), with a slope of 0.103 on a log-log model of NO<sub>2</sub> versus traffic density. [Gauderman et al. \(2005\)](#) measured the correlation between NO<sub>2</sub> concentrations and various traffic metrics in 12 southern California communities. Traffic on major roadways within these communities was stated to range from 50,000 to 270,000 vehicles per day. On average across the communities, the Spearman correlation between NO<sub>2</sub> concentration and increasing distance to freeway was  $r = -0.54$ , but the correlation between NO<sub>2</sub> concentration and traffic volume within 150 m of a freeway was  $r = 0.24$ .

The contribution of mobile source emissions to NO<sub>2</sub> concentration varies with strength of additional sources. For example, [Ducret-Stich et al. \(2013\)](#) modeled NO<sub>2</sub> concentration as a function of background NO<sub>2</sub> concentration; light-duty (highway: 19,010 vehicles per day, main road: 7,047 vehicles per day) and heavy duty (highway: 3,030 vehicles per day, main road: 143 vehicles per day) traffic counts; and meteorological, topographic, and temporal variability in the Swiss Alps with a model out-of-sample  $R^2 = 0.91$ . They observed that background NO<sub>2</sub> concentration contributed 83% of the variability in the model, while heavy-duty and light-duty traffic counts contributed 8 and 7%, respectively. Similarly, NO<sub>x</sub> has been found to have mixed correlation with traffic density in a nationwide long-term exposure epidemiologic study of the U.S. Veterans Cohort [1976–2001 ([Lipfert et al., 2009](#))]. In this study, annual vehicle-miles traveled per square mile averaged 12.17 (standard deviation: 15.3). In areas deemed high traffic density (higher traffic than the average 1985 traffic density), Pearson  $r = 0.27$ , while for areas of low traffic density (lower traffic than the average 1985 traffic density),  $r = 0.56$ .

**Table 3-2 Near- and on-road measurements of nitrogen dioxide, nitric oxide, and the sum of nitric oxide and nitrogen dioxide.**

Reference	Location and Date	Distance to Road (m) <sup>a</sup>	Traffic Counts	Averaging Time	NO (ppb)	NO <sub>2</sub> (ppb)	NO <sub>x</sub> (ppb)
† <a href="#">Beckerman et al. (2008)</a>	Toronto, Canada Site 1, Aug 2004	28, 47, 57, 107, 126, 194, 209, 382, 507, 742, 986	395,400 veh/day	1-week integrated	44.2 (19.9) <sup>b</sup> ; 77.6 <sup>c</sup>	14.6 (2.8) <sup>b</sup> ; 18.6 <sup>c</sup>	NR
	Toronto, Canada Site 2, Aug 2004	4, 28, 38, 56, 105, 114, 175, 246, 335, 346, 438, 742, 875	349,100 veh/day	1-week integrated	70.5 (62.7) <sup>b</sup> ; 239.3 <sup>c</sup>	17.5 (4.6) <sup>b</sup> ; 28.2 <sup>c</sup>	NR
† <a href="#">Zhu et al. (2008)</a>	Los Angeles, CA I-710 (mostly diesel trucks), NR	0	NR; up to 25% diesel	2-h avg of 1-min data unfiltered	NR	NR	432 (66.3) <sup>b</sup>
	Los Angeles, CA I-405 (mostly autos), NR	0	NR; about 5% diesel	2-h avg of 1-min data unfiltered	NR	NR	267 (114) <sup>b</sup>
† <a href="#">Fujita et al. (2011)</a>	Los Angeles, CA I-110 (mostly autos), Sep–Dec 2004	0	259,500–261,000 veh/day; 12,631–13,375 heavy-duty veh/day	2-h avg of 1-min data (morning)	347 (235) <sup>b</sup>	NR	411 (250) <sup>b</sup>
	Los Angeles, CA I-405 (mostly autos), Sep–Dec 2004	0	276,857–289,167 veh/day; 12,755–13,100 heavy-duty veh/day	2-h avg of 1-min data (morning)	198 (94) <sup>b</sup>	NR	245 (100) <sup>b</sup>
	Los Angeles, CA SR-60 (mostly autos), Sep–Dec 2004	0	249,333 veh/day; 16,775 heavy-duty veh/day	2-h avg of 1-min data (morning)	329 (114) <sup>b</sup>	NR	388 (120) <sup>b</sup>

**Table 3-2 (Continued): Near- and on-road measurements of nitrogen dioxide, nitric oxide, and the sum of nitric oxide and nitrogen dioxide.**

Reference	Location and Date	Distance to Road (m) <sup>a</sup>	Traffic Counts	Averaging Time	NO (ppb)	NO <sub>2</sub> (ppb)	NO <sub>x</sub> (ppb)
† <a href="#">Fujita et al. (2011)</a> (Continued)	Los Angeles, CA I-710 truck route, Sep–Dec 2004	0	190,571 veh/day; 28,502 heavy-duty veh/day	2-h avg of 1-min data (morning)	361 (143) <sup>b</sup>	NR	426 (154) <sup>b</sup>
	Los Angeles, CA I-110 (mostly autos), Sep–Dec 2004	0	259,500–261,000 veh/day; 12,631–13,375 heavy-duty veh/day	2-h avg of 1-min data (afternoon)	95 (49) <sup>b</sup>	NR	148 (62) <sup>b</sup>
	Los Angeles, CA I-405 (mostly autos), Sep–Dec 2004	0	276,857–289,167 veh/day; 12,755–13,100 heavy-duty veh/day	2-h avg of 1-min data (afternoon)	98 (56) <sup>b</sup>	NR	140 (64) <sup>b</sup>
	Los Angeles, CA SR-60 (mostly autos), Sep–Dec 2004	0	249,333 veh/day; 16,775 heavy-duty veh/day	2-h avg of 1-min data (afternoon)	112 (55) <sup>b</sup>	NR	170 (65) <sup>b</sup>
	Los Angeles, CA truck route, Sep–Dec 2004	0	190,571 veh/day; 28,502 heavy-duty veh/day	2-h avg of 1-min data (afternoon)	258 (114) <sup>b</sup>	NR	321 (125) <sup>b</sup>
† <a href="#">Fruin et al. (2008)</a>	Los Angeles, CA I-10 (mostly autos), Feb–April 2003	0	Approx. 10,000 heavy-duty veh/day	2-to-4-h avg of 20-s data	280 <sup>d</sup>	NR	NR
	Los Angeles, CA I-710 (mostly diesel trucks), Feb–April 2003	0	Approx. 25,000 heavy-duty veh/day	2-to-4-h avg of 20-s data	390 <sup>d</sup>	NR	NR

**Table 3-2 (Continued): Near- and on-road measurements of nitrogen dioxide, nitric oxide, and the sum of nitric oxide and nitrogen dioxide.**

Reference	Location and Date	Distance to Road (m) <sup>a</sup>	Traffic Counts	Averaging Time	NO (ppb)	NO <sub>2</sub> (ppb)	NO <sub>x</sub> (ppb)
† <a href="#">MacNaughton et al. (2014)</a>	Boston, MA bike path separate from vehicle traffic, NR	0	12,900 veh-km	Average over 40 3-h sampling periods with 1-min data	NR	14.7 (0.582) <sup>b</sup>	NR
	Boston, MA bike lane adjacent to vehicle traffic, NR	0	6,250 veh-km	Average over 40 3-h sampling periods with 1-min data	NR	19.5 (0.343) <sup>b</sup>	NR
	Boston, MA designated bike lane shared between bikes and buses, NR	0	5,220 veh-km	Average over 40 3-h sampling periods with 1-min data	NR	24.2 (1.72) <sup>b</sup>	NR

Aug = August; avg = average; CA = California; Dec = December; Feb = February; h = hour; I = interstate; m = meters; MA = Massachusetts; min = minute; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = the sum of NO and NO<sub>2</sub>; NR = not reported; ppb = parts per billion; s = second; Sep = September; SR = state route; veh/day = vehicles per day; veh-km = vehicle-kilometers.

<sup>a</sup>Distance of 0 m indicates on-road measurements.

<sup>b</sup>Average (standard deviation).

<sup>c</sup>Maximum.

<sup>d</sup>Average of medians.

†Studies published since 2008 ISA for Oxides of Nitrogen.

Natural experiments provide an opportunity to test the sensitivity of ambient NO<sub>2</sub> concentration to changes in traffic conditions. For example, [Levy et al. \(2006\)](#) measured NO<sub>2</sub> concentrations across the Boston, MA metropolitan area using one-week integrated samples that were deployed the week prior to the 2004 Democratic National Convention (DNC), during the week of the 2004 DNC, and during the week after the 2004 DNC. Traffic data were not reported for this study. [Levy et al. \(2006\)](#) hypothesized that there were four types of sites: (1) sites with concentration decreases around closed-down roads that were not near alternate routes, (2) sites with concentration increases around alternate routes but not near closed roads, (3) sites with no change because they were not near closures or alternate routes, and (4) sites with unclear impacts. Sites hypothesized to have decreasing NO<sub>2</sub> concentration did in fact have a median 42% reduction in concentration. Likewise, sites hypothesized to have increasing NO<sub>2</sub> concentration did have a median 15% increase in concentration. Sites hypothesized to have no change or unclear impacts had 12% and 30% reductions in NO<sub>2</sub> concentration, respectively.

Several recent studies have evaluated the use of central site NO<sub>2</sub> or NO<sub>x</sub> concentration as a surrogate for personal exposure to traffic pollution mixtures. In a near-road environment, NO<sub>x</sub> concentration can be correlated with concentrations of pollutants that are also associated with health effects, including UFP and water soluble metals ([Sánchez Jiménez et al., 2012](#)); PAHs ([Brook et al., 2007](#)); sum of the VOCs benzene, toluene, ethylbenzene, and xylene (BTEX) ([Beckerman et al., 2008](#)); and EC ([Minguillón et al., 2012](#)) or BC ([Clougherty et al., 2013](#)). Correlations generally in the range of 0.6–0.8 of NO<sub>2</sub> concentration with CO, NO<sub>x</sub>, and EC (or BC) concentration forms the basis for a proposed multipollutant mobile source indicator that combines these three species into an Integrated Mobile Source Indicator (IMSI) for traffic-related air pollution. The IMSI is a weighted average of mobile source pollutant concentrations weighted by the ratio of mobile source to total emissions for each pollutant, which [Pachon et al. \(2012\)](#) developed using CO, NO<sub>x</sub>, and EC. Although the IMSI is not currently used in any epidemiologic studies of the health effects of NO<sub>2</sub> or NO<sub>x</sub>, it is an informative tool that may shed light on the relationship between traffic-related sources and human exposures, as shown in [Equation 3-1](#).

$$IMSI_{EB} = \frac{\frac{Emission_{EC,mobile}}{Emission_{EC,total}} \times C'_{EC} + \frac{Emission_{NO_x,mobile}}{Emission_{NO_x,total}} \times C'_{NO_x} + \frac{Emission_{CO,mobile}}{Emission_{CO,total}} \times C'_{CO}}{\frac{Emission_{EC,mobile}}{Emission_{EC,total}} + \frac{Emission_{NO_x,mobile}}{Emission_{NO_x,total}} + \frac{Emission_{CO,mobile}}{Emission_{CO,total}}}$$

**Equation 3-1**

Note that  $C'$  = average concentration normalized by the standard deviation of concentration. Urban street-side (mostly street canyon) NO and NO<sub>2</sub> concentrations have been measured and compared with downwind sites, including those located in parks and reference sites (i.e., sites that are located away from or upwind from traffic-related emissions). Criteria pollutant concentrations were sampled using high-density siting throughout the five boroughs of New York City, NY with 2-week integrated samples per season (25 samplers deployed for 2 weeks during 6 sampling sessions per season to make 150 sites within New York City, NY) ([Ross et al., 2013](#)). Consistent with [Karner et al. \(2010\)](#), the street-side sites generally showed higher NO concentrations compared with NO<sub>2</sub> concentrations (NO: mean 31.82 ppb, max 151.76 ppb; NO<sub>2</sub>: mean 27.60 ppb, max 87.18 ppb) in [Ross et al. \(2013\)](#) (see [Table 3-3](#)) for concentration, traffic, and land use summary data). The NO concentration on average was lower than the NO<sub>2</sub> concentration away from the road, for example at park sites (NO: mean 18.88 ppb, max 45.15 ppb; NO<sub>2</sub>: mean 22.13 ppb max 36.94 ppb). The ranges for overall and truck traffic density, census population, and building areas were all higher for the street-side sites compared with the park sites. In a mobile van study of street canyons in Helsinki, Finland operating continuous monitors during rush hour on a roadway with approximately 40,000 vehicles per day (roughly 10% diesel, with sampling interval: 1-minute), [Pirjola et al. \(2012\)](#) found that the topographical characteristics of the roadway influenced the concentration gradient. They studied concentration profiles on the upwind and downwind sides within a street canyon and observed downwind-to-upwind concentration ratios of 0.28 and 0.70 for NO and NO<sub>2</sub>, respectively, when the street canyon aspect ratio (building height-to-street width) was 0.55. When the aspect ratio increased to 0.70, downwind-to-upwind concentration ratios decreased to 0.18 and 0.65 for NO and NO<sub>2</sub>, respectively.

**Table 3-3 Summary (mean, range) within 300 m of monitoring sites, by site type, in a spatially dense monitoring campaign in New York City, NY, based on 2-week integrated samples per season.**

	Street-Side Sites <sup>a</sup> (n = 138)	Park Sites <sup>a</sup> (n = 12)	Reference Sites <sup>b</sup> (n = 5)	Regulatory Sites <sup>c</sup> (n = 5)
NO <sub>2</sub> concentration (ppb)	27.6 (8.32–87.2) <sup>d</sup>	22.1 (8.10–36.9) <sup>d</sup>	20.2 (9.43–38.2) <sup>d</sup>	22.7 (17.1–34.2) <sup>d</sup>
NO concentration (ppb)	31.8 (2.69–152) <sup>d</sup>	18.9 (4.93–45.2) <sup>d</sup>	15.9 (5.42–54.8) <sup>d</sup>	12.1 (3.30–40.0) <sup>d</sup>
Roadway length (km)	4.3–6.0	2.1–3.7	1.9–2.5	
Traffic density (vehicle-km/h)	561–2,800	302–2,560	119–783	
Truck density (vehicle-km/h)	13.4–83.2	0.910–24.4	5.80–13.5	
2000 census population (number)	1,316–5,819	117–3,455	0–522.7	
Building area (m <sup>2</sup> )	90.7–382	0–163	0–38.5	
Residential space area (m <sup>2</sup> )	53.79–242	0–124	0–30.7	
Commercial space area (m <sup>2</sup> )	15.6–105	0–29.0	0–18.7	
Industrial space area (m <sup>2</sup> )	0–7.19	0–4.65	0–0	

km = kilometer; km/h = kilometer per hour; m<sup>2</sup> = meters squared; n = sample size; NAAQS = National Ambient Air Quality Standards; NO<sub>2</sub> = nitrogen dioxide; NO = nitric oxide; NY = New York; ppb = parts per billion.

<sup>a</sup>150 passive monitoring sites sampled at 25 sites over two weeks and then moved over six sampling periods, repeated over three seasons for a total of 48 weeks of sampling.

<sup>b</sup>Five continuous monitoring sites distributed in each borough of New York City, NY.

<sup>c</sup>Five continuous monitoring sites maintained by New York State to assess NAAQS compliance.

<sup>d</sup>avg (range).

Source: Modified from Table 1 and Table 5 of [Matte et al. \(2013\)](#).

NO<sub>2</sub> and NO emissions, concentrations, and therefore exposures, are also subject to interventions in the built environment. After a tunnel was built in Sydney, Australia to reduce urban pollution levels, [Cowie et al. \(2012\)](#) observed statistically significant reductions in NO<sub>2</sub> and NO<sub>x</sub> concentrations by 1.4 and 4.6 ppb, adjusted for meteorology, based on 2-week passive sampler measurements taken at three periods during fall 2006–2008. Traffic was reported to be 90,000 vehicles per day on the surface road and 43,446–57,814 vehicles per day in the tunnel. [Beever and Carslaw \(2005\)](#) studied the impact on annual NO<sub>x</sub> emissions of the London congestion pricing zone implemented in 2003 to reduce traffic in central London, U.K. Overall, they reported a 12% decrease in NO<sub>x</sub> emissions within the congestion pricing zone and a 1.5% increase in NO<sub>x</sub> emissions at the surrounding ring road, related to some individuals rerouting their drives to the surrounding ring road where no payment was required. Traffic count data were not

provided. Similarly, [Panteliadis et al. \(2014\)](#) studied the impact of congestion pricing in Amsterdam, the Netherlands and observed a 6.6% reduction in NO<sub>2</sub> concentrations at a roadside measurement, with an 11% reduction in the traffic contribution to ambient NO<sub>2</sub> concentrations. Approximately 15,000 vehicles per day travelled on the road. However, [Masiol et al. \(2014\)](#) analyzed the effects of traffic-free Sundays over 13 years on air quality in the Po Valley of Italy and saw no appreciable change in NO<sub>2</sub> levels for a roadway with traffic of more than 75,000 vehicles per day. [Rao et al. \(2014\)](#) studied the influence of tree canopies on NO<sub>2</sub> concentrations in Portland, OR using LUR modeling and observed a 38% reduction in NO<sub>2</sub> concentrations related to increasing the tree canopy at higher elevations in the city; traffic count data were not reported. [MacNaughton et al. \(2014\)](#) measured NO<sub>2</sub> exposures of bicyclists in Boston, MA using real-time monitoring (3-hour avg of 1-minute data) equipment and GPS and observed that riding in a shared bicycling/bus lane, traffic density, background NO<sub>2</sub> concentration, and vegetation density were associated with measured NO<sub>2</sub> exposures. The city of Beijing, China restricted traffic during the 2008 Olympics, thus creating a natural experiment in pollution reduction. [Zhang et al., 2013](#) reported that the average of 1-hour NO<sub>2</sub> concentration measurements dropped from  $25.6 \pm 3.66$  ppb to  $14.6 \pm 3.76$  ppb when comparing periods before (June 2–July 20) and during (July 21–September 19) the Olympic games. After the Olympics (September 20–October 30), concentrations increased back up to  $41.4 \pm 3.81$  ppb. [Huang et al. \(2012a\)](#) reported concentration reductions of 21.6% and 12.9% for the periods before and during the Olympics compared with the previous year. The reduced NO<sub>2</sub> concentrations that followed these interventions suggest that controls can lead to reduced NO<sub>2</sub> exposures. Traffic count data were not reported for the Beijing, China Olympics studies.

---

### 3.3.1.2 Other Outdoor Sources

As described in [Section 2.3](#), other sources contributing to ambient NO<sub>x</sub> emissions include nonroad mobile sources, electric generating units, industrial sources, and wildfires. Nonroad mobile sources, such as airports, shipping ports, and rail yards, can contribute substantially to local and regional ambient NO<sub>x</sub> concentrations ([Kim et al., 2011](#); [Williams et al., 2009](#); [Vutukuru and Dabdub, 2008](#); [Carslaw et al., 2006](#); [Unal et al., 2005](#)). [Carslaw et al. \(2012a\)](#) took advantage of the natural experiment of the Icelandic volcano eruption of 2010, when airports across Europe were shut down for 6 days, to evaluate the local effect on airport NO<sub>x</sub> concentrations. Downwind of the airport, a 38% reduction in average NO<sub>x</sub> concentrations (from 42 ppb down to 26 ppb) was observed. At shipping ports and airports, traffic from ground-level support activities can also contribute a large portion to NO<sub>x</sub> emissions from these sources ([Klapmeyer and Marr,](#)

[2012](#); [Kim et al., 2011](#)). Outside of urban centers where traffic is not a dominant source, other sources of NO<sub>x</sub> may include wildfires and residential wood burning. As such, NO<sub>x</sub> concentration may not always be a reliable proxy for traffic pollution. [Section 2.3](#) discusses different sources of NO<sub>x</sub> in more detail.

---

### 3.3.2 Indoor Dynamics

#### 3.3.2.1 Sources, Sinks, and Penetration

The general understanding of oxide of nitrogen production indoors has not changed since the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)). Indoor sources of oxides of nitrogen are combustion-based, including gas stoves, gas heating, oil furnaces, coal stoves, wood burning stoves, kerosene heaters, smoking, candle burning, and to a lesser extent, electric cooking. The magnitude of indoor oxides of nitrogen depends on ventilation of the indoor space and appliances, source strength, and rate of pollutant reaction. Recent studies show associations between indoor combustion and indoor NO<sub>2</sub> levels ([Vrijheid et al., 2012](#); [Kornartit et al., 2010](#); [Park et al., 2008](#)) or indoor NO<sub>x</sub> levels ([Cattaneo et al., 2014](#)), depending on what was measured during the study. HONO can also be emitted directly during combustion or through surface reactions. [Park et al. \(2008\)](#) measured HONO and NO<sub>2</sub> concentrations during combustion and compared their results with older studies in the peer-reviewed literature, as shown in [Table 3-4](#). High peak-to-mean ratios suggest high temporal variability of exposures that might be differentiated from exposures of outdoor origin through time-series analysis. This review also generally found higher HONO concentrations in the presence of indoor combustion sources. Oxides of nitrogen can be lost through indoor deposition and ventilation ([U.S. EPA, 2008c](#)). [Sarwar et al. \(2002\)](#) reported deposition velocities of  $6-7 \times 10^{-5}$  m/seconds for NO<sub>2</sub>, HONO, HNO<sub>3</sub>, HO<sub>2</sub>NO<sub>2</sub>, NO<sub>3</sub><sup>-</sup>, and N<sub>2</sub>O<sub>5</sub>. Much lower deposition velocities (not detected– $2 \times 10^{-6}$  m/s) were reported for NO, PAN, and organic NO<sub>3</sub><sup>-</sup> species.

**Table 3-4 Indoor nitrogen dioxide and nitrous acid concentrations in the presence and absence of combustion.**

Study	Combustion Source	Measurement Frequency	NO <sub>2</sub> (ppb)		HONO (ppb)	
			Peak	24-h avg	Peak	24-h avg
<a href="#">Brauer et al. (1990)<sup>a</sup></a>	No source (background)	15 min	29	17	8	5
	Gas range <sup>a</sup>	15 min	157	36	35	13
	Convective space heater <sup>a</sup>	15 min	955	209	106	42
<a href="#">Brauer et al. (1990)<sup>b</sup></a>	No source	15 min	5.0	1.8	3.5	3.4
	Gas range <sup>b</sup>	15 min	37	8	31	9.6
<a href="#">Brauer et al. (1991)<sup>c</sup></a>	Unknown	15 min	NR	NR	NR	1–12
<a href="#">Spengler et al. (1993)<sup>d</sup></a>	Gas range, stove, furnace	24 h	NR	60 (24–115)	NR	4.7 (2–8)
<a href="#">Simon and Dasgupta (1995)<sup>e</sup></a>	Kerosene heater	8 min	NR	NR	5–10	NR
<a href="#">Leaderer et al. (1999)<sup>f</sup></a>	No source <sup>f</sup>	24 h	NR	NR	NR	0.8 (0.0–2.9)
	Gas stoves <sup>f</sup>	24 h	NR	NR	NR	4.0 (0.0–11.3)
	Kerosene heaters <sup>f</sup>	24 h	NR	NR	NR	6.8 (0.2–35.9)
	No source <sup>f</sup>	24 h	NR	NR	NR	2.4 (0.1–20.1)
	Gas stoves <sup>f</sup>	24 h	NR	NR	NR	5.5 (0.4–20.1)
<a href="#">Khoder (2002)<sup>g</sup></a>	Gas appliances (summer)	24 h	NR	39 (20–73)	NR	3.7 (1.3–7.3)
	Gas appliances (winter)	24 h	NR	65 (27–120)	NR	6.8 (1.6–12.5)
<a href="#">Lee et al. (2002)<sup>h</sup></a>	Gas range, etc.	6 day	NR	28 (4.3–52.0)	NR	4.6 (0.1–21.1)

**Table 3-4 (Continued): Indoor nitrogen dioxide and nitrous acid concentrations in the presence and absence of combustion.**

Study	Combustion Source	Measurement Frequency	NO <sub>2</sub> (ppb)		HONO (ppb)	
			Peak	24-h avg	Peak	24-h avg
<a href="#">Jarvis et al. (2005)</a> <sup>i</sup>	Gas hob		NR	12.8	NR	4.1
	Gas oven		NR	12.8	NR	5.0
<a href="#">†Hong et al. (2007)</a> <sup>j</sup>	Gas range	4 min	81.1	NR	9.3	NR
<a href="#">†Park et al. (2008)</a> <sup>k</sup>	Gas range	4 min	189.3	19.4	15.2	2.1

avg = average; h = hour; HONO = nitrous acid; IL = Illinois; kcal/h = kilocalories per hour; MA = Massachusetts; min = minute; NM = New Mexico, NO<sub>2</sub> = nitrogen dioxide; NR = not reported; ppb = parts per billion.

<sup>a</sup>Location: Chicago, IL research home, unvented combustion condition; gas range operation hours: 1 h (with one burner and 2,320 kcal/h); convective space heater operation hours: 4 h (with one burner and 2,785 kcal/h).

<sup>b</sup>Location: Maryland research home, unvented combustion condition; gas range operation hours: 1 h (with one burner and 2,320 kcal/h).

<sup>c</sup>Location: 11 Boston, MA homes (winter).

<sup>d</sup>Location: 10 homes in Albuquerque, NM (winter).

<sup>e</sup>Location: Four different home environments with a small kerosene heater (2,270 kcal/h).

<sup>f</sup>Location: 58 homes (summer) and 223 homes (winter) in southwest Virginia and Connecticut; 39 inside homes without gas stoves (summer); 19 inside homes with gas stoves (summer); 74 inside kerosene-heater homes (winter); 96 inside homes without kerosene heaters and gas stoves (winter); 52 inside homes without kerosene heaters and with gas stoves (winter).

<sup>g</sup>Location: Four homes in suburban residential areas in Greater Cairo, Egypt.

<sup>h</sup>Location: 119 homes in southern California (spring).

<sup>i</sup>Location: Homes in European community.

<sup>j</sup>Location: Living room of an apartment in Gwangju, Korea (May 2006).

<sup>k</sup>Location: Korean apartment (city and year unspecified, October).

Source: Reprinted with permission of Elsevier, [Park et al. \(2008\)](#).

<sup>†</sup>Studies published since the 2008 ISA for Oxides of Nitrogen.

### 3.3.2.2 Indoor Chemistry

The 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) described well-established reactions involving oxides of nitrogen and other indoor air pollutants for gas-phase and surface chemistry that serves as both a source and sink for oxides of nitrogen. Knowledge of indoor chemistry helps identify potential sources of uncertainty in estimates of indoor exposure to ambient oxides of nitrogen. Moreover, epidemiologic studies of indoor exposure may providing supporting evidence to the assessment of health effects from ambient NO<sub>2</sub> exposure. Identification of the uncertainty in those exposure estimates can aid interpretation of those studies.

For gas-phase reactions, indoor NO can be oxidized to NO<sub>2</sub> via reaction with O<sub>3</sub> or HO<sub>2</sub> radicals generated by indoor O<sub>3</sub> chemistry or VOCs found in household products. NO<sub>2</sub> can react with O<sub>3</sub> to form NO<sub>3</sub> radicals that may subsequently oxidize organic compounds. NO<sub>2</sub> also reacts with free radicals to produce PAN. NO<sub>2</sub> removed through

surface reactions was known to contribute to NO levels indoors either by surface reduction of NO<sub>2</sub> or by reaction of NO<sub>2</sub> with aqueous HONO on indoor surfaces ([Spicer et al., 1989](#)). Conversion of NO<sub>2</sub> to HONO occurs through a number of indoor surface reactions, and the reaction increases with increased relative humidity ([U.S. EPA, 2008c](#)). A recent study has demonstrated the role of irradiance in humidity-driven surface reaction of NO<sub>2</sub> to HONO on paints ([Bartolomei et al., 2014](#)). Surface reactions of NO and OH radicals may also produce HONO, but the reaction rate is slower than for NO<sub>2</sub>.

Indoor combustion can lead to direct emission of NO and HONO, and conversion of NO to NO<sub>2</sub> can lead to secondary HONO production from heterogeneous reactions involving NO<sub>2</sub> on indoor surfaces. [Park et al. \(2008\)](#) observed HONO to be correlated with both NO (Spearman  $r = 0.64$ ) and NO<sub>2</sub> ( $r = 0.68$ ) during combustion. They noted that HONO concentrations were 4–8% of NO<sub>2</sub> concentrations during gas range operations but rose to ~25% of NO<sub>2</sub> concentrations after combustion ceased, which underscores the role of surface reaction as the major source of HONO production. In a model of combustion products for oxides of nitrogen during candle and incense burning, [Loupa and Rapsomanikis \(2008\)](#) observed simultaneous NO and HONO production, the latter of which were in agreement with older test chamber results of HONO production during combustion ([De Santis et al., 1996](#)). These studies on surface reactions of NO<sub>2</sub> provide insight into indoor NO<sub>2</sub> sinks that may reduce NO<sub>2</sub> exposures as well as exposures to HONO, of which health effects are less well understood.

Recent gas-phase indoor chemistry work has shed light on processes involving organic compounds and/or secondary organic aerosols (SOA). [Carslaw et al. \(2012b\)](#) modeled indoor reactions forming SOA and observed that for their base case simulation, organic nitrates constituted 64% of the overall SOA, while PANs constituted an additional 21%. In sensitivity tests varying ambient concentrations and meteorological conditions, organic nitrates varied from 23–76% of the SOA, and PAN varied from 6–42%. [Nøjgaard et al. \(2006\)](#) investigated the interference of NO<sub>2</sub> in ozonolysis of monoterpenes in a simulation of indoor air chemistry and observed that NO<sub>2</sub> reacted with O<sub>3</sub> and hence reduced SOA formation from ozonolysis of alkenes  $\alpha$ -pinene and  $\beta$ -pinene while increasing the mode of the SOA size distribution. Intermediate NO<sub>3</sub> products may play a role in this process, as described above. However, the presence of NO<sub>2</sub> had less effect on ozonolysis of *d*-limonene, and this is thought to occur because the ozonolysis reaction rate is faster. In chamber experiments and computational chemistry models, [Cao and Jang \(2008\)](#) and [Cao and Jang \(2010\)](#) tested toluene SOA formation in the presence of low ( $\leq 3$  ppb), medium (90–135 ppb), and high (280–315 ppb) NO<sub>x</sub> concentrations. They found that the organic matter component of the toluene SOA yield generally decreased with increasing NO<sub>x</sub> concentrations, especially when high NO concentrations (~222–242 ppb) were present. [Ji et al. \(2012\)](#) explored rate constants of NO<sub>2</sub> reactions

with various low molecular weight aldehydes found indoors and observed that the reaction rates,  $k$ , increased in the following order:

$k_{\text{formaldehyde}} < k_{\text{acetaldehyde}} < k_{\text{propanal}} < k_{\text{butanal}}$ . [Ji et al. \(2012\)](#) concluded from this observation that  $\text{NO}_2$  reacts more with longer chain, low-molecular-weight aldehydes compared with shorter chain, low-molecular-weight aldehydes.  $\text{RC(=O)}$  radicals and HONO were both observed to be products of these reactions. These sinks may result in lower  $\text{NO}_2$  exposures, but little information is available regarding organic nitrate reaction product exposures.

Reactions involving  $\text{N}_2\text{O}_5$  (formed by reaction of  $\text{NO}_2$  and  $\text{NO}_3$  in the presence of another molecule) in an indoor context have been studied in recent years. In an examination of  $\text{NO}_3$  and  $\text{N}_2\text{O}_5$  (measured as the sum of those two species) in an office building, [Nøjgaard \(2010\)](#) observed that alkenes remove more indoor  $\text{NO}_3$  and  $\text{N}_2\text{O}_5$  than either ventilation or surface deposition. [Griffiths et al. \(2009\)](#) studied  $\text{N}_2\text{O}_5$  uptake by organic aerosols in a reaction cell and large chamber (260  $\text{m}^3$ ) and observed little  $\text{N}_2\text{O}_5$  uptake by solid organic aerosols, more efficient uptake by liquid aerosols, and uptake that increased with increasing RH.  $\text{N}_2\text{O}_5$  uptake by dicarboxylic acids (oxalic acid, malonic acid, succinic acid, and glutaric acid) was 30–90% of that by  $(\text{NH}_4)_2\text{SO}_4$  and  $(\text{NH}_4)_2\text{SO}_4$ -mixed dicarboxylic acid aerosols at similar RH.  $\text{N}_2\text{O}_5$  uptake by malonic or azelaic acid in the presence of higher RH is consistent with findings of [Thornton et al. \(2003\)](#) for experiments conducted in a reaction cell. [Raff et al. \(2009\)](#) suggested that  $\text{N}_2\text{O}_5$  autoionizes to  $\text{NO}_2 + \text{NO}_3^-$  and then reacts quickly with water to form  $\text{HNO}_3$ ; it is possible that  $\text{HNO}_3$  might then participate in the liquid aerosol reactions described by [Griffiths et al. \(2009\)](#) and [Thornton et al. \(2003\)](#). [Raff et al. \(2009\)](#) also proposed autoionization of  $\text{N}_2\text{O}_5$  as a likely mechanism for reaction with HCl, which would result in nitrosyl chloride (ClNO) and  $\text{HNO}_3$  formation while  $\text{NO}_2$  and water vapor experienced an intermediate surface reaction to form HONO, which would react with HCl. Complexity of reactions involving  $\text{N}_2\text{O}_5$  in creating  $\text{NO}_2$  as an intermediary reaction product also lends uncertainty to  $\text{NO}_2$  exposure assessment. This uncertainty may lead to variability in personal or indoor  $\text{NO}_2$  exposure measurements.

---

## 3.4 Exposure Assessment and Epidemiologic Inference

The 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) examined several factors influencing assessment of exposure to ambient oxides of nitrogen and measurements used to represent exposures. These factors include high spatial and temporal variability of  $\text{NO}_2$  concentrations in urban areas and near roads, location of  $\text{NO}_2$  samplers, and ventilation of indoor microenvironments. The 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) concluded that errors associated with the use of  $\text{NO}_2$  concentrations measured at central

site monitors as exposure metrics for epidemiologic studies tended to bias the health effect estimate towards the null for both short-term exposure and long-term exposure epidemiologic studies. The following sections explore new evidence regarding a conceptual exposure model, exposure metrics employed in epidemiologic studies, personal-ambient relationships, factors that introduce exposure error, potential confounding, and how the exposure errors may or may not introduce bias and uncertainty into epidemiologic health effect estimates, depending on the epidemiologic study design.

---

### 3.4.1 Conceptual Model of Total Personal Exposure

Total personal exposure ( $E_T$ ) integrates the product of microenvironmental concentration and fraction of time spent in a microenvironment across an individual's microenvironmental exposures:

$$E_T = \sum_j^n C_j t_j$$

**Equation 3-2**

where  $C_j$  = average NO<sub>2</sub> concentration in the  $j$ th microenvironment,  $t_j$  = fraction of total time spent in the  $j$ th microenvironment, and  $n$  = total number of microenvironments which the individual has encountered ([U.S. EPA, 2008c](#); [Klepeis et al., 2001](#)). Hence, both the microenvironmental NO<sub>2</sub> concentration and time-activity aspects of total exposure must be considered.

Alternatively, based on the principle of mass balance, an individual's total NO<sub>2</sub> exposure can be expressed as the sum of its ambient NO<sub>2</sub> exposure ( $E_a$ ) and nonambient NO<sub>2</sub> exposure ( $E_{na}$ ) components ([U.S. EPA, 2008c](#); [Wilson and Brauer, 2006](#)):

$$E_T = E_a + E_{na}$$

**Equation 3-3**

$E_a$  represents the amount of NO<sub>2</sub> exposure derived from outdoor sources, and  $E_{na}$  represents the amount of NO<sub>2</sub> exposure from indoor sources. The microenvironmental formulation presented in [Equation 3-2](#) and the component formulation presented in [Equation 3-3](#) can be rectified by recognizing that  $E_a$  and  $E_{na}$  can both be expressed in terms of microenvironmental concentrations and time spent in each outdoor and indoor microenvironment. During the fraction of a day spent in each outdoor microenvironment ( $y_{o,j}$ ), ambient exposure to NO<sub>2</sub> having an outdoor concentration of  $C_{o,j}$  is:

$$E_{o,j} = y_{o,j}C_{o,j}$$

**Equation 3-4**

Indoor NO<sub>2</sub> exposures in the *j*th microenvironment ( $E_{i,j}$ ) are more complicated because some part of indoor exposure may emanate from nonambient sources, and some part of indoor exposure infiltrates from outdoors. Indoor exposures from nonambient sources are given as  $E_{na,j}$ . Exposures in each indoor microenvironment from ambient sources are also influenced by infiltration of outdoor NO<sub>2</sub> ( $INF_j$ ), time spent indoors ( $y_{i,j}$ ), and  $C_{o,j}$ :

$$E_{i,j} = y_{i,j}INF_j \cdot C_{o,j} + E_{na,j}$$

**Equation 3-5**

Infiltration is a function of the *j*th microenvironment's air exchange rate ( $a_j$ ), air pollutant penetration ( $P_j$ ), and decay rate ( $k_j$ ):

$$INF_j = P_j a_j / (a_j + k_j)$$

**Equation 3-6**

Hence, indoor NO<sub>2</sub> exposure for microenvironment *j* is the sum of the ambient and nonambient components:

$$E_{i,j} = y_{i,j} [P_j a_j / (a_j + k_j)] C_{o,j} + E_{na,j}$$

**Equation 3-7**

Finally,  $E_a$  can be described as the sum of the outdoor NO<sub>2</sub> exposure and the ambient component of the indoor NO<sub>2</sub> exposure, summed over *j* indoor microenvironments ([U.S. EPA, 2008c](#); [Wilson and Brauer, 2006](#); [Wilson et al., 2000](#)):

$$E_a = \sum_{j=1}^n y_{o,j} C_{o,j} + \sum_{j=1}^n y_{i,j} [P_j a_j / (a_j + k_j)] C_{o,j}$$

**Equation 3-8**

Ambient concentration of NO<sub>2</sub> is often used as a surrogate for human exposure. In concert, a second simplifying assumption is often made that the exposed individual resides in one indoor microenvironment, such that time-activity data are reduced to "time indoors" and "time outdoors." Errors associated with this approach, which may vary depending on the epidemiologic study design in which the exposure surrogate is used, are described in detail in [Section 3.4.3](#). In this case, outdoor microenvironmental NO<sub>2</sub> exposures ( $E_o$ ) are expressed simply as the product of the fraction of all time spent

outdoors ( $y_o$ ) and ambient NO<sub>2</sub> concentration ( $C_a$ ):  $E_o = y_o C_a$ . Furthermore, based on the assumption that the individual occupies only one indoor and one outdoor microenvironment, then the infiltration term can be simplified to  $y_i[(P \times a)/(a + k)]$ , and because  $y_o + y_i = 1$ :

$$E_a = \{y_o + y_i[(P \times a)/(a + k)]\}C_a$$

**Equation 3-9**

Then, an exposure factor ( $\alpha$ ) can be defined to express the influence of time-weighting and infiltration on NO<sub>2</sub> exposure:

$$\alpha = y_o + (1 - y_o)[(P \times a)/(a + k)]$$

**Equation 3-10**

Last, an approximate expression for total personal exposure is obtained:

$$E_T = \alpha C_a + E_{na}$$

**Equation 3-11**

Comparison of [Equations 3-3](#), [3-9](#), and [3-11](#) reveals that  $\alpha$  can also be approximated as the ratio  $E_a/C_a$ . Subsequent sections examine how  $E_a$ ,  $\alpha$ , and  $C_a$  are modeled or measured, and how errors and uncertainties in the simplifying assumptions behind [Equations 3-9](#), [3-10](#), and [3-11](#) may influence health effect estimates computed from epidemiologic studies of varying design.

---

### 3.4.2 Personal-Ambient Relationships and Nonambient Exposures

Personal exposure measurements typically capture both ambient and nonambient exposure contributions; for the purpose of this document, these are referred to as “total personal exposure” measurements. The 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) concluded that literature relating ambient NO<sub>2</sub> concentrations measured by a central site monitor to personal NO<sub>2</sub> exposures was mixed for studies of both short-term and long-term NO<sub>2</sub> exposure, with some studies finding associations between the personal and central site monitors and other studies finding no association. These inconsistencies reflected various factors that influence exposure in respective studies, including proximity and strength of sources of ambient and nonambient NO<sub>x</sub>, spatiotemporal variability of NO<sub>2</sub> concentrations, and time-activity behavior of the exposed sample population. Recent studies have found that personal NO<sub>2</sub> concentration measurements taken for adults and children tend to be more highly correlated with indoor concentrations compared with outdoor or ambient concentrations, although wide variability in the correlations was observed ([Tables 3-5](#) and [3-6](#)). Personal-outdoor

(i.e., measurements taken outdoors but not at a central site monitor) correlations also tended to be higher for summer compared with winter. This is not surprising because open windows and greater time spent outdoors during summer likely increase exposure to outdoor air ([Brown et al., 2009](#)). The study results indicate that, for epidemiologic studies of short-term exposure, indoor sources of NO<sub>2</sub> can add noise to the ambient NO<sub>2</sub> exposure signal. As described further in [Section 3.4.5.1](#), uncertainty in the NO<sub>2</sub> exposure term can lead to negative bias and added uncertainty in the epidemiologic health effect estimate for short-term exposure studies.

**Table 3-5 Ambient, outdoor, transport, indoor, and personal nitrogen dioxide measurements (ppb) across studies.**

Study	Location	Time Period	Sampling Interval	Ambient (Central Site)	Outdoor (Outside Residence)	Transport	Indoor	Personal	Personal-Ambient Slope <sup>a,b</sup>
† <a href="#">Sarnat et al. (2012)</a>	El Paso, TX (large city)	Jan–May, 2008	96-h	14.0–20.6 <sup>c</sup>	4.5–14.2 <sup>c</sup>	NR <sup>d</sup>	4.0–8.1 <sup>c</sup>	NR	NR
	Ciudad Juarez, Mexico (large city)			NR	18.7–27.2 <sup>c</sup>	NR	23.1–120.8	NR	NR
† <a href="#">Williams et al. (2012b)</a> ; † <a href="#">Meng et al. (2012a)</a>	Detroit, MI (large city)	Summer, 2004–2007	24-h	Williams: 22.0 <sup>e</sup> ; Meng: 22.0 <sup>e</sup> ; 22.7 <sup>c</sup>	NR	NR	NR	Total: Williams: 25.5 <sup>c</sup> ; Meng: 25.4 <sup>c</sup> ; Ambient: 16.0 <sup>e</sup> ; 21.0 <sup>c</sup>	Meng: 0.24; 0.13 <sup>f</sup>
		Winter, 2004–2007		24.0 <sup>e</sup> ; 23.9 <sup>c</sup>	NR	NR	NR	Total: 24.0 <sup>e</sup> ; 35.6 <sup>c</sup> ; Ambient: 18.0 <sup>e</sup> ; 20.4 <sup>c</sup>	Meng: 0.08; 0.07 <sup>f</sup>
† <a href="#">Suh and Zanobetti (2010b)</a>	Metropolitan Atlanta, GA (large city)	Fall, 1999–Spring, 2000	24-h	17.96 <sup>e</sup> ; 17.13 <sup>c</sup>	NR	NR	NR	8.08 <sup>e</sup> ; 11.60 <sup>c</sup>	NR

**Table 3-5 (Continued): Ambient, outdoor, transport, indoor, and personal nitrogen dioxide measurements (ppb) across studies.**

Study	Location	Time Period	Sampling Interval	Ambient (Central Site)	Outdoor (Outside Residence)	Transport	Indoor	Personal	Personal-Ambient Slope <sup>a,b</sup>
† <a href="#">Brown et al. (2009)</a>	Metropolitan Boston, MA (large city)	Nov 1999–Jan 2000	24-h	25.8 <sup>a</sup> ; 26.8 <sup>c</sup>	NR	NR	NR	10.4 <sup>a</sup> ; 12.9 <sup>c</sup>	All: 0.19 Windows closed: 0.09 Windows open: 0.31 Low AER: 0.21 High AER: 0.15
		Jun–Jul 2000		22.0 <sup>a</sup> ; 22.8 <sup>c</sup>	NR	NR	NR	13.9 <sup>a</sup> ; 17.4 <sup>c</sup>	All: 0.23 Windows closed: 0.64 Windows open: 0.10 Low AER: 0.34 High AER: 0.19
† <a href="#">Delfino et al. (2008a)</a>	Riverside and Whittier, CA (SoCAB) (large city)	Jul–Dec 2003 (Riverside); Jul–Dec 2004 (Whittier)	24-h	25.3 <sup>a</sup> ; 25.0 <sup>c</sup>	NR	NR	NR	26.7 <sup>a</sup> ; 28.6 <sup>c</sup>	NR
† <a href="#">Delgado-Saborit (2012)</a>	Birmingham, U.K. (large city)	Jul–Oct 2011	5-min	47 <sup>c</sup>	64 <sup>c</sup>	Car: 40 <sup>c</sup> Bus: 71 <sup>c</sup> Bike: 125 <sup>c</sup> Train: 58 <sup>c</sup>	Office: 14 <sup>c</sup> Home: 17 <sup>c</sup>	All: 23 <sup>c</sup> Gas oven: 31 <sup>c</sup> Electric oven: 19 <sup>c</sup>	1-h avg: 0.044 Sampling event: 0.14

**Table 3-5 (Continued): Ambient, outdoor, transport, indoor, and personal nitrogen dioxide measurements (ppb) across studies.**

Study	Location	Time Period	Sampling Interval	Ambient (Central Site)	Outdoor (Outside Residence)	Transport	Indoor	Personal	Personal-Ambient Slope <sup>a,b</sup>
† <a href="#">Kornartit et al. (2010)</a>	Hertfordshire, U.K. (Greater London Area) (large city)	Winter 2000	7-day	NR	NR	NR	Electric oven: Bedroom: 7.8 <sup>c</sup> Living room: 7.9 <sup>c</sup> Kitchen: 7.1 <sup>c</sup>	Electric oven: 8.1 <sup>c</sup>  Gas oven: 11.2 <sup>c</sup>	NR
		Summer 2001		NR	NR	NR	Electric oven: Bedroom: 12.7 <sup>c</sup> Living room: 13.1 <sup>c</sup> Kitchen: 11.0 <sup>c</sup>	Electric oven: 13.3 <sup>c</sup>  Gas oven: 14.6 <sup>c</sup>	NR
							Gas oven: Bedroom: 14.3 <sup>c</sup> Living room: 14.7 <sup>c</sup> Kitchen: 14.2 <sup>c</sup>		

**Table 3-5 (Continued): Ambient, outdoor, transport, indoor, and personal nitrogen dioxide measurements (ppb) across studies.**

Study	Location	Time Period	Sampling Interval	Ambient (Central Site)	Outdoor (Outside Residence)	Transport	Indoor	Personal	Personal-Ambient Slope <sup>a,b</sup>
† <a href="#">Lee et al. (2013)</a>	Seoul, South Korea (large city)	Jul 2008	NR	29.5 <sup>f</sup> ; 30.7 <sup>c</sup>	NR	NR	Home: 24.4 <sup>g</sup> ; 25.7 <sup>c</sup> Work: 19.2 <sup>g</sup> ; 21.5 <sup>c</sup>	25.3 <sup>g</sup> ; 27 <sup>c</sup>	NR
		Jan 2009	NR	29.5 <sup>g</sup> ; 31.1 <sup>c</sup>	NR	NR	Home: 20.9 <sup>g</sup> ; 24.9 <sup>c</sup> Work: 27.9 <sup>g</sup> ; 29.9 <sup>c</sup>	22.5 <sup>g</sup> ; 24.2 <sup>c</sup>	NR
	Daegu, South Korea (mid-sized city)	Jul 2008	NR	19.9 <sup>g</sup> ; 21.1 <sup>c</sup>	NR	NR	Home: 19.3 <sup>g</sup> ; 20.3 <sup>c</sup> Work: 21.3 <sup>g</sup> ; 22.8 <sup>c</sup>	21.4 <sup>g</sup> ; 22.6 <sup>c</sup>	NR
		Jan 2009	NR	23.0 <sup>g</sup> ; 24.3 <sup>c</sup>	NR	NR	Home: 23.3 <sup>g</sup> ; 25.1 <sup>c</sup> Work: 20.3 <sup>g</sup> ; 22.9 <sup>c</sup>	20.3 <sup>g</sup> ; 21.7 <sup>c</sup>	NR
	Asan, South Korea (small city)	Jul 2008	NR	26.0 <sup>g</sup> ; 27.9 <sup>c</sup>	NR	NR	Home: 23.8 <sup>g</sup> ; 24.9 <sup>c</sup> Work: 21.1 <sup>g</sup> ; 25.6 <sup>c</sup>	22.6 <sup>g</sup> ; 24.3 <sup>c</sup>	NR
		Jan 2009	NR	21.6 <sup>g</sup> ; 23.9 <sup>c</sup>	NR	NR	Home: 20.3 <sup>g</sup> ; 22.9 <sup>c</sup> Work: 13.0 <sup>g</sup> ; 18.6 <sup>c</sup>	19.9 <sup>g</sup> ; 22.3 <sup>c</sup>	NR

**Table 3-5 (Continued): Ambient, outdoor, transport, indoor, and personal nitrogen dioxide measurements (ppb) across studies.**

Study	Location	Time Period	Sampling Interval	Ambient (Central Site)	Outdoor (Outside Residence)	Transport	Indoor	Personal	Personal-Ambient Slope <sup>a,b</sup>
† <a href="#">Lee et al. (2013)</a> (Continued)	Suncheon, South Korea (rural)	Jul 2008	NR	15.0 <sup>g</sup> ; 15.9 <sup>c</sup>	NR	NR	Home: 13.0 <sup>g</sup> ; 14.3 <sup>c</sup> Work: 12.0 <sup>g</sup> ; 14.5 <sup>c</sup>	14.0 <sup>g</sup> ; 16.3 <sup>c</sup>	NR
		Jan 2009	NR	12.5 <sup>g</sup> ; 15.2 <sup>c</sup>	NR	NR	Home: 15.9 <sup>g</sup> ; 20.4 <sup>c</sup> Work: 9.3 <sup>g</sup> ; 12.9 <sup>c</sup>	12.9 <sup>g</sup> ; 15.7 <sup>c</sup>	NR
	Total	Jul 2008	NR	21.7 <sup>g</sup> ; 23.7 <sup>c</sup>	NR	NR	Home: 19.5 <sup>g</sup> ; 21.2 <sup>c</sup> Work: 18.4 <sup>g</sup> ; 21.4 <sup>c</sup>	20.5 <sup>g</sup> ; 22.6 <sup>c</sup>	NR
		Jan 2009	NR	20.6 <sup>g</sup> ; 23.6 <sup>c</sup>	NR	NR	Home: 19.9 <sup>g</sup> ; 23.3 <sup>c</sup> Work: 16.4 <sup>g</sup> ; 21.1 <sup>c</sup>	18.6 <sup>g</sup> ; 21.0 <sup>c</sup>	NR
† <a href="#">Du et al. (2011)</a>	Beijing, China	Oct 2006	Varied with transit times	NR	NR	Subway: 20 <sup>c</sup> ; Nonsubway: 22 <sup>c</sup> ; Taxi drivers: 25 <sup>c</sup>	NR	NR	NR

**Table 3-5 (Continued): Ambient, outdoor, transport, indoor, and personal nitrogen dioxide measurements (ppb) across studies.**

Study	Location	Time Period	Sampling Interval	Ambient (Central Site)	Outdoor (Outside Residence)	Transport	Indoor	Personal	Personal-Ambient Slope <sup>a,b</sup>
<a href="#">†Physick et al. (2011)</a>	Melbourne, Australia (large city)	May 2006; Jun 2006; Apr 2007; May 2007	Ambient: 1 h; Personal: Participants wore two sets of passive samplers. One was worn for 48 h. One was worn only during the hours spent at home, at work, in transit, or while performing other activities.	6:00 p.m.to 8:00 a.m.: 19.8 <sup>e</sup> ; 18.7 <sup>c</sup> 8:00 a.m. to 6:00 p.m.: 20.3 <sup>e</sup> ; 21.2 <sup>c</sup>	NR	NR	Home: 17.2 <sup>e</sup> ; 16.8 <sup>c</sup> Work: 21.6 <sup>e</sup> ; 21.7 <sup>c</sup>	Total: 12.2 <sup>h</sup> Home: 8.2 <sup>h</sup> Work: 14.7 <sup>h</sup> Transit: 23.4 <sup>h</sup> Other: 17.4 <sup>h</sup>	NR
<a href="#">†Schembari et al. (2013)</a>	Barcelona, Spain (large city)	Nov 2008 and Oct 2009	7-day	NR	18.7 <sup>g,i</sup> ; 19.4 <sup>c,i</sup>	NR	19.2 <sup>g,i</sup> ; 20.6 <sup>c,i</sup>	17.7 <sup>g,i</sup> ; 18.6 <sup>c,i</sup>	1.01 <sup>k</sup>
<a href="#">†Molloy et al. (2012)</a>	Melbourne, Australia (large city)	Aug 2008–Dec 2008; Jan 2009–Apr 2009	7-day	NR	9.5 <sup>e</sup> ; 10.0 <sup>c</sup>	NR	7.9 <sup>e</sup> ; 8.4 <sup>c</sup>	NR	0.9 <sup>k</sup>
<a href="#">†Pegas et al. (2012)</a>	Aveiro, Portugal (small city center, suburb)	Apr–Jun 2010	7-day	NR	City center: 10.5 <sup>c,i</sup> ; Suburb: 10.1 <sup>c,i</sup>	NR	City center: 7.4 <sup>c,i,j</sup> ; Suburb: 6.9 <sup>c,i,j</sup>	NR	NR

**Table 3-5 (Continued): Ambient, outdoor, transport, indoor, and personal nitrogen dioxide measurements (ppb) across studies.**

Study	Location	Time Period	Sampling Interval	Ambient (Central Site)	Outdoor (Outside Residence)	Transport	Indoor	Personal	Personal-Ambient Slope <sup>a,b</sup>	
† <a href="#">Chatzidiakou et al. (2014)</a>	Suburban London, U.K.	Nov 2011	5-day	NR	7.4	NR	3.7 <sup>l</sup>	NR	NR	
				NR	5.1	NR	2.9 <sup>l</sup>	NR	NR	
				NR	5.1	NR	2.7 <sup>l</sup>	NR	NR	
	London, U.K.				NR	19	NR	13 <sup>l</sup>	NR	NR
					NR	20	NR	16 <sup>l</sup>	NR	NR
					NR	22	NR	18 <sup>l</sup>	NR	NR
† <a href="#">Rivas et al. (2014)</a>	Barcelona and Sant Cugat del Vallès, Spain	Jan–Jun 2012	4-day	22 <sup>c</sup> ; 20 <sup>d</sup>	25 <sup>c</sup> ; 24 <sup>d</sup>	NR	16 <sup>c</sup> ; 16 <sup>d</sup>	NR	NR	

AER = air exchange rate; a.m. = ante meridiem; Aug = August; avg = average; CA = California; Dec = December; GA = Georgia; h = hour; Jan = January; MA = Massachusetts; MI = Michigan; min = minute; Nov = November; NR = not reported; Oct = October; ppb = parts per billion; SoCAB = South Coast Air Basin; TX = Texas; U.K. = United Kingdom.

<sup>a</sup>Unadjusted models only.

<sup>b</sup>Total personal NO<sub>2</sub> exposure vs. ambient concentration unless noted otherwise.

<sup>c</sup>Average.

<sup>d</sup>Median.

<sup>e</sup>Personal exposure to ambient NO<sub>2</sub> vs. ambient concentration.

<sup>f</sup>Geometric mean.

<sup>g</sup>Data provided by the authors for Figure 1 of [Physick et al. \(2011\)](#).

<sup>h</sup>Reported in µg/m<sup>3</sup> and converted to ppb assuming 25°C and 760 mm Hg.

<sup>i</sup>Averaged over 4 classrooms and 2 weeks.

<sup>j</sup>Indoor-outdoor ratio, rather than slope, is reported for [Schembari et al. \(2013\)](#).

<sup>k</sup>Integrated measurement over 2 weeks.

<sup>l</sup>Estimated from reported indoor-outdoor ratio and outdoor NO<sub>2</sub> concentration.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

**Table 3-6 Correlations between measured nitrogen dioxide concentrations from personal, outdoor, indoor, and ambient monitors.**

Study	Location	Personal-Ambient <sup>a</sup>	Personal-Outdoor <sup>b</sup>	Personal-Indoor	Outdoor <sup>b</sup> -Indoor
<a href="#">†Sarnat et al. (2012)<sup>c</sup></a>	Ciudad Juarez, Mexico; El Paso, TX	NR	NR	NR	CJ-A: 0.36; CJ-B: 0.92; EP-A: 0.66; EP-B: 0.01
<a href="#">†Williams et al. (2012a)<sup>c</sup></a>	Wayne County, MI	All Subjects: 0.11; Vest-compliant (>60%) <sup>e</sup> : 0.14	NR	NR	NR
<a href="#">†Suh and Zanobetti (2010b)<sup>c</sup></a>	Atlanta, GA	0.12	NR	NR	NR
<a href="#">†Brown et al. (2009)</a>	Boston, MA	Winter: 0.00; Summer: 0.03	NR	NR	NR
<a href="#">†Delfino et al. (2008a)</a>	2 southern California cities	0.43	NR	NR	NR
<a href="#">Kousa et al. (2001)</a>	Helsinki, Finland; Basel, Switzerland; Prague, Czech Republic	NR	0.61	0.73	0.66
<a href="#">†Delgado-Saborit (2012)</a>	Birmingham, U.K.	1-h NO <sub>2</sub> : 0.024; Sampling event NO <sub>2</sub> : 0.15	NR	NR	NR
<a href="#">†Lee et al. (2013)</a>	Seoul, South Korea	NR	Summer: 0.39; Winter: 0.47	Summer: 0.50; Winter: 0.55	Summer: 0.71; Winter: 0.22
	Daegu, South Korea	NR	Summer: 0.43; Winter: 0.47	Summer: 0.32; Winter: 0.59	Summer: 0.65; Winter: 0.57
	Asan, South Korea	NR	Summer: 0.62; Winter: 0.11	Summer: 0.63; Winter: 0.37	Summer: 0.67; Winter: 0.37
	Suncheon, South Korea	NR	Summer: 0.46; Winter: 0.56	Summer: 0.46; Winter: 0.60	Summer: 0.77; Winter: 0.80
	All 4 cities	NR	Summer: 0.58; Winter: 0.53	Summer: 0.60; Winter: 0.55	Summer: 0.78; Winter: 0.55

**Table 3-6 (Continued): Correlations between measured nitrogen dioxide concentrations from personal, outdoor, indoor, and ambient monitors.**

Study	Location	Personal-Ambient <sup>a</sup>	Personal-Outdoor <sup>b</sup>	Personal-Indoor	Outdoor <sup>b</sup> -Indoor
† <a href="#">Sahsuvaroglu et al. (2009)</a> <sup>d</sup>	Lake Ontario, Canada (winter)	NR	All Subjects: 0.002; Non-ETS: 0.020	All Subjects: 0.430; Non-ETS: 0.283	NR
	Lake Ontario, Canada (spring)	NR	All Subjects: 0.233; Non-ETS: 0.187	All Subjects: 0.589; Non-ETS: 0.599	NR
	Lake Ontario, Canada (summer)	NR	All Subjects: 0.067; Non-ETS: 0.011	All Subjects: 0.822; Non-ETS: 0.783	NR
	Lake Ontario, Canada (all seasons)	NR	All Subjects: 0.517; Non-ETS: 0.540	All Subjects: 0.729; Non-ETS: 0.693	NR
† <a href="#">Schembari et al. (2013)</a> <sup>d</sup>	Barcelona, Spain	NR	0.58	0.78	0.53
† <a href="#">Vieira et al. (2012)</a> <sup>c</sup>	São Paulo, Brazil	NR	<0.35	NR	All subjects: 0.13; Non-ETS: 0.42
† <a href="#">Van Roosbroeck et al. (2008)</a> <sup>c</sup>	the Netherlands (3 schools)	NR	0.35	NR	NR

CJ-A = Ciudad Juarez Site A; CJ-B = Ciudad Juarez Site B; EP-A = El Paso Site A; EP-B = El Paso Site B; ETS = Environmental Tobacco Smoke; GA = Georgia; h = hour; MA = Massachusetts; MI = Michigan; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; TX = Texas; U.K. = United Kingdom.

<sup>a</sup>Ambient = central site monitor.

<sup>b</sup>Outdoor = outside residence.

<sup>c</sup>Spearman coefficient.

<sup>d</sup>Pearson coefficient.

<sup>e</sup>Subjects wore the sampling vests at least 60% of the sampling period.

†Studies published since the 2008 ISA for Oxides of Nitrogen

Several studies have investigated factors that influence the relationship between short-term personal exposure measurements and ambient concentrations. It was observed that, even when the median or average total personal NO<sub>2</sub> exposures and ambient concentrations were comparable, the total personal exposure measurements and central site monitor concentrations might not have always been correlated. For example, [Williams et al. \(2012a\)](#) measured total personal NO<sub>2</sub> exposures for the Detroit Exposure

and Aerosol Research Study (DEARS) population of nonsmoking adults in 24-hour intervals and found a low association (Spearman  $r = 0.14$  for participants complying with study protocols;  $r = 0.11$  for all participants) between total personal NO<sub>2</sub> exposure with NO<sub>2</sub> concentrations measured at central site monitors. This result indicated the influence of nonambient sources on the DEARS participants' total personal NO<sub>2</sub> exposures, suggesting that total personal NO<sub>2</sub> exposures and ambient NO<sub>2</sub> concentrations are not always well correlated. Likewise, ([Suh and Zanobetti, 2010b](#)) measured correlation of Spearman  $r = 0.12$  between 24-hour total personal NO<sub>2</sub> exposure and central site NO<sub>2</sub> concentration measurements among an Atlanta panel of 30 adults. [Vieira et al. \(2012\)](#) calculated Spearman correlations between 12-hour outdoor NO<sub>2</sub> concentration, indoor NO<sub>2</sub> concentration, and personal NO<sub>2</sub> exposure measurements. All correlations between personal and outdoor NO<sub>2</sub> concentration measurements were below  $r = 0.35$ . Indoor and outdoor NO<sub>2</sub> concentrations were more correlated ( $r = 0.42$ ), although when smokers were included, correlation between indoor and outdoor NO<sub>2</sub> concentration dropped ( $r = 0.13$ ). [Van Roosbroeck et al. \(2008\)](#) compared personal NO<sub>2</sub> exposure measurements for children obtained over 1 to 4 weeks in a panel study with NO<sub>2</sub> concentration measurements taken outside the children's schools, and they observed Pearson correlation of  $r = 0.35$ . Outdoor school NO<sub>2</sub> concentrations underestimated personal NO<sub>2</sub> exposures when used as a surrogate, but when additional variables representing indoor exposures (such as exposure to gas cooking and unvented water heaters) were added to the model,  $r$  increased to 0.77, suggesting that indoor sources played a large role in NO<sub>2</sub> exposure among the study participants. [Bellander et al. \(2012\)](#) measured personal NO<sub>2</sub> exposure using 7-day integrated diffusion samplers and modeled it as a function of NO<sub>2</sub> concentrations measured at an urban area, rural area, roadside, and outside of the participants' homes and places of work in Stockholm County, Sweden. They observed slopes ranging from 0.25–0.37 ( $R^2 = 0.01$ –0.20). [Kousa et al. \(2001\)](#) developed a time-weighted microenvironmental model of NO<sub>2</sub> exposure based on time-activity data and 48-hour microenvironmental NO<sub>2</sub> concentration measurements. The microenvironmental model agreed well with personal exposure measurements ( $\beta = 0.90$ ;  $R^2 = 0.74$ ).

[Meng et al. \(2012b\)](#) performed a random effects meta-analysis of 15 studies that calculated slopes and correlations between personal NO<sub>2</sub> measurements of  $E_T$  and central site ambient NO<sub>2</sub> concentrations for 32 sample populations, of which 7 were from daily average analyses, 8 were from longitudinal panel analyses, and 17 were from analyses whose correlations were pooled over short time periods up to 1 week in length. Metaregression results are shown in [Table 3-7](#). [Meng et al. \(2012b\)](#) found that the magnitude and correlation of associations between personal NO<sub>2</sub> exposure and ambient NO<sub>2</sub> concentration depended on several factors, including study design (pooled data across days, longitudinal panel, or daily average), season, meteorological conditions,

ambient PM<sub>2.5</sub> concentration, and pre-existing cardiopulmonary disease of the exposure subjects. Together, the low associations reported in these studies indicate that most of the total personal NO<sub>2</sub> exposure measurements for these studies were influenced either by nonambient sources or by spatially variable NO<sub>2</sub> concentrations not well detected by the central site monitor. However, [Meng et al. \(2012b\)](#) also stated that the longitudinal panel studies included in their meta-analysis had several measurements below detection limit that could have erroneously reduced the correlations, which otherwise would be expected to be higher.

**Table 3-7 Metaregression results from 15 studies examining the relationship between personal nitrogen dioxide exposure measurements and ambient concentrations.**

Study Design	Based on Original Studies		Corrected for Publication Bias	
	Slope	Correlation	Slope	Correlation
Pooled <sup>a</sup>	0.40	0.42	0.30	0.37
Longitudinal panel <sup>b</sup>	0.14	0.16	0.14	0.16
Temporal average <sup>c</sup>	0.29	0.72	0.20	0.45

h = hour.

<sup>a</sup>Pooled analyses: [Piechocki-Minguy et al. \(2006\)](#), [Linn et al. \(1996\)](#), [Liard et al. \(1999\)](#), [Gauvin et al. \(2001\)](#), [Alm et al. \(1998\)](#), [Brown et al. \(2009\)](#), [Sarnat et al. \(2006\)](#), [Delfino et al. \(2008a\)](#). Averaging period varies among the studies between 24 h and 13 weeks.

<sup>b</sup>Longitudinal analyses: [Sarnat et al. \(2005\)](#), [Sarnat et al. \(2001\)](#), [Sarnat et al. \(2000\)](#), [Linaker et al. \(2000\)](#), [Kim et al. \(2006a\)](#), [Koutrakis et al. \(2005\)](#). 24-h measurements were made between 5–12 days during one or more seasons.

<sup>c</sup>Temporal average analyses: Averaging period varies among the studies. [Mukala et al. \(2000\)](#): 13 1-week periods; [Liard et al. \(1999\)](#): 140 24-h periods; [Alm et al., 1998](#): 6 1-week periods.

Source: Reprinted with permission from Elsevier; [Meng et al. \(2012b\)](#).


### 3.4.3 Factors Contributing to Error in Estimating Exposure to Ambient Nitrogen Dioxide

Recent studies of factors influencing exposure error build from the existing literature presented in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), which have focused on time-activity patterns, spatial variability of ambient NO<sub>2</sub> concentrations, infiltration, nonambient exposures, and instrument accuracy and precision, as described in the subsequent subsections. These factors can influence epidemiologic results for studies of short-term and long-term NO<sub>2</sub> exposure, as detailed further in [Section 3.4.5](#).

### 3.4.3.1 Activity Patterns

#### Temporal Patterns

The complex human activity patterns across the population (all ages) are illustrated in [Figure 3-3 \(Klepeis et al., 2001\)](#) for data from the National Human Activity Pattern Survey (NHAPS). This figure is presented to illustrate the diversity of daily activities among the entire population as well as the proportion of time spent in each microenvironment. Time-activity data become an important source of uncertainty when considering that ambient exposures vary in different microenvironments (e.g., transit, residential), and that exposure assignment is typically based on the assumption that study participants are in one location (residential) for the study duration.



Source: Reprinted with permission of Nature Publishing Group, [Klepeis et al. \(2001\)](#).

**Figure 3-3** Distribution of time sample population spends in various environments, from the U.S. National Human Activity Pattern Survey (all ages).

Different time-activity patterns have been found when analyzing data for different populations or lifestyles. For example, [Wu et al. \(2010\)](#) observed activity patterns for a panel of adults and children from Camden, NJ communities with larger percentages of nonwhites (85%) and those below the poverty line (33%) compared with NHAPS. The study participants spent more time outdoors compared with the nationwide cohort (3.8 hours vs. 1.8 hours nationally); note that [Wu et al. \(2010\)](#) undersampled participants ages 65+ years, and the median age of the population studied in [Wu et al. \(2010\)](#) was 27 years compared with 35 years nationwide. Other recent time-activity panel studies have included working adults ([Isaacs et al., 2013](#); [Bellander et al., 2012](#); [Kornartit et al., 2010](#)), pregnant women ([Iñiguez et al., 2009](#)), adolescents ([DeCastro et al., 2007](#)), and children ([Mölter et al., 2012](#); [Xue et al., 2004](#)). In many cases, the time-activity data were limited to residential, occupational, school, and outdoor location categories to simplify assignment of concentrations to which the subjects were estimated to be exposed in each microenvironment. The implication of these findings is, given that time-activity data vary among different populations, the one-location assumption used in many studies varies in accuracy among those different populations. However, because few studies are as large as NHAPS, it would be premature to make conclusions about time-activity data for smaller cohorts.

Time spent in different locations has also been found to vary by age. [Table 3-8](#) summarizes NHAPS data reported for four age groups, termed Very Young (0–4 years), School Age (5–17 years), Working (18–64 years), and Retired (65+ years) ([Klepeis et al., 1996](#)). The working population spent the least amount of time outdoors, while the school age population spent the most time outdoors. NHAPS respondents aged 65 and over spent somewhat more time outdoors than adults aged 18–64, with a greater fraction of time spent outdoors at a residence. Children aged 0–4 also spent most of their outdoor time in a residential outdoor location. On average, the fraction of time spent outdoors by school age respondents was 2.62 percentage points higher than working respondents, corresponding to approximately 38 minutes more time outdoors per day. Moreover, in a comparison of children (mostly less than age 8 years), adults mostly under age 55 years, and adults older than age 55 years, a larger proportion of children reported spending over 30 minutes performing vigorous outdoor physical activity ([Wu et al., 2011b](#)). Increased time spent outdoors or more time outdoors performing vigorous physical activity not only could have implications for differential exposure error in these age groups but also could influence NO<sub>2</sub> exposure of children and older adults and their risk of NO<sub>2</sub>-related health effects ([Section 7.5.1](#)).

**Table 3-8 Mean fraction of time spent in outdoor locations by various age groups in the National Human Activity Pattern Survey study.**

Age Group	Residential-Outdoor	Other Outdoor	Total Outdoors
0–4 yr	5.38%	0.96%	6.34%
5–17 yr	5.05%	2.83%	7.88%
18–64 yr	2.93%	2.33%	5.26%
65+ yr	4.48%	1.27%	5.75%

yr = year.

Source: Data from [Klepeis et al. \(1996\)](#).

Recently, [Kornartit et al. \(2010\)](#) tested the associations between time-weighted exposure estimates from area samples with personal sampling measurements for a London, U.K. panel study. [Kornartit et al. \(2010\)](#) measured NO<sub>2</sub> concentration for 1 week with passive Palmes tube samplers in several outdoor and indoor microenvironments for 55 subjects aged 21–60 years and correlated a time-weighted average of those microenvironmental NO<sub>2</sub> concentration measurements with personal NO<sub>2</sub> exposure measurements, also measured with Palmes tubes. They observed a slope of 0.94 for the relationship between time-weighted average microenvironmental NO<sub>2</sub> concentrations and personal NO<sub>2</sub> exposures ( $R^2 = 0.85$ ) in winter and a slope of 0.59 ( $R^2 = 0.65$ ) in summer. Higher levels of NO<sub>2</sub> were observed for both time-weighted average concentrations and personal exposures in summer compared with winter. However, correlations between personal NO<sub>2</sub> exposure and time-weighted microenvironmental NO<sub>2</sub> concentrations were higher in winter, implying panel studies using personal NO<sub>2</sub> exposure measurements may be more dominated by indoor sources during cold-weather months. The authors concluded that the time-weighting approach provided a reasonable approximation of personal exposure but sometimes underestimated it.

### Exertion Levels

Together with location, exertion level is an important determinant of exposure. [Table 3-9](#) summarizes ventilation rates for different age groups at several levels of activity as presented in Table 6-2 of the U.S. EPA’s *Exposure Factors Handbook* ([U.S. EPA, 2011b](#)). Most of the age-related variability is seen for moderate and high intensity activities, except for individuals under 1 year. For moderate intensity, ventilation rate increases with age through childhood and adulthood until age 61, after which a moderate

decrease is observed. Ventilation rate is most variable for high intensity activities. Children aged 1 to <11 years have ventilation rates of approximately 40 L/minute, while children aged 11+ years and adults have ventilation rates of approximately 50 L/minute. The peak is observed for the 51 to <61 year age group, at 53 L/minute, with lower ventilation rates for older adults. The role of physical activity as a modifier of health effect estimates is discussed in [Section 7.6.3](#).

**Table 3-9 Mean ventilation rates (L/min) at different activity levels for different age groups.**

Age Group (yr)	Sleep or Nap	Sedentary/Passive	Light Intensity	Moderate Intensity	High Intensity
Birth to <1	3.0	3.1	7.6	14	26
1 to <2	4.5	4.7	12	21	38
2 to <3	4.6	4.8	12	21	39
3 to <6	4.3	4.5	11	21	37
6 to <11	4.5	4.8	11	22	42
11 to <16	5.0	5.4	13	25	49
16 to <21	4.9	5.3	12	26	49
21 to <31	4.3	4.2	12	26	50
31 to <41	4.6	4.3	12	27	49
41 to <51	5.0	4.8	13	28	52
51 to <61	5.2	5.0	13	29	53
61 to <71	5.2	4.9	12	26	47
71 to <81	5.3	5.0	12	25	47
81+	5.2	4.9	12	25	48

yr = year.

Source: Data from Exposure Factors Handbook ([U.S. EPA, 2011b](#))

A dramatic increase in ventilation rate occurs as exercise intensity increases. For children and adults <31 years, high intensity activities result in nearly double the ventilation rate for moderate activity, which itself is nearly double the rate for light activity. Children have other important differences in ventilation compared to adults. As discussed in [Chapter 5](#), children tend to have a greater oral breathing contribution than adults, and

they breathe at higher minute ventilations relative to their lung volumes. Both of these factors tend to increase dose normalized to lung surface area.

Longitudinal activity pattern information is also an important determinant of exposure, as different people may exhibit different patterns of time spent outdoors over time due to age, gender, employment, and lifestyle-dependent factors. These differences may manifest as higher mean exposures or more frequent high-exposure episodes for some individuals. The extent to which longitudinal variability in individuals contributes to the population variability in activity and location can be quantified by the ratio of between-person variance to total variance in time spent in different locations and activities (the intraclass correlation coefficient, ICC). [Xue et al. \(2004\)](#) quantified ICC values in time-activity data collected by Harvard University for 160 children aged 7–12 years in southern California ([Geyh et al., 2000](#)). For time spent outdoors, the ICC was approximately 0.15, indicating that 15% of the variance in outdoor time was due to between-person differences. The ICC value might be different for other population groups.

The U.S. EPA's National Exposure Research Laboratory (NERL) has consolidated many of the most important human activity databases into one comprehensive database called the Consolidated Human Activity Database (CHAD). The current version of CHAD contains data from 19 human activity pattern studies (including NHAPS), which were conducted between 1982 and 1998 and evaluated to obtain over 33,000 person-days of 24-hour human activities in CHAD ([McCurdy et al., 2000](#)). The surveys include probability-based recall studies conducted by the U.S. EPA and the California Air Resources Board, as well as real-time diary studies conducted in individual U.S. metropolitan areas using both probability-based and volunteer subject panels. All ages of both genders are represented in CHAD. The data for each subject consist of one or more days of sequential activities, in which each activity is defined by start time, duration, activity type, and microenvironmental classification (i.e., location). Activities vary from one minute to one hour in duration, with longer activities being subdivided into clock-hour durations to facilitate exposure modeling. CHAD also provides information on the level of exertion associated with each activity, which can be used by exposure models, including the APEX model, to estimate ventilation rate and pollutant dose.


---

### 3.4.3.2 Spatial Variability in Nitrogen Dioxide Concentrations

Data for spatial variability in ambient NO, NO<sub>2</sub>, and NO<sub>x</sub> concentrations are provided in [Section 2.5](#) for national, urban, neighborhood, and micro scales. The data illustrate that


national variation in wintertime concentrations largely follows the degree of urbanization, while variation at urban and smaller scales is influenced by source location, source strength, meteorology, and natural and urban topography. Gradients in near-road concentrations of NO<sub>2</sub> and NO indicate spatial variability at finer scales within 500 m of the road (see [Figures 2-16](#) and [2-17](#) in [Section 2.5.3](#) and [Figure 3-2](#) in [Section 3.3.1.1](#)). [Figure 3-4](#) illustrates regional-scale variability in background levels of daily 1-hour max NO<sub>2</sub> concentration based on Pearson correlation between monitor pairs for urban and rural monitors across the U.K. ([Butland et al., 2013](#)). Likewise, [Figure 3-5](#) depicts urban-scale variability for NO<sub>2</sub> and NO<sub>x</sub>, based on a semivariogram function ([Goldman et al., 2010](#)).

The correlation between the true exposure and the measured NO<sub>2</sub> concentration will decrease with increasing distance from the monitor. Moreover, the magnitude of the error in exposure estimation may increase with distance between the monitor and the subject. This is an issue for both central site monitors and fixed site passive monitors ([Table 3-1](#) and [Section 3.2.1](#)). Hence, there is a potential for exposure error if the ambient NO<sub>2</sub> concentration measured at a given site differs from the concentration at the location of an epidemiologic study participant, and this issue is present regardless of the spatial scale of the epidemiology study. Similarly, when a spatial model (including LUR, IDW, and CTM) is not sufficiently finely resolved, then the estimated concentration assigned as a participant's exposure may have additional error ([Table 3-1](#) and [Section 3.2.2](#)).



Note: D = distance; km = kilometer; loge = natural log; P = Pearson correlation; R-sq = coefficient of determination" or  $R^2$   
 Source: Reproduced from BMC Medical Research Methodology [Butland et al. \(2013\)](#)

**Figure 3-4 Regional-scale variability in nitrogen dioxide for urban and rural area data across the United Kingdom.**



Note: km = kilometer; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = the sum of nitric oxide and nitrogen dioxide.;  $\gamma'$  = semivariogram. On the y-axis,  $\gamma'$  denotes the semivariogram (i.e., a unitless function that describes the ratio between spatial and temporal variance of the differences between two observations).

Source: Reprinted with the permission of American Chemical Society, [Goldman et al. \(2010\)](#).

**Figure 3-5 Urban-scale variability in nitrogen dioxide and the sum of nitric oxide and nitrogen dioxide in Atlanta, GA.**

### 3.4.3.3 Infiltration and Building Ventilation

Given that people spend the majority of their time indoors, building air exchange rates influence exposure to ambient NO<sub>2</sub>. In an analysis of daily average NO<sub>2</sub> concentration and exposure data from the DEARS, [Meng et al. \(2012a\)](#) observed seasonal differences, with slopes of  $0.24 \pm 0.04$  for  $E_T$  versus the concentration measured at a central site monitor,  $C_{a,csm}$ , and of  $0.13 \pm 0.06$  for  $E_a$  versus  $C_{a,csm}$  for summer measurements. For winter measurements, the associations were lower ( $E_T$  vs.  $C_{a,csm}$ : slope =  $0.08 \pm 0.05$ ;  $E_a$  vs.  $C_{a,csm}$ : slope =  $0.07 \pm 0.07$ ). [Meng et al. \(2012a\)](#) found that high air exchange rate (>1.3 air changes per hour), no central air conditioning, use and nonuse of window fans, and presence of old carpeting were determinants of  $\alpha$ , the exposure factor defined in [Equation 3-10](#) and approximated by the ratio of  $E_a$  to  $C_a$ , for NO<sub>2</sub> in summer; none of these factors were determinants of  $\alpha$  for NO<sub>2</sub> in winter. In [Mölter et al. \(2012\)](#), outdoor exposures were calculated with LUR, while indoor exposures were calculated using the probabilistic model for indoor pollution exposures (INDAIR) model that accounts both for infiltration due to home ventilation characteristics and indoor sources. Sensitivity to air exchange rate of INDAIR predictions of indoor NO<sub>2</sub> in the absence of indoor sources

underscores potential for bias and uncertainty in  $\alpha$ , which depends on air exchange rate, penetration, and indoor deposition ([Dimitroulopoulou et al., 2006](#)).

---

#### 3.4.3.4 Instrument Accuracy and Precision

The influence of instrument error ([Section 2.4.1](#), [Section 3.2.1.2](#)) on health effect estimates from epidemiologic studies varies with study design. Intermonitor comparison is often used to estimate instrument precision.

For epidemiologic studies of short-term exposure, [Goldman et al. \(2010\)](#) investigated instrument precision error at locations where ambient monitors were collocated. Instrument precision error increased with increasing concentration. If instrument error and concentration are positively correlated, then error in the exposure estimates will be larger in locations where there are more prevalent or stronger sources or at times when NO<sub>2</sub> emissions are higher for a given location. Moreover, if error is positively correlated with concentration, then it would be anticipated that the magnitude of the instrument error is largest at times of day when emissions are highest, such as rush hour. Depending on specific conditions such as sampler type (e.g., passive vs. continuous), meteorological conditions, or presence of interferants, instrument errors may vary in total magnitude or direction ([Section 3.2.1](#)) so that error is not always positively correlated with concentration. Instrument error was also observed to exhibit some autocorrelation at 1- and 2-day lags in the [Goldman et al. \(2010\)](#) study. Hence, the diurnal variability in relative NO<sub>2</sub> instrument error does not change substantially from day to day. For epidemiologic studies of short-term NO<sub>2</sub> exposure, the influence of instrument error would not be expected to change if the health data were obtained on a daily basis.

Instrumentation bias could be anticipated to influence exposure estimates used in long-term NO<sub>2</sub> exposure studies in some situations. For example, LUR exposure may be overestimated when the LUR is fit using passive monitoring data, if the passive monitors are positively biased ([Section 3.2.1.2](#)). Ambient temperature and relative humidity would not be expected to vary greatly within a city. Because climate and ambient sources are more likely to differ among cities, instrumentation error could have a larger influence on the comparison of exposures among cities.

---

#### 3.4.4 Confounding

To assess the independent effects of NO<sub>2</sub> in an epidemiologic study of health effects, it is necessary to identify ([Bateson et al., 2007](#)): (1) which copollutants (e.g., PM<sub>2.5</sub>, UFP, BC) and additional exposures (e.g., noise, traffic levels) are potential confounders of the

health effect-NO<sub>2</sub> relationship so that their correlation with NO<sub>2</sub> can be tested and, if needed, they are accounted for in the epidemiologic model; (2) the time period over which correlations might exist so that potential confounders are considered appropriately for the time period relevant for the epidemiologic study design (e.g., pollutants or other factors that are correlated over the long term might not be important for a short-term exposure epidemiologic study); and (3) the spatial correlation structure across multiple pollutants, if the epidemiologic study design is for long-term exposure. Given that a covariate must be correlated with both the exposure and the health effect to be a confounder, the potential for confounding of NO<sub>2</sub>-related health effects can vary by the health endpoint of interest.

For monitors that do show high correlations, copollutant epidemiologic models may be appropriate to adjust the effect estimate for each pollutant for confounding by the other pollutant (Tolbert et al., 2007). As discussed in the 2010 ISA for Carbon Monoxide (U.S. EPA, 2010b), copollutant models can help identify which is the better predictor of the effect, particularly if the etiologically linked pollutant is measured with more error than the other pollutant. Because NO<sub>2</sub> exhibits a relatively high degree of exposure error compared with other criteria pollutants (Section 3.4.3), copollutant models in which the NO<sub>2</sub> effect estimate remains robust provide additional evidence for an independent health effect of NO<sub>2</sub>.

This section considers temporal copollutant correlations and how relationships among copollutants may change in space. Temporal copollutant correlations are computed from the time series of concentrations for two different collocated pollutants. Temporal correlations are informative for epidemiologic studies of short-term NO<sub>2</sub> exposure when the sampling interval is a month or less for each of the copollutants. Temporal correlations are informative for epidemiologic studies of long-term NO<sub>2</sub> exposures when sampling intervals are months to years. Spatial relationships are evaluated by comparing within-pollutant variation across space for different pollutants. The following sections review co-exposures that can potentially confound the relationship between a health effect and NO<sub>2</sub> exposure over different temporal and spatial resolutions.

---

#### **3.4.4.1 Temporal Relationships among Ambient Nitrogen Dioxide and Copollutant Exposures**

Studies and analyses reported in the 2008 ISA for Oxides of Nitrogen (U.S. EPA, 2008c) demonstrated that ambient NO<sub>2</sub> concentration was correlated with several traffic-related pollutants in urban and suburban areas generally in the range of Pearson  $r = 0.5$  to  $0.8$  for PM<sub>2.5</sub> and CO and  $r = 0.8$  to  $0.9$  for EC. These results suggest that in some cases NO<sub>2</sub> concentration can be a surrogate for traffic pollution (U.S. EPA, 2008c). In contrast,

correlations between NO<sub>2</sub> and O<sub>3</sub> concentrations ranged from  $r = -0.7$  to 0.1. Numerous air quality, exposure, and epidemiologic studies have more recently evaluated associations between concentrations of ambient NO<sub>2</sub> and those of other pollutants. Many of these studies report Pearson or Spearman correlations of ambient NO<sub>2</sub> concentrations with those of other criteria pollutants, mainly focusing on concentrations related to traffic sources (PM<sub>2.5</sub>, CO, PM<sub>10</sub>). A few studies have explored associations between NO<sub>2</sub> concentrations and those of other traffic-related pollutants, such as EC, UFP, and VOCs. Data for correlations between NO<sub>2</sub> concentrations and concentrations of other criteria pollutants are summarized in [Table 3-10](#), broken into short- and long-term exposure studies. [Figure 3-6](#) plots data for correlations between NO<sub>2</sub> concentrations and concentrations of all copollutants for which data were available, including PM<sub>2.5</sub>, PM<sub>10</sub>, PM<sub>10-2.5</sub>, O<sub>3</sub>, CO, SO<sub>2</sub>, EC, OC, UFP, particle number concentration (PNC), toluene, and benzene. [Figure 3-6](#) separates the data by averaging period. “Within-hourly” denotes averaging time ranging from 20 seconds to 1-hour daily max. “Within daily” is noted for averaging time ranging from 3 to 24 hours. Three-hour averaging times are typically applied during rush hour measurement periods. “Within monthly” refers to averaging times ranging from 84 hours to 1 month. “Annual or longer-term correlations” are for studies that averaged the data over a period of 1 to 5 years. The studies presented in [Table 3-10](#) only include monitored data and not correlations computed from LUR studies. Some of these studies used personal or area sampling in lieu of central site monitoring. Note that, while [Table 3-10](#) and [Figure 3-6](#) are informative for considering the influence of averaging time on correlations, small sample sizes for any given pollutant and averaging period preclude making definitive conclusions about the observations. In particular, the number of near-road studies reporting correlations between NO<sub>2</sub> concentrations and concentrations of copollutants was too small to make any conclusions about differences in NO<sub>2</sub>-copollutant correlations between near-road and central site or personal measures.

The higher the copollutant correlation, the more difficult it is to disentangle the health effects of NO<sub>2</sub> exposure from those of the copollutants. This is particularly true of traffic-related copollutants, and recent evidence indicates that copollutant confounding adds such uncertainty. [Figure 3-6](#) shows the range of temporal NO<sub>2</sub>-copollutant correlation coefficients among the studies in [Table 3-10](#) plus one additional measurement study that did not include other criteria air pollutants ([Williams et al., 2012a](#)). Existing studies indicate that NO<sub>2</sub> concentration has, in general, correlations over Pearson  $r = 0.5$  with concentrations of other NAAQS and traffic-related pollutants. Similar to findings in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), the strongest temporal correlations are typically observed for NO<sub>2</sub> concentrations with concentrations of primary traffic-related pollutants, such as benzene, CO, EC, and PNC. A wide range of temporal correlations is observed for NO<sub>2</sub> concentrations with PM<sub>2.5</sub>, PM<sub>10</sub>, and SO<sub>2</sub>

concentrations. Correlations of NO<sub>2</sub> concentrations with PM<sub>2.5</sub> and PM<sub>10</sub> concentrations tend to be positive for the within-hourly, within-daily, and long-term metrics. For the within-monthly measures, median correlations are closer to zero. The reason for this difference is unknown, but fewer data are available for the within-monthly correlations. The lowest temporal correlations are typically observed for NO<sub>2</sub> concentrations with O<sub>3</sub> and PM<sub>10-2.5</sub> concentrations, with correlations having a wide range in magnitude ( $r = -0.71$  to  $0.66$ ; median  $r = 0.15$ ). These observations are not surprising given the nonlinear relationship between NO<sub>2</sub> concentration and instantaneous O<sub>3</sub> production rate observed close to the location of emission ([Pusede and Cohen, 2012](#); [LaFranchi et al., 2011](#); [Murphy et al., 2007, 2006](#)). Temporal correlations for near-road studies are highlighted in red for [Figure 3-6](#). It is notable that the near-road correlations did not appear to be systematically different from the urban scale correlations. Statistical testing for near-road versus urban scale interpollutant correlations was not performed given the small number of near-road studies.

### **Short-Term Temporal Correlations**

For the shorter time periods (within hourly and within daily), UFP, BC, CO, and EC concentrations tended to have higher correlations with NO<sub>2</sub> concentration, while O<sub>3</sub> concentration had several negative correlations with NO<sub>2</sub> concentration. The within-daily category had the most data for PM<sub>2.5</sub> and PM<sub>10</sub> concentration, and a wide range of correlations was observed with NO<sub>2</sub> concentrations for each of those copollutants. Fewer data were available for within-monthly correlations. Black carbon, benzene, and toluene concentrations were observed to have the highest correlations with NO<sub>2</sub> concentration in this temporal category. Across time-averaging periods, there is not a discernible pattern with respect to correlations of near-road measurements.

**Table 3-10 Synthesis of nitrogen dioxide ambient-ambient copollutant correlations from measurements reported in the literature.**

Study <sup>a</sup>	Averaging Time	Location	Scale	Correlation Measure	CO	O <sub>3</sub>	SO <sub>2</sub>	PM <sub>2.5</sub>	PM <sub>10</sub>
<b>Short-term exposure studies</b>									
† <a href="#">Polidori and Fine (2012a)</a>	1 min	Los Angeles, CA (15 m downwind of I-710) summer	Near road	Pearson	0.65	NR	NR	NR	NR
		Los Angeles, CA (80 m downwind of I-710) summer	Near road	Pearson	0.65	NR	NR	NR	NR
		Los Angeles, CA (background) summer	Urban	Pearson	0.66	NR	NR	NR	NR
		Los Angeles, CA (15 m downwind of I-710) winter	Near road	Pearson	0.60	NR	NR	NR	NR
		Los Angeles, CA (80 m downwind of I-710) winter	Near road	Pearson	0.62	NR	NR	NR	NR
		Los Angeles, CA (background) winter	Urban	Pearson	0.79	NR	NR	NR	NR
† <a href="#">Levy et al. (2014)</a>	<2 min	Montreal, Canada (all year)	Urban	Pearson	0.48	-0.45	0.11	0.29	0.39
		Montreal, Canada (summer)	Urban	Pearson	0.77	-0.74	0.17	0.34	0.35
		Montreal, Canada (fall)	Urban	Pearson	0.40	-0.33	0.25	0.26	0.30
		Montreal, Canada (winter)	Urban	Pearson	0.16	-0.36	0.04	0.34	0.35

**Table 3-10 (Continued): Synthesis of nitrogen dioxide ambient-ambient correlations from measurements reported in the literature.**

Study <sup>a</sup>	Averaging Time	Location	Scale	Correlation Measure	CO	O <sub>3</sub>	SO <sub>2</sub>	PM <sub>2.5</sub>	PM <sub>10</sub>
<a href="#">†Padró-Martínez et al. (2012)</a>	2 min	Boston, MA	Urban	Spearman	0.51	NR	NR	0.21	NR
<a href="#">†Chuang et al. (2008)</a>	Hourly	Boston, MA	Urban	Pearson	NR	NR	NR	0.38	0.33
<a href="#">†Strickland et al. (2010)</a>	1-h daily max	Atlanta, GA (cold season)	Urban	Spearman	0.59	0.11	0.36	0.37	0.46
		Atlanta, GA (warm season)	Urban	Spearman	0.54	0.42	0.37	0.36	0.44
<a href="#">†Villeneuve et al. (2007)</a>	1-h daily max	Edmonton, Canada	Urban	Pearson	0.74	NR	NR	NR	NR
<a href="#">†Jalaludin et al. (2007)</a>	1-h daily max	Sydney, Australia	Urban	NR	0.6	0.25	0.46	0.65	0.48
<a href="#">Mortimer et al. (2002)</a>	1-h daily max	8 U.S. cities	Urban	NR	NR	0.27	NR	NR	NR
<a href="#">Burnett et al. (2000)</a>	1-h daily max	8 Canadian cities	Urban	NR	0.65	0.12	0.49	0.53	0.53
<a href="#">Mar et al. (2000)</a>	1-h daily max	Phoenix, AZ	Urban	NR	0.87	NR	0.57	0.77	0.53
<a href="#">Tolbert et al. (2007)</a>	1-h daily max	Atlanta, GA	Urban	Spearman	0.7	0.44	0.36	0.47	0.53

**Table 3-10 (Continued): Synthesis of nitrogen dioxide ambient-ambient correlations from measurements reported in the literature.**

Study <sup>a</sup>	Averaging Time	Location	Scale	Correlation Measure	CO	O <sub>3</sub>	SO <sub>2</sub>	PM <sub>2.5</sub>	PM <sub>10</sub>
<a href="#">†Darrow et al. (2011a)</a>	1-h daily max	Atlanta, GA	Urban	Partial Spearman	0.61	0.40	NR	0.50	NR
	Morning commute (7:00 a.m.–10:00 a.m.)	Atlanta, GA	Urban	Partial Spearman	0.57	-0.16	NR	0.46	NR
	Daytime (8:00 a.m.–7:00 p.m.)	Atlanta, GA	Urban	Partial Spearman	0.53	-0.07	NR	0.41	NR
	Nighttime (12:00 a.m.–6:00 a.m.)	Atlanta, GA	Urban	Partial Spearman	0.66	-0.66	NR	0.52	NR
<a href="#">Moshhammer et al. (2006)</a>	8-h avg	Linz, Austria	Urban	Pearson	NR	NR	NR	0.54	0.62
<a href="#">†Darrow et al. (2011a)</a>	24-h avg	Atlanta, GA	Urban	Partial Spearman	0.66	-0.15	NR	0.20	NR

**Table 3-10 (Continued): Synthesis of nitrogen dioxide ambient-ambient correlations from measurements reported in the literature.**

Study <sup>a</sup>	Averaging Time	Location	Scale	Correlation Measure	CO	O <sub>3</sub>	SO <sub>2</sub>	PM <sub>2.5</sub>	PM <sub>10</sub>
<a href="#">†Faustini et al. (2011)</a>	24-h avg	Milan, Italy	Urban	Pearson	NR	NR	NR	NR	0.79
		Mestre, Italy	Urban	Pearson	NR	NR	NR	NR	0.66
		Turin, Italy	Urban	Pearson	NR	NR	NR	NR	0.72
		Bologna, Italy	Urban	Pearson	NR	NR	NR	NR	0.66
		Florence, Italy	Urban	Pearson	NR	NR	NR	NR	0.65
		Pisa, Italy	Urban	Pearson	NR	NR	NR	NR	0.57
		Rome, Italy	Urban	Pearson	NR	NR	NR	NR	0.5
		Cagliari, Italy	Urban	Pearson	NR	NR	NR	NR	0.23
		Taranto, Italy	Urban	Pearson	NR	NR	NR	NR	0.19
		Palermo, Italy	Urban	Pearson	NR	NR	NR	NR	0.22
<a href="#">†Samoli et al. (2011)</a>	24-h avg	Athens, Greece	Urban	NR	NR	NR	0.55	NR	NR
<a href="#">Ko et al. (2007a)</a>	24-h avg	Hong Kong, China	Urban	Pearson	NR	0.34	0.66	0.44	0.4
<a href="#">†Mehta et al. (2013)</a>	24-h avg	Ho Chi Minh City, Vietnam (dry season)	Urban	NR	NR	0.44	0.29	NR	0.78
		Ho Chi Minh City, Vietnam (wet season)	Urban	NR	NR	0.17	0.01	NR	0.18

**Table 3-10 (Continued): Synthesis of nitrogen dioxide ambient-ambient correlations from measurements reported in the literature.**

Study <sup>a</sup>	Averaging Time	Location	Scale	Correlation Measure	CO	O <sub>3</sub>	SO <sub>2</sub>	PM <sub>2.5</sub>	PM <sub>10</sub>
<a href="#">†Andersen et al. (2008a)</a>	24-h avg	Copenhagen, Denmark	Near road	Spearman	NR	-0.58	NR	0.41	0.43
<a href="#">Mannes et al. (2005)</a>	24-h avg	Sydney, Australia	Urban	Pearson	0.57	0.29	NR	0.66	0.47
<a href="#">Schildcrout et al. (2006)</a>	24-h avg	Albuquerque, NM	Urban	NR	0.76	0.04	NR	NR	0.26
	24-h avg	Baltimore, MD	Urban	NR	0.69	0.44	0.49	NR	0.62
		Boston, MA	Urban	NR	0.8	0.47	0.68	NR	0.48
		Denver, CO	Urban	NR	0.85	0.24	0.56	NR	0.64
		San Diego, CA	Urban	NR	0.92	0.39	0.23	NR	0.55
		St. Louis, MO	Urban	NR	0.71	0.42	0.58	NR	0.45
		Toronto, Canada	Urban	NR	0.63	0.4	0.63	NR	0.64
<a href="#">†Liu et al. (2009b)</a>	24-h avg	Ontario, Canada	Urban	Spearman	NR	-0.51	0.18	0.71	NR
<a href="#">†Strak et al. (2013a)</a>	24-h avg	Locations across the Netherlands	Urban	Spearman	NR	-0.62	NR	0.45	0.49
<a href="#">†O'Connor et al. (2008)</a>	24-h avg	Inner-cities across the U.S.	Urban	NR	0.54	-0.31	0.59	0.59	NR
<a href="#">Timonen et al. (2006)</a>	24-h avg	Amsterdam, the Netherlands	Urban	Spearman	0.76	NR	NR	0.49	NR
		Erfurt, Germany	Urban	Spearman	0.86	NR	NR	0.82	NR
		Helsinki, Finland	Urban	Spearman	0.32	NR	NR	0.35	NR

**Table 3-10 (Continued): Synthesis of nitrogen dioxide ambient-ambient correlations from measurements reported in the literature.**

Study <sup>a</sup>	Averaging Time	Location	Scale	Correlation Measure	CO	O <sub>3</sub>	SO <sub>2</sub>	PM <sub>2.5</sub>	PM <sub>10</sub>
<a href="#">†Guo et al. (2009)</a>	24-h avg	Beijing, China	Urban	Pearson	NR	NR	0.53	0.67	NR
<a href="#">Rojas-Martinez et al. (2007a)</a>	24-h avg	Mexico City, Mexico	Urban	Pearson	NR	0.17	NR	NR	0.25
<a href="#">Sarnat et al. (2001)</a>	24-h avg	Baltimore, MD (summer)	Urban	Spearman	0.75	0.02	NR	0.37	NR
		Baltimore, MD (winter)	Urban	Spearman	0.76	-0.71	-0.17	0.75	NR
<a href="#">Sarnat et al. (2005)</a>	24-h avg	Boston, MA (summer)	Near road	Spearman	NR	NR	NR	0.44	NR
		Boston, MA (winter)	Near road	Spearman	NR	NR	NR	0.64	NR
<a href="#">Kim et al. (2006a)</a>	24-h avg	Toronto, Canada	Near road	Spearman	0.72	NR	NR	0.44	NR
<a href="#">Roberts and Martin (2006)</a>	24-h avg	Cleveland, OH	Urban	NR-pairwise	0.67	0.36	0.56	NR	0.63
		Nashville, TN	Urban	NR-pairwise	0.36	0.26	0.08	NR	0.44
<a href="#">Andersen et al. (2007)</a>	24-h avg	Copenhagen, Denmark	Urban	Spearman	0.74	NR	NR	NR	0.42
<a href="#">†Chen et al. (2008)</a>	24-h avg	Shanghai, China	Urban	NR	NR	NR	0.73	NR	0.71
<a href="#">†Arhami et al. (2009)</a>	24-h avg	San Gabriel Valley, CA (summer/fall)	Urban	Spearman	NR	NR	NR	0.1	0.31
		San Gabriel Valley, CA (fall/winter)	Urban	Spearman	NR	NR	NR	0.44	0.34
		Riverside, CA (summer/fall)	Urban	Spearman	NR	NR	NR	0.07	0.21
		Riverside, CA (fall/winter)	Urban	Spearman	NR	NR	NR	0.56	0.64

**Table 3-10 (Continued): Synthesis of nitrogen dioxide ambient-ambient correlations from measurements reported in the literature.**

Study <sup>a</sup>	Averaging Time	Location	Scale	Correlation Measure	CO	O <sub>3</sub>	SO <sub>2</sub>	PM <sub>2.5</sub>	PM <sub>10</sub>
<a href="#">†Delfino et al. (2009)</a>	24-h avg	San Gabriel Valley and Riverside, CA (aggregated)	Urban	NR	0.79	-0.42	NR	0.19	NR
<a href="#">†Baxter et al. (2013)</a>	24-h avg	Boston, MA	Urban	Spearman	NR	NR	NR	0.41	NR
		Pittsburgh, PA	Urban	Spearman	NR	NR	NR	0.46	NR
		Memphis, TN	Urban	Spearman	NR	NR	NR	0.27	NR
		Detroit, MI	Urban	Spearman	NR	NR	NR	0.59	NR
		Milwaukee, WI	Urban	Spearman	NR	NR	NR	0.55	NR
		San Diego, CA	Urban	Spearman	NR	NR	NR	0.57	NR
		Riverside, CA	Urban	Spearman	NR	NR	NR	0.37	NR
<a href="#">†Williams et al. (2012c)</a>	24-h avg	Research Triangle Park, NC	Urban	Spearman	NR	-0.12	NR	0.03	NR
<a href="#">†Williams et al. (2012a)</a>	24-h avg	Detroit, MI	Near road	Spearman	NR	NR	NR	NR	NR
<a href="#">†Delfino et al. (2008a)</a>	24-h avg	Los Angeles, CA	Urban	Spearman	NR	NR	NR	0.36	NR
<a href="#">†Suh and Zanobetti (2010b)</a>	24-h avg	Atlanta, GA	Urban	Spearman	NR	NR	NR	0.47	NR
<a href="#">†Schembari et al. (2013)</a>	24-h avg	Barcelona, Spain	Urban	Spearman	NR	NR	NR	0.41	NR

**Table 3-10 (Continued): Synthesis of nitrogen dioxide ambient-ambient correlations from measurements reported in the literature.**

Study <sup>a</sup>	Averaging Time	Location	Scale	Correlation Measure	CO	O <sub>3</sub>	SO <sub>2</sub>	PM <sub>2.5</sub>	PM <sub>10</sub>
<a href="#">†Laurent et al. (2013)</a>	24-h avg	Los Angeles and Orange counties, CA	Urban	Pearson	0.83	-0.81	NR	0.77	0.70
<a href="#">†Peters et al. (2009)</a>	24-h avg	Erfurt, Germany	Urban	Spearman	0.68	-0.55	0.54	0.63	0.64
<a href="#">†Sánchez Jiménez et al. (2012)</a>	24-h avg	Glasgow, U.K.	Near road	Spearman	0.6	NR	NR	NR	0.83
		Glasgow, U.K.	Background	Spearman	0.4	NR	NR	NR	0.69
		Glasgow, U.K.	Background	Spearman	0.74	NR	NR	NR	NR
		London, U.K.	Near road	Spearman	0.3	NR	NR	0.49	0.67
		London, U.K.	Background	Spearman	0.61	NR	NR	0.42	0.37
<a href="#">†Steinvil et al. (2009)</a>	24-h avg	Tel Aviv, Israel	Urban	Partial Pearson	0.75	-0.34	0.70	NR	0.076
<a href="#">†Steinvil et al. (2008)</a>	24-h avg	Tel Aviv, Israel	Urban	Partial Pearson	0.86	-0.78	0.72	NR	0.082
<a href="#">†Tao et al. (2012)</a>	24-h avg	Guangzhou, Foshan, Zhongshan, and Zhuhai, China	Urban-regional	Pearson	0.72	0.17	0.82	NR	0.82
<a href="#">†Wichmann et al. (2012)</a>	24-h avg	Copenhagen, Denmark (warm period)	Urban	Spearman	0.62	NR	NR	NR	0.47
		Copenhagen, Denmark (cold period)	Urban	Spearman	0.72	NR	NR	NR	0.46

**Table 3-10 (Continued): Synthesis of nitrogen dioxide ambient-ambient correlations from measurements reported in the literature.**

Study <sup>a</sup>	Averaging Time	Location	Scale	Correlation Measure	CO	O <sub>3</sub>	SO <sub>2</sub>	PM <sub>2.5</sub>	PM <sub>10</sub>
<a href="#">†Dimitriou and Kassomenos (2014)</a>	24-h avg	London, U.K. (cold period)	Urban	Pearson	NR	NR	NR	0.52	0.49
			Near road	Pearson	NR	NR	NR	0.49	0.70
		London, U.K. (warm period)	Urban	Pearson	NR	NR	NR	0.63	0.56
			Near road	Pearson	NR	NR	NR	0.60	0.67
		Paris, France (cold period)	Urban	Pearson	NR	NR	NR	0.65	0.71
			Near road	Pearson	NR	NR	NR	0.60	0.68
		Paris, France (warm period)	Urban	Pearson	NR	NR	NR	0.54	0.50
			Near road	Pearson	NR	NR	NR	0.75	0.83
		Copenhagen, Denmark (cold period)	Urban	Pearson	NR	NR	NR	0.31	0.35
			Near road	Pearson	NR	NR	NR	0.36	0.37
		Copenhagen, Denmark (warm period)	Urban	Pearson	NR	NR	NR	0.42	0.42
			Near road	Pearson	NR	NR	NR	0.53	0.55

**Table 3-10 (Continued): Synthesis of nitrogen dioxide ambient-ambient correlations from measurements reported in the literature.**

Study <sup>a</sup>	Averaging Time	Location	Scale	Correlation Measure	CO	O <sub>3</sub>	SO <sub>2</sub>	PM <sub>2.5</sub>	PM <sub>10</sub>
† <a href="#">Dimitriou and Kassomenos (2014)</a>  (Continued)	24-h avg  (Continued)	Hamburg, Germany (cold period)	Urban	Pearson	NR	NR	NR	0.21	0.23
			Near road	Pearson	NR	NR	NR	0.40	0.52
		Hamburg, Germany (warm period)	Urban	Pearson	NR	NR	NR	0.50	0.51
			Near road	Pearson	NR	NR	NR	0.69	0.70
		Stockholm, Sweden (cold period)	Urban	Pearson	NR	NR	NR	0.20	0.24
			Near road	Pearson	NR	NR	NR	0.49	0.45
		Stockholm, Sweden (warm period)	Urban	Pearson	NR	NR	NR	0.38	0.45
			Near road	Pearson	NR	NR	NR	0.58	0.52
† <a href="#">Clougherty et al. (2013)</a>	84-h avg	New York, NY	Urban	Pearson	NR	NR	0.51	0.74	NR
† <a href="#">Sarnat et al. (2012)</a>	96-h avg	El Paso, TX (Site A)	Urban	Spearman	NR	NR	NR	-0.39	-0.3
		El Paso, TX (Site B)	Near road	Spearman	NR	NR	NR	-0.28	-0.1
		Ciudad Juarez, Mexico (Site A)	Urban	Spearman	NR	NR	NR	-0.28	-0.1
		Ciudad Juarez, Mexico (Site B)	Near road	Spearman	NR	NR	NR	0	0.11
† <a href="#">Greenwald et al. (2013)</a>	96-h avg	2 sites in El Paso, TX	Urban	Pearson	NR	NR	-0.22	0.2	0.31

**Table 3-10 (Continued): Synthesis of nitrogen dioxide ambient-ambient correlations from measurements reported in the literature.**

Study <sup>a</sup>	Averaging Time	Location	Scale	Correlation Measure	CO	O <sub>3</sub>	SO <sub>2</sub>	PM <sub>2.5</sub>	PM <sub>10</sub>
† <a href="#">Wheeler et al. (2008)</a>	2 week	Windsor, Canada (all year)	Urban	Spearman	NR	NR	0.85	NR	NR
		Windsor, Canada (winter)	Urban	Spearman	NR	NR	0.84	NR	NR
		Windsor, Canada (spring)	Urban	Spearman	NR	NR	0.61	NR	NR
		Windsor, Canada (summer)	Urban	Spearman	NR	NR	0.51	NR	NR
		Windsor, Canada (fall)	Urban	Spearman	NR	NR	0.66	NR	NR
† <a href="#">Trasande et al. (2013)</a>	1-month avg	United States	Varies	Pearson	0.12	-0.023	-0.10	-0.090	-0.011
<b>Long-term exposure studies</b>									
† <a href="#">Dadvand et al. (2014c)</a>	9 month	Barcelona, Spain	Urban	Spearman	NR	NR	NR	0.48	0.33
† <a href="#">Katanoda et al. (2011)</a>	1-yr avg	Japanese cities	Urban	Pearson	NR	NR	0.76	NR	NR
† <a href="#">Dong et al. (2011)</a>	1-yr avg	7 cities across China	Urban	NR	0.23	0.66	0.52	NR	0.7
† <a href="#">Hwang and Lee (2010)</a>	1-yr avg	14 Taiwanese communities	Urban	NR	0.86	-0.07	0.55	0.37	NR
† <a href="#">Heinrich et al. (2013)</a>	1-yr avg	North Rhine-Westphalia, Germany	Urban	Spearman	NR	NR	NR	0.50	NR
† <a href="#">Ducret-Stich et al. (2013)</a>	1-yr avg	Swiss Alps	Near road	Spearman	NR	NR	NR	NR	0.51
			On highway	Spearman	NR	NR	NR	NR	0.04–0.63

**Table 3-10 (Continued): Synthesis of nitrogen dioxide ambient-ambient correlations from measurements reported in the literature.**

Study <sup>a</sup>	Averaging Time	Location	Scale	Correlation Measure	CO	O <sub>3</sub>	SO <sub>2</sub>	PM <sub>2.5</sub>	PM <sub>10</sub>
<a href="#">†Eeftens et al. (2012)</a>	1-yr avg	Oslo, Norway	Urban	Spearman	NR	NR	NR	0.24	0.34
		Stockholm County, Sweden	Urban	Spearman	NR	NR	NR	0.75	0.80
		Helsinki/Turku, Finland	Urban	Spearman	NR	NR	NR	0.71	0.80
		Copenhagen, Denmark	Urban	Spearman	NR	NR	NR	0.40	0.60
		Kaunas, Lithuania	Urban	Spearman	NR	NR	NR	0.04	0.17
		Manchester, U.K.	Urban	Spearman	NR	NR	NR	0.40	0.59
		London/Oxford, U.K.	Urban	Spearman	NR	NR	NR	0.84	0.82
		the Netherlands/ Belgium	Urban	Spearman	NR	NR	NR	0.57	0.74
		Ruhr Area, Germany	Urban	Spearman	NR	NR	NR	0.69	0.65
		Munich/Augsberg, Germany	Urban	Spearman	NR	NR	NR	0.29	0.67
		Vorarlberg, Austria	Urban	Spearman	NR	NR	NR	0.04	0.35
		Paris, France	Urban	Spearman	NR	NR	NR	0.86	0.91
		Gyor, Hungary	Urban	Spearman	NR	NR	NR	0.02	0.12
		Lugano, Switzerland	Urban	Spearman	NR	NR	NR	0.66	0.83
		Turin, Italy	Urban	Spearman	NR	NR	NR	0.65	0.67
		Rome, Italy	Urban	Spearman	NR	NR	NR	0.73	0.75
Barcelona, Spain	Urban	Spearman	NR	NR	NR	0.90	0.69		


**Table 3-10 (Continued): Synthesis of nitrogen dioxide ambient-ambient correlations from measurements reported in the literature.**

Study <sup>a</sup>	Averaging Time	Location	Scale	Correlation Measure	CO	O <sub>3</sub>	SO <sub>2</sub>	PM <sub>2.5</sub>	PM <sub>10</sub>
<a href="#">†Eeftens et al. (2012)</a>	1-yr avg	Cataluña, Spain	Urban	Spearman	NR	NR	NR	0.72	0.63
(Continued)	(Continued)	Athens, Greece	Urban	Spearman	NR	NR	NR	0.49	0.70
		Heraklion, Greece	Urban	Spearman	NR	NR	NR	0.18	0.37
<a href="#">McConnell et al. (2003)</a>	4-yr avg	12 communities in southern California	Urban	Pearson	NR	0.59	NR	0.54	0.2
<a href="#">†Gan et al. (2012a)</a>	5-yr avg	Vancouver, Canada	Urban	Spearman	NR	NR	NR	0.47	NR

a.m. = ante meridiem; avg = average; AZ = Arizona; CA = California; CO = Colorado; CO = carbon monoxide; GA = Georgia; h = hour; I = interstate; m = meter; MA = Massachusetts; max = maximum; MD = Maryland; MI = Michigan; min = minute; MO = Missouri; NC = North Carolina; NM = New Mexico; NR = not reported; NY = New York; O<sub>3</sub> = ozone; OH = Ohio; PA = Pennsylvania; PM<sub>2.5</sub> = in general terms, particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm, a measure of fine particles; PM<sub>10</sub> = in general terms, particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm, a measure of thoracic particles (i.e., that subset of inhalable particles thought small enough to penetrate beyond the larynx into the thoracic region of the respiratory tract); SO<sub>2</sub> = sulfur dioxide; TN = Tennessee; TX = Texas; U.K. = United Kingdom; U.S. = United States of America; WI = Wisconsin; yr = year.

<sup>a</sup>Correlation data computed from land use regression studies are not included here.

†Studies published since the 2008 ISA for Oxides of Nitrogen



BC = black carbon; CO = carbon monoxide; EC = elemental carbon; LUR = land use regression; O[3] = ozone; OC = organic carbon; PM[2.5] = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5  $\mu\text{m}$ ; PM[10] = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10  $\mu\text{m}$ ; PM[10-2.5] = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10  $\mu\text{m}$  and greater than 2.5  $\mu\text{m}$ ; PNC = particle number concentration; SO[2] = sulfur dioxide; UFP = ultrafine particles.

Notes: Boxes represent the interquartile range of the data with the median line plotted, and 90th and 10th percentile of the data are plotted as the whiskers. Correlation data computed from LUR studies are not included here. Correlations shown by closed red circles come from near-road studies, and correlations shown by open black circles either come from urban-regional scale studies or do not specify the study's spatial scale.

Source: National Center for Environmental Assessment 2014 analysis of data from studies referenced in [Table 3-10](#).

**Figure 3-6 Summary of temporal nitrogen dioxide-copollutant correlation coefficients from measurements reported in studies listed in Table 3-10, sorted by temporal averaging period.**

Fewer studies have explored seasonal correlations between NO<sub>2</sub> concentration and concentrations of copollutants. Among these, a majority of studies report correlations of NO<sub>2</sub> concentration with PM<sub>2.5</sub> and PM<sub>10</sub> concentrations. In general, studies show stronger correlations of NO<sub>2</sub> concentration with PM<sub>2.5</sub> and PM<sub>10</sub> concentrations during cooler seasons compared with warmer seasons. [Connell et al. \(2005\)](#) investigated associations between PM<sub>2.5</sub> concentration and gaseous copollutant concentration in Steubenville, OH using linear regression. NO<sub>2</sub> concentration was more strongly correlated with PM<sub>2.5</sub> concentration during the fall ( $R^2 = 0.53$ ) and winter ( $R^2 = 0.53$ ) seasons compared with the spring ( $R^2 = 0.27$ ) and summer ( $R^2 = 0.086$ ) seasons. Similarly, [Sarnat et al. \(2005\)](#) found positive associations between PM<sub>2.5</sub> concentration and NO<sub>2</sub> concentration during both seasons (summer:  $\beta = 0.44$ ; winter:  $\beta = 0.64$ ), with stronger associations in the winter in Baltimore, MD. [Arhami et al. \(2009\)](#) evaluated relationships between ambient copollutants at two sites in southern California (San Gabriel Valley, CA and Riverside, CA) for warmer and cooler seasons. During the warm season, the Spearman correlation coefficient (average among sites) was  $r = 0.09$  between NO<sub>2</sub> concentration and PM<sub>2.5</sub> concentration, whereas during the winter the correlation was  $r = 0.50$ . However, they did not observe a consistent seasonal trend between NO<sub>2</sub> concentration and PM<sub>10</sub> concentration. While associations between NO<sub>2</sub> concentration and PM<sub>10</sub> concentration were substantially lower during the summer ( $r = 0.21$ ) at the Riverside, CA site, correlations were relatively similar during both seasons at the San Gabriel Valley, CA site (summer PM<sub>10</sub>:  $r = 0.31$ ; winter PM<sub>10</sub>:  $r = 0.34$ ). In contrast, for a study of copollutant variation in Montreal, Canada, [Levy et al. \(2014\)](#) reported higher magnitude Pearson correlations for concentrations of several copollutants in summer (CO:  $r = 0.77$ ; O<sub>3</sub>:  $r = -0.74$ ; SO<sub>2</sub>:  $r = 0.17$ ; PM<sub>2.5</sub>:  $r = 0.34$ ; UFP:  $r = 0.77$ ; BC:  $r = 0.80$ ; PM<sub>10</sub>:  $r = 0.35$ ) compared with winter (CO:  $r = 0.16$ ; O<sub>3</sub>:  $r = -0.36$ ; SO<sub>2</sub>:  $r = 0.04$ ; PM<sub>2.5</sub>:  $r = 0.34$ ; UFP:  $r = 0.71$ ; BC:  $r = 0.55$ ; PM<sub>10</sub>:  $r = 0.35$ ). The [Levy et al. \(2014\)](#) study measured the pollutants' concentrations using near-real-time instrumentation with recording intervals ranging from 1 second to 2 minutes.

The relationship between NO<sub>2</sub> concentration and O<sub>3</sub> concentration may also have seasonal patterns, although limited seasonal data exist between these two pollutants. In the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), ambient concentrations of NO<sub>2</sub> and O<sub>3</sub> from several sites across Los Angeles, CA were compared during a multiyear period. Slightly positive correlations between these two pollutants were observed during the summer (Spearman  $r = 0.0$  to  $0.4$ ), while negative correlations were observed during the winter ( $r = -0.5$  to  $-0.8$ ). The slightly positive correlations during the summer can be attributed in part to increased photochemical activity, resulting in enhanced O<sub>3</sub> formation. Higher O<sub>3</sub> concentrations increase the ratio of NO<sub>2</sub> concentration to NO concentration

due to enhanced oxidation, thereby resulting in a stronger correspondence between NO<sub>2</sub> concentration and O<sub>3</sub> concentration during the summer. The magnitude of the relationship between NO<sub>2</sub> concentration and O<sub>3</sub> concentration may be dampened by the nonlinear relationship between the two species ([Pusede and Cohen, 2012](#)). Only one study in [Table 3-10](#) reported seasonal differences in the correlation between NO<sub>2</sub> concentration and O<sub>3</sub> concentration. [Sarnat et al. \(2001\)](#) measured daily concentrations of gaseous and PM pollutants during different seasons in Baltimore, MD. Similar to the trends reported in the 2008 ISA for Oxides of Nitrogen, they observed a negative correlation between NO<sub>2</sub> concentration and O<sub>3</sub> concentration during the winter ( $r = -0.71$ ) and a near-zero correlation during the summer ( $r = 0.02$ ). However, because there is a lack of studies reporting such correlations, it is uncertain whether or not this seasonal trend exists between the two pollutants in different locations.

Recent studies have also compared NO<sub>2</sub>-copollutant temporal correlations across different regions in the U.S., based on central site monitoring data. [Baxter et al. \(2013\)](#) studied differences in air pollution for the Northeast (Boston, MA; Pittsburgh, PA), South (Memphis, TN; Birmingham, AL), Midwest (Milwaukee, WI; Detroit, MI), and West (San Diego, CA; Riverside, CA). Average Spearman correlation coefficients between PM<sub>2.5</sub> concentration and NO<sub>2</sub> concentration for each region were different (Northeast:  $r = 0.44$ ; South [data available for Memphis only]:  $r = 0.27$ ; Midwest:  $r = 0.57$ ; West:  $r = 0.47$ ). [Schildcrout et al. \(2006\)](#) compared a number of gaseous and particulate pollutants in different cities across the U.S., including Albuquerque, NM; Baltimore, MD; Boston, MA; and Denver, CO. While correlations between ambient NO<sub>2</sub> concentration and CO concentration were relatively similar in all four locations, larger differences were observed between correlations of NO<sub>2</sub> concentration and PM<sub>10</sub> concentration, ranging from a Spearman correlation of  $r = 0.64$  in Denver, CO to  $r = 0.26$  in Albuquerque, NM. Other multicity studies conducted outside of the U.S. show that NO<sub>2</sub>-copollutant correlations are widely variable across cities ([Faustini et al., 2011](#); [Dales et al., 2010, 2009b](#); [Stieb et al., 2008](#); [Timonen et al., 2006](#)).

A small subset of studies investigated temporal correlations between NO<sub>2</sub> concentration and concentrations of traffic-related VOCs, such as BTEX. In these studies, correlations between NO<sub>2</sub> concentration and VOC concentrations are variable. [Brook et al. \(2007\)](#) demonstrated that concentrations of benzo(e)pyrene and hopanes, specific mobile source tracers, were more strongly correlated with NO<sub>2</sub> concentration (Spearman  $r = 0.27$ – $0.80$ ) compared to PM<sub>2.5</sub> concentration ( $r = 0.26$ – $0.62$ ) at several urban sites in Canada. [Beckerman et al. \(2008\)](#) observed correlations between NO<sub>2</sub> concentration and BTEX concentration of Pearson  $r = 0.46$ – $0.85$  in a near-road field campaign. In a panel study, [Greenwald et al. \(2013\)](#) compared ambient concentrations of traffic pollutants monitored outside two schools in El Paso, TX, including one school within close proximity to a

major roadway with heavy diesel truck traffic. A Pearson correlation of  $r = 0.77$  was observed between NO<sub>2</sub> concentration and BTEX concentration, suggesting that both pollutants are related to traffic sources.

### Long-Term Temporal Correlations

Epidemiology studies of long-term NO<sub>2</sub> exposure for which interpollutant correlations were computed were substantially less numerous than for epidemiology studies of short-term exposure ([Atkinson et al., 2013](#); [Heinrich et al., 2013](#); [Gan et al., 2012a](#); [Darrow et al., 2011a](#); [Dong et al., 2011](#); [Katanoda et al., 2011](#); [Hwang and Lee, 2010](#); [Delfino et al., 2009](#); [Delfino et al., 2008a](#); [McConnell et al., 2003](#)). For long-term averages, most of the studies collected data for correlations with PM<sub>2.5</sub> and PM<sub>10</sub> concentrations. In each case, the median correlations were near 0.5, and the correlations were positive and ranging from near 0 to near 0.9. The sample size for other copollutants was low in the long-term averages. Median correlations were comparable between long-term exposure and short-term exposure epidemiology studies for concentrations of CO, SO<sub>2</sub>, PM<sub>2.5</sub>, BC, and PM<sub>10</sub>. The largest difference was for the correlation between NO<sub>2</sub> concentration and O<sub>3</sub> concentration, which was 0.59 over the long-term exposure epidemiology studies and 0.17 for all studies pooled. However, given that only three long-term studies were available to compute correlation between NO<sub>2</sub> concentration and O<sub>3</sub> concentration and one of those three studies reported a negative correlation, there is insufficient information to make a conclusion regarding independence of the effects of NO<sub>2</sub> concentration and O<sub>3</sub> concentration. Long-term correlations were not computed for concentrations of UFP, EC, OC, PNC, PM<sub>10-2.5</sub>, benzene, and toluene, and the small relative number of long-term exposure epidemiology studies compared with short-term exposure epidemiology studies reporting temporal correlations add uncertainty to these numbers.

---

#### 3.4.4.2 Spatial Variability among Ambient Nitrogen Dioxide and Copollutants

When an epidemiologic study design relies on spatial contrasts to draw conclusions, such as for an epidemiologic study of long-term exposure, unmeasured spatial correlation between copollutants may lead to positive bias in the health effect estimate for each of the pollutants included in the model. [Paciorek \(2010\)](#) performed simulations and analyzed case study data (of the relationship between birth weight data and BC concentrations in eastern Massachusetts) to test the effect of spatial errors on health effect estimates in long-term exposure epidemiologic studies. He identified unmeasured spatial confounding as a key driver in biasing health effect estimates in a spatial regression.

[Paciorek \(2010\)](#) maintained that bias can be reduced when variation in the exposure metric occurs at a smaller spatial scale than that of the unmeasured confounder.

[Dionisio et al. \(2013\)](#) compared the coefficient of variation ( $CV = \sigma/\mu$ ) of six air pollutants' concentrations across space using a hybrid AERMOD-background model of concentrations in the Atlanta, GA metropolitan area. They observed the following ordinal relationship of the covariates' CVs:  $NO_x (0.88) > CO (0.58) > EC (0.50) > PM_{2.5} (0.13) > O_3 (0.07) > SO_4 (0.05)$ . [Dionisio et al. \(2013\)](#) did not report the CV for  $NO_2$  concentration, which would be expected to have a lower CV than  $NO_x$  concentration. Likewise, [Goldman et al. \(2012\)](#) and [Ivy et al. \(2008\)](#) both used monitoring data from the Atlanta, GA metropolitan area to estimate spatial correlation functions, and they observed that  $NO_2$  concentration and  $NO_x$  concentration, along with CO,  $SO_2$ , and EC concentrations, had substantially steeper spatial correlograms than  $O_3$ ,  $PM_{10}$ ,  $PM_{2.5}$ ,  $SO_4$ ,  $NO_3$ ,  $NH_4$ , and OC concentrations. [Sajani et al. \(2011\)](#) also observed that spatial correlation decreased more substantially with distance between monitoring sites for  $NO_2$  concentration compared with  $PM_{10}$  and  $O_3$  concentrations when looking at six Italian cities.

Changes in correlations across space have been observed in a small number of studies. For their long-term near-road study, [Ducret-Stich et al. \(2013\)](#) point out that the temporal correlations of  $NO_2$  concentration with EC and PNC concentrations were high close to the highway where they obtained measurements and decreased with increasing distance from the road. This suggests that the influence of  $NO_2$  exposure on health effects might be better detected in an epidemiologic study of long-term exposure when the participants are further from the road so that an independent effect can be detected. [Atari et al. \(2009\)](#) tested the relationship between  $NO_2$  concentration and  $SO_2$  concentration across individual-level and census tract-level spatial resolutions, which were estimated by a LUR model developed for testing odor threshold in Sarnia, Canada. They observed higher spatial correlation when averaging over a census tract ( $r = 0.65$ ) compared with individual-level resolution ( $r = 0.49$ ). These findings illustrate greater spatial variability for  $NO_2$ ,  $NO_x$ , CO,  $SO_2$ , and EC concentrations compared with concentrations of the other pollutants. Based on the conclusions of [Paciorek \(2010\)](#), the observations noted in [Dionisio et al. \(2013\)](#), [Goldman et al. \(2012\)](#), [Ivy et al. \(2008\)](#), [Sajani et al. \(2011\)](#), [Atari et al. \(2009\)](#), and [Sánchez Jiménez et al. \(2012\)](#) suggest that differences in the spatial variability of  $NO_2$  concentration compared with copollutants having different spatial variation make it unlikely that copollutant confounding will occur everywhere in space. This is consistent with the findings of [Ducret-Stich et al. \(2013\)](#) regarding differences in copollutant correlations over space.

---

#### 3.4.4.3 Relationships among Personal, Indoor, and Ambient Nitrogen Dioxide and Copollutant Exposures

Many studies have investigated the relationship between personal exposure and ambient concentrations of NO<sub>2</sub> and other pollutants to evaluate the use of central site measurements as a proxy for personal exposure to ambient air pollution. Other studies have explored relationships between indoor NO<sub>2</sub> concentration and copollutant concentrations to understand sources and personal exposure in an indoor environment. [Tables 3-11](#), [3-12](#), [3-13](#), and [3-14](#) present correlations of ambient NO<sub>2</sub> concentration, personal NO<sub>2</sub> exposure, or indoor NO<sub>2</sub> concentration with similar measurements of copollutants. A limited number of studies reported in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) investigated the relationship between personal NO<sub>2</sub> exposure and personal exposures or ambient concentrations of other pollutants (e.g., PM<sub>2.5</sub>, EC, CO, volatile organic compounds, and HONO). Short-term correlation of personal NO<sub>2</sub> exposure with these pollutants ranged from Spearman  $r = 0.26$  to  $r = 0.71$ . Similar to the results in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), correlations of  $r = -0.33$  to  $r = 0.44$  were observed between personal NO<sub>2</sub> exposure and personal exposures or ambient concentrations of other regional (PM<sub>2.5</sub>) and traffic-related pollutants (e.g., EC, OC). Additionally, personal exposures or ambient concentrations of O<sub>3</sub> consistently showed a negative or no correlation with personal exposures or ambient concentrations of NO<sub>2</sub>. More recent studies report indoor NO<sub>2</sub>-copollutant correlations and observe a broader range of correlations between NO<sub>2</sub> concentration and EC concentration of  $r = -0.37$  to  $r = 0.66$ .

**Table 3-11 Pearson correlation coefficients between ambient nitrogen dioxide and personal copollutants.**

Study	Location	n	Averaging Times	PM <sub>2.5</sub>	EC	OC	O <sub>3</sub>
<a href="#">†Delfino et al. (2008a)</a>	Los Angeles, CA	≤170	All: 24 h	0.32	0.2	0.16	NR
<a href="#">†Suh and Zanobetti (2010b)</a>	Atlanta, GA	≤277	All: 24 h	0.25	0.33	NR	-0.09
<a href="#">†Williams et al. (2012a)</a>	Chapel Hill, NC	≤357	All: 24 h	-0.19	-0.17	NR	-0.01
<a href="#">†Schembari et al. (2013)</a>	Barcelona, Spain	≤65	NO <sub>2</sub> : 7 day; PM <sub>2.5</sub> /EC: 2 day	0.21	0.44	NR	NR

CA = California; EC = elemental carbon; GA = Georgia; h = hour; n = sample size; NC = North Carolina; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; O<sub>3</sub> = ozone; OC = organic carbon; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

**Table 3-12 Pearson correlation coefficients between personal nitrogen dioxide and ambient copollutants.**

Study	Location	n	Averaging Times	PM <sub>2.5</sub>	EC	OC	O <sub>3</sub>
<a href="#">†Delfino et al. (2008a)</a>	Los Angeles, CA	≤170	All: 24 h	0.21	0.2	0.18	NR
<a href="#">†Suh and Zanobetti (2010b)</a>	Atlanta, GA	≤277	All: 24 h	0.2	0.22	NR	NR
<a href="#">†Williams et al. (2012a)</a>	Chapel Hill, NC	≤326	All: 24 h	0.33	-0.3	NR	-0.26
<a href="#">†Schembari et al. (2013)</a>	Barcelona, Spain	≤65	NO <sub>2</sub> : 7 day; PM <sub>2.5</sub> /EC: 2 day	0.28	0.22	NR	NR

CA = California; EC = elemental carbon; GA = Georgia; h = hour; n = sample size; NC = North Carolina; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; O<sub>3</sub> = ozone; OC = organic carbon; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

**Table 3-13 Pearson correlation coefficients between personal nitrogen dioxide and personal copollutants.**

Study	Location	n	Averaging Times	PM <sub>2.5</sub>	EC	OC	O <sub>3</sub>
† <a href="#">Delfino et al. (2008a)</a>	Los Angeles, CA	≤486	All: 24 h	0.38	0.22	0.2	NR
† <a href="#">Suh and Zanobetti (2010b)</a>	Atlanta, GA	≤277	All: 24 h	0.29	0.49	NR	-0.03
† <a href="#">Williams et al. (2012a)</a>	Chapel Hill, NC	≤326	All: 24 h	0.06	0.33	NR	-0.11
† <a href="#">Schembari et al. (2013)</a>	Barcelona, Spain	≤65	NO <sub>2</sub> : 7 day; PM <sub>2.5</sub> /EC: 2 day	0.11	0.3	NR	NR

CA = California; EC = elemental carbon; GA = Georgia; h =hour; n = samples size; NC = North Carolina; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; O<sub>3</sub> = ozone; OC = organic carbon; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

**Table 3-14 Correlation coefficients between indoor nitrogen dioxide and indoor copollutants.**

Study	Location	n	Averaging Times	PM	EC	OC	O <sub>3</sub>
† <a href="#">Sarnat et al. (2012)</a> <sup>a</sup>	El Paso, TX (Site A)	15	NO <sub>2</sub> : 4 day; PM <sub>2.5</sub> /EC:2 day	-0.35 (PM <sub>2.5</sub> )	0.58	NR	NR
		-0.26 (PM <sub>10-2.5</sub> )					
		-0.19 (PM <sub>10</sub> )					
	El Paso, TX (Site B)	15	NO <sub>2</sub> : 4 day; PM <sub>2.5</sub> /EC:2 day	0.06 (PM <sub>2.5</sub> )	-0.37	NR	NR
	0.28 (PM <sub>10-2.5</sub> )						
	0.12 (PM <sub>10</sub> )						
Ciudad Juarez, Mexico (Site A)	Ciudad Juarez, Mexico (Site A)	15	NO <sub>2</sub> : 4 day; PM <sub>2.5</sub> /EC:2 day	-0.29 (PM <sub>2.5</sub> )	0.66	NR	NR
				-0.58 (PM <sub>10-2.5</sub> )			
				-0.5 (PM <sub>10</sub> )			
Ciudad Juarez, Mexico (Site B)	Ciudad Juarez, Mexico (Site B)	15	NO <sub>2</sub> : 4 day; PM <sub>2.5</sub> /EC:2 day	-0.04 (PM <sub>2.5</sub> )	0.45	NR	NR
				-0.5 (PM <sub>10-2.5</sub> )			
				-0.34 (PM <sub>10</sub> )			
† <a href="#">Greenwald et al. (2013)</a> <sup>b</sup>	2 sites in El Paso, TX	18-26	All: 4 day	0.76 (PM <sub>2.5</sub> )	0.45	NR	NR
				0.83 (PM <sub>10</sub> )			

EC = elemental carbon; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; O<sub>3</sub> = ozone; OC = organic carbon; PM = particulate matter; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm; PM<sub>10-2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm and greater than 2.5 µm; TX = Texas.

<sup>a</sup>Spearman correlation.

<sup>b</sup>Pearson correlation.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

In addition to these findings, higher correlations were typically observed between ambient concentrations of NO<sub>2</sub> and other traffic-related pollutants (Section 3.4.3.1) compared to personal measurements [e.g., correlations among personal exposure measurements in Table 3-13; (Schembari et al., 2013; Williams et al., 2012a; Suh and Zanobetti, 2010b; Delfino et al., 2008a)]. For example, (Suh and Zanobetti, 2010b) observed a stronger relationship between ambient NO<sub>2</sub>:EC ( $r = 0.61$ ) and ambient NO<sub>2</sub>:PM<sub>2.5</sub> ( $r = 0.47$ ) compared to personal NO<sub>2</sub>:EC ( $r = 0.49$ ) and personal NO<sub>2</sub>:PM<sub>2.5</sub> ( $r = 0.29$ ). Delfino et al. (2008a) observed similar results in the NO<sub>2</sub>:EC relationship in a health study investigating the relationship between traffic-related pollution and lung function decrements in Los Angeles, CA. While the ambient NO<sub>2</sub>:EC correlation was  $r = 0.61$ , lower correlations were observed for personal NO<sub>2</sub>:EC ( $r = 0.22$ ). Additionally, a small number of time-series studies have used NO<sub>2</sub> concentration in receptor models to relate health effects to sources/factors (Baxter et al., 2013; Cakmak et al., 2009; Halonen et al., 2009; Mar et al., 2000). Each of these studies used factor analysis, the U.S. EPA positive matrix factorization method,<sup>1</sup> or PCA analysis and found high loadings of NO<sub>2</sub> and traffic-related copollutants (e.g., EC, OC, CO) on the same factor, which was attributed to traffic-related pollution.

Correlations between NO<sub>2</sub> and VOC concentrations also suggest different sources for personal exposure. For example, Martins et al. (2012) estimated personal NO<sub>2</sub> and BTEX exposures during four 1-week periods using a microenvironmental approach that combined outdoor and indoor concentrations with time-activity patterns. It consistently observed correlations of  $r = -0.42$  to  $r = 0.14$  between NO<sub>2</sub> concentration and BTEX concentration during different seasons. The lack of correlation between these pollutants can be attributed in part to differences in sources between indoor and outdoor microenvironments. While exposure to VOCs, namely benzene, was attributed mainly to indoor sources, NO<sub>2</sub> concentration was largely associated with traffic sources. These studies emphasize that proximity to roadways and time spent in various indoor and outdoor microenvironments can impact the relationship between NO<sub>2</sub> and traffic-related VOCs.

Weaker correlations observed between personal measurements of NO<sub>2</sub> exposure and other traffic-related pollutant exposures (compared to ambient concentration correlations) suggest that personal exposure to NO<sub>2</sub> may include a number of outdoor and indoor sources comprising traffic and nontraffic emissions (e.g., gas stoves, residential wood burning, biomass burning). These observations provide further evidence that nonambient sources of NO<sub>2</sub> provide interference to the ambient NO<sub>2</sub> measurement signal. At the same time, the weaker correlations between total personal NO<sub>2</sub> exposure and copollutant

---

<sup>1</sup><http://intranet.epa.gov/heads/products/pmf/pmf.htm>.

exposures indicate that for panel studies of total personal NO<sub>2</sub> exposure, ambient copollutants would be less likely to confound health effect estimates for personal NO<sub>2</sub> exposure. Titration conditions for NO, NO<sub>2</sub>, and O<sub>3</sub> also likely differ from indoors to outdoors, given variation in solar radiation and other atmospheric factors that influence atmospheric chemistry. Additionally, personal exposures are influenced by building air exchange rate and time-activity patterns that differ among study participants. This is in contrast to ambient NO<sub>2</sub> concentrations, which appear to be largely driven by variability in traffic pollution in many areas. This type of exposure error associated with ambient concentrations is discussed in more detail in [Section 3.4.3.3](#).

Few studies have reported indoor NO<sub>2</sub>-copollutant correlations for short-term averaging times, focusing on correlations between NO<sub>2</sub> concentration and PM concentration in different size fractions as well as NO<sub>2</sub> concentration and BC concentration. In these studies, correlations of Spearman  $r = -0.37$  to  $0.66$  were observed between indoor NO<sub>2</sub> concentration and EC concentration; however, lower correlations are observed for indoor NO<sub>2</sub> concentration and PM concentration compared with NO<sub>2</sub> concentration and EC concentration. [Sarnat et al. \(2012\)](#) measured indoor concentrations of NO<sub>2</sub>, EC, PM<sub>2.5</sub>, PM<sub>10-2.5</sub>, and PM<sub>10</sub> at four elementary schools in two cities near the U.S.-Mexico border: El Paso, TX and Ciudad Juarez, Mexico. NO<sub>2</sub> and PM concentrations showed weaker and/or inverse correlations at all four elementary schools ( $r = -0.58$  to  $0.12$ ). [Greenwald et al. \(2013\)](#) later conducted a follow-up study to [Sarnat et al. \(2012\)](#) and measured similar pollutants at the same schools in El Paso, TX. Although [Greenwald et al. \(2013\)](#) reported similar NO<sub>2</sub>-EC correlations to those reported in [Sarnat et al. \(2012\)](#), stronger correlations were observed between NO<sub>2</sub> and PM<sub>2.5</sub> concentrations ( $r = 0.76$ ) and between NO<sub>2</sub> and PM<sub>10</sub> concentrations ( $r = 0.83$ ). Differences in the NO<sub>2</sub>-PM correlations between these two studies reflect that NO<sub>2</sub> and PM can have many different sources in indoor environments, which impact their temporal and spatial patterns. Moreover, the results of [Greenwald et al. \(2013\)](#) suggest the potential for confounding of NO<sub>2</sub> health effect estimates by PM based on indoor concentrations. Taken together, the existence and extent of such confounding is uncertain.

In general, ambient NO<sub>2</sub> concentration would not necessarily be expected to correlate well with personal exposures of copollutants. For example, in the case where the exposed population spends time at residences or workplaces sufficiently far from the near-road environment, personal NO<sub>2</sub> exposure would not be expected to correlate with ambient copollutants of traffic-related origin. Low correlations between ambient NO<sub>2</sub> concentration and personal exposures to copollutants could support inferences regarding the independent effects of NO<sub>2</sub>.

---

#### 3.4.4.4 Traffic and Noise as Confounders

For the purpose of inferring causality from the body of epidemiologic studies of short-term and long-term exposure to traffic-related pollutants, the Health Effects Institute Report on Traffic-Related Air Pollution ([HEI, 2010](#)) raised the concern that distance-to-road models are especially subject to confounding the associations between health effects and exposures because traffic indicators may encompass additional information, such as noise, unmeasured air pollutants, stress, and socioeconomic status, that may also be associated with the health effects of interest. However, recent evidence is mixed regarding the correlations of NO and NO<sub>2</sub> concentrations with traffic and noise levels. Most of these studies are for short-term exposure. Hence, the role of traffic and noise as confounders or independent variables in the relationship between health effects and NO or NO<sub>2</sub> exposure is unclear.

Several studies have examined the relationship of traffic-related noise with NO and NO<sub>2</sub> concentrations. [Kheirbek et al. \(2014\)](#) added noise level meters to the dense New York, NY monitoring project described in [Ross et al. \(2013\)](#) and observed that 1-week avg noise level, obtained at 60 locations during Fall 2012, correlated with Pearson  $r = 0.59$  for NO<sub>2</sub> concentration and  $r = 0.61$  for NO concentration. [Davies et al. \(2009\)](#) measured 2-week avg of NO<sub>2</sub> and NO<sub>x</sub> concentrations concurrently with 5-minute noise samples at 103 sites and observed correlations of  $r = 0.53$  for NO<sub>2</sub> concentration and  $r = 0.64$  for NO<sub>x</sub> concentration. [Gan et al. \(2012b\)](#) calculated the correlations among air pollutants and noise from road traffic and aircraft using 5-minute data from 103 sites in Vancouver, Canada during 2003 (dates not stated). They observed lower correlations for NO<sub>2</sub> concentration with road traffic noise (Spearman  $r = 0.33$ ) and aircraft noise ( $r = 0.14$ ) compared with the correlation of NO concentration with these two noise sources (road traffic:  $r = 0.41$ ; aircraft:  $r = 0.26$ ). For both NO<sub>2</sub> and NO concentration, correlations were higher for road traffic noise than aircraft noise. Over a 5-year avg, [Gan et al. \(2012a\)](#) reported the correlation between NO<sub>2</sub> concentration and noise from road traffic of Spearman  $r = 0.33$  from [Gan et al. \(2012b\)](#), as well as a correlation between NO concentration and noise from road traffic of Spearman  $r = 0.39$ .

[Ross et al. \(2011\)](#) also examined relationships of different frequency noises with NO and NO<sub>2</sub> concentrations using continuous monitors collecting 48,000 samples per second for six 24-hour periods in August 2009. [Ross et al. \(2011\)](#) measured the relationships between traffic level, noise, and concentrations of NO<sub>2</sub> and NO in New York, NY as part of the [Ross et al. \(2013\)](#) study. Unweighted noise of all frequencies was uncorrelated with NO<sub>2</sub> concentration (Spearman  $r = -0.01$ ) but correlation increased for NO concentration (Spearman  $r = 0.43$ ) for all times. Correlations were higher for medium frequency noise (NO<sub>2</sub>:  $r = 0.22$ ; NO:  $r = 0.57$ ). Correlations between noise and traffic

counts segregated by fleet mix were generally higher for cars (unweighted noise:  $r = 0.37$ ; medium frequency:  $r = 0.33$ ), trucks (unweighted noise:  $r = 0.64$ ; medium frequency:  $r = 0.71$ ), and buses (unweighted noise:  $r = 0.61$ ; medium frequency:  $r = 0.60$ ) compared with the correlations with nonsegregated traffic data. Likewise, at night, high frequency noise was correlated with NO<sub>2</sub> concentration ( $r = 0.83$ ) and NO concentration ( $r = 0.73$ ).

Distance to road has also been observed to influence the relationship between noise and NO<sub>2</sub> concentration for both long-term and short-term noise and NO<sub>2</sub> exposure studies. For the years 1987–1996, [Beelen et al. \(2009\)](#) estimated correlations among 1-year avg NO<sub>2</sub> concentration, traffic level, and noise, and they observed correlations between traffic and noise depending on spatial designation ( $r = 0.30$ – $0.38$ ) and for the correlation of NO<sub>2</sub> concentration and noise ( $r = 0.46$ ). When segregating loud noise  $\geq 65$  dBA, correlation dropped ( $r = 0.22$ ). Note that [Beelen et al. \(2009\)](#) did not specify whether Pearson or Spearman correlations were computed. [Ross et al. \(2011\)](#) noted within-day variability in these relationships, where truck and car traffic are correlated ( $r = 0.81$ ) during the morning rush hour but inversely correlated at night ( $r = -0.67$ ). [Dadvand et al. \(2014c\)](#) measured 24-hour avg noise, NO<sub>x</sub> concentration, and NO<sub>2</sub> concentration at 50-m, 200-m, 500-m, and beyond 500-m buffers from the road in Barcelona, Spain from 2001–2005 and observed that all three decreased with increasing distance from the road. Measured temporal Spearman correlation of noise was  $r = 0.45$  for NO<sub>2</sub> concentration and  $r = 0.56$  for NO<sub>x</sub> concentration. [Allen et al. \(2009\)](#) also studied the relationship between NO<sub>2</sub> concentration, UFP concentration, and 5-minute avg A-weighted equivalent noise for 105 locations in Chicago, IL and Riverside, CA using measurements taken in December 2006 and April 2007. After adjustment for regional unspecified air pollutant concentration gradients, Pearson correlations with noise were  $r = 0.16$ – $0.62$  for NO<sub>2</sub> concentration (winter Chicago, IL:  $r = 0.16$ ; spring Chicago, IL:  $r = 0.41$ ; spring Riverside, CA:  $r = 0.62$ ) and  $0.49$ – $0.62$  for NO concentration. In Chicago, IL, correlations of noise with NO and NO<sub>2</sub> concentrations were higher within a 100-m buffer of the road, while correlations of noise with NO and NO<sub>2</sub> concentrations were lower within a 100-m buffer in Riverside.

For short-term exposure studies, more evidence is available to consider the relationship between traffic-related noise and NO<sub>2</sub> concentration compared with long-term exposure studies. Collectively, these studies suggest that potential for confounding of NO<sub>2</sub> effects by noise may be influenced by temporal and spatial resolution of the data, noise frequency, and fleet mix. Specifically, confounding is less probable as distance from the road increases. However, total noise may be unlikely to act as a confounder. It should be noted that noise would also have to be etiologically related to the health outcome under

consideration to confound the relationship between the health effect and NO<sub>2</sub> exposure. When noise is decomposed by frequency, confounding is more likely.

---

### 3.4.5 Implications for Epidemiologic Studies of Different Designs

Estimates of NO<sub>2</sub> exposures are subject to errors that can vary in nature, as described in [Section 3.4.3](#). Classical error is defined as error scattered around the true personal exposure and independent of the measured exposure. Classical error results in bias of the epidemiologic health effect estimate that is often towards the null. Classical error can also cause inflation or reduction of the standard error of the health effect estimate. Berkson error is defined as error scattered around the exposure surrogate (in most cases, the central site monitor measurement) and independent of the true value ([Goldman et al., 2011](#); [Reeves et al., 1998](#)).

Definitions for Berkson-like and classical-like errors were developed for modeled exposures. These errors depend on how exposure metrics are averaged across space. [Szpiro et al. \(2011a\)](#) defined Berkson-like and classical-like errors as errors sharing some characteristics with Berkson and classical errors, respectively, but with some differences. Specifically, Berkson-like errors occur when the modeled exposure does not capture all of the variability in the true exposure. Berkson-like errors increase the variability around the health effect estimate in a manner similar to pure Berkson error, but Berkson-like errors are spatially correlated and not independent of predicted exposures, unlike pure Berkson errors. [Szpiro and Paciorek \(2013a\)](#) simulated Berkson-like errors' influence on health effect estimates (see also, [Szpiro and Paciorek \(2013b\)](#)). For the case simulated where spatial variability in the exposure estimates from measured concentrations exceeded the spatial variability in the true exposures (which were modeled to be uniform), the health effect estimates were biased away from the null. For the case simulated where covariates were included in the health model but not the exposure model, the health effect estimates were biased towards the null. Hence, Berkson-like error can lead to bias of the health effect estimate in either direction. Classical-like errors can add variability to predicted exposures and can bias health effect estimates in a manner similar to pure classical errors, but they differ from pure classical errors in that the variability in estimated exposures is also not independent across space.

The results of [Meng et al. \(2012b\)](#), described in [Section 3.4.2](#), illustrated that epidemiologic study design can influence the relationship between personal exposure to NO<sub>2</sub> and ambient concentrations ([Table 3-7](#)). This meta-analysis found that correlations were highest for short-term exposure community time-series epidemiology studies (designated as “daily average” in [Table 3-7](#)), and correlations were lowest for

longitudinal panel cohort studies. The following sections consider how exposure assessment errors may influence interpretation of health effect estimates for epidemiologic studies of different designs.

---

### 3.4.5.1 Community Time-Series Studies

In most short-term exposure epidemiologic studies of the health effects of NO<sub>2</sub>, the health effect endpoint is modeled as a function of ambient exposure,  $E_a$ , which is defined as the product of ambient concentration,  $C_a$ , and  $\alpha$ , a term encompassing time-weighted averaging and infiltration of NO<sub>2</sub> (Section 3.4.1). Community time-series epidemiologic studies capturing the exposures and health outcomes of a large cohort frequently use the concentration measured at a central site monitor ( $C_{a,csm}$ ) as a surrogate for  $E_a$  in an epidemiologic model (Wilson et al., 2000). At times, an average (unweighted or weighted) of central site monitored concentrations is used for the  $E_a$  surrogate. For studies involving thousands of participants, it is not feasible to measure personal exposures. Moreover, for community time-series epidemiology studies of short-term exposure, the temporal variability in concentration is of primary importance to relate to variability in the health effect estimate (Zeger et al., 2000). The magnitude of bias in the health effect estimate will decrease and the precision of the health effect estimate will increase as the temporal correlation of  $C_{a,csm}$  with the true air pollutant exposure increases. Spatial variability in NO<sub>2</sub> concentrations across the study area could attenuate an epidemiologic health effect estimate if the exposures are not correlated in time with  $C_{a,csm}$  when central site monitoring is used to represent exposure. If exposure assessment methods that more accurately capture spatial variability in the concentration distribution over a study area are employed, then the confidence intervals around the health effect estimate may decrease. The following several paragraphs describe studies that tested the influence of different types of exposure error on the health effect estimate. Because the majority of these studies were conducted for one metropolitan area (Atlanta, GA), caution must be taken when interpreting the study results described.

Goldman et al. (2011) simulated the effect of classical and Berkson errors due to spatiotemporal variability among ambient or outdoor air pollutant concentrations over a large urban area on health effect estimates of emergency department (ED) visits for a time-series study of cardiovascular disease. The relative risk (RR) per ppm was negatively biased in the case of classical error (1-hour daily max NO<sub>2</sub>: -1.3%; 1-hour daily max NO<sub>x</sub>: -1.1%) and negligibly positively biased in the case of Berkson error (1-hour daily max NO<sub>2</sub>: 0.0042%; 1-hour daily max NO<sub>x</sub>: 0.0030%). The 95% confidence interval range for RR per ppm was wider for Berkson error (1-hour daily max

NO<sub>2</sub>: 0.028; 1-hour daily max NO<sub>x</sub>: 0.023) compared with classical error (1-hour daily max NO<sub>2</sub>: 0.0025; 1-hour daily max NO<sub>x</sub>: 0.0043).

Recent studies have explored the effect of spatial exposure measurement error on health effect estimates to test the appropriateness of using central site monitoring for time-series studies. [Goldman et al. \(2010\)](#) simulated spatial exposure measurement error based on a semivariogram function across monitor sites with and without temporal autocorrelation at 1- and 2-day lags. Their goal was to analyze the influence of spatiotemporal variability among ambient or outdoor concentrations over a large urban area on a time-series study of ED visits for cardiovascular disease. A random term was calculated through Monte Carlo simulations based on the data distribution from the semivariogram, which estimated the change in spatial variability in exposure with distance from the monitoring site. The average of the calculated random term was added to a central site monitor concentration time series (considered in this study to be the base case) to estimate population exposure to NO<sub>2</sub> subject to spatial error. For the analysis with temporal autocorrelation considered, RR per ppm for 1-hour daily max NO<sub>2</sub> dropped slightly to 1.0046 (95% CI: 1.0026, 1.0065), and RR per ppm for 1-hour daily max NO<sub>x</sub> dropped to 1.0079 (95% CI: 1.0057, 1.0100) when both were compared with the central site monitor RR per ppm = 1.0139 (for all air pollutants).<sup>1</sup> When temporal autocorrelation was not considered, RR per ppm dropped to 1.0044 for 1-hour daily max NO<sub>2</sub> and 1.0074 for 1-hour daily max NO<sub>x</sub>. The results of [Goldman et al. \(2010\)](#) suggest that spatial exposure measurement error from use of central site monitoring concentration data results in biasing the health effect estimate towards the null, but the magnitude of the change in effect was small.

[Goldman et al. \(2012\)](#) also studied the effect of different types of spatial averaging of the exposure surrogate on bias in the health effect risk ratio and the effect of correlation between measured and “true” ambient exposures of NO<sub>2</sub> and NO<sub>x</sub> to analyze the influence of spatiotemporal variability among ambient or outdoor concentrations over a large urban area on health effect estimates. Concentrations were simulated at alternate monitoring locations using the geostatistical approach described above for [Goldman et al. \(2010\)](#) for the 20-county Atlanta, GA metropolitan area for comparison with concentration measurements obtained directly from monitors at those sites. Geostatistical-simulated concentrations were considered to be “true” in this study, and other exposure assignment methods were assumed to have some error. Five different exposure assignment approaches were tested: using concentrations from a single central site monitor, averaging the simulated concentrations across all monitoring sites, performing a population-weighted average of concentrations across all monitoring sites,

---

<sup>1</sup>Note that 95% CIs were not reported for the central site monitor RR or for the cases where temporal autocorrelation was not considered.

performing an area-weighted average of concentrations across all monitoring sites, and population-weighted averaging of the geostatistically simulated concentrations (Table 3-15). [Goldman et al. \(2012\)](#) observed that the exposure measurement error was somewhat correlated with both the measured and true values, reflecting both Berkson and classical error components. For the central site monitor, the exposure measurement errors were somewhat inversely correlated with the true value but had relatively higher positive correlation with the measured value. For the other exposure assignment methods, the exposure measurement errors were inversely correlated with the true exposures, while they had positive but lower magnitude correlation with the measured concentrations. At the same time, the exposure measurement bias, given by the ratio of the exposure measurement error to the measured concentration, was much higher in magnitude at the central site monitor than for the other exposure assignment methods for NO<sub>2</sub> concentrations. For NO<sub>x</sub> concentrations, exposure measurement bias for the central site monitor was much higher than for the other exposure assignment methods with the exception of the area-weighted average, which produced a large negative exposure measurement bias. Hence, compared with other exposure assignment methods, the health effect estimate would likely have greater bias towards the null with reduced precision when a central site monitor is used to measure NO<sub>2</sub> concentration as a surrogate for exposure. However, exposure error is also likely to cause some bias and imprecision in the effect estimate for other exposure surrogate methods. These findings suggest more Berkson error in the more spatially resolved exposure assignment methods compared with the central site monitor and more classical error for the central site monitor estimate compared with the other exposure assignment techniques. Hence, more bias and less precision would be anticipated for the health effect estimate calculated from the central site monitor compared with the more spatially resolved methods. It was observed that the more spatially variable air pollutants studied in [Goldman et al. \(2012\)](#) also had more bias in the health effect estimates. This was noted across exposure assignment methods but was more pronounced for the central site measurement data.

[Butland et al. \(2013\)](#) conducted a simulation study to test how spatial resolution of the NO<sub>2</sub> concentration measures used for exposure assignment influences health effect estimates in a time-series epidemiologic model of mortality in urban and rural areas. The test domain was subdivided into squares ranging in area from 1 km<sup>2</sup> to 25 km<sup>2</sup>. Health effect estimates simulated using the 1-km<sup>2</sup> resolution area were considered to be “true,” and mortality estimates were sampled from a Poisson distribution of mortality data. Monitor data were simulated based on a lognormal distribution using the correlogram among pairs of NO<sub>2</sub> concentration monitors to establish the variability of the distribution as a function of distance. The error structure in the model was constructed to include both Berkson and classical components. Health effect estimates for mortality based on NO<sub>2</sub> exposures were attenuated by 29 and 38% for urban and rural areas, respectively, when

reducing the spatial resolution from 1 km<sup>2</sup> to 25 km<sup>2</sup> over a 3-year time-series analysis. Because the [Butland et al. \(2013\)](#) study was conducted in the U.K., where the NO<sub>2</sub> monitoring network has a larger number of near-road sites, the nature and magnitude of the exposure error can be expected to differ for the U.S.

**Table 3-15 The influence of exposure metrics on error in health effect estimates.**

Exposure Estimation Approach	Bias[(Z - Z*)/Z] <sup>a</sup>	R <sup>2</sup> (Z, Z*) <sup>b</sup>	R[(Z - Z*), Z*] <sup>c</sup>	R[(Z - Z*), Z] <sup>c</sup>
<b>NO<sub>2</sub></b>				
Central site monitor	0.62	0.24	-0.46	0.61
Unweighted average	0.25	0.38	-0.73	0.20
Population-weighted average	0.18	0.38	-0.78	0.14
Area-weighted average	-0.07	0.38	-0.87	-0.04
Geostatistical model— population-weighted average	N/A	0.45	-0.82	0.0017
<b>NO<sub>x</sub></b>				
Central site monitor	0.71	0.33	-0.11	0.81
Unweighted average	0.31	0.45	-0.63	0.29
Population-weighted average	0.03	0.46	-0.81	0.02
Area-weighted average	-0.88	0.47	-0.96	-0.31
Geostatistical model— population-weighted average	N/A	0.52	-0.80	-0.00042

N/A = not applicable; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = the sum of nitric oxide and NO<sub>2</sub>; R = Pearson correlation; R<sup>2</sup> = coefficient of determination; Z = the measured concentration; Z\* = the true concentration.

Note: Model errors were based on comparisons between measured data and simulated data at several monitoring sites. Errors were estimated for a single central site monitor, various monitor averages, and values computed from a geostatistical model. Z denotes the measured concentration, and Z\* denotes the true concentration, considered here to be from the chemical transport model. Bias in the exposure metric is given as the proportion of error between the measurement and true value to the measurement.

<sup>a</sup>Data are from Figure 5 and provided by the authors ([Goldman, 2013](#)).

<sup>b</sup>Data are from Figure 4 and provided by the authors ([Mulholland, 2013](#)).

<sup>c</sup>Pearson correlation.

Source: Data compiled from Table 1, Figure 4, and Figure 5; used with permission of Elsevier, [Goldman et al. \(2012\)](#).

[Sarnat et al. \(2010\)](#) studied the spatial variability of concentrations of NO<sub>2</sub>, CO, O<sub>3</sub>, and PM<sub>2.5</sub> in the Atlanta, GA metropolitan area and how it affects interpretation of epidemiologic results, using time-series data for circulatory disease ED visits. Sensitivity to spatial variability was examined at slightly greater than neighborhood scale (8 km) in this study. Interestingly, [Sarnat et al. \(2010\)](#) found that relative risk varied with distance between the monitor and study population when comparing urban to rural locations, but distance of the study population to the monitor was not an important factor when comparing urban population groups. This suggests that, even for spatially heterogeneous NO<sub>2</sub>, urban-scale concentration measures may produce results comparable to neighborhood-scale concentration measures if the sites were comparable throughout the city, for example, as a result of similar traffic patterns. However, [Sarnat et al. \(2010\)](#) cautioned that, because their study was limited to 8-km radii, it is not possible to interpret this work with respect to near-road and on-road microscale concentrations.

In a study of the effect of concentration metric choice (central site, arithmetic average across space, or population-weighted average) used to assign exposure in a time-series epidemiologic model, [Strickland et al. \(2011\)](#) found that choice of the concentration metric resulted in large differences in the observed associations between ED visits for pediatric asthma and exposure for spatially heterogeneous NO<sub>2</sub> but not for spatially homogeneous PM<sub>2.5</sub> when using a unit standardization for computing the relative risk. However, when [Strickland et al. \(2011\)](#) used IQR for standardization, there were little differences among the relative risk estimates across the concentration metrics. The differences observed between unit and IQR standardization are due to the fact that the IQR reflects the spatial variability in the exposure metrics for the spatial and population-weighted averages.

Error type also influences the health effect estimate from time-series studies. [Dionisio et al. \(2014\)](#) decomposed the exposure measurement error into spatial and population-based components. Spatial error was defined as the difference between concentration simulated by an AERMOD dispersion model and concentration measured at a central site monitor, and population error was defined as the difference between the SHEDS exposure model (using only ambient sources) and the dispersion model. Errors were computed for each ZIP code centroid. Three pollutants with high spatial variability (NO<sub>x</sub>, CO, EC) termed “local” and three pollutants with low spatial variability (PM<sub>2.5</sub>, O<sub>3</sub>, SO<sub>4</sub>) termed “regional” by the authors were included in the study. Although NO<sub>2</sub> concentration was not included explicitly, the local pollutant results are relevant. [Dionisio et al. \(2014\)](#) observed more variability in both the spatial and population components of the exposure measurement error across the ZIP codes for the local pollutants compared with the regional pollutants. Attenuation of the health effect estimate by the spatial error component was much larger for the local pollutants compared with the regional

pollutants, and the amount of bias by the spatial error component was roughly the same for NO<sub>x</sub>, CO, and EC. However, the population error component caused much more attenuation of the health effect estimate for NO<sub>x</sub> compared with CO and EC. In fact, CO had negligible bias of the health effect estimate due to the population error component. This discrepancy is possibly related to the deposition rate of NO<sub>x</sub> and differences in sunlight affecting the NO<sub>2</sub>/NO<sub>x</sub> ratio indoors compared with CO, which has a zero deposition rate and is modeled as not reactive in SHEDS. Given that NO<sub>2</sub> has a higher deposition rate than NO, the results of [Dionisio et al. \(2014\)](#) suggest that health effect estimates modeled in time-series studies of NO<sub>x</sub> exposure are likely extendable to NO<sub>2</sub> (see [Section 3.3.2.1](#) for information related to deposition of indoor NO<sub>2</sub>). Hence, it is likely that spatial variability and indoor deposition both cause bias in the health effect estimate for studies of NO<sub>2</sub> exposure.

Nonambient sources of NO<sub>2</sub> tend to diminish the correlation between NO<sub>2</sub> concentration measured at a central site monitor and total personal NO<sub>2</sub> exposure measurements ([Section 3.4.2](#)). Analyses of time-series epidemiologic studies have suggested that nonambient contributions introduce Berkson error into the exposure term, where the error does not bias health effect estimates for ambient NO<sub>2</sub> assuming that nonambient NO<sub>2</sub> sources are independent of ambient sources, but it does cause the confidence intervals around the health effect estimates to widen ([Sheppard, 2005](#); [Wilson et al., 2000](#)). No data from cohort studies are available to test if this theory can be applied more broadly to all epidemiologic studies. [Sheppard et al. \(2005\)](#) simulated the effect of nonambient sources for a time-series study of the health effects of PM exposure and found that, as long as the ambient and nonambient sources were uncorrelated, the nonambient exposures would widen the confidence interval around the health effect estimates but would not bias the health effect estimate. This result is generalizable to NO<sub>2</sub> because it did not depend on the particle size distribution. Moreover, the data in [Table 3-6](#) and [Section 2.3](#) illustrate seasonal variability in ambient NO<sub>2</sub> concentrations and in the relationship between ambient concentrations of NO<sub>2</sub> and personal NO<sub>2</sub> exposure. Therefore, it can be anticipated that the influence of nonambient NO<sub>2</sub> exposures on the confidence interval around the health effect estimate would vary with season.

Exposure measurement error related to instrument precision has a smaller effect on health effect estimates in time-series studies compared with error related to spatial gradients in the concentration because instrument precision would not be expected to modify the ability of the instruments to respond to changes in concentration over time. [Goldman et al. \(2010\)](#) investigated the influence of instrument error on health effect estimates in a time-series epidemiology study by studying differences in exposure assignments and health effect estimates obtained using copollutant monitors. In this study, a random error term based on observations from copollutant monitors was added to a central site

monitor's concentration time series to simulate population estimates for ambient air concentrations subject to instrument precision error in 1,000 Monte Carlo simulations. Very little changes in the risk ratios were observed for 1-hour daily max NO<sub>2</sub> and 1-hour daily max NO<sub>x</sub> concentrations. For 1-hour daily max NO<sub>2</sub> concentration, the RR per ppm of NO<sub>2</sub> concentration with simulated instrument precision error was 1.0133 compared with RR per ppm = 1.0139 for the central site monitor. For 1-hour daily max NO<sub>x</sub> concentration with simulated instrument precision error, RR per ppm = 1.0132 compared with the central site monitor's RR of 1.0139. The amount of bias in the health effect estimate related to instrument precision was very small.

---

### 3.4.5.2 Long-Term Average Cohort Studies

For cohort epidemiologic studies of long-term human exposure to NO<sub>2</sub>, where the difference in the magnitude of the concentration is of most interest, if  $C_{a,csm}$  is used as a surrogate for  $E_a$ , then  $\alpha$  can be considered to encompass the exposure measurement error related to uncertainties in the time-activity data and air exchange rate. Spatial variability in NO<sub>2</sub> concentrations across the study area could lead to bias in the health effect estimate if  $C_{a,csm}$  is not representative of  $E_a$ . This could occur, for example, if the study participants are clustered in a location where their NO<sub>2</sub> exposure is higher or lower than the exposure estimated at a modeled or measurement site. There is limited information regarding whether  $C_{a,csm}$  is a biased exposure surrogate in the near-road environment for epidemiologic studies of long-term exposure.

Sensitivity of the epidemiologic model to the temporal and spatial characteristics of exposure data depends on the temporal characteristics of the disease process. Birth outcome studies serve as an example where the exposure window becomes an important consideration that helps to delineate short-term exposure from long-term exposure epidemiologic study design. For example, [Ross et al. \(2013\)](#) studied the role of spatial and temporal resolution of NO<sub>2</sub> estimates in the application of LUR to study the relationship between birth outcome data in New York City (NY) and NO<sub>2</sub> exposure. Seasonal variability was more evident when averaging NO<sub>2</sub> estimates across the final 6 weeks of gestation compared with the entire gestation period, but temporal variation had less influence on NO<sub>2</sub> predictions compared with PM<sub>2.5</sub> predictions. This finding reflects the fact that variability in NO<sub>2</sub> concentrations is more prominent in space than in time compared with PM<sub>2.5</sub> concentrations. Additionally, [Brauer et al. \(2008\)](#) studied the influence of NO<sub>2</sub> exposure models (IDW of central site monitoring data and LUR) on health effect estimates for birth outcomes data in Vancouver, Canada between 1999–2002. IDW produced monthly average NO<sub>2</sub> concentrations matched to the month of pregnancy, while LUR was built using a dense passive sampling network deployed in

2003. [Brauer et al. \(2008\)](#) observed higher adjusted odds ratios for IDW compared with LUR (which produced health effect estimates closer to null, see [Section 6.4.3](#)). This finding may have been related to temporal coincidence of the monitoring and health data for the IDW and nearest monitor approaches; temporal coincidence is not possible for LUR. [Clark et al. \(2010\)](#) compared IDW with LUR for the analysis of asthma risk, based on hospitalizations in British Columbia (BC), Canada, from in utero and first-year-of-life exposure to NO<sub>2</sub>, NO, and other pollutants. They observed comparable adjusted odds ratios for the first year of NO<sub>2</sub> exposure and higher adjusted odds ratio for IDW compared with LUR for in utero NO<sub>2</sub> exposures ([Section 6.4.3](#)). The biologically relevant time period in eliciting a birth outcome likely determines whether spatial or temporal variation in concentration is more important to the epidemiologic model. It is possible that, if the biologically relevant time period is short, then temporal variability may play a larger role. In that case, the seasonal differences in NO<sub>2</sub> concentration become more important for measuring an effect. If the biologically relevant time period is longer, then the spatial contrasts evident in concentration maps become more important so that exposure error can lead to over- or under-estimation of the effect.

Spatial resolution of the exposure estimates has been evaluated to examine the influence of spatial exposure error in cohort studies. This has been considered with spatially resolved alternatives to central site monitoring data, such as data from a LUR, to describe exposure of individuals within a cohort that is spatially dispersed within a study area ([Section 3.2.2](#)). [Sellier et al. \(2014\)](#) and [Lepeule et al. \(2010\)](#) evaluated various approaches to estimate exposure (nearest central site monitor, geostatistical model, LUR model, dispersion model) in a study of birth weight among a French mother-child cohort in the French cities of Nancy and Poitiers. Correlations among the methods varied with respect to methodology, distance, and land use type. For example, the correlation between LUR and dispersion modeling had a minimum Pearson  $r = 0.58$  (for urban locations), while the correlation between central site monitoring and LUR had a minimum  $r = 0.20$  (also for urban locations). No effect of the method was observed on change in birth weight, but confidence intervals around the health effect estimate generally increased for dispersion models, which tended to be the most spatially heterogeneous among the four methods studied.

The influence of spatial exposure error on health effect estimates varies with the particular study parameters, such as model selection and location. [Madsen et al. \(2010\)](#) compared odds ratios for birth weight from the National Birth Registry of Norway per quartiles of NO<sub>2</sub> concentrations estimated from a near-road monitoring station and a dispersion model. Higher exposure variability was captured by the dispersion model, but the adjusted odds ratio showed an effect only for the near-road monitoring station exposure data, where time-averaged or residential exposures were likely to be

overestimated. [Wu et al. \(2011a\)](#) compared health effect estimates for birth outcomes from four hospitals in Los Angeles, CA and Orange counties, CA given NO<sub>2</sub> concentrations as estimated using nearest monitors and LUR. Odds ratios for NO<sub>2</sub> concentrations were comparable for nearest monitor and LUR for Los Angeles County, CA, where the LUR was fit, but the odds ratio decreased for Orange County in comparison with nearest monitor. This is consistent with studies reporting higher exposure error when LUR models are fit in one city and applied elsewhere, as described in [Section 3.2.2.1](#). [Ghosh et al. \(2012a\)](#) compared health effect estimates for low birth weight based on birth certificate data and NO<sub>2</sub> concentration estimates from LUR (scaled to account for seasonal fluctuations in concentration) to nearest monitoring station in Los Angeles County, CA and found negligible difference between the health effect estimates obtained with each exposure assignment method.

Minimization of error in the exposure estimate does not always minimize error in the health effect estimate. [Szpiro et al. \(2011a\)](#) performed a simulation study to evaluate bias and uncertainty of the health effect estimate obtained when using correctly specified and misspecified exposure simulation conditions, where correct specification was considered for comparison purposes to be the use of three spatial prediction variables and misspecification implied unmeasured error in the model. LUR was used to simulate exposure; the misspecified model omitted a geographic covariate in the LUR. [Szpiro et al. \(2011a\)](#) also reduced the amount of variability in the third covariate when simulating the monitoring network data in an additional set of simulations. Prediction accuracy of the exposure estimate was higher for the correctly specified model compared with the misspecified model. However, the health effect estimate was more variable for the correctly specified model compared with the misspecified model when the variability in the exposure covariate in the monitoring data decreased. The results of [Szpiro et al. \(2011a\)](#) suggested that use of more accurately defined exposure metrics in a cohort study does not necessarily improve health effect estimates, and their influence depends on the relative variability of the exposure covariates. The [Szpiro et al. \(2011a\)](#) simulations were for a generic air pollutant but are relevant for NO<sub>2</sub>.

[Basagaña et al. \(2013\)](#) also investigated the effect of differences in LUR model fitting on error in the epidemiologic health effect estimates in a simulation study based on cardiovascular disease data from the Girona (Italy) Heart Registry. For the exposure estimate, [Basagaña et al. \(2013\)](#) fit three LUR models with 20, 40, or 80 measurement locations. For this simulation study, the model considered correctly specified contained five covariates. As a comparison case, [Basagaña et al. \(2013\)](#) fit misspecified models containing 20 or 100 covariates (including the five original covariates). The misspecification effectively added error to the model. The simulated exposure error produced a combination of Berkson-like and classical-like errors on the health effect

estimate. Compared with the true health effect estimate, bias towards the null was observed to increase with decreasing number of measurement locations used to fit the LUR model. At the same time, the mean squared error of the health effect estimate increased with decreasing number of measurement locations. Moreover, bias towards the null and mean squared error also grew with increasing the number of covariates from 5 to 20 to 100. Notably, in-sample  $R^2$  did not trend with the number of variables while out-of-sample  $R^2$  increased with increasing number of sites (based on sites not collocated with the samplers used for model fitting), suggesting that in-sample  $R^2$  is not a sufficient measure of LUR model quality.

Error correction is a relatively new approach to estimate the correct standard error and potentially correct for bias in longitudinal cohort studies ([Szpiro et al., 2011b](#)). [Szpiro and Paciorek \(2013a\)](#) established that two conditions must hold for the health effect estimate to be predicted correctly: the exposure estimates from monitors must come from the same underlying distribution as the true exposures, and the health effect model includes all covariates relevant to the population. [Szpiro and Paciorek \(2013a\)](#) performed several simulations to investigate what happens when these conditions are violated. In one set of simulations, the distribution of the exposure was varied. When the assigned exposure measurements were set to be uniform across space, the health effect estimate was biased away from the null with different standard error compared with the case when the exposure subjects were collocated with the study participants. When an additional spatial covariate was omitted, the health effect estimate was biased towards the null with different standard errors compared with the correctly specified model. Bias correction and bootstrap calculation of the standard errors improved the model prediction, even when the true model contained several degrees of freedom. ([Spiegelman, 2013](#)) noted that the new measurement error correction methods developed by [Szpiro and Paciorek \(2013a\)](#) are a version of regression calibration. This study illustrated the influence of classical-like and Berkson-like errors on long-term exposure cohort study health effect estimates through these simulations.

Not accounting for time-activity patterns of study participants adds uncertainty to exposure estimates obtained via spatial modeling such as LUR. [Setton et al. \(2011\)](#) investigated how both spatial variability and unaccounted study participant mobility bias health effect estimates in long-term exposure epidemiologic models of health effects from  $\text{NO}_2$  exposure in a simulation study based on data from cohorts in southern California and Vancouver, Canada. In this case, concentration at each participant's home was modeled (using the Comprehensive Air Quality Model with Extensions [CAMx] for southern California and using LUR and IDW interpolation of monitoring data for Vancouver). Populations were simulated using human activity data for Vancouver, Canada and transportation survey data for southern California. Bias in the health effect

estimate increased in magnitude towards the null with distance from home and time spent away from home. Moreover, when spatial variability increased (through comparison of spatially variable LUR-derived NO<sub>2</sub> concentrations with a smoother monitor-based approach for mapping NO<sub>2</sub> concentrations for the Vancouver, Canada data), the health effect estimate obtained from the IDW-based approach was closer to the null compared with the LUR-based health effect estimate. [Setton et al. \(2011\)](#) interpreted this finding as evidence of the influence of smoothing spatially heterogeneous concentration profiles on the health effect estimate.

Instrumentation bias could be anticipated to influence health effect estimates from epidemiologic studies of long-term NO<sub>2</sub> exposures in some situations. [Section 3.2.1.2](#) describes how passive monitors are likely to overestimate exposure given the influences of ambient temperature, relative humidity, and presence of copollutants. Therefore, LUR exposure may be overestimated when the LUR is fit using passive monitoring data. [Sections 2.4.1](#) and [3.2.1.1](#) describe how the presence of copollutants can also cause NO<sub>2</sub> concentrations measured using central site monitors to be overestimated. Overestimating exposure can bias health effect estimates. Ambient temperature and relative humidity would not be expected to vary greatly within a city. However, local copollutant concentrations may be spatially variable such that an LUR model fit, and resulting health effect estimates, could have some differential bias in the health effect estimates across a city related to instrument error. Because climate and ambient sources are more likely to differ among cities, instrumentation error could have a larger influence on the comparison of health effect estimates among cities when LUR or central site monitors are used to estimate exposures.

In the case of long-term exposure cohort studies, nonambient contributions to the total personal exposure estimates would be expected to widen the confidence interval around the health effect estimates by adding noise to the exposure signal. Also, addition of any non-negative nonambient component to the personal exposure measurement would result in an overestimate of exposure to ambient NO<sub>2</sub>, because the average total personal NO<sub>2</sub> exposure would have to be either equal to or greater than the average personal exposure to ambient NO<sub>2</sub>. This exposure error could bias the health effect estimate towards the null.

---

### 3.4.5.3 Panel Studies

Consideration of errors in use of  $C_{a,csm}$  as a surrogate for  $E_a$  provides information on the impact of this proxy measure on health effect estimates in panel studies. [Van Roosbroeck et al. \(2008\)](#) evaluated health effect estimates among a panel of children for associations

of four respiratory outcomes with 48-hour NO<sub>2</sub> data from a single monitor located at the children's school. These health effect estimates were compared with those obtained from personal NO<sub>2</sub> monitoring to capture spatial variability in NO<sub>2</sub> concentrations and time-activity data. [Van Roosbroeck et al. \(2008\)](#) observed that health effect estimates were biased towards the null by roughly one-half to one-third when using a single monitor outside the school in lieu of personal exposure monitors. In this case, bias in the single-monitor health effect estimate was likely influenced by the spatial variability of the NO<sub>2</sub> concentration profile, time-activity of the study participants, and infiltration of ambient NO<sub>2</sub> indoors. The authors also adjusted the health effect estimate for nonambient sources, including parental smoking, gas cooking, and presence of an unvented water heater.

[Sarnat et al. \(2012\)](#) considered the influence of exposure surrogate on health effect estimates obtained for a panel of school children. This study was conducted along the U.S.-Mexico border in El Paso, TX and Ciudad Juarez, Mexico, and 96-hour avg concentrations measured from central site chemiluminescent monitors, passive monitors outside the children's schools, and passive monitors inside the children's schools were all used as surrogates for exposure to NO<sub>2</sub>. The largest health effect estimate was observed for measurements outside the school. In comparison, the health effect estimates for NO<sub>2</sub> measured inside the schools and at central site monitors were several times smaller ([Table 5-16](#)). Based on the comparison between outdoor and central site monitoring results, [Sarnat et al. \(2012\)](#) concluded that exposure error from using central site measurements, in lieu of measurements at the site of exposure, could lead to biasing the health effect estimate towards the null. They proposed that this bias was related to the failure of central site monitors to capture intra-urban spatial variability. The 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) also did not find conclusive evidence of the influence of exposure measurement error on health effect estimates from panel epidemiologic studies of NO<sub>2</sub> exposure. In general, there is uncertainty regarding the influence of NO<sub>2</sub> monitor placement on the magnitude and directionality of bias of the health effect estimate as related to use of central site monitors in lieu of localized monitors in panel studies. As for epidemiologic studies of long-term NO<sub>2</sub> exposure ([Section 3.4.5.2](#)), panel studies with multiple sites could be affected by instrumentation error, which could lead to overestimates of exposure at some but not all locations. This could have a differential influence on health effect estimates, especially for intercity comparisons.

---

## 3.5 Conclusions

This chapter presents the current state of the science for assessment of human exposure to NO<sub>2</sub>. It builds upon the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), which concluded that errors associated with the use of NO<sub>2</sub> concentrations measured at central site monitors as exposure metrics for epidemiologic studies tended to bias the health effect estimate towards the null for both short- and long-term exposure epidemiologic studies. As detailed within this chapter, recent studies provide support for the conclusions presented in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) for short-term exposure studies but differ in some cases for long-term exposure studies.

Commonly used exposure assessment methods include central site monitors, passive monitors, LUR, CTM, and dispersion models ([Section 3.2](#)). The influence of measurement errors from each of these techniques varies with study design. These methods are listed in [Table 3-1](#), along with their application (i.e., the design of the study in which they are used) and associated errors. Community time-series studies of short-term NO<sub>2</sub> exposure typically use central site monitoring. Panel studies tend to employ central site monitors or, in some cases, passive monitors. Studies of long-term NO<sub>2</sub> exposure often use a variety of methods, including central site monitors, LUR, dispersion models, spatial smoothing techniques, and spatiotemporal models. Errors associated with these methods vary in importance based on their application. LUR estimates of NO<sub>2</sub> exposure have been validated by independent methods when the model was trained and applied in the same general location so that the exposure estimates and true exposures are assumed to come from the same data distribution. Dispersion modeling can be subject to errors related to simplifying assumptions about the meteorology, urban or natural topography, or photoreactivity of NO to form NO<sub>2</sub>. Additionally, NO<sub>2</sub> exposure estimates from inverse distance weighting or other spatial smoothing techniques can be subject to error if the spatial scale of monitoring does not capture all sources. Studies employing exposure estimates obtained using these methods often report  $R^2$  (whether in-sample or out-of-sample varies with study), bias, and/or mean squared error to describe the quality of the exposure estimates. Given that these metrics do not always correlate, caution must be taken to interpret the quality of exposure data from an individual study on the basis of one metric.

Factors contributing to error in NO<sub>2</sub> exposure assessment include temporal activity of epidemiologic study participants, spatial variability of NO<sub>2</sub> concentrations across the study area, infiltration of NO<sub>2</sub> indoors, and instrument accuracy and precision ([Section 3.4.3](#)). With respect to time-activity data, variability within and among different populations causes the limitation of having only one monitoring location in many studies to have varying influence on exposure estimates within and among those different

populations. In general, spatial misalignment can occur when the time-activity patterns of study participants are not factored into the study design or when the location where NO<sub>2</sub> exposure is estimated does not coincide with the residential, school, or work location of interest. Spatial variability of human exposure can add uncertainty to the exposure estimate if it is not characterized by the monitors. As a result, there is a potential for exposure error if the ambient NO<sub>2</sub> concentration measured at a given site differs from that at the location of an epidemiologic study participant, and this issue is present regardless of the spatial scale of the epidemiology study. At the same time, the influence of spatial variability depends strongly on the temporal design of the epidemiologic study, as described in the paragraphs below. Infiltration and air exchange rate influence indoor levels of NO<sub>2</sub> in the absence of indoor sources and hence presents the potential for bias and uncertainty in  $\alpha$ , which depends on air exchange rate, penetration, and indoor deposition. NO<sub>2</sub> monitors are often subject to positive biases resulting from interference by NO<sub>Y</sub> species.

Community time-series epidemiologic studies most commonly use central site monitors to estimate human exposure to ambient NO<sub>2</sub> ([Section 3.4.5.1](#)). Temporal variability in exposure is the relevant feature of the exposure data in a community time-series study. Additionally, personal exposure measurements cannot feasibly be obtained for health studies with large numbers of participants. There is some uncertainty associated with using central site measurements of NO<sub>2</sub> concentrations to represent personal exposure because the temporal variability of the central site exposure estimate may differ from the temporal variability of the true exposure. Exposure estimates using NO<sub>2</sub> concentration measurements from central site monitors do not capture the spatial variability of the concentration field, which becomes a more important source of error for time-series epidemiology studies if the NO<sub>2</sub> concentrations at the locations of the study participants are not well correlated with measurements at the central site monitor. Nonambient contributions and differential infiltration of NO<sub>2</sub> can also add error or uncertainty to a health effect estimate. Instrument precision and accuracy are not thought to have a substantial influence on health effect estimates in time-series studies. Simulation studies testing the influence of exposure error in time-series studies suggest that exposure error may widen the confidence intervals of the health effect estimate and bias the estimate towards the null. This implies that reported health effect estimates for time-series studies of NO<sub>2</sub> exposure are potentially lower than true health effect estimates or that the reported confidence intervals around those health effect estimates are wider than the true confidence intervals.

Long-term exposure epidemiology studies compare subjects or populations at different locations ([Section 3.4.5.2](#)). Therefore, spatial, rather than temporal, contrasts are more important in epidemiologic studies of long-term exposure. NO<sub>2</sub> concentrations measured

at central site monitors are often used to represent exposures when human health cohorts are compared among cities. There is some uncertainty associated with using central site measurements of NO<sub>2</sub> concentrations to represent personal exposure, because the distribution of concentrations measured at a central site monitor may vary from the distribution of true exposures. LUR models, CTMs, dispersion models, spatial smoothing models, and spatiotemporal models may be used to estimate exposure at the residential locations of study participants in epidemiologic studies of long-term exposure, because those models are designed to capture spatial variability of NO<sub>2</sub> concentration within a geographic area, such as a city. Differences between the exposure estimates and the true exposures can add bias or reduce the precision of the health effect estimate. Moreover, positive biases from measurement of NO<sub>Y</sub> artifacts have the potential to enhance spatial contrasts in exposure models. The magnitude and direction of bias and the size of confidence intervals depend on differences between the distribution of true exposures and the distribution of concentrations estimated by the exposure assignment method.

Panel epidemiologic studies of NO<sub>2</sub> exposure using central site monitors are subject to exposure error due to spatial misalignment between the monitored ambient NO<sub>2</sub> concentration and the true personal exposure to ambient NO<sub>2</sub> ([Section 3.4.5.3](#)). Available panel studies that compare health effect estimates among exposure assessment techniques have suggested that such spatial misalignment leads to attenuating the health effect estimate. However, only a limited number of panel studies have examined the influence of exposure measurement error on health effect estimates. For this reason, it is difficult to reach a conclusion about the magnitude and direction of error in the health effect estimates related to exposure error.

Confounding can occur when common sources emit multiple pollutants and other stressors (e.g., noise) and therefore have the potential to increase uncertainty in identifying whether the copollutants are independently associated with a health effect ([Section 3.4.4](#)). Studies of noise suggest that total noise may be unlikely to act as a confounder. However, when noise is decomposed by frequency, confounding of the independent effect of NO<sub>2</sub> is more likely for high frequency noises that are associated with truck traffic. For traffic-related pollutants, NO (reacting to NO<sub>2</sub>), CO, EC, UFP, and benzene are commonly co-emitted and can be highly correlated with NO<sub>2</sub> in time and space. During winter, NO<sub>2</sub> emitted from heating fuel sources can also be highly correlated with PM<sub>2.5</sub> and PM<sub>10</sub>. For both short-term exposure and long-term exposure epidemiologic studies, it is difficult to distinguish the health effect associated with NO<sub>2</sub> exposure among health effects attributed to other highly correlated pollutants. The temporal correlations among copollutants may vary over space. For epidemiologic studies of long-term NO<sub>2</sub> exposure, bias related to copollutant confounding can be reduced when the spatial scale of the NO<sub>2</sub> exposure metric is smaller than the spatial

scale of the correlated copollutants. Bias related to copollutant confounding may be less likely for unstable copollutants (e.g., UFP) or air pollutants that disperse more quickly than NO<sub>2</sub> (e.g., CO), compared with more spatially homogeneous pollutants (e.g., PM<sub>2.5</sub>). However, panel studies based on personal exposure measurements or outdoor residential measurements do not appear to have high copollutant confounding, especially when receptors live far from busy roads. Therefore, panel studies may be the best design for demonstrating if NO<sub>2</sub> has independent health effects.

---

# CHAPTER 4      DOSIMETRY AND MODES OF ACTION FOR INHALED OXIDES OF NITROGEN

---

## 4.1      Introduction

This chapter has two main purposes. The first is to describe the principles that underlie the dosimetry of nitrogen dioxide (NO<sub>2</sub>) and nitric oxide (NO) and to discuss factors that influence it. The second is to describe the modes of action that may lead to the health effects that will be presented in [Chapter 5](#) and [Chapter 6](#). This chapter is not intended to be a comprehensive overview, but rather to update the basic concepts derived from the NO<sub>2</sub> and NO literature presented in the 1993 Air Quality Criteria for Oxides of Nitrogen (AQCD) and the 2008 Integrated Science Assessment (ISA) for Oxides of Nitrogen ([U.S. EPA, 2008a, c, 1993a, b](#)) and to introduce the recent relevant literature.

In [Section 4.3](#), particular attention is given to chemical properties of inhaled NO<sub>2</sub> and NO that affect absorption, distribution, metabolism, and elimination. Inhaled NO<sub>2</sub> and NO, and subsequent reaction products, are discussed in relation to endogenous production of these chemical species. Because few NO<sub>2</sub> dosimetry studies have been published since the 1993 AQCD ([U.S. EPA, 1993a](#)), much of the information from that report has been pulled forward into the current document and is discussed in the context of more recent research. The topics of dosimetry and modes of action are bridged by reactions of NO<sub>2</sub> with components of the epithelial lining fluid (ELF) and by reactions of NO with heme proteins, processes that play roles in both uptake and biological responses.

[Section 4.3](#) highlights findings of studies published since the 2008 ISA ([U.S. EPA, 2008c](#)) that provide insight into the biological pathways affected by exposure to NO<sub>2</sub> and NO. Earlier studies that represent the current state of the science are also discussed. Studies conducted at more environmentally relevant concentrations of NO<sub>2</sub> and NO (i.e., ≤5,000 parts per billion [ppb], [Section 1.1](#)) are of greater interest because biological pathways responsible for effects at higher concentrations may not be identical to those occurring at lower concentrations. Some studies at higher concentrations are included if they were early demonstrations of key biological pathways or if they are recent demonstrations of potentially important new pathways. This information is used to develop a mode of action framework for inhaled NO<sub>2</sub> and NO that serves as a guide to interpreting health effect evidence presented in subsequent chapters; in [Chapter 5](#) and [Chapter 6](#).

---

## 4.2 Dosimetry of Inhaled Oxides of Nitrogen

### 4.2.1 Introduction

This section provides a brief overview of NO<sub>2</sub> and NO dosimetry and updates information provided in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008a, c](#)). Dosimetry refers to the measurement or estimation of the amount of a compound, or its reaction products, absorbed and/or generated at specific sites in the respiratory tract during an exposure. New to this ISA is the inclusion of basic information regarding the endogenous production of NO<sub>2</sub> and NO. It is important to consider inhaled NO<sub>2</sub> and NO and their subsequent reaction products in relation to endogenous production of these chemical species. To establish an environmentally relevant context, ambient NO<sub>2</sub> and NO concentrations are briefly discussed below; more detail is provided in [Chapter 2](#).

Ambient concentrations of NO<sub>2</sub> and NO are variable. For example, ambient NO<sub>2</sub> concentrations are highest in the winter months, near major roadways, during weekday morning hours, and decrease moderately during the afternoon (see Atlanta, GA data in [Figures 2-20](#) and [2-21](#)). One-hour average, near-road (15 m) NO<sub>2</sub> concentrations in Los Angeles, CA ranged from 3 to 80 ppb with median values of about 40 ppb in the winter and 30 ppb in the summer months of 2009 ([Polidori and Fine, 2012b](#)). Away from major roadways, 1-hour average NO<sub>2</sub> concentrations may still reach 50 to 70 ppb with median NO<sub>2</sub> concentrations between roughly 10 to 30 ppb depending on the season and distance from roadways ([Polidori and Fine, 2012b](#)). As will be discussed, the uptake of inhaled NO<sub>2</sub> may potentially increase levels of NO<sub>2</sub>-derived reaction products beyond levels endogenously occurring in the respiratory tract.

Similar to NO<sub>2</sub>, ambient NO concentrations are highest in the winter months near major roadways during weekday morning hours, but decrease to very low levels during the afternoon (see Atlanta, GA data in [Figures 2-20](#) and [2-21](#)). One-hour average, near-road (15 m) NO concentrations in Los Angeles, CA ranged from 0 ppb to over 400 ppb with median values of about 50 ppb in the winter and 20 ppb in the summer months of 2009 ([Polidori and Fine, 2012b](#)). Away from major roadways, 1-hour average NO concentrations may still reach 250 ppb, but median NO concentrations are 5 ppb or less ([Polidori and Fine, 2012b](#)). For the same roadway (Interstate 710), [Zhu et al. \(2008\)](#) reported on-road NO<sub>x</sub> (i.e., the sum of NO and NO<sub>2</sub>) concentrations of around 400 ppb (average of eight 2-hour samples collected between 10:00 a.m. and noon during the period from June 2006 to May 2007). As will be discussed, these ambient NO concentrations are generally in the range of those occurring endogenously in the respiratory tract.

---

## 4.2.2 Dosimetry of Nitrogen Dioxide

NO<sub>2</sub> is a highly reactive gas that occurs as a radical (technically a resonance structure) wherein the unpaired electron is more localized to the nitrogen atom than either of the oxygen atoms. Once inhaled, NO<sub>2</sub> first encounters the aqueous phase of the ELF, which is a contiguous but biologically complex aqueous fluid layer that covers all of the respiratory tract surfaces ([Bastacky et al., 1995](#)). The ELF composition shows appreciable heterogeneity with respect to anatomic site and species. The ELF of alveolar surfaces and conducting airway surfaces has a monomolecular layer of surface active lipids ([Bernhard et al., 2004](#); [Hohlfeld, 2002](#); [Mercer et al., 1994](#)), largely fully saturated, which reduces surface tension and may provide a resistive barrier to the interfacial transfer of NO<sub>2</sub> ([Sections 4.2.2.1.2 and 4.2.2.1.3](#)). Upon dissolution into the ELF, NO<sub>2</sub> is converted from a gas to a nonelectrolyte solute, and thus becomes subject to partitioning and reaction/diffusion. Thus, the ELF represents the initial barrier between NO<sub>2</sub> contained within the intra-respiratory tract gas phase and the underlying epithelia ([Postlethwait and Bidani, 1990](#)). NO<sub>2</sub> chemically interacts with antioxidants, unsaturated lipids, and other compounds in the ELF. It preferentially reacts with one electron donors (e.g., small molecular weight antioxidants, protein thiols, etc.), undergoes radical-radical addition reactions, may abstract allylic hydrogen atoms from polyunsaturated fatty acids, and through a complex series of reactions, can add to unsaturated fatty acids to generate nitrolipids ([Bonacci et al., 2012](#); [Rudolph et al., 2010](#); [O'Donnell et al., 1999](#)). The compounds thought responsible, in large part, for the health effects of inhaled NO<sub>2</sub> are the reaction products themselves or the metabolites of these products in the ELF. Quantifications of absolute NO<sub>2</sub> absorption reported in the 1993 AQCD and the 2008 ISA ([U.S. EPA, 2008c, 1993a](#)) are briefly discussed below for thoroughness.

---

### 4.2.2.1 Mechanisms of Absorption of Nitrogen Dioxide

At the time of the 1993 AQCD ([U.S. EPA, 1993a](#)), it was thought that inhaled NO<sub>2</sub> probably reacted with the water molecules in the ELF to form nitrous acid (HNO<sub>2</sub>) and nitric acid (HNO<sub>3</sub>). However, some limited data suggested that the absorption of NO<sub>2</sub> was linked to reactive substrates in the ELF and subsequent nitrite (NO<sub>2</sub><sup>-</sup>) production. By the time of the 2008 ISA ([U.S. EPA, 2008c](#)), chemical reactions between NO<sub>2</sub> and ELF substrates were more readily recognized as governing NO<sub>2</sub> absorption in the respiratory tract.

#### 4.2.2.1.1 Reactions of Nitrogen Dioxide with Water and Solutes

Previous studies have demonstrated that it is not NO<sub>2</sub> but instead the NO<sub>2</sub> dimer, dinitrogen tetroxide (N<sub>2</sub>O<sub>4</sub>), that reacts with water to yield NO<sub>2</sub><sup>-</sup> and nitrate [NO<sub>3</sub><sup>-</sup>; ([Finlayson-Pitts et al., 2003](#); [Schwartz and White, 1983](#); [England and Corcoran, 1974](#))]. However, in aqueous solutions, NO<sub>2</sub> rapidly reacts with many solutes (e.g., ascorbate and urate), particularly those that are easily oxidized. At environmentally relevant concentrations of NO<sub>2</sub> (e.g., around 100 ppb), the direct reactions of NO<sub>2</sub> with dissolved substrates become important because, at equilibrium, there is very little N<sub>2</sub>O<sub>4</sub> compared to NO<sub>2</sub>. For example, using the difference in Gibbs energies for the formation of gaseous NO<sub>2</sub> and N<sub>2</sub>O<sub>4</sub> ([Chase, 1998](#)), one can calculate that at equilibrium, when the concentration of NO<sub>2</sub> is 1,000 and 100 ppb, there are  $1.48 \times 10^5$  and  $1.48 \times 10^6$ , respectively, molecules of NO<sub>2</sub> for each molecule of N<sub>2</sub>O<sub>4</sub>. Thus, at environmental exposure levels there are approximately 1.5 million NO<sub>2</sub> molecules for each N<sub>2</sub>O<sub>4</sub> molecule. At these concentrations, it is far more likely for NO<sub>2</sub> (compared to N<sub>2</sub>O<sub>4</sub>) to penetrate into the aqueous milieu of the ELF. Ensuing reactions of NO<sub>2</sub> with dissolved reactive substrates become more likely than reaction with a second NO<sub>2</sub> molecule (to form N<sub>2</sub>O<sub>4</sub>). During uptake by pure water, all reactions occur via N<sub>2</sub>O<sub>4</sub> regardless of the concentration of NO<sub>2</sub>. However, in the presence of dissolved reactive substrates and at low, environmentally relevant concentrations of NO<sub>2</sub>, this process (i.e., reactions occurring via N<sub>2</sub>O<sub>4</sub>) becomes unlikely, and instead uptake occurs via direct reactions of NO<sub>2</sub> with reactive substrates. This resembles reactive uptake of NO<sub>2</sub> by the ELF that would entail direct reactions of NO<sub>2</sub> with, for example, dissolved small molecular weight antioxidants like glutathione (GSH), ascorbate, or urate.

[Enami et al. \(2009\)](#) revisited the discussions regarding NO<sub>2</sub> reaction with water versus ELF solutes. Because the authors postulated that NO<sub>2</sub> effects are largely due to nitrate formation and acidification via proton production, this issue warrants some discussion. The claim by [Enami et al. \(2009\)](#) that “antioxidants catalyze the hydrolytic decomposition of NO<sub>2</sub>...but are not consumed in the process” is problematic in view of the vast existing environmental health literature that regards NO<sub>2</sub> as an oxidant gas ([Pryor et al., 2006](#); [Augusto et al., 2002](#); [Ford et al., 2002](#); [Kirsch et al., 2002](#); [Wardman, 1998](#); [Postlethwait et al., 1995](#); [Huie, 1994](#); [Neta et al., 1988](#); [Finlayson-Pitts et al., 1987](#); [Kikugawa and Kogi, 1987](#); [Prütz et al., 1985](#); [Pryor and Lightsey, 1981](#)). However, [Enami et al. \(2009\)](#) measured nitrate without measuring nitrite, and therefore, their data do not strongly support their contention, except to suggest that some hydrolysis of NO<sub>2</sub> may be occurring because nitrate was detected. Nitrite data are important because any excess nitrite found (reaction with water generally yields a 1:1 ratio of nitrite and nitrate; thus, a yield of nitrite above 1 would be considered in excess) would indicate that it is the

main product formed as a result of one-electron oxidations by NO<sub>2</sub>. Thus, by not measuring nitrite, an important index to assess oxidation by NO<sub>2</sub> was missed.

Note that [Enami et al. \(2009\)](#) conducted their experiments in the absence of oxygen, which makes their model inapplicable to the lung. At environmentally relevant concentrations and physiologic temperatures, intra-pulmonary gas phase NO<sub>2</sub> will exist in its monomeric form. Furthermore, in the presence of aqueous-phase reactive substrates, nitrite, but little or no nitrate, is formed during controlled in vitro exposures. Thus, broad reactivity of NO<sub>2</sub> with a diversity of reactive substrates (solutes) within the ELF facilitates chemical interactions with antioxidants, lipids, and proteins/peptides/amino acids.

#### **4.2.2.1.2 Governing Determinants of Nitrogen Dioxide Absorption within the Respiratory Tract**

The absorption of inhaled NO<sub>2</sub> into the ELF is governed by a process termed “reactive absorption” that involves dissolution followed by chemical reaction with reactive substrates in the ELF ([Postlethwait and Bidani, 1990](#)), as well as reactions within the interfacial region. Due to the limited aqueous solubility of NO<sub>2</sub> and thus the rapid saturation of the aqueous phase interfacial thin film ([Bidani and Postlethwait, 1998](#)), the net flux of NO<sub>2</sub> into reactant-free water is constrained by the relatively slow direct reaction of NO<sub>2</sub> with water (see above) compared with its radical reactions with biological substrates (further discussion below). Thus, rapid reactions with ELF substrates provide the net driving force for NO<sub>2</sub> mass transfer from the intra-pulmonary gas phase into the ELF ([Bidani and Postlethwait, 1998](#); [Postlethwait and Bidani, 1994](#); [Postlethwait et al., 1991a](#); [Postlethwait and Bidani, 1990](#)). Concentrations of “free” solute NO<sub>2</sub> are likely negligible due to reaction-mediated removal. Empirical evidence suggests that acute NO<sub>2</sub> uptake in the lower respiratory tract is rate governed by chemical reactions of NO<sub>2</sub> with ELF constituents rather than solely by gas solubility in the ELF, wherein the reaction between NO<sub>2</sub> and water does not significantly contribute to the absorption of inhaled NO<sub>2</sub> ([Postlethwait and Bidani, 1994, 1990](#)). Absorption was also observed to increase with increasing temperature, an indication of chemical reaction rather than aqueous solubility, where solubility increases with temperature decrements ([Postlethwait and Bidani, 1990](#)). [Postlethwait et al. \(1991b\)](#) proposed that inhaled NO<sub>2</sub> (≤10,000 ppb) did not penetrate the ELF to reach underlying sites and suggested that cytotoxicity likely was initiated by products formed during NO<sub>2</sub> reactions with ELF constituents. Subsequently, the reactive absorption of NO<sub>2</sub> was examined in a number of studies that sought to identify the substrates that predominantly drive NO<sub>2</sub> reactive absorption and to quantify the mass transfer kinetics of NO<sub>2</sub> in the respiratory tract.

Uptake was observed to be first-order with respect to NO<sub>2</sub> at concentrations less than 10,000 ppb, to be aqueous substrate dependent, and to be saturable, meaning that the absolute amount of NO<sub>2</sub> uptake would reach a maximum value even if reactive substrate concentrations were in significant excess ([Postlethwait et al., 1991a, b](#)).

The absorption of inhaled NO<sub>2</sub> is thought to be coupled with either radical-mediated hydrogen abstraction to form HNO<sub>2</sub> ([Postlethwait and Bidani, 1994, 1989](#)) or electron transfer from ELF anionic species that directly reduces NO<sub>2</sub> to nitrite ([Adgent et al., 2012](#)). Both mechanisms produce an organic radical from the initial ELF substrate. At physiologic pH, any formed HNO<sub>2</sub> subsequently dissociates to hydrogen ion (H<sup>+</sup>) and nitrite. The concentration of the resulting nitrite is likely insufficient to alter physiological function because basal nitrite levels may not change appreciably in either the respiratory tract or the circulation due to ambient NO<sub>2</sub> exposure. This is, in part, because nitrite will diffuse into the underlying epithelial cells and vascular space where, in the presence of red blood cells, it is oxidized to nitrate [[Postlethwait and Bidani, 1989](#); [Postlethwait and Mustafa, 1981](#)]; [Section 4.2.2.5](#)]. Consequently, by default, effects are probably attributable to the organic radical secondary oxidants formed ([Adgent et al., 2012](#); [Velsor et al., 2003](#); [Velsor and Postlethwait, 1997](#)) and/or to the proton load, although the ELF buffering capacity is anticipated to compensate for environmentally relevant exposure-related proton generation.

[Postlethwait et al. \(1995\)](#) sought to determine the preferential absorption substrates for NO<sub>2</sub> in the ELF lavaged from male Sprague-Dawley rats. Because bronchoalveolar lavage (BAL) fluid collected from rats may be diluted up to 100 times relative to the native ELF (the dilution will be procedure specific), the effect of concentrating the BAL fluid on NO<sub>2</sub> absorption was also investigated. A linear association was found between the first-order rate constant for NO<sub>2</sub> absorption and the relative concentration of the BAL fluid constituents. This suggested that concentration of the reactive substrates in the ELF determines, in part, the rate of NO<sub>2</sub> absorption. The absorption due to specific ELF constituents was also examined in chemically pure solutions. Albumin, reduced cysteine, glutathione, ascorbate, and urate were the hydrophilic moieties found to be the most active substrates for NO<sub>2</sub> absorption. Unsaturated fatty acids (such as oleic, linoleic, and linolenic) were also identified as active absorption substrates and thought to account for up to 20% of NO<sub>2</sub> absorption. Vitamins A and E exhibited the greatest reactivity of the substrates that were examined. However, the low concentrations of urate (the ELF of rodents and some primates contains significantly less urate than the ELF of humans due to differences in nitrogenous waste metabolism) and vitamins A and E were thought to preclude them from being appreciable substrates in vivo. The authors concluded that ascorbate and glutathione were the primary NO<sub>2</sub> absorption substrates in rat ELF. [Postlethwait et al. \(1995\)](#) also found that the pulmonary surfactant component,

dipalmitoyl phosphatidylcholine (DPPC), was relatively unreactive towards NO<sub>2</sub>, and subsequent studies documented that compressed monomolecular interfacial films of DPPC inhibit NO<sub>2</sub> absorption in vitro ([Connor et al., 2001](#)). Documenting whether surface active phospholipids (which comprise surfactant) inhibit NO<sub>2</sub> mass transfer in vivo is extremely challenging because any in situ manipulations that disrupt the surface tension-lowering actions of a surfactant lead to a plethora of pathophysiologic sequelae. However, even though such potentially important influences on NO<sub>2</sub> mass transfer have not been verified in vivo, modeling studies could estimate how such effects would influence the intra-pulmonary distribution of inhaled NO<sub>2</sub>, local mass transfer rates, and thus dosimetry.

#### **4.2.2.1.3 Reaction/Diffusion of Nitrogen Dioxide in the Epithelial Lining Fluid, Potential for Penetration to Underlying Cells**

Because the uptake of NO<sub>2</sub> from inhaled air into the ELF is governed by reactive absorption, it may be postulated that rapid ELF reactions prevent NO<sub>2</sub> from reaching underlying respiratory tract tissues. To evaluate this supposition, consideration must be given to the time required for NO<sub>2</sub> to diffuse through some thickness of the ELF versus the rate of NO<sub>2</sub> reactions with substrates in that ELF.

The ELF varies in composition and thickness with distal progression into the lung. The ELF of most of the tracheobronchial region may generally be described as consisting of two layers: an upper mucus layer and a periciliary layer, which surrounds the cilia ([Button et al., 2012](#); [Widdicombe, 2002](#); [Widdicombe and Widdicombe, 1995](#); [Van As, 1977](#)). The length of motile human cilia is about 7 µm in the distal nasal airways, trachea, and bronchi and around 5 µm in the bronchioles ([Yaghi et al., 2012](#); [Song et al., 2009](#); [Clary-Meinesz et al., 1997](#); [Widdicombe and Widdicombe, 1995](#)). In the healthy lung, the thickness of the periciliary layer is roughly the length of the cilia ([Song et al., 2009](#); [Widdicombe and Widdicombe, 1995](#)). This periciliary layer forms a continuous liquid lining over the tracheobronchial airways; whereas the upper mucus layer is discontinuous and diminishes or is absent in smaller bronchioles ([Widdicombe, 2002](#); [Van As, 1977](#)). The periciliary layer may be the only ELF layer (i.e., there is little to no overlaying mucus) in the ciliated airways of infants and healthy adults who are unaffected by pathology related to disease, infection, or other stimuli ([Bhaskar et al., 1985](#)).

The ELF covering the alveolar surface is considerably thinner than the periciliary layer found in the tracheobronchial region. The alveolar ELF consists of two layers: an upper surfactant layer and a subphase fluid ([Ng et al., 2004](#)). [Bastacky et al. \(1995\)](#) conducted a low-temperature scanning electron microscopy analysis of rapidly frozen samples (9 animals; 9,339 measurements) of rat lungs inflated to approximately 80% total lung

capacity. The alveolar ELF was found to be continuous, but of varied depth. Three distinct ELF areas were described: (1) a thin layer [0.1  $\mu\text{m}$  median depth, geometric standard deviation (GSD)  $\sim 2.16$ ]<sup>1</sup> over relatively flat areas and comprising 80% of the alveolar surface, (2) a slightly thinner layer (0.08  $\mu\text{m}$ , GSD  $\sim 1.79$ ) over protruding features and accounting for 10% of the surface, and (3) a thick layer (0.66  $\mu\text{m}$ , GSD  $\sim 2.18$ ) occurring at alveolar junctions and accounting for 10% of the surface. Based on these distributions of thicknesses, 10% of the alveolar region is covered by an ELF layer of 0.04  $\mu\text{m}$  or less. Presuming that these depths would also occur in humans at 80% total lung capacity and assuming isotropic expansion and contraction, depths should be expected to be 20–40% greater during normal tidal breathing (rest and light exercise) when the lung is inflated to between 50–60% total lung capacity averaged across the respiratory cycle. During tidal breathing, a median ELF depth of 0.12–0.14  $\mu\text{m}$  would be expected over 80% of the alveolar surface with 10% of the alveolar surface having a median depth of around 0.05  $\mu\text{m}$  or less. Considering the entire distribution of depths during tidal breathing, about 30, 60, and 90% of the alveolar surface would be estimated to have a lining layer thickness of less than or equal to 0.1, 0.2, and 0.5  $\mu\text{m}$ , respectively.

The root mean square distance ( $d$ ) that  $\text{NO}_2$  can diffuse in some time ( $t$ ) is given by the Einstein-Smoluchowski equation:

$$d = \sqrt{2Dt}$$

**Equation 4-1**

where  $D$  is the molecular diffusion coefficient of  $\text{NO}_2$ . A  $D$  value for  $\text{NO}_2$  in water at 25°C of  $1.4 \times 10^{-9} \text{ m}^2/\text{sec}$  has been reported and will be used in the calculations ([Ford et al., 2002](#)). In the lung, the  $D$  for  $\text{NO}_2$  would be increased by temperature and decreased by the higher viscosity of the ELF compared to water. The time available for diffusion can be estimated based on the half-time for reactions between  $\text{NO}_2$  and reactive substrates, assuming pseudo first-order kinetics apply. This half-time ( $\tau$ ) has the form:

$$\tau = \frac{\ln(2)}{\sum_i^n k_i c_i}$$

**Equation 4-2**

where  $\sum_i^n k_i c_i$  is the summation of the products of the second-order rate constants ( $k_i$ ) and substrate concentrations ( $c_i$ ) for the primary reactive substances in the ELF.

---

<sup>1</sup> Although the authors stated that the distributions appeared to be log-normal, they did not report the geometric standard deviation (GSD) for the three distinct areas they described. The GSD values were calculated from 25, 50, and 75th percentiles of the distributions.

Substituting  $\tau$  for  $t$  in [Equation 4-1](#) yields:

$$d = \sqrt{\frac{2D \ln(2)}{\sum_i^n k_i c_i}}$$

**Equation 4-3**

and approximates the distance  $\text{NO}_2$  may diffuse before it chemically reacts with ELF constituent molecules (e.g., antioxidants, proteins, lipids). A similar approach of comparing the half-time in [Equation 4-2](#) to the time for diffusion through the ELF or other phase boundaries such as a membrane bilayer (see [Equation 4-1](#) and solve for  $t$ ) was originally applied by [Pryor \(1992\)](#) and later by [Ford et al. \(2002\)](#).

In considering the classes of ELF biomolecules that react with  $\text{NO}_2$ , one may focus on the water-soluble, small molecular weight antioxidants (e.g., ascorbate, urate, glutathione), which exist in the ELF in high concentrations and are very reactive toward  $\text{NO}_2$  and consequently have large  $k_i c_i$  terms. Lipids, on the other hand, would not be expected to considerably decrease the transit time of  $\text{NO}_2$  because only those lipids containing fatty acids with two or more double bonds have significant reactivity towards  $\text{NO}_2$ , and the lipids in the ELF are highly saturated.

The reaction rate constants of  $3.5 \times 10^7 \text{ M}^{-1}\text{sec}^{-1}$ ,  $2 \times 10^7 \text{ M}^{-1}\text{sec}^{-1}$ , and  $2 \times 10^7 \text{ M}^{-1}\text{sec}^{-1}$  were assumed for the small molecular weight antioxidants ascorbate, urate, and glutathione, respectively ([Ford et al., 2002](#)). These rates were determined in solution using the pulse radiolysis fast kinetics technique. The kinetics of ascorbate and urate were directly monitored, while in the case of glutathione,  $\text{ABTS}^{2-}$  [2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)] was used to produce the intense chromophore  $\text{ABTS}^{\bullet-}$  (note, here and elsewhere the superscript  $\bullet$  designates a radical species) from its reaction with the glutathionyl radical.

Species and anatomical loci must be considered when selecting appropriate concentrations of reactive ELF biomolecules. [Table 4-1](#) illustrates the small molecular weight antioxidant composition differences between human and rat bronchoalveolar ELF and the differences between human nasal and bronchoalveolar ELF ([Squadrito et al., 2010](#); [van der Vliet et al., 1999](#)). Predicted by [Equation 4-3](#) and shown in [Table 4-1](#),  $\text{NO}_2$  is predicted to penetrate 0.2 to 0.6  $\mu\text{m}$  into the ELF and would not likely reach airway tissues in the bronchi or bronchioles. Even extending the time for diffusion to  $5\tau$ ,  $\text{NO}_2$  would only be predicted to penetrate 0.5 to 1.3  $\mu\text{m}$  into the ELF, which does not approach the 5  $\mu\text{m}$  depth expected in the ciliated airways. However, minimal  $\text{NO}_2$  diffusion through the ELF in the bronchi and bronchioles does not preclude the potential for  $\text{NO}_2$

reactions with cilia or potential importance of reaction products reaching the underlying tissues in these regions.

**Table 4-1 Small molecular weight antioxidant concentrations in epithelial lining fluid and predicted penetration distances for nitrogen dioxide.**

Species—Site	Ascorbate	Urate	Glutathione	$\sum_i^n k_i c_i$ (sec <sup>-1</sup> )	ELF Penetration Distance (μm)	ELF Thickness (μm)
<b>Substrate Concentration, c<sub>i</sub> (μM)<sup>a</sup></b>						
Human—nasal	28 ± 19	225 ± 105	<0.5	5.5 × 10 <sup>3</sup>	0.6	7 <sup>c</sup>
Human—bronchoalveolar	40 ± 18	207 ± 167	109 ± 64	7.7 × 10 <sup>3</sup>	0.5	5–7 <sup>c,d</sup> <0.1–0.5 <sup>e</sup>
Rat—bronchoalveolar	1,004 ± 325	81 ± 27	43 ± 15	3.8 × 10 <sup>4</sup>	0.2	5–7 <sup>c,d</sup> <0.1–0.5 <sup>e</sup>
<b>Rate Constant, k<sub>i</sub> (M<sup>-1</sup>sec<sup>-1</sup>)<sup>b</sup></b>						
	3.5 × 10 <sup>7</sup>	2 × 10 <sup>7</sup>	2 × 10 <sup>7</sup>			

ELF = epithelial lining fluid.

<sup>a</sup>Substrate concentrations from [van der Vliet et al. \(1999\)](#) for human and from [Squadrito et al. \(2010\)](#) for rat.

<sup>b</sup>Reaction rate constants from [Ford et al. \(2002\)](#).

<sup>c</sup>Based on length of cilia.

<sup>d</sup>Tracheobronchial airways.

<sup>e</sup>Alveolar airways.

In the alveolar region, the thickness of the ELF is sufficiently thin ( $\leq 0.2$  μm over 60% of the alveolar surface) for NO<sub>2</sub> to diffuse through. There are some important differences between the ELF of the alveolar region and the ELF of the tracheobronchial airways. In studies modeling NO<sub>2</sub> and ozone (O<sub>3</sub>) uptake, a first-order rate constant has been assumed for the alveolar ELF, which is 60-times slower than that of the tracheobronchial ELF ([Miller et al., 1985](#); [1982](#)). The slower reaction rate in the alveolar ELF would increase the estimated potential diffusion distance to nearly 4 μm, well beyond the depth of the alveolar ELF. Additionally, the presence of DPPC, a principle component of pulmonary surfactant, has been shown in vitro to reduce the uptake of NO<sub>2</sub> and O<sub>3</sub> by inhibiting their ability to reach and react with the underlying subphase fluid containing ascorbate, glutathione, and uric acid ([Connor et al., 2004](#); [Connor et al., 2001](#)). The physical properties of the interfacial saturated phospholipids may act to reduce the diffusivity of NO<sub>2</sub>. Both the DPPC and the overall slower reaction rate in the alveolar

ELF would increase diffusive resistance and increase the back diffusion of NO<sub>2</sub> from the surfactant into the gas phase. Nonetheless, the time for NO<sub>2</sub> diffusion through a 0.2- $\mu$ m alveolar ELF is over two orders of magnitude faster than the NO<sub>2</sub> reaction rate half-time in the alveolar ELF. Thus, of the inhaled NO<sub>2</sub> reaching the alveolar region and diffusing into the ELF, an appreciable amount of NO<sub>2</sub> may reasonably be expected to diffuse through the ELF to reach underlying tissues over much of the alveolar surface. Reaction rates in these underlying tissues are expected to exceed those in the alveolar and tracheobronchial ELF and would more rapidly consume NO<sub>2</sub> ([Pryor, 1992](#); [Miller et al., 1985](#)).

---

#### 4.2.2.2 Epithelial Lining Fluid Interactions with Nitrogen Dioxide

Small molecular weight antioxidants vary appreciably across species. For example, due to the lack of urate oxidase, humans, primates, and select other species have increased levels of urate. Conversely, rodent concentrations of urate are small compared to humans. Such differences need to be recognized when considering preferential reactive absorption substrates and the profile of products formed via reaction with NO<sub>2</sub>. Glutathione and ascorbate are the primary NO<sub>2</sub>-absorption substrates in rat ELF with near 1:1 stoichiometric yields of NO<sub>2</sub> uptake to nitrite formation, suggesting that one-electron reduction of NO<sub>2</sub> is a predominant reaction pathway that also yields the corresponding organic radical ([Postlethwait et al., 1995](#)).

Beyond cell-specific differential susceptibility and the airway lumen concentration of NO<sub>2</sub>, site-specific injury was proposed to depend on the rate of bioactive reaction product formation relative to the extent of quenching (detoxification) of these products within the ELF. [Velsor and Postlethwait \(1997\)](#) investigated the mechanisms of acute cellular injury from NO<sub>2</sub> exposure. In an in vitro test system using red blood cells, the maximal levels of membrane oxidation were observed at low antioxidant levels versus null (absent antioxidants) or high antioxidant levels. Glutathione- and ascorbate-related membrane oxidation was superoxide- and hydrogen peroxide-dependent, respectively. The authors proposed that increased absorption of NO<sub>2</sub> occurred at the higher antioxidant concentrations, but little secondary oxidation of the membrane occurred because the reactive species (e.g., superoxide and hydrogen peroxide) generated during absorption were quenched. A lower rate of NO<sub>2</sub> absorption occurred at the low antioxidant concentrations, but oxidants were not quenched and so were available to interact with the cell membrane. Further in vitro analyses also suggested that exposure-related responses may not be strictly linear with respect to the inhaled NO<sub>2</sub> dose (concentration and/or time) because the dependence of NO<sub>2</sub> absorption and biologic target oxidation demonstrated a bell-shaped function with respect to the initial antioxidant concentration

([Adgent et al., 2012](#); [Velsor et al., 2003](#)). Because the ELF varies throughout the respiratory tract, the heterogeneous distribution of epithelial injury observed following NO<sub>2</sub> exposures may be explained, in part, by the ELF-dependent effects on local NO<sub>2</sub> uptake and product formation. However, it should be noted that while these dose-response relationships have been documented in vitro, in vivo validation has not yet been accomplished due to the complexities in reproducibly modulating in situ ELF compositions. Importantly, such in vitro results are difficult to directly extrapolate to the in vivo situation, as precise rates of NO<sub>2</sub> uptake, and thus product formation, are a function of many factors including gas-phase NO<sub>2</sub> concentration, aqueous substrate concentrations, surface area, gas flow, and pH of the ELF ([Adgent et al., 2012](#); [Bidani and Postlethwait, 1998](#)). However, an in vivo study of healthy male albino mice (5 weeks old) suggested that a low dose of ascorbate (25 mg/kg) may exacerbate inflammatory responses in terminal bronchial tissues following NO<sub>2</sub> exposure (20,000 ppb; 4 hour/day, 10 days); whereas at a higher dose of ascorbate (100 mg/kg), NO<sub>2</sub>-exposed mice tissues were similar to tissues from filter air-exposed controls ([Zhang et al., 2010b](#)). These in vivo responses seem parallel to those observed in vitro.

Antioxidant levels also vary spatially between lung regions and temporally with NO<sub>2</sub> exposure. While in vitro studies have clearly illustrated the role of antioxidants in mediating NO<sub>2</sub> uptake and membrane oxidation, the temporal dynamics of biological responses to NO<sub>2</sub> that occur in vivo are far more complex. Given the rapid reactions of inhaled NO<sub>2</sub> with various biological substrates, the short half-life of some primary and secondary reaction products as well as the continuous turnover of the ELF, specific chemical species do not likely persist at any given anatomic locale for any appreciable time. [Kelly et al. \(1996a\)](#) examined the effect of a 4-hour NO<sub>2</sub> (2,000 ppb) exposure on antioxidant levels in bronchial lavage (BL) fluid and BAL fluid of 44 healthy nonsmoking adults (19–45 years, median 24 years). The baseline concentrations of urate and ascorbate were strongly correlated between the BL fluid and BAL fluid within individuals ( $r = 0.88, p < 0.001$ ;  $r = 0.78, p = 0.001$ ; respectively); whereas the concentrations of glutathione in the BL fluid and BAL fluid were not correlated. At 1.5 hours after the NO<sub>2</sub> exposure, urate and ascorbate were significantly reduced in both lavage fractions, while glutathione levels were significantly increased but only in BL fluid. By 6 hours post-exposure, ascorbate levels had returned to baseline in both lavage fractions, but urate had become significantly increased in both lavage fractions and glutathione levels remained elevated in BL fluid. By 24 hours post-exposure, all antioxidant levels had returned to baseline. The levels of glutathione in BAL fluid did not change from baseline at any time point in response to NO<sub>2</sub> exposure.

The depletion of urate and ascorbate, but not glutathione, has also been observed with ex vivo exposure of human BAL fluid to NO<sub>2</sub>. [Kelly et al. \(1996b\)](#) collected BAL fluid

from male lung cancer patients (n = 16) and exposed the BAL fluid ex vivo at 37°C to NO<sub>2</sub> (50 to 2,000 ppb; 4 hours) or O<sub>3</sub> (50 to 1,000 ppb; 4 hours). [Kelly and Tetley \(1997\)](#) also collected BAL fluid from lung cancer patients (n = 12; 54 ± 16 years) and exposed the BAL fluid ex vivo to NO<sub>2</sub> (50 to 1,000 ppb; 4 hours). Both studies found that NO<sub>2</sub> depletes urate and ascorbate, but not glutathione, from BAL fluid. [Kelly et al. \(1996b\)](#) noted a differential consumption of the antioxidants, with urate loss being greater than that of ascorbate, which was lost at a much greater rate than glutathione. [Kelly and Tetley \(1997\)](#) found that the rates of urate and ascorbate consumption were correlated with their initial concentrations in the BAL fluid, such that higher initial antioxidant concentrations were associated with a greater rate of antioxidant depletion. Illustrating the complex interaction of antioxidants, these studies also suggest that glutathione oxidized by NO<sub>2</sub> may be again reduced by urate and/or ascorbate.

Human and animal results stemming from samples obtained after exposure should be viewed with appropriate caution. As detailed below, secondary reactions within the ELF, sample handling, and importantly, the temporal sequence of exposure relative to sample acquisition may all confound data interpretation. Because the ELF is a dynamic compartment, samples obtained after exposure (>30 minutes) may not reflect biochemical conditions present during exposure. This is a critical point, because while there is some value in quantifying the net short-term effects on ELF composition due to exposure, the biological consequences of exposure are largely a function of the ELF conditions during exposure, which initiate a cascade of events leading to alterations in cell signaling, cell injury, inflammation, and so forth. Thus, measurements of ELF components should be interpreted in the context of ELF turnover time, clearance of “stable” reaction products, and species generated/regenerated as a consequence of secondary redox reactions. Reported measurements may reflect net effects on individual antioxidants but lend limited insights into the initial reactions of NO<sub>2</sub> within the ELF, and by extension, into what bioactive products may be formed and how differences in ELF constituent profiles govern biological outcomes. A clear example is evident in the work of [Ford et al. \(2002\)](#), who characterized the reaction of the GSH radical (GS•) with urate (UH<sub>2</sub><sup>-</sup>) at a pH (6.0) slightly below the recognized ELF pH (~6.8 to 7.0). NO<sub>2</sub> more readily reacts with glutathione than urate, producing GS• and NO<sub>2</sub><sup>-</sup>. However, the subsequent reaction  $GS^{\bullet} + UH_2^{-} \rightarrow GSH + UH^{\bullet-}$  has a rate constant of  $\sim 3 \times 10^7 \text{ M}^{-1} \text{ sec}^{-1}$ , which could translate to an initial NO<sub>2</sub> reaction with glutathione followed by reduction of the thiyl radical by urate. This could result in an apparent, but potentially inaccurate, conclusion of direct loss of urate during subsequent analyses. In addition, some reports have suggested observations that include significant levels of the ascorbate oxidation product dehydroascorbate (DHA). As with the example of secondary urate oxidation, such observations need to be evaluated with caution as the half-life of DHA under biological conditions is very short (minutes; the ascorbyl radical dismutation produces reduced

ascorbate and DHA; and DHA spontaneously decomposes to its keto acid). Furthermore, because high redox couples are maintained in the ELF, and the ELF is constantly turning over due to secretion and mucociliary clearance, it is unlikely that any appreciable accumulation of DHA would occur. Therefore, care must be taken to avoid introducing methodological artifacts (e.g., ascorbate oxidation during sample acquisition, handling, and/or storage) that could significantly confound data interpretation. Consequently, an understanding of the precise and preferential substrates is needed to discern the genesis of species differences and the products formed that account for NO<sub>2</sub> exposure-related cellular perturbations.

Given the above considerations, variability in antioxidant concentrations and reactions among species may affect NO<sub>2</sub> dose and health outcomes. Guinea pigs and mice have a lower basal activity of glutathione transferase and glutathione peroxidase and lower  $\alpha$ -tocopherol levels in the lung compared to rats ([Ichinose et al., 1988](#); [Sagai et al., 1987](#)). Human nasal lavage fluid has a high proportion of urate and low levels of ascorbate; whereas mice, rats, and guinea pigs have high levels of ascorbate and undetectable levels of urate. Glutathione is not detected in the nasal lavage fluid of most of these species, except monkeys. Guinea pigs and rats have a higher antioxidant-to-protein ratio in nasal lavage fluid and BAL fluid than humans ([Hatch, 1992](#)). The BAL fluid profile differs from that of the nasal lavage fluid. Humans have a higher proportion of glutathione and less ascorbate in their BAL fluid compared to guinea pigs and rats ([Slade et al., 1993](#); [Hatch, 1992](#)). Rats have the highest antioxidant-to-protein mass ratio in their BAL fluid ([Slade et al., 1993](#)). Antioxidant defenses also vary with age ([Servais et al., 2005](#)) and exposure history ([Duan et al., 1996](#)). In the case of another reactive gas, O<sub>3</sub>, some studies have found that differences in antioxidant levels among species and lung regions did not appear to be the primary factor affecting O<sub>3</sub>-induced tissue injury ([Duan et al., 1996](#); [1993](#)). However, close correlations have been observed between site-specific O<sub>3</sub> dose and the degree of epithelial injury, as well as the depletion of reduced glutathione in monkeys ([Plopper et al., 1998](#)). For both NO<sub>2</sub> and O<sub>3</sub>, differences in reactive substrates among species and regions of the respiratory tract are recognized, but the importance of these differences in relation to tissue injury is not fully understood.

---

#### **4.2.2.3 Regional and Total Respiratory Absorption of Nitrogen Dioxide**

Very limited work related to the quantification of NO<sub>2</sub> uptake has been published since the 1993 AQCD ([U.S. EPA, 1993a](#)) or the subsequent 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)). Consequently, only an abbreviated discussion of this is included.

#### 4.2.2.3.1 Experimental Studies of Nitrogen Dioxide Uptake

##### Upper Respiratory Tract Absorption

The nasal uptake of NO<sub>2</sub> has been experimentally measured in dogs, rabbits, and rats under conditions of unidirectional flow. [Yokoyama \(1968\)](#) reported  $42.1 \pm 14.9\%$  [mean  $\pm$  standard deviation (SD)] uptake of NO<sub>2</sub> in the isolated nasal passages of two dogs (3.5 L/min) and three rabbits (0.75 L/min) exposed to 4,000 and 41,000 ppb NO<sub>2</sub>. Uptake did not appear to depend on the exposure concentration and was relatively constant over a 10- to 15-minute period. [Cavanagh and Morris \(1987\)](#) measured 28 and 25% uptake of NO<sub>2</sub> (40,400 ppb) in the noses of four naïve and four previously exposed rats (0.10 L/min; 4-hours; 40,400 ppb), respectively, and uptake was constant over the 24-minute period it was monitored.

[Kleinman and Mautz \(1991\)](#) measured the penetration of NO<sub>2</sub> through the upper airways during inhalation in six tracheostomized dogs exposed to 1,000 or 5,000 ppb NO<sub>2</sub>. Uptake in the nasal passages was significantly greater at 1,000 ppb than at 5,000 ppb, although the magnitude of this difference was not reported. The mean uptake of NO<sub>2</sub> (1,000 ppb) in the nasal passages decreased from 80 to 70% as the ventilation rate increased from about 3 to 7 L/min. During oral breathing, uptake was not dependent on concentration. The mean oral uptake of NO<sub>2</sub> (1,000 and 5,000 ppb) decreased from 60 to 30% as the ventilation rate increased from 3 to 7 L/min. Although nasal uptake tended to be greater than oral uptake, the difference was not statistically significant. The tendency for greater nasal than oral uptake on NO<sub>2</sub> is consistent with that observed for O<sub>3</sub> as described in Chapter 5 of the 2013 ISA for Ozone ([U.S. EPA, 2013e](#)).

Overall, NO<sub>2</sub> fractional absorption (uptake efficiency) in the upper respiratory tract is greater in the nasal passage than in the oral passage and decreases with increasing ventilation rates. As a result, a greater proportion of inhaled NO<sub>2</sub> is delivered to the lower respiratory tract at higher ventilation rates associated with exercise. In humans, exercise causes a shift in the breathing pattern from nasal to oronasal relative to rest. Because the nasal passages scrub gas-phase NO<sub>2</sub> more efficiently than the mouth and because uptake efficiency decreases with increasing flow, exercise delivers a disproportionately greater quantity of the inhaled mass to the lower respiratory tract, where the NO<sub>2</sub> is readily absorbed.

Additionally, children tend to have a greater oral breathing contribution than adults at rest and during exercise ([Bennett et al., 2008](#); [Becquemin et al., 1999](#)). [Chadha et al. \(1987\)](#) found that the majority (11 of 12) of patients with asthma or allergic rhinitis also breathe oronasally at rest. Thus, compared to healthy adults, children and individuals with asthma might be expected to have greater NO<sub>2</sub> penetration into the lower respiratory tract.

Furthermore, normalized to body mass, median daily ventilation rates ( $\text{m}^3/\text{kg}$  per day) decrease over the course of life ([Brochu et al., 2011](#)). This decrease in ventilation relative to body mass is rapid and nearly linear from infancy through early adulthood. Relative to normal-weight adults (25–45 years of age), ventilation rates normalized to body mass are increased 1.5-times in normal-weight children (7–10 years of age) and doubled in normal-weight infants (0.22–0.5 years of age). Relative to their body mass, children, and especially infants, respire greater amounts of air and associated pollutants than adults and have a greater portion of respired pollutants reaching the lower respiratory tract than adults.

### Lower Respiratory Tract Absorption

[Postlethwait and Mustafa \(1989\)](#) investigated the effect of exposure concentration and breathing frequency on the uptake of  $\text{NO}_2$  in isolated perfused rat lungs. To evaluate the effect of exposure concentration, the lungs were exposed to  $\text{NO}_2$  (4,000 to 20,000 ppb) while ventilated at 50 breaths/min with a tidal volume ( $V_T$ ) of 2.0 mL. To examine the effect of breathing frequency, the lungs were exposed to  $\text{NO}_2$  (5,000 ppb) while ventilated at 30–90 breaths/min with a  $V_T$  of 1.5 mL. All exposures were for 90 minutes. The uptake of  $\text{NO}_2$  ranged from 59 to 72% with an average of 65% and was not affected by exposure concentration or breathing frequency. A combined regression analysis showed a linear relationship between  $\text{NO}_2$  dose to the lungs and total inhaled dose. Illustrating variability in  $\text{NO}_2$  uptake measurements, [Postlethwait and Mustafa \(1989\)](#) observed 59%  $\text{NO}_2$  uptake in lungs ventilated at 30 breaths/min with a  $V_T$  of 1.5 mL; whereas [Postlethwait and Mustafa \(1981\)](#) measured 35%  $\text{NO}_2$  uptake for the same breathing condition. In another study, 73% uptake of  $\text{NO}_2$  was reported for rat lungs ventilated at 50 breaths/min with a  $V_T$  of 2.3 mL ([Postlethwait et al., 1992](#)). It should be noted that typical breathing frequencies are around 80, 100, and 160 breaths/min for rats during sleep, rest, and light exercise, respectively ([de Winter-Sorkina and Cassee, 2002](#)). Hence, the breathing frequencies at which  $\text{NO}_2$  uptake has been measured are lower than for rats breathing normally. Furthermore, one must consider the potential impacts of the methods used to measure  $\text{NO}_2$  uptake (mass balance; wet chemical versus automated analyzer which may or may not include a dilution component due to the sampling rate) and the lack of perfusion of the bronchial circulation in isolated rat lungs ([Postlethwait et al., 1990](#)). In addition to measuring uptake in the upper respiratory tract, [Kleinman and Mautz \(1991\)](#) also measured  $\text{NO}_2$  uptake in the lower respiratory tract of tracheostomized dogs. In general, about 90%  $\text{NO}_2$  uptake in the lung was independent of ventilation rates from 3 to 16 L/min.

## Total Respiratory Tract Absorption

[Bauer et al. \(1986\)](#) measured the uptake of NO<sub>2</sub> (300 ppb) in 15 adults with asthma exposed for 30 minutes (20 minutes at rest, then 10 minutes exercising on a bicycle ergometer) via a mouthpiece during rest and exercise. There was a statistically significant increase in uptake from 72% during rest to 87% during exercise. The minute ventilation also increased from 8.1 L/min during rest to 30.4 L/min during exercise. Hence, exercise increased the NO<sub>2</sub> dose rate by 4.5-times in these subjects. In an earlier study by [Wagner \(1970\)](#), seven healthy adults inhaled a NO<sub>2</sub>/NO mixture containing 290 to 7,200 ppb NO<sub>2</sub> for brief (but unspecified) periods. The average NO<sub>2</sub> uptake during 4,100-ppb and 7,200-ppb exposures was 82% during normal respiration ( $V_T$ , 0.4 L) and 92% during maximal respiration ( $V_T$ , 2 to 4 L). [Kleinman and Mautz \(1991\)](#) also measured the total respiratory tract uptake of NO<sub>2</sub> (5,000 ppb) in nontracheostomized female beagle dogs standing at rest or exercising on a treadmill. The dogs breathed through a small face mask. Total respiratory tract uptake of NO<sub>2</sub> was 78% during rest and increased to 94% during exercise. This increase in uptake may largely be due to the increase in  $V_T$  from 0.18 L during rest to 0.27 L during exercise. Coupled with an increase in minute ventilation from 3.8 L/min during rest to 10.5 L/min during exercise, the dose rate of NO<sub>2</sub> was 3.3-times greater for the dogs during exercise than rest.

### 4.2.2.3.2 Dosimetry Models of Nitrogen Dioxide Uptake

Few theoretical studies have investigated NO<sub>2</sub> dosimetry. The original seminal dosimetry model of [Miller et al. \(1982\)](#) was developed before much of the above information regarding NO<sub>2</sub> reaction/diffusion within the ELF had been obtained. In this model, there was a strong distinction between uptake and dose. Uptake referred to the amount of NO<sub>2</sub> being removed from gas phase per lung surface area ( $\mu\text{g}/\text{cm}^2$ ); whereas dose referred to the amount of NO<sub>2</sub> per lung surface area ( $\mu\text{g}/\text{cm}^2$ ) that diffused through the ELF and reached the underlying tissues.

[Miller et al. \(1982\)](#), and subsequently [Overton \(1984\)](#), did not attempt to predict the amount of reactants in the ELF or the transport of reaction products to the tissues. They assumed that reactions of NO<sub>2</sub> with constituents in the ELF were protective in that these reactions reduced the flux of NO<sub>2</sub> to the tissues. Others have postulated that NO<sub>2</sub> reaction products formed in the ELF, rather than NO<sub>2</sub> itself, could mediate responses ([Velsor and Postlethwait, 1997](#); [Postlethwait and Bidani, 1994](#); [Overton, 1984](#)). Overall, these modeling studies predict that the net NO<sub>2</sub> uptake (NO<sub>2</sub> flux to air-liquid interface) is relatively constant from the trachea to the terminal bronchioles and then rapidly decreases in the pulmonary region. The pattern of net NO<sub>2</sub> uptake rate is expected to be similar among species and unaffected by age in humans. However, the NO<sub>2</sub> uptake per unit

surface area may be several times higher in infants compared to adults, because children under age 5 have a much smaller surface area in the extrathoracic (nasal) and alveolar regions ([Sarangapani et al., 2003](#)).

The predicted tissue dose and dose rate of NO<sub>2</sub> (NO<sub>2</sub> flux to liquid–tissue interface) are low in the trachea, increase to a maximum in the terminal bronchioles and the first generation of the pulmonary region, and then decrease rapidly with distal progression. The site of maximal NO<sub>2</sub> tissue dose is predicted to be fairly similar among species, ranging from the first generation of respiratory bronchioles in humans to the alveolar ducts in rats. However, estimates of NO<sub>2</sub> penetration in [Table 4-1](#) showed that NO<sub>2</sub> is not expected to go deeper than 0.2 to 0.6 μm into the ELF of the ciliated airways before reacting with substrates. The production of toxic NO<sub>2</sub> reaction products in the ELF and the movement of the reaction products to the tissues have not been modeled.

Contrary to what in vitro studies have shown ([Velsor and Postlethwait, 1997](#)), modeling studies have generally considered NO<sub>2</sub> reactions in the ELF to be protective. The complex interactions among antioxidants, spatial differences in antioxidants across respiratory tract regions, temporal changes in ELF constituent levels in response to NO<sub>2</sub> exposure, and species differences in antioxidant defenses need to be considered in the next generation of dosimetric models. Current NO<sub>2</sub> dosimetry models are inadequate to put response data collected from animals and humans on a comparative footing with each other and with exposure conditions in epidemiologic studies. Total dose or liquid dose of NO<sub>2</sub> could be used as a first approximation for inter-species dosimetric comparisons using currently available NO<sub>2</sub> models.

As stated above, the total dose or uptake (μg per cm<sup>2</sup> surface area) of NO<sub>2</sub> is predicted to be relatively constant across the tracheobronchial airways with a rapid decrease in dose with progression into the gas exchange region ([Miller et al., 1982](#)). The model used by [Miller et al. \(1982\)](#) for NO<sub>2</sub> was generally the same as that subsequently used by [Miller et al. \(1988\)](#) for O<sub>3</sub>. [Miller et al. \(1988\)](#) predicted that the total dose of O<sub>3</sub> is relatively similar among several mammalian species (namely, the rabbit, guinea pig, rat, and human). The total dose of NO<sub>2</sub> would also be expected to be relatively similar among these mammalian species. Although it may not be strictly appropriate to apply identical reaction rates for each of these species, varying the reaction rate from zero to that of O<sub>3</sub> increased the predicted total dose of NO<sub>2</sub> by less than 5 times in the trachea and bronchi. This is small relative to the 400-times decrease in total dose from the first generation of respiratory bronchioles to the alveolar sacs ([Miller et al., 1982](#)).

[Asgharian et al. \(2011\)](#) recently developed a model for soluble and reactive gas uptake that applied many of the basic concepts described by [Miller et al. \(1985\)](#). Unlike [Miller et al. \(1985\)](#), who separately considered liquid and tissue layers, [Asgharian et al. \(2011\)](#)

lumped the liquid layer lining the airways and the tissue layer together with the same diffusion and reaction rates. The model predicted that formaldehyde could penetrate to a maximum of 200  $\mu\text{m}$  in tracheal tissue during inhalation before being removed by reactions. Because predictions were for a single breath, it is possible that deeper tissues may be reached during continuous breathing. Applying the model to experimental  $\text{O}_3$  data, [Asgharian et al. \(2011\)](#) estimated a first-order reaction rate of  $10^5 \text{ sec}^{-1}$  (i.e., half-time of only 7  $\mu\text{sec}$ ). By comparison, the rate of  $0.018 \text{ sec}^{-1}$  (i.e., half-time of 39 sec) was used for formaldehyde. Lumping the liquid and tissue layers may be appropriate for the relatively slow-reacting formaldehyde, but it is perhaps less so for  $\text{O}_3$  and  $\text{NO}_2$ , which are expected to be removed by reactions within the liquid layer of ciliated airways ([Table 4-1](#)). For the rapidly reacting gases  $\text{O}_3$  and  $\text{NO}_2$ , a distinction between liquid and tissue compartments may be mechanistically important to discern whether the gas itself or its reaction products are associated with health outcomes.

Existing dosimetric models can predict the total dose per surface area of distinct areas of the lungs (e.g., individual generations of the tracheobronchial airways and alveolar region). This total dose appears to be very similar among several mammalian species. Similarly, the site of maximal  $\text{NO}_2$  tissue dose, near the beginning of the gas exchange region, is also predicted to be fairly similar among species. However, differences in potential  $\text{NO}_2$  reactive substrates and reaction products among species have not been considered in modeling efforts. Thus, despite the predicted similarities in total  $\text{NO}_2$  dose and site of maximal tissue dose, there is uncertainty related to inter-species differences in concentrations of reactive substrates and reaction products formed within the ELF and tissues. The importance of specific reaction products in mediating health effects in different species is similarly unclear. With regard to humans, individuals with asthma are more likely to experience health effects from ambient  $\text{NO}_2$  exposures than healthy individuals ([Section 7.3.1](#)). Specific aspects of asthma pathology that may affect  $\text{NO}_2$  uptake and disposition and that may be included in dosimetric models have not been identified. Furthermore, most models have focused on the lungs and have not considered the inter-species differences in the dose to nasal passages nor the potential importance of neural or other pathways in affecting health outcomes. Although total dose in the tracheobronchial airways and tissue dose in the alveolar region can be predicted, modeling efforts do not sufficiently link these endpoints to subsequent downstream events.

---

#### 4.2.2.4 Endogenous Generation, Metabolism, Distribution, and Elimination of Nitrogen Dioxide

Along with carbon monoxide (CO), NO<sub>2</sub> is a criteria pollutant believed to be produced endogenously in the lung and other tissues. Evidence in support of a claim for endogenously produced O<sub>3</sub> [e.g., [Babior et al. \(2003\)](#)] has received much criticism ([Pryor et al., 2006](#); [Kettle et al., 2004](#); [Sies, 2004](#); [Smith, 2004](#)) and is here considered controversial. A useful discussion of the issues can be found in [Drahl \(2009\)](#).

This endogenous production and function of NO<sub>2</sub> may have important implications in interpreting health effects studies. NO<sub>2</sub> can be produced endogenously by various processes, including the acidification of nitrite  
( $2 \text{H}^+ + 2 \text{NO}_2^- \rightarrow 2 \text{HNO}_2 \rightarrow \text{H}_2\text{O} + \text{N}_2\text{O}_3 \rightarrow \text{NO} + \text{NO}_2 + \text{H}_2\text{O}$ ) (as can transpire in phagolysosomes), the decomposition of peroxyxynitrite and/or the nitrosoperoxy carbonate anion ( $\text{ONOO}^- + \text{CO}_2 \rightarrow \text{ONOOCO}_2^- \rightarrow \text{CO}_3^{\bullet-} + \text{NO}_2$ ), and the action of peroxidases when using nitrite and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) as substrates. Nitrated proteins form when tyrosine residues are first oxidized to a tyrosyl radical intermediately followed by radical–radical addition of NO<sub>2</sub> to produce 3-nitrotyrosine. NO<sub>2</sub> is the terminal nitrating agent, and the presence of nitrated proteins provides solid evidence for the endogenous production of NO<sub>2</sub> per se. Endogenous NO<sub>2</sub> is expected to increase with dietary consumption of nitrite and nitrate (the latter of which occurs in substantial concentrations in some leafy vegetables like spinach) as well as during immune responses and inflammation. There is no known antioxidant enzymatic process for the decomposition of NO<sub>2</sub>, probably because NO<sub>2</sub> undergoes spontaneous reactions with small molecular weight antioxidants, such as glutathione and ascorbate, which result in formation of nitrite and antioxidant radicals. These reactions are so fast that they only allow NO<sub>2</sub> to diffuse small distances in the submicrometer range before reacting ([Table 4-1](#)) NO<sub>2</sub> is slightly hydrophobic ([Squadrito and Postlethwait, 2009](#)) and faces no significant physical barriers to prevent it from readily traversing biological membranes. But due to its high reactivity, NO<sub>2</sub> is unlikely to become systemically distributed; therefore, its endogenous, steady-state levels in distant tissues are unlikely to be affected by inhaled NO<sub>2</sub>.

Regarding the lung, understanding the balance between endogenous products and those derived from inhaled ambient NO<sub>2</sub> is a complex and challenging issue. Because inhaled NO<sub>2</sub> predominantly undergoes univalent reduction to nitrite during reactive absorption, changes in nitrite concentrations can be used as a surrogate for initial considerations of how inhaled NO<sub>2</sub> compares with that produced endogenously. For example, rat lung ELF contains low (μM to nM) levels of nitrite, with nitrate being substantially more prevalent. Due to salivary and gut microflora nitrate reductase activity and to reactions of nitrite, especially with heme proteins to yield nitrate, there is a constant cyclic flux between

nitrite and nitrate, with nitrate being the primary excretion product in urine. In a rat, there would be a net accumulation of approximately 0.3  $\mu\text{mol}$  of nitrite, assuming for simplicity a gas phase concentration of 200 ppb  $\text{NO}_2$ , a minute ventilation of 150 mL/min, an exposure time of 4 hours, quantitative conversion of  $\text{NO}_2$  to nitrite, 100% uptake efficiency, an ELF volume of 150  $\mu\text{L}$ , and no ELF clearance [even though nitrite has been shown to diffuse out of the ELF quickly ([Postlethwait and Bidani, 1989](#))]. If the  $\text{NO}_2$ -derived nitrite were evenly distributed throughout the ELF pool, this would equate to an additional 2 mM concentration of nitrite. However, in vitro studies using isolated lungs have not reported increases of this magnitude consequent to 10,000–20,000-ppb  $\text{NO}_2$  exposures, well above ambient concentrations, demonstrating that the ELF is a dynamic compartment and that small molecular weight reaction products (though charged) move readily from the respiratory tract surface to the vascular space.

Both nitrite and nitrate levels are very diet dependent, and diet represents the primary source for both ions. Although environmental exposures at current ambient  $\text{NO}_2$  concentrations would likely have a minimal effect on the overall balance of nitrite and nitrate outside the respiratory tract, how inhaled  $\text{NO}_2$  compares with endogenous production rates or amounts within the respiratory tract remains essentially unknown. However, the uptake of inhaled  $\text{NO}_2$  may potentially increase levels of nitrite and/or other reaction products beyond levels endogenously occurring in the respiratory tract.

---

#### 4.2.2.5 Metabolism, Distribution, and Elimination of Products Derived from Inhaled Nitrogen Dioxide

As stated earlier,  $\text{NO}_2$  absorption may generate some  $\text{HNO}_2$ , which subsequently dissociates to  $\text{H}^+$  and nitrite. Nitrite enters the underlying epithelial cells and subsequently the blood. In the presence of red blood cells and/or heme proteins, nitrite is oxidized to nitrate ([Postlethwait and Mustafa, 1981](#)). Nitrate is the primary stable oxide of nitrogen product, and it is subsequently excreted in the urine. Nitrate can also be converted to nitrite by bacterial reduction in saliva, the gastrointestinal tract, and the urinary bladder.

There has been concern that inhaled  $\text{NO}_2$  may lead to the production of N-nitrosamines, many of which are carcinogenic because inhaled  $\text{NO}_2$  can contribute to blood levels of nitrite and nitrate. Nitrite has been found to react with secondary amines to form N-nitrosamines. However, nitrosamines are not detected in tissues of animals exposed by inhalation to  $\text{NO}_2$  unless precursors to nitrosamines and/or inhibitors of nitrosamine metabolism are co-administered. [Rubenchik et al. \(1995\)](#) could not detect N-nitrosodimethylamine (NDMA) in tissues of mice exposed to 4,000 to 4,500 ppb  $\text{NO}_2$

for 1 hour. However, NDMA was found in tissues when mice were simultaneously given oral doses of amidopyrine and 4-methylpyrazole, an inhibitor of NDMA metabolism. [Van Stee et al. \(1983\)](#) reported N-nitrosomorpholine (NMOR) production in mice gavaged with 1 g of morpholine/kg body weight per day and then exposed (5–6 hours daily for 5 days) to 16,500–20,500 ppb NO<sub>2</sub>. NMOR is a nitrosamine and potent animal carcinogen. The single site containing the greatest amount of NMOR was the gastrointestinal tract, as would be expected due to the pH-dependent facilitation of N-nitrosation chemistry. Later, [Van Stee et al. \(1995\)](#) exposed mice to approximately 20,000 ppb <sup>15</sup>NO<sub>2</sub> and 1 g/kg morpholine simultaneously. N-nitrosomorpholine was found in the body of the exposed mice. Of the NMOR in the body, 98.4% was labeled with <sup>15</sup>N which was derived from the inhaled <sup>15</sup>NO<sub>2</sub>, and 1.6% was derived presumably from endogenous sources.

Inhaled NO<sub>2</sub> may also be involved in the production of mutagenic (and carcinogenic) nitro derivatives of other co-exposed compounds, such as polycyclic aromatic hydrocarbons (PAHs), via nitration reactions. [Miyanishi et al. \(1996\)](#) co-exposed rats, mice, guinea pigs, and hamsters to 20,000 ppb NO<sub>2</sub> and various PAHs (pyrene, fluoranthene, fluorene, anthracene, or chrysene). Nitro derivatives of these PAHs, which were found to be highly mutagenic in the Ames/*S. typhimurium* assay, were excreted in the urine of these animals. Specifically, the nitrated metabolites of pyrene (1-nitro-6/8-hydroxypyrene and 1-nitro-3-hydroxypyrene) was detected in the urine. Further studies indicated that these metabolites are nitrated by an ionic reaction in vivo after the hydroxylation of pyrene in the liver.

Endogenous NO<sub>2</sub> production and the cyclic inter-conversion of nitrite and nitrate may provide the precursors that drive formation of nitrosamine and other nitro derivatives. However, because ambient NO<sub>2</sub> contributes only modest amounts of nitrite/nitrate relative to dietary intake, any substantial contribution to systemic formation of nitrosamines and other nitro derivatives is not likely. The relative importance of inhaled NO<sub>2</sub> in formation of N-nitrosamines or other nitro derivatives has yet to be demonstrated.

---

### 4.2.3 Dosimetry of Nitric Oxide

NO occurs within the respiratory tract gas phase due to the following: (1) inhalation of ambient NO and (2) off-gassing from its endogenous production within pulmonary tissues, airspace surface inflammatory cells, and blood. The net uptake of NO within the gas exchange regions depends on the balance between the intra-pulmonary gas phase concentration (discussed below) and the inhaled ambient concentration.

While NO exists as a radical species, it is much less reactive than many other radical species. However, it selectively participates in radical–radical reactions such as with superoxide radical anions [ $O_2^{\bullet-}$ , which produces peroxynitrite ( $ONOO^-$ )], thiyl radicals [e.g., cysteine ( $Cys^\bullet$ ), glutathione ( $GS^\bullet$ ), which produce S-nitrosothiols (RSNO)], and organic peroxy radicals ([Madej et al., 2008](#); [Goldstein et al., 2004](#)). In addition, NO reacts with heme-containing proteins such as hemoglobin ([Pacher et al., 2007](#)). Although the radical-based reactions generally occur at near diffusion-controlled rates, the prevalence of non-NO radical species at any given time is low. Thus, in terms of the overall uptake and tissue diffusion of NO within the lung, interception due to reactions is not expected to consume appreciable amounts of the total NO involved in mass transfer from the alveolar to the vascular space. Inhaled NO uptake occurs against the background of endogenous NO production, which is derived primarily from the catalytic activities of the several isoforms of nitric oxide synthase [NOS; ([Förstermann and Sessa, 2012](#))]. Estimates of nitrite and/or nitrate stemming from NO production via NOS suggest that endogenous NO production, even during inflammatory states, is at best modest compared to dietary intake; although, under specific conditions, plasma levels have been shown to transiently increase due to nondietary, endogenous biological activities. Additional endogenously generated NO may also occur from the acidification of nitrite in the presence of electron donors, such as within phagolysosomes, by dissociation of RSNO, and by complex interactions within red blood cells that likely lead to the release of NO ([Weitzberg et al., 2010](#)). In combination, these processes result in the appearance of NO within the intra-pulmonary gas phase, the concentration of which can be measured in expired breath (eNO).

Reported eNO concentrations from the lower respiratory tract span a broad range (~5 to >300 ppb), with nasal/sinus concentrations generally accepted as being greater than that measured from the lower respiratory tract [e.g., [See and Christiani \(2013\)](#); [Alexanderson et al. \(2012\)](#); [Gelb et al. \(2012\)](#); [Noda et al. \(2012\)](#); [Taylor \(2012\)](#); [Bautista et al. \(2011\)](#); [Linhares et al. \(2011\)](#); [Olin et al. \(1998\)](#)]. Levels of eNO are affected by a variety of factors including disease state, diet, sex (or height), species, smoking history, and environmental exposures. Although eNO from the lower respiratory tract is increased by asthma, this is not the case for nasal NO ([ATS/ERS, 2005](#)).

For the general U.S. population, results of the 2007–2011 National Health and Nutrition Examination Survey show a geometric mean eNO of 9.7 ppb in children (n = 1,855; 6–11 years of age; 10% with current asthma) and 13.3 ppb in teenagers and adults [n = 11,420; 12–80 years of age; 8% with current asthma; ([See and Christiani, 2013](#))]. In healthy, never-smokers [558 males (M), 573 females (F); 25–75 years of age], [Olin et al. \(2007\)](#) reported a geometric mean eNO of 16.6 ppb (95% reference interval, 6 to 47 ppb). The eNO levels increased with age and height of the individuals but did not depend on

sex. In healthy children (23 M, 28 F; 1–5 years of age), a geometric mean eNO of 7 ppb (95% CI: 3, 12) has been reported ([van der Heijden et al., 2014](#)). The eNO levels in these children were unrelated to age, height, weight, or sex. These eNO levels correspond to NO output rates of about 40–50 nL/min from the lower respiratory tract of healthy adults and about 20–30 nL/min for healthy children.

[Kharitonov et al. \(2005\)](#) reported nasal NO concentrations of 750 ppb (95% CI: 700, 810) in children [n = 20; 10 ± 3 (SD) years] and 900 ppb (95% CI: 870, 930) in adults (n = 29; 38 ± 11 years of age). Another study of healthy adults (n = 10; 18–35 years of age) found a nasal NO concentration of 670 ppb. Higher NO concentrations (9,100 ± 3,800 ppb; n = 5) have been reported for the paranasal sinuses of healthy adults ([Lundberg et al., 1995](#)). Asthma and current rhinitis do not appear to affect nasal NO concentrations ([Alexanderson et al., 2012](#); [Kharitonov et al., 2005](#)). Nasal NO is reduced by exercise ([ATS/ERS, 2005](#)). The nasal NO concentrations described above correspond to NO output rates of about 300 nL/min for the nasal airways of adults with or without asthma and 230 nL/min for children with or without asthma. Nasal NO output rates of healthy primates are in the range of 200 to 450 nL/min ([ATS/ERS, 2005](#)). With a NO output of 730 nL/min, a large contribution to nasal NO appears to derive from the paranasal sinuses. Based on these NO output rates, the nasal passages may contribute, on average, roughly 15–20 ppb NO to the lower respiratory tract during rest.

The other primary approach to noninvasive assessment of the respiratory tract surface is exhaled breath condensate (EBC), which captures aerosolized materials contained in exhaled air, including those directly related to reactive nitrogen chemistry (e.g., nitrite, nitrate, 3-nitrotyrosine). Unfortunately, measurements of eNO and EBC (which rely on relatively new analytical methods) do not necessarily produce comparable results ([Rava et al., 2012](#); [Dressel et al., 2010](#); [Malinovschi et al., 2009](#); [Cardinale et al., 2007](#); [Vints et al., 2005](#); [Chambers and Ayres, 2001](#); [Olin et al., 2001](#); [Zetterquist et al., 1999](#); [Olin et al., 1998](#); [Jilma et al., 1996](#)). Given the endogenous production of NO and the lack of a correlation between the two measurements, neither eNO nor EBC can be employed as a metric of exposure history with any significant degree of specificity for inhaled ambient NO.

The absorption of inhaled NO proceeds similarly to oxygen and CO. In a study of seven healthy adults, [Wagner \(1970\)](#) observed an average NO (5,000 ppb) uptake of 88% during normal respiration ( $V_T$ , 0.4 L) and 92% during maximal respiration ( $V_T$ , 2 to 4 L). Because blood acts as a near “infinite” sink for NO, it has been proposed as an alternative to CO for measuring pulmonary diffusing capacity [e.g., ([Chakraborty et al. \(2004\)](#); [Heller et al. \(2004\)](#))]. NO absorption follows Henry’s law for dissolution into the aqueous phase, followed by diffusion into the vascular space where it interacts with red blood cell

hemoglobin to ultimately form nitrate. Thus, due to its chemical conversion, NO net flux from alveolar gas phase to the blood occurs when the alveolar concentration exceeds that found in tissue and/or blood. Mass transfer resistances may be encountered ([Borland et al., 2010](#); [Chakraborty et al., 2004](#)), but their combined effects are likely small due to the low (ppb) concentrations of NO.

The formation of RSNO within the ELF may contribute to the overall epithelial cell uptake via an L-type amino acid transporter [LAT ([Torok et al., 2012](#); [Brahmajothi et al., 2010](#))]. An in vitro study by [Brahmajothi et al. \(2010\)](#) showed that pre-incubation of cultured alveolar epithelial cells with L-cysteine increased intracellular RSNO concentrations by 3-times compared with diffusive transport. This increase involved transport via the LAT. LAT transport was further augmented by addition of glutathione and was independent of sodium transport. The authors concluded that NO gas uptake by alveolar epithelium occurred predominantly by forming extracellular S-nitroso-L-cysteine, which was then transported by LAT rather than by diffusion. Subsequently, [Torok et al. \(2012\)](#) also showed that LAT transport exceeded diffusive transport in isolated mice lungs. However, the precise extent of contribution of LAT transport remains unclear because formation of RSNO requires several steps due to the slow direct reactivity of NO with reduced thiols. In vivo, the time for these reactions may exceed the time for diffusion into and through alveolar epithelial cells. Furthermore, because blood acts as a sink for NO (i.e., a near zero boundary condition), lower intracellular concentrations of NO would occur in vivo compared to the nonzero boundary conditions in cell cultures and isolated lungs ([Asgharian et al., 2011](#)). While diffusive transport of NO is known and relatively well characterized, the importance of LAT transport in vivo has not been determined.

Ambient NO levels are likely similar to those endogenously occurring within the lung airspaces, except during morning commutes or near major roadways where they may possibly exceed endogenous levels. It is not known whether periods of high ambient NO exposure could alter endogenous NO production within the respiratory tract or alter pathways affected by endogenous NO. It is important to note that in the clinical setting, therapeutic administration is a very different situation wherein >10,000 ppb NO may be administered continuously for prolonged periods.

---

#### 4.2.4 Summary of Dosimetry

The uptake of inhaled NO<sub>2</sub> in the respiratory tract is governed by “reactive absorption,” which involves chemical reactions with antioxidants, unsaturated lipids, and other compounds in the ELF. In vitro studies have clearly illustrated the role of antioxidants in

mediating NO<sub>2</sub> uptake. The rapid reactions of NO<sub>2</sub> with tracheobronchial ELF substrates provides a net driving force for NO<sub>2</sub> mass transfer from the gas phase into the ELF. Concentrations of “free” solute NO<sub>2</sub> are likely negligible due to its reaction-mediated removal. Thus, it is not NO<sub>2</sub> itself, but rather its reaction products that are believed to interact with the apical surfaces of the tracheobronchial epithelium. At high substrate concentrations, oxidants/cytotoxic products are at least partially quenched due to secondary antioxidant reactions. At low substrate concentration, ELF-derived oxidants/cytotoxic products have a lower probability of being intercepted by unreacted antioxidants and instead may reach underlying targets.

Within the alveolar region, much of the inhaled NO<sub>2</sub> entering the ELF will diffuse through rapidly enough to avoid reactions and will reach underlying tissue surfaces. A principle component of pulmonary surfactant, DPPC, may partially reduce the uptake of NO<sub>2</sub> by slowing its diffusion and decreasing reaction with substrates in the subphase fluid. Reducing the reactive absorption increases diffusive resistance and back diffusion into the air phase, thereby reducing uptake from the gas phase. Nonetheless, rapid reactions of NO<sub>2</sub> with tissues will maintain a concentration gradient for NO<sub>2</sub> through the alveolar ELF to the underlying tissues.

Exercise, relative to rest, increases the dose rate of NO<sub>2</sub> to the respiratory tract because of greater NO<sub>2</sub> penetration through the extrathoracic airways and a greater intake rate of NO<sub>2</sub>. The uptake of NO<sub>2</sub> by the upper respiratory tract decreases with increasing ventilation rates occurring with activity. This causes a greater proportion of inhaled NO<sub>2</sub> to be delivered to the lower respiratory tract. In humans, exercise results in a shift in the breathing pattern from nasal to oronasal relative to rest. Because the nasal passages scrub gas-phase NO<sub>2</sub> more efficiently than the mouth and because uptake efficiency decreases with increasing flow, exercise delivers a disproportionately greater quantity of the inhaled mass to the lower respiratory tract, where the NO<sub>2</sub> is readily absorbed. Experimental studies have shown that exercise increases the dose rate of NO<sub>2</sub> to the respiratory tract by 3- to 5-times compared to resting exposures.

Compared to healthy adults, children and individuals with asthma might be expected to have greater NO<sub>2</sub> penetration into the lower respiratory tract. Children tend to have a greater oral breathing contribution than adults at rest and during exercise. Limited data also suggest that patients with asthma or allergic rhinitis breathe oronasally at rest. Because the nasal passages scrub gas-phase NO<sub>2</sub> more efficiently, a greater quantity of the inhaled NO<sub>2</sub> may reach the lower respiratory tract of oronasally breathing individuals. The dose rate to the lower airways of children compared to adults is increased further because children breathe at higher minute ventilations relative to their lung volumes.

Current dosimetry models for NO<sub>2</sub> do not adequately consider reactive absorption and secondary reactions that affect the probability of oxidants and/or cytotoxic products reaching target sites. Differences in potential NO<sub>2</sub> reactive substrates and reaction products among species have not been considered in modeling efforts. Although the models predict similar total NO<sub>2</sub> dose in the tracheobronchial airways and sites of maximal NO<sub>2</sub> tissue dose (i.e., near the beginning of the gas exchange region) among several mammalian species, the models do not sufficiently link these NO<sub>2</sub> doses to specific reaction products and downstream events. It is unclear to what extent environmental exposures at current ambient NO<sub>2</sub> concentrations might affect the overall balance of nitrite and nitrate in the respiratory tract or how ambient NO<sub>2</sub> uptake compares with endogenous production rates/amounts in the respiratory tract. Systemic nitrite and nitrate levels are highly dependent on diet and not likely affected by ambient NO<sub>2</sub> exposures. However, the uptake of inhaled NO<sub>2</sub> could increase levels of nitrite and/or other reaction products beyond levels that are endogenously occurring in the respiratory tract.

The uptake of inhaled NO occurs against the background of endogenous NO production in the respiratory tract. In terms of the overall uptake and tissue diffusion of NO within the lung, interception due to reactions is not expected to consume appreciable amounts of the total NO involved in mass transfer from the alveolar to the vascular space. The absorption of inhaled NO proceeds similarly to oxygen and CO. Blood acts as a near “infinite” sink for NO. Absorption of NO follows Henry’s law for dissolution into the aqueous phase, and is followed by diffusion into the vascular space, where it interacts with red blood cell hemoglobin to ultimately form nitrate. Ambient NO concentrations are likely similar to those endogenously occurring within the lung airspaces, except during morning commutes or near major roadways, where they may possibly exceed endogenous levels. It is not known whether periods of high ambient NO exposure could alter endogenous NO production within the respiratory tract or alter pathways affected by endogenous NO.

---

## **4.3 Modes of Action for Inhaled Oxides of Nitrogen**

### **4.3.1 Introduction**

The purpose of this section is to describe the biological pathways that underlie health effects resulting from short- and long-term exposures to NO<sub>2</sub> and NO. Extensive research carried out over several decades in humans and in laboratory animals has yielded much information about these pathways. This section will discuss some of the representative

studies, placing particular emphasis on studies published since the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008a, c](#)) and on studies in humans. This information will be used to develop a mode of action framework for inhaled NO<sub>2</sub> and NO.

Mode of action refers to a sequence of key events, endpoints, and outcomes that result in a given toxic effect ([U.S. EPA, 2005](#)). In contrast, elucidation of *mechanism of action* requires a more detailed understanding of key events, usually at the molecular level ([U.S. EPA, 2005](#)). The framework developed in this chapter will include some mechanistic information on initiating events at the molecular level but mainly will focus on the effects of NO<sub>2</sub> and NO at the cellular, tissue, organ, and organism level.

NO<sub>2</sub> is a radical species and a highly reactive oxidant gas [([Fukuto et al., 2012](#)); [Table 4-2](#)]. It is well known that oxidation and nitration products, which are formed as a result of NO<sub>2</sub> exposure, initiate numerous responses at the cellular, tissue, and whole organ level of the respiratory system. Exposure to NO<sub>2</sub> may also have effects outside the respiratory tract. NO is a radical species and a gas that is more selective in its reactivity than NO<sub>2</sub> [([Fukuto et al., 2012](#)); [Table 4-2](#)]. Once inhaled, NO rapidly crosses the alveolar capillary barrier into the vascular compartment and avidly binds to hemoglobin. Subsequent reactions with hemoglobin lead to the generation of circulating nitrate, nitrite, and methemoglobin.

**Table 4-2 Chemical properties of nitrogen dioxide and nitric oxide that contribute to proposed modes of action.**

NO <sub>2</sub>	NO
Radical species	Radical species
Somewhat hydrophobic	Very hydrophobic
Very reactive	Selectively reactive
Less diffusible	More diffusible
Reactions with: (1) unsaturated fatty acids (2) thiols (3) low molecular weight antioxidants	Radical-radical reactions with: (1) superoxide to form peroxyxynitrite (2) thiyl radicals to form RSNO (3) organic peroxy radicals
Reacts with amino acids, proteins, and lipids to form nitrated species	Reacts with heme-containing proteins, transition metals, and oxygen
Initiates radical reactions and lipid peroxidation	Quenches radical reactions
Metabolites include nitrite and nitrate	Metabolites include nitrite and nitrate

RSNO = S-nitrosothiols.

Both NO<sub>2</sub> and NO are formed endogenously in cells and tissues ([Sections 4.2.2.4](#) and [4.2.3](#)). Formation of endogenous NO is catalyzed by NOS. Three pathways contribute to the formation of endogenous NO<sub>2</sub>: (1) acidification of nitrite, usually occurring in the phagolysosomes; (2) reaction of peroxynitrite with carbonate to form nitrosoperoxycarbonate anion, which decomposes to carbonate anion and NO<sub>2</sub>; and (3) reaction of peroxidases using nitrite and hydrogen peroxide as substrates. These enzymatic and nonenzymatic pathways are enhanced during immune responses and inflammation, leading to higher endogenous levels of NO and NO<sub>2</sub>. Furthermore, dietary consumption of nitrate leads to increased levels of NO in the stomach and to increased circulating levels of nitrite due to activity of the enterosalivary cycle ([Weitzberg and Lundberg, 2013](#); [Lundberg et al., 2011](#)). The contribution of environmentally relevant concentrations of inhaled NO<sub>2</sub> and NO to levels of circulating nitrite and nitrate is thought to be minimal ([Sections 4.2.2.4](#) and [4.2.3](#)). However, inhaled NO<sub>2</sub> may act on the same targets as endogenous NO<sub>2</sub> produced during inflammation in the respiratory tract ([Ckless et al., 2011](#)). Endogenous NO<sub>2</sub> is thought to contribute to the development of lung disease; inhaled NO<sub>2</sub> may further this process.

The following subsections describe the current understanding of biological pathways that may be responsible for the pulmonary and extrapulmonary effects of inhaled NO<sub>2</sub> and NO. For NO<sub>2</sub>, this includes the formation of oxidation and nitration products ([Section 4.3.2.1](#)), activation of neural reflexes ([Section 4.3.2.2](#)), initiation of inflammation ([Section 4.3.2.3](#)), alteration of epithelial barrier function ([Section 4.3.2.4](#)), enhancement of bronchial smooth muscle reactivity ([Section 4.3.2.5](#)), modification of innate/adaptive immunity ([Section 4.3.2.6](#)), and remodeling of airways and alveoli ([Section 4.3.2.7](#)). The potential induction of carcinogenesis is also briefly described ([Section 4.3.2.8](#)). While NO<sub>2</sub> exposure may result in effects occurring outside of the respiratory tract, biological pathways underlying extrapulmonary effects of NO<sub>2</sub> are not well understood ([Section 4.3.2.9](#)). Activation of neural reflexes and release of inflammatory or vasoactive mediators from the lung to the bloodstream are possibilities. Inhaled NO impacts the pulmonary and systemic vasculature mainly through interaction with heme proteins ([Section 4.3.3](#)). Other effects of NO may be due to circulating metabolites (such as nitrite, nitrate, and methemoglobin), interactions with redox-active transition metals, or reactions with thiol and superoxide radicals. Because endogenous NO is an important mediator of cell signaling, inhaled NO has the potential to disrupt cell signaling.

---

## 4.3.2 Nitrogen Dioxide

---

### 4.3.2.1 Formation of Oxidation and Nitration Products

The 2008 ISA and the 1993 AQCD for Oxides of Nitrogen ([U.S. EPA, 2008a, c, 1993a](#)) summarized biochemical effects observed in the respiratory tract after NO<sub>2</sub> exposure. These effects have been attributed to the strong oxidizing potential of NO<sub>2</sub>, resulting in the formation of reactive oxygen species (ROS). Key responses include oxidation of membrane polyunsaturated fatty acids, thiol groups, and antioxidants. Chemical alterations of lipids, amino acids, proteins, and enzymes can lead to functional changes in membranes, enzymes, and oxidant/antioxidant status. For example, lipid peroxidation of unsaturated fatty acids in membranes may alter membrane fluidity and permeability. As a result, epithelial barrier functions may be impaired, and phospholipases may be activated leading to the release of arachidonic acid. In addition, oxidation of protein thiols may result in enzyme dysfunction. Further, consumption of low molecular weight antioxidants by NO<sub>2</sub> may result in decreased antioxidant defenses. Effects may occur directly through the action of NO<sub>2</sub> or secondarily due to its reaction products, such as organic radicals, ROS, or reactive nitrogen species (RNS). Later effects may occur due to the release of ROS and/or RNS by leukocytes responding to cell damage.

As summarized in the 2008 ISA and the 1993 AQCD ([U.S. EPA, 2008a, c, 1993a](#)), considerable attention has been paid to the effects of NO<sub>2</sub> on the antioxidant defense system in the ELF and in respiratory tract tissue. Studies in humans and animals exposed to NO<sub>2</sub> have demonstrated changes in low molecular weight antioxidants, such as glutathione, ascorbate, and  $\alpha$ -tocopherol, and in the activities of enzymes responsible for glutathione synthesis or maintenance of redox status. For example, a controlled human exposure study found depletion of urate and ascorbate, but not glutathione, in BAL fluid 1.5 hours following a 4-hour exposure to 2,000 ppb NO<sub>2</sub> ([Kelly et al., 1996a](#)). While these results may be interpreted as evidence that NO<sub>2</sub> prefers to react with urate or ascorbate over glutathione, an alternative interpretation is that glutathione reacts with NO<sub>2</sub> and that the product of the reaction is reduced by urate or ascorbate ([Section 4.2.2.2](#)). Other studies have found that antioxidant status modulates the effects of NO<sub>2</sub> inhalation. For example, in a controlled human exposure study, supplementation with ascorbate and  $\alpha$ -tocopherol decreased the levels of lipid peroxidation products found in BAL fluid following a 3-hour exposure to 4,000 ppb NO<sub>2</sub> ([Mohsenin, 1991](#)). Additionally, changes in lung antioxidant enzyme activity have been reported in animals exposed to NO<sub>2</sub> ([U.S. EPA, 2008c](#)). For example, long-term exposure to NO<sub>2</sub> resulted in decreased glutathione peroxidase activity in weanling mice that were  $\alpha$ -tocopherol

deficient, while supplementation with  $\alpha$ -tocopherol resulted in an increase in glutathione peroxidase activity ([Ayaz and Csallany, 1978](#)). Thus, NO<sub>2</sub> inhalation is capable of perturbing glutathione-dependent reactions. These changes may reflect altered cell populations because injury induced by NO<sub>2</sub> exposure may result in the influx of inflammatory cells or the proliferation of resident epithelial or mesenchymal cells. Changes in cell populations due to proliferative repair may also account for the upregulation of Phase II, Phase I, and glycolytic enzymes that have been observed following NO<sub>2</sub> exposure.

As discussed in [Section 4.2.2.1.2](#), reactive absorption of NO<sub>2</sub> gas occurs by reactions with antioxidants and other components of the ELF. Studies employing in vitro and in vivo systems point to the ability of antioxidants to both react with NO<sub>2</sub> to form reactive intermediates and to quench those reactive intermediate species. NO<sub>2</sub> exposure in the presence of ELF antioxidants resulted in the formation of superoxide and hydrogen peroxide in an in vitro cell system ([Velsor and Postlethwait, 1997](#)). In this study, quenching of NO<sub>2</sub>-derived secondary oxidants was dependent on antioxidant concentration, with lower concentrations promoting and higher concentrations reducing oxidative injury. A recent in vivo study provided additional support for this mechanism. Supplementation of mice with ascorbate had a biphasic effect, with a lower dose of ascorbate promoting and a higher dose of ascorbate reducing lung injury and inflammation induced by exposure to 20,000 ppb NO<sub>2</sub> ([Zhang et al., 2010b](#)). Thus, toxicity resulting from NO<sub>2</sub> exposure may be due to a product derived from the initial ELF substrate and/or to secondary reaction products formed. These reaction products may not be long lived due to short half-lives and/or continuous turnover of the ELF. Further, quenching of reaction products by ELF antioxidants may limit damage to the respiratory epithelium. The heterogeneous distribution of epithelial injury due to reactive intermediates formed from inhaled NO<sub>2</sub> may reflect ELF-dependent local effects because the ELF is nonuniform in composition and quantity along the respiratory tract. Furthermore, localized endogenous formation of NO<sub>2</sub> in the respiratory tract could overwhelm the antioxidant capacity and contribute to epithelial injury.

Nitrogen-based metabolites and RNS are also formed in the ELF as a result of NO<sub>2</sub> exposure. Nitrite is the primary product of the chemical reactions of NO<sub>2</sub> in the respiratory tract. As discussed in [Section 4.2.2.1.2](#), nitrite formed in the ELF can diffuse into respiratory tract epithelial cells and subsequently into the vascular space. While levels of nitrite may not change appreciably in the respiratory tract, a localized effect of nitrite on epithelial cells cannot be ruled out. However, based on numerous studies investigating the effects of increased systemic nitrite on various tissues and organs, it seems unlikely that nitrite is responsible for the toxicity of NO<sub>2</sub>. Nitrite has been found to protect against ischemia-reperfusion injury in the heart and other organs ([Weitzberg and](#)

[Lundberg, 2013](#)). In addition, systemic nitrite administration prevented airway and epithelial injury due to exposure to chlorine gas in rats ([Yadav et al., 2011](#)). Further, nitrite is known to have a direct relaxing effect on smooth muscle [([Folinsbee, 1992](#)); [Section 4.3.4.1](#)], suggesting that it may play a role in bronchodilation.

RNS, such as RSNO and nitrated proteins, fatty acids, and lipids, may be formed in the respiratory tract following NO<sub>2</sub> exposure. Evidence for these reaction products is mainly provided by in vitro cell systems and ex vivo systems ([Section 4.3.4](#)). However, [Matalon et al. \(2009\)](#) recently demonstrated the nitration of surfactant protein D (SP-D) in mice exposed to 20,000 ppb NO<sub>2</sub> for 4 hours. SP-D nitration was accompanied by protein cross-linking and a decrease in SP-D aggregating activity, which could potentially impact microbial clearance, immune regulation, and surfactant metabolism. In addition to inhibiting protein function, nitration of proteins may induce antigenicity or trigger immune reactions ([Daiber and Muenzel, 2012](#)). Further, the presence of nitrated amino acids such as 3-nitrotyrosine in cells or tissues is an indicator of endogenous NO<sub>2</sub> and peroxynitrite formation. Other potential RNS formed may have less deleterious effects. For example, nitrated (or nitro) fatty acids have a direct relaxing effect on smooth muscle, perhaps even on airway smooth muscle ([Que et al., 2009](#); [Lima et al., 2005](#)). In addition, RSNOs are known to be bronchodilators ([Que et al., 2009](#)). Additional discussion of the biological effects of these products of NO<sub>2</sub> metabolism is found in [Section 4.3.4](#).

Collectively, these studies provide evidence for the formation of oxidation and nitration products as a result of NO<sub>2</sub> exposure. Responses included lipid peroxidation and nitration of SP-D in the respiratory tract. In addition, NO<sub>2</sub> exposure altered antioxidant systems. While studies in humans involved ambient-relevant exposures to NO<sub>2</sub>, studies conducted in experimental animals or in vitro systems mainly involved higher concentrations of NO<sub>2</sub> (i.e., >5,000 ppb).

---

#### **4.3.2.2 Activation of Neural Reflexes**

NO<sub>2</sub> is classified as a pulmonary irritant ([Alarie, 1973](#)). Pulmonary irritants stimulate afferent nerve endings in the lung, resulting in increased respiratory rate, decreased V<sub>T</sub>, and subsequent rapid shallow breathing. Sometimes pulmonary irritants also stimulate mild bronchoconstriction, bradycardia, and hypotension ([Alarie, 1973](#)). All of these pathways involve the vagus nerve.

Numerous studies investigated pulmonary irritant effects of NO<sub>2</sub> exposure using respiratory rate as an indicator of neural reflex activation. In guinea pigs, NO<sub>2</sub> exposure (5,200–13,000 ppb; 2–4 hours) by nose-cone resulted in statistically significant increases

in respiratory rate and decreases in  $V_T$  ([Murphy et al., 1964](#)). These responses were concentration and time dependent and were reversible when animals were returned to clean air. In contrast, no changes in these respiratory parameters were observed with 4-hour exposures to 16,000 and 50,000 ppb NO. In another study, guinea pigs exposed to 7,000–146,000 ppb NO<sub>2</sub> for 1 hour demonstrated a concentration-dependent increase in respiratory rate 10 minutes following exposure and a concentration-dependent decrease in  $V_T$  10 minutes, 2 hours, and 19 hours following exposure ([Silbaugh et al., 1981](#)). NO<sub>2</sub> exposure-induced increases in respiratory rate have also been reported in rats ([Freeman et al., 1966](#)) and mice ([McGrath and Smith, 1984](#)). In mice, statistically significant increases in respiratory rate and decreases in  $V_T$  were found in response to an 8-minute exposure to 100,000 ppb NO<sub>2</sub>, but not to 15,000 or 50,000 ppb NO<sub>2</sub> ([McGrath and Smith, 1984](#)). In this latter study, continuous pre-exposure to 5,000 ppb NO<sub>2</sub> for 3 days lessened the response to 100,000 ppb NO<sub>2</sub>, suggesting the development of tolerance or an attenuated response to NO<sub>2</sub> ([U.S. EPA, 1993a](#)). In rats, continuous exposure to 800 ppb and higher concentrations of NO<sub>2</sub> resulted in elevated respiratory rates throughout life ([Freeman et al., 1966](#)). However, no NO<sub>2</sub> exposure-induced increases in respiratory rate in human subjects have been reported. In fact, respiratory rates tended to decrease in humans exposed to 0–480 ppb for 20 minutes ([Bylin et al., 1985](#)). The authors proposed that NO<sub>2</sub> in this range of concentrations did not act as a pulmonary irritant in humans.

NO<sub>2</sub> has been shown to elicit a small increase in airway resistance, which is consistent with mild bronchoconstriction, in humans but not in rabbits or guinea pigs [[Alarie \(1973\)](#) and studies cited below]. One study in human subjects at rest found a nonmonotonic response to NO<sub>2</sub> in terms of airway resistance ([Bylin et al., 1985](#)). In this study, specific airway resistance was increased after 20 minutes of exposure to 250 ppb NO<sub>2</sub> and was decreased after 20 minutes of exposure to 480 ppb NO<sub>2</sub>. The authors suggested that reflex bronchoconstriction occurred at the lower concentration and that other mechanisms counteracted this effect at the higher concentration. Other controlled human exposure studies found no change in airway resistance with acute exposures of 530–1,100 ppb NO<sub>2</sub> and increases in airway resistance with acute exposures above 1,600–2,500 ppb in healthy human subjects ([U.S. EPA, 1993a](#)). Human subjects with chronic lung disease exposed for 5 minutes to 2,100 ppb NO<sub>2</sub> also exhibited increased airway resistance ([von Nieding and Wagner, 1979](#)). In addition, both forced expiratory volume in 1 second (FEV<sub>1</sub>) and forced vital capacity were decreased in healthy human subjects exposed to 2,000 ppb NO<sub>2</sub> for 4 hours ([Blomberg et al., 1999](#)). These changes in pulmonary function are consistent with reflex bronchoconstriction. Because the response was lessened with each successive exposure on 4 consecutive days, [Blomberg et al. \(1999\)](#) suggested the development of tolerance or an attenuated response.

Some evidence points to NO<sub>2</sub> exposure-induced histamine release from mast cells, rather than reflex bronchoconstriction, as the mechanism underlying changes in airway resistance. A study in rats showed that mast cell degranulation occurred after acute exposure to NO<sub>2</sub> [500 ppb for 4 hours; 1,000 ppb for 1 hour; ([Thomas et al., 1967](#))]. In addition, a histamine-suppressive agent, but not atropine or  $\beta$ -agonists, blocked NO<sub>2</sub>-mediated increases in airway resistance in healthy humans and in humans with chronic lung disease exposed to 5,000–8,000 ppb NO<sub>2</sub> for 5 minutes ([von Nieding and Wagner, 1979](#)). Because atropine inhibits vagal responses, these findings indicate that neural reflexes were not involved in NO<sub>2</sub>-induced changes in pulmonary function in human subjects. More recent studies in animals have provided experimental evidence for a relationship between lipid peroxidation/oxidative stress and the release of histamine by allergen-activated mast cells ([Beaven, 2009](#); [Gushchin et al., 1990](#)). Taken together, these studies suggest that NO<sub>2</sub> exposure may lead to lipid peroxidation, which may promote mast cell-mediated changes in pulmonary function, albeit at high concentrations.

There is some experimental support for NO<sub>2</sub> exposure-induced cardiovascular reflexes. An acute exposure to NO<sub>2</sub> in an occupational setting resulted in tachycardia in one case report ([U.S. EPA, 1993a](#); [Bates et al., 1971](#)), while rats exposed acutely to 20,000 ppb or higher concentrations of NO<sub>2</sub> exhibited bradycardia ([U.S. EPA, 1993a](#); [Tsubone et al., 1982](#)). This latter response was abolished by injection of atropine, which inhibits vagal responses. Further, a decreased heart rate, which was not accompanied by an increase in respiratory rate, was observed in mice exposed to 1,200 and 4,000 ppb NO<sub>2</sub> for 1 month ([Suzuki et al., 1981](#)). The lack of respiratory rate response suggests that the decreased heart rate was due to a different mechanism than rapid stimulation of irritant receptors by NO<sub>2</sub>. Controlled human exposure studies have also examined the effects of NO<sub>2</sub> on heart rate and heart rate variability ([Section 5.3.10.1](#)). Older studies and one recent study failed to find statistically significant changes in heart rate at ambient-relevant concentrations of NO<sub>2</sub>. A recent controlled human exposure study involving a 1-hour exposure to 400 ppb NO<sub>2</sub> failed to find an effect on heart rate variability in subjects with coronary heart disease ([Scaife et al., 2012](#)). However, a second recent controlled human exposure study reported an effect on heart rate variability resulting from a 2-hour exposure to 500 ppb NO<sub>2</sub> ([Huang et al., 2012b](#)). Altered heart rate variability found in epidemiologic studies ([Section 5.3.10.1](#)) is consistent with a possible effect of NO<sub>2</sub> exposure on autonomic tone.

Collectively, these studies show that NO<sub>2</sub> is a pulmonary irritant that may affect airway function and cardiac function through activation of neural reflexes involving the vagus nerve. Experimental NO<sub>2</sub> exposures in animals resulted in increased respiratory rate, decreased V<sub>T</sub>, reflex bronchoconstriction, and bradycardia. Responses were rapid, concentration dependent, and variable among species. Evidence that reflex responses

occur in humans is weak because no increases in respiratory rate have been reported as a result of NO<sub>2</sub> exposure. Further, modest increases in airway resistance in human subjects exposed to NO<sub>2</sub> were not blocked by atropine, which inhibits vagal responses. Findings attributed to reflex bronchoconstriction in humans may be due to alternative pathways such as mast cell degranulation. The recent demonstration that NO<sub>2</sub> exposure (500 ppb; 2 hours) resulted in altered heart rate variability suggests the possible activation of a neural reflex in humans. However, the clearest evidence for reflex responses mediated by the vagus nerve involved exposures of experimental animals to NO<sub>2</sub> at concentrations higher than those considered ambient-relevant (i.e., >5,000 ppb).

---

#### 4.3.2.3 Initiation of Inflammation

As summarized in the 2008 ISA and the 1993 AQCD for Oxides of Nitrogen ([U.S. EPA, 2008a, c, 1993a](#)), NO<sub>2</sub> exposure-induced membrane perturbations resulted in the release of arachidonic acid and the formation of eicosanoid products ([Sections 5.2.2.5 and 5.2.7.4](#)). Animal toxicological and controlled human exposure studies have found increases in concentrations of eicosanoids in BAL fluid immediately or 1 hour following a 2–3-hour exposure to 1,000 ppb NO<sub>2</sub> ([Jörres et al., 1995](#); [Schlesinger et al., 1990](#)). Eicosanoids play an important role in the recruitment of neutrophils. Interestingly, higher concentrations (3,000 and 10,000 ppb; 2 hours) or longer durations (500 ppb; 12 hours) of exposure to NO<sub>2</sub> resulted in inhibited eicosanoid production ([Robison and Forman, 1993](#); [Schlesinger et al., 1990](#)).

Recently, acute exposure of mice to 10,000 ppb and higher concentrations of NO<sub>2</sub> was shown to activate the transcription factor, nuclear factor kappa-light-chain enhancer of activated B cells (NFκB), in the airway epithelium ([Ather et al., 2010](#); [Bevelander et al., 2007](#)). NFκB activation resulted in the production of pro-inflammatory cytokines. Inflammation and acute lung injury in this model were found to be dependent on an active NFκB pathway. Controlled human exposure studies demonstrated increased levels of cytokines IL-6 and IL-8 in BAL fluid following NO<sub>2</sub> exposure. IL-8 levels were increased at 1.5 and 16 hours following a 4-hour exposure to 2,000 ppb NO<sub>2</sub>, while levels of IL-6 were increased at 16 hours following the exposure [[U.S. EPA, 2008c](#); [Devlin et al., 1999](#); [Blomberg et al., 1997](#)]; [Section 5.2.7.4](#)]. Because IL-6 and IL-8 are under NFκB transcriptional regulation, these studies suggest that exposure to 2,000 ppb NO<sub>2</sub> may have led to an increase in IL-6 and IL-8 by stimulating the NFκB pathway in human subjects.

Airway inflammation often occurs following NO<sub>2</sub> exposure. Studies in rodents exposed acutely (1 hour to 3 days) to NO<sub>2</sub> (500–30,000 ppb) have demonstrated airway

inflammation, mainly consisting of neutrophils and macrophages and sometimes of mast cells and lymphocytes, by histological technique or sampling of BAL fluid [as summarized in ([Poynter et al. \(2006\)](#); [Pagani et al. \(1994\)](#); [Sandström et al. \(1990\)](#))]. Numerous studies in healthy human subjects exposed to NO<sub>2</sub> have documented airway inflammation in endobronchial biopsy tissue and in sputum, BL fluid, and BAL fluid. Many of these studies were conducted while subjects were exercising intermittently and exposed to 1,500–4,000 ppb NO<sub>2</sub> for a few hours. Neutrophilia was a prominent feature ([U.S. EPA, 2008c](#); [Frampton et al., 2002](#); [Devlin et al., 1999](#); [Azadniv et al., 1998](#); [Blomberg et al., 1997](#)). In addition, other types of inflammatory cells, including macrophages, lymphocytes, and mast cells, have been demonstrated ([Frampton et al., 2002](#); [Sandström et al., 1991](#); [Sandström et al., 1990](#)).

Controlled human exposure studies have also evaluated the effects of repeated NO<sub>2</sub> exposure on airway inflammation in healthy adults. Persistent neutrophilic inflammation, demonstrated by increased numbers of neutrophils and increased levels of myeloperoxidase in the BL fluid, was observed following 4 consecutive days of 4-hour exposure to 2,000 ppb NO<sub>2</sub> ([Blomberg et al., 1999](#)). Repeated exposure also led to the upregulation of cytokines characteristic of the T helper cell 2 (Th2) inflammatory response and also of inter-cellular adhesion molecule 1 (ICAM-1) in respiratory epithelium ([U.S. EPA, 2008c](#); [Pathmanathan et al., 2003](#)). Upregulation of ICAM-1 suggests a potential mechanism for the persistent neutrophil influx that was observed ([Blomberg et al., 1999](#)). A study of repeated exposure to 4,000 ppb (exposure every other day for a total of six exposures) found inflammatory responses that differed from those observed after a single exposure ([Sandström et al., 1992a](#)). In particular, numbers of mast cells and lymphocytes in the lavage fluid, which were increased following a single exposure, were not increased following repeated exposure. Furthermore, repeated exposure to 1,500 ppb NO<sub>2</sub> (by the same protocol) resulted in smaller numbers of some lymphocyte subpopulations in BAL obtained following exposure compared with numbers in BAL obtained prior to exposure ([Sandström et al., 1992b](#)). In contrast, no changes in lymphocyte subpopulations were reported following repeated exposure to 600 ppb NO<sub>2</sub> (4 exposures over 6 days), with the exception of a slight increase in natural killer cells ([Rubinstein et al., 1991](#)).

Recently, a controlled human exposure study investigated the effects of repeated NO<sub>2</sub> exposure on eosinophilic airway inflammation in subjects with atopic asthma ([Ezratty et al., 2014](#)). Subjects were exposed to 200 or 600 ppb NO<sub>2</sub> for 30 minutes on the first day and twice for 30 minutes on the second day. Compared with baseline, the number and percentage of eosinophils and the amount of eosinophil cationic protein (ECP) in sputum were significantly increased after the three exposures to 600, but not 200 ppb NO<sub>2</sub>. Furthermore, ECP was highly correlated with eosinophil counts in sputum. No increases

in either of these parameters were observed 6 hours after the first exposure to 600 ppb NO<sub>2</sub>. While the design of this study did not include an allergen challenge, several other studies examined eosinophilic inflammation and other allergic responses to NO<sub>2</sub> and an allergen (Sections [4.3.2.6.2](#), [4.3.2.6.3](#), and [5.2.2.5](#)). Studies investigating eosinophilic inflammation suggest that exposure to NO<sub>2</sub> may prime eosinophils for subsequent activation by allergens in previously sensitized individuals ([Davies et al., 1997](#); [Wang et al., 1995b](#)).

Collectively, these studies in animals and humans demonstrate that NO<sub>2</sub> exposure initiated inflammation in the respiratory tract. Responses included increases in eicosanoids, cytokines, neutrophils, and eosinophils in the airways. Many, but not all, of these studies involved ambient-relevant exposures to NO<sub>2</sub>.

---

#### 4.3.2.4 Alteration of Epithelial Barrier Function

Lipid peroxidation and altered phospholipid composition in the respiratory tract following NO<sub>2</sub> exposure may affect membrane fluidity and airway epithelial barrier function. NO<sub>2</sub> exposure-induced inflammation may further impair epithelial barrier function. Increases in vascular permeability may occur, leading to the influx of plasma proteins such as albumin into the airway lumen.

As summarized in the 2008 ISA and the 1993 AQCD for Oxides of Nitrogen ([U.S. EPA, 2008a, c, 1993a](#)), numerous studies have demonstrated increases in biomarkers of increased permeability, such as protein and albumin, as well as biomarkers of cellular injury, such as lactate dehydrogenase (LDH) and shed epithelial cells, in BAL fluid following exposure to NO<sub>2</sub> (Section [5.2.7.4](#)). Because LDH can be oxidatively inactivated, use of this indicator may underestimate the extent of injury during oxidative stress. Many, but not all, of these effects were observed at NO<sub>2</sub> concentrations that are higher than ambient-relevant levels. Notably, one controlled human exposure study found increased albumin levels in BL fluid following 4 consecutive days of 4-hour exposure to 2,000 ppb NO<sub>2</sub> ([Blomberg et al., 1999](#)).

Several studies in experimental animals found that antioxidant deficiency worsened the cellular injury and/or impaired epithelial barrier function following NO<sub>2</sub> exposure. Ascorbate deficiency enhanced protein levels in the BAL fluid of NO<sub>2</sub>-exposed guinea pigs, suggesting a role for BAL fluid ascorbate in preventing the deleterious effects of NO<sub>2</sub> ([Hatch et al., 1986](#)). Similarly,  $\alpha$ -tocopherol deficiency enhanced lipid peroxidation in NO<sub>2</sub>-exposed rats ([Sevanian et al., 1982a](#)). Recently, selenium deficiency was found to enhance the injury response in rats exposed to 1,000–50,000 ppb (acute, subacute, and chronic exposures) NO<sub>2</sub> ([de Burbure et al., 2007](#)). Levels of both BAL fluid total protein

and serum club cell secretory protein were increased in selenium-deficient rats exposed to NO<sub>2</sub>. Selenium supplementation diminished this response, which suggests that the selenium-containing enzyme, glutathione peroxidase, may have played an important mitigating role; however, a role for other selenium-dependent processes cannot be ruled out.

Increases in lung permeability due to high concentrations of NO<sub>2</sub> (100,000 ppb and above) are known to cause death from pulmonary edema ([Lehnert et al., 1994](#); [Gray et al., 1954](#)). At lower concentrations, more subtle effects have been reported. Exposure of rats to 5,000 and 10,000 ppb NO<sub>2</sub> for 3 or 25 days resulted in epithelial degeneration and necrosis and in proteinaceous edema ([Barth et al., 1995](#)), while exposure to 800–10,000 ppb NO<sub>2</sub> for 1 and 3 days resulted in concentration-dependent increases in BAL fluid protein ([Müller et al., 1994](#)). BAL fluid protein was also elevated in guinea pigs exposed for 1 week to 400 ppb NO<sub>2</sub> ([Sherwin and Carlson, 1973](#)).

High concentrations of NO<sub>2</sub> (70,000 ppb; 30 minutes) were found to enhance translocation of instilled antigen from the lung to the bloodstream of guinea pigs ([Matsumura, 1970](#)). More subtle increases in lung permeability due to NO<sub>2</sub> exposure could enhance the translocation of an antigen to local lymph nodes and subsequently to the circulation ([U.S. EPA, 2008c](#); [Gilmour et al., 1996](#)) and/or to the immunocompetent and inflammatory cells underlying the epithelium that are involved in allergic reactions ([Jenkins et al., 1999](#)). However, increased lung permeability following exposure to NO<sub>2</sub> does not always lead to allergic sensitization ([Alberg et al., 2011](#)). Increased epithelial permeability may alternatively contribute to the activation of neural reflexes and the stimulation of smooth muscle receptors by allowing greater access of an agonist ([Dimeo et al., 1981](#)).

Susceptibility to NO<sub>2</sub> exposure-induced lung injury was investigated in several mice strains with differing genetic backgrounds ([Kleeberger et al., 1997](#)). Lavageable total protein, a biomarker for increased lung permeability, was variable among mouse strains following a 3-hour exposure to 15,000 ppb NO<sub>2</sub>. In addition, repeated exposure to NO<sub>2</sub> (10,000 ppb, 6 hour/day, 5 consecutive days) resulted in adaptation of the permeability response in one of the tested strains but not in the other. Although specific genes were not identified, this study provided evidence that genetic components conferred susceptibility to NO<sub>2</sub>, at least in terms of lung permeability.

Collectively, these studies in animals and humans demonstrate that NO<sub>2</sub> exposure increased airway permeability. Responses included increased protein and albumin in BAL or BL fluid and were enhanced by antioxidant deficiency. While many of these studies involved exposures that were at higher concentrations than those considered ambient-relevant, a study in humans and several studies in animals provided evidence of

increased airway permeability following exposure to ambient-relevant concentrations of NO<sub>2</sub>.

---

#### 4.3.2.5 Enhancement of Bronchial Smooth Muscle Reactivity

Exposure to NO<sub>2</sub> enhanced the inherent reactivity of airway smooth muscle in human subjects with and without asthma [(Folinsbee, 1992); Section 5.2.2.1] and in animal models (see below). This “airway responsiveness” is defined as the sensitivity of airways to a variety of natural or pharmacological stimuli (O’Byrne et al., 2009). Airway hyperresponsiveness (AHR) is a key feature of asthma, which is a chronic inflammatory disease of the airways. As summarized in the 2008 ISA for Oxides of Nitrogen (U.S. EPA, 2008c) and in Section 5.2.2.1, numerous studies found that human subjects exposed to NO<sub>2</sub> were more sensitive to the nonspecific stimuli methacholine than human subjects exposed to air. Subjects with asthma exhibited greater sensitivity than subjects without asthma when similarly exposed. In addition, several studies found that NO<sub>2</sub> exposure enhanced airway responsiveness to specific stimuli, such as allergens, in subjects with mild allergic asthma.

Exercise during exposure to NO<sub>2</sub> appeared to modify airway responsiveness in subjects with asthma [(Folinsbee, 1992); Section 5.2.2.1]. Mechanisms by which this occurs are not understood, but two hypotheses have been postulated. First, exercise-induced refractoriness, which has been demonstrated in some subjects with asthma, may alter responsiveness to NO<sub>2</sub> (Magnussen et al., 1986). A second hypothesis is that nitrite formed by reactions of NO<sub>2</sub> in the ELF mediates compensatory relaxation of airway smooth muscle (Folinsbee, 1992). Exercise would increase the total dose of NO<sub>2</sub> to the respiratory tract, thus increasing nitrite formation. Recent studies have shown that RNS have bronchodilatory effects. For example, endogenous RSNOs are an important modulator of airway responsiveness in subjects with asthma and in eosinophilic inflammation (Lee et al., 2011b; Que et al., 2009).

Animal toxicological studies have also demonstrated NO<sub>2</sub>-induced AHR to nonspecific and specific challenges, as summarized in the 2008 ISA and the 1993 AQCD (U.S. EPA, 2008a, c, 1993a) and in Section 6.2.2.3. Exposures ranged from acute to subchronic in these studies, and results suggest that more than one mechanism may have contributed to the observed AHR. Acute exposure of guinea pigs to NO<sub>2</sub> (10 minutes; 7,000 ppb and higher) resulted in concentration-dependent AHR to histamine, which was administered immediately after exposure (Silbaugh et al., 1981). This response was short-lived because no enhanced responsiveness was seen at 2 and 19 hours post-exposure to NO<sub>2</sub>. The rapidity of the response and the concomitant change in respiratory rate suggest enhanced

vagally mediated reflex responses ([Section 4.3.2.2](#)) as a possible underlying mechanism. A 7-day exposure to 4,000 ppb NO<sub>2</sub> also induced AHR to histamine in guinea pigs ([Kobayashi and Shinozaki, 1990](#)). Eicosanoids were proposed to play a role in this response. In addition, a study in mice sensitized and challenged with ovalbumin found that short-term exposure to NO<sub>2</sub> (25,000 ppb, but not 5,000 ppb; 3 days) resulted in AHR to methacholine ([Poynter et al., 2006](#)). This enhanced sensitivity correlated with an increase in numbers of eosinophils, suggesting eosinophilic inflammation as a possible underlying mechanism in this model of allergic airway disease. A subchronic study demonstrated dose-dependent AHR to histamine in NO<sub>2</sub>-exposed guinea pigs [1,000–4,000 ppb, 24 hour/day, 6–12 weeks; ([U.S. EPA, 2008c](#); [Kobayashi and Miura, 1995](#))]. Specific airway resistance in the absence of a challenge agent also was increased, which indicates the development of airway obstruction. This finding suggests airway remodeling as a possible underlying mechanism for AHR. Another subchronic exposure study (5,000 ppb NO<sub>2</sub>, 4 hour/day, 5 days/week, 6 weeks) found a delayed bronchial response, which was measured as increased respiratory rate and was suggestive of AHR, in guinea pigs sensitized and challenged with *Candida albicans* and exposed to NO<sub>2</sub> ([Kitabatake et al., 1995](#)).

Mechanisms underlying the effects of NO<sub>2</sub> on airway responsiveness are not well understood. Effects of NO<sub>2</sub> exposure on redox status in the respiratory tract should be considered because asthma pathogenesis, including airway inflammation, responsiveness, and remodeling, may be under redox control ([Comhair and Erzurum, 2010](#); [Kloek et al., 2010](#)). In support of this mechanism, supplementation with the antioxidant ascorbate was found to prevent nonspecific AHR in subjects with asthma who were exposed to 2,000 ppb NO<sub>2</sub> ([Mohsenin, 1987b](#)).

Several different inflammatory pathways may underlie the increased airway responsiveness following NO<sub>2</sub> exposure ([Krishna and Holgate, 1999](#)). First, mast cell activation may contribute to NO<sub>2</sub> exposure-induced AHR. As discussed in [Section 4.3.2.2](#), acute exposure to NO<sub>2</sub> led to mast cell activation in rats and possibly in human subjects. Histamine released by mast cells can directly bind to receptors on smooth muscle cells and cause contraction. This response would have the appearance of reflex bronchoconstriction but would not involve neural pathways. Secondly, neutrophilic and eosinophilic inflammation, which have been demonstrated following single and repeated exposures to NO<sub>2</sub> ([Section 4.3.2.3](#)), may play a role. Neutrophils and other inflammatory cell types release mediators, such as IL-13, IL-17A, and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), which can alter the calcium sensitivity of the smooth muscle and enhance a contractile response to a stimulus ([Kudo et al., 2013b](#)). Eosinophils can release ECP and other mediators involved in allergen-induced asthmatic responses. This pathway may contribute to the enhanced immune response to allergens demonstrated following

NO<sub>2</sub> exposure ([Section 4.3.2.6.2](#)). Eosinophil release of ECP may also cause damage to the airway epithelium in allergic airway disease ([Ohashi et al., 1994](#)). This damage may result in epithelial shedding and mucociliary dysfunction, which may allow greater access of allergens to the airway epithelium and submucosa. In addition, epithelial shedding may lead to greater exposure of sensory nerve endings on nerve fibers and to enhanced activation of neural reflexes and airway smooth muscle contraction ([Hesterberg et al., 2009](#); [Cockcroft and Davis, 2006c](#)). These processes may explain the close relationship that has been observed between epithelial shedding and AHR ([Ohashi et al., 1994](#)). Thus, neutrophilic and/or eosinophilic airway inflammation following NO<sub>2</sub> exposure may contribute to AHR through the release of mediators or by impairing epithelial barrier function ([Section 4.3.2.4](#)). Thirdly, chronic airway inflammation may cause structural changes in the airway walls that enhance the contractile response of the smooth muscle to a given stimuli ([Cockcroft and Davis, 2006c](#)).

Evidence also supports a role for endogenous NO<sub>2</sub> in mediating AHR. Increased peroxynitrite formation occurs during inflammatory states, resulting from the reaction of NO and superoxide. Peroxynitrite subsequently reacts with CO<sub>2</sub> to form nitrosoperoxylcarbonate anion, which decomposes to carbonate radical and NO<sub>2</sub> ([Section 4.2.2.4](#)). Recent studies provided evidence that endogenous peroxynitrite contributes to AHR in animal models of allergic airway disease ([Section 4.3.2.6.2](#)). These studies demonstrate that NO metabolism is dysfunctional in inflamed lungs and results in enhanced peroxynitrite formation. Amelioration of the dysfunction resulted in less oxidative stress, airway remodeling and airway responsiveness ([Ahmad et al., 2011](#); [Mabalirajan et al., 2010b](#); [Maarsingh et al., 2009](#); [Maarsingh et al., 2008](#)). These studies highlight the possibility that inhaled NO<sub>2</sub> can add to the lung burden of endogenous NO<sub>2</sub>, which contributes to AHR and allergic airway disease in animal models ([Section 4.3.2.6.2](#)).

Collectively, these studies in animals and humans demonstrate that NO<sub>2</sub> exposure enhanced bronchial smooth muscle reactivity. The majority of these studies involved ambient-relevant exposures to NO<sub>2</sub>. Antioxidant supplementation reduced this response in humans. Experimental studies in animals suggest the involvement of mast cells, neutrophilic and eosinophilic inflammation, airway remodeling, and endogenous NO<sub>2</sub> in enhancing bronchial smooth muscle reactivity.

---

#### **4.3.2.6 Modification of Innate/Adaptive Immunity**

Host defense depends on effective barrier function and on innate and adaptive immunity ([Al-Hegelan et al., 2011](#)). The effects of NO<sub>2</sub> on barrier function in the airways were

discussed above ([Section 4.3.2.4](#)). This section focuses on the mechanisms by which exposure to NO<sub>2</sub> could impact innate and adaptive immunity. Both tissue damage and foreign pathogens are triggers for the activation of the innate immune system. Innate immune system activation results in the influx of inflammatory cells, such as neutrophils, mast cells, basophils, eosinophils, monocytes, and dendritic cells, and the generation of cytokines, such as TNF- $\alpha$ , IL-1, IL-6, keratinocyte chemoattractant, and IL-17. Further, innate immunity encompasses complement, collectins, and the phagocytic functions of macrophages, neutrophils, and dendritic cells. In addition, the airway epithelium contributes to innate immune responses. Innate immunity is highly dependent on cell signaling networks involving toll-like receptor (TLR) 4 in airway epithelium and other cell types. Adaptive immunity provides immunologic memory through the actions of B and T lymphocytes. Important links between the two systems are provided by dendritic cells and antigen presentation.

#### **4.3.2.6.1 Impairment of Host Defenses**

As summarized in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008a, c](#)), potential mechanisms by which NO<sub>2</sub> exposure may impair host defenses include ciliary dyskinesia, damage to ciliated epithelial cells, and altered alveolar macrophage function, all of which may contribute to altered mucociliary transport and/or clearing infectious and noninfectious particles from the lung. Altered alveolar macrophage function and other potential mechanisms, such as increases in pro-inflammatory mediators and cytokines, increased immunoglobulin E (IgE) concentrations, interactions with allergens, and altered lymphocyte subsets, reflect modification of innate and/or adaptive immunity. These changes may underlie susceptibility to infection, which has been observed in animals exposed to NO<sub>2</sub> ([Section 5.2.5.1](#)). Furthermore, dosimetric considerations suggest that inhaled NO<sub>2</sub> may diffuse partly through the ELF in the tracheobronchial region before reacting with ELF solutes ([Section 4.2.2.1.3](#)). Diffusion may allow NO<sub>2</sub> to reach cilia before transforming into other products. Thus, NO<sub>2</sub> may impact the structure or function of cilia.

Controlled human exposure studies have demonstrated reduced mucociliary activity due to depressed ciliary function, depressed phagocytic activity, and superoxide production in alveolar macrophages, and altered humoral- and cell-mediated immunity following exposure to 1,500–4,000 ppb NO<sub>2</sub> for a few hours [([Frampton et al., 2002](#); [Devlin et al., 1999](#); [Helleday et al., 1995](#); [Sandström et al., 1992a](#); [Sandström et al., 1992b](#); [Sandström et al., 1991](#)); [Section 5.2.5.4](#)]. Studies involving repeated daily exposure to 1,500 ppb NO<sub>2</sub> (but not 600 ppb NO<sub>2</sub>) found reductions in lymphocyte subpopulations ([Sandström et al., 1992b](#); [Rubinstein et al., 1991](#); [Sandström et al., 1990](#)). Furthermore, repeated daily

exposure to 2,000 ppb NO<sub>2</sub> resulted in upregulation of ICAM-1 in bronchial biopsy specimens ([Pathmanathan et al., 2003](#)). These findings suggest a potential mechanism underlying susceptibility to viral infection because ICAM-1 is a major receptor for rhinoviruses and respiratory syncytial viruses. Finally, enhanced susceptibility of airway epithelium to influenza viral infection was suggested in a study involving exposure to 1,000–3,000 ppb NO<sub>2</sub> over 3 days, although the study results did not achieve statistical significance ([Goings et al., 1989](#)). Humans exposed to 600 and 1,500 ppb NO<sub>2</sub> for 3 hours exhibited an increased injury response, as measured in bronchial epithelial cells, resulting from influenza and respiratory syncytial virus ([Frampton et al., 2002](#)). Epidemiologic evidence for associations between exposure to NO<sub>2</sub> and increased respiratory infections is somewhat inconsistent ([Sections 5.2.5.2 and 5.2.5.3](#)).

As summarized in the 2008 ISA and 1993 AQCD for Oxides of Nitrogen ([U.S. EPA, 2008a, c, 1993a](#)), studies in NO<sub>2</sub>-exposed animals (500–10,000 ppb) have demonstrated altered mucociliary clearance and several changes in alveolar macrophages. These changes include morphological evidence of damage to alveolar macrophages (membrane bleb formation and mitochondrial damage), decreased viability, and decreased function (decreased superoxide production, decreased phagocytic capacity, and decreased migration towards a stimulus) ([Robison et al., 1993](#); [Davis et al., 1992](#); [Rose et al., 1989b](#); [Schlesinger et al., 1987](#); [Schlesinger and Gearhart, 1987](#); [Suzuki et al., 1986](#); [Greene and Schneider, 1978](#); [Dowell et al., 1971](#)). A recent study involving exposure to 20,000 ppb NO<sub>2</sub> demonstrated nitration of SP-D, a surfactant protein that functions as a collectin ([Matalon et al., 2009](#)). Nitration was accompanied by cross-linking and a decrease in SP-D aggregating activity, which could impact the role of SP-D in microbial clearance and surfactant metabolism. Infectivity models have shown increased mortality and decreased bactericidal activity ([U.S. EPA, 2008c](#); [Jakab, 1987](#); [Miller et al., 1987](#); [Ehrlich, 1980](#); [Ehrlich et al., 1977](#)) as a result of NO<sub>2</sub> exposure ([Sections 5.2.5.1 and 6.2.7](#)).

Collectively, these studies in animals and humans demonstrate that NO<sub>2</sub> exposure impaired host defense. Responses in humans included reduced mucociliary activity and altered humoral and cell-mediated immunity, while responses in experimental animals included changes in alveolar function and SP-D nitration. Many of these studies involved ambient-relevant exposures to NO<sub>2</sub>.

#### **4.3.2.6.2 Exacerbation of Allergic Airway Disease**

Inhaled allergens activate an acute immune response in allergen-sensitive individuals. This response is characterized by early and late phases. Key players in the early asthmatic response are mast cells and basophils, which release mediators following allergen binding

to IgE receptors on their cell surfaces. These mediators include histamine and cysteinyl leukotrienes, which bind airway smooth muscle receptors and induce contraction. Mediators also activate T lymphocyte subsets (i.e., CD4<sup>+</sup> T cells), resulting in the release of Th2 cytokines that can recruit mast cells and cause airway smooth muscle contraction. Th2 cytokines also promote the influx and activation of eosinophils and neutrophils. Airway mucosal eosinophilia is characteristic of asthma and rhinitis. Eosinophils exert their effects via degranulation and cytolysis, resulting in release of ECP and other mediators ([Erjefält et al., 1999](#)). Th2 cytokines also activate B lymphocytes, resulting in the production of allergen-specific IgE. These responses initiated by Th2 cytokines contribute to the late asthmatic response, which is characterized by airway obstruction generally occurring 3–8 hours following an antigen challenge ([Cockcroft and Davis, 2006c](#)), and to other responses occurring greater than >8 hours following an antigen challenge.

### **Exogenous Nitrogen Dioxide**

As summarized in the 2008 ISA ([U.S. EPA, 2008c](#)) and in [Section 5.2.2.1](#), exposure to NO<sub>2</sub> affects the acute immune response to inhaled allergens. Several controlled human exposure studies found that NO<sub>2</sub> exposure enhanced airway responsiveness to specific stimuli, such as house dust mite (HDM) allergen ([Jenkins et al., 1999](#); [Tunnicliffe et al., 1994](#)) in subjects with mild allergic asthma. Further, repeated exposure to NO<sub>2</sub> resulted in an enhanced response to a dose of allergen that was asymptomatic when given alone ([Strand et al., 1998](#)). Airway responses were measured during the first 2 hours after allergen challenge which falls within the timeline of the early phase asthmatic response. These results provide evidence that NO<sub>2</sub> exposure exacerbates the early phase asthmatic response to allergen challenge, as measured by enhanced contraction of airway smooth muscle cell.

Controlled human exposure studies also demonstrated that NO<sub>2</sub> exposure exacerbated the late phase asthmatic response to allergen challenge in subjects with mild allergic asthma. Airway obstruction, measured as a spontaneous fall in FEV<sub>1</sub> occurring after resolution of the early asthmatic response (generally 3–8 hours after an antigen challenge), was observed in subjects with asthma exposed to 400 ppb NO<sub>2</sub> for 1 hour ([Tunnicliffe et al., 1994](#)) and to 250 ppb NO<sub>2</sub> for 30 minutes for 4 consecutive days ([Strand et al., 1998](#)). Other studies measured cell counts and mediators characteristic of the late phase asthmatic response. Increased numbers of neutrophils and increased levels of ECP in BAL and BL fluid, both indicators of inflammatory response to allergen challenge, were reported following exposure to 260 ppb NO<sub>2</sub> for 15–30 minutes ([Barck et al., 2005a](#); [Barck et al., 2002](#)). Furthermore, increased ECP levels were observed in sputum and blood, and an increase in myeloperoxidase (indicator of neutrophil activation) was seen

in blood. In subjects with allergic rhinitis, NO<sub>2</sub> exposure (400 ppb for 6 hours) increased eosinophil activation, measured by ECP in nasal lavage, following nasal allergen provocation ([Wang et al., 1995a](#)). These studies suggest that exposure to NO<sub>2</sub> may prime eosinophils for subsequent activation by an allergen in previously sensitized individuals ([Davies et al., 1997](#); [Wang et al., 1995b](#)). However, another study found decreased sputum eosinophils 6 hours after HDM challenge in subjects with HDM-sensitive allergic asthma exposed to 400 ppb NO<sub>2</sub> for 3 hours ([Witten et al., 2005](#)).

Late phase allergic responses were also investigated in animal models of allergic airway disease ([Section 5.2.2.5](#)). Increased specific immune response to HDM allergen, including enhanced antigen-specific serum IgE, and increased lung inflammation were demonstrated in Brown Norway rats sensitized to and challenged with HDM allergen followed by 3-hour exposure to 5,000 ppb NO<sub>2</sub> ([Gilmour et al., 1996](#)). Similarly, a recent study showed that NO<sub>2</sub> exposure (25,000 ppb, 6 hour/day for 3 days) increased the degree and duration of the allergic inflammatory response in mice sensitized and challenged with ovalbumin ([Poynter et al., 2006](#)). Both neutrophilic and eosinophilic airway inflammation were found in these studies; exposure of mice to a lower concentration of NO<sub>2</sub> (5,000 ppb) failed to induce this response. Two other studies in ovalbumin-sensitized and ovalbumin-challenged mice found decreased eosinophilic inflammation in response to 5,000 ppb NO<sub>2</sub>; however, one of these studies found an increase in eosinophils following exposure to 20,000 ppb NO<sub>2</sub> ([Hubbard et al., 2002](#); [Proust et al., 2002](#)). This increase in eosinophils was accompanied by increased levels of eosinophil peroxidase, a marker of activation. Both responses were observed 3 days, but not 1 day, after the 3-hour NO<sub>2</sub> exposure. These results in animal models provide some evidence of NO<sub>2</sub>-mediated enhancement of late phase allergic responses, albeit in many cases at higher concentrations than those considered ambient relevant. It is important to note that eosinophil activation and eosinophil influx reflect different processes and that only the study by [Hubbard et al. \(2002\)](#) measured markers of activation. The ovalbumin-sensitized and ovalbumin-challenged mouse model may not mimic the eosinophil degranulation and cytolysis that are characteristic of asthma and allergic rhinitis in humans ([Malm-Erjefält et al., 2001](#)). Hence, interspecies differences may account for the differing results of animal and controlled human exposure studies.

Collectively, these studies demonstrate that inhaled NO<sub>2</sub> enhanced both early and late phase responses to inhaled allergens in humans with asthma and allergy. Furthermore, exposure to NO<sub>2</sub> augmented allergic inflammation in some rodent models of allergic airway disease. Many, but not all, of these studies involved ambient-relevant exposures to NO<sub>2</sub>. These results provide evidence for NO<sub>2</sub>-induced exacerbation of allergic airway disease in the presence of an allergen challenge. Evidence for NO<sub>2</sub>-induced airway

eosinophilia in the absence of an allergen challenge was described in [Section 4.3.2.3](#). Hence, NO<sub>2</sub> exposure may lead to asthma exacerbations by multiple pathways.

## Endogenous Nitrogen Dioxide

Several recent animal toxicological studies have explored the role of endogenous NO and peroxynitrite, the latter of which decomposes to form NO<sub>2</sub>, on allergic airway disease in animal models. The decomposition of peroxynitrite to NO<sub>2</sub> is one of the three pathways contributing to the formation of endogenous NO<sub>2</sub> ([Section 4.3.1](#)). In one study, upregulating the enzyme endothelial nitric oxide synthase (eNOS; and presumably NO production) decreased airway inflammation, airway remodeling, and airway responsiveness in a mouse model of asthma ([Ahmad et al., 2011](#)). Asthma phenotype-related features, such as cell infiltrates, mucus hypersecretion, peribronchial collagen, and Th2 cytokines, were also diminished. Further, decreased inducible nitric oxide synthase (iNOS) expression and 3-nitrotyrosine immunostaining in the airway epithelium were reported, as were diminished epithelial injury and apoptosis. Because 3-nitrotyrosine is a marker of NO<sub>2</sub>/peroxynitrite formation, these findings suggest that an increase in NO may have resulted in reduced peroxynitrite. While it is known that NO rapidly reacts with superoxide to form peroxynitrite and that superoxide levels are increased in inflammation, it is also known that excess NO will react with peroxynitrite and quench peroxynitrite's reactivity. In fact, [Stenger et al. \(2010\)](#) found that high concentrations of inhaled NO (10,000 ppb) prevented the formation of 3-nitrotyrosine in the lungs of neonatal mice exposed to hyperoxia.

In a second set of studies, increased levels of the NOS substrate L-arginine were found to decrease airway inflammation and airway responsiveness in a guinea pig model of asthma ([Maarsingh et al., 2009](#)). Similarly, increased L-arginine levels reduced peroxynitrite formation and airway responsiveness in a mouse model of asthma ([Mabalirajan et al., 2010b](#)). Markers of allergic inflammation (e.g., eosinophilia and Th2 cytokines), markers of oxidative and nitrative stress, and markers of airway remodeling, such as goblet cell metaplasia and subepithelial fibrosis, were also decreased. Further, increased L-arginine levels reduced mitochondrial dysfunction and airway injury ([Mabalirajan et al., 2010a](#)). Limited availability of L-arginine is known to uncouple NOS enzyme activity, resulting in the production of superoxide in addition to NO. This situation is commonly found in disease models and leads to peroxynitrite formation. Increasing L-arginine availability is a common strategy used to prevent enzyme uncoupling and peroxynitrite formation. Another approach was employed in a study by [North et al. \(2009\)](#) where inhibition of the enzyme arginase 1 (arginase 1 decreases arginine availability) was found to decrease airway responsiveness in a mouse model of asthma. Similar findings were reported using arginase inhibition in a guinea pig model of

allergic asthma where arginase was upregulated ([Maarsingh et al., 2008](#)). Inhibition of arginase resulted in amelioration of the asthma phenotype. These effects were attributed to decreased enzyme uncoupling, thus promoting the formation of NO, diminishing the generation of superoxide, and reducing the formation of peroxynitrite. In contrast, a different study found that arginase inhibition resulted in increased S-nitrosylated and nitrated proteins, increased inflammation, mucous cell metaplasia, NFκB activation, and increased airway responsiveness in a mouse model of asthma ([Ckless et al., 2008](#)). However, the same study also found reduced levels of antigen-specific IgE and IL-4. Thus, only some features of the asthma phenotype were ameliorated by arginase inhibition. The authors suggested that peroxynitrite, whose presence was indicated by the increase in nitrated proteins in mice treated with arginase, may have contributed to increased airway responsiveness in this model.

Evidence for similar pathways in humans is provided by a study in which endogenous markers of reactive nitrogen and oxygen chemistry were measured in individuals with and without asthma ([Anderson et al., 2011](#)). Levels of total nitrite and nitrate were higher in the BAL fluid of subjects with asthma compared to healthy subjects. In subjects with asthma, upregulation of iNOS was observed, and it was greater in distal airways compared with more proximal airways. In addition, levels of dihydroethidium-positive cells, which are capable of producing ROS (such as superoxide), were higher in both the BL and BAL fluid of subjects with asthma compared with healthy subjects. Levels of arginase were also higher in BAL fluid of subjects with asthma compared with healthy subjects. These results suggest that uncoupling of NOS and/or NOS dysfunction, resulting in enhanced peroxynitrite/NO<sub>2</sub> formation, may contribute to the asthma phenotype in human subjects. These findings also provide biological plausibility for results of another study demonstrating a correlation between increased airway responsiveness and the induction of iNOS, the induction of arginase, and the production of superoxide in subjects with asthma.

Collectively, these studies provide evidence that the balance between endogenous NO and peroxynitrite influenced features of the asthma phenotype in animal models of allergic airway disease and possibly in adults with asthma. Enhanced levels of superoxide, which are characteristic of asthma and other inflammatory states, favored the formation of peroxynitrite at the expense of NO. Evidence from experimental studies indicated that peroxynitrite and other RNS are found in and contribute to allergic airway disease in animal models. Thus, inhaled NO<sub>2</sub> may exacerbate allergic airway disease by adding to the lung burden of RNS in inflammatory states.

#### 4.3.2.6.3 T-Helper Cell 2 Skewing and Allergic Sensitization

A controlled human exposure study demonstrated that repeated daily exposures of healthy adults to NO<sub>2</sub> resulted in increased expression of the interleukins IL-5, IL-10, IL-13, and the protein ICAM-1 in the respiratory epithelium following the last exposure [([Pathmanathan et al., 2003](#)); [Section 5.2.7.4](#)]. These interleukins are characteristic of a Th2 inflammatory response. IL-5 is known to promote eosinophilia, while IL-13 is known to promote mucus production and AHR ([Bevelander et al., 2007](#)). These findings suggest a potential mechanism whereby repeated exposure to NO<sub>2</sub> may exert a pro-allergic influence. Further, upregulation of ICAM-1 suggests a potential mechanism for leukocyte influx. A separate study by these same investigators found persistent neutrophilic inflammation following the 4 days of repeated exposure ([Blomberg et al., 1999](#)).

In addition, two studies in animals examined the effects of longer term exposures to NO<sub>2</sub> on the development of allergic responses ([Sections 5.2.7.4](#) and [6.2.2.3](#)). In one study, exposure of guinea pigs to 3,000 or 9,000 ppb NO<sub>2</sub> increased the numbers of eosinophils in nasal epithelium and mucosa after 2 weeks ([Ohashi et al., 1994](#)). In the other, exposure to 4,000 ppb NO<sub>2</sub> for 12 weeks led to enhanced IgE-mediated release of histamine from mast cells isolated from guinea pigs ([Fujimaki and Nohara, 1994](#)). This response was not found in mast cells from rats similarly exposed. Both studies provide further evidence for NO<sub>2</sub> having a pro-allergic influence.

Furthermore, a recent study in mice provides evidence that NO<sub>2</sub> may act as an adjuvant promoting the development of allergic airway disease in response to a subsequent inhalation exposure to ovalbumin ([Bevelander et al., 2007](#)). Findings included AHR, mucous cell metaplasia, and eosinophilic inflammation. In addition, ovalbumin-specific IgE and IgG1, CD4<sup>+</sup> T cells biased toward Th2, and a T helper cell 17 (Th17) phenotype in the blood were demonstrated. These results are consistent with an allergic asthma phenotype in humans. The eosinophilic inflammation, mucus gene upregulation, and ovalbumin-specific IgE production were found to be dependent on TLR2 and myeloid differentiation primary response gene (88) pathways. TLR2 is known to promote maturation of dendritic cells, inflammation, and Th2 skewing. A subsequent study in the same model found that NO<sub>2</sub> exposure had several effects on pulmonary CD11c<sup>+</sup> dendritic cells, including increased cytokine production, upregulation of maturation markers, increased antigen uptake, migration to the lung-draining lymph node, and improved ability to stimulate naïve CD4<sup>+</sup> T cells ([Hodgkins et al., 2010](#)). Dendritic cells are key players in adaptive immune responses by regulating CD4<sup>+</sup>-mediated T cell responses through the presentation of antigens in the draining lymph node. Further, dendritic cells can express a distinct pattern of co-stimulatory molecules and produce cytokines that

create an environment for T cell polarization, thus skewing the T helper cell response. Changes reported in these two studies are consistent with the promotion of allergic sensitization and suggest a role for TLR2 in mediating this effect. A third study by these same investigators found that NO<sub>2</sub> exposure resulted in antigen-specific IL-17A generation from Th17 cells, which is characteristic of the severe asthma phenotype that is unresponsive to glucocorticoid treatment in humans ([Martin et al., 2013](#)). Although all studies involved 1-hour exposures to high concentrations of NO<sub>2</sub> (10,000–15,000 ppb), they are included here because they describe potentially new mechanisms by which inhaled NO<sub>2</sub> may exert its effects. It should additionally be noted that airway inflammation was seen in mice exposed to 15,000 ppb, but not to 10,000 ppb, NO<sub>2</sub> for 1 hour and that pulmonary damage was minimal in this model ([Martin et al., 2013](#)).

In contrast, a similar study failed to find that NO<sub>2</sub> acted as an adjuvant in a mouse model of allergic airway disease ([Alberg et al., 2011](#)). The exposure consisted of 5,000 or 25,000 ppb NO<sub>2</sub> for 4 hours and followed exposure to ovalbumin which was administered intra-nasally. Adjuvant activity was measured as the production of allergen-specific IgE antibodies. Methodological differences in study design with respect to the timing of ovalbumin and NO<sub>2</sub> exposures and the route of ovalbumin exposure may account for differences in findings between this study and others. In fact, [Bevelander et al. \(2007\)](#) found that NO<sub>2</sub> promoted allergic sensitization when NO<sub>2</sub> exposure occurred before, but not after, ovalbumin exposure.

It has been hypothesized that both endogenous and exogenous ROS and/or RNS can alter the balance between tolerance and allergic sensitization from an inhaled agent ([Ckless et al., 2011](#)). Some activities of dendritic cells and T cells, such as maturation of the antigen presenting capacity of dendritic cells, dendritic cell stimulation of CD4<sup>+</sup> T cells, and polarization of T cells, are redox sensitive. Endogenous ROS and RNS are produced by a variety of respiratory tract cells, including epithelial cells, dendritic cells, T lymphocytes, macrophages, neutrophils, and eosinophils, especially during inflammation. Peroxynitrite formation, myeloperoxidase activity and/or nitrite acidification may also be enhanced during inflammation and contribute to endogenous NO<sub>2</sub> levels. ROS and RNS are thought to promote the allergic phenotype. Air pollution-derived exogenous ROS and RNS can potentially contribute to oxidative and/or nitrative stress in the respiratory tract and influence the adaptive immune response that occurs once dendritic cells are activated. Thus, recent studies suggest the possibility of an interaction between inhaled NO<sub>2</sub> and the NO<sub>2</sub> endogenously formed in the respiratory tract.

Collectively, these studies in humans and animals provide evidence that NO<sub>2</sub> exposure can lead to the development of allergic responses in nonallergic individuals or animals via Th2 skewing and allergic sensitization. Many, but not all, of these studies involved

ambient-relevant exposures to NO<sub>2</sub>. It should also be noted that increased prevalence of allergic sensitization was found in a few epidemiologic studies in relation to NO<sub>2</sub> exposure ([Section 6.2.4.1](#)).

---

#### 4.3.2.7 Remodeling of Airways and Alveoli

As summarized in the 2008 ISA and the 1993 AQCD for Oxides of Nitrogen ([U.S. EPA, 2008a, c, 1993a](#)), numerous studies have examined morphological changes in the respiratory tract resulting from chronic NO<sub>2</sub> exposure. The sites and types of morphological lesions produced by exposure to NO<sub>2</sub> were similar in all species when effective concentrations were used ([U.S. EPA, 1993a](#)). The centriacinar region, including the terminal conducting airways, the alveolar ducts, and the alveoli, exhibited the greatest sensitivity to NO<sub>2</sub> exposure, while the nasal cavity was minimally affected. The cells most injured in the centriacinar region were the ciliated cells of the bronchiolar epithelium and the Type I cells of the alveolar epithelium. These were replaced with nonciliated bronchiolar cells and Type II cells, respectively, which were relatively resistant to continued NO<sub>2</sub> exposure. Some lesions rapidly resolved post-exposure. One study found that collagen synthesis rates were increased in NO<sub>2</sub>-exposed rats. Because collagen is an important structural protein in the lung and because increased total lung collagen is characteristic of pulmonary fibrosis, it was proposed that NO<sub>2</sub> exposure may cause fibrotic-like diseases. Exposure to NO<sub>2</sub> also enhanced pre-existing emphysema-like conditions in animal models ([U.S. EPA, 2008c](#)). Other studies demonstrated that NO<sub>2</sub> exposure induced air space enlargements in the alveolar region and suggested that chronic exposures could result in permanent alterations resembling emphysema-like diseases ([U.S. EPA, 1993a](#)). A recent study confirmed and extended these findings. NO<sub>2</sub> exposure in rats (10,000 ppb for 21 days) caused increased apoptosis of alveolar epithelial cells and enlargement of air spaces ([Fehrenbach et al., 2007](#)). Further, alveolar septal cell turnover was increased, and changes in extracellular matrix were reported. However, there was no loss of alveolar walls (i.e., total alveolar wall volume or total alveolar surface area), indicating that the lesions induced did not meet the 1985 National Heart, Lung, and Blood Institute definition of human emphysema ([U.S. EPA, 1993a](#)).

A chronic-duration study in rats exposed to 9,500 ppb NO<sub>2</sub> for 7 hour/day, 5 days/week for 24 months found an additional effect on morphology ([Mauderly et al., 1990](#)). Bronchiolar epithelium was observed in centriacinar alveoli, and this response progressed with increasing length of exposure. This has been termed “alveolar bronchiolization” ([Nettesheim et al., 1970](#)), reflecting the replacement of one type of epithelium by another. Long-term consequences of alveolar bronchiolization are not known.

The relationship between NO<sub>2</sub> exposure-induced morphologic changes in animal models and impaired lung development seen in epidemiological studies is not clear. Effects of NO<sub>2</sub> exposure on lung morphology in rats have been shown to be age dependent ([U.S. EPA, 2008a, c, 1993a](#)). Six-week-old rats exposed to NO<sub>2</sub> for 6 weeks were more sensitive to the effects of NO<sub>2</sub> exposure than 1-day-old rats exposed for 6 weeks ([Chang et al., 1986](#)). In humans, the respiratory and immune systems are immature in newborns, and the respiratory system continues to develop until about 20 years of age. This suggests the potential for NO<sub>2</sub> exposure-induced permanent morphological changes in humans if exposure should occur during critical windows of development. However, experimental evidence to substantiate this claim is currently lacking.

Evidence from animal models of allergic airway disease suggests a role for endogenous NO<sub>2</sub> in airway remodeling. These studies, described above in [Section 4.3.2.6.2](#), found that decreased NO bioavailability during inflammation favored the formation of peroxynitrite, which decomposes to NO<sub>2</sub>. Interventions that reduced peroxynitrite formation, as evidenced by decreased 3-nitrotyrosine immunostaining, resulted in an amelioration of airway remodeling, as measured by mucus hypersecretion, peribronchial collagen, goblet cell metaplasia, subepithelial fibrosis, and epithelial apoptosis ([Ahmad et al., 2011](#); [Mabalirajan et al., 2010b](#)). Exposure to inhaled NO<sub>2</sub> was found to enhance allergic airway inflammation and airway responsiveness in experimental animals previously sensitized and challenged with an allergen ([Poynter et al., 2006](#)). Airway remodeling was not evaluated in this study which involved acute exposures to NO<sub>2</sub>. Whether repeated or chronic exposures to NO<sub>2</sub> lead to airway remodeling in the context of allergic airway disease is not known. However, in nonallergic guinea pigs, subchronic exposure to NO<sub>2</sub> (60–4,000 ppb, 24 hour/day, 6–12 weeks) enhanced both airway responsiveness and specific airway resistance, suggesting that airway remodeling may have contributed to the development of AHR ([Kobayashi and Miura, 1995](#)).

Collectively, these studies in animals demonstrate that NO<sub>2</sub> exposure altered respiratory tract morphology. This included lesions in the centriacinar region and the alveolar region. Many, but not all, of these studies involved higher than ambient-relevant exposures to NO<sub>2</sub>. A role for endogenous NO<sub>2</sub> in airway remodeling has also been demonstrated in allergic animals. Increased specific airway resistance, a physiologic change, suggests that subchronic exposure to ambient-relevant concentrations of NO<sub>2</sub> may also lead to airway remodeling.

---

#### 4.3.2.8 Potential Induction of Carcinogenesis

Some studies have explored the potential carcinogenicity of NO<sub>2</sub>. There is no clear evidence that NO<sub>2</sub> acts as a carcinogen [(U.S. EPA, 2008a, c, 1993a); Section 6.6.9]. However, NO<sub>2</sub> may act as a tumor promoter at the site of contact, possibly due to its ability to produce cellular damage and promote regenerative cell proliferation. In addition, it has been shown to be genotoxic and mutagenic in some systems, including human nasal epithelial mucosa cells ex vivo exposed to urban-level concentrations [100 ppb; (Koehler et al., 2011, 2010)]. Some studies demonstrated that inhaled NO<sub>2</sub> at high concentrations (e.g., 20,000 ppb) can contribute to the formation of mutagens and carcinogens if other precursor chemicals are found in the body (e.g., N-nitrosomorpholine from morpholine and nitro-pyrene from pyrene) [(U.S. EPA, 2008c); Section 4.2.2.5].

---

#### 4.3.2.9 Transduction of Extrapulmonary Responses

While the respiratory tract has been viewed as the primary target of inhaled NO<sub>2</sub>, effects outside the respiratory tract have been demonstrated in numerous controlled human exposure and toxicological studies (U.S. EPA, 2008a, c, 1993a). These include hematological effects and effects on the heart, central nervous system, liver, and kidneys and on reproduction and development. Epidemiologic evidence of associations between NO<sub>2</sub> exposure and some extrapulmonary effects has also been described (Sections 5.3, 6.3 and 6.4).

Some NO<sub>2</sub>-induced effects that have been demonstrated are briefly described here. Two controlled human exposure studies involving NO<sub>2</sub> inhalation over several hours found effects on circulating red blood cells, including reduced hemoglobin and hematocrit levels; one of these also found reduced acetylcholinesterase activity [(Frampton et al., 2002; Posin et al., 1978); Section 5.3.10]. Changes in lymphocyte numbers and subsets in the peripheral blood have been demonstrated in human subjects following exposure to NO<sub>2</sub> (Frampton et al., 2002; Sandström et al., 1992a). A recent controlled human exposure study found altered blood lipids (Huang et al., 2012b). Studies in experimental animals have demonstrated decreases in red blood cell number as well as increases in diphosphoglycerate, sialic acid, and methemoglobin following several days of NO<sub>2</sub> exposure (Section 5.3.10). However, changes in hematocrit and hemoglobin did not occur following longer term exposure to NO<sub>2</sub>. Increases in blood glutathione levels and altered blood lipids resulting from NO<sub>2</sub> exposure have also been reported (U.S. EPA, 2008c). More recent studies in rats exposed for 7 days to NO<sub>2</sub> (2,660 or 5,320 ppb NO<sub>2</sub>) have shown mild pathology of brain and heart tissue, which was accompanied by markers of inflammation and/or oxidative stress [(Li et al., 2012a; Li et al., 2011a); Section 5.3.10].

In addition, animal studies demonstrated reproductive and developmental effects resulting from exposure to NO<sub>2</sub> during gestation. These included decreased litter size and neonatal weight and effects on postnatal development ([Section 6.4](#)). Many, but not all, of these extrapulmonary effects in animal models have been observed at concentrations of NO<sub>2</sub> that are higher than ambient-relevant concentrations.

Given the reactivity of NO<sub>2</sub>, extrapulmonary effects are likely due to NO<sub>2</sub>-derived reaction products rather than to NO<sub>2</sub> itself. One pathway by which a reaction product could mediate extrapulmonary effects of NO<sub>2</sub> would be the activation of pulmonary irritant receptors that results in cardiovascular reflex responses ([Section 4.3.2.2](#)). Evidence suggests that the reduction in heart rate observed after acute exposure of experimental animals to high concentrations of NO<sub>2</sub> may be due to stimulation of pulmonary irritant receptors. However, much weaker evidence exists for activation of pulmonary irritant receptors in humans because studies have observed no increases in respiratory rate or decreases in heart rate, which are indicators of pulmonary irritant receptor involvement. A recent controlled human exposure study found altered heart rate variability following exposure to an ambient-relevant concentration of NO<sub>2</sub> [500 ppb; ([Huang et al., 2012b](#))]; whether this effect was due to pulmonary irritant receptor stimulation is unclear.

Alternatively, NO<sub>2</sub>-derived reaction products in the lung may diffuse or migrate into the circulation. One reaction product of inhaled NO<sub>2</sub>, nitrite, is known to gain access to the circulation. In the presence of red blood cell hemoglobin, nitrite is oxidized to nitrate ([Postlethwait and Mustafa, 1981](#)) and nitrosylhemoglobin and methemoglobin are formed. Nitrite has known effects on blood cells, vascular cells, and other tissues. Much recent attention has been paid to nitrite's systemic vasodilatory effects that occur under hypoxic conditions. As discussed in the 2008 ISA and the 1993 AQCD for Oxides of Nitrogen ([U.S. EPA, 2008a, c, 1993a](#)), one controlled human exposure study demonstrated that NO<sub>2</sub> exposure (4,000 ppb, 75 minutes, intermittent exercise) resulted in a reduction in blood pressure ([Linn et al., 1985b](#)), which is consistent with the systemic vasodilatory properties of nitrite under conditions of low oxygen. However, studies from other laboratories did not see this effect ([Section 5.3.6.2](#)). Furthermore, dosimetric considerations suggest that contributions of nitrite derived from ambient NO<sub>2</sub> to plasma levels of nitrite are small compared to nitrite derived from dietary sources ([Section 4.2.2.4](#)).

Besides nitrite and nitrate, other NO<sub>2</sub>-derived reaction products may translocate to the circulation. The formation of fatty acid epoxides followed by transport to the circulation and then to the liver was postulated to explain the effect of NO<sub>2</sub> exposure (250 ppb, 3 hours) on pentobarbital-induced sleeping time in mice ([Miller et al., 1980](#)). Findings of

lipid peroxidation and markers of oxidative stress in some animal studies ([Li et al., 2012a](#); [Li et al., 2011a](#)), which utilized higher than ambient-relevant concentrations of NO<sub>2</sub>, also suggest the presence of circulating ROS or RNS. However, there is no experimental evidence to date for the translocation of NO<sub>2</sub>-derived ROS or RNS to the circulation following NO<sub>2</sub> exposure.

A third pathway by which a NO<sub>2</sub>-derived reaction product may transduce extrapulmonary responses is the diffusion or migration of inflammatory or vasoactive mediators from the lung into the circulation. This possibility is consistent with changes in peripheral blood inflammatory cells and in tissue markers of inflammation that have been observed following exposure to NO<sub>2</sub>. Confirmation that this mechanism occurs in human subjects exposed to ambient-relevant concentrations of NO<sub>2</sub> was provided by a recent study [[\(Channell et al., 2012\)](#); [Section 5.3.10.4](#)]. Exposure of healthy human subjects to NO<sub>2</sub> (500 ppb for 2 hours) resulted in circulating pro-inflammatory factors in the plasma. Application of plasma to cultured endothelial cells resulted in upregulation of ICAM-1 and vascular cell adhesion molecule 1, as well as the release of IL-8 into the supernatant of the cultured cells. Furthermore, the amount of soluble lectin-like receptor for oxidized low-density lipoprotein (sLOX) was increased in plasma obtained 24 hours post-exposure. Changes in plasma high density lipoprotein levels were observed in a separate study employing the same exposure parameters ([Huang et al., 2012b](#)). These findings point to a pathway by which inhaled NO<sub>2</sub> leads to circulating soluble factors that promote inflammatory signaling in the vasculature.

Collectively, these studies demonstrate that NO<sub>2</sub> exposure resulted in extrapulmonary effects in humans and animals. Responses included altered blood lipids and cells, altered pentobarbital-induced sleeping time, altered heart rate variability, increased plasma sLOX, and changes in the brain and heart. Mechanisms underlying these responses are unclear although there is evidence for circulating pro-inflammatory factors. Many of these studies were conducted using ambient-relevant concentrations of NO<sub>2</sub>.

---

### 4.3.3 Nitric Oxide

As summarized in the 2008 ISA and 1993 AQCD for Oxides of Nitrogen ([U.S. EPA, 2008a, c, 1993a](#)) and a recent review ([Hill et al., 2010](#)), the synthesis of endogenous NO in cells is catalyzed by three different isoforms of NOS (eNOS, iNOS, neuronal NOS). NO is involved in intra-cellular signaling in virtually every cell and tissue. In general, low levels of endogenous NO play important roles in cellular homeostasis, while higher levels are important in cellular adaptation and still higher levels are cytotoxic. Further,

signaling functions of NO may be altered in the presence of acute inflammation ([Hill et al., 2010](#)).

Like NO<sub>2</sub>, NO is a radical species [([Fukuto et al., 2012](#)); [Table 4-2](#)]. However, it is more selectively reactive than NO<sub>2</sub> ([Hill et al., 2010](#)). In addition, it is more hydrophobic and can more easily cross cell membranes and diffuse much greater distances compared with NO<sub>2</sub>. As a result, there may be overlap between endogenous and exogenous NO in terms of biological targets and pathways. The following discussion focuses on common mechanisms underlying the effects of both endogenous and exogenous NO.

Because NO has a high affinity for heme-bound iron, many of its actions are related to its interactions with heme proteins ([Hill et al., 2010](#)). For example, activation of the heme protein, guanylate cyclase, is responsible for smooth muscle relaxation and vasodilation of pulmonary and systemic vessels and possibly for bronchodilator effects. Inhaled NO rapidly reacts with soluble guanylate cyclase in the pulmonary arterial smooth muscle. At the same time, inhaled NO rapidly diffuses into the circulation and reacts with red blood cell hemoglobin to form nitrosylhemoglobin, which is subsequently oxidized to methemoglobin and nitrate. Increased blood concentrations of nitrosylhemoglobin and methemoglobin have been reported in mice exposed for 1 hour to 20,000–40,000 ppb NO, as well as in mice exposed chronically to 2,400 and 10,000 ppb NO ([U.S. EPA, 1993a](#)). Some S-nitrosohemoglobin may be formed in partially deoxygenated blood ([Wenmalm et al., 1993](#)). NO can also disrupt iron-sulfur centers in proteins ([Hill et al., 2010](#)). Furthermore, redox reactions of NO and transition metals, such as iron and copper, facilitate S-nitrosylation of protein and nonprotein thiols. Binding of NO to iron- and copper-containing proteins in the mitochondria may play an important role in mitochondrial respiration. NO also rapidly reacts with superoxide, an oxygen-derived radical species, to produce the potent oxidant peroxynitrite ([Hill et al., 2010](#)). Peroxynitrite subsequently reacts with CO<sub>2</sub> to form the nitrosoperoxycarbonate anion, followed by decomposition to carbonate radical and NO<sub>2</sub> ([Section 4.2.2.4](#)).

Endogenous NO is formed in the respiratory tract at high levels ([Section 4.2.3](#)), and it has physiologic functions. The paranasal sinuses are a major source of NO in air derived from the nasal airways, with average levels of 9,100 ppb NO (n = 5) measured in the sinuses ([Lundberg et al., 1995](#)). Expression of iNOS was found to be higher in epithelial cells of the paranasal sinuses than in epithelial cells of the nasal cavity. This NO produced by nasal airways is thought to play a role in sinus host defense through bacteriostatic activity. In addition, NO produced by nasal airways was found to modulate pulmonary function in humans through effects on pulmonary vascular tone and blood flow ([Lundberg et al., 1996](#)). In healthy subjects, a comparison of nasal and oral breathing demonstrated that nasal airway NO enhanced transcutaneous oxygen tension.

In intubated patients, nasal airway NO increased arterial oxygenation and decreased pulmonary vascular resistance. Additionally, endogenous NO has been shown to act as a bronchodilator ([Belvisi et al., 1992](#)). Endogenous NO produced at high concentrations by phagocytic cells is also known to participate in the killing of bacteria and parasites; this contributes to host defense ([U.S. EPA, 2008c](#)). Another effect of endogenous NO on host defense is modulation of ciliary beat frequency ([Jain et al., 1993](#)). Specifically, NO derived from more distal airways was found to increase ciliary beat frequency. Furthermore, endogenous NO production can be upregulated during inflammation ([Anderson et al., 2011](#)). In fact, induction of iNOS in proximal or distal airways of subjects with asthma results in levels of NO in exhaled breath as high as 20–50 ppb [([Alving et al., 1993](#); [Hamid et al., 1993](#)); [Section 4.2.3](#)].

Endogenous NO has known pro- and anti-inflammatory effects; thus its role in inflammatory lung disease is not clear. While both eNOS and iNOS contribute to NO production in the lung, the relatively low levels of NO produced by eNOS are thought to be more important in metabolic homeostasis ([Ahmad et al., 2011](#)). Some evidence points to a role of iNOS-derived NO in the pathogenesis of asthma because it has been correlated with inflammation, epithelial injury, and clinical exacerbations of asthma [([Anderson et al., 2011](#)); [Section 4.3.2.6.2](#)]. Furthermore, iNOS was upregulated to a greater extent in the distal airways than in more proximal airways in subjects with asthma. This is of interest because asthma is a disease of the small airways. As mentioned above, signaling functions of NO may be altered in the presence of acute inflammation ([Hill et al., 2010](#)), which is characterized by enhanced levels of superoxide. Superoxide reacts with NO to form peroxynitrite, which has been shown in animal models to play a role in the pathogenesis of allergic airway disease ([Section 4.3.2.6.2](#)).

NO exposure has been shown to alter pulmonary function, pulmonary morphology, and vascular function ([U.S. EPA, 2008a, c, 1993a](#)). Studies in animals have demonstrated that inhaled NO reverses acute methacholine-induced bronchoconstriction ([Hogman et al., 1993](#); [Dupuy et al., 1992](#)). This reversal was observed with exposures of 5,000 ppb NO in guinea pigs and 80,000 ppb in rabbits. Chronic inhalation exposures have been found to alter the morphology of the alveolar septal units in rats ([Mercer et al., 1995](#)). This effect was not seen with chronic inhalation exposures to NO<sub>2</sub> at similar concentrations (500 ppb with twice daily spikes of 1,500 ppb). In addition, inhaled NO has been shown to alter transferrin and red blood cells in mice. Further, acute inhalation exposure of NO decreased pulmonary vascular resistance in pigs and reduced pulmonary arterial pressure in a rodent model of chronic pulmonary hypertension. A recent study also found that inhaled NO (1,000, 5,000, 20,000, and 80,000 ppb) selectively dilated pulmonary blood vessels, improved ventilation-perfusion mismatch, and reduced hypoxemia-induced pulmonary vascular resistance in a pig model ([Lovich et al., 2011](#)).

Inhaled NO is used clinically at concentrations higher than those that are environmentally relevant. Although it can cause both pulmonary and systemic vasodilation, effects on pulmonary vasculature occur at lower concentrations than those required for vasodilation of systemic vessels. This selectivity for pulmonary vasculature is likely due to the rapid scavenging of NO by hemoglobin in the blood. Hence, inhaled NO has been used to mitigate pulmonary hypertension in newborns and adults. High concentrations of inhaled NO are also known to alter ciliary beating and mucus secretion in the airways, to increase renal output, to alter distribution of systemic blood flow, to alter coagulation, fibrinolysis, and platelet functions, and to modulate the inflammatory response ([U.S. EPA, 2008c](#)).

Endogenous NO is an important mediator of cardiovascular homeostasis. It has anti-inflammatory and antithrombotic effects, is cytoprotective, and induces antioxidant defenses ([Wang and Widlansky, 2009](#)). Two recent studies in animal models demonstrate that high concentrations of inhaled NO may result in vascular toxicity. One of these studies found rapid formation of plasma nitrites/nitrates in rats exposed for 1 hour to 3,000–10,000 ppb NO ([Knuckles et al., 2011](#)). Plasma nitrites/nitrates doubled after an hour of exposure to 3,000 ppb NO and tripled after an hour of exposure to 10,000 ppb NO. These changes were accompanied by an enhanced constriction response to endothelin-1 in coronary arterioles, which reflected altered vasomotor tone. Although this latter effect appears to run counter to the vasodilator role of NO, it should be noted that the high concentrations of NO used in this study are known to inhibit eNOS activity in other models ([Griscavage et al., 1995](#)). The increase in aortic eNOS content reported is consistent with enzyme inactivation and turnover. Another recent animal toxicological study conducted in ApoE<sup>-/-</sup> mice, a model of atherosclerosis, found that exposure to very high concentrations of inhaled NO over the course of a week (17,000 ppb NO for 6 hour/day for 7 days) led to increases in messenger ribonucleic acid for aortic endothelin-1 and matrix metalloproteinase (MMP)-9, as well as to enhanced vascular gelatinase activity ([Campen et al., 2010](#)). These effects, which are biomarkers of vascular remodeling and plaque vulnerability, were not seen with 2,000 ppb NO<sub>2</sub>. The authors suggested that the activity of eNOS was uncoupled, resulting in oxidative stress due to the production of superoxide instead of, or in addition to, NO. Both of these studies suggest that inhaled NO has the potential to disrupt normal signaling processes mediated by endogenous NO.

As mentioned above, endogenous NO plays key signaling roles in virtually every cell and tissue ([Hill et al., 2010](#)) and, as such, is an important mediator of homeostasis. Inhaled NO at high concentrations has the potential to have beneficial or deleterious effects on multiple organ systems. An important consideration is whether effects are mediated by an NO metabolite, by the release of NO from a metabolite that serves as a storage pool of

NO, or through methemoglobin formation in the blood. Further discussion of the biological functions of NO metabolites is found below.

---

#### 4.3.4 Metabolites of Nitric Oxide and Nitrogen Dioxide

---

##### 4.3.4.1 Nitrites/Nitrates

Rapid appearance of nitrite and nitrate in the blood was demonstrated in rats exposed for 1–2 hours to 5,000–40,000 ppb NO<sub>2</sub> ([Oda et al., 1981](#)). Elevated levels of blood nitrite and nitrate were maintained as long as the exposure to NO<sub>2</sub> continued. A small increase in levels of nitrosylhemoglobin, but not methemoglobin, was detected in blood. The lack of accumulation of methemoglobin was likely due to reduction of methemoglobin to hemoglobin catalyzed by methemoglobin reductase. Two other studies measured methemoglobin in the blood of mice exposed to NO<sub>2</sub>, with conflicting results ([U.S. EPA, 1993a](#)). Rapid formation of plasma nitrites/nitrates has also been demonstrated in rats exposed for 1 hour to 3,000–10,000 ppb NO ([Knuckles et al., 2011](#)).

Recently, it has been proposed that nitrite is a storage form of NO because it can be reduced back to NO under conditions of low oxygen tension in a reaction catalyzed by deoxyhemoglobin ([Gladwin et al., 2005](#)). In addition, nitrite is a signaling molecule in its own right and does not require conversion to NO for this activity ([Bryan, 2006](#)). Nitrite can increase cyclic guanosine monophosphate (cGMP) levels and heat shock protein 20 expression, decrease cytochrome P450 activity, and alter heme oxygenase-1 expression ([Bryan et al., 2005](#)). Nitrite is also bactericidal ([Major et al., 2010](#)). Furthermore, under acidic conditions, nitrite can react with thiols to form RSNOs. Nitrite also reacts with hemoglobin to form iron-nitrosyl-hemoglobin and with oxyhemoglobin to form nitrate. Nitrite acts as a vasodilator under hypoxic conditions, through a reaction catalyzed by deoxyhemoglobin ([Cosby et al., 2003](#)). The venous circulation may be more sensitive to nitrite than the arterial circulation ([Maher et al., 2008](#)).

A recent study found that inhaled nitrite decreased pulmonary blood pressure in newborn lambs with hemolysis-induced pulmonary vasoconstriction ([Blood et al., 2011](#)). Nitrite was converted to NO in lung tissue by a mechanism that did not require reaction with deoxyhemoglobin in the circulation. This mechanism resulted in increased exhaled NO gas as well as the relaxation of vascular smooth muscle, which led to pulmonary vasodilation. Although concentrations of inhaled nitrite employed were high (0.87 mol/L sodium nitrite), this study is discussed here because it illustrates a novel biological

activity of lung nitrite that is normally formed by reactions of NO<sub>2</sub> and NO in the ELF and/or the blood.

---

#### 4.3.4.2 S-Nitrosothiols

RSNOs are found endogenously in tissues and extracellular fluids. High concentrations of RSNOs are found in the lung, and their levels may vary depending on disease status ([Que et al., 2009](#)). For example, levels of RSNOs in BAL fluid were higher in individuals with asthma compared with healthy subjects ([Que et al., 2009](#)). Transport of RSNOs from extracellular compartments into isolated perfused lungs and cultured alveolar epithelial cells occurs via a specific amino acid transport pathway ([Torok et al., 2012](#); [Brahmajothi et al., 2010](#)).

Some S-nitrosohemoglobin may be formed in partially deoxygenated blood following inhalation of NO ([Wennmalm et al., 1993](#)). However, inhaled NO mainly reacts with red blood cell hemoglobin to form nitrosylhemoglobin, which is subsequently oxidized to methemoglobin and nitrate ([Hill et al., 2010](#)). The exact mechanisms by which RSNO formation occurs are not completely clear ([Fukuto et al., 2012](#)). NO does not react directly with thiol groups, but it can form RSNOs via reactions with thiyl groups and through intermediate formation of N<sub>2</sub>O<sub>3</sub> or metal nitrosyls, such as nitrosylhemoglobin ([Fukuto et al., 2012](#); [Hill et al., 2010](#)). Recent evidence suggests that NO may diffuse into extracellular fluid and be transformed to RSNOs ([Torok et al., 2012](#); [Brahmajothi et al., 2010](#)). These experiments were conducted ex vivo in isolated perfused lungs and in vitro in cultured lung epithelial cells, neither of which is a blood-perfused system. Hence it is not clear whether this mechanism contributes to RSNO formation in vivo where the majority of inhaled NO diffuses rapidly across the alveolar capillary barrier and binds to hemoglobin.

RSNOs are thought to serve as a storage or delivery form of NO and to play a role in cell signaling ([Fukuto et al., 2012](#); [Hill et al., 2010](#)). They may mediate protein S-glutathionylation and thiol oxidation reactions that can act as redox switches to initiate cell signaling events or alter enzyme activity ([Hill et al., 2010](#)).

In the lung, RSNOs act as endogenous bronchodilators ([Que et al., 2009](#)) and suppress inflammation by decreasing activation of the transcription factor NFκB ([Marshall and Stamler, 2001](#)). Furthermore, augmentation of airway RNSOs by ethyl nitrite inhalation protected against lipopolysaccharide-induced lung injury in an animal model ([Marshall et al., 2009](#)). Several findings suggest an inverse relationship between endogenous airway RSNO levels and airway responsiveness. First, levels of airway S-nitrosoglutathione levels were decreased in children with asthmatic respiratory failure and in adults with

asthma ([Que et al., 2009](#); [Gaston et al., 1998](#)). Second, the enzyme nitrosogluthione reductase (GSNOR), which regulates airway S-nitrosogluthione content, was expressed at higher levels in BAL cell lysates in human subjects with asthma than in healthy subjects ([Que et al., 2009](#)). GSNOR expression was inversely correlated with S-nitrosogluthione content. In addition, GSNOR activity in BAL fluid was increased and was inversely correlated with airway responsiveness in human asthma ([Que et al., 2009](#)). Third, levels of airway RSNOs were inversely correlated with airway responsiveness in human subjects with eosinophilic inflammation ([Lee et al., 2011b](#)).

---

#### 4.3.4.3 Nitrated Fatty Acids and Lipids

Nitration of unsaturated fatty acids and lipids can occur during inflammation and ischemia/reperfusion by reactions with NO and nitrite-derived species. ([Higdon et al., 2012](#); [Khoo et al., 2010](#)). However, there is no firm evidence that these reactions occur following exposure to inhaled NO<sub>2</sub>. Nitrated fatty acids (also known as nitro-fatty acids) can release NO, which stimulates vascular smooth muscle relaxation through cGMP-dependent pathways in vitro ([Lima et al., 2005](#)). However, most of the cell signaling effects of nitrated fatty acids in vivo are likely due to post-translational modification of proteins ([Khoo et al., 2010](#)). These electrophilic species react with susceptible thiol groups in transcription factors ([Higdon et al., 2012](#); [Bonacci et al., 2011](#)).

Nitro-fatty acids, such as nitro-oleic acid and nitro-linoleic acid, are anti-inflammatory ([Bonacci et al., 2011](#)) and vasculoprotective ([Khoo et al., 2010](#)). These effects are mediated via activation of the peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ ) and antioxidant response element (ARE) pathways and suppression of NF $\kappa$ B and signal transducer and activator of transcription 1 pathways ([Bonacci et al., 2011](#)). In a mouse model, nitro-oleic acid upregulated vascular eNOS and heme oxygenase-1 and inhibited angiotensin II-induced hypertension ([Khoo et al., 2010](#); [Zhang et al., 2010a](#)). Nitro-oleic acid protected against ischemia/reperfusion injury in a mouse model ([Rudolph et al., 2010](#)). Nitro-oleic acid also activated MMPs (a pro-inflammatory effect) through thiol alkylation in vitro and inhibited MMP expression in macrophages through activation of PPAR $\gamma$  ([Bonacci et al., 2011](#)). Expression of MMP was also suppressed in a mouse model of atherosclerosis.

---

#### 4.3.4.4 Nitrate Amino Acids and Proteins


Peroxynitrite and NO<sub>2</sub> can react with amino acids to produce nitrated amino acids and proteins ([Hill et al., 2010](#)). These products can also be formed from nitrite and peroxide in a reaction catalyzed by myeloperoxidase. Nitration of proteins may cause inhibition of protein function and/or induce antigenicity. Specific antibodies formed against nitrated proteins may trigger immune reactions ([Daiber and Muenzel, 2012](#)). The presence of nitrated amino acids, such as 3-nitrotyrosine, in cells or tissues is an indicator of NO<sub>2</sub> and/or peroxynitrite formation. A recent animal toxicological study reported formation of nitrated SP-D resulting from in vivo exposure to 20,000 ppb NO<sub>2</sub> ([Matalon et al., 2009](#)). This modification was accompanied by cross-linking and loss of aggregating activity.

---

#### 4.3.5 Mode of Action Framework

This section describes the key events, endpoints, and outcomes that comprise the modes of action proposed for inhaled NO<sub>2</sub> and NO. Here, key events are subclinical effects, endpoints are effects that are generally measured in the clinic, and outcomes are health effects at the organism level. Biological pathways discussed above that may contribute to health effects resulting from short- and long-term exposures to NO<sub>2</sub> and NO ([Chapter 5](#) and [Chapter 6](#)) are summarized as a part of this analysis. These proposed modes of action are based on the available evidence and may not reflect all of the pathophysiology underlying health effects.

[Figure 4-1](#) depicts the proposed mode of action linking respiratory effects to short-term exposure to NO<sub>2</sub>.



Note: Pathways indicated by a dotted line are those for which evidence is limited to findings from experimental animal studies, while evidence from controlled human exposure studies is available for pathways indicated by a solid line. Dashed lines indicate proposed links to the outcomes of asthma exacerbation and respiratory tract infections. Key events are subclinical effects, endpoints are effects that are generally measured in the clinic, and outcomes are health effects at the organism level. NO<sub>2</sub> = nitrogen dioxide; ELF = epithelial lining fluid.

Source: National Center for Environmental Assessment.

**Figure 4-1 Summary of evidence for the mode of action linking short-term exposure to nitrogen dioxide and respiratory effects.**

Because inhalation of NO<sub>2</sub> results in redox reactions in the respiratory tract, the initiating event in the development of respiratory effects is the formation of oxidation and/or nitration products in the ELF and possibly in airway or alveolar epithelium. Reactive intermediates formed are responsible for a variety of downstream key events that may include respiratory tract inflammation and/or oxidative stress, impaired epithelial barrier function, altered mucociliary clearance, activation and/or sensitization of neural reflexes, mast cell degranulation, and increased allergic responses. These key events may collectively lead to several endpoints including bronchoconstriction, AHR, and impaired host defenses. Bronchoconstriction is characteristic of an asthma attack, and AHR often leads to bronchoconstriction in response to a trigger. Thus, the endpoints of bronchoconstriction and AHR may be linked to the outcome of asthma exacerbation (Section 5.2.2), while the endpoint of impaired host defenses may be linked to the outcome of respiratory tract infection (Section 5.2.5).


The strongest evidence for this mode of action comes from controlled human exposure studies. NO<sub>2</sub> exposure resulted in enhanced inflammatory mediators (e.g., eicosanoids,

interleukins) and neutrophils in BL and/or BAL fluid of healthy subjects. Repeated exposure of healthy subjects led to increased albumin levels in BL fluid, suggesting impaired epithelial barrier function. In addition, repeated exposure of subjects with asthma to NO<sub>2</sub> enhanced allergic responses such as increased numbers of eosinophils and levels of a biomarker of eosinophil activation in sputum. Increased airway resistance was demonstrated following NO<sub>2</sub> exposure in healthy human subjects; this response did not involve vagally mediated neural reflexes. There may be a role for mast cell degranulation in mediating the increase in airway resistance in humans; however, evidence for this is indirect as it was based on use of a histamine-suppressive agent. NO<sub>2</sub> exposure also enhanced airway responsiveness to nonspecific challenges, especially in subjects with asthma. Antioxidant supplementation dampened NO<sub>2</sub> exposure-induced lipid peroxidation and airway responsiveness, providing support for in vitro findings implicating redox reactions in the ELF. In addition, both early and late asthmatic responses to an allergen challenge (e.g., AHR, neutrophil, and eosinophil activation) were enhanced by NO<sub>2</sub> exposure. NO<sub>2</sub>-induced impairment of ciliary function and alveolar macrophage phagocytic activity suggested impairment of host defenses.

Experimental studies in animals suggest that vagally mediated neural reflexes, mast cell degranulation, and production of eicosanoids, which may sensitize receptors on nerve fibers and signal the influx of neutrophils, may contribute to NO<sub>2</sub> exposure-induced AHR. Exposure to NO<sub>2</sub> also enhanced allergic responses (e.g., IgE, eosinophilic, and neutrophilic inflammation). Nitration of the collectin protein SP-D and inhibition of its aggregating activity were also observed following exposure to very high concentrations of NO<sub>2</sub>. This may potentially impact microbial clearance and surfactant metabolism. NO<sub>2</sub> exposure-induced alteration of mucociliary clearance and alveolar macrophages has also been demonstrated, suggesting an impairment of host defenses.

Furthermore, there is some evidence for enhanced endogenous formation of peroxynitrite, which decomposes to NO<sub>2</sub>, in both human subjects with asthma and animal models of allergic airway disease. In experimental animals, endogenous peroxynitrite/NO<sub>2</sub> formation was associated with AHR and allergic inflammatory responses. Reduction of peroxynitrite formation lessened airway responsiveness, allergic inflammation, and airway remodeling. These findings raise the possibility that inhaled NO<sub>2</sub> can add to the lung burden of endogenous NO<sub>2</sub> which is found in and contributes to AHR and allergic airway disease.

[Figure 4-2](#) depicts the proposed mode of action for respiratory effects due to long-term exposure to NO<sub>2</sub>.



Note: Pathways indicated by a dotted line are those for which evidence is limited to findings from experimental animal studies, while evidence from controlled human exposure studies is available for pathways indicated by a solid line. The dashed line indicates a proposed link to the outcome of new onset asthma/asthma exacerbation. Key events are subclinical effects, endpoints are effects that are generally measured in the clinic, and outcomes are health effects at the organism level. NO<sub>2</sub> = nitrogen dioxide.

Source: National Center for Environmental Assessment.

**Figure 4-2 Summary of evidence for the mode of action linking long-term exposure to nitrogen dioxide and respiratory effects.**

The initiating events in the development of respiratory effects due to long-term NO<sub>2</sub> exposure are recurrent and/or chronic respiratory tract inflammation and oxidative stress. These are the driving factors for potential downstream key events, allergic sensitization, airway inflammation, and airway remodeling, that may lead to the endpoint AHR. The resulting outcome may be new asthma onset, which presents as an asthma exacerbation that leads to physician-diagnosed asthma ([Section 6.2.2](#)).


The strongest evidence for this mode of action in humans comes from controlled human exposure studies involving repeated exposures of healthy subjects to NO<sub>2</sub> over several days. Findings included upregulation of Th2 cytokines in respiratory epithelium, which is characteristic of allergic skewing and part of the allergic sensitization pathway. In addition, persistent airway neutrophilia and upregulation of ICAM-1 in airway epithelium were observed. Reductions in lymphocyte subpopulations, suggesting impaired host defense, also occurred. Although these were short-term exposure studies, findings suggest that cumulative effects may occur over time and the possibility that recurrent or chronic exposure to NO<sub>2</sub> may lead to the development of asthma.

Studies in experimental animals exposed to NO<sub>2</sub> for several weeks found nasal eosinophilia and enhanced mast cell responses. Other evidence suggests that endogenous NO<sub>2</sub> acts as an adjuvant promoting the development of allergic airway disease in

response to an inhaled allergen. This is consistent with mechanistic studies that suggest that allergic sensitization involves several redox-sensitive steps and that ROS and RNS promote the development of an allergic phenotype.

Findings that reduction of endogenous peroxynitrite production decreased airway remodeling in animal models of allergic airway disease suggest that endogenous NO<sub>2</sub> may contribute to airway remodeling. Subchronic exposure to NO<sub>2</sub> enhanced both airway responsiveness and specific airway resistance, suggesting that airway remodeling may have contributed to the development of AHR in this nonallergic animal model. Thus, evidence points to the possibility that inhaled NO<sub>2</sub> can add to the lung burden of endogenous NO that contributes to airway remodeling. Mechanistic studies indicate that inflammatory mediators and structural changes occurring due to airway remodeling can alter the contractility of airway smooth muscle. Thus, persistent inflammation, allergic sensitization, and airway remodeling due to enhanced endogenous NO<sub>2</sub> production or to long-term NO<sub>2</sub> exposure may contribute to the development of AHR. The development of AHR may be linked to the outcome of new onset asthma.

[Figure 4-3](#) depicts the proposed mode of action for extrapulmonary effects due to short- or long-term exposure to NO<sub>2</sub>.



Note: Pathways indicated by a dotted line are those for which evidence is limited to findings from experimental animal studies, while evidence from controlled human exposure studies is available for pathways indicated by a solid line. Dashed lines indicate potential links to outcomes related to cardiovascular or other organ effects. Key events are subclinical effects, endpoints are effects that are generally measured in the clinic, and outcomes are health effects at the organism level. NO<sub>2</sub> = nitrogen dioxide; ELF = epithelial lining fluid.

Source: National Center for Environmental Assessment.


**Figure 4-3 Summary of evidence for the mode of action linking exposure to nitrogen dioxide with extrapulmonary effects.**

There is more uncertainty regarding the mode of action for extrapulmonary effects of inhaled NO<sub>2</sub>. However, evidence suggests the following. The initiating events occur in the respiratory tract, where redox reactions lead to the formation of oxidation and/or nitration products in the ELF. Reactive intermediates formed are responsible for downstream key events that may include activation/sensitization of neural reflexes and respiratory tract inflammation/oxidative stress. This latter key event may lead to diffusion or migration of inflammatory or vasoactive mediators into the circulation. Circulating mediators may result in systemic inflammation and/or oxidative stress, which may affect other organs (Sections 5.3, 6.3 and 6.4). Alternatively, circulating mediators may result in inflammatory activation of endothelial cells, which may lead to the endpoint endothelial dysfunction. Activation of neural reflexes may lead to the endpoint of altered heart rate and/or heart rate variability. Endothelial dysfunction and altered heart rate/heart rate variability may result in cardiovascular effects (Sections 5.3 and 6.3). It should be noted that activation of neural pathways was also depicted in Figure 4-1 (short-term exposure and respiratory effects) because activation of neural pathways may impact airway function as well as cardiac function.

The strongest evidence for this mode of action in humans comes from recent controlled human exposure studies. Both altered heart rate variability and altered blood lipids have been demonstrated. Whether altered heart rate variability was due to stimulation of pulmonary irritant receptors is unclear because no studies in humans exposed to NO<sub>2</sub> have observed increases in respiratory rate or decreases in heart rate. In addition, plasma from human subjects exposed to NO<sub>2</sub> was found to contain increased levels of sLOX compared with plasma from control subjects. This plasma also stimulated endothelial cell activation in an in vitro assay. These results indicate that diffusion or migration of an inflammatory or vasoactive mediator into the circulation occurred that may transduce a downstream effect in the vasculature or in other organs. This possibility is consistent with changes in peripheral blood lymphocyte number and subsets, as well as with altered blood lipids, which have been observed in humans following exposure to NO<sub>2</sub>. These findings point to a pathway by which inhaled NO<sub>2</sub> leads to circulating soluble factors that promote inflammatory signaling in the vasculature and/or other organs.

In experimental animal studies, findings of altered blood glutathione levels and lipids, decreased pentobarbital-induced sleeping time, and mild pathology in brain and heart accompanied by tissue markers of oxidative stress and inflammation, are consistent with the possibility that exposure to NO<sub>2</sub> results in circulating soluble factors that promote inflammatory signaling and/or oxidative stress. There is also some support for activation of neural reflexes because bradycardia was demonstrated in experimental animals that were exposed to very high concentrations of NO<sub>2</sub>. This response was inhibited by atropine indicating the involvement of pulmonary irritant receptors and the vagus nerve. These findings are consistent with NO<sub>2</sub>-induced changes in respiratory rate demonstrated in other studies in experimental animals.

[Figure 4-4](#) depicts the mode of action linking extrapulmonary effects with exposure to NO.



Note: Pathways indicated by a dotted line are those for which evidence is limited to findings from experimental animal studies. No links to endpoints or outcomes are proposed. Key events are subclinical effects. NO = nitric oxide.

Source: National Center for Environmental Assessment.

**Figure 4-4 Summary of evidence for the mode of action linking exposure to nitric oxide with extrapulmonary effects.**

Because NO has a high affinity for heme proteins and because there is no barrier to its diffusion across membranes, it rapidly crosses cell membranes and binds to heme proteins. Inhaled NO diffuses across the alveolar capillary barrier and binds to hemoglobin in red blood cells. To a lesser extent, inhaled NO also diffuses across airway epithelium to react with soluble guanylate cyclase in airway smooth muscle. Diffusion across cell membranes and binding to heme proteins comprise the initiating events in the mode of action for inhaled NO. The resulting key events include reactions with hemoglobin to form nitrosylhemoglobin, methemoglobin, nitrate, and possibly S-nitrosohemoglobin, and activation of soluble guanylate cyclase, which produces a mediator that relaxes airway smooth muscle. Because health effects of inhaled NO have not been identified in [Chapter 5](#) and [Chapter 6](#), no endpoints or outcomes have been included in this analysis.

## 4.4 Summary

This chapter provides a foundation for understanding how exposure to the gaseous air pollutants NO<sub>2</sub> and NO may lead to health effects. This discussion encompasses the many steps between uptake into the respiratory tract or the circulation and the biological responses that ensue. While NO<sub>2</sub> reacts with components of the ELF and with the respiratory epithelium, NO reacts with heme proteins in the circulation. These chemical interactions are responsible for targeting these oxides of nitrogen species to different tissues (i.e., NO<sub>2</sub> to the respiratory tract and NO to the circulation). Biologic responses to

inhaled NO<sub>2</sub> and NO were organized in a mode of action framework that may be used to guide interpretation of health effects evidence presented in subsequent chapters.

---

# CHAPTER 5 INTEGRATED HEALTH EFFECTS OF SHORT-TERM EXPOSURE TO OXIDES OF NITROGEN

---

## 5.1 Introduction

---

### 5.1.1 Scope of Chapter

---

The preceding chapters describe the widespread potential for human exposure to ambient oxides of nitrogen ([Chapters 2 and 3](#)) and the capability for ambient-relevant concentrations of inhaled NO<sub>2</sub> to initiate a cascade of molecular, cellular, and organ responses, particularly in the airways ([Chapter 4](#)). These lines of evidence point to the potential for ambient exposure to oxides of nitrogen to induce health effects. However, the preceding chapters also identify the importance of assessing exposure measurement error due to heterogeneity in ambient concentrations of oxides of nitrogen, effects of other correlated pollutants, and the extent to which information on a proposed mode of action is available to support biological plausibility. With consideration of these issues, this chapter summarizes, integrates, and evaluates the evidence for relationships between various health effects and short-term (i.e., minutes up to 1 month, [Section 1.5](#)) exposure to oxides of nitrogen. The chapter sections comprise evaluations of the epidemiologic, controlled human exposure, and animal toxicological evidence for the effects of short-term exposure to oxides of nitrogen on health outcomes related to respiratory effects ([Section 5.2](#)), cardiovascular effects ([Section 5.3](#)), and total mortality ([Section 5.4](#)). Reproductive and developmental effects also have been examined in relation to short-term exposure to oxides of nitrogen. This evidence is evaluated with studies of long-term exposure in [Chapter 6](#) because associations are often compared among various short- and long-term exposure periods that are difficult to distinguish.

Individual sections for broad health categories (i.e., respiratory, cardiovascular, mortality) begin with a summary of conclusions from the 2008 ISA for Oxides of Nitrogen followed by an evaluation of recent (i.e., published since the completion of the 2008 ISA for Oxides of Nitrogen) studies that builds upon evidence from previous reviews. Within each of these sections, results are organized into smaller outcome groups [e.g., asthma exacerbation, myocardial infarction (MI)] that comprise a continuum of clinical to subclinical outcomes and events. The discussion of individual outcomes and events is then organized by specific scientific discipline (i.e., epidemiology, controlled human

exposure, toxicology). This organization permits clear description of the extent of coherence and biological plausibility for the effects of oxides of nitrogen on a group of related outcomes, and in turn, transparent characterization of the weight of evidence in drawing conclusions.

Sections for each of the broad health categories conclude with an integrated assessment of the evidence and a conclusion regarding causality. A determination of causality was made for each broad health category by evaluating the evidence for each category independently with the causal framework (described in the [Preamble](#) to the ISA). Findings for mortality informed multiple causal determinations. Findings for cause-specific mortality (i.e., respiratory, cardiovascular) were used to assess the continuum of effects and inform the causal determinations for respiratory and cardiovascular effects. A separate causal determination was made for total mortality based on the evidence for nonaccidental causes of mortality combined and also based on the extent of biological plausibility provided by evidence for the spectrum of cardiovascular and respiratory effects that are underlying causes of mortality. Judgments of causality were made by evaluating the evidence over the full range of concentrations in animal toxicological, controlled human exposure, and epidemiologic studies defined in this ISA to be relevant to ambient exposure (i.e., up to 5,000 ppb NO<sub>2</sub> or NO; [Section 1.2](#)). Experimental studies that examined higher NO<sub>2</sub> or NO concentrations were evaluated particularly to inform judgments about plausible modes of action.

---

## **5.1.2 Evidence Evaluation and Integration to Form Causal Determinations**

### **5.1.2.1 Evaluation of Individual Studies**

As described in the [Preamble](#) to the ISA ([Section 5.a](#)), causal determinations were informed by the evidence integrated across scientific disciplines (e.g., exposure, animal toxicology, epidemiology) and related outcomes and judgments of the strength of inference from individual studies. These judgments were formed by evaluating strengths as well as various sources of bias and uncertainty related to aspects such as study design, study population characterization, exposure assessment, outcome assessment, consideration of confounding, and statistical methodology. This evaluation was applied to controlled human exposure, animal toxicological, and epidemiologic studies included in this ISA from previous assessments and those published since the 2008 ISA for Oxides of Nitrogen. The aspects are described in the [Appendix](#) to the ISA and are consistent with current best practices employed in other approaches for reporting or evaluating health

science data.<sup>1</sup> Additionally, the aspects are compatible with published the U.S. EPA guidelines related to cancer, neurotoxicity, reproductive toxicity, and developmental toxicity ([U.S. EPA, 2005](#), [1998b](#), [1996b](#), [1991](#)).

These aspects were not used as a checklist or criteria to define the quality of a study, and judgments were made without considering the results of a study. The presence or absence of particular features did not necessarily define a less informative study or exclude a study from consideration in the ISA. These aspects were not criteria for a particular determination of causality in the five-level hierarchy. As described in the [Preamble](#), causal determinations were based on judgments of the overall strengths and limitations of the collective body of available studies and the coherence of evidence across scientific disciplines and related outcomes. Further, the study aspects described in the [Appendix](#) are not intended to be a complete list that affect the strength of inference from a study, but they comprise the major aspects considered in this ISA to evaluate studies. Where possible, study considerations, for example, exposure assessment and confounding (i.e., bias due to a relationship with the outcome and correlation with exposures to oxides of nitrogen), are framed to be specific to oxides of nitrogen. Thus, judgments of the strength of inference from a study can vary depending on the specific pollutant being assessed.

Confounding in epidemiologic studies was a key source of bias evaluated in this ISA. Epidemiologic studies of short-term exposure to oxides of nitrogen relied primarily on temporal variation in exposure (e.g., day-to-day changes in ambient NO<sub>2</sub> concentrations) and health effects. Other risk factors for health effects also exhibit similar temporal trends as oxides of nitrogen and include meteorological variables, season, long-term time trends, medication use, and copollutant exposures. These factors and others specified in the [Appendix](#) are important to evaluate as potential confounders of associations for oxides of nitrogen, particularly given the small effect sizes typically observed. Epidemiologic studies reviewed in this ISA varied in the extent to which they considered potential confounding. Because no single study considered all potential confounders, and not all factors were examined in the collective body of studies, residual confounding by unmeasured factors is possible. Residual confounding also is possible by poorly measured factors. In this ISA, potential confounding was assessed as the extent to which the collection of studies examined factors that are well documented in the literature to be associated with exposure to oxides of nitrogen and health outcomes.

In epidemiologic studies evaluated in this ISA, confounding was assessed primarily using multivariable models that include NO<sub>2</sub> concentrations and the putative confounder in the

---

<sup>1</sup> See, for example, NTP OHAT approach ([Rooney et al., 2014](#)), IRIS Preamble ([U.S. EPA, 2013p](#)), ToxRTool ([Klimisch et al., 1997](#)), STROBE guidelines ([von Elm et al., 2007](#)), and ARRIVE guidelines ([Kilkenny et al., 2010](#)).

same model. The NO<sub>2</sub> effect estimate represents the effect of NO<sub>2</sub> keeping the level of the covariate constant. In the ISA, confounding is assessed by examining the change in the magnitude of the effect estimate and width of the 95% CI for NO<sub>2</sub> in multivariable models, not just a change in statistical significance. The limitations of multivariable models are well recognized. If NO<sub>2</sub> and the potential confounder are highly correlated, the collinearity (i.e., covariates predict each other) introduced by including them in the same model can misleadingly decrease or increase the magnitude or precision of the effect estimates for NO<sub>2</sub> or the potential confounder. Collinearity can occur, for example, if pollutants are from the same sources or are derived from NO<sub>2</sub> [e.g., ozone (O<sub>3</sub>)], or if meteorology affects formation of both pollutants. Adding correlated but noncausal variables can produce models that fit the data poorly, and residual confounding is possible if confounders are excluded or poorly measured.

Studies reviewed in this ISA predominantly evaluated copollutant confounding by copollutant models (NO<sub>2</sub> plus one copollutant). Inference about the independent effects of NO<sub>2</sub> from copollutant models can be limited because differences in the spatial distributions of NO<sub>2</sub> and the copollutant may not satisfy the assumptions of equal measurement error or constant correlations for NO<sub>2</sub> and the copollutant ([Gryparis et al., 2007](#)). Further, copollutant models for NO<sub>2</sub> assumed linear relationships with the copollutant, and nonlinear relationships are possible because of varying near-road gradients ([Figure 3-2](#)). Other methods for evaluating copollutant confounding do not require the aforementioned assumptions, including a hierarchical Bayesian approach that estimates single-pollutant effects in a particular location then combines these single-pollutant effects across locations in a model as the predictor and outcome, respectively ([Gryparis et al., 2007](#); [Schwartz and Coull, 2003](#)). Such Bayesian models are unavailable for NO<sub>2</sub>. Models examining joint effect or interaction terms for NO<sub>2</sub> and a copollutant potentially can provide information on confounding and synergistic effects. These are available only to a limited extent, particularly for traffic-related copollutants. Because examination of copollutant confounding is based largely on copollutant models, their limitations are considered in drawing inferences about independent associations for NO<sub>2</sub>. Emphasis is placed on results based on exposure assessment methods that likely produce comparable measurement error for NO<sub>2</sub> and copollutants, such as ambient or total personal and microenvironmental exposure assessment.

---

### 5.1.2.2 Integration of Scientific Evidence

In addition to strength of inference from individual studies, causal determinations were based on integrating multiple lines of evidence. As detailed in the [Preamble](#), evidence integration involved evaluating the consistency and coherence of findings within and

across disciplines as well as within and across related outcomes. Based on this evaluation, judgments were formed on the extent to which chance, confounding, and other biases could be ruled out with reasonable confidence in the evidence base as a whole. Examples of evidence integration are summarized below.

To increase comparability of results across epidemiologic studies, the ISA presents effect estimates for associations with health outcomes scaled to the same increment of oxide of nitrogen concentration.<sup>1</sup> The increments for standardization vary by averaging time (e.g., 24-h avg, 1-h max) and oxide of nitrogen. For 24-h average, effect estimates were scaled to a 20-ppb increase for NO<sub>2</sub> or NO and a 40-ppb increase for NO<sub>x</sub>. For a 1-h maximum, effect estimates were scaled to a 30-ppb increase for NO<sub>2</sub>, an 80-ppb increase for NO, and a 100-ppb increase for NO<sub>x</sub>. For an 8-h maximum, the increments for standardization are 25 ppb for NO<sub>2</sub>, 45 ppb for NO, and 65 ppb for NO<sub>x</sub>. These increments were derived by calculating the U.S.-wide percentile distributions for a given averaging time and then calculating the approximate difference between the median (a typical pollution day) and the 95th percentile (a more polluted day) for a given averaging time [for 1-h maximum, see [Table 2-3](#) and for 24-h average and 8-h maximum, see [Supplemental Table S5-1](#); ([U.S. EPA, 2015g](#))].

There were common exceptions to this standardization method. Averaging times other than 24-h average or 1-h maximum were examined, for example, 2- to 15-h averages. Effect estimates based on these averaging times were not standardized but are presented in the ISA as reported in their respective studies. Some studies reported effect estimates in terms of  $\mu\text{g}/\text{m}^3$  increases in oxides of nitrogen, which could be converted to ppb and standardized for NO<sub>2</sub> and NO but not NO<sub>x</sub>. This conversion could not be made for NO<sub>x</sub> because the proportions of NO<sub>2</sub> and NO are unknown for the various NO<sub>x</sub> metrics. Also, data are not available to calculate the percentiles of NO<sub>x</sub> concentrations in  $\mu\text{g}/\text{m}^3$  at a national scale for the U.S. or other countries. Therefore, the ISA presents effect estimates based on  $\mu\text{g}/\text{m}^3$  of NO<sub>x</sub> as they are reported in their respective studies.

Integrating evidence across scientific disciplines can help address uncertainties within a particular discipline. For example, controlled human exposure and animal toxicological studies can provide direct evidence for health effects related to NO<sub>2</sub> or NO exposures. Experimental evidence for effects from a controlled exposure and coherence with epidemiologic findings may help understand whether epidemiologic associations with health outcomes plausibly reflect an independent effect of ambient NO<sub>2</sub> exposure or could be confounded by other factors. Experimental studies additionally can provide biological plausibility for observed effects by identifying key events in the modes of

---

<sup>1</sup> This is in contrast with reported effect estimates that are scaled to various changes in concentration, such as interquartile range for the study period or an arbitrary unit such as 10 ppb.

action. Thus, the integration of evidence across a spectrum of related outcomes and across disciplines was used to inform uncertainties for any particular outcome or discipline due to factors such as chance, publication bias, selection bias, and confounding by copollutant exposures or other factors. The evaluation of health effects also drew upon information on potential error associated with various exposure assessment methods and the uptake and distribution of oxides of nitrogen in the body. The subsequent sections assess strength of inference from studies and integrate multiple lines of evidence to characterize relationships between oxides of nitrogen and various health effects.

---

## 5.2 Respiratory Effects

---

### 5.2.1 Introduction

The 2008 ISA for Oxides of Nitrogen concluded that evidence was sufficient to infer a likely to be causal relationship between short-term exposure to NO<sub>2</sub> and respiratory effects ([U.S. EPA, 2008c](#)), emphasizing a large body of epidemiologic evidence. In studies that were not available until after the completion of the 1993 AQCD for Oxides of Nitrogen ([U.S. EPA, 1993a](#)), short-term increases in ambient NO<sub>2</sub> concentrations were consistently associated with increases in respiratory-related hospital admissions and ED visits. The coherence of these findings with NO<sub>2</sub>-related increases in respiratory symptoms in children with asthma supported an effect of NO<sub>2</sub> exposure on asthma exacerbation. NO<sub>2</sub> was not consistently related to lung function decrements across epidemiologic and controlled human exposure studies or across populations with varying respiratory conditions such as asthma or COPD. However, epidemiologic studies of children and adults with asthma observed associations with lung function measured by supervised spirometry ([U.S. EPA, 2008c](#)).

The 2008 ISA identified multiple lines of evidence as supporting an independent relationship between short-term NO<sub>2</sub> exposure and respiratory effects. Controlled human exposure studies demonstrated NO<sub>2</sub>-induced increases in airway responsiveness in adults with asthma. These findings for increased airway responsiveness, a characteristic feature of asthma, provided biological plausibility for epidemiologic evidence for asthma exacerbation. Further, airway responsiveness was increased following <1 to 6-hour exposures to NO<sub>2</sub> at concentrations in the range of 100 to 300 ppb, which are not much higher than peak ambient concentrations ([Section 2.5](#)).

Previous epidemiologic studies also indicated independent associations for NO<sub>2</sub>. Personal and indoor NO<sub>2</sub> were associated with respiratory effects, and associations with both personal and ambient NO<sub>2</sub> were observed in copollutant models that adjusted for fine particulate matter (PM<sub>2.5</sub>) or a traffic-related copollutants such as carbon monoxide (CO). In the few available results, NO<sub>2</sub>-related respiratory effects were observed with adjustment for elemental carbon (EC), organic carbon (OC), or ultrafine particles (UFP); other traffic-related copollutants were not examined for potential confounding. Controlled human exposure and animal toxicological studies also demonstrated NO<sub>2</sub>-induced impairments in host defense, changes in the oxidant/antioxidant balance, and increases in pulmonary inflammation at concentrations of 1,500 to 5,000 ppb NO<sub>2</sub>, higher than those demonstrated to increase airway responsiveness ([U.S. EPA, 2008c](#)). The 2008 ISA did not explicitly link these NO<sub>2</sub>-induced biochemical and immunological changes to lines of evidence for asthma exacerbation. Although there was coherence of evidence across related outcomes and disciplines supporting a relationship between short-term ambient NO<sub>2</sub> exposure and respiratory effects, due to the high correlations of NO<sub>2</sub> with other traffic-related pollutants and limited analysis of potential confounding, sufficient uncertainty was noted in the epidemiologic evidence about the role of NO<sub>2</sub> as an indicator for another traffic-related pollutant or a mixture of such pollutants.

As will be described in the following sections, consistent with the body of evidence presented in the 2008 ISA for Oxides of Nitrogen, recent studies continue to demonstrate respiratory effects related to short-term NO<sub>2</sub> exposure. The majority of the recent evidence is from epidemiologic studies, which expand on findings for associations between ambient NO<sub>2</sub> and a broad array of respiratory effects from subclinical increases in pulmonary inflammation to respiratory mortality, but particularly for effects related to asthma exacerbation. Because there are few recent controlled human exposure and animal toxicological studies, previous findings are a large basis of the characterization and integration of evidence. Where available, results from recent studies are evaluated in the context of results from previous studies. To clearly characterize differences in the weight of evidence and the extent of coherence among disciplines and related outcomes, the discussion of scientific information is organized by respiratory outcome group (e.g., asthma exacerbation, allergy exacerbation, respiratory infection).

---

## 5.2.2 Asthma Exacerbation

As detailed in the preceding section, previous studies provided several lines of evidence in support of a relationship between short-term NO<sub>2</sub> exposure and asthma exacerbation, represented as respiratory effects in populations with asthma. This evidence is corroborated by recent studies. In characterizing the current state of the evidence, this

section begins with effects on increasing airway responsiveness and decreasing lung function. These are indications of bronchoconstriction and airway obstruction, which can lead to poorer control of asthma symptoms and potentially hospital admissions or ED visits for asthma. The evaluation of clinical indicators of asthma exacerbation follows with discussion of pulmonary inflammation and oxidative stress, which are part of the proposed mode of action for asthma exacerbation and mediate decreases in lung function and increases in airway responsiveness ([Figure 4-1](#)).

---

### 5.2.2.1 Airway Responsiveness in Individuals with Asthma

#### Overview

Controlled human exposure studies evaluating the effect of inhaled NO<sub>2</sub> on the inherent responsiveness of the airways to challenge by bronchoconstricting agents have had mixed results. However, meta-analyses show statistically significant effects of NO<sub>2</sub> on the airway responsiveness of individuals with asthma. This section describes analyses showing that a statistically significant fraction (i.e., 70% of individuals with asthma exposed to NO<sub>2</sub> at rest) experience increases in airway responsiveness following 30-minute exposures to NO<sub>2</sub> in the range of 200 to 300 ppb and following 60-minute exposures to 100 ppb. The distribution of changes in airway responsiveness is log-normally distributed. About a quarter of the individuals exposed at rest experience a clinically relevant reduction in their provocative dose due to NO<sub>2</sub> relative to air exposure. A variety of factors that may affect the assessment of airway responsiveness and how those factors may directionally bias the results of individual studies are briefly considered.

#### Background

Bronchial challenge agents can be classified as nonspecific [e.g., histamine, sulfur dioxide (SO<sub>2</sub>), cold air] or specific (i.e., an allergen). Nonspecific agents can be differentiated between “direct” stimuli (e.g., histamine, carbachol, and methacholine) which act on airway smooth muscle receptors and “indirect” stimuli (e.g., exercise, cold air) which act on smooth muscle through intermediate pathways, especially via inflammatory mediators ([Cockcroft and Davis, 2006c](#)). Specific allergen challenges (e.g., house dust mite, cat allergen) also act “indirectly” via inflammatory mediators to initiate smooth muscle contraction and bronchoconstriction. This section focuses on changes in airway responsiveness to bronchial challenge attributable to NO<sub>2</sub> in individuals with asthma. Discussed in [Section 4.3.2.5](#), toxicological studies have

demonstrated increased airway responsiveness to nonspecific challenges following short-term exposure. Described in [Sections 5.2.2.5](#) and [4.3.2.6](#), altered responses to specific allergens following NO<sub>2</sub> exposure have also been demonstrated in human and animal studies.

Responses to bronchial challenge are typically quantified in terms of the provocative dose (PD) or provocative concentration (PC) of an agent required to produce a 20% reduction in FEV<sub>1</sub> (PD<sub>20</sub> or PC<sub>20</sub>, respectively) or a 100% increase in specific airway resistance (sRaw) (PD<sub>100</sub> or PC<sub>100</sub>, respectively). In the general population, airway responsiveness is log-normally distributed with individuals having airway hyperresponsiveness (AHR) tending to be those with asthma ([Postma and Boezen, 2004](#); [Cockcroft et al., 1983](#)). Along with symptoms, variable airway obstruction, and airway inflammation, AHR is a primary feature in the clinical definition and characterization of asthma severity ([Reddel et al., 2009](#)). However, not all individuals with asthma experience airway hyperresponsiveness. The range in airway responsiveness among individuals with asthma extends into the range of healthy individuals without asthma ([Cockcroft, 2010](#)). In asthma, there is a strong relationship between the degree of nonspecific airway responsiveness and the intensity of the early airway response to specific allergens to which individuals have become sensitized ([Cockcroft and Davis, 2006a](#)).

In studies investigating the effect of NO<sub>2</sub> exposure on airway responsiveness, individuals with asthma generally have a lower PD of a bronchial challenge agent than healthy individuals to produce a given reduction in lung function. In the study by [Morrow and Utell \(1989a\)](#), the average PD of carbachol producing a given change in lung function in individuals with mild-to-moderate asthma was 16 times lower than in age-matched healthy controls. Similarly, [Hazucha et al. \(1983\)](#) reported a 10–12 times lower average baseline PD<sub>100</sub> to methacholine in individuals with mild asthma than healthy age-matched controls. The PDs for asthma in [Morrow and Utell \(1989a\)](#) did not overlap with those of the healthy controls, whereas [Hazucha et al. \(1983\)](#) observed an overlap with 2 of 15 subjects with asthma being relatively unresponsive to bronchial challenge. Thus, individuals with asthma are generally at risk at baseline relative to healthy individuals without NO<sub>2</sub> or other agents, further increasing their airway responsiveness. The bronchoconstrictive response to indirect acting agents (especially specific allergens) can be more difficult to predict and control than the bronchoconstrictive response to nonspecific agents that act directly on airway smooth muscle receptors ([O'Byrne et al., 2009](#)). Consequently, most of the available literature relevant to the evaluation of the effects of NO<sub>2</sub> on airway responsiveness has focused primarily on the responses of individuals with asthma to bronchial challenge with “nonspecific” bronchoconstricting agents (e.g., methacholine, SO<sub>2</sub>, cold air).

In healthy adults without asthma or AHR, there is likely little or no clinical significance of transient, small increases in airway responsiveness following low-level NO<sub>2</sub> inhalation exposures. In individuals with asthma, however, transient changes in airway responsiveness in response to NO<sub>2</sub> may have clinical consequences due to their tendency to already have greater baseline airway responsiveness than healthy individuals. Increased airway responsiveness is linked with airway inflammation and airway remodeling ([Chetta et al., 1996](#)), increased risk for exacerbation ([Van Schayck et al., 1991](#)), reduced lung function ([Xuan et al., 2000](#)), and increased symptoms ([Murray et al., 1981](#)). A variety of environmental challenges can transiently increase AHR and worsen asthma control, including allergen exposures ([Strand et al., 1997](#); [Brusasco et al., 1990](#)), viral infections ([Cheung et al., 1995](#); [Fraenkel et al., 1995](#)), cigarette smoke ([Tashkin et al., 1993](#)), O<sub>3</sub> ([Kehrl et al., 1999](#)), and other respiratory irritants ([Kinsella et al., 1991](#)). Transient increases in airway responsiveness following NO<sub>2</sub> or other pollutant exposures have the potential to increase symptoms and worsen asthma control, even if the pollutant exposure does not cause acute decrements in lung function.

Four meta-analyses in the peer-reviewed literature have assessed the effects of NO<sub>2</sub> exposure on airway responsiveness in individuals with asthma ([Brown, 2015](#); [Goodman et al., 2009](#); [Kjaergaard and Rasmussen, 1996](#); [Folinsbee, 1992](#)). [Kjaergaard and Rasmussen \(1996\)](#) reported statistically significant effects of NO<sub>2</sub> exposure on the airway responsiveness of subjects with asthma exposed to less than or equal to 300 ppb NO<sub>2</sub> but not for exposures in excess of 300 ppb NO<sub>2</sub>. With consideration given to activity level during exposure, [Folinsbee \(1992\)](#) found statistically significant increases in airway responsiveness of subjects with asthma exposed to NO<sub>2</sub> at rest across all concentration ranges (namely, <200 ppb, 200 to 300 ppb, and >300 ppb). However, there was no statistically significant effect of NO<sub>2</sub> exposures on responsiveness during exercise. For instance, following exposures between 200 and 300 ppb NO<sub>2</sub>, 76% of subjects exposed at rest had increased responsiveness, which was statistically significant, whereas only 52% of subjects exposed while exercising had increased responsiveness, which was not a statistically significant change. The analyses of [Folinsbee \(1992\)](#) and [Kjaergaard and Rasmussen \(1996\)](#) in effect assessed nonspecific responsiveness because few studies of allergen responsiveness were available.

The analyses conducted by [Folinsbee \(1992\)](#) were detailed in Chapter 15 of the 1993 AQCD for Oxides of Nitrogen ([U.S. EPA, 1993a](#)). Results of these analyses appeared in Table 15-10 of the 1993 AQCD and supported the conclusion that NO<sub>2</sub> exposure increases airway responsiveness in individuals with asthma. The results of a slightly modified analysis focusing exclusively on nonspecific responsiveness appeared in Tables 3.1-3 of the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008b, c](#)). The overall conclusion of that modified analysis was that NO<sub>2</sub> exposures as low as 100 ppb (the

lowest concentration experimentally evaluated) conducted during rest, but not exercise, increased nonspecific responsiveness of individuals with asthma. Due to differences in study protocols (e.g., rest versus exercise) in the NO<sub>2</sub>-airway responsiveness literature, the original ([Folinsbee, 1992](#)) and updated meta-analyses in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008b](#)) assessed only the fraction of individuals experiencing increased or decreased airway responsiveness following NO<sub>2</sub> exposure.

[Goodman et al. \(2009\)](#) provided meta-analyses and meta-regressions evaluating the effects of NO<sub>2</sub> exposure on airway responsiveness in subjects with asthma. By considering studies of specific allergen and nonspecific responsiveness following NO<sub>2</sub> exposure, [Goodman et al. \(2009\)](#) evaluated a larger number of studies than the analysis in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008b](#)), which was limited to nonspecific responsiveness in subjects with asthma in an attempt to reduce the heterogeneity among studies. [Goodman et al. \(2009\)](#) evaluated changes in three endpoints following NO<sub>2</sub> exposure relative to a control air exposure: (1) the fraction of subjects with asthma experiencing increases in responsiveness, (2) the PD of the bronchial challenge agent, and (3) the FEV<sub>1</sub> response to the challenge agent. Overall, statistically significant effects of NO<sub>2</sub> exposure on each of these three endpoints were observed. Consistent with the meta-analysis provided in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), [Goodman et al. \(2009\)](#) found 64% (95% CI: 58, 71) of subjects with asthma exposed at rest to NO<sub>2</sub> experienced an increase in airway responsiveness, whereas there was no effect of NO<sub>2</sub> exposure during exercise with 52% (95% CI: 43, 60) having an increase in responsiveness. Additionally, NO<sub>2</sub> exposure resulted in statistically significant reductions in PD as well as increases in the FEV<sub>1</sub> decrement following bronchial challenge.

[Goodman et al. \(2009\)](#) concluded that, “NO<sub>2</sub> is not associated with clinically relevant effects on AHR at exposures up to 600 ppb based primarily on the small magnitude of effects and the overall lack of exposure-response associations.” Relative to therapeutic agents used to treat airway responsiveness, which may be considered effective if they more than double the PD for methacholine, the authors concluded that a –50% change in the PD due to NO<sub>2</sub> exposure would be considered adverse. Using the summary statistics provided in individual studies, the effect of NO<sub>2</sub> exposure was a –27% (95% CI: –37, –18) change in the PD. Stratifying by rest and exercise exposure, the NO<sub>2</sub>-induced changes in PD were –30% (95% CI: –38, –22) and –24% (95% CI: –40, –7), respectively. Thus, the authors concluded that the effects of NO<sub>2</sub> exposure on airway responsiveness were sufficiently small so as not to be considered adverse. Based on the lack of a monotonic increase in responsiveness with exposure, the authors also suggested that NO<sub>2</sub> is not a causal factor. However, as airway responsiveness data is log-normally distributed ([Postma and Boezen, 2004](#); [Cockcroft et al., 1983](#)), use of arithmetic mean PD

data may affect the validity of some analyses in the [Goodman et al. \(2009\)](#) study. For example, in the study by [Bylin et al. \(1988\)](#) following exposure to 140 ppb NO<sub>2</sub>, there was an arithmetic mean increase of 17% in the PD relative to filtered air, which was driven by a few individuals; whereas, the median and geometric mean show a 24% and 16% decrease, respectively, in the PD following NO<sub>2</sub> relative to filtered air exposure. Based on this example, incorrectly assuming data to be normally distributed can lead to the conclusion that airway responsiveness is decreased following NO<sub>2</sub> exposure, whereas it was actually increased in most individuals.

None of the above described meta-analyses provided a comprehensive assessment of the clinical relevance of changes in airway responsiveness, the potential for methodological biases in the original papers, or the distribution of responses. The remainder of this section provides such analyses of airway responsiveness data and a discussion of factors that may have affected the experimental determination of airway responsiveness as presented by [Brown \(2015\)](#). In review of this ISA, [Roux and Frey \(2015\)](#) expressed support of this meta-analysis and suggested that it facilitated the inferences that could be drawn from the original controlled human exposure studies (see page 2 of cover letter and page 7 of consensus comments). Detailed descriptions of individual studies are provided in the 1993 AQCD for Oxides of Nitrogen ([U.S. EPA, 1993a](#)) and 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)). As done in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), the fraction of individuals having an increase in airway responsiveness following NO<sub>2</sub> exposure was assessed. Due to considerable variability in exposure protocols and the potential for this variability in protocols to affect estimates of PD (see Factors Affecting Airway Responsiveness and Dose-response), the magnitude of NO<sub>2</sub>-induced changes in PD was not evaluated in the original work by [Folinsbee \(1992\)](#) or in related documents of the U.S. EPA ([U.S. EPA, 2008b, c, 1993a](#)). Herein, the magnitude of the PD change for nonspecific agents is evaluated in studies that presented individual subject data for persons with asthma exposed to NO<sub>2</sub> at rest. The focus on resting exposures and nonspecific challenges when assessing the magnitude of change in PD (dPD) was due to the statistically significant effects of NO<sub>2</sub> exposure on airway responsiveness for these conditions as reported in the 2008 ISA for Oxides of Nitrogen [see Section 3.1.3.2 of [U.S. EPA \(2008c\)](#)]. In assessing the magnitude of PD change, additional consideration was given to individuals experiencing a doubling-dose change in PD following exposure to NO<sub>2</sub> relative to filtered air. In a joint statement of the American Thoracic Society (ATS) and European Respiratory Society, one doubling dose change in PD is recognized as a potential indicator, although not a validated estimate, of clinically relevant changes in airway responsiveness ([Reddel et al., 2009](#)). Additional analyses also evaluate the distribution of PD responses to NO<sub>2</sub> and the concentration/dose-response relationship.

## New Analyses

As an update to Table 3.1-2 in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), [Tables 5-1](#) and [5-2](#) present studies selected for inclusion into the meta-analyses by [Brown \(2015\)](#). Relative to Table 3.1-2 in the 2008 ISA, [Tables 5-1](#) and [5-2](#) add data that either are new or were previously excluded for 155 subject exposures from nine studies ([Riedl et al., 2012](#); [Witten et al., 2005](#); [Barck et al., 2002](#); [Jenkins et al., 1999](#); [Strand et al., 1998](#); [Strand et al., 1997](#); [Tunncliffe et al., 1994](#); [Morrow and Utell, 1989a](#); [Orehek et al., 1976](#)). The meta-analysis in the 2008 ISA focused on nonspecific airway responsiveness, although studies examining allergen challenges were discussed in Section 3.1.3.1 and Annex Table AX5.3-2 of the 2008 ISA. With respect to the studies in [Tables 5-1](#) and [5-2](#), subjects recruited for these studies ranged in age from 18 to 50 years with the exception of [Avol et al. \(1989\)](#) who studied children ages 8–16 years. The disease status of subjects was mild asthma in most studies, but ranged from inactive asthma up to severe asthma in a few studies.

For studies that assessed airway responsiveness at multiple time points post-exposure or over repeated days of exposure, the data from the first time point and first day of exposure were selected for inclusion in [Tables 5-1](#) and [5-2](#) to reduce the heterogeneity among studies. Selection of the earliest time point assessing airway responsiveness was, in part, due to late phase responses (3–8 hours post-allergen challenge) being mechanistically different from early phase responses (<30 minutes post-allergen challenge) ([O'Byrne et al., 2009](#); [Cockcroft and Davis, 2006c](#)). [Tables 5-1](#) and [5-2](#) are sorted by NO<sub>2</sub> exposure concentration, so studies that evaluated multiple NO<sub>2</sub> exposure concentrations appear in multiple rows.

**Table 5-1 Resting exposures to nitrogen dioxide and airway responsiveness in individuals with asthma.**

Reference	N	NO <sub>2</sub> ppb	Exp. (min)	Chall- enge Type	End Point	Time Post- exp min	Change in AR <sup>a</sup>		Average PD ± SE <sup>b</sup>		p-value <sup>c</sup>
							+	-	Air	NO <sub>2</sub>	
<a href="#">Ahmed et al. (1983a)</a>	20	100	60	CARB	sGaw	NA	13	7	6.0 ± 2.4	2.7 ± 0.8	NA
<a href="#">Ahmed et al. (1983b)</a>	20	100	60	RAG	sGaw	IM	10	8	9.0 ± 5.7	11.7 ± 7.6	n.s.
<a href="#">Hazucha et al. (1983)</a>	15	100	60	METH	sRaw	20	6	7	1.9 ± 0.4	2.0 ± 1.0	n.s.
<a href="#">Orehek et al. (1976)</a>	20	100	60	CARB	sRaw	IM	14	3	0.56 ± 0.08	0.36 ± 0.05	<0.01 <sup>d</sup>
<a href="#">Tunnicliffe et al. (1994)</a>	8	100	60	HDM	FEV <sub>1</sub>	IM	3	5	-14.62 ΔFEV <sub>1</sub>	-14.41 ΔFEV <sub>1</sub>	n.s.
<a href="#">Bylin et al. (1988)</a>	20	140	30	HIST	sRaw	25	14	6	0.39 ± 0.07	0.28 ± 0.05	n.s.
<a href="#">Orehek et al. (1976)</a>	4	200	60	CARB	sRaw	IM	3	0	0.60 ± 0.10	0.32 ± 0.02	n.s.
<a href="#">Jörres and Magnussen (1990)</a>	14	250	30	SO <sub>2</sub>	sRaw	27	11	2	46.5 ± 5.1	37.7 ± 3.5	<0.01
<a href="#">Barck et al. (2002)</a>	13	260	30	BIR, TIM	FEV <sub>1</sub>	240	5	7	-5 ± 2 ΔFEV <sub>1</sub>	-4 ± 2 ΔFEV <sub>1</sub>	n.s.
<a href="#">Strand et al. (1997)</a>	18	260	30	BIR, TIM	sRaw	240	9	9	860 ± 450	970 ± 450	n.s.
<a href="#">Strand et al. (1998)</a>	16	260	30	BIR	FEV <sub>1</sub>	240	11	4	-0.1 ± 0.8 ΔFEV <sub>1</sub>	-2.5 ± 1.0 ΔFEV <sub>1</sub>	0.03
<a href="#">Bylin et al. (1988)</a>	20	270	30	HIST	sRaw	25	14	6	0.39 ± 0.07	0.24 ± 0.04	<0.01
<a href="#">Tunnicliffe et al. (1994)</a>	8	400	60	HDM	FEV <sub>1</sub>	IM	8	0	-14.62 ΔFEV <sub>1</sub>	-18.64 ΔFEV <sub>1</sub>	0.009

**Table 5-1 (Continued): Resting exposures to nitrogen dioxide and airway responsiveness in individuals with asthma.**

Reference	N	NO <sub>2</sub> ppb	Exp. (min)	Chall- enge Type	End Point	Time Post- exp min	Change in AR <sup>a</sup>		Average PD ± SE <sup>b</sup>		p-value <sup>c</sup>
							+	-	Air	NO <sub>2</sub>	
<a href="#">Bylin et al. (1985)</a>	8	480	20	HIST	sRaw	20	5	0	>30	>20	0.04
<a href="#">Mohsenin (1987a)</a>	10	500	60	METH	pEF	IM	7	2	9.2 ± 4.7	4.6 ± 2.6	0.042
<a href="#">Bylin et al. (1988)</a>	20	530	30	HIST	sRaw	25	12	7	0.39 ± 0.07	0.34 ± 0.08	n.s.

BIR = birch; CARB = carbachol; Exp. = exposure, FEV<sub>1</sub> = forced expiratory volume in 1 second; HDM = house dust mite allergen; HIST = histamine; IM = immediately after exposure; METH = methacholine; NA = not available; NO<sub>2</sub> = nitrogen dioxide; n.s. = less than marginal statistical significance, *p* > 0.10; pEF = partial expiratory flow at 40% vital capacity; RAG = ragweed; SO<sub>2</sub> = sulfur dioxide; sGaw = specific airway conductance; sRaw = specific airway resistance; TIM = timothy pollen.

<sup>a</sup>Change in airway responsiveness (AR): number of individuals showing increased (+) or decreased (-) airway responsiveness after NO<sub>2</sub> exposure compared to air.

<sup>b</sup>PD ± SE: arithmetic or geometric mean provocative dose (PD) ± standard error (SE). See individual papers for PD calculation and dosage units. ΔFEV<sub>1</sub> indicates the change in FEV<sub>1</sub> response at a constant challenge dose.

<sup>c</sup>Statistical significance of increase in AR to bronchial challenge following NO<sub>2</sub> exposure compared to filtered air as reported in the original study unless otherwise specified. Statistical tests varied between studies (e.g., sign test, *t*-test, analysis of variance).

<sup>d</sup>Statistical significance for all individuals with asthma from analysis by [Dawson and Schenker \(1979\)](#), [Orehek et al. \(1976\)](#) only tested for differences in subsets of individuals classified as “responders” and “nonresponders.”

**Table 5-2 Exercising exposures to nitrogen dioxide and airway responsiveness in individuals with asthma.**

Reference	n	NO <sub>2</sub> ppb	Exp. Min	Challenge Type	End Point	Time Post- exp min	Change in AR <sup>a</sup>		Average PD ± SE <sup>b</sup>		p- value <sup>c</sup>
							+	-	Air	NO <sub>2</sub>	
<a href="#">Roger et al. (1990)</a>	19	150	80	METH	sRaw	120	10 <sup>d</sup>	7 <sup>d</sup>	3.3 ± 0.7	3.1 ± 0.7	n.s.
<a href="#">Kleinman et al. (1983)</a>	31	200	120	METH	FEV <sub>1</sub>	IM	20	7	8.6 ± 2.9	3.0 ± 1.1	<0.05
<a href="#">Jenkins et al. (1999)</a>	11	200	360	HDM	FEV <sub>1</sub>	IM	6	5	2.94	2.77	n.s.
<a href="#">Jörres and Magnussen (1991)</a>	11	250	30	METH	sRaw	60	6	5	0.41 ± 1.6	0.41 ± 1.6	n.s.
<a href="#">Strand et al. (1996)</a>	19	260	30	HIST	sRaw	30	13	5	296 ± 76	229 ± 56	0.08
<a href="#">Avol et al. (1988)</a>	37	300	120	COLD	FEV <sub>1</sub>	60	11 <sup>d</sup>	16 <sup>d</sup>	-8.4 ± 1.8 ΔFEV <sub>1</sub>	-10.7 ± 2.0 ΔFEV <sub>1</sub>	n.s.
<a href="#">Avol et al. (1989)</a>	34	300	180	COLD	FEV <sub>1</sub>	60	12 <sup>d</sup>	21 <sup>d</sup>	-5 ± 2 ΔFEV <sub>1</sub>	-4 ± 2 ΔFEV <sub>1</sub>	n.s.
<a href="#">Bauer et al. (1986)</a>	15	300	30	COLD	FEV <sub>1</sub>	60	9	3	0.83 ± 0.12	0.54 ± 0.10	<0.05

**Table 5-2 (Continued): Exercising exposures to nitrogen dioxide and airway responsiveness in individuals with asthma.**

Reference	n	NO <sub>2</sub> ppb	Exp. Min	Challenge Type	End Point	Time Post- exp min	Change in AR <sup>a</sup>		Average PD ± SE <sup>b</sup>		p- value <sup>c</sup>
							+	-	Air	NO <sub>2</sub>	
<a href="#">Morrow and Utell (1989a)</a>	20	300	240	CARB	FEV <sub>1</sub>	30	7 <sup>e</sup>	2 <sup>e</sup>	3.31 ± 8.64 <sup>e</sup> ΔFEV <sub>1</sub>	-6.98 ± 3.35 <sup>e</sup> ΔFEV <sub>1</sub>	n.s.
<a href="#">Roger et al. (1990)</a>	19	300	80	METH	sRaw	120	8 <sup>d</sup>	9 <sup>d</sup>	3.3 ± 0.7	3.3 ± 0.8	n.s.
<a href="#">Rubinstein et al. (1990)</a>	9	300	30	SO <sub>2</sub>	sRaw	60	4	5	1.25 ± 0.23	1.31 ± 0.25	n.s.
† <a href="#">Riedl et al. (2012)</a>	15	350	120	METH	FEV <sub>1</sub>	90	6	7	7.5 ± 2.6	7.0 ± 3.8	n.s.
† <a href="#">Riedl et al. (2012)</a>	15	350	120	CA	FEV <sub>1</sub>	90	4	11	-6.9 ± 1.7 ΔFEV <sub>1</sub>	-0.5 ± 1.7 ΔFEV <sub>1</sub>	<0.05 <sup>f</sup>
<a href="#">Jenkins et al. (1999)</a>	10	400	180	HDM	FEV <sub>1</sub>	IM	7	3	3.0	2.78	0.018
<a href="#">Witten et al. (2005)</a>	15	400	180	HDM	FEV <sub>1</sub>	IM	8	7	550 ± 240	160 ± 60	n.s.
<a href="#">Avol et al. (1988)</a>	37	600	120	COLD	FEV <sub>1</sub>	60	13 <sup>e</sup>	16 <sup>e</sup>	-8.4 ± 1.8 ΔFEV <sub>1</sub>	-10.4 ± 2.2 ΔFEV <sub>1</sub>	n.s.
<a href="#">Roger et al. (1990)</a>	19	600	80	METH	sRaw	120	11 <sup>d</sup>	8 <sup>d</sup>	3.3 ± 0.7	3.7 ± 1.1	n.s.

CARB = carbachol; CA = cat allergen; COLD = cold-dry air; Exp. = exposure; FEV<sub>1</sub> = forced expiratory volume in 1 second; HDM = house dust mite allergen; HIST = histamine; IM = immediately after exposure; METH = methacholine; NO<sub>2</sub> = nitrogen dioxide; n.s. = less than marginal statistical significance, p > 0.10; SO<sub>2</sub> = sulfur dioxide; sRaw = specific airway resistance.

<sup>a</sup>Change in airway responsiveness (AR): number of individuals showing increased (+) or decreased (-) airway responsiveness after NO<sub>2</sub> exposure compared to air.

<sup>b</sup>PD ± SE: arithmetic or geometric mean provocative dose (PD) ± standard error (SE). See individual papers for PD calculation and dosage units. ΔFEV<sub>1</sub> indicates the change in FEV<sub>1</sub> response at a constant challenge dose.

<sup>c</sup>Statistical significance of increase in AR to bronchial challenge following NO<sub>2</sub> exposure compared to filtered air as reported in the original study. Statistical tests varied between studies (e.g., sign test, t-test, analysis of variance).

<sup>d</sup>Number of individuals having an increase or decrease in airway responsiveness is from [Folinsbee \(1992\)](#).

<sup>e</sup>Data for 0.25% carbachol challenge from Appendix H of [Morrow and Utell \(1989b\)](#).

<sup>f</sup>Significantly greater ΔFEV<sub>1</sub> in response to a constant challenge dose following exposure to filtered air than NO<sub>2</sub> (i.e., a protective effect of NO<sub>2</sub> exposure).

†Study published since the 2008 ISA for Oxides of Nitrogen.

### ***Fraction of Individuals with Nitrogen Dioxide-Induced Increase in Airway Responsiveness***

[Tables 5-1](#) and [5-2](#) present all of the studies with data on the fraction of individuals experiencing a change (increase or decrease) in airway responsiveness following both NO<sub>2</sub> and filtered air exposures. The statistical significance reported in the original publications for changes in airway responsiveness following NO<sub>2</sub> exposure compared to filtered air is also provided in these tables. Based on all listed studies, the general

tendency of most studies is toward increased airway responsiveness following NO<sub>2</sub> exposure with some studies reaching statistical significance. Fewer studies showed no effect or a tendency for decreased airway responsiveness following NO<sub>2</sub>. Published since the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), one study reported a statistically significant decrease in airway responsiveness following NO<sub>2</sub>, but the authors attributed the protective effect of NO<sub>2</sub> to chance ([Riedl et al., 2012](#)).

Based on the summary data in [Tables 5-1](#) and [5-2](#), the fraction of individuals experiencing an NO<sub>2</sub>-induced increase in airway responsiveness was assessed in a manner consistent with the analysis conducted by [Folinsbee \(1992\)](#). Specifically, a two-tailed sign test was used to assess the statistical significance of directional changes in airway responsiveness between the NO<sub>2</sub> and filter air exposure days. The nonparametric sign test assumes only that the responses of each subject are independent and makes no assumptions about the distribution of the response data. This test allows estimation of whether a statistically significant fraction of individuals experience an increase or decrease in airway responsiveness, but does not provide information on the magnitude of the change in that endpoint.

[Table 5-3](#) provides the fraction of individuals experiencing an NO<sub>2</sub>-induced increase in airway responsiveness to nonspecific agents. Footnotes for this table indicate the group from [Tables 5-1](#) and [5-2](#) that were included in the analyses. For example, in [Table 5-3](#) footnote c, the results for resting exposures (see [Table 5-1](#)) to 100 ppb NO<sub>2</sub> are for the 33 individuals having an increase in nonspecific responsiveness and the 17 individuals having a decrease in nonspecific responsiveness in the studies by [Ahmed et al. \(1983a\)](#), [Hazucha et al. \(1983\)](#), and [Orehek et al. \(1976\)](#). [Table 5-3](#) updates Table 3.1-3 of the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) and is consistent with the prior conclusion that statistically significant increases in nonspecific airway responsiveness (following resting NO<sub>2</sub> exposures) occur in the range of 200 and 300 ppb NO<sub>2</sub> for 30-minute exposures and at 100 ppb NO<sub>2</sub> for 60-minute exposures in individuals with asthma. Similar to the sign test, the fraction of individuals experiencing an increase in airway responsiveness in [Table 5-3](#) is relative to those individuals having a change in responsiveness and does not consider those individuals having no change in responsiveness. A fraction of 0.5 indicates an equal number of individuals having increases and decreases in responsiveness and no effect of NO<sub>2</sub> exposure on responsiveness. Increases in airway responsiveness were not observed following exercising exposures to NO<sub>2</sub>. In general, statistically significant effects of NO<sub>2</sub> exposure on airway responsiveness to allergen challenge were not found by [Brown \(2015\)](#), except at NO<sub>2</sub> concentrations over 300 ppb. This may be, in part, due to the small number of individuals in the analysis. Considering both specific and nonspecific challenges, statistically significant effects of NO<sub>2</sub> on airway responsiveness were again found for

resting but not exercising exposures ([Brown, 2015](#)). Given differing mechanisms of effect (see discussion of bronchial challenge agent later in this section), preference was given to the analysis of nonspecific responsiveness ([Table 5-3](#)).

**Table 5-3 Fraction of individuals with asthma having nitrogen dioxide-induced increase in airway responsiveness to a nonspecific challenge.**

NO <sub>2</sub> Concentration (ppb)	All Exposures <sup>a,b</sup>	Exposure with Exercise <sup>a,b</sup>	Exposure at Rest <sup>a,b</sup>
[NO <sub>2</sub> ] = 100	0.66 (50; <i>p</i> = 0.033)	-	0.66 (50; <i>p</i> = 0.033) <sup>c</sup>
100 ≤ [NO <sub>2</sub> ] < 200	0.66 (87; <i>p</i> = 0.005)	0.59 (17; <i>p</i> = 0.63) <sup>d</sup>	0.67 (70; <i>p</i> = 0.006) <sup>e</sup>
200 ≤ [NO <sub>2</sub> ] ≤ 300	0.59 (199; <i>p</i> = 0.011)	0.55 (163; <i>p</i> = 0.21) <sup>f</sup>	0.78 (36; <i>p</i> = 0.001) <sup>g</sup>
[NO <sub>2</sub> ] > 300	0.57 (94; <i>p</i> = 0.18)	0.49 (61; <i>p</i> = 1.0) <sup>h</sup>	0.73 (33; <i>p</i> = 0.014) <sup>i</sup>
All [NO <sub>2</sub> ]	0.60 (380; <i>p</i> < 0.001)	0.54 (241; <i>p</i> = 0.25)	0.71 (139; <i>p</i> < 0.001)

<sup>a</sup>Data are the fraction of subjects with asthma having an increase in airway responsiveness following NO<sub>2</sub> versus air exposure. Values in parentheses are number of individuals with asthma having a change (±) in responsiveness and the *p*-value for a two-tailed sign test.

<sup>b</sup>Analysis is for the 380 subjects with asthma in [Tables 5-1](#) and [5-2](#) having a change (±) in nonspecific airway responsiveness.

<sup>c</sup>33 increases, 17 decreases; 100 ppb data from [Ahmed et al. \(1983a\)](#), [Hazucha et al. \(1983\)](#), and [Orehek et al. \(1976\)](#).

<sup>d</sup>10 increases, 7 decreases; 150 ppb data from [Roger et al. \(1990\)](#).

<sup>e</sup>47 increases, 23 decreases; 100 ppb data from [Ahmed et al. \(1983a\)](#), [Hazucha et al. \(1983\)](#), and [Orehek et al. \(1976\)](#); 140 ppb data from [Bylin et al. \(1988\)](#).

<sup>f</sup>90 increases, 73 decreases; 200 ppb data from [Kleinman et al. \(1983\)](#); 250 ppb data from [Jörres and Magnussen \(1991\)](#); 260 ppb data from [Strand et al. \(1996\)](#); 300 ppb data from [Avol et al. \(1988\)](#), [Avol et al. \(1989\)](#), [Bauer et al. \(1986\)](#), [Morrow and Utell \(1989a\)](#), [Roger et al. \(1990\)](#), and [Rubinstein et al. \(1990\)](#).

<sup>g</sup>28 increases, 8 decreases; 200 ppb data from [Orehek et al. \(1976\)](#); 250 ppb data from [Jörres and Magnussen \(1990\)](#); 270 ppb data from [Bylin et al. \(1988\)](#).

<sup>h</sup>30 increases, 31 decreases; 350 ppb data from [Riedl et al. \(2012\)](#); 600 ppb data from [Avol et al. \(1988\)](#) and [Roger et al. \(1990\)](#).

<sup>i</sup>24 increases, 9 decreases; 480 ppb data from [Bylin et al. \(1985\)](#); 500 ppb data from [Mohsenin \(1987a\)](#); 530 ppb data from [Bylin et al. \(1988\)](#).

### ***Magnitude and Distribution of Nitrogen Dioxide-Induced Increase in Airway Responsiveness***

Individual subject airway responsiveness data for nonspecific challenges following resting exposures to filtered air and NO<sub>2</sub> were available from five studies ([Jörres and Magnussen, 1990](#); [Bylin et al., 1988](#); [Mohsenin, 1987a](#); [Bylin et al., 1985](#); [Orehek et al., 1976](#)). Data were obtained for 72 individuals and 116 NO<sub>2</sub> exposures. Twenty individuals in the [Bylin et al. \(1988\)](#) study were exposed to three NO<sub>2</sub> concentrations and four

individuals in the [Orehek et al. \(1976\)](#) study were exposed to two NO<sub>2</sub> concentrations. The dPD due to NO<sub>2</sub> for each individual was assessed as:


$$dPD = \frac{PD_{NO_2}}{PD_{air}}$$

**Equation 5-1**

where: PD<sub>NO<sub>2</sub></sub> and PD<sub>air</sub> are the PD following NO<sub>2</sub> and air exposures, respectively. Given that airway responsiveness is recognized as being log-normally distributed ([Postma and Boezen, 2004](#); [Cockcroft et al., 1983](#)), this method of assessing dPD provides nonnegative values for log transformation and plotting. The distribution of dPD data [median and geometric standard deviation (GSD)] was determined for each study and overall for all subjects as described by [Brown \(2015\)](#).

To assess the potential “adversity” or clinical relevance of changes in dPD, a sign test was utilized to determine whether there were a statistically greater number of individuals experiencing a doubling dose reduction in dPD (<0.5) versus those having a doubling dose increase in dPD (>2). A sensitivity analysis was performed to ensure that no single study or group of exposures affected the distribution of dPD and assessment of a doubling dose change. Finally, dose-response was assessed by regressing the logarithms of dPD against NO<sub>2</sub> exposure concentration and against the product of NO<sub>2</sub> exposure concentration and duration.

As described above, the dPD for each individual was calculated as the PD following NO<sub>2</sub> divided by the PD following air exposure. Hence, a dPD greater than one suggests reduced responsiveness, whereas a dPD less than one suggests increased responsiveness following NO<sub>2</sub> exposure. The dPD from the five studies providing individual PD data following resting exposures to NO<sub>2</sub> and filtered air are illustrated in [Figure 5-1](#). All of the median responses illustrated in [Figure 5-1](#) show increased responsiveness following NO<sub>2</sub> exposure (i.e., an NO<sub>2</sub>-induced reduction in the PD). Note that the dPD values are on a log scale. The untransformed dPD data from [Bylin et al. \(1988\)](#) and [Mohsenin \(1987a\)](#) were positively skewed with a few individuals having large values of dPD. This results in a large difference between the median dPD and arithmetic mean dPD. For example, at the 140 ppb concentration in the [Bylin et al. \(1988\)](#) study, the median dPD of 0.73 suggests NO<sub>2</sub> increased responsiveness, which is consistent with 14 individuals having an increase in responsiveness versus 6 having a decrease, whereas the arithmetic mean dPD of 1.15 erroneously suggests a reduction in responsiveness. The untransformed dPD data from [Bylin et al. \(1985\)](#), [Jörres and Magnussen \(1990\)](#), and [Orehek et al. \(1976\)](#) were more symmetrical than that from [Bylin et al. \(1988\)](#) and [Mohsenin \(1987a\)](#).




Note: dPD = provocative dose; NO<sub>2</sub> = nitrogen dioxide; ppb = parts per billion. Points illustrate the responses of 72 individual subjects, and bars are median responses. Doubling dose changes are illustrated by horizontal dotted lines. Data are from Or76 (Orehek et al., 1976), By88 (Bylin et al., 1988), Jö90 (Jörres and Magnussen, 1990), By85 (Bylin et al., 1985), and Mo87 (Mohsenin, 1987a).

**Figure 5-1 Change in provocative dose due to exposure to nitrogen dioxide in resting individuals with asthma.**

A clinically relevant NO<sub>2</sub>-induced increase in responsiveness (dPD <0.5) was observed in 24% of the data, while 8% had a double dose decrease in responsiveness (dPD >2). Of the 28 responses where dPD was <0.5, 17 were from [Bylin et al. \(1988\)](#). Of the nine responses where dPD was >2, eight were again from the [Bylin et al. \(1988\)](#) study. Subject 1 in the [Bylin et al. \(1988\)](#) study had the three highest dPD in [Figure 5-1](#), which generally reflects the reproducibility of response. For all subjects in the [Bylin et al. \(1988\)](#) study, the Spearman's rank correlation between the 140 and 530 ppb exposures was 0.56 ( $p = 0.01$ ) and was 0.48 ( $p = 0.03$ ) between the 270 ppb exposure and both the 140 and 530 ppb exposures. Clearly this study had the potential to affect both the assessment of a doubling dose change in dPD as well as the distribution of responses and illustrates the necessity of the sensitivity analysis. Both [Bylin et al. \(1988\)](#) and [Orehek et al. \(1976\)](#) exposed subjects to more than one NO<sub>2</sub> concentration. As stated above, a doubling dose, NO<sub>2</sub>-induced increase in responsiveness (dPD <0.5), was observed in 24% of the data. This fraction may be affected by the multiple exposures in these two studies.

If only a single exposure concentration from the [Bylin et al. \(1988\)](#) study is considered and only the lower concentration from the [Orehek et al. \(1976\)](#) study is considered, a doubling dose, NO<sub>2</sub>-induced increase in responsiveness (dPD <0.5), is observed in 21–22% of the 72 individual subjects in [Figure 5-1](#). The variability in this fraction of individuals (i.e., 21% or 22%) depends on what parts of the [Bylin et al. \(1988\)](#) study are excluded to avoid double counting.

[Figure 5-2](#) illustrates a log-probability plot of the dPD data. The data are log-normally distributed with an estimated (from fitted line on plot) median of 0.75 and a GSD of 1.88. The lowest and highest dPD were assigned the cumulative probabilities of 0.1% and 99.9%. Removing these two values did not affect the median and only slightly reduced the geometric standard deviation from 1.88 to 1.87. Most of the data (namely 69%) suggests an NO<sub>2</sub>-induced increase in responsiveness (dPD <1) due to NO<sub>2</sub> exposure, while 24% of the data suggests decrease responsiveness (dPD >1). Even though this 69% was relative to all responses (i.e., increases, decreases, and no change in responsiveness), it is remarkably similar to the 71% for all NO<sub>2</sub> concentrations in [Table 5-3](#) having an increase in responsiveness relative to only those having a change in responsiveness and ignoring those having no change in responsiveness. Also consistent with the results in [Table 5-3](#), a two-tailed sign test shows a statistically significant ( $p < 0.001$ ) reduction in the dPD in 74% of the 108 dPD responses not equal to one. Of the 37 dPD having more than a doubling dose change, 76% show a clinically relevant NO<sub>2</sub>-induced reduction in dPD ( $p = 0.003$ ; two-tailed sign test).



Note: dPD = provocative dose. Data are for 72 individuals and 116 NO<sub>2</sub> exposures illustrated in [Figure 5-1](#). Line is log-normal fit (0.75, median dPD; 1.88, geometric standard deviation). Table within figure is the number of observations within intervals of dPD. Doubling dose changes are illustrated by horizontal dotted lines. The discontinuity between the 70th and 77th percentiles is due to 8 of the 116 dPD being equal to one.

**Figure 5-2** **Log-normal distribution of change in provocative dose due to exposure to nitrogen dioxide in resting individuals with asthma.**

The sensitivity analysis performed by [Brown \(2015\)](#) showed that the NO<sub>2</sub>-induced increase in airway responsiveness overall and the clinically relevant, doubling dose increase in responsiveness were robust to exclusion of individual studies and subparts of studies with multiple exposures. Also evaluated in this sensitivity analysis, the concentration range of the data set was split into roughly halves and thirds to determine whether effects were more marked for a specific range of concentrations. That analysis suggested more of an NO<sub>2</sub> effect on airway responsiveness following lower concentration ( $\leq 140$  ppb) exposures.

Using the full dPD data set of 116 exposures, linear regression did not show an association between log-transformed dPD and either NO<sub>2</sub> concentration ( $p = 0.44$ ) or concentration  $\times$  exposure duration ( $p = 0.89$ ).

## **Factors Affecting Airway Responsiveness and Dose-Response**

### ***Exercise***

In considering why increases in airway responsiveness occurred only after resting exposure to NO<sub>2</sub>, [Folinsbee \(1992\)](#) and [Bylin \(1993\)](#) suggested that exercise itself may affect the mechanisms responsible for increased responsiveness. Recent literature continues to support the possibility that exercise may lead to a period of reduced airway responsiveness. The review by [O'Byrne et al. \(2009\)](#) noted with repeated bouts of exercise, the bronchoconstrictive response to exercise can be abolished in many individuals with asthma. Refractory periods (i.e., periods during which airway responsiveness to challenge is diminished) following exercise of 40 minutes to 3 hours have been reported ([Dryden et al., 2010](#)).

A comparison of two studies that utilized the same challenge agent following the same duration of NO<sub>2</sub> exposure and nearly the same exposure concentration supports the conclusion that exercise may diminish the subsequent responsiveness to bronchial challenge. [Jörres and Magnussen \(1990\)](#) found a statistically significant increase in airway responsiveness to a SO<sub>2</sub> challenge in subjects with asthma following exposure to 250 ppb NO<sub>2</sub> for 30 minutes at rest; whereas, [Rubinstein et al. \(1990\)](#) found no change in responsiveness to a SO<sub>2</sub> challenge following exposure of subjects with asthma to 300 ppb NO<sub>2</sub> for 30 minutes with 20 minutes of exercise. An effect of exercise refractoriness is consistent with greater increases in airway responsiveness following resting than exercising exposures to NO<sub>2</sub> as shown in [Table 5-3](#).

### ***Bronchial Challenge Delivery and Assessment***

Variations in methods for administering the bronchoconstricting agents may substantially affect the results ([Cockcroft and Davis, 2006b](#); [Cockcroft et al., 2005](#)). A repeated measures study of 55 subjects with asthma evaluating two ATS-recommended methods of methacholine delivery found a highly statistically significant ( $p < 0.00001$ ), twofold difference in PC<sub>20</sub> which was attributable to the delivery method ([Cockcroft and Davis, 2006b](#)). Even in the same subjects exposed by the same investigators in the same facility to the same bronchial challenge agent, there can be a doubling dose difference due to the delivery method. The difference observed by [Cockcroft and Davis \(2006b\)](#) may, in part, be due to the use of full vital capacity inspirations with breath-hold as part of the delivery

technique that yielded the higher PC<sub>20</sub>. The maximal lung inflations are recognized to induce bronchodilation.

The full vital capacity inspiration required for FEV<sub>1</sub> measurements when assessing airway response to challenge may cause a partial reversal of bronchospasm versus the use of other measures such as specific airway resistance or conductance ([Jackson et al., 2004](#); [Beaupré and Orehek, 1982](#); [Orehek et al., 1981](#)). [Brown \(2015\)](#) suggested that the use of forced vital capacity (FVC) maneuvers likely contributed to the lack of statistically significant effects in NO<sub>2</sub> studies employing exercising exposures. For nonspecific challenges ([Table 5-3](#)), responsiveness was assessed using FVC maneuvers in only 6% of 139 individuals exposed at rest versus 62% of 241 individuals exposed during exercise. However, inconsistent with the supposition by [Brown \(2015\)](#) for studies with exercise exposure protocols, [Table 5-2](#) shows that the studies showing statistically significant effects utilized full FVC maneuvers.

### ***Bronchial Challenge Agent***

Bronchial challenge agents differ in the mechanisms by which they cause bronchoconstriction, acting either “directly” or “indirectly” on bronchial smooth muscle receptors. Even similarly delivered nonspecific, direct acting agents may affect the lung differently. In a comparison of responses to methacholine and histamine in healthy volunteers not having AHR, [Verbanck et al. \(2001\)](#) reported that histamine caused an overall narrowing of the airways (i.e., similar between parallel lung regions), whereas methacholine caused a differential narrowing of parallel airways, which altered ventilation distribution. The differential effects of these two direct acting agents may, in part, be due to their differing target receptors and the distribution of these receptors in the airways ([O'Byrne et al., 2009](#)). Comparison of the airway responsiveness among bronchial challenge agents is complicated by the differing mechanisms by which they initiate bronchoconstriction.

The lack of statistical significance for changes in responsiveness to allergen challenges reported by [Brown \(2015\)](#) does not necessarily diminish the potential importance of allergen exposures. First, use of FVC maneuvers in NO<sub>2</sub> studies may have biased results toward not finding an effect on airway responsiveness, although this did not appear to be true for studies with exercise protocols as was discussed above. Second, 80% of children with asthma are thought to be sensitized to common household allergens ([O'Byrne et al., 2009](#)). Third, individuals with asthma may experience an early phase response to allergen challenge with declines in lung function within 30 minutes, which primarily reflects release of histamine and other mediators by airway mast cells. Approximately half of those individuals having an early phase response also have a late phase response with a decline in lung function 3–8 hours after the challenge, which reflects enhanced airway

inflammation and mucous production ([O'Byrne et al., 2009](#); [Cockcroft and Davis, 2006c](#)). The early response may be reversed with bronchodilators, whereas the late response requires steroidal treatment. Studies have reported NO<sub>2</sub>-induced effects on allergen responsiveness for both the early phase ([Jenkins et al., 1999](#); [Strand et al., 1998](#); [Tunnicliffe et al., 1994](#)) and late phase ([Strand et al., 1998](#); [Tunnicliffe et al., 1994](#)). These effects were observed following 30-minute resting exposures to concentrations as low as 260 ppb NO<sub>2</sub>. Finally, the response to an allergen is not only a function of the concentration of inhaled allergen, but also the degree of sensitization as measured by the level of allergen-specific IgE and responsiveness to nonspecific agents ([Cockcroft and Davis, 2006a](#)). These factors make it difficult to predict the level of responsiveness to an allergen, and although rare, severe bronchoconstriction can occur with inhalation of very low allergen concentrations ([O'Byrne et al., 2009](#)). It is a concern, given the ubiquity of allergens and potential severity of responses to allergen inhalation, that NO<sub>2</sub> exposure might augment these responses. The responsiveness to allergens in animals and humans is also addressed in [Sections 4.3.2.6](#) and [5.2.2.5](#).

### ***Subject Inclusion/Exclusion***

Exercise is a major trigger of asthma symptoms in between 60 and 90% of people with asthma ([Dryden et al., 2010](#)). In their study of NO<sub>2</sub> effects on airway responsiveness, [Roger et al. \(1990\)](#) reported that all of their volunteers with asthma experienced either cold air or exercise-induced bronchoconstriction. [Morrow and Utell \(1989a\)](#) reported that, "Many of the asthmatic subjects were unable to undertake the carbachol challenge after either NO<sub>2</sub> or air exposures, presumably because of pre-existing exercise-induced bronchoconstriction." Consequently, in their study, data on changes in airway responsiveness were only available for 9 of 20 subjects. Thus, the existence of exercise-induced bronchospasm and symptoms may have caused an underlying difference in the health status of subjects for which airway responsiveness was evaluated between studies involving resting versus exercising exposures. Assessing those individuals with less responsive airways could bias results toward not finding an effect of NO<sub>2</sub> on airway responsiveness in studies utilizing exercising exposures.

### ***Medication Usage***

There was a wide range in restrictions on asthma medication usage among NO<sub>2</sub> studies. It is recommended that short-acting bronchodilators be stopped 8 hours before and long-acting bronchodilators 36 hours before the bronchial challenge ([Reddel et al., 2009](#)). Even after withholding salmeterol (a long-acting bronchodilator) for 24 hours, there is still a greater than twofold reduction in airway responsiveness relative to an unmedicated baseline ([Reddel et al., 2009](#)). In their NO<sub>2</sub> study, [Hazucha et al. \(1983\)](#) required that subjects not receive steroid therapy or daily bronchodilator therapy for a month prior to

bronchial challenge testing. Other NO<sub>2</sub> study investigators recorded asthma medication usage and asked subjects to refrain from using for defined periods of time depending on the medication, such as 8 hours for short-acting bronchodilators [e.g., ([Witten et al., 2005](#); [Avol et al., 1988](#))]. Restrictions were far less in some studies, for example, [Kleinman et al. \(1983\)](#) asked subjects to withhold bronchodilators for at least 4 hours prior to exposure, but subjects were not excluded for noncompliance because medication usage was generally balanced between filtered air and NO<sub>2</sub> exposure days. Still other studies provided no indication of asthma medications or prohibitions for study inclusion [e.g., ([Bylin et al., 1988](#))]. Pretreatment (500 mg, 4 times per day for 3 days) with ascorbic acid was shown to prevent NO<sub>2</sub>-induced increases in airway responsiveness of healthy individuals ([Mohsenin, 1987b](#)). Thus, the use of asthma medications or dietary antioxidants may have reduced the ability of studies to identify an effect of NO<sub>2</sub> on airway responsiveness and may have affected observed provocative doses.

### ***Effect of Challenge Time Following Nitrogen Dioxide Exposure***

With respect to the data in [Tables 5-1](#) and [5-2](#), bronchial challenges were delivered an average of 60 minutes post-exposure. For nonspecific agents, on average, challenges were delivered 16 minutes following resting exposures and 67 minutes following exercise exposures ( $p < 0.01$ ). Although challenges may take upwards of 40 minutes to complete ([Mohsenin, 1987a](#)), the difference in the time when challenge agents were delivered could plausibly affect differences in airway responsiveness among studies. The existing data on airway responsiveness following NO<sub>2</sub> exposure are insufficient to assess the influence of challenge delivery timing on airway responsiveness in those studies.

### ***Effect of Repeated Nitrogen Dioxide Exposures***

Two studies evaluated repeated sequential daily exposures to NO<sub>2</sub> on airway responsiveness ([Ezratty et al., 2014](#); [Strand et al., 1998](#)). From these studies, it is unclear whether repeated ambient NO<sub>2</sub> exposures would have little effect or augment responses observed.

### ***Extraneous Factors***

Although some early studies progressively increased NO<sub>2</sub> exposure concentrations for safety purposes, the majority of controlled human exposure studies investigating the effects of NO<sub>2</sub> are of a randomized, controlled, crossover design in which subjects were exposed, without knowledge of the exposure condition and in random order to clean filtered air (the control), and depending on the study, to one or more NO<sub>2</sub> concentrations. The filtered air control exposure provides an unbiased estimate of the effects of the experimental procedures on the outcome(s) of interest. Comparison of responses following this filtered air exposure to those following NO<sub>2</sub> exposure allows for estimation

of the effects of NO<sub>2</sub> itself on an outcome measurement while controlling for independent effects of the experimental procedures.

### ***Dose-Response***

[Folinsbee \(1992\)](#) noted that greater NO<sub>2</sub> doses occur with exercise due to both the increased ventilation rates and a tendency for increased exposure duration. However, in his and other meta-analyses, the effects of NO<sub>2</sub> exposure on airway responsiveness were found following resting exposures, but not exercising exposures to NO<sub>2</sub>.

The dose-response of NO<sub>2</sub> on airway responsiveness may be modulated by a number of factors that have been described in this section. The finding of greater airway responsiveness following exposures at rest compared to exercise, despite a lower intake dose of NO<sub>2</sub> during the resting exposures, is consistent with an effect of exercise refractoriness. Issues related to subject selection and medication may have reduced observed effects of NO<sub>2</sub> on airway responsiveness and contributed to variability within and among studies. Both the choice of bronchial challenge agent and method of delivery would also have likely contributed to variability among studies. Methodological differences, if randomly occurring, among studies such as the choice of challenge agents, challenge delivery method, and asthma medication usage would likely add variability to assessment of airway responsiveness and thereby bias data toward the null of no discernible dose-response.

A few studies investigated the effects of NO<sub>2</sub> exposure on airway responsiveness at more than one concentration during resting exposures ([Tunncliffe et al., 1994](#); [Bylin et al., 1988](#); [Orehek et al., 1976](#)). However, these studies provide, at best, limited support for increasing airway responsiveness with increasing NO<sub>2</sub> concentration in individuals with asthma. Additionally, linear regression performed by [Brown \(2015\)](#) did not show an association between log-transformed dPD in [Figure 5-1](#) and either NO<sub>2</sub> concentration ( $p = 0.44$ ) or concentration  $\times$  exposure duration ( $p = 0.89$ ). The study by [Roger et al. \(1990\)](#) that used an exercise protocol also showed no dose-response relationship. In reviewing a draft of this ISA, a CASAC Panel member commented that a dose-response relationship would not necessarily be expected to be identified from a relatively small group of only 72 individuals [see page A-8 of ([Roux and Frey, 2015](#))].

### **Summary**

There is a wide range of airway responsiveness influenced by many factors, including exercise, medications, cigarette smoke, air pollutants, respiratory infections, disease status, and respiratory irritants. In the general population, airway responsiveness is log-normally distributed with individuals having asthma generally being more responsive

than healthy age-matched controls. Nonspecific bronchial challenge agents causing bronchoconstriction may act directly (i.e., histamine, carbachol, and methacholine) on airway smooth muscle receptors or act indirectly (i.e., exercise, cold air) through intermediate pathways, especially via inflammatory mediators. Specific challenge agents (i.e., allergens) also act indirectly on smooth muscle to initiate bronchoconstriction.

Likely affecting the observed changes in airway responsiveness due to NO<sub>2</sub> exposure, there are methodological differences among NO<sub>2</sub> studies including subject activity level (rest versus exercise) during NO<sub>2</sub> exposure, asthma medication usage, choice of airway challenge agent (e.g., direct and indirect nonspecific stimuli), method of administering the bronchoconstricting agents, and the physiological endpoint used to assess airway responsiveness. Most of these intra-study differences likely contributed to variability and uncertainty in comparison among studies of provocative doses and lung function responses to bronchial challenge agents.

The analyses excerpted from [Brown \(2015\)](#) show that the airway responsiveness of individuals with asthma is increased by brief exposures to NO<sub>2</sub>. There was a statistically significant fraction of individuals with asthma exposed to NO<sub>2</sub> at rest who experienced an increase in responsiveness. About 70% had an increase in nonspecific airway responsiveness following 30-minute exposures to NO<sub>2</sub> in the range of 200 to 300 ppb and following 60-minute exposures to 100 ppb. The median response of these individuals is an NO<sub>2</sub>-induced reduction in dPD to 0.75 (1.88, geometric standard deviation). About a quarter of the exposed individuals experienced a clinically relevant, doubling dose reduction in their dPD due to NO<sub>2</sub> exposure. The fraction experiencing a doubling dose increase in responsiveness was also statistically significant and robust to exclusion of individual studies. Results showed minimal change in airway responsiveness for individuals exposed to NO<sub>2</sub> during exercise.

---

### 5.2.2.2 Lung Function Changes in Populations with Asthma

The lung function endpoint described in this section differs from airway responsiveness in [Section 5.2.2.1](#) in that subjects are not given a bronchoconstricting agent prior to measurement of airflow or volume. Compared with evidence for airway responsiveness, the 2008 ISA for Oxides of Nitrogen reported weak evidence in controlled human exposure studies for the effects of NO<sub>2</sub> exposure on lung function changes in adults with asthma ([U.S. EPA, 2008c](#)). Epidemiologic evidence in people with asthma also was weak. Most recent studies were epidemiologic and support associations between ambient NO<sub>2</sub> concentrations and lung function decrements in children with asthma.

## Epidemiologic Studies

Collectively, previous and recent studies found associations between increases in ambient NO<sub>2</sub> concentrations and decrements in supervised spirometry measures (primarily FEV<sub>1</sub>) in children with asthma. Across the various populations examined, results are less consistent for lung function measured under unsupervised conditions, primarily peak expiratory flow (PEF) at home. Results also are inconsistent for NO and NO<sub>x</sub>. Ambient concentrations of NO<sub>2</sub>, locations, and time periods for epidemiologic studies of lung function are presented in [Table 5-4](#).

**Table 5-4 Mean and upper percentile concentrations of nitrogen dioxide in epidemiologic studies of lung function in populations with asthma.**

Study <sup>a</sup>	Location	Study Period	NO <sub>2</sub> Metric Analyzed	Mean/Median Concentration (ppb)	Upper Percentile Concentration (ppb)
<a href="#">†Delfino et al. (2008a)</a>	Riverside, CA	Jul–Dec 2003	24-h avg total personal	28.6	Max: 105.7
	Whittier, CA	Jul–Dec 2004	24-h avg central site	25.0	Max: 29.2
<a href="#">†Smargiassi et al. (2014)</a>	Montreal, QC, Canada	Oct 2009–Apr 2010	24-h avg total personal	6.3	75th: 7.4 Max: 70.6
<a href="#">†O'Connor et al. (2008)</a>	Boston, MA; Bronx, NY; Chicago, IL; Dallas, TX; New York, NY; Seattle, WA; Tucson, AZ	Aug 1998–Jul 2001	24-h avg	NR	NR
<a href="#">†Gillespie-Bennett et al. (2011)</a>	Bluff, Christchurch, Dunedin, Porirua, Hutt Valley, New Zealand	Sep 2006	4-week avg	3.9	NR
<a href="#">†Wiwatanadate and Trakultivakorn (2010)</a>	Chiang Mai, Thailand	Aug 2005–Jun 2006	24-h avg	17.2	90th: 26.5 Max: 37.4

**Table 5-4 (Continued): Mean and upper percentile concentrations of nitrogen dioxide in epidemiologic studies of lung function in populations with asthma.**

Study <sup>a</sup>	Location	Study Period	NO <sub>2</sub> Metric Analyzed	Mean/Median Concentration (ppb)	Upper Percentile Concentration (ppb)
<a href="#">Mortimer et al. (2002)</a>	Bronx and East Harlem, NY; Chicago, IL; Cleveland, OH; Detroit, MI; St. Louis, MO; Washington, DC	Jun–Aug 1993	4-h avg (6 a.m.–10 a.m.)	NR	NR
<a href="#">Just et al. (2002)</a>	Paris, France	Apr–Jun 1996	24-h avg	28.6c	Max: 59.0c
† <a href="#">Odajima et al. (2008)</a>	Fukuoka, Japan	Apr–Sep 2002	3-h avg (7 p.m.–10 p.m.)	20.0	Max: 51.3
		Oct 2002–Mar 2003		11.0	Max: 49.0
<a href="#">Delfino et al. (2003)</a>	Los Angeles, CA (Huntington Park area)	Nov 1999–Jan 2000	1-h max 8-h max	7.2 5.9	90th: 9 Max: 14 90th: 8 Max: 11
† <a href="#">Holquin et al. (2007)</a>	Ciudad Juarez, Mexico	2001–2002	1-week avg	18.2	NR
† <a href="#">Barraza-Villarreal et al. (2008)</a>	Mexico City, Mexico	Jun 2003–Jun 2005	8-h max	37.4	Max: 77.6
† <a href="#">Liu et al. (2009b)</a> <a href="#">Dales et al. (2009a)</a>	Windsor, ON, Canada	Oct–Dec 2005	24-h avg	19.8	95th: 29.5
† <a href="#">Hernández-Cadena et al. (2009)</a>	Mexico City, Mexico	May–Sep 2005	1-h max	57	75th: 69 Max: 116
† <a href="#">Martins et al. (2012)</a>	Viseu, Portugal	Jan and Jun 2006 and 2007	1-week avg <sup>b</sup>	Across 4 periods: 4.5, 3.5, 9.8, 8.2 <sup>c</sup>	Max across 4 periods: 4.6, 4.0, 10.9, 9.4 <sup>c</sup>
† <a href="#">Greenwald et al. (2013)</a>	El Paso, TX	Mar–Jun 2010	96-h avg	School A: 6.5 School B: 17.5	NR
† <a href="#">Spira-Cohen et al. (2011)</a>	Bronx, NY	Spring 2002, Spring/Fall 2004, Spring 2005	6-h avg (9 a.m.–3 p.m.)	NR	NR
† <a href="#">Yamazaki et al. (2011)</a>	Yotsukaido, Japan	Oct–Dec 2000	1-h avg (6 p.m.–7 p.m.)	32.6	NR

**Table 5-4 (Continued): Mean and upper percentile concentrations of nitrogen dioxide in epidemiologic studies of lung function in populations with asthma.**

Study <sup>a</sup>	Location	Study Period	NO <sub>2</sub> Metric Analyzed	Mean/Median Concentration (ppb)	Upper Percentile Concentration (ppb)
† <a href="#">Qian et al. (2009a)</a>	Boston, MA; New York, NY; Madison, WI; Denver, CO; Philadelphia, PA; San Francisco, CA	Feb 1997– Jan 1999	24-h avg	20.8	75th: 28.8 Max: 60.7
<a href="#">Lagorio et al. (2006)</a>	Rome, Italy	May–Jun, Nov–Dec 1999	24-h avg	37.6 <sup>c</sup>	Max: 54.3 <sup>c</sup>
<a href="#">McCreanor et al. (2007)</a>	London, U.K.	Nov–Mar 2003–2005	2-h avg (10:30 a.m.– 12:30 p.m.)	Oxford St: 75.5 <sup>c</sup> Hyde Park: 11.5 <sup>c</sup>	Max: 154 <sup>c</sup> Max: 77.7 <sup>c</sup>
† <a href="#">Maestrelli et al. (2011)</a>	Padua, Italy	1999–2003	24-h avg	Across seasons and years: 20.9–37.0 <sup>c</sup>	Range of 75th: 23.0–42.5 <sup>c</sup>
† <a href="#">Canova et al. (2010)</a>	Padua, Italy	Summer/Fall 2004, Winter/ Summer/Fall 2005	24-h avg	27.2 <sup>c</sup>	48.1 <sup>c</sup>
<a href="#">Hiltermann et al. (1998)</a>	Bilthoven, the Netherlands	July–Oct 1995	24-h avg	11.2 <sup>c</sup>	22.5 <sup>c</sup>
† <a href="#">Wiwatanadate and Liwsrisakun (2011)</a>	Chiang Mai, Thailand	Aug 2005– Jun 2006	24-h avg	17.2	90th: 26.5 Max: 37.4
<a href="#">Park et al. (2005)</a>	Incheon, South Korea	Mar–Jun 2002	24-h avg	Control days: 31.6 Dust days: 20.7	NR

a.m. = ante meridiem; Aug = August; avg = average; AZ = Arizona; CA = California; CO = Colorado; DC = District of Columbia; Dec = December; Feb = February; IL = Illinois; MA = Massachusetts; MI = Michigan; MO = Missouri; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; NY = New York; OH = Ohio; ON = Ontario; PA = Pennsylvania; QC = Québec; TX = Texas; WA = Washington; WI = Wisconsin; UK = United Kingdom.

<sup>a</sup>Studies presented in order of first appearance in the text of this section.

<sup>b</sup>Subject-level exposure estimates calculated from outdoor NO<sub>2</sub> at schools and other locations plus time-activity patterns.


<sup>c</sup>Concentrations converted from µg/m<sup>3</sup> to ppb using the conversion factor of 0.532 assuming standard temperature (25°C) and pressure (1 atm).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

### **Children with Asthma**

In contrast with studies reviewed in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), several recent studies of children with asthma conducted spirometry under

supervised conditions, and most indicate a relationship with short-term NO<sub>2</sub> exposure ([Figure 5-3](#) and [Table 5-5](#)). Studies of supervised spirometry measured lung function daily, weekly, biweekly, or seasonally, whereas lung function at home was measured daily. Among the latter studies, some reported an association with NO<sub>2</sub> ([Gillespie-Bennett et al., 2011](#); [Delfino et al., 2008a](#); [O'Connor et al., 2008](#)), whereas others did not ([Wiwatanadate and Trakultivakorn, 2010](#); [Odajima et al., 2008](#); [Just et al., 2002](#); [Mortimer et al., 2002](#)). Several studies that reported no association with home lung function measurements did not provide quantitative results, including NCICAS ([Odajima et al., 2008](#); [Delfino et al., 2003](#); [Just et al., 2002](#); [Mortimer et al., 2002](#)). Thus, the relative magnitude and precision of their results cannot be assessed. Results also are inconsistent among U.S. multicity studies [National Cooperative Inner-city Asthma Study (NCICAS), Inner City Asthma Study (ICAS)] ([O'Connor et al., 2008](#); [Mortimer et al., 2002](#)). However, a relationship between ambient NO<sub>2</sub> and PEF is indicated in children with asthma in a recent meta-analysis ([Weinmayr et al., 2010](#)) that included mostly European studies as well as some studies reviewed in the 2008 ISA for Oxides of Nitrogen.



Note: avg = average; CI = confidence interval; FEV<sub>1</sub> = forced expiratory volume in 1 second; h = hour; max = maximum; NO<sub>2</sub> = nitrogen dioxide. Black = studies from the 2008 Integrated Science Assessment for Oxides of Nitrogen, red = recent studies. Results are separated into two plots for the two most common indices of FEV<sub>1</sub> examined in studies. Results from more informative studies in terms of the exposure assessment method and potential confounding considered are presented first in each plot. Study details and quantitative results are reported in [Table 5-5](#). [Table 5-5](#) presents results for an array of lung function indices; some of these did not have sufficient numbers to present in a figure.

<sup>a</sup>Effect estimates are standardized to a 20-ppb increase for 24-h avg NO<sub>2</sub> and a 30-ppb increase in 1-h maximum NO<sub>2</sub>. Effect estimates for 1-h average to 12-h average NO<sub>2</sub> are not standardized but presented as they are reported in their respective studies ([Section 5.1.2.2](#)).

<sup>b</sup>Studies with home-based FEV<sub>1</sub> measurements. All other studies conducted supervised spirometry.

**Figure 5-3 Associations of nitrogen dioxide ambient concentrations or personal exposure with percentage change in forced expiratory volume in 1 second (top plot) and change in percent predicted forced expiratory volume in 1 second (bottom plot) in children and adults with asthma.**

**Table 5-5 Epidemiologic studies of lung function in children and adults with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<b>Children with asthma: studies with small spatial scale exposure assessment and/or examination of copollutant confounding</b>				
<p>†<a href="#">Delfino et al. (2008a)</a> Riverside, Whittier, CA n = 53, ages 9–18 yr, persistent asthma and exacerbation in previous 12 mo Repeated measures. Home spirometry; measurements checked daily by research staff. Examined daily for 10 days. 519 observations. Recruitment by referral from school nurses. Parent report of physician-diagnosed asthma. Nonsmokers from nonsmoking homes. No information on participation rate. Mixed effects model with random effect for subject with pollutant concentrations centered on subject mean and adjusted for personal relative humidity, personal temperature, and follow-up period. Adjustment for city, beta agonist use, weekend, gas stove use did not alter results.</p>	NO <sub>2</sub> -total personal 24-h avg		% predicted FEV <sub>1</sub> All subjects	With 1-h max PM <sub>2.5</sub> : –1.3 (–2.8, 0.22)
	Monitoring checked daily; all samples above detection limit of 2.1 ppb ( <a href="#">Staimer et al., 2005</a> )	0–1 avg	–1.7 (–3.2, –0.19)	Moderate correlation with NO <sub>2</sub> . Spearman <i>r</i> = 0.38 for personal PM <sub>2.5</sub> , 0.36 for central site PM <sub>2.5</sub> . PM <sub>2.5</sub> not altered by adjustment for NO <sub>2</sub> . EC, OC not associated with FEV <sub>1</sub> . Central site NO <sub>2</sub> with personal PM <sub>2.5</sub> : –0.86 (–2.6, 0.89).
	Central site and personal NO <sub>2</sub> moderately correlated. <i>r</i> = 0.43.	0	All subjects –1.5 (–2.3, –0.57)	
			No bronchodilator, n = 37 –1.7 (–2.7, –0.75)	
			Bronchodilator use, n = 16 –0.70 (–2.9, 1.5)	
	NO <sub>2</sub> -central site 24-h avg Site within 8 or 16 km of homes.	0	All subjects –1.3 (–2.4, –0.15)	

**Table 5-5 (Continued): Epidemiologic studies of lung function in children and adults with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<p>†<a href="#">Smargiassi et al. (2014)</a> Montreal, QC, Canada n = 72, ages 7–12 yr, 29% with ED visit in previous 12 mo, 43% using steroid medication during study Repeated measures. Supervised spirometry. Examined daily for 10 days. 700 observations. Residence near oil refineries &amp; high traffic areas. Recruitment from asthma clinic or schools. Asthma ascertained by respirologist or parental report of physician diagnosis. No information on participation rate. Linear mixed effects models with random effect for subject, random and fixed effect for study day and adjusted for age, sex, height, month, day of week, asthma medication use, parental education, ethnicity, personal temperature, personal humidity.</p>	<p>NO<sub>2</sub>-total personal 24-h avg 99% samples above limit of detection 65% time spent indoors</p>	0	<p>FEV<sub>1</sub>: 0.56% (–1.8, 2.9) FVC: 0.36% (–1.4, 2.2) FEF<sub>25–75%</sub>: 0.35% (–4.7, 5.4)</p>	<p>No copollutant model. No consistent associations with personal PM<sub>2.5</sub>, benzene, total polycyclic aromatic hydrocarbons. Correlations among pollutants = –0.11 to 0.11.</p>
<p>†<a href="#">Martins et al. (2012)</a>, <a href="#">Martins (2013)</a> Viseu, Portugal n = 51, mean age 7.3 (SD: 1.1) yr, 53% with atopy. Repeated measures. Supervised spirometry. Four measurements over two different seasons. Recruitment from urban and suburban schools. ~66% participation rate. Parental report of wheeze in previous 12 mo. GEE adjusted for age, sex, parental smoking, parental education, atopy, time of visit, average temperature, relative humidity. Also included height, weight, older siblings, mold or dampness in home, fireplace in home, pets in home because they changed at least one pollutant effect estimate &gt;10%.</p>	<p>NO<sub>2</sub>-modeled personal outdoor 24-h avg Estimated from school outdoor NO<sub>2</sub>, 20 city locations, MM5/CHIMERE modeling, and daily activity patterns. 20% time spent at school, 65% at home.</p>	0–4 avg	<p>FEV<sub>1</sub>: –22% (–38, –1.5) FEV<sub>1</sub>/FVC: –10% (–20, 0.83) FEF<sub>25–75%</sub>: –33% (–54, –2.6) FEV<sub>1</sub> after bronchodilator: 19% (3.5, 37)</p>	<p>For FEV<sub>1</sub>: with PM<sub>10</sub>: –27% (–67, 60) with benzene: –3.6% (–29, 31) with ethylbenzene: –17% (–41, 17) Benzene unaltered by adjustment for NO<sub>2</sub>. Ethylbenzene &amp; PM<sub>10</sub> attenuated. Correlations with NO<sub>2</sub> negative or weakly positive. Spearman <i>r</i> = –0.82 to –0.55 for PM<sub>10</sub>, –0.42 to 0.14 for VOCs.</p>

**Table 5-5 (Continued): Epidemiologic studies of lung function in children and adults with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<p>†<a href="#">Greenwald et al. (2013)</a> El Paso, TX n = 38, mean age 10 yr, 76% Mexican-American Repeated measures. Supervised spirometry. Examined weekly for 13 weeks. 413–441 observations. Recruitment from schools in low- and high-traffic area. No information on participation rate. School record of physician-diagnosed asthma. GLM with subject as random effect and adjusted for school, temperature, relative humidity, indoor NO.</p>	<p>NO<sub>2</sub>-school outdoor School A: residential area School B: 91 m from major road.</p> <hr/> <p>NO<sub>2</sub>-school indoor Most samples above limit detection of 2.88 ppb (<a href="#">Raysoni et al., 2011</a>) All 24-h avg</p>	0–3 avg	<p>FEV<sub>1</sub>: School A: 25% (–15, 84) School B: –17% (–32, 0.12)</p> <hr/> <p>School A: 38% (–12, 116) School B: –14% (–32, 7.2)</p>	<p>No copollutant model. BC, SO<sub>2</sub> (central site) associated with FEV<sub>1</sub>. Moderate correlation with NO<sub>2</sub>. Pearson <math>r = 0.62</math>, <math>-0.22</math>. School BTEX associated with FEV<sub>1</sub>, highly correlated with NO<sub>2</sub>. <math>r = 0.77</math>.</p>
<p>†<a href="#">Holquin et al. (2007)</a> Ciudad Juarez, Mexico n = 95, ages 6–12 yr, 78% mild, intermittent asthma, 58% atopy Repeated measures. Supervised spirometry. Examined biweekly for 4 mo. 87% participation. Self-report of physician-diagnosed asthma. Linear and nonlinear mixed effects model with random effect for subject and school adjusted for sex, body mass index, day of week, season, maternal and paternal education, passive smoking exposure.</p>	<p>NO<sub>2</sub>-school outdoor 24-h avg Schools located 239–692 m from homes.</p>	0–6 avg	FEV <sub>1</sub> : –2.4% (–5.1, 0.24)	<p>No copollutant model. No association with PM<sub>2.5</sub>, EC. Weak to moderate correlations with NO<sub>2</sub>. Spearman <math>r = 0.30</math> for PM<sub>2.5</sub>, 0.49 for EC. Road density at home not school associated with lung function.</p>
<p>†<a href="#">Spira-Cohen (2013)</a>, <a href="#">Spira-Cohen et al. (2011)</a> Bronx, NY n = 40, ages 10–12 yr, 100% nonwhite, 44% with asthma ED visit or hospital admission in previous 12 mo Repeated measures. Supervised spirometry. Examined daily for 1 mo. 454 observations. No information on participation rate. Recruitment from schools by referrals from school nurses. Parental report of physician-diagnosed asthma. Mixed effects model with subject as random effect adjusted for height, sex, temperature. Adjustment for school (indicator of season) did not alter results.</p>	<p>NO<sub>2</sub>-school outdoor 6-h avg (9 a.m.–3 p.m.) Schools 53–737 m from highways with varying traffic counts. Most children walk to school. 89% time spent indoors.</p>	0	<p>FEV<sub>1</sub>: 0.56% (–3.9, 5.1) PEF: 2.2% (–2.4, 6.8) Per 60-ppb increase NO<sub>2</sub> (5th–95th percentile change)</p>	<p>NO<sub>2</sub> effect estimate adjusted for personal EC not reported. Personal EC associated with lung function and not altered by NO<sub>2</sub> adjustment. Personal EC-School NO<sub>2</sub> correlation NR. School EC-School NO<sub>2</sub> moderately correlated. <math>r = 0.36</math>.</p>

**Table 5-5 (Continued): Epidemiologic studies of lung function in children and adults with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<p>†<a href="#">Gillespie-Bennett et al. (2011)</a> Bluff, Dunedin, Christchurch, Porirua, Hutt Valley, New Zealand n = 358, ages 6–13 yr Cross-sectional. Home spirometry. Multiple measures of lung function, one NO<sub>2</sub> measurement. Recruitment from a home heating intervention. 77% participation. Mixed effects model with log-transformed NO<sub>2</sub> and random effect for subject. Adjustment for age, sex, region, ethnicity, intervention, income, temperature did not alter results.</p>	<p>NO<sub>2</sub>-home outdoor  NO<sub>2</sub>-home indoor Mean 6.1 ppb; no information on limit of detection</p>	<p>4-week avg</p>	<p>Per log increase NO<sub>2</sub>: Evening FEV<sub>1</sub> –88 (–191, 15) mL  Evening FEV<sub>1</sub> –13 (–26, –0.38) mL</p>	<p>No copollutant model. No other pollutants examined.</p>
<p>†<a href="#">Liu (2013)</a>, <a href="#">Liu et al. (2009b)</a> Windsor, ON, Canada n = 182, ages 9–14 yr Repeated measures. Supervised spirometry. Examined weekly for 4 weeks, same day of week. 672 observations. Recruitment from schools. No information on participation rate. Parental report of physician-diagnosed asthma. Mixed effect model with random effect for subject and adjusted for testing period, temperature, relative humidity, daily medication use.</p>	<p>NO<sub>2</sub>-central site 24-h avg Average of 2 sites 99% subjects live within 10 km of sites.</p>	<p>0  0–2 avg</p>	<p>FEV<sub>1</sub>: –1.2% (–3.2, 0.84) FEF<sub>25–75%</sub>: –4.8% (–8.6, –0.94)  FEV<sub>1</sub>: –2.3% (–5.5, 0.92) FEF<sub>25–75%</sub>: –8.0 (–14, –1.6)</p>	<p>For lag 0–2 avg NO<sub>2</sub> and FEV<sub>1</sub> with PM<sub>2.5</sub>: 1.2% (–3.8, 6.4) with SO<sub>2</sub>: –1.5% (–4.9, 2.2)  PM<sub>2.5</sub> association not altered by NO<sub>2</sub> adjustment, SO<sub>2</sub> attenuated. NO<sub>2</sub> highly correlated with PM<sub>2.5</sub>. Spearman <i>r</i> = 0.71 for PM<sub>2.5</sub>, 0.18 for SO<sub>2</sub>.</p>
<p>†<a href="#">Dales et al. (2009a)</a> Windsor, ON, Canada n = 182, ages 9–14 yr Repeated measures. Same cohort as above. Unsupervised peak flow. Examined daily for 4 weeks, same day of week. 672 observations. Recruitment from schools. No information on participation rate. Parental report of physician-diagnosed asthma. Mixed effect model with random effect for subject and adjusted for sex, testing period, day of week, daily mean temperature, relative humidity, time spent outdoors.</p>	<p>NO<sub>2</sub>-central site 12-h avg (8 a.m.–8 p.m.) Average of 2 sites; 99% subjects live within 10 km of sites. Mean 1.6 and 2.2 h/day spent outdoors.</p>	<p>0</p>	<p>Evening % predicted FEV<sub>1</sub>: –0.10 (–0.31, 0.10) Diurnal change FEV<sub>1</sub>: –0.34% (–0.64, –0.04) Per 9.8 ppb increase in NO<sub>2</sub> (interquartile range)</p>	<p>Copollutant model results only in figure. Evening FEV<sub>1</sub>: NO<sub>2</sub> becomes positive with PM<sub>2.5</sub> adjustment. Diurnal change FEV<sub>1</sub>: NO<sub>2</sub> not altered by adjustment for PM<sub>2.5</sub> or SO<sub>2</sub>. SO<sub>2</sub> and PM<sub>2.5</sub> not altered by adjustment for NO<sub>2</sub>. NO<sub>2</sub> highly correlated with PM<sub>2.5</sub>. Pearson <i>r</i> = 0.68.</p>

**Table 5-5 (Continued): Epidemiologic studies of lung function in children and adults with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<b>Children with asthma: studies with central site exposure assessment and no examination of copollutant confounding</b>				
<p><a href="#">Delfino et al. (2003)</a> Los Angeles, CA (Huntington Park area) n = 22, ages 10–16 yr, 100% Hispanic, 27% on anti-inflammatory medication Repeated measures. Home peak flow. Recruitment from schools. 92% follow-up participation. Nonsmoking children from nonsmoking homes. Self or parental report of physician-diagnosed asthma. General linear mixed effects model with autoregressive parameter and subject specific intercept and adjusted for respiratory infections. Adjustment for weekend or max temperature did not alter results.</p>	<p>NO<sub>2</sub>-central site 8-h max 1 site within 4.8 km of home and school.</p>	<p>0 1</p>	<p>No quantitative data. Only reported no statistically significant association with PEF.</p>	<p>No copollutant model. Associations found with EC, OC, PM<sub>10</sub> but not VOCs. Moderate to high correlations with 8-h max NO<sub>2</sub>. Spearman <math>r = 0.38</math> (PM<sub>10</sub>) to 0.62 (OC). For VOCs, <math>r = 0.57</math> (benzene) to 0.72 (xylene).</p>
<p><a href="#">†Barraza-Villarreal et al. (2008)</a> Mexico City, Mexico n = 163–179, ages 6–14 yr, 54% persistent asthma, 89% atopy Repeated measures. Supervised spirometry. Examined every 15 days for mean 22 weeks. 1,503 observations. No information of participation rate. Recruitment from pediatric clinic. Asthma severity assessed by pediatric allergist. Linear mixed effects model with random effect for subject and adjusted for minimum temperature, time, sex, body mass index, ICS use. Adjustment for outdoor activity, smoking exposure, allergy medication, season did not alter results.</p>	<p>NO<sub>2</sub>-central site 1-h max Site within 5 km of school or home. Low correlation for school vs. central site: Spearman <math>r = 0.21</math></p>	<p>1–4 avg</p>	<p>FEV<sub>1</sub>: 0% (1.1, 1.04) FVC: -0.11% (-1.2, 0.95)</p>	<p>No copollutant model PM<sub>2.5</sub> associated with FEV<sub>1</sub> and FVC. Moderate correlation with NO<sub>2</sub>. Pearson <math>r = 0.61</math></p>
<p><a href="#">†Hernández-Cadena et al. (2009)</a> Mexico City, Mexico n = 85, ages 7–12 yr, 62% mild, intermittent asthma, 90% atopy Cross-sectional. Supervised spirometry. Recruitment from asthma and allergy clinic. Atopy and asthma severity assessed at clinic. Linear regression adjusted for sex, pet ownership in previous 12 mo, visible mold in home, lag 1 max temperature. Adjustment for age and passive smoking exposure did not alter results. Did not examine potential confounding by SES.</p>	<p>NO<sub>2</sub>-central site 1-h max Site within 5 km of home or school. 24-h avg and 8-h max similar results but less precise.</p>	<p>0</p>	<p>FEV<sub>1</sub> response to bronchodilator: -39% (-64, 5.4)</p>	<p>No copollutant model. O<sub>3</sub>, not PM<sub>2.5</sub> associated with FEV<sub>1</sub> response. O<sub>3</sub> moderately correlated with NO<sub>2</sub>. <math>r = 0.35</math>.</p>

**Table 5-5 (Continued): Epidemiologic studies of lung function in children and adults with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p><a href="#">Mortimer et al. (2002)</a> Bronx and East Harlem, NY; Chicago, IL; Cleveland, OH; Detroit, MI; St. Louis, MO; Washington, DC (NCICAS) n = 846, ages 4–9 yr Repeated measures. Home peak flow. Examined daily for four 2-week periods. Recruitment from ED visits and clinics. Parent report of physician-diagnosed asthma and symptoms in previous 12 mo or asthma symptoms for &gt;6 weeks, or family history of asthma. Participation from 55% full cohort. Sample representative of full cohort except for greater asthma medication use. Mixed effects model adjusted for city, follow-up period, day of study, 24-h rainfall, 12-h avg temperature.</p>	<p>NO<sub>2</sub>-central site 4-h avg (6 a.m.–10 a.m.) Average of all city monitors.</p>	<p>Single-day lags 1 to 6 1–5 avg 1–4 avg 0–4 avg 0–3 avg</p>	<p>No quantitative data. Only reported no association with PEF.</p>	<p>No copollutant model. O<sub>3</sub> associated with PEF. Weak correlation with NO<sub>2</sub>. <i>r</i> = 0.27.</p>
<p><a href="#">†O'Connor et al. (2008)</a> Boston, MA; Bronx, NY; Chicago, IL; Dallas, TX; New York, NY; Seattle, WA; Tucson, AZ (ICAS) n = 861, ages 5–12 yr, persistent asthma and atopy, 82% black or Hispanic Repeated measures. Home spirometry. Examined for 2 weeks every 6 mo for 2 yr. 70% of maximum data obtained. Recruited from intervention study. Mixed effects model adjusted for site, month, sitexmonth interaction, temperature, intervention group.</p>	<p>NO<sub>2</sub>-central site 24-h avg All monitors close to home and not near industry. Median distance to site = 2.3 km.</p>	<p>1–5 avg</p>	<p>% predicted FEV<sub>1</sub>: –1.3 (–1.9, –0.78) % predicted PEF: –1.6 (–2.2, –1.1)</p>	<p>Only three-pollutant model analyzed with PM<sub>2.5</sub> and O<sub>3</sub>. Associations also found with PM<sub>2.5</sub>, CO, SO<sub>2</sub>, and O<sub>3</sub>. Moderate correlations with NO<sub>2</sub>. <i>r</i> = 0.59 for PM<sub>2.5</sub>, 0.54 for CO, 0.59 for SO<sub>2</sub>. Weak correlation with O<sub>3</sub>. <i>r</i> = –0.31.</p>
<p><a href="#">†Yamazaki et al. (2011)</a> Yotsukaido, Japan n = 17, ages 8–15 yr, 100% atopy Repeated measures. Supervised peak flow before medication use. Examined daily during long-term hospital stay. No air conditioning in hospital. Permitted to go outside if asthma stable. Poor generalizability. 1,198 observations. GEE adjusted for sex, age, height, temperature, day of week, temporal trends.</p>	<p>NO<sub>2</sub>-central site 1-h avg (various times of day) Monitor adjacent to hospital. No major roads nearby.</p>	<p>0</p>	<p>No quantitative data. PEF decreases with increasing NO<sub>2</sub> in preceding 0 to 23 hours. Strongest associations at 0 h and 12 h.</p>	<p>Only three-pollutant model analyzed with PM<sub>2.5</sub> and O<sub>3</sub>. PM<sub>2.5</sub>, not O<sub>3</sub>, also associated with evening PEF. PM<sub>2.5</sub> moderately to highly correlated with NO<sub>2</sub>. <i>r</i> = 0.54 to 0.78 depending on time of day.</p>

**Table 5-5 (Continued): Epidemiologic studies of lung function in children and adults with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p><a href="#">Just et al. (2002)</a> Paris, France n = 82, ages 7–15 yr, asthma attack in previous 12 mo and daily asthma medication use, 90% atopy Repeated measures. Home peak flow. Examined daily for 3 mo. 82% participation. Recruitment from hospital outpatients. GEE adjusted for time trend, day of week, pollen, temperature, humidity.</p>	<p>NO<sub>2</sub>-central site 24-h avg Average of 14 sites</p>	<p>NR</p>	<p>No quantitative data. Only reported no relationship with PEF.</p>	<p>No copollutant model. O<sub>3</sub> associated with PEF. No correlation with NO<sub>2</sub>. Pearson <math>r = 0.09</math>.</p>
<p><a href="#">†Odajima et al. (2008)</a> Fukuoka, Japan n = 70, ages 4–11 yr, 66% with asthma exacerbation Repeated measures. Home peak flow. Examined daily for 1 yr. &gt;15,000 observations. Participation rate not reported. Recruitment from hospital where received treatment. GEE adjusted for age, sex, height, growth of child, temperature.</p>	<p>NO<sub>2</sub>-central site 3-h avg 24-h avg 1 site</p>		<p>No quantitative data. Only reported no association with PEF.</p>	<p>Only three-pollutant model analyzed with suspended PM and O<sub>3</sub>. Suspended PM associated with PEF in warm season. Weak correlation with NO<sub>2</sub>. <math>r = 0.30</math> for 24-h avg.</p>
<p><a href="#">†Wiwatanadate and Trakultivakorn (2010)<sup>b</sup></a> Chang Mai, Thailand n = 31, ages 4–11 yr, asthma plus symptoms in previous 12 mo, 52% mild intermittent Repeated measures. Home peak flow. Examined daily for 1 yr. 97% participation. Recruitment from allergy clinic. GLM with random effect for subject and adjusted for time trend, day of week, height, weight, atmospheric pressure, temperature, sunshine duration.</p>	<p>NO<sub>2</sub>-central site 24-h avg 1 site within 25 km of homes.</p>	<p>0 1</p>	<p>PEF –1.8 (–5.4, 1.8) L/min 2.6 (–1.2, 6.4) L/min</p>	<p>No copollutant model. No consistent (across various lags of exposure) associations found for PM<sub>2.5</sub>, CO, PM<sub>10</sub>, SO<sub>2</sub>, or O<sub>3</sub>.</p>

**Table 5-5 (Continued): Epidemiologic studies of lung function in children and adults with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<b>Adults with Asthma: studies with small spatial scale exposure assessment and/or examination of copollutant confounding</b>				
<p><a href="#">McCreaon et al. (2007)</a> London, U.K. n = 31 mild asthma, 32 moderate asthma, ages 19–55 yr, all with airway hyperresponsiveness, 84% with atopy Randomized cross-over natural experiment. Supervised spirometry. Exposure on busy road and park. 55 observations. Participation rate not reported. Recruitment from advertisements and volunteer databases. Mixed effects model with random effect for subject and adjusted for temperature, relative humidity.</p>	<p>NO<sub>2</sub>-personal outdoor 2-h avg Measured next to subjects during outdoor exposures.</p>	<p>0-h       22-h Post-exposure</p>	<p>FEV<sub>1</sub>: -0.22% (-0.40, -0.05) FEF<sub>25-75%</sub>: -0.78% (-1.4, -0.13)   FEV<sub>1</sub>: -0.13% (-0.35, 0.10) FEF<sub>25-75%</sub>: -0.75% (-1.6, 0.10) per 5.3 ppb NO<sub>2</sub></p>	<p>For FEF<sub>25-75%</sub> with UFP: -0.47% (-1.3, 0.39) with EC: -0.43% (-1.1, 0.26) with PM<sub>2.5</sub>: -0.48% (-1.3, 0.3)  Moderate correlations with NO<sub>2</sub>. Spearman <i>r</i> = 0.58 for UFP and EC, 0.60 for PM<sub>2.5</sub>.</p>
<p><a href="#">†Qian et al. (2009b)</a> Boston, MA; New York, NY; Denver, CO; Philadelphia, PA; San Francisco, CA; Madison, WI n = 119, ages 12–65 yr, persistent asthma, nonsmokers Repeated measures. Home PEF. No information on participation rate. Study population representative of full cohort. Examined daily for 16 weeks. &gt;14,000 observations. Trial of asthma medication, a priori comparison of medication regimen. Linear mixed effects model adjusted for age, sex, center, season, race/ethnicity, week, daily average temperature and humidity. Adjustment for viral infections did not alter results.</p>	<p>NO<sub>2</sub>-central site 24-h avg Average of all monitors within 32 km of subject ZIP code centroid.</p>	<p>0</p>	<p>PEF All subjects -0.68% (-1.3, -0.06) Placebo -0.29% (-1.4, 0.80) Beta-agonist -1.1% (-2.1, -0.05) ICS -0.61% (-1.7, 0.39)</p>	<p>with SO<sub>2</sub>: -0.11% (-0.87, 0.64) with PM<sub>10</sub>: -0.80% (-1.7, 0.10) with O<sub>3</sub>: -0.68% (-1.3, -0.05) SO<sub>2</sub> slightly attenuated with NO<sub>2</sub> adjustment. PM<sub>10</sub>, O<sub>3</sub> not associated with PEF. Correlations NR.</p>
<b>Adults with Asthma: studies with central site exposure assessment and no examination of copollutant confounding</b>				
<p><a href="#">†Maestrelli et al. (2011)</a> Padua, Italy n = 32, mean age 39.6 (SD: 7.5) yr, 81% persistent asthma Repeated measures. Supervised spirometry. 6 measures over 2 yr. 166 observations. Selected from database of beta-agonist users (&gt;6/yr for 3 yr), diagnosis clinically confirmed. 76% follow-up participation. Dropouts did not differ from participants. GEE adjusted for daily average temperature, atmospheric pressure, humidity, asthma medication use, current smoking.</p>	<p>NO<sub>2</sub>-central site 24-h avg Average of 2 city sites</p>	<p>0</p>	<p>% predicted FEV<sub>1</sub>: 1.1 (-6.6, 8.7)</p>	<p>No copollutant model. CO associated with FEV<sub>1</sub>. No association with personal or central site PM<sub>2.5</sub>. No association for central site PM<sub>10</sub>, SO<sub>2</sub>, O<sub>3</sub>. Correlations with NO<sub>2</sub> NR.</p>

**Table 5-5 (Continued): Epidemiologic studies of lung function in children and adults with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<a href="#">Lagorio et al. (2006)</a> Rome, Italy n = 11, ages 18–64 yr, 100% mild, intermittent asthma Repeated measures. Supervised spirometry. Examined 2/week for two 1-mo periods. Mean 9, 15 observations/subject. Participation rate not reported. Recruitment of nonsmokers from outpatient clinic. GEE adjusted for season, temperature, humidity, beta-agonist use.	NO <sub>2</sub> -central site 24-h avg Average of 5 city sites	0 0–1 avg	% predicted FEV <sub>1</sub> : –4.1 (–6.7, –1.6) –4.8 (–7.5, –2.1)	No copollutant model. CO at lag 0–2 avg associated with FEV <sub>1</sub> . No association for PM <sub>2.5</sub> , PM <sub>10</sub> , PM <sub>10–2.5</sub> , O <sub>3</sub> . Low to moderate correlations with NO <sub>2</sub> . Spearman <i>r</i> = 0.05 for CO, 0.17 for O <sub>3</sub> , 0.43–0.51 for PM.
<a href="#">†Canova et al. (2010)</a> Padua, Italy n = 19, ages 15–44 yr, 81% moderate/severe asthma Repeated measures. Home PEF/FEV <sub>1</sub> . Examined for five 30-day periods for 2 yr. Recruitment from prescription database of subjects with mean >6 prescription/yr for 3 yr. 50% subjects provided fewer than 33% maximum observations. GEE adjusted for temperature, humidity, atmospheric pressure, ICS use, smoking status.	NO <sub>2</sub> -central site 24-h avg 2 city sites	0, 1, 2, 3, 0–1 avg, 0–3 avg	Results reported only in a figure. NO <sub>2</sub> shows null associations with PEF and FEV <sub>1</sub> .	No copollutant model. CO associated with PEF. Moderate correlation with NO <sub>2</sub> . Spearman <i>r</i> = 0.48.
<a href="#">Park et al. (2005)</a> Incheon, South Korea n = 64 with asthma, ages 16–75 yr, 31% with severe asthma Repeated measures. Home PEF. Examined daily for 3–4 mo. Recruited from medical center. GEE model, covariates NR.	NO <sub>2</sub> -central site 24-h avg 10 city sites	0	PEF 0.45 (–1.1, 1.9) L/min	No copollutant model. CO, PM <sub>10</sub> , O <sub>3</sub> associated with PEF. No association for SO <sub>2</sub> .
<a href="#">†Wiwatanadate and Liwsrisakun (2011)</a> Chiang Mai, Thailand n = 121 with asthma and symptoms in previous 12 mo, ages 13–78 yr, 48% moderate/severe persistent asthma Repeated measures. Home PEF. Examined daily for 10 mo. Recruited from allergy clinic patients. GLM with random effect for subject and adjusted for sex, age, asthma severity, day of week, weight, pressure, temperature, sunshine duration, rain.	NO <sub>2</sub> -central site 24-h avg 1 city site	5	Evening PEF: 1.0 (0.0, 2.0) Average PEF: 1.6 (0.60, 2.6) Units of PEF not reported.	Only multipollutant models analyzed. No associations with PM <sub>10</sub> , SO <sub>2</sub> , O <sub>3</sub> . Interactions between NO <sub>2</sub> and copollutant or meteorological variables reported not to be statistically significant.

**Table 5-5 (Continued): Epidemiologic studies of lung function in children and adults with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<a href="#">Hiltermann et al. (1998)</a> Bilthoven, the Netherlands n = 60 with asthma, ages 18–55 yr, all with airway hyperresponsiveness, 87% with atopy Repeated measures. Home PEF. Examined daily for 4 mo. Recruitment from outpatient clinic. Model adjusted for allergen concentrations, smoking exposure, day of week, temperature, linear and quadratic term for study day	NO <sub>2</sub> -central site 24-h avg 1 city site Site within 20 km of subjects' homes. 3 city sites highly correlated. <i>r</i> = 0.88.	0 0–6 avg	Diurnal change PEF –0.75 (–8.1, 6.6) L/min –3.0 (–16, 10) L/min	No copollutant model. BS at lag 0 associated with PEF. No association with PM <sub>10</sub> or O <sub>3</sub> .

Note: More informative studies in terms of the exposure assessment method and potential confounding considered are presented first.

a.m. = ante meridiem; avg = average; BC = black carbon; BS = black smoke; AZ = Arizona; BTEX = benzene, toluene, ethylbenzene, xylene; CA = California; CI = confidence interval; CO = carbon monoxide, Colorado; DC = District of Columbia; EC = elemental carbon; ED = emergency department; FEV<sub>25–75%</sub> = forced expiratory flow from 25% to 75% of vital capacity; FEV<sub>1</sub> = forced expiratory volume in 1 second; FVC = forced vital capacity; GEE = generalized estimating equations; GLM = generalized linear model; ICAS = Inner City Asthma Study; ICS = inhaled corticosteroid; IL = Illinois; MA = Massachusetts; MI = Michigan; MO = Missouri; NCICAS = National Cooperative Inner-city Asthma Study; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; NY = New York; O<sub>3</sub> = ozone; OC = organic carbon; OH = Ohio; ON = Ontario; PA = Pennsylvania; PEF = peak expiratory flow; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 μm; QC = Québec; SD = standard deviation; SES = socioeconomic status; SO<sub>2</sub> = sulfur dioxide; TX = Texas; UFP = ultrafine particles, UK = United Kingdom; VOC = volatile organic compound; WA = Washington; WI = Wisconsin.

<sup>a</sup>Effect estimates were standardized to a 20-ppb increase in 24-h avg NO<sub>2</sub>, a 25-ppb increase in 8-h max NO<sub>2</sub>, and a 30-ppb increase in 1-h max NO<sub>2</sub>. Effect estimates for other averaging times (1-h avg to 12-h avg) are not standardized but presented as they are reported in their respective studies ([Section 5.1.2.2](#)).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

With respect to the populations with supervised spirometry, most studies identified children with asthma by parental report of physician-diagnosed asthma. Children were recruited mostly from schools, supporting the likelihood that study populations were representative of the general population of children with asthma. Based on a priori hypotheses, results did not demonstrate larger NO<sub>2</sub>-associated decrements in lung function in children with asthma than children without asthma ([Barraza-Villarreal et al., 2008](#); [Holguin et al., 2007](#)). Study populations represented a range of asthma severity, as ascertained by Global Initiative for Asthma guidelines, ED visit or hospital admission for asthma in the previous year, or medication use. Post hoc analyses pointed to stronger associations among children with asthma not taking inhaled corticosteroid (ICS) ([Hernández-Cadena et al., 2009](#); [Liu et al., 2009b](#)) or not taking controller bronchodilators ([Delfino et al., 2008a](#)). It is not clear what these results indicate about risk varying by asthma severity, but bronchodilator use has been shown to reduce airway responsiveness in response to a challenge agent ([Section 5.2.2.1](#)). Further, the larger associations in ICS nonusers together with observations of NO<sub>2</sub>-associated lung function decrements in populations with high prevalence of atopy (53%, 58%) ([Martins et al., 2012](#); [Holguin et al., 2007](#)) are supported by findings for NO<sub>2</sub>-induced increases in allergic inflammation ([Section 5.2.2.5](#)) and findings for mast cell degranulation (which leads to histamine release) mediating NO<sub>2</sub>-induced lung function decrements ([Section 4.3.2.2](#)).

For children with asthma, key evidence for NO<sub>2</sub>-associated decrements in lung function measured under supervised conditions is provided by studies that assessed exposure in subjects' locations [total personal NO<sub>2</sub> ([Smargiassi et al., 2014](#); [Delfino et al., 2008a](#)), personal outdoor NO<sub>2</sub> estimated from measurements at school and other locations and time-activity data ([Martins et al., 2012](#)) or outdoor school NO<sub>2</sub> ([Greenwald et al., 2013](#); [Spira-Cohen et al., 2011](#); [Holguin et al., 2007](#))]. Among these studies, few reported participation rates (66%, 87%; [Table 5-5](#)); however, none reported issues with selective participation according to any subject characteristic or NO<sub>2</sub> exposure. These studies examined limited lags of NO<sub>2</sub> exposure but were similar in finding associations with multiday averages (i.e., lag 0–1 avg, 0–4 avg) of 24-h avg NO<sub>2</sub>. Studies that measured or estimated personal exposures provide evidence of an effect of outdoor NO<sub>2</sub> exposure on decreasing lung function. There is good indication that the time-weighted average of microenvironmental NO<sub>2</sub> concentrations for children with wheeze in Portugal ([Martins et al., 2012](#)) well represented their personal outdoor exposure. Other studies show agreement between microenvironmental and personal NO<sub>2</sub> concentrations ([Section 3.4.4.1](#)), and [Martins et al. \(2012\)](#) found school and home indoor NO<sub>2</sub> concentrations to be below the limit of detection.

Studies of total personal NO<sub>2</sub> produced contrasting results. Among children with asthma in the Los Angeles, CA area, slightly larger decrements in percent predicted FEV<sub>1</sub> were found with total personal NO<sub>2</sub> (-1.5 [95% CI: -2.3, -0.57] per 20-ppb increase in lag 0 day NO<sub>2</sub>) than central site NO<sub>2</sub> (-1.3 [95% CI: -2.4, -0.15]) ([Delfino et al., 2008a](#)). A Spearman correlation of 0.43 between personal and central site NO<sub>2</sub> indicated that ambient NO<sub>2</sub> had some influence on personal exposures. In contrast, total personal NO<sub>2</sub> exposure was not associated with lung function among children with asthma living near NO<sub>2</sub> emissions sources (i.e., oil refineries, high traffic roads) in Montreal, Canada ([Smargiassi et al., 2014](#)). Both studies of total personal exposure examined children for 10 consecutive days, and the total number of observations was higher in [Smargiassi et al. \(2014\)](#) than in [Delfino \(2006\)](#) (~700 versus ~500). In both studies, all or nearly all personal NO<sub>2</sub> measures were above the limit of detection ([Table 5-5](#)). However, it is uncertain whether the Montreal study was sufficiently powered to detect associations with NO<sub>2</sub> exposures, which were far lower than in the Los Angeles, CA study (mean: 6.3 ppb versus 28.6 ppb) and showed low variability among children and days (IQR: 2.9 ppb versus 16.8 ppb). Also, the Montreal study did not provide evidence that lung function was associated with total personal exposures to PM<sub>2.5</sub>, VOCs, or polycyclic aromatic hydrocarbons ([Smargiassi et al., 2014](#)).

Among studies of outdoor school NO<sub>2</sub>, associations with FEV<sub>1</sub> were found in populations in El Paso, TX, and Ciudad Juarez, Mexico, which are located along the U.S./Mexico border [([Greenwald et al., 2013](#); [Holguin et al., 2007](#)); [Figure 5-3](#) and [Table 5-5](#)]. Between two El Paso schools, associations were limited to the school located near a major road and characterized by higher outdoor pollutant concentrations and a larger percentage of Mexican-American children ([Greenwald et al., 2013](#)). No association with FEV<sub>1</sub> was found in children with asthma in Bronx, NY for school NO<sub>2</sub> averaged over the 6-h school day ([Spira-Cohen et al., 2011](#)). An effect of NO<sub>2</sub> is supported by similar FEV<sub>1</sub> decrements for outdoor and indoor NO<sub>2</sub> (means for both ~ 17 ppb) in an El Paso school ([Greenwald et al., 2013](#)). Larger lung function decrements were observed in association with home outdoor than indoor NO<sub>2</sub> among children in five New Zealand towns ([Gillespie-Bennett et al., 2011](#)), but the results have weak implications as multiple daily FEV<sub>1</sub> measures were related to a single 4-week average of NO<sub>2</sub>.

Compared with NO<sub>2</sub> exposures estimated for subjects' locations, NO<sub>2</sub> measured at central sites is less clearly associated with lung function decrements. Among studies that measured ambient NO<sub>2</sub> at central sites, some found associations with lung function decrements ([Yamazaki et al., 2011](#); [Dales et al., 2009a](#); [Hernández-Cadena et al., 2009](#); [Liu et al., 2009b](#); [O'Connor et al., 2008](#)). Many studies reported lack of association ([Wiwatanadate and Trakultivakorn, 2010](#); [Barraza-Villarreal et al., 2008](#); [Odajima et al., 2008](#); [Just et al., 2002](#); [Mortimer et al., 2002](#)) ([Table 5-5](#)). In this group were studies that

did not report quantitative results, and it is not possible to assess the extent to which their findings do or do not suggest associations. Across the studies examining central site NO<sub>2</sub>, exposures were assigned as ambient measurements from a site located within 5 or 10 km of subjects' homes or schools, measurements averaged among city monitors, or measurements from one site. The central site NO<sub>2</sub> assessment method did not appear to influence results; however, in Mexico City, a low correlation ( $r = 0.21$ ) between central site and school NO<sub>2</sub> suggests that the central site may not have adequately represented the variability within the study area ([Barraza-Villarreal et al., 2008](#)).

Adjustment for potential confounding varied among studies but in most cases included temperature. Several studies adjusted for (or considered in preliminary analyses) relative humidity; a few adjusted for day of the week, smoking exposure, or asthma medication use ([Table 5-5](#)). Lung function was associated with PM<sub>10</sub>, SO<sub>2</sub>, and O<sub>3</sub>, which showed negative or weakly positive correlations with NO<sub>2</sub> (e.g.,  $-0.72$  for PM<sub>10</sub> to  $0.18$  for SO<sub>2</sub>). Copollutant models were analyzed for SO<sub>2</sub>, and NO<sub>2</sub> associations with FEV<sub>1</sub> diurnal change were unaltered, although both pollutants were measured at central sites within 10 km of homes ([Dales et al., 2009a](#)).

Most studies found associations with PM<sub>2.5</sub> and the traffic-related pollutants black/elemental carbon (BC/EC) and VOCs. Copollutant models with PM<sub>2.5</sub> produced positive associations for 12-h avg and 24-h avg NO<sub>2</sub> with FEV<sub>1</sub> for children in Windsor, Canada but unaltered associations with FEV<sub>1</sub> diurnal change [([Dales et al., 2009a](#); [Liu et al., 2009b](#)); [Table 5-5](#)]. PM<sub>2.5</sub> effect estimates adjusted for NO<sub>2</sub> did not change. For this study, high NO<sub>2</sub>-PM<sub>2.5</sub> correlations ( $r = 0.71$ ) and differential exposure error with central site measurements limit inference from copollutant models. Among studies with stronger inference due to exposure assessment in subjects' locations, there is evidence of confounding by the VOC benzene but evidence for NO<sub>2</sub> associations that are independent of PM<sub>2.5</sub> or EC. For children with wheeze in Portugal, the association of modeled personal outdoor NO<sub>2</sub> with FEV<sub>1</sub> was attenuated ( $-3.7\%$  [95% CI:  $-33, 25$ ] per 20-ppb increase in 1-week avg NO<sub>2</sub>) with adjustment for benzene (Spearman  $r = -0.42$  to  $0.14$ ). Outdoor school NO<sub>2</sub> but not PM<sub>2.5</sub> or EC was associated with FEV<sub>1</sub> in children with asthma in Ciudad Juarez, Mexico ([Holguin et al., 2007](#)). In a detailed analysis of total personal and central site measures, [Delfino et al. \(2008a\)](#) found the association of personal NO<sub>2</sub> with FEV<sub>1</sub> to be robust ( $-1.3$ -point [95% CI:  $-2.8, 0.22$ ] change in percent predicted FEV<sub>1</sub> per 20-ppb increase in NO<sub>2</sub>) to adjustment for personal PM<sub>2.5</sub>, which was weakly correlated with personal NO<sub>2</sub> (Spearman  $r = 0.38$ ). Adjustment for personal PM<sub>2.5</sub> ( $r = 0.32$ ) reduced the association of central site NO<sub>2</sub> with FEV<sub>1</sub> ( $-0.86$ -point [95% CI:  $-2.6, 0.89$ ] change per 20-ppb increase in NO<sub>2</sub>). The attenuation could indicate that ambient NO<sub>2</sub> is an indicator of personal PM<sub>2.5</sub> but also could indicate less exposure measurement error for personal PM<sub>2.5</sub> than central site NO<sub>2</sub>. Nonetheless, the moderate

personal-ambient NO<sub>2</sub> correlation ( $r = 0.43$ ) and the copollutant model results for personal NO<sub>2</sub> provide evidence for effects of ambient NO<sub>2</sub> on FEV<sub>1</sub> that are independent of PM<sub>2.5</sub> exposure.

### **Adults with Asthma**

Most previous and recent studies of lung function in adults with asthma were based on PEF measured at home. Except for the recent multicity U.S. study ([Qian et al., 2009b](#)), studies indicated no association or inconsistent associations among the various lung function parameters or NO<sub>2</sub> exposure lags examined ([Wiwatanadate and Liwsrisakun, 2011](#); [Canova et al., 2010](#); [Park et al., 2005](#); [Hiltermann et al., 1998](#)). Subjects generally were recruited from outpatient clinics or doctors' offices, and the nonrandom selection of the general population may produce study populations less representative of the asthma population. Most studies examined 24-h NO<sub>2</sub> that was assessed primarily from central site measurements, and results are equally inconsistent for NO<sub>2</sub> exposures assigned from one site or averaged from multiple city sites.

Although the few results for supervised spirometry are inconsistent overall [[Maestrelli et al., 2011](#); [McCreanor et al., 2007](#); [Lagorio et al., 2006](#)]; [Table 5-5](#)], the strongest study with personal outdoor pollutant measurements shows associations for NO<sub>2</sub> that are independent of PM<sub>2.5</sub> or the traffic-related copollutants EC or UFP. Across studies, lung function was associated with EC, UFP, PM<sub>2.5</sub>, and CO, which were moderately correlated with NO<sub>2</sub> (Spearman  $r = 0.43$ – $0.60$ ) ([McCreanor et al., 2007](#); [Lagorio et al., 2006](#)). Potential confounding by CO was not examined. Among adults in London, U.K. with mild to moderate asthma, NO<sub>2</sub> measured next to subjects while walking outdoors (next to a high-traffic road allowing only diesel buses and taxis and in a park) was associated with decrements in FEV<sub>1</sub> and forced expiratory flow from 25 to 75% of vital capacity (FEF<sub>25–75%</sub>) ([McCreanor et al., 2007](#)). NO<sub>2</sub>-related decrements occurred 2 to 22 hours after exposure. A 5.3-ppb increase in 2-h avg NO<sub>2</sub> was associated with a  $-0.22\%$  (95% CI:  $-0.40, -0.05$ ) change in FEV<sub>1</sub> and  $-0.78\%$  (95% CI:  $-1.4, -0.13$ ) change in FEF<sub>25–75%</sub>. NO<sub>2</sub>-associated decrements in FEV<sub>1</sub> were attenuated to near null with adjustment for UFP ([McCreanor et al., 2007](#)). Associations with FEF<sub>25–75%</sub> decreased in magnitude and precision with adjustment for UFP, EC, or PM<sub>2.5</sub> but remained negative (e.g.,  $-0.47\%$  [95% CI:  $-1.3, 0.39$ ] per 5.3-ppb increase in 2-h avg NO<sub>2</sub> with adjustment for UFP, Spearman  $r = 0.58$ ). Effect estimates for UFP, EC, and PM<sub>2.5</sub> were unaltered or less attenuated with adjustment for NO<sub>2</sub>. Thus, results indicate NO<sub>2</sub> associations that are weaker but independent of those for UFP, EC, and PM<sub>2.5</sub>. PM<sub>10</sub> and SO<sub>2</sub> also were associated with lung function in adults with asthma and were more weakly correlated with NO<sub>2</sub>. In the U.S. multicity study, NO<sub>2</sub>-PEF associations were attenuated with adjustment for SO<sub>2</sub> ([Qian et al., 2009b](#)). However, with exposures assessed from

measurements averaged across central site monitors within 32 km of subjects' ZIP codes, it is not clear how well subjects' actual exposures to NO<sub>2</sub> or SO<sub>2</sub> were represented.

### **Controlled Human Exposure Studies**

Most controlled human exposure studies of lung function examined adults and were reviewed in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)). Consistent with epidemiologic findings, most controlled human exposure studies did not report effects on lung function in adults with asthma. Exposures ranged from 200 to 4,000 ppb NO<sub>2</sub> for 30 minutes to 6 hours, and most studies incorporated exercise in the exposure period to assess lung function during various physiological conditions ([Table 5-6](#)).

Several studies examined NO<sub>2</sub> exposures in the range of 120 to 400 ppb, and most did not observe concurrent or subsequent changes in lung function or airway resistance in adolescents with asthma ([Koenig et al., 1987](#)) or adults with asthma ([Riedl et al., 2012](#); [Jenkins et al., 1999](#); [Vagaggini et al., 1996](#); [Jörres and Magnussen, 1991](#); [Kleinman et al., 1983](#)). Only [Bauer et al. \(1986\)](#), who exposed adults with asthma to 300 ppb NO<sub>2</sub> for 30 minutes, reported statistically significant decrements in forced expiratory flow rates. A few studies examined both airway responsiveness and lung function ([Jenkins et al., 1999](#); [Bauer et al., 1986](#); [Kleinman et al., 1983](#)), and only [Bauer et al. \(1986\)](#) observed NO<sub>2</sub>-induced changes in both lung function and airway responsiveness ([Section 5.2.2.1](#)). Evidence for NO<sub>2</sub>-induced changes in lung function in adults with asthma are equally weak for higher NO<sub>2</sub> exposures, with 1,000 ppb NO<sub>2</sub> exposure resulting in small reductions in FEV<sub>1</sub> ([Jörres et al., 1995](#)) but 4,000 ppb NO<sub>2</sub> producing no changes in airway resistance ([Linn et al., 1985b](#)).

There is no strong evidence for interactions between NO<sub>2</sub> and O<sub>3</sub> in controlled human exposure studies. [Jenkins et al. \(1999\)](#) found no change in lung function in adults with asthma following exposure to 200 ppb NO<sub>2</sub> for 6 hours (with or without 200 ppb O<sub>3</sub>) or 400 ppb NO<sub>2</sub> for 3 hours (without 400 ppb O<sub>3</sub>). Statistically significant decreases in FEV<sub>1</sub> were found following the 3-hour exposure to O<sub>3</sub> and O<sub>3</sub> + NO<sub>2</sub>. Thus, results indicated an effect of O<sub>3</sub> exposure alone.

**Table 5-6 Characteristics of controlled human exposure studies of lung function in individuals with asthma.**

Study	Disease Status; Sample Size; Sex; Age (mean $\pm$ SD)	Exposure Details	Endpoints Examined
<a href="#">Koenig et al. (1987)</a>	Asthma; (1) n = 4 M, 6 F (2) n = 7 M, 3 F; Healthy; (1) n = 3 M, 7 F (2) n = 4 M, 6 F; 14.4 yr (range: 12–19)	(1) 120 ppb NO <sub>2</sub> , (2) 180 ppb NO <sub>2</sub> ; (1–2) Exposures were 30 min at rest with 10 min of exercise at $\dot{V}_E = 32.5$ L/min	Pulmonary function tests before, during, and after exposure. Symptoms immediately after and 1 day after.
<a href="#">Jenkins et al. (1999)</a>	Asthma; n = 9 M, 2 F; 31.2 $\pm$ 6.6 yr	(1) 200 ppb NO <sub>2</sub> for 6 h (2) 200 ppb NO <sub>2</sub> + 100 ppb O <sub>3</sub> for 6 h (3) 400 ppb NO <sub>2</sub> for 3 h (4) 400 ppb NO <sub>2</sub> + 200 ppb O <sub>3</sub> for 3 h (1–4) Exercise 10 min on/40 min off at $\dot{V}_E = 32$ L/min)	Pulmonary function tests before and after exposure.
<a href="#">Kleinman et al. (1983)</a>	Asthma; n = 12 M, 19 F; 31 $\pm$ 11 yr	200 ppb for 2 h; Exercise 15 min on/15 min off at $\dot{V}_E = \sim 2$ times resting	Pulmonary function testing before and after exposure. Symptoms before, immediately after, and day after exposure.
<a href="#">Jörres and Magnussen (1991)</a>	Asthma; n = 9 M, 2 F; 29 yr (range: 17–55)	250 ppb for 1 h; Rest for 20 min followed by 10 min of exercise ( $\dot{V}_E = 30$ L/min)	Airway resistance measured before, during, and after exposure.
<a href="#">Bauer et al. (1986)</a>	Asthma; n = 15; 33 $\pm$ 7.8 yr	300 ppb for 30 min (20 min at rest, 10 min of exercise at $\dot{V}_E > 3$ times resting)	Pulmonary function before, during, and after exposure.
<a href="#">Vagaggini et al. (1996)</a>	Asthma; n = 4 M, 4 F; 29 $\pm$ 14 yr Healthy; n = 7 M; 34 $\pm$ 5 yr	300 ppb for 1 h; Exercise at $\dot{V}_E = 25$ L/min	Symptoms before and 2 h after exposure. Cell counts in sputum 2-h post-exposure.
<a href="#">†Riedl et al. (2012)</a>	Asthma Phase 1: methacholine challenge; n = 10 M, 5 F; 37.3 $\pm$ 10.9 yr Phase 2: cat allergen challenge; n = 6 M, 9 F; 36.1 $\pm$ 12.5 yr	350 ppb for 2 h; Exercise 15 min on/15 min off at $\dot{V}_E = 15$ –20 L/min	Symptoms before, during, 1–22 h after exposure.

**Table 5-6 (Continued): Characteristics of controlled human exposure studies of lung function in individuals with asthma.**

Study	Disease Status; Sample Size; Sex; Age (mean ± SD)	Exposure Details	Endpoints Examined
<a href="#">Jörres et al. (1995)</a>	Asthma; n = 8 M, 4 F; 27 ± 5 yr Healthy; n = 5 M, 3 F; 27 yr (range: 21–33)	1,000 ppb for 3 h; Exercise 10 min on/10 min off at individual's maximum workload	Pulmonary function tests before, during, and after exposure. Symptoms immediately, 6 h, and 24 h after exposure. BAL fluid analysis 1 h after exposure (cell counts, histamine, prostaglandins).
<a href="#">Linn et al. (1985b)</a>	Asthma; n = 12 M, 11 F; range: 18–34 yr Healthy; n = 16 M, 9 F; range: 20–36 yr	4,000 ppb for 75 min; Two 15-min periods of exercise at $\dot{V}_E = 25$ L/min and 50 L/min	Airway resistance before, during, and after exposure. Symptoms before, during, immediately after, 1 day after and 1 week after exposure.

BAL = bronchoalveolar lavage; F = female, M = male; NO<sub>2</sub> = nitrogen dioxide; O<sub>3</sub> = ozone; SD = standard deviation; V<sub>E</sub> = minute ventilation.

†Study published since the 2008 ISA for Oxides of Nitrogen

### 5.2.2.3 Respiratory Symptoms and Asthma Medication Use in Populations with Asthma

The preceding epidemiologic evidence describing associations between short-term increases in ambient NO<sub>2</sub> concentrations and decreases in lung function in children with asthma, particularly those with atopy, supports evidence for NO<sub>2</sub>-related increases in respiratory symptoms in children with asthma. Decreased lung function can indicate airway obstruction ([Section 4.3.2](#)), which can cause symptoms. Also providing a biologically plausible link between NO<sub>2</sub> exposure and respiratory symptoms is evidence for NO<sub>2</sub>-induced increases in airway responsiveness ([Section 5.2.2.1](#)) and pulmonary inflammation ([Section 5.2.2.5](#) and [Figure 4-1](#)). Epidemiologic studies reviewed in the 2008 ISA for Oxides of Nitrogen consistently found increased respiratory symptoms in children with asthma in association with increases in indoor, personal, and ambient NO<sub>2</sub> concentrations ([U.S. EPA, 2008c](#)). These epidemiologic findings largely are unsupported by controlled human exposure studies of symptoms in adolescents or adults with asthma. Recent studies, most of which were epidemiologic, continue to indicate associations

between short-term increases in ambient NO<sub>2</sub> concentration and increases in respiratory symptoms in children with asthma.

### Epidemiologic Studies

Epidemiologic studies examined respiratory symptoms in relation to ambient NO<sub>2</sub> concentrations rather than NO or NO<sub>x</sub>, and evidence is stronger for children with asthma than adults with asthma. Across the various populations examined, symptom data were collected by having subjects or their parents complete daily diaries for periods of 2 weeks to several months. Heterogeneity in the number of consecutive days of follow-up and the frequency of diary collection from study subjects do not appear to influence results. Ambient NO<sub>2</sub> concentrations, locations, and time periods for epidemiologic studies of respiratory symptoms are presented in [Table 5-7](#).

**Table 5-7 Mean and upper percentile concentrations of nitrogen dioxide in epidemiologic studies of respiratory symptoms in populations with asthma.**

Study <sup>a</sup>	Location	Study Period	NO <sub>2</sub> Metric Analyzed	Mean/Median Concentration ppb	Upper Percentile Concentrations ppb
<a href="#">Schildcrout et al. (2006)</a>	Albuquerque, NM Baltimore, MD Boston, MA Denver, CO San Diego, CA St. Louis, MO Toronto, ON, Canada	Nov 1993– Sep 1995	24-h avg NO <sub>2</sub>	Across cities: 17.8–26.0	90th: across cities 26.7–36.9 ppb
<a href="#">Romieu et al. (2006)</a>	Mexico City, Mexico	Oct 1998–Apr 2000	1-h max NO <sub>2</sub>	66	Max: 298
<a href="#">Segala et al. (1998)</a>	Paris, France	Nov 1992– May 1993	24-h avg NO <sub>2</sub>	30.3 <sup>b</sup>	Max: 64.9 <sup>b</sup>
† <a href="#">Patel et al. (2010)</a>	New York City and nearby suburb, NY	2003–2005, months NR	24-h avg NO <sub>2</sub>	NR	NR
† <a href="#">Barraza-Villarreal et al. (2008)</a> , † <a href="#">Escamilla-Nuñez et al. (2008)</a>	Mexico City, Mexico	Jun 2003– Jun 2005	8-h max NO <sub>2</sub>	37.4	Max: 77.6

**Table 5-7 (Continued): Mean and upper percentile concentrations of nitrogen dioxide in epidemiologic studies of respiratory symptoms in populations with asthma.**

Study <sup>a</sup>	Location	Study Period	NO <sub>2</sub> Metric Analyzed	Mean/Median Concentration ppb	Upper Percentile Concentrations ppb
<a href="#">†Mann et al. (2010)</a>	Fresno/Clovis, CA	Winter–Summer, 2000–2005	24-h avg NO <sub>2</sub>	Median: 18.6	75th: 24.7 Max: 52.4
<a href="#">†Zora et al. (2013)</a>	El Paso, TX	Mar–Jun 2010	96-h avg NO <sub>2</sub>	School 1: 9.3 School 2: 3.4	Max: 16.2 Max: 7.5
<a href="#">Jalaludin et al. (2004)</a>	Western and Southwestern Sydney, Australia	Feb–Dec 1994	15-h avg NO <sub>2</sub> (6 a.m.–9 p.m.)	15.0	Max: 47.0
<a href="#">†Spira-Cohen et al. (2011)</a>	Bronx, NY	Spring 2002, spring/fall 2004, spring 2005	6-h avg NO <sub>2</sub> (9 a.m.–3 p.m.)	NR	NR
<a href="#">†Sarnat et al. (2012)</a>	El Paso, TX and Ciudad Suarez, Mexico	Jan–Mar 2008	96-h avg NO <sub>2</sub>	El Paso schools: 4.5, 14.2; central sites: 14.0, 18.5, 20.5 Ciudad Juarez schools: 18.7, 27.2; central site: none	NR
<a href="#">†Holquin et al. (2007)</a>	Ciudad Juarez, Mexico	2001–2002	1-week avg NO <sub>2</sub>	18.2	NR
<a href="#">†Gillespie-Bennett et al. (2011)</a>	Bluff, Dunedin, Christchurch, Porirua, Hutt Valley, New Zealand	Sep 2006	4-week avg NO <sub>2</sub>	3.9	NR
<a href="#">†Gent et al. (2009)</a>	New Haven County, CT	Aug 2000–Feb 2004	NO <sub>2</sub> —avg time NR	NR	NR
<a href="#">Delfino et al. (2003)</a>	Los Angeles, CA (Huntington Park area)	Nov 1999–Jan 2000	1-h max NO <sub>2</sub> 8-h max NO <sub>2</sub>	7.2 5.9	90th: 9.0; max: 14 90th: 7.9; max: 11
<a href="#">Delfino et al. (2002)</a>	Alpine, CA	Mar–Apr 1996	1-h max NO <sub>2</sub> 8-h max NO <sub>2</sub>	24 15	Max: 53 Max: 34
<a href="#">†O'Connor et al. (2008)</a>	Boston, MA Bronx, NY Chicago, IL Dallas, TX New York, NY Seattle, WA Tucson, AZ	Aug 1998–Jul 2001	24-h avg NO <sub>2</sub>	NR	NR

**Table 5-7 (Continued): Mean and upper percentile concentrations of nitrogen dioxide in epidemiologic studies of respiratory symptoms in populations with asthma.**

Study <sup>a</sup>	Location	Study Period	NO <sub>2</sub> Metric Analyzed	Mean/Median Concentration ppb	Upper Percentile Concentrations ppb
<a href="#">Mortimer et al. (2002)</a>	Bronx & East Harlem, NY Chicago, IL Cleveland, OH Detroit, MI St. Louis, MO Washington, DC	Jun–Aug 1993	4-h avg NO <sub>2</sub> (6 a.m.–10 a.m.)	NR	NR
<a href="#">Just et al. (2002)</a>	Paris, France	Apr–Jun 1996	24-h avg NO <sub>2</sub>	28.6 <sup>b</sup>	Max: 59.0 <sup>b</sup>
† <a href="#">Ostro et al. (2001)</a>	Los Angeles and Pasadena, CA	Aug–Oct 1993	1-h max NO <sub>2</sub>	Los Angeles: 79.5 Pasadena: 68.1	Max: 220 Max: 170
<a href="#">Boezen et al. (1998)</a>	Amsterdam, Meppel, the Netherlands	Winter 1993–1994	24-h avg NO <sub>2</sub>	24.5 <sup>b</sup> 14.2 <sup>b</sup>	Max: 40.4 <sup>b</sup> Max: 28.9 <sup>b</sup>
<a href="#">Forsberg et al. (1998)</a>	Landskrona, Sweden	Jan–Mar, yr NR	24-h avg NO <sub>2</sub>	16.2 <sup>b</sup>	Max: 38.1 <sup>b</sup>
<a href="#">von Klot et al. (2002)</a>	Erfurt, Germany	Sep 1996–Nov 1997	24-h avg NO <sub>2</sub>	24.5 <sup>b</sup>	Max: 63.3 <sup>b</sup>
† <a href="#">Maestrelli et al. (2011)</a>	Padua, Italy	1999–2003	24-h avg NO <sub>2</sub>	Across seasons and yr: 20.9–37.0 <sup>b</sup>	75th: 23.0–42.5 <sup>b</sup>
† <a href="#">Wiwatanadate and Liwsrisakun (2011)</a>	Chiang Mai, Thailand	Aug 2005–Jun 2006	24-h avg NO <sub>2</sub>	17.2	90th: 26.5 Max: 37.4
<a href="#">Hiltermann et al. (1998)</a>	Bilthoven, the Netherlands	Jul–Oct 1995	24-h avg NO <sub>2</sub>	11.2 <sup>b</sup>	Max: 22.5 <sup>b</sup>
† <a href="#">Laurent et al. (2009)</a>	Strasbourg, France	2004, all yr	24-h avg NO <sub>2</sub> Dispersion model	18.6 <sup>b</sup>	NR
† <a href="#">Carlsen et al. (2012)</a>	Reykjavik, Iceland	Mar 2006–Dec 2009	24-h avg NO <sub>2</sub> 1-h max	11.7 <sup>b</sup> 27.4 <sup>b</sup>	97.5th: 30.4 <sup>b</sup> 97.5th: 61.0 <sup>b</sup>

**Table 5-7 (Continued): Mean and upper percentile concentrations of nitrogen dioxide in epidemiologic studies of respiratory symptoms in populations with asthma.**

Study <sup>a</sup>	Location	Study Period	NO <sub>2</sub> Metric Analyzed	Mean/Median Concentration ppb	Upper Percentile Concentrations ppb
† <a href="#">Kim et al. (2012)</a>	Seoul and Kyunggi Province, South Korea	2005–2009	24-h avg NO <sub>2</sub>	Asthma exacerbation 34.3 spring, 26.6 summer, 30.6 fall, 38.8 winter	75th: asthma exacerbation: 41.3 spring, 35.3 summer, 42.0 fall, 46.8 winter
				No asthma exacerbation: 32.7 spring, 26.0 summer, 30.6 fall, 37.7 winter	No asthma exacerbation: 41.4 spring, 35.2 summer, 41.6 fall, 48.9 winter
† <a href="#">Karakatsani et al. (2012)</a>	Amsterdam, the Netherlands	Oct 2002–Mar 2004	24-h avg NO <sub>2</sub>	20.4 <sup>b</sup>	Max: 51.8 <sup>b</sup>
	Athens, Greece			21.2 <sup>b</sup>	Max: 59.0 <sup>b</sup>
	Birmingham, U.K.			18.3 <sup>b</sup>	Max: 44.2 <sup>b</sup>
	Helsinki, Finland			12.1 <sup>b</sup>	Max: 41.4 <sup>b</sup>
† <a href="#">Feo Brito et al. (2007)</a>	Ciudad Real Puertollano, Spain	May–Jun 2000–2001	24-h avg NO <sub>2</sub>	17.4 <sup>b</sup>	Max: 35.6 <sup>b</sup>
				29.5 <sup>b</sup>	Max: 100.5 <sup>b</sup>

a.m. = ante meridiem; Aug = August; avg = average; AZ = Arizona; CA = California; CO = Colorado; CT = Connecticut; DC = District of Columbia; Dec = December; Feb = February; IL = Illinois; MD = Maryland; MA = Massachusetts; MI = Michigan; MO = Missouri; NM = New Mexico; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; NY = New York; OH = Ohio; ON = Ontario; ppb = parts per billion; TX = Texas; UK = United Kingdom; WA = Washington.

<sup>a</sup>Studies presented in order of first appearance in the text of this section.

<sup>b</sup>Concentrations converted from µg/m<sup>3</sup> to ppb using the conversion factor of 0.532 assuming standard temperature (25°C) and pressure (1 atm).

†Studies published since the 2008 ISA for Oxides of Nitrogen.


### **Children with Asthma**

Several recent studies add to the evidence for increases in respiratory symptoms in children with asthma associated with short-term increases in ambient NO<sub>2</sub>. Across previous and recent studies, there is heterogeneity in the magnitude and precision (width of 95% CIs) of the association. However, the results collectively indicate a pattern of elevated risk of respiratory symptoms across the various symptoms and lags of NO<sub>2</sub> exposure examined ([Figure 5-4](#) and [Table 5-9](#)). The consistency of findings also is supported by a meta-analysis of 24 mostly European studies and some U.S. studies, including several reviewed in the 2008 ISA for Oxides of Nitrogen. In the meta-analysis,

there was some evidence of publication bias with exclusion of the multicounty European PEACE studies, but with adjustment for publication bias, an increase in 24-h avg NO<sub>2</sub> was associated with increased risk of asthma symptoms ([Weinmayr et al., 2010](#)). Across individual studies reviewed in this ISA, the most consistent results were for total respiratory or asthma symptoms, wheeze, and cough. Increases in ambient NO<sub>2</sub> concentrations were not consistently associated with increases in rescue inhaler or beta-agonist use in children with asthma ([Patel et al., 2010](#); [Gent et al., 2009](#); [Romieu et al., 2006](#); [Schildcrout et al., 2006](#); [Segala et al., 1998](#)).

Study populations were recruited from schools, asthma or allergy clinics, or doctors' offices. Asthma was identified by parental report of physician-diagnosed asthma or clinical examination. Neither of these methodological issues appeared to affect whether an association was found. In studies that reported data on follow-up participation, rates were 7–92%, and no study reported selective dropout among a particular group within the study population. A priori-determined comparisons of children with and without asthma were inconsistent. [Patel et al. \(2010\)](#) found stronger associations in children with asthma. Another study found stronger associations in children without asthma, but 72% of that group had atopy ([Barraza-Villarreal et al., 2008](#); [Escamilla-Nuñez et al., 2008](#)).

Atopy could influence NO<sub>2</sub>-related respiratory symptoms. Many asthma study populations had high prevalence of atopy (47–89%), and larger NO<sub>2</sub>-associated increases in symptoms were found in children with asthma who also had allergies ([Zora et al., 2013](#); [Mann et al., 2010](#)). These results were based on 16 to 47% of the study populations but are coherent with experimental evidence for NO<sub>2</sub>-induced allergic responses in adults with asthma and animal models of allergic disease ([Section 5.2.2.5](#)). Study populations also varied in asthma severity; some comprised mostly children with mild, intermittent asthma and others comprised children with persistent asthma. Comparisons by asthma severity indicated larger NO<sub>2</sub>-related increases in respiratory symptoms among children with mild, intermittent asthma than severe or moderate asthma ([Mann et al., 2010](#); [Segala et al., 1998](#)), but these results also were based on small numbers of subjects. [Jalaludin et al. \(2004\)](#) found that elevated risk was limited to children with more severe asthma (asthma plus airway hyperresponsiveness). But, results were based on a three-pollutant model, which can produce unreliable results because of potential multicollinearity.



Note: avg = average; CI = confidence interval; GSTM1 = glutathione S-transferase mu 1; h = hour; max = maximum; NO<sub>2</sub> = nitrogen dioxide; NR = not reported. Black = studies from the 2008 Integrated Science Assessment for Oxides of Nitrogen, red = recent studies. Results from more informative studies in terms of the exposure assessment method and potential confounding considered are presented first within an outcome group. Study details and quantitative results are reported in [Table 5-8](#). The figure presents a subset of results included in [Table 5-8](#) for which quantitative results were available for NO<sub>2</sub> examined as a linear variable and for specific outcomes examined by multiple studies.

<sup>a</sup>Effect estimates are standardized to a 20-ppb, 25-ppb, and 30-ppb increase for 24-h avg, 8-h max, and 1-h max NO<sub>2</sub>, respectively. Effect estimates for other averaging times (4-h avg to 15-h avg) are not standardized and presented as reported in their respective studies ([Section 5.1.2.2](#)).

**Figure 5-4 Associations of ambient nitrogen dioxide concentrations with respiratory symptoms and asthma medication use in children with asthma.**

**Table 5-8 Epidemiologic studies of respiratory symptoms and asthma medication use in children with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Odds Ratio (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<b>Studies with small spatial scale exposure assessment and/or examination of copollutant confounding</b>				
<p>†<a href="#">Zora et al. (2013)</a> El Paso, TX n = 36, mean age 9.3 (SD: 1.5) yr, 47% with atopy Repeated measures. Asthma control questionnaire given weekly at school for 13 weeks. Questionnaire ascertains symptoms, activity limitations, asthma medication use. Recruitment from schools via school nurses. Parent report of physician-diagnosed asthma. No information on participation rate. Linear mixed effects model adjusted for random subject effect and humidity, temperature, school.</p>	<p>NO<sub>2</sub>-school outdoor 24-h avg 1 school 91 m from major road, 1 school in residential area.</p>	<p>0–4 avg</p>	<p>Change in asthma control score (higher score indicates poorer control): Allergy, n = 17 0.56 (–0.10, 1.2) No allergy, n = 19 –0.29 (–1.1, 0.49)</p>	<p>No copollutant models analyzed for subgroups. BC, benzene, toluene, also associated with poorer asthma control. Correlations with NO<sub>2</sub> weak to high. Spearman <i>r</i> = 0.29 to 0.56 for BC, 0.37 to 0.71 for benzene, 0.16 to 0.71 for toluene.</p>
<p>†<a href="#">Sarnat et al. (2012)</a> El Paso, TX and Ciudad Juarez, Mexico n = 29 per city, ages, 6–12 yr, asthma and current symptoms Repeated measures. Daily symptom diaries. Recruitment from schools representing a gradient of traffic, subjects from nonsmoking homes. No information on participation rate. Self-report of physician-diagnosed asthma. GLM with subject as random effect and adjustment for school, temperature, relative humidity. Adjustment for medication use, cold symptoms did not alter results.</p>	<p>NO<sub>2</sub>-school outdoor 24-h avg In each city, 1 school 91 m from major road, 1 in residential area.</p>	<p>0–4 avg</p>	<p>No quantitative results reported; associations reported to be consistent with the null.</p>	<p>No copollutant model.</p>

**Table 5-8 (Continued): Epidemiologic studies of respiratory symptoms and asthma medication use in children with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Odds Ratio (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p><a href="#">†Holquin et al. (2007)</a> Ciudad Juarez, Mexico n = 95, ages 6–12 yr, 78% mild, intermittent asthma, 58% with atopy Repeated measures. Daily symptom diaries given by parents for 4 mo, checked biweekly. 87% participation. Parent report of physician-diagnosed asthma. Linear and nonlinear mixed effects model with random effect for subject and school adjusted for sex, body mass index, day of week, season, maternal and paternal education, passive smoking exposure.</p>	<p>NO<sub>2</sub>-school outdoor 24-h avg Schools located 239–692 m from homes.</p>	<p>0–6 avg</p>	<p>No quantitative results reported. No air pollutants reported to be associated with respiratory symptoms</p>	<p>No copollutant model. Road density at home and school reported not to be associated with respiratory symptoms.</p>
<p><a href="#">†Spira-Cohen et al. (2011); Spira-Cohen (2013)</a> Bronx, NY n = 40, ages 10–12 yr, 100% nonwhite, 44% with asthma ED visit or hospital admission in previous 12 mo Repeated measures. Daily symptom diaries for 1 mo, checked daily. 454 observations. Recruitment from schools by referrals from school nurses. Parental report of physician-diagnosed asthma. 89% time indoors. No information on participation rate. Mixed effects model with subject as random effect adjusted for temperature, height, sex. Adjustment for school (indicator of season) did not alter results.</p>	<p>NO<sub>2</sub>-school outdoor 6-h avg (9 a.m.–3 p.m.) Schools 53–737 m from highways with varying traffic counts. Most children walk to school.</p>	<p>0</p>	<p>Total symptoms: 1.1 (0.84, 1.5) Wheeze: 1.2 (0.75, 1.9) OR per 60-ppb increase NO<sub>2</sub> (5th to 95th percentile)</p>	<p>Personal EC associated with symptoms with NO<sub>2</sub> adjustment. No quantitative data reported.</p>
<p><a href="#">†Gillespie-Bennett et al. (2011)</a> Bluff, Dunedin, Christchurch, Porirua, Hutt Valley, New Zealand n = 358, ages 6–13 yr Cross-sectional. Daily symptom diaries for 112 days. Recruitment from a home heating intervention. 77% participation. Mixed effects model with log-transformed NO<sub>2</sub> and random effect for subject. Adjustment for age, sex, region, ethnicity, intervention, income, temperature did not alter results.</p>	<p>NO<sub>2</sub>-home outdoor 24-h avg 1 measure per subject.</p> <hr/> <p>NO<sub>2</sub>-home indoor 24-h avg Up to 4 measures per subject.</p>	<p>4-week avg</p>	<p>Lower respiratory symptom: 1.1 (0.78, 1.5) Reliever inhaler: 1.5 (0.96, 2.3) OR per log increase NO<sub>2</sub></p> <hr/> <p>Lower respiratory symptom: 1.14 (1.12, 1.16) Reliever inhaler: 1.14 (1.11, 1.17) OR per log increase NO<sub>2</sub></p>	<p>No copollutant model. No other pollutants examined.</p>

**Table 5-8 (Continued): Epidemiologic studies of respiratory symptoms and asthma medication use in children with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Odds Ratio (95% CI) Single-Pollutant Models	Copolutant Examination
<p><a href="#">†Gent et al. (2009)</a> New Haven county, CT n = 149, ages 4–12 yr Repeated measures. Daily symptom diaries reported monthly. Recruitment from larger cohort, pediatric asthma clinic, and school. Parent report of physician-diagnosed asthma. No information on participation rate. GEE adjusted for season, day of week, date, motor vehicle factor obtained by source apportionment.</p>	<p>NO<sub>2</sub>-central site Avg time not reported</p>	0	NR	<p>With source apportionment factor of EC, zinc, lead, copper, selenium Wheeze: 1.1 (0.99, 1.2) Inhaler: 1.0 (0.97, 1.1)</p>
<p><a href="#">Delfino et al. (2003)</a> Los Angeles, CA (Huntington Park) n = 16, ages 10–16 yr, 100% Hispanic, 27% on anti-inflammatory medication Repeated measures. Daily symptom diaries for 3 months, collected weekly. Recruitment from schools of nonsmoking children from nonsmoking homes. Self or parental report of physician diagnosed asthma. 92% follow-up participation. GEE with autoregressive parameter and adjusted for respiratory infections. Excluded potential confounding by weekend, maximum temperature.</p>	<p>NO<sub>2</sub>-central site 4.8 km of home &amp; school</p>	0	<p>Asthma symptoms not interfering with daily activity</p>	<p>Copolutant model results only in figure. ORs for NO<sub>2</sub> not altered by xylene or toluene adjustment. Smaller but positive ORs for NO<sub>2</sub>, wider 95% CI with adjustment for benzene, ethylbenzene, acetaldehyde, formaldehyde. Moderate to high correlations with 8-h max NO<sub>2</sub>. Spearman <math>r = 0.57</math> (benzene) to <math>0.72</math> (xylene). No interactions between NO<sub>2</sub> and VOCs. ORs for VOCs attenuated with NO<sub>2</sub> adjustment. No copollutant model with EC or OC. <math>r = 0.54</math> &amp; <math>0.62</math>, respectively. No association with CO.</p>
	<p>8-h max 1-h max</p>		<p>1.3 (1.1, 1.5) 1.2 (0.96, 1.4)</p>	
	<p>8-h max 1-h max</p>		<p>Asthma symptoms interfering with daily activity ORs per 1.4 ppb increase in 8-h max and 2.0-ppb increase in 1-h max NO<sub>2</sub> (interquartile ranges).</p>	

**Table 5-8 (Continued): Epidemiologic studies of respiratory symptoms and asthma medication use in children with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Odds Ratio (95% CI) Single-Pollutant Models	Copolutant Examination
<p><a href="#">Delfino et al. (2002)</a> Alpine, CA and adjacent areas n = 22, ages 9–19 yr, 36% with mild persistent or more severe asthma, 77% with atopy Repeated measures. 92% follow-up. Daily symptom diaries for 61 days, collected weekly or biweekly. 1,248 observations (94% of expected). Recruitment from schools. Asthma diagnosis based on referrals from health maintenance organization and newspaper advertisements. Subjects were nonsmokers from nonsmoking homes. GEE with autoregressive lag 1 correlation matrix with no covariates. Adjustment for day of week, linear trend, temperature, humidity did not alter results. Adjustment for respiratory infection increased pollutant ORs.</p>	<p>NO<sub>2</sub>-central site 1-h max</p> <hr/> <p>8-h max 1 site 1–4.7 km from subjects' homes</p>	<p>0</p>	<p>Symptoms interfering with daily activity All subjects: 1.4 (0.82, 2.2) No anti-inflammatory medication, n = 12 1.8 (0.89, 3.6) On anti-inflammatory medication, n = 10 0.91 (0.21, 4.0)</p> <hr/> <p>All subjects: 1.7 (0.94, 2.9) No anti-inflammatory medication, n = 12 2.3 (1.1, 4.6) On anti-inflammatory medication, n = 10 1.1 (0.22, 5.5)</p>	<p>Positive interaction for 8-h max NO<sub>2</sub> with 1-h max PM<sub>10</sub> (<math>p &lt; 0.01</math>) and 1-h max O<sub>3</sub> (<math>p = 0.12</math>). Fungi and pollen allergen associated with symptoms. No NO<sub>2</sub>-allergen interactions. No quantitative results for NO<sub>2</sub>-allergen copollutant models, but ORs reported to decrease. Moderate correlations with NO<sub>2</sub>. Pearson <math>r = 0.29</math> for fungi, 0.27 for pollen, 0.55 for PM<sub>10</sub>.</p>
<p><a href="#">Schildcrout et al. (2006)</a> Albuquerque, NM; Baltimore, MD; Boston, MA; Denver, CO; San Diego, CA; St. Louis, MO; Toronto, ON, Canada (CAMP cohort) n = 990, ages, 5–12 yr, mild to moderate asthma Repeated measures. Daily symptom diaries for 21–201 days. No information on participation rate. GEE for individual cities combined for study-wide estimates. City-specific models adjusted for day of week, ethnicity, annual family income, response to methacholine, maximum temperature, humidity, temperature × humidity, calendar date. Pollutant analyzed as daily deviation from subject mean.</p>	<p>NO<sub>2</sub>-central site 24-h avg Average of multiple sites within 80 km of ZIP code.</p>	<p>0 0–2 sum</p>	<p>Asthma symptoms: 1.06 (1.00, 1.12) Rescue Inhaler use: 1.04 (1.00, 1.08) Asthma symptoms: 1.05 (1.01, 1.09)</p>	<p>Joint effect models NO<sub>2</sub> + CO: 1.07 (1.0, 1.14) NO<sub>2</sub>+SO<sub>2</sub>: 1.06 (0.98, 1.15) NO<sub>2</sub>+PM<sub>10</sub>: 1.06 (0.99, 1.13) Moderate to high correlations with NO<sub>2</sub>. <math>r = 0.23</math> to 0.58 for SO<sub>2</sub>, 0.26 to 0.64 for PM<sub>10</sub>, 0.63 to 0.92 for CO.</p>

**Table 5-8 (Continued): Epidemiologic studies of respiratory symptoms and asthma medication use in children with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Odds Ratio (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p><a href="#">†Mann et al. (2010)</a> Fresno, Clovis, CA n = 280, ages 6–11 yr, 47% mild persistent asthma, 25% moderate to severe asthma, 63% with atopy Repeated measures. Daily symptom diaries for 14 days every 3 mo. Recruitment from schools, advertisements, physician’s offices, local media. Imputed wheeze values for 7.6% days. Participation from 89% of original cohort. Group examined representative of original cohort. GEE adjusted for fitted daily mean wheeze, home ownership, race, sex, asthma severity, panel group, 6-mo cohort, 1-h minimum temperature. Adjustment for medication use did not alter results.</p>	<p>NO<sub>2</sub>-central site 24-h avg 1 site within 20 km of homes.</p>	<p>2</p>	<p>Wheeze: All subjects: 1.2 (1.1, 1.5) <hr/>Fungi allergic, n = 85 1.6 (1.2, 2.1) <hr/>Cat allergic, n = 49 1.7 (1.1, 2.6) <hr/>Boys, intermittent asthma, n = 47 2.6 (1.6, 4.1)</p>	<p>With PM<sub>10-2.5</sub>, all subjects: 1.1 (0.95, 1.4). PM<sub>10-2.5</sub> association not altered by NO<sub>2</sub> adjustment. Weak correlation with NO<sub>2</sub>. r = 0.12.</p>
<p><a href="#">Mortimer et al. (2002)</a> Bronx and East Harlem, NY; Chicago, IL; Cleveland, OH; Detroit, MI; St. Louis, MO; Washington, DC (NCICAS cohort) n = 846, ages 4–9 yr Repeated measures. Daily symptom data collected for 2-week periods every 3 mo. Recruitment from ED visits and clinics. Parent report of physician-diagnosed asthma and symptoms in previous 12 mo or asthma symptoms for &gt;6 weeks, or family history of asthma. Participation from 55% full cohort. Sample representative of full cohort except for greater asthma medication use. Mixed effects model adjusted for city, follow-up period, day of study, 24-h rainfall, 12-h avg temperature.</p>	<p>NO<sub>2</sub>-central site 4-h avg (6 a.m.–10 a.m.) Average of all city monitors.</p>	<p>Lag 1–6 avg</p>	<p>Morning symptoms: 1.5 (1.0, 2.2) OR per 20-ppb increase in NO<sub>2</sub> (interquartile range).</p>	<p>With O<sub>3</sub> (summer): 1.4 (0.93, 2.1) Weak correlation with NO<sub>2</sub>. r = 0.27. O<sub>3</sub> effect estimate also slightly attenuated. SO<sub>2</sub> and PM<sub>10</sub> also associated with symptoms. Correlations with NO<sub>2</sub> not reported.</p>

**Table 5-8 (Continued): Epidemiologic studies of respiratory symptoms and asthma medication use in children with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Odds Ratio (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<b>Studies with central site exposure assessment and no examination of copollutant confounding</b>				
<p><a href="#">Jalaludin et al. (2004)</a> Sydney, Australia n = 125, mean age 9.6 yr, 45 with wheeze, asthma, and airway hyperresponsiveness, 60 with wheeze and asthma, 20 with wheeze Repeated measures. Daily symptom diary mailed in monthly for 11 mo. Recruitment from schools. Parent report of physician-diagnosed asthma. 84% follow-up participation. GEE adjusted for time trend, temperature, humidity, number of hours spent outdoors, total pollen and Alternaria, season.</p>	<p>NO<sub>2</sub>-central site 15-h avg (6 a.m.–9 p.m.) Site within 2 km of schools.</p>	0	<p>Wheeze: 1.0 (0.94, 1.1) Wet cough: 1.05 (1.00, 1.10) Beta agonist use: 1.01 (0.97, 1.05) OR per 8.2 ppb increase in NO<sub>2</sub> (interquartile range)</p>	<p>NO<sub>2</sub> associations found in children with asthma/airway hyperresponsiveness but examined only in multipollutant model with O<sub>3</sub> and PM<sub>10</sub>. Negative or weak correlations with NO<sub>2</sub>. <i>r</i> = -0.31 for O<sub>3</sub>, 0.26 for PM<sub>10</sub>.</p>
<p>†<a href="#">Escamilla-Nuñez et al. (2008)</a> Mexico City, Mexico n = 147, ages 6–14 yr, 43% with persistent asthma, 89% atopy Repeated measures. Symptom data collected every 15 days for mean 22 weeks. Children with asthma recruited from pediatric clinic. Asthma severity assessed by pediatric allergist. No information on participation rate. Linear mixed effects model with random effect for subject and adjusted for asthma severity, atopy, lag 1 minimum temperature, time, sex. Adjustment for outdoor activities, smoking exposure, season did not alter results.</p>	<p>NO<sub>2</sub>-central site 1-h max Site within 5 km of school or home.</p>	1	<p>Cough: 1.07 (1.02, 1.12) Wheeze: 1.08 (1.02, 1.14)</p>	<p>No copollutant model. PM<sub>2.5</sub> and O<sub>3</sub> also associated with symptoms. No statistically significant interaction between NO<sub>2</sub> and PM<sub>2.5</sub> or O<sub>3</sub>. Quantitative results not reported.</p>
<p>†<a href="#">Barraza-Villarreal et al. (2008)</a> Mexico City, Mexico n = 126, ages 6–14 yr, 44% persistent asthma, 89% with atopy Part of same cohort as above. No information on participation rate. Linear mixed effects model with random effect for subject and adjusted for sex, body mass index, lag 1 minimum temperature, ICS use, time. Adjustment for outdoor activities, smoking exposure, anti-allergy medication use, season did not alter results.</p>	<p>NO<sub>2</sub>-central site 1-h max Site within 5 km of school or home. Low correlation for central site vs. school: Spearman <i>r</i> = 0.21</p>	0	<p>Wheeze: 1.09 (1.03, 1.15) Cough: 1.09 (1.04, 1.14)</p>	<p>No copollutant model. PM<sub>2.5</sub> and O<sub>3</sub> also associated with symptoms. Moderate correlations with NO<sub>2</sub>. Pearson <i>r</i> = 0.61 for PM<sub>2.5</sub>, 0.28 for O<sub>3</sub>.</p>

**Table 5-8 (Continued): Epidemiologic studies of respiratory symptoms and asthma medication use in children with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Odds Ratio (95% CI) Single-Pollutant Models	Copolutant Examination
<p><a href="#">Romieu et al. (2006)</a> Mexico City, Mexico n = 151, mean age 9 yr, mild or moderate asthma Repeated measures. Daily symptom diaries 61–92 days per subject, collected weekly. Recruitment from allergy clinic as part of a Vitamin C/E supplementation trial. Diagnosis by clinical examination. 99% follow-up participation. GEE adjusted for supplementation group, minimum temperature, smoking exposure, asthma severity, time.</p>	<p>NO<sub>2</sub>-central site 1-h max Site within 5 km of home.</p>	<p>1–6 avg</p>	<p>Cough by genotype: GSTM1 null 1.09 (1.00, 1.19) GSTM1 positive 1.19 (1.11, 1.27)  GSTP1 Ile/Ile or Ile/Val 1.19 (1.11, 1.27) GSTP1 Val/Val 1.08 (0.99, 1.18)  BD use by genotype: GSTM1 null 0.94 (0.87, 1.02) GSTM1 positive 1.09 (1.02, 1.17)  GSTP1 Ile/Ile or Ile/Val 1.08 (1.02, 1.14) GSTP1 Val/Val 0.94 (0.85, 1.04)</p>	<p>No copollutant model. Associations with O<sub>3</sub> found with different variants than NO<sub>2</sub>. Moderate correlation with NO<sub>2</sub>. Pearson <math>r = 0.57</math> for O<sub>3</sub> and PM<sub>10</sub>.</p>
<p><a href="#">Ostro et al. (2001)</a> Central Los Angeles and Pasadena, CA n = 138 (83% LA), ages 8–13 yr, 85% mild or moderate asthma, 100% African-American Repeated measures. 90% follow-up. Daily symptom diaries for 13 weeks, mailed in weekly. Excluded subjects returning diaries after 2 weeks. 9,126 observations. Recruitment from hospitals, urgent care clinics, medical practices, asthma camps in Los Angeles and school nurses in Pasadena. GEE adjusted for day of study, age, income, town, lag 1 temperature, lag 1 humidity.</p>	<p>NO<sub>2</sub>-central site 1-h max Los Angeles site within 16 km of 90% of subjects' homes. Pasadena site within 8 km of subjects' homes.</p>	<p>3</p>	<p>Shortness of breath: 1.08 (0.99, 1.18) Wheeze: 1.08 (1.02, 1.13) Cough: 1.07 (1.00, 1.15) No quantitative results for extra medication use but reported not to be associated with NO<sub>2</sub>.</p>	<p>No copollutant model. Symptoms associated with PM<sub>2.5</sub>, PM<sub>10</sub>, fungi. Weak to moderate correlations with NO<sub>2</sub>. <math>r = 0.18</math> for pollen, 0.26–0.48 for fungi, 0.34 for PM<sub>2.5</sub>, 0.63 for PM<sub>10</sub>.</p>

**Table 5-8 (Continued): Epidemiologic studies of respiratory symptoms and asthma medication use in children with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Odds Ratio (95% CI) Single-Pollutant Models	Copolutant Examination
<p><a href="#">†Patel et al. (2010)</a> New York City and nearby suburb, NY n = 57, ages 14–20 yr Repeated measures. Daily symptom diaries for 4–6 weeks, collected weekly. Recruitment from schools. Self-report of physician-diagnosed asthma. 75–90% participation across schools. GLMM with random effect for subject and school and adjusted for weekend, daily 8-h max O<sub>3</sub>, urban location. Adjustment for season, pollen counts did not alter results.</p>	<p>NO<sub>2</sub>-central site 24-h avg 1 site 2.2–9.0 km from schools, 1 site 40 km from schools.</p>	0	<p>Wheeze: 1.16 (0.93, 1.45) Chest tightness: 1.26 (1.00, 1.58)</p>	<p>No copollutant model with BC. BC also associated with symptoms. Across locations, moderate to high correlations with NO<sub>2</sub>. Spearman <math>r = 0.56</math>–<math>0.90</math>.</p>
<p><a href="#">Just et al. (2002)</a> Paris, France n = 82, ages 7–15 yr, asthma attack in previous 12 mo and daily asthma medication use, 90% atopy Repeated measures. Daily symptom diaries for 3 mo, collected weekly. Recruitment from hospital outpatients. 82% participation. GEE adjusted for time trend, day of week, pollen, temperature, humidity.</p>	<p>NO<sub>2</sub>-central site 24-h avg Average of 11 sites</p>	0	<p>Asthma attack: 1.75 (0.82, 3.70) Night cough: 2.11 (1.20, 3.71)</p>	<p>No copollutant model BS associated with cough. High correlation with NO<sub>2</sub>. Pearson <math>r = 0.92</math>.</p>
<p><a href="#">Segala et al. (1998)</a> Greater Paris area, France n = 43 mild asthma, 41 moderate asthma, 89% atopy, 69% ICS users, ages 7–15 yr Repeated measures. Daily symptom diary for 25 weeks, collected weekly. Recruitment from outpatients of children’s hospital. 84% follow-up participation. GEE adjusted for day of week, time trend, temperature, humidity, age, sex.</p>	<p>NO<sub>2</sub>-central site 24-h avg Average of 8 sites</p>	<p>0 <hr/>3 <hr/>3 <hr/>0</p>	<p>Incident asthma: Mild asthma, n = 43 1.89 (1.13, 3.15) <hr/>Moderate asthma, n = 41 1.31 (0.85, 2.03) <hr/>Beta-agonist use: Mild asthma, n = 43 1.27 (0.82, 1.98) <hr/>Moderate asthma, n = 41 1.56 (0.51, 4.73)</p>	<p>No copollutant model. Associations also found with BS, PM13, &amp; SO<sub>2</sub>. Moderate correlations with NO<sub>2</sub>. Pearson <math>r = 0.61</math> for BS, 0.55 for PM13, 0.54 for SO<sub>2</sub>.</p>

**Table 5-8 (Continued): Epidemiologic studies of respiratory symptoms and asthma medication use in children with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Odds Ratio (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p><a href="#">†O'Connor et al. (2008)</a> Boston, MA; Bronx, NY; Chicago, IL; Dallas, TX; New York, NY; Seattle, WA; Tucson, AZ (ICAS cohort) n = 861, ages 5–12 yr, persistent asthma and atopy, 82% black or Hispanic Repeated measures. Symptom data collected for 2 week period every 2 mo for 2 yr. Recruitment from intervention of physician feedback. 89% of maximum possible diaries obtained. Mixed effects model adjusted for site, mo, site×mo interaction, temperature, intervention group.</p>	<p>NO<sub>2</sub>-central site 24-h avg All monitors near home, not near industry. Median distance to site = 2.3 km.</p>	<p>1–19 avg</p>	<p>Wheeze-cough: 1.17 (0.99, 1.37) Slow Play: 1.25 (1.04, 1.51) Missed school in 2 week period: 1.65 (1.18, 2.32)</p>	<p>Only 3-pollutant model analyzed. Associations also found with PM<sub>2.5</sub> and CO. Moderate correlations with NO<sub>2</sub>. <i>r</i> = 0.59 for PM<sub>2.5</sub>, 0.54 for CO.</p>

Note: More informative studies in terms of the exposure assessment method and potential confounding considered are presented first.

a.m. = ante meridiem; avg = average; AZ = Arizona; BC = black carbon; BD = bronchodilator; BS = black smoke; CA = California; CAMP = Childhood Asthma Management Program; CI = confidence interval; CO = carbon monoxide, Colorado; CT = Connecticut; DC = District of Columbia; EC = elemental carbon; ED = emergency department; GEE = generalized estimating equations; GLM = generalized linear model; GLMM = generalized linear mixed model; GSTM1 = glutathione S-transferase mu 1; GSTP1 = glutathione s-transferase Pi 1; ICAS = Inner City Asthma Study; ICS = inhaled corticosteroid; IL = Illinois; MA = Massachusetts; MD = Maryland; MI = Michigan; MO = Missouri; NCICAS = National Cooperative Inner-city Asthma Study; NM = New Mexico; NO<sub>2</sub> = nitrogen dioxide; NY = New York; O<sub>3</sub> = ozone; OC = organic carbon; OH = Ohio; ON = Ontario; OR = odds ratio; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 μm; SD = standard deviation; SO<sub>2</sub> = sulfur dioxide; TX = Texas; Val = valine; WA = Washington; VOC = volatile organic compound.

<sup>a</sup>Effect estimates are standardized to a 20 ppb for 24-h avg NO<sub>2</sub>, 25 ppb for 8-h max, and a 30-ppb increase for 1-h max NO<sub>2</sub>. Effect estimates for other averaging times are not standardized but presented as they are reported in their respective studies ([Section 5.1.2.2](#)).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

Several studies are noteworthy for NO<sub>2</sub> exposure assessment in subjects' locations or analysis of the influence of other traffic-related pollutants on NO<sub>2</sub> associations. NO<sub>2</sub> concentrations at home or school, where subjects spend large portions of time, may better represent ambient exposures for that location. In a group of 17 children with asthma and allergy in El Paso, TX, a 20-ppb increase in outdoor school 4-day avg NO<sub>2</sub> was associated with a 0.56 (95% CI: -0.10, 1.2)-point poorer asthma control score (composite of symptoms, activity limitation and asthma medication use) ([Zora et al., 2013](#)). Among children in Bronx, NY, the wide 95% CIs did not provide strong evidence for associations of 6-h avg school-day NO<sub>2</sub> (9 a.m.–3 p.m.) with total symptoms (OR: 1.1 [95% CI: 0.84, 1.5] per 60-ppb NO<sub>2</sub>) or wheeze (OR: 1.2 [95% CI: 0.75, 1.9]) ([Spira-Cohen et al., 2011](#)). Other studies did not indicate associations of school or home NO<sub>2</sub> with respiratory symptoms in children with asthma, but it is unclear whether the results represent inconsistency in the evidence base. Studies conducted in El Paso, TX and Ciudad Juarez, Mexico only reported that NO<sub>2</sub> was not associated with respiratory symptoms in children with asthma but did not report quantitative results ([Sarnat et al., 2012](#); [Holguin et al., 2007](#)). Outdoor home NO<sub>2</sub> was associated with reliever inhaler use but not respiratory symptoms among children with asthma in multiple New Zealand towns ([Gillespie-Bennett et al., 2011](#)). However, daily outcomes were analyzed with a single 4-week sample of NO<sub>2</sub>, which cannot represent temporal variability in exposure. Home indoor NO<sub>2</sub>, which was represented as up to four measurements per subject, showed stronger associations with both outcomes.

Most studies observed NO<sub>2</sub>-related increases in respiratory symptoms with adjustment for temperature, humidity, season, and day of week. A few studies additionally adjusted for asthma medication use, colds, smoking exposure, and allergens ([Table 5-9](#)). In addition to NO<sub>2</sub>, studies with school and central site exposure assessment found symptoms associated with the traffic-related pollutants EC/BC, black smoke (BS), OC, CO, and VOCs, which showed a wide range of correlations with NO<sub>2</sub> ( $r = 0.16–0.92$ ) ([Table 5-9](#)). Analysis of confounding by traffic-related copollutants is limited in both the number of studies and array of copollutants. The only study that analyzed copollutant models for school measurements found that neither NO<sub>2</sub> nor BC was associated with asthma control in a copollutant model ([Zora et al., 2013](#)). However, these results were based on the whole study population. NO<sub>2</sub> and BC were associated with asthma control only in children with asthma and allergies; thus, the copollutant model results do not clearly inform potential confounding. There are NO<sub>2</sub> associations with asthma symptoms that are independent of EC or a VOC, but potential differential exposure error for pollutants measured at central sites limits inference. Among children in Los Angeles, CA, CO was not associated with symptoms, and NO<sub>2</sub>-asthma symptom associations were relatively unchanged with adjustment for various VOCs. NO<sub>2</sub> concentrations were assigned from a

central site within 4.8 km of children's homes, and although it is not certain whether variability within neighborhoods is adequately represented, the high correlations observed among monitors in that Los Angeles area ([Section 2.5.3](#)) provide some confidence in the NO<sub>2</sub> metrics to represent the broad variability the study area. In New Haven County, CT, NO<sub>2</sub> was associated with wheeze with adjustment for a source apportionment factor comprising EC, zinc, lead, copper, and selenium (OR: 1.08 [95% CI: 0.99, 1.18] per unspecified increase in lag 0 day NO<sub>2</sub>) ([Gent et al., 2009](#)). However, the central site monitor was located 0.9 to 30 km (mean 10 km) from children's homes.

In limited analysis, interactions between NO<sub>2</sub> and traffic-related copollutants in affecting asthma symptoms are not demonstrated. These analyses of interactions or joint effects neither inform the potential for confounding. For children in Los Angeles, CA, no NO<sub>2</sub>-VOC interaction was found ([Delfino et al., 2003](#)). In the multicity Childhood Asthma Management Program (CAMP) study, the joint effect of NO<sub>2</sub> and CO (OR: 1.07 [95% CI: 1.00, 1.14] for a 20-ppb increase in lag 0–2 day sum of 24-h avg NO<sub>2</sub>) was similar to the NO<sub>2</sub> (OR: 1.05 [95% CI: 1.01, 1.09]) and CO single-pollutant ORs ([Schildcrout et al., 2006](#)). While these results indicate a lack of multiplicative interaction between NO<sub>2</sub> and CO, they may not be reliable given that pollutants were averaged from sites up to 80 km from subjects' ZIP code centroids. Interactions with NO<sub>2</sub> were not found consistently for PM<sub>10</sub> and not found at all for SO<sub>2</sub>, O<sub>3</sub>, or allergens ([Schildcrout et al., 2006](#); [Delfino et al., 2002](#)). These copollutants were not examined as potential confounding factors. An NO<sub>2</sub>-wheeze association decreased in magnitude and precision (i.e., wider 95% CI) with adjustment for PM<sub>10-2.5</sub> ( $r = 0.12$ ) ([Mann et al., 2010](#)), based on exposures assessed from a site up to 20 km of children's homes.

Other studies largely corroborate the aforementioned evidence but do not provide a strong basis for assessing an independent effect of NO<sub>2</sub> exposure on respiratory symptoms in children with asthma because of both central site exposure assessment and no examination of potential confounding by other traffic-related pollutants ([Table 5-8](#)). Confounding by PM<sub>10</sub>, SO<sub>2</sub>, or O<sub>3</sub> was not examined either. These pollutants were moderately correlated with NO<sub>2</sub> ( $r = 0.28$ – $0.31$ ) in most studies, although some reported higher correlations ( $r = 0.54$ – $0.68$ ) ([Ostro et al., 2001](#); [Segala et al., 1998](#)). Multipollutant models were analyzed for traffic-related copollutants but can produce unreliable results because of potential collinearity ([Kim et al., 2012](#); [Escamilla-Nuñez et al., 2008](#); [O'Connor et al., 2008](#)). These multi- and single-city studies used central sites located 2–16 km from children's homes or schools ([Patel et al., 2010](#); [Barraza-Villarreal et al., 2008](#); [Escamilla-Nuñez et al., 2008](#); [Romieu et al., 2006](#); [Jalaludin et al., 2004](#); [Ostro et al., 2001](#)), averaged across city sites ([O'Connor et al., 2008](#); [Just et al., 2002](#); [Mortimer et al., 2002](#)), or an unspecified method ([Segala et al., 1998](#)). Low within-city correlations in NO<sub>2</sub> were reported for Mexico City, Mexico ([Barraza-Villarreal et al., 2008](#); [Escamilla-](#)

[Nuñez et al., 2008](#)), and high correlations for NO<sub>2</sub> are reported for Los Angeles/Pasadena ([Ostro et al., 2001](#)) (Section 2.5.3). For other locations, information was not reported to assess whether the temporal variation in NO<sub>2</sub> metrics represented the variation across the study areas. The recent multicity ICAS found increases in symptoms, slow play, and missed school in association with a 19-day avg of 24-h avg NO<sub>2</sub> ([O'Connor et al., 2008](#)), but there is potential for residual temporal confounding for associations with NO<sub>2</sub> exposure on the order of weeks. ICAS could not examine shorter lags because symptom data were collected with a time resolution of 2 weeks.

In addition to the limited findings from copollutant models with traffic-related pollutants, studies that show increases in respiratory symptoms in association with increases in indoor NO<sub>2</sub> averaged over 3 to 7 days provide some support for an independent effect of NO<sub>2</sub> exposure ([Lu et al., 2013](#); [Hansel et al., 2008](#)). Previous findings indicated reductions in respiratory symptoms after an intervention to switch to flued gas heaters led to a reduction in indoor classroom NO<sub>2</sub> concentrations ([Pilotto et al., 2004](#)). Although potential differences in pollutant mixtures between the indoor and outdoor environments are not well characterized, a recent study found that correlations of NO<sub>2</sub> with BC, PM, and SO<sub>2</sub> differed between the indoor and outdoor school environments ([Sarnat et al., 2012](#)). At most of the schools, indoor concentrations of NO<sub>2</sub> (medians 3.5–83.9 ppb), BC (medians 0–1.1 µg/m<sup>3</sup>), PM<sub>2.5</sub> (medians 7–22.8 µg/m<sup>3</sup>), and PM<sub>10–2.5</sub> (medians 6.5–38.9 µg/m<sup>3</sup>) were well above the limits of detection [2.88 ppb NO<sub>2</sub>, 0.42 µg/m<sup>3</sup> BC, 4.62 µg/m<sup>3</sup> PM<sub>2.5</sub>, 2.69 µg/m<sup>3</sup> PM<sub>10–2.5</sub> ([Raysoni et al., 2011](#))]. In [Hansel et al. \(2008\)](#), most indoor NO<sub>2</sub> samples (25th percentile 13.7 ppb) were above the 6.8-ppb limit of detection, and indoor–outdoor NO<sub>2</sub> correlations were low ( $R^2 = 0.06$ ). These results suggest that NO<sub>2</sub> may exist as part of a different pollutant mixture in the indoor and outdoor environments. The differing sources for indoor and outdoor NO<sub>2</sub> indicate that health effects related to indoor NO<sub>2</sub> exposure may not be confounded by the same traffic-related copollutants as outdoor NO<sub>2</sub>.

### ***Adults with Asthma***

Previous and recent evidence indicates associations of ambient NO<sub>2</sub> concentrations with respiratory symptoms ([Maestrelli et al., 2011](#); [Wiwatanadate and Liwsrisakun, 2011](#); [von Klot et al., 2002](#); [Boezen et al., 1998](#); [Forsberg et al., 1998](#)) and asthma medication use or sales ([Carlsen et al., 2012](#); [Laurent et al., 2009](#); [von Klot et al., 2002](#); [Forsberg et al., 1998](#); [Hiltermann et al., 1998](#)) among adults with asthma or bronchial hyperresponsiveness. Most studies were conducted in Europe and recruited subjects primarily from clinics, doctors' offices, and administrative databases. Subjects represented a mix of asthma severity and prevalence of ICS use and atopy. A few studies did not find associations with symptoms, including [Kim et al. \(2012\)](#), who analyzed only

a multipollutant model with SO<sub>2</sub>, PM<sub>10</sub>, O<sub>3</sub>, and CO, the results of which can be unstable. Null results also were reported in studies with more reliable statistical analysis: one conducted in four European countries ([Karakatsani et al., 2012](#)) and one with adults with asthma and allergy ([Feo Brito et al., 2007](#)). Results from the latter study contrast those from experimental studies showing NO<sub>2</sub>-induced allergic inflammation in humans with asthma and animal models of allergic disease ([Section 5.2.2.5](#)). Across studies, respiratory symptoms were associated with Lag Day 0 NO<sub>2</sub>. Medication use or sales were associated more strongly with multiday averages of NO<sub>2</sub> (i.e., lag 3–5 avg, 0–5 avg, 0–6 avg) than with single-day lags ([Carlsen et al., 2012](#); [von Klot et al., 2002](#); [Hiltermann et al., 1998](#)), and [Carlsen et al. \(2012\)](#) found a stronger association for beta-agonist sales with 1-h max than 24-h avg NO<sub>2</sub>.

Despite some supporting evidence, there is limited basis for inferring NO<sub>2</sub> effects on respiratory symptoms in adults with asthma. Most studies assigned NO<sub>2</sub> exposure from a single central site monitor located in the community and did not report information to assess whether the NO<sub>2</sub> metrics were representative of the temporal variability across the study areas and of subjects' ambient exposures. With exception of [Boezen et al. \(1998\)](#), the studies found associations with PM<sub>2.5</sub> and the traffic-related pollutants CO, BS, UFP, and few of the studies analyzed potential confounding. Confounding is an uncertainty also for the association between beta-agonist sales and block-level NO<sub>2</sub> estimated with a dispersion model ([Laurent et al., 2009](#)). Dispersion model estimates were highly correlated with measured concentrations ( $r = 0.87$ ), but other traffic-related pollutants were not examined. Only [von Klot et al. \(2002\)](#) conducted copollutant modeling and found an association between lag 0–4 day avg NO<sub>2</sub> and beta-agonist use with adjustment for PM<sub>2.5</sub> or UFP (OR: 1.22 [95% CI: 1.05, 1.43] per 20-pbb increase in NO<sub>2</sub>, with adjustment for UFP, Pearson  $r = 0.66$ ). The NO<sub>2</sub>-wheeze association was attenuated with adjustment for UFP (OR: 1.02 [95% CI: 0.86, 1.21]). Copollutant effect estimates were attenuated with NO<sub>2</sub> adjustment. Thus, an independent NO<sub>2</sub> association was found for medication use, but an independent association with wheeze was not discerned for either NO<sub>2</sub> or UFP.

### **Controlled Human Exposure Studies**

Controlled human exposure studies, including the single recent study, do not provide strong evidence for NO<sub>2</sub>-induced increases in respiratory symptoms in adults or adolescents with asthma. NO<sub>2</sub> exposures of 120–350 ppb for 30 minutes to 2 hours with exercise ([Table 5-9](#)) tended to result in no change in symptoms during or after (immediately to 1 week) exposure to NO<sub>2</sub> ([Vagaggini et al., 1996](#); [Koenig et al., 1987](#); [Kleinman et al., 1983](#)). NO<sub>2</sub> exposures of 1,000 and 4,000 ppb also did not induce respiratory symptoms in adults with asthma ([Jörres et al., 1995](#); [Linn et al., 1985b](#)).

[Vagaggini et al. \(1996\)](#) reported a small, but statistically significant increase in symptom score during 300 ppb NO<sub>2</sub> exposures in healthy adults but not those with asthma. [Riedl et al. \(2012\)](#) reported an increase in symptom score in adults with asthma during, but not after, exposure to 350 ppb NO<sub>2</sub> for 2 hours with alternating periods of exercise. The increase in symptom score corresponded to a mild increase in any two symptoms or moderate elevation of any one symptom. Unlike studies of airway responsiveness ([Section 5.2.2.1](#)), most symptom studies did not include a challenge agent with NO<sub>2</sub> exposure. [Riedl et al. \(2012\)](#) was unique in assessing symptoms in subjects exposed to allergen after NO<sub>2</sub> exposure but found no change in symptoms.

**Table 5-9 Characteristics of controlled human exposure studies of respiratory symptoms in individuals with asthma.**

Study	Disease Status; Sample Size; Sex; Age (mean ± SD)	Exposure Details	Time of Symptom Assessment
<a href="#">Koenig et al. (1987)</a>	Asthma; n = 4 or 7 M, 3 or 6 F Healthy; n = 3 or 4 M, 6 or 7 F 14.4 yr (range: 12–19)	120 ppb or 180 ppb NO <sub>2</sub> ; Exposures were 30 min at rest, 10 min of moderate exercise.	Immediately after, a day after, and a week after exposure.
<a href="#">Kleinman et al. (1983)</a>	Asthma; n = 12 M, 19 F; 31 ± 1 yr	200 ppb for 2 h; Exercise 15 min on/15 min off at $\dot{V}_E = \sim 2$ times resting	Before, immediately after, and day after exposure.
<a href="#">Vagaggini et al. (1996)</a>	Asthma; n = 4 M, 4 F; 29 ± 14 yr Healthy; n = 7 M; 34 ± 5 yr	300 ppb for 1 h; Exercise at $\dot{V}_E = 25$ L/min	Before and 2 h after exposure.
† <a href="#">Riedl et al. (2012)</a>	Asthma Phase 1 (methacholine challenge); n = 10 M, 5 F; 37.3 ± 10.9 yr Phase 2 (cat allergen challenge); n = 6 M, 9 F; 36.1 ± 12.5 yr	350 ppb for 2 h; Exercise 15 min on/15 min off at $\dot{V}_E = 15\text{--}20$ L/min	Before, during, 1–22 h after exposure.
<a href="#">Jörres et al. (1995)</a>	Asthma; n = 8 M, 4 F; 27 ± 5 yr Healthy; n = 5 M, 3 F; 27 yr (range: 21–33)	1,000 ppb for 3 h; Exercise 10 min on/10 min off at individual's maximum workload	Immediately and 6 and 24 h after exposure.
<a href="#">Linn et al. (1985b)</a>	Asthma; n = 12 M, 11 F; (range: 18–34 yr) Healthy; n = 16 M, 9 F; (range: 20–36 yr)	4,000 ppb for 75 min; Two 15 min periods of exercise at $\dot{V}_E = 25$ L/min and 50 L/min	Before, during, immediately after, 1 day after, and 1 week after exposure.

F = female; L/min = liters per minute; M = male; NO<sub>2</sub> = nitrogen dioxide; ppb = parts per billion; SD = standard deviation;  $\dot{V}_E$  = minute ventilation; yr = year.

†Study published since the 2008 ISA for Oxides of Nitrogen.

---

#### 5.2.2.4 Hospital Admissions and Emergency Department Visits for Asthma

The evidence for NO<sub>2</sub>-related effects on increasing airway responsiveness, decreasing lung function, and increasing respiratory symptoms detailed in the preceding sections are all indicators of asthma exacerbation that may lead people with asthma to seek medical interventions. Thus, the preceding evidence is coherent with associations observed between short-term increases in ambient NO<sub>2</sub> concentrations and hospital admissions and ED visits for asthma. Since the completion of the 2008 ISA for Oxides of Nitrogen, epidemiologic studies have continued to examine the association between short-term exposure to ambient NO<sub>x</sub> or NO<sub>2</sub> and respiratory-related hospital admissions and ED visits, but are primarily limited to single-city studies. As summarized in [Section 5.2.6.2](#), the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) included the first thorough evaluation of respiratory morbidity in the form of respiratory-related hospital admissions and ED visits, including those for asthma. Previous studies of asthma hospital admissions and ED visits consistently reported positive associations with short-term increases in ambient NO<sub>2</sub> concentration ([Figure 5-7](#) and [Table 5-13](#)). The few studies that analyzed copollutant models with CO or PM<sub>2.5</sub> generally observed robust NO<sub>2</sub> associations ([U.S. EPA, 2008c](#)). Confounding by other traffic-related pollutants was not examined. The strongest evidence for associations between short-term NO<sub>2</sub> exposures and asthma-related hospital admissions and ED visits was from studies of all ages and children.

For asthma as well as other respiratory outcome groups, studies of hospital admissions and ED visits are evaluated separately because often only a small percentage of respiratory-related ED visits will be admitted to the hospital. Therefore, ED visits may represent potentially less serious, but more common, outcomes. The air quality characteristics of the city, or across all cities, and the exposure assignment approach used in each asthma hospital admission and ED visit study evaluated in this section are presented in [Table 5-10](#). Other recent studies of asthma hospital admissions and ED visits are not the focus of this evaluation because they were conducted in small individual cities, encompass a short study duration, and/or had insufficient sample size. In addition to these limitations, none examined potential copollutant confounding. The full list of these studies, as well as study specific details, can be found in [Supplemental Table S5-3](#) ([U.S. EPA, 2015h](#)).

**Table 5-10 Mean and upper percentile concentrations of oxides of nitrogen in studies of asthma hospital admissions and emergency department visits.**

Study	Location Years	Exposure Assignment	Metric	Mean/Median Concentration ppb	Upper Percentile of Concentrations (ppb)	Copollutant Examination
<b>Hospital Admissions</b>						
<a href="#">Linn et al. (2000)</a>	Los Angeles, CA (1992–1995)	Average of NO <sub>2</sub> concentrations over all monitors.	24-h avg	3.4	NR	Correlations ( <i>r</i> ): Range across seasons CO: 0.84–0.94 PM <sub>10</sub> : 0.67–0.88 O <sub>3</sub> : –0.23 to 0.35 Copollutant models: none
<a href="#">Burnett et al. (1999)</a>	Toronto, ON, Canada (1980–1994)	Average of NO <sub>2</sub> concentrations from 4 monitors.	24-h avg	25.2	NR	Correlations ( <i>r</i> ): PM <sub>2.5</sub> : 0.55 PM <sub>10-2.5</sub> : 0.38 PM <sub>10</sub> : 0.57 CO: 0.64 SO <sub>2</sub> : 0.54 O <sub>3</sub> : –0.08 Copollutant models: none
<a href="#">†Samoli et al. (2011)</a>	Athens, Greece (2001–2004)	Average of NO <sub>2</sub> concentrations across 14 monitors.	1-h max	44.4	75th: 53.1	Correlations ( <i>r</i> ): SO <sub>2</sub> : 0.55 Copollutant models: PM <sub>10</sub> , SO <sub>2</sub> , O <sub>3</sub>

**Table 5-10 (Continued): Mean and upper percentile concentrations of oxides of nitrogen in studies of asthma hospital admissions and emergency department visits.**

Study	Location Years	Exposure Assignment	Metric	Mean/Median Concentration ppb	Upper Percentile of Concentrations (ppb)	Copollutant Examination
<a href="#">†Iskandar et al. (2012)</a>	Copenhagen, Denmark (2001–2008)	All hospitals located within 15 km of a central site monitor.	24-h avg	NO <sub>2</sub> : 11.3 NO <sub>x</sub> : 14.5	75th: NO <sub>2</sub> : 14.2 NO <sub>x</sub> : 17.7	Correlations ( <i>r</i> ): NO <sub>x</sub> : 0.93 PM <sub>10</sub> : 0.43 PM <sub>2.5</sub> : 0.33 UFP: 0.51 Copollutant models: NO <sub>x</sub> , PM <sub>2.5</sub> , PM <sub>10</sub> , UFP
<a href="#">†Ko et al. (2007b)</a>	Hong Kong, China (2000–2005)	Average of NO <sub>2</sub> concentrations across 14 monitors.	24-h avg	28.3	75th: 33.8 Max: 79.5	Correlations ( <i>r</i> ): SO <sub>2</sub> : 0.57 PM <sub>10</sub> : 0.76 O <sub>3</sub> : 0.41 PM <sub>2.5</sub> : 0.77 Copollutant models: O <sub>3</sub>
<a href="#">†Son et al. (2013)</a>	8 South Korean cities (2003–2008)	Average of hourly ambient NO <sub>2</sub> concentrations from monitors in each city.	24-h avg	11.5–36.9	NR	Correlations ( <i>r</i> ): PM <sub>10</sub> : 0.5 O <sub>3</sub> : -0.1 SO <sub>2</sub> : 0.6 CO: 0.7 Copollutant models: none

**Table 5-10 (Continued): Mean and upper percentile concentrations of oxides of nitrogen in studies of asthma hospital admissions and emergency department visits.**

Study	Location Years	Exposure Assignment	Metric	Mean/Median Concentration ppb	Upper Percentile of Concentrations (ppb)	Copollutant Examination
<b>ED Visits</b>						
<a href="#">Peel et al. (2005)</a>	Atlanta, GA (1993–2000)	Average of NO <sub>2</sub> concentrations from monitors for several monitoring networks.	1-h max	45.9	NR	Correlations ( <i>r</i> ): PM <sub>2.5</sub> : 0.46 PM <sub>10</sub> : 0.49 PM <sub>10-2.5</sub> : 0.46 UFP: 0.26 PM <sub>2.5</sub> water soluble Metals: 0.32 PM <sub>2.5</sub> sulfate: 0.17 PM <sub>2.5</sub> acidity: 0.10 PM <sub>2.5</sub> OC: 0.63 PM <sub>2.5</sub> EC: 0.61 Oxygenated HCs: 0.30 O <sub>3</sub> : 0.42 CO: 0.68 SO <sub>2</sub> : 0.34 Copollutant models: none
<a href="#">Tolbert et al. (2000)</a>	Atlanta, GA (1993–1995)	Concentrations from one central site NO <sub>x</sub> monitor.	1-h max	81.7	Max: 306	Correlations ( <i>r</i> ): PM <sub>10</sub> : 0.44 O <sub>3</sub> : 0.51 Copollutant models: none

**Table 5-10 (Continued): Mean and upper percentile concentrations of oxides of nitrogen in studies of asthma hospital admissions and emergency department visits.**

Study	Location Years	Exposure Assignment	Metric	Mean/Median Concentration ppb	Upper Percentile of Concentrations (ppb)	Copollutant Examination
<a href="#">Jaffe et al. (2003)</a>	2 Ohio cities (Cincinnati and Cleveland) (1991–1996)	When more than 1 NO <sub>2</sub> monitor operating in a day, monitor with highest 24-h avg concentration used.	24-h avg	Cincinnati: 50 Cleveland: 48	NR	Correlations ( <i>r</i> ): Cincinnati PM <sub>10</sub> : 0.36 O <sub>3</sub> : 0.60 SO <sub>2</sub> : 0.07 Cleveland PM <sub>10</sub> : 0.34 SO <sub>2</sub> : 0.28 O <sub>3</sub> : 0.42 Copollutant models: none
<a href="#">Ito et al. (2007)</a>	New York, NY (1999–2002)	Average of NO <sub>2</sub> concentrations from 15 monitors.	24-h avg	31.1	NR	Correlations ( <i>r</i> ): NR Copollutant models: PM <sub>2.5</sub> , O <sub>3</sub> , SO <sub>2</sub> , CO
<a href="#">ATSDR (2006)</a>	Bronx and Manhattan, NY (1999–2000)	NO <sub>2</sub> concentrations from 1 monitor in Bronx and 1 in Manhattan.	24-h avg	Bronx: 36 Manhattan: 31	NR	Correlations ( <i>r</i> ): Bronx O <sub>3</sub> : 0.03 SO <sub>2</sub> : 0.47 FRM PM <sub>2.5</sub> : 0.61 Max PM <sub>2.5</sub> : 0.55 Manhattan: NR Copollutant models: O <sub>3</sub> , FRM and Max PM <sub>2.5</sub> , SO <sub>2</sub>
<a href="#">†Strickland et al. (2010)</a>	Atlanta, GA (1993–2004)	Combined daily NO <sub>2</sub> concentrations across monitors using population weighting.	1-h max	23.3	NR	Correlations ( <i>r</i> ): NR Copollutant models: O <sub>3</sub>

**Table 5-10 (Continued): Mean and upper percentile concentrations of oxides of nitrogen in studies of asthma hospital admissions and emergency department visits.**

Study	Location Years	Exposure Assignment	Metric	Mean/Median Concentration ppb	Upper Percentile of Concentrations (ppb)	Copollutant Examination
<a href="#">†Sarnat et al. (2013a)</a>	Atlanta, GA (1999–2002)	NO <sub>x</sub> concentrations predicted using fused spatially interpolated background pollutant concentrations and local-scale AERMOD output for 186 ZIP codes.	24-h avg	NO <sub>x</sub> : 30.1	75th: 40.1 95th: 94.4 Max: 517.8	Correlation ( <i>r</i> ) with NO <sub>x</sub> : CO: 0.93 O <sub>3</sub> : -0.03 PM <sub>2.5</sub> : 0.40 Copollutant models: none
<a href="#">†Villeneuve et al. (2007)</a>	Edmonton, AB, Canada (1992–2002)	Average of NO <sub>2</sub> concentrations across 3 monitoring stations.	24-h avg	50th: 17.5 Summer 50th: 28.5 Winter	75th: 22.0 summer 75th: 35.5 winter	Correlations ( <i>r</i> ): CO: 0.74 Copollutant models: CO
<a href="#">†Jalaludin et al. (2008)</a>	Sydney, Australia (1997–2001)	Average of NO <sub>2</sub> concentrations across 14 monitoring stations.	1-h max	23.2	Max: 59.4	Correlations ( <i>r</i> ): PM <sub>10</sub> : 0.67 PM <sub>2.5</sub> : 0.68 O <sub>3</sub> : 0.21 CO: 0.71 SO <sub>2</sub> : 0.52 Copollutant models: PM <sub>10</sub> , PM <sub>2.5</sub> , O <sub>3</sub> , CO, SO <sub>2</sub>
<a href="#">†Stieb et al. (2009)</a>	7 Canadian cities (1992–2003)	Average NO <sub>2</sub> concentrations from all monitors in each city. Number of NO <sub>2</sub> monitors in each city ranged from 1–14.	24-h avg	9.3–22.7	75th: 12.3–27.6	Correlations ( <i>r</i> ) only reported by city and season. Copollutant models: none
<a href="#">†Orazio et al. (2009)</a>	6 Italian cities (1996–2002)	Average of NO <sub>2</sub> concentrations from all monitors in each city.	24-h avg	21.4–41.2	NR	Correlations ( <i>r</i> ): NR Copollutant models: none

**Table 5-10 (Continued): Mean and upper percentile concentrations of oxides of nitrogen in studies of asthma hospital admissions and emergency department visits.**

Study	Location Years	Exposure Assignment	Metric	Mean/Median Concentration ppb	Upper Percentile of Concentrations (ppb)	Copollutant Examination
<a href="#">†Strickland et al. (2011)</a>	Atlanta, GA (1993–2004)	NO <sub>2</sub> concentrations obtained from 3 networks of stationary monitors. Each air pollutant measured by at least 3 monitoring stations. 3 exposure metrics used: (1) 1 downtown monitor was selected to be the central site monitor, (2) all monitors used to calculate unweighted average of pollutant concentrations for all monitors, and (3) population-weighted average concentration.	1-h max	Central monitor: 42.0 Unweighted average: 27.7 Population-weighted average: 22.0	NR	Correlations ( <i>r</i> ): NR Copollutant models: none
<a href="#">†Li et al. (2011b)</a>	Detroit, MI (2004–2006)	Average of NO <sub>2</sub> concentrations from 2 monitors in Detroit metropolitan area that measure NO <sub>2</sub> .	24-h avg	15.7	75th: 21.2 Max: 55.2	Correlations ( <i>r</i> ), range across monitors: CO: 0.37–0.40 PM <sub>2.5</sub> : 0.56–0.66 SO <sub>2</sub> : 0.42–0.55 Copollutant models: none
<a href="#">†Gass et al. (2014)</a>	Atlanta, GA (1999–2009)	Population-weighted average NO <sub>2</sub> concentrations based on same methods as <a href="#">Strickland et al. (2010)</a> .	24-h avg	NR	NR	Correlations ( <i>r</i> ): NR Copollutant models: none

**Table 5-10 (Continued): Mean and upper percentile concentrations of oxides of nitrogen in studies of asthma hospital admissions and emergency department visits.**

Study	Location Years	Exposure Assignment	Metric	Mean/Median Concentration ppb	Upper Percentile of Concentrations (ppb)	Copollutant Examination
<a href="#">†Winqvist et al. (2014)</a>	Atlanta, GA (1998–2004)	Population-weighted average of NO <sub>2</sub> concentrations.	1-hr max	Warm (May–Oct): 22.3 Cold (Nov–April): 25.6	75th: Warm: 28.7 Cold: 31.7	Correlations ( <i>r</i> ): Warm: O <sub>3</sub> : 0.54 CO: 0.75 SO <sub>2</sub> : 0.44 PM <sub>2.5</sub> : 0.52 EC: 0.68 Sulfate: 0.27 Secondary PM <sub>2.5</sub> : 0.31 Cold: O <sub>3</sub> : 0.30 CO: 0.74 SO <sub>2</sub> : 0.41 PM <sub>2.5</sub> : 0.49 EC: 0.57 Sulfate: 0.08 Secondary PM <sub>2.5</sub> : 0.12

**Table 5-10 (Continued): Mean and upper percentile concentrations of oxides of nitrogen in studies of asthma hospital admissions and emergency department visits.**

Study	Location Years	Exposure Assignment	Metric	Mean/Median Concentration ppb	Upper Percentile of Concentrations (ppb)	Copollutant Examination
<b>Physician Visits</b>						
† <a href="#">Burra et al. (2009)</a>	Toronto, ON, Canada (1992–2001)	Average of NO <sub>2</sub> concentrations from 6 monitors.	1-h max	39.2	95th: 60 Max: 105	Correlations ( <i>r</i> ): NR Copollutant models: none
† <a href="#">Sinclair et al. (2010)</a>	Atlanta, GA (1998–2002)	NO <sub>2</sub> concentrations collected as part of AIRES at SEARCH Jefferson street site.	1-h max	1998–2000: 49.8 2000–2002: 35.5 1998–2002: 41.7	NR	Correlations ( <i>r</i> ): NR Copollutant models: none

Avg = average; AERMOD = American Meteorological Society/Environmental Protection Agency Regulatory Model; ATSDR = Agency for Toxic Substances and Disease Registry; AIRES = Aerosol Research Inhalation Epidemiology Study; AB = Alberta; CA = California; CO = carbon monoxide; EC = elemental carbon; ED = emergency department; FRM = Federal Reference Method; GA = Georgia; MI = Michigan; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; NR = not reported; NY = New York; O<sub>3</sub> = ozone; OC = organic carbon; ON = Ontario; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm; SEARCH = Southeastern Aerosol Research and Characterization; SO<sub>2</sub> = sulfur dioxide; UFP = ultrafine particles.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

## Hospital Admissions

Generally, studies evaluated in the 2008 ISA for Oxides of Nitrogen that examined the effect of short-term NO<sub>2</sub> exposures on asthma hospital admissions were limited to single cities. The results of these studies should be viewed with caution because they tended to include ages <5 years in the study population, which is problematic considering the difficulty in reliably diagnosing asthma within this age range [National Asthma Education and Prevention Program Expert ([NAEPP, 2007](#))]. However, it is unlikely the inclusion of these individuals in a study would introduce a systematic positive bias. In contrast, the majority of studies on asthma ED visits (discussed in the next section) have excluded ages <2 years in analyses to account for this difficulty.

In a time-series study conducted in Athens, Greece, [Samoli et al. \(2011\)](#) evaluated the association of multiple ambient air pollutants and pediatric asthma hospital admissions for ages 0–14 years. In an all-year analysis, the authors reported a positive association with NO<sub>2</sub> (6.4% [95% CI: -3.8, 17.6]; lag 0 increase for a 30-ppb increase in 1-h max NO<sub>2</sub> concentrations). An examination of additional lags (quantitative results not presented) revealed a similar pattern of associations at lag 2 and a 0–2 days distributed lag. In copollutant analyses, NO<sub>2</sub> risk estimates were robust when O<sub>3</sub> (7.6% [95% CI: -2.7, 19.0]) was included in the model, and were attenuated but remained positive with wide confidence intervals when including PM<sub>10</sub> in the model (3.1% [95% CI: -7.3, 14.6]). There was evidence of confounding of the NO<sub>2</sub> association when SO<sub>2</sub> was included in the model as demonstrated by an effect estimate and confidence interval for NO<sub>2</sub> reflective of a null association (-4.3% [95% CI: -16.9, 10.2]). Of the two copollutants examined, SO<sub>2</sub> was most highly correlated with NO<sub>2</sub> ( $r = 0.55$ ).

The association between short-term air pollution exposures and asthma hospital admissions in children (0–18 years of age) was also examined in a study conducted by [Iskandar et al. \(2012\)](#) in Copenhagen, Denmark. In a time-stratified case-crossover analysis using an a priori lag of 0–4 days, the authors reported positive associations for both NO<sub>2</sub> (OR: 1.3 [95% CI: 1.1, 1.6] for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations) and NO<sub>x</sub> (OR: 1.6 [95% CI: 1.3, 2.1] for a 40-ppb increase in 24-h avg NO<sub>x</sub> concentrations), which are larger in magnitude than those observed in [Samoli et al. \(2011\)](#). Within this study NO<sub>x</sub> and NO<sub>2</sub> were highly correlated ( $r = 0.93$ ). Correlations for NO<sub>x</sub> and NO<sub>2</sub> with PM<sub>2.5</sub> and UFPs ranged from,  $r = 0.28$ – $0.33$  and  $r = 0.45$ – $0.51$ , respectively. The high correlation between NO<sub>x</sub> and NO<sub>2</sub>, and the fact NO<sub>2</sub> is part of NO<sub>x</sub>, suggests that these pollutants should not be included in the same model due to the inability to clearly examine whether one pollutant has an independent effect compared to

the other. In additional copollutant models, NO<sub>2</sub> and NO<sub>x</sub> associations remained relatively unchanged in models with PM<sub>2.5</sub> or UFP ([Table 5-11](#)).

**Table 5-11 Copollutant model results from Iskandar et al. (2012) for a 20-ppb increase in 24-h average nitrogen dioxide (NO<sub>2</sub>) concentrations and a 40-ppb increase in 24-h average NO<sub>x</sub> (sum of NO and NO<sub>2</sub>) concentrations.**

Pollutant	Copollutant	Odds Ratio (95% CI)
NO <sub>x</sub>	---	1.6 (1.3, 2.1)
	NO <sub>2</sub>	1.7 (0.8, 3.5)
	PM <sub>10</sub>	1.4 (1.1, 1.8)
	PM <sub>2.5</sub>	1.6 (1.2, 2.1)
	UFP	1.6 (1.2, 2.2)
NO <sub>2</sub>	---	1.3 (1.1, 1.6)
	NO <sub>2</sub>	1.0 (0.6, 1.6)
	PM <sub>10</sub>	1.3 (1.0, 1.5)
	PM <sub>2.5</sub>	1.4 (1.2, 1.7)
	UFP	1.5 (1.2, 1.8)

CI = confidence interval; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm; ppb = parts per billion; UFP = ultrafine particles.

Source: [Iskandar et al. \(2012\)](#)

[Ko et al. \(2007b\)](#) examined the association between short-term increases in NO<sub>2</sub> and asthma hospital admissions for all ages at both single- and multi-day lags in Hong Kong, China. In a time-series analysis the authors reported positive associations at single-day lags that were smaller in magnitude than those observed in [Samoli et al. \(2011\)](#) [e.g., 3.4% (95% CI: 1.9, 5.4); lag 0 for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations]. However, the results of [Ko et al. \(2007b\)](#) are consistent with those of [Son et al. \(2013\)](#) in eight South Korean cities, who found the strongest association at lag 0 between short-term NO<sub>2</sub> exposures and asthma as well as allergic disease hospital admissions, which encompasses asthma (3.6% [95% CI: 0.5, 6.8] and 3.8% [95% CI: 1.0, 6.6], respectively for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations). Unlike [Samoli](#)

[et al. \(2011\)](#) and [Son et al. \(2013\)](#), [Ko et al. \(2007b\)](#) found the strongest evidence of an association between short-term NO<sub>2</sub> exposures and asthma hospital admissions at multiday lags of 0–3 (10.9% [95% CI: 8.1, 13.8]) and 0–4 (10.9% [95% CI: 8.1, 13.4]) days. In a copollutant model with O<sub>3</sub>, although risk estimates remained positive (2.3% [95% CI: -0.8, 5.8]; lag 0–4 days), evidence indicated a reduction in NO<sub>2</sub> risk estimates. The attenuation occurred even though NO<sub>2</sub> and O<sub>3</sub> were not strongly correlated ( $r = 0.41$ ) in Hong Kong, China. In contrast, [Samoli et al. \(2011\)](#) observed an increase in NO<sub>2</sub> risk estimates with adjustment for O<sub>3</sub> but attenuation with adjustment for PM<sub>10</sub> or SO<sub>2</sub>.

### **Emergency Department Visits**

Similar to the asthma hospital admission studies evaluated in the 2008 ISA for Oxides of Nitrogen, the majority of ED visit studies were limited to single-city studies. However, these studies provided additional information regarding potential seasonal differences in risk estimates, indicating some evidence of larger associations during warmer months.

[Strickland et al. \(2010\)](#) examined the association between NO<sub>2</sub> exposure and pediatric asthma ED visits (ages 5–17 years) in Atlanta, GA, using air quality data over the same years as two studies [[Darrow et al. \(2011a\)](#) and [Tolbert et al. \(2007\)](#)] that focused on total respiratory ED visits ([Section 5.2.6](#)). However, unlike [Darrow et al. \(2011a\)](#) and [Tolbert et al. \(2007\)](#), which used a single-site, centrally located monitor and the average of multiple monitors to assign exposure, [Strickland et al. \(2010\)](#) used population weighting to combine daily pollutant concentrations across monitors. In this study, the authors developed a statistical model using hospital-specific, time-series data that is essentially equivalent to a time-stratified case-crossover analysis (i.e., using interaction terms between year, month, and day of week to mimic the approach of selecting referent days within the same month and year as the case day). [Strickland et al. \(2010\)](#) reported an 8.6% (95% CI: 4.2, 13.3) increase in ED visits for a 30-ppb increase in 1-h max NO<sub>2</sub> concentrations at lag 0–2 days in an all-year analysis. The potential confounding effects of other pollutants on the NO<sub>2</sub>-asthma ED visit relationship was only examined in a copollutant model with O<sub>3</sub>, and correlations between pollutants were not presented. In the copollutant model, NO<sub>2</sub> risk estimates were found to be relatively unchanged upon the inclusion of O<sub>3</sub> (quantitative results not presented).

The magnitude of the association between short-term NO<sub>2</sub> concentrations and asthma ED visits observed in [Strickland et al. \(2010\)](#) is larger than that observed in [Sarnat et al. \(2013a\)](#) in a study also conducted in Atlanta, GA, which focused on the influence of air exchange rates on air pollution-asthma ED visit associations detailed in [Chapter 3](#). Instead of using monitored NO<sub>2</sub> concentrations, [Sarnat et al. \(2013a\)](#) estimated NO<sub>x</sub> exposures by “fus(ing) spatially interpolated background concentrations and the

local-scale air quality model AERMOD output for the 186 ZIP code centroids” in the Atlanta metro area. Also, focusing on a lag of 0–2 days, the authors reported a 1.3% increase in asthma ED visits (95% CI: 0.0, 2.4) for a 40-ppb increase in 24-h avg NO<sub>x</sub> concentrations. They did not examine copollutant models but found NO<sub>x</sub> to be highly correlated with CO ( $r = 0.93$ ). The magnitude of the association differs between [Strickland et al. \(2010\)](#) and [Sarnat et al. \(2013a\)](#), which could be a reflection of: (1) exposure measurement error and differences in exposure assessment methods for NO<sub>x</sub> compared to NO<sub>2</sub> and (2) the different age ranges included in both studies. The latter explanation is supported by earlier studies conducted in Atlanta, GA by [Tolbert et al. \(2000\)](#) and [Peel et al. \(2005\)](#) that focused on all ages and that reported associations similar in magnitude to that observed in [Sarnat et al. \(2013a\)](#) ([Figure 5-7](#)).

Additional evidence for an association between short-term increases in NO<sub>2</sub> concentrations and asthma ED visits comes from studies conducted in Edmonton, Canada ([Villeneuve et al., 2007](#)) and Sydney, Australia ([Jalaludin et al., 2008](#)). [Villeneuve et al. \(2007\)](#) reported evidence of positive associations between short-term NO<sub>2</sub> concentrations and asthma ED visits for multiple lag structures (lag 1, lag 0–2, and lag 0–4 days) in the population aged 2 years and older. The authors observed the strongest association for lag 0–4 days (4.5% [95% CI: 0, 7.5] for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations). There was no evidence of an association at lag 0. In this study, NO<sub>2</sub> and CO were strongly correlated ( $r = 0.74$ ), and as a result, associations were examined in copollutant models for each age group examined in the study, focusing on the warm season (April–September). In copollutant models with CO, NO<sub>2</sub> associations with asthma ED visits were relatively similar to single-pollutant results except for one age group, 15–44 years, but in all instances NO<sub>2</sub> associations were larger in magnitude than those for CO (quantitative results not provided).

In a study focusing on children 1–14 years old, [Jalaludin et al. \(2008\)](#) examined air pollution associations with asthma ED visits for single day lags up to 3 days as well as the average of 0–1 day lags. [Jalaludin et al. \(2008\)](#) observed a similar magnitude of an association for both lag 0 (7.5% [95% CI: 4.5, 10.5]) and lag 0–1 days (7.8% [95% CI: 4.5, 11.1] for a 30-ppb increase in 1-h max NO<sub>2</sub> concentrations). An examination of the potential confounding effects of other pollutants was assessed in copollutant models with PM<sub>10</sub>, PM<sub>2.5</sub>, O<sub>3</sub>, CO, or SO<sub>2</sub>. NO<sub>2</sub> was moderately to weakly correlated with each of these pollutants ( $r$  ranging from 0.21–0.71). In copollutant models, the NO<sub>2</sub>-asthma ED visit association remained positive, but was slightly attenuated with the magnitude of the association ranging from a 4.2–6.1% increase in asthma ED visits. In addition to analyzing ages 1–14 years, the authors examined whether risks varied among age ranges within this study population (see [Chapter 7](#)).

In contrast with the majority of the evidence, short-term increases in NO<sub>2</sub> concentrations were not associated with asthma ED visits in a multicity study conducted in seven Canadian cities ([Stieb et al., 2009](#)). Compared to the other asthma ED visit studies evaluated, mean NO<sub>2</sub> concentrations across the cities included in this study were the lowest with all cities having mean 24-h avg concentrations <23 ppb ([Table 5-10](#)). [Stieb et al. \(2009\)](#) examined the association between short-term NO<sub>2</sub> exposure and a number of respiratory-related ED visits for all ages. There was no evidence that NO<sub>2</sub> was associated with asthma ED visits at single-day lags of 0 to 2 days (0.0% [95% CI: -2.6, 2.7]; lag 2 for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations). Additionally, there was no evidence of associations between respiratory-related ED visits, including asthma, and air pollution averaged over subdaily time scales (i.e., 3-h avg of ED visits versus 3-h avg pollutant concentrations).

### **Emergency Department Visits for Wheeze**

As stated previously [[National Asthma Education and Prevention Program Expert \(NAEPP, 2007\)](#)], asthma is difficult to diagnose in children less than 5 years of age; however, asthma-like symptoms in children within this age range are often presented in the form of transient wheeze. Although studies that examine ED visits for wheeze do not directly inform the relationship between short-term NO<sub>2</sub> exposures and asthma, they can add supporting evidence. Notably, some studies that examine asthma ED visits, as well as hospital admissions, often include International Classification of Diseases (ICD) codes for wheeze in the definition of asthma [e.g., ([Sarnat et al., 2013a](#))]. [Orazzo et al. \(2009\)](#) examined the association between NO<sub>2</sub> and wheeze ED visits in children, (ages 0–2 years) in six Italian cities. Daily counts of wheeze were examined in relation to air pollution using a time-stratified case-crossover approach in which control days were matched on day of week in the same month and year as the case day. PM<sub>10</sub>, SO<sub>2</sub>, CO, and O<sub>3</sub> were also evaluated, but correlations with NO<sub>2</sub> were not reported nor were copollutant analyses conducted. The authors reported positive associations between short-term 24-h avg NO<sub>2</sub> exposures and wheeze ED visits when examining various multiday lags (0–1 through 0–6 days) with risk estimates ranging from 1.1% (95% CI: -1.2, 3.4) for lag 0–1 days to 2.5% (95% CI: -0.9, 6.0) for lag 0–6 days.

### **Outpatient and Physician Visit Studies**

Several recent studies examined the association between ambient NO<sub>2</sub> concentrations and less severe asthma exacerbation, which are often encountered through physician or outpatient (nonhospital, nonED) visits. [Burra et al. \(2009\)](#) examined asthma physician visits among patients aged 1–17 and 18–64 years focusing on differences by sex and

income within age categories in Toronto, Canada. The authors reported evidence of consistently positive associations between short-term increases in NO<sub>2</sub> concentrations and asthma physician visits across the single- and multi-day lags examined (i.e., 0, 0–1, 0–2, 0–3, and 0–4 days). The magnitude of the effect estimates were found to be similar between sexes, income quintiles, and both within and between ages. In a study conducted in Atlanta, GA, [Sinclair et al. \(2010\)](#) examined the association between air pollution and a number of respiratory-related (including asthma) outpatient visits to a managed care organization. The authors separated the analysis into two time periods to compare the air pollutant concentrations and relationships for acute respiratory visits for the 25-month time period examined in [Sinclair and Tolsma \(2004\)](#) (i.e., August 1998–August 2000) and an additional 28-month time period of available data from the Atlanta Aerosol Research Inhalation Epidemiology Study (AIRES) (i.e., September 2000–December 2002). Across the two time periods, mean 1-h max NO<sub>2</sub> concentrations were lower in the 28-month versus the 25-month time period, 35.5 versus 49.8 ppb, respectively ([Table 5-10](#)). A comparison of the two time periods indicated that risk estimates across outcomes tended to be larger in the earlier 25-month period compared to the later 28-month period, with evidence of consistently positive associations at lags of 0–2 and 3–5 days for asthma, but confidence intervals were relatively large.

### **Examination of Seasonal Differences**

In addition to examining the association between short-term NO<sub>2</sub> concentrations and asthma hospital admissions and ED visits in all-year analyses, some studies also conducted seasonal analyses. Overall, these studies generally provide evidence of larger associations in the warm or summer season compared to cooler months ([Figure 5-7](#)). Notably, these studies did not examine potential copollutant confounding by season, and the correlation between personal and ambient measures differ by season ([Section 3.4.2](#)), both of which could influence the results of the studies presented below.

In the study of eight South Korean cities, [Son et al. \(2013\)](#) examined potential seasonal differences across respiratory hospital admission outcomes, including asthma and allergic disease. For both outcomes, the association with NO<sub>2</sub> was largest in magnitude during the summer (asthma: 16.2% [95% CI: 5.1, 28.6], lag 0; allergic disease: 15.9 [95% CI: 4.6, 28.5], lag 0 for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations) despite the lowest NO<sub>2</sub> concentrations during the summer season (<20 ppb compared to >24 ppb in the other seasons) across the eight cities. However, when using the warm season as the referent in Hong Kong, China, [Ko et al. \(2007b\)](#) reported evidence of larger effects in the winter (i.e., December to March), suggesting that differences in seasonal associations may vary by geographic location. The difference in seasonal associations by geographic location is further highlighted in a study by [Samoli et al. \(2011\)](#) conducted in Athens, Greece that

reported results consistent with [Son et al. \(2013\)](#). Although risk estimates for asthma hospital admissions were relatively consistent across winter, spring, and autumn, ranging from a 13.1 to a 13.8% increase per 20-ppb increase in 24-h avg NO<sub>2</sub>, the largest percentage increase was observed for the summer (28.7% [95% CI: -3.4, 71.3]).


The asthma ED visit studies that conducted seasonal analyses also reported seasonal patterns similar to those observed in the hospital-admission studies. [Villeneuve et al. \(2007\)](#) reported associations to be generally stronger in the warm season (e.g., 21.4% [95% CI: 13.6, 31.0] at lag 0–4 days for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations) than in the cold season (-2.9% [95% CI: -7.3, 1.5]) in Edmonton, Canada. Additionally, [Jalaludin et al. \(2008\)](#) found evidence of larger effects during the warm months (November–April) compared to the cold months (May–October) in Sydney, Australia ([Figure 5-7](#)). These results are consistent with [Strickland et al. \(2010\)](#), which reported stronger associations during the warm season (i.e., May–October) (16.0% [95% CI: 9.1, 23.5]; lag 0–2 days) than the cold season (3.8% [95% CI: -1.9, 9.6]; lag 0–2 days) in a study of pediatric asthma ED visits in Atlanta, GA. Additional support for these seasonal differences in associations was presented by [Orazzo et al. \(2009\)](#), who focused on wheeze ED visits in six Italian cities, where associations were slightly larger in the summer compared to the winter, but the confidence intervals were wide and overlapping (quantitative results not provided). In the study of seven Canadian cities, [Stieb et al. \(2009\)](#) also conducted seasonal analyses but did not present detailed results. However, the authors did state that there was no evidence of consistent associations during the winter months (October–March) between any pollutant and respiratory outcomes, including asthma.

Additional evidence for potential seasonal differences in NO<sub>2</sub>-associations with asthma hospital admissions and ED visits comes from the analysis of asthma physician visits by [Sinclair et al. \(2010\)](#). When focusing on asthma in children, the authors reported larger risk estimates in the warm season at all lags for the 25-month period (e.g., warm: 9.6% [95% CI: -7.4, 30.0]; cold: 1.2% [95% CI: -12.4, 16.8] at lag 0–2 days for a 30-ppb increase in 1-h max NO<sub>2</sub> concentrations), with less consistent evidence for seasonal differences in the 28-month period.

### **Concentration-Response Relationship**

To date, few studies have examined the concentration-response (C-R) relationship between NO<sub>2</sub> exposures and respiratory morbidity. In recent studies, [Strickland et al. \(2010\)](#) and [Li et al. \(2011b\)](#) examined the shape of the NO<sub>2</sub>-pediatric asthma ED visit relationship using different analytical approaches. [Strickland et al. \(2010\)](#) examined the C-R relationship by conducting quintile and locally weighted scatterplot smoothing

(LOESS) C-R analyses. In the quintile analysis, NO<sub>2</sub> associations were positive and stronger at quintiles representing higher concentrations, ranging from 28 ppb to >181 ppb, relative to the first quintile (i.e., NO<sub>2</sub> concentrations <28 ppb). Additionally, the LOESS C-R relationship analysis provides evidence indicating elevated NO<sub>2</sub> associations along the distribution of concentrations from the 5th to 95th percentile ([Figure 5-5](#)). Collectively, these analyses do not provide evidence of a threshold.



Note: ppb = parts per billion. Solid line = locally weighted scatterplot smoothing concentration-response estimates. Dashed lines = twice-standard error estimates. Results are from generalized additive models. Results are presented for the 5th to 95th percentiles of nitrogen dioxide concentrations.

Source: Reprinted with permission of the American Thoracic Society, ([Strickland et al., 2010](#)).

**Figure 5-5** Concentration-response function for the association between 3-day average (lag 0–2) nitrogen dioxide concentrations and emergency department visits for pediatric asthma in the Atlanta, GA area.

In a study conducted in Detroit, MI, [Li et al. \(2011b\)](#) focused on the C-R relationship by examining whether there is evidence of a deviation from linearity. Associations were

examined in both a time-series and time-stratified case-crossover study design assuming: (1) no deviation from linearity and (2) a change in linearity at 23 ppb [i.e., the maximum likelihood estimate within the 10th to 95th percentile concentration where a change in linearity may occur (~80th percentile)]. The analysis assumed a deviation in linearity but did not assume zero risk below the inflection point. The focus of the analysis was on identifying whether risk increased above the risk observed in the linear models at NO<sub>2</sub> concentrations above 23 ppb. In the analyses assuming linearity, effect estimates varied across models for a 0–4-day lag (time series: 2.9% [95% CI: -7.9, 15.1]; case-crossover: 9.1% [95% CI: -0.83, 20.2] for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations). In the models that assumed a deviation from linearity, the authors did not observe evidence of higher risk in either the time-series or case-crossover analyses at NO<sub>2</sub> concentrations greater than 23 ppb.

### **Exposure Assignment**

Questions often arise in air pollution epidemiologic studies with regard to the method used to assign exposure. [Strickland et al. \(2011\)](#) assessed this question in a study conducted in Atlanta, GA focusing on pediatric asthma ED visits. Using data from the warm season from a previous analysis ([Strickland et al., 2010](#)), [Strickland et al. \(2011\)](#) examined the relative influence of different exposure assignment approaches (i.e., central site monitor, unweighted average across available monitors, and population-weighted average) on the magnitude and direction of associations between NO<sub>2</sub> and pediatric asthma hospital admission. [Strickland et al. \(2011\)](#) reported that effect estimates per IQR increase in NO<sub>2</sub> were similar across the metrics; however, based on a standardized increment, the magnitude of the association between NO<sub>2</sub> and pediatric asthma ED visits varied (central site monitor: 7.9% [95% CI: 4.2, 11.8] < unweighted average: 12.1% [95% CI: 6.7, 17.9] < population-weighted average: 16.2% [95% CI: 9.1, 23.7] for a 30-ppb increase in 1-h max NO<sub>2</sub> concentrations at lag 0–2 days). Although [Strickland et al. \(2011\)](#) represents one study in one location, the results suggest that the different approaches used to assign exposure across the studies evaluated may alter the magnitude, but not direction, of the associations observed.


### **Nitrogen Dioxide within the Multipollutant Mixture**

Another important question often encountered during the review of any criteria air pollutant is whether the pollutant has an independent effect on human health. In the case of NO<sub>2</sub>, this is questioned because NO<sub>2</sub> is often found to be highly correlated with other traffic-related pollutants. However, ambient exposures to criteria air pollutants are in the form of mixtures, which make answering this question difficult and primarily limited to

examining copollutant models. Recent studies conducted by [Gass et al. \(2014\)](#) and [Winquist et al. \(2014\)](#), both of which use pediatric asthma ED visit data from Atlanta, GA, use novel approaches to assess whether specific mixtures are more strongly associated with health effects compared to others. Although the primary objective of these types of studies is not to directly assess the independent effects of a pollutant, the studies can inform the role of NO<sub>2</sub> in the air pollution mixture.

[Gass et al. \(2014\)](#) used a classification and regression tree (C&RT) approach to examine the association between short-term exposures to unique daily multipollutant mixtures of NO<sub>2</sub>, CO, PM<sub>2.5</sub>, and O<sub>3</sub>, and pediatric (i.e., ages 2–18 years) asthma ED visits in Atlanta. C&RT is a supervised learning approach that creates various groupings of pollutants based on an outcome variable, which differs from similar techniques, such as principal component analysis, that do not consider the outcome ([Gass et al., 2014](#)). For this approach, daily pollutant concentrations were divided into quartiles with the referent group comprised of all days in which each pollutant was in the lowest quartile. The C&RT analysis identified 13 different unique daily pollutant combinations or terminal nodes. Similar to [Strickland et al. \(2010\)](#), [Gass et al. \(2014\)](#) examined the relationship between each combination and pediatric asthma ED visits using a Poisson model in the context of a time-referent case-crossover analysis. Of the 13 unique combinations, 5 of the largest relative risks (RRs) (i.e., RR ranging from 1.05 to 1.08) were observed for combinations where NO<sub>2</sub> concentrations were in the 3rd or 4th quartile. Of note for three of the five combinations with the largest RRs, PM<sub>2.5</sub> concentrations were also high, with concentrations in the 4th quartile. However, the RR largest in magnitude was observed for a combination where NO<sub>2</sub> concentrations were low (1st and 2nd quartiles) and PM<sub>2.5</sub> concentrations were high (4th quartile). Overall, these results suggest that high daily concentrations of NO<sub>2</sub> in combination with low and high daily concentrations of PM<sub>2.5</sub> can impact respiratory morbidity.

[Winquist et al. \(2014\)](#) took a different approach to examining multipollutant mixtures by estimating the joint effect (i.e., the combined effect) of pollutants often associated with specific air pollution sources. Associations between short-term NO<sub>2</sub> exposures and pediatric asthma ED visits (i.e., ages 5–17) were examined in single-pollutant models and also in a multipollutant context in joint models for pollutant combinations representative of oxidant gases (i.e., O<sub>3</sub>, NO<sub>2</sub>, SO<sub>2</sub>), traffic (i.e., CO, NO<sub>2</sub>, EC), and criteria pollutants (i.e., O<sub>3</sub>, CO, NO<sub>2</sub>, SO<sub>2</sub>, PM<sub>2.5</sub>). Using the model detailed in [Strickland et al. \(2010\)](#), the authors reported results for an IQR increase for lag 0–2 days in single-pollutant analyses as well as three types of joint effect models [i.e., no interaction terms (primary), first-order multiplicative interactions between pollutants (interactions), and nonlinear pollutant terms (nonlinear)] ([Figure 5-6](#)).



Note: CO = carbon monoxide; EC = elemental carbon; h = hour; JE = joint model estimate; max = maximum; NO<sub>2</sub> = nitrogen dioxide; O<sub>3</sub> = ozone; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm; ppb = parts per billion; SO<sub>2</sub> = sulfur dioxide; SO<sub>4</sub> = sulfate; SPE = single-pollutant model estimate. Results are presented for an interquartile range increase in each pollutant. Interquartile range for nitrogen dioxide = 12.87 ppb.

Source: Reprinted with permission from Wolters Kluwer Health, [Winquist et al. \(2014\)](#).

**Figure 5-6 Rate ratio and 95% confidence intervals for asthma-related emergency department visits in single-pollutant and joint effect models for each pollutant at lag 0–2 days.**

Across pollutant combinations that contained NO<sub>2</sub>, in the warm season, joint effect models reported consistent positive associations with pediatric asthma ED visits. For each pollutant combination the association observed was larger in magnitude than any single-pollutant association, including NO<sub>2</sub>, but not equivalent to the sum of each individual pollutant association for a specific combination. Furthermore, in the warm season analysis, associations across the different joint effects models were found to be relatively similar. The results during the cold season were inconsistent; however, for the combination of traffic pollutants, results from the joint effects models were relatively similar to the single-pollutant results. The results of [Winquist et al. \(2014\)](#) suggest that NO<sub>2</sub> in combination with other pollutants is associated with asthma ED visits, but also highlight the difficulty in separating out the independent effect of a pollutant that is part of a mixture where multiple pollutants are often highly correlated.

## Summary of Asthma Hospital Admissions and Emergency Department Visits


Recent studies that examined the association between short-term NO<sub>2</sub> exposure and asthma hospital admissions and ED visits consistently report positive associations and support the results of U.S. and Canadian studies evaluated in the 2008 ISA for Oxides of Nitrogen ([Figure 5-7](#) and [Table 5-12](#)). Across asthma hospital admission and ED visit studies, there was some evidence of a different pattern of associations for each outcome, with more immediate effects (i.e., lag 0) for asthma hospital admissions and evidence of prolonged effects for asthma ED visits, with a number of studies showing effects at multiday lags ranging from 0–2 to 0–4 days. The studies that examined potential confounding by PM<sub>2.5</sub> or the traffic-related pollutants UFP or CO showed evidence that associations between short-term NO<sub>2</sub> exposures and asthma hospital admissions and ED visits remained relatively unchanged in copollutant models with (i.e., similar in magnitude or attenuated slightly, but remaining positive). NO<sub>2</sub> is often found to be highly correlated with these copollutants; therefore, the ability to determine whether short-term NO<sub>2</sub> exposures are independently associated with asthma hospital admissions and ED visits is limited. Recent studies of multipollutant exposures further inform the effect of short-term NO<sub>2</sub> exposures on respiratory morbidity, specifically asthma. These studies demonstrate that high daily concentrations of NO<sub>2</sub> in combination with high daily concentrations of other pollutants, such as PM<sub>2.5</sub>, can impact respiratory morbidity and that associations are observed between asthma ED visits and NO<sub>2</sub> in combination with other traffic-related pollutants, oxidants, and criteria pollutants.

A number of recent studies also examined whether there was evidence that the association between short-term NO<sub>2</sub> exposures and asthma hospital admissions and ED visits was modified by season or some other individual- or population-level factor ([Chapter 7](#)). An examination of seasonal differences in NO<sub>2</sub>-asthma hospital admission and ED visit associations provide some evidence of NO<sub>2</sub> effects being larger in magnitude in the summer or warm season, and that seasonal associations may vary by geographic location. Studies of individual- and population-level factors, provide evidence of differences in associations by lifestage, with larger NO<sub>2</sub> effects for children and older adults, and more limited evidence for differences by sex, race/ethnicity, and socioeconomic status (SES), specifically insurance status ([Chapter 7](#)). Additionally, there is evidence that exposure differences, specifically whether a population lives in housing with low or high air exchange rates, may influence the association between short-term NO<sub>x</sub> exposures and asthma ED visits.

Some recent studies also examined various study design issues, including model specification and exposure assignment. An examination of model specification, as detailed in [Section 5.2.6](#), indicates that the relationship between short-term NO<sub>2</sub>

exposures and respiratory-related hospital admissions, including those for asthma and allergic disease, are sensitive to using less than 6 degrees of freedom (*df*) per year to account for temporal trends, but robust to alternative lags and *df*, ranging from 3 to 6, for weather covariates ([Son et al., 2013](#)). An examination of various exposure assignment approaches including single central site, average of multiple monitors, and population-weighted average, suggests that each approach can influence the magnitude, but not direction, of the NO<sub>2</sub>-asthma ED-visit risk estimate ([Strickland et al., 2011](#)).

Finally, a few recent studies examined whether the shape of the NO<sub>2</sub>-asthma ED visit relationship is linear or provides evidence of a threshold. These studies provide evidence of a linear, no-threshold relationship between short-term NO<sub>2</sub> exposures and asthma ED visits ([Li et al., 2011b](#); [Strickland et al., 2010](#)).



Note: CA = California; CI = confidence interval; ED = emergency department; GA = Georgia; MI = Michigan; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO<sub>2</sub> and nitric oxide; NY = New York. Black = studies from the 2008 ISA for Oxides of Nitrogen, red = recent studies. Circles = NO<sub>2</sub>, triangles = NO<sub>x</sub>, solid symbols = all year, horizontal stripes = warm/summer months, vertical stripes = cool/winter months. Results are standardized to a 20-ppb increase in 24-h avg NO<sub>2</sub>, a 30-ppb increase in 1-h max NO<sub>2</sub>, a 40-ppb increase in 24-h avg NO<sub>x</sub>, and a 100-ppb increase in 1-h max NO<sub>x</sub>. a = results were presented for four seasons; however the summer and winter estimates represented the largest and smallest estimates across seasons; b = this estimate is for allergic disease, which includes asthma; c = risk estimate for NO<sub>2</sub>; d = risk estimate for NO<sub>x</sub>; e = time-series results; f = case-crossover results.

**Figure 5-7 Percentage increase in asthma hospital admissions and emergency department visits in relation to short-term increases in ambient nitrogen dioxide concentrations.**

**Table 5-12 Corresponding risk estimates for studies presented in Figure 5-7.**

Study	Location	Age	Avg Time	Season	Lag	% Increase (95% CI)
<b>Hospital Admissions</b>						
<a href="#">Burnett et al. (1999)</a>	Toronto, ON, Canada	All	24-h avg	All	0	2.6 (0.5, 4.9)
† <a href="#">Son et al. (2013)</a>	8 South Korean cities	All	24-h avg	All	0	3.6 (0.5, 6.8)
				Summer		16.2 (5.1, 28.6)
				Winter		-1.1 (-6.5, 4.5)
<a href="#">Ko et al. (2007b)</a>	Hong Kong, China	All	24-h avg	All	0-4	10.9 (8.1, 13.8)
† <a href="#">Samoli et al. (2011)</a>	Athens, Greece	0-14	1-h max	All	0	6.4 (-3.8, 17.6)
				Summer		28.7 (-3.4, 71.3)
				Winter		12.9 (-6.6, 36.5)
† <a href="#">Iskandar et al. (2012)</a>	Copenhagen, Denmark	0-18	24-h avg	All	0-4	34.0 (13.0, 58.0) <sup>a</sup>
						62.0 (25.0, 107) <sup>b</sup>
<a href="#">Linn et al. (2000)</a>	Los Angeles, CA	<30	24-h avg	All	0	2.8 (0.8, 4.9)
† <a href="#">Son et al. (2013)</a> <sup>c,d</sup>	8 South Korean cities	All	24-h avg	All	0	3.8 (1.0, 6.6)
				Summer		15.9 (4.6, 28.4)
				Winter		-0.3 (-5.4, 5.1)
<b>ED Visits</b>						
<a href="#">Tolbert et al. (2000)</a>	Atlanta, GA	All	1-h max	All	1	2.4 (-2.6, 8.0) <sup>b</sup>
<a href="#">Peel et al. (2005)</a>	Atlanta, GA	All	1-h max	All	0-2	2.1 (-0.4, 4.5)
† <a href="#">Sarnat et al. (2013a)</a>	Atlanta, GA	All	24-h avg	All	0-2	1.3 (0.0, 2.4) <sup>b</sup>
<a href="#">Ito et al. (2007)</a>	New York, NY	All	24-h avg	All	0-1	12.0 (7.0, 15.0)
<a href="#">ATSDR (2006)</a>	Bronx, NY	All	24-h avg	All	0-4	6.0 (1.0, 10.0)
<a href="#">ATSDR (2006)</a>	Manhattan, NY	All	24-h avg	All	0-4	-3.0 (-18.0, 14.0)
† <a href="#">Stieb et al. (2009)</a>	7 Canadian cities	All	24-h avg	All	2	0.0 (-2.6, 2.7)

**Table 5-12 (Continued): Corresponding risk estimates for studies presented in Figure 5-7.**

Study	Location	Age	Avg Time	Season	Lag	% Increase (95% CI)
† <a href="#">Jalaludin et al. (2008)</a>	Sydney, Australia	1–14	1-h max	All	0–1	7.8 (4.5, 11.1)
				Warm	0	8.4 (4.2, 12.5)
				Cold	0	4.4 (–1.7, 10.4)
<a href="#">Peel et al. (2005)</a>	Atlanta, GA	2–18	1-h max	All	0–2	4.1 (0.8, 7.6)
† <a href="#">Li et al. (2011b)</a>	Detroit, MI	2–18	24-h avg	All	0–4 <sup>e</sup>	2.9 (–7.9, 15.1)
				All	0–4 <sup>f</sup>	9.1 (–0.8, 20.2)
† <a href="#">Villeneuve et al. (2007)</a>	Edmonton, AB, Canada	2+	24-h avg	All	0–4	4.5 (0.0, 7.5)
				Warm		21.4 (13.6, 31.0)
				Cold		–2.9 (–7.3, 1.5)
† <a href="#">Strickland et al. (2010)</a>	Atlanta, GA	5–17	1-h max	All	0–2	8.6 (4.2, 13.3)
				Warm		16.0 (9.1, 23.5)
				Cold		3.8 (–1.9, 9.6)
<a href="#">Jaffe et al. (2003)</a>	2 Ohio cities	5–34	24-h avg	Summer	1	6.1 (–2.0, 14.0)

AB = Alberta; avg = average; ATSDR = Agency for Toxic Substances and Disease Registry; CA = California; CI = confidence interval; ED = emergency department; GA = Georgia; max = maximum; MI = Michigan; NY = New York; ON = Ontario.

<sup>a</sup>Risk estimate for NO<sub>2</sub>.

<sup>b</sup>Risk estimate for NO<sub>x</sub>.

<sup>c</sup>Results were presented for four seasons; the summer and winter estimates represented the largest and smallest estimates for each season.

<sup>d</sup>Estimate for allergic disease, which includes asthma.

<sup>e</sup>Time-series analysis results.

<sup>f</sup>Case-crossover analysis results.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

### 5.2.2.5 Subclinical Effects Underlying Asthma Exacerbation: Pulmonary Inflammation and Oxidative Stress

The evidence described in the preceding sections for NO<sub>2</sub>-related increases in airway responsiveness ([Section 5.2.2.1](#)), decreases in lung function and increases in respiratory symptoms in children with asthma ([Sections 5.2.2.2](#) and [5.2.2.3](#)), and asthma hospital admissions and ED visits ([Section 5.2.2.4](#)) is coherent and consistent with a sequence of key events by which NO<sub>2</sub> can plausibly lead to asthma exacerbation. Adding to the

proposed mode of action is evidence indicating NO<sub>2</sub> exposure-related pulmonary inflammation, a key early event in asthma exacerbation that can mediate increases in airway responsiveness ([Section 4.3.2.5](#)). The initiation of inflammation by NO<sub>2</sub> exposure is supported by observations of NO<sub>2</sub>-induced increases in eicosanoids, which mediate recruitment of neutrophils ([Section 4.3.2.3](#)). The 2008 ISA for Oxides of Nitrogen described evidence for NO<sub>2</sub>-induced increases in pulmonary inflammation in some controlled human exposure studies and animal toxicological studies ([U.S. EPA, 2008c](#)), with generally consistent findings for increased allergic inflammation in humans. Such findings were coherent with results from the few available epidemiologic studies in children with asthma indicating associations between short-term increases in ambient NO<sub>2</sub> concentrations and increases in exhaled nitric oxide (eNO). Other potential early events linking NO<sub>2</sub> exposure to asthma exacerbation are increases in reactive oxygen species (ROS) and reactive nitrogen species. Many transcription factors regulating expression of pro-inflammatory cytokines are redox sensitive, and reactive species also can induce pulmonary injury ([Section 4.3.2.1](#)). Most information on the effects of NO<sub>2</sub> on pulmonary oxidative stress and injury is in healthy people and animal models, and findings are inconsistent at ambient-relevant concentrations ([Section 5.2.7.4](#)). The key evidence providing insight into a potential mode of action for NO<sub>2</sub>-induced asthma exacerbation continues to be the findings from previous experimental studies for allergic inflammation and the recent epidemiologic studies that continue to find NO<sub>2</sub>-associated increases in pulmonary inflammation and oxidative stress. Biological indicators of pulmonary inflammation and oxidative stress included those measured in exhaled breath; bronchoalveolar, bronchial, and nasal lavage fluid; and sputum. Indicators of systemic inflammation in blood are evaluated in the context of cardiovascular effects in [Section 5.3](#).

## **Experimental Studies**

As described in [Section 5.2.2.1](#), controlled human exposure studies in adults with asthma and allergy demonstrated increases in airway responsiveness in response to NO<sub>2</sub> exposure with or without allergen challenge. These observations are supported by findings in experimental studies involving adults with asthma and allergy and in a rat model of allergic airway disease that NO<sub>2</sub> exposure with or without an allergen challenge resulted in increased indicators of allergic inflammation. The indicators include increases in IgE and the influx and/or activation of eosinophils and neutrophils. Results provide evidence that NO<sub>2</sub> exposure can lead to exacerbation of allergic airways disease (discussed below and in [Section 4.3.2.6](#)) and also provide support for epidemiologic evidence of NO<sub>2</sub>-associated increases in inflammation in children with asthma and allergy.

The 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) described several studies that examined inflammatory responses in adults with mild allergic asthma who were exposed to NO<sub>2</sub> followed by a specific allergen challenge ([Table 5-13](#)). In a series of studies from the Karolinska Institute in Sweden, adults at rest were exposed to air or 260 ppb NO<sub>2</sub> for 15–30 minutes followed by an antigen (birch or timothy pollen) challenge 4 hours later. BAL and bronchial wash fluids were collected 19 hours after the allergen challenge. NO<sub>2</sub> exposure for 30 minutes increased polymorphonuclear cells (PMN) in the BAL and bronchial wash fluids and increased ECP in the bronchial wash fluid compared with air exposure ([Barck et al., 2002](#)). Reduced cell viability of BAL cells and reduced volume of BAL fluid were also reported. ECP is released by activated eosinophils; it is toxic to respiratory epithelial cells and thought to play a role in the pathogenesis of airway injury in asthma. In a subsequent study, [Barck et al. \(2005a\)](#) exposed adults with mild allergic asthma to air or NO<sub>2</sub> for 15 minutes on Day 1 and twice on Day 2, and for 15 minutes with allergen challenges following all of the exposures. NO<sub>2</sub> exposure induced an increased level of ECP in both sputum and blood and increased myeloperoxidase levels in blood. These results suggest that NO<sub>2</sub> may prime circulating eosinophils and enhance activation of airway eosinophils and neutrophils in response to an inhaled allergen. Nasal responses to nasal allergen challenge were also examined following a 30-minute exposure to NO<sub>2</sub> ([Barck et al., 2005b](#)). No enhancement of nasal allergen responses was observed in adult subjects. As noted in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), these studies indicate that brief exposures to 260 ppb NO<sub>2</sub> can enhance allergen responsiveness in individuals with asthma.

**Table 5-13 Characteristics of controlled human exposure studies of pulmonary inflammation in populations with asthma.**

Study	Disease Status; Sample Size; Sex; Age (mean ± SD)	Exposure Details	Endpoints Examined
<a href="#">Barck et al. (2002)</a>	Adults with mild asthma and allergy to birch or timothy pollen; n = 6 M, 7 F; 29 yr	Histamine inhalation test to confirm airway hyperresponsiveness. 266 ppb NO <sub>2</sub> for 30 min Inhaled allergen challenge 4 h after pollutant exposure.	Albumin in serum samples. BW and BAL cell parameters-volume recovered, cell viability, total cell counts, macrophage concentrations, % of neutrophils, # eosinophils, # mast cells (performed 19 h after allergen challenge). ECP, MPO, IL-5, IL-8, eotaxin, ICAM-1.
<a href="#">Barck et al. (2005a)</a>	Adults with mild asthma and allergy to birch or timothy pollen; n = 10 M, 8 F; 32 yr	260 ppb NO <sub>2</sub> Day 1: one 15 min exposure with bronchial challenge 4 h after exposure. Day 2: two 15 min exposures with bronchial challenge 3 h after 2nd exposure.	Total and differential cells counts of induced sputum and venous blood (samples taken on morning of Days 1–3). ECP, MPO in sputum.
<a href="#">Barck et al. (2005b)</a>	Adults with rhinitis and mild asthma; n = 9 M, 7 F; 31 yr;	Seasonal allergy confirmed by positive nasal challenge of allergen. AHR confirmed by histamine test. 260 ppb NO <sub>2</sub> Nasal allergen challenge 4 h after exposure.	Total and differential cell counts and cell viability in NAL (performed before exposure, before allergen challenge, and 1 h, 4 h, and 18 h after challenge). ECP and MPO in NAL fluid and blood.
<a href="#">Wang et al. (1995a); Wang et al. (1995b)</a>	Adults with seasonal rhinitis; n = 6 M, 10 F; 26 yr;	Nasal provocation with grass pollen allergen to confirm increase in nasal airway resistance. (1) 400 ppb NO <sub>2</sub> for 6 h (2) 400 ppb NO <sub>2</sub> for 6 h + allergen challenge	Nasal lavage for inflammatory mediators fluid-ECP, MCT, MPO, IL-8 (30 min after allergen challenge).
<a href="#">Wang et al. (1999)</a>	Adults with grass allergy; n = 8 M, 8 F; 32 yr	Nasal airway resistance tests at rest, after saline, and after allergen challenge to confirm reactivity for inclusion in study. (1) 200 µg Fluticasone propionate (FP) + 400 ppb NO <sub>2</sub> for 6 h (2) Matched placebo + 400 ppb NO <sub>2</sub> for 6 h	NAL—total and differential cell counts (30 min after allergen challenge). Immunoassay of NAL fluid-ECP, RANTES.

**Table 5-13 (Continued): Characteristics of controlled human exposure studies of pulmonary inflammation in populations with asthma**

Study	Disease Status; Sample Size; Sex; Age (mean ± SD)	Exposure Details	Endpoints Examined
<a href="#">Witten et al. (2005)</a>	Adults with asthma and house dust mite allergy; n = 6 M, 9 F; 32 yr	Inhaled allergen challenge to determine predicted allergen PC20. 400 ppb NO <sub>2</sub> for 3 h w/intermittent exercise  2nd inhaled allergen challenge, starting at 4 doubling doses less than APC20 and doubling until 20% decrease in FEV <sub>1</sub> .	Total and differential cell counts in induced sputum—macrophages, lymphocytes, neutrophils, and eosinophils (samples taken at 6 and 26 h after allergen challenge).
† <a href="#">Riedl et al. (2012)</a>	Phase 1: adults with mild asthma; n = 10 M, 5 F; 37 yr Phase 2: adults with mild asthma and cat allergy; n = 6 M, 9 F; 36 yr	Inhalation challenge to detect bronchoconstrictive response Phase 1: methacholine; Phase 2: cat allergen). (1) 100 µg/m <sup>3</sup> DEP for 2 h with intermittent exercise (2) 350 ppb NO <sub>2</sub> control for 2 h with intermittent exercise	Total counts and differential cell counts (alveolar macrophages, lymphocytes, PMNs, eosinophils) in induced sputum (taken 22 h after exposure).  Induced sputum fluid assay-RANTES, eotaxin, ECP, IgG, IgG4, IgA, IgM, IgE.  Cat-specific IL-4, IL-5, IL-8, IL-12, GM-CSF, IFN-γ, TNF-α, tryptase.
<a href="#">Vagaggini et al. (1996)</a>	Asthma; n = 4 M, 4 F; 29 ± 14 yr Healthy; n = 7 M; 34 ± 5 yr	300 ppb for 1 h; Exercise at $\dot{V}_E = 25$ L/min	Cell counts in sputum 2-h post-exposure.
<a href="#">Jörres et al. (1995)</a>	Asthma; n = 8 M, 4 F; 27 ± 5 yr Healthy; n = 5 M, 3 F; 27 yr (range: 21–33)	1,000 ppb for 3 h; Exercise 10 min on/10 min off at individual's maximum workload.	BAL fluid analysis 1 h after exposure (cell counts, histamine, prostaglandins).

AHR = airway hyperresponsiveness; BAL = bronchoalveolar lavage; BW = bronchial wash; DEP = diesel exhaust particles; ECP = eosinophil cationic protein; F = female; FEV<sub>1</sub> = forced expiratory volume in 1 second; GM-CSF = granulocyte macrophage-colony stimulating factor; h = hour; HDM = house dust mite; ICAM-1 = intercellular adhesion molecule 1; IL = interleukin; L/min = liters per minute; M = male; min = minutes; MPO = myeloperoxidase; NAL = nasal lavage; NO<sub>2</sub> = nitrogen dioxide; PC = provocative concentration; PEF = peak expiratory flow; PMN = polymorphonuclear cells; yr = year.

†Study published since the 2008 ISA for Oxides of Nitrogen.

Additional studies have been performed using longer NO<sub>2</sub> exposures ([Table 5-13](#)). ([Wang et al. \(1999\)](#); [Wang et al. \(1995a\)](#); [Wang et al. \(1995b\)](#)) found that exposure of adults to 400 ppb NO<sub>2</sub> for 6 hours enhanced allergen responsiveness in the nasal mucosa in subjects with allergic rhinitis. Mixed grass pollen was used as the challenge agent and was administered immediately after the NO<sub>2</sub> exposure. Responses included increased numbers of eosinophils and increased levels of myeloperoxidase and ECP in nasal lavage fluid collected 30 minutes after the allergen challenge. [Witten et al. \(2005\)](#) did not observe enhanced airway inflammation with allergen challenge in adults with asthma and

allergy to HDM allergen who were exposed to 400 ppb NO<sub>2</sub> for 3 hours with intermittent exercise. HDM allergen was administered immediately after the NO<sub>2</sub> exposure and a decrease in sputum eosinophils was found 6 hours later ([Witten et al., 2005](#)). Sputum ECP levels were increased although this change did not reach statistical significance. The authors suggested that their findings may be explained by a decreased transit of eosinophils across the bronchial mucosa occurring concomitantly with NO<sub>2</sub>-induced eosinophilic activation. Other investigators have noted that numbers of eosinophils do not always correlate with allergic disease activity ([Erjefält et al., 1999](#)). Airway mucosal eosinophilia is a characteristic feature of asthma and rhinitis; eosinophils exert their effects via degranulation or cytolysis resulting in release of ECP and other mediators. However, under conditions favoring eosinophil cytolysis, ECP concentrations may be high and numbers of eosinophils may be low.

As noted in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), differing findings between the studies in allergic individuals could be due to differences in timing of the allergen challenge, the use of multiple- or single-allergen challenges, the use of BAL fluid versus sputum versus nasal lavage fluid, exercise versus rest during exposure, differences in subjects, or chance. Furthermore, study protocols varied in the timing of biological sample collection post-exposure to NO<sub>2</sub> or allergen. A recent study of adults with mild allergic asthma also did not find enhanced airway inflammatory responses following exposure to NO<sub>2</sub> (350 ppb NO<sub>2</sub>, 2 hours, intermittent exercise) [([Riedl et al., 2012](#)); [Table 5-14](#)]. Subjects exposed to NO<sub>2</sub> followed by methacholine challenge 1.5 hours later had increased levels of blood IgM and decreased levels of sputum IgG4, interleukin (IL)-4, eotaxin, RANTES, and fibrinogen measured 22 hours after exposure. Subjects exposed to NO<sub>2</sub> followed by cat allergen 1.5 hours later did not exhibit changes in sputum cell counts measured 22 hours after exposure. While these results are not consistent with NO<sub>2</sub> enhancing airway inflammatory responses, importantly, markers of eosinophil activation were not measured.

Several other studies investigated allergic inflammation following NO<sub>2</sub> exposure in the absence of a challenge. [Vagaggini et al. \(1996\)](#) observed a decrease in eosinophils in sputum collected from adults with asthma following a 1-hour exposure to 300 ppb NO<sub>2</sub>, though this decrease was not statistically significant. In contrast, a recent controlled human exposure study reported an increase in eosinophils and ECP following repeated NO<sub>2</sub> exposure in adults with atopic asthma [Ezratty et al. \(2014\)](#). Subjects were exposed to 203 or 581 ppb NO<sub>2</sub> for 30 minutes on one day and twice for 30 minutes on the second day. Compared with baseline, statistically significant increases in the amount of ECP and the number and percentage of eosinophils in sputum were observed after the three exposures to 600, but not 200 ppb NO<sub>2</sub>. Furthermore, ECP was highly correlated with eosinophil count in sputum. No increases in either of these parameters were observed

6 hours after the first exposure to 600 ppb NO<sub>2</sub>. [Jörres et al. \(1995\)](#) exposed healthy adults and those with asthma and allergy to 1,000 ppb NO<sub>2</sub> for 3 hours and performed bronchoscopy 1 hour later. The macroscopic appearance of the bronchial epithelium was altered after exposure in adults with asthma compared to healthy controls; however, no accompanying changes in cell counts in the BAL fluid were observed. Eicosanoid levels were also measured; thromboxane B2 was increased in healthy adults and those with asthma following NO<sub>2</sub> exposure while prostaglandin D2 was increased and 6-keto prostaglandin F1 $\alpha$  was decreased after exposure only in adults with asthma. Because eicosanoids are known mediators of inflammation, these results suggest that exposure to NO<sub>2</sub> resulted in activation of cell signaling pathways associated with inflammation.

Allergic inflammatory responses were also investigated in animal models of allergic airways disease ([Table 5-14](#)). These studies involved sensitization and challenge with an antigen followed by exposure to NO<sub>2</sub>. In several studies in mice, which were sensitized and challenged with ovalbumin, NO<sub>2</sub> exposure over several hours or days failed to increase allergic inflammatory responses. Exposures to 700 or 5,000 ppb NO<sub>2</sub> for 3 hours on a single day, for 2 hours on 3 consecutive days or for 6 hours on 3 consecutive days either reduced or had no effect on indicators of eosinophil inflammation such as eosinophil counts, eosinophil peroxidase activity, and total cellularity ([Poynter et al., 2006](#); [Hubbard et al., 2002](#); [Proust et al., 2002](#)). Other findings included decreases in IL-5 levels in the BAL fluid at both 24 and 72 hours after exposure to 5,000 ppb NO<sub>2</sub> and reductions in perivascular and peribronchial cellular infiltrates after exposure to 700 ppb NO<sub>2</sub>. Others have noted that the ovalbumin-induced airway inflammation in mice does not involve substantial eosinophil degranulation or cytolysis, which is characteristic of asthma and allergic rhinitis in humans ([Malm-Erjefält et al., 2001](#)). This suggests that species-related differences may account for NO<sub>2</sub>-induced decreases in eosinophilic inflammation seen in mouse models. Mechanisms underlying the NO<sub>2</sub>-induced decrease in airways eosinophilia are unknown.

In contrast with evidence in mice, NO<sub>2</sub> exposure of rats, which were sensitized and challenged with HDM allergen, enhanced specific immune responses and increased the numbers of lymphocytes, neutrophils, and eosinophils in the airways, albeit with exposure (3 hours) to 5,000 ppb NO<sub>2</sub> ([Gilmour et al., 1996](#)). In this study, the most pronounced responses occurred when rats were exposed to NO<sub>2</sub> immediately after sensitization and immediately after challenge with HDM antigen. Rats exposed to NO<sub>2</sub> twice had increased levels of antigen-specific IgG and IgA and increased levels of IgE in BAL fluid 7 days post-exposure to NO<sub>2</sub>. In addition, an increase in the ratio of inflammatory cells (i.e., lymphocytes, neutrophils, eosinophils) to alveolar macrophages was observed 7 days post-exposure to NO<sub>2</sub>, although the total number of lavagable cells did not change.

In summary, several controlled human exposure studies of adults with asthma and allergy found that exposures to 260 ppb NO<sub>2</sub> for 15–30 minutes or 400 ppb NO<sub>2</sub> for 6 hours increased inflammatory responses to an allergen challenge. These responses included increases in number and activation of eosinophils and neutrophils. In the absence of an allergen challenge, repeated exposure to 600 ppb NO<sub>2</sub> for 30 minutes also enhanced allergic inflammation in subjects with asthma and allergy. Other studies involving a single exposure to NO<sub>2</sub> (300–350 ppb, 1–2 hours; 1,000 ppb, 3 hours) did not show these responses. Allergic inflammation was also enhanced by a 3-hour exposure to 5,000 ppb NO<sub>2</sub> in a rat model of allergic airways disease, as demonstrated by increases in IgE levels and numbers of eosinophils and neutrophils. These results provide evidence for NO<sub>2</sub>-induced exacerbation of allergic airways disease both in the presence and absence of an allergen challenge ([Section 4.3.2.6](#)).

**Table 5-14 Characteristics of animal toxicological studies of pulmonary inflammation.**

Study	Species (Strain); Sample Size; Sex; Age	Exposure Details	Endpoints Examined
<a href="#">Proust et al. (2002)</a>	Mice (BALB/c); n = 5/group; M; 6–7 weeks;	Immunization with injection of 10 µg OVA (Day 0 and Day 7) Challenge with either 10 µg OVA or saline control (Day 14) Exposure following OVA/saline challenge: 5,000 ppb NO <sub>2</sub> Challenge to 0.1 M aerosol of methacholine for 20 sec	Endpoints examined 24 h after exposure: BAL fluid total and differential cell counts Eosinophil peroxidase activity Immunoassay of IL-4, IL-5 Anti-OVA IgE and IgG1 in serum Lung histology
<a href="#">Hubbard et al. (2002)</a>	Mice (CB57Bl/6); n = NR; M/F; adult	Sensitization by weekly injections of 25 µg OVA for 3 weeks Challenge with 20 mg/m <sup>3</sup> OVA aerosol for 1 h for 3 days or 10 days Exposure following OVA aerosol challenge: (1) 700 ppb NO <sub>2</sub> for 2 h (2) 5,000 ppb NO <sub>2</sub> for 2 h	Total and differential cell counts from lung lavage (24 h after exposure) Histology analysis (24 h after exposure)
<a href="#">Poynter et al. (2006)</a>	Mice (C57BL/6); n, sex, and age NR	Sensitization by 20 µg of OVA via i.p. injections on Days 0 and 7 Challenge with OVA aerosol (1% in phosphate buffered saline) for 30 min on Days 14–16 Exposures subsequent to OVA challenge: (1) 5,000 ppb NO <sub>2</sub> for 6 h/day for 1, 3, 5 days Select groups given 20-day recovery period Methacholine challenge (0, 3.125, 12.5, 50 mg/mL in aerosol)	Endpoints examined after last day of exposure or after 20 day recovery: BAL fluid—total and differential cell counts; LDH Histopathology analysis mRNA levels of Gob5, Muc5AC, Th2, dendritic cell chemokine CCL20 and eotaxin-1
<a href="#">Gilmour et al. (1996)</a>	Rats (brown Norway); n = 5/group; F; 6 weeks	Immunization with 100 µg antigen ( <i>D. farina</i> and <i>D. pteronyssinus</i> ) + killed <i>Bordetella pertussis</i> in 0.3 mL saline Challenge with 50 µg allergen (2 weeks after immunization), followed by: 5,000 ppb NO <sub>2</sub> for 3 h	Endpoints examined 7 days after exposure: Total and differential cell counts from lung lavage Antigen-specific IgG, IgA, IgE antibodies in serum and lavage fluid Lymphocyte proliferation responsiveness

BAL = bronchoalveolar lavage; F = female; h = hour; IL = interleukin; LDH = lactate dehydrogenase; M = male; mRNA = messenger RNA; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; OVA = ovalbumin; Th2 = T-derived lymphocyte helper 2.

## Epidemiologic Studies of Populations with Asthma

The observations described in the preceding sections for NO<sub>2</sub>-induced increases in allergic inflammation provide support for the epidemiologic associations observed for ambient or personal NO<sub>2</sub> with increases in inflammation in children with asthma and allergy. The limited evidence in adults with asthma is inconclusive. The number of these epidemiologic studies of pulmonary inflammation has increased dramatically since the 2008 ISA for Oxides of Nitrogen, and recent studies expand on previous studies with exposure assessment conducted in subjects' locations (e.g., homes, schools) and additional examination of potential confounding by traffic-related copollutants. Ambient NO<sub>2</sub> concentrations, locations, and time periods for epidemiologic studies of pulmonary inflammation and oxidative stress are presented in [Table 5-15](#).

As in previous studies, the majority of evidence is for eNO. Across studies, eNO was collected with a similar protocol, following the guidelines established by [ATS \(2000a\)](#). eNO assessment methods also accounted for NO in the collection room, although eNO has not been shown to be a reliable indicator of NO exposure ([Section 4.2.3](#)). eNO has not been examined in controlled human exposure or animal toxicological studies of NO<sub>2</sub> exposure, but several observations support the epidemiologic findings. NO<sub>2</sub> exposure has been shown to increase some pro-inflammatory cytokines and increase neutrophils and eosinophils ([Section 4.3.2.6](#)), which can activate inducible nitric oxide synthase or produce NO in the lung during an inflammatory response ([Barnes and Liew, 1995](#)). Higher eNO has been associated with higher eosinophil counts ([Brody et al., 2013](#)). Further, eNO commonly is higher in children and adults with asthma and increases during acute exacerbation ([Soto-Ramos et al., 2013](#); [Carraro et al., 2007](#); [Jones et al., 2001](#); [Kharitonov and Barnes, 2000](#)).

**Table 5-15 Mean and upper percentile concentrations of nitrogen dioxide in epidemiologic studies of pulmonary inflammation and oxidative stress in populations with asthma.**

Study <sup>a</sup>	Location	Study Period	NO <sub>2</sub> Metric Analyzed	Mean Concentration ppb	Upper Percentile Concentrations ppb
<a href="#">†Liu et al. (2009b)</a>	Windsor, ON, Canada	Oct–Dec 2005	24-h avg NO <sub>2</sub>	19.8	95th: 29.5
<a href="#">†Barraza-Villarreal et al. (2008)</a>	Mexico City, Mexico	Jun 2003–Jun 2005	8-h max NO <sub>2</sub>	37.4	Max: 77.6
<a href="#">Delfino et al. (2006)</a>	Riverside, CA Whittier, CA	Aug–Dec 2003 Jul–Nov 2004	24-h avg NO <sub>2</sub>	Personal: 24.3 Personal: 30.9	Max: 47.6 Max: 106
<a href="#">†Delfino et al. (2013)</a>	Riverside, CA Whittier, CA		8-h max NO <sub>2</sub>	Central site: 39.3 Central site: 35.1	Max: 72.4 Max: 96
	2 sites combined		24-h avg NO <sub>2</sub>	Central site: 27.4	Max: 73.8
<a href="#">†Martins et al. (2012)</a>	Viseu, Portugal	Jan and Jun, 2006 and 2007	1-week avg NO <sub>2</sub> <sup>b</sup>	Across 4 periods: 4.5, 3.5, 9.8, 8.2 <sup>c</sup>	Max across 4 periods: 4.6, 4.0, 10.9, 9.4 <sup>c</sup>
<a href="#">†Sarnat et al. (2012)</a>	El Paso, TX and Ciudad Juarez, Mexico	Jan–Mar 2008	96-h avg NO <sub>2</sub>	El Paso school: 4.5, 14.2, central sites: 14.0, 18.5, 20.5 Ciudad Juarez school: 18.7, 27.2, central site: none	NR
<a href="#">†Greenwald et al. (2013)</a>	El Paso, TX	Mar–Jun 2010	96-h avg NO <sub>2</sub>	School A: 6.5 School B: 17.5	NR
<a href="#">†Holquin et al. (2007)</a>	Ciudad Juarez, Mexico	2001–2002	1-week avg NO <sub>2</sub>	18.2	NR
<a href="#">†Flamant-Hulin et al. (2010)</a>	Clermont-Ferrand, France	NR	5-day avg NO <sub>2</sub>	Schools <14 ppb: 10.1 Schools >14 ppb: 17.4	Across schools: 75th: 14.0 <sup>c</sup> Max: 19.7 <sup>c</sup>
<a href="#">†Lin et al. (2011)</a>	Beijing, China	Jun 2007 Sep 2007 Dec 2007 Jun 2008 Sep 2008	24-h avg NO <sub>2</sub>	24.3 30.4 45.3 26.6 25.9	NR NR NR NR NR
<a href="#">†Liu et al. (2014a)</a>	Munich and Wesel, Germany	NR	24-h avg NO <sub>2</sub>	15.9 <sup>c</sup>	95th: 29.7 <sup>c</sup>
<a href="#">†Berhane et al. (2011)</a>	13 southern California communities	Sep–Jun 2004–2005	24-h avg NO <sub>2</sub>	NR	NR

**Table 5-15 (Continued): Mean and upper percentile concentrations of nitrogen dioxide in epidemiologic studies of pulmonary inflammation and oxidative stress in populations with asthma.**

Study <sup>a</sup>	Location	Study Period	NO <sub>2</sub> Metric Analyzed	Mean Concentration ppb	Upper Percentile Concentrations ppb
<a href="#">†Romieu et al. (2008)</a>	Mexico City, Mexico	Jan–Oct 2004	8-h max NO <sub>2</sub>	35.3	Max: 73.5
<a href="#">†Qian et al. (2009a)</a>	Boston, MA; New York City, NY; Philadelphia, PA; Madison, WI; Denver, CO; San Francisco, CA	Feb 1997–Jan 1999	24-h avg NO <sub>2</sub>	23.6	75th: 28.8 Max: 48.1
<a href="#">†Maestrelli et al. (2011)</a>	Padua, Italy	1999–2003	24-h avg NO <sub>2</sub>	Range across seasons and years: 20.9–37.0 <sup>c</sup>	Range of 75th: 23.0–42.5 <sup>c</sup>

Avg = average; Aug = August; CA = California; CO = Colorado; Dec = December; Feb = February; MA = Massachusetts; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; NY = New York; ON = Ontario; PA = Pennsylvania; TX = Texas; WI Wisconsin.

<sup>a</sup>Studies presented in order of first appearance in the text of this section.


<sup>b</sup>Subject-level exposure estimates calculated from outdoor NO<sub>2</sub> at schools and other locations plus time-activity patterns.

<sup>c</sup>Concentrations converted from µg/m<sup>3</sup> to ppb using the conversion factor of 0.532 for NO<sub>2</sub> assuming standard temperature (25°C) and pressure (1 atm).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

### **Children with Asthma**

Several recent and previous studies found associations between short-term increases in ambient NO<sub>2</sub> concentration and increases in pulmonary inflammation in children with asthma. Children were recruited mostly from schools, supporting the likelihood that study populations were representative of the general population of children with asthma. Asthma was identified as self- or parental report of physician-diagnosed asthma, but the studies varied in whether they assessed asthma severity or required the presence of current symptoms in subjects. Larger associations were found in children not using ICS in some ([Sarnat et al., 2012](#); [Liu et al., 2009b](#)), but not all, ([Delfino et al., 2006](#)) studies. Because of the heterogeneity in the definition of ICS use and lack of assessment of ICS compliance, it is not clear whether ICS use represents well-controlled or more severe asthma across populations. Across studies, associations varied in magnitude and statistical significance; however, the consistent pattern of increasing eNO with increasing short-term NO<sub>2</sub> exposure provides evidence of an association ([Figure 5-8](#) and [Table 5-17](#)). Most studies analyzed multiple endpoints, pollutants, lags of exposure, or subgroups; however, with a few exceptions ([Liu et al., 2009b](#); [Barraza-Villarreal et al., 2008](#)), a pattern of association was found across the multiple comparisons, thus reducing the likelihood of associations found by chance alone or from publication bias.



Note: Anti-inflamm med = anti-inflammatory medication; Anti-LT = anti-leukotriene medication; avg = average; CI = confidence interval; eNO = exhaled nitric oxide; h = hour; ICS = inhaled corticosteroid; max = maximum; NO<sub>2</sub> = nitrogen dioxide. Black = studies from the 2008 Integrated Science Assessment for Oxides of Nitrogen, red = recent studies. Results from more informative studies in terms of exposure assessment method and potential confounding considered are presented first. Study details and quantitative results reported in [Table 5-16](#). [Table 5-16](#) presents results for an array of indications of inflammation and oxidative stress for which there was not sufficient numbers to present in a figure. For some studies, eNO results could not be presented in the figure because results were not reported in terms of percentage change eNO.

<sup>a</sup>Effect estimates are standardized to a 20-ppb increase for 24-h avg NO<sub>2</sub> and 30-ppb increase for 1-h max NO<sub>2</sub>.

**Figure 5-8 Associations of personal or ambient nitrogen dioxide with exhaled nitric oxide in populations with asthma.**

**Table 5-16 Epidemiologic studies of pulmonary inflammation and oxidative stress in children and adults with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<b>Children with asthma: studies with small spatial scale exposure assessment and/or examination of copollutant confounding</b>				
<p><a href="#">Delfino et al. (2006)</a> Riverside, Whittier, CA n = 45, ages 9–18 yr, persistent asthma and exacerbation in previous 12 mo Repeated measures. Examined daily for 10 days, 372 observations. Recruitment in schools of nonsmokers from nonsmoking homes. No information on participation rate. Self-report of physician-diagnosed asthma. Mixed effects model with random effect for subject with pollutant concentrations centered on subject mean and adjusted for personal measures of relative humidity, measures of personal temperature, follow-up period. Adjustment for city, daily beta-agonist use, weekend did not alter results.</p>	NO <sub>2</sub> -total personal 24-h avg	0	eNO: All subjects: 1.2% (-2.0, 4.3)	<p>Copollutant model results in figure only. With PM<sub>2.5</sub>, EC, or OC: NO<sub>2</sub> results robust but increase in 95% CI. Copollutant results robust to NO<sub>2</sub> adjustment. Weak correlations for personal exposures. Spearman r = 0.20–0.33. Stronger correlations for central site pollutants. Pearson r = 0.25–0.70. Central site CO not associated with eNO.</p>
	<p>Compliance assessed with motion detectors. Monitoring checked daily; all samples above detection limit of 2.1 ppb (<a href="#">Staimer et al., 2005</a>)</p>	0–1 avg	All subjects: 7.5% (2.0, 13)	
		No anti-inflammatory medication, n = 14: 2.6% (-9.9, 15)		
		Anti-inflammatory medication, n = 31: 9.3% (3.1, 16)		
		ICS use, n = 19: 7.0% (0.23, 14)		
		Anti-leukotrienes + ICS use, n = 12 9.1% (-3.7, 22)		
NO <sub>2</sub> -central site 8-h max	0	All subjects: 0.81% (-4.5, 6.1)		
		0–1 avg	All subjects: 11% (3.2, 19)	

**Table 5-16 (Continued): Epidemiologic studies of pulmonary inflammation and oxidative stress in children and adults with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p>†<a href="#">Delfino et al. (2013)</a> Riverside, Whittier, CA Same population and methodology as <a href="#">Delfino et al. (2006)</a> above. Analysis also indicated lack of confounding by respiratory infections.</p>	<p>NO<sub>2</sub>-central site 24-h avg 1 site Riverside within 12 km of subjects' homes 2 sites Whittier averaged, distance NR</p>	<p>0 1 0-1 avg</p>	<p>eNO: -0.12% (-3.8, 3.7) 5.0% (1.2, 9.1) 9.0% (2.9, 15)</p>	<p>For lag 0-1 avg: With oxidative potential of PM<sub>2.5</sub>: 3.8% (-5.1, 14) With in vitro ROS from PM<sub>2.5</sub>: 5.8% (-1.9, 14) Copolutant associations attenuated with NO<sub>2</sub> adjustment. Moderate correlations with NO<sub>2</sub>. Spearman <i>r</i> = 0.43 for ROS, 0.49 for oxidative potential.</p>
<p>†<a href="#">Martins (2013)</a>, <a href="#">Martins et al. (2012)</a> Viseu, Portugal n = 51, mean age 7.3 (SD: 1.1) yr, 53% with atopy Repeated measures. 4 measurements over 2 different seasons. Recruitment from urban and suburban schools. ~66% participation rate. Parental report of wheeze in previous 12 mo. GEE adjusted for age, sex, parental smoking, parental education, atopy, time of visit, average temperature, relative humidity. Also included height, weight, older siblings, mold/dampness in home, fireplace in home, pets in home because their inclusion changed the effect estimate for at least 1 pollutant by &gt;10%.</p>	<p>NO<sub>2</sub>-subject modeled outdoor 24-h avg Estimated from school outdoor NO<sub>2</sub>, 20 city locations, MM5/CHIMERE modeling, and daily activity patterns. 20% time spent at school, 65% at home.</p>	<p>0-4 avg</p>	<p>eNO: 14% (-12, 40) Exhaled breath condensate pH: -2.6% (-3.9, -1.3)</p>	<p>For EBC pH only: With PM<sub>10</sub>: 0.30 (-3.0, 3.6) With benzene: -1.7 (-3.6, 0.26) With ethylbenzene: -1.6 (-3.7, 0.49) PM<sub>10</sub> robust to adjustment for NO<sub>2</sub>. VOCs attenuated to null. Negative or weakly positive correlations with NO<sub>2</sub>. Spearman <i>r</i> = -0.82 to -0.55 for PM<sub>10</sub>, -0.42 to 0.14 for various VOCs.</p>

**Table 5-16 (Continued): Epidemiologic studies of pulmonary inflammation and oxidative stress in children and adults with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p>†<a href="#">Sarnat et al. (2012)</a> El Paso, TX and Ciudad Suarez, Mexico n = 29 per city, ages 6–12 yr, asthma and current symptoms Repeated measures. Examined weekly for 16 weeks, 697 observations. Recruitment from schools representing a gradient of traffic, subjects from nonsmoking homes. No information on participation rate. Self-report of physician-diagnosed asthma. GLM with subject as random effect and adjustment for school, temperature, relative humidity, indoor NO. Adjustment for medication use, cold symptoms did not alter results. Most indoor samples above limit detection of 2.88 ppb (<a href="#">Raysoni et al., 2011</a>).</p>	<p>NO<sub>2</sub>-school outdoor Each city: one school 91 m from major road, one in residential area.</p> <hr/> <p>NO<sub>2</sub>-school indoor</p> <hr/> <p>NO<sub>2</sub>-central site 1 site in El Paso, TX near major road. All 24-h avg</p>	0–4 avg	<p>eNO: All subjects: 6.3% (2.5, 10) No ICS use, n = 10: 6.6% (2.6, 11) ICS use, n = 19: 1.1% (–8.9, 12)</p> <hr/> <p>All subjects: 0.53% (0.11, 1.0)</p> <hr/> <p>All subjects: 1.7% (–1.0, 4.5)</p>	<p>With O<sub>3</sub>: 8.8% (4.6, 13) No copollutant model with PM<sub>2.5</sub> or PM<sub>10–2.5</sub>, which were associated with eNO. No association with BC among all subjects. Weak to moderate correlations with NO<sub>2</sub>. Spearman <i>r</i> = –0.39 to 0.32 for PM<sub>2.5</sub>; –0.24 to 0.04 for PM<sub>10–2.5</sub>.</p>
<p>†<a href="#">Greenwald et al. (2013)</a> El Paso, TX n = 38, mean age 10 yr, 76% Mexican-American Repeated measures. Examined weekly for 13 weeks, 436 observations. Recruitment from schools in low- and high-traffic area. No information on participation rate. School record of physician-diagnosed asthma. GLM with subject as random effect and adjusted for school, temperature, relative humidity, indoor NO. Most indoor samples above limit detection of 2.88 ppb (<a href="#">Raysoni et al., 2011</a>).</p>	<p>NO<sub>2</sub>-school outdoor School A: residential area, School B: 91 m from major road.</p> <hr/> <p>NO<sub>2</sub>-school indoor All 24-h avg</p>	0–3 avg	<p>eNO: School A: –0.86% (–38, 58) School B: 30% (–3.1, 73)</p> <hr/> <p>School A: –16% (–53, 47) School B: 5.6% (–19, 37%)</p>	<p>No copollutant model. BC, VOCs (central site) associated with eNO. Moderate correlations with NO<sub>2</sub>. Pearson <i>r</i> = 0.47–0.62. BTEX associated with eNO. Highly correlated with NO<sub>2</sub>. <i>r</i> = 0.77.</p>
<p>†<a href="#">Holquin et al. (2007)</a> Ciudad Juarez, Mexico n = 95, ages 6–12 yr, 78% mild asthma, 58% with atopy Repeated measures. Examined biweekly for 4 mo. 87% participation. Self-report of physician-diagnosed asthma. Linear and nonlinear mixed effects model with random effect for subject and school adjusted for sex, body mass index, day of week, season, maternal and paternal education, passive smoking exposure.</p>	<p>NO<sub>2</sub>-school outdoor 24-h avg Schools located 239–692 m from homes.</p>	0–6 avg	<p>No quantitative results reported for eNO. No association was reported.</p>	<p>No copollutant model. Road density but not PM<sub>2.5</sub> or EC associated with eNO.</p>

**Table 5-16 (Continued): Epidemiologic studies of pulmonary inflammation and oxidative stress in children and adults with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<p>†<a href="#">Zhu (2013)</a>; <a href="#">Lin et al. (2011)</a> Beijing, China n = 36, ages 9–12 yr, 22% with asthma Repeated measures before and after Olympics. Examined daily for five 2-week periods. 1,581 observations. Recruitment from school. Selection from 437 (60%) students who responded to initial survey, 95% follow-up participation. GEE adjusted for temperature, relative humidity, body mass index.</p>	<p>NO<sub>2</sub>-central site 24-h avg Site 650 m from school.</p>	<p>0 1</p>	<p>eNO: All subjects: 22% (18, 26) Asthma: 23% (16, 31) Asthma: 12% (4.0, 20)</p>	<p>Among all subjects: With BC: 5.6% (0.38, 11) With PM<sub>2.5</sub>: 14% (9.5, 19) No change in BC with NO<sub>2</sub> adjustment. PM<sub>2.5</sub> reduced but positive. NO<sub>2</sub> highly correlated with BC (<i>r</i> = 0.68), moderately correlated with PM<sub>2.5</sub> (<i>r</i> = 0.30).</p>
<p>†<a href="#">Flamant-Hulin et al. (2010)</a> Clermont-Ferrand, France n = 34, mean age: 10.7 (SD: 0.7) yr, 44% with atopy Cross-sectional. Recruitment from schools. 69% participation rate. Self- or parental-report of lifetime asthma. For some subjects, eNO measured up to 1 week before pollutants. GEE adjusted for atopy, mother's birth region, parental education, family history of allergy, prenatal and childhood smoking exposure. Did not consider potential confounding by weather.</p>	<p>NO<sub>2</sub>-school outdoor 24-h avg</p> <hr/> <p>NO<sub>2</sub>-school indoor 24-h avg No information on limit of detection</p>	<p>0–4 avg</p> <hr/> <p>0</p>	<p>log eNO comparing ≥14.3 vs. &lt;14.3 ppb NO<sub>2</sub>: 0 (–0.14, 0.14)</p> <hr/> <p>0 (–0.13, 0.14)</p>	<p>No copollutant model. PM<sub>2.5</sub>, acetaldehyde associated with eNO.</p>
<p>†<a href="#">Liu (2013)</a>, <a href="#">Liu et al. (2009b)</a> Windsor, ON, Canada n = 182, ages 9–14 yr Repeated measures. Examined weekly for 4 weeks, same day of week. 672 observations. Recruitment from schools. No information on participation rate. Parental report of physician-diagnosed asthma. Mixed effect model with random effect for subject and adjusted for testing period, temperature, relative humidity, daily medication use.</p>	<p>NO<sub>2</sub>-central site 24-h avg Average of 2 sites. 99% subjects live within 10 km of sites.</p>	<p>0 1 0–2 avg 0 1 0–2 avg</p>	<p>eNO: 17% (–5.8, 47) 7.7% (–12, 32) 1.5% (–32, 50) TBARS: 48% (3.9, 111) 22% (–11, 67) 131% (23, 334)</p>	<p>For TBARS only: with PM<sub>2.5</sub>: 31% (–30, 145) with SO<sub>2</sub>: 43% (–10, 126) Small decrease in PM<sub>2.5</sub> estimate with adjustment for NO<sub>2</sub>. NO<sub>2</sub> highly correlated with PM<sub>2.5</sub> (Spearman <i>r</i> = 0.71), weakly with SO<sub>2</sub> (<i>r</i> = 0.18).</p>

**Table 5-16 (Continued): Epidemiologic studies of pulmonary inflammation and oxidative stress in children and adults with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p><a href="#">†Liu et al. (2014a)</a> Munich and Wesel, Germany n = 192, age 10 yr Cross-sectional. Recruitment from GINIplus, LISApplus birth cohort studies. No information reported on participation rate or ascertainment. Parental report of physician-diagnosed asthma. GAM adjusted for cohort, city, sex, parental education, parental history of atopy, indoor gas pollution, current pets, maternal prenatal smoking, smoking exposure at age 10 yr, temperature. Results not altered by adjustment for asthma medication use or annual avg NO<sub>2</sub> estimated from land use regression models.</p>	<p>NO<sub>2</sub>-central site 24-h avg 1 site per city in suburban locations.</p>	<p>0</p>	<p>eNO: Both cities: 51% (-11, 154) Results in figure show association only in Munich, null in Wesel.</p>	<p>With PM<sub>10</sub>: 23% (-37, 137) among children with asthma. PM<sub>10</sub> results not altered with NO<sub>2</sub> adjustment. 34% (15, 56) among all 1,985 children. PM<sub>10</sub> association attenuated with NO<sub>2</sub> adjustment. Moderate correlated with NO<sub>2</sub>. Spearman <i>r</i> = 0.59.</p>
<p><b>Children with asthma: studies with central site exposure assessment and no examination of copollutant confounding</b></p>				
<p><a href="#">†Barraza-Villarreal et al. (2008)</a> Mexico City, Mexico n = 119–129, ages 6–14 yr, 54% persistent asthma, 89% atopy Repeated measures. Examined every 15 days for mean 22 weeks. 1,004 observations. Recruited from pediatric clinic. Asthma severity assessed by pediatric allergist. No information on participation rate. Linear mixed effects model with random effect for subject and adjusted for sex, body mass index, lag one minimum temperature, ICS use, time. Adjustment for outdoor activities, smoking exposure, anti-allergy medication use, season did not alter results.</p>	<p>NO<sub>2</sub>-central site 8-h max Monitors within 5 km of school or home. Low correlation for school vs. central site: Spearman <i>r</i> = 0.21</p>	<p>0</p>	<p>eNO: 8.4% (7.9, 9.0) Interleukin-8: 1.2% (1.1, 1.3) Exhaled breath condensate pH: -0.5% (-1.5, 0.50)</p>	<p>No copollutant model. PM<sub>2.5</sub> and O<sub>3</sub> associated with eNO and IL-8. Moderate or weak correlation with NO<sub>2</sub>. Pearson <i>r</i> = 0.61 for PM<sub>2.5</sub>, 0.28 for O<sub>3</sub>.</p>

**Table 5-16 (Continued): Epidemiologic studies of pulmonary inflammation and oxidative stress in children and adults with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p><a href="#">†Romieu et al. (2008)</a> Mexico City, Mexico n = 107, mean age 9.5 yr. 48% persistent asthma, 90% atopy Repeated measures. EBC collected every 2 weeks for 2–16 weeks. 480 observations. Recruitment from allergy clinic. No information on participation rate. 25% EBC samples below detection limit, assigned random value 0–4.1 nmol. Malondialdehyde associated with wheeze and asthma medication use. GEE model adjusted for sex, school shift, temperature, chronological time. Adjustment for outdoor activities, parental smoking did not alter results.</p>	<p>NO<sub>2</sub>-central site 8-h max Similar results for 1-h max and 24-h avg. Monitors within 5 km of school or home.</p>	0	<p>Log malondialdehyde: 0.13 (–0.10, 0.35)</p>	<p>No copollutant model. PM<sub>2.5</sub>, distance to closest Avenue; 4.5-h traffic count, and O<sub>3</sub> also associated with malondialdehyde. Moderate correlation with NO<sub>2</sub>. Pearson <i>r</i> = 0.44 for O<sub>3</sub> and 0.54 for PM<sub>2.5</sub>.</p>
<p><a href="#">†Berhane et al. (2011)</a> 13 Southern CA towns n = 169, ages 6–9 yr Cross-sectional. Recruitment from schools. Parental report of physician-diagnosed asthma and history of respiratory allergy. Linear regression adjusted for community, race/ethnicity, age, sex, asthma, asthma medication use, history of respiratory allergy, eNO collection time, body mass index, smoking exposure, parental education, questionnaire language, season, multiple temperature metrics, eNO collected outdoors.</p>	<p>NO<sub>2</sub>-central site 24-h avg Sites in each community. # sites in each community NR.</p>	1–6 avg	eNO: –6.7% (–31 26%)	<p>No copollutant model. PM<sub>2.5</sub>, PM<sub>10</sub>, O<sub>3</sub> associated with eNO. Moderate or weak correlations with NO<sub>2</sub>. Pearson <i>r</i> = 0.47 for PM<sub>2.5</sub>, 0.49 for PM<sub>10</sub>, 0.15 for O<sub>3</sub>.</p>
<b>Adults with asthma: central site exposure assessment, no examination of potential confounding by traffic-related copollutants</b>				
<p><a href="#">†Qian et al. (2009a)</a> Boston, MA; New York, NY; Denver, CO; Philadelphia, PA; San Francisco, CA; Madison, WI. n = 119, ages 12–65 yr, persistent asthma, nonsmokers Repeated measures. Examined every 2–4 weeks for 16 weeks. 480 person-days. No information on participation rate. Study population representative of full cohort. Asthma medication trial and a priori comparison of medication regimens. Linear mixed effects model adjusted for age, sex, race/ethnicity, center, season, week, daily average temperature, daily average humidity. Adjustment for viral infections did not alter results.</p>	<p>NO<sub>2</sub>-central site 24-h avg Average of all monitors within 51 km of subject ZIP code centroid.</p>	0	<p>eNO: All subjects: 1.1% (0.52, 1.7) Placebo: 0.79% (–0.08, 1.7) Beta-agonist use: 0.86% (0.08, 1.6) ICS use: 1.8% (0.62, 2.9)</p>	<p>With PM<sub>10</sub>: 0.69% (–0.09, 1.5) With O<sub>3</sub>: 0.94% (0.43, 1.5) With SO<sub>2</sub>: 1.2% (0.52, 1.9) Copolutant effect estimates attenuated with adjustment for NO<sub>2</sub>. Correlations NR.</p>
		0–3 avg	All subjects: 0.94% (0.09, 1.8)	

**Table 5-16 (Continued): Epidemiologic studies of pulmonary inflammation and oxidative stress in children and adults with asthma.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p>†<a href="#">Maestrelli et al. (2011)</a> Padua, Italy n = 32, mean age 39.6 (SD: 7.5) yr, 81% persistent asthma Repeated measures. Examined 6 times over 2 yr. Selected from database of beta-agonist users (&gt;6/yr for 3 yr), diagnosis clinically confirmed. 76% follow-up participation. Dropouts did not differ from participants. GEE adjusted for daily average temperature, humidity, atmospheric pressure, asthma medication use, current smoking status.</p>	<p>NO<sub>2</sub>-central site 24-h avg 2 sites in city</p>	<p>0</p>	<p>eNO (ppb): All subjects: 3.1 (-14, 21) Nonsmokers, n = 22: 2.9 (-20, 26)</p> <hr/> <p>Exhaled breath condensate pH: All subjects: 0 (-0.19, 0.21) Nonsmokers: -0.09 (-0.24, 0.05)</p>	<p>No copollutant model. Personal and central site PM<sub>2.5</sub> and PM<sub>10</sub> not associated with eNO. No associations with central site CO. Association found with O<sub>3</sub> and SO<sub>2</sub>. Correlations NR.</p>

Note: More informative studies in terms of the exposure assessment method and potential confounding considered are presented first.

avg = average; BC = black carbon; BTEX = sum of the VOCs benzene, toluene, ethylbenzene, xylene; CI = confidence interval; CA = California; CO = carbon monoxide, Colorado; EBC = exhaled breath condensate; EC = elemental carbon; eNO = exhaled nitric oxide; GAM = generalized additive models; GEE = generalized estimating equation; GINIPlus = German Infant Nutritional Intervention plus environmental and genetic influences; GLM = generalized linear model; ICS = inhaled corticosteroid; IL = interleukin; MA = Massachusetts; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; NY = New York; O<sub>3</sub> = ozone; OC = organic carbon; ON = Ontario; PA = Pennsylvania; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm; ROS = reactive oxygen species; SD = standard deviation; TBARS = thiobarbituric acid reactive substances; TX = Texas; VOC = volatile organic compound; WI = Wisconsin.

<sup>a</sup>Effect estimates are standardized to a 20 ppb increase for 24-h avg NO<sub>2</sub> and 25 ppb increase for 8-h max NO<sub>2</sub>.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

Key evidence is provided by studies with NO<sub>2</sub> exposures assessed for subjects' locations, comparison of various exposure metrics, and/or examination of confounding by traffic-related copollutants. These studies examined a limited number of exposure lags but specified them a priori. Across studies, associations were found with multiday averages of NO<sub>2</sub> (i.e., 0–1 avg to 0–6 avg) ([Figure 5-8](#) and [Table 5-16](#)), with [Delfino et al. \(2006\)](#) finding a stronger association of eNO with lag 0–1 avg than lag 0 or 1 day NO<sub>2</sub>. As reported by a few studies, participation rates were high (87, 95%, [Table 5-16](#)). Selective participation by certain groups was not indicated. Strong exposure assessment was characterized as personal monitoring ([Delfino et al., 2006](#)); estimation of individual outdoor exposures based on monitoring, modeling, and daily activity patterns ([Martins et al., 2012](#)); monitoring at or near schools ([Greenwald et al., 2013](#); [Sarnat et al., 2012](#); [Lin et al., 2011](#); [Holguin et al., 2007](#)); or examination of central site ambient concentrations that were temporally correlated with total personal NO<sub>2</sub> measures ([Delfino et al., 2013](#)).

In comparisons with central site NO<sub>2</sub>, associations with eNO were similar to personal NO<sub>2</sub> among children with asthma in Riverside and Whittier, CA [([Delfino et al., 2013](#); [Delfino et al., 2006](#)); [Figure 5-8](#) and [Table 5-16](#)]. An increase in 8-h max NO<sub>2</sub> assigned from each child's community central site was associated with a similar increase in eNO as 24-h avg personal NO<sub>2</sub> based on the interquartile ranges of NO<sub>2</sub> (1.4% [95% CI: 0.39, 2.3] per 12-ppb increase in 8-h max central site NO<sub>2</sub> and 1.6% [95% CI: 0.43, 2.8] per 17-ppb increase in 24-h avg personal NO<sub>2</sub>). Personal and central site NO<sub>2</sub> were moderately correlated (Spearman  $r = 0.43$ ). Thus, despite the potential for greater exposure measurement error due to within-community variability in ambient NO<sub>2</sub> concentrations and variation in time-activity patterns ([Section 3.4.4](#)), daily variation in ambient NO<sub>2</sub> is to some extent represented in daily variation in personal NO<sub>2</sub> exposures of these children that is associated with eNO. Such results provide a rationale for drawing inferences about ambient NO<sub>2</sub> exposure from associations observed with total personal NO<sub>2</sub> exposures. All total personal NO<sub>2</sub> exposures were above the LOD, supporting the reliability of the associations with eNO ([Delfino et al., 2006](#); [Staimer et al., 2005](#)).

Among children with wheeze in Portugal, a 20-ppb increase in 1-week avg individual estimates of ambient NO<sub>2</sub> exposure was associated with a 14% (95% CI: -12, 40) increase in eNO and a -2.6% (95% CI: -3.9, -1.3) change in exhaled breath condensate (EBC) pH ([Martins et al., 2012](#)). School and home indoor NO<sub>2</sub> concentrations were nondetectable, providing support for an association with ambient NO<sub>2</sub>. No issues with LOD were reported for ambient measurements. Further, time-weighted averages of microenvironmental NO<sub>2</sub> have shown good agreement with personal NO<sub>2</sub> ([Section 3.4.3.1](#)). Children were reported to spend 85% of time at home or school, underscoring the importance of the individual-level exposure estimation in this study.

Evidence also points to associations of eNO in children with asthma with NO<sub>2</sub> concentrations measured outside schools. Of the studies conducted in communities along the Texas/Mexico border, most found NO<sub>2</sub>-associated increases in eNO. eNO was more strongly associated with outdoor school NO<sub>2</sub> than central site NO<sub>2</sub> ([Sarnat et al., 2012](#)) or school indoor NO<sub>2</sub> [([Greenwald et al., 2013](#); [Sarnat et al., 2012](#)); [Figure 5-8](#) and [Table 5-16](#)]. In the Texas/Mexico study, a 20-ppb increase in 96-h avg NO<sub>2</sub> concentration was associated with increases in eNO of 6.3% (95% CI: 2.5, 10) for outdoor school, 0.5% (95% CI: 0.1, 1.0) for indoor school, and 1.7% (95% CI: -1.0, 4.5) for central site. Most indoor NO<sub>2</sub> measurements were above the LOD. NO<sub>2</sub> from the single central site in El Paso was moderately to strongly correlated (Spearman  $r = 0.63$ – $0.91$ ) with school NO<sub>2</sub> ([Sarnat et al., 2012](#)), suggesting that for some schools, the central site measures captured temporal variation in school-based measures. However, the variability in NO<sub>2</sub> found across schools (coefficient of variation = 59%) indicates that the stronger associations with outdoor school NO<sub>2</sub> may be attributable to school measurements better representing variability in NO<sub>2</sub> within the area and exposures of children. Misrepresenting temporal variability in short-term exposure has been shown to influence health effect estimates ([Section 3.4.5.1](#)). [Holguin et al. \(2007\)](#) did not find an association with eNO in children with asthma in Ciudad Juarez schools. No association was found in a study of children in France ([Flamant-Hulin et al., 2010](#)). However, this study had weaker methodology because of its cross-sectional design, comparison of eNO between low and high NO<sub>2</sub> (means 10.1 and 17.4 ppb), and for some subjects, measurement of eNO 1 week before NO<sub>2</sub>. NO<sub>2</sub> measured within 650 m of subjects' schools (lag 0 day of 24-h avg) was associated with eNO among children in Beijing, China examined before and after the 2008 Olympics ([Lin et al., 2011](#)).

With regard to confounding, most studies that assessed exposures in subjects' locations adjusted for temperature and humidity, with a few additionally adjusting for asthma medication use ([Sarnat et al., 2012](#); [Delfino et al., 2006](#)). An array of copollutants was examined, and most studies found associations with PM<sub>2.5</sub> and with the traffic-related copollutants EC/BC, OC, and VOCs. These copollutants showed a wide range of correlations with NO<sub>2</sub> (Pearson or Spearman  $r = -0.43$  to  $0.77$ ). There is some evidence for NO<sub>2</sub> effects on pulmonary inflammation that are independent from PM<sub>2.5</sub>, EC/BC, or OC. NO<sub>2</sub>-eNO associations were found with adjustment for personal PM<sub>2.5</sub>, EC, or OC. Personal exposure measures, all of which were above the limit of detection (LOD), were more weakly correlated with NO<sub>2</sub> (Spearman  $r = 0.20$ – $0.33$ ) than central site measures ( $r = 0.20$ – $0.70$ ) ([Delfino et al., 2006](#)). For central site NO<sub>2</sub>, associations with eNO decreased but remained positive with adjustment for BC or the oxidative potential of ambient PM<sub>2.5</sub> extracts measured in vitro [([Delfino et al., 2013](#); [Lin et al., 2011](#)); [Table 5-16](#), [Figures 5-16](#) and [5-17](#)]. The latter results support an independent association with NO<sub>2</sub> because oxidative stress is a key early event in the mode of action proposed for

NO<sub>2</sub>, traffic-related copollutants, and PM<sub>2.5</sub> ([Appendix](#) to the ISA). The studies conducted in El Paso, TX and Ciudad Juarez, Mexico did not analyze copollutant models with EC/BC or PM<sub>2.5</sub>. However, NO<sub>2</sub> associations were less variable across schools than were PM<sub>2.5</sub> associations, and in Ciudad Juarez, NO<sub>2</sub>, but not EC/BC or PM<sub>2.5</sub>, was associated with eNO ([Sarnat et al., 2012](#); [Holguin et al., 2007](#)).

Pulmonary inflammation also was associated with VOCs ([Greenwald et al., 2013](#); [Martins et al., 2012](#)). In the El Paso schools, because of the high correlation (Pearson  $r = 0.77$ ) between NO<sub>2</sub> and the sum of benzene, toluene, ethylbenzene, xylene (BTEX), an independent association is not discernible for either pollutant. Reporting copollutant-adjusted results only for EBC pH, [Martins et al. \(2012\)](#) found that associations for individual estimates of outdoor NO<sub>2</sub> exposure were similar after adjustment for a VOC, which showed no or negative correlations with NO<sub>2</sub> (range of Spearman  $r$  across four visits =  $-0.42$  to  $0.14$ ; [Table 5-16](#)). VOC estimates were attenuated to the null with adjustment for NO<sub>2</sub>; thus, NO<sub>2</sub> may have confounded associations for VOCs. There was no report of outdoor or indoor VOC or outdoor NO<sub>2</sub> measurements being below the detection limit. Other pollutants, O<sub>3</sub>, SO<sub>2</sub>, PM<sub>10</sub>, and PM<sub>10-2.5</sub>, were associated with pulmonary inflammation and oxidative stress but did not show strong positive correlations with NO<sub>2</sub> ( $r = -0.72$  to  $0.18$ ). NO<sub>2</sub> effect estimates increased with adjustment for O<sub>3</sub> measured at school ([Sarnat et al., 2012](#)) and became null with individual estimates of PM<sub>10</sub> ([Martins et al., 2012](#)). But PM<sub>10</sub> and NO<sub>2</sub> were strongly to moderately negatively correlated ( $r = -0.82$  to  $-0.55$ ).

Other studies have a weaker basis for inferring an independent effect of NO<sub>2</sub> on pulmonary inflammation and oxidative stress in children with asthma. They all assigned NO<sub>2</sub> exposure as ambient concentrations from one city central site or sites 5 km or 10 km from subjects' homes. While the studies adjusted for potential confounding by meteorological factors and asthma medication use, most did not examine confounding by traffic-related copollutants. Findings were variable for indicators of inflammation among eNO, IL-8, and EBC pH, as well as indicators of oxidative stress related to lipid peroxidation. Some studies found associations with ambient NO<sub>2</sub> ([Liu et al., 2014a](#); [Barraza-Villarreal et al., 2008](#)) or inconsistent associations across the lags of exposure or specific endpoints examined ([Liu et al., 2009b](#)). In the others, effect estimates with wide 95% CIs did not support associations [([Berhane et al., 2011](#); [Romieu et al., 2008](#)); [Figure 5-8](#) and [Table 5-16](#)]. Studies also found associations with traffic proximity and volume and with PM<sub>2.5</sub>, which was moderately to highly correlated with NO<sub>2</sub> ( $r = 0.49-0.71$ ) ([Liu et al., 2014a](#); [Berhane et al., 2011](#); [Liu et al., 2009b](#); [Romieu et al., 2008](#));([Barraza-Villarreal et al., 2008](#)). Copollutant modeling was conducted in a study of children in Windsor, Canada, and effect estimates for NO<sub>2</sub> were largely attenuated with adjustment for PM<sub>2.5</sub> [([Liu et al., 2009b](#)); [Table 5-17](#)]. PM<sub>2.5</sub> estimates were less altered

with adjustment for NO<sub>2</sub>; however, the reliability of the copollutant model is questionable because of the high NO<sub>2</sub>-PM<sub>2.5</sub> correlation ( $r = 0.71$ ). In the limited analysis of copollutant models with PM<sub>10</sub> ( $r = 0.59$ ) or SO<sub>2</sub> ( $r = 0.18$ ), NO<sub>2</sub> remained associated with pulmonary inflammation or oxidative stress ([Liu et al., 2014a](#); [Liu et al., 2009b](#)).

### ***Adults with Asthma***

Epidemiologic studies of pulmonary inflammation in adults with asthma, which were not available for the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), show contrasting associations with ambient NO<sub>2</sub>. Both studies examined adults predominately with persistent asthma, assessed NO<sub>2</sub> exposure from central site monitors, and adjusted for temperature and humidity. In a U.S. multicity (Boston, MA; New York, NY; Philadelphia, PA; San Francisco, CA; Madison, WI) study nested within an asthma medication trial, a 20-ppb increase in lag 0 day of 24-h avg NO<sub>2</sub> was associated with a 0.26-ppb (95% CI: 0.12, 0.40) increase in eNO ([Qian et al., 2009a](#)). A similar increase in eNO was found for lag 0–3 day avg NO<sub>2</sub> but not lags 1, 2 or 3. A larger effect was estimated in the daily ICS group than the placebo or beta-agonist groups only for lag 0 day NO<sub>2</sub>. Among children and adults with asthma in Padua, Italy, a large percentage of whom reported ICS use, lag 0 day of 24-h avg ambient NO<sub>2</sub> was not associated with eNO or exhaled breath condensate pH ([Maestrelli et al., 2011](#)). The U.S. multicity study did not indicate whether the NO<sub>2</sub> concentration averaged from monitors within 32 km of subjects' homes adequately represented the temporal variability in exposure and did not examine whether the association for ambient NO<sub>2</sub> was independent of other traffic-related pollutants. Copollutant models were examined only for PM<sub>10</sub>, SO<sub>2</sub>, and O<sub>3</sub>, in which NO<sub>2</sub> remained associated with eNO ([Qian et al., 2009a](#)). Adjustment for NO<sub>2</sub> attenuated the effect estimates for PM<sub>10</sub>, SO<sub>2</sub>, and O<sub>3</sub>, indicating that the copollutant associations were confounded by NO<sub>2</sub>.

---

#### **5.2.2.6 Summary of Asthma Exacerbation**

Evidence integrated across the array of health outcomes and disciplines strongly supports a relationship between short-term NO<sub>2</sub> exposure and asthma exacerbation. The evidence for allergic inflammation, increased airway responsiveness, and clinical events, such as respiratory symptoms in populations with asthma as well as ED visits and hospital admissions for asthma, is consistent with the sequence of events in the proposed mode of action linking short-term NO<sub>2</sub> exposure and asthma exacerbation ([Figure 4-1](#)) and supports the biological plausibility for a relationship. Much of this evidence, especially from experimental studies, was described in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)). Recent findings, primarily from epidemiologic studies, continue to indicate

NO<sub>2</sub>-associated increases in asthma exacerbation. Many recent epidemiologic studies contribute additional exposure assessment in subjects' locations and examination of potential confounding by or interactions with other traffic-related pollutants.

The primary evidence demonstrating that NO<sub>2</sub> can independently exacerbate asthma is that NO<sub>2</sub>-induced increases in airway responsiveness in adults with asthma, particularly in response to nonspecific bronchoconstrictors and exposures in which subjects did not exercise ([Section 5.2.2.1](#)). Of all the health outcomes examined in controlled human exposure studies of NO<sub>2</sub>, increased airway responsiveness was induced by the lowest NO<sub>2</sub> concentrations, 100 ppb for 1 hour and 200–300 ppb for 30 minutes. Further, a meta-analysis indicates a clinically relevant doubling reduction in provocative dose in adults with asthma in response to NO<sub>2</sub> exposure relative to air exposure. Increased airway responsiveness can lead to poorer asthma control. Thus, the evidence for relatively low NO<sub>2</sub> exposures inducing clinically relevant increases in airway responsiveness in adults with asthma provides key support that ambient concentrations of NO<sub>2</sub> can exacerbate asthma. Most experimental studies did not report lung function changes, respiratory symptoms, or an array of inflammatory responses following exposure to NO<sub>2</sub> (120–4,000 ppb for 30 minutes–6 hours) in adults with asthma or animal models of allergic disease in the absence of challenge with a bronchoconstrictor ([Sections 5.2.2.2](#), [5.2.2.3](#), and [5.2.2.5](#)). However, there are several observations of NO<sub>2</sub>-induced allergic inflammation, most consistently indicated as increases in eosinophil number and activation of eosinophils and/or neutrophils following exposures with and without an allergen challenge ([Section 5.2.2.5](#)). Similar to airway responsiveness, allergic inflammation was enhanced by lower NO<sub>2</sub> exposures than many other health effects examined in experimental studies: 260 ppb NO<sub>2</sub> for 15–30 minutes or 400 ppb NO<sub>2</sub> for 6 hours. The evidence for NO<sub>2</sub>-induced allergic inflammation also demonstrates that NO<sub>2</sub> exposure plausibly can lead to an asthma exacerbation.

Epidemiologic studies generally did not find NO<sub>2</sub>-associated changes in inflammatory cell counts in populations with asthma; however, they did consistently indicate ambient or personal NO<sub>2</sub>-associated increases in eNO ([Figure 5-8](#) and [Table 5-16](#)). These findings are coherent with experimental evidence for allergic inflammation because increases in eosinophils and neutrophils are linked with NO production during an inflammatory response. The limited studies in adults with asthma produced conflicting results, but the large body of findings in children with asthma shows a consistent pattern of association across the various lags of exposure and outcomes examined. T-derived lymphocyte helper 2 (Th2)-mediated airway obstruction can lead to a decrease in lung function. Thus, the evidence for NO<sub>2</sub>-induced allergic inflammation supports the epidemiologic associations observed for ambient or personal NO<sub>2</sub> concentrations with lung function decrements in children with asthma as measured by supervised spirometry

([Section 5.2.2.2](#)). In fact, the evidence for NO<sub>2</sub>-related increases in allergic inflammation provides biological plausibility for the associations observed for NO<sub>2</sub> with the array of asthma-related effects in populations with asthma that have a high prevalence of atopy (53–84%) and groups of children with asthma not using anti-inflammatory ICS ([Hernández-Cadena et al., 2009](#); [Liu et al., 2009b](#); [Barraza-Villarreal et al., 2008](#); [Escamilla-Nuñez et al., 2008](#)). Although information is limited, a role for allergic inflammation in NO<sub>2</sub>-induced lung function decrements is supported by evidence for changes in lung function mediated by mast cell degranulation. Mast cell degranulation leads to histamine release ([Section 4.3.2.2](#)). Neural reflexes do not appear to mediate lung function changes in response to ambient-relevant NO<sub>2</sub> exposures.

Consistent with the evidence for airway responsiveness and allergic inflammation, epidemiologic studies consistently demonstrate associations of increases in ambient NO<sub>2</sub> concentration with increases in asthma symptoms in children ([Section 5.2.2.3](#)) and asthma hospital admissions and ED visits among subjects of all ages and children ([Section 5.2.2.4](#)). The robustness of evidence is demonstrated by associations found in studies conducted in diverse locations in the U.S., Canada, and Asia, including several multicity studies. NO<sub>2</sub> was associated with the use or sale of asthma medication in adults with asthma but not children with asthma. Individual epidemiologic studies examined multiple outcomes and lags of exposure; however, a pattern of association was consistently observed with NO<sub>2</sub>, which does not point to a higher probability of findings due to chance alone.

The evidence for asthma is substantiated by several studies with strong exposure assessment characterized by measuring NO<sub>2</sub> concentrations in subjects' location(s). Respiratory symptoms, lung function decrements, and pulmonary inflammation were associated with personal total and ambient NO<sub>2</sub> exposures ([Martins et al., 2012](#); [Delfino et al., 2008a](#); [McCreanor et al., 2007](#)) and NO<sub>2</sub> measured outside schools ([Greenwald et al., 2013](#); [Zora et al., 2013](#); [Sarnat et al., 2012](#); [Holguin et al., 2007](#)). Imparting confidence in results for personal exposure metrics, no issues were reported regarding a large number of NO<sub>2</sub> measurements being near the LOD. Given the high variability in NO<sub>2</sub> concentrations, measurements in subjects' locations may better represent temporal variation in ambient NO<sub>2</sub> exposures than area-wide central site concentrations ([Sections 2.5.3](#) and [3.4.4](#)). Observations that daily variation in central site ambient NO<sub>2</sub> was related to variation in total personal NO<sub>2</sub> ( $r = 0.43$ ) ([Delfino et al., 2008a](#)) and that indoor home or school NO<sub>2</sub> concentrations were negligible ([Martins et al., 2012](#)) provide additional support for a relationship of asthma exacerbation with ambient NO<sub>2</sub> exposure.

A key uncertainty noted in the 2008 ISA for Oxides of Nitrogen was whether NO<sub>2</sub> had an effect independent of other traffic-related pollutants and PM<sub>2.5</sub> ([U.S. EPA, 2008c](#)).

Epidemiologic studies of asthma-related respiratory effects found associations with NO<sub>2</sub> as well as with PM<sub>2.5</sub>, CO, BC/EC, UFP, other PM constituents, and VOCs ([Figures 5-16](#) and [5-17](#)). Among the studies that examined confounding by one of these copollutants, most indicate an independent association with NO<sub>2</sub>. The predominant method for evaluation was copollutant models, which have well-recognized limitations for distinguishing independent pollutant associations ([Section 5.1.2.2](#)). However, several studies with strong exposure assessment provide a sound basis for inferring an independent NO<sub>2</sub> association, when integrated with experimental evidence.

In populations with asthma, personal total and ambient NO<sub>2</sub> and NO<sub>2</sub> measured outside or 0.65 km from children's schools were associated with respiratory symptoms, decreased lung function, and pulmonary inflammation with adjustment for BC/EC, UFP, OC, or PM<sub>2.5</sub> ([Martins et al., 2012](#); [Lin et al., 2011](#); [Delfino et al., 2008a](#); [McCreanor et al., 2007](#); [Delfino et al., 2006](#)) ([Figures 5-16](#) and [5-17](#)). Also supporting an independent association for NO<sub>2</sub>, some studies found associations with school or personal NO<sub>2</sub> but not EC, OC, or PM<sub>2.5</sub> ([Sarnat et al., 2012](#); [Delfino et al., 2008a](#); [Holguin et al., 2007](#)). In a few cases, adjustment for UFP or a VOC attenuated the NO<sub>2</sub> association with one outcome in a study but not another ([Martins et al., 2012](#); [McCreanor et al., 2007](#)), indicating the potential for confounding to differ by outcome. Among children with asthma in El Paso, TX, school NO<sub>2</sub> was not associated with asthma control score after adjusting for BC ([Zora et al., 2013](#)). However, a copollutant model was not examined in the group with atopy, to whom the association with NO<sub>2</sub> was limited. Copollutant associations adjusted for NO<sub>2</sub> were robust in some cases ([Lin et al., 2011](#); [Delfino et al., 2006](#)) and attenuated in other cases ([Martins et al., 2012](#); [Delfino et al., 2008a](#)). Thus, in some studies, NO<sub>2</sub> appeared to confound associations for traffic-related copollutants. The spatial alignment of NO<sub>2</sub> with subjects' location(s) may have reduced differences in exposure measurement error between NO<sub>2</sub> and copollutant, thereby improving the reliability of copollutant model results. Correlations between NO<sub>2</sub> and traffic-related copollutants varied widely ( $r = -0.42$  to  $0.75$ ), and inference from copollutant model results also is improved by the low NO<sub>2</sub>-copollutant correlations found for personal measurements ( $r = 0.20$ – $0.33$  for EC, OC, PM<sub>2.5</sub> and  $-0.42$  to  $0.08$  for benzene and ethylbenzene) ([Martins et al., 2012](#); [Delfino et al., 2006](#)). Neither study reported issues regarding measurements being below LOD for any of the pollutants examined.

Consistent with findings for NO<sub>2</sub> exposures in subjects' locations, copollutant models based on central site concentrations indicate ambient NO<sub>2</sub> remains associated with asthma-related effects with adjustment for CO, UFP, a source apportionment factor comprising EC and various metals, PM<sub>2.5</sub>, or oxidative potential of PM<sub>2.5</sub> extracts ([Delfino et al., 2013](#); [Iskandar et al., 2012](#); [Dales et al., 2009a](#); [Gent et al., 2009](#); [Jalaludin et al., 2008](#); [Villeneuve et al., 2007](#); [Delfino et al., 2003](#); [von Klot et al., 2002](#)). For

pollutants measured at central sites, the impact of copollutant adjustment on NO<sub>2</sub> associations also differed by outcomes within studies ([Liu et al., 2009b](#); [Andersen et al., 2008a](#); [von Klot et al., 2002](#)). Central site NO<sub>2</sub> tended to show moderate correlations with traffic-related copollutants ( $r = 0.28$ – $0.56$ , but  $0.66$  for UFP and  $0.71$  for PM<sub>2.5</sub>), but differences in spatial distributions may result in differential exposure measurement error and render copollutant model results unreliable. Differential error may influence findings from [Delfino et al. \(2008a\)](#), where the association between ambient NO<sub>2</sub> and lung function remained positive but was reduced with adjustment for personal PM<sub>2.5</sub>.

Epidemiologic evidence also indicates that NO<sub>2</sub> associations with asthma-related effects are independent of nontraffic pollutants and other temporally varying factors ([Tables 5-5, 5-8, and 5-16](#)). In most cases, NO<sub>2</sub> associations were found with adjustment for SO<sub>2</sub>, PM<sub>10</sub>, PM<sub>10-2.5</sub>, or O<sub>3</sub> ([Liu et al., 2014a](#); [Sarnat et al., 2012](#); [Mann et al., 2010](#); [Patel et al., 2010](#); [Strickland et al., 2010](#); [Dales et al., 2009a](#); [Qian et al., 2009a](#); [Jalaludin et al., 2008](#); [Mortimer et al., 2002](#)). In some copollutant models, associations for NO<sub>2</sub> as well as SO<sub>2</sub> or PM<sub>10</sub> were attenuated ([Martins et al., 2012](#); [Liu et al., 2009b](#); [Qian et al., 2009a](#)), and an independent or confounding effect was not distinguished for either NO<sub>2</sub> or copollutant. In exception, [Samoli et al. \(2011\)](#) indicated that the NO<sub>2</sub> association with asthma ED visits was confounded by SO<sub>2</sub> or PM<sub>10</sub> but not vice versa. Most epidemiologic studies found associations between NO<sub>2</sub> and asthma-related effects with adjustment for potential confounding by temperature, humidity, and season. As examined in fewer studies, NO<sub>2</sub> associations persisted with adjustment for day of week, smoking, and asthma medication use.

[Gass et al. \(2014\)](#) and [Winqvist et al. \(2014\)](#) show increases in asthma ED visits when ambient concentrations of NO<sub>2</sub> are jointly high with PM<sub>2.5</sub>, CO, EC, O<sub>3</sub>, and/or SO<sub>2</sub>. Such joint effect analyses do not provide insight into independent effects of NO<sub>2</sub>. These and other epidemiologic studies ([Schildcrout et al., 2006](#); [Delfino et al., 2003](#)) do not provide evidence of synergistic interactions between NO<sub>2</sub> and PM<sub>2.5</sub>, CO, EC, or VOCs. Such interactions are not clearly demonstrated in controlled human exposure studies either ([Jenkins et al., 1999](#); [Devalia et al., 1994](#); [Hazucha et al., 1994](#); [Adams et al., 1987](#)).

Another line of evidence indicating that short-term NO<sub>2</sub> exposure may have an independent effect on asthma exacerbation is the coherence of evidence for indoor and outdoor NO<sub>2</sub>. Except for [Greenwald et al. \(2013\)](#), indoor home or school NO<sub>2</sub> concentrations were associated with respiratory symptoms and pulmonary inflammation in children with asthma ([Lu et al., 2013](#); [Sarnat et al., 2012](#); [Hansel et al., 2008](#)). In both cohorts, most indoor measurements were above the LOD ([Raysoni et al., 2011](#); [Diette et al., 2007](#)). [Sarnat et al. \(2012\)](#) found that correlations between NO<sub>2</sub> and copollutants differed between the indoor and outdoor environments for BC, PM, and SO<sub>2</sub>, suggesting

that NO<sub>2</sub> may exist as part of different pollutant mixtures in the indoor and outdoor environments.

In summary, evidence for increased airway responsiveness and allergic inflammation in experimental studies clearly demonstrates that short-term NO<sub>2</sub> exposure can induce effects related to asthma exacerbation. That these hallmarks of asthma are enhanced by exposures to 100–400 ppb NO<sub>2</sub> substantiates the supposition that ambient NO<sub>2</sub> exposures can exacerbate asthma. Further, these effects are coherent with epidemiologic associations consistently observed for short-term increases in NO<sub>2</sub> concentrations with asthma-related hospital admissions, ED visits, symptoms, and pulmonary inflammation. Key epidemiologic evidence comprises the associations with outdoor and indoor NO<sub>2</sub> exposures assessed in subjects' locations, many of which persist in copollutant models with another traffic-related pollutant or PM<sub>2.5</sub>. Not all asthma-related effects are associated with NO<sub>2</sub> or show coherence between epidemiologic and experimental studies, particularly lung function assessed in the absence of a bronchoconstricting agent. Potential confounding has not been assessed for all correlated traffic-related pollutants, and reliable methods are not available for simultaneous control for multiple pollutants. However, the integrated evidence for airway responsiveness and allergic inflammation in experimental studies and asthma-related effects in epidemiologic studies sufficiently provides a biologically plausible link between short-term NO<sub>2</sub> exposure and asthma exacerbation.

---

### 5.2.3 Allergy Exacerbation

The evidence from experimental studies for the effects of short-term NO<sub>2</sub> and allergen co-exposure on increasing allergic inflammation in adults with asthma and animal models of allergic disease ([Section 5.2.2.5](#)) not only supports NO<sub>2</sub>-related asthma exacerbation but also indicates that NO<sub>2</sub>-induced allergy exacerbation may be biologically plausible. Support also is provided by in vitro findings that NO<sub>2</sub> can increase the allergenicity of pollen ([Cuinica et al., 2014](#); [Sousa et al., 2012](#)). Studies examining clinical indications of allergy exacerbation have become available since the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)). In contrast with asthma exacerbation, short-term NO<sub>2</sub> exposure is not clearly related with clinical indications of allergy exacerbation.

Equivocal epidemiologic evidence in adults with allergies is indicated by associations of ambient NO<sub>2</sub> with physician visits, allergic rhinitis, or nonspecific respiratory symptoms that are either inconsistent across the lags of exposure examined ([Villeneuve et al., 2006b](#)), negative, or positive but with wide 95% CIs ([Annesi-Maesano et al., 2012b](#); [FEO Brito et al., 2007](#)). Results from [Annesi-Maesano et al. \(2012b\)](#) are based on a

multipollutant model, which can produce unreliable results ([Table 5-17](#)). Studies only reported that ambient NO<sub>2</sub> exposure was assigned as concentrations from one central site or the average of multiple sites. And it is uncertain whether the temporal variability in these NO<sub>2</sub> metrics adequately represented the variability in ambient concentrations across the study area or in subjects' ambient exposures. Similarly inconclusive, a recent controlled human exposure study of adults with allergic asthma did not find increases in allergic inflammation after a 3-hour exposure to 350 ppb NO<sub>2</sub> and found increases in respiratory symptoms only during exposure ([Riedl et al., 2012](#)).

In children with allergies, increases in ambient NO<sub>2</sub> were associated with decreases in lung function ([Correia-Deur et al., 2012](#); [Barraza-Villarreal et al., 2008](#)), with an association with cough found in a cohort in Mexico City ([Barraza-Villarreal et al., 2008](#); [Escamilla-Núñez et al., 2008](#)). Strengths of these studies include the clinical assessment of allergy and the supervised measurement of lung function. Although not specific to allergy exacerbation, lung function can decrease during an allergy exacerbation due to airway obstruction caused by Th2 cytokine-mediated inflammation. The studies in children aimed to account for heterogeneity in ambient NO<sub>2</sub> concentrations. In one cohort, exposures were assigned from sites within 5 km of children's home or school, but a Pearson correlation of  $r = 0.21$  between school and central site NO<sub>2</sub> indicates the variability at the central site may not represent the variability in the subjects' locations ([Barraza-Villarreal et al., 2008](#)). Another study examined NO<sub>2</sub> from a central site in the backyard of the subjects' school ([Correia-Deur et al., 2012](#)), providing a stronger basis for inference of NO<sub>2</sub> effects. Increases in NO<sub>2</sub> lagged 2 hours, averaged over the same day, and averaged over 3 days were associated with decreases in PEF. However, counter to expectation, associations were observed for the 36 children identified as having atopy with a less stringent definition (one positive test among skin prick test, serum IgE, or blood eosinophils:  $-0.87\%$  [95% CI:  $-1.7, -0.04$ ] per 20-ppb increase in lag 0 day NO<sub>2</sub>), not the 28 children with atopy defined more stringently (all three tests positive:  $-0.30\%$  [95% CI:  $-1.7, 1.1$ ]).

**Table 5-17 Epidemiologic studies of allergy exacerbation.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p>†<a href="#">Correia-Deur et al. (2012)</a> São Paolo, Brazil, Apr–Jul 2004 n = 36, one test positive (see below); n = 28, three tests positive, ages 9–11 yr Repeated measures. Daily supervised spirometry for 15 school days. Number of observations not reported. Recruitment from school. 86% participation. Allergic sensitization ascertained by skin prick test, blood eosinophils, and serum IgE. GEE with autoregressive correlation matrix adjusted for date, school absence, temperature, humidity.</p>	<p>NO<sub>2</sub>-outdoor school 24-h avg, lag 0 day Mean: 69.9 ppb<sup>b</sup> 75th: 84.5 ppb<sup>b</sup> 90th: 102 ppb<sup>b</sup></p>	<p>% change PEF: Group with 1 positive test –0.87% (–1.7, –0.04) Group with 3 positive tests –0.30% (–1.7, 1.1)</p>	<p>All subjects, lag 0 With CO (<i>r</i> = 0.51) –1.5% (–3.0, 0) With SO<sub>2</sub> (<i>r</i> = 0.60) –1.9% (–3.3, –0.37) With PM<sub>10</sub> (<i>r</i> = 0.59) –0.75% (–4.4, 3.1) With O<sub>3</sub> (<i>r</i> = 0.40) –1.5% (–3.3, 0.38) Associations for CO &amp; O<sub>3</sub> not altered by NO<sub>2</sub> adjustment. SO<sub>2</sub> &amp; PM<sub>10</sub> attenuated.</p>
<p>†<a href="#">Barraza-Villarreal et al. (2008)</a> Mexico City, Mexico, Jun 2003–Jun 2005 n = 50, ages 6–14 yr, 72% with atopy Repeated measures. Examined every 15 days for mean 22 weeks. Participation rate not reported. 1,503 observations. Recruitment from friends or schoolmates of subjects with asthma. Clinical assessment of allergy. Supervised spirometry. Linear mixed effects model with random effect for subject and adjusted for sex, BMI, temperature, ICS use, time. Adjustment for outdoor activities, smoking exposure, anti-allergy medication use, season did not alter results.</p>	<p>NO<sub>2</sub>-central site 8-h max NO<sub>2</sub> Closest site, within 5 km of homes or schools. <i>R</i> = 0.21 for central site and school NO<sub>2</sub>. Mean: 37.4 ppb Max: 77.6 ppb</p>	<p>OR for cough: lag 0–1 day avg 1.28 (1.04, 1.57) % change FEV<sub>1</sub>: lag 1–4 day avg –0.64% (–2.1, 0.82)</p>	<p>No copollutant model. PM<sub>2.5</sub> associated with lung function and cough. Moderate correlation with NO<sub>2</sub>. Pearson <i>r</i> = 61.</p>
<p>†<a href="#">Escamilla-Nuñez et al. (2008)</a> Mexico City, Mexico, Jun 2003–Jun 2005 n = 50, ages 6–14 yr, 79% with atopy Part of same cohort as above. Participation rate not reported. Linear mixed effects model with random effect for subject and adjusted for atopy, temperature, time, sex. Adjustment for outdoor activities, smoking exposure, season did not alter results.</p>	<p>NO<sub>2</sub>-central site 1-h max NO<sub>2</sub>, lag 0–1 day avg Closest site, within 5 km of homes or schools Mean: 68.6 ppb Upper percentile: NR</p>	<p>OR for cough: 1.23 (1.03, 1.47)</p>	<p>Only multipollutant model with O<sub>3</sub> and PM<sub>2.5</sub> analyzed. Moderate correlation between PM<sub>2.5</sub> and NO<sub>2</sub>. Pearson <i>r</i> = 0.62.</p>

**Table 5-17 (Continued): Epidemiologic studies of allergy exacerbation.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p><a href="#">Villeneuve et al. (2006b)</a> Toronto, ON, Canada, 1995–2000 n = 52,971 physician visits for allergic rhinitis, ages 65 yr or older Time-series analysis. GLM adjusted for temperature, relative humidity, daily number visits for influenza, allergen levels, natural spline for time trend.</p>	<p>NO<sub>2</sub>-central site 24-h avg, lag 0 day Average of 9 city sites. Mean: 25.4 ppb Max: 71.7 ppb</p>	<p>Quantitative results NR NO<sub>2</sub> associated with physician visits for allergic rhinitis at lag 0 day. Negative or null associations at lag 1 day to 6 days.</p>	<p>No copollutant model. Association also observed for SO<sub>2</sub> but not PM<sub>2.5</sub> or CO. Correlations with NO<sub>2</sub> NR.</p>
<p>†<a href="#">Feo Brito et al. (2007)</a> Ciudad Real and Puertollano, Spain May–Jun 2000 or 2001 n = 137, ages NR, mild/moderate asthma and pollen allergy Repeated measures, 90% follow-up participation. Daily symptom diaries. Number of observations not reported. Recruitment from allergy clinics. Clinical assessment of allergy. Poisson regression adjusted only for linear and quadratic terms for season.</p>	<p>NO<sub>2</sub>-central site 24-h avg 4 sites in Puertollano, 1 mobile site in Ciudad Real Mean and Max Ciudad Real: 17.4<sup>b</sup>, 35.6<sup>b</sup> Puertollano: 29.5<sup>b</sup>, 100<sup>b</sup></p>	<p>% change in symptoms: Ciudad Real, Lag Day 4 4.75% (–5.75, 16.4) Puertollano, Lag Day 3 –3.00% (–9.55, 4.03)</p>	<p>No copollutant model. PM<sub>10</sub>, SO<sub>2</sub>, O<sub>3</sub> associated with symptoms only in Puertollano. Moderate correlation with NO<sub>2</sub>. R = 0.67, 0.36, 0.36. Pollen associated with symptoms only in Ciudad Real. R with NO<sub>2</sub> = –0.10 &amp; 0.16 for two pollen types.</p>
<p>†<a href="#">Annesi-Maesano et al. (2012b)</a> Multiple metropolitan locations, France, May–Aug 2004 n = 3,708 with severe allergic rhinitis, ages 6 yr and older, 82% adults Cross-sectional. Recruitment from physicians' offices. No information on participation rate. Clinical assessment of allergy and symptom severity. Multilevel model adjusted for age, date of physician visit, asthma status, postal code. Did not consider confounding by meteorology or SES.</p>	<p>NO<sub>2</sub>-central site 24-h avg, Lag Day 1 Site in postal code of home. Mean: 9.9<sup>b</sup> Max: 38.9<sup>b</sup></p>	<p>NR</p>	<p>Only multipollutant model analyzed with SO<sub>2</sub>, O<sub>3</sub>, PM<sub>10</sub>, pollen. Correlation only reported for pollen, r = –0.12.</p>

Note: More informative studies in terms of the exposure assessment method and potential confounding considered are presented first.

Avg = average; Aug = August; BMI = body mass index; CI = confidence interval; CO = carbon monoxide; FEV<sub>1</sub> = forced expiratory volume in 1 second; GEE = generalized estimating equations; GLM = generalized linear model; ICS = inhaled corticosteroid; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; O<sub>3</sub> = ozone; ON = Ontario; OR = odds ratio; PEF = peak expiratory flow; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm; ppb = parts per billion; SES = socioeconomic status; SO<sub>2</sub> = sulfur dioxide.

<sup>a</sup>Effect estimates are standardized to a 20 ppb for 24-h avg NO<sub>2</sub>.

<sup>b</sup>Concentrations converted from µg/m<sup>3</sup> to ppb using the conversion factor of 0.532 assuming standard temperature (25°C) and pressure (1 atm).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

Respiratory effects in populations with allergy were associated with the traffic-related pollutant CO and with PM<sub>2.5</sub>, so it is unclear whether the supporting epidemiologic

evidence represents an independent effect of NO<sub>2</sub>. Only [Correia-Deur et al. \(2012\)](#) examined copollutant models, which indicated that the NO<sub>2</sub>-PEF association in children with and without allergies combined is independent of CO ([Table 5-17](#)). School-based NO<sub>2</sub> and CO may have similar exposure error, providing basis for good inference from the copollutant model results. NO<sub>2</sub> also remained associated with PEF with adjustment for school SO<sub>2</sub> concentrations. However, both NO<sub>2</sub> and PM<sub>10</sub> ( $r = 0.59$ ) associations were attenuated when adjusted for each other, and a confounding or independent effect cannot be distinguished for either pollutant. NO<sub>2</sub> effects could be confounded by O<sub>3</sub> in the warm season, and interactions between O<sub>3</sub> and allergens have been reported ([U.S. EPA, 2013e](#)). However, NO<sub>2</sub> was associated with PEF after adjustment for O<sub>3</sub> ( $r = 0.40$ ) [([Correia-Deur et al., 2012](#)); [Table 5-17](#)].

In summary, the evidence does not clearly indicate whether NO<sub>2</sub> exposure independently induces allergy exacerbation. While there is evidence for effects on key events in the proposed mode of action, the limited evidence for effects on clinical events related to allergy exacerbation is inconclusive. Further, in the limited analysis of key copollutants, there is evidence for an effect of NO<sub>2</sub> on lung function decrements independent of CO measured at children's schools but uncertainty regarding confounding by PM<sub>2.5</sub> or the array of traffic-related copollutants that were not examined ([Appendix](#) to the ISA).

---

#### **5.2.4 Exacerbation of Chronic Obstructive Pulmonary Disease**

COPD is characterized by deterioration of lung tissue and airflow limitation. In exacerbation of COPD, episodes of reduced airflow, which can be indicated by decreases in lung function, can lead to symptoms such as cough, sputum production, and shortness of breath. Severe exacerbation can lead to ED visits or hospital admissions. This spectrum of outcomes comprises the majority of investigations of the effects of short-term NO<sub>2</sub> exposure on COPD exacerbation, and as described in the sections that follow, the consistency of findings from previous and recent studies varies among outcomes. A key early event in COPD exacerbation is pulmonary inflammation, which mediates narrowing of the airways and reduces airflow. As described in [Section 5.2.4.3](#), limited recent information does not show NO<sub>2</sub>-related increases in pulmonary inflammation in adults with COPD.

---

#### 5.2.4.1 Lung Function Changes and Respiratory Symptoms in Adults with Chronic Obstructive Pulmonary Disease

Evidence does not clearly indicate a relationship for NO<sub>2</sub> exposure with changes in lung function or respiratory symptoms in adults with COPD. Evidence is inconsistent in both controlled human exposure and epidemiologic panel studies, many of which examine both respiratory symptoms and lung function. Most of these studies were reviewed in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), and the only recent study, which is epidemiologic, does not support associations for ambient NO<sub>2</sub> concentrations with either respiratory symptoms or lung function decrements in adults with COPD.

##### Lung Function Changes

Epidemiologic studies recruited adults with COPD from clinics, and the nonrandom selection of the general population may produce study populations less representative of the COPD population. NO<sub>2</sub> exposures were assessed primarily as 24-h averages of central site NO<sub>2</sub> measurements, and results are equally inconsistent for NO<sub>2</sub> exposures assigned from one site or averaged from multiple city sites ([Table 5-18](#)). Most previous and recent epidemiologic studies of adults with COPD assessed lung function with unsupervised home measurements, and associations with ambient NO<sub>2</sub> concentrations were inconsistent among the various lung function parameters (e.g., FEV<sub>1</sub>, PEF) or NO<sub>2</sub> exposure lags (0-, 1-, 2-, or 2- to 7-day avg) examined ([Peacock et al., 2011](#); [Silkoff et al., 2005](#); [Higgins et al., 1995](#)). [Lagorio et al. \(2006\)](#) found an association between ambient NO<sub>2</sub> concentrations and FEV<sub>1</sub> ([Table 5-18](#)), with similar effects estimated for adults with COPD and asthma.

In addition to the inconsistent evidence for changes in lung function in adults with COPD, there is uncertainty regarding an independent association of NO<sub>2</sub> from that of copollutants. Studies did not examine a broad array of traffic-related copollutants, and inference about confounding is limited by potential differential exposure error for pollutants measured at central sites. [Lagorio et al. \(2006\)](#) found FEV<sub>1</sub> decrements in association with NO<sub>2</sub> but not PM<sub>2.5</sub>, which was moderately correlated with NO<sub>2</sub>. Only [Peacock et al. \(2011\)](#) conducted copollutant modeling, and the NO<sub>2</sub>-PEF effect estimate was attenuated with adjustment for BS. In contrast, the effect estimate for BS was relatively unchanged with adjustment for NO<sub>2</sub>. With respect to PM<sub>10</sub>, no association was found with FEV<sub>1</sub> ([Lagorio et al., 2006](#)), or the NO<sub>2</sub> association with PEF was attenuated with adjustment for PM<sub>10</sub> ([Peacock et al., 2011](#)).

**Table 5-18 Epidemiologic panel studies of adults with chronic obstructive pulmonary disease.**

Study Population Examined and Methodological Details	Oxide of Nitrogen Metrics Analyzed	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p><a href="#">†Peacock et al. (2011)</a> London, U.K., Oct 1995–Oct 1997 n = 28–94, ages 40–83 yr Repeated measures. Home PEF. Examined daily for 21–709 days. Recruitment from outpatient clinic. 75% follow-up. GEE adjusted for temperature, season. Lung function measures adjusted for indoor temperature and time spent outdoors.</p>	<p>NO<sub>2</sub>-central site 1-h max NO<sub>2</sub>, lag 1 day 1 city site Mean: 51.4 ppb 75th: 56 ppb</p>	<p>PEF: 0.17% (0.03, 0.32) PEF &gt;20% below predicted: OR: 1.0 (0.86, 1.2) Symptomatic fall in PEF: OR: 1.1 (0.97, 1.3)</p>	<p>Symptomatic fall in PEF With BS: 1.1 (0.84, 1.3) With PM<sub>10</sub>: 0.97 (0.81, 1.2) Correlations NR. 95% CI for BS also increased. No change in OR for PM<sub>10</sub> with NO<sub>2</sub> adjustment.</p>
<p><a href="#">Silkoff et al. (2005)</a> Denver, CO, Winters 1999–2000 and 2000–2001 n = 34 with COPD, mean age 66 yr, 75% severe COPD Repeated measures. Home PEF. Recruitment from outpatient clinics, research registries, advertisements. 93–96% diaries completed. Mixed effects model with random effect for subjects and adjusted for temperature, relative humidity, barometric pressure.</p>	<p>NO<sub>2</sub>-central site 24-h avg, lag 0, 1, 2 days 1 city site Means: 1999–2000: 16 ppb 2000–2001: 29 ppb 75th and Max: 1999–2000: 30, 54 ppb 2000–2001: 36, 54 ppb</p>	<p>No quantitative data. Negative, positive, and null associations with symptoms across NO<sub>2</sub> lags.</p>	<p>No copollutant model. Mixed positive, negative, null associations for PM<sub>2.5</sub>, PM<sub>10</sub>, O<sub>3</sub>.</p>
<p><a href="#">Desqueyroux et al. (2002)</a> Paris, France, Oct 1995–Mar 1996, Apr–Sept 1996 n = 39, severe COPD, mean age 67 yr Repeated measures. Recruitment from physicians' offices. No information on participation. GEE adjusted for FEV<sub>1</sub>, smoking, CO<sub>2</sub> pressure, oxygen treatment, dyspnea, temperature, humidity, season, holiday.</p>	<p>NO<sub>2</sub>-central site 24-h avg, lag 1–5 day avg Average of 15 city sites Means for Periods 1 &amp; 2 31.4, 26.1 ppb<sup>b</sup> Max for Periods 1 &amp; 2 68.1, 56.4 ppb<sup>b</sup></p>	<p>Physician visits for COPD exacerbation OR: 0.76 (0.28, 2.10)</p>	<p>with O<sub>3</sub>: 0.47 (0.02, 9.45) O<sub>3</sub> association robust to NO<sub>2</sub> adjustment. Correlations not reported. SO<sub>2</sub> and PM<sub>10</sub> not associated with COPD.</p>
<p><a href="#">Lagorio et al. (2006)</a> Rome, Italy, May–Jun, Nov–Dec 1999 n = 11, ages 40–64 yr, nonsmokers Repeated measures. Supervised spirometry. Examined 2/week for two 1-mo periods. Mean observations per subject = 15. Recruitment from outpatient clinic. Participation rate NR. GEE adjusted for season, temperature, humidity, beta-agonist use.</p>	<p>NO<sub>2</sub>-central site 24-h avg, lag 0 day Average of 5 city sites within 2 km of subjects' census tracts. Mean: 37.6 ppb<sup>b</sup> Max: 54.3 ppb<sup>b</sup></p>	<p>% predicted FEV<sub>1</sub>: –2.3 (–3.6, –1.0)</p>	<p>No copollutant model. Lung function associated with PM<sub>2.5</sub>, PM<sub>10</sub>. Moderate correlation with NO<sub>2</sub>. Spearman <i>r</i> = 0.43 for PM<sub>2.5</sub>, 0.45 for PM<sub>10</sub>.</p>

**Table 5-18 (Continued): Epidemiologic panel studies of adults with chronic obstructive pulmonary disease.**

Study Population Examined and Methodological Details	Oxide of Nitrogen Metrics Analyzed	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<a href="#">Harre et al. (1997)</a> Christchurch, New Zealand, Jun–Aug 1994 n = 40, ages 55–83 yr, nonsmokers Repeated measures. Home PEF. Recruitment from doctors' offices, COPD support group, advertisements. 66% participation. Log-linear model adjusted for day of study, temperature, wind speed, CO, PM <sub>10</sub> , SO <sub>2</sub> .	NO <sub>2</sub> -central site 24-h avg, lag 1 day Number of sites NR. Concentrations NR	PEF: -0.72% (-1.5, 0.07)	Only multipollutant model analyzed. PM <sub>10</sub> , CO, SO <sub>2</sub> not associated with PEF.
† <a href="#">Brüske (2014)</a> ; <a href="#">Bruske et al. (2010)</a> Erfurt, Germany, Oct 2001–May 2002 n = 38, ages 35–78 yr, all male, 53% also with asthma Repeated measures. Examined 2/mo for 6 mo. 381 observations after excluding concurrent fever or infection. Method of recruitment and COPD assessment and participation rate NR. Additive mixed models with random intercept for subject and adjusted for infection/antibiotic use in previous 2 weeks, long-term time trend, temperature, humidity as linear terms or penalized splines. Also evaluated confounding by barometric pressure and corticosteroid use.	NO <sub>2</sub> -central site 24-h avg, lag 0–23 h before blood collection 1 site 3.5 km from subjects' homes. Mean: 13.5 ppb <sup>b</sup> 75th: 16.6 ppb <sup>b</sup>	PMN: -8.0% (-18, 3.1) Lymphocytes: 8.4% (-5.0, 24)	PMN with UFP: 7.3% (-14, 34). Lymphocytes with UFP: 8.4% (-7.2, 27) CO associated with lymphocytes. NO <sub>2</sub> highly correlated with UFP and CO. Spearman <i>r</i> = 0.66, 0.78. No copollutant model for NO.
	NO-central site Mean: 10.8 ppb <sup>b</sup> 75th: 14.0 ppb <sup>b</sup>	PMN: -0.80% (-10, 9.9) Lymphocytes: 13% (-1.9, 23) NO <sub>2</sub> and NO reported not to be associated with eosinophils. No quantitative results.	

Note: More informative studies in terms of the outcome examined, exposure assessment method, and potential confounding considered are presented first.

Avg = average; Aug = August; BS = black smoke; CI = confidence interval; CO = carbon monoxide, Colorado; CO<sub>2</sub> = carbon dioxide; COPD = chronic obstructive pulmonary disease; Dec = December; FEV<sub>1</sub> = forced expiratory volume in 1 second; GEE = generalized estimating equations; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; O<sub>3</sub> = ozone; OR = odds ratio; PEF = peak expiratory flow; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 μm; PMN = polymorphonuclear cells; SO<sub>2</sub> = sulfur dioxide; UFP = ultrafine particles; UK = United Kingdom.

<sup>a</sup>Effect estimates were standardized to a 20-ppb increase in 24-h avg NO<sub>2</sub> or a 30-ppb increase 1-h max NO<sub>2</sub>.

<sup>b</sup>Concentrations converted from μg/m<sup>3</sup> to ppb using the conversion factor of 0.532 assuming standard temperature (25°C) and pressure (1 atm).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

Similar to the epidemiologic studies, the controlled human exposure studies, which were reviewed in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), have mixed results regarding decrements in lung function with NO<sub>2</sub> exposure. Studies examined older adults diagnosed with COPD, and most incorporated exercise in the exposure period to assess lung function during varying physiological conditions ([Table 5-19](#)). Effects are

inconsistent with 1- to 4-hour exposures in the range of 200 to 500 ppb NO<sub>2</sub>, with decrements in FVC and FEV<sub>1</sub> observed following exposure to 300 ppb NO<sub>2</sub> ([Vagaggini et al., 1996](#); [Morrow et al., 1992](#)) but not 400 or 500 ppb NO<sub>2</sub> ([Gong et al., 2005](#); [Linn et al., 1985a](#)). No effect was observed after exposure to 1,000 or 2,000 ppb NO<sub>2</sub> ([Linn et al., 1985a](#)). Furthermore, [Gong et al. \(2005\)](#) did not find NO<sub>2</sub> to enhance lung function decrements induced by PM exposures.

## Respiratory Symptoms

The limitations and uncertainties described above for the evidence base relating NO<sub>2</sub> exposure to lung function changes in adults with COPD largely apply to the evidence base for respiratory symptoms. Most epidemiologic panel studies recruited adults with COPD from outpatient clinics or doctors' offices. Association between ambient NO<sub>2</sub> and respiratory symptoms are either null ([Peacock et al., 2011](#); [Desqueyroux et al., 2002](#)) or inconsistent across the lags of exposure or range of outcomes examined [([Silkoff et al., 2005](#); [Harre et al., 1997](#)); [Table 5-18](#)]. Results are equally inconsistent for individual symptoms of cough, wheeze, dyspnea, total symptoms, and medication use ([Table 5-18](#)). No pattern of association was found for either 24-h avg or 1-h max NO<sub>2</sub> or for a particular lag day of exposure examined (0, 1, or longer). Most of these studies assigned exposures from a single central site, but associations with symptoms and medication were inconsistent for NO<sub>2</sub> assigned from the closest site ([Desqueyroux et al., 2002](#)) or site within 5 km ([Harre et al., 1997](#)).

In the studies that found associations with specific symptoms or lags of NO<sub>2</sub>, associations also were found with PM<sub>2.5</sub> and the traffic-related pollutants BS and CO ([Peacock et al., 2011](#); [Silkoff et al., 2005](#); [Harre et al., 1997](#)). Among adults in New Zealand, an increase in 24-h avg NO<sub>2</sub> was associated with an increase in inhaler use in a multipollutant model with CO, PM<sub>10</sub>, and SO<sub>2</sub> ([Harre et al., 1997](#)), which has weak implications because of multicollinearity. A recent study of adults in London, U.K. found that associations between Lag Day 1 of 1-h max NO<sub>2</sub> and dyspnea were null with adjustment for BS or PM<sub>10</sub> ([Peacock et al., 2011](#)), but the potential differential exposure error for pollutants measured at central sites limits inference from the results. Thus, in the few associations found between increases in ambient NO<sub>2</sub> concentration and increases in symptoms or medication among adults with COPD, there is uncertainty as to whether ambient NO<sub>2</sub> has effects independent of other traffic-related pollutants. The equally inconsistent findings from controlled human exposure studies ([Table 5-19](#)) do not address uncertainties in the epidemiologic evidence base. Some studies reported no change in symptom score in adults with COPD ([Gong et al., 2005](#); [Morrow et al., 1992](#)), though some studies reported small, but statistically significant increases in symptom scores during NO<sub>2</sub> exposures of 300–2,000 ppb for 1 hour with exercise ([Vagaggini et al., 1996](#); [Linn et al., 1985a](#)).

**Table 5-19 Characteristics of controlled human exposure studies of adults with chronic obstructive pulmonary disease.**

Study	Disease Status; Sample Size; Sex; Age (mean ± SD)	Exposure Details	Endpoints Examined
<a href="#">Morrow et al. (1992)</a>	COPD; n = 13 M, 7 F (14 current smokers, 6 former smokers); 59.9 ± 7.0 yr Healthy; n = 10 M, 10 F (13 never smokers, 4 former smokers, 3 current smokers)	300 ppb for 4 h; Three 7-min periods of exercise at $\dot{V}_E = \sim 4$ times resting	Pulmonary function tests before, during, and after exposure and 24-h post-exposure. Symptoms before, during, and after exposure and 24-h post-exposure.
<a href="#">Vagaggini et al. (1996)</a>	COPD; n = 7 M; 58 ± 12 yr Healthy; n = 7 M; 34 ± 5 yr	300 ppb for 1 h; Exercise at $\dot{V}_E = 25$ L/min	Pulmonary function tests before and 2 h after exposure. Symptoms before and 2 h after exposure.
<a href="#">Gong et al. (2005)</a>	COPD; n = 9 M, 9 F; 72 ± 7 yr Healthy; n = 2 M, 4 F; 68 ± 11 yr	(1) 400 ppb NO <sub>2</sub> for 2 h (2) 200 µg/m <sup>3</sup> CAPs for 2 h (3) 400 ppb NO <sub>2</sub> + 200 µg/m <sup>3</sup> CAPs for 2 h (1–3) Exercise 15 min on/15 min off at $\dot{V}_E = \sim 2$ times resting	Pulmonary function tests before and immediately after exposure and 4 h and 22-h post-exposure. Symptoms before, during, and after exposure.
<a href="#">Linn et al. (1985a)</a>	COPD; n = 13 M, 9 F (1 never smoker, 13 former smokers, 8 current smokers); 60.8 ± 6.9 yr	500, 1,000, or 2,000 ppb for 1 h; Exercise 15 min on/15 min off $\dot{V}_E = 16$ L/min	Pulmonary function tests before, during, and after exposure. Symptoms before, during, immediately after, 1 day after, and 1 week after exposure.

CAPs = concentrated ambient particles; COPD = chronic obstructive pulmonary disease; F = female; h = hours; L/min = liters per minute; M = male; min = minutes; NO<sub>2</sub> = nitrogen dioxide; SD = standard deviation; yr = years.

#### 5.2.4.2 Hospital Admissions and Emergency Department Visits for Chronic Obstructive Pulmonary Disease

In contrast with the inconsistent evidence for the effects of short-term NO<sub>2</sub> exposure on lung function changes and respiratory symptoms in adults with COPD ([Section 5.2.4.1](#)), epidemiologic evidence is consistent for NO<sub>2</sub>-related increases in hospital admissions and ED visits for COPD. The few studies of COPD hospital admissions or ED visits evaluated in the 2008 ISA for Oxides of Nitrogen provided initial evidence of a positive association between short-term NO<sub>2</sub> exposures and COPD hospital admissions and ED

visits, with more studies focusing on hospital admissions ([Figure 5-9](#) and [Table 5-21](#)). However, these studies were more limited in their evaluation of potential confounders and other factors that may modify the relationships of NO<sub>2</sub> exposure with COPD hospital admissions and ED visits. Consistent with the 2008 ISA for Oxides of Nitrogen, a few recent studies have examined COPD hospital admissions and ED visits and generally add to the initial evidence of a positive association observed in the 2008 ISA for Oxides of Nitrogen. The air quality characteristics of the study cities and the exposure assignment approach used in each study evaluated in this section are presented in [Table 5-20](#). Other recent studies of COPD hospital admissions and ED visits are not the focus of this evaluation, as detailed in [Section 5.2.2.4](#), but the full list of these studies and study details, can be found in [Supplemental Table S5-3 \(U.S. EPA, 2015h\)](#).

**Table 5-20 Mean and upper percentile concentrations of nitrogen dioxide in studies of hospital admission and emergency department visits for chronic obstructive pulmonary disease.**

Study	Location Years	Exposure Assignment	Metric	Mean Concentration (ppb)	Upper Percentile of Concentrations (ppb)	Copollutant Examination
<b>Hospital Admissions</b>						
<a href="#">†Faustini et al. (2013)</a>	6 Italian cities (2001–2005)	Average of NO <sub>2</sub> concentrations over all monitors within each city. Number of NO <sub>2</sub> monitors in each city ranged from 1–5 <sup>a</sup>	24-h avg	24.1–34.6	NR	Correlations ( <i>r</i> ), across cities: PM <sub>10</sub> : 0.22–0.79 Copollutant models: PM <sub>10</sub>
<a href="#">Ko et al. (2007a)</a>	Hong Kong, China (2000–2004)	Average of NO <sub>2</sub> concentrations across 14 monitors.	24-h avg	27.2	75th: 34.0 Max: 83.8	Correlations ( <i>r</i> ): PM <sub>2.5</sub> : 0.44 PM <sub>10</sub> : 0.40 SO <sub>2</sub> : 0.66 O <sub>3</sub> : 0.34 Copollutant models: none
<a href="#">†Qiu et al. (2013b)</a>	Hong Kong, China (1998–2007)	Of 14 monitors, average NO <sub>2</sub> based on data from 10 monitors. 3 monitors sited near roads and 1 monitor on a remote island were excluded.	24-h avg	30.9	NR	Correlations ( <i>r</i> ): NR Copollutant models: PM <sub>10</sub>
<a href="#">†Wong et al. (2009)</a>	Hong Kong, China (1996–2002)	Average of NO <sub>2</sub> concentrations across 8 monitors.	24-h avg	31.2	75th: 37.0 Max: 89.4	Correlations ( <i>r</i> ): NR Copollutant models: none

**Table 5-20 (Continued): Mean and upper percentile concentrations of nitrogen dioxide in studies of hospital admission and emergency department visits for chronic obstructive pulmonary disease.**

Study	Location Years	Exposure Assignment	Metric	Mean Concentration (ppb)	Upper Percentile of Concentrations (ppb)	Copollutant Examination
<b>Emergency Department Visits</b>						
<a href="#">†Stieb et al. (2009)</a>	7 Canadian cities (1992–2003)	Average NO <sub>2</sub> concentrations from all monitors in each city. Number of NO <sub>2</sub> monitors in each city ranged from 1–14.	24-h avg	9.3–22.7	75th: 12.3–27.6	Correlations ( <i>r</i> ) only reported by city and season. Copollutant models: none
<a href="#">†Arbex et al. (2009)</a>	São Paulo, Brazil (2001–2003)	Average of NO <sub>2</sub> concentrations across 4 monitors.	1-h max	63.0	75th: 78.6 Max: 204.6	Correlations ( <i>r</i> ): PM <sub>10</sub> : 0.60 SO <sub>2</sub> : 0.63 CO: 0.56 Copollutant models: none

avg = average; CO = carbon monoxide; max = maximum; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; O<sub>3</sub> = ozone; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm; SO<sub>2</sub> = sulfur dioxide.

<sup>a</sup>Monitoring information obtained from [Colais et al. \(2012\)](#).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

## Hospital Admissions

Consistent with the 2008 ISA for Oxides of Nitrogen, relatively few recent studies have focused on the outcome of COPD hospital admissions, but these studies build upon the initial evidence of a positive association (Figure 5-9). [Faustini et al. \(2013\)](#) examined the relationship between short-term air pollution exposures and respiratory-related hospital admissions, including COPD, specifically on the adult population (i.e., individuals 35 years of age and older) in six Italian cities. In a time-series analysis, the authors examined the lag structure of associations through single-day lags as well as cumulative lags using cubic polynomial distributed lags to identify whether the NO<sub>2</sub> effect on respiratory-related hospital admissions was immediate (lag 0, lag 0–1 days), delayed (lag 2–5 days), or prolonged (lag 0–3, 0–5 days). For COPD hospital admissions, the authors observed stronger evidence for immediate (lag 0: 4.6% [95% CI: 0.64, 8.6] for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations) NO<sub>2</sub> effects on COPD hospital admissions. Smaller associations were observed when examining prolonged effects, (3.3% for lag 0–3 days and 3.1% for lag 0–5 days). There was no evidence for delayed effects (lag 2–5 days). In a copollutant model with PM<sub>10</sub> at lag 0, the association between NO<sub>2</sub> and COPD hospital admissions remained relatively unchanged compared to the single-pollutant model results (3.9% [95% CI: -1.7, 9.8]).

In a study conducted in Hong Kong, China from 2000–2004, [Ko et al. \(2007a\)](#) also examined the lag structure of associations between short-term air pollution exposures and COPD hospital admissions. In analyses of both single-day lags and multiday averages, [Ko et al. \(2007a\)](#) observed the largest magnitude of an association at lags ranging from 0–3 to 0–5 days (10.1% [95% CI: 8.5, 12.2] for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations at both 0–3 and 0–5 day lags). These associations are larger in magnitude than those reported by [Qiu et al. \(2013b\)](#) at lag 0–3 (4.7% [95% CI: 3.3, 6.2] for a 20 ppb increase in 24-h avg NO<sub>2</sub> concentrations) for a study also conducted in Hong Kong, China, but for a longer duration (1998–2007). Although [Ko et al. \(2007a\)](#) reported associations larger in magnitude for multiday averages, the authors also observed a positive association across single-day lags, with lag 0 having one of the stronger associations (3.4% [95% CI: 1.9, 5.0]), which is of similar magnitude to the lag 0 effect observed in [Faustini et al. \(2013\)](#). [Ko et al. \(2007a\)](#) only examined the potential confounding effects of copollutants through the use of three- and four-pollutant models, which are difficult to interpret. In comparisons of the single-pollutant results for NO<sub>2</sub> and the other pollutants examined (O<sub>3</sub>, PM<sub>2.5</sub>, and PM<sub>10</sub>), similar patterns of associations were observed across pollutants. Additionally, [Ko et al. \(2007a\)](#) examined whether there was evidence of seasonal differences in NO<sub>2</sub>-COPD hospital admission associations. When using the warm season as the referent, the authors reported evidence of larger

associations in the cold season (i.e., December to March). These results are consistent with the results of [Ko et al. \(2007b\)](#) for asthma ([Section 5.2.2.4](#)) and support potential differences in seasonal associations by geographic location.

In addition to examining the association between short-term air pollution exposures and COPD hospital admissions, [Qiu et al. \(2013b\)](#) also examined whether air pollution associations with COPD hospital admissions were modified by the interaction between season and humidity. In models stratifying by both season (warm: May–October; cold: November–April) and humidity (high or humid:  $\geq 80\%$ ; low or dry:  $< 80\%$ ) the authors found larger NO<sub>2</sub> associations in the cool season and high humidity days (5.6 and 6.3%, respectively) compared to the warm season and low humidity days (3.8 and 4.6%, respectively) for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations at lag 0–3 days. When examining the joint effect of season and humidity, [Qiu et al. \(2013b\)](#) found that the magnitude of the association was larger when season and humidity were considered together. Specifically, the largest associations were observed for the combination of warm season and humid days (7.3% [95% CI: 3.7, 11.1]; lag 0–3) and cool season and dry days (9.3% [95% CI: 6.2, 12.5]; lag 0–3). In a series of copollutant models with PM<sub>10</sub> and all combinations of season and humidity, NO<sub>2</sub>-COPD hospital admission associations were attenuated. Null associations were observed in models for warm season plus dry days and cool season plus humid days. These results further highlight the different seasonal patterns in NO<sub>2</sub> associations that have been reported across different geographic areas as well as the potential influence of different weather conditions on NO<sub>2</sub>-related health effects.

### **Emergency Department Visits**


As in the 2008 ISA for Oxides of Nitrogen, relatively few studies have examined the relationship between short-term NO<sub>2</sub> exposures and ED visits, compared to hospital admissions. In the seven Canadian cities discussed previously, consistent with the asthma ED visits results, [Stieb et al. \(2009\)](#) did not find evidence of associations between 24-h avg NO<sub>2</sub> and COPD ED visits at individual lags ranging from 0 days (0.1% [95% CI: -6.1, 6.8] for a 20-ppb increase in 24-h avg NO<sub>2</sub>) to 2 days (-5.2% [95% CI: -12.4, 2.7]). Additionally, there was no evidence of consistent associations between any pollutant and COPD ED visits at subdaily time scales (i.e., 3-h avg of ED visits versus 3-h avg pollutant concentrations).

[Arbex et al. \(2009\)](#) also examined the association between COPD and several ambient air pollutants, including NO<sub>2</sub>, in a single-city study conducted in São Paulo, Brazil, for individuals over age 40 years. Associations between NO<sub>2</sub> exposure and COPD ED visits were examined in both single-day lags (0 to 6 days) and a polynomial distributed lag

model (0–6 days). However, for NO<sub>2</sub>, only those results that were statistically significant were presented, that is, for individuals 65 years of age and older for lag 5 days (4.3% [95% CI: 0.5, 8.3] for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations) and a distributed lag of 0–5 days (9.6% [95% CI: 0.2, 19.9]). The authors did not analyze copollutant models but reported moderate correlations between NO<sub>2</sub> and PM<sub>10</sub> ( $r = 0.60$ ), SO<sub>2</sub> ( $r = 0.63$ ), and CO ( $r = 0.56$ ).

### **Summary of Chronic Obstructive Pulmonary Disease Hospital Admissions and Emergency Department Visits**

In combination with those studies evaluated in the 2008 ISA for Oxides of Nitrogen, recent studies add to the growing body of literature that has examined the association between short-term NO<sub>2</sub> exposures and COPD hospital admissions and ED visits. Overall, these studies have reported consistent positive associations with evidence of NO<sub>2</sub>-COPD hospital admissions and ED visits occurring immediately (lag 0) as well as a few days after exposure (average of lags up to 5 days) ([Figure 5-9](#)). However, caution should be used in inferring the independent effects of NO<sub>2</sub> exposure due to the relative sparseness of copollutant model analyses as well as the high correlation often observed between NO<sub>2</sub> and other traffic-related pollutants (e.g., CO, PM<sub>2.5</sub>). Additionally, studies that have focused on COPD hospital admissions and ED visits have not thoroughly examined potential seasonal differences in associations; however, initial evidence suggests that the combination of season and weather conditions, such as humidity, may have a larger effect on NO<sub>2</sub>-COPD hospital admission associations than either individually. Additionally, these studies have provided limited information on individual- or population-level factors that could modify the NO<sub>2</sub>-hospital-admission or ED visit relationship, or the shape of the C-R relationship.



Note: CA = California; CAN = Canada; CI = confidence interval; DL =distributed lag; ED = emergency department; GA = Georgia; LA = Los Angeles. Black = studies from the 2008 Integrated Science Assessment for Oxides of Nitrogen, red = recent studies. Effect estimates are standardized to a 20-ppb increase in 24-h avg nitrogen dioxide and 30-ppb increase in 1-h max nitrogen dioxide.

**Figure 5-9 Percentage increase in chronic obstructive pulmonary disease hospital admissions and emergency department visits in relation to nitrogen dioxide concentrations.**

**Table 5-21 Corresponding risk estimate for studies presented in Figure 5-9.**

Study	Location	Age	Averaging Time	Lag	% Increase (95% CI)
<b>Hospital Admissions</b>					
<a href="#">Ko et al. (2007a)</a>	Hong Kong, China	All	24-h avg	0–3	10.1 (8.5, 12.2)
† <a href="#">Qiu et al. (2013b)<sup>a</sup></a>	Hong Kong, China	All	24-h avg	0–3	2.2 (0.8, 4.4)
† <a href="#">Wong et al. (2009)<sup>a</sup></a>	Hong Kong, China	All	24-h avg	0–1	7.1 (5.1, 9.1)
		65+	24-h avg	0–1	4.6 (2.4, 6.8)
† <a href="#">Yang et al. (2005)</a>	Vancouver, BC, Canada	65+	24-h avg	1	19.0 (4.0, 37.0)
† <a href="#">Moolgavkar (2003)</a>	Cook County, IL	65+	24-h avg	0	4.9 (1.6, 8.2)
	LA County, CA	65+	24-h avg	0	3.6 (2.8, 4.5)
† <a href="#">Faustini et al. (2013)</a>	6 Italian cities	35+	24-h avg	0–5 DL	3.1 (–2.6, 9.2)
<b>Emergency Department Visits</b>					
<a href="#">Peel et al. (2005)</a>	Atlanta, GA	All	1-h max	0–2	5.3 (0.9, 9.9)
† <a href="#">Stieb et al. (2009)</a>	7 Canadian cities	All	24-h avg	0	0.1 (–6.1, 6.8)
† <a href="#">Arbex et al. (2009)</a>	São Paulo, Brazil	65+	24-h avg	0–5 DL	9.6 (0.2, 19.9)

avg = average; BC = British Columbia; CA = California; CI = confidence interval; DL = distributed lag; GA = Georgia; IL = Illinois.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

#### 5.2.4.3 Subclinical Effects Underlying Chronic Obstructive Pulmonary Disease—Pulmonary Inflammation

Exacerbation of COPD can be precipitated by increases in airway responsiveness and pulmonary inflammation. While there is some supporting evidence for an effect of NO<sub>2</sub> exposure in initiation of inflammation (Sections 4.3.2.3 and 4.3.2.1), the effects of NO<sub>2</sub> on airway responsiveness and inflammation are not well characterized in adults with COPD. Thus, little information is available to propose a mode of action that would

support the associations observed between ambient NO<sub>2</sub> concentrations and hospital admissions and ED visits for COPD (Section 5.2.4.1). In a recent epidemiologic study, neither ambient NO<sub>2</sub> nor NO was associated with indicators of inflammation such as increases in the numbers of blood eosinophils or lymphocytes in adults with COPD consistently among Lag Days 0, 1, and 2 [(Bruske et al., 2010); Table 5-18]. NO<sub>2</sub> at Lag Day 0 was associated with an increase in neutrophils only with adjustment for UFP. However, the 95% CI was wide, indicating an imprecise association. Further limiting inference from the copollutant model, NO<sub>2</sub> and UFP were measured at central sites and were highly correlated (Spearman  $r = 0.68$ ). UFP and OC were associated with decreases in neutrophils, of which the relation to COPD exacerbation is not clear. Vagaggini et al. (1996) found no changes in either adults with COPD or healthy adults in inflammatory cell counts in sputum following a 1-hour exposure to 300 ppb NO<sub>2</sub>.

---

#### 5.2.4.4 Summary of Exacerbation of Chronic Obstructive Pulmonary Disease

Evidence for the effects of short-term NO<sub>2</sub> exposure on COPD exacerbation is inconsistent among the various outcomes examined and across scientific disciplines. In epidemiologic studies, short-term increases in ambient NO<sub>2</sub> concentration are consistently associated with increases in hospital admissions and ED visits for COPD (Section 5.2.4.2). However, NO<sub>2</sub>-related increases in respiratory symptoms or decreases in lung function in adults with COPD are not consistently observed in epidemiologic or controlled human exposure studies (Section 5.2.4.1). Further, a proposed mode of action for NO<sub>2</sub> effects on COPD exacerbation is not clear. In limited examination, an epidemiologic and controlled human exposure study do not indicate NO<sub>2</sub>-related increases in inflammation in adults with COPD (Section 5.2.4.3). Epidemiologic studies assigned NO<sub>2</sub> exposure as central site ambient concentrations (average of multiple monitors, nearest site), and many found associations with PM<sub>2.5</sub> and with the traffic-related pollutants CO, BS, and UFP. Epidemiologic studies have not adequately informed the potential for confounding by PM<sub>2.5</sub> or traffic-related copollutants, particularly for the associations observed between NO<sub>2</sub> and COPD hospital admissions and ED visits. Because of the inconsistent evidence across disciplines for effects on clinical indications of COPD exacerbation and the lack of evidence for effects on underlying mechanisms, there is uncertainty regarding a relationship between short-term NO<sub>2</sub> exposure and COPD exacerbation.

---

## 5.2.5 Respiratory Infection

The respiratory tract is protected from exogenous pathogens and particles through various lung host defense mechanisms that include mucociliary clearance, particle transport and detoxification by alveolar macrophages, and innate and adaptive immunity. The 2008 ISA for Oxides of Nitrogen reported clear evidence from animal toxicological studies for NO<sub>2</sub>-induced susceptibility to bacterial or viral infection with some coherence with results from controlled human exposure and epidemiologic studies ([U.S. EPA, 2008c](#)). There is some mechanistic support for these observations, with NO<sub>2</sub>-induced impairments in alveolar macrophage (AM) function found in some but not all animal toxicological studies. Effects on mucociliary clearance and activity were not in a consistent direction, but the exact mechanism by which mucociliary clearance could impair host defense is not well characterized. Recent contributions to the evidence base are limited to epidemiologic studies. These studies show associations between increases in ambient NO<sub>2</sub> concentrations and increases in hospital admissions and ED visits for respiratory infections but do not consistently show associations with respiratory infections reported or diagnosed in children.

---

### 5.2.5.1 Susceptibility to Bacterial or Viral Infection in Experimental Studies

A large body of evidence, provided by studies reviewed in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), demonstrates increased susceptibility of rodents to viral or bacterial infection following short-term NO<sub>2</sub> exposure. These studies used a variety of experimental approaches but in most cases included an infectivity model of exposing animals to NO<sub>2</sub> or filtered air and then combining treatment groups for a brief exposure to an aerosol of a viable agent, such as *Streptococcus zooepidemicus*, *Streptococcus pyogenes*, *Staphylococcus aureus*, and *Klebsiella pneumoniae*. Toxicological studies measured mortality over a specified number of days following the challenge, and both toxicological and controlled human exposure studies examined endpoints such as bacterial clearance and viral inactivation by cells isolated from BAL or nasal fluid ([Table 5-22](#)). While there are differences in sensitivity across species to various infectious organisms, host defense mechanisms are shared, and the infectivity model is well accepted as an indicator of impaired or weakened pulmonary defense.

#### Mortality from Bacterial Infection

Compared to clear air exposure, short-term exposures of mice to 500 ppb NO<sub>2</sub> did not increase mortality following bacterial infection ([Ehrlich, 1980](#); [Ehrlich et al., 1979](#); [Gardner et al., 1979](#)). Each of these studies demonstrated that exposures of 500 ppb NO<sub>2</sub>

increased mortality or decreased survival time with long-term exposures (>1 month), but higher concentrations of 1,500 to 5,000 ppb were required to increase mortality due to bacterial infection for short-term exposures. In such examinations of the relationship between NO<sub>2</sub> concentration and time, concentration was found to be more important than time in determining mortality due to bacterial infection ([Ehrlich et al., 1979](#); [Gardner et al., 1979](#)). Other studies also reported bacterial infection-related mortality or shorter survival time in mice in response to NO<sub>2</sub> exposures (3 hours) of 2,000 or 3,000 ppb ([Sherwood et al., 1981](#); [Illing et al., 1980](#); [Ehrlich et al., 1977](#)), but 2-hour exposures to NO<sub>2</sub> at concentrations less than 5,000 ppb did not increase mortality in [Purvis and Ehrlich \(1963\)](#).

**Table 5-22 Characteristics of experimental studies of susceptibility to infection.**

Study	Species (Strain); Sample Size; Sex; Age	Exposure Details	Endpoints Examined
<b>Mortality from Infection</b>			
<a href="#">Ehrlich (1980)</a>	(1,2) Mice; (3) Mice, hamsters, and squirrel monkeys; n ≥ 88/group; 6–8 weeks	(1) 500 ppb NO <sub>2</sub> continuously for 1 week–1 yr (2) 1,500 ppb NO <sub>2</sub> continuously for 2 h–3 mo (3) 1,500–50,000 ppb NO <sub>2</sub> for 2 h (1–3) <i>Klebsiella pneumoniae</i> challenge immediately after exposure.	(1–3) Mortality
<a href="#">Ehrlich et al. (1979)</a>	Mice (CD2 F1, Cd-1); n = 99–127/group; F; 6–8 weeks	(1) 500 ppb NO <sub>2</sub> 3 h/day, 5 days/week for 1 mo (2) 100 ppb NO <sub>2</sub> continuously + 500 ppb 3/h day, 5 days/week for 1 mo (1–2) <i>Streptococcus pyogenes</i> challenge immediately after exposure.	(1–2) Mortality
<a href="#">Gardner et al. (1979)</a>	Mice (Swiss albino); n = 20/group; F; age NR	(1) 500 ppb NO <sub>2</sub> continuously for 7 days–1 yr (2) 1,500 ppb NO <sub>2</sub> continuously for 2 h–21 days (3) 1,500 ppb NO <sub>2</sub> 7 h/day for 7 h–11 days (3) 3,500 ppb NO <sub>2</sub> continuously for 30 min–16 days (4) 3,500 ppb NO <sub>2</sub> 7 h/day for 7 h–13 days (1–4) <i>Streptococcus pyogenes</i> challenge immediately after exposure.	Mortality

**Table 5-22 (Continued): Characteristics of experimental studies of susceptibility to infection.**

Study	Species (Strain); Sample Size; Sex; Age	Exposure Details	Endpoints Examined
<a href="#">Ehrlich et al. (1977)</a>	Mice (CF-1); n = 5-88/group; F; 5-8 weeks	0, 1,500, 2,000, 3,500, or 5,000 ppb NO <sub>2</sub> for 3 h <i>Streptococcus pyogenes</i> challenge immediately after exposure.	Mortality
<a href="#">Iling et al. (1980)</a>	Mice (CD-1); n = 16/group; F; 5-6 weeks	1,000 ppb, 3,000 ppb NO <sub>2</sub> , or air for 3 h; With or without continuous exercise; <i>Streptococcus pyogenes</i> challenge immediately after exposure.	Mortality after <i>Streptococcus pyogenes</i> challenge.
<a href="#">Purvis and Ehrlich (1963)</a>	Mice (Swiss Webster and albino); n > 25/group; sex and age NR	1,500, 2,500, 3,500, or 5,000 ppb NO <sub>2</sub> for 2 h; <i>Klebsiella pneumoniae</i> challenge 0-27 h post-exposure.	Mortality
<a href="#">Graham et al. (1987)</a>	Mice (CD-1); n = 5-12/group; sex NR; 4-6 weeks	(1) 4,500 ppb NO <sub>2</sub> for 1, 3.5, and 7 h (2) 1,500 ppb NO <sub>2</sub> continuously with a daily spike of 4,500 ppb for 1, 3.5, and 7 h; (1-2) <i>Streptococcus zooepidemicus</i> challenge immediately and 18 h after exposure.	Mortality
<b>Bacterial Clearance and Virus Inactivation</b>			
<a href="#">Davis et al. (1991)</a>	Mice (C57BL/6N); 8-10 weeks; n = 6/group	0, 500, 1,000, 2,000, or 5,000 ppb NO <sub>2</sub> for 4 h; <i>Mycoplasma pulmonis</i> challenge immediately after exposure.	Bacterial clearance, bactericidal activity.
<a href="#">Parker et al. (1989)</a>	Mice (C57BL/6N and C3H/HeN); 6-10 weeks	0 and 5,000 ppb NO <sub>2</sub> for 4 h; <i>Mycoplasma pulmonis</i> challenge immediately after exposure.	Histopathological evaluation, bacterial infection and clearance 4 h up to 7 days post-challenge, BAL fluid cell counts.
<a href="#">Jakab (1988)</a>	Mice (Swiss); n = 6-10/group; F; age NR	0, 2,500, 4,000, or 5,000 ppb NO <sub>2</sub> for 4 h Challenge with <i>Staphylococcus aureus</i> , <i>Proteus mirabilis</i> , or <i>Pasteurella pneumotropica</i> immediately before exposure, after exposure, or in between two NO <sub>2</sub> exposures	Bactericidal activity immediately after bacteria and NO <sub>2</sub> exposure or 4 hours after NO <sub>2</sub> and bacteria exposure.
<a href="#">Sherwood et al. (1981)</a>	Mice (Swiss albino); n = 8-24/group; M; age NR	1,000 ppb NO <sub>2</sub> for 24 and 48 h; <i>Streptococcus</i> (Group C) challenge immediately after exposure.	Bacterial counts 0-48 h post-challenge, bacterial clearance, histopathological evaluation, mortality.

**Table 5-22 (Continued): Characteristics of experimental studies of susceptibility to infection.**

Study	Species (Strain); Sample Size; Sex; Age	Exposure Details	Endpoints Examined
<a href="#">Goldstein et al. (1974)</a>	Mice (Swiss albino); n = 30/group; M; age NR	(1) 1,740 ppb NO <sub>2</sub> + 110 ppb O <sub>3</sub> (2) 1,490 ppb NO <sub>2</sub> + 200 ppb O <sub>3</sub> (3) 2,300 ppb NO <sub>2</sub> + 200 ppb O <sub>3</sub> (4) 1,780 ppb NO <sub>2</sub> + 270 ppb O <sub>3</sub> (5) 4,180 ppb NO <sub>2</sub> + 210 ppb O <sub>3</sub> (1-5) 17 h; <i>Staphylococcus aureus</i> challenge immediately after exposure.	Bacterial counts, bactericidal activity, and bacterial clearance 0 h and 4 h after challenge.
<a href="#">Goldstein et al. (1973)</a>	Mice (Swiss albino); n = 30/group; M; age NR	(1) <i>Staphylococcus aureus</i> challenge immediately before exposure; 0, 1,900, and 3,800 ppb NO <sub>2</sub> for 4 h (2) <i>Staphylococcus aureus</i> challenge immediately after exposure; 0, 1,000, or 2,300 ppb NO <sub>2</sub> for 17 h;	(1) Bacterial counts and bactericidal activity 5 h after challenge (i.e., 1 h after exposure). (2) Bacterial counts and bactericidal activity 0 h and 4 h after challenge.
<a href="#">Frampton et al. (2002)</a>	Human; (1,2) n = 12 M, 9 F; F = 27.1 ± 4.1 yr M = 26.9 ± 4.5 yr	(1) 600 ppb for 3 h, (2) 1,500 ppb for 3 h; (1,2) Exercise 10 min on/20 min off at $\dot{V}_E = 40$ L/min	Viral titers in AM and bronchial epithelial cells after influenza and RSV challenge.
<a href="#">Frampton et al. (1989)</a>	Human; (1) n = 7 M, 2 F; 30 yr (range: 24-37) (2) n = 11 M, 4 F; 25 yr (range: 19-37)	(1) 600 ppb for 3 h, (2) Three 15-min peak exposures to 2,000 ppb with continuous 500 ppb for 3 h; (1,2) Exercise 10 min on/20 min off at $\dot{V}_E = \sim 4$ times resting	Inactivation of influenza virus by BAL cells.
<a href="#">Goings et al. (1989)</a>	Human; (1) n = 44 (2) n = 43 (3) n = 65; sex NR; range: 18-35 yr	(1) 2,000 ppb for 2 h (2) 3,000 ppb for 2 h (3) 1,000 or 2,000 ppb for 2 h	Nasal wash virus isolation and count 4 days after virus administration. Serum and nasal wash antibody response 4 weeks after virus administration.

AM = alveolar macrophage; BAL = bronchoalveolar fluid; F = female; h = hour; IL = interleukin; L/min = liters per minute; M = male; min = minutes; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; O<sub>3</sub> = ozone; ppb = parts per billion; RSV = respiratory syncytial virus; SD = standard deviation; yr = years.

Most studies in mice examined continuous NO<sub>2</sub> exposures, but there is no indication that peak exposures superimposed on a lower continuous background level of NO<sub>2</sub> alter susceptibility to infection. Compared to clean air exposure, 4,500 ppb NO<sub>2</sub> spikes alone and the spikes superimposed on a 1,500 ppb NO<sub>2</sub> background exposure similarly increased mortality when infection occurred immediately after NO<sub>2</sub> exposure ([Graham et al., 1987](#)). Mortality increased in proportional to duration of the 4,500 ppb spike from 1 to 3.5 to 7 hours. In mice challenged 18 hours after NO<sub>2</sub> exposure, increases in mortality were statistically significant only with 3.5- and 7-hour exposures to 4,500 ppb NO<sub>2</sub> (combining groups with spike alone and with 1,500 background NO<sub>2</sub> exposure).

Limited analysis indicates that effects of NO<sub>2</sub> exposure on mortality from infection may differ among species. Increases in *K. pneumoniae* infection mortality were observed in mice after a 2-hour exposure to 3,500 ppb NO<sub>2</sub> but in hamsters and squirrel monkeys only at higher than ambient-relevant NO<sub>2</sub> concentrations (greater than 35,000 ppb and 50,000 ppb, respectively) ([Ehrlich, 1980](#)). The effects of NO<sub>2</sub> also were observed to vary by infectious organism. NO<sub>2</sub> exposure (1,000 ppb, 24 or 48 hours) shortened survival time in mice after infection with the virulent group C Streptococci but not *Staphylococcus aureus* ([Sherwood et al., 1981](#)).

### **Bacterial Clearance, Virus Inactivation**

Consistent with findings for mortality from bacterial infection, NO<sub>2</sub> exposures of mice in the range of 1,000 to 5,000 ppb reduced bacterial clearance and/or bactericidal activity from the lungs ([Davis et al., 1991](#); [Parker et al., 1989](#); [Jakab, 1988](#); [Sherwood et al., 1981](#); [Goldstein et al., 1974](#); [Goldstein et al., 1973](#)). In these studies, mice were challenged with radiolabeled bacteria either immediately before or after NO<sub>2</sub> exposures of 4 to 48 hours. For four-hour exposures, bacterial clearance was not affected with 500 ppb NO<sub>2</sub> ([Davis et al., 1991](#)) but decreased with NO<sub>2</sub> concentrations of 5,000 ppb and higher ([Parker et al., 1989](#); [Jakab, 1988](#); [Goldstein et al., 1973](#)). Concentration-dependent decreases in bactericidal activity were observed but only with higher than ambient-relevant NO<sub>2</sub> exposures ([Jakab, 1988](#); [Goldstein et al., 1974](#); [Goldstein et al., 1973](#)). For NO<sub>2</sub> concentrations in the range of 1,000 to 2,500 ppb, bacterial clearance was reduced only with 17- to 48-hour exposures ([Sherwood et al., 1981](#); [Goldstein et al., 1973](#)) or in immunocompromised mice ([Jakab, 1988](#)). NO<sub>2</sub>-induced reductions in bactericidal activity and bacterial clearance also were observed in the lungs of mice strains known to be free of all mice pathogens ([Davis et al., 1991](#); [Parker et al., 1989](#)). As with mortality, the effects of NO<sub>2</sub> on bacterial clearance and killing varied by infectious organism. Increased bacterial proliferation was observed in NO<sub>2</sub>-exposed (1,000 ppb, 24 or 48 hours) mice after infection with the virulent group C Streptococci but not

*Staphylococcus aureus* ([Sherwood et al., 1981](#)). A 4-hour exposure to 5,000 ppb NO<sub>2</sub> resulted in a decrease in bactericidal activity after challenge with *Staphylococcus aureus*; however, NO<sub>2</sub> exposure at concentrations less than 20,000 ppb did not affect killing of *Proteus mirabilis* or *Pasteurella pneumotropica* ([Jakab, 1988](#)).

Compared with animal toxicological studies, controlled human exposure studies are few in number and do not provide evidence for NO<sub>2</sub>-induced infectivity. Controlled human exposure studies also differed from toxicological studies in examining infectivity in response to viral not bacterial exposure. NO<sub>2</sub> exposures of 600 ppb did not lead to inactivation of live influenza virus in AMs or bronchial epithelial cells collected from adults or alteration in titers of influenza or respiratory syncytial virus ([Frampton et al., 2002](#); [Frampton et al., 1989](#)). [Frampton et al. \(1989\)](#) reported a trend of decreased inactivation of influenza virus, although results were not statistically significant. Repeated exposures to higher NO<sub>2</sub> concentrations of 1,000 to 3,000 ppb also did not affect inactivation of administered influenza, whether NO<sub>2</sub> exposure was repeated over a single day with a lower background NO<sub>2</sub> exposure ([Frampton et al., 1989](#)) or over 3 consecutive days ([Goings et al., 1989](#)). The 3-day exposure study lacked a sham control; thus, results have weaker implications.

---

#### 5.2.5.2 Respiratory Infections Reported or Diagnosed in Children

In contrast with findings in mouse models, epidemiologic evidence does not clearly indicate a relationship between short-term NO<sub>2</sub> exposure and respiratory infection in children (ages 0–15 years) as reported by self or parents or more objectively ascertained as laboratory-confirmed or physician-diagnosed cases. Some studies found associations ([Esposito et al., 2014](#); [Lu et al., 2014](#); [Stern et al., 2013](#); [Ghosh et al., 2012b](#); [Just et al., 2002](#)); others did not find associations or found inconsistent associations among the outcomes examined [([Altuğ et al., 2014](#); [Stern et al., 2013](#); [Xu et al., 2013](#)); [Table 5-23](#)]. [Xu et al. \(2013\)](#) did not provide strong evidence for an association of ambient NO<sub>2</sub> with laboratory-confirmed cases of influenza (RR: 1.01 [95% CI: 0.97, 1.04] for an unreported increment in NO<sub>2</sub>); however, study limitations preclude strong inferences from the results. There were a mean of only two influenza cases per day, and potential collinearity in a multipollutant model with PM<sub>10</sub> and O<sub>3</sub> (Spearman *r* for correlation with NO<sub>2</sub> = 0.62 and -0.42, respectively) limits inference about NO<sub>2</sub> effects.

Results indicating associations between ambient NO<sub>2</sub> or NO<sub>x</sub> and respiratory infections also have weak implications ([Esposito et al., 2014](#); [Lu et al., 2014](#); [Stern et al., 2013](#); [Ghosh et al., 2012b](#); [Just et al., 2002](#)). All of these studies assigned exposure from central site concentrations (one city site or average of multiple sites) ([Table 5-23](#)). None reported

information on the spatial distribution of subjects around the monitoring site(s) or the within-city variability in NO<sub>2</sub> or NO<sub>x</sub> concentrations to ascertain potential exposure measurement error and its impact on effect estimates. A few studies examined more spatially resolved exposure metrics but also have uncertain implications. [Ghosh et al. \(2012b\)](#) reported similar results in analyses restricted to homes for which central site NO<sub>x</sub> better represented exposure but did not report how these homes were selected. Further, the adequacy of NO<sub>x</sub> to serve as an indicator of NO<sub>2</sub> could vary among subjects because of varying NO<sub>2</sub> to NO<sub>x</sub> ratios across locations ([Section 2.5.3](#)). NO<sub>2</sub> at the central site nearest to schools was associated with pneumonia prevalence ([Lu et al., 2014](#)). However, pneumonia was ascertained as “ever having a diagnosis” and may not be temporally matched to exposure assessed for a 3-year period. The only study that measured NO<sub>2</sub> in subjects’ location (i.e., school) did not observe associations with colds ([Altuğ et al., 2014](#)). The importance of the microenvironmental measures in this study is underscored by the variability in traffic volume and road length reported within the study area.

Uncertainty regarding confounding by PM<sub>2.5</sub> and traffic-related copollutants also limits any strong inferences from the results of these studies. In addition to NO<sub>2</sub>, respiratory infections were associated with BS and PM<sub>2.5</sub>. Other copollutants, such as PM<sub>10</sub>, SO<sub>2</sub>, and O<sub>3</sub>, also were associated with respiratory infection ([Table 5-23](#)). Studies did not examine other traffic-related PM components, CO, copollutant models, or other methods to assess the independent or mixture effects of NO<sub>2</sub>. Where reported, NO<sub>2</sub> was moderately to highly correlated with copollutants ( $r = 0.92$  for BS; 0.6–0.8 for unspecified copollutants) ([Ghosh et al., 2012b](#); [Just et al., 2002](#)).

**Table 5-23 Epidemiologic studies of respiratory infections reported or diagnosed in children.**

Study Population Examined and Methodological Details	Oxide of Nitrogen Metrics Analyzed	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p><a href="#">†Altuğ et al. (2014)</a> Eskisehir, Turkey, Feb–Mar, 2007 n = 605, ages 9–13 yr Cross-sectional. Self-reported respiratory infections. Recruitment from schools of participants of a larger study. Participation rate not reported. Logistic regression adjusted for sex, age, asthma, parental smoking, coal or wood stove use, parental education, height, weight, daily average temperature.</p>	<p>NO<sub>2</sub>-outdoor school 24-h avg, lag 0–6 day avg 1 site at each of 16 schools Means &amp; max (ppb) Suburban: 9.4, 13 Urban: 13, 18 Urban-traffic: 21, 28</p>	<p>Common cold last 7 days: OR: 1.86 (0.41, 8.42) Common cold at the moment: OR: 4.59 (0.79, 26)</p>	<p>No copollutant model. O<sub>3</sub> associated with colds. Strong inverse correlation with NO<sub>2</sub>. Pearson <i>r</i> = –0.80. NO<sub>2</sub> and PM<sub>2.5</sub> reported to be highly correlated.</p>
<p><a href="#">†Esposito et al. (2014)</a> Milan, Italy, Jan–Dec 2012 n = 718, ages 2–18 yr, 329 with wheeze or asthma, 389 healthy children Repeated measures. Daily symptom diaries for 12 mo. Diaries checked weekly, clinic visits conducted every 2 mo. Recruited from respiratory disease section (wheeze/asthma) and outpatient surgery (healthy) sections of pediatric clinic. 89% follow-up participation. Followed cohort similar to cohort at baseline. GEE adjusted for age, sex, siblings, parental education, smokers in home, season, day of week, temperature, humidity.</p>	<p>NO<sub>2</sub>-central site 1-h max, Lag 0–2 day avg 8 city sites, 7 surrounding area Weighted avg at municipality level Tertiles (T) in ppb 1: &lt;47.3<sup>b</sup> 2: 47.3–60.1<sup>b</sup> 3: &gt;60.1<sup>b</sup></p>	<p>RR for pneumonia with T1 as reference Children with asthma: T2: 1.20 (0.75, 1.90) T3: 1.56 (1.01, 2.42) Healthy children: T2: 1.45 (0.80, 0.63) T3: 1.02 (0.93, 1.12)</p>	<p>No copollutant model. PM<sub>10</sub> associated with pneumonia. Correlations NR.</p>
<p><a href="#">Just et al. (2002)</a> Paris, France, Apr–Jun 1996 n = 82, ages 7–15 yr, children with asthma, 90% atopy Repeated measures. Daily symptom diaries for 3 mo, collected weekly. Recruitment from hospital outpatients. 82% follow-up participation. GEE adjusted for time trend, day of week, pollen, temperature, humidity.</p>	<p>NO<sub>2</sub>-central site 24-h avg, lag 0 day Average of 11 sites Mean: 28.6 ppb<sup>b</sup> Max: 59.0 ppb<sup>b</sup></p>	<p>Respiratory infection: OR: 7.19 (2.53, 20.4)</p>	<p>No copollutant model. BS associated with cough and infection. High correlation with NO<sub>2</sub>. Pearson <i>r</i> = 0.92.</p>

**Table 5-23 (Continued): Epidemiologic studies of respiratory infections reported or diagnosed in children.**

Study Population Examined and Methodological Details	Oxide of Nitrogen Metrics Analyzed	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p>†<a href="#">Stern et al. (2013)</a> Bern, Basel, Switzerland, Apr 1999–Feb 2011 n = 366, ages 0–1 yr Repeated measures. Symptoms reported weekly by telephone for 1 yr. Recruitment from birth cohort. 95% follow-up participation. GAM adjusted for study week, sex, siblings, nursery care, prenatal maternal smoking, postnatal maternal smoking, birth weight, maternal atopy, parental education.</p>	<p>NO<sub>2</sub>-central site 2-h avg, lag 5–11 day avg 2 sites Rural mean: 8.1 ppb<sup>b</sup> Urban mean: 25.6 ppb<sup>b</sup> Upper percentiles NR</p>	<p>Incidence respiratory tract infection: RR: 1.20 (0.82, 1.75) Days with respiratory tract infection: NO<sub>2</sub> &lt; 26 ppb: reference category NO<sub>2</sub> &gt; 26 ppb: 18% (0, 39)</p>	<p>No copollutant model. PM<sub>10</sub> lag 7 days associated with respiratory infection. Correlation NR.</p>
<p>†<a href="#">Xu et al. (2013)</a> Brisbane, Australia, 2001–2008, winters only n = 2,922 influenza cases, ages 0–14 yr Time-series. Laboratory-confirmed cases of influenza referred by public or private health sector. Only mean 2/day. No information available on subjects' residential location. Poisson regression adjusted for lag 0–9 day avg temperature, lag 0–9 day avg PM<sub>10</sub>, lag 0–9 day avg O<sub>3</sub>, PM<sub>10</sub>-temperature interaction.</p>	<p>NO<sub>2</sub>-central site 24-h avg, lag 0–9 day avg # sites NR Mean: 5.9 ppb<sup>b</sup> 75th: 7.3 ppb<sup>b</sup> Max: 13.3 ppb<sup>b</sup></p>	<p>Daily influenza counts: RR: 1.01 (0.97, 1.04) increment of NO<sub>2</sub> NR. Results are presented only for a multipollutant model that also includes PM<sub>10</sub> and O<sub>3</sub>.</p>	<p>Only multipollutant model analyzed.</p>
<p>†<a href="#">Ghosh et al. (2012b)</a> Teplice and Prachatic, Czech Republic, May 1994–Jun 2003 n = 1,113 children, ages 0–4.5 yr Repeated measures. Physician-diagnosed infections between ages 0–4.5 yr ascertained from medical records. Recruitment from birth cohort. Participation rate not reported. GEE with exchangeable correlation and adjusted for city, year of birth, day of week, fuel used for heating and cooking, season, 7-day avg temperature. Restricted analyses to children for whom central site may better represent exposure (method not reported).</p>	<p>NO<sub>x</sub>-central site 24-h avg, lag 0–2 day avg 2 sites Mean, 75th (µg/m<sup>3</sup>) Teplice: 59.2, 73.3 Prachatic: 20.3, 24.4</p>	<p>Acute bronchitis: Birth to age 2 yr: RR: 1.09 (1.01, 1.16) per 35 µg/m<sup>3</sup> NO<sub>x</sub> Age 2 yr–4.5 yr: RR: 1.05 (0.94, 1.14) per 35 µg/m<sup>3</sup> NO<sub>x</sub></p>	<p>No copollutant model. Association with PM<sub>2.5</sub> reported in separate paper. Moderate to high correlations reported with unspecified copollutants. <i>r</i> = 0.6–0.8</p>

**Table 5-23 (Continued): Epidemiologic studies of respiratory infections reported or diagnosed in children.**

Study Population Examined and Methodological Details	Oxide of Nitrogen Metrics Analyzed	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<p>†<a href="#">Lu et al. (2014)</a><sup>b</sup> Changsha, China, Sep 2011–Jan 2012 n = 2706, ages 3–6 yr Cross-sectional. Recruitment from schools. 59% participation. Potential temporal mismatch of exposure (2008–2011) and ever having pneumonia diagnosis. Two-level model. Pneumonia first adjusted for parental atopy, antibiotic use, new furniture in home, coal, wood or gas used in home, painted walls/air conditioning in home, pets in home, visible mold/dampness in home. Adjusted pneumonia prevalence regressed with NO<sub>2</sub>. Confounding by meteorological factors not examined.</p>	<p>NO<sub>2</sub>-central site 24-h avg Nearest to school, distance NR Concentrations NR 2008–2011: 7 days &gt;63.8 ppb<sup>b</sup> standard before 2012 89 days &gt;42.6 ppb<sup>b</sup> standard 2012</p>	<p>OR for NO<sub>2</sub> &gt; 63.8 ppb 1 day/yr 1.04 (1.02, 1.05)</p>	<p>No copollutant model. PM<sub>10</sub> and SO<sub>2</sub> associated with pneumonia. Correlations NR.</p>

Note: More informative studies in terms of the exposure assessment method and potential confounding considered are presented first.

avg = average; BS = black smoke; CI = confidence interval; Dec = December; Feb = February; GAM = generalized additive model; GEE = generalized estimating equations; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; NR = not reported; O<sub>3</sub> = ozone; OR = odds ratio; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 μm; ppb = parts per billion; RR = relative risk; SO<sub>2</sub> = sulfur dioxide; yr = year.

<sup>a</sup>Effect estimates are standardized to a 20 ppb for 24-h avg NO<sub>2</sub>. NO<sub>x</sub> effect estimates are presented as reported in the study ([Section 5.1.2.2](#)).

<sup>b</sup>Concentrations converted from μg/m<sup>3</sup> to ppb using the conversion factor of 0.532 assuming standard temperature (25°C) and pressure (1 atm).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

---

### 5.2.5.3 Hospital Admissions and Emergency Department Visits for Respiratory Infections

To date, relatively few studies have examined the association between short-term NO<sub>2</sub> exposures and hospital admissions and ED visits due to respiratory infections. The 2008 ISA for Oxides of Nitrogen identified studies that evaluated a number of respiratory infection outcomes, such as upper respiratory infections (URIs), pneumonia, bronchitis, allergic rhinitis, and lower respiratory disease. Across these outcomes, studies have generally not provided consistent evidence of an association between NO<sub>2</sub> and hospital admissions and ED visits due to respiratory infections ([U.S. EPA, 2008c](#)). Recent studies add to the body of literature evaluated in the 2008 ISA for Oxides of Nitrogen, but compared to other respiratory-related hospital admission and ED visit outcomes the total body of literature remains limited. The air quality characteristics of the city, or across all cities, and the exposure assignment approach used in each respiratory infection-related hospital admission and ED visit study evaluated in this section are presented in [Table 5-24](#). As detailed in [Section 5.2.2.4](#), other recent studies of respiratory infection-related hospital admissions and ED visits are not the focus of this evaluation, and the full list of these studies, as well as study details, can be found in [Supplemental Table S5-3 \(U.S. EPA, 2015h\)](#).

**Table 5-24 Mean and upper percentile concentrations of nitrogen dioxide in studies of hospital admissions and emergency department visits for respiratory infection.**

Study	Location Years	Type of Visit (ICD9/10)	Exposure Assignment	Metric	Mean Concentration ppb	Upper Percentile Concentrations ppb	Copollutant Examination
<b>Hospital Admissions</b>							
<a href="#">Burnett et al. (1999)</a>	Toronto, ON, Canada (1980–1994)	Respiratory infection (464, 466, 480–7, 494)	Average of NO <sub>2</sub> concentrations across 4 monitors.	24-h avg	25.2	NR	Correlations (r): PM <sub>2.5</sub> : 0.55 PM <sub>10-2.5</sub> : 0.38 PM <sub>10</sub> : 0.57 CO: 0.64 SO <sub>2</sub> : 0.54 O <sub>3</sub> : -0.08 Copollutant models: none
<a href="#">Lin et al. (2005)</a>	Toronto, ON, Canada (1998–2001)	Respiratory infection (464, 466, 480–487)	Average of NO <sub>2</sub> concentrations across 7 monitors.	24-h avg	25.5	75th: 29.3	Correlations (r): PM <sub>2.5</sub> : 0.48 PM <sub>10-2.5</sub> : 0.40 PM <sub>10</sub> : 0.54 CO: 0.20 SO <sub>2</sub> : 0.61 O <sub>3</sub> : 0.0 Copollutant models: none
<a href="#">Karr et al. (2006)</a>	Southern Los Angeles County, CA (1995–2000)	Acute bronchiolitis (466.1)	34 NO <sub>2</sub> monitors, exposure assigned based on nearest monitor to residential ZIP code.	1-h max	59	75th: 69 90th: 90	Correlations (r): NR Copollutant models: none

**Table 5-24 (Continued): Mean and upper percentile concentrations of nitrogen dioxide in studies of hospital admissions and emergency department visits for respiratory infection.**

Study	Location Years	Type of Visit (ICD9/10)	Exposure Assignment	Metric	Mean Concentration ppb	Upper Percentile Concentrations ppb	Copollutant Examination
<a href="#">Zanobetti and Schwartz (2006)</a>	Boston, MA (1995–1999)	Pneumonia (480–487)	Average of NO <sub>2</sub> concentrations across 5 monitors.	24-h avg	NR	50th: 23.2	Correlations ( <i>r</i> ): PM <sub>2.5</sub> : 0.55 BC: 0.70 CO: 0.67 O <sub>3</sub> : -0.14 PM nontraffic: 0.14 Copollutant models: none
<a href="#">†HEI (2012)</a> <a href="#">†Mehta et al. (2013)</a>	Ho Chi Minh City, Vietnam (2003–2005)	Acute lower respiratory infection (J13–16, 18, 21)	Average of NO <sub>2</sub> concentrations across 9 monitors.	24-h avg	11.7	Max: 29.2	Correlations ( <i>r</i> ): Dry season: PM <sub>10</sub> : 0.78 O <sub>3</sub> : 0.44 SO <sub>2</sub> : 0.29 Rainy season: PM <sub>10</sub> : 0.18 O <sub>3</sub> : 0.17 SO <sub>2</sub> : 0.01 Copollutant models: SO <sub>2</sub> , PM <sub>10</sub> , O <sub>3</sub>
<a href="#">†Ségala et al. (2008)</a>	Paris, France (1997–2001)	Bronchiolitis	Average of NO <sub>2</sub> concentrations from 21 monitors, representative of urban background.	24-h avg	27.0	Max: 90.4	Correlations ( <i>r</i> ): BS: 0.83 PM <sub>10</sub> : 0.74 SO <sub>2</sub> : 0.78 Copollutant models: none

**Table 5-24 (Continued): Mean and upper percentile concentrations of nitrogen dioxide in studies of hospital admissions and emergency department visits for respiratory infection.**

Study	Location Years	Type of Visit (ICD9/10)	Exposure Assignment	Metric	Mean Concentration ppb	Upper Percentile Concentrations ppb	Copollutant Examination
<a href="#">†Faustini et al. (2013)</a>	6 Italian cities (2001–2005)	LRTI (466, 480–487)	Average of NO <sub>2</sub> concentrations over all monitors within each city. Number of NO <sub>2</sub> monitors in each city ranged from 1–5. <sup>a</sup>	24-h avg	24.1–34.6	NR	Correlations ( <i>r</i> ), across cities: PM <sub>10</sub> : 0.22–0.79 Copollutant models: PM <sub>10</sub>
<b>ED Visits</b>							
<a href="#">Peel et al. (2005)</a>	Atlanta, GA (1993–2000)	Upper respiratory infection (460–6,477) Pneumonia (480–486)	Average of NO <sub>2</sub> concentrations from monitors for several monitoring networks.	1-h max	45.9	NR	Correlations ( <i>r</i> ): PM <sub>2.5</sub> : 0.46 PM <sub>10</sub> : 0.49 PM <sub>10-2.5</sub> : 0.46 UFP: 0.26 PM <sub>2.5</sub> water-soluble metals: 0.32 PM <sub>2.5</sub> sulfate: 0.17 PM <sub>2.5</sub> acidity: 0.10 PM <sub>2.5</sub> OC: 0.63 PM <sub>2.5</sub> EC: 0.61 Oxygenated HCs: 0.30 O <sub>3</sub> : 0.42 CO: 0.68 SO <sub>2</sub> : 0.34 Copollutant models: none

**Table 5-24 (Continued): Mean and upper percentile concentrations of nitrogen dioxide in studies of hospital admissions and emergency department visits for respiratory infection.**

Study	Location Years	Type of Visit (ICD9/10)	Exposure Assignment	Metric	Mean Concentration ppb	Upper Percentile Concentrations ppb	Copollutant Examination
<a href="#">†Stieb et al. (2009)</a>	7 Canadian cities (1992–2003)	Respiratory infection (464, 466, 480–487)	Average NO <sub>2</sub> concentrations from all monitors in each city. Number of NO <sub>2</sub> monitors in each city ranged from 1–14.	24-h avg	9.3–22.7	75th: 12.3–27.6	Correlations ( <i>r</i> ) only reported by city and season. Copollutant models: none
<a href="#">†Ségala et al. (2008)</a>	Paris, France (1997–2001)	Bronchiolitis	Average of NO <sub>2</sub> concentrations across 21 monitors, representative of urban background.	24-h avg	27.0	Max: 90.4	Correlations ( <i>r</i> ): BS: 0.83 PM <sub>10</sub> : 0.74 SO <sub>2</sub> : 0.78 Copollutant models: none
<a href="#">†Zemek et al. (2010)</a>	Edmonton, AB, Canada (1992–2002)	Otitis media (382.9)	Average of NO <sub>2</sub> concentrations across 3 monitors.	24-h avg	21.9	75th: 27.6	Correlations ( <i>r</i> ): NR Copollutant models: none
<b>Physician Visits</b>							
<a href="#">†Sinclair et al. (2010)</a>	Atlanta, GA (1998–2002)	Upper respiratory infection Lower respiratory infection	NO <sub>2</sub> concentrations collected as part of AIREs at SEARCH Jefferson Street site.	1-h max	1998–2000: 49.8 2000–2002: 35.5 1998–2002: 41.7	NR	Correlations ( <i>r</i> ): NR Copollutant models: none

AB = Alberta; AIREs = Aerosol Research Inhalation Epidemiology Study; avg = average; BC = black carbon; BS = black smoke; CA = California; CO = carbon monoxide; EC = elemental carbon; ED = emergency department; GA = Georgia; HC = hydrocarbons; LRTI = lower respiratory tract infection; MA = Massachusetts; MI = Michigan; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; NY = New York; O<sub>3</sub> = ozone; OC = organic carbon; ON = Ontario; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm; SO<sub>2</sub> = sulfur dioxide; UFP = ultrafine particles.

<sup>a</sup>Monitoring information obtained from [Colais et al. \(2012\)](#).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

## Hospital Admissions

Few recent studies have examined the association between short-term NO<sub>2</sub> exposures and respiratory infection hospital admissions. A time-series study conducted in Ho Chi Minh City, Vietnam ([Mehta et al., 2013](#); [HEI, 2012](#)) examined the association between short-term air pollution exposures and pediatric (ages 28 days–5 years) hospital admissions for acute lower respiratory infections (ALRI, including bronchiolitis and pneumonia). In a time-stratified case-crossover analysis focused only on the average of a 1–6 day lag, there was no evidence of an association between NO<sub>2</sub> and ALRI hospital admissions in the all-year analysis (–4.0% [95% CI: –18.0, 12.5] for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations).

In an additional study that also examined respiratory infections (i.e., bronchiolitis) in children, [Ségala et al. \(2008\)](#) focused on associations with winter (October–January) air pollution because it is the time of year when respiratory syncytial virus (RSV) activity peaks. It has been hypothesized that air pollution exposures may increase the risk of respiratory infections, including bronchiolitis due to RSV ([Ségala et al., 2008](#)). Focusing on children <3 years of age in Paris, France, the authors conducted a bidirectional case-crossover analysis along with a time-series analysis to examine air pollution (i.e., PM<sub>10</sub>, BS, NO<sub>2</sub>, SO<sub>2</sub>) associations with bronchiolitis ED visits and hospital admissions. Although the authors specify the bidirectional case-crossover approach was used to “avoid time-trend bias,” other have shown the bidirectional approach to bias results ([Ségala et al., 2008](#); [Levy et al., 2001](#)). In the case-crossover analysis, NO<sub>2</sub> was associated with bronchiolitis hospital admissions (15.9% [95% CI: 7.7, 29.0], lag 0–4 days for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations); NO<sub>2</sub> was not examined in the time-series analysis. Although a positive association was observed, the authors did not analyze copollutant models. The lack of copollutant analyses complicates the interpretation of these results because the pollutants were highly correlated, ranging from an  $r = 0.74$  to 0.83.

[Faustini et al. \(2013\)](#), in the analysis of air pollution in six Italian cities, also examined associations with lower respiratory tract infection (LRTI) hospital admissions. However, the authors only focused on LRTIs in individuals with COPD over the age of 35 years. In this population, the largest associations were observed at lag 2–5 days (10.0% [95% CI: –2.7, 24.3]), and there was no evidence of an immediate effect. This is in contrast to the results for COPD hospital admissions, where the strongest associations were observed at lag 0 and 0–1 days. The authors examined the NO<sub>2</sub> association with LRTI hospital admissions in copollutant models with PM<sub>10</sub> at lag 0–5 days, and consistent with the

other endpoints examined, reported that the association remained positive but was attenuated (7.8% [95% CI: -6.5, 24.2]).

### **Emergency Department Visits**

Studies that examined the effect of air pollution on ED visits attributed to respiratory infections have focused on similar outcomes to those examined in the studies of hospital admissions. [Stieb et al. \(2009\)](#), in their study of seven Canadian cities, also examined the association between short-term NO<sub>2</sub> concentrations and respiratory infection ED visits. The authors reported positive associations at lags of 1 and 2 days, but the confidence intervals were wide, providing little evidence of an association. However, [Ségala et al. \(2008\)](#) in the study of winter (October–January) air pollution in Paris, France (discussed above) reported evidence of an association between short-term NO<sub>2</sub> concentrations and bronchiolitis ED visits (11.8% [95% CI: 7.7, 20.1]; lag 0–4 day avg for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations) in a bidirectional case-crossover analysis. As mentioned previously, the interpretation of these results is complicated by the lack of copollutant analyses and the high correlation between pollutants examined ( $r = 0.74$  to  $0.83$ ).

In an additional study conducted in Edmonton, Alberta, Canada, [Zemek et al. \(2010\)](#) examined otitis media (i.e., ear infections) ED visits, for ages 1–3 years. Associations were examined for single-day lags of 0 to 4 days in all-year as well as seasonal analyses. The authors observed that NO<sub>2</sub> was associated with increases in ED visits for otitis media in the all-year analysis at lag 2 days (7.9% [95% CI: 1.6, 12.8] for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations). When examining whether there was evidence of seasonal patterns in associations, the authors found that the magnitude of the association was larger in the warm months of April–September (16.1% [95% CI: 3.1, 31.2]) compared to the cold months of October–March (4.7% [95% CI: 0, 11.2]) at lag 2 days for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations. Importantly, the pattern of associations for CO were similar to that observed for NO<sub>2</sub>, and the authors did not report correlations between pollutants or analyze copollutant models.


### **Outpatient and Physician Visits**

In addition to examining severe occurrences of a respiratory infection that would require a trip to a hospital, studies have begun to explore whether air pollution may lead to less severe cases, which would be indicated by trips to an outpatient facility. In a study conducted in Atlanta, GA, [Sinclair et al. \(2010\)](#) examined respiratory infection (e.g., upper respiratory infections, lower respiratory infections) outpatient visits to a managed care organization. As detailed in [Section 5.2.2.4](#), the authors separated the analysis into two time periods to compare air pollutant concentrations and relationships

for acute respiratory visits. The two time periods were the 25-month time period examined in [Sinclair and Tolsma \(2004\)](#) and an additional 28-month time period of available data from AIREs. Across the two time periods, mean 1-h max NO<sub>2</sub> concentrations were lower in the 28-month versus the 25-month time period, 49.8 ppb versus 35.5 ppb, respectively ([Table 5-24](#)). For both outcomes, the daily number of outpatient visit counts varied, with LRI being rather small (i.e., 12 per day) compared to that for URI (i.e., 263 per day). A comparison of the two time periods indicated that risk estimates for LRI and URI tended to be larger in the earlier 25-month period compared to the later 28-month period with relatively wide confidence intervals for both outcomes. Additionally, the lag structure of associations varied between each time period. For LRI, the largest magnitude of an association was for both lag 0–2 and 3–5 day avg in the earlier time period, but only lag 3–5 day avg in the latter time period. For URI, the largest associations were for lag 0–2 and 3–5 days for the earlier time period, but a positive association was only observed for lag 6–8 days in the latter time period. The authors also examined potential seasonal differences in associations, but the inconsistent results between the two time periods with respect to the lag structure of associations complicates the interpretation of seasonal results.

### **Summary of Respiratory Infection Hospital Admissions and Emergency Department Visits**

Recent studies that examined the association between short-term NO<sub>2</sub> exposure and hospital admissions and ED visits due to respiratory infections add to the body of evidence detailed in the 2008 ISA for Oxides of Nitrogen, but studies have not consistently examined similar respiratory infection outcomes ([Figure 5-9](#) and [Table 5-25](#)). Of the studies evaluated, the strongest associations are for studies that focused on children, specifically less than 5 years of age. These studies demonstrate associations with respiratory infection, bronchiolitis, and otitis media, specifically during certain times of the year depending on geographic location. The relatively small number of studies that have examined hospital admissions and ED visits due to respiratory infections has resulted in an inadequate assessment of the lag structure of associations and potential copollutant confounding.



Note: CA =California; CAN = Canada; CI = confidence interval; DL = distributed lag; ED = emergency department; GA = Georgia; MA = Massachusetts. Black = studies from the 2008 Integrated Science Assessment for Oxides of Nitrogen, red = recent studies. Solid symbols = all year, horizontal stripes = warm/summer months, vertical stripes = cool/winter months. a = results are for the dry season (November–April); b = Lower Respiratory Infection in people with chronic obstructive pulmonary disease. Effect estimates are standardized to a 20-ppb increase in 24-h avg nitrogen dioxide and 30-ppb increase in 1-h max nitrogen dioxide.

**Figure 5-10 Percentage increase in respiratory infection-related hospital admissions and emergency department visits in relation to nitrogen dioxide concentrations.**

**Table 5-25 Corresponding risk estimate for studies presented in Figure 5-10.**

Study	Location	Age	Avg Time	Lag	Season	% Increase (95% CI)
<b>Hospital Admissions</b>						
<b>Respiratory Infection</b>						
† <a href="#">Mehta et al. (2013)</a>	Ho Chi Minh, Vietnam	28 days–5 yr	24-h avg	1–6	All	–4.0 (–18.0, 12.5)
					Dry <sup>a</sup>	35.9 (3.0, 79.3)
<a href="#">Lin et al. (2005)</a>	Toronto, ON, Canada	0–14	24-h avg	0–5	All	41.1 (15.6, 73.7)
† <a href="#">Faustini et al. (2013)<sup>b</sup></a>	6 Italian cities	35+	24-h avg	0–5 DL	All	6.9 (–4.3, 19.4)
<a href="#">Burnett et al. (1999)</a>	Toronto, ON, Canada	All	24-h avg	2	All	5.4 (3.5, 7.4)
<b>Bronchiolitis</b>						
<a href="#">Karr et al. (2006)</a>	LA County, CA	0–1	1-h max	1	Winter	–3.5 (–5.8, –1.2)
† <a href="#">Ségala et al. (2008)</a>	Paris, France	<3	24-h avg	0–4	Winter	15.9 (7.7, 29.0)
<b>Pneumonia</b>						
<a href="#">Zanobetti and Schwartz (2006)</a>	Boston, MA	65+	24-h avg	0–1	All	2.7 (–3.0, 8.4)
<b>ED Visits</b>						
<b>Respiratory Infection</b>						
† <a href="#">Stieb et al. (2009)</a>	7 Canadian cities	All	24-h avg	2	All	0.7 (–1.5, 2.8)
<a href="#">Peel et al. (2005)</a>	Atlanta, GA	All	1-h max	0–2	All	2.9 (0.9, 4.7)
<b>Bronchiolitis</b>						
† <a href="#">Ségala et al. (2008)</a>	Paris, France	<3	24-h avg	0–4	Winter	11.8 (7.7, 20.1)
<b>Pneumonia</b>						
<a href="#">Peel et al. (2005)</a>	Atlanta, GA	All	1-h max	0–2	All	0.0 (–2.5, 2.9)

**Table5-25 (Continued): Corresponding risk estimate for studies presented in Figure 5-10.**

Study	Location	Age	Avg Time	Lag	Season	% Increase (95% CI)
<b>Otitis Media</b>						
† <a href="#">Zemek et al. (2010)</a>	Edmonton, AB, Canada	1-3	24-h avg	2	All	7.9 (1.6, 12.8)
					Summer	16.1 (3.1, 31.2)
					Winter	4.7 (0.0, 11.2)

AB = Alberta; avg = average; CA = California; CI = confidence interval; DL = distributed lag, ED = emergency department; GA = Georgia; MA = Massachusetts; ON = Ontario.

<sup>a</sup>Dry season was defined as November–April.

<sup>b</sup>LRTI in people with COPD.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

#### 5.2.5.4 Subclinical Effects Underlying Respiratory Infections

Overall, NO<sub>2</sub> exposure has not been related with consistent changes in subclinical effects that have been identified as key events in the proposed mode of action for respiratory infections ([Figure 4-1](#)), with the direction of change varying across studies. Some support for the effects of NO<sub>2</sub> on respiratory infection morbidity and mortality observed in toxicological studies and some epidemiologic studies is provided by toxicological findings for NO<sub>2</sub>-induced impairments in alveolar macrophage function. There is uncertainty about the effects of NO<sub>2</sub> on alveolar macrophages and immunoglobulin antibody responses as examined in controlled human exposure and epidemiologic studies, respectively.

#### Mucociliary and Alveolar Clearance

Airborne substances small enough to be respired may be trapped in the epithelial lining fluid in the conducting airways and physically removed or cleared from the airway by ciliated epithelial cells. This pulmonary clearance consists of mucociliary and alveolar clearance. Recent animal toxicological studies and studies reviewed in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) demonstrated that NO<sub>2</sub> exposures higher than 5,000 ppb, which are above those considered ambient-relevant, functionally impair pulmonary clearance and damage the ciliated epithelium of the airway. However, animal toxicological and controlled human exposure studies with NO<sub>2</sub> exposures of 5,000 ppb or less, which were reviewed in the 2008 ISA, often show increased pulmonary clearance.

Exposures of rabbits to 300 ppb NO<sub>2</sub> for 2 hours, given as a single exposure or repeated over 14 days [([Schlesinger et al., 1987](#); [Schlesinger and Gearhart, 1987](#); [Vollmuth et al., 1986](#)); [Table 5-26](#)] had no effect on mucociliary or alveolar clearance or accelerated clearance as measured by retention of radioactive tracer microspheres. Results were similar in rabbits and rats exposed to 1,000 ppb NO<sub>2</sub>. Increased particle clearance was observed after a single-day 2-hour exposure ([Vollmuth et al., 1986](#)) and after repeated 2- or 7-hour exposures over 11 to 22 days ([Schlesinger and Gearhart, 1987](#); [Ferin and Leach, 1975](#)). Another study observed no change in clearance in rabbits exposed to 1,000 ppb NO<sub>2</sub> for 2 hours per day for 14 days ([Schlesinger et al., 1987](#)).

An effect of NO<sub>2</sub> exposure on pulmonary clearance also is unclear based on ciliary activity measurements. The uncertainty is due largely to limitations in study design. Guinea pigs exposed to 3,000 ppb NO<sub>2</sub> for 6 hours/day and 6 days/week for 2 weeks had concentration-dependent reductions in ciliary activity ([Ohashi et al., 1994](#)). However, ciliary beat (measured by light refraction) was examined in nasal tissues excised after animals were exposed. This method could have affected the outcome and be less representative of changes that occur from human ambient exposure. In a controlled human exposure study of healthy adults, there was no ciliary activity 45 minutes after a 20-minute exposure to 1,500 or 3,500 ppb NO<sub>2</sub> ([Helleday et al., 1995](#)). In contrast, increases in ciliary activity were reported 24 hours after a 4-hour exposure to 3,500 ppb NO<sub>2</sub>. Importantly, baseline measurements for each subject were used as control values, and therefore, the study lacked air controls and subject blinding.

**Table 5-26 Characteristics of experimental studies of subclinical lung host defense effects.**

Study	Species (Strain); Sample Size; Sex; Age	Exposure Details	Endpoints Examined
<b>Mucociliary and alveolar clearance</b>			
<a href="#">Vollmuth et al. (1986)</a>	Rabbits (New Zealand White); n = 5/group; M; age NR	300, 1,000, or 3,000 ppb for 2 h	Retained tracer particles for 14 days following exposure.
<a href="#">Schlesinger and Gearhart (1987)</a> <a href="#">Schlesinger et al. (1987)</a>	Rabbits (New Zealand White); n = 5/group; M; age NR	300 or 1,000 ppb for 2h/day up to 14 days	Retained radioactively labeled tracer particles after each of the 14 days of NO <sub>2</sub> exposure. Retention in alveolated and tracheobronchial regions of lung.
<a href="#">Ferin and Leach (1975)</a>	Rats (Long-Evans), n = 5–10/group; sex and age NR	1,000–24,000 ppb NO <sub>2</sub> for 11 or 22 days (7 h/day, 5 days/week)	Retained titanium dioxide particles at 8, 25, and 130 days post-exposure.
<a href="#">Ohashi et al. (1994)</a>	Guinea pigs (Hartley); n = 10/group; sex and age NR	3,000 or 9,000 ppb for 6 h/day, 6 days/week for 2 weeks	Ciliary beat in excised nasal tissue 24 h after exposure.
<a href="#">Helleday et al. (1995)</a>	Humans; n = 14 M, 10 F; 27 yr (range: 23–30 yr)	(1) 1,500 ppb for 45 min (2) 3,500 ppb for 45 min (3) 3,500 ppb for 4 h Baseline/control obtained 2 weeks prior.	Fiberoptic bronchoscopy to record mucociliary activity frequency. (1) and (2) 45 min following exposure. (3) 24 h following exposure.
<b>Function and Morphology of Alveolar Macrophages</b>			
<a href="#">Goldstein et al. (1977)</a>	Rats (Sprague-Dawley); n = NR; F; age NR	500, 1,000, or 2,400 ppb NO <sub>2</sub> for 1 and 2 h	Agglutination of AMs.
<a href="#">Rombout et al. (1986)</a>	Rats (Wistar); n = 3–6/group; F; 6 weeks	500, 1,390, or 2,800 ppb NO <sub>2</sub> for 1, 2, 4, 8, 16, and 28 days	Histopathological evaluation.
<a href="#">Mochitate et al. (1986)</a>	Rats (Wistar); n = 6/group; M; 19–23 weeks	4,000 ppb NO <sub>2</sub> continuously up to 10 days	BAL fluid cell counts and AM function and morphology.
<a href="#">Suzuki et al. (1986)</a>	Rats (Fischer 344); n = 8/group; M; 7 weeks	4,000 NO <sub>2</sub> ppb for 1, 3, 5, 7, and 10 days	AM activity (phagocytosis and superoxide production), SOD and glucose-6-phosphate dehydrogenase activity.
<a href="#">Hooftman et al. (1988)</a>	Rats (Wistar); n = 10/group; M; age NR	4,000, 10,000, or 25,000 ppb NO <sub>2</sub> for 6 h/day, 5 days/week for 7–21 days	Histopathological evaluation, analysis of BAL fluid, and AM function and morphology.

**Table 5-26 (Continued): Characteristics of experimental studies of subclinical lung host defense effects.**

Study	Species (Strain); Sample Size; Sex; Age	Exposure Details	Endpoints Examined
<a href="#">Azadniv et al. (1998)</a>	Humans; n = 11 M, 4 F; Early phase: 28.1 ± 3.5 yr Late phase: 27.4 ± 4.2 yr	2,000 ppb for 6 h; Exercise for approximately 10 of every 30 min at $\dot{V}_E = 40$ L/min	Alveolar macrophage function 1 h (early phase) and 18 h (late phase) after exposure.
<a href="#">Dowell et al. (1971)</a>	Dogs (beagle); n = 11; sex and age NR	3,000 ppb NO <sub>2</sub> for 1 h	Histopathological evaluation and lung surfactant properties.
<a href="#">Robison et al. (1990)</a>	Rats (Sprague-Dawley); n, sex, and age NR	100, 500, or 1,000 ppb NO <sub>2</sub> for 1 h; AMs exposed ex vivo	Viability, LTB <sub>4</sub> production, neutrophil chemotaxis, superoxide production.
<a href="#">Robison et al. (1993)</a>	Rats (Sprague Dawley); n > 4/group; sex and age NR	500 ppb NO <sub>2</sub> for 8 h/day for 0.5, 1, 5, or 10 days	BAL fluid cell counts and arachidonate metabolite levels, AM arachidonate metabolism, respiratory burst activity, and glutathione content.
<a href="#">Amoruso et al. (1981)</a>	Rats (Sprague-Dawley); n = 4/group F; age NR	1,300, 1,900, or 6,100 ppb NO <sub>2</sub> for 3 h	Analysis of BAL fluid and superoxide production by AMs (PMA stimulation).
<a href="#">Devlin et al. (1999)</a>	Humans; n = 11 M; range: 18–35 yr	2,000 ppb for 4 h; Exercise for 15 min on/15 min off at $\dot{V}_E = 50$ L/min	BAL fluid macrophage superoxide production and phagocytosis.
<a href="#">Schlesinger (1987b)</a>	Rabbits (New Zealand White); n = 5/group M; age NR	310 or 1,030 ppb NO <sub>2</sub> for 2 h/day for 2, 6, and 13 days	Viability and AM activity (mobility, attachment, and phagocytosis).
<a href="#">Rose et al. (1988)</a> <a href="#">Rose et al. (1989a)</a>	Mice (CD-1); n > 4/group; sex NR; 4–6 weeks	(1) 1,000, 2,500, or 5,000 ppb NO <sub>2</sub> for 6 h/day for 2 days; intratracheal inoculation with murine <i>Cytomegalovirus</i> ; 4 additional days (6 h/day) of exposure. (2) re-inoculation 30 days (air) post-primary inoculation.	Infection 5 and 10 days post-inoculation, histopathological evaluation, and analysis of BAL fluid (LDH, albumin, macrophages).
<a href="#">Pinkston et al. (1988)</a>	Human AMs isolated from 14 M and 1 F; 29 ± 3.9 yr	5,000 ppb for 3 h (ex vivo)	Cell viability and release of neutrophil chemotactic factor and IL-1.

**Table 5-26 (Continued): Characteristics of experimental studies of subclinical lung host defense effects.**

Study	Species (Strain); Sample Size; Sex; Age	Exposure Details	Endpoints Examined
<b>Other Subclinical Effects</b>			
<a href="#">Frampton et al. (2002)</a>	Humans; (1,2) n = 12 M, 9 F; F = 27.1 ± 4.1 yr M = 26.9 ± 4.5 yr	(1) 600 ppb for 3 h, (2) 1,500 ppb for 3 h; (1,2) Exercise 10 min on/20 min off at $\dot{V}_E = 40$ L/min	Bronchial and alveolar lavage fluid cell viability and differential counts 3.5 h post-exposure, influenza and RSV challenge in BAL cells, peripheral blood characterization.
<a href="#">Pathmanathan et al. (2003)</a>	Humans; n = 8 M, 4 F 26 yr (range: 21–32)	2,000 ppb for 4 h/day for 4 days; Exercise 15 min on/15 min off at 75 watts	Biomarkers in bronchial epithelium-exotoxin, GM-CSF, Gro- $\alpha$ , I-CAM 1, IL-5, IL-6, IL-8, IL-10, IL-13, total and active NF- $\kappa$ B, and TNF- $\alpha$ (fiberoptic bronchoscopy after end of last exposure).

AM = alveolar macrophages; BAL = bronchoalveolar lavage; F = female; GM-CSF = granulocyte macrophage-colony stimulating factor; h = hour; I-CAM = intercellular adhesion molecule; IL = interleukin; L/min = liters per minute; LDH = lactate dehydrogenase; M = male; min = minute; NF- $\kappa$ B = nuclear factor kappa-light chain-enhancer of activated B cells; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; PMA = phorbol myristate acetate; ppb = parts per billion; RSV = respiratory syncytial virus; SD = standard deviation; SOD = superoxide dismutase; TNF- $\alpha$  = tumor necrosis factor; yr = years.

### Function and Morphology of Alveolar Macrophages

NO<sub>2</sub> exposure shows variable effects on AM numbers, morphology, and superoxide production, but there is indication of effects on AM phagocytosis. The inconsistencies present across studies could be the result of strain or sex differences in response to NO<sub>2</sub> or reflect true uncertainty. In limited examination, 500 ppb NO<sub>2</sub> exposures of rats (see [Table 5-26](#) for study details) were demonstrated to decrease AM agglutination ([Goldstein et al., 1977](#)) but not to increase AM numbers in BAL fluid ([Rombout et al., 1986](#)). NO<sub>2</sub> exposures of 4,000 ppb NO<sub>2</sub> (repeated over 7–21 days) tended to increase numbers of AM in BAL from rats ([Mochitate et al., 1986](#); [Suzuki et al., 1986](#)) but not in all studies ([Hooftman et al., 1988](#)). Changes in AM morphology were not observed in human exposed to 2,000 ppb NO<sub>2</sub> ([Azadniv et al., 1998](#)) but were observed in dogs and rats exposed to 3,000 or 4,000 ppb NO<sub>2</sub> ([Hooftman et al., 1988](#); [Dowell et al., 1971](#)).

NO<sub>2</sub> exposure was shown to decrease the ability of AMs to produce superoxide anion (indicating reduced respiratory burst) but not in all studies. NO<sub>2</sub> exposures of 100 or 500 ppb (details in [Table 5-26](#)) did not consistently decrease superoxide production in AM isolated from rats ([Robison et al., 1993](#); [Robison et al., 1990](#)), although a decrease was observed after 500 ppb NO<sub>2</sub> exposure that was repeated up to 10 days. NO<sub>2</sub> exposures in the range of 1,000 to 4,000 ppb tended to decrease superoxide anion

production in AMs from male and female rats ([Robison et al., 1990](#); [Suzuki et al., 1986](#)), with [Robison et al. \(1990\)](#) demonstrating a concentration-dependent decrease following a 1-hour exposure to NO<sub>2</sub> at concentrations of 1,000 ppb and higher. Conversely, AMs isolated from Sprague Dawley female rats showed no change in superoxide production in response to 1,300 or 1,900 ppb NO<sub>2</sub> exposure ([Amoruso et al., 1981](#)). Similar to animal toxicological studies, controlled human exposure studies did not demonstrate a consistent effect of ambient-relevant NO<sub>2</sub> exposures on superoxide production from AM, with 2,000 ppb NO<sub>2</sub> exposures ([Table 5-26](#)) of healthy subjects with intermittent exercise leading to decreased production ([Devlin et al., 1999](#)) or increased release ([Azadniv et al., 1998](#)) from AMs.

There is more consistent evidence for ambient-relevant NO<sub>2</sub> exposures to decrease phagocytic capacity of AMs. Such effects were observed in AMs from rabbits exposed to 300 ppb NO<sub>2</sub> for 2 or 6 days ([Schlesinger, 1987b](#)). However, all animals were co-exposed to 0.5 mg/m<sup>3</sup> sulfuric acid, and an independent effect of NO<sub>2</sub> exposure could not be assessed. Decreased phagocytosis was observed in AMs of rabbits, rodents ([Rose et al., 1989a](#); [Schlesinger, 1987b](#); [Suzuki et al., 1986](#)), and humans ([Devlin et al., 1999](#)) following exposures of 1,000 to 5,000 ppb NO<sub>2</sub> for 1 to 7 days. However, NO<sub>2</sub> exposure increased uptake of murine *Cytomegalovirus* in AMs from rats ([Rose et al., 1989a](#)). In contrast, [Hooftman et al. \(1988\)](#) found no changes in phagocytosis of latex microspheres by AMs from rats below 10,000 ppb NO<sub>2</sub> at 1, 2, or 3 weeks. In vitro exposure of human AMs to 5,000 ppb NO<sub>2</sub> for 3 hours did not result in statistically significant changes in release of neutrophil chemotactic factor (IL-8) or IL-1 or changes in markers of macrophage activity ([Pinkston et al., 1988](#)).

### **Other Subclinical Effects**

As examined in a few studies of humans, bronchial epithelial cells showed increased virus-induced cytotoxicity as measured by lactate dehydrogenase (LDH) release following exposure to 600 and 1,500 ppb NO<sub>2</sub> ([Frampton et al., 2002](#)) as well as increased expression of intercellular adhesion molecule 1 (ICAM-1), an extracellular receptor for viruses following exposure to 2,000 ppb NO<sub>2</sub> ([Pathmanathan et al., 2003](#)).

### **Immunoglobulin Antibody Response**

Immunoglobulin M antibodies increase in response to infections, and a recent epidemiologic study of adults infected with human immunodeficiency virus and hospitalized for pneumocystis pneumonia found a 34% (95% CI: 6.5, -60) diminished antibody response to pneumocystis proteins per 20-ppb increase in 24-h avg ambient NO<sub>2</sub> concentrations (lag 0–2 day avg) ([Blount et al., 2013](#)). Potential confounding by

traffic-related copollutants or factors such as meteorology, sex, and SES was not examined. Further, because subjects were distributed at varying distances of the single central site monitor, which was located within 1 km of major roads, the impact of exposure measurement error on the results is uncertain. Thus, the results do not strongly inform the understanding of the effects of NO<sub>2</sub> on respiratory infections.

---

#### 5.2.5.5 Summary of Respiratory Infection

The strongest evidence for an effect of short-term NO<sub>2</sub> exposure on respiratory infections is from toxicological studies, although results vary by exposure concentration. NO<sub>2</sub> exposures of 500 or 600 ppb, whether for a few hours, 1 week, or 1 month, did not affect infection-induced mortality or bacterial clearance or killing in experimental animals or affect virus titers or inactivation in humans (Table 5-22). Susceptibility to bacterial infection did increase in experimental animals following NO<sub>2</sub> exposures of 2 to 48 hours in the range of 1,000 to 5,000 ppb. Thus, there is some evidence from toxicological studies to support the associations observed in some epidemiologic studies between increases in ambient NO<sub>2</sub> concentrations (5- to 7-day avg) and increases in respiratory infections. Although many epidemiologic studies observed null or imprecise associations with wide 95% CIs for hospital admissions, ED visits, and parental reports of infection (Table 5-23 and Figure 5-10), some observed associations with hospital admissions or ED visits for bronchiolitis, ear infection, or any respiratory infection. Epidemiologic associations were observed in study populations with respiratory disease (i.e., children with asthma, adults with COPD). Most epidemiologic studies did not examine copollutant confounding, and respiratory infections also were associated with PM<sub>2.5</sub>, the traffic-related pollutants BS, OC, and CO, as well as other highly correlated pollutants such as PM<sub>10</sub> and SO<sub>2</sub> ( $r = 0.74$  to  $0.92$ ). The toxicological evidence is not conclusive, but there is some biological plausibility for NO<sub>2</sub>-induced impaired host defense. Some studies demonstrated effects on potential mechanistic events underlying susceptibility to infection. Results vary across studies, with NO<sub>2</sub> exposures in the range of 1,000 to 5,000 ppb showing variable effects on pulmonary clearance and superoxide production by AMs but decreasing phagocytic activity in AMs isolated from exposed experimental animals and humans. In both experimental animals and humans, NO<sub>2</sub> exposures of 100 to 500 ppb (Table 5-26) did not consistently affect pulmonary clearance or AM numbers or superoxide production. There was heterogeneity across studies in animal species, strain, and sex that may or may not have contributed to inconsistencies observed in response to NO<sub>2</sub>. Although NO<sub>2</sub> exposure shows inconsistent effects on various endpoints related to respiratory infection, there is some supporting epidemiologic evidence for incidence of respiratory infections, evidence in mice for susceptibility to infection, and evidence from

experimental studies for decreased AM function that provides some indication that short-term NO<sub>2</sub> exposure may increase risk of respiratory infection.

---

## 5.2.6 Aggregated Respiratory Conditions

In addition to individual respiratory conditions, epidemiologic studies examined respiratory effects as an aggregate of multiple respiratory conditions (e.g., asthma, COPD, respiratory infections). The studies from the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) and recent studies consistently show associations between short-term increases in ambient NO<sub>2</sub> concentration and increases in aggregated respiratory conditions. This evidence is based primarily on hospital admissions and ED visits for all respiratory diseases, which are the focus of the discussion in this section. Other outcomes include lung function in adults with asthma or COPD and sales of medication for asthma and COPD combined or cough and mucus combined. As described in preceding sections, evidence for the effects of short-term NO<sub>2</sub> exposure varies among specific respiratory outcome groups. Thus, it is not clear whether the evidence for aggregated respiratory conditions reflects associations with each respiratory condition equally or a particular condition(s).

---

### 5.2.6.1 Respiratory Symptoms, Lung Function, and Medication Use

Outcomes such as lung function decrements in adults with asthma and/or COPD ([Rice et al., 2013](#); [Higgins et al., 2000](#)) and increases in the sale of medication for asthma and COPD combined or for cough and mucus combined ([Pitard et al., 2004](#); [Zeghnoun et al., 1999](#)) were associated with ambient NO<sub>2</sub> (24-h avg, lagged 0 to 7 days or 0–1 day avg) in a small group of epidemiologic studies, with exception of the [Higgins et al. \(1995\)](#) study. However, uncertainties in these studies result in weak inference of the independent effects of NO<sub>2</sub>. Associations with medication sales were modeled with GAM in S-plus ([Pitard et al., 2004](#)), which can produce biased results ([U.S. EPA, 2006](#)). In the Framingham cohort study, lung function was associated with PM<sub>2.5</sub> ( $r = 0.63$ ) ([Rice et al., 2013](#)), and a copollutant model was not analyzed. The other lung function studies did not report what potential confounding factors were examined ([Higgins et al., 2000](#); [1995](#)). Another uncertainty is potential exposure measurement error produced by the use of central site ambient concentrations to represent ambient exposure. The Framingham study averaged NO<sub>2</sub> concentrations from sites in the Boston, MA area ([Rice et al., 2013](#)). With one or two observations per subject collected over 3–9 years, the analysis relied on both temporal and spatial contrasts in exposure. With individuals distributed across a 40 km area and variability in ambient NO<sub>2</sub> observed across a range of 3 to 10 km in

Boston ([Section 2.5.2](#)), it is not clear how well the average area concentration represents ambient exposure of study subjects.

---

#### **5.2.6.2 Hospital Admissions and Emergency Department Visits for All Respiratory Diseases**

Epidemiologic studies examining the association between short-term NO<sub>2</sub> exposures and respiratory-related hospital admissions or ED visits were not available until after the completion of the 1993 AQCD for Oxides of Nitrogen. As a result, the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) contained the first thorough evaluation of respiratory morbidity in the form of respiratory-related hospital admissions and ED visits. The majority of the studies evaluated consisted of single-city, time-series studies that examined all respiratory hospital admissions or ED visits with additional cause-specific studies, as discussed in previous sections. Studies of all respiratory hospital admissions and ED visits consistently reported positive associations with short-term NO<sub>2</sub> exposures ([Figure 5-13](#) and [Table 5-28](#)). In the few analyses of copollutant models with PM<sub>2.5</sub> or a traffic-related copollutant among CO, UFP, benzene, or BS, NO<sub>2</sub> associations were generally found to be robust ([U.S. EPA, 2008c](#)). The evidence supporting NO<sub>2</sub>-associated increases in all respiratory disease hospital admission and ED visits contributed heavily to the 2008 ISA for Oxides of Nitrogen conclusion that “there is a likely causal relationship between short-term exposure to NO<sub>2</sub> and effects on the respiratory system” ([U.S. EPA, 2008c](#)). The air quality characteristics of the cities and the exposure assignment approach used in each study evaluated in this section are presented in [Table 5-27](#). As detailed in [Section 5.2.2.4](#), other recent studies of all respiratory disease hospital admissions and ED visits are not the focus of this evaluation, and the full list of these studies, as well as study details, can be found in [Supplemental Table S5-3](#) ([U.S. EPA, 2015h](#)).

**Table 5-27 Mean and upper percentile concentrations of nitrogen dioxide in studies of hospital admissions and emergency department visits for aggregated respiratory conditions.**

Study	Location Years	Exposure Assignment	Metric	Mean Concentration ppb	Upper Percentile Concentrations ppb	Copollutant Examination
<a href="#">Yang et al. (2003)</a>	Vancouver, BC, Canada (1986– 1998)	Average of NO <sub>2</sub> concentrations from 30 monitors.	24-h avg	18.7	NR	Correlations ( <i>r</i> ): O <sub>3</sub> : -0.32 Copollutant models: O <sub>3</sub>
<a href="#">Fung et al. (2006)</a>	Vancouver, BC, Canada (1995– 1999)	Average of NO <sub>2</sub> concentrations over all monitors.	24-h avg	16.8	Max: 33.9	Correlations ( <i>r</i> ): CO: 0.74 CoH: 0.72 O <sub>3</sub> : -0.32 SO <sub>2</sub> : 0.57 PM <sub>10</sub> : 0.54 PM <sub>2.5</sub> : 0.36 PM <sub>10-2.5</sub> : 0.52 Copollutant models: none
<a href="#">Burnett et al. (2001)</a>	Toronto, ON, Canada (1980– 1994)	Average of NO <sub>2</sub> concentrations from 4 monitors.	1-h max	44.1	146	Correlations ( <i>r</i> ): O <sub>3</sub> : 0.52 Copollutant models: O <sub>3</sub>
<a href="#">†Cakmak et al. (2006)</a>	10 Canadian cities (1993– 2000)	Average of NO <sub>2</sub> concentrations over all monitors within each city.	24-h avg	21.4	Max: 44–134	Correlations ( <i>r</i> ): NR Copollutant models: none
<a href="#">†Wong et al. (2009)</a>	Hong Kong, China (1996– 2002)	Average of NO <sub>2</sub> concentrations across 8 monitors.	24-h avg	31.2	75th: 37.0 Max: 89.4	Correlations ( <i>r</i> ): NR Copollutant models: none
<a href="#">†Dales et al. (2006)</a>	11 Canadian cities (1986– 2000)	Average of NO <sub>2</sub> concentrations over all monitors within each city.	24-h avg	21.8	95th: 21–43	Correlations ( <i>r</i> ), across cities: PM <sub>10</sub> : -0.26 to 0.69 O <sub>3</sub> : -0.55 to 0.05 SO <sub>2</sub> : 0.20–0.67 CO: 0.13–0.76 Copollutant models: none

**Table 5-27 (Continued): Mean and upper percentile concentrations of nitrogen dioxide in studies of hospital admissions and emergency department visits for aggregated respiratory conditions.**

Study	Location Years	Exposure Assignment	Metric	Mean Concentration ppb	Upper Percentile Concentrations ppb	Copollutant Examination
<a href="#">†Son et al. (2013)</a>	8 South Korean cities (2003– 2008)	Hourly ambient NO <sub>2</sub> concentrations from monitors in each city.	24-h avg	11.5–36.9	NR	Correlations ( <i>r</i> ): PM <sub>10</sub> : 0.5 O <sub>3</sub> : -0.1 SO <sub>2</sub> : 0.6 CO: 0.7 Copollutant models: none
<a href="#">†Atkinson et al. (2012)</a>	Meta-analysis (Asia) (years NR)	NR	24-h avg	NR	NR	Correlations ( <i>r</i> ): NR Copollutant models: none
<a href="#">†Faustini et al. (2013)</a>	6 Italian cities (2001– 2005)	Average of NO <sub>2</sub> concentrations over all monitors within each city. Number of NO <sub>2</sub> monitors in each city ranged from 1–5. <sup>a</sup>	24-h avg	24.1–34.6	NR	Correlations ( <i>r</i> ), across cities: PM <sub>10</sub> : 0.22–0.79 Copollutant models: PM <sub>10</sub>

**Table 5-27 (Continued): Mean and upper percentile concentrations of nitrogen dioxide in studies of hospital admissions and emergency department visits for aggregated respiratory conditions.**

Study	Location Years	Exposure Assignment	Metric	Mean Concentration ppb	Upper Percentile Concentrations ppb	Copollutant Examination
<a href="#">Peel et al. (2005)</a>	Atlanta, GA (1993– 2000)	Average of NO <sub>2</sub> concentrations from monitors for several monitoring networks.	1-h max	45.9	NR	Correlations (r): PM <sub>2.5</sub> : 0.46 PM <sub>10</sub> : 0.49 PM <sub>10-2.5</sub> : 0.46 UFP: 0.26 PM <sub>2.5</sub> Water Soluble Metals: 0.32 PM <sub>2.5</sub> Sulfate: 0.17 PM <sub>2.5</sub> Acidity: 0.10 PM <sub>2.5</sub> OC: 0.63 PM <sub>2.5</sub> EC: 0.61 Oxygenated HCs: 0.30 O <sub>3</sub> : 0.42 CO: 0.68 SO <sub>2</sub> : 0.34 Copollutant models: none
<a href="#">Tolbert et al. (2007)</a>	Atlanta, GA (1993– 2004)	Average of NO <sub>2</sub> concentrations from monitors for several monitoring networks.	1-h max	81.7	306	Correlations (r): PM <sub>2.5</sub> : 0.47 PM <sub>10</sub> : 0.53 PM <sub>10-2.5</sub> : 0.4 PM <sub>2.5</sub> Sulfate: 0.14 PM <sub>2.5</sub> OC: 0.62 PM <sub>2.5</sub> EC: 0.64 PM <sub>2.5</sub> TC: 0.65 PM <sub>2.5</sub> Water Soluble Metals: 0.32 Oxygenated HCs: 0.24 O <sub>3</sub> : 0.44 CO: 0.70 SO <sub>2</sub> : 0.36 Copollutant models: CO, PM <sub>10</sub> , O <sub>3</sub>

**Table 5-27 (Continued): Mean and upper percentile concentrations of nitrogen dioxide in studies of hospital admissions and emergency department visits for aggregated respiratory conditions.**

Study	Location Years	Exposure Assignment	Metric	Mean Concentration ppb	Upper Percentile Concentrations ppb	Copollutant Examination
<a href="#">†Darrow et al. (2011a)</a>	Atlanta, GA (1993– 2004)	Epidemiologic analysis used NO <sub>2</sub> concentrations from 1 centrally located monitor. Assessment of spatial heterogeneity relied upon all monitors from ARIES and the U.S. EPA.	1-h max 24-h avg Commute <sup>b</sup> Daytime <sup>b</sup> Nighttime <sup>b</sup>	1-h max: 43 24-h avg: 22 Commute: 21 Daytime: 17 Nighttime: 25	75th: 1-h max: 53 24-h avg: 28 Commute: 27 Daytime: 22 Nighttime: 35  Max: 1-h max: 181 24-h avg: 74 Commute: 97 Daytime: 82 Nighttime: 97	Correlations ( <i>r</i> ), for averaging times specified in current NAAQS: CO, 1-h: 0.61 O <sub>3</sub> , 8-h: 0.34 PM <sub>2.5</sub> , 24-h: 0.42 Copollutant models: none

Avg = average; BC = British Columbia; CO = carbon monoxide; CoH = coefficient of haze; EC = elemental carbon; ED = emergency department; GA = Georgia; HC = hydrocarbon; NAAQS = National Ambient Air Quality Standards; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; O<sub>3</sub> = ozone; OC = organic carbon; ON = Ontario; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm; SO<sub>2</sub> = sulfur dioxide; TC = total carbon; UFP = ultrafine particles; U.S. EPA = United States Environmental Protection Agency.

<sup>a</sup>Monitoring information obtained from [Colais et al. \(2012\)](#).

<sup>b</sup>Commute = 7 ante meridiem (a.m.)– 10 a.m., 4 p.m.–7 p.m., Daytime = 8 a.m.–7 p.m., Nighttime = 12 a.m.–6 a.m.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

## Hospital Admissions

Multicity studies conducted in Canada ([Cakmak et al., 2006](#); [Dales et al., 2006](#)), Italy ([Faustini et al., 2013](#)) and Korea ([Son et al., 2013](#)), as well as a single-city study conducted in Hong Kong, China ([Wong et al., 2009](#)) observed associations between short-term NO<sub>2</sub> concentrations and hospital admissions for all respiratory diseases, each focusing on a different age range ([Figure 5-13](#) and [Table 5-28](#)). Additional support for an association between short-term NO<sub>2</sub> exposures and respiratory hospital admissions comes from a meta-analysis of studies conducted in Asian cities ([Atkinson et al., 2012](#)).

[Cakmak et al. \(2006\)](#) focused on all ages in 10 Canadian cities with the primary objective of the study being to examine the potential modification of the effect of ambient air pollution on daily respiratory hospital admissions by education and income using a time-series analysis conducted at the city level (the effect measure modification analysis is discussed in [Chapter 7](#)). The authors calculated a pooled estimate across cities for each pollutant using a random effects model by first selecting the lag day with the strongest

association from the city-specific models. For NO<sub>2</sub>, the mean lag day across cities that provided the strongest association and for which the pooled effect estimate was calculated was 1.4 days. At this lag, [Cakmak et al. \(2006\)](#) reported a 2.3% increase (95% CI: 0.2, 4.5) in respiratory hospital admissions for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations. This result is consistent with a study conducted in Hong Kong, China that examined whether influenza modifies the relationship between air pollution exposure and hospital admissions ([Wong et al., 2009](#)). [Wong et al. \(2009\)](#) observed a 3.2% (95% CI: 1.9, 4.5) increase in all respiratory disease hospital admissions for all ages at lag 0–1 days for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations, with an association slightly smaller in magnitude for acute respiratory disease (2.1% [95% CI: -0.1, 4.3]), which comprises approximately 39% of all respiratory disease hospital admissions in Hong Kong, China. [Cakmak et al. \(2006\)](#) also examined the potential confounding by other pollutants but only through the use of a multipollutant model (i.e., two or more additional pollutants included in the model). These models are difficult to interpret due to the multicollinearity between pollutants and are not evaluated in this ISA.

In an additional multicity study conducted in 11 Canadian cities, [Dales et al. \(2006\)](#) focused on NO<sub>2</sub>-associated respiratory hospital admissions in neonatal infants (ages 0–27 days). The investigators used a statistical analysis approach similar to [Cakmak et al. \(2006\)](#) (i.e., time-series analysis to examine city-specific associations, and then a random effects model to pool estimates across cities). [Dales et al. \(2006\)](#) observed that the mean lag day across cities that provided the strongest association for NO<sub>2</sub> was 1 day, which corresponded to a 6.5% (95% CI: 3.5, 9.6) increase in neonatal respiratory hospital admissions for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations. Similar to [Cakmak et al. \(2006\)](#), [Dales et al. \(2006\)](#) only examined the potential confounding effects of other pollutants on the NO<sub>2</sub>-respiratory hospital admission association through the use of multipollutant models, which are not informative due to multicollinearity between pollutants.

The results of [Cakmak et al. \(2006\)](#) and [Wong et al. \(2009\)](#), which focus on all ages, are further supported by [Son et al. \(2013\)](#), a study that examined the association between short-term exposures to air pollution and respiratory-related hospital admissions in eight South Korean cities. South Korea has unique demographic characteristics with some indicators more in line with other more developed countries (e.g., life expectancy, percentage of population living in urban areas), but because it represents a rapidly developing Asian country, it is likely to have different air pollution, social, and health patterns than less industrialized Asian nations or Western nations that developed earlier ([Son et al., 2013](#)). In a time-series analysis using a two-stage Bayesian hierarchical model, [Son et al. \(2013\)](#) examined both single-day lags and cumulative lags up to 3 days (i.e., lag 0–3). The authors only presented NO<sub>2</sub> results for the strongest lag and observed

a 3.6% increase (95% CI: 1.0, 6.1) in respiratory disease hospital admissions at lag 0 for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations. These results are consistent with those of a meta-analysis of studies conducted in Asian cities by [Atkinson et al. \(2012\)](#), which in a random effects model based on five estimates, reported a 3.5% increase (95% CI: 0.6, 6.5) in respiratory hospital admissions for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations.

[Son et al. \(2013\)](#) did not conduct copollutant analyses; however, similar patterns of associations were observed across pollutants that were moderately [PM<sub>10</sub> ( $r = 0.5$ ); SO<sub>2</sub> ( $r = 0.6$ )] to highly correlated [CO ( $r = 0.7$ )] with NO<sub>2</sub>. [Son et al. \(2013\)](#) also examined potential seasonal differences in all respiratory disease hospital-admission associations. The authors reported that the association with NO<sub>2</sub> was largest in magnitude during the summer (8.3% [95% CI: 2.8, 14.3], lag 0). However, across the eight cities, NO<sub>2</sub> concentrations were lowest during the summer season (<20 ppb compared to >24 ppb in the other seasons), which complicates the interpretation of these results.

[Faustini et al. \(2013\)](#) focused on examining the relationship between short-term air pollution exposures and respiratory hospital admissions, specifically on the adult population (i.e., individuals 35 years of age and older) in six Italian cities. In a time-series analysis the authors examined the lag structure of associations through single-day lags as well as cumulative lags, using cubic polynomial distributed lags, in an attempt to identify whether the NO<sub>2</sub> effect on respiratory-related hospital admissions was immediate (lag 0, lag 0–1 days), delayed (lag 2–5 days), or prolonged (lag 0–3, 0–5 days). The authors reported that NO<sub>2</sub> was most strongly associated with all respiratory hospital admissions at lag 0–5 days (4.6% [95% CI: 0.87, 8.3] for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations), which differs from [Cakmak et al. \(2006\)](#) and [Dales et al. \(2006\)](#) where the strongest effects were observed at lags less than 2 days. However, [Faustini et al. \(2013\)](#) did observe positive associations, although smaller in magnitude (ranging from 2.5–2.9%) at the shorter lags (i.e., lag 0 and 0–1 days). [Faustini et al. \(2013\)](#) only examined potential copollutant confounding of NO<sub>2</sub> associations in models with PM<sub>10</sub>, and reported that the NO<sub>2</sub> association with respiratory hospital admissions at lag 0–5 days was attenuated slightly, but remained positive (3.3% [95% CI: –1.1, 7.8]).

## Emergency Department Visits

Studies of ED visits for aggregated respiratory conditions that were evaluated in the 2008 ISA for Oxides of Nitrogen were few in number and focused almost exclusively on study populations consisting of all ages, and U.S. studies were limited to Atlanta, GA. Building on the previous studies conducted in Atlanta, GA ([Tolbert et al., 2007](#); [Peel et al., 2005](#)), [Darrow et al. \(2011a\)](#) examined associations between short-term air pollution exposures

and all respiratory ED visits. To examine the association between the various NO<sub>2</sub> exposure metrics and respiratory ED visits, the authors conceptually used a time-stratified case-crossover framework in which control days were selected as those days within the same calendar month and maximum temperature as the case day. However, instead of conducting a traditional case-crossover analysis, the authors used a Poisson model with indicator variables for each of the strata (i.e., parameters of the control days). [Darrow et al. \(2011a\)](#) only reported results for a 1 day lag in NO<sub>2</sub> concentrations. For a 30-ppb increase in 1-h max NO<sub>2</sub> concentrations, the authors reported a 1.4% increase (95% CI: 0.8, 2.1) in all respiratory ED visits. These results are slightly smaller than those reported by [Peel et al. \(2005\)](#) and [Tolbert et al. \(2007\)](#), but this could be attributed to the fact that the latter two studies used a multiday average of NO<sub>2</sub> concentrations (i.e., lag 0–2 days) instead of the single-day lag used in [Darrow et al. \(2011a\)](#).


### ***Model Specification—Sensitivity Analyses***

A question that often arises in the examination of associations between air pollution and a health effect is whether the statistical model employed adequately controls for the potential confounding effects of temporal trends and meteorological conditions. [Son et al. \(2013\)](#), in the study of eight South Korean cities, conducted a sensitivity analysis to identify whether risk estimates changed depending on the *df* used to control for temporal trends and meteorology covariates (i.e., temperature, humidity, and barometric pressure). Similar to the other respiratory-related hospital admission outcomes examined, the authors reported that the association between short-term NO<sub>2</sub> exposures and all respiratory disease hospital admissions was sensitive to using less than 6 *df* per year to control for temporal trends, but was stable when using 6–10 *df* per year. Additionally, when varying the number of *df* used for the meteorology covariates from 3 to 6 *df* as well as the lag structure (i.e., lag 0 and lag 0–3 days), the NO<sub>2</sub> association remained robust (i.e., relatively unchanged).

### ***Exposure Assignment***

In addition to model specification, the method used to assign exposure in epidemiologic studies has been suggested to influence the magnitude and direction of air pollution-health effects associations. As discussed in [Section 5.2.2.4](#), [Strickland et al. \(2011\)](#) examined exposure assignment in the case of asthma ED visits in Atlanta, GA and found that different exposure assignment approaches could influence the magnitude, but not direction of associations. [Darrow et al. \(2011a\)](#) also used data from Atlanta, GA to examine the influence of alternative exposure metrics on the association between short-term NO<sub>2</sub> concentrations and all respiratory ED visits along with the spatial variability of each exposure metric.

To examine whether all respiratory ED visits associations differed depending on the exposure metric used, [Darrow et al. \(2011a\)](#) used five different exposure metrics: (1) 1-h max; (2) 24-h avg; (3) commuting period (7:00 a.m. to 10:00 a.m. and 4:00 p.m. to 7:00 p.m.); (4) daytime avg (8:00 a.m. to 7:00 p.m.); and (5) nighttime avg (12:00 a.m. to 6:00 a.m.). The authors reported relatively consistent results (using an a priori lag of 1 day) across exposure metrics with the largest estimate found for the nighttime avg and the smallest for the daytime metrics ([Figure 5-11](#)). The larger risk estimate for the nighttime metric could be a reflection of NO<sub>2</sub> during this exposure duration being a better surrogate for NO<sub>2</sub> concentrations on the previous day ([Darrow et al., 2011a](#)). The correlations of 1-h max NO<sub>2</sub> with most of the other NO<sub>2</sub> metrics were lower than those for other pollutants examined in the study (i.e.,  $r < 0.60$ ). However, 1-h max NO<sub>2</sub> was highly correlated with 24-h avg NO<sub>2</sub> ( $r = 0.79$ ), which is the other NO<sub>2</sub> metric often examined in epidemiologic studies.




Note: ave = average; hr = hour; IQR = interquartile range; max = maximum; NO<sub>2</sub> = nitrogen dioxide. Partial Spearman correlation coefficient between a priori metrics (shaded in gray) and other pollutant metrics shown above the x-axis.

Source: Reprinted with permission of Nature Publishing Group ([Darrow et al., 2011a](#)).

**Figure 5-11 Risk ratio and 95% confidence intervals for associations between various lag 1 day nitrogen dioxide metrics and respiratory emergency department visits.**

In the analysis of the spatial correlation of exposure metrics for NO<sub>2</sub>, [Darrow et al. \(2011a\)](#) found that unlike O<sub>3</sub> and PM<sub>2.5</sub>, which were spatially homogenous, there was evidence that correlations for NO<sub>2</sub> metrics decreased dramatically as distance from the central site monitor increased ([Figure 5-12](#)). This was especially true for the 1-h max and nighttime metrics ( $r < 0.20$ ) at 60 km. The 24-h avg metric was also reduced ( $r = \sim 0.40$ ), but not as dramatically as the 1-h max. Although reduced at greater distances, moderate correlations ( $r = \sim 0.50$ ) were reported with the central site monitor for the daytime and


commute time metrics. Overall, these results suggest evidence of potential exposure misclassification for NO<sub>2</sub> with increasing distance from the central site monitor across exposure metrics.



Note: ave = average; hr = hour; km = kilometer; max = maximum; NO<sub>2</sub> = nitrogen dioxide.  
Source: Reprinted with permission of Nature Publishing Group, [Darrow et al. \(2011a\)](#).

**Figure 5-12** Spatial correlations for nitrogen dioxide metrics in the Atlanta, GA area.

As detailed within this section, hospital admission and ED visit studies of all respiratory diseases consistently report positive associations with short-term increases in ambient NO<sub>2</sub> concentrations. As presented in [Figure 5-13](#) and [Table 5-28](#), associations are consistently observed in studies evaluated in the 2008 ISA for Oxides of Nitrogen as well as recent studies.



Note: CI = confidence interval; DL = distributed lag; ED = emergency department; GA = Georgia. Black circles = studies from the 2008 Integrated Science Assessment for Oxides of Nitrogen, red = recent studies. a = This estimate is for acute respiratory diseases, which comprise approximately 39% of all respiratory disease hospital admissions in Hong Kong, China. Effect estimates are standardized to a 20-ppb increase in 24-h NO<sub>2</sub> or 30-ppb increase in 1-h max NO<sub>2</sub>.

**Figure 5-13 Percentage increase in all respiratory disease hospital admissions and emergency department visits in relation to nitrogen dioxide concentrations.**

**Table 5-28 Corresponding risk estimate for studies presented in Figure 5-13.**

Study	Location	Age	Avg Time	Lag	% Increase (95% CI)
<b>Hospital Admissions</b>					
<a href="#">†Cakmak et al. (2006)</a>	10 Canadian cities	All	24-h avg	1.4	2.3 (0.2, 4.5)
<a href="#">†Atkinson et al. (2012)</a>	Meta-analysis (Asia)	All	24-h avg	---	3.5 (0.6, 6.5)
<a href="#">†Son et al. (2013)</a>	8 South Korean cities	All	24-h avg	0	3.6 (1.0, 6.1)
<a href="#">†Dales et al. (2006)</a>	11 Canadian cities	0–27 days	24-h avg	1	6.5 (3.5, 9.6)
<a href="#">Burnett et al. (2001)</a>	Toronto, ON, Canada	<2	1-h max	0–1	13.3 (5.3, 22.0)
<a href="#">Yang et al. (2003)</a>	Vancouver, BC, Canada	<3	24-h avg	1	19.1 (7.4, 36.3)
<a href="#">†Faustini et al. (2013)</a>	6 Italian cities	35+	24-h avg	0–5 DL	4.6 (0.9, 8.3)
<a href="#">Fung et al. (2006)</a>	Vancouver, BC, Canada	65+	24-h avg	0–2	9.1 (1.5, 17.2)
<a href="#">†Wong et al. (2009)<sup>a</sup></a>	Hong Kong, China	All	24-h avg	0–1	3.2 (1.9, 4.5)
		65+	24-h avg	0–1	4.0 (2.4, 5.7)
<a href="#">Yang et al. (2003)</a>	Vancouver, BC, Canada	65+	24-h avg	1	19.1 (11.2, 27.5)
<a href="#">†Wong et al. (2009)<sup>a</sup></a>	Hong Kong, China	All	24-h avg	0–1	2.1 (–0.1, 4.3)
		65+	24-h avg	0–1	1.7 (–0.6, 4.0)
<b>Emergency Department Visits</b>					
<a href="#">Peel et al. (2005)</a>	Atlanta, GA	All	1-h max	0–2	2.4 (0.9, 4.1)
<a href="#">Tolbert et al. (2007)</a>	Atlanta, GA	All	1-h max	0–2	2.0 (0.5, 3.3)
<a href="#">†Darrow et al. (2011a)</a>	Atlanta, GA	All	1-h max	1	1.4 (0.8, 2.1)

avg = average; BC = British Columbia; CI = confidence interval; DL = distributed lag; GA = Georgia; max = maximum; ON = Ontario.

<sup>a</sup>This estimate is for acute respiratory diseases, which comprise approximately 39% of all respiratory disease hospital admissions in Hong Kong, China.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

---

### 5.2.6.3 Summary of Aggregated Respiratory Conditions

Previous and recent epidemiologic studies consistently indicate associations between short-term increases in ambient NO<sub>2</sub> concentrations and increases in respiratory effects aggregated across specific conditions such as asthma, COPD, and respiratory infections. A majority of the available evidence is for hospital admissions for all respiratory diseases combined ([Figure 5-13](#) and [Table 5-29](#)), with a few additional studies of ED visits for all respiratory diseases, lung function in adults with asthma or COPD, or medication sales for unspecified respiratory effects. Associations of NO<sub>2</sub> with respiratory disease hospital admissions and ED visits are observed to be larger for children and older adults; limited evidence points to differences in risk by sex and SES.

With respect to the lag structure of associations, evidence indicates that the largest increase in all respiratory hospital admissions and ED visits occurs within the first few days after NO<sub>2</sub> exposure, specifically lags of 0 to 2 days. An examination of model specification indicated the NO<sub>2</sub>-respiratory hospital admission relationship was robust to alternative lags and *df* for weather covariates ([Son et al., 2013](#)). Thus, varying approaches to modeling weather did not appear to be a source of confounding. NO<sub>2</sub> effect estimates were sensitive to using less than 6 *df* per year to account for temporal trends, but most studies did not model temporal trends with fewer *df*. The limited analysis of potential seasonal differences suggests that NO<sub>2</sub> associations with all respiratory disease hospital admissions are stronger during the summer ([Son et al., 2013](#)). In a comparison of averaging times, similar associations with all respiratory disease ED visits were observed for 1-h max and 24-h avg NO<sub>2</sub> ([Darrow et al., 2011a](#)).

The epidemiologic evidence for associations of NO<sub>2</sub> with aggregated respiratory effects is based on exposure assessment from central site monitors. In two study locations, Boston, MA ([Section 2.5.2](#)) and Atlanta, GA ([Darrow et al., 2011a](#)), between-monitor correlation in ambient NO<sub>2</sub> concentration decreased with increasing distance. Thus, it is unclear the extent to which temporal variation in central site NO<sub>2</sub> concentrations represent variation in exposure among subjects. Also, studies of aggregated respiratory effects did not thoroughly examine potential confounding by traffic-related copollutants, which in many studies, showed moderate to high ( $r = 0.61$ – $0.76$ , [Table 5-28](#)) correlations with NO<sub>2</sub>. In limited analysis of copollutant models, NO<sub>2</sub> associations with all respiratory hospital admissions and ED visits persisted with adjustment for CO or PM<sub>2.5</sub> ([Tolbert et al., 2007](#)) ([Figures 5-16](#) and [5-17](#)). However, potential differential measurement error resulting from central site exposure assessment limits inference from the copollutant model results. Further, given the variable nature of evidence for the effects of short-term NO<sub>2</sub> exposure among specific respiratory conditions ([Sections 5.2.2](#), [5.2.4](#), and [5.2.5](#)), it is not clear

whether the evidence for aggregated respiratory conditions reflects associations with each respiratory condition equally or a particular condition(s).

---

## 5.2.7 Respiratory Effects in Healthy Populations

Similar to populations with asthma and COPD, an array of respiratory outcomes has been examined in relation to short-term exposure to NO<sub>2</sub> in healthy populations. The 2008 ISA for Oxides of Nitrogen did not draw inferences specifically about respiratory effects of NO<sub>2</sub> exposure in healthy populations ([U.S. EPA, 2008c](#)) but described epidemiologic associations of short-term increases in ambient NO<sub>2</sub> concentration with increases in respiratory symptoms and decreases in lung function in children. Evidence from experimental studies varied across outcomes, indicating no effects on respiratory symptoms or lung function in healthy adults. However, NO<sub>2</sub> exposure did affect underlying key events, inducing increases in airway responsiveness and PMNs in healthy adults generally at 1,000-ppb NO<sub>2</sub> exposure or higher. Recent evidence, which is from epidemiologic studies, continues to indicate NO<sub>2</sub>-related respiratory effects in healthy populations, most consistently seen as increases in pulmonary inflammation.

---

### 5.2.7.1 Airway Responsiveness in Healthy Individuals

Recent studies are not available, but the 2008 ISA for Oxides of Nitrogen reported that increases in nonspecific airway responsiveness were observed in healthy adults following 1- to 3-hour NO<sub>2</sub> exposures in the range of 1,500 to 3,000 ppb ([U.S. EPA, 2008c](#)). Studies of airway responsiveness in healthy individuals were generally conducted using volunteers ages 18 to 35+ years. [Mohsenin \(1988\)](#) found that a 1-hour resting exposure to 2,000 ppb NO<sub>2</sub> increased responsiveness to methacholine. A mild increase in responsiveness to carbachol was observed following a 3-hour exposure to 1,500 ppb NO<sub>2</sub> with moderate intermittent exercise ( $\dot{V}_E = 40$  L/min; 10 of 30 minutes) ([Frampton et al., 1991](#)). [Kulle and Clements \(1988\)](#) also showed a tendency for greater FEV<sub>1</sub> decrements from methacholine challenge following 2-hour resting exposures to 2,000 and 3,000 ppb NO<sub>2</sub>. Resting exposures to 100 ppb NO<sub>2</sub> for 1 hour did not affect carbachol or methacholine responsiveness in healthy subjects ([Ahmed et al., 1983a](#); [Hazucha et al., 1983](#)). Two meta-analyses of the available literature confirm statistically significant effects of NO<sub>2</sub> exposures above 1,000 ppb, but not below, on airway responsiveness in healthy individuals ([Kjaergaard and Rasmussen, 1996](#); [Folinsbee, 1992](#)).

---

### 5.2.7.2 Lung Function Changes in Healthy Populations

Compared with evidence for airway responsiveness to an inhaled bronchoconstrictor, the 2008 ISA for Oxides of Nitrogen reported weak evidence for the effects of NO<sub>2</sub> exposure on changes in lung function in the absence of a bronchoconstrictor in controlled human exposure and epidemiologic studies of healthy adults ([U.S. EPA, 2008c](#)). A small body of epidemiologic studies of children in the general population indicated associations between increases in ambient NO<sub>2</sub> concentration and decrements in lung function measured by supervised spirometry. Several recent studies, which are epidemiologic, contribute inconsistent evidence for ambient NO<sub>2</sub>-associated lung function decrements in children in the general population.

#### **Epidemiologic Studies of Children in the General Population**

As in other populations, ambient NO<sub>2</sub> concentrations are more consistently associated with lung function decrements in children in the general population as measured by supervised spirometry than by home PEF. However, many studies of supervised spirometry did not find associations with ambient NO<sub>2</sub> concentrations. Locations, time periods, and ambient concentrations of oxides of nitrogen for these studies are presented in [Table 5-29](#). The studies recruited children from schools, supporting the likelihood that study populations were representative of the population of children in the study areas.

The most informative studies of lung function in children are those examining NO<sub>2</sub> concentrations outdoor schools or at a central site adjacent to schools, which may represent a component of the subjects' ambient exposures. These metrics were inconsistently associated with lung function in children ([Altuğ et al., 2014](#); [Castro et al., 2009](#); [Moshhammer et al., 2006](#); [Scarlett et al., 1996](#)). The inconsistent evidence does not appear to be related to the health status of the study population. NO<sub>2</sub> was not associated with lung function in children without respiratory symptoms ([Altuğ et al., 2014](#)), but results were inconsistent in groups of children with prevalence of asthma or wheeze of 5 or 9% ([Castro et al., 2009](#); [Scarlett et al., 1996](#)). Associations were found with same-day NO<sub>2</sub> and NO<sub>2</sub> averaged over 3 to 8 days but were inconsistent for Lag Day 1. [Linn et al. \(1996\)](#) found that a 20-ppb increase in lag 0 of central site NO<sub>2</sub> was associated with a -5.2 mL (95% CI: -13, 2.3) change in evening FEV<sub>1</sub> among children in three southern California communities. These results have relatively strong inference about an association with ambient NO<sub>2</sub> exposure because daily average personal and ambient NO<sub>2</sub> were reported to be well correlated ( $r = 0.63$ ).

**Table 5-29 Mean and upper percentile oxides of nitrogen concentrations in epidemiologic studies of lung function in the general population.**

Study <sup>a</sup>	Location	Study Period	Exposure Metric Analyzed	Mean/Median Concentration ppb	Upper Percentile Concentrations ppb
<a href="#">†Altuğ et al. (2014)</a>	Eskisehir, Turkey	Feb–Mar 2007	24-h avg NO <sub>2</sub>	Suburban: 9.4, Urban: 13.0 Traffic: 21.2	Max: 13.1 Max: 17.7 Max: 28.2
<a href="#">†Castro et al. (2009)</a>	Rio de Janeiro, Brazil	May, Jun, Sep, Oct 2004	24-h avg NO <sub>2</sub>	49.2 <sup>b</sup>	Max: 115 <sup>b</sup>
<a href="#">Moshhammer et al. (2006)</a>	Linz, Austria	School yr 2000–2001	8-h avg NO <sub>2</sub> (12–8 a.m.)	NR	NR
			24-h avg NO <sub>2</sub>	9.3 <sup>b</sup>	75th: 11.4 <sup>b</sup>
<a href="#">Scarlett et al. (1996)</a>	Surrey, U.K.	Jun–Jul 1994	1-h max NO <sub>2</sub>	34.9	Max: 82
<a href="#">Linn et al. (1996)</a>	Upland, Rubidoux, Torrance, CA	School yr 1992–1994	24-h avg NO <sub>2</sub>	33	Max: 96
<a href="#">Ofstedal et al. (2008)</a>	Oslo, Norway	Nov 2001–Dec 2002	24-h avg NO <sub>2</sub>	14.4 <sup>b</sup>	Max: 59.2 <sup>b</sup>
<a href="#">†Padhi and Padhy (2008)</a>	West Bengal, India	Jun 2006–Jul 2007	24-h avg NO <sub>2</sub> indoor	LPG: 37.7, Biomass fuel: 71.7	75th: LPG: 44, Biomass fuel: 90
			24-h avg NO indoor	LPG: 27.5, Biomass fuel: 46.7	75th: LPG: 30, Biomass fuel: 55
<a href="#">†Eenhuizen et al. (2013)</a>	3 study areas in the Netherlands	Oct 2000–Nov 2001	24-h avg NO <sub>2</sub>	16.0 <sup>b</sup>	75th: 23.2 <sup>b</sup> Max: 47.9 <sup>b</sup>
<a href="#">†Chang et al. (2012)</a>	Taipei, Taiwan	Dec 1996–May 1997	6-day avg NO <sub>2</sub>	31.8	75th: 41.7
<a href="#">†Bagheri Lankarani et al. (2010)</a>	Tehran, Iran	NR	24-h avg NO <sub>2</sub>	75.5, 17.6 <sup>b</sup>	Max: 119, 25.5 <sup>b</sup>
			24-h NO	51.6, 40.4 <sup>b</sup>	Max: 85.1, 110 <sup>b</sup>
			24-avg NO <sub>x</sub>	72.9, 38.8 <sup>b</sup>	Max: 122, 94.7 <sup>b</sup>
<a href="#">Steerenberg et al. (2001)</a>	Utrecht, the Netherlands	Feb–Mar 1998	24-h avg NO <sub>2</sub>	28.2 <sup>b</sup>	Max: 44.7 <sup>b</sup>
			24-h avg NO	30.2 <sup>b</sup>	Max: 168 <sup>b</sup>
	Bilthoven, the Netherlands		24-h avg NO <sub>2</sub>	25.5 <sup>b</sup>	Max: 49.5 <sup>b</sup>
			24-h avg NO	7.4 <sup>b</sup>	Max: 85.6 <sup>b</sup>

**Table 5-29 (Continued): Mean and upper percentile oxides of nitrogen concentrations in epidemiologic studies of lung function in the general population.**

Study <sup>a</sup>	Location	Study Period	Exposure Metric Analyzed	Mean/Median Concentration ppb	Upper Percentile Concentrations ppb
<a href="#">Peacock et al. (2003)</a>	Rochester-upon-Medway, U.K.	Nov 1996–Feb 1997	24-h avg NO <sub>2</sub> 1-h max NO <sub>2</sub>	17.4, 17.1, 19.2 28.5, 28.1, 31.8	Max: 39, 39, 43 Max: 67, 71, 98
† <a href="#">Correia-Deur et al. (2012)</a>	São Paulo, Brazil	Apr–Jul 2004	24-h avg	Mean: 69.9 <sup>b</sup>	75th: 84.5 <sup>b</sup> 90th: 102 <sup>b</sup>
<a href="#">van der Zee et al. (2000)</a> <a href="#">van der Zee et al. (1999)</a>	Rotterdam, Nunspeet, Bodegraven/Reeuwij, Amsterdam, Meppel, the Netherlands	Three winters 1992–1993 1993–1994 1994–1995	24-h avg NO <sub>2</sub>	27.1, 17.6 <sup>b</sup> 25.5, 13.3 <sup>b</sup> 25.0, 11.7 <sup>b</sup>	Max: 50, 44.2 <sup>b</sup> Max: 40.4, 28.7 <sup>b</sup> Max: 43.6, 30.3 <sup>b</sup>
<a href="#">Ranzi et al. (2004)</a>	Emiglia-Romagna, Italy	Feb–May 1999	24-h avg NO <sub>2</sub>	Urban: 37.0 <sup>b</sup> Rural: 18.51 <sup>b</sup>	NR NR
<a href="#">Ward et al. (2000)</a>	West Midlands, U.K.	Jan–Mar 1997 May–Jul 1997	24-h avg NO <sub>2</sub>	NR	NR
<a href="#">Roemer et al. (1998)</a>	Sweden, Germany, Finland, Hungary, Norway, Italy, Greece, Czech Republic, the Netherlands	Winter 1993–1994	24-h avg NO <sub>2</sub>	Across locations: 6.7–39.8 <sup>b</sup>	NR
<a href="#">Timonen and Pekkanen (1997)</a>	Kuopio, Finland	Feb–Apr 1994	24-h avg NO <sub>2</sub>	Urban: 14.9 <sup>b</sup> Suburban: 7.4 <sup>b</sup>	Max: 41.5 <sup>b</sup> Max: 27.1 <sup>b</sup>
<a href="#">Schindler et al. (2001)</a>	Aarau, Basel, Davos, Geneva, Lugano, Montana, Payerne, Wald, Switzerland	NR	24-h avg NO <sub>2</sub>	19.5 <sup>b</sup>	Max: 69.3 <sup>b</sup>
† <a href="#">Steinvil et al. (2009)</a>	Tel Aviv, Israel	Sep 2002–Nov 2007	24-h avg NO <sub>2</sub>	19.3	75th: 25.3 Max: 59.9
† <a href="#">Cakmak et al. (2011a)</a>	14 Canadian cities	Mar 2006–Mar 2007	24-h avg NO <sub>2</sub>	12.6	95th: 29.4
† <a href="#">Lepeule et al. (2014)</a>	Boston, MA area	1999–2009	24-h avg NO <sub>2</sub>	20.2 <sup>b</sup>	95th: 23.9 <sup>b</sup>
† <a href="#">Son et al. (2010)</a>	Ulsan, South Korea	2003–2007	24-h avg NO <sub>2</sub>	21.4	75th: 26.1 Max: 44.8

**Table 5-29 (Continued): Mean and upper percentile oxides of nitrogen concentrations in epidemiologic studies of lung function in the general population.**

Study <sup>a</sup>	Location	Study Period	Exposure Metric Analyzed	Mean/Median Concentration ppb	Upper Percentile Concentrations ppb
† <a href="#">Agarwal et al. (2012)</a>	Patiala, Punjab area, India	Aug–Jan 2007–2009	1-mo avg NO <sub>2</sub>	For 2008 Aug–Sep: 8.4 <sup>b</sup> Oct–Nov: 21.9 <sup>b</sup> Dec–Jan: 17.4 <sup>b</sup>	NR
† <a href="#">Weichenthal et al. (2011)</a>	Ottawa, ON, Canada	NR	1-h avg NO <sub>2</sub>	High traffic: 4.8 Low traffic: 4.6	Max: 11 Max: 10
† <a href="#">Thaller et al. (2008)</a>	Galveston, TX	Summers 2002, 2003, 2004	24-h avg NO <sub>2</sub> 1-h max NO <sub>2</sub>	1.2 3.2	Max: 7.1 Max: 27.7
† <a href="#">Strak et al. (2012)</a>	Bilthoven, the Netherlands	Mar–Oct 2009	5-h avg NO <sub>x</sub> 5-h avg NO <sub>2</sub>	36 20	Max: 96 Max: 34
† <a href="#">Dales et al. (2013)</a>	Sault Ste. Marie, ON, Canada	May–Aug 2010	10-h avg NO <sub>2</sub> (8 a.m.–6 p.m.)	Near steel plant: 7.1 Distant site: 4.5	NR

a.m. = ante meridiem; Aug = August; avg = average; CA = California; Dec = December; Feb = February; LPG = liquefied petroleum gas; MA = Massachusetts; max = maximum; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; NR = not reported; ON = Ontario; ppb = parts per billion; TX = Texas; U.K. = United Kingdom.

<sup>a</sup>Studies presented in order of first appearance in the text of this section.

<sup>b</sup>NO<sub>2</sub> concentrations converted from µg/m<sup>3</sup> to ppb by multiplying by 0.532, NO concentrations converted by multiplying by 0.815. Both conversions assume standard temperature (25°C) and pressure (1 atm).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

In the studies examining ambient NO<sub>2</sub> metrics representing subjects' school or personal (total or indoor) exposure, there is uncertainty regarding confounding by PM<sub>2.5</sub> or traffic-related copollutants. Associations were found with CO, PM<sub>1</sub>, and PM<sub>2.5</sub> ([Castro et al., 2009](#); [Padhi and Padhy, 2008](#); [Moshhammer et al., 2006](#); [Linn et al., 1996](#)); other traffic-related pollutants were not examined. There is some information on potential confounding of NO<sub>2</sub>-related lung function decrements in children by PM<sub>2.5</sub>, and results are inconclusive. [Ofstedal et al. \(2008\)](#) observed high correlations ( $r = 0.83$ – $0.95$ ) among NO<sub>2</sub>, PM<sub>2.5</sub>, and PM<sub>10</sub> estimated by a dispersion model. [Linn et al. \(1996\)](#) did not provide quantitative results and indicated only that NO<sub>2</sub> effect estimates lost statistical significance with adjustment for PM<sub>2.5</sub> measured at schools, which could have differential exposure error than NO<sub>2</sub> measured at central sites. Among children in Austria, with pollutants measured at a site adjacent to the school, NO<sub>2</sub> effect estimates were unchanged with adjustment for moderately correlated PM<sub>2.5</sub> ( $r = 0.54$ ) ([Moshhammer et al., 2006](#)). A 25-ppb increase in lag 1 of 8-h avg NO<sub>2</sub> (12–8 a.m.) was associated with a –4.1% change

(95% CI: -6.4, -1.7) in FEV<sub>1</sub> in the single-pollutant model and a -4.7% change (95% CI: -7.3, -2.0) with adjustment for PM<sub>2.5</sub>. PM<sub>2.5</sub> effect estimates were attenuated or became positive with adjustment for NO<sub>2</sub>. While these results indicate an independent association with NO<sub>2</sub>, other model covariates were not specified, and potential confounding by other factors such as weather cannot be assessed.

Among studies of supervised spirometry, evidence was inconsistent for associations with NO<sub>2</sub> and NO ascertained from central sites ([Eenhuizen et al., 2013](#); [Chang et al., 2012](#); [Bagheri Lankarani et al., 2010](#); [Ofstedal et al., 2008](#); [Steerenberg et al., 2001](#)). Results were inconsistent for PEF as well as FEV<sub>1</sub>, and no association was found with a measure of airway resistance. Controlled human exposure studies, conducted in healthy adults, do not consistently indicate effects on ambient-relevant NO<sub>2</sub> exposures on FEV<sub>1</sub> (see below) or airway resistance ([Section 4.3.2.2](#)). In addition to the inconsistent findings, there is uncertainty as to whether the NO<sub>2</sub> concentrations from an average of area central sites or one central site represent the variability in NO<sub>2</sub> concentrations across the study area or subjects' ambient exposure, particularly in the many cross-sectional studies that make up the evidence base. Inconsistencies also were found between studies that measured NO<sub>2</sub> at sites located 2 km from children's schools ([Chang et al., 2012](#); [Steerenberg et al., 2001](#)). Repeated measures and cross-sectional studies found associations with adjustment for time-varying factors such as weather as well as between-subject factors such as height, weight, smoking exposure, and SES. However, copollutant confounding was not examined, and lung function also was associated with the traffic-related pollutants CO and BS ([Chang et al., 2012](#); [Steerenberg et al., 2001](#)) as well as PM<sub>10</sub>, SO<sub>2</sub>, and O<sub>3</sub>.

A fairly large body of studies, conducted in various European countries, does not strongly support NO<sub>2</sub>-associated decrements in home measurements of PEF in children. These studies were similar to studies of supervised lung function in that they examined populations that included children with respiratory symptoms, asthma, or atopy and measured NO<sub>2</sub> concentrations at central sites and schools. Outdoor school NO<sub>2</sub> concentrations were associated with an increase in PEF in children with 25% wheeze prevalence ([Peacock et al., 2003](#)). Associations with central site NO<sub>2</sub> tended to be positive ([Roemer et al., 1998](#); [Timonen and Pekkanen, 1997](#)) or null ([Ranzi et al., 2004](#); [Ward et al., 2000](#); [van der Zee et al., 1999](#)). A recent study found an NO<sub>2</sub>-associated decrease in PEF among children that was independent of CO ([Correia-Deur et al., 2012](#)) ([Table 5-30](#)) but did not report information to assess whether NO<sub>2</sub> and CO averaged across multiple sites in the city adequately represented exposure or had comparable exposure measurement error.

**Table 5-30 Epidemiologic studies of lung function in children and adults in the general population.**

Study Population Examined and Methodological Details	Oxide of Nitrogen Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<b>Children in the General Population</b>				
<p><a href="#">Linn et al. (1996)</a> Upland, Rubidoux, Torrance, CA n = 269, 4th–5th grades Repeated measures. Supervised spirometry. Examined 1 week/season for 2 yr. Recruitment from schools. 75–90% follow-up participation across communities. Repeated measures ANOVA adjusted for year, day, temperature, rain. Time spent outdoors = 101–136 min across seasons and communities.</p>	<p>NO<sub>2</sub>-central site 24-h avg # sites NR, no site in Torrance <i>r</i> = 0.63 correlation with personal NO<sub>2</sub></p>	0	<p>p.m. FEV<sub>1</sub>: –5.2 mL (–13, 2.3) p.m. FVC: –3.6 mL (–12, 4.6) Diurnal change FEV<sub>1</sub>: –7.8 (–14, –1.5) Diurnal change FVC: –2.2 (–9.6, 4.9)</p>	<p>No quantitative results. NO<sub>2</sub> association reported to lose statistical significance with adjustment for PM<sub>2.5</sub> measured at school. Lung function weakly associated with O<sub>3</sub>. Weak correlation with PM<sub>2.5</sub>. <i>r</i> = 0.25.</p>
<p>†<a href="#">Castro et al. (2009)</a> Rio de Janeiro, Brazil n = 118, ages 6–15 yr, 18.4% with asthma Repeated measures. Supervised PEF. Recruitment from school. Examined daily for 6 weeks. 9–122 observations per subject. No information on participation rate. Mixed effects model with random effect for subject and adjusted for weight, height, sex, age, asthma, smoking exposure, time trend, temperature, relative humidity.</p>	<p>NO<sub>2</sub>-school outdoor 24-h avg School was within 2 km of homes</p>	<p>1 1–2 avg 1–3 avg</p>	<p>PEF (L/min): 0.04 (–0.58, 0.65) –0.60 (–1.3, 0.14) –0.83 (–1.7, 0.02)</p>	<p>No copollutant model. Associations also found with PM<sub>10</sub>. Associations with CO and SO<sub>2</sub> had wide 95% CIs.</p>

**Table 5-30 (Continued): Epidemiologic studies of lung function in children and adults in the general population.**

Study Population Examined and Methodological Details	Oxide of Nitrogen Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<p><a href="#">Scarlett et al. (1996)</a> Surrey, U.K. n = 154, ages 7–11 yr, 9% with wheeze Repeated measures. Supervised spirometry. Examined daily for 6 weeks. Recruitment from school. No information on participation rate. Lung function adjusted for machine, operator, day of week. Individual subject regressions adjusted for temperature, humidity, pollen. Pooled estimates obtained using weighting method.</p>	<p>NO<sub>2</sub>-school outdoor 1-h max</p>	<p></p>	<p>FEV<sub>0.75</sub>: 0.30% (–0.29, 0.89) FVC: 5.5% (–5.1, 17)</p>	<p>No copollutant model. Association found with PM<sub>10</sub>. No to moderate correlations with NO<sub>2</sub>. <i>r</i> = 0.07 for PM<sub>10</sub>, 0.50 for 8-h max O<sub>3</sub>.</p>
<p><a href="#">Moshhammer et al. (2006)</a> Linz, Austria n = 163, ages 7–10 yr Repeated measures. Supervised spirometry. Examined every 2 weeks for school yr. Recruitment from schools. No information on participation rate. GEE model, covariates not specified.</p>	<p>NO<sub>2</sub>-central site 8-h avg (12 a.m.–8 a.m.) Site adjacent to school</p>	<p>0</p>	<p>FEV<sub>1</sub>: –4.1% (–6.4, –1.7) FVC: –2.7% (–5.1, –0.33)</p>	<p>With PM<sub>2.5</sub>: –4.7% (–7.3, –2.0) PM<sub>2.5</sub> results attenuated or become positive. Associations also found for PM<sub>1</sub>, PM<sub>10</sub>. Moderate correlations with NO<sub>2</sub>. <i>r</i> = 0.53 for PM<sub>1</sub>, 0.54 for PM<sub>2.5</sub>, 0.62 for PM<sub>10</sub>.</p>
<p><a href="#">†Altuğ et al. (2014)</a> Eskisehir, Turkey; Feb–Mar 2007 n = NR, ages 9–13 yr, no upper respiratory symptoms Cross-sectional. Supervised spirometry. Recruitment from schools of participants of a larger study. No information on participation rate. Logistic regression adjusted for sex, age, asthma, parental smoking, coal or wood stove use, parental education, height, weight, daily average temperature.</p>	<p>NO<sub>2</sub>-outdoor school 24-h avg 1 site at each of 16 schools</p>	<p>0–6 avg</p>	<p>FEV<sub>1</sub>: 0% (–14, 17) FVC: 3.8% (–7.3, 16)</p>	<p>No copollutant model. O<sub>3</sub> associated with PEF only. Strong inverse correlation with NO<sub>2</sub>. Pearson <i>r</i> = –0.80. NO<sub>2</sub> and PM<sub>2.5</sub> reported to be highly correlated.</p>

**Table 5-30 (Continued): Epidemiologic studies of lung function in children and adults in the general population.**

Study Population Examined and Methodological Details	Oxide of Nitrogen Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p><a href="#">Ofteidal et al. (2008)</a> Oslo, Norway n = 2,170, ages 9–10 yr, 5.5% with asthma Cross-sectional. Supervised spirometry. Recruitment from a birth cohort. 67% participation, 60% follow-up. Examined subjects had more “Westernized” parents. Linear regression adjusted for age, sex, height, BMI, current asthma, early life maternal smoking, parental ethnicity, education, smoking, and atopy, lag 1–3 temperature, neighborhood variables (% married, % with income &lt; median, etc.), long-term NO<sub>2</sub>.</p>	<p>NO<sub>2</sub>-dispersion model NO<sub>2</sub>-central site 24-h avg 1 city site</p>	<p>1–3 avg 1–7 avg 1–30 avg</p>	<p>Quantitative results not reported. Association observed with lag 1–3-day avg and 1–7-day avg. Larger effect estimated for lag 1–30-day avg. Central site no association.</p>	<p>No copollutant model. No association reported for PM<sub>2.5</sub>. Correlations among pollutants = 0.83–0.95. Short-term association attenuated with adjustment for early or lifetime NO<sub>2</sub>. <i>r</i> = 0.46–0.77 among NO<sub>2</sub> metrics.</p>
<p><a href="#">Steerenberg et al. (2001)</a> Utrecht and Bilthoven, the Netherlands n = 126, ages 8–13 yr, 28% respiratory disease, 20% allergy Repeated measures. Supervised PEF. Examined 1/week for 7–8 weeks. Recruitment from urban and suburban schools. 65% participation. Mixed effects model adjusted for sex, age, # cigarettes smoked in home, presence of a cold, history of respiratory symptoms and allergy. No consideration for potential confounding by meteorological factors.</p>	<p>NO<sub>2</sub>-central site 15-h avg (8 a.m.–11 p.m.) 24-h avg Site within 2 km of schools NO-central site 15-h avg (8 a.m.–11 p.m.) 24-h avg</p>	<p>0 0–2 avg 15-h avg 0–2 avg</p>	<p>PEF (mL/min): Urban: –17 (–35,0) Suburban: 7, <i>p</i> &gt; 0.05 Urban: 0, <i>p</i> &gt; 0.05 Suburban: 6, <i>p</i> &gt; 0.05 Urban: 1, <i>p</i> &gt; 0.05 Suburban: 0, <i>p</i> &gt; 0.05 Urban: –6 (–12, 0) Suburban: 6, <i>p</i> &gt; 0.05</p>	<p>No copollutant model. BS associated with PEF. Correlation with NO<sub>2</sub> and NO NR. Association also found with PM<sub>10</sub>.</p>
<p>†<a href="#">Chang et al. (2012)</a> Taipei, Taiwan n = 2,919, ages 12–16 yr Cross-sectional. Supervised spirometry. Recruitment from schools. No information on participation rate. Regression model adjusted for residence in district, age, sex, height, weight, temperature, rainfall.</p>	<p>NO<sub>2</sub>-central site 4-h avg (8 a.m.–12 p.m.) 10-h avg (8 a.m.–6 p.m.) Average of 5 city sites within 2 km of schools</p>	<p>0 1 2</p>	<p>FEV<sub>1</sub> (mL): –25 (–57, 7.5) –41 (–70, –11) –2.5 (–50, 45)</p>	<p>No copollutant model. Associations also found with SO<sub>2</sub>, CO, O<sub>3</sub>, PM<sub>10</sub>.</p>

**Table 5-30 (Continued): Epidemiologic studies of lung function in children and adults in the general population.**

Study Population Examined and Methodological Details	Oxide of Nitrogen Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<p>†<a href="#">Eenhuizen et al. (2013)</a> 3 study areas in the Netherlands n = 880, age 8 yr Cross-sectional. Recruitment from intervention study of mattress allergy covers. Valid data on 49% subjects, who had higher parental education, less likely to have pets. Linear regression adjusted for sex, age, height, weight, prenatal smoke exposure, smoking in home, gas stove, parental allergy, dampness in home, parental education, season, temperature, humidity.</p>	<p>NO<sub>2</sub>-central site 1 site</p>	<p>0 1</p>	<p>Interrupter resistance (kPAxs/L): 0 (-0.04, 0.04) -0.02 (-0.06, 0.03) Positive effect estimate indicates increase in resistance</p>	<p>No associations with PM<sub>10</sub> or BS. Moderate correlations with NO<sub>2</sub>. Pearson <i>r</i> = 0.47 for PM<sub>10</sub>, 0.60 for BS.</p>
<p>†<a href="#">Bagheri Lankarani et al. (2010)</a> Tehran, Iran n = 562, elementary school age Repeated measures. Examined daily for 6 weeks. No information on participation rate. 158 case-days. Case crossover with control dates as 2 weeks before and after case date. Conditional logistic regression adjusted for daily temperature, lag 0–6-day avg PM<sub>10</sub>.</p>	<p>NO-central site 24-h avg 2 city sites</p>	<p>0–6 avg</p>	<p>PEF &lt;50% predicted: OR: 18 (1, 326)</p>	<p>No copollutant model. PM<sub>10</sub> associated with decreased odds of large PEF decrement.</p>
<p>†<a href="#">Padhi and Padhy (2008)</a> West Bengal, India n = 755 from biomass fuel homes, 372 from liquefied petroleum gas homes, ages 5–10 yr Cross-sectional. Supervised spirometry. Recruitment method and participation not reported. Multiple regression adjusted for unspecified covariates.</p>	<p>NO<sub>2</sub>-indoor home 24-h avg</p>	<p>NR</p>	<p>Biomass fuel homes Lung function units NR FEV<sub>1</sub>: -1.05 (-1.75, -0.35) FVC: -1.09 (-1.58, -0.61) Liquefied gas petroleum homes FEV<sub>1</sub>: -5.41 (-8.33, -2.50) FVC: -5.17 (-9.17, -1.17)</p>	<p>No copollutant model. CO also associated with lung function. Correlation with NO<sub>2</sub> NR. SPM, SO<sub>2</sub>, O<sub>3</sub> also associated with lung function.</p>

**Table 5-30 (Continued): Epidemiologic studies of lung function in children and adults in the general population.**

Study Population Examined and Methodological Details	Oxide of Nitrogen Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<p><a href="#">†Correia-Deur et al. (2012)</a> São Paulo, Brazil n = 31, ages 9–11 yr, no allergic sensitization Repeated measures. Daily supervised spirometry for 15 school days. Number of observations not reported. Recruitment from school. 86% participation. Allergic sensitization ascertained by skin prick test, blood eosinophils, and serum IgE. GEE with autoregressive correlation matrix adjusted for date, school absence, temperature, humidity.</p>	<p>NO<sub>2</sub>-outdoor school 24-h avg</p>	<p>0</p>	<p>PEF: -1.0% (-1.7, -0.35)</p>	<p>Lag 0, all subjects With CO: -1.5% (-3.0, 0) Moderate correlation with NO<sub>2</sub>. <i>r</i> = 0.51. CO association persists with NO<sub>2</sub> adjustment. with SO<sub>2</sub>: -1.9% (-3.3, -0.4) with PM<sub>10</sub>: -0.8% (-4.4, 3.1) with O<sub>3</sub>: -1.5% (-3.3, 0.38) Moderate correlations with NO<sub>2</sub>. <i>r</i> = 0.59, 0.60, 0.40. O<sub>3</sub> association persists with NO<sub>2</sub> adjustment. SO<sub>2</sub> &amp; PM<sub>10</sub> attenuated.</p>
<p><a href="#">Peacock et al. (2003)</a> Rochester-upon-Medway, U.K. n = 177, ages 7–13 yr, 25% with wheeze Repeated measures. Home PEF. Examined daily for 13 weeks. 14–63 observations/subject. Recruitment from rural and urban schools. No information on participation rate. Individual subject regressions adjusted for day of week, date, temperature. Estimates pooled using weighting method.</p>	<p>NO<sub>2</sub>-outdoor school 24-h avg</p>	<p>0–4 avg</p>	<p>PEF: -0.20 (-3.0, 2.6) OR for PEF &gt; 20%: 2.3 (1.0, 5.4)</p>	<p>No copollutant model. PM<sub>2.5</sub> also associated with PEF decrement &gt;20%. Correlation NR.</p>
<p><a href="#">van der Zee et al. (1999)</a> Rotterdam, Bodegraven/Reeuwijk, Amsterdam, Meppel, Nunspeet, the Netherlands n = 633, ages 7–11 yr, 50% with symptoms, 33% with asthma Repeated measures. Home PEF. Examined daily for 3 mo. Recruitment from school and mail. 47% responded to initial survey, 80% follow-up participation. Logistic regression adjusted for minimum temperature, day of week, time trend, influenza.</p>	<p>NO<sub>2</sub>-central site 24-h avg 1 site per community</p>	<p>0</p>	<p>ORs Urban: 0.96 (0.79, 1.2) Suburban: 0.77 (0.54, 1.1) Urban: 1.1 (0.93, 1.3) Suburban: 0.99 (0.72, 1.4)</p>	<p>Associations found for PM<sub>10</sub>, BS, SO<sub>4</sub>, and SO<sub>2</sub> in urban area. Correlations NR.</p>

**Table 5-30 (Continued): Epidemiologic studies of lung function in children and adults in the general population.**

Study Population Examined and Methodological Details	Oxide of Nitrogen Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<p><a href="#">Roemer et al. (1998)</a> Germany, Finland, the Netherlands, Czech Republic, Norway, Italy, Greece, Hungary, Sweden—26 locations n = 2,010, ages 6–12 yr, atopy prevalence: 7–81% Repeated measures. Home PEF. Examined daily for 2 mo. 85% of enrolled included in analysis. Regression model adjusted for minimum temperature, school day, time trend. Individual panel results combined in a meta-analysis.</p>	<p>NO<sub>2</sub>-central site 24-h avg</p>	<p>0 0–6 avg</p>	<p>PEF (L/min): 0.15 (–0.19, 0.49) 0.23 (–1.2, 1.6)</p>	<p>Association found with PM<sub>10</sub> and BS, but not consistently across lags.</p>
<p><a href="#">Ranzi et al. (2004)</a> Emilia-Romagna, Italy n = 118, ages 6–11 yr, 77% with asthma, 67% with atopy Repeated measures. Home PEF. Examined daily for 12 weeks. 98.4% follow-up participation. Recruited from schools. GLM adjusted for sex, medication use, symptoms, temperature, humidity</p>	<p>NO<sub>2</sub>-central site 24-h avg # sites NR</p>	<p>0</p>	<p>No quantitative data. Figure shows no association in group with and without atopy.</p>	<p>PM<sub>2.5</sub> associated with PEF in urban group.</p>
<p><a href="#">Ward et al. (2000)</a> West Midlands, U.K. n = 147, age 9 yr, 24% with symptoms, 31% with atopy Repeated measures. Home PEF. Examined daily for two 8-week periods. Recruitment from schools. Individual subject regressions adjusted for time trend, day of week, meteorological variables, pollen count. Individual regressions pooled with weighting method.</p>	<p>NO<sub>2</sub>-central site 24-h avg 2 sites</p>	<p>0, 1, 2, 3, 0–4 avg</p>	<p>No quantitative data. Figure shows no association across lags, except at Lag Day 0 in symptomatic group.</p>	<p>No copollutant model. Associations with PM<sub>2.5</sub> equally inconsistent.</p>

**Table 5-30 (Continued): Epidemiologic studies of lung function in children and adults in the general population.**

Study Population Examined and Methodological Details	Oxide of Nitrogen Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<a href="#">Timonen and Pekkanen (1997)</a> Kuopio, Finland n = 169, ages 7–12 yr, children with cough Repeated measures. Home PEF. Examined daily for 3 mo. Recruitment from schools. 86% participation. Linear mixed model adjusted for time trend, weekend, minimum temperature, relative humidity.	NO <sub>2</sub> -central site 24-h avg # sites NR 26% missing data were modeled, r = 0.58	0	FEV <sub>1</sub> Urban: 11 (–14, 35) Suburban: –6.5 (–40, 27)	Associations found for SO <sub>2</sub> in urban group. Weak correlations with NO <sub>2</sub> . r = 0.22.
		1–4 avg	PEF Urban: 13 (–24, 50) Suburban: –22 (–87, 43)	
<b>Adults in the General Population</b>				
<a href="#">†Strak et al. (2012)</a> Utrecht area, the Netherlands n = 31, adults ages 19–26 yr, all healthy, nonsmoking Repeated measures. Supervised spirometry. Examined 3–7 times. 107 observations. Recruitment from university. No information on participation rate. Well-defined outdoor exposures at various traffic/nontraffic sites. Heart rate maintained during intermittent exercise. Higher probability of associations found by chance alone. Mixed effects model adjusted for temperature, relative humidity, season, high/low pollen, respiratory infection.	NO <sub>2</sub> -personal outdoor 5-h avg Measured next to subjects during outdoor exposures	0-h	FVC post-exposure: –4.3% (–7.4, –1.0)	FVC with PNC: NO <sub>2</sub> : –3.0% (–7.2, 1.4) NO <sub>x</sub> : –0.11% (–2.6, 2.5) Moderate to high correlation with NO <sub>2</sub> . Spearman r = 0.56, 0.75.
		2-h	–3.5% (–6.5, –0.43)	
		18-h	–4.5% (–7.4, –1.4)	
	NO <sub>x</sub> -personal outdoor 5-h avg	0-h	–1.6% (–2.6, –0.51)	PNC association attenuated with adjustment for NO <sub>2</sub> or NO <sub>x</sub> .
		2-h	–2.0% (–4.9, –0.16)	
		18-h	–2.5% (–5.4, –0.69)	

**Table 5-30 (Continued): Epidemiologic studies of lung function in children and adults in the general population.**

Study Population Examined and Methodological Details	Oxide of Nitrogen Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<p><a href="#">†Dales et al. (2013)</a> Sault Ste. Marie, ON, Canada n = 59, adults mean (SD) age 24.2 (5.8) yr, all healthy Repeated measures. Supervised spirometry. Examined 10 times. Total observations NR. Recruitment from university. No information on participation rate. Well-defined outdoor exposures near steel plant and university campus 4.5 km away. Exposures occurred at rest except for 30-min exercise to increase heart rate to 60% predicted maximum. Mixed effect model with autoregressive correlation matrix and adjusted for site, day of week, mean temperature, humidity. Well-defined outdoor exposures near steel plant and university campus 4.5 km away. Exposures occurred at rest except for 30-min exercise to increase heart rate to 60% predicted maximum. Mixed effect model with autoregressive correlation matrix and adjusted for site, day of week, mean temperature, humidity.</p>	<p>NO<sub>2</sub>-on site of outdoor exposure 10-h avg (8 a.m.-6 p.m.)</p>	<p>0-h Post-exposure</p>	<p>% predicted FEV<sub>1</sub>: -10.9 (-13.3, -8.6) % predicted FVC: -9.2 (-14.5, -3.9)</p>	<p>No copollutant model. Associations found with UFP and PM<sub>2.5</sub>. Correlations NR. All pollutants higher at steel plant than at university campus. Associations also found with SO<sub>2</sub> and O<sub>3</sub>.</p>
<p><a href="#">†Weichenthal et al. (2011)</a> Ottawa, ON, Canada n = 42, adults ages 19–58 yr, from nonsmoking homes, 95% white, 62% with allergies, 33% with asthma Repeated measures. Supervised spirometry. Most examined 3 times. 118 observations. 1-h outdoor exposures during cycling in low and high traffic areas. Recruitment from public advertisements. No information on participation rate. Differential exposure measurement error for personal PM and VOCs and central site NO<sub>2</sub>. Mixed effects models with random subject effect adjusted for temperature during cycling, average heart rate. Adjustment for relative humidity, day of week did not affect results.</p>	<p>NO<sub>2</sub>-central site 1-h avg 1 site</p>	<p>1-h 4-h Post-exposure</p>	<p>FEV<sub>1</sub> (L): 0.54 (-0.15, 1.2) 0.40 (-0.12, 0.92)</p>	<p>No copollutant model. Lung function not associated with O<sub>3</sub> or VOCs, UFP, BC, PM<sub>2.5</sub>.</p>

**Table 5-30 (Continued): Epidemiologic studies of lung function in children and adults in the general population.**

Study Population Examined and Methodological Details	Oxide of Nitrogen Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p><a href="#">†Thaller et al. (2008)</a> Galveston, TX n = 142, lifeguards at work, ages 16–27 yr, 13% with asthma, 22% with allergies Repeated measures. Supervised spirometry. Recruitment from worksite. 1,140 observations. Self-report of physician-diagnosed asthma. 81% follow-up participation. GLM, covariates not specified.</p>	<p>NO<sub>2</sub> &amp; NO<sub>x</sub>-central site 24-h avg, 1-h max 1 site 4–12 km from beaches</p>	0	<p>No quantitative data. NO<sub>2</sub> and NO<sub>x</sub> reported not to be significantly associated with lung function.</p>	<p>No copollutant model.</p>
<p><a href="#">Schindler et al. (2001)</a> Aarau, Basel, Davos, Geneva, Lugano, Montana, Payerne, Wald, Switzerland n = 3,912, ages 18–60 yr, nonsmokers Cross-sectional. Supervised spirometry. Recruitment from registry and SALPADIA cohort. Sample representative of full cohort. Regression model adjusted for sex, age, height, weight, day of week, temperature, relative humidity. Adjustment for asthma medication or wheeze did not alter results.</p>	<p>NO<sub>2</sub>-central site 24-h avg 1 site per city</p>	<p>0 0–3 avg</p>	<p>FEV<sub>1</sub>: –2.5% (–4.5, –0.48) –2.9% (–5.9, 0.21)</p>	<p>With TSP: –1.2% (–3.8, 1.6)</p>
<p><a href="#">van der Zee et al. (2000)</a> Rotterdam, Bodegraven/Reeuwijk, Amsterdam, Meppel, Nunspeet, the Netherlands n = 274, ages 50–70 yr, no symptoms in previous 12 mo Repeated measures. Home PEF. Examined daily for 3 mo. Recruitment from mailings. 81% enrolled included in final analysis. Logistic regression adjusted for minimum temperature, day of week, time trend, influenza.</p>	<p>NO<sub>2</sub>-central site 24-h avg 1 site per community</p>	<p>0 0–4 avg</p>	<p>OR for PEF decrease &gt;10% Urban: 0.85 (0.59, 1.2) Suburban: 0.72 (0.50, 1.05) Urban: 0.46 (0.20, 1.08) Suburban: 0.56 (0.27, 1.16)</p>	<p>No copollutant model. PEF associated with PM<sub>10</sub> and SO<sub>4</sub> in urban group. Wide range of correlations with NO<sub>2</sub>. Spearman <i>r</i> = 0.16–0.72 for PM<sub>10</sub>, 0.25–0.65 for BS.</p>

**Table 5-30 (Continued): Epidemiologic studies of lung function in children and adults in the general population.**

Study Population Examined and Methodological Details	Oxide of Nitrogen Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p>†<a href="#">Cakmak et al. (2011a)</a> 15 cities, Canada n = 5,011, ages 6–79 yr, mean age 39 yr Cross-sectional. Supervised spirometry. Recruitment by random sampling of households. No information on participation rate. GLMM adjusted for age, sex, income, education, smoking, random effect for site. Adjustment for temperature and relative humidity did not alter results.</p>	<p>NO<sub>2</sub>-central site 24-h avg # sites NR</p>	0	<p>% predicted FEV<sub>1</sub>: –1.6 (–2.9, –0.35)</p>	<p>No copollutant model. O<sub>3</sub> and PM<sub>2.5</sub> also associated with lung function. Correlations NR.</p>
<p>†<a href="#">Lepeule et al. (2014)</a>, <a href="#">Lepeule (2014)</a> Boston, MA area n = 776, all male, mean (SD) age at baseline 72.3 (6.8) yr, Normative Aging Study Longitudinal. Supervised spirometry. Examined 1–4 times over 10 yr. No information on recruitment over follow-up participation. Linear mixed effects model adjusted for age, log-height, race, education, standardized weight, smoking status, pack-years smoking, chronic lung condition, methacholine responsiveness, medication use season, day of week, visit number, temperature, humidity. Adjusting for cardiovascular disease did not alter results.</p>	<p>NO<sub>2</sub>-central site 24-h avg Average of 5 sites in Boston area. Median 21.4 km from subjects' homes.</p>	<p>0 0–2 avg 0–27 avg</p>	<p>FEV<sub>1</sub>: –0.08% (–1.92, 1.80) –1.00% (–3.45, 1.51) –13.0% (–17.9, 7.75) Low IL-6 gene methylation: –11.6% (–17.5, –5.32) High IL-6 gene methylation: –13.0% (–18.7, –6.95)</p>	<p>No copollutant model. Associations found with BC, CO, PM<sub>2.5</sub>. Moderate correlation with NO<sub>2</sub>. Spearman <i>r</i> = 0.59, 0.52, 0.62, respectively. BC and PM<sub>2.5</sub> measured at one Boston site. Association also found with O<sub>3</sub>. <i>r</i> = –0.31.</p>
<p>†<a href="#">Steinvil et al. (2009)</a> Tel Aviv, Israel n = 2,380, mean age 43 (SD: 11) yr, healthy nonsmokers Cross-sectional. Supervised spirometry. Recruitment from ongoing survey of individuals attending health center. No information on participation rate. Linear regression adjusted for sex, age, height, BMI, exercise intensity, education, temperature, relative humidity, season, year.</p>	<p>NO<sub>2</sub>-central site 24-h avg 3 sites within 11 km of homes</p>	<p>0 5 0–6 avg</p>	<p>FEV<sub>1</sub> (mL): –16 (–64, 33) –55 (–103, –6.3) –97 (–181, –13)</p>	<p>w/CO (lag 5): –19 (–88, 50) w/SO<sub>2</sub> (lag 5): –7.8 (–72, 56) SO<sub>2</sub> and CO results persist with adjustment for NO<sub>2</sub>. High correlations with NO<sub>2</sub>. Pearson <i>r</i> = 0.75 for CO, 0.70 for SO<sub>2</sub>.</p>

**Table 5-30 (Continued): Epidemiologic studies of lung function in children and adults in the general population.**

Study Population Examined and Methodological Details	Oxide of Nitrogen Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<p>†<a href="#">Son et al. (2010)</a> Ulsan, South Korea n = 2,102, mean age 45 (SD: 17) yr, mean % predicted FEV<sub>1</sub>: 83% Cross-sectional. Supervised spirometry. Recruitment during meeting of residents. No information on participation. Regression model adjusted for age, sex, BMI. Did not consider potential confounding by weather, season, or time trend. High correlation among exposure assessment methods. <i>r</i> = 0.84–0.96.</p>	NO <sub>2</sub> -central site	0–2 avg	% predicted FVC:	Associations found with PM <sub>10</sub> , O <sub>3</sub> , SO <sub>2</sub> , CO. NO <sub>2</sub> effect estimate slightly reduced with adjustment for O <sub>3</sub> . No copollutant model with PM <sub>10</sub> or SO <sub>2</sub> .
	13 site average		–7.9 (–10, –5.6)	
	Nearest site		–6.9 (–8.8, –5.0)	
	Inverse distance weighting		–6.9 (–9.1, –4.7)	
	Kriging		–7.4 (–9.8, –5.1)	
	All 24-h avg			
<p>†<a href="#">Agarwal et al. (2012)</a> 5 locations with agricultural burning around Patiala City, Punjab, India. n = 50, ages 13–53 yr, 80% adults, no respiratory conditions Repeated measures. Supervised spirometry. Examined 2 times/mo for 6 mo in each of 3 years. Total observations NR. No information on recruitment method. 40% follow-up participation. Linear regression. Did not report whether covariates were included.</p>	NO <sub>2</sub> -central site	1-mo avg	FEV <sub>1</sub> : –8.9%, <i>p</i> = 0.054	No copollutant model. Association found with PM <sub>2.5</sub> . Correlation with NO <sub>2</sub> NR. Association also found with PM <sub>10</sub> and SO <sub>2</sub> .
	24-h avg		FVC: –7.5%, <i>p</i> = 0.064	
	1 site per location			

Note: Studies are organized by population examined, and more informative studies in terms of exposure assessment method and potential confounding considered are presented first.

a.m. = ante meridiem; ANOVA = analysis of variance; avg = average; BC = black carbon; BMI = body mass index; BS = black smoke; CA = California; CI = confidence interval; CO = carbon monoxide; Feb = February; FEV<sub>0.75</sub> = forced expiratory volume in 0.75 seconds; FEV<sub>1</sub> = forced expiratory volume in 1 second; FVC = forced vital capacity; GEE = generalized estimating equations; GLM = Generalized linear model; GLMM = generalized linear mixed model; (kPaxs/L): = kilopascals times seconds per liter; IgE = immunoglobulin E; IL = interleukin; MA = Massachusetts; max = maximum; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; NR = not reported; O<sub>3</sub> = ozone; ON = Ontario; OR = odds ratio; PEF = peak expiratory flow; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 μm; PNC = particle number concentration; SALPADIA = Study on Air Pollution and Lung Disease in Adults; SD = standard deviation; SO<sub>2</sub> = sulfur dioxide; SO<sub>4</sub> = sulfate; SPM = suspended particulate matter; TSP = total suspended particles; TX = Texas; UFP = ultrafine particles; U.K. = United Kingdom; VOC = volatile organic compound.

<sup>a</sup>Effect estimates were standardized to a 20-ppb increase in 24-h avg NO<sub>2</sub> and a 30-ppb increase 1-h max NO<sub>2</sub>. Effect estimates for other averaging times (1-h avg to 15-h avg) are not standardized but presented as they are reported in their respective studies ([Section 5.1.2.2](#)).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

### **Adults in the General Population**

In studies of adults in the general population reviewed in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), increases in ambient NO<sub>2</sub> concentration were associated with decrements in lung function as measured by supervised spirometry ([Schindler et al., 2001](#)) but not home peak flow ([van der Zee et al., 2000](#)). Recent studies conducted supervised spirometry, and while the results are inconsistent overall, the studies with stronger exposure assessment and/or examination of copollutant confounding indicate ambient NO<sub>2</sub>-associated decreases in lung function in healthy adults. Overall, studies examined a wide range of ages (i.e., 18–79 years) and a mix of healthy populations and those including adults with asthma or allergies, but these factors did not appear to influence the results. [van der Zee et al. \(2000\)](#) found no association in adults with or without respiratory symptoms. Locations, time periods, and ambient concentrations of oxides of nitrogen for these studies are presented in [Table 5-30](#).

Many studies that found lung function decrements in adults in the general population in association with higher ambient NO<sub>2</sub> concentrations do not strongly inform the independent effects of NO<sub>2</sub> exposure ([Lepeule et al., 2014](#); [Cakmak et al., 2011a](#); [Son et al., 2010](#); [Steinvil et al., 2009](#)). A major uncertainty is potential confounding. [Son et al. \(2010\)](#) did not examine confounding by meteorological or other time-varying factors. Studies found associations with PM<sub>2.5</sub> and the traffic-related pollutants CO and BC, which were moderately to highly correlated with NO<sub>2</sub> ( $r = 0.56–0.75$ ) ([Lepeule et al., 2014](#); [Agarwal et al., 2012](#); [Cakmak et al., 2011a](#); [Son et al., 2010](#); [Steinvil et al., 2009](#)). Copollutant models were not analyzed, except in [Steinvil et al. \(2009\)](#), where the NO<sub>2</sub> effect estimate was attenuated with CO adjustment, and NO<sub>2</sub> results were mixed among the various lags examined. Lung function also was associated with PM<sub>10</sub>, total suspended particles (TSP), SO<sub>2</sub>, and O<sub>3</sub>, and in copollutant models, NO<sub>2</sub> associations remained with adjustment for TSP or O<sub>3</sub> ([Son et al., 2010](#); [Schindler et al., 2001](#)) but not for highly correlated SO<sub>2</sub> ( $r = 0.70$ ) ([Steinvil et al., 2009](#)). Another uncertainty is whether NO<sub>2</sub> concentrations measured at the nearest central site, one site, averaged across multiple sites, or spatially interpolated by inverse distance weighting or kriging were equally representative of ambient exposure among subjects distributed within a city or across multiple communities. Differences in exposure measurement error between subjects may influence results, particularly in cross-sectional studies ([Cakmak et al., 2011a](#); [Son et al., 2010](#); [Steinvil et al., 2009](#); [Schindler et al., 2001](#)) and a longitudinal study collecting one to four measures of lung function over 10 years ([Lepeule et al., 2014](#)).

Ambient concentrations may better represent exposures in situations when people are outdoors. In adults cycling in various traffic and nontraffic locations or lifeguards working outdoors, lung function before and after repeated outdoor exposures were not

associated with NO<sub>2</sub> assessed from a central site ([Weichenthal et al., 2011](#); [Thaller et al., 2008](#)). However, in healthy adults, lung function decrements were associated with NO<sub>2</sub> measured on site of outdoor activity in locations that varied in traffic ([Strak et al., 2012](#)) or distance from a steel plant ([Dales et al., 2013](#)). Lung function decreased immediately after and 2 to 18 hours after the outdoor exposure period ([Dales et al., 2013](#); [Strak et al., 2012](#)). These studies have stronger inference than the aforementioned central site studies because NO<sub>2</sub> measurements are aligned with subjects in both time and space. Both outdoor exposure studies found associations with PM<sub>2.5</sub> and/or the highly correlated ( $r = 0.67\text{--}0.87$ ) traffic-related PM<sub>2.5</sub> absorbance, EC, metal components of PM<sub>2.5</sub>, and UFP/particle number concentration (PNC). Only [Strak et al. \(2012\)](#) examined copollutant models and found that NO<sub>2</sub> associations persisted with adjustment for PNC, EC, PM<sub>2.5</sub>, or another PM<sub>2.5</sub> component. A 25-ppb increase in 5-h avg NO<sub>2</sub> was associated with a  $-4.3\%$  (95% CI:  $-7.4, -1.0$ ) change in FVC and a  $-3.0\%$  (95% CI:  $-7.2, 1.4$ ) change with adjustment for PNC. The NO<sub>x</sub> association was attenuated with adjustment for PNC. Effect estimates for EC, absorbance, and PNC were attenuated with adjustment for NO<sub>2</sub>, indicating that NO<sub>2</sub> may have confounded associations for copollutants.

### Controlled Human Exposure Studies

Similar to the epidemiologic studies, controlled human exposure studies generally did not report effects of NO<sub>2</sub> on lung function in healthy adults. Overall, exposures ranged from 200 to 4,000 ppb NO<sub>2</sub> for 40 minutes to 5 hours, and most studies incorporated exercise in the exposure period to assess lung function during various physiological conditions ([Table 5-31](#)). As examined in many studies, NO<sub>2</sub> exposures of 120–600 ppb (40 minutes to 4 hours) did not affect lung function of healthy adolescents ([Koenig et al., 1987](#)), young adults ([Huang et al., 2012b](#); [Frampton et al., 2002](#); [Vagaggini et al., 1996](#); [Hazucha et al., 1994](#); [Frampton et al., 1991](#); [Frampton et al., 1989](#); [Adams et al., 1987](#)), or older adults ([Gong et al., 2005](#); [Morrow et al., 1992](#)). NO<sub>2</sub> exposures in this range (400, 500 ppb) did not show additive or synergistic effects with exposure to concentrated ambient particles (CAPs) in the size range of PM<sub>2.5</sub> ([Huang et al., 2012b](#); [Gong et al., 2005](#)), which in the ambient air often is moderately to highly correlated with NO<sub>2</sub> ([Figure 3-6](#)). Lack of additivity or synergy also was observed for co-exposures of NO<sub>2</sub> and O<sub>3</sub>, which often are weakly correlated in the ambient air ([Figure 3-6](#)). Decreases in lung function and increases in airway resistance in response to O<sub>3</sub> exposure were not affected by co-exposures to 600 ppb NO<sub>2</sub> ([Hazucha et al., 1994](#); [Adams et al., 1987](#)).

Lung function generally was not altered by higher NO<sub>2</sub> exposures of 1,000–4,000 ppb (1.5 to 5 hours) ([Frampton et al., 2002](#); [Devlin et al., 1999](#); [Jörres et al., 1995](#); [Frampton et al., 1989](#); [Linn et al., 1985b](#)), including intermittent spikes of 2,000 ppb NO<sub>2</sub> superimposed on a 3-hour background exposure to 50 ppb NO<sub>2</sub> ([Frampton et al., 1991](#)).

A few controlled human exposure studies did report NO<sub>2</sub>-induced changes in lung function in healthy adults. [Rasmussen et al. \(1992\)](#) observed statistically nonsignificant increases in FVC and FEV<sub>1</sub> during and after a 5-hour exposure to 2,300 ppb NO<sub>2</sub>. NO<sub>2</sub> exposures repeated over multiple days had contrasting effects, with a 4-hour exposure to 2,000 ppb NO<sub>2</sub> inducing a decrease in FEV<sub>1</sub> and FVC only on the first day of a 4-day exposure ([Blomberg et al., 1999](#)), and a 2-hour exposure to 1,000 ppb NO<sub>2</sub> inducing a 1.5% drop in FVC only on the second day of a 2-day exposure ([Hackney et al., 1978](#)).

**Table 5-31 Characteristics of controlled human exposure studies of lung function and respiratory symptoms in healthy adults.**

Study	Disease Status <sup>a</sup> ; Sample Size; Sex; Age (mean ± SD)	Exposure Details	Endpoints Examined
<a href="#">Koenig et al. (1987)</a>	Healthy; (1) n = 3 M, 7 F (2) n = 4 M, 6 F Asthma; (1) n = 4 M, 6 F (2) n = 7 M, 3 F; 14.4 yr (range: 12–19)	(1) 120 ppb NO <sub>2</sub> , (2) 180 ppb NO <sub>2</sub> ; (1–2) Exposures were 30 min at rest with 10 min of moderate exercise	Pulmonary function tests before, during, and after exposure.
<a href="#">†Huang et al. (2012b)</a>	(1) n = 11 M, 3 F (2) n = 6 M, 7 F (3) n = 7 M, 6 F; 24.6 ± 4.3 yr	(1) 500 ppb NO <sub>2</sub> for 2 h, (2) 500 ppb NO <sub>2</sub> + 73.4 ± 9.9 µg/m <sup>3</sup> CAPs for 2 h, (3) 89.5 ± 10.7 µg/m <sup>3</sup> CAPs for 2 h; (1–3) Exercise 15 min on/15 min off at $\dot{V}_E = 25$ L/min	Pulmonary function tests before, immediately after, and 18 h after exposure.
<a href="#">Frampton et al. (2002)</a>	(1,2) n = 12 M, 9 F; F = 27.1 ± 4.1 yr M = 26.9 ± 4.5 yr	(1) 600 ppb for 3 h, (2) 1,500 ppb for 3 h; (1,2) Exercise 10 min on/20 min off at $\dot{V}_E = 40$ L/min	Pulmonary function tests before and after exposure.
<a href="#">Vagaggini et al. (1996)</a>	Healthy; n = 7; M; 34 ± 5 yr Asthma; n = 4 M, 4 F; 29 ± 14 yr COPD; n = 7; M; 58 ± 12 yr	300 ppb for 1 h; Exercise at $\dot{V}_E = 25$ L/min	Pulmonary function tests before and 2 h after exposure.

**Table 5-31 (Continued): Characteristics of controlled human exposure studies of lung function and respiratory symptoms in healthy adults.**

Study	Disease Status <sup>a</sup> ; Sample Size; Sex; Age (mean ± SD)	Exposure Details	Endpoints Examined
<a href="#">Hazucha et al. (1994)</a>	n = 21; F; 22.9 ± 3.6 yr	(1) 600 ppb NO <sub>2</sub> for 2 h, air for 3 h, 300 ppb O <sub>3</sub> for 2 h, (2) Air for 5 h, 300 ppb O <sub>3</sub> for 2 h; (1,2) Exercise for 15 min on/15 min off at $\dot{V}_E = 35$ L/min	Pulmonary function tests before, during, and after exposure; airway reactivity after exposure. Times for symptoms assessment not reported.
<a href="#">Frampton et al. (1991)</a>	(1) n = 7 M, 2 F; 29.9 ± 4.2 yr (2) n = 12 M, 3 F; 25.3 ± 4.6 yr (3) n = 11 M, 4 F; 23.5 ± 2.7 yr	(1) 600 ppb for 3 h, (2) 1,500 ppb for 3 h, (3) 50 ppb for 3 h + 2,000 ppb peak for 15 min/h; (1-3) Exercise 10 min on/20 min off at $\dot{V}_E = \sim 4$ times resting	Pulmonary function tests before, during, and after exposure; airway reactivity 30 min after exposure. Symptoms after exposure.
<a href="#">Frampton et al. (1989)</a>	(1) n = 7 M, 2 F; 30 yr (range: 24-37) (2) n = 11 M, 4 F; 25 yr (range: 19-37)	(1) 600 ppb for 3 h, (2) 1,500 ppb for 3 h; (1,2) Exercise 10 min on/20 min off at $\dot{V}_E = \sim 4$ times resting	Pulmonary function tests before, during, and after exposure.
<a href="#">Adams et al. (1987)</a>	(1-3) n = 20 M, 20 F; F = 21.4 ± 1.5 yr M = 22.7 ± 3.3 yr	(1) 600 ppb NO <sub>2</sub> for 1 h, (2) 300 ppb O <sub>3</sub> for 1 h, (3) 600 ppb NO <sub>2</sub> and 300 ppb O <sub>3</sub> for 1 h; (1-3) Exercise during entire exposure at $\dot{V}_E = 75$ L/min (M) and $\dot{V}_E = 50$ L/min (F)	Pulmonary function before and after exposure. Symptoms following exposure.
<a href="#">Gong et al. (2005)</a>	Healthy; n = 2 M, 4 F; 68 ± 11 yr COPD; n = 9 M, 9 F; 72 ± 7 yr	(1) 400 ppb NO <sub>2</sub> for 2 h, (2) 200 µg/m <sup>3</sup> CAPs for 2 h, (3) 400 ppb NO <sub>2</sub> + 200 µg/m <sup>3</sup> CAPs for 2 h; (1-3) Exercise 15 min on/15 min off at $\dot{V}_E = \sim 2$ times resting	Pulmonary function tests before and immediately after exposure and 4 h and 22 h after exposure. Symptoms before, during, and after exposure.
<a href="#">Morrow et al. (1992)</a>	Healthy; n = 10 M, 10 F (13 never smokers, 4 former smokers, 3 current smokers) COPD; n = 13 M, 7 F (14 current smokers, 6 former smokers); 59.9 ± 7.0 yr	300 ppb for 4 h; Three 7-min periods of exercise at $\dot{V}_E = \sim 4$ times resting	Pulmonary function tests before, during, immediately after, and 24 h after exposure. Symptoms 24 h after exposure.
<a href="#">Devlin et al. (1999)</a>	n = 11; M; range: 18-35 yr	2,000 ppb for 4 h; Exercise for 15 min on/15 min off at $\dot{V}_E = 50$ L/min	Aerosol bolus dispersion (deposition, FEV <sub>1</sub> and sRaw).

**Table 5-31 (Continued): Characteristics of controlled human exposure studies of lung function and respiratory symptoms in healthy adults.**

Study	Disease Status <sup>a</sup> ; Sample Size; Sex; Age (mean ± SD)	Exposure Details	Endpoints Examined
<a href="#">Jörres et al. (1995)</a>	Healthy; n = 5 M, 3 F; 27 yr (range: 21–33) Asthma; n = 8 M, 4 F; 27 ± 5 yr	1,000 ppb for 3 h; Exercise 10 min on/10 min off at individual's maximum workload	Symptoms immediately and 6 and 24 h after exposure.
<a href="#">Linn et al. (1985b)</a>	Healthy; n = 16 M, 9 F; range: 20–36 yr Asthma; n = 12 M, 11 F; range: 18–34 yr	4,000 ppb for 75 min; Two 15-min periods of exercise at $\dot{V}_E = 25$ L/min and 50 L/min	Airway resistance before, during, and after exposure. Symptoms before, during, immediately after, and 24 h after exposure.
<a href="#">Rasmussen et al. (1992)</a>	n = 10 M, 4 F; 34.4 yr (range: 22–66)	2,300 ppb for 5 h	Pulmonary function tests before, 2 times during, and 3 times after exposure. Symptoms before, during, and after exposure.
<a href="#">Blomberg et al. (1999)</a>	n = 8 M, 4 F; 26 yr (range: 21–32)	2,000 ppb, 4 h/day for 4 days; Exercise 15 min on/15 min off at workload of 75 watts	Pulmonary function before and after exposure.
<a href="#">Hackney et al. (1978)</a>	n = 16; M; 26.9 ± 5.0 yr	1,000 ppb, 2 h/day for 2 days; Exercise 15 min on/15 min off at $\dot{V}_E = 2$ times resting	Pulmonary function tests before and after each exposure. Symptoms after each exposure.

CAPs = concentrated ambient particles; COPD = chronic obstructive pulmonary disease; F = female; FEV<sub>1</sub> = forced expiratory volume in 1 second; M = male; NO<sub>2</sub> = nitrogen dioxide; O<sub>3</sub> = ozone; ppb = parts per billion; SD = standard deviation; sRaw = specific airway resistance;  $\dot{V}_E$  = minute ventilation.

<sup>a</sup>Subjects were healthy individuals unless described otherwise.

†Study published since the 2008 ISA for Oxides of Nitrogen

### 5.2.7.3 Respiratory Symptoms in Healthy Populations

#### Epidemiologic Studies of Children in the General Population

Respiratory symptoms in relation to short-term NO<sub>2</sub> exposure have not been examined in epidemiologic studies of healthy adults; however, associations are indicated in school-aged children in the general population ([Table 5-32](#) and [5-33](#)). NO<sub>2</sub>-associated increases in respiratory symptoms also were found in infants ([Stern et al., 2013](#); [Andersen et al., 2008a](#); [Peel et al., 2007](#)) ([Table 5-33](#)). These results have weaker

implications because symptoms such as wheeze are common in infancy and may not clearly distinguish children who do and do not develop respiratory conditions like asthma later in life ([Cano Garcinuno and Mora Gandarillas, 2013](#)). Further, [Peel et al. \(2007\)](#) examined apnea in infants on home cardiorespiratory monitors, a group unrepresentative of the general population. Another uncertainty is whether the temporal variation in ambient NO<sub>2</sub> concentrations from one central site in the area adequately represents variation in ambient NO<sub>2</sub> exposure of infants, particularly those on cardiorespiratory monitors, who may not spend much time outdoors away from home.

In school-aged children, not all results were statistically significant, but a pattern of elevated odds ratios indicates consistency in association between short-term NO<sub>2</sub> exposure and respiratory symptoms ([Table 5-33](#)). Evidence is stronger for cough than wheeze, which is identified more with asthma. Children were recruited primarily from schools but also from a birth cohort, suggesting study populations were representative of the general populations. A wide range of participation rates was reported ([Table 5-33](#)), but no study reported issues with differential participation by a particular group. The health status of study populations was not always specified, and it is not clear whether the NO<sub>2</sub>-associated increases in respiratory symptoms reflect associations among all children or those with a respiratory disease. For example, associations were reported in populations with parental history of asthma ([Rodriguez et al., 2007](#)) or with 27% asthma prevalence ([Ward et al., 2002](#)). Findings for symptoms are uncertain in healthy children. NO<sub>2</sub> was not associated with respiratory symptoms in children without asthma ([Patel et al., 2010](#)) but was associated with new diagnosis of asthma in children ([Wendt et al., 2014](#)) ([Table 5-33](#)). Findings that an increase in a 5-day avg of ambient NO<sub>2</sub> concentrations may induce respiratory symptoms that precipitate an asthma diagnosis have uncertain implications. Asthma diagnosis was ascertained from Medicaid claims as a record of an outpatient or inpatient visit for asthma or dispensing events of asthma medication during a three-year period ([Wendt et al., 2014](#)). Among children older than age 3 years, what is defined as a diagnosis instead could represent an exacerbation of previously diagnosed asthma. Among children younger than age 3 years, the reliability of an asthma diagnosis is uncertain. The uncertainty of basing a new asthma diagnosis on a three-year review of medical records is underscored by observations that NO<sub>2</sub> associations were stronger in children older than age 4 years than in children ages 1–4 years ([Table 5-33](#)).

**Table 5-32 Mean and upper percentile concentrations of nitrogen dioxide in epidemiologic studies of respiratory symptoms in children in the general population.**

Study <sup>a</sup>	Location	Study Period	NO <sub>2</sub> Metric Analyzed	Mean/Median Concentration ppb	Upper Percentile Concentrations ppb
† <a href="#">Stern et al. (2013)</a>	Bern, Basel, Switzerland	Apr 1999–Feb 2011	24-h avg NO <sub>2</sub>	Rural: 8.1 <sup>b</sup> Urban: 25.6 <sup>b</sup>	NR NR
† <a href="#">Andersen et al. (2008a)</a>	Copenhagen, Denmark	Dec 1998–Dec 2004	24-h avg NO <sub>2</sub>	11.8	75th: 14.6
† <a href="#">Peel et al. (2011)</a>	Atlanta, GA	Aug 1998–Dec 2002	1-h max NO <sub>2</sub>	41.7	90th: 65.6 Max: 109.2
<a href="#">Rodriguez et al. (2007)</a>	Perth, Australia	Jun 1996–Jul 1998	1-h max NO <sub>2</sub> 24-h avg NO <sub>2</sub>	18 7	Max: 48 Max: 24
<a href="#">Ward et al. (2002)</a>	Birmingham, Sandwell, U.K.	Jan–Mar 1997 May–Jul 1997	24-h avg NO <sub>2</sub>	18 13.3	Max: 35 Max: 29
† <a href="#">Patel et al. (2010)</a>	New York City and nearby suburb, NY	2003–2005, mo NR	24-h avg NO <sub>2</sub>	NR	NR
† <a href="#">Wendt et al. (2014)</a>	Harris County, TX (Houston area)	2005–2007	1-h max NO <sub>2</sub>	39.26	75th: 48.00 Max: 108
<a href="#">Schwartz et al. (1994)</a>	Watertown, MA; Steubenville, OH; Topeka, KS; St. Louis, MO; Portage, WI; Kingston-Harriman, TN	Apr–Aug 1984–1988	24-h avg NO <sub>2</sub>	13.3	75th: 24.1 Max: 44.2
† <a href="#">Moon et al. (2009)</a>	Seoul, Incheon, Busan, Jeju, South Korea	Apr–May 2003	24-h avg NO <sub>2</sub>	NR	NR

Aug = August; avg = average; Dec = December; Feb = February; GA = Georgia; KS = Kansas; MA = Massachusetts; max = maximum; MO = Missouri; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; NY = New York; OH = Ohio; ppb = parts per billion; TN = Tennessee; TX = Texas; U.K. = United Kingdom; WI = Wisconsin.

<sup>a</sup>Studies presented in order of first appearance in the text of this section.

<sup>b</sup>Concentrations converted from µg/m<sup>3</sup> to ppb using the conversion factor of 0.532 assuming standard temperature (25°C) and pressure (1 atm).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

Despite the associations found with respiratory symptoms in children, there is uncertainty regarding the extent to which the results reflect an independent relationship with NO<sub>2</sub>. Ambient NO<sub>2</sub> exposures were assigned from one central site per city or the average across multiple sites per city. In the study of asthma diagnosis, effect estimates were

similar for 1-h max NO<sub>2</sub> assigned to subjects as the average NO<sub>2</sub> across 17 sites covering the 4,400-km<sup>2</sup> area of Harris County, TX and the nearest site within 9.7 km of the ZIP code centroid (Wendt et al., 2014). The two NO<sub>2</sub> exposure metrics differed in mean concentration, 39.3 ppb versus 27.7 ppb, but the temporal variability of each metric was not reported to assess whether large differences in temporal variability in NO<sub>2</sub> occurred within the study area.

Studies of respiratory symptoms in children also did not adequately examine whether NO<sub>2</sub> associations were independent of PM<sub>2.5</sub> and traffic-related copollutants. Symptoms also were related to PM<sub>2.5</sub>, CO, BS, and UFP, which tended to be highly correlated with NO<sub>2</sub> ( $r = 0.61$ – $0.75$ ) (Wendt et al., 2014; Moon et al., 2009; Andersen et al., 2008a; Rodriguez et al., 2007; Ward et al., 2002). In Harris County, TX, 1-h max NO<sub>2</sub> remained associated with diagnosis of asthma in a copollutant model with 24-h avg PM<sub>2.5</sub> (Table 5-33) (Wendt et al., 2014). NO<sub>2</sub> was weakly correlated with PM<sub>2.5</sub> ( $r = 0.21$ ), and while the variability in ambient PM<sub>2.5</sub> concentrations was not reported, NO<sub>2</sub> concentrations were reported to vary across the county. In infants, ORs for both NO<sub>2</sub> and UFP decreased with mutual adjustment (Table 5-33); thus, an independent or confounding effect was not discerned for either pollutant (Andersen et al., 2008a). Copollutant models were examined in the U.S. Six Cities study for PM<sub>10</sub> and SO<sub>2</sub>. ORs for cough decreased with PM<sub>10</sub> or SO<sub>2</sub> adjustment to 1.37 (95% CI: 0.98, 2.12) and 1.42 (95% CI: 0.90, 2.22) for a 20-ppb increase in NO<sub>2</sub>, respectively (Schwartz et al., 1994). The width of 95% CIs is inflated when presented for a 20-ppb increase in NO<sub>2</sub>, which is double the 10-ppb interquartile range for the study areas. The OR for PM<sub>10</sub> was robust to NO<sub>2</sub> adjustment. Thus, PM<sub>10</sub> may partly confound NO<sub>2</sub> associations. While the positive ORs for NO<sub>2</sub> in the U.S. Six Cities study suggest an independent association for NO<sub>2</sub> as well, the potentially differential exposure measurement error for central site NO<sub>2</sub>, SO<sub>2</sub>, and PM<sub>10</sub> limits inference from the copollutant model results. This limited inference also applies to the aforementioned results from copollutant models with PM<sub>2.5</sub> or UFP.

**Table 5-33 Epidemiologic studies of respiratory symptoms in children in the general population.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Odds Ratio (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p><a href="#">†Wendt et al. (2014)</a> Harris County, TX (Houston area) n = 18,264 cases in incident asthma, ages 1–17 yr Case-crossover. Incident asthma cases ascertained for 2004–2007 from Medicaid database. Medicaid enrollment required only for 13 mo. Date of diagnosis defined as earliest date of asthma diagnosis on inpatient or outpatient record or earliest of four asthma medication dispensing events in a year. Uncertainty as to whether outcome represents incident asthma. Conditional logistic regression adjusted for temperature, humidity, mold spores, tree pollen, grass pollen, weed pollen.</p>	<p>NO<sub>2</sub>-central site 1-h max Average of 17 sites in 4,400 km<sup>2</sup> area Mean: 39.3 ppb</p>	<p>0–5 avg</p>	<p>Asthma diagnosis May–Oct All ages: 1.22 (1.09, 1.36) 1–4 yr: 1.05 (1.00, 1.09) 15–17 yr: 1.57 (1.06, 2.32) Nov–Apr All ages: 1.03 (0.93, 1.14)</p>	<p>All ages, NO<sub>2</sub> average over 17 county sites, May–Oct. With 24-h avg PM<sub>2.5</sub>: 1.20 (1.06, 1.36) With 8-h max O<sub>3</sub>: 1.11 (0.90, 1.37) Low or moderate correlations with NO<sub>2</sub>. <i>r</i> = 0.21 for PM<sub>2.5</sub>, 0.49 for O<sub>3</sub>. O<sub>3</sub> means similar for county average and site within 9 km. PM<sub>2.5</sub> and O<sub>3</sub> attenuated with adjustment for NO<sub>2</sub>.</p>
<p><a href="#">Schwartz et al. (1994)</a> Watertown, MA; Kingston-Harriman, TN; St. Louis, MO; Steubenville, OH; Portage, WI; Topeka, KS n = 1,844, grades 2–5 Repeated measures. Daily symptom diaries for 5 mo, collected every 2 weeks. Recruitment from schools. No information on participation rate. Logistic regression adjusted for Lag Day 1 temperature, day of week, city.</p>	<p>NO<sub>2</sub>-central site 24-h avg 1 site per community</p>	<p>0 0–3 avg 1</p>	<p>Cough: 1.21 (0.92, 1.59) 1.61 (1.08, 2.40) Lower respiratory symptoms: 1.44 (0.96, 2.16)</p>	<p>For cough With PM<sub>10</sub>: 1.37 (0.98, 2.12) With O<sub>3</sub>: 1.61 (1.08, 2.41) With SO<sub>2</sub>: 1.42 (0.90, 2.22) PM<sub>10</sub> and O<sub>3</sub> robust to adjustment for NO<sub>2</sub>. SO<sub>2</sub> reduced. Moderate correlations with NO<sub>2</sub>. <i>r</i> = 0.36 for PM<sub>10</sub>, 0.35 for PM<sub>2.5</sub>, 0.51 for SO<sub>2</sub>, –0.28 for O<sub>3</sub>.</p>

**Table 5-33 (Continued): Epidemiologic studies of respiratory symptoms in children in the general population.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Odds Ratio (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p><a href="#">†Moon et al. (2009)</a> Seoul, Incheon, Busan, Jeju, South Korea n = 696, ages NR Repeated measures. Daily symptom diaries for 2 mo. Recruitment from schools. 69% participation rate. GEE adjusted for temperature, relative humidity.</p>	<p>NO<sub>2</sub>-central site 24-h avg # sites NR</p>	0	<p>Lower respiratory symptoms All subjects: 1.02 (1.00, 1.05) Seoul: 1.08 (0.99, 1.18) Incheon: 1.08 (0.99, 1.18) Busan: 1.04 (0.96,1.12) Jeju: 0.97 (0.89, 1.06)</p>	<p>No copollutant model. Association also found with CO. Correlation NR.</p>
<p><a href="#">†Patel et al. (2010)</a> New York City and nearby suburb, NY n = 192 children without asthma, ages 14–20 yr Repeated measures. Daily symptom diaries for 4–6 weeks, collected weekly. Recruitment from schools. Self-report of physician-diagnosed asthma. 75–90% participation across schools. GLMM with random effect for subject and school and adjusted for weekend, 8-h max O<sub>3</sub>, urban location. Adjustment for season, pollen counts did not alter results.</p>	<p>NO<sub>2</sub>-central site 24-h avg 1 site 2.2–9.0 km from schools, 1 site 40 km from schools</p>	0	<p>Wheeze: 0.88 (0.75, 1.03) Chest tightness 0.96 (0.75, 1.23)</p>	<p>No copollutant model with BC. BC also associated with symptoms. Across locations, moderately to highly correlated with NO<sub>2</sub>. Spearman <i>r</i> = 0.56–0.90 for BC.</p>
<p><a href="#">Ward et al. (2002)</a> Birmingham, Sandwell, U.K. n = 162, age 9 yr, 27% with asthma, 31% with atopy Repeated measures. Daily symptom diaries for two 8-week periods, collected weekly. Recruitment from schools. 61% participation rate. Logistic regression adjusted for time trend, temperature, school day.</p>	<p>NO<sub>2</sub>-central site 24-h avg Multiple sites</p>	0	<p>Cough Winter: 0.78 (0.57, 1.09) Summer: 1.14 (1.01, 1.27)</p>	<p>No copollutant model. PM<sub>2.5</sub> associated with cough.</p>

**Table 5-33 (Continued): Epidemiologic studies of respiratory symptoms in children in the general population.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Odds Ratio (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<a href="#">Rodriguez et al. (2007)</a> Perth, Australia n = 263, ages 0–5 yr, 1 parent with asthma or other atopic disease Repeated measures. Daily symptom diary from birth to age 5 yr. Recruitment from birth cohort. >80% follow-up participation until yr 4 and 5. GEE adjusted for temperature, humidity.	NO <sub>2</sub> -central site 24-h max 10-site average 24-h avg	0	Wheeze (unit NR): 1.00 (0.99, 1.01) Cough: 1.01 (1.00, 1.02) Wheeze: 1.01 (0.98, 1.04) Cough: 1.03 (1.00, 1.06)	No copollutant model. Associations also found for PM <sub>2.5</sub> , BS at lag 0.
<a href="#">†Andersen et al. (2008a)</a> Copenhagen, Denmark n = 205, ages 0–3 yr, all with maternal asthma Repeated measures. Daily symptom diaries from birth to 3 yr, collected every 6 mo. Recruitment from birth cohort. 95% follow-up participation. Mean 805 observations/subject. GEE adjusted for age, sex, smoking exposure, paternal asthma, temperature, calendar season.	NO <sub>2</sub> -central site 24-h avg 1 site within 15 km of homes	0	Wheeze Age 0–1 yr: 3.13 (1.27, 7.77) Age 2–3 yr: 1.71 (0.94, 3.10) <hr/> Age 0–1 yr: 3.26 (1.14, 9.26) Age 2–3 yr: 1.80 (0.87, 3.72)	For age 0–1 yr With UFP: 1.19 (0.14, 75) With PM <sub>10</sub> : 2.46 (0.72, 8.4) UFP & PM <sub>10</sub> associations attenuated with adjustment for NO <sub>2</sub> . UFP & CO highly correlated with NO <sub>2</sub> . Spearman <i>r</i> = 0.67, 0.75. Moderate correlation for PM <sub>10</sub> . <i>r</i> = 0.43.
<a href="#">†Stern et al. (2013)</a> Bern, Base, Switzerland n = 366, ages 0–1 yr Repeated measures. Symptoms reported weekly by telephone for 1 yr. Recruitment from birth cohort. 95% follow-up participation. GAM adjusted for study week, sex, siblings, nursery care, maternal atopy, birth weight, prenatal & post-natal maternal smoking, parental education.	NO <sub>2</sub> -central site 1-week avg 2 site, urban and rural	5	Daytime respiratory symptom composite: 1.20 (1.04, 1.39)	No copollutant model. PM <sub>10</sub> lag 7 associated with respiratory symptoms. Correlation NR.

**Table 5-33 (Continued): Epidemiologic studies of respiratory symptoms in children in the general population.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Odds Ratio (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p>†<a href="#">Peel et al. (2011)</a> Atlanta, GA area n = 4,277, mean age 46 days, 84% premature births Repeated measures. Followed for mean of 42 days. 111,000 person-days. Recruitment from referral center for home cardiorespiratory monitoring of infants. Limited generalizability. Apnea events collected electronically. No information on participation rate. GEE adjusted for long-term trends, age.</p>	<p>NO<sub>2</sub>-central site 1-h max 1 site</p>	<p>0-1 avg</p>	<p>Apnea: 1.02 (0.96, 1.08)</p>	<p>With O<sub>3</sub>: 1.00 (0.96, 1.05) O<sub>3</sub> association robust to NO<sub>2</sub> adjustment. Moderate correlation with NO<sub>2</sub>. Spearman <i>r</i> = 0.45. No association with PM<sub>10</sub>, coarse PM.</p>

Note: Studies are organized by population examined, and more informative studies in terms of the exposure assessment method and potential confounding considered are presented first.

avg = average; BC = British Columbia; BS = black smoke; CI = confidence interval; CO = carbon monoxide; GA = Georgia; GAM = generalized additive model; GEE = generalized estimating equations; GLMM = Generalized linear mixed model; KS = Kansas; MA = Massachusetts; max = maximum; MO = Missouri; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; NR = not reported; NY = New York; O<sub>3</sub> = ozone; OH = Ohio; OR = odds ratio; PM = particulate matter; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 μm; ppb = parts per billion; SO<sub>2</sub> = sulfur dioxide; TN = Tennessee; TX = Texas; UFP = ultrafine particles; U.K. = United Kingdom; WI = Wisconsin.

<sup>a</sup>Effect estimates are standardized to 20 ppb for 24-h avg NO<sub>2</sub>, 25 ppb for 8-h max, a 30-ppb increase for 1-h max NO<sub>2</sub>, and 40-ppb increase in 24-h avg NO<sub>x</sub>.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

## Controlled Human Exposure Studies

Controlled human exposure studies of respiratory symptoms in healthy populations do not strongly inform whether the epidemiologic findings for NO<sub>2</sub>-related increases in respiratory symptoms in children in the general population plausibly could reflect an independent effect of NO<sub>2</sub> exposure. The controlled human exposure studies were reviewed in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), and most with NO<sub>2</sub> exposures of 300–600 ppb for 1–3 hours ([Table 5-31](#)) did not observe changes in symptom score 24 hours later ([Gong et al., 2005](#); [Hazucha et al., 1994](#); [Morrow et al., 1992](#); [Adams et al., 1987](#)). NO<sub>2</sub> exposures of 400 or 600 ppb also did not affect respiratory symptoms with simultaneous or sequential O<sub>3</sub> or PM<sub>2.5</sub> CAPs co-exposures [[Gong et al., 2005](#); [Hazucha et al., 1994](#); [Adams et al., 1987](#); [Table 5-31](#)]. In exception, [Frampton et al. \(1991\)](#) reported statistically nonsignificant increases in symptom score following 600 ppb NO<sub>2</sub> exposure. NO<sub>2</sub> exposures of 1,000 to 4,000 largely had no effect on respiratory symptoms in healthy adults either ([Jörres et al., 1995](#); [Rasmussen et al., 1992](#); [Linn et al., 1985b](#); [Hackney et al., 1978](#)).

---

### 5.2.7.4 Subclinical Respiratory Effects in Healthy Populations: Pulmonary Inflammation, Injury, and Oxidative Stress

Pulmonary inflammation, injury, and oxidative stress are mediators of respiratory symptoms and decreases in lung function ([Section 4.3.5](#)). Consistent with the evidence described in the preceding sections, epidemiologic studies show ambient NO<sub>2</sub>-related increases in pulmonary inflammation and oxidative stress in children and adults in the general population. The few analyses of copollutant models indicate associations for NO<sub>2</sub> persist with adjustment for another traffic-related pollutant. Supporting an independent effect of NO<sub>2</sub> in healthy populations, experimental studies report evidence for pulmonary inflammation as PMN increases. Also, limited evidence from experimental studies indicates development of an allergic phenotype with repeated NO<sub>2</sub> exposures. Effects on other indicators of inflammation and oxidative stress were observed more consistently at higher than ambient-relevant NO<sub>2</sub> concentrations.

## Epidemiologic Studies

Together, the few epidemiologic studies from the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) and most recent studies found associations between increases in ambient oxides of nitrogen and increases in pulmonary inflammation or oxidative stress among children and adults in the general population and healthy populations. Locations, time

periods, and ambient concentrations of oxides of nitrogen for these studies are presented in [Table 5-34](#). In this group of studies are several with exposure assessment methods that aim to account for the high variability in ambient oxides of nitrogen.

**Table 5-34 Mean and upper percentile concentrations of oxides of nitrogen in epidemiologic studies of pulmonary inflammation and oxidative stress in the general population.**

Study <sup>a</sup>	Location	Study Period	Exposure Metric Analyzed	Mean Concentration ppb	Upper Percentile Concentrations (ppb)
<a href="#">†Flamant-Hulin et al. (2010)</a>	Clermont-Ferrand, France	NR	5-day avg NO <sub>2</sub>	Schools <14.0: 10.1 Schools >14.0: 17.4	Across schools: 75th: 14.0 <sup>b</sup> , Max: 19.7 <sup>b</sup>
<a href="#">†Lin et al. (2011)</a>	Beijing, China	Jun 2007 Sep 2007 Dec 2007 Jun 2008 Sep 2008	24-h avg NO <sub>2</sub>	24.3 30.4 45.3 26.6 25.9	NR NR NR NR NR
<a href="#">†Liu et al. (2014a)</a>	Munich, Wesel, Germany	NR	24-h avg NO <sub>2</sub>	15.9 <sup>c</sup>	95th: 29.7 <sup>b</sup>
<a href="#">†Berhane et al. (2011)</a>	13 southern California communities	Sep–Jun 2004–2005	24-h avg NO <sub>2</sub>	NR	NR
<a href="#">†Patel et al. (2013)</a>	New York, NY	May–Jun 2005	24-h avg NO <sub>2</sub>	Median: 23.3	NR
<a href="#">†Altuğ et al. (2014)</a>	Eskisehir, Turkey	Feb–Mar 2007	24-h avg NO <sub>2</sub>	Suburban: 9.4 <sup>b</sup> Urban: 13.0 <sup>b</sup> Urban-traffic: 21.2 <sup>b</sup>	Max: 13.1 <sup>b</sup> Max: 17.7 <sup>b</sup> Max: 28.2 <sup>b</sup>
<a href="#">Holquin et al. (2007)</a>	Ciudad Juarez, Mexico	2001–2002	1-week avg NO <sub>2</sub>	18.2	NR
<a href="#">Steerenberg et al. (2001)</a>	Utrecht Bilthoven, the Netherlands	Feb–Mar 1998	24-h avg NO <sub>2</sub> 24-h avg NO 24-h avg NO <sub>2</sub> 24-h avg NO	28.2 <sup>b</sup> 30.2 <sup>b</sup> 25.5 <sup>b</sup> 7.4 <sup>b</sup>	Max: 44.7 <sup>b</sup> Max: 168 <sup>b</sup> Max: 49.5 <sup>b</sup> Max: 85.6 <sup>b</sup>
<a href="#">†Chen et al. (2012a)</a>	New Taipei City, Taiwan	Oct–Jun 2007; Jun–Nov 2009	24-h avg NO <sub>2</sub>	21.7	NR

**Table 5-34 (Continued): Mean and upper percentile concentrations of oxides of nitrogen in epidemiologic studies of pulmonary inflammation and oxidative stress in the general population.**

Study <sup>a</sup>	Location	Study Period	Exposure Metric Analyzed	Mean Concentration ppb	Upper Percentile Concentrations (ppb)
<a href="#">†Salam et al. (2012)</a>	13 southern California communities	2004–2007, school year	24-h avg NO <sub>2</sub>	19.0	Max: 39.4
<a href="#">Steenenberg et al. (2003)</a>	the Netherlands, city NR	May–Jun; year not reported	24-h avg NO <sub>2</sub> 24-h avg NO	17.3 <sup>b</sup> 6.3 <sup>b</sup>	Max: 28.3 <sup>b</sup> Max: 34.5 <sup>b</sup>
<a href="#">†Steenhof et al. (2013)</a> <a href="#">†Strak et al. (2012)</a>	the Netherlands, city NR	Mar–Oct 2009	5-h avg NO <sub>2</sub> 5-h avg NO <sub>x</sub>	36 20	Max: 96 Max: 34
<a href="#">Adamkiewicz et al. (2004)</a>	Steubenville, OH	Sep–Dec 2000	1-h avg NO <sub>2</sub> 24-h avg NO <sub>2</sub> 1-h avg NO 24-h avg NO	9.2 10.9 15 11.2	75th: 12.8, Max: 32.9 75th: 14.6, Max: 23.8 75th: 16.1, Max: 215 75th: 14.2, Max: 70.7
<a href="#">†Weichenthal et al. (2011)</a>	Ottawa, ON, Canada	NR	1-h avg NO <sub>2</sub>	High traffic: 4.8 Low traffic: 4.6	Max: 11 Max: 10
<a href="#">†Chimenti et al. (2009)</a>	Palermo, Sicily, Italy	Nov Feb Jul; year NR	7-day avg NO <sub>2</sub>	31.7 <sup>b</sup> 27.1 <sup>b</sup> 33.9 <sup>b</sup>	NR NR NR
<a href="#">†Madsen et al. (2008)</a>	Oslo, Norway	Jan–Jun 2000	24-h avg NO <sub>2</sub> 7-day avg NO <sub>2</sub>	NR NR	NR NR

avg = average; Dec = December; Feb = February; h = hour; Max = maximum; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; NR = not reported.

<sup>a</sup>Studies presented in order of first appearance in the text of this section.

<sup>b</sup>Concentrations converted from µg/m<sup>3</sup> to ppb using the conversion factor of 0.532 for NO<sub>2</sub> and 0.815 for NO assuming standard temperature (25°C) and pressure (1 atm).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

### ***Children in the General Population***

Ambient NO<sub>2</sub> was associated with pulmonary inflammation and oxidative stress in populations of children, in which the prevalence of asthma ranged from 7.5 to 59% and prevalence of allergy ranged from 20 to 56% ([Patel et al., 2013](#); [Berhane et al., 2011](#); [Lin et al., 2011](#); [Steenenberg et al., 2001](#)). Except for [Altuğ et al. \(2014\)](#), studies demonstrated associations in groups without asthma or allergy, with no consistent difference in magnitude of association between children with and without respiratory

disease [(Liu et al., 2014a; Berhane et al., 2011; Lin et al., 2011); Figure 5-14 and Table 5-35]. These findings suggest associations between NO<sub>2</sub> exposure and pulmonary inflammation in healthy children.


Among children, associations for NO<sub>2</sub> varied among the various indicators of oxidative stress and inflammation. As examined in one study each, associations were not observed with PMNs, eosinophils, exhaled breath condensate pH, or methylation of inducible nitric oxide synthase (iNOS) (Patel et al., 2013; Chen et al., 2012a; Salam et al., 2012; Steerenberg et al., 2001). But several study results pointed to associations with eNO (Berhane et al., 2011; Lin et al., 2011; Steerenberg et al., 2001) (Figure 5-14 and Table 5-35). Most of these studies assigned exposure from one central site per community located between 1 and 14 km of subjects' homes. Further, associations were found with CO, BC, BS, and PM<sub>2.5</sub>, and copollutant models were not analyzed. Moderate to strong correlations were reported for NO<sub>2</sub> with PM<sub>2.5</sub> and BC ( $r = 0.47-0.80$ ) (Patel et al., 2013; Berhane et al., 2011). Thus, the extent to which the results for central site NO<sub>2</sub> reflect an independent association with NO<sub>2</sub> is uncertain.

Other studies examined confounding by traffic-related copollutants and/or ambient NO<sub>2</sub> measurements spatially aligned with a location of subjects, which may better represent ambient microenvironmental exposure. Outdoor school NO<sub>2</sub>, averaged over 5 or 7 days, was not associated with pulmonary inflammation in children without respiratory disease (Altuğ et al., 2014; Flamant-Hulin et al., 2010; Holguin et al., 2007). However, Holguin et al. (2007) did not report quantitative results to assess whether there was suggestion of association. And, the cross-sectional comparison of high versus low NO<sub>2</sub> in Flamant-Hulin et al. (2010) lacks the sensitivity to discern incremental changes in eNO that may occur with incremental changes in NO<sub>2</sub> exposure. Also, for some subjects, eNO was measured days before NO<sub>2</sub> was measured.

The study with the strongest inference about NO<sub>2</sub>-related increases in pulmonary inflammation in healthy children was conducted in Beijing, China before and after the 2008 Olympics (Lin et al., 2011). Although results were based on 28 children without asthma, a large number of measurements was collected per child. NO<sub>2</sub> and copollutants were measured at a site 0.65 km from schools, improving the spatial alignment of pollutants with subjects over the aforementioned central site studies. A 20-ppb increase in lag 0 day of 24-h avg NO<sub>2</sub> was associated with a 22% (95% CI: 18, 26) increase in eNO. This effect estimate was attenuated two to fourfold with adjustment for BC or PM<sub>2.5</sub> but remained positive (e.g., 5.6% [95% CI: 0.38, 11] with adjustment for BC). Adjustment for NO<sub>2</sub> attenuated the association of eNO with PM<sub>2.5</sub> but not BC. Thus, the NO<sub>2</sub> association was partly confounded, by BC especially. However, the results also indicate associations for NO<sub>2</sub> that are independent of PM<sub>2.5</sub> or BC in this population of children

without asthma. Supporting inferences from the copollutant models, NO<sub>2</sub>, PM<sub>2.5</sub>, and BC measured near children’s school may have comparable exposure measurement error.

Although [Lin et al. \(2011\)](#) found that eNO increased in relation to ambient NO<sub>2</sub> measured near subjects’ school and independently of PM<sub>2.5</sub> or the traffic-related BC, other studies had weaker inference. Outdoor school NO<sub>2</sub> was not associated with eNO in children without respiratory disease, but these studies either did not report quantitative results or had other methodological limitations. eNO was consistently associated with NO<sub>2</sub> measured at central sites and also with PM<sub>2.5</sub> and the traffic-related copollutants CO, BC, and BS. Thus, there is uncertainty in the epidemiologic evidence as a whole regarding an independent association of NO<sub>2</sub> exposure with pulmonary inflammation and/or oxidative stress in healthy children.



Note: avg = average; CI = confidence interval; eNO = exhaled nitric oxide; h = hour; km = kilometer; NO<sub>2</sub> = nitrogen dioxide. Black = studies from the 2008 Integrated Science Assessment for Oxides of Nitrogen, red = recent studies. Results are presented first for children then adults. Within each of these groups, results from more informative studies in terms of the exposure assessment method and potential confounding considered are presented first. Study details and quantitative results reported in [Table 5-35](#).

<sup>a</sup>Effect estimates are standardized to a 20-ppb increase for 24-h avg NO<sub>2</sub>. Effect estimates for 5-h or 1-h avg NO<sub>2</sub> are not standardized but are presented as reported in their respective studies ([Section 5.1.2.2](#)).

**Figure 5-14 Associations between ambient nitrogen dioxide concentrations and exhaled nitric oxide among children and adults in the general population.**

**Table 5-35 Epidemiologic studies of pulmonary inflammation, injury, and oxidative stress in children and adults in the general population.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<b>Children in the general population: studies with small spatial scale exposure assessment and/or examination of copollutant confounding</b>				
<p><a href="#">†Zhu (2013); Lin et al. (2011)</a> Beijing, China n = 36, ages 9–12 yr, 8 with asthma, 28 without asthma Repeated measures before and after Olympics. Examined daily for five 2-week periods. 1,581 observations. Recruitment from school. 60% responded to initial survey, 95% follow-up participation. GEE adjusted for temperature, relative humidity, body mass index.</p>	<p>NO<sub>2</sub>-central site 24-h avg Site 0.65 km from schools</p>	<p>0 1</p>	<p>eNO: All subjects: 22% (18, 26) No asthma: 22% (18, 26) No asthma: 9.5% (5.8, 13)</p>	<p>With BC: 5.6% (0.38, 11) With PM<sub>2.5</sub>: 14% (9.5, 19) BC robust to adjustment for NO<sub>2</sub>, PM<sub>2.5</sub> reduced but positive. Moderate correlations with NO<sub>2</sub>. Spearman <math>r = 0.30</math> for PM<sub>2.5</sub>, 0.68 for BC.</p>
<p><a href="#">†Flamant-Hulin et al. (2010)</a> Clermont-Ferrand, France n = 70 without asthma, mean age: 10.7 (SD: 0.7) yr, 75% no atopy Cross-sectional. Recruitment from schools. 69% participation. Self or parental report of no asthma. For some subjects, eNO measured up to 1 week before pollutants. GEE adjusted for atopy, mother's birth region, parental education, family history of allergy, smoking exposure. Did not consider confounding by meteorology.</p>	<p>NO<sub>2</sub>-school outdoor 24-h avg NO<sub>2</sub>-school indoor 24-h avg</p>	<p>0–4 avg 0–4 avg</p>	<p>log eNO comparing ≥14.3 vs. &lt;14.3 ppb NO<sub>2</sub> –0.09 (–0.22, –0.04) log eNO comparing ≥16.3 vs. &lt;16.3 ppb NO<sub>2</sub> –0.16 (–0.11, –0.20)</p>	<p>No copollutant model. Acetaldehyde and PM<sub>2.5</sub> associated with eNO. Correlations with NO<sub>2</sub> not reported.</p>

**Table 5-35 (Continued): Epidemiologic studies of pulmonary inflammation, injury, and oxidative stress in children and adults in the general population.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<b>Children in the general population: studies with central site exposure assessment and no examination of copollutant confounding</b>				
<a href="#">†Chen et al. (2012a)</a> New Taipei City, Taiwan n = 100, mean age 10.6 (SD: 2.5) yr, 33% asthma, 33% atopy Repeated measures. Examined 3–4 times/mo for 10 mo. 824 observations. Recruited from schools. A priori recruitment of children with and without asthma or atopy. Participants similar to nonparticipants. Mixed effects model adjusted for school, age, sex, body mass index, upper respiratory infection, asthma/allergic rhinitis attack, asthma medication use, temperature, humidity, day of week, sampling time, parental education, smoking exposure at home.	NO <sub>2</sub> -central site	0	No quantitative data. NO <sub>2</sub> reported not to affect eosinophils, PMNs, monocytes, IL-8.	No copollutant model. Associations found for PM <sub>2.5</sub> , O <sub>3</sub> but not CO. Moderate to no correlation with NO <sub>2</sub> . Pearson $r = 0.61$ for PM <sub>2.5</sub> , $-0.01$ for O <sub>3</sub> .
	24-h avg	1		
	1 site 2.5 km from schools, most homes 1 km of schools	2		
		3		
<a href="#">Steerenberg et al. (2001)</a> Utrecht (Urban, near busy roadway) and Bilthoven (Suburban), the Netherlands n = 126, ages 8–13 yr, 28% respiratory disease, 20% allergy Repeated measures. Examined 1/week for 7–8 weeks. Recruitment from urban and suburban schools. 65% participation. Nonstandardized eNO collection. Mixed effects model adjusted for sex, age, # cigarettes smoked in home, presence of a cold, history of respiratory symptoms, allergy. No consideration for potential confounding by meteorological factors.	NO <sub>2</sub> -central site	0–6 avg	eNO: Urban: 35% (0, 70) <sup>b</sup> Suburban: 3.0%, $p > 0.05$ IL-8 (units NR) Urban OR: 1.08, $p > 0.05$ Suburban OR: 1.03, $p > 0.05$	No copollutant model. PM <sub>10</sub> and BS also associated with eNO, IL-8, uric acid, urea.
	NO-central site	0–6 avg	eNO: Urban: 6.6% (0, 13) <sup>b</sup> Suburban: 7.3% (0, 15) <sup>b</sup> IL-8 (units NR) Urban OR: 1.05, $p > 0.05$ Suburban OR: 0.95, $p > 0.05$	
	All 24-h avg Site within 1.9 km of schools			

**Table 5-35 (Continued): Epidemiologic studies of pulmonary inflammation, injury, and oxidative stress in children and adults in the general population.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<p><a href="#">†Patel et al. (2013)</a> New York City, NY n = 36, ages 14–19 yr, 94% nonwhite, 50% with asthma Repeated measures. EBC collected 2/week for 4 weeks. 217 observations. Recruitment from schools. 89–90% participation rate. A priori recruitment of children with and without asthma or atopy. Self-report of physician-diagnosed asthma and symptoms in previous 12 mo. Mixed effects model with random effects for subject and adjusted for school, daily average temperature, 8-h max O<sub>3</sub>. Adjustment for day of week and humidity did not alter results.</p>	<p>NO<sub>2</sub>-central site 24-h avg Site 14 km from schools</p>	<p>0 0–3 avg</p>	<p>EBC 8-isoprostane: 1.7 (0.63, 2.7) log units 3.1 (1.3, 4.9) log units</p> <hr/> <p>EBC pH: -0.05 (-0.79, 0.68) -0.11 (-1.2, 1.0)</p>	<p>No copollutant model. BC also associated with EBC pH and 8-isoprostane. School BC moderately to highly correlated with NO<sub>2</sub>. Pearson <i>r</i> = 0.62, 0.80.</p>
<p><a href="#">†Berhane et al. (2011)</a> Anaheim, Glendora, Long Beach, Mira Loma, Riverside, San Dimas, Santa Barbara, Upland, CA, Children’s Health Study n = 169, ages 6–9 yr Cross-sectional. Recruitment from schools. Parental report of physician-diagnosed asthma and history of respiratory allergy. Two different methods used for eNO measurement. No information on participation rate. Linear regression adjusted for community, age, sex, race/ethnicity, asthma, asthma medication use, history of respiratory allergy, eNO collection time, body mass index percentile, smoking exposure, parental education, questionnaire language, season, multiple temperature metrics, eNO collected outdoors.</p>	<p>NO<sub>2</sub>-central site 24-h avg Sites in each community. # sites in each community NR</p>	<p>1–6 avg</p>	<p>eNO No asthma: 11% (-3.2, 28) No respiratory allergy: 9.1% (-3.6, 23)</p>	<p>No copollutant model. PM<sub>2.5</sub>, PM<sub>10</sub>, O<sub>3</sub> associated with eNO. Moderate or weak correlations with NO<sub>2</sub>. Pearson <i>r</i> for warm and cold season = 0.47, 0.65 for PM<sub>2.5</sub>; 0.49, 0.55 for PM<sub>10</sub>; 0.15, -0.4 for O<sub>3</sub>.</p>
<p><a href="#">†Salam et al. (2012)</a> Same cohort as above n = 940, ages 6–11 yr, 14% asthma, 56% respiratory allergy Cross-sectional. Recruitment from schools. Subjects representative of full cohort. Linear regression model adjusted for age, sex, ethnicity, asthma, respiratory allergy, parental education, smoking exposure, community, month of eNO collection. No consideration for confounding by meteorology.</p>	<p>NO<sub>2</sub>-central site 24-h avg Sites in each community. # sites in each community NR</p>	<p>1–7 avg</p>	<p>iNOS promoter methylation: 0.40% (-1.0, 1.8) iNOS methylation not strong predictor of eNO.</p>	<p>No copollutant model. PM<sub>2.5</sub> associated with higher iNOS promoter methylation. Moderate correlation with NO<sub>2</sub>. Spearman <i>r</i> = 0.36.</p>

**Table 5-35 (Continued): Epidemiologic studies of pulmonary inflammation, injury, and oxidative stress in children and adults in the general population.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copolutant Examination
<b>Adults in the general population: studies with small spatial scale exposure assessment and/or examination of copollutant confounding</b>				
<p>†<a href="#">Strak (2013)</a>; <a href="#">Strak et al. (2012)</a>            †<a href="#">Steenhof et al. (2013)</a>            Utrecht area, the Netherlands            n = 31, adults ages 19–26 yr, all healthy, nonsmoking            Repeated measures. Examined 3–7 times.            107 observations. Recruitment from university. Well-defined outdoor exposures at various sites: underground train station, two traffic sites, farm, and urban background site. Heart rate maintained during intermittent exercise. Multiple comparisons could result in higher probability of associations found by chance alone. No information on participation rate. Mixed effects model adjusted for temperature, relative humidity, season, high/low pollen, respiratory infection.</p>	<p>NO<sub>2</sub> and NO<sub>x</sub>-on site of outdoor activity            5-h avg</p>	<p>0-h            post-exposure</p> <hr/> <p>2-h</p>	<p>eNO:            NO<sub>2</sub>: 6.9% (-1.9, 16)            NO<sub>x</sub>: 4.7% (-1.8, 11)            Per 10.54 ppb increase in NO<sub>2</sub> and 28.05 ppb increase in NO<sub>x</sub></p> <hr/> <p>NO<sub>2</sub>            IL-6: 66% (-10, 142)            NAL protein: 60% (0, 121)<sup>b</sup></p>	<p>With PNC:            -7.4% (-19, 3.9) for NO<sub>2</sub>            -5.8% (-14, 2.4) for NO<sub>x</sub>            With EC:            4.1% (-6.0, 14) for NO<sub>2</sub>            2.0% (-7.3, 11) for NO<sub>x</sub>            PNC association persists NO<sub>2</sub>/NO<sub>x</sub> adjustment. EC &amp; Abs attenuated.            For IL-6:            With PNC: 95% (0, 190)            With OC: 67% (-10, 144)            Copollutant results robust.            Moderate to high correlations with NO<sub>2</sub> &amp; NO<sub>x</sub>. Spearman <i>r</i> = 0.56, 0.75 for PNC, 0.74, 0.87 for Abs, 0.67, 0.87 for EC.</p>

**Table 5-35 (Continued): Epidemiologic studies of pulmonary inflammation, injury, and oxidative stress in children and adults in the general population.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<b>Adults in the general population: studies with central site exposure assessment and no examination of copollutant confounding</b>				
<p><a href="#">†Chimenti et al. (2009)</a> Palermo, Sicily, Italy n = 9, male adults mean age 40 (SD: 3.8) yr, all healthy, nonsmoking Repeated measures. Examined during 3 outdoor races. No information on participation rate. Statistical analyses limited to correlation analyses. No consideration for potential confounding factors or repeated measures.</p>	<p>NO<sub>2</sub>-central site Averaging time NR 10 sites</p>	<p>NR</p>	<p>No correlations with plasma PMN or eosinophils. No results reported for CC16.</p>	<p>No copollutant model. Associations found with O<sub>3</sub> and PM<sub>2.5</sub>.</p>
<p><a href="#">†Weichenthal et al. (2011)</a> Ottawa, Canada n = 42, adults ages 19–58 yr, from nonsmoking homes, 95% white, 62% with allergies, 33% with asthma Repeated measures. Most examined 3 times. 118 observations. 1-h outdoor exposures during cycling in low and high traffic areas. Recruitment from public advertisements. No information on participation rate. Mixed effects models with random subject effect adjusted for temperature during cycling, average heart rate. Adjustment for relative humidity, day of week did not affect results.</p>	<p>NO<sub>2</sub>-central site 1-h avg 1 site</p>	<p>1-h 4-h post-exposure</p>	<p>eNO: -0.01% (-0.08, 0.06) -0.04% (-0.09, 0.01) Per 4-ppb increase in NO<sub>2</sub></p>	<p>No copollutant model. PM<sub>2.5</sub> associated with eNO. Moderate correlation with NO<sub>2</sub>. Spearman <i>r</i> = 0.31 for low traffic site, 0.45 for high traffic site. Potential differential exposure error for personal PM species and VOCs vs. central site NO<sub>2</sub>.</p>
<p><a href="#">†Madsen et al. (2008)</a> Oslo, Norway n = 1,004, male adults ages 67–77 yr, 10% with respiratory disease Cross-sectional. Recruitment from a larger cohort to represent a range of home outdoor NO<sub>2</sub>. No information on participation rate. GLM adjusted for age, respiratory disease, alcohol consumption, smoking status, # cigarettes/day, smoking exposure, education, hour of exam, body mass index, temperature.</p>	<p>NO<sub>2</sub>-central site NO<sub>2</sub>-dispersion model No information on model validation.</p>	<p>0–7 avg</p>	<p>CC16: 30% (7.8, 57) 3.8% (-7.3, 16)</p>	<p>No copollutant model. PM<sub>2.5</sub> (central site and home) associated with CC16. Moderate correlation with NO<sub>2</sub>. Spearman <i>r</i> for home = 0.59.</p>

**Table 5-35 (Continued): Epidemiologic studies of pulmonary inflammation, injury, and oxidative stress in children and adults in the general population.**

Study Population Examined and Methodological Details	NO <sub>2</sub> Metrics Analyzed	Lag Day	Effect Estimate (95% CI) Single-Pollutant Model <sup>a</sup>	Copollutant Examination
<a href="#">Adamkiewicz et al. (2004)</a> Steubenville, OH n = 29, adults ages 53–90 yr, nonsmoking, 28% with asthma, 24% with COPD Repeated measures. Examined weekly for 12 weeks. 138–244 total observations. No information on participation rate. GLM with subject-specific intercept and adjusted for time of day, day of week, study week, temperature, pressure, relative humidity. Several NO <sub>2</sub> measurements missing.	NO <sub>2</sub> -central site 24-h avg	0	eNO: 3.8% (–7.3, 16%)	No copollutant model for NO <sub>2</sub> . NO with PM <sub>2.5</sub> : 9.2% (–1.7, 20)
	NO-central site 24-h avg 1 site	0	30% (7.8, 57%)	PM <sub>2.5</sub> result robust. Correlations NR. Ambient NO robust to adjustment for indoor NO.

Note: Studies are organized by population examined, and more informative studies in terms of the exposure assessment method and potential confounding considered are presented first.

Abs = absorbance coefficient; avg = average; BC = British Columbia; BS = black smoke; CC16 = club cell protein; CI = confidence interval; CO = carbon monoxide; COPD = chronic obstructive pulmonary disease; EBC = exhaled breath condensate; EC = elemental carbon; eNO = exhaled nitric oxide; GEE = generalized estimating equation; GLM = generalized linear mixed effects model; IL = interleukin; iNOS = inducible nitric oxide synthase; m = meters; NAL = nasal lavage; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide, NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; NR = not reported; O<sub>3</sub> = ozone; OC = organic carbon; OR = odds ratio; PM = particulate matter; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 μm; PMN = polymorphonuclear leukocyte; PNC = particle number concentration; SD = standard deviation; VOC = volatile organic compound; yr = years.

<sup>a</sup>Effect estimates are standardized to 20 ppb for 24-h avg NO<sub>2</sub> or NO and 25 ppb for 8-h max NO<sub>2</sub>. Effect estimates for other averaging times (1-h avg to 15-h avg) are not standardized but presented as they are reported in their respective studies ([Section 5.1.2.2](#)).

<sup>b</sup>95% CI estimated for p = 0.05 based on reported p-value < 0.05.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

### **Adults in the General Population**

Among a few studies of older adults reviewed in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) and recent studies of older adults and adults performing outdoor exercise, several results point to increases in pulmonary inflammation in association with increases in ambient NO<sub>2</sub> concentrations. Pulmonary inflammation was indicated as increases in eNO, nasal lavage IL-6, and indicators of pulmonary injury and lung permeability such as club cell protein (CC16) and nasal lavage protein levels ([Table 5-35](#)). Associations adjusted for PM<sub>2.5</sub> or a traffic-related copollutant were found for 24-h avg NO ([Adamkiewicz et al., 2004](#)) and with 5-h avg NO<sub>2</sub> for some outcomes ([Steenhof et al., 2013](#); [Strak et al., 2012](#)). The epidemiologic findings have some support from controlled human exposure and toxicological studies (described in sections that follow), although the evidence for pulmonary injury is inconsistent.

In populations of mostly healthy adults performing outdoor exercise for <1 to 5 hours, increases in pulmonary inflammation were associated with NO<sub>2</sub> measured at the locations of outdoor exposures but not at central sites. Compared with studies that do not account for time-activity patterns, examination of subjects during time spent outdoors may better reflect effects related to ambient exposures, particularly when pollutants are measured in subjects' outdoor locations. In these studies, subjects had 3–5 separate outdoor exposure periods. In some studies, exposures occurred in locations that represented a gradient of traffic volume. Among adults running or cycling outdoors for 35–90 minutes, eNO and inflammatory cell counts (as measured by PMNs and eosinophils) were not associated with NO<sub>2</sub> measured at central sites ([Weichenthal et al., 2011](#); [Chimenti et al., 2009](#)) ([Figure 5-14](#) and [Table 5-35](#)). However, increases in eNO and nasal lavage IL-6 and protein were found in healthy adults in association with 5-h avg NO<sub>x</sub> and NO<sub>2</sub> measured on the site of outdoor exposures ([Steenhof et al., 2013](#); [Strak et al., 2012](#)), which account for variability in exposure better than central site measurements. Increases in eNO and nasal lavage IL-6 and protein were found immediately after and 2 hours after exposures ended but not the morning after, indicating a transient increase in pulmonary inflammation. Multiple analyses were conducted across pollutants, including several PM<sub>2.5</sub> components, but the consistency in results does not support the likelihood that the NO<sub>2</sub> associations were found by chance alone ([Strak et al., 2012](#)).

Among healthy adults, eNO also was associated with EC, absorbance coefficient (Abs), and PNC ([Strak et al., 2012](#)); IL-6 also was associated with PM<sub>2.5</sub> and OC ([Steenhof et al., 2013](#)). In copollutant models, associations of eNO with NO<sub>x</sub> and NO<sub>2</sub> were attenuated with adjustment for EC or Abs and became negative with adjustment for PNC ([Strak et al., 2012](#)). The PNC effect estimate was robust to adjustment for NO<sub>x</sub> or NO<sub>2</sub>. NO<sub>x</sub> and NO<sub>2</sub> were highly correlated with PNC and EC (e.g.,  $r = 0.75$  for NO<sub>x</sub> and PNC

and 0.71 for NO<sub>2</sub> and EC). However, NO<sub>2</sub> remained associated with nasal lavage IL-6 and protein after adjustment for PNC, PM<sub>2.5</sub>, EC, or OC (e.g., 67% [95% CI: -10, 144] increase in IL-6 per 30-ppb increase in 5-h avg NO<sub>2</sub> and 95% [95% CI: 0, 190] with adjustment for PNC). Thus, in this study of well-defined outdoor exposures, there is evidence of confounding of NO<sub>2</sub>-eNO associations by PNC but associations of NO<sub>2</sub> with IL-6, nasal lavage protein, and lung function that are independent of many key traffic-related copollutants ([Figures 5-16](#) and [5-17](#)).

Increases in pulmonary inflammation were associated with 24-h avg NO or NO<sub>2</sub> measured at central monitoring sites among older adults (ages: 53–90 years) ([Madsen et al., 2008](#); [Adamkiewicz et al., 2004](#)). Multiday averages of NO<sub>2</sub> (e.g., lag 0–4 day avg, 0–7 day avg) were associated with CC16 ([Madsen et al., 2008](#)). However, there is uncertainty in older adults regarding independent associations for NO<sub>2</sub> as [Madsen et al. \(2008\)](#) found an association with central site not home NO<sub>2</sub>, and each study found associations with PM<sub>2.5</sub> and traffic-related copollutants. Among older adults in Steubenville, OH, the association between NO and eNO decreased with adjustment for PM<sub>2.5</sub> but remained positive ([Adamkiewicz et al., 2004](#)). The PM<sub>2.5</sub> effect estimate increased. The copollutant model result has uncertain inference because of potential differential exposure measurement error and unreported correlations for NO<sub>2</sub> and PM<sub>2.5</sub>.

### **Controlled Human Exposure and Toxicological Studies of Pulmonary Inflammation**

As reviewed in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), several controlled human exposure and toxicological studies examined the effects of NO<sub>2</sub> exposure on markers of pulmonary inflammation such as differential inflammatory cell counts, eicosanoids, and cytokines. In these studies, the typical protocol consisted of a single- or multi-day exposure to NO<sub>2</sub> (100–5,000 ppb) followed 1 to 24 hours later by collection of bronchial wash or BAL fluid ([Tables 5-36](#) and [5-37](#)). The consistency and biological significance of effects across studies is difficult to evaluate given the variety of exposure circumstances and timing when effects were measured, but there is evidence for NO<sub>2</sub>-induced pulmonary inflammation in healthy adults that is most consistently demonstrated by increases in PMNs.

In limited analysis, NO<sub>2</sub> exposures (1–3 hours) of 300–600 ppb tended not to affect PMN levels ([Huang et al., 2012b](#); [Vagaggini et al., 1996](#)). ([Frampton et al. \(2002\)](#); [Frampton et al. \(1989\)](#)) observed a statistically nonsignificant increase after a 3-hour exposure to 600 ppb. In most groups of healthy adults, PMNs did increase after exposure to NO<sub>2</sub> in the range of 1,000 to 3,500 ppb given for 20 minutes to 6 hours as a single exposure ([Frampton et al., 2002](#); [Devlin et al., 1999](#); [Azadniv et al., 1998](#); [Jörres et al., 1995](#);

[Helleday et al., 1994](#)) or given for 4 hours over 3 or 4 days ([Solomon et al., 2000](#); [Blomberg et al., 1999](#)). In exception, 2,000-ppb NO<sub>2</sub> spikes superimposed on a background exposure of 50 ppb NO<sub>2</sub> did not affect PMNs ([Frampton et al., 1989](#)). [Helleday et al. \(1994\)](#) found that a 20-minute exposure to 3,500 ppb NO<sub>2</sub> increased bronchial PMNs in nonsmoking adults and increased alveolar PMNs in smoking adults. In contrast with findings in healthy humans, NO<sub>2</sub> exposures in the range of 300 to 5,000 ppb did not affect PMN levels in mice, rats, or rabbits whether exposure occurred on a single day or was repeated over 2 to 13 days ([Poynter et al., 2006](#); [Pagani et al., 1994](#); [Schlesinger et al., 1990](#)). PMNs did increase in one study of rabbits, but an independent effect of 1,000 ppb NO<sub>2</sub> could not be discerned because exposure co-occurred with H<sub>2</sub>SO<sub>4</sub> ([Schlesinger, 1987a](#)).

Experimental studies of healthy humans and animal models provide inconsistent evidence for the effects of short-term NO<sub>2</sub> exposure on eicosanoid levels. In humans, exposure to 1,000 or 2,000 ppb NO<sub>2</sub> for 3 or 4 hours increased thromboxane B<sub>2</sub> levels but not an array of other prostaglandins ([Devlin et al., 1999](#); [Jörres et al., 1995](#)). Increases in thromboxane also were observed in rabbits after a 2-hour exposure to 1,000 ppb but not 3,000 ppb NO<sub>2</sub> ([Schlesinger et al., 1990](#)). Lower NO<sub>2</sub> exposures of 100 ppb (4 hours) increased enzymes that form eicosanoids with ex vivo exposure of rat AMs, but eicosanoid levels increased in a statistically nonsignificant manner with ex vivo exposure and decreased with in vivo exposure ([Robison and Forman, 1993](#)).

Both controlled human exposure and toxicological studies tended to show lack of effect of short-term NO<sub>2</sub> exposure (300–5,000 ppb for 1 hour–7 days) on indicators of pulmonary inflammation such as BAL fluid levels of IL-6 and IL-8 ([Huang et al., 2012b](#); [Pathmanathan et al., 2003](#)) as well as lymphocytes ([Huang et al., 2012b](#); [Frampton et al., 2002](#); [Vagaggini et al., 1996](#); [Jörres et al., 1995](#); [Müller et al., 1994](#); [Pagani et al., 1994](#)). There were a few controlled human exposure studies of healthy adults that showed increased pulmonary inflammation as increased lymphocytes with 600 ppb NO<sub>2</sub> exposure ([Frampton et al., 2002](#)) or increased IL-6 and IL-8 ([Devlin et al., 1999](#)) or ICAM-1 ([Pathmanathan et al., 2003](#)) with 2,000 ppb NO<sub>2</sub> exposure. In examination of NO<sub>2</sub>-copollutant co-exposures, there was no additive or synergistic effect with PM<sub>2.5</sub> CAPs for lymphocytes or PMNs in humans ([Huang et al., 2012b](#)). However, there is evidence of synergistic effects with O<sub>3</sub> for some eicosanoids in rabbits ([Schlesinger et al., 1990](#)).

### **Controlled Human Exposure and Toxicological Studies of Pulmonary Injury**

In contrast with pulmonary inflammation, controlled human exposure studies of healthy adults generally did not show NO<sub>2</sub>-induced pulmonary injury as measured by BAL or

bronchial wash fluid levels of protein, LDH, or albumin. Null effects were observed in response to a wide range of NO<sub>2</sub> exposures (600–3,500 ppb; [Table 5-37](#)) given for 20 minutes to 6 hours on a single day or repeated over 3 or 4 days ([Frampton et al., 2002](#); [Solomon et al., 2000](#); [Blomberg et al., 1999](#); [Devlin et al., 1999](#); [Azadniv et al., 1998](#); [Helleday et al., 1994](#)). Pulmonary injury in healthy adults was indicated in a few studies as an increase in LDH following a 2-hour 500-ppb NO<sub>2</sub> exposure ([Huang et al., 2012b](#)) and an increase in albumin following a 4-hour 2,000-ppb NO<sub>2</sub> exposure repeated over 4 days ([Blomberg et al., 1999](#)). A wide range of NO<sub>2</sub> exposures (100–5,000 ppb for 1 hour–20 days; [Table 5-38](#)) showed no effect BAL protein, LDH, albumin, lipid, or surfactant in rodents ([Müller et al., 1994](#); [Pagani et al., 1994](#); [Robison and Forman, 1993](#); [Rose et al., 1989a](#); [Last and Warren, 1987](#); [Selgrade et al., 1981](#)). When BAL fluid protein, LDH, or albumin increased in rodents, NO<sub>2</sub> exposures often were 5,000 ppb for a few hours on a single day or on 2–5 days ([Poynter et al., 2006](#); [Müller et al., 1994](#); [Rose et al., 1989a](#); [Last and Warren, 1987](#); [Hatch et al., 1986](#); [Gregory et al., 1983](#)). Lower NO<sub>2</sub> exposures of 400–3,000 ppb increased indicators of pulmonary injury in rodents deficient in dietary antioxidant vitamin intake ([Selgrade et al., 1981](#); [Sherwin and Carlson, 1973](#)) or with longer duration exposures of 1–3 weeks ([Gregory et al., 1983](#); [Elsayed and Mustafa, 1982](#); [Sherwin et al., 1972](#)).

In rats, 5,000 ppb NO<sub>2</sub> exposure (not lower) over 1–7 days induced minor morphologic changes in the respiratory tract indicative of mild pulmonary injury. Such changes included thickened interstitium and inflammatory cell accumulation ([Müller et al., 1994](#)), increased collagen synthesis, a feature of fibrosis ([Last and Warren, 1987](#)), slight interstitial edema ([Barth et al., 1995](#)), a few necroses of the bronchiolar epithelium (bronchi were normal), and increased proliferative index in bronchioles and bronchi ([Barth and Müller, 1999](#)). As examined by ([Barth and Müller \(1999\)](#); [Barth et al. \(1995\)](#)), neither edema nor club cell proliferative index were increased after a 25-day exposure to 5,000 ppb NO<sub>2</sub>.

### **Controlled Human Exposure and Toxicological Studies of Oxidative Stress and Antioxidant Status**

Although toxicological studies demonstrate NO<sub>2</sub>-induced pulmonary oxidative stress and antioxidant capacity at higher than ambient-relevant concentrations of NO<sub>2</sub>, effects in toxicological and controlled human exposure studies of healthy rodent models and humans are more variable with ambient-relevant exposures. There is heterogeneity observed across the array of indicators of pulmonary oxidative stress and antioxidant capacity examined: lipid peroxidation, antioxidant enzymes, uric acid, and glutathione or glutathione-related enzymes ([Tables 5-37](#) and [5-38](#)). Indicators of lipid peroxidation increased in BAL fluid of healthy adults exposed to 4,000 ppb NO<sub>2</sub> for 3 hours

([Mohsenin, 1991](#)) but were not altered with 2,000 ppb NO<sub>2</sub> (4 hours) ([Kelly et al., 1996a](#)). Inconsistency also was observed in rats, with 400 ppb NO<sub>2</sub> (2 weeks) inducing no effect in rats or guinea pigs ([Ichinose and Sagai, 1989](#)) but 3,000 ppb NO<sub>2</sub> (1 week) increasing lipid peroxidation in rats deficient in antioxidant Vitamin E (neutralizes reactive oxygen species) ([Sevanian et al., 1982b](#)).

Effects on antioxidants were similarly variable. [Blomberg et al. \(1999\)](#) found no changes in glutathione, ascorbic acid, or uric acid levels in humans 1.5 hours after 4 consecutive days of exposure to 2,000 ppb NO<sub>2</sub> for 4 hours. A study of the kinetics of antioxidant response in the respiratory tract indicates that NO<sub>2</sub> exposure may have a transient effect. A single exposure to 2,000 ppb NO<sub>2</sub> reduced levels of uric acid and ascorbic acid in bronchial wash and BAL fluid 1.5 hours post-exposure ([Kelly et al., 1996a](#)). Six and 24 hours after exposure, the levels of these antioxidants returned to baseline or increased. Glutathione increased in the bronchial wash 1.5 and 6 hours after exposure, but no changes in glutathione were found in the BAL fluid or for reduced glutathione at any time after exposure. In rodents, 400 ppb NO<sub>2</sub> exposure for 2 weeks did not affect Vitamin C or Vitamin E levels (neutralize reactive oxygen species) in lung homogenates ([Ichinose and Sagai, 1989](#)), but a 5,000 ppb NO<sub>2</sub> exposure for 24 hours increased oxidized glutathione in BAL fluid ([Pagani et al., 1994](#)). Total glutathione was slightly diminished in BAL fluid but was increased in the peripheral blood. Because of the heterogeneity across studies in NO<sub>2</sub> exposure and antioxidants examined as well as the time of antioxidant measurement, it is not clear whether the variable results indicate inconsistent effects on oxidative stress, an increase in antioxidants in response to the increased presence of reactive oxidant species induced by NO<sub>2</sub> exposure, and/or oxidative stress due to depleted antioxidant capacity.

The lack of clarity as to whether NO<sub>2</sub> exposure stimulates antioxidants in response to increased oxidant species and/or results in oxidative stress also applies to results for changes in antioxidant enzymes. Enzyme levels or activities were examined in rodents with exposures of 1 to 4 weeks. Exposures of rodents to 400 or 500 ppb NO<sub>2</sub> did not alter activity of glutathione peroxidase (GPx), glutathione S-transferase (GST), superoxide dismutase (SOD), glutathione reductase, glucose-6-phosphate dehydrogenase, or 6-phosphogluconate dehydrogenase ([Ichinose et al., 1988](#); [Ayaz and Csallany, 1978](#)). Higher exposures of 1,000 to 5,000 ppb NO<sub>2</sub> had effects in varying directions. Continuous 4-week exposure of rats to 1,000 ppb NO<sub>2</sub> led to decreased GPx ([Ayaz and Csallany, 1978](#)). Four-week exposure to 1,000 and 5,000 ppb NO<sub>2</sub> for 6 hours a day increased GPx, GST, and SOD in BAL fluid of rats ([de Burbure et al., 2007](#)). With 1,000 ppb NO<sub>2</sub>, SOD levels returned to control levels by 48 hours post-exposure. Exposure of mice to 4,800 ppb NO<sub>2</sub> for 8 hours a day for 8 days induced no change in GST or glutathione reductase, but a statistically nonsignificant decrease in GPx was observed

([Mustafa et al., 1984](#)). For both 400 ppb NO<sub>2</sub> ([Ichinose and Sagai, 1989](#)) and 4,800 ppb NO<sub>2</sub> ([Mustafa et al., 1984](#)), combined exposure with O<sub>3</sub> did increase GPx synergistically, indicating responses may vary depending on the level of oxidants produced.

Another explanation for the variable effects of NO<sub>2</sub> exposure on indicators of pulmonary oxidative stress, antioxidant capacity, and pulmonary injury may be variation among subjects in antioxidant status. Discussed in detail in [Section 7.6.1](#), Vitamin C and/or E supplementation attenuated the effects of NO<sub>2</sub> exposure (1,000 or 4,000 ppb) on reduced antioxidant enzyme activity in rodents and increased lipid peroxidation (as well as airway responsiveness, [Section 5.2.2.1](#)) in healthy humans. As additional support, NO<sub>2</sub> exposure (1,000–4,800 ppb) increased indicators of pulmonary injury and oxidative stress in rodents deficient in dietary Vitamin C or E.

### **Controlled Human Exposure and Toxicological Studies of Development of a Pro-Allergic Phenotype**

A few experimental studies indicate that repeated exposures to NO<sub>2</sub> may promote Th2 skewing, which may have implications for allergic sensitization and development of Th2-related conditions such as asthma ([Section 4.3.2.6](#)). In guinea pigs, 2-week exposure to 3,000 ppb NO<sub>2</sub> led to an increase in eosinophils in the nasal epithelium and submucosa [([Ohashi et al., 1994](#)); [Table 5-37](#)]. In healthy adults, 2,000-ppb NO<sub>2</sub> exposure for 6 hours on 4 consecutive days increased expression of the Th2 cytokines IL-5, IL-10, and IL-13 in the bronchial epithelium ([Pathmanathan et al., 2003](#)). IL-5 promotes eosinophilia, and IL-13 promotes airway hyperresponsiveness and mucus production.

**Table 5-36 Characteristics of controlled human exposure studies of pulmonary inflammation, injury, and oxidative stress in healthy adults.**

Study	Disease Status <sup>a</sup> ; Sample Size; Sex; Age (Mean ± SD)	Exposure Details	Endpoints Examined
<a href="#">Azadniv et al. (1998)</a>	n = 11 M, 4 F; Early phase: 28.1 ± 3.5 yr Late phase: 27.4 ± 4.2 yr	2,000 ppb for 6 h; Exercise for approximately 10 of every 30 min at $\dot{V}_E = 40$ L/min	BAL fluid analysis 1 h and 18 h after exposure. Protein concentration, differential cell counts.
<a href="#">Blomberg et al. (1999)</a>	n = 8 M, 4 F; 26 yr (range: 21–32)	2,000 ppb, 4 h/day for 4 days; Exercise 15 min on/15 min off at workload of 75 watts	Cell counts from bronchial biopsies, BW, and BAL fluid 1.5 h after exposure; protein concentration, IL-8, MPO, hyaluronic acid, glutathione, ascorbic acid, and uric acid in BAL fluid and BW 1.5 h after exposure, blood parameters.
<a href="#">Devlin et al. (1999)</a>	n = 10 M; range: 18–35 yr	2,000 ppb for 4 h; Exercise for 15 min on/15 min off at $\dot{V}_E = 50$ L/min	Bronchial and alveolar lavage fluid contents 16 h after exposure. LDH activity, tissue plasminogen factor activity, IL-6 activity, IL-8 activity, PGE <sub>2</sub> levels, total protein, ascorbate, urate, and glutathione.
<a href="#">Frampton et al. (1989)</a>	(1) n = 7 M, 2 F; 30 yr (range: 24–37) (2) n = 11 M, 4 F; 25 yr (range: 19–37)	(1) 600 ppb for 3 h, (2) 50 ppb for 3 h + 2,000 ppb peak for 15 min/h; (1,2) Exercise 10 min on/20 min off at $\dot{V}_E = \sim 4$ times resting	BAL fluid cell viability and differential counts 3.5 h after exposure, IL-1 activity in BAL fluid cells.
<a href="#">Frampton et al. (2002)</a>	(1,2) n = 12 M, 9 F; F = 27.1 ± 4.1 yr M = 26.9 ± 4.5 yr	(1) 600 ppb for 3 h, (2) 1,500 ppb for 3 h; (1,2) Exercise 10 min on/20 min off at $\dot{V}_E = 40$ L/min	Bronchial and alveolar lavage fluid cell viability and differential counts 3.5 h after exposure, peripheral blood characterization.
<a href="#">Helleday et al. (1994)</a>	n = 8 nonsmokers; sex NR; median: 26 yr (range: 24–35) n = 8 smokers; sex NR; median: 29 yr (range: 28–32)	3,500 ppb for 20 min; Exercise last 15 min at 75 watts	BW and BAL fluid analysis. Protein concentration, differential cell counts.
<a href="#">†Huang et al. (2012b)</a>	(1) n = 11 M, 3 F (2) n = 6 M, 7 F (3) n = 7 M, 6 F; 24.6 ± 4.3 yr	(1) 500 ppb NO <sub>2</sub> for 2 h, (2) 500 ppb NO <sub>2</sub> + 73.4 ± 9.9 µg/m <sup>3</sup> CAPs for 2 h, (3) 89.5 ± 10.7 µg/m <sup>3</sup> CAPs for 2 h; (1–3) Exercise 15 min on/15 min off at $\dot{V}_E = 25$ L/min	Cell counts and concentrations of IL-6, IL-8, α1-antitrypsin, and LDH in BAL fluid 18 h after exposure.

**Table 5-36 (Continued): Characteristics of controlled human exposure studies of pulmonary inflammation, injury, and oxidative stress in healthy adults.**

Study	Disease Status <sup>a</sup> ; Sample Size; Sex; Age (Mean ± SD)	Exposure Details	Endpoints Examined
<a href="#">Jörres et al. (1995)</a>	Healthy; n = 5 M, 3 F; 27 yr (range: 21–33) Asthma; n = 8 M, 4 F; 27 ± 5 yr	1,000 ppb for 3 h; Exercise 10 min on/10 min off at individual's maximum workload	BAL fluid analysis 1 h after exposure (cell counts, histamine, eicosanoids).
<a href="#">Kelly et al. (1996a)</a>	n = 44; sex NR; median: 24 yr (range: 19–45)	2,000 ppb for 4 h; Exercise 15 min on/15 min off at 75 watts	Antioxidant concentrations and malondialdehyde in BAL fluid and BW at 1.5, 6, or 24 h after exposure.
<a href="#">Mohsenin (1991)</a>	n = 10 M, 9 F; range: 21–33 yr	4,000 ppb for 3 h; Prior to exposure, 4-week course of daily placebo or Vitamin C and Vitamin E.	BAL fluid immediately after exposure ( $\alpha$ 1-protease inhibitor, elastase inhibitory capacity, TBARS, conjugated dienes, and phospholipid phosphorus in lipid extraction, albumin).
<a href="#">Pathmanathan et al. (2003)</a>	n = 8 M, 4 F; 26 yr (range: 21–32)	2,000 ppb for 4 h/day for 4 days; Exercise 15 min on/15 min off at 75 watts	Biomarkers in bronchial epithelium-exotoxin, GM-CSF, Gro- $\alpha$ , I-CAM 1, IL-5, IL-6, IL-8, IL-10, IL-13, total and active NF $\kappa$ B, and TNF- $\alpha$ (fiberoptic bronchoscopy after end of last exposure).
<a href="#">Solomon et al. (2000)</a>	n = 11 M, 4 F; 29.3 ± 4.8 yr	2,000 ppb for 4 h/day for 3 days; Exercise 30 min on/30 min off at $\dot{V}_E = 25$ L/min	BW and BAL fluid analysis immediately after exposure. Differential cell counts, LDH, peripheral blood parameters.
<a href="#">Vagaggini et al. (1996)</a>	Healthy; n = 7 M; 34 ± 5 yr Asthma; n = 4 M, 4 F; 29 ± 14 yr COPD; n = 7 M; 58 ± 12 yr	300 ppb for 1 h; Exercise at $\dot{V}_E = 25$ L/min	Cell counts in sputum 2 h after exposure.

BAL = bronchoalveolar lavage; BW = bronchial wash; CAPs = concentrated ambient particles; COPD = chronic obstructive pulmonary disease; F = female; GM-CSF = granulocyte macrophage-colony stimulating factor; I-CAM = intercellular adhesion molecule; IL = interleukin; LDH = lactate dehydrogenase; M = male; MPO = myeloperoxidase; NF $\kappa$ B = nuclear factor kappa-light-chain-enhancer of activated B cells; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; PGE2 = prostaglandin E2; ppb = parts per billion; SD = standard deviation; TBARS = thiobarbituric acid reactive substances; TNF- $\alpha$  = tumor necrosis factor alpha;  $\dot{V}_E$  = minute ventilation; yr = year.

<sup>a</sup>Subjects were healthy individuals unless described otherwise.

†Study published since the 2008 ISA for Oxides of Nitrogen.

**Table 5-37 Characteristics of animal toxicological studies of pulmonary inflammation, injury, and oxidative stress.**

Study	Species (Strain); Sample Size; Sex; Age	Exposure Details	Endpoints Examined
<a href="#">Ayaz and Csallany (1978)</a>	Mice (C57BL/6J); n = 24-40/group; F; 18 months	500 or 1,000 ppb NO <sub>2</sub> for 17 mo, continuous; Animals had Vitamin E-deficient or Vitamin E-supplemented diets.	Glutathione peroxidase activity.
<a href="#">Barth et al. (1995)</a>	Rats (Sprague Dawley); n = 7/group; M; age NR	5,000, 10,000, or 20,000 ppb NO <sub>2</sub> for 3 or 25 days	Histological evaluation, morphometry, parenchymal and vascular damage, pulmonary arterial thickness, average medial thickness.
<a href="#">Barth and Müller (1999)</a>	Rats (Sprague Dawley); n = 5/group; M; age NR	5,000, 10,000, or 20,000 ppb NO <sub>2</sub> for 3 or 25 days	Club cell morphology, cellular proliferation, epithelial proliferation.
<a href="#">de Burbure et al. (2007)</a>	Rats (Wistar); n = 8/group; M 8 weeks	(1) 1,000 ppb NO <sub>2</sub> for 6 h/day, 5 days/week for 4 weeks; (2) 10,000 ppb NO <sub>2</sub> for 6 h/day, 5 days/week for 4 weeks; (3) 5,000 ppb NO <sub>2</sub> for 6 h/day for 5 days; (1-3) Animals had selenium-deficient or selenium-supplemented diets.	BAL fluid lipid peroxidation, antioxidant enzyme levels, protein concentration, cell counts, oxidant production, selenium levels, and peripheral blood parameters.
<a href="#">Elsayed and Mustafa (1982)</a>	Rats (Sprague-Dawley); n = 12/group; sex NR; 8 weeks	3,000 ppb for 7 days; Animals had Vitamin E-deficient or Vitamin E-supplemented diets.	Lung tissue protein content, lipid peroxidation, content, induction of antioxidant enzymes.
<a href="#">Gregory et al. (1983)</a>	Rats (Fischer 344); n = 4-6/group; sex NR; 14-16 weeks	(1) 1,000 or 5,000 ppb NO <sub>2</sub> for 7 h/day for 5 days/week for up to 15 weeks; (2) 1,000 ppb NO <sub>2</sub> for 0.5 h, 5,000 ppb NO <sub>2</sub> for 1.5 h; (3) 1,000 ppb NO <sub>2</sub> for 3 h, 5,000 ppb NO <sub>2</sub> for 1.5 h; (4) 1,000 ppb NO <sub>2</sub> for 0.5 h for 5 days/week for up to 15 weeks	Histopathological evaluation, BAL fluid and lung homogenate biochemical analysis (protein concentration, LDH, glucose-6-phosphate dehydrogenase, alkaline phosphatase, glutathione reductase, and glutathione peroxidase).
<a href="#">Hatch et al. (1986)</a>	Guinea pigs (Hartley); n = >3/group; sex NR; young adult	4,800 ppb NO <sub>2</sub> for 3 h in deficient and normal animals; 4,500 ppb NO <sub>2</sub> for 16 h; Animals had Vitamin C deficient or normal diets.	BAL fluid protein and antioxidant concentrations, 16 h after the 3 h exposure and within 2 h after the 16 h exposure.

**Table 5-37 (Continued): Characteristics of animal toxicological studies of pulmonary inflammation, injury, and oxidative stress.**

Study	Species (Strain); Sample Size; Sex; Age	Exposure Details	Endpoints Examined
<a href="#">Ichinose and Sagai (1989)</a>	Rats (Wistar), guinea pig (Hartley); n = 6/group; M; 10 weeks	400 ppb NO <sub>2</sub> , 400 ppb O <sub>3</sub> , or 400 ppb NO <sub>2</sub> + 400 ppb O <sub>3</sub> for 24 h/day for 2 weeks	Lipid peroxidation, antioxidant protective enzymes, total proteins, TBA reactants, nonprotein sulfhydryls in lung homogenates, immediately after exposure.
<a href="#">Last and Warren (1987)</a>	Rats (Sprague Dawley); n ≥ 4/group; M; age NR	5,000 ppb NO <sub>2</sub> , 1.0 mg/m <sup>3</sup> NaCl or H <sub>2</sub> SO <sub>4</sub> , 5,000 ppb NO <sub>2</sub> + 1.0 mg/m <sup>3</sup> NaCl, 5,000 ppb NO <sub>2</sub> + 1.0 mg/m <sup>3</sup> H <sub>2</sub> SO <sub>4</sub> for 23.5 h/day for 1, 3, or 7 days	Collagen synthesis, BAL fluid protein content and lavagable enzyme activities, immediately after exposure.
<a href="#">Müller et al. (1994)</a>	Rats (Sprague Dawley); n = 4; M; age NR	800, 5,000, or 10,000 ppb NO <sub>2</sub> for 1 and 3 days	BAL fluid cell counts and protein concentration, phospholipid component, SP-A, morphological changes.
<a href="#">Mustafa et al. (1984)</a>	Mice (Swiss Webster); n = 6/group; M; 8 weeks	(1) 4,800 ppb NO <sub>2</sub> ; (2) 4,500 ppb O <sub>3</sub> ; (2) 4,800 ppb NO <sub>2</sub> + 4,500 ppb O <sub>3</sub> ; (1-3) for 8 h/day for 7 days	Physical and biochemical lung parameters (lung weight, DNA, protein contents, oxygen consumption, sulfhydryl metabolism, NADPH-generating enzyme activities), immediately after exposure.
<a href="#">Ohashi et al. (1994)</a>	Guinea pigs (Hartley); n = 10/group; F; age NR	3,000 or 9,000 ppb NO <sub>2</sub> for 6 h/day, 6 times/week for 2 weeks	Pathology of mucosal samples: accumulation of eosinophils, epithelial injury, mucociliary dysfunction (taken 24 h after end of exposure period).
<a href="#">Pagani et al. (1994)</a>	Rats (CD Cobs); n = 5/group; M; age NR	5,000 or 10,000 ppb NO <sub>2</sub> for 24 h and 7 days	Analysis of BAL fluid and superoxide anion production by AMs.
<a href="#">Poynter et al. (2006)</a>	Mice (C57BL/6); n = 5/group; sex and age NR	5,000 or 25,000 ppb NO <sub>2</sub> for 6 h/day for 1, 3, or 5 days	Analysis of BAL fluid and histopathological evaluation immediately or 20 days after exposure.
<a href="#">Robison and Forman (1993)</a>	Rat (Sprague Dawley); n = 3/group; M; age NR	100, 1,000, 5,000, or 20,000 ppb NO <sub>2</sub> for 1, 2, and 4 h ex vivo	Enzymatic production of arachidonate metabolites in AMs, cyclooxygenase products.
<a href="#">Robison et al. (1993)</a>	Rats (Sprague Dawley); n > 4/group; sex and age NR	500 ppb NO <sub>2</sub> for 8 h/day for 0.5, 1, 5, or 10 days	BAL fluid cell counts and arachidonate metabolite levels, AM arachidonate metabolism, respiratory burst activity, and glutathione content.

**Table 5-37 (Continued): Characteristics of animal toxicological studies of pulmonary inflammation, injury, and oxidative stress.**

Study	Species (Strain); Sample Size; Sex; Age	Exposure Details	Endpoints Examined
<a href="#">Rose et al. (1989a)</a>	Mice (CD-1); n > 4/group; sex NR; 4–6 weeks	(1) 1,000, 2,500, or 5,000 ppb NO <sub>2</sub> for 6 h/day for 2 days; intra-tracheal inoculation with murine Cytomegalovirus; 4 additional days (6 h/day) of exposure; (2) Re-inoculation 30 days (air) post-primary inoculation	Infection 5 and 10 days post-inoculation, histopathological evaluation, and analysis of BAL fluid (LDH, albumin, macrophages).
<a href="#">Selgrade et al. (1981)</a>	Guinea pigs (Hartley); n = 7–31/group; M; age NR	(1) 400, 1,000, 3,000, or 5,000 ppb NO <sub>2</sub> for 72 h (2) 400 ppb NO <sub>2</sub> for 1 week (3) 5,000 ppb NO <sub>2</sub> for 3 h; (1–3) Animals had Vitamin C-supplemented diet or normal diet.	Protein concentration in BAL fluid, lipid profile of BAL fluid, histological evaluation of lung.
<a href="#">Sevanian et al. (1982b)</a>	Rats (Sprague Dawley); n = 8/group; sex NR; 8 weeks	3,000 ppb NO <sub>2</sub> for 7 days Animals had Vitamin E-deficient or Vitamin E-supplemented diets.	Protein content, fatty acid composition, lipid peroxidation in lung microsomes.
<a href="#">Sherwin et al. (1972)</a>	Guinea pigs; n = 4/group; M; age NR	2,000 ppb NO <sub>2</sub> continuously for 7, 14, or 21 days	Histopathological evaluation, cellular damage by LDH staining.
<a href="#">Sherwin and Carlson (1973)</a>	Guinea pigs; n = 9/group; M; age NR	400 ppb NO <sub>2</sub> continuously for 1 week	Protein concentration in BAL fluid.
<a href="#">Schlesinger (1987a)</a>	Rabbit (New Zealand White); M; n = 5/group	0.5 mg/m <sup>3</sup> H <sub>2</sub> SO <sub>4</sub> + 300 ppb NO <sub>2</sub> , 0.5 mg/m <sup>3</sup> H <sub>2</sub> SO <sub>4</sub> + 1,000 ppb NO <sub>2</sub> for 2 h/day for 2, 6, or 13 days	Cell counts in BAL fluid, AM function 24 h after exposure.
<a href="#">Schlesinger et al. (1990)</a>	Rabbits (New Zealand White); n = 3/group; M; age NR	(1) 1,000, 3,000, or 10,000 ppb NO <sub>2</sub> for 2 h; (2) 3,000 ppb NO <sub>2</sub> + 300 ppb O <sub>3</sub> for 2 h; (3) 100, 300, or 1,000 ppb O <sub>3</sub> for 2 h	Eicosanoids in BAL fluid, immediately and 24 h after exposure.

AM = alveolar macrophage; BAL = bronchoalveolar lavage; DNA = deoxyribonucleic acid; H<sub>2</sub>SO<sub>4</sub> = sulfuric acid; F = female; LDH = lactate dehydrogenase; M = male; NaCl = sodium chloride; NADPH = reduced nicotinamide adenine dinucleotide phosphate; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; O<sub>3</sub> = ozone; ppb = parts per billion; SP-A = surfactant protein A; TBA = thiobarbituric acid.

---

### 5.2.7.5 Summary of Respiratory Effects in Healthy Individuals

The 2008 ISA for Oxides of Nitrogen did not make a specific assessment about the respiratory effects of short-term exposure to oxides of nitrogen in healthy populations ([U.S. EPA, 2008c](#)). However, previous and recent epidemiologic evidence indicates ambient NO<sub>2</sub>-associated increases in respiratory symptoms and pulmonary inflammation in children in the general population. Results from experimental studies of healthy populations are variable; some show effects on events that may mediate the occurrence of respiratory symptoms with NO<sub>2</sub> exposures of 1,000 ppb and above but not lower.

Epidemiologic studies consistently show associations of short-term increases in ambient NO<sub>2</sub> with cough and pulmonary inflammation in school-aged children ([Tables 5-34](#) and [5-36](#)). While evidence overall is inconsistent, NO<sub>2</sub>-associated lung function decrements were observed in healthy adults in studies characterized as having strong exposure assessment with NO<sub>2</sub> and copollutants measured on site of outdoor exposures near busy roads or a steel plant ([Dales et al., 2013](#); [Strak et al., 2012](#)). In children, cough and pulmonary inflammation were associated with same-day or 2- to 5-day averages (no clear difference among lags) of 24-h avg NO<sub>2</sub>. However, there is some indication of lung function decrements and increased pulmonary inflammation in healthy adults related to shorter-duration NO<sub>2</sub> exposures (5- or 10-hour) that persist 0 to 18 hours after exposure. Although there is some epidemiologic evidence for NO<sub>2</sub>-related respiratory effects in healthy adults, it is not clear to what extent the evidence in children reflects effects in healthy children as most studies did not report the health status of study populations.

Despite the epidemiologic evidence supporting NO<sub>2</sub>-related respiratory effects in healthy populations, there is uncertainty as to whether the results can be attributed to NO<sub>2</sub> exposure specifically. Associations also were observed with PM<sub>2.5</sub> and an array of traffic-related pollutants, and few studies examined confounding by these copollutants. As examined for lung function and pulmonary inflammation, NO<sub>2</sub> associations persisted in copollutant models with PM<sub>2.5</sub> or a traffic-related copollutant among BC, OC, PNC, or PM<sub>2.5</sub> metal component ([Steenhof et al., 2013](#); [Strak et al., 2012](#); [Lin et al., 2011](#)). That some of the copollutant effect estimates were attenuated with adjustment for NO<sub>2</sub> indicates that NO<sub>2</sub> may have confounded copollutant associations. Providing good inference from copollutant model results, NO<sub>2</sub> and copollutants were measured near school or on location of outdoor exposures. Such informative epidemiologic studies in healthy populations are few in number. Studies of symptoms in healthy populations did not assess confounding by traffic-related copollutants, and while NO<sub>2</sub> associations in the U.S. multicity study persisted with adjustment for PM<sub>10</sub> or SO<sub>2</sub> ([Schwartz et al., 1994](#)),

symptom studies assigned NO<sub>2</sub> exposure from central sites. Limited evidence associating indoor NO<sub>2</sub> at ice arenas with respiratory symptoms in hockey players ([Salonen et al., 2008](#)) provides some coherence for the findings for outdoor NO<sub>2</sub>.

There is limited evidence from experimental studies demonstrating that NO<sub>2</sub> exposure independently induces respiratory effects in healthy populations and reducing uncertainty in the epidemiologic evidence base. Controlled human exposure studies do not indicate an effect of NO<sub>2</sub> exposures of 200–4,000 ppb (40 minutes to 5 hours) on respiratory symptoms or lung function in healthy adults ([Sections 5.2.7.2](#) and [5.2.7.3](#)). Both controlled human exposure and toxicological studies show variable effects on pulmonary inflammation, injury, and oxidative stress ([Section 5.2.7.4](#)). Controlled human exposure studies show increases in airway responsiveness and PMNs as well as development of a pro-allergic phenotype in healthy adults, but effects are observed with NO<sub>2</sub> exposures of 1,000 ppb and above, not lower concentrations ([Sections 5.2.7.1](#) and [5.2.7.4](#)). These are key events underlying respiratory symptoms or development of allergic disease or asthma ([Section 4.3.5](#)); however, the variable findings among NO<sub>2</sub> exposure concentrations and/or specific endpoints limit the extent of support to the epidemiologic evidence for respiratory effects in healthy populations.

---

## 5.2.8 Respiratory Mortality

Studies evaluated in the 2008 ISA for Oxides of Nitrogen that examined the association between short-term NO<sub>2</sub> exposure and cause-specific mortality consistently found positive associations with respiratory mortality, with some evidence indicating that the magnitude of the effect was larger compared to total and cardiovascular mortality. Recent multicity studies conducted in Asia ([Wong et al., 2008](#)), China ([Meng et al., 2013](#); [Chen et al., 2012b](#)), and Italy ([Faustini et al., 2013](#); [Chiusolo et al., 2011](#)), as well as a meta-analysis of studies conducted in Asian cities ([Atkinson et al., 2012](#)) add to the initial body of evidence indicating larger respiratory mortality effects ([Section 5.4.3](#) and [Figure 5-23](#)). However, an additional multicity study conducted in Italy ([Bellini et al., 2007](#)), an extension of [Biggeri et al. \(2005\)](#), observed relatively consistent risk estimates across mortality outcomes, which differs from the results of the original analysis and complicates interpretation of whether there is differential risk among mortality outcomes.


The initial observation of consistent positive NO<sub>2</sub> associations with respiratory mortality was examined in a few studies that conducted copollutant analyses. As with the interpretation of NO<sub>2</sub> associations with total mortality ([Section 5.4.4](#)), it is difficult to examine whether NO<sub>2</sub> is independently associated with respiratory mortality because NO<sub>2</sub> is often highly correlated with other traffic-related pollutants. In the 17 Chinese

cities study [China Air Pollution and Health Effects Study (CAPES)], [Chen et al. \(2012b\)](#) found that NO<sub>2</sub> risk estimates for respiratory mortality were slightly attenuated, but remained positive in copollutant models with PM<sub>10</sub> and SO<sub>2</sub> (9.8% [95% CI: 5.5, 14.2]; with PM<sub>10</sub>: 6.7% [95% CI: 2.9, 10.7]; with SO<sub>2</sub>: 7.0% [95% CI: 3.2, 11.0]; for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations at lag 0–1 days). These results are consistent with those of [Meng et al. \(2013\)](#) for COPD mortality in a study of four Chinese cities (i.e., 7.1% [95% CI: 5.4, 8.9]; lag 0–1 for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations; with PM<sub>10</sub>: 6.0% [95% CI: 3.2, 8.8]; and with SO<sub>2</sub>: 6.9% [95% CI: 4.2, 9.5]). [Chiusolo et al. \(2011\)](#) also found evidence that associations between short-term NO<sub>2</sub> exposure and respiratory mortality remained robust in copollutant models in a study of 10 Italian cities. In both an all-year analysis of NO<sub>2</sub> with PM<sub>10</sub> (NO<sub>2</sub>: 13.7% [95% CI: 2.9, 25.8]; NO<sub>2</sub> with PM<sub>10</sub>: 13.4% [95% CI: 2.9, 24.9]; for a 20-ppb increase in NO<sub>2</sub> concentrations at lag 1–5 days), and a warm season (April–September) analysis of NO<sub>2</sub> with O<sub>3</sub> (NO<sub>2</sub>: 41.3% [95% CI: 16.2, 71.7]; NO<sub>2</sub> with O<sub>3</sub>: 43.4% [95% CI: 14.6, 79.5]; for a 20-ppb increase in NO<sub>2</sub> concentrations at lag 1–5 days) NO<sub>2</sub> associations with respiratory mortality were relatively unchanged. However, when focusing on a subset of respiratory mortality, specifically those deaths occurring out-of-hospital, in six Italian cities, [Faustini et al. \(2013\)](#) reported evidence of an attenuation of the NO<sub>2</sub>-respiratory mortality association in copollutant models with PM<sub>10</sub> (NO<sub>2</sub>: 24.5% [95% CI: 7.4, 44.2]; lag 0–5 for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations; NO<sub>2</sub> with PM<sub>10</sub>: 11.8% [95% CI: -7.5, 35.0]). Overall, the limited number of studies that have examined the potential confounding effects of copollutants on the NO<sub>2</sub>-respiratory mortality relationship generally indicate that associations remain relatively unchanged, but it is difficult to disentangle the independent effects of NO<sub>2</sub>.

Of the studies evaluated, only the studies conducted in Italy examined potential seasonal differences in the NO<sub>2</sub>-respiratory mortality relationship ([Chiusolo et al., 2011](#); [Bellini et al., 2007](#)). In a study of 15 Italian cities, [Bellini et al. \(2007\)](#) found that risk estimates for respiratory mortality were dramatically increased in the summer from 1.4 to 9.1% for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations at lag 0–1 days, respectively, with no evidence of an association in the winter. These results were further confirmed in a study of 10 Italian cities ([Chiusolo et al., 2011](#)), which also observed an increase in risk estimates for respiratory mortality in the warm season (i.e., April–September) compared to all-year analyses. [Chiusolo et al. \(2011\)](#) did not conduct analyses only for the winter season. Although the respiratory mortality results are consistent with those observed in the total mortality analyses conducted by [Bellini et al. \(2007\)](#) and [Chiusolo et al. \(2011\)](#), as discussed in [Section 5.4](#), studies conducted in Asian cities observed different seasonal patterns, and it remains unclear whether the seasonal patterns observed for total mortality would be similar to those observed for respiratory mortality in these cities.

An uncertainty that often arises when examining the relationship between short-term air pollution exposures and cause-specific mortality is whether the lag structure of associations and the C-R relationship provide results that are consistent with what is observed for total mortality. [Chiusolo et al. \(2011\)](#) in a study of 10 Italian cities found the strongest evidence for an effect of NO<sub>2</sub> on respiratory mortality at longer lags, with the largest association at lag 2–5 days, which is indicative of a delayed effect ([Figure 5-24](#)). These results are supported by the study of ([Faustini et al., 2013](#)) in six Italian cities, which found the strongest evidence of an NO<sub>2</sub>-association with out-of-hospital respiratory mortality at lags 2–5 and 0–5 days. Evidence of an immediate effect at lag 0–1 day avg was also observed, but the magnitude of the association was smaller compared to lags 2–5 and 0–5 days. However, [Chen et al. \(2012b\)](#) in CAPES reported the largest effect at single-day lags of 0 and 1 and the average of lag 0–1 days providing support for an immediate effect of NO<sub>2</sub> on respiratory mortality ([Figure 5-25](#)). When examining longer lags, [Chen et al. \(2012b\)](#) reported that the magnitude of the association was similar, albeit slightly smaller, for a 0–4 day lag, suggesting a potential prolonged effect. In a study of COPD mortality in four Chinese cities (all four are examined in CAPES), [Meng et al. \(2013\)](#) reported slightly different results than CAPES' respiratory mortality results. When examining single-day lags from 0 to 7 days, the authors reported the largest association for Lag Day 0. However, larger associations were observed in multiday lag analyses with a similar magnitude of an association observed for lags 0–1 and 0–7 days, and the largest magnitude of an association overall for lag 0–4 days.

To date, analyses detailing the C-R relationship between air pollution and cause-specific mortality have been limited. In the analysis of four Chinese cities, [Meng et al. \(2013\)](#) also examined the NO<sub>2</sub> and COPD mortality C-R relationship in each individual city. To examine the assumption of linearity, the authors fit both a linear and spline model to the city-specific NO<sub>2</sub>-COPD mortality relationship. [Meng et al. \(2013\)](#) then computed the deviance between the two models to determine if there was evidence of nonlinearity. An examination of the deviance did not indicate that the spline model improved the overall fit of the NO<sub>2</sub>-COPD mortality relationship across the cities examined ([Figure 5-15](#)).



COPD = chronic obstructive pulmonary disease; NO<sub>2</sub> = nitrogen dioxide.

Source: Reprinted with permission of Elsevier, [Meng et al. \(2013\)](#).

**Figure 5-15 City-specific concentration-response curves of nitrogen dioxide and daily chronic obstructive pulmonary disease mortality in four Chinese cities.**

### 5.2.9 Summary and Causal Determination

Evidence indicates that there is a causal relationship between short-term NO<sub>2</sub> exposure and respiratory effects based on the coherence among multiple lines of evidence and biological plausibility for effects on asthma exacerbation. There is some support for NO<sub>2</sub>-related exacerbation of respiratory allergy and COPD, respiratory infection, respiratory mortality, and respiratory effects in healthy populations. However, because of inconsistency among lines of evidence and consequent uncertainty about the effects of NO<sub>2</sub> exposure, evidence for these other nonasthma respiratory effects does not strongly contribute to the determination of a causal relationship.

The determination of a causal relationship represents a change from the “sufficient to infer a likely causal relationship” concluded in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)). Consistent with previous findings, recent epidemiologic results indicate associations between ambient NO<sub>2</sub> concentrations and asthma-related respiratory effects. Biological plausibility continues to be provided by the NO<sub>2</sub>-induced increases in airway responsiveness and allergic inflammation demonstrated in experimental studies. The 2008 ISA cited uncertainty as to whether NO<sub>2</sub> has an effect independent from other traffic-related pollutants, and additional copollutant model results show ambient NO<sub>2</sub>-associated increases in asthma-related effects with adjustment for PM<sub>2.5</sub>, BC/EC, UFP, OC, metals, VOCs, or CO. Thus, much of the evidence for NO<sub>2</sub>-related respiratory effects was available in the 2008 ISA. However, the 2008 ISA emphasized epidemiologic findings and did not assess the coherence and biological plausibility for various respiratory conditions separately, which is important given that the weight of evidence varies among respiratory conditions. More than new findings, the evidence integrated across outcomes related to asthma exacerbation, with due weight given to the experimental evidence, is sufficient to rule out chance, confounding, and other biases with reasonable confidence and support a change in conclusion from likely to be causal to causal relationship. The evidence for a causal relationship is detailed below using the framework described in the [Preamble \(Table II\)](#). The key evidence as it relates to the causal framework is presented in [Table 5-39](#).

---

### 5.2.9.1 Evidence on Asthma Exacerbation

A causal relationship between short-term NO<sub>2</sub> exposure and respiratory effects is strongly supported by evidence for effects on clinical events and pulmonary responses that indicate and mediate asthma exacerbation. The evidence from controlled human exposure studies for NO<sub>2</sub>-induced increases in airway responsiveness in adults with asthma is sufficient to support the biological plausibility for the effects of NO<sub>2</sub> exposure on asthma exacerbation. Increased airway responsiveness can lead to asthma symptoms such as wheeze. Increases in airway responsiveness and doubling reduction in provocative dose are demonstrated in adults with asthma following 200 to 300 ppb NO<sub>2</sub> exposures at rest for 30 minutes and 100 ppb for 1 hour [([Brown, 2015](#); [Folinsbee, 1992](#)); [Section 5.2.2.1](#)]. The findings for clinically relevant airway responsiveness with NO<sub>2</sub> exposures not much higher than peak ambient concentrations ([Section 2.5.3](#)) particularly support an effect on asthma exacerbation of ambient NO<sub>2</sub> exposures. Further linking short-term NO<sub>2</sub> exposure to asthma exacerbation is evidence for NO<sub>2</sub> exposures of 260–400 ppb enhancing allergic inflammation (e.g., eosinophil activation, Th2 cytokines, PMNs) in humans with allergic asthma and a rat model of allergic disease [([Ezratty et al., 2014](#); [Barck et al., 2005a](#);

[Barck et al., 2002](#); [Wang et al., 1999](#)); [Sections 4.3.2.6 and 5.2.2.5](#)]. NO<sub>2</sub>-associated increases in pulmonary inflammation also were found in epidemiologic studies of populations with asthma ([Section 5.2.2.5](#)). In experimental studies, ambient-relevant NO<sub>2</sub> exposures increased eicosanoids (involved in PMN recruitment) but did not consistently affect pulmonary injury or oxidative stress ([Section 5.2.7.4](#)). These inconsistent findings for other events in the proposed mode of action linking NO<sub>2</sub> exposure and asthma exacerbation are not considered to weaken the evidence for a relationship with NO<sub>2</sub> because the effects were studied mostly in healthy humans and animal models.

Also supporting a causal relationship is the coherence of NO<sub>2</sub>-induced increases in airway responsiveness and allergic inflammation with the epidemiologic associations observed between short-term increases in ambient NO<sub>2</sub> concentration and increases in asthma symptoms in children [([Zora et al., 2013](#); [Gent et al., 2009](#); [Delfino et al., 2003](#); [Delfino et al., 2002](#)); [Section 5.2.2.3](#)] and increases in asthma hospital admissions and ED visits among subjects of all ages and children [([Iskandar et al., 2012](#); [Strickland et al., 2010](#); [Jalaludin et al., 2008](#); [Villeneuve et al., 2007](#)); [Section 5.2.2.4](#)]. Epidemiologic evidence for NO<sub>2</sub>-related decreases in lung function in populations with asthma is inconsistent as a whole, but associations were found with lung function measured under supervised conditions [([Greenwald et al., 2013](#); [Martins et al., 2012](#); [Delfino et al., 2008a](#); [Holguin et al., 2007](#); [McCreanor et al., 2007](#); [Delfino et al., 2003](#)); [Section 5.2.2.2](#)]. Most controlled human exposure studies found no effect of NO<sub>2</sub> exposure (120–4,000 ppb) on respiratory symptoms or lung function in adults with asthma. In contrast with airway responsiveness, symptom and lung function assessments did not include challenge with a bronchoconstrictor.

Individual epidemiologic studies examined multiple outcomes and lags of exposure, and not all studies had statistically significant results. However, the pattern of association observed for NO<sub>2</sub> supports the consistency of evidence and does not indicate a high probability of associations found by chance alone. Consistency also is demonstrated as evidence for NO<sub>2</sub>-related asthma exacerbation across diverse locations in North America, Europe, and Asia, including recent multicity studies. Most evidence was for multiday lags of NO<sub>2</sub> exposure of 2 to 5 days, but associations also were found with lags of 0 or 1 day. A larger magnitude of association is not clearly indicated for a particular lag of exposure. Asthma hospital admissions and ED visits were associated with 24-h avg and 1-h max NO<sub>2</sub>, and risk estimates ranged from a 4.5 to 34% increase per 20-ppb increase in 24-h avg NO<sub>2</sub> or 30-ppb increase in 1-h max NO<sub>2</sub>. Symptoms and lung function in children with asthma were associated primarily with 24-h avg NO<sub>2</sub>. The recruitment of children from schools supports the likelihood that study populations were representative of the general population of children with asthma. Issues with selective participation by certain groups were not reported. The concentration-response relationship was analyzed

for pediatric asthma ED visits in Atlanta, GA and Detroit, MI, and neither a threshold nor deviation from linearity was found in the range of 24-h avg or 1-h max ambient NO<sub>2</sub> concentrations examined ([Li et al., 2011b](#); [Strickland et al., 2010](#)).

Allergic inflammation promotes bronchoconstriction and airway obstruction. Thus, strengthening the link between NO<sub>2</sub>-related increases in allergic inflammation and airway responsiveness and epidemiologic evidence for asthma exacerbation are the NO<sub>2</sub>-associated increases in symptoms and decreases in lung function in populations of children with asthma with high prevalence of atopy (e.g., 47–84%). Airway obstruction in response to allergens can lead to lung function decrements and respiratory symptoms. The evidence for NO<sub>2</sub>-induced increases in airway responsiveness and allergic inflammation provides sufficient biological plausibility for the asthma-related effects observed in epidemiologic studies.

---

#### **5.2.9.2 Evidence on Nonasthma Respiratory Effects**

Epidemiologic studies demonstrate associations of ambient NO<sub>2</sub> concentrations with hospital admissions and ED visits for all respiratory causes combined ([Table 5-39](#)), suggesting that the respiratory effects of short-term NO<sub>2</sub> exposure may extend beyond exacerbation of asthma. However, when other respiratory conditions are evaluated individually, there is uncertainty about relationships with NO<sub>2</sub> because of inconsistency among disciplines and/or inconsistency of findings across the array of clinical and subclinical effects. Where epidemiologic associations were found, limited examination of potential confounding by traffic-related copollutants results in weak inference about NO<sub>2</sub> effects. Experimental evidence for NO<sub>2</sub>-induced increases in airway responsiveness and allergic inflammation supports effects on allergy exacerbation, but epidemiologic evidence is inconsistent ([Section 5.2.3](#)). For COPD exacerbation and respiratory infection ([Sections 5.2.4](#) and [5.2.5](#)), evidence from epidemiologic, controlled human exposure, and toxicological studies is inconsistent across outcomes such as hospital admissions, ED visits, symptoms, lung function, and immune cell function; thus, a direct effect of NO<sub>2</sub> exposure is not clearly demonstrated ([Table 5-39](#)). Epidemiologic studies consistently found NO<sub>2</sub>-associated increases in respiratory mortality ([Section 5.2.8](#)), but the spectrum of respiratory effects that can lead to mortality is not entirely clear. Among the leading causes of mortality, COPD, and respiratory infections are the ones related to respiratory causes ([Hoyert and Xu, 2012](#)), but these conditions are not clearly related to NO<sub>2</sub> exposure. Epidemiologic evidence also indicates ambient NO<sub>2</sub>-associated respiratory effects in healthy populations ([Section 5.2.7](#)), as cough and pulmonary inflammation in children in the general population and healthy adults. However, an independent effect of NO<sub>2</sub> is uncertain because of limited support from experimental studies.

---

### 5.2.9.3 Evaluation of Nitrogen Dioxide Exposure Assessment

Most epidemiologic evidence indicating ambient NO<sub>2</sub>-related asthma exacerbation is based on exposure assessment from central site monitors. Substantiating the epidemiologic evidence are several findings for associations with NO<sub>2</sub> measurements in subjects' location(s), including personal total and outdoor NO<sub>2</sub> as well as NO<sub>2</sub> measured outside schools ([Greenwald et al., 2013](#); [Zora et al., 2013](#); [Martins et al., 2012](#); [Sarnat et al., 2012](#); [Delfino et al., 2008a](#); [Holguin et al., 2007](#); [McCreanor et al., 2007](#)). Ambient NO<sub>2</sub> concentrations are highly variable across locations ([Sections 2.5.2](#) and [2.5.3](#)). Thus, compared to measurements at central sites, NO<sub>2</sub> measurements in subjects' locations may better represent temporal variation in subjects' ambient exposures in those locations. NO<sub>2</sub> concentrations summed across individuals' microenvironments have shown good agreement with total personal NO<sub>2</sub> ([Section 3.4.3.1](#)), demonstrating that microenvironmental ambient concentrations are important determinants of exposure. Imparting confidence in results for personal NO<sub>2</sub>, no issues were reported regarding measurements being near the LOD. Further supporting asthma exacerbation in relation to ambient NO<sub>2</sub> exposure, for some study areas, central site concentrations were reported to be correlated with total personal NO<sub>2</sub> ([Delfino et al., 2008a](#)), outdoor school NO<sub>2</sub> ([Sarnat et al., 2012](#)), or NO<sub>2</sub> measured at other central sites in the area ([Section 2.5.2](#)). In support of exposure assessment from central sites, larger ambient NO<sub>2</sub>-associated increases in respiratory hospital admissions and ED visits were found in the warm season. Personal-ambient NO<sub>2</sub> correlations are higher in the warm than cold season ([Section 3.4.4.3](#)), pointing to lower potential NO<sub>2</sub> exposure error.

The studies with microenvironmental exposure assessment provide some, albeit far from conclusive, indication that short-term NO<sub>2</sub> exposures near sources may be related to respiratory effects. Respiratory effects were associated with ambient NO<sub>2</sub> measured across locations with varying traffic intensities or distance to highways ([Steenhof et al., 2013](#); [Strak et al., 2012](#)). Other studies compared NO<sub>2</sub> associations among locations, observing respiratory effects in association with NO<sub>2</sub> at a school in a high but not low traffic area ([Greenwald et al., 2013](#); [Sarnat et al., 2012](#)) or larger respiratory effects near a steel plant than in a residential area ([Dales et al., 2013](#)). However, none of the latter studies examined whether the findings were attributable to NO<sub>2</sub> independently of correlated copollutants or differences between schools in population characteristics such as race/ethnicity, body mass index, or asthma medication use. Informing this uncertainty, [McCreanor et al. \(2007\)](#) found that adults with asthma had larger decreases in lung function and increases in eosinophil activation after walking along a high traffic road in London, U.K. than after walking in a park. Results from copollutant models provide evidence that respiratory effects associated with personal ambient NO<sub>2</sub> exposures near high traffic roads were independent of personal ambient EC, UFP, or PM<sub>2.5</sub> exposures.

Whether estimated from central sites or subjects' locations, NO<sub>2</sub> exposure metrics largely were integrated over 24 hours or 2–15 hours. The diurnal temporal pattern of exposure (e.g., acute peaks) underlying the associations of respiratory effects with daily average or multiday averages of NO<sub>2</sub> is unclear. However, studies conducted in outdoor locations with varying traffic intensities indicate increases in pulmonary inflammation and decreases in lung function in association with 2- or 5-h avg NO<sub>2</sub> exposures that ranged between 5.7 and 153.7 ppb ([Strak et al., 2012](#); [McCreanor et al., 2007](#)).

---

#### 5.2.9.4 Evaluation of Confounding

Also indicating an independent effect of NO<sub>2</sub> exposure on asthma exacerbation are epidemiologic associations found for NO<sub>2</sub> with statistical adjustment for potential confounding factors such as temperature, humidity, season, medication use, and, in particular, copollutants. Based on a common source and moderate to high correlations with NO<sub>2</sub>, confounding by other traffic-related pollutants is a major concern ([Sections 1.4.3](#) and [5.1.2.1](#)). Copollutant models were the predominant method used for evaluating copollutant confounding, and most of these studies found that NO<sub>2</sub> associations persisted with adjustment for PM<sub>2.5</sub>, BC/EC, OC, UFP, PNC ([Figure 5-16](#) and [Table 5-38](#)), PM<sub>2.5</sub> metal components, VOCs, or CO ([Figure 5-17](#) and [Table 5-38](#)). Copollutant models also indicated that NO<sub>2</sub> associations with asthma and other respiratory effects were independent of PM<sub>10-2.5</sub>, PM<sub>10</sub>, SO<sub>2</sub>, or O<sub>3</sub> [[Supplemental Figure S5-1 \(U.S. EPA, 2015a\)](#)]. O<sub>3</sub> ( $r = -0.61$  to  $0.45$ ) and PM<sub>10</sub> ( $r = -0.71$  to  $0.59$ ) showed a wide range of correlations with NO<sub>2</sub>, from strongly negative to moderately positive; SO<sub>2</sub> was moderately correlated with NO<sub>2</sub> ( $r = 0.31$ – $0.56$ ). Inference regarding confounding by PM<sub>2.5</sub> and traffic-related copollutants is strongest for exposures assessed in subjects' locations. Exposure measurement error may be similar for NO<sub>2</sub> and copollutants, thereby improving the reliability of copollutant models. These studies reported a wide range of correlations for NO<sub>2</sub> with PM<sub>2.5</sub> and traffic-related copollutants ( $r = -0.42$  to  $0.68$ ). Also strengthening inference from copollutant models, in some studies, personal NO<sub>2</sub> was not strongly positively correlated with personal copollutants ( $r = 0.20$ – $0.33$  for EC, OC, PM<sub>2.5</sub>;  $-0.42$  to  $0.08$  for ethylbenzene and benzene) ([Martins et al., 2012](#); [Delfino et al., 2006](#)). No issues were reported regarding personal exposure metrics for any of these pollutants being near the LOD. As examined in multiple populations with asthma, associations of lung function and pulmonary inflammation with personal total or outdoor NO<sub>2</sub> and NO<sub>2</sub> measured within 650 m of a children's school persisted with adjustment for PM<sub>2.5</sub> or BC/EC ([Martins et al., 2012](#); [Lin et al., 2011](#); [Delfino et al., 2008a](#); [McCreanor et al., 2007](#); [Delfino et al., 2006](#)). Results were similar in a study of healthy adults ([Steenhof et al., 2013](#); [Strak et al., 2012](#)). In some cases, the

95% CIs for NO<sub>2</sub> associations are exaggerated because the increment used to standardize effect estimates is far larger than the variability in NO<sub>2</sub> concentrations during the study period ([Martins et al., 2012](#); [Strak et al., 2012](#)). Most studies examining exposures at subjects' locations did not examine CO in single- or co-pollutant models. However, among children in the general population, the association between outdoor school NO<sub>2</sub> and lung function persisted with adjustment for CO ([Correia-Deur et al., 2012](#)).

As examined in only one or two studies with exposures assessed in subjects' locations, NO<sub>2</sub> associations persisted with adjustment for OC or metal PM<sub>2.5</sub> components such as iron and copper ([Steenhof et al., 2013](#); [Strak et al., 2012](#); [Delfino et al., 2006](#)). Information on potential confounding by UFP/PNC or VOCs also is limited, and results from copollutant models are more variable. However, rather than clearly demonstrating confounding of NO<sub>2</sub> associations, results show that adjustment for UFP/PNC or benzene attenuated one outcome in a study but not another ([Steenhof et al., 2013](#); [Martins et al., 2012](#); [Strak et al., 2012](#); [McCreanor et al., 2007](#)). There also was some evidence that NO<sub>2</sub> exposure confounded associations for traffic-related copollutants or PM<sub>2.5</sub>. Some associations of personal ambient PM<sub>2.5</sub>, EC/BC, OC, copper, UFP/PNC, or benzene with respiratory effects were attenuated with adjustment for personal ambient NO<sub>2</sub> ([Martins et al., 2012](#); [Strak et al., 2012](#); [McCreanor et al., 2007](#)). Also indicating an independent association for NO<sub>2</sub>, some studies found associations with school or personal NO<sub>2</sub> but not EC, OC, or PM<sub>2.5</sub> ([Sarnat et al., 2012](#); [Delfino et al., 2008a](#); [Holguin et al., 2007](#)).

Copollutant models based on central site concentrations indicate that ambient NO<sub>2</sub> remains associated with asthma- and nonasthma-related respiratory effects with adjustment for PM<sub>2.5</sub> ([Iskandar et al., 2012](#); [Dales et al., 2009a](#); [Jalaludin et al., 2008](#); [Villeneuve et al., 2007](#); [von Klot et al., 2002](#)) or as examined in fewer studies, UFP, CO, VOCs, or a source apportionment factor comprising EC and various metals ([Delfino et al., 2013](#); [Gent et al., 2009](#); [Tolbert et al., 2007](#); [Delfino et al., 2003](#)). Several traffic-related PM constituents are shown to induce oxidative stress ([Appendix](#)), and [Delfino et al. \(2013\)](#) found an NO<sub>2</sub> association with adjustment for the oxidative potential of PM<sub>2.5</sub> extracts. Observations that ambient NO<sub>2</sub>-associated increases in respiratory hospital admissions and ED visits are larger in the warm than cold season also point to an NO<sub>2</sub> association that may be independent of PM<sub>2.5</sub>. NO<sub>2</sub>-PM<sub>2.5</sub> correlations are lower in the warm season ([Section 3.4.4.1](#)), pointing to lower potential confounding by PM<sub>2.5</sub>. NO<sub>2</sub> and O<sub>3</sub> are not strongly positively correlated in the warm season. As with NO<sub>2</sub> measured in subjects' locations, some central site NO<sub>2</sub> associations were attenuated with adjustment for PM<sub>2.5</sub> or UFP for some but not all outcomes within the same studies ([Dales et al., 2009a](#); [Liu et al., 2009b](#); [von Klot et al., 2002](#)), and a clear confounding effect was not demonstrated. Similar to NO<sub>2</sub> measured in subjects' locations, central site NO<sub>2</sub> showed a range of correlations with traffic-related pollutants ( $r = 0.43\text{--}0.74$ ).

However, because spatial distributions may differ ([Section 3.3.1.1](#)), exposure measurement error may differ between central site concentrations of NO<sub>2</sub> and traffic-related copollutants, resulting in weaker inference from copollutant models.

Confounding by any particular copollutant was examined to a limited extent, and not all potentially correlated pollutants were examined. Further, inference from copollutant models can be limited ([Section 5.1.2.2](#)), and methods to adjust for multiple copollutants simultaneously are not reliable. Thus, residual confounding is likely. However, evidence integrated from copollutant models based on pollutants measured in subjects' locations and from controlled human exposure studies support an effect of ambient NO<sub>2</sub> exposure on asthma exacerbation independent of other traffic-related pollutants.

---

#### **5.2.9.5 Evaluation of Nitrogen Dioxide-Copollutant Mixture Effects**

As a component of an air pollution mixture, NO<sub>2</sub> potentially can induce health effects in combination with other pollutants. Controlled human exposure studies, with well-defined NO<sub>2</sub>-copollutant co-exposures, do not provide strong evidence that NO<sub>2</sub> exposure affects lung function and airway responsiveness differentially when occurring alone or as part of a mixture with PM<sub>2.5</sub> ([Gong et al., 2005](#)), SO<sub>2</sub> ([Devalia et al., 1994](#)), or O<sub>3</sub> (simultaneous or sequential exposure) ([Jenkins et al., 1999](#); [Hazucha et al., 1994](#); [Adams et al., 1987](#)). Interactions with CO, EC/BC, or UFP have not been examined in controlled human exposure studies. Limited epidemiologic findings point to increases in asthma-related symptoms and ED visits when short-term averages of ambient NO<sub>2</sub> concentration are jointly high with PM<sub>2.5</sub>, the traffic-related pollutants CO and EC, and/or O<sub>3</sub> and SO<sub>2</sub> ([Gass et al., 2014](#); [Winquist et al., 2014](#); [Schildcrout et al., 2006](#)). However, there is no clear indication that the combined effects of NO<sub>2</sub> with PM<sub>2.5</sub>, CO, EC, or VOCs are larger than effects estimated for NO<sub>2</sub> alone ([Gass et al., 2014](#); [Winquist et al., 2014](#); [Schildcrout et al., 2006](#); [Delfino et al., 2003](#)). These epidemiologic studies of joint effects or interactions have limited inference because exposure measurement error in the central site pollutant metrics may obscure interactions between personal exposures. They also do not provide information on whether NO<sub>2</sub> has an independent effect from other pollutants.

---

#### **5.2.9.6 Indoor Nitrogen Dioxide-Related Asthma Exacerbation**


A causal relationship between NO<sub>2</sub> and respiratory effects also is supported by the coherence of asthma-related effects associated with ambient and indoor NO<sub>2</sub> ([Table 5-39](#)). No issues were reported regarding a large number of indoor measurements being near the LOD. In schools in Ciudad Juarez, Mexico, correlations of NO<sub>2</sub> with BC, PM<sub>2.5</sub>,

PM<sub>10</sub>, PM<sub>10-2.5</sub>, and SO<sub>2</sub> differed indoors and outdoors, suggesting that NO<sub>2</sub> was part of a different pollutant mixture indoors and outdoors. NO<sub>2</sub> also may be part of different mixtures inside homes and classrooms because gas heaters and not stoves are a major source of classroom NO<sub>2</sub>. Cooking has been shown to be a more important determinant of indoor UFP than heating systems ([Weichenthal et al., 2007](#)). Thus, associations with indoor classroom NO<sub>2</sub> may be less likely to be confounded by UFP than are associations with indoor home NO<sub>2</sub> or ambient NO<sub>2</sub>. Mean concentrations of indoor NO<sub>2</sub>, averaged over 3 to 7 days, were in the range of ambient concentrations ([Table 5-39](#)), except for a mean of 121 ppb at one school. Indoor NO<sub>2</sub> concentrations, particularly at home, can exhibit acute peaks that deviate from the mean ([Table 3-4](#)). As with ambient NO<sub>2</sub>, the temporal pattern of NO<sub>2</sub> concentrations underlying associations of asthma-related effects with multiday averages of indoor NO<sub>2</sub> is not understood.

---

#### 5.2.9.7 Conclusion


Multiple lines of evidence support a relationship between short-term NO<sub>2</sub> exposure and asthma exacerbation. Some findings point to effects on allergy, COPD, respiratory infection, respiratory effects in healthy populations, and respiratory mortality, but there is inconsistency among disciplines and outcomes. The NO<sub>2</sub>-induced increases in allergic inflammation and airway responsiveness in controlled human exposure studies of adults with asthma comprise the key evidence that NO<sub>2</sub> exposure can independently exacerbate asthma and support the epidemiologic evidence for asthma hospital admissions and ED visits, as well as symptoms, lung function decrements, and pulmonary inflammation in populations with asthma. These studies found associations with 24-h avg and 1-h max NO<sub>2</sub> concentrations, at lags of 0 or 1 day and multiday averages of 2 to 5 days. The range of mean ambient concentrations was 11.3–30.9 ppb for 24-h avg NO<sub>2</sub>, 75.5 ppb for 2-h avg NO<sub>2</sub>, and 23.0–44.4 ppb for 1-h max NO<sub>2</sub>. The epidemiologic evidence is substantiated by findings for NO<sub>2</sub> measured in subjects' location(s), including personal, ambient school, ambient near-road, or indoor concentrations. Further, associations of personal total or ambient NO<sub>2</sub> or school NO<sub>2</sub> with asthma-related effects persist with adjustment for PM<sub>2.5</sub> or a traffic-related pollutant such as BC/EC, UFP, OC, a PM<sub>2.5</sub> metal, or VOC. Inference from copollutant models is limited as is the breadth of analysis of traffic-related copollutants and copollutant interactions. Thus, epidemiologic evidence for NO<sub>2</sub>-associated asthma exacerbation and biological plausibility from NO<sub>2</sub>-induced increases in airway responsiveness and allergic inflammation in adults with asthma together are sufficient to conclude that there is a causal relationship between short-term NO<sub>2</sub> exposure and respiratory effects.



Note: BS = black smoke; CI = confidence interval; EC/BC = elemental/black carbon, ED = emergency department; eNO = exhaled nitric oxide; FEF<sub>25-75%</sub> = forced expiratory flow between 25 and 75% of forced vital capacity; FEV<sub>1</sub> = forced expiratory volume in 1 second; FVC = forced vital capacity; km = kilometer; m = meter; NO<sub>2</sub> = nitrogen dioxide, PEF = peak expiratory flow; PM<sub>2.5</sub> = particles with a nominal mean aerodynamic diameter less than equal to 2.5 μm, PNC = particle number concentration; UFP = ultrafine particles. Black = studies reviewed in the 2008 Integrated Science Assessment for Oxides of Nitrogen, Red = recent studies, Closed circles = NO<sub>2</sub> effect estimate in a single-pollutant model; open circles = NO<sub>2</sub> effect estimate adjusted for a copollutant. Magnitude and precision of effect estimates should not be compared among different outcomes. Results are organized by copollutant analyzed then by exposure assessment method. Percentage change in FEF<sub>25-75%</sub>, FEV<sub>1</sub>, or FVC refers to percentage decrease. Quantitative results presented in [Table 5-38](#).

<sup>a</sup>To fit results in the figure, effect estimates are multiplied by 10. <sup>b</sup>Copollutant is ROS generated from PM<sub>2.5</sub> extract. <sup>c</sup>Copollutant is a source apportionment factor comprising EC and various metals. <sup>d</sup>Effect estimates standardized to a 20-ppb increase for 24-h avg NO<sub>2</sub> and a 30-ppb increase for 1-h max NO<sub>2</sub>. Effect estimates for 2-h, 5-h, or 15-h avg NO<sub>2</sub> are not standardized but presented as reported in their respective studies (see [Section 5.1.2.2](#)).

**Figure 5-16 Associations of ambient or personal nitrogen dioxide with respiratory effects adjusted for fine particulate matter, elemental/black carbon, or particle number concentration/ultrafine particles.**



Note: CI = confidence interval; CO = carbon monoxide; EBC = exhaled breath condensate; ED = emergency department; FEV<sub>1</sub> = forced expiratory volume in 1 second; NO<sub>2</sub> = nitrogen dioxide; PEF = peak expiratory flow; TWA = time-weighted average; VOC = volatile organic compound. Black = studies reviewed in the 2008 Integrated Science Assessment for Oxides of Nitrogen, Red = recent studies, Closed circles = NO<sub>2</sub> effect estimate in a single-pollutant model; open circles = NO<sub>2</sub> effect estimate adjusted for a copollutant. Magnitude and precision of effect estimates should not be compared among different outcomes. Results are organized by copollutant analyzed then by exposure assessment method. Percentage change in EBC pH, FEV<sub>1</sub>, and PEF refers to percentage decrease. Quantitative results presented in [Table 5-38](#).

<sup>a</sup>Effect estimates standardized to a 20-ppb increase for 24-avg NO<sub>2</sub> and a 30-ppb increase for 1-h max NO<sub>2</sub>.

**Figure 5-17 Associations of ambient nitrogen dioxide with respiratory effects adjusted for a volatile organic compound or carbon monoxide.**

**Table 5-38 Corresponding effect estimates for nitrogen dioxide-associated respiratory effects in single- and copollutant models presented in Figures 5-16 and 5-17.**

Study	Respiratory Outcome	NO <sub>2</sub> Averaging Time and Lag	Exposure Assessment Method	Correlation with NO <sub>2</sub>	% Change in Outcome (95% CI) per Increase in NO <sub>2</sub> <sup>a</sup>	
					Single-Pollutant Model	Copollutant Model
<a href="#">McCreanor et al. (2007)</a>	FEF <sub>25-75%</sub>	2-h avg Lag 0 h	Personal ambient	0.60	7.8 (1.3, 14) <sup>b</sup> per 5.3 ppb NO <sub>2</sub>	With PM <sub>2.5</sub> : 4.8 (-2.5, 13) <sup>b</sup>
				0.58		With EC: 4.3 (-2.6, 11) <sup>b</sup>
				0.58		With UFP: 4.7 (-3.9, 13) <sup>b</sup>
<a href="#">†Delfino et al. (2008a)</a>	FEV <sub>1</sub> % predicted	24-h avg Lag 0-1-day avg	Total personal	0.38	1.7 (0.19, 3.2)	With PM <sub>2.5</sub> : 1.3 (-0.22, 2.8)
			Central site within 8 or 16 km of homes	0.36	1.3 (0.15, 2.4)	With PM <sub>2.5</sub> : 0.86 (-0.89, 2.6)
<a href="#">†Zhu (2013); Lin et al. (2011)</a>	eNO	24-h avg Lag 0 day	Central site 0.65 km of school	0.30	22 (18, 26)	With PM <sub>2.5</sub> : 14 (9.5, 19)
				0.68		With BC: 5.6 (0.38, 11)
<a href="#">Moshammer et al. (2006)</a>	FEV <sub>1</sub>	8-h avg (12-8 a.m.) Lag 0 day	Central site next to school	0.54	8.9 (3.7, 14) <sup>b</sup> per 5.32 ppb NO <sub>2</sub>	With PM <sub>2.5</sub> : 10 (4.2, 16) <sup>b</sup>
<a href="#">ATSDR (2006)</a>	Asthma ED visits	24-h avg Lag 0-4-day avg	Central site: 1 site	0.61	5.8 (0.59, 11)	With PM <sub>2.5</sub> : 3.5 (-1.8, 9.0)
<a href="#">†Delfino et al. (2013)</a>	eNO	24-h avg Lag 0-1-day avg	Central site: 1 or 2 sites per city	0.43	9.0 (2.9, 15)	With PM <sub>2.5</sub> : 5.8 (-1.9, 14) <sup>c</sup>
<a href="#">Jalaludin et al. (2008)</a>	Asthma ED visits	1-h max Lag 0-1-day avg	Central site: city average	0.45 warm 0.68 cold	7.4 (4.5, 10)	With PM <sub>2.5</sub> : 4.5 (1.3, 7.8)

**Table 5-38 (Continued): Corresponding effect estimates for nitrogen dioxide-associated respiratory effects in single- and copollutant models presented in Figures 5-16 and 5-17.**

Study	Respiratory Outcome	NO <sub>2</sub> Averaging Time and Lag	Exposure Assessment Method	Correlation with NO <sub>2</sub>	% Change in Outcome (95% CI) per Increase in NO <sub>2</sub> <sup>a</sup>	
					Single-Pollutant Model	Copollutant Model
<a href="#">†Liu (2013); Liu et al. (2009b)</a>	FEV <sub>1</sub>	24-h avg Lag 0–2-day avg	Central site within 10 km of homes	0.71	1.2 (–0.84, 3.2)	With PM <sub>2.5</sub> : –1.2 (–6.4, 3.8)
<a href="#">†Iskandar et al. (2012)</a>	Asthma hospital admissions	24-h avg Lag 0–4-day avg	Central site within 15 km of hospital	0.33 <hr/> 0.51	30 (10, 60)	With PM <sub>2.5</sub> : 40 (20, 70) <hr/> With UFP: 50 (20, 80)
<a href="#">von Klot et al. (2002)</a>	Wheeze	24-h avg Lag 0–4-day avg	Central site 50 m from traffic	0.68 <hr/> 0.66	15 (2.0, 28)	With PM <sub>2.5</sub> : 12 (–7.0, 35) <hr/> With UFP: 2.0 (–14, 21)
	Beta agonist use			0.68 <hr/> 0.66	20 (5.0, 37)	With PM <sub>2.5</sub> : 25 (5.0, 49) <hr/> With UFP: 22 (5.0, 43)
<a href="#">†Strak (2013); Strak et al. (2012)</a>	FVC	5-h avg Lag 0 h	Location of outdoor exposures	0.67 <hr/> 0.56	1.8 (0.44, 3.2) per 10.54 ppb NO <sub>2</sub>	With EC: 2.3 (0, 4.6) <hr/> With PNC: 1.3 (–0.58, 3.1)
	eNO			0.67 <hr/> 0.56	6.9 (–1.9, 16) per 10.54 ppb NO <sub>2</sub>	With EC: 4.1 (–6.0, 14) <hr/> With PNC: –7.4 (–19, 3.9)
<a href="#">†Gent et al. (2009)</a>	Wheeze	NR Lag 0 day	Central site	0.49	NR	With source apportionment factor of EC, zinc, copper, lead: 8.0 (–1.0, 18)
<a href="#">†Peacock et al. (2011)</a>	Symptomatic fall in PEF	1-h max Lag 1 day	Central site: 1 site	NR	13 (–3.0, 31)	With BS: 6.2 (–17, 34)

**Table 5-38 (Continued): Corresponding effect estimates for nitrogen dioxide-associated respiratory effects in single- and copollutant models presented in Figures 5-16 and 5-17.**

Study	Respiratory Outcome	NO <sub>2</sub> Averaging Time and Lag	Exposure Assessment Method	Correlation with NO <sub>2</sub>	% Change in Outcome (95% CI) per Increase in NO <sub>2</sub> <sup>a</sup>	
					Single-Pollutant Model	Copollutant Model
† <a href="#">Brüske (2014)</a> ; <a href="#">Bruske et al. (2010)</a>	Lymphocytes in BAL fluid	24-h avg Lag 0–23 h	Central site within 3.5 km of homes	0.66	8.4 (–5.0, 24)	With UFP: 8.4 (–7.2, 27)
† <a href="#">Martins (2013)</a> ; <a href="#">Martins et al. (2012)</a>	EBC pH	24-h avg Lag 0–4-day avg	Individual TWA based on outdoor monitoring, modeling, time-activity data	–0.42 to 0.14 across time periods	2.6 (1.3, 3.9)	With benzene: 1.7 (–0.26, 3.6)
	FEV <sub>1</sub>	22 (1.5, 38)			With ethylbenzene: 1.6 (–0.49, 3.7)	
						With benzene: 3.6 (–31, 29)
						With ethylbenzene: 17 (–17, 41)
† <a href="#">Correia-Deur et al. (2012)</a>	PEF	24-h avg Lag 0 day	Outdoor school	0.51	1.9 (–0.38, 4.1)	With CO: 1.5 (0, 3.0)
<a href="#">Tolbert (2009)</a> ; <a href="#">Tolbert et al. (2007)</a>	Respiratory ED visits	1-h max Lag 0–2-day avg	Central sites: city average	0.70	2.6 (1.3, 3.9)	With CO: 2.2 (0.78, 3.7)
<a href="#">Jalaludin et al. (2008)</a>	Asthma ED visits	1-h max Lag 0–1-day avg	Central sites: city average	0.71 warm 0.55 cold	7.4 (4.5, 10)	With CO: 4.2 (0.78, 3.7)

avg = average; a.m. = ante meridiem; ATSDR = Agency for Toxic Substances and Disease Registry; BC = black carbon; BS = black smoke; CO = carbon monoxide; EC = elemental carbon; eNO = exhaled breath condensate; EBC = exhaled breath condensate; ED = emergency department; FEF<sub>25–75%</sub> = forced expiratory flow between 25 and 75% of forced vital capacity; FEV<sub>1</sub> = forced expiratory flow in 1 second; FVC = forced vital capacity; NR = not reported; PEF = peak expiratory flow; PM<sub>2.5</sub> = particles with a nominal mean aerodynamic diameter less than or equal to 2.5 µm, PNC = particle number concentration; TWA = time-weighted average; UFP = ultrafine particles.

<sup>a</sup>Single- and copollutant model results are standardized to a 20-ppb increase in 24-h avg NO<sub>2</sub> and 30-ppb increase in 1-h max NO<sub>2</sub>. Results based on other averaging times are not standardized but presented as reported in their respective studies (Section 5.1.2.2). Percentage change in FEF<sub>25–75%</sub>, FEV<sub>1</sub>, FVC, PEF, and EBC pH refers to percentage decrease.

<sup>b</sup>To fit results in [Figure 5-16](#), results are multiplied by 10.

<sup>c</sup>Copollutant specifically is reactive oxygen species generated from ambient PM<sub>2.5</sub> extracts.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

**Table 5-39 Summary of evidence for a causal relationship between short-term nitrogen dioxide exposure and respiratory effects.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
<b>Asthma Exacerbation</b>			
Consistent evidence from multiple, high-quality controlled human exposure studies. Rules out chance, confounding, and other biases with reasonable confidence	NO <sub>2</sub> increases airway responsiveness in adults with asthma exposed at rest following nonspecific or allergen challenge in several individual studies and meta-analyses.	<a href="#">Folinsbee (1992)</a> , <a href="#">†Brown (2015)</a> , <a href="#">†Goodman et al. (2009)</a>  <a href="#">Section 5.2.2.1, Table 5-1</a>	100 ppb for 1 h 200–300 ppb for 30 min
	Clinical relevance supported by findings of a doubling reduction in provocative dose in response to NO <sub>2</sub> .	<a href="#">†Brown (2015)</a>	100 ppb for 1 h, 140 ppb for 30 min
Epidemiologic evidence from multiple, high-quality studies provides some support for independent NO <sub>2</sub> association	NO <sub>2</sub> associations with lung function and pulmonary inflammation persist in copollutant models with PM <sub>2.5</sub> or a traffic-related copollutant—EC/BC, OC, UFP, or VOC in studies with exposure assessment in subjects' locations.  Some studies show weak-moderate correlations for personal ambient and total NO <sub>2</sub> with traffic-related copollutants ( $r = -0.42$ to $0.49$ ).	<a href="#">Delfino et al. (2006)</a> , <a href="#">†Delfino et al. (2008a)</a> , <a href="#">†Martins et al. (2012)</a> , <a href="#">McCreanor et al. (2007)</a>  <a href="#">Figures 5-16 and 5-17, Table 5-38</a>	Personal outdoor mean 2-h avg at near-road site: 75.5 ppb Total personal mean 24-h avg: 28.6 ppb
	Most central site NO <sub>2</sub> associations persist with adjustment for PM <sub>2.5</sub> , EC/metals factor, UFP, or CO.  Potential for differential exposure measurement error limits inference from copollutant models with central site measurements.  Symptoms, medication use: <a href="#">†Gent et al. (2009)</a> , <a href="#">von Klot et al. (2002)</a>	Asthma hospital admissions, ED visits: <a href="#">†Villeneuve et al. (2007)</a> , <a href="#">†Jalaludin et al. (2008)</a> , <a href="#">Ito et al. (2007)</a> , <a href="#">†Iskandar et al. (2012)</a> , <a href="#">ATSDR (2006)</a>	Overall study mean 24-h avg: 11.3–31.3 ppb Overall study mean 1-h max: 23–44 ppb
Some associations were attenuated with adjustment for PM <sub>2.5</sub> or UFP.	<a href="#">†Liu et al. (2009b)</a> , <a href="#">von Klot et al. (2002)</a>		
Indoor NO <sub>2</sub> associated with increases in asthma-related effects in children.	<a href="#">†Sarnat et al. (2012)</a> , <a href="#">†Lu et al. (2013)</a> , <a href="#">†Hansel et al. (2008)</a>  No association in <a href="#">†Greenwald et al. (2013)</a>	Means of 3- to 7-day avg: 18.7–121 ppb 75th: 31 ppb Max: 394 ppb	

**Table 5-39 (Continued): Summary of evidence for a causal relationship between short-term nitrogen dioxide exposure and respiratory effects.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
(Continued) (Epidemiologic evidence from multiple, high-quality studies provides some support for independent NO <sub>2</sub> association)	Most associations for microenvironmental and central site NO <sub>2</sub> persist in copollutant models with PM <sub>10</sub> , SO <sub>2</sub> , or O <sub>3</sub> .  NO <sub>2</sub> associations persist with adjustment for meteorology, time trends, season, medication use.	<a href="#">Supplemental Figure S5-1 (U.S. EPA, 2015a)</a>	(Continued)
Consistent epidemiologic evidence for NO <sub>2</sub> metrics with lower potential for exposure measurement error	Asthma-related effects associated with NO <sub>2</sub> measured in subjects' locations (personal total and ambient, school outdoor) or combined across central sites based on population density.  Better alignment with subjects' locations compared to central site NO <sub>2</sub> .	† <a href="#">Greenwald et al. (2013)</a> , † <a href="#">Holquin et al. (2007)</a> , † <a href="#">Delfino et al. (2008a)</a> , † <a href="#">McCreanor et al. (2007)</a> , † <a href="#">Sarnat et al. (2012)</a> , † <a href="#">Zora et al. (2013)</a> , † <a href="#">Delfino et al. (2006)</a> , † <a href="#">Strickland et al. (2010)</a>  No association: † <a href="#">Smargiassi et al. (2014)</a> , † <a href="#">Spira-Cohen et al. (2011)</a>	Personal outdoor mean 2-h avg: 75.5 ppb Total personal mean 24-h avg: 28.6 ppb Outdoor school mean 1-week avg: 3.4–18.2 ppb Central site population-weighted mean 1-h max: 23.3 ppb
Consistent epidemiologic evidence from other studies with more uncertainty regarding confounding and exposure measurement error	Increases in asthma hospital admissions, ED visits in diverse populations in association with 24-h avg and 1-h max NO <sub>2</sub> , lags 0 and 3 to 5-day avg among all ages and children.  No association in recent Canadian multicity study.	<a href="#">Ito et al. (2007)</a> , † <a href="#">Iskandar et al. (2012)</a> , <a href="#">ATSDR (2006)</a> <a href="#">Section 5.2.2.4, Figure 5-7</a>	Mean 24-h avg: 21.4–41.2 ppb
	Coherence with increases in respiratory symptoms and decrements in lung function in populations with asthma in association with 24-h avg, 2-4 h avg NO <sub>2</sub> , 1-h max, lags 0, 3 to 6-day avg.  Panel studies of children examined representative populations recruited from schools. No reports of selective participation by particular groups.	<a href="#">Sections 5.2.2.2 and 5.2.2.3, Figures 5-3 and 5-4</a>	City mean 24-h avg: 17.8–26 ppb
Evidence for key events in proposed mode of action  Allergic responses	Increases in eosinophil activation, IgE, Th2 cytokines in adults with asthma.	<a href="#">Barck et al. (2005a)</a> , <a href="#">Barck et al. (2002)</a> , <a href="#">Wang et al. (1995a)</a> , † <a href="#">Ezratty et al. (2014)</a>  <a href="#">Sections 4.3.2.6 and 5.2.2.5</a> <a href="#">Figure 4-1</a>	Humans: 260 ppb 15–30 min, 400 ppb 6 h, 581 ppb for 30 min, 2 days

**Table 5-39 (Continued): Summary of evidence for a causal relationship between short-term nitrogen dioxide exposure and respiratory effects.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
Evidence for key events in proposed mode of action	Increases in PMNs and prostaglandins in healthy adults.	<a href="#">Section 5.2.7.4</a>	1,500–3,500 ppb 20 min or 3–4 h
Inflammation	Increases in eNO in children with asthma in association with 24-h avg NO <sub>2</sub> .	<a href="#">Delfino et al. (2006)</a> , <a href="#">†Sarnat et al. (2012)</a> , <a href="#">†Martins et al. (2012)</a> <a href="#">Section 5.2.7.4</a>	Total personal mean 24-h avg: 24.3, 30.9 ppb Ambient mean 1-week avg: 4.5–20 ppb
Inconsistent effects on oxidative stress, pulmonary injury	See Respiratory Effects in Healthy Individuals below.		
<b>COPD Exacerbation</b>			
Inconsistent epidemiologic evidence and uncertainty regarding NO <sub>2</sub> independent effects	Increases in COPD hospital admissions and ED visits.  Inconsistent associations with lung function decrements and symptoms in adults with COPD.	<a href="#">†Faustini et al. (2013)</a> , <a href="#">†Ko et al. (2007b)</a> , <a href="#">†Arbex et al. (2009)</a> <a href="#">Section 5.2.4.2</a>  <a href="#">Section 5.2.4.1</a>	Mean 24-h avg: 24.1–63.0 ppb Mean 1-h max: 63.0 ppb
Inconsistent evidence from controlled human exposure studies	Lung function decrements not consistently found in adults with COPD.	<a href="#">Morrow et al. (1992)</a> , <a href="#">Vagaggini et al. (1996)</a> <a href="#">Section 5.2.4.1</a>	300 ppb for 1 h, 4 h
Lack of evidence to propose a mode of action	Increased inflammation in healthy adults but not in adults with COPD.	<a href="#">†Bruske et al. (2010)</a> <a href="#">Sections 5.2.4.3 and 5.2.7.4</a>	1,500–3,500 ppb 20 min or 3–4 h
<b>Respiratory Infection</b>			
Consistent animal toxicological evidence with relevant NO <sub>2</sub> exposures	Mortality from bacterial or viral infection in animals with NO <sub>2</sub> exposures of 1,500 ppb and higher, not lower concentrations.	<a href="#">Ehrlich et al. (1977)</a> , <a href="#">Ehrlich et al. (1979)</a> , <a href="#">Ehrlich (1980)</a> , <a href="#">Graham et al. (1987)</a> <a href="#">Section 5.2.5.1</a>	1,500–5,000 ppb for 3 h 1,500 ppb with 4,500 ppb spike of 1–7.5 h
Inconsistent epidemiologic evidence and uncertainty regarding NO <sub>2</sub> independent effects	Associations with hospital admissions and ED visits for respiratory infections. All results based on central site NO <sub>2</sub> , and some have wide 95% CIs.  Inconsistent evidence for parental reports of infection or laboratory-confirmed infections.	<a href="#">†Zemek et al. (2010)</a> , <a href="#">†Mehta et al. (2013)</a> , <a href="#">†Stieb et al. (2009)</a> , <a href="#">†Faustini et al. (2013)</a> , <a href="#">Just et al. (2002)</a> , <a href="#">†Stern et al. (2013)</a>  <a href="#">Sections 5.2.5.3 and 5.2.5.2.</a>	Overall study mean 24-h avg: 11.7–28.6 ppb City mean 24-h avg: 9.3–34.6 ppb

**Table 5-39 (Continued): Summary of evidence for a causal relationship between short-term nitrogen dioxide exposure and respiratory effects.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
Limited evidence for key events in proposed mode of action	Decreased AM function indicated by diminished superoxide production. No consistent effect on pulmonary clearance.	<a href="#">Section 5.2.5.4</a>	
<b>Respiratory Effects in Healthy Individuals</b>			
Limited epidemiologic evidence and uncertainty regarding NO <sub>2</sub> independent effects	Consistent evidence for respiratory symptoms in children. All based on central site NO <sub>2</sub> and no examination of confounding by traffic-related copollutants.	<a href="#">Schwartz et al. (1994)</a> <a href="#">Section 5.2.7.3</a> , <a href="#">Table 5-33</a>	Mean 24-h avg: 13 ppb
	Lung function not consistently associated with NO <sub>2</sub> measured at subjects' locations or central site NO <sub>2</sub> correlated ( $r = 0.63$ ) with total personal. But, personal ambient NO <sub>2</sub> associations persist with adjustment for PM <sub>2.5</sub> , EC, OC, copper, iron, or UFP.	† <a href="#">Strak et al. (2012)</a> , <a href="#">Moshhammer et al. (2006)</a> , <a href="#">Linn et al. (1996)</a> <a href="#">Section 5.2.7.2</a> , <a href="#">Table 5-30</a>	Max for 5-h avg: 96 ppb Max for 24-h avg: 96 ppb 75th for 24-h avg: 11.4 ppb
Limited and inconsistent evidence from controlled human exposure studies	Increases in airway responsiveness found in healthy adults above 1,000 ppb NO <sub>2</sub> , not lower concentrations.	<a href="#">Folinsbee (1992)</a> , <a href="#">Kjaergaard and Rasmussen (1996)</a> <a href="#">Section 5.2.7.1</a>	1,000–2,000 ppb for 3 h
	Respiratory symptoms or lung function examined in adults; changes generally not found.	<a href="#">Sections 5.2.7.2 and 5.2.7.3</a>	200–4,000 ppb for 2–5 h
Limited evidence for key events in proposed mode of action Inflammation	Increases in PMNs and prostaglandins in healthy adults.	<a href="#">Frampton et al. (2002)</a> , <a href="#">Frampton et al. (1989)</a> <a href="#">Section 5.2.7.4</a>	1,500–3,500 ppb for 3 h
	Limited epidemiologic evidence for associations of NO <sub>2</sub> measured in subjects' locations with increases in pulmonary inflammation in children and adults. Associations persist with adjustment for BC/EC, OC, UFP, or PM <sub>2.5</sub> .	† <a href="#">Strak et al. (2012)</a> , † <a href="#">Steenhof et al. (2013)</a> , † <a href="#">Lin et al. (2011)</a> <a href="#">Section 5.2.7.4</a> , <a href="#">Table 5-35</a>	Mean 24-h avg: 9.3, 33 ppb Mean 5-h avg across sites with varying traffic: 20 ppb

**Table 5-39 (Continued): Summary of evidence for a causal relationship between short-term nitrogen dioxide exposure and respiratory effects.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
Inconsistent effects on oxidative stress, pulmonary injury	Inconsistent changes in antioxidants in experimental studies but found in humans and rodents with lower dietary antioxidant vitamins.	Sections <a href="#">4.3.2.3</a> and <a href="#">5.2.7.4</a>	Humans: 2,000 ppb for 4 h, 1 day or 4 days Rodents: 1,000–5,000 ppb for 3–7 days
	Increases in LDH, CC16, BAL fluid protein inconsistently found in humans, rodents. Limited evidence for impaired epithelial barrier function.	Sections <a href="#">4.3.2.4</a> and <a href="#">5.2.7.4</a>	Humans: 600–2,000 ppb for 3–4 h, 1–4 days Animal models: 400–2,000 ppb for 1–3 weeks
<b>Respiratory Mortality</b>			
Consistent epidemiologic evidence but uncertainty regarding NO <sub>2</sub> independent effect	Multicity studies consistently observe associations of respiratory mortality with 24-h avg NO <sub>2</sub> at lag 0–1 days. Results based on NO <sub>2</sub> averaged across central sites. Potential confounding by traffic-related copollutants not assessed. NO <sub>2</sub> results robust to adjustment for PM <sub>10</sub> , SO <sub>2</sub> , or O <sub>3</sub> .	† <a href="#">Wong et al. (2008)</a> , † <a href="#">Chen et al. (2012b)</a> , † <a href="#">Chiusolo et al. (2011)</a> , † <a href="#">Bellini et al. (2007)</a> , <a href="#">Biggeri et al. (2005)</a>  Section <a href="#">5.2.8</a>	Means across cities for 24-h avg: 13.5–55.5 ppb
Uncertainty due to limited coherence with respiratory morbidity evidence	Evidence for asthma exacerbation in adults but limited coherence among lines of evidence for effects on COPD and respiratory infection. Uncertainty regarding spectrum of effects that can lead to respiratory mortality.		

AM = alveolar macrophage; ATSDR = Agency for Toxic Substances and Disease Registry; avg = average; BAL = bronchoalveolar lavage; BC = black carbon; CC16 = club cell protein; CI = confidence interval; CO = carbon monoxide; COPD = chronic obstructive pulmonary disease; EC = elemental carbon; ED = emergency department; eNO = exhaled nitric oxide; IgE = immunoglobulin E; LDH = lactate dehydrogenase; max = maximum; NO<sub>2</sub> = nitrogen dioxide; O<sub>3</sub> = ozone; OC = organic carbon; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 μm; PMN = polymorphonuclear cells; ppb = parts per billion; SO<sub>2</sub> = sulfur dioxide; Th2 = T-derived lymphocyte helper 2; UFP = ultrafine particles; VOC = volatile organic compound.

<sup>a</sup>Based on aspects considered in judgments of causality and weight of evidence in causal framework in [Tables I](#) and [II](#) of the [Preamble](#).

<sup>b</sup>Describes the key evidence and references, supporting or contradicting, contributing most heavily to causal determination and, where applicable, to uncertainties or inconsistencies. References to earlier sections indicate where full body of evidence is characterized.

<sup>c</sup>Describes the NO<sub>2</sub> concentrations with which the evidence is substantiated (for experimental studies, ≤ 5,000 ppb).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

---

## 5.3 Cardiovascular Effects

---

### 5.3.1 Introduction

The 2008 ISA for Oxides of Nitrogen concluded that the “available evidence on the effects of short-term exposure to NO<sub>2</sub> on cardiovascular health effects was inadequate to infer the presence or absence of a causal relationship” ([U.S. EPA, 2008c](#)). Multiple studies found associations between short-term exposure to NO<sub>2</sub> and rates of hospital admission or ED visits for cardiovascular diseases (CVDs), yet it was unclear at that time whether these results supported a direct effect of short-term NO<sub>2</sub> exposure on cardiovascular morbidity or were confounded by other correlated pollutants. Additionally, epidemiologic studies available at the time of the last review provided inconsistent evidence for associations between short-term NO<sub>2</sub> exposure and other cardiovascular events such as arrhythmia among patients with implanted cardioverter defibrillators and subclinical measures associated with cardiovascular events, such as heart rate variability (HRV) and electrocardiographic (ECG) markers of cardiac repolarization. Experimental studies available at the time of the 2008 ISA for Oxides of Nitrogen did not provide biological plausibility for the cardiovascular effects observed in epidemiologic studies. There was limited evidence from controlled human exposure studies demonstrating a reduction in hemoglobin and some evidence from toxicological studies for effects of NO<sub>2</sub> on various hematological parameters in animals, but these studies were limited and inconsistent. Overall, the experimental studies could not address the uncertainty related to copollutant confounding in epidemiologic studies of hospital admission or ED visits for CVDs in the 2008 ISA for Oxides of Nitrogen.

The following sections review the published studies pertaining to the cardiovascular effects of short-term exposure to oxides of nitrogen in humans, animals, and cells. When compared to the 2008 ISA for Oxides of Nitrogen, the recent epidemiologic and toxicological studies provide evidence for effects of NO<sub>2</sub> exposure on a broader array of cardiovascular effects and mortality. Still, substantial uncertainties remain concerning potential confounding by other traffic-related pollutants, exposure measurement error, and the limited mechanistic evidence to describe a role for NO<sub>2</sub> in the manifestation of cardiovascular diseases, including key events in the proposed mode of action. The majority of the recent evidence is from epidemiologic studies, which suggest that exposure to NO<sub>2</sub> may result in the triggering of MI. To clearly characterize the evidence underlying causality, the discussion of the evidence is organized into groups of related

outcomes [e.g., MI including ischemic heart disease (IHD), arrhythmia, and cardiac arrest]. Evidence for subclinical effects (e.g., HRV, blood biomarkers of cardiovascular effects) that potentially underlie the development, progression, or indication of various clinical events is discussed in [Section 5.3.10](#), and may provide biological plausibility for multiple outcomes.

---

## 5.3.2 Myocardial Infarction

Several lines of evidence are evaluated to assess the relationship between short-term NO<sub>2</sub> exposure and triggering of an MI: hospital admissions and ED visits for MI, IHD, or angina as well as ST-segment amplitude changes. An MI or heart attack occurs as a consequence of IHD, resulting in insufficient blood flow to the heart that overwhelms myocardial repair mechanisms and leads to muscle tissue death. In addition, IHD includes the diagnosis of angina. Symptoms of angina are similar to those of MI; however, where MI results in damage to the heart muscle, angina does not result in myocardial necrosis. As angina may indicate an increased risk for future MI, studies of angina are part of the evaluation of a relationship between short-term NO<sub>2</sub> exposure and MI. Finally, acute MI may be characterized by deviations in ST segment amplitude, which may serve as a nonspecific marker of myocardial ischemia.


---

### 5.3.2.1 Hospital Admissions and Emergency Department Visits for Myocardial Infarction and Ischemic Heart Disease

The 2008 ISA for Oxides of Nitrogen concluded that the epidemiologic evidence consistently supported the associations between short-term increases in ambient NO<sub>2</sub> concentrations and hospital admissions or ED visits for cardiac diseases ([U.S. EPA, 2008c](#)). This conclusion continues to be supported by studies published since the 2008 ISA, as reviewed below ([Figure 5-18](#) and [Table 5-40](#)). However, potential copollutant confounding, especially from other traffic-related pollutants (e.g., EC, CO), and limited mechanistic evidence are still key uncertainties, and make it difficult to interpret the results of these studies. Additionally, all of the studies in this section use central site monitors to estimate ambient NO<sub>2</sub> exposure, which may result in misclassification of the exposure due to the high variability in NO<sub>2</sub> ([Section 3.4.5.1](#)).

A number of studies rely on clinical registries, which are generally less susceptible to misclassification of the outcome and exposure. The strongest evidence of an association between ambient NO<sub>2</sub> and the risk of MI comes from a study using clinical registry data from the U.K.'s Myocardial Ischaemia National Audit Project ([Bhaskaran et al., 2011](#)),

which found a 5.8% (95% CI: 1.7, 10.6) increase in risk of MI per 30-ppb increase in 1-h max NO<sub>2</sub> concentrations in the 6 hours preceding the event. This study is unique because it included detailed data on the timing of MI onset in more than 79,000 patients from 15 conurbations in England and Wales, which allowed examination of association with ambient NO<sub>2</sub> in the hours preceding MI. NO<sub>2</sub> results were robust to a number of sensitivity analyses that evaluated key aspects of study design and model specification (e.g., stricter diagnosis criteria, different time strata). Additionally, [Bhaskaran et al. \(2011\)](#) restricted analyses to urban areas to reduce heterogeneity that may have resulted in measurement bias from the use of fixed site monitors to assess NO<sub>2</sub> exposure. The findings for NO<sub>2</sub> were more pronounced in those aged between 60 and 80 years, among those with prior coronary heart disease, and for events occurring in the autumn and spring. Conversely, in a smaller study of only 429 MI events, [Turin et al. \(2012\)](#) did not observe a consistent positive association using data from the Takashima County Stroke and AMI Registry in Central Japan. Cases were cross-checked by research physicians, epidemiologists, and cardiologists, thereby minimizing potential misclassification of the outcome.



Note: CI = confidence interval; h = hours; IHD = ischemic heart disease; MI = myocardial infarction; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; sARR = secondary arrhythmia; sCHF = secondary congestive heart failure; yr = years. Black = studies from the 2008 Integrated Science Assessment for Oxides of Nitrogen, red = recent studies. Circles = NO<sub>2</sub>, triangles = NO. Relative risks are standardized to a 20-ppb or 30-ppb increase in NO<sub>2</sub> or NO concentration for 24-h average and 1-h maximum metrics, respectively. Studies are organized first by averaging time, then by recent study or previous study, then in descending order of mean NO<sub>2</sub> concentration (in parts per billion).

**Figure 5-18 Associations between short-term exposure to oxides of nitrogen and hospital admissions for ischemic heart disease.**

**Table 5-40 Corresponding risk estimates for hospital admissions for ischemic heart disease for studies presented in Figure 5-18.**

Study	Location	Health Effect	Relative Risk <sup>a</sup> (95% CI)	Copollutant Examination <sup>b</sup>
<a href="#">†Thach et al. (2010)</a>	Hong Kong, China	IHD	Lag 0–1 avg: 1.04 (1.02, 1.05)	No copollutant models.
<a href="#">†Qiu et al. (2013a)</a>	Hong Kong, China	IHD	Lag 0–3 avg All year: 1.09 (1.08, 1.11) Warm season: 1.05 (1.03, 1.08) Cool season: 1.15 (1.12, 1.18)	No copollutant models. NO <sub>2</sub> and PM <sub>10</sub> correlation: Pearson $r = 0.76$ .
<a href="#">†Hsieh et al. (2010)</a>	Taipei, Taiwan	MI	Lag 0–3 avg ≥23°C: 1.24 (1.16, 1.35) <23°C: 1.26 (1.18, 1.35)	NO <sub>2</sub> : robust to PM <sub>10</sub> , SO <sub>2</sub> , CO, or O <sub>3</sub> inclusion in copollutant models.  Copollutants: all but O <sub>3</sub> attenuated by NO <sub>2</sub> adjustment.  NO <sub>2</sub> correlations (Pearson $r$ ): PM <sub>10</sub> : 0.55; SO <sub>2</sub> : 0.51; CO: 0.71; O <sub>3</sub> : 0.02.
<a href="#">†Tsai et al. (2012)</a>	Kaohsiung, Taiwan	MI	Lag 0–2 avg Hypertension ≥23°C: 1.24 (1.12, 1.38) <23°C: 1.29 (1.16, 1.44) No hypertension ≥23°C: 1.29 (1.18, 1.40) <23°C: 1.24 (1.14, 1.35)	No copollutant models.  NO <sub>2</sub> correlations (Pearson $r$ ): PM <sub>10</sub> : 0.48; SO <sub>2</sub> : 0.45; CO: 0.77; O <sub>3</sub> : -0.01.

**Table 5-40 (Continued): Corresponding risk estimates for hospital admissions for ischemic heart disease for studies presented in Figure 5-18.**

Study	Location	Health Effect	Relative Risk <sup>a</sup> (95% CI)	Copollutant Examination <sup>b</sup>
<a href="#">†Cheng et al. (2009a)</a>	Kaohsiung, Taiwan	MI	Lag 0–2 avg $\geq 25^{\circ}\text{C}$ : 1.23 (1.06, 1.44) $< 25^{\circ}\text{C}$ : 1.76 (1.55, 2.02)	NO <sub>2</sub> : attenuated by CO or O <sub>3</sub> adjustment on warm days and PM <sub>10</sub> on cool days. Robust to SO <sub>2</sub> adjustment.  Copollutants: all but CO and O <sub>3</sub> on warm days attenuated by NO <sub>2</sub> adjustment.  NO <sub>2</sub> correlations (Pearson <i>r</i> ): PM <sub>10</sub> : 0.73; SO <sub>2</sub> : 0.53; CO: 0.66; O <sub>3</sub> : 0.09.
<a href="#">†Bell et al. (2008)</a>	Taipei, Taiwan	IHD	All 13 monitors Lag 0: 1.10 (1.02, 1.18) Lag 1: 1.05 (0.98, 1.13) Lag 0–3 avg: 1.03 (0.98, 1.21) 5 city monitors Lag 0: 1.09 (1.02, 1.16) Lag 1: 1.05 (0.98, 1.12) Lag 0–3 avg: 1.08 (0.99, 1.20) 8 correlated monitors Lag 0: 1.09 (1.02, 1.17) Lag 1: 1.05 (0.98, 1.12) Lag 0–3 avg: 1.08 (0.97, 1.20)	No copollutant models.
<a href="#">†Goggins et al. (2013)</a>	Hong Kong, China; Taipei, Taiwan; Kaohsiung, Taiwan	MI	Lag 0 Hong Kong: 1.04 (1.02, 1.07) Taipei: 1.09 (1.05, 1.13) Kaohsiung: 1.05 (0.98, 1.13)	No copollutant models.
<a href="#">†Szyszkowicz (2009)</a>	6 Canadian cities	Angina	Lag 0: 1.04 (1.03, 1.05)	No copollutant models.
<a href="#">†Szyszkowicz (2007)</a>	Montreal, QC, Canada	IHD	Lag 1: 1.13 (1.04, 1.22)	No copollutant models.

**Table 5-40 (Continued): Corresponding risk estimates for hospital admissions for ischemic heart disease for studies presented in Figure 5-18.**

Study	Location	Health Effect	Relative Risk <sup>a</sup> (95% CI)	Copollutant Examination <sup>b</sup>
<a href="#">†Stieb et al. (2009)</a>	7 Canadian cities	MI	Lag 0: 1.03 (1.00, 1.05) Lag 1: 1.03 (1.00, 1.06)	NO <sub>2</sub> association attenuated by CO.
<a href="#">†Vencloviene et al. (2011)</a>	Kaunas, Lithuania	MI	Lag 0–1 avg <65 yr: 1.19 (0.96, 1.48) ≥65 yr: 0.97 (0.81, 1.17)	No results provided for other pollutants.
<a href="#">†Turin et al. (2012)</a>	Takashima County, Japan	MI	Lag 0: 1.14 (0.92, 1.40) Lag 1: 0.87 (0.70, 1.08)	NO <sub>2</sub> : robust to TSP or SO <sub>2</sub> adjustment. Attenuated by O <sub>3</sub> adjustment.  Copollutants: TSP and SO <sub>2</sub> attenuated by NO <sub>2</sub> adjustment. No associations between O <sub>3</sub> and MI regardless of NO <sub>2</sub> adjustment.
<a href="#">†Nuvolone et al. (2011)</a>	Tuscany, Italy	MI	Lag 0: 1.04 (0.97, 1.12) Lag 1: 1.08 (1.00, 1.15)	NO <sub>2</sub> : robust to PM <sub>10</sub> adjustment. Attenuated by CO adjustment.  Copollutants: PM <sub>10</sub> not associated with MI after NO <sub>2</sub> adjustment. No association between CO and MI regardless of NO <sub>2</sub> adjustment. No correlations reported.
<a href="#">†Wichmann et al. (2012)</a>	Copenhagen, Denmark	MI	Warm season Lag 0: 0.99 (0.86, 1.14) Lag 1: 1.10 (0.96, 1.26) <hr/> Lag 0–1 avg: 1.08 (0.932, 1.27) Cool season Lag 0: 1.01 (0.91, 1.11) Lag 1: 1.08 (0.98, 1.19) Lag 0–1 avg: 1.07 (0.95, 1.20)	No copollutant models.
<a href="#">†Larrieu et al. (2007)</a>	8 French cities	IHD	Lag 0–1 avg 1.07 (1.03, 1.10)	No copollutant models.

**Table 5-40 (Continued): Corresponding risk estimates for hospital admissions for ischemic heart disease for studies presented in Figure 5-18.**

Study	Location	Health Effect	Relative Risk <sup>a</sup> (95% CI)	Copollutant Examination <sup>b</sup>
<a href="#">†Rich et al. (2010)</a>	New Jersey	MI	Lag 0 Transmural: 1.14 (0.96, 1.32)	NO <sub>2</sub> : slightly attenuated by PM <sub>2.5</sub> adjustment.  Copollutants: PM <sub>2.5</sub> association attenuated by adjustment for NO <sub>2</sub> .  NO <sub>2</sub> and PM <sub>2.5</sub> correlation: <i>r</i> = 0.44.
<a href="#">Mann et al. (2002)</a>	Los Angeles, CA	IHD	With sARR Lag 0: 1.04 (1.02, 1.06) Lag 1: 1.02 (1.00, 1.04) Lag 0–1 avg: 1.03 (1.01, 1.05) With sCHF Lag 0: 1.05 (1.01, 1.08) Lag 1: 1.04 (1.01, 1.08) Lag 0–1 avg: 1.05 (1.02, 1.09) No secondary disease Lag 0: 1.03 (1.01, 1.04) Lag 1: 1.03 (1.01, 1.04) Lag 0–1 avg: 1.03 (1.02, 1.05)	No copollutant models.
		MI	Lag 0 1.04 (1.02, 1.06)	
<a href="#">Poloniecki et al. (1997)</a>	London, U.K.	IHD, MI, angina	Lag 1: 1.00 (0.98, 1.02) Lag 1: 1.02 (1.01, 1.03) Lag 1: 1.01 (1.00, 1.03)	NO <sub>2</sub> : robust to O; Attenuated by CO, SO <sub>2</sub> , and BS.
<a href="#">Linn et al. (2000)</a>	Los Angeles, CA	MI	Lag 0: 1.02 (1.00, 1.04)	No copollutant models.
<a href="#">Wong et al. (1999)</a>	Hong Kong, China	IHD	Lag 0–1: 1.04 (1.00, 1.08)	No copollutant models.

**Table 5-40 (Continued): Corresponding risk estimates for hospital admissions for ischemic heart disease for studies presented in Figure 5-18.**

Study	Location	Health Effect	Relative Risk <sup>a</sup> (95% CI)	Copollutant Examination <sup>b</sup>
<a href="#">Pönkä and Virtanen (1996)</a>	Helsinki, Finland	IHD	NO <sub>2</sub> Lag 0: 1.17 (0.96, 1.42) Lag 1: 0.95 (0.77, 1.16) NO Lag 0: 1.01 (0.96, 1.05) Lag 1: 1.10 (1.05, 1.15)	No copollutant models.
<a href="#">Barnett et al. (2006)</a>	7 Australian and New Zealand cities	IHD	Lag 0–1 avg ≥65 yr: 1.10 (1.04, 1.17) 15–64 yr: 1.03 (0.96, 1.10)	No copollutant models.
		MI	Lag 0–1 avg ≥65 yr: 1.18 (1.04, 1.35) 15–64 yr: 1.07 (0.96, 1.20)	
<a href="#">von Klot et al. (2005)</a>	5 European cities	MI	Lag 0 Ages >35 yr, MI survivors: 1.14 (0.99, 1.32)	NO <sub>2</sub> : robust to PM <sub>10</sub> or O <sub>3</sub> adjustment.
		Angina	Lag 0: 1.16 (1.03, 1.31)	
<a href="#">†Bhaskaran et al. (2011)</a>	England and Wales, U.K.	MI	Lag 1–6 h: 1.06 (1.02, 1.11) Lag 7–12 h: 0.95 (0.90, 0.99) Lag 13–18 h: 0.99 (0.94, 1.05) Lag 19–24 h: 1.00 (0.96, 1.05) Lag 0–2 day avg: 0.98 (0.93, 1.02)	No copollutant models.  NO <sub>2</sub> correlations: PM <sub>10</sub> : 0.48; O <sub>3</sub> : -0.58; CO: 0.61; SO <sub>2</sub> : 0.31.
<a href="#">Atkinson et al. (1999b)</a>	London, U.K.	IHD	Lag 0 0–64 yr: 1.01 (0.99, 1.04) 65+ yr: 1.03 (1.01, 1.04)	No copollutant models analyzed for IHD.

**Table 5-40 (Continued): Corresponding risk estimates for hospital admissions for ischemic heart disease for studies presented in Figure 5-18.**

Study	Location	Health Effect	Relative Risk <sup>a</sup> (95% CI)	Copollutant Examination <sup>b</sup>
<a href="#">Peel et al. (2007)</a>	Atlanta, GA	IHD	Lag 0–2 avg Case crossover: 1.04 (1.00, 1.07) Time series: 1.04 (1.01, 1.08)	No copollutant models.
<a href="#">Jalaludin et al. (2006)</a>	Sydney, Australia	IHD	Ages >65 yr Lag 0: 1.07 (1.01, 1.13) Lag 1: 1.02 (0.97, 1.08) Lag 0–1 avg: 1.01 (0.99, 1.03)	No copollutant models analyzed for IHD.
<a href="#">Simpson et al. (2005a)</a>	4 Australian cities	IHD	Lag 0–1 avg: 1.06 (1.03, 1.09)	No copollutant models analyzed for IHD.

avg = average; BS = black smoke; CA = California; CI = confidence interval; CO = carbon monoxide; GA = Georgia; IHD = ischemic heart disease; MI = myocardial infarction; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; O<sub>3</sub> = ozone; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 μm; QC = Quebec; sARR = secondary arrhythmia; sCHF = secondary congestive heart failure; SO<sub>2</sub> = sulfur dioxide, TSP = total suspended particles; U.K. = United Kingdom.

<sup>a</sup>Effect estimates are standardized to a 20-ppb or 30-ppb increase in NO<sub>2</sub> or NO for 24-h avg and 1-h max metrics, respectively.

<sup>b</sup>Relevant relative risks for copollutant models can be found in [Supplemental Figures S5-2, S5-3, S5-4, and S5-5 \(U.S. EPA, 2015b, c, d, e\)](#).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

A number of studies based on administrative data have also been published since the 2008 ISA for Oxides of Nitrogen. In six areas in central Italy, [Nuvolone et al. \(2011\)](#) found an 8% (95% CI: 0, 15) increase in risk of hospital admission for MI per 20-ppb increase in 24-h avg NO<sub>2</sub> on the previous day. Similar associations were seen in relation to lags 2 to 4 days prior to hospital admission. The association at lag 2 was robust to adjustment for PM<sub>10</sub> in a copollutant model, and remained positive, though somewhat attenuated, by adjustment for CO [[Supplemental Figures S5-2, \(U.S. EPA, 2015b\)](#) and [S5-3, \(U.S. EPA, 2015c\)](#)]. The association with NO<sub>2</sub> was somewhat more pronounced among females and in the cold season. Using data from 14 hospitals in seven Canadian cities, [Stieb et al. \(2009\)](#) found a 2.8% (95% CI: 0.2, 5.4) increase in risk of ED visits for the composite endpoint of acute MI or angina per 20-ppb increase in 24-h avg NO<sub>2</sub> on the same day. However, the overall association was heavily influenced by the association observed in Edmonton, and exclusion of the data from Edmonton from the analysis attenuated the results. Furthermore, the association observed from the data including Edmonton was weakened in magnitude and precision (wider 95% CI) in a copollutant

model adjusting for CO (1.3% [95% CI: -2.9, 5.6] increase per 20 ppb increase in 24 h avg NO<sub>2</sub> on the same day). [Larrieu et al. \(2007\)](#) observed a positive association between hospital admissions for IHD and NO<sub>2</sub> concentrations in eight French cities. The magnitude of the association was higher for older adults (i.e., ≥65 years) than for the general population. In large single-city studies, [Szyszkowicz \(2007\)](#), [Thach et al. \(2010\)](#), and [Franck et al. \(2014\)](#) found that NO<sub>2</sub> was associated with increased risk of hospital admission for IHD in Montreal, Canada; Hong Kong, China; and Santiago, Chile, respectively. [Qiu et al. \(2013a\)](#) also reported an overall association between NO<sub>2</sub> concentrations risk of ED visits for IHD in Hong Kong, China that was stronger in the cool season and on low humidity days.

In New Jersey, [Rich et al. \(2010\)](#) found a relative risk of 1.14 (95% CI: 0.96, 1.32) per 20-ppb increase in 24-h avg NO<sub>2</sub> for hospitalization for transmural MIs, but that association was attenuated by adjustment for PM<sub>2.5</sub> in a copollutant model [1.05 (95% CI: 0.85, 1.28)]. No results were reported for all MIs or for nontransmural infarcts. NO<sub>2</sub> was positively associated with hospital admissions for MI in Taipei, Taiwan ([Goggins et al., 2013](#); [Tsai et al., 2012](#); [Hsieh et al., 2010](#)); Kaohsiung, Taiwan ([Tsai et al., 2012](#); [Cheng et al., 2009a](#)); and Hong Kong, China ([Goggins et al., 2013](#)). The associations reported by [Hsieh et al. \(2010\)](#) remained relatively unchanged after adjustment for PM<sub>10</sub>, SO<sub>2</sub>, CO, or O<sub>3</sub> in copollutant models, as did the results from [Cheng et al. \(2009a\)](#), with the exception of CO and O<sub>3</sub> on warm days. NO<sub>2</sub> was also positively associated with hospital admissions for IHD in Taipei, Taiwan ([Bell et al., 2008](#)). In an effort to reduce uncertainty related to the use of central site monitors, [Bell et al. \(2008\)](#) estimated NO<sub>2</sub> exposure over the entire Taipei area (average of 13 monitors), within Taipei City only (average of 5 monitors), and using a subset of monitors where all pairs of monitors had NO<sub>2</sub> correlations greater than 0.75 (8 monitors). The authors reported consistent results across the multiple exposure metrics, with the exception of stronger associations observed using the city or correlated monitors at lag 0–3 avg ([Table 5-40](#)). [Wichmann et al. \(2012\)](#) found that NO<sub>2</sub> was positively associated with risk of acute MI hospital admissions in Copenhagen, Denmark, but only in the warm months of the year. NO<sub>2</sub> was not associated with risk of hospital admission for acute coronary syndrome in Lithuania ([Vencloviene et al., 2011](#)).

---

### 5.3.2.2 Hospital Admissions and Emergency Department Visits for Angina Pectoris

The preceding epidemiologic evidence describing associations between short-term increases in ambient NO<sub>2</sub> concentrations and increased hospital admissions and ED visits for MI and IHD is supported by evidence for increases in hospital admissions and ED visits for angina. Angina pectoris results from an imbalance between the demand for oxygen in the heart and the delivery by the coronary artery. Reduction in coronary blood

flow due to atherosclerosis is a common cause of this imbalance. Unstable angina, where the coronary artery is not completely occluded, can lead to MI.

The 2008 ISA for Oxides of Nitrogen did not include specific discussion of angina but did report results from two studies that examined associations between ambient NO<sub>2</sub> concentrations and angina hospital admissions ([U.S. EPA, 2008c](#)). In a study of five European cities, [von Klot et al. \(2005\)](#) examined the relationship between short-term air pollution and hospital readmissions of myocardial infarction survivors. The authors reported a 16% (95% CI: 3, 31) increase in risk of hospital readmissions for angina pectoris per 20-ppb increase in 24-h avg NO<sub>2</sub> on the same day. [Poloniecki et al. \(1997\)](#) observed a smaller, but statistically significant association between NO<sub>2</sub> concentrations on the previous day and angina hospital admissions in London, U.K. ([Table 5-40](#)). Neither study evaluated copollutant models.

More recent studies add to the limited, but consistent evidence of an association between ambient NO<sub>2</sub> exposure and angina hospital admissions and ED visits. [Szyszkowicz \(2009\)](#) found that NO<sub>2</sub> concentrations were associated with risk of ED visits for chest pain in six Canadian cities. The magnitude of association was stronger in the warm season, with a 5.9% increase in risk (95% CI: 3.3, 8.6) than in the cold season, with a 3.2% increase in risk (95% CI: 1.5, 5.0) at lag 1 per 20-ppb increase in 24-h avg NO<sub>2</sub>. As discussed in [Section 5.3.2.1](#), [Stieb et al. \(2009\)](#) examined the composite endpoint of acute MI or angina ED visits in a study of seven Canadian cities that included overlapping data with [Szyszkowicz \(2009\)](#). [Stieb et al. \(2009\)](#) observed a positive association between ambient NO<sub>2</sub> and MI/angina that was still positive, but attenuated, imprecise, and no longer statistically significant after adjustment for CO in a copollutant model. In addition to limited interpretability from using a composite endpoint, the results were also largely influenced by data from one city, as detailed in [Section 5.3.2.1](#).

---

### 5.3.2.3 ST-Segment Amplitude

ST-segment changes (either ST-segment elevation or depression) on the electrocardiogram are considered a nonspecific marker of myocardial ischemia. While the 2008 ISA for Oxides of Nitrogen did not review any epidemiologic studies of ambient oxides of nitrogen concentrations and markers of myocardial ischemia ([U.S. EPA, 2008c](#)), a few recent studies report associations ([Table 5-41](#)). [Chuang et al. \(2008\)](#) conducted a repeated-measures study of Boston-area adults with a history of coronary heart disease and examined the association between ambient pollutants and ST-segment changes. The authors reported a RR of 3.29 (95% CI: 1.82, 5.92) for ST-segment depression of  $\geq 0.1$  mm per 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations over the

previous 24 hours. This finding was robust to additional adjustment for PM<sub>2.5</sub> in a copollutant model (RR: 3.29 [95% CI: 1.65, 6.59]).

[Delfino et al. \(2011\)](#) used a similar design to study 38 older, nonsmoking adult residents of four retirement homes in the Los Angeles area with a documented history of coronary artery disease. A particular strength of this study is that the authors measured pollutant concentrations outside of the residence, which improved spatial matching of NO<sub>2</sub> concentrations to subjects' locations. The authors observed an OR of 3.83 (95% CI: 1.20, 12.16) for ST-segment depression  $\geq 1.0$  mm per 17.4-ppb increase in mean 1-hour NO<sub>2</sub> concentrations preceding measurement over the previous 3 days. Other averaging periods from 8 hours to 4 days gave similar or slightly weaker results. NO<sub>2</sub> was more strongly associated with ST depression than was NO<sub>x</sub>. No copollutant models were evaluated.

**Table 5-41 Epidemiologic studies of ST-segment amplitude.**

Study	Location Sample Size	Mean NO <sub>2</sub> ppb	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)
<a href="#">†Chuang et al. (2008)</a>	Boston, MA n = 48	24-h avg NO <sub>2</sub> 21.4 75th: 24.9 Max: 44.5	Citywide avg	ST segment change (mm) 12-h: -0.02 (-0.05, 0.00) 24-h: -0.08 (-0.12, -0.05) RR for ST-segment depression ≥0.1 mm 12-h: 1.15 (0.72, 1.82) 24-h: 3.29 (1.82, 5.92)
<a href="#">†Delfino et al. (2011)</a>	Los Angeles, CA n = 38	1-h NO <sub>2</sub> : 27.5 1-h NO <sub>x</sub> : 46.6	Outdoor monitor at retirement community	OR for ST-segment depression ≥1.0 mm NO <sub>2</sub> per 17.4-ppb increase in 1-h mean: 1-h: 1.18 (0.90, 1.54) 8-h: 1.65 (1.08, 2.52) 24-h: 2.47 (1.27, 4.78) 2-day: 3.22 (1.26, 8.23) 3-day: 3.83 (1.20, 12.16) 4-day: 2.68 (0.78, 9.20) NO <sub>x</sub> per 42.3-ppb increase in 1-h mean: 1-h: 1.17 (0.97, 1.42) 8-h: 1.33 (0.96, 1.86) 24-h: 1.56 (0.88, 2.76) 2-day: 1.69 (0.76, 3.72) 3-day: 1.81 (0.57, 5.72) 4-day: 1.53 (0.33, 7.02)

avg = average; CA = California; CI = confidence interval; h = hours; MA = Massachusetts; max = maximum; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; OR = odds ratio; ppb = parts per billion; RR = relative risk; ST-segment = segment of the electrocardiograph between the end of the S wave and beginning of the T wave.

<sup>a</sup>Effect estimates are standardized to a 20-ppb or 30-ppb increase in NO<sub>2</sub> or 40-ppb or 100-ppb increase in NO<sub>x</sub> concentration for 24-h avg and 1-h max metric, respectively.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

---

#### 5.3.2.4 Summary of Myocardial Infarction

In summary, the epidemiologic data available continue to support associations between short-term increases in ambient NO<sub>2</sub> concentrations and increased risk of triggering an MI. However, potential copollutant confounding by traffic-related pollutants was not examined extensively in these studies. In the studies that did analyze copollutant models to adjust for another traffic pollutant, the findings were generally inconsistent.

Associations between ambient NO<sub>2</sub> and risk of hospital admissions or ED visits for MI and IHD were attenuated by adjustment for CO in two studies ([Nuvolone et al., 2011](#); [Stieb et al., 2009](#)) but remained robust in a few studies conducted in Taiwan ([Hsieh et al., 2010](#); [Cheng et al., 2009a](#); [Yang, 2008](#)). Additionally, [Rich et al. \(2010\)](#) reported that an association between short-term NO<sub>2</sub> exposure and hospital admission for MI was attenuated by the inclusion of PM<sub>2.5</sub> in a copollutant model. There is limited, but consistent evidence of an association between NO<sub>2</sub> and angina pectoris ([Stieb et al., 2009](#); [Szyszkowicz, 2009](#); [von Klot et al., 2005](#); [Poloniecki et al., 1997](#)). However, only one study examined a copollutant model, in which the NO<sub>2</sub> association was attenuated in magnitude and precision after adjustment for CO ([Stieb et al., 2009](#)). None of the reviewed studies of MI, IHD, or angina utilized copollutant models to adjust for potential confounding by EC or VOCs. Additionally, all of the studies of MI-related health effects used central site monitors to assess ambient NO<sub>2</sub> exposures. Central site monitors have noted limitations in capturing the variation in NO<sub>2</sub> ([Section 3.4.4.2](#)), and none of the studies of MI reported information on the extent to which concentrations at central site monitors captured the temporal variation in NO<sub>2</sub> across the study area.

In addition to hospital admission and ED visit studies, a few available epidemiologic studies report an association between short-term increases in NO<sub>2</sub> and ST-segment changes on the electrocardiogram of older adults with a history of coronary artery disease. These results potentially indicate an association between NO<sub>2</sub> and increased risk of myocardial ischemia in a population with pre-existing cardiovascular disease. No studies from the 2008 ISA of Oxides of Nitrogen are available on ST-segment changes for comparison. Once again, there was limited assessment of potential confounding by traffic pollutants in copollutant models, although [Chuang et al. \(2008\)](#) reported that the association between NO<sub>2</sub> and ST-segment changes was robust to PM<sub>2.5</sub> adjustment.

---

### 5.3.3 Arrhythmia and Cardiac Arrest

#### 5.3.3.1 Panel Epidemiologic Studies

The 2008 ISA for Oxides of Nitrogen found little epidemiologic evidence of an association between short-term changes in ambient NO<sub>2</sub> concentrations and cardiac arrhythmias ([U.S. EPA, 2008c](#)). There continues to be limited epidemiologic evidence for such an association, either from panel studies of patients with ICDs or panel studies of arrhythmias detected on ambulatory ECG recordings ([Table 5-42](#)).

In a study of patients with ICDs, [Ljungman et al. \(2008\)](#) found that NO<sub>2</sub> was associated with increased risk of confirmed ventricular tachyarrhythmias (VT). The association with PM<sub>10</sub> and PM<sub>2.5</sub> was stronger than the association for NO<sub>2</sub>. There was no evidence of effect measure modification by city, distance from the nearest ambient monitor at the time of the event, number of events, type of event (ventricular fibrillation versus ventricular tachycardia), age, history of IHD, left ventricular ejection fraction, diabetes, body mass index, or use of beta blockers. However, a stronger association between NO<sub>2</sub> and risk of VT was observed for the 22 subjects who were outdoors at the time of ICD activation. Because the authors accounted for personal activity/behavior, exposure measurement error may have been reduced for subjects who were outdoors given that more time spent outdoors is likely to correspond to a greater personal-ambient correlation ([Section 3.4.4.1](#)). In a similar study, [Anderson et al. \(2010\)](#) observed generally null associations between ICD activation and ambient NO, NO<sub>2</sub>, or NO<sub>x</sub> concentrations. [Anderson et al. \(2010\)](#) only had the study cardiologist review the electrocardiograms from about 60% of ICD activations (confirming 87% of those cases as VT), potentially leading to greater misclassification of the outcome than in the study by [Ljungman et al. \(2008\)](#). Recently, [Link et al. \(2013\)](#) examined a panel of patients with dual chamber ICDs. They observed positive associations between ICD-detected arrhythmias and atrial fibrillations  $\geq 30$  seconds and NO<sub>2</sub> concentrations that were generally stronger when the authors used a 2-hour lag compared to a 2-day lag. Finally, [Metzger et al. \(2007\)](#) observed generally null associations between NO<sub>2</sub> concentrations and VT events over a 10-year period in Atlanta, GA.

Using a different approach, [Bartell et al. \(2013\)](#) used ECG monitors to evaluate VT events in 50 older adult, nonsmoking residents of four retirement communities in the greater Los Angeles area. The study reported a 35% (95% CI: -1, 82) increase in the daily rate of VT events per 40-ppb increase in 24-h avg NO<sub>x</sub>. The estimated effect of 3- and 5-day avg NO<sub>x</sub> on the daily rate of VT was somewhat stronger, though markedly less precise (i.e., wider confidence limits around the effect estimates). [Bartell et al. \(2013\)](#) measured pollutant concentrations outside of each of the retirement communities, which

improved spatial matching of NO<sub>2</sub> concentrations to subjects' locations. Conversely, [Barclay et al. \(2009\)](#) generally observed weak and inconsistent associations between NO<sub>2</sub> or NO and incident arrhythmias detected on ambulatory ECG recordings in a repeated measures study of nonsmoking adults with stable heart failure.

**Table 5-42 Epidemiologic studies of arrhythmia and cardiac arrest.**

Study	Location Sample Size	Mean NO <sub>2</sub> (ppb)	Exposure Assessment	Selected Effect Estimates (95% CI) <sup>a</sup>
<a href="#">†Ljungman et al. (2008)</a>	Gothenburg and Stockholm, Sweden n = 211 (266 events)	24-h avg NO <sub>2</sub> : 11.8 Stockholm: 8.3	Central monitor 1 in Gothenburg average of 2 in Stockholm	Ventricular tachyarrhythmia (OR) 2-h avg: 1.37 (0.53, 3.64) 24-h avg: 1.26 (0.49, 3.32)
<a href="#">†Anderson et al. (2010)</a>	London, U.K. n = 705 (5,462 device activations)	24-h avg NO <sub>2</sub> : 12.1 24-h avg NO <sub>x</sub> : 24.1 24-h avg NO: 19.4	Central monitor Citywide avg	ICD activations (OR) NO <sub>2</sub> , lag 0–1 avg: 0.93 (0.70, 1.24) NO <sub>x</sub> , lag 0–1 avg: 0.92 (0.86, 1.08) NO, lag 0–1 avg: 0.96 (0.93, 1.04)
<a href="#">†Link et al. (2013)</a>	Boston, MA n = 176 (328 atrial fibrillation episodes ≥30 sec)	24-h avg NO <sub>2</sub> : 16.1	Central monitor Citywide avg	ICD-detected arrhythmias (OR) 24-h lag: 1.23 (0.75, 2.10) 2-h lag: 1.57 (0.97, 2.47)
<a href="#">Metzger et al. (2007)</a>	Atlanta, GA n = 518	1-h max NO <sub>2</sub> : 44.9 90th: 68 Max: 181	Central monitor	All arrhythmia events (OR) All yr: 1.00 (0.95, 1.05) Warm season: 1.00 (0.93, 1.08) Cold season: 1.01 (0.94, 1.08) Events resulting in cardiac pacing or defibrillation: All yr: 1.01 (0.94, 1.10) Events resulting in defibrillation: All yr: 1.07 (0.93, 1.23)
<a href="#">†Bartell et al. (2013)</a>	Los Angeles, CA n = 50 (302 subject h of VT observed)	24-h avg NO <sub>x</sub> : 42.3 Max: 183.7	Monitors on trailers at each of 4 retirement communities	Ventricular tachyarrhythmia (RR) 24-h avg: 1.35 (0.99, 1.82) 3-day avg: 1.74 (0.47, 6.40) 5-day avg: 1.65 (0.56, 4.93)

**Table 5-42 (Continued): Epidemiologic studies of arrhythmia and cardiac arrest.**

Study	Location Sample Size	Mean NO <sub>2</sub> (ppb)	Exposure Assessment	Selected Effect Estimates (95% CI) <sup>a</sup>
† <a href="#">Barclay et al. (2009)</a>	Aberdeen, Scotland, U.K. n = 132	24-h avg NO <sub>2</sub> : 30.1 NO: 14.7	Central monitor	All arrhythmias (change in magnitude) NO <sub>2</sub> : 3.193 (-3.600, 9.985) NO: 3.524 (-3.059, 10.107) Ventricular ectopic beats NO <sub>2</sub> : 3.642 (-4.837, 12.121) NO: 4.588 (-3.628, 12.803) Ventricular couplets NO <sub>2</sub> : 0.356 (-7.395, 8.106) NO: -0.085 (-7.601, 7.431) Ventricular runs NO <sub>2</sub> : 2.443 (-2.537, 7.422) NO: 2.219 (-2.618, 7.055) Supraventricular ectopic beats NO <sub>2</sub> : 2.888 (-4.833, 10.608) NO: -2.688 (-10.170, 4.794) Supraventricular couplets NO <sub>2</sub> : 5.209 (-1.896, 12.313) NO: 1.366 (-5.542, 8.274) Supraventricular runs NO <sub>2</sub> : 3.441 (-1.760, 8.641) NO: 2.298 (-2.753, 7.348)

avg = average; CA = California; CI = confidence interval; GA = Georgia; h = hours; ICD = implantable cardioverter defibrillators; MA = Massachusetts; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; OR = odds ratio; RR = relative risk; U.K. = United Kingdom; VT = ventricular tachyarrhythmias.

<sup>a</sup>Effect estimates are standardized to a 20-ppb or 30-ppb increase in NO<sub>2</sub> or NO or 40-ppb or 100-ppb increase in NO<sub>x</sub> concentration for 24-h avg and 1-h max metrics, respectively.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

### 5.3.3.2 Out-of-Hospital Cardiac Arrest

The majority of out-of-hospital cardiac arrests are due to cardiac arrhythmias. [Dennekamp et al. \(2010\)](#) observed generally positive, though weak, associations between NO<sub>2</sub> concentrations and risk of out-of-hospital cardiac arrest ([Table 5-43](#)). A similar approach was used by [Silverman et al. \(2010\)](#) using data from out-of-hospital cardiac arrests in New York City and observed generally null associations with NO<sub>2</sub> concentrations in all year and cold season analyses, and a positive association in the warm season analysis. [Straney et al. \(2014\)](#) also reported null associations between out-of-hospital cardiac arrest and ambient NO<sub>2</sub> concentrations from a case-crossover study in Perth, Australia. In other studies of out-of-hospital cardiac arrest, [Ensor et al.](#)

(2013) found inconsistent and weak associations with ambient NO<sub>2</sub> concentrations in Houston, while [Wichmann et al. \(2013\)](#) reported similarly inconsistent associations with NO<sub>x</sub> in Copenhagen. However, [Wichmann et al. \(2013\)](#) observed a positive association between ambient NO<sub>x</sub> concentration and out-of-hospital cardiac arrest in females (46% [95% CI: 8, 99] increase per 40-ppb increase in 24-h avg NO<sub>x</sub> at lag 3), although there were slightly under two thirds the amount of cases observed in females compared to males. None of the out-of-hospital cardiac arrest studies examined potential copollutant confounding of NO<sub>2</sub> or NO<sub>x</sub> associations. No studies from the 2008 ISA for Oxides of Nitrogen are available for comparison.

**Table 5-43 Epidemiologic studies of out-of-hospital cardiac arrest.**

Study	Location Sample Size	Mean NO <sub>2</sub> (ppb)	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)
<a href="#">†Dennekamp et al. (2010)</a>	Melbourne, Australia n = 8,434	24-h avg NO <sub>2</sub> 12.0 75th: 15.16	Central site monitor	% change in out-of-hospital cardiac arrest Lag 0: 3.23 (-10.19, 18.51) Lag 1: 7.69 (-7.29, 25.11) Lag 2: -4.51 (-17.53, 10.56) Lag 3: 7.37 (-7.11, 24.13) Lag 0-1 avg: 9.28 (-7.54, 29.14)
<a href="#">†Silverman et al. (2010)</a>	New York City, NY n = 8,216	24-h avg NO <sub>2</sub> 50th: 27 75th: 32 95th: 43	Central site monitor Citywide avg	No quantitative results presented for NO <sub>2</sub> .

**Table 5-43 (Continued): Epidemiologic studies of out-of-hospital cardiac arrest.**

Study	Location Sample Size	Mean NO <sub>2</sub> (ppb)	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)
<a href="#">†Straney et al. (2014)</a>	Perth, Australia n = 8,551	1-h max NO <sub>2</sub> 50th: 3.0 75th: 8.1 95th: 19.8	Nearest central site monitor (avg and/or max distances not specified)	OR Lag 0-h: 1.008 (0.992, 1.030) Lag 1-h: 1.000 (0.979, 1.021) Lag 2-h: 0.987 (0.967, 1.004) Lag 3-h: 0.992 (0.971, 1.013) Lag 0-1-h: 1.004 (0.987, 1.026) Lag 0-3-h: 0.996 (0.975, 1.017) Lag 0-12-h: 0.996 (0.971, 1.026)
<a href="#">†Ensor et al. (2013)</a>	Houston, TX n = 11,677	24-h avg NO <sub>2</sub> 9.11 75th: 11.66 95th: 16.87	Central site monitor Citywide avg	% change in out-of-hospital cardiac arrests Lag 0: 3.2 (-11.3, 18.9) Lag 1: -2.5 (-14.7, 11.0) Lag 2: -1.4 (-13.8, 12.6) Lag 3: 3.2 (-9.6, 17.7) Lag 4: 1.1 (-11.5, 15.3) Lag 0-1: -0.4 (-14.4, 16.1) Lag 1-2: -2.8 (-16.3, 12.9)
<a href="#">†Wichmann et al. (2013)</a>	Copenhagen, Denmark n = 4,657	24-h avg NO <sub>x</sub> 14.75 75th: 18.35	Central site monitor	% change in out-of-hospital cardiac arrests Lag 0: -13.5 (-28.6, 5.0) Lag 1: 5.4 (-12.7, 27.4) Lag 2: -9.2 (-25.0, 11.6) Lag 3: 16.0 (-4.0, 40.2) Lag 4: 8.7 (-10.2, 31.2) Lag 5: 5.4 (-13.1, 27.9) Males, lag 3: 2.2 (-19.7, 30.1) Females, lag 3: 46.1 (7.8, 98.7)

avg = average; CI = confidence interval; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; NY = New York; OR = odds ratio; TX = Texas.

<sup>a</sup>Effect estimates are standardized to a 20-ppb or 30-ppb increase in NO<sub>2</sub> or NO or 40-ppb or 100-ppb increase in NO<sub>x</sub> concentration for 24-h avg and 1-h max metrics, respectively.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

---

### 5.3.3.3 Hospital Admissions and Emergency Department Visits for Arrhythmias

There are a limited number of studies examining associations between short-term NO<sub>2</sub> exposure and hospital admissions with a primary discharge diagnosis related to arrhythmias. Using data from 14 hospitals in seven Canadian cities, [Stieb et al. \(2009\)](#) found no association between NO<sub>2</sub> and risk of hospital admission for arrhythmias. However, [Tsai et al. \(2009\)](#) reported a positive association in Taipei, Taiwan that was stronger on cool days (OR: 1.34 [95% CI: 1.25, 1.44] per 20-ppb increase in 24-h avg NO<sub>2</sub>) than warm days (OR: 1.19 [95% CI: 1.10, 1.28] per 20-ppb increase in 24-h avg NO<sub>2</sub>). Both cool and warm day associations remained robust in copollutant models with PM<sub>10</sub>, SO<sub>2</sub>, CO, or O<sub>3</sub>; however, potential confounding by most of the traffic-related pollutants of concern was not evaluated.

---

### 5.3.3.4 Summary of Arrhythmia and Cardiac Arrest

In summary, there is currently inconsistent epidemiologic evidence for an association between 24-h avg NO<sub>2</sub>, NO, or NO<sub>x</sub> and risk of cardiac arrhythmias as examined in patients with ICDs, continuous ECG recordings, out-of-hospital cardiac arrest, and hospital admissions. The reviewed studies rarely adjusted for copollutant confounding by traffic pollutants, focused almost exclusively on ventricular arrhythmias, and are potentially limited by misclassification of the outcome. Additionally, the majority of studies used central site monitors to estimate ambient NO<sub>2</sub> exposure. Central site monitors have noted limitations in capturing the variation in NO<sub>2</sub> ([Section 3.4.4.2](#)), and none of the studies of arrhythmia and cardiac arrest reported information on the extent to which concentrations at central site monitors captured the temporal variation in NO<sub>2</sub> across the study area

---


## 5.3.4 Cerebrovascular Disease and Stroke

### 5.3.4.1 Hospital Admissions and Emergency Department Visits

The 2008 ISA for Oxides of Nitrogen found that the epidemiologic evidence for associations between short-term changes in NO<sub>2</sub> concentrations and hospital admissions or ED visits for cerebrovascular diseases was generally inconsistent and provided little support for an independent NO<sub>2</sub> effect ([U.S. EPA, 2008c](#)). Recent studies also provide inconsistent evidence ([Figure 5-19](#) and [Table 5-44](#)).

Generally, studies based on clinical registries are less susceptible to misclassification of the outcome and exposure, which may explain the stronger evidence provided by these studies than that based on administrative data. [Wellenius et al. \(2012\)](#) reviewed the medical records of 1,705 Boston-area patients hospitalized with neurologist-confirmed acute ischemic stroke and found an OR for ischemic stroke onset of 1.32 (95% CI: 1.08, 1.63) per 20-ppb increase in NO<sub>2</sub> concentration averaged over the 24 hours preceding hospitalization for stroke. A unique strength of this study was the availability of information on the date and time of stroke symptom onset in most patients, thereby potentially reducing misclassification of the exposure. Copollutant models were not evaluated.

[Andersen et al. \(2010\)](#) obtained data on strokes in Copenhagen, Denmark from the Danish National Indicator Project and found a positive association between ambient NO<sub>x</sub> concentrations and risk of ischemic stroke but not hemorrhagic stroke. The strongest association was observed in relation to NO<sub>x</sub> levels 4 days earlier and for those suffering a mild stroke, but the association was attenuated after adjustment for UFP. Using data from a stroke registry in Como, Italy, [Vidale et al. \(2010\)](#) found that NO<sub>2</sub> was associated with risk of ischemic stroke hospital admission. On the other hand, [Turin et al. \(2012\)](#) did not observe any association using data from the Takashima County Stroke and AMI Registry in central Japan. Similarly, [Oudin et al. \(2010\)](#) found no association between modeled residential NO<sub>x</sub> concentration and risk of ischemic or hemorrhagic stroke within the context of a Swedish quality register for stroke.



Note: CBV = cerebrovascular; CI = confidence interval; hr = hour; yr = years. Black = studies from the 2008 Integrated Science Assessment for Oxides of Nitrogen, red = recent studies. Circles = NO<sub>2</sub>, diamonds = NO<sub>x</sub>. Relative risks are standardized to a 20-ppb or 30-ppb increase in NO<sub>2</sub> concentration and 40 ppb or 100 ppb for NO<sub>x</sub> concentrations for 24-h avg and 1-h max metrics, respectively. Studies are organized first by averaging time, then recent versus previous study, then descending order of mean concentration (in parts per billion).

**Figure 5-19 Associations between short-term exposure to oxides of nitrogen and hospital admissions for cerebrovascular disease and stroke.**

**Table 5-44 Corresponding risk estimates for hospital admissions for cerebrovascular disease and stroke for studies presented in Figure 5-19.**

Study	Location	Health Effect	Selected Relative Risks <sup>a</sup> 95% CI	Copollutant Examination <sup>b</sup>
<a href="#">†Thach et al. (2010)</a>	Hong Kong, China	Stroke	Lag 0–1 avg: 1.01 (1.00, 1.03)	No copollutant models.
<a href="#">†Zheng et al. (2013)</a>	Lanzhou, China	Cerebrovascular disease	Lag 0: 1.05 (1.02, 1.08) Lag 0–3 avg: 1.06 (1.02, 1.10)	NO <sub>2</sub> : associations were robust to adjustment for SO <sub>2</sub> ; associations increased with adjustment for PM <sub>10</sub> .  Copollutants: SO <sub>2</sub> (positive) associations and PM <sub>10</sub> (negative) associations robust to adjustment for NO <sub>2</sub> .  NO <sub>2</sub> correlations (Spearman <i>r</i> ): PM <sub>10</sub> : 0.64; SO <sub>2</sub> : 0.64.
<a href="#">†Bell et al. (2008)</a>	Taipei, Taiwan	Cerebrovascular disease	All 13 monitors Lag 0: 1.01 (0.95, 1.07) Lag 1: 0.97 (0.92, 1.03)  Lag 0–3 avg: 1.04 (0.96, 1.12)  5 city monitors Lag 0: 1.01 (0.96, 1.06) Lag 1: 0.97 (0.92, 1.02)  Lag 0–3 avg: 1.04 (0.96, 1.12)  8 correlated monitors Lag 0: 1.01 (0.96, 1.06) Lag 1: 0.97 (0.92, 1.02)  Lag 0–3 avg: 1.04 (0.96, 1.12)	No copollutant models.
<a href="#">†Xiang et al. (2013)</a>	Wuhan, China	Stroke	Warm season Lag 0: 0.99 (0.93, 1.06) Lag 0–2 avg: 0.96 (0.88, 1.05)  Cool season Lag 0: 1.11 (1.05, 1.18) Lag 0–2 avg: 1.12 (1.04, 1.21)	NO <sub>2</sub> : cold season association robust to PM <sub>10</sub> adjustment.  Copollutants: PM <sub>10</sub> no longer associated with stroke hospital admissions in the cold season after NO <sub>2</sub> adjustment.  No correlations reported.

**Table 5-44 (Continued): Corresponding risk estimates for hospital admissions for cerebrovascular disease and stroke for studies presented in Figure 5-19.**

Study	Location	Health Effect	Selected Relative Risks <sup>a</sup> 95% CI	Copollutant Examination <sup>b</sup>
<a href="#">†Villeneuve et al. (2012)</a>	Edmonton, Canada	Stroke	Lag 0–2 avg Warm: 1.42 (0.94, 2.17) Cool: 0.98 (0.84, 1.15)	Ischemic stroke during warm season NO <sub>2</sub> : associations robust to adjustment for SO <sub>2</sub> ; slightly attenuated but positive after adjustment for CO, O <sub>3</sub> , or PM <sub>2.5</sub> .
		Ischemic stroke	Lag 0–2 avg Warm: 2.37 (1.27, 4.41) Cool: 0.90 (0.69, 1.13)	Copollutants: CO, O <sub>3</sub> , and PM <sub>2.5</sub> associations attenuated by adjustment for NO <sub>2</sub> . No association between SO <sub>2</sub> and ischemic stroke.
		Hemorrhagic stroke	Lag 0–2 avg Warm: 1.50 (0.59, 4.32) Cool: 0.98 (0.64, 1.50)	Hemorrhagic stroke during warm season NO <sub>2</sub> : associations attenuated after adjustment for SO <sub>2</sub> and O <sub>3</sub> , but increased after adjustment for CO or PM <sub>2.5</sub> .
		Transient ischemic stroke	Lag 0–2 avg Warm: 0.67 (0.33, 1.42) Cool: 1.11 (0.80, 1.45)	Copollutants: SO <sub>2</sub> and O <sub>3</sub> associations robust to NO <sub>2</sub> adjustment; CO no longer associated with hemorrhagic stroke after NO <sub>2</sub> adjustment.
<a href="#">†Turin et al. (2012)</a>	Takashima County, Japan	Stroke	Lag 0: 0.98 (0.89, 1.08) Lag 1: 0.98 (0.89, 1.08)	No evidence of an association between NO <sub>2</sub> and stroke. Copollutant models did not change the results.
		Cerebral infarction	Lag 0: 0.98 (0.87, 1.10) Lag 1: 1.00 (0.89, 1.12)	
		Intracerebral hemorrhage	Lag 0: 1.06 (0.85, 1.33) Lag 1: 0.94 (0.75, 1.16)	
		Subarachnoid hemorrhage	Lag 0: 1.12 (0.80, 1.56) Lag 1: 1.02 (0.73, 1.42)	
<a href="#">†Wellenius et al. (2012)</a>	Boston, MA	Ischemic stroke	Lag 24 h preceding event: 1.32 (1.08, 1.63)	No copollutant models.

**Table 5-44 (Continued): Corresponding risk estimates for hospital admissions for cerebrovascular disease and stroke for studies presented in Figure 5-19.**

Study	Location	Health Effect	Selected Relative Risks <sup>a</sup> 95% CI	Copollutant Examination <sup>b</sup>
<a href="#">†Andersen et al. (2010)</a>	Copenhagen, Denmark	Ischemic stroke	NO <sub>x</sub> Lag 0: 1.20 (0.96, 1.48) Lag 1: 0.96 (0.79, 1.20) Lag 0–4 avg: 1.36 (0.96, 1.89)	NO <sub>x</sub> : no longer associated with ischemic stroke after adjustment for UFP. Copollutants: UFP association robust after adjustment for NO <sub>x</sub> .
		Hemorrhagic stroke	Lag 0: 0.96 (0.48, 1.81) Lag 1: 1.14 (0.59, 2.20) Lag 0–4 avg: 0.43 (0.13, 1.36)	
		Mild ischemic stroke	Lag 0–4 avg: 1.61 (0.79, 3.30)	
<a href="#">†Larrieu et al. (2007)</a>	8 French cities	Stroke	All ages: 0.99 (0.96, 1.03) ≥65 yr: 1.01 (0.97, 1.05)	No copollutant models.
<a href="#">Poloniecki et al. (1997)</a>	London, U.K.	Cerebrovascular disease	Lag 1: 0.99 (0.98, 1.00)	No copollutant models examined.
<a href="#">Linn et al. (2000)</a>	Los Angeles, CA	Cerebrovascular disease	Lag 0: 1.01 (0.99, 1.02)	No copollutant models. NO <sub>2</sub> correlations: PM <sub>10</sub> : 0.67 to 0.88; O <sub>3</sub> : -0.23 to 0.35; CO: 0.84 to 0.94
		Occlusive stroke	Lag 0: 1.04 (1.02, 1.06)	
<a href="#">Tsai et al. (2003)</a>	Kaohsiung, Taiwan	Cerebral stroke	Lag 0–2 avg 20+°C: 1.68 (1.38, 2.04) <20°C: 0.78 (0.44, 1.37)	NO <sub>2</sub> : Ischemic stroke and hemorrhagic stroke associations robust to SO <sub>2</sub> , CO, or O <sub>3</sub> adjustment. Attenuated, but positive after PM <sub>10</sub> adjustment. Copollutants: PM <sub>10</sub> , SO <sub>2</sub> , CO, and O <sub>3</sub> ischemic stroke and hemorrhagic stroke associations attenuated by adjustment for NO <sub>2</sub> .
		Ischemic stroke	Lag 0–2 avg 20+°C: 1.67 (1.48, 1.87) <20°C: 1.19 (0.78, 1.84)	

**Table 5-44 (Continued): Corresponding risk estimates for hospital admissions for cerebrovascular disease and stroke for studies presented in Figure 5-19.**

Study	Location	Health Effect	Selected Relative Risks <sup>a</sup> 95% CI	Copollutant Examination <sup>b</sup>
<a href="#">Wong et al. (1999)</a>	Hong Kong, China	Cerebrovascular disease	Lag 0–1 avg: 1.03 (0.99, 1.07)	No copollutant models.
<a href="#">Villeneuve et al. (2006a)</a>	Edmonton, AB, Canada	Ischemic stroke	Ages 65 yr and older Lag 0: 1.04 (0.96, 1.15) Lag 1: 1.07 (0.97, 1.17)	Ischemic stroke during warm season NO <sub>2</sub> : warm season associations robust to adjustment for SO <sub>2</sub> or CO; increase with adjustment for PM <sub>10</sub> or PM <sub>2.5</sub> ; attenuated with adjustment for O <sub>3</sub> .
		Hemorrhagic stroke	Lag 0: 1.07 (0.96, 1.21) Lag 1: 1.06 (0.94, 1.20)	Hemorrhagic stroke during warm season NO <sub>2</sub> : warm season associations robust to SO <sub>2</sub> , O <sub>3</sub> , PM <sub>2.5</sub> , or PM <sub>10</sub> adjustment (large increases in CIs in models with PM); but attenuated with adjustment for CO. NO <sub>2</sub> warm season correlations (Pearson <i>r</i> ): SO <sub>2</sub> : 0.22; O <sub>3</sub> : -0.09; CO: 0.59; PM <sub>2.5</sub> : 0.52; PM <sub>10</sub> : 0.57.
		Cerebral stroke	Lag 0: 0.99 (0.90, 1.07) Lag 1: 0.91 (0.84, 1.00)	
<a href="#">Wellenius et al. (2005)</a>	9 U.S. cities	Ischemic stroke, hemorrhagic stroke	Lag 0: 1.05 (1.03, 1.07) Lag 0: 1.01 (0.96, 1.06)	No copollutant models.
<a href="#">Pönkä and Virtanen (1996)</a>	Helsinki, Finland	Cerebrovascular disease	Lag 0: 0.96 (0.87, 1.07) Lag 1: 0.98 (0.87, 1.09)	No copollutant models.
<a href="#">Ballester et al. (2001)</a>	Valencia, Spain	Cerebrovascular disease	Lag 2: 1.22 (1.04, 1.44)	NO <sub>2</sub> : associations were robust to adjustment for SO <sub>2</sub> or BS.
<a href="#">Peel et al. (2007)</a>	Atlanta, GA	Cerebrovascular disease	Lag 0–2 avg Case crossover: 1.05 (1.01, 1.09) Time series: 1.06 (1.02, 1.11)	No copollutant models.

**Table 5-44 (Continued): Corresponding risk estimates for hospital admissions for cerebrovascular disease and stroke for studies presented in Figure 5-19.**

Study	Location	Health Effect	Selected Relative Risks <sup>a</sup> 95% CI	Copollutant Examination <sup>b</sup>
<a href="#">†Chen et al. (2014c)</a>	Edmonton, AB, Canada	Ischemic stroke	Lag 1–8 h avg All year: 1.06 (0.98, 1.14) Warm season: 1.39 (1.13, 1.71) Cold season: 0.98 (0.89, 1.08)	No copollutant models.
<a href="#">Jalaludin et al. (2006)</a>	Sydney, Australia	Stroke	Ages 65 yr and older Lag 0: 0.95 (0.88, 1.02) Lag 1: 0.96 (0.90, 1.03) Lag 0–1 avg: 0.95 (0.88, 1.02)	No copollutant models analyzed for cerebrovascular disease.

AB = Alberta; avg = average; BS = black smoke; CA = California; CI = confidence interval; CO = carbon monoxide; GA = Georgia; MA = Massachusetts; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; O<sub>3</sub> = ozone; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 μm; SO<sub>2</sub> = sulfur dioxide; UFP = ultrafine particles; U.K. = United Kingdom; U.S. = United States.

<sup>a</sup>Effect estimates are standardized to a 20-ppb or 30-ppb increase in NO<sub>2</sub> or 40-ppb or 60-ppb increase in NO<sub>x</sub> concentration for 24-h avg and 1-h max metrics, respectively.

<sup>b</sup>Relevant relative risks for copollutant models can be found in [Supplemental Figures S5-2, S5-3, S5-4, and S5-5 \(U.S. EPA, 2015b, c, d, e\)](#).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

Additional studies based on administrative data are also available. A number of the administrative data studies were conducted in Edmonton, Canada and used similar or identical data sources. The most thorough Edmonton study observed an association between NO<sub>2</sub> and ED visits for ischemic stroke in the warm season (OR: 2.37 [95% CI: 1.27, 4.41] per 20-ppb increase in lag 0–2 day avg NO<sub>2</sub>) and an imprecise (i.e., wide 95% CI) association between hemorrhagic stroke in the warm season (OR: 1.50 [95% CI: 0.59, 4.32] per 20-ppb increase in lag 0–2 day avg NO<sub>2</sub>) ([Villeneuve et al., 2012](#)). [Villeneuve et al. \(2012\)](#) also examined copollutant models in which ischemic stroke associations were robust to adjustment for SO<sub>2</sub> (OR: 2.34 [95% CI: 1.25, 4.37]), and remained positive, but slightly attenuated after adjustment for CO (OR: 2.05 [95% CI: 0.92, 4.61]), O<sub>3</sub> (OR: 1.92 [95% CI: 0.98, 3.78]), and PM<sub>2.5</sub> (OR: 1.98 [95% CI: 0.94, 4.20]). The hemorrhagic stroke associations were attenuated after adjustment for SO<sub>2</sub> or O<sub>3</sub> but were robust to adjustment for the traffic-related pollutant CO or PM<sub>2.5</sub>. There is the potential for misclassification of the exposure due to differences in the timing of stroke symptoms and the corresponding ED visit; however, after surveying a subset of the study population, [Villeneuve et al. \(2012\)](#) observed that roughly 75% of patients visited the

emergency room on the same day that their symptoms presented. Further, when the authors adjusted the assigned pollution levels from the day of the ED visit to the day of symptom presentation, they observed no systematic differences in assigned pollution levels. [Szyszkowicz \(2008\)](#) observed a positive association between 24-h avg NO<sub>2</sub> and ED visits for ischemic stroke in Edmonton, Canada but only within specific subgroups according to sex, season, and age. In a recent related study, [Chen et al. \(2014c\)](#) used the same data, but applied hourly NO<sub>2</sub> values to their models. The authors reported an association between NO<sub>2</sub> and ED visits for acute ischemic stroke that remained relatively consistent across lag days. However, that association was almost entirely influenced by the association observed in the warm season, as the association in the cold season was null.

[Zheng et al. \(2013\)](#) conducted a time-series study in Lanzhou, China and found a positive association between NO<sub>2</sub> and all cerebrovascular hospital admissions. The strongest relationships were observed on same-day and 3-day cumulative lags. [Zheng et al. \(2013\)](#) also reported stronger associations in women and the elderly. [Xiang et al. \(2013\)](#) observed a positive association between NO<sub>2</sub> and hospital admissions for all strokes in the cold season in Wuhan, China that was robust in a copollutant model including PM<sub>10</sub>. Conversely, in Taipei, Taiwan, [Bell et al. \(2008\)](#) did not observe an association between NO<sub>2</sub> and cerebrovascular disease. As mentioned in [Section 5.3.2.1](#), [Bell et al. \(2008\)](#) attempted to reduce uncertainty related to the use of central site monitors by estimating NO<sub>2</sub> exposure over the entire Taipei area (average of 13 monitors), within Taipei City only (average of 5 monitors), and using a subset of monitors where all pairs of monitors had NO<sub>2</sub> correlations greater than 0.75 (8 monitors). The null findings were consistent across the three exposure assignment techniques. In a 7-year study of Hong Kong, China residents, [Thach et al. \(2010\)](#) also reported no association between NO<sub>2</sub> and all cerebrovascular hospital admissions.

---

#### 5.3.4.2 Summary of Cerebrovascular Disease and Stroke

In summary, the epidemiologic data provide generally inconsistent evidence for a potential association between ambient NO<sub>2</sub> concentrations and risk of hospital admission for cerebrovascular disease and stroke. Clinical registry studies reported both positive ([Wellenius et al., 2012](#); [Andersen et al., 2010](#); [Vidale et al., 2010](#)) and null ([Turin et al., 2012](#); [Oudin et al., 2010](#)) associations. Evidence for an association based on administrative databases came from studies using similar or identical data sets ([Chen et al., 2014c](#); [Villeneuve et al., 2012](#); [Szyszkowicz, 2008](#)). A limited number of studies evaluated potential confounding by PM<sub>2.5</sub> or traffic pollutants (e.g., UFP, CO, BS), and associations with NO<sub>2</sub> were not consistently observed in copollutant models.

Additionally, the majority of the studies of cerebrovascular disease and stroke used central site monitors to estimate ambient NO<sub>2</sub> exposure. Central site monitors have noted limitations in capturing the variation in NO<sub>2</sub> ([Section 3.4.4.2](#)), and none of the studies of cerebrovascular disease and stroke reported information on the extent to which concentrations at central site monitors captured the temporal variation in NO<sub>2</sub> across the study area.

---

### 5.3.5 Decompensation of Heart Failure

Two recent studies found associations between short-term increases in ambient NO<sub>2</sub> concentration and hospital admissions or ED visits for heart failure. In the study of seven Canadian cities described in [Table 5-40](#), [Stieb et al. \(2009\)](#) observed a 5.1% (95% CI: 1.3, 9.2) increase in risk of ED visits for heart failure per 20-ppb increase in 24-h avg NO<sub>2</sub>. Unlike the results for the composite endpoint of MI or acute angina, the increased risk of ED visits for heart failure was not dominated by results from a single city. In Taipei, Taiwan, [Yang \(2008\)](#) found that risk of hospital admission for heart failure were associated with NO<sub>2</sub> concentrations but only on days where the mean ambient temperature was  $\geq 20^{\circ}\text{C}$ . The association on warm days remained relatively unchanged after copollutant adjustment for PM<sub>10</sub>, SO<sub>2</sub>, CO, or O<sub>3</sub>.

---

### 5.3.6 Increased Blood Pressure and Hypertension

#### 5.3.6.1 Epidemiologic Studies

Epidemiologic studies of NO<sub>2</sub> and blood pressure (BP) were not available for the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), but several studies are now available for review ([Table 5-45](#)). There is little evidence from longitudinal studies of the association between NO<sub>2</sub> and BP. A number of longitudinal studies measured BP in subjects in Beijing before, during, and after the 2008 Beijing Olympics when citywide air pollution control measures substantially reduced ambient levels of most criteria pollutants. One study reported that NO<sub>2</sub> concentrations during the Olympics were reduced by close to 22% versus the previous month and 13% versus the same period the previous summer ([Huang et al., 2012a](#)). Other ambient pollutants (except O<sub>3</sub>) were reduced by similar or larger amounts. [Huang et al. \(2012a\)](#) measured BP repeatedly in participants with pre-existing cardiovascular disease in Beijing and found no association between NO<sub>2</sub> and either systolic or diastolic BP. Focusing on healthy young adults, [Zhang et al. \(2013\)](#) and [Rich et al. \(2012\)](#) each observed no clear association between NO<sub>2</sub> and either systolic or

diastolic BP among participants assessed before, during, and after the 2008 Beijing Olympics.

**Table 5-45 Epidemiologic studies of blood pressure.**

Study	Location Sample Size	Mean NO <sub>2</sub> (ppb)	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)
<a href="#">†Williams et al. (2012a)</a>	Detroit, MI n = 65	24-h avg NO <sub>2</sub> : 24.0 75th: 28.0 Max: 100.0	Personal monitoring & central site monitor	No quantitative results presented.
<a href="#">†Huang et al. (2012a)</a>	Beijing, China n = 40	2007, Visit 1: 33.8 2007, Visit 2: 26.3 2008, Visit 3: 29.2 2008, Visit 4: 22.9	Central site monitor	Change in SBP (mmHg) per IQR (NR) increase in NO <sub>2</sub> 30-min: 1.8 (-0.5, 4.0) 2-h: 0.0 (-2.6, 2.6) 12-h: 0.7 (-3.2, 4.6) 24-h: -0.8 (-6.6, 5.0) Change in DBP (mmHg) per IQR (NR) increase in NO <sub>2</sub> 30-min: 1.1 (-0.9, 3.0) 2-h: -0.1 (-2.3, 2.1) 12-h: 0.7 (-2.1, 4.5) 24-h: 1.5 (-3.4, 6.4)
<a href="#">†Rich et al. (2012)</a> and <a href="#">†Zhang et al. (2013)</a>	Beijing, China n = 125	24-h avg NO <sub>2</sub> : Entire study: 27.0 Before: 26.0 During: 13.9 After: 41.4	Central site monitor	No quantitative results presented; results presented graphically. Generally inconsistent results with SBP: positive and negative associations across lags. Generally null and inconsistent associations with DBP across lags 0-6.
<a href="#">†Liu et al. (2014c)</a>	Sault Ste. Marie, ON, Canada n = 61	1-h max NO <sub>2</sub> : Site 1: 3.9 95th: 9.5 Site 2: 5.8 95th: 13.8	Central site monitor	Change in SBP (mmHg) Lag 0: -1.04 (-4.20, 2.12) Lag 1: 2.08 (-1.36, 5.52) Change in DBP (mmHg) Lag 0: -1.32 (-3.88, 1.28) Lag 1: 1.64 (-1.36, 4.60)
<a href="#">†Cakmak et al. (2011a)</a>	Canada n = 5,604	24-h avg NO <sub>2</sub> : 12.6	Central site monitor Citywide avg	Change in resting SBP (mmHg) Lag 0: 1.76 (0.35, 3.17) Change in resting DBP (mmHg) Lag 0: 2.11 (1.12, 3.10)

**Table 5-45 (Continued): Epidemiologic studies of blood pressure.**

Study	Location Sample Size	Mean NO <sub>2</sub> (ppb)	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)
<a href="#">†Chuang et al. (2010)</a>	Taiwan n = 7,578	24-h avg NO <sub>2</sub> : 22.4 Max: 65.5	Nearest central site monitor (within 10 km)	No quantitative results presented for NO <sub>2</sub> .
<a href="#">†Chen et al. (2012c)</a>	Taiwan n = 9,238	24-h avg NO <sub>2</sub> : 13.9 to 26.1 across locations Max: 34.3 to 49.1	Central site monitor Citywide avg	Change in SBP (mmHg) Lag 0: -0.81 (-2.16, 0.55) Lag 0-1 avg: -1.17 (-2.34, -0.01) Lag 0-2 avg: -4.20 (-5.22, -3.17) Change in DBP (mmHg) Lag 0: 1.03 (0.11, 1.95) Lag 0-1 avg: 1.54 (0.75, 2.32) Lag 0-2 avg: -0.01 (-0.71, 0.68) Pulse Pressure Change Lag 0: -2.55 (-3.62, -1.48) Lag 0-1 avg: -2.09 (-3.02, -1.18) Lag 0-2 avg: -3.22 (-4.04, -2.40)
<a href="#">†Choi et al. (2007)</a>	Incheon, South Korea n = 10,459	24-h avg NO <sub>2</sub> : Warm season: 22.5 75th: 26.9 Max: 49.3	Central site monitor Citywide avg	Change in SBP (mmHg) Lag 0: 2.24 ( $p = 0.002$ ) Lag 1: 2.40 ( $p < 0.001$ ) Lag 2: -0.04 ( $p = 0.534$ ) Change in DBP (mmHg) Lag 0: 2.02 ( $p = 0.645$ ) Lag 1: 2.12 ( $p = 0.016$ ) Lag 2: -0.04 ( $p = 0.331$ )
		Cool season: 29.2 75th: 34.7 Max: 74.0		Change in SBP (mmHg) Lag 0: 2.06 ( $p = 0.181$ ) Lag 1: 2.06 ( $p = 0.195$ ) Lag 2: -0.06 ( $p = 0.223$ ) Change in DBP (mmHg) Lag 0: -0.02 ( $p = 0.573$ ) Lag 1: 2.00 ( $p = 0.445$ ) Lag 2: 2.02 ( $p = 0.445$ )

avg = average; CI = confidence interval; DBP = diastolic blood pressure; h = hours; IQR = interquartile range; Max = maximum; MI = Michigan; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; ON = Ontario; ppb = parts per billion; SBP = systolic blood pressure.

<sup>a</sup>Effect estimates are standardized to a 20-ppb or 30-ppb increase in NO<sub>2</sub> for 24-h avg and 1-h max metrics, respectively.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

In the Detroit, MI area, [Williams et al. \(2012a\)](#) measured BP up to 10 times in each of 65 adult participants and found no association between BP and either total personal or ambient NO<sub>2</sub> concentrations. A strength of this study was the authors' use of personal

exposure measurements, which are less susceptible to exposure error due to the variability in NO<sub>2</sub> concentrations and variation in time-activity patterns than central site monitoring (Section 3.4.4). Similarly, in a randomized cross-over study designed to examine the cardiovascular effects of exposure to steel plant emissions in Ontario, Canada, [Liu et al. \(2014c\)](#) measured NO<sub>2</sub> exposure near subjects' randomized exposure location and reported no association between NO<sub>2</sub> and either systolic or diastolic BP.

Results of cross-sectional studies of the association between NO<sub>2</sub> and BP measured on the same day or with the NO<sub>2</sub> measurement lagged 1–3 days before the BP measurement have also been mixed. [Cakmak et al. \(2011a\)](#) used cross-sectional data from a national population-based survey of children and adults in Canada and found a 1.76-mmHg (95% CI: 0.35, 3.17 mmHg) increase in systolic BP and a 2.11-mmHg (95% CI: 1.12, 3.10) increase in diastolic BP per 20-ppb increase in 24-h avg NO<sub>2</sub> on the same day. [Chuang et al. \(2010\)](#) used cross-sectional data from a national population-based health screening of adults in Taiwan and reported finding no association between BP and NO<sub>2</sub> levels, although quantitative results were not presented. On the other hand, [Chen et al. \(2012c\)](#) used cross-sectional data from a different population-based health screening in adults across six townships in Taiwan and found a 4.20-mmHg decrease (95% CI: -5.22, -3.17) in systolic BP per 20-ppb increase in 24-h avg NO<sub>2</sub> at lag 0–2 day avg and a 1.54 mmHg increase (95% CI: 0.75, 2.32) in diastolic BP per 20-ppb increase in 24-h avg NO<sub>2</sub> at lag 0–2 day avg. [Choi et al. \(2007\)](#) observed positive associations between NO<sub>2</sub> concentrations and systolic BP during the warm and cold seasons at lags 0 and 1, though the associations with diastolic BP were generally null.

---

### 5.3.6.2 Controlled Human Exposure Studies

The 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) reviewed controlled human studies of cardiac output and BP (Table 5-50); several of these studies also examined heart rate (HR) as described in Section 5.3.10.1. NO<sub>2</sub> exposure generally did not increase cardiac output or BP in healthy adults or those with COPD. These endpoints have not been evaluated in recent controlled human exposure studies of NO<sub>2</sub>.

Cardiac output is the volume of blood pumped out by each of the two ventricles per minute. It is directly related to HR, as the output of each ventricle is the product of the HR (beats/minute) and the stroke volume (mL of blood/beat). BP is the product of cardiac output and vascular resistance. Cardiac output, vascular resistance, and BP interact moment-to-moment to ensure systemic circulatory demands are met.

[Folinsbee et al. \(1978\)](#) exposed three groups of five young healthy adult males to 600 ppb NO<sub>2</sub> for 2 hours with intermittent exercise. The authors reported no changes in cardiac

output or BP. [Drechsler-Parks \(1995\)](#) exposed eight older healthy adults to filtered air, 600 ppb NO<sub>2</sub>, 450 ppb O<sub>3</sub>, and NO<sub>2</sub> + O<sub>3</sub> for 2 hours with intermittent exercise. There was no change in stroke volume or cardiac output following exposure to NO<sub>2</sub> or O<sub>3</sub> alone compared to filtered air; however, a decrease in cardiac output was observed following NO<sub>2</sub> + O<sub>3</sub> exposure compared to O<sub>3</sub> and filtered air exposures ( $p < 0.05$ ). [Gong et al. \(2005\)](#) reported no change in BP after exposure to 400 ppb NO<sub>2</sub> for 2 hours with intermittent exercise in volunteers with COPD and healthy volunteers. One controlled human exposure study examined exposure to higher concentrations of NO<sub>2</sub>. [Linn et al. \(1985b\)](#) reported a small, but statistically significant decrease in BP after exposure to approximately 4,000 ppb NO<sub>2</sub> for 75 minutes with exercise. In both healthy volunteers and those with asthma, the mean BP decrease was about 5 mmHg relative to controls.

---

#### **5.3.6.3 Hospital Admissions and Emergency Department Visits**

In contrast with findings for changes in BP, the limited number of available studies report associations between NO<sub>2</sub> and ED visits for hypertension. In Beijing, China, [Guo et al. \(2010\)](#) found that NO<sub>2</sub> was associated with ED visits for hypertension, and the association remained relatively unchanged in copollutant models adjusting for PM<sub>10</sub> or SO<sub>2</sub>. Similarly, in Edmonton, Canada, [Szyszkowicz et al. \(2012\)](#) found that ED visits for hypertension were positively associated with NO<sub>2</sub> in single-pollutant models. The association was attenuated in a multipollutant model adjusting for SO<sub>2</sub> and PM<sub>10</sub>, but results from multipollutant models are difficult to interpret given the potential for multicollinearity among pollutants. Importantly, neither study evaluated confounding by traffic-related pollutants.

---

#### **5.3.6.4 Summary of Blood Pressure and Hypertension**

In summary, there is little evidence from available epidemiologic studies to suggest that short-term exposure to ambient NO<sub>2</sub> is associated with increased BP in the population overall. There is no evidence of an association from longitudinal studies and mixed evidence from cross-sectional studies. However, cross-sectional studies have inherent limitations in the establishment of temporal relationships and are more prone to confounding by factors that differ between individual participants. Controlled human exposure studies show no evidence to suggest that short-term exposure to ambient-relevant concentrations of NO<sub>2</sub> alone alter BP or cardiac output.

---

### 5.3.7 Venous Thromboembolism

Venous thromboembolism is a term that includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT occurs when a blood clot develops in the deep veins, most commonly in the lower extremities. A part of the clot can break off and travel to the lungs, causing a PE, which can be life threatening.

Two recent studies found associations between NO<sub>2</sub> and venous thrombosis and/or PE; however, both studies were small, and neither evaluated potential copollutant confounding. A study covering the metropolitan region of Santiago, Chile, found a 9.7% (95% CI: 4.1, 15.4) and 8.4% (95% CI: 5.0, 11.8) increase in hospital admissions for venous thrombosis and PE, respectively, per 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations (Dales et al., 2010). Spiezia et al. (2014) also examined the association between ambient air pollution and PE hospital admissions in a small case-control study of 105 adults in Padua, Italy. The authors observed an increase in the risk of unprovoked PE for subjects who were in the upper tertile of NO<sub>x</sub> exposure (average exposure for the month leading up to hospitalization  $\geq 124 \mu\text{g}/\text{m}^3$ ) compared to those in the bottom two exposure tertiles (OR: 2.35 [95% CI: 0.76, 7.25]).

---

### 5.3.8 Aggregated Cardiovascular Effects

Many epidemiologic studies consider the composite endpoint of all cardiovascular diseases, which typically includes all diseases of the circulatory system (e.g., heart diseases and cerebrovascular diseases). Most studies reviewed in the 2008 ISA for Oxides of Nitrogen found positive associations between ambient NO<sub>2</sub> concentrations and risk of hospital admissions or ED visits for all cardiovascular diseases (U.S. EPA, 2008c) (Figure 5-20 and Table 5-46). However, it was unclear at that time whether these results truly indicated effects of NO<sub>2</sub> or were confounded by other correlated pollutants. Several additional studies are now available with broadly consistent results, though uncertainty still remains with regard to potential confounding by PM<sub>2.5</sub> and traffic-related pollutants.


Ito et al. (2011) observed that risk of CVD hospital admission was associated with NO<sub>2</sub> concentrations at lag 0 in New York City. Results from copollutant models were not reported. Zheng et al. (2013) and Son et al. (2013) observed seasonal variation in the strength of association between NO<sub>2</sub> and CVD hospital admission in Lanzhou, China and 8 cities in South Korea, respectively. In contrast, Ito et al. (2011) did not find any seasonal differences in New York, NY. A study in Santiago, Chile reported an increase in risk of CVD hospital admissions per increase in 24-h avg NO<sub>2</sub>; the effect estimate remained relatively unchanged after adjustment for highly correlated PM<sub>2.5</sub> ( $r = 0.87$ ) and

the traffic-related copollutant CO [ $r = 0.94$ ; no quantitative results, results presented graphically; (Franck et al., 2014)]. In Beijing, China, Guo et al. (2009) reported an association between ambient NO<sub>2</sub> concentrations and risk of CVD hospital admissions at lag 0 (OR: 1.05 [95% CI: 1.00, 1.11] per 20-ppb increase in 24-h avg NO<sub>2</sub>), but this association was attenuated and had a wide 95% CI in copollutant models adjusting for either PM<sub>2.5</sub> (OR: 1.02 [95% CI: 0.96, 1.09]) or SO<sub>2</sub> (OR: 1.01 [95% CI: 0.94, 1.08]). Sarnat et al. (2013b) reported a positive association between NO<sub>x</sub> concentrations and CVD ED visits in Atlanta. This study compared the strength of the association across exposure assessment techniques and estimated larger effects using spatially refined ambient concentration metrics (AERMOD, Air Pollution Exposure model, and a hybrid model of background concentrations and AERMOD) in contrast to central site monitoring data. However, there is uncertainty regarding the extent to which an association with NO<sub>x</sub> reflects an association with NO<sub>2</sub> (Sections 1.1 and 2.5).

In Shanghai, China, Chen et al. (2010b) found a 1.4% (95% CI: -2, 5) increased risk of hospital admission for CVD per 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations (lag 0–1<sub>day</sub> avg). This association was robust to additional adjustment for PM<sub>10</sub> but was attenuated after adjustment for SO<sub>2</sub> [Supplemental Figure S5-5; (U.S. EPA, 2015e)]. A study in São Paulo, Brazil also found a positive association with some evidence that the association was stronger among patients with a secondary diagnosis of diabetes mellitus (Filho et al., 2008). Jevtić et al. (2014) reported a positive association that was robust to the inclusion of SO<sub>2</sub> in a copollutant model in Novi Sad, Serbia. Studies from Copenhagen, Denmark (Andersen et al., 2008b); Madrid, Spain (Linares and Diaz, 2010); Reykjavik, Iceland (Carlsen et al., 2013); and Taipei, Taiwan (Chan et al., 2008) reported null or negative associations between NO<sub>2</sub> concentrations and risk of hospital admission for CVD. A study in Guangzhou, China also found no clear association between NO<sub>2</sub> and CVD hospital admissions, with observed associations alternating between positive and negative depending on the lags examined (Zhang et al., 2014).

In summary, evidence reported in the 2008 ISA for Oxides of Nitrogen combined with recent epidemiologic data continues to consistently show associations between ambient NO<sub>2</sub> concentrations and risk of hospital admission for cardiovascular diseases (Figure 5-20 and Table 5-46). However, despite generally consistent evidence, a limited number of studies evaluated potential confounding by correlated copollutants, particularly PM<sub>2.5</sub> and the traffic-related copollutants EC, UFP, and VOCs, resulting in uncertainty about the independent effect of NO<sub>2</sub> on cardiovascular disease hospital admissions and ED visits (Table 5-46). Further, exposures were represented as ambient concentrations at central site monitors, which have noted limitations in capturing the variation in NO<sub>2</sub> (Section 3.4.4.2). None of the studies reported information on the extent

to which concentrations at central site monitors captured the temporal variation in NO<sub>2</sub> across the study area.



Note: AERMOD = American Meteorological Society/Environmental Protection Agency Regulatory Model; AERMOD/BG = AERMOD/background concentration hybrid model; CI = confidence interval; CS = central site; h = hour; MI = myocardial infarction; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; yr = years. Black = studies from the 2008 Integrated Science Assessment for Oxides of Nitrogen, red = recent studies. Circles = NO<sub>2</sub>, triangles = NO, diamonds = NO<sub>x</sub>. Relative risks are standardized to a 20-ppb or 30-ppb increase in NO<sub>2</sub> or NO concentrations and 40 ppb or 100 ppb for NO<sub>x</sub> concentrations for 24-h avg and 1-h max metrics, respectively. Studies are organized first by averaging time, then by recent versus previous studies, then in descending order of mean concentration (in parts per billion, ppb). [Franck et al. \(2014\)](#) not presented due to lack of quantitative results.

**Figure 5-20 Associations between short-term exposure to oxides of nitrogen and hospital admissions for all cardiovascular disease.**

**Table 5-46 Corresponding effect estimates for hospital admissions for all cardiovascular disease studies presented in Figure 5-20.**

Study	Location	Relative Risk <sup>a</sup> (95% CI)	Copollutant Examination <sup>b</sup>
<a href="#">†Guo et al. (2009)</a>	Beijing, China	Lag 0: 1.05 (1.00, 1.11) Lag 1: 1.03 (0.985, 1.09)	NO <sub>2</sub> : associations attenuated by PM <sub>2.5</sub> or SO <sub>2</sub> adjustment. Copollutants: PM <sub>2.5</sub> and SO <sub>2</sub> associations robust to adjustment for NO <sub>2</sub> . NO <sub>2</sub> correlations (Pearson <i>r</i> ): PM <sub>2.5</sub> : 0.67; SO <sub>2</sub> : 0.53.
<a href="#">†Chen et al. (2010b)</a>	Shanghai, China	Lag 0: 0.997 (0.970, 1.025) Lag 1: 1.02 (0.99, 1.05) Lag 0–1 avg: 1.014 (0.98, 1.05)	NO <sub>2</sub> : associations robust to adjustment for PM <sub>10</sub> ; attenuated by SO <sub>2</sub> adjustment. Copollutants: PM <sub>10</sub> and SO <sub>2</sub> associations attenuated by adjustment for NO <sub>2</sub> . NO <sub>2</sub> correlations (Pearson <i>r</i> ): PM <sub>10</sub> : 0.70; SO <sub>2</sub> : 0.76.
<a href="#">†Zhang et al. (2014)</a>	Guangzhou, China	Lag 0: 1.03 (0.98, 1.08) Lag 1: 1.02 (0.95, 1.08) Lag 2: 0.97 (0.91, 1.03)	No copollutant models. NO <sub>2</sub> correlations (Spearman <i>r</i> ): PM <sub>10</sub> : 0.82; SO <sub>2</sub> : 0.60.
<a href="#">†Ito et al. (2011)</a>	New York City, NY	Lag 0: 1.04 (1.03, 1.05) Lag 1: 1.01 (1.00, 1.02)	No copollutant models.
<a href="#">†Son et al. (2013)</a>	8 cities, South Korea	Lag 0: 1.04 (1.02, 1.06) Lag 1: 1.00 (0.98, 1.01)	No copollutant models. NO <sub>2</sub> correlations (Pearson <i>r</i> ): PM <sub>10</sub> : 0.5; SO <sub>2</sub> : 0.6; CO: 0.7; O <sub>3</sub> : -0.1.
<a href="#">†Larrieu et al. (2007)</a>	8 French cities	Lag 0–1 avg: 1.02 (1.00, 1.04)	No copollutant models.
<a href="#">†Sarnat et al. (2013b)</a>	Atlanta, GA	Lag 0–2 avg NO <sub>x</sub> Central site: 1.01 (1.00, 1.01) Background (km <sup>2</sup> weighting): 1.05 (1.01, 1.09) AERMOD: 1.01 (1.00, 1.02) Hybrid background-AERMOD: 1.01 (1.00, 1.02)	No copollutant models.
<a href="#">Poloniecki et al. (1997)</a>	London, U.K.	Lag 1: 1.02 (1.00, 1.04)	No copollutant models analyzed for CVD.
<a href="#">Chang et al. (2005)</a>	Taipei, Taiwan	Lag 0–2 avg ≥20°C: 1.39 (1.32, 1.45) <20°C: 1.23 (1.12, 1.37)	NO <sub>2</sub> : associations robust to adjustment for PM <sub>10</sub> , SO <sub>2</sub> , CO, or O <sub>3</sub> , with the exception of PM <sub>10</sub> on cold days.

**Table 5-46 (Continued): Corresponding effect estimates for hospital admissions for all cardiovascular disease studies presented in Figure 5-20.**

Study	Location	Relative Risk <sup>a</sup> (95% CI)	Copollutant Examination <sup>b</sup>
<a href="#">Yang et al. (2004)</a>	Kaohsiung, Taiwan	Lag 0–2 avg ≥25°C: 1.46 (1.31, 1.62) <25°C: 2.54 (2.27, 2.84)	NO <sub>2</sub> : associations robust to adjustment for PM <sub>10</sub> , SO <sub>2</sub> , CO, or O <sub>3</sub> on cold days. Positive but somewhat attenuated after adjustment on warm days. Robust with SO <sub>2</sub> adjustment.
<a href="#">Linn et al. (2000)</a>	Los Angeles, CA	Lag 0: 1.03 (1.02, 1.04)	No copollutant models. NO <sub>2</sub> correlations: PM <sub>10</sub> : 0.67 to 0.88; O <sub>3</sub> : -0.23 to 0.35; CO: 0.84 to 0.94.
<a href="#">Wong et al. (1999)</a>	Hong Kong, China	Lag 0–1 avg: 1.05 (1.03, 1.08)	No copollutant models.
<a href="#">von Klot et al. (2005)</a>	5 European cities	Lag 0: 1.16 (1.07, 1.27)	NO <sub>2</sub> : associations robust to adjustment for PM <sub>10</sub> or O <sub>3</sub> .
<a href="#">Andersen et al. (2008b)</a>	Copenhagen, Denmark	Lag 0–3 avg: 1.00 (0.93, 1.10)	No evidence of an association between NO <sub>2</sub> and CVD. Copollutant models did not change the results.
<a href="#">Hinwood et al. (2006)</a>	Perth, Australia	Lag 1: 1.08 (1.04, 1.13)	No copollutant models.
<a href="#">Llorca et al. (2005)</a>	Torrelavega, Spain	Lag 0 NO <sub>2</sub> : 1.11 (1.05, 1.17) NO: 1.13 (1.07, 1.19)	No copollutant models.
<a href="#">†Filho et al. (2008)</a>	São Paulo, Brazil	Diabetes Lag 0: 1.00 (1.00, 1.00) Lag 1: 1.00 (0.99, 1.00) Lag 0–1 avg: 1.00 (1.00, 1.00) No diabetes Lag 0: 1.00 (1.00, 1.00) Lag 1: 1.00 (0.99, 1.00) Lag 0–1 avg: 1.00 (1.00, 1.00)	No copollutant models. NO <sub>2</sub> correlations (Pearson <i>r</i> ): PM <sub>10</sub> : 0.68; SO <sub>2</sub> : 0.62; CO: 0.58; O <sub>3</sub> : 0.41.
<a href="#">Atkinson et al. (1999b)</a>	London, U.K.	Lag 0: 1.01 (1.00, 1.02)	NO <sub>2</sub> : association attenuated by adjustment for BS. Copollutants: BS robust to adjustment for NO <sub>2</sub> .
<a href="#">Peel et al. (2007)</a>	Atlanta, GA	Lag 0–2 avg Case crossover: 1.04 (1.02, 1.06) Time series: 1.04 (1.02, 1.06)	No copollutant models.

**Table 5-46 (Continued): Corresponding effect estimates for hospital admissions for all cardiovascular disease studies presented in Figure 5-20.**

Study	Location	Relative Risk <sup>a</sup> (95% CI)	Copollutant Examination <sup>b</sup>
<a href="#">Tolbert et al. (2007)</a>	Atlanta, GA	Lag 0–2 avg: 1.02 (1.01, 1.03)	NO <sub>2</sub> : association attenuated after adjustment for CO or PM <sub>2.5</sub> TC. Copollutants: CO and PM <sub>2.5</sub> TC associations robust to adjustment for NO <sub>2</sub> . NO <sub>2</sub> correlations (Spearman <i>r</i> ): CO: 0.70; PM <sub>2.5</sub> TC: 0.65.
<a href="#">Fung et al. (2005)</a>	Windsor, ON, Canada	<65 yr Lag 0: 0.99 (0.90, 1.13) Lag 0–1 avg: 1.04 (0.93, 1.16) ≥65 yr Lag 0: 1.02 (0.96, 1.07) Lag 0–1 avg: 1.02 (0.98, 1.05)	Copollutant results not reported for NO <sub>2</sub> .
<a href="#">Jalaludin et al. (2006)</a>	Sydney, Australia	Lag 0: 1.06 (1.02, 1.09) Lag 0–1 avg: 1.01 (0.98, 1.05) Lag 1: 1.04 (1.01, 1.08)	NO <sub>2</sub> : associations robust to adjustment for PM <sub>10</sub> , PM <sub>2.5</sub> , SO <sub>2</sub> , O <sub>3</sub> , or BS in adults aged 65 yr and older. Attenuated after CO adjustment. Copollutants: CO, PM <sub>2.5</sub> , SO <sub>2</sub> , O <sub>3</sub> , and BS associations robust to NO <sub>2</sub> adjustment; PM <sub>10</sub> association attenuated. NO <sub>2</sub> correlations: BS: 0.35 to 0.59; PM <sub>10</sub> : 0.44 to 0.67; PM <sub>2.5</sub> : 0.45 to 0.68; O <sub>3</sub> : 0.21 to 0.45; CO: 0.55 to 0.71; SO <sub>2</sub> : 0.52 to 0.56.
<a href="#">Simpson et al. (2005a)</a>	4 Australian cities	Lag 0: 1.07 (1.05, 1.09) Lag 0–1 avg: 1.07 (1.05, 1.09)	NO <sub>2</sub> : associations robust to adjustment for BS; attenuated, but positive after O <sub>3</sub> adjustment. Copollutants: O <sub>3</sub> negative association robust to adjustment for NO <sub>2</sub> ; BS association attenuated, but positive after adjustment for NO <sub>2</sub> .
<a href="#">Ballester et al. (2006)</a>	Spain	24-h NO <sub>2</sub> Lag 0–1 avg: 1.01 (1.00, 1.03) 1-h NO <sub>2</sub> Lag 0: 1.04 (0.99, 1.09)	NO <sub>2</sub> : associations robust to adjustment for O <sub>3</sub> ; attenuated but positive with CO or SO <sub>2</sub> adjustment. Copollutants: CO, BS, PM <sub>10</sub> , SO <sub>2</sub> , and O <sub>3</sub> associations robust to NO <sub>2</sub> adjustment.

**Table 5-46 (Continued): Corresponding effect estimates for hospital admissions for all cardiovascular disease studies presented in Figure 5-20.**

Study	Location	Relative Risk <sup>a</sup> (95% CI)	Copollutant Examination <sup>b</sup>
<a href="#">Morgan et al. (1998)</a>	Sydney, Australia	Lag 0 24-h NO <sub>2</sub> : 1.09 (1.06, 1.12) 1-h NO <sub>2</sub> : 1.06 (1.04, 1.09)	No copollutant models. NO <sub>2</sub> correlations: O <sub>3</sub> : -0.09; PM: 0.53.

avg = average; AERMOD = American Meteorological Society/Environmental Protection Agency Regulatory Model; BS = black smoke; CA = California; CI = confidence interval; CO = carbon monoxide; CVD = cardiovascular disease; GA = Georgia; h = hours; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; O<sub>3</sub> = ozone; ON = Ontario; NY = New York; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm; SO<sub>2</sub> = sulfur dioxide; TC = total carbon; U.K. = United Kingdom.

<sup>a</sup>Relative risks are standardized to a 20-ppb or 30-ppb increase in NO<sub>2</sub> or NO or 40-ppb or 100-ppb increase in NO<sub>x</sub> concentration for 24-h avg and 1-h max metrics, respectively.

<sup>b</sup>Relevant relative risks for copollutant models can be found in Supplemental [Figures S5-2, S5-3, S5-4, and S5-5 \(U.S. EPA, 2015b, c, d, e\)](#).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

### 5.3.9 Cardiovascular Mortality

Studies that examined the association between short-term increases in ambient NO<sub>2</sub> concentration and cause-specific mortality and that were evaluated in the 2008 ISA for Oxides of Nitrogen consistently reported positive associations. Across studies, there was evidence that the magnitude of the NO<sub>2</sub>-cardiovascular mortality relationship was similar or slightly larger than that for total mortality. Recent multicity studies as well as a meta-analysis of studies conducted in Asian cities ([Atkinson et al., 2012](#)) provide evidence that is consistent with those studies evaluated in the 2008 ISA for Oxides of Nitrogen ([Section 5.4](#) and [Figure 5-23](#)).

The NO<sub>2</sub>-cardiovascular mortality relationship was further examined in a few studies that analyzed copollutant models. Importantly, it is difficult to examine whether NO<sub>2</sub> is independently associated with cardiovascular mortality because NO<sub>2</sub> often is highly correlated with other traffic-related pollutants. No study examined potential confounding by traffic-related pollutants or PM<sub>2.5</sub>. In the 17 Chinese cities study (CAPES), [Chen et al. \(2012b\)](#) found that NO<sub>2</sub> risk estimates for cardiovascular mortality were slightly attenuated but remained positive in copollutant models with PM<sub>10</sub> or SO<sub>2</sub> (6.9% [95% CI: 3.8, 10.1] for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations at lag 0–1 avg; 4.6% [95% CI: 1.1, 8.1] with PM<sub>10</sub>; 5.7% [95% CI: 2.5, 9.0] with SO<sub>2</sub>). [Chen et al. \(2013b\)](#) reported similar results when examining stroke mortality in a subset of eight CAPES

cities [i.e., 5.6% increase in stroke mortality (95% CI: 3.4, 8.0) at lag 0–1 day avg for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations. A slight attenuation of the association was observed in copollutant models with PM<sub>10</sub> (4.5% [95% CI: 1.8, 7.3]) or SO<sub>2</sub> (5.2% [95% CI: 2.1, 8.3]). Also, [Chiusolo et al. \(2011\)](#) found evidence that associations between short-term NO<sub>2</sub> exposure and cardiovascular mortality remained robust in copollutant models in a study of 10 Italian cities. In an all-year analysis, a 20-ppb increase in NO<sub>2</sub> at lag 0–5 avg was associated with a 10.5% (95% CI: 5.9, 14.8) increase in cardiovascular mortality and a 10.1% (95% CI: 4.0, 16.4) increase adjusted for PM<sub>10</sub>. In a warm season analysis (April–September), the NO<sub>2</sub> effect estimate was 19.2% (95% CI: 11.4, 27.4) and 18.8% (95% CI: 10.7, 27.5) with adjustment for O<sub>3</sub>. Overall, the limited number of studies that have examined the potential confounding effects on the NO<sub>2</sub>-cardiovascular mortality relationship indicate that associations remain relatively unchanged with adjustment for PM<sub>10</sub> or SO<sub>2</sub>, but it remains difficult to disentangle the independent effects of NO<sub>2</sub> as confounding by more highly traffic-related copollutants has not been examined.


Of the multicity studies evaluated, only the studies conducted in Italy examined potential seasonal differences in the NO<sub>2</sub>-cause-specific mortality relationship ([Chiusolo et al., 2011](#); [Bellini et al., 2007](#)). Additional information with regard to whether there is evidence of seasonal differences in NO<sub>2</sub>-cardiovascular mortality associations is provided by single-city studies conducted in the U.S. ([Sacks et al., 2012](#); [Ito et al., 2011](#)). In a study of 15 Italian cities, [Bellini et al. \(2007\)](#) found that risk estimates for cardiovascular mortality were dramatically increased in the summer from 1.5 to 7.3% for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations at lag 0–1 avg, respectively, with no evidence of an association in the winter. These results were corroborated in a study of 10 Italian cities ([Chiusolo et al., 2011](#)), which observed an increase in risk estimates for cardiovascular mortality in the warm season (i.e., April–September) compared to all-year analyses. [Chiusolo et al. \(2011\)](#) did not conduct analyses with only the winter season. U.S. studies conducted in New York, NY ([Ito et al., 2011](#)) and Philadelphia, PA ([Sacks et al., 2012](#)) do not provide consistent evidence indicating seasonal differences ([Section 5.4.6](#)). Overall, the cardiovascular mortality results from the multicity studies conducted in Italy are consistent with those observed in the total mortality analyses conducted by [Bellini et al. \(2007\)](#) and [Chiusolo et al. \(2011\)](#). However, as discussed in [Section 5.4.3](#), studies conducted in Asian cities observed very different seasonal patterns, and it remains unclear if the seasonal patterns observed for total mortality would be similar to those observed for cardiovascular mortality in these cities.

An uncertainty that often arises when examining the relationship between short-term air pollution exposures and cause-specific mortality is whether analyses that examine statistical modeling parameters, the lag structure of associations, and the C-R relationship

provide results that are consistent with those observed for total mortality. In a study conducted in Philadelphia, PA, [Sacks et al. \(2012\)](#) examined whether the various modeling approaches to control for both temporal trends/seasonality and weather used in a number of multicity studies [e.g., National Morbidity, Mortality, and Air Pollution Study (NMMAPS), Air Pollution and Health: A European Approach (APHEA)] influence air pollution-cardiovascular mortality associations when using the same data set. Across models, the authors reported that associations of NO<sub>2</sub> with cardiovascular mortality were relatively consistent, with the percentage increase in cardiovascular mortality for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations ranging from 1.4 to 2.0%. The results of [Sacks et al. \(2012\)](#) support those of [Chen et al. \(2013b\)](#), which found that NO<sub>2</sub>-stroke mortality associations were robust to using 4 to 10 *df* per year to control for temporal trends.

Studies that examined the lag structure of associations for cardiovascular mortality reported results consistent with those observed for total mortality ([Section 5.4.7](#)). In a study of 10 Italian cities, [Chiusolo et al. \(2011\)](#) reported evidence of an immediate effect of NO<sub>2</sub> at lag 0–1 avg on cardiovascular mortality but also provided evidence for a prolonged effect due to the magnitude of the association being larger at lag 0–5 avg ([Figure 5-24](#)). These results are consistent with those of [Chen et al. \(2012b\)](#) in the CAPES study. The authors found the largest effect at single-day lags of 0 and 1 and the average of lag 0–1\_days providing support for an immediate effect of NO<sub>2</sub> on cardiovascular mortality ([Figure 5-25](#)). However, when examining longer lags [Chen et al. \(2012b\)](#) reported that the magnitude of the association was slightly larger for a 0–4\_day lag suggesting a potential prolonged effect. In an analysis of stroke mortality, [Chen et al. \(2013b\)](#) reported similar results in a subset of eight Chinese cities from CAPES.

To date, analyses detailing the C-R relationship between air pollution and cause-specific mortality have been limited. In the analysis of eight Chinese cities, [Chen et al. \(2013b\)](#) also examined the air pollution and stroke mortality C-R relationship. To examine the assumption of linearity, the authors fit both a linear and spline model to the NO<sub>2</sub>-stroke mortality relationship. [Chen et al. \(2013b\)](#) then computed the deviance between the two models to determine if there was any evidence of nonlinearity. An examination of the deviance did not indicate that the spline model improved the overall fit of the NO<sub>2</sub>-stroke mortality relationship ([Figure 5-21](#)).



Note: NO<sub>2</sub> = nitrogen dioxide. The black line represents the mean estimate, and the dotted lines are 95% confidence intervals. Source: Reprinted with permission of Wolters Kluwer Health, [Chen et al. \(2013b\)](#).

**Figure 5-21 Pooled concentration-response curve for nitrogen dioxide and daily stroke mortality in eight Chinese cities for lag 0–1 day.**

### 5.3.10 Subclinical Effects Underlying Cardiovascular Effects

The following subsections review studies of subclinical effects that serve as useful measures of physiological and biochemical responses and could provide mechanistic evidence to describe a role for NO<sub>2</sub> in the manifestation of cardiovascular diseases. These subclinical effects are not widely validated markers of specific clinical cardiovascular outcomes but could potentially underlie the development, progression, or indication of various clinical events and provide biological plausibility for multiple outcomes.

---

### 5.3.10.1 Heart Rate and Heart Rate Variability

HRV provides a noninvasive marker of cardiac autonomic nervous system function. The rhythmic variation in the intervals between heart beats can be quantified in either the time domain or the frequency domain ([TFESC and NASPE, 1996](#)). Common time-domain measures of HRV include the standard deviation of all normal-to-normal intervals (SDNN, an index of total HRV) and the root-mean-square of successive differences (rMSSD, an index influenced mainly by the parasympathetic nervous system). In the frequency domain, HRV is usually divided into the high frequency (HF) and low frequency (LF) components, as well as the ratio of the LF to HF components (LF/HF) ([TFESC and NASPE, 1996](#)). Decreases in indices of HRV have been associated with increased risk of cardiovascular events in prospective cohort studies ([La Rovere et al., 2003](#); [Kikuya et al., 2000](#); [Tsuji et al., 1996](#); [Tsuji et al., 1994](#)).

#### **Epidemiologic Studies**

The 2008 ISA for Oxides of Nitrogen reported that there was insufficient evidence to determine whether exposure to oxides of nitrogen was associated with changes in cardiac autonomic control as assessed by indices of HRV ([U.S. EPA, 2008c](#)). Additional studies are now available for review ([Table 5-47](#)) that provide evidence for an association between exposure to NO<sub>2</sub> and HRV among those with pre-existing disease but not in healthy individuals.

**Table 5-47 Epidemiologic studies of heart rate/heart rate variability.**

Study	Location and Sample Size	Pre-Existing Condition	Mean NO <sub>2</sub> ppb	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)
<a href="#">Timonen et al. (2006)</a>	Amsterdam, the Netherlands; Erfurt, Germany; Helsinki, Finland n = 131	Coronary artery disease	24-h avg NO <sub>2</sub> Amsterdam: 22.7 Erfurt: 15.4 Helsinki: 16.5	Central monitor	SDNN (msec) Lag 0: -1.05 (-3.50, 1.39) Lag 1: -1.28 (-3.98, 1.43) Lag 2: -3.01 (-5.94, -0.11) Lag 3: -0.68 (-3.42, 2.07) Lag 0-4: -4.59 (-9.32, 0.15) LF/HF (% change) Lag 0: -3.01 (-15.4, 9.77) Lag 1: -16.5 (-30.1, -3.01) Lag 2: -17.7 (-32.0, -3.01) Lag 3: -1.88 (-15.4, 11.7) Lag 0-4: -26.0 (-50.1, -1.88) HF (% change) Lag 0: 4.51 (-33.5, 18.4) Lag 1: 4.51 (-10.2, 19.6) Lag 2: 1.88 (-13.9, 18.1) Lag 3: -1.88 (-16.9, 13.2) Lag 0-4: 4.51 (-22.2, 30.8)
<a href="#">†Zanobetti et al. (2010)</a>	Boston, MA n = 46 (aged 43-75 yr)	Coronary artery disease	2-h avg NO <sub>2</sub> 50th: 21 75th: 27 95th: 36  72-h avg NO <sub>2</sub> 50th: 21 75th: 25 95th: 31	Central monitor Citywide avg	HF (% change) 2-h: -6.7 (-10.8, -2.5) per 11-ppb increase 120-h: -9.4 (-14.1, -4.4) per 6-ppb increase All other results presented graphically, no quantitative results.
<a href="#">†Bartell et al. (2013)</a>	Los Angeles, CA n = 50	Coronary artery disease	24-h avg NO <sub>x</sub> : 42.3 Max: 183.7	Monitors on trailers parked at each of 4 retirement communities	No quantitative results presented; results presented graphically. Generally null associations between NO <sub>x</sub> and SDNN medication use in participants taking and not taking acetylcholine esterase inhibitors.

**Table 5-47 (Continued): Epidemiologic studies of heart rate/heart rate variability.**

Study	Location and Sample Size	Pre-Existing Condition	Mean NO <sub>2</sub> ppb	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)	
<a href="#">†Barclay et al. (2009)</a>	Aberdeen, Scotland, U.K. n = 132	Stable heart failure	24-h avg NO <sub>2</sub> : 30.1 24-h avg NO: 14.7	Central monitor	HR (bpm) NO <sub>2</sub> : 0.40 (0.00, 0.80) NO: 0.35 (-0.04, 0.74) SDNN (msec) NO <sub>2</sub> : 0.62 (-0.59, 1.83) NO: 0.61 (-0.56, 1.78) SDANN (msec) NO <sub>2</sub> : 0.51 (-0.87, 1.89) NO: 0.57 (-0.77, 1.91) rMSSD (msec) NO <sub>2</sub> : 0.40 (0.00, 0.80) NO: 0.35 (-0.04, 0.74) pNN50 (%) NO <sub>2</sub> : 1.57 (-3.85, 6.99) NO: 0.91 (-4.35, 6.17)	LF power (units NR) NO <sub>2</sub> : 2.35 (-1.05, 5.76) NO: 1.94 (-1.33, 5.21) LF normalized (units NR) NO <sub>2</sub> : -0.86 (-2.82, 1.10) NO: -0.18 (-2.07, 1.70) HF power (units NR) NO <sub>2</sub> : 3.37 (-1.17, 7.90) NO: 2.90 (-1.46, 7.25) HF normalized (units NR) NO <sub>2</sub> : 0.72 (-1.55, 3.00) NO: 1.41 (-0.78, 3.56) LF/HF ratio NO <sub>2</sub> : -1.09 (-3.93, 1.75) NO: -1.05 (-3.78, 1.67)
<a href="#">†Goldberg et al. (2008)</a>	Montreal, QC, Canada n = 31	Stable heart failure	24-h avg NO <sub>2</sub> 17.9 Max: 54.1	Central monitor citywide avg	Pulse rate (mean difference) Lag 0: -0.07 (-0.09, 0.80) Lag 1: 0.78 (-0.14, 1.71) Lag 0-2: 0.99 (-0.34, 2.32)	
<a href="#">†Suh and Zanobetti (2010a)</a>	Atlanta, GA n = 30	MI or COPD	24-h avg NO <sub>2</sub> Ambient: 17.1 Personal: 11.6	Central monitor Citywide avg Personal	SDNN (% change) Ambient: -0.64 (-11.1, 10.4) Personal: -3.48 (-10.7, 3.9) rMSSD (% change) Ambient: -6.60 (-30.6, 20.9) Personal: -14.5 (-29.9, 1.70) pNN50 (% change) Ambient: 0.30 (-38.3, 47.4) Personal: -32.3 (-56.5, -5.65)	HF (% change) Ambient: -1.49 (-37.1, 41.3) Personal: -21.4 (-44.9, 4.48) LF/HF (% change) Ambient: 13.7 (-4.11, 33.1) Personal: 9.7 (-2.34, 22.2)

**Table 5-47 (Continued): Epidemiologic studies of heart rate/heart rate variability.**

Study	Location and Sample Size	Pre-Existing Condition	Mean NO <sub>2</sub> ppb	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)
<a href="#">†Huang et al. (2012a)</a>	Beijing, China n = 40	CVD	1-h max NO <sub>2</sub> 2007, Visit 1: 33.8 2007, Visit 2: 26.3 2008, Visit 3: 29.2 2008, Visit 4: 22.9	Central monitor	SDNN (% change) 1-h: -1.9 (-3.4, -0.3) 4-h: -3.9 (-5.7, -2.2) 12-h: -3.6 (-5.5, -1.6) rMSSD (% change) 1-h: 1.4 (-1.1, 3.9) 4-h: -2.2 (-5.7, 1.5) 12-h: -2.2 (-6.1, 2.0) LF (% change) 1-h: -5.4 (-9.3, -1.4) 4-h: -8.9 (-13.2, -4.3) 12-h: -7.9 (-12.8, -2.8) HF (% change) 1-h: -3.5 (-8.2, 1.4) 4-h: -5.1 (-11.0, 1.3) 12-h: -3.7 (-10.4, 3.5)
<a href="#">†Williams et al. (2012b)</a>	Detroit, MI n = 65	CVD risk factors (hypertension, hyperlipidemia, diabetes)	24-h avg NO <sub>2</sub> 24.0 75th: 28.0 Max: 100.0	Personal monitor	HR (bpm) -2.95 (-4.82, -0.80)
<a href="#">†Laumbach et al. (2010)</a>	New Brunswick, NJ n = 21	Diabetes	NO <sub>2</sub> 50th: 25.9 75th: 32.8 Max: 61.1	In-vehicle monitor	HF (% change) -11.9 (-105, 80.8) LF/HF ratio (% change) -107 (-298, 83.4)
<a href="#">†Peel et al. (2011)</a>	Atlanta, GA n = 4,277	Healthy infants	1-h max NO <sub>2</sub> 41.7 90th: 65.6 Max: 109.2	Central monitor	Bradycardia (OR) 1.04 (1.00, 1.08)
<a href="#">†Chuang et al. (2007a)<sup>b</sup></a>	Taipei, Taiwan n = 76	Healthy	24-h avg NO <sub>2</sub> 17.3 Max: 53.1	Central monitor	"We found no associations between HRV indices and NO <sub>2</sub> ." No quantitative results presented.
<a href="#">†Jia et al. (2011)</a>	Beijing, China n = 20	Healthy	24-h avg NO <sub>x</sub> 35.0	Central monitor	"No significant effects are found between daily average...NO <sub>x</sub> on HRV indices." No quantitative results presented.

**Table 5-47 (Continued): Epidemiologic studies of heart rate/heart rate variability.**

Study	Location and Sample Size	Pre-Existing Condition	Mean NO <sub>2</sub> ppb	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)	
<a href="#">†Park et al. (2010)</a>	Baltimore, MD; Chicago, IL; Forsyth County, NC; Los Angeles, CA; New York, NY; St. Paul, MN n = 5,465	Healthy	24-h avg NO <sub>2</sub> Lag 0-1: 23.5	Central monitor Citywide avg	“There were no significant associations of HRV with gaseous pollutants (data not shown).” No quantitative results presented.	
<a href="#">†Chuang et al. (2007b)</a>	Taipei, Taiwan n = 46	Healthy	1-h max NO <sub>2</sub> 38.4	Central monitor Avg of monitors within 1 km of residence	“...NO <sub>2</sub> ...exposures were not associated with any HRV indices in our study participants (data not shown).” No quantitative results presented.	
<a href="#">†Min et al. (2008)</a>	Taein Island, South Korea n = 1,349	Healthy	24-h avg NO <sub>2</sub> 24 75th: 30 Max: 119	Central monitor	SDNN (% change) 6-h: -2.45 (-6.28, 1.53) 9-h: -3.89 (-8.31, 0.71) 12-h: -3.81 (-8.75, 1.34) 24-h: -1.72 (-6.71, 3.51) 48-h: 2.93 (-2.33, 8.42) 72-h: 1.20 (-3.81, 6.42)	HF (% change) 6-h: -1.08 (-10.8, 9.47) 9-h: -3.31 (-14.3, 8.88) 12-h: -2.38 (-14.7, 11.5) 24-h: -4.53 (-16.6, 8.94) 48-h: 4.42 (-8.72, 19.1) 72-h: 4.18 (-8.52, 18.4)
					LF (% change) 6-h: -8.61 (-16.9, 0.31) 9-h: -12.2 (-21.5, -2.11) 12-h: -12.3 (-22.6, -0.88) 24-h: -5.71 (-16.6, 6.33) 48-h: 3.69 (-8.22, 16.9) 72-h: 5.84 (-6.19, 18.5)	

**Table 5-47 (Continued): Epidemiologic studies of heart rate/heart rate variability.**

Study	Location and Sample Size	Pre-Existing Condition	Mean NO <sub>2</sub> ppb	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)	
† <a href="#">Weichenthal et al. (2011)</a> <sup>b</sup>	Ottawa, ON, Canada n = 42	Healthy	1-h max NO <sub>2</sub> 4.8	Central monitor	ΔLF (msec <sup>2</sup> )	ΔSDNN (msec)
					1-h: -532 (-2872, 1807)	1-h: -18.8 (-113, 72.0)
					2-h: 12.0 (-2468, 2490)	2-h: -75.0 (-150, -2.55)
					3-h: 578 (-2055, 3218)	3-h: -39.8 (-120, 40.5)
					4-h: -398 (-3533, 2025)	4-h: -12.0 (-82.5, 61.5)
					ΔHF (ms <sup>2</sup> )	ΔrMSSD (msec)
					1-h: -420 (-1785, 953)	1-h: -12.0 (-48.8, 24.8)
					2-h: -488 (-1612, 638)	2-h: -12.0 (-41.3, 17.3)
					3-h: -24.0 (-1020, 975)	3-h: 2.33 (-30.0, 34.5)
					4-h: -248 (-1418, 923)	4-h: -2.10 (-33.0, 29.3)
					ΔLF:HF	ΔpNN50 (%)
					1-h: 5.70 (-2.10, 13.5)	1-h: -3.30 (-31.5, 24.8)
					2-h: 10.5 (2.63, 18.8)	2-h: -8.25 (-33.0, 15.8)
					3-h: 12.8 (4.20, 21.8)	3-h: -3.23 (-29.3, 22.5)
4-h: 7.50 (-1.80, 17.3)	4-h: 1.28 (-26.3, 29.3)					
† <a href="#">Shields et al. (2013)</a>	Mexico City, Mexico n = 16	Healthy	1-h max NO <sub>2</sub> 130	In-vehicle Monitor	LF (% change)	LF/HF (% change)
					-0.69 (-1.91, 0.57)	-0.45 (-1.53, 0.64)
					HF (% change)	SDNN (% change)
-0.24 (-1.80, 1.47)	-1.03 (-1.55, -0.49)					

**Table 5-47 (Continued): Epidemiologic studies of heart rate/heart rate variability.**

Study	Location and Sample Size	Pre-Existing Condition	Mean NO <sub>2</sub> ppb	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)
<a href="#">†Rich et al. (2012)<sup>b</sup></a>	Beijing, China n = 12	Healthy	24-h avg NO <sub>2</sub> Entire study: 27.0 Before: 26.0 During: 13.9 After: 41.4	Central monitor	No quantitative results presented; results presented graphically. Positive, but statistically nonsignificant increase in heart rate, generally consistent across lags from 0 to 6.
<a href="#">†Zhang et al. (2013)<sup>b</sup></a>	Beijing, China n = 125	Healthy	24-h avg NO <sub>2</sub> Before: 25.6 During: 14.6 After: 41.4	Central monitor	No quantitative results presented; results presented graphically. Statistically significant decreases in SDNN and rMSSD in the early lags (0 to 1); measurable but statistically nonsignificant decreases across lags 2 and 3; and generally null associations in lags 4, 5, and 6.

avg = average; bpm = beats per minute; CA = California; CI = confidence interval; COPD = chronic obstructive pulmonary disease; CVD = cardiovascular disease; GA = Georgia; HF = high frequency; HR = heart rate; HRV = heart rate variability; LF = low frequency; LF/HF = LF to HF components; IL = Illinois; max = maximum; MD = Maryland; MI = myocardial infarction or Michigan; MN = Minnesota; NJ = New Jersey; NC = North Carolina; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; NY = New York; OR = odds ratio; pNN50 = percentage of pairs of successive normal sinus intervals that exceeds 50 milliseconds divided by the total number of successive pairs of normal sinus intervals; ppb = parts per billion; rMSSD = root-mean-square of successive differences; SDANN = standard deviation of average normal-to-normal intervals; SDNN = standard deviation of all normal-to-normal intervals; U.K. = United Kingdom; U.S. = United States.

<sup>a</sup>Relative risks are standardized to a 20-ppb or 30-ppb increase in NO<sub>2</sub> or NO or 40-ppb or 100-ppb increase in NO<sub>x</sub> concentration for 24-h avg and 1-h max metrics, respectively.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

The multicountry ULTRA study assessed the longitudinal association between ambient pollution and HRV among older adults with stable coronary artery disease in Amsterdam, the Netherlands; Erfurt, Germany; and Helsinki, Finland ([Timonen et al., 2006](#)). In each participant, HRV was assessed multiple times over a 6-month period, resulting in a total of 1,266 repeated measures. Pooling results across the three cities, the authors found a 3.01 msec (95% CI: -5.94, -0.11) decrease in SDNN and a 17.67% (95% CI: -31.95, -3.01) decrease in LF/HF associated with a 20-ppb increase in 24-hour average NO<sub>2</sub> concentrations at Lag Day<sub>2</sub>. The magnitudes of these associations were somewhat larger in relation to the 5-day moving average of NO<sub>2</sub>. The authors report that these effects were robust to adjustment for other pollutants in copollutant models, including UFP, PM<sub>2.5</sub>, or CO, but detailed results were not provided. These results were reportedly similar in men and women and after exclusion of those exposed to environmental tobacco smoke at home. Most associations with HF were positive.

[Huang et al. \(2012a\)](#) measured HRV repeatedly in participants with pre-existing cardiovascular disease in Beijing in the summer of 2007 and again in the summer of 2008, including one measurement period during the 2008 Beijing Olympics when citywide air pollution control measures substantially reduced ambient concentrations of most criteria pollutants as described in more detail in [Section 5.3.6.1](#). In single-pollutant models, an unspecified IQR increase in 1-h max NO<sub>2</sub> was associated with a 3.6% decrease (95% CI: -5.5, -1.6) in SDNN, and a 7.9% decrease (95% CI: -12.8, -2.8) in LF. The association with SDNN was stronger among those with a higher C-reactive protein (CRP), women, and those without a history of diabetes, but body mass index (BMI) did not appear to modify the association. [Rich et al. \(2012\)](#) also examined the association between heart rate and NO<sub>2</sub> concentrations before, during and after the 2008 Beijing Olympics. The authors observed increases in heart rate that were generally consistent in magnitude across lags from 0 to 6 days. In expanded results from the same protocol, [Zhang et al. \(2013\)](#) reported that NO<sub>2</sub> was inversely associated with SDNN and rMSSD, with stronger associations in the earlier lags (0 to 3). The HR association with NO<sub>2</sub> was somewhat attenuated, but still positive after adjustment for PM<sub>2.5</sub>, CO, SO<sub>2</sub>, or OC, and no longer positive after adjustment for EC. The decrements in rMSSD and SDNN associated with increased ambient NO<sub>2</sub> remained relatively unchanged after adjustment for PM<sub>2.5</sub>, CO, SO<sub>2</sub>, OC, or EC.

Some studies ([Laumbach et al., 2010](#); [Suh and Zanobetti, 2010b](#)) assessed personal exposures, which tend to reduce uncertainty in the NO<sub>2</sub> exposure estimate when compared to the use of citywide averages ([Section 3.4.4.2](#)). [Suh and Zanobetti \(2010a\)](#) examined people that had either recently experienced an MI or had COPD. Same-day total personal exposures to NO<sub>2</sub> were associated with decreased HRV. Decreases in pNN50 (proportion of pairs of successive normal sinus intervals exceeds 50 milliseconds

divided by the total number of successive pairs of normal sinus intervals) were the largest among the individuals with COPD, while NO<sub>2</sub>-associated decrements in HF were the largest among individuals with a recent MI, but were less precise when all individuals or individuals with COPD were included in the analysis. Associations were more pronounced when examining personal as opposed to ambient measures of NO<sub>2</sub>. Copollutant confounding was not assessed. [Laumbach et al. \(2010\)](#) studied the effects of in-vehicle exposure to traffic-related pollutants among a group of individuals with diabetes. The authors did not observe any strong evidence of an association between HF HRV and in-vehicle exposure to NO<sub>2</sub>. [Weichenthal et al. \(2011\)](#) measured NO<sub>2</sub> at central site monitors and carried out a cross-over trial with 42 healthy adults who cycled for 1 hour on high- and low-traffic routes as well as indoors. Results were inconsistent among the many measures of HRV examined, but mean concentrations of NO<sub>2</sub> were associated with decreases in SDNN and increases in LF/HF.

In a repeated-measures study of Boston-area patients with clinically significant coronary artery disease, [Zanobetti et al. \(2010\)](#) found that HF was inversely associated with ambient NO<sub>2</sub> concentrations. This association remained robust after adjustment for PM<sub>2.5</sub> in a copollutant model. Among a population reporting a substantial prevalence of cardiovascular risk factors (i.e., hypertension, diabetes, hyperlipidemia), [Williams et al. \(2012a\)](#) observed a strong association between NO<sub>2</sub> concentrations and reduced heart rate. On the other hand, [Barclay et al. \(2009\)](#) reported no association between NO<sub>2</sub> or NO and indices of HRV in a repeated-measures study of nonsmoking patients with stable heart failure. [Bartell et al., 2013](#)) observed generally null associations between NO<sub>2</sub> and SDNN medication use in retirement residents with coronary artery disease in the greater Los Angeles area. Also, [Goldberg et al. \(2008\)](#) followed 31 Montreal-area participants with stable heart failure for 2 months and found no association between pulse rate and NO<sub>2</sub> concentrations.

Infants are potentially at greater risk of pollution-related health effects ([AAP, 2004](#)). [Peel et al. \(2011\)](#) examined data from 4,277 Atlanta-area infants prescribed home cardiorespiratory monitors and observed a slightly elevated risk of bradycardia (OR: 1.04 [95% CI: 1.00, 1.08]) per 30-ppb increase in 1-h max NO<sub>2</sub> concentrations averaged over the previous 2 days and measured at a central site monitor. The clinical or public health significance of this finding is unclear.

The majority of the above studies focused on infants or participants with a documented history of heart disease, with the exception of the Beijing Olympics studies ([Zhang et al., 2013](#); [Rich et al., 2012](#)). In contrast to the pre-existing disease studies, there is little evidence that HRV is associated with NO<sub>2</sub> concentrations in healthy participants. For example, a repeated-measures study of young healthy participants in Taipei, Taiwan

found no association between NO<sub>2</sub> and HRV indices ([Chuang et al., 2007a](#)). Another repeated-measures study in Mexico City observed small decrements in SDNN associated with increases in NO<sub>2</sub>, but no association between NO<sub>2</sub> and LF/HF ([Shields et al., 2013](#)). In Beijing, [Jia et al. \(2011\)](#) assessed HRV two times in each of 20 healthy participants and reported no association between oxides of nitrogen and HRV. However, this study was quite small, and detailed results were not shown.

Cross-sectional analyses of populations with or without a history of heart disease have also tended to yield null results. In a cross-sectional analysis of 5,465 participants, ages 45–84 years, from the multicity Multiethnic Study of Atherosclerosis, [Park et al. \(2010\)](#) found no association between NO<sub>2</sub> concentrations and indices of HRV. A cross-sectional study from Taipei also observed no association between NO<sub>2</sub> and HRV among 46 older adults with cardiovascular disease risk factors ([Chuang et al., 2007b](#)). A cross-sectional study of 1,349 healthy participants in Taean Island, South Korea by [Min et al. \(2008\)](#), found that NO<sub>2</sub> was associated with decreases in the LF component of HRV, but not with changes in SDNN or the HF component.

In summary, current evidence suggests that among participants with pre-existing or elevated risk for cardiovascular disease, ambient NO<sub>2</sub> concentrations are associated with alterations in cardiac autonomic control as assessed by indices of HRV; however, evidence for differential effects between populations with and without pre-existing diseases and conditions is limited. In this specific subgroup of the population, NO<sub>2</sub> seems to be associated with changes in HRV, which is consistent with relative increases in sympathetic nervous system activity and/or decreases in parasympathetic nervous system activity. In contrast, this association has not been commonly apparent among healthier participants. In the two studies that examined copollutant models with PM<sub>2.5</sub> or a traffic-related pollutant among UFP, CO, or OC, NO<sub>2</sub> associations in the pre-existing disease populations generally persisted. However, inference about the independent effect of NO<sub>2</sub> is limited given the high correlations among pollutants and potential differential exposure measurement error resulting from use of central site ambient pollutant measurements.

### **Controlled Human Exposure Studies**

Controlled human exposure studies evaluating HRV were not available for review in the 2008 ISA for Oxides of Nitrogen; since then, two studies are available ([Table 5-50](#)). [Huang et al. \(2012b\)](#) evaluated changes in various HRV parameters following NO<sub>2</sub> exposure in healthy adult volunteers performing intermittent exercise. Exposure to 500 ppb NO<sub>2</sub> did not alter HRV time domain intervals. LF/HF slightly increased, although this change was not statistically significant. The authors reported an 11.6 and

13% decrease in the HF domain normalized for heart rate (HF<sub>n</sub>) 1 and 18 hours after exposure, respectively. Combined exposure to NO<sub>2</sub> and PM<sub>2.5</sub> CAPs increased LF/HF (1 hour;  $p = 0.062$ ), as well as the low frequency domain normalized for heart rate (1 hour;  $p = 0.021$ ) and cardiac t-wave amplitude (18 hour;  $p = 0.057$ ). CAPs exposure alone did not induce such changes. Epidemiologic studies found NO<sub>2</sub>-associated decreases in HRV primarily in adults with or at risk for cardiovascular disease. However, a recent study in resting adults with stable coronary heart disease and impaired left ventricular systolic function showed no statistically significant changes in HRV after exposure to 400 ppb NO<sub>2</sub> for 1 hour while seated ([Scaife et al., 2012](#)); however, the study had only 75% power to detect significant differences in the HF domain of 50% or less.

The few studies reviewed in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c, 1993a](#)) reported mixed effects of NO<sub>2</sub> exposure on HR; a recent study shows no effect. [Folinsbee et al. \(1978\)](#) and [Drechsler-Parks \(1995\)](#) exposed healthy adult males and healthy older adults, respectively, to approximately 600 ppb NO<sub>2</sub> for 2 hours and reported no changes in HR. Changes in HR were also examined in potentially at-risk populations exposed to NO<sub>2</sub>. Exposure to 400 ppb NO<sub>2</sub> did not alter HR in adults with coronary heart disease ([Scaife et al., 2012](#)) and resulted in a statistically nonsignificant increase in adults with COPD and healthy volunteers ([Gong et al., 2005](#)). Among healthy volunteers and those with asthma, NO<sub>2</sub> exposure resulted in no change in HR ([Linn et al., 1985a](#)).

In summary, there is limited, inconsistent evidence from controlled human exposure studies to suggest NO<sub>2</sub> alone or in combination with CAPs exposure during exercise alters HRV. Additionally, there appears to be no evidence from controlled human exposure studies that NO<sub>2</sub> exposure alters HR.

## **Toxicological Studies**

Toxicology studies examining HRV changes were not available for review in the 2008 ISA for Oxides of Nitrogen. Similar to controlled human exposure studies, a recent study in rats found mixed evidence for changes in HR and HRV ([Table 5-51](#)). [Ramos-Bonilla et al. \(2010\)](#) examined body weight, HR, and HRV, following exposure of aged inbred mice to an ambient mixture consisting of PM, CO, and NO<sub>2</sub>. Animals were exposed to either filtered or unfiltered outdoor Baltimore air for 6 hours daily for 40 weekdays. In multipollutant models, statistically significant declines in HR were associated with NO<sub>2</sub> at lag 3 and the 7-day cumulative concentration with adjustment for PM and CO. However, HRV changes were not associated with NO<sub>2</sub> exposure. The independent effects of each pollutant are difficult to distinguish in multipollutant models because of potential multicollinearity among pollutants.

### 5.3.10.2 QT-Interval Duration

The QT interval provides an ECG marker of ventricular repolarization. Prolongation and increased variability of the QT interval is associated with increased risk of life-threatening ventricular arrhythmias. Consistent with the weak epidemiologic evidence for associations of NO<sub>2</sub> exposure with arrhythmias (Section 5.3.3), the limited evidence from epidemiologic and controlled human exposure studies does not clearly indicate an effect of short-term NO<sub>2</sub> exposure on markers of ventricular repolarization.

In the Normative Aging Study, [Baja et al. \(2010\)](#) found imprecise associations between heart-rate-corrected QT interval (QTc) and 10-hour moving average of NO<sub>2</sub> concentrations among older, generally white men but observed associations with NO<sub>2</sub> concentrations at lags 3 and 4 hours (longer lags or moving averages were not considered) (Table 5-48). The only study from the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) available for comparison found that 24-h avg NO<sub>2</sub> concentrations were positively associated with increased QTc duration, but this association was imprecise (i.e., had wide confidence intervals), and the 6-hour moving average of NO<sub>2</sub> was not associated with an increase in QTc duration ([Henneberger et al., 2005](#)).

**Table 5-48 Epidemiologic studies of QT-interval duration.**

Study	Location Sample Size	Mean Concentration ppb	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)
<a href="#">†Baja et al. (2010)</a>	Boston, MA n = 580	1-h max NO <sub>2</sub> 19 ppb during ECG monitoring 21 ppb 10 h before monitoring	Central site	Change in QTc (msec) 10-h lag: 5.91 (-2.03, 13.85) 4-h lag: 6.28 (-0.02, 12.55)
<a href="#">Henneberger et al. (2005)</a>	Erfurt, Germany n = 56	24-h avg NO <sub>2</sub> : 18.2 75th: 22.6 Max: 36.4  24-h avg NO: 19.4 75th: 24.2 Max: 110.1	Citywide avg	QTc (msec) NO <sub>2</sub> , lag 6–11 h: 9.77 (2.23, 17.3) T-wave complexity (%) NO, lag 0–23: 0.15 (0.02, 0.28) T-wave amplitude (μV) NO, lag 0–5 h: -2.10 (-4.16, -0.03)

avg = average; CI = confidence interval; ECG = electrocardiographic; MA = Massachusetts; max = maximum; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; QTc = corrected QT interval.

<sup>a</sup>Effect estimates are standardized to a 20-ppb or 30-ppb increase in NO<sub>2</sub> or NO for 24-h avg and 1-h max metrics, respectively.

†Study published since the 2008 ISA for Oxides of Nitrogen.

There were no controlled human exposure studies evaluating changes in the QT interval available for the 2008 ISA for Oxides of Nitrogen, and the single recent study found NO<sub>2</sub>-induced changes in QT interval that are in the opposite direction as that associated with arrhythmias. [Huang et al. \(2012b\)](#) found a small (quantitative results not reported) decrease in QTc at 1 and 18 hours after a 2-hour exposure to 500 ppb NO<sub>2</sub> in healthy exercising adults ([Table 5-50](#)). NO<sub>2</sub> exposure also induced a 29.9% decrease ( $p = 0.001$ ) in the QT variability index (QTVI). However, when volunteers were exposed to both PM<sub>2.5</sub> and NO<sub>2</sub>, the QTVI synergistically increased.

---

### 5.3.10.3 Vascular Reactivity

The vascular endothelium plays a fundamental role in the maintenance of vascular tone that is involved in the regulation of blood pressure and blood flow. In a controlled human exposure study, [Langrish et al. \(2010\)](#) examined the effects of NO<sub>2</sub> on vascular endothelial tone and fibrinolytic function. In a random crossover double-blind study, healthy male volunteers were exposed to 4,000 ppb of NO<sub>2</sub> for 1 hour with intermittent exercise. This study employed infusion of endothelial-dependent vasodilators, bradykinin and acetylcholine, and endothelial-independent vasodilators, sodium nitroprusside and verapamil, to examine vascular endothelial tone. The results demonstrated that NO<sub>2</sub> did not attenuate the vasodilator response to these vasoactive agents.

Epidemiologic studies provide inconsistent evidence regarding a potential association between NO<sub>2</sub> and vascular function. In the EPA's Detroit Exposure and Aerosol Research Study, [Williams et al. \(2012a\)](#) found that total personal NO<sub>2</sub> concentrations were associated with inconsistent changes in brachial artery diameter (positive association at lag 1 and negative association at lag 2) and increases (i.e., presumably beneficial) in flow-mediated dilatation. No associations were observed with ambient measures of NO<sub>2</sub>. [Ljungman et al. \(2014\)](#) reported no consistent associations between 1-, 2-, 3-, 5-, and 7-day moving averages of NO<sub>x</sub> and peripheral arterial tonometry ratio in the Offspring and Third Generation Cohorts of the Framingham Heart Study.

In summary, the available controlled human exposure and epidemiologic evidence is limited and inconsistent, and therefore does not support the presence of an association between ambient NO<sub>2</sub> concentrations and vascular reactivity.

---

### 5.3.10.4 Blood Biomarkers of Cardiovascular Effects

Several epidemiologic and toxicological studies have explored the potential relationship between NO<sub>2</sub> and biomarkers of cardiovascular risk. In particular, markers of

inflammation, cell adhesion, coagulation, and thrombosis have been evaluated in a number of epidemiologic studies published since the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)). These biomarkers also have been examined in controlled human exposure and animal toxicological studies.

## Epidemiologic Studies

Levels of some circulating systemic inflammatory markers appear to be related to NO<sub>2</sub> concentrations among participants with a history of heart disease ([Table 5-49](#)). [Delfino et al. \(2008b\)](#) followed nonsmoking elderly subjects with a history of coronary artery disease living in retirement communities in Los Angeles, CA and measured plasma biomarkers weekly over a 12-week period. The authors observed that indoor and/or outdoor NO<sub>2</sub> concentrations measured at the retirement homes were associated with increases IL-6 and the soluble tumor necrosis factor  $\alpha$  receptor II (sTNF $\alpha$ -RII), markers of systemic inflammation, but not associated with a number of other biomarkers of inflammation and vascular injury including CRP, P-selectin, D-dimer, TNF- $\alpha$ , soluble intercellular adhesion molecule-1 (sICAM-1), or soluble vascular adhesion molecule-1 (sVCAM-1). In subsequent analysis of overlapping populations, [Delfino et al. \(2009\)](#) and [Delfino et al. \(2010\)](#) found that NO<sub>2</sub> and NO<sub>x</sub> were both associated with circulating levels of IL-6. [Delfino et al. \(2009\)](#) also observed positive associations with P-selectin, TNF-RII, and CRP. Working with the same study population, [Wittkopp et al. \(2013\)](#) also found an association between NO<sub>x</sub> concentrations and increases in IL-6 and TNF- $\alpha$ , but only for participants with mitochondrial haplogroup H, which has been linked to oxidative damage and increased risk of age-related diseases. Similarly, [Ljungman et al. \(2009\)](#) repeatedly measured plasma IL-6 in 955 MI survivors from six European cities, and found that NO<sub>2</sub> was associated with increased levels of IL-6, and that the strength of the association varied in individuals with specific variants of inflammatory genes. However, in studies conducted among patients with stable chronic heart failure, no associations were observed between any biomarkers (including hematological markers and markers of inflammation) and NO<sub>2</sub> concentrations ([Barclay et al., 2009](#); [Wellenius et al., 2007](#)). None of these studies examined potential confounding by traffic-related copollutants.

In Augsburg, Germany, [Brüske et al. \(2011\)](#) measured lipoprotein-associated phospholipase A<sub>2</sub> (Lp-PLA<sub>2</sub>), a marker of vascular inflammation and an independent predictor of coronary heart disease events and stroke, up to six times in 200 participants with a history of myocardial infarction. They found that Lp-PLA<sub>2</sub> was associated with both NO and NO<sub>2</sub>. However, the association was negative at short lags and positive at longer lags, making interpretation of these results difficult.

**Table 5-49 Epidemiologic studies of biomarkers of cardiovascular effects.**

Study	Location Sample Size	Pre- Existing Condition	Mean NO <sub>2</sub> ppb	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)	
† <a href="#">Delfino et al. (2008b)</a>	Los Angeles, CA n = 29	Coronary artery disease	24-h avg NO <sub>2</sub> Outdoor: 33.1 Max: 59.8  Indoor: 32.3 Max: 53.5	Indoor and outdoor home measurements	Outdoor: CRP (ng/mL) Lag 0: 1,125 (-314, 2,565) Lag 0-2: 1,027 (-465, 2,520) Fibrinogen (µg/mL) Lag 0: -110 (-504, 283) Lag 0-2: -110 (-502, 281) IL-6 (pg/mL) Lag 0: 1.32 (0.48, 2.18) Lag 0-2: 1.17 (0.28, 2.08) IL-6R (pg/mL) Lag 0: -493 (-9,387, -249) Lag 0-2: -3,212 (-7,789, 1,365) TNF-α (pg/mL) Lag 0: 0.13 (-0.26, 0.52) Lag 0-2: 0.15 (-0.22, 0.54) TNF-RII (pg/mL) Lag 0: 290 (-41, 623) Lag 0-2: 240 (-82, 562)	P-selectin (ng/mL) Lag 0: 5.13 (-1.02, 11.3) Lag 0-2: 1.49 (-5.04, 8.02) VCAM-1 (ng/mL) Lag 0: 53.7 (-11.4, 119) Lag 0-2: 18.3 (-45.5, 82.0) ICAM-1 (pg/mL) Lag 0: 5.4 (-9.0, 19.7) Lag 0-2: 0.58 (-13.5, 14.6) SOD (U/g Hb) Lag 0: -541 (-1,021, -63) Lag 0-2: -571 (-1,036, -106) GPx (U/g Hb) Lag 0: -1.99 (-3.68, -0.26) Lag 0-2: 1.15 (-2.81, 0.58) MPO (ng/mL) Lag 0: -5.34 (-14.92, 4.33) Lag 0-2: -1.15 (-10.81, 8.44)

**Table 5-49 (Continued): Epidemiologic studies of biomarkers of cardiovascular effects.**

Study	Location Sample Size	Pre- Existing Condition	Mean NO <sub>2</sub> ppb	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)	
<a href="#">†Delfino et al. (2009)</a>	Los Angeles, CA n = 60	Coronary artery disease	24-h avg NO <sub>2</sub> Phase 1: 26.4 Phase 2: 28.3 <hr/> 24-h avg NO <sub>x</sub> Phase 1: 37.2 Phase 2: 53.9	Hourly outdoor home air measurements	NO <sub>x</sub> : IL 6 (pg/mL) Lag 0: 0.31 (0.16, 0.46) Lag 0-2: 0.31 (0.13, 0.47) P-selectin (ng/mL) Lag 0: 2.03 (0.13, 3.92) Lag 0-2: 3.05 (0.90, 5.20) TNF-RII (pg/mL) Lag 0: 88.5 (10.6, 166) Lag 0-2: 115 (25.0, 207) TNF-α (pg/mL) Lag 0: 0.01 (-0.08, 0.10) Lag 0-2: 0.06 (-0.04, 0.15)	NO <sub>x</sub> : CRP (ng/mL) Lag 0: 626 (284, 969) Lag 0-2: 544 (148, 940) SOD (U/g Hb) Lag 0: -134 (-269, 2.88) Lag 0-2: -128 (-286, 29.8) GPx (U/g Hb) Lag 0: -0.23 (-0.81, 0.35) Lag 0-2: -0.18 (-0.85, 0.48)
<a href="#">†Delfino et al. (2010)</a>	Los Angeles, CA n = 60	Coronary artery disease	Warm season 24-h avg NO <sub>2</sub> : 26.4 24-h avg NO <sub>x</sub> : 37.2  Cool season 24-h avg NO <sub>2</sub> : 28.3 24-h avg NO <sub>x</sub> : 53.9	Hourly outdoor home air measurements	IL-6 (pg/mL) NO <sub>2</sub> : 0.48 (-0.06, 1.05) NO <sub>x</sub> : 0.61 (0.26, 0.95)	
<a href="#">†Wittkopp et al. (2013)</a>	Los Angeles, CA n = 36	Coronary artery disease	24-h avg NO <sub>x</sub> : 45.35 Max: 188.00	Hourly outdoor home air measurements	No quantitative results presented; results presented graphically. Statistically significant positive associations between 1-, 2-, 3-, and 5-day avg NO <sub>x</sub> and IL-6 (pg/mL) and TNF-α (pg/mL) in haplogroup H participants. Statistically nonsignificant, but negative associations between 1-, 2-, 3-, and 5-day avg NO <sub>x</sub> and IL-6 (pg/mL) and TNF-α (pg/mL) in haplogroup U participants.	

**Table 5-49 (Continued): Epidemiologic studies of biomarkers of cardiovascular effects.**

Study	Location Sample Size	Pre- Existing Condition	Mean NO <sub>2</sub> ppb	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)	
† <a href="#">Ljungman et al. (2009)</a>	6 European cities n = 955 (total n = 5,539 measurements)	MI	24-h avg NO <sub>2</sub> 22.6	Central monitor Citywide avg	IL-6 (% change) Overall: 4.02 (0.47, 8.04) IL-6 genetic variants IL-6 rs2069832 (1,1): 7.33 (2.13, 12.8) IL-6 rs2069832 (1,2): 2.84 (-1.18, 7.09) IL-6 rs2069832 (2,2): -1.18 (-8.27, 5.91) IL-6 rs2069840 (1,1): 4.26 (-0.95, 9.46) IL-6 rs2069840 (1,2): 4.02 (0.00, 8.04) IL-6 rs2069840 (2,2): 4.02 (-3.55, 11.6)	IL-6 rs2069845 (1,1): 6.62 (1.18, 12.1) IL-6 rs2069845 (1,2): 3.07 (-0.95, 7.33) IL-6 rs2069845 (2,2): 0.47 (-6.15, 7.57) IL-6 rs2070011 (1,1): 4.96 (-0.24, 10.2) IL-6 rs2070011 (1,2): 3.78 (-0.24, 7.80) IL-6 rs2070011 (2,2): 2.60 (-4.26, 9.69) IL-6 rs1800790 (1,1): 2.36 (-2.13, 6.86) IL-6 rs1800790 (1,2): 6.62 (1.42, 11.8) IL-6 rs1800790 (2,2): 10.4 (0.24, 21.0)
† <a href="#">Brüske et al. (2011)</a>	Augsburg, Germany n = 200	MI	24-h avg NO <sub>2</sub> 20.8 75th: 24.7 Max: 38.2  24-h avg NO 24.0 75th: 25.8 Max: 141.1	Central monitor	Lp-PLA <sub>2</sub> (% Change) NO <sub>2</sub> , lag 4: 7.28 (3.00, 11.56) NO, lag 4: 2.74 (-0.21, 5.70) "Inverse associations were observed for ... NO <sub>2</sub> with Lp-PLA <sub>2</sub> at Lag Days 1-2 and positive associations were estimated ...with Lp-PLA <sub>2</sub> lagged 4 and 5 days."	

**Table 5-49 (Continued): Epidemiologic studies of biomarkers of cardiovascular effects.**

Study	Location Sample Size	Pre-Existing Condition	Mean NO <sub>2</sub> ppb	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)	
<a href="#">†Barclay et al. (2009)</a>	Aberdeen, Scotland, U.K. n = 132	Stable chronic heart failure	24-h avg NO <sub>2</sub> : 30.1  24-h avg NO: 14.7	Central monitor	Hemoglobin NO <sub>2</sub> : 0.04 (-0.29, 0.36) NO: -0.01 (-0.33, 0.31)  Mean corpuscular hemoglobin NO <sub>2</sub> : 0.05 (-0.16, 0.26) NO: -0.04 (-0.24, 0.17)  Platelets NO <sub>2</sub> : -0.05 (-0.87, 0.77) NO: 0.25 (-0.56, 1.05)  Hematocrit NO <sub>2</sub> : -0.02 (-0.35, 0.32) NO: 0.10 (-0.23, 0.43)  WBC NO <sub>2</sub> : -0.72 (-1.67, 0.23) NO: -0.71 (-1.64, 0.22)  CRP NO <sub>2</sub> : 0.42 (-5.26, 6.11) NO: 0.89 (-4.69, 6.47)	IL-6 NO <sub>2</sub> : 6.28 (0.59, 11.9) NO: 2.77 (-2.81, 8.34)  vWF NO <sub>2</sub> : 2.16 (-0.33, 4.66) NO: 3.52 (1.09, 5.95)  E-selectin NO <sub>2</sub> : 1.16 (-0.37, 2.70) NO: 0.48 (-1.02, 1.99)  Fibrinogen NO <sub>2</sub> : -0.22 (-1.76, 1.32) NO: 0.20 (-1.32, 1.71)  Factor VII NO <sub>2</sub> : 0.27 (-1.44, 1.99) NO: 0.34 (-1.35, 2.02)  D-dimer NO <sub>2</sub> : -0.24 (-2.78, 2.29) NO: -0.32 (-2.81, 2.18)
<a href="#">Wellenius et al. (2007)</a>	Boston, MA n = 28	Stable chronic heart failure	24-h avg NO <sub>2</sub> 20.7	Central monitor Citywide avg	"No significant associations were observed between any other pollutant and BNP levels at any of the lags examined." No quantitative results presented.	
<a href="#">†Hildebrandt et al. (2009)</a>	Erfurt, Germany n = 38	COPD	24-h avg NO <sub>2</sub> 13.5  24-h NO 10.7	Central monitor	Increases in fibrinogen and prothrombin fragment 1 + 2 associated with NO concentrations. A decrease in vWF was associated with NO <sub>2</sub> concentrations. No quantitative results presented for NO or NO <sub>2</sub> .	

**Table 5-49 (Continued): Epidemiologic studies of biomarkers of cardiovascular effects.**

Study	Location Sample Size	Pre- Existing Condition	Mean NO <sub>2</sub> ppb	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)	
<a href="#">†Dadvand et al. (2014b)</a>	Barcelona, Spain n = 242	COPD	24-h avg NO <sub>2</sub> : 30.7	Residential land use regression	CRP (% change) Lag 1: 2.99 (-21.6, 34.2) Lag 2: 26.1 (-3.47, 64.1) Lag 5: 54.9 (23.2, 94.5) TNF-α (% change) Lag 1: 3.90 (-24.6, 41.5) Lag 2: 10.6 (-19.4, 51.4) Lag 5: 26.5 (-4.51, 66.9) IL-6 (% change) Lag 1: 10.5 (-13.5, 40.1) Lag 2: 4.31 (-18.3, 32.9) Lag 5: 21.3 (-2.47, 50.4)	IL-8 (% change) Lag 1: 7.94 (-2.07, 19.0) Lag 2: 8.09 (-2.00, 19.1) Lag 5: 3.44 (-5.37, 13.1) Fibrinogen (% change) Lag 1: 3.57 (-1.84, 9.09) Lag 2: 3.26 (-2.00, 8.72) Lag 5: 10.4 (5.59, 15.6) HGF (% change) Lag 1: 3.11 (-3.91, 10.6) Lag 2: 5.57 (-1.58, 13.2) Lag 5: 9.99 (3.44, 17.0)
<a href="#">†Khafaie et al. (2013)</a>	Pune City, India n = 1,392	Type II diabetes	24-h avg NO <sub>x</sub> : 21.1	Central site monitor citywide avg	No quantitative results presented; results presented graphically. NO <sub>x</sub> was statistically significantly associated with increases in CRP at lags 0, 1, 2, 4, and 0-7. There were no measurable differences between winter and summer associations.	
<a href="#">†Bind et al. (2012)</a>	Boston, MA n = 704	Healthy	24-h avg NO <sub>2</sub> 18 95th: 35	Central site monitor citywide avg	Fibrinogen (% change) Lag 0-2: 8.18 (4.73, 11.6)	
<a href="#">†Ren et al. (2011)</a>	Boston, MA n = 320	Healthy	24-h avg NO <sub>2</sub> 17.8	Central site monitor	8-OhdG (% change) Lag 0: 28.5 (-19.4, 76.4) Lag 0-6: 90.0 (-12.2, 192)	Lag 0-13: 167 (28.8, 306) Lag 0-20: 195 (44.9, 345)
<a href="#">†Thompson et al. (2010)</a>	Toronto, Canada n = 45	Healthy	24-h avg NO <sub>2</sub> 23.8	Central site monitor	Quantitative results not presented.	

**Table 5-49 (Continued): Epidemiologic studies of biomarkers of cardiovascular effects.**

Study	Location Sample Size	Pre- Existing Condition	Mean NO <sub>2</sub> ppb	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)	
<a href="#">†Rudez et al. (2009)</a>	Rotterdam, the Netherlands n = 40	Healthy	24-h avg NO <sub>2</sub> 50th: 19.7 75th: 25.5 Max: 43.1  24-h NO: 50th: 5.6 75th: 12 Max: 130.4	Central site monitor	Maximal platelet aggregation (% change) Lag 0–6 h NO <sub>2</sub> : -4.11 (-13.0, 4.82) NO: 5.42 (-18.3, 29.6) Lag 0–12 h NO <sub>2</sub> : -4.64 (-15.0, 5.89) NO: 2.92 (-22.5, 28.3) Lag 0–24 h NO <sub>2</sub> : -5.36 (-18, 7.68) NO: 7.92 (-12.5, 28.8) Lag 24–48 h NO <sub>2</sub> : -1.07 (-11.8, 9.46) NO: 5.00 (-17.1, 27.1) Lag 48–72 h NO <sub>2</sub> : 10.0 (2.68, 17.3) NO: 25.42 (10.00, 40.42);  Late aggregation (% change) Lag 0–6 h NO <sub>2</sub> : 5.89 (-9.46, 21.1) NO: 33.8 (-5.00, 72.1) Lag 0–12 h NO <sub>2</sub> : 13.4 (-4.11, 30.7) NO: 35.4 (-2.92, 73.3) Lag 0–24 h NO <sub>2</sub> : 17.7 (-4.46, 39.8) NO: 37.1 (4.67, 69.2) Lag 24–48 h NO <sub>2</sub> : 3.39 (-16.1, 22.7) NO: 22.9 (-6.25, 51.7)	Thrombin generation—peak (% change) Lag 0–6 h NO <sub>2</sub> : -2.68 (-9.82, 4.46) NO: -1.67 (-15.0, 11.7) Lag 0–12 h NO <sub>2</sub> : -1.25 (-9.11, 6.61) NO: -1.67 (-12.9, 9.58) Lag 0–24 h NO <sub>2</sub> : -1.07 (-9.46, 7.32) NO: -2.50 (-16.3, 10.8) Lag 24–48 h NO <sub>2</sub> : 14.3 (4.29, 24.3) NO: 17.1 (4.58, 30.0) Lag 48–72 h NO <sub>2</sub> : 6.61 (-2.68, 16.1) NO: 5.00 (-6.67, 16.7) Lag 72–96 h NO <sub>2</sub> : -0.36 (-8.57, 7.86) NO: 14.6 (1.67, 27.9) Lag 0–96 h NO <sub>2</sub> : 1.79 (-7.3, 10.7) NO: 12.9 (-7.1, 32.5)  Thrombin generation—lag time (% change) Lag 0–6 h NO <sub>2</sub> : 0.00 (-2.86, 2.86) NO: -0.42 (-5.83, 4.58) Lag 0–12 h NO <sub>2</sub> : 0.00 (-3.21, 3.04) NO: 0.00 (-4.58, 4.17)

**Table 5-49 (Continued): Epidemiologic studies of biomarkers of cardiovascular effects.**

Study	Location Sample Size	Pre- Existing Condition	Mean NO <sub>2</sub> ppb	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)	
† <a href="#">Rudez et al. (2009)</a>  (Continued)	Rotterdam, the Netherlands  n = 40  (Continued)	Healthy  (Continued)	24-h avg NO <sub>2</sub> 50th: 19.7 75th: 25.5 Max: 43.1  24-h NO: 50th: 5.6 75th: 12 Max: 130.4  (Continued)	Central site monitor  (Continued)	Late aggregation (% change)  (Continued):  Lag 48–72 h NO <sub>2</sub> : 15.9 (4.64, 27.1) NO: 32.9 (9.58, 55.8) Lag 72–96 h NO <sub>2</sub> : 8.57 (–7.68, 24.8) NO: 14.2 (–23.8, 52.5) Lag 0–96 h NO <sub>2</sub> : 28.8 (8.93, 48.6) NO: 54.2 (20.4, 87.9)	Thrombin generation—lag time (% change)  (Continued):  Lag 0–24 h NO <sub>2</sub> : 0.36 (–2.86, 3.57) NO: 2.50 (–2.50, 7.50) Lag 24–48 h NO <sub>2</sub> : –5.54 (–9.11, –1.79) NO: –7.50 (–12.1, –2.92) Lag 48–72 h NO <sub>2</sub> : –4.46 (–7.68, 1.07) NO: –3.33 (–7.50, 1.25) Lag 72–96 h NO <sub>2</sub> : 0.00 (–3.21, 3.04) NO: –5.83 (–10.8, –0.83) Lag 0–96 h NO <sub>2</sub> : –1.25 (–4.46, 1.96) NO: –4.58 (–11.7, 2.08)
† <a href="#">Steenhof et al. (2014)</a>	Utrecht, the Netherlands n = 31	Healthy	5-h avg NO <sub>2</sub> : 20	Central site monitor at each of 5 sites	No quantitative results presented; results presented graphically. NO <sub>2</sub> was statistically significantly associated with decreases in eosinophils and lymphocytes 2-h after exposure. Null associations were observed between NO <sub>2</sub> and WBC count, neutrophils, or monocytes.	
† <a href="#">Strak et al. (2013b)</a>	Utrecht, the Netherlands n = 31	Healthy	5-h avg NO <sub>2</sub> : 20	Central site monitor at each of 5 sites	Endogenous thrombin [in Factor XII-mediated thrombin generation pathway (% Change)]. All sites: 65.5 (7.63, 145) Outdoor: 76.1 (–2.23, 155)	

**Table 5-49 (Continued): Epidemiologic studies of biomarkers of cardiovascular effects.**

Study	Location Sample Size	Pre- Existing Condition	Mean NO <sub>2</sub> ppb	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)	
<a href="#">Steinvil et al. (2008)</a>	Tel Aviv, Israel n = 3,659	Healthy	24-h avg NO <sub>2</sub> 19.5 75th: 25.3	Central site monitor  citywide avg	CRP (% change) Lag 0 Men: 0.31 (-7.87, 12.6) Women: -4.72 (-17.3, 9.45) Lag 1 Men: -7.87 (-17.3, 9.45); Women: -3.15 (-15.8, 11.0) Lag 2 Men: -1.57 (-11.02, 11.02); Women: 0.00 (-12.60, 15.75) Fibrinogen (mg/dL) Lag 0 Men: -9.92 (-15.6, -4.25) Women: -12.4 (-19.8, -5.20) Lag 1 Men: -7.87 (-13.9, -2.05) Women: -5.51 (-12.9, 1.89) Lag 2 Men: -7.09 (-13.1, -1.10) Women: -1.42 (-9.45, 6.46)	WBC (cells/μL) Lag 0 Men: 22.1 (-156, 200) Women: -83.5 (-306, 139) Lag 1 Men: 39.4 (-146, 224) Women: -20.5 (-244, 203) Lag 2 Men: -36.2 (-227, 154) Women: 18.9 (-219, 255)
<a href="#">†Hildebrandt et al. (2009)</a>	Erfurt, Germany n = 38	Healthy	24-h avg NO <sub>2</sub> 13.5 24-h NO 10.7	Central monitor	Increases in fibrinogen and prothrombin fragment 1 + 2 associated with NO concentrations. A decrease in vWF was associated with NO <sub>2</sub> concentrations. No quantitative results presented for NO or NO <sub>2</sub> .	
<a href="#">†Khafaie et al. (2013)</a>	Pune City, India n = 1,392	Healthy	24-h avg NO <sub>x</sub> : 21.1	Citywide avg	No quantitative results presented; results presented graphically. NO <sub>x</sub> was statistically significantly associated with increases in CRP at lags 0, 1, 2, 4, and 0-7. There were no measurable differences between winter and summer associations.	
<a href="#">†Kelishadi et al. (2009)</a>	Isfahan, Iran (2004-2005) n = 374	Healthy	24-h avg: 35.8 75th: 47.2 Max: 271	Citywide avg	NO <sub>2</sub> positively associated with CRP and markers of oxidative stress (oxidized-LDL, malondialdehyde, and conjugated diene).	

**Table 5-49 (Continued): Epidemiologic studies of biomarkers of cardiovascular effects.**

Study	Location Sample Size	Pre- Existing Condition	Mean NO <sub>2</sub> ppb	Exposure Assessment	Selected Effect Estimates <sup>a</sup> (95% CI)	
<a href="#">†Lee et al. (2011c)</a>	Allegheny County, PA (1997–2001) n = 2,211	Healthy	7-day avg: 8.4 75th: 10.1 Max: 25.4	Citywide avg	No quantitative results presented. "... NO <sub>2</sub> ... associations [with CRP] were negligible for both the entire population and nonsmokers only."	
<a href="#">Chuang et al. (2007a)</a>	Taipei, Taiwan n = 76	Healthy	24-h avg NO <sub>2</sub> 17.3 Max: 53.1	Central monitor	"There was no association between NO <sub>2</sub> and any of the blood markers." No quantitative results presented.	
<a href="#">Baccarelli et al. (2007)</a>	Lombardia, Italy n = 1,213	Healthy	24-h avg NO <sub>2</sub> Median: 22.7 75th: 33.7 Max: 194.2	Central site monitor citywide avg	Homocysteine difference (% change) Lag 24 h: 0.24 (-2.86, 3.57) Lag 0–6 day: -2.21 (-6.0, 1.72)	Homocysteine, post-methionine-load (% change) Lag 24 h: 0.00 (-2.86, 2.86) Lag 0–6 day: 0.49 (-2.9, 4.17)
<a href="#">†Rich et al. (2012)</a>	Beijing, China n = 125	Healthy	24-h avg NO <sub>2</sub> Entire study: 27.0 Before: 26.0 During: 13.9 After: 41.4	Central site monitor	No quantitative results presented; results presented graphically. Positive and statistically significant increase in P-selectin, generally consistent across lags from 0 to 6. Generally null associations with soluble CD40 ligand across lags from 0–6. Positive, statistically significant increases in vWF and fibrinogen at early lags (lag 0, lag 1) but null, or negative at later lags. Generally null or negative associations with WBC across lags 0–6.	
<a href="#">†Zhang et al. (2013)</a>	Beijing, China n = 125	Healthy	24-h avg NO <sub>2</sub> Before: 25.6 During: 14.6 After: 41.4	Central monitor	No quantitative results presented; results presented graphically. Statistically significant increase in fibrinogen at lag 0. Positive, but statistically nonsignificant at lags 1, 2, 3, and 6.	

8-OHdG = urinary 8-hydroxy-deoxyguanosine; avg = average; CA = California; CI = confidence interval; COPD = chronic obstructive pulmonary disease; CRP = C-reactive protein; GPx = glutathione peroxidase; h = hours; HGF = hepatocyte growth factor; ICAM-1 = intercellular adhesion molecule 1; IL = interleukin; IL-6R = interleukin 6 receptor; LDL = low density lipoprotein; Lp-PLA2 = lipoprotein-associated phospholipase A2; MA = Massachusetts; max = maximum; MI = myocardial infarction; MPO = myeloperoxidase; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; PA = Pennsylvania; SOD = superoxide dismutase; TNF-α = tumor necrosis factor alpha; TNF-RII = TNF-receptor II; VCAM-1 = vascular adhesion molecule-1; vWF = von Willebrand factor; WBC = white blood cells.

<sup>a</sup>Effect estimates are standardized to a 20-ppb or 30-ppb increase in NO<sub>2</sub> or NO or 40-ppb or 100-ppb increase in NO<sub>x</sub> concentration for 24-h avg and 1-h max metrics, respectively.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

The results have been more heterogeneous in participants without a history of heart disease. One semiexperimental design assessed changes in blood biomarker levels in healthy participants exposed to ambient air pollution at five locations in the Netherlands with contrasting air pollution characteristics ([Steenhof et al., 2014](#); [Strak et al., 2013b](#)). A particular strength of these studies is the measurement of pollutants at the location of participants' outdoor exposure, which minimizes measurement error from time-activity patterns and variability in NO<sub>2</sub> concentration ([Sections 3.4.4.1](#) and [3.4.4.2](#)). [Steenhof et al. \(2014\)](#) reported that NO<sub>2</sub> was negatively associated with both eosinophil and lymphocyte counts. Importantly, this could either be due to eosinophils and lymphocytes leaving the blood and infiltrating stressed tissue, or a decrease in formation of eosinophils and lymphocytes. The associations were relatively unchanged after adjustment for PM<sub>2.5</sub>, EC, OC, or PM<sub>10</sub> in copollutant models. [Strak et al. \(2013b\)](#) observed an increase in thrombin generation in the endogenous pathway (Factor XII-mediated) associated with ambient outdoor NO<sub>2</sub>, that was robust to adjustment for EC or OC, and slightly attenuated after adjustment for PM<sub>2.5</sub>.

Among older men participating in the Normative Aging Study, [Bind et al. \(2012\)](#) found that NO<sub>2</sub> was associated with fibrinogen, sVCAM-1, and sICAM-1, but not CRP. In this same cohort, [Ren et al. \(2011\)](#) found that NO<sub>2</sub> was positively linked with urinary 8-hydroxy-29-deoxyguanosine (8-OhdG) concentrations, a marker of oxidative stress resulting in deoxyribonucleic acid (DNA) damage. [Thompson et al. \(2010\)](#) analyzed the baseline data on IL-6 and fibrinogen from 45 nonsmoking subjects who participated in a controlled human exposure study in Toronto, Canada. Using baseline blood samples allowed the authors to measure the association between systemic inflammation and ambient NO<sub>2</sub>, prior to controlled exposure. The authors found that NO<sub>2</sub> concentrations were not associated with either IL-6 or fibrinogen overall, but IL-6 was associated with NO<sub>2</sub> in the winter months. In Rotterdam, the Netherlands, [Rudez et al. \(2009\)](#) measured CRP, fibrinogen, and markers of platelet aggregation and thrombin generation up to 13 times in 40 healthy participants. Both NO<sub>2</sub> and NO were associated with markers of platelet aggregation and thrombin generation, but neither NO<sub>2</sub> nor NO was associated with CRP or fibrinogen.

During the Beijing Olympics, NO<sub>2</sub> was positively associated with increases in biomarkers indicative of the thrombosis-endothelial dysfunction mechanism (i.e., P-selectin) and increases in fibrinogen among healthy young adults ([Zhang et al., 2013](#); [Rich et al., 2012](#)). The association with P-selectin was attenuated, but remained positive after adjustment for PM<sub>2.5</sub>, CO, O<sub>3</sub>, SO<sub>2</sub>, EC, or OC; whereas the association between NO<sub>2</sub> and fibrinogen was generally robust to the above pollutants, with the exception of EC and OC. Among 3,659 individuals in Tel-Aviv, Israel, [Steinvil et al. \(2008\)](#) found a null

association between NO<sub>2</sub> concentrations and CRP and a negative association with fibrinogen and white blood cell counts. [Baccarelli et al. \(2007\)](#) observed generally null associations between NO<sub>2</sub> concentrations and total homocysteine among subjects in Lombardia, Italy. Similarly, [Chuang et al. \(2007a\)](#) observed no association between NO<sub>2</sub> and any blood markers, including markers of systemic inflammation and oxidative stress, as well as fibrinolytic and coagulation factors.

Other subgroups that might be at increased risk of pollution-related health effects have also been studied. In a cross-sectional study of COPD patients in Barcelona, Spain, there was evidence of a positive association between NO<sub>2</sub> and multiple biomarkers of inflammation and tissue repair, including CRP, TNF $\alpha$ , IL-6, IL-8, fibrinogen, and hepatocyte growth factor (HGF) ([Dadvand et al., 2014b](#)). These associations were generally strongest at lags of 4 or 5 days. A particular strength of this study is that the authors used validated land use regression models to estimate ambient NO<sub>2</sub> exposure at residential locations. In a repeated-measures study of male patients with chronic pulmonary disease in Germany, [Hildebrandt et al. \(2009\)](#) reported that NO was positively associated with fibrinogen and prothrombin levels but not other markers of coagulation; however, detailed results were not presented in the paper. [Khafaie et al. \(2013\)](#) observed a positive association between NO<sub>2</sub> and CRP in a cross-sectional study of Type II diabetes patients in Pune City, India. In another cross-sectional analysis of pregnant women in Allegheny County, PA, there was no association between NO<sub>2</sub> and CRP ([Lee et al., 2011c](#)). Among 374 Iranian children aged 10–18 years, [Kelishadi et al. \(2009\)](#) found that NO<sub>2</sub> was associated with CRP and markers of oxidative stress.

### **Controlled Human Exposure Studies**

Markers of inflammation, oxidative stress, cell adhesion, coagulation, and thrombosis have been evaluated in a few controlled human exposure studies published since the 2008 ISA for Oxides of Nitrogen [([U.S. EPA, 2008c](#)); and [Table 5-50](#)]. Similar to epidemiologic studies, controlled human exposure studies also report evidence for increases in some inflammatory markers, but not consistently across all studies. There is also evidence for hematological changes following NO<sub>2</sub> exposure, and a recent study reported endothelial cell activation.

**Table 5-50 Characteristics of controlled human exposure studies of cardiovascular effects.**

Study	Disease Status <sup>a</sup> ; Sample Size; Sex; Age (mean±SD)	Exposure Details	Endpoints Examined
<a href="#">†Channell et al. (2012)</a>	Primary hCAECs from n = 7 adults; M/F; 25.3 ± 5.5 yr	500 ppb NO <sub>2</sub> for 2 h Intermediate intermittent exercise (15 min on/off; $\dot{V}_E = 25$ L/min per m <sup>2</sup> of BSA). Plasma samples collected before exposures, immediately after, and 24-h post-exposure. hCAECs treated with 10 or 30% diluted plasma samples for 24 h.	LOX-1 protein measured from plasma pre-, immediately post-, and 24-h post-exposure. ICAM-1 and VCAM-1 mRNA from hCAECs and IL-8 and MCP-1 protein from cell supernatant measured immediately post-exposure to plasma.
<a href="#">Drechsler-Parks (1995)</a>	n = 8; M/F; 65.9 ± 9 yr	600 ppb NO <sub>2</sub> for 2 h Intermittent exercise (20 min on/off; $\dot{V}_E = 26$ –29 L/min)	HR calculated throughout exposure. Cardiac output measured during the last 2 min of each exercise period.
<a href="#">Folinsbee et al. (1978)</a>	n = 5/group; M; 20–25 yr	600 ppb NO <sub>2</sub> for 2 h Exercise for 15, 30, or 60 min; $\dot{V}_E = 33$ L/min.	HR, BP, and cardiac output measured during exposure.
<a href="#">Frampton et al. (2002)</a>	n = 12; M; 26.9 ± 4.5 yr n = 9; F; 27.1 ± 4.1 yr	600 and 1,500 ppb NO <sub>2</sub> for 3 h Intermittent exercise (10 min on/20 min off; $\dot{V}_E = 40$ L/min)	Venous blood collected for hematocrit, hemoglobin, and red blood cell count 3.5 h post-exposure.
<a href="#">Gong et al. (2005)</a>	Healthy nonsmokers; n = 6; 68 ± 11 yr Ex-smokers with COPD; n = 18; 72 ± 7 yr	400 ppb NO <sub>2</sub> for 2 h Intermittent exercise (15 min on/off; $\dot{V}_E = 22$ –26 L/min)	HR and BP measured immediately post, 4-h post, and Day 2.
<a href="#">†Huang et al. (2012b)</a>	n = 23; M/F; 24.56 ± 4.28 yr	1) 500 ppb NO <sub>2</sub> for 2 h 2) 500 ppb NO <sub>2</sub> + 73.4 ± 9.9 µg/m <sup>3</sup> CAPs for 2 h Intermittent exercise (15 min on/off; $\dot{V}_E = 25$ L/min per m <sup>2</sup> of BSA)	IL-6, coagulation factors, and lipid panel in peripheral blood; HRV; and HR measured 1 and 18 h post-exposure.
<a href="#">†Langrish et al. (2010)</a>	n = 10; M; median age 24 yr	4,000 ppb NO <sub>2</sub> for 1 h Intermittent exercise ( $\dot{V}_E = 25$ L/min) Vasodilator administered 4 h after exposure: 5, 10, 20 µg/min acetylcholine 100, 300, 1,000 pmol/min bradykinin 2, 4, 8 µg/min sodium nitroprusside 10, 30, 100 µg/min verapamil. Infusion in brachial artery for 6 min/dose during forearm venous occlusion plethysmography. Each vasodilator administration separated by a 20-min washout period.	Hemoglobin concentration measured 4 and 6 h after exposure. Forearm blood flow and tissue-plasminogen activator and plasminogen-activator inhibitor Type I measured 4 h post-exposure.

**Table 5-50 (Continued): Characteristics of controlled human exposure studies of cardiovascular effects.**

Study	Disease Status <sup>a</sup> ; Sample Size; Sex; Age (mean±SD)	Exposure Details	Endpoints Examined
<a href="#">Linn et al. (1985a)</a>	With asthma; n = 23; M/F; 18–34 yr Without asthma; n = 25; 20–36 yr	3,850–4,210 ppb NO <sub>2</sub> for 75 min Light and heavy intermittent exercise (15 min of each; light $\dot{V}_E$ = 25 L/min; heavy $\dot{V}_E$ = 50 L/min)	HR and BP measured throughout exposure.
<a href="#">Posin et al. (1978)</a>	n = 8–10; sex and age NR	1,000 and 2,000 ppb NO <sub>2</sub> for 2.5 h Light intermittent exercise (15 min on/off)	Acetylcholinesterase, glutathione, glucose-6-phosphate dehydrogenase, lactate dehydrogenase, erythrocyte glutathione reductase, erythrocyte glutathione peroxidase, alpha-tocopherol, TBARS, serum glutathione reductase, 2,3 diphosphoglycerate, hemoglobin, hematocrit.
<sup>†</sup> <a href="#">Riedl et al. (2012)</a>	(1) n= 10 M, 5 F; 37.3 ± 10.9 yr;  (2) n = 6 M, 9 F; 36.1 ± 2.5 yr	(1–2) 350 ppb NO <sub>2</sub> for 2 h Intermittent exercise (15 min on/off; $\dot{V}_E$ = 15–20 L/min × m <sup>2</sup> BSA) (1) Methacholine challenge post-exposure. (2) Cat allergen challenge post-exposure.	Serum levels of IL-6, ICAM-1, fibrinogen, factor VII, and vWF. Serum collected 22.5 h post-exposure.
<sup>†</sup> <a href="#">Scaife et al. (2012)</a>	Stable coronary heart disease or impaired left ventricular systolic function; n = 18; M/F; median age 68 yr	400 ppb NO <sub>2</sub> for 1 h	HR and HRV monitored continuously for 24 h post-exposure.

BP = blood pressure; BSA = body surface area; CAP = concentrated air particle; COPD = chronic obstructive pulmonary disease; F = female; hCAEC = human coronary artery endothelial cells; HR = heart rate; HRV = heart rate variability; ICAM-1 = intercellular adhesion molecule 1; IL = interleukin; LOX-1 = receptor for oxidized low-density lipoprotein; M = male; MCP-1 = monocyte chemoattractant protein-1; mRNA = messenger RNA; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; ppb = parts per billion; SD = standard deviation; TBARS – thiobarbituric acid reactive substances; VCAM-1 = vascular adhesion molecule-1;  $\dot{V}_E$  = minute ventilation; vWF = von Willebrand factor.

<sup>a</sup>Subjects are healthy unless otherwise specified.

<sup>†</sup>Studies published since the 2008 ISA for Oxides of Nitrogen.

In healthy adults, exposure to 500 ppb NO<sub>2</sub> for 2 hours with intermittent exercise did not alter circulating IL-8, a pro-inflammatory cytokine, or coagulation factors and induced a statistically nonsignificant increase in the pro-inflammatory cytokine, IL-6 ([Huang et al., 2012b](#)). Lipid profile changes were also reported. There was a 4.1% increase in blood total cholesterol ( $p = 0.059$ ) and a 5.9% increase in high density lipoprotein cholesterol

( $p = 0.036$ ) 18 hours after exposure, but no changes in low density lipoprotein or very low density lipoprotein cholesterol or triglycerides.

The controlled human exposure study by [Langrish et al. \(2010\)](#) examined the effects of NO<sub>2</sub> on fibrinolytic function. The endogenous fibrinolytic pathway was assessed by sampling venous concentrations of tissue-plasminogen activator and plasminogen-activator inhibitor Type I at baseline and 4 hours after exposure. Concentrations of these proteins were not affected by exposure to NO<sub>2</sub>.

Atherosclerosis is a chronic inflammatory disease; early stages of the disease include inflammatory activation of endothelial cells and adhesion of leukocytes to the vascular endothelium. [Channell et al. \(2012\)](#) reported endothelial cell activation in an in vitro model following NO<sub>2</sub> exposure. Plasma samples were collected from healthy volunteers exposed to filtered air or 500 ppb NO<sub>2</sub> for 2 hours with intermittent exercise. Primary human coronary artery endothelial cells (hCAECs) were then treated with a dilution of these plasma samples (10 or 30% in media) for 24 hours. Increases in messenger RNA (mRNA) expression levels of endothelial cell adhesion molecules, vascular adhesion molecule-1 (VCAM-1) and ICAM-1, from hCAECs were observed for both post-exposure time points compared to control. Cells treated with plasma (30%) collected immediately post NO<sub>2</sub> exposure had a statistically significant greater release of IL-8 but not monocyte chemoattractant protein-1 (MCP-1). In addition, plasma collected 24 hours post NO<sub>2</sub> exposure had a significant increase (30%) in soluble lectin-like oxLDL receptor (LOX-1) levels, a protein recently found to play a role in the pathogenesis of atherosclerosis ([Sections 4.3.2.9 and 4.3.5](#)).

[Riedl et al. \(2012\)](#) reported on the cardiovascular effects of healthy volunteers and individuals with asthma exposed to 350 ppb NO<sub>2</sub> for 2 hours with intermittent exercise. No statistically significant differences were found in IL-6, ICAM-1, and blood coagulation factors [i.e., factor VII, fibrinogen, and von Willebrand factor (vWF)] the morning after NO<sub>2</sub> exposure.

The 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) reported NO<sub>2</sub>-induced hematological changes. [Frampton et al. \(2002\)](#) reported decreases in hematocrit, hemoglobin, and red blood cell (RBC) count in healthy volunteers 3.5 hours after exposure to 600 or 1,500 ppb NO<sub>2</sub> for 3 hours with intermittent exercise. Results from this study support those of [Posin et al. \(1978\)](#), in which hematocrit and hemoglobin levels were decreased in young males exposed to 1,000 or 2,000 ppb NO<sub>2</sub> for approximately 2.5 hours with intermittent exercise. However, a recent study reported no change in hemoglobin levels 4 and 6 hours post-exposure to 4,000 ppb NO<sub>2</sub> for 1 hour ([Langrish et al., 2010](#)).

## Toxicological Studies

Similar to epidemiologic and controlled human exposure studies, several recent toxicological studies examined the relationship between short-term NO<sub>2</sub> exposure and biomarkers of cardiovascular effects, including markers of oxidative stress, inflammation, and cell adhesion ([Table 5-51](#)). These observations add to those from the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) on various hematological parameters in animals including RBC turnover and methemoglobin levels.

Recently, the effects of NO<sub>2</sub> on markers of oxidative stress were examined by [Li et al. \(2011a\)](#). Rats exposed to 2,660 or 5,320 ppb NO<sub>2</sub> for 7 days had a small, but statistically significant decrease in the activity of the antioxidant enzyme Cu/Zn-SOD and, at the higher dose, an increase in malondialdehyde (an indicator of lipid peroxidation) in heart tissue. These changes were accompanied by mild pathological changes in the heart. However, there were no changes in Mn-SOD or GPx activity or protein carbonyl levels at either exposure concentration. [Campen et al. \(2010\)](#) reported apolipoprotein E knockout mice (ApoE<sup>-/-</sup>) exposed to 200 or 2,000 ppb NO<sub>2</sub> had a concentration-dependent decrease (statistically significant linear trend) in the expression of the antioxidant enzyme HO-1 in the aorta. Together, these results demonstrate that NO<sub>2</sub> inhalation may perturb the oxidative balance in the heart and aorta.

The effects of NO<sub>2</sub> on antioxidant capacity were also examined in the context of diet ([de Burbure et al., 2007](#)). Rats were placed on low (Se-L) or supplemented (Se-S) selenium (Se) diets and were exposed to 5,000 ppb NO<sub>2</sub> for 5 days. Se is an integral component of the antioxidant enzyme GPx. GPx levels in RBCs increased in both groups immediately and 48 hours after exposure; however, plasma levels were decreased in Se-L diet rats at both time points. SOD activity in RBCs also decreased in Se-L diet rats at both time points but increased in Se-S diet rats 48 hours after exposure. Overall, NO<sub>2</sub> exposure stimulated antioxidant mechanisms with high Se but were mixed with low Se.

**Table 5-51 Characteristics of animal toxicological studies of cardiovascular effects.**

Study	Species (Strain); Sample Size; Sex; Age	Exposure Details	Endpoints Examined
<a href="#">†Campen et al. (2010)</a>	Mice (ApoE-/-); n = 5–10/group; M; 8 weeks	200 ppb or 2,000 ppb NO <sub>2</sub> for 6 h/day for 7 days High-fat diet	ET-1, MMP-9, HO-1, and TIMP-1 mRNA expression in aorta. TBARS and MMP-2/9 activity in aorta. Endpoints measured 18 h post-exposure.
<a href="#">de Burbure et al. (2007)</a>	Rats (Wistar); n = 8/group; M; 8 weeks	(1) 1,000 ppb NO <sub>2</sub> for 6 h/day, 5 days/week for 28 days (2) 5,000 ppb NO <sub>2</sub> for 6 h/day for 5 days (1–2) 30 min Selenium: 6 µg/day or 1.3 µg/day	GPx in plasma and RBC lysate; SOD activity in RBC lysate; GST activity in RBC lysate; TBARS in plasma. Endpoints examined immediately and 48 h after exposure.
<a href="#">Kunimoto et al. (1984)</a>	Rats (Wistar); n = 6/group; M; 16–20 weeks	4,000 ppb NO <sub>2</sub> continuously for 1, 4, 7, and 10 days	ATPase activity, sialic acid, and hexose in RBC membranes measured after 1, 4, 7, and 10 days of exposure.
<a href="#">†Li et al. (2011a)</a>	Rats (Wistar); n = 6/group; M; adults	2,660 or 5,320 ppb NO <sub>2</sub> , 6 h/day for 7 days	Haematoxylin and eosin staining of heart tissue; SOD activity, GPx activity, MDA level, and PCO level in heart tissue; ET-1, eNOS, TNF-α, IL-1, and ICAM-1 mRNA and protein levels in heart tissue; cardiac myocyte apoptosis. Endpoints examined 18 h post-exposure.
<a href="#">Mersch et al. (1973)</a>	Guinea pigs; n = 8; age and sex NR	360 ppb NO <sub>2</sub> continuously for 7 days	D-2,3-diphosphoglycerate content in RBCs; collection time NR.
<a href="#">Mochitate and Miura (1984)</a>	Rats (Wistar); n = 6; M; 16–20 weeks	4,000 ppb NO <sub>2</sub> continuously for 1, 3, 5, 7, and 10 days	PK and PFK activity and hemoglobin content in RBC measured after 1, 3, 5, 7, and 10 days of exposure.
<a href="#">Nakajima and Kusumoto (1968)</a>	Mice (ICR); n NR; M; 4 weeks	800 ppb NO <sub>2</sub> continuously for 5 days	Methemoglobin in blood from the heart taken immediately after exposure.
<a href="#">†Ramos-Bonilla et al. (2010)</a>	Mice (AKR/J); n = 3/group; M; 180 days	Low-pollution: 21.2 ppb NO <sub>2</sub> , 465 ppb CO, 11.5 µg/m <sup>3</sup> PM High-pollution: 36.1 ppb NO <sub>2</sub> , 744 ppb CO, 36.7 µg/m <sup>3</sup> PM 6 h/day, 5 days/week for 40 weekdays	HR, various heart rate variability parameters by electrocardiograph, body weight. Endpoints measured throughout exposure.

CO = carbon monoxide; eNOS = endothelial nitric oxide synthase; ET-1 = endothelin-1; GPx = glutathione peroxidase; GST = glutathione-S-transferase; HO-1 = heme-oxygenase-1; HR = heart rate; ICAM-1 = intercellular adhesion molecule 1; IL = interleukin; M = male; MDA = malondialdehyde; MMP = matrix metalloproteinase; mRNA = messenger RNA; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; PCO = protein carbonyl; PFK = phosphofructokinase; PK = pyruvate kinase; ppb = parts per billion; PM = particulate matter; RBC = red blood cell; Se = selenium; SOD = superoxide dismutase; TBARS = thiobarbituric acid reactive substances; TNF-α = tumor necrosis factor-alpha; TIMP-1 = tissue inhibitor of metalloproteinases-1.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

The effects of NO<sub>2</sub> on vascular tone modifiers, endothelin-1 (ET-1), and endothelial nitric oxide synthase (eNOS) were recently examined in two studies ([Li et al., 2011a](#); [Campen et al., 2010](#)). ET-1 is a potent vasoconstrictor while the enzyme eNOS catalyzes the production of NO, which induces vasodilation. [Campen et al. \(2010\)](#) did not see a statistically significant increase in ET-1 expression level in the aorta after exposure of mice to 200 or 2,000 ppb NO<sub>2</sub>. However, higher than ambient-relevant NO<sub>2</sub> exposures induced a statistically significant increase in ET-1 in the heart at the mRNA (10,640 ppb) and protein level (5,320 and 10,640 ppb) ([Li et al., 2011a](#)). eNOS mRNA and protein levels were increased at both 2,660 and 5,320 ppb NO<sub>2</sub> and decreased to control levels at 10,640 ppb NO<sub>2</sub>.

Studies also reported changes in some inflammatory markers and adhesion molecules after NO<sub>2</sub> exposure in animals, and some were observed with ambient-relevant exposures. ICAM-1 transcription and protein levels were increased in the heart after both 2,660 and 5,320 ppb NO<sub>2</sub> exposures. These results are consistent with the increase in ICAM-1 mRNA ([Channell et al., 2012](#)) found in vitro as described above. [Li et al. \(2011a\)](#) observed a statistically significant increase in TNF mRNA levels in the heart at 5,320 ppb NO<sub>2</sub>. In addition, IL-1 expression and protein levels were increased; however, this effect was in response to a higher NO<sub>2</sub> concentration.

The 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) reported on several animal studies examining hematological parameters. Three studies indicate elevated levels of a younger population of RBCs following NO<sub>2</sub> exposure. In RBCs, levels of D-2,3-diphosphoglycerate, important in hemoglobin-oxygen dissociation, were increased in guinea pigs following a 7-day continuous exposure to 360 ppb NO<sub>2</sub> ([Mersch et al., 1973](#)). [Kunimoto et al. \(1984\)](#) reported an increase in RBC sialic acid after 24 hours of exposure to 4,000 ppb NO<sub>2</sub>. Similarly, [Mochitate and Miura \(1984\)](#) reported an elevation of the glycolytic enzymes, pyruvate kinase and phosphofructokinase, after a 7-day continuous exposure to 4,000 ppb NO<sub>2</sub>. These results suggest an increase in RBC turnover after NO<sub>2</sub> exposure. [Nakajima and Kusumoto \(1968\)](#) reported that mice exposed to 800 ppb NO<sub>2</sub> continuously for 5 days had no change in the oxygen-carrying metalloproteins hemoglobin and methemoglobin.

### **Summary of Blood Biomarkers of Cardiovascular Effects**

In summary, the evidence across disciplines for changes in blood biomarkers of cardiovascular effects is inconsistent, and supportive evidence for NO<sub>2</sub>-induced systemic inflammation is limited. Some epidemiologic evidence suggests the presence of an association between NO<sub>2</sub> concentrations and some markers of systemic inflammation among participants with a history of heart disease. This association is not consistently

observed in healthy individuals. Other potentially at-risk populations are not clearly identified due to contrasting or limited evidence. An important limitation of the epidemiologic evidence is that potential confounding by traffic-related pollutants was not evaluated in these studies. Thus, the possibility remains that the observed associations are the artifact of correlated pollutants. Controlled human exposure studies evaluating systemic inflammation demonstrated inconsistent results with ambient-relevant NO<sub>2</sub> exposures. Toxicological studies reported an increase in some inflammatory mediators, as well as oxidative stress effects in RBC, the heart, and aorta of rodents. Short-term NO<sub>2</sub> exposure causes a slight reduction in hematocrit and hemoglobin levels associated with a decrease in RBC levels in controlled human exposure studies and an increase in RBC turnover in toxicological studies. The clinical significance of these hematological changes is unknown (Section 4.3.2.9). Evidence has not shown NO<sub>2</sub> to alter circulating blood coagulation factors or modify responses to vasodilators in controlled human exposure studies. However, in rats, higher than ambient-relevant NO<sub>2</sub> exposure was found to induce the expression and production of the vasoconstrictor ET-1.

Overall, there is preliminary evidence, albeit not entirely consistent, from controlled human exposure and toxicological studies that suggests systemic inflammation and oxidative stress can occur after exposure to NO<sub>2</sub>. However, changes in other blood biomarkers, such as coagulation or vasomotor response, are not observed in relation to NO<sub>2</sub> exposure.

---

### 5.3.11 Summary and Causal Determination

Available evidence is suggestive of, but not sufficient to infer, a causal relationship between short-term exposure to NO<sub>2</sub> and cardiovascular effects. The strongest evidence comes from epidemiologic studies of adults and consistently demonstrates associations between short-term increases in ambient NO<sub>2</sub> concentration and triggering of an MI. Such associations are indicated by NO<sub>2</sub>-associated hospital admissions and ED visits for MI, IHD, and angina; ST-segment alterations; and mortality from cardiovascular disease. There is a lack of experimental studies that evaluate similar clinical outcomes in order to assess the coherence across disciplines. However, some controlled human exposure and toxicological studies provide limited evidence for potential biologically plausible mechanisms, including inflammation and oxidative stress. Evidence for other cardiovascular effects is inconsistent.

This conclusion represents a change from the 2008 ISA for Oxides of Nitrogen, which concluded the “available evidence on the effects of short-term exposure to NO<sub>2</sub> on cardiovascular health effects was inadequate to infer the presence or absence of a causal

relationship at this time” ([U.S. EPA, 2008c](#)). Specifically, the epidemiologic panel studies and toxicological studies available at the time of the last review were inconsistent. Most epidemiologic studies reviewed in the 2008 ISA for Oxides of Nitrogen found positive associations between ambient NO<sub>2</sub> concentrations and risk of hospital admissions or ED visits for all cardiovascular diseases ([U.S. EPA, 2008c](#)). However, it was unclear at that time whether these results supported a direct effect of short-term NO<sub>2</sub> exposure on cardiovascular morbidity or were confounded by other correlated pollutants. Recent epidemiologic studies have further evaluated this uncertainty using copollutant models and comparing associations of NO<sub>2</sub> with those of other criteria pollutants. While some recent studies show independent associations of NO<sub>2</sub> with cardiovascular effects after adjusting for some pollutants, uncertainties still remain regarding the potential for NO<sub>2</sub> to serve as an indicator for other traffic-related pollutants or mixtures. Specifically, there are limited epidemiologic studies evaluating PM<sub>2.5</sub> or traffic-related pollutants (i.e., BC/EC, UFP, OC, VOCs) in copollutant models with NO<sub>2</sub>. In some studies, associations of NO<sub>2</sub> and cardiovascular effects were attenuated in with adjustment for PM<sub>2.5</sub> or UFP [[Supplemental Figure S5-2, \(U.S. EPA, 2015b\)](#)].

There continues to be a lack of experimental evidence that is coherent with the epidemiologic studies to strengthen the inference of causality for NO<sub>2</sub>-related cardiovascular effects, including MI. Further, the limited mechanistic evidence to describe a role for NO<sub>2</sub> in the triggering of cardiovascular diseases, including key events in the proposed mode of action, remains from the 2008 ISA for Oxides of Nitrogen. The evidence for cardiovascular effects, with respect to the causal determination for short-term exposure to NO<sub>2</sub>, is detailed below using the framework described in the [Preamble \(Tables I and II\)](#). The key evidence, supporting or contradicting, as it relates to the causal framework, is summarized in [Table 5-52](#).

---

#### **5.3.11.1 Evidence on Triggering a Myocardial Infarction**

The causal determination for the relationship between short-term NO<sub>2</sub> exposure and cardiovascular effects is based on the evidence for effects related to triggering an MI, including findings for hospital admissions and ED visits for IHD, MI, or angina and ST-segment amplitude changes. Time-series studies of adults in the general population consistently report positive associations between 24-h avg and 1-h max NO<sub>2</sub> concentrations and hospital admissions and ED visits for IHD and MI among adults ([Section 5.3.2.1](#) and [Figure 5-18](#)). Risk estimates ranged from 0.87 to 1.76 per a 20- or 30-ppb increase in NO<sub>2</sub>; most of the risk estimates were greater than 1.00. Symptoms of MI are similar to those of angina; however, where MI results in damage to the heart muscle, angina does not result in myocardial necrosis. However, angina may indicate an

increased risk for future MI. IHD is an over-arching category of related ischemic events that includes both acute MI and angina, as well as events related to older MI and other IHD-related events. Observations of increased hospital admissions and ED visits for MI and IHD are coherent with epidemiologic studies reporting increased hospital admissions and ED visits for angina ([Section 5.3.2.2](#)). Among those hospitalized, ST-segment decreases are considered a nonspecific marker of myocardial ischemia. A small number of epidemiologic panel studies reported associations between short-term exposure to NO<sub>2</sub> and ST-segment changes on the electrocardiogram of older adults with a history of coronary artery disease ([Section 5.3.2.3](#)).

Coherent with the increase in hospital admissions and ED visits for IHD, MI, and angina, single-city studies from the U.S. ([Ito et al., 2011](#); [Peel et al., 2007](#); [Tolbert et al., 2007](#)) and multicity studies conducted in Europe and Australia and New Zealand ([Larrieu et al., 2007](#); [Ballester et al., 2006](#); [Barnett et al., 2006](#); [von Klot et al., 2005](#)) report positive associations with all CVD hospital admissions in adults with adjustment for numerous potential confounding factors, including weather and time trends ([Section 5.3.8](#)). In turn, this evidence is coherent with positive associations reported in epidemiologic studies of short-term increases in ambient NO<sub>2</sub> concentration and cardiovascular mortality in adults ([Section 5.3.9](#)). These include studies reviewed in the 2008 ISA for Oxides of Nitrogen and recent multicity studies that generally report a similar or slightly larger magnitude for the NO<sub>2</sub> cardiovascular mortality relationship compared to total mortality.

Recent controlled human exposure and animal toxicological studies provide preliminary evidence for a potentially biologically plausible mechanism for short-term exposure to NO<sub>2</sub> leading to cardiovascular disease, including IHD. Reactive intermediates or inflammatory mediators that have migrated from the respiratory tract into the circulation could result in systemic inflammation and/or oxidative stress, which could mediate effects in the heart and vasculature ([Sections 4.3.2.9](#) and [4.3.5](#)). These nonspecific effects could promote the triggering of an MI. There is limited and not entirely consistent evidence in humans and animals for increased systemic and tissue specific oxidative stress ([Channell et al., 2012](#); [Li et al., 2011a](#)). In addition, evidence in animal and cell models and in some controlled human exposure studies report NO<sub>2</sub>-mediated increases in inflammatory markers ([Channell et al., 2012](#); [Huang et al., 2012b](#); [Li et al., 2011a](#)).

A key uncertainty that remains since the 2008 ISA for Oxides of Nitrogen is the potential for confounding by other correlated traffic-related pollutants given a common source and moderate to high correlations with NO<sub>2</sub>. Recent studies evaluated this uncertainty using copollutant models and comparing associations of NO<sub>2</sub> with those of other pollutants. NO<sub>2</sub> associations with cardiovascular disease outcomes persisted in some but not all copollutant models with CO [[Supplemental Figure S5-3, \(U.S. EPA, 2015c\)](#)]. Further, not

all analyses reported NO<sub>2</sub> as the strongest predictor of cardiovascular effects. Two studies reported that associations with cardiovascular hospital admissions were not robust in models adjusting for ambient CO concentrations ([Tolbert et al., 2007](#); [Barnett et al., 2006](#)). [Tolbert et al. \(2007\)](#) also reported associations with CO, EC, and OC that were stronger or similar in magnitude to those for NO<sub>2</sub>. Confounding of NO<sub>2</sub>-cardiovascular effect associations by PM<sub>2.5</sub> or UFP was examined to a limited extent, and EC/BC and VOCs were generally not examined as confounders, resulting in the potential for unmeasured confounding. A larger number of studies examined copollutant models with PM<sub>10</sub> or TSP [[Supplemental Figure S5-2, \(U.S. EPA, 2015b\)](#)], O<sub>3</sub> [[Supplemental Figure S5-4; \(U.S. EPA, 2015d\)](#)], or SO<sub>2</sub> [[Supplemental Figure S5-5; \(U.S. EPA, 2015e\)](#)] and reported robust NO<sub>2</sub> associations with various cardiovascular disease outcomes and cardiovascular mortality ([Chen et al., 2012b](#); [Chiusolo et al., 2011](#)). While copollutant models are a common statistical tool used to evaluate the potential for confounding, inferences from their results can be limited ([Section 5.1.2.2](#)) due to high correlations among pollutants. Further, copollutant models with cardiovascular effects were based on pollutants measured at central site monitors, which could result in differential exposure measurement error. Residual confounding due to unmeasured copollutants ([Section 5.1.2.2](#)) also is possible because reliable methods to adjust for multiple copollutants simultaneously are not available. Without consistent and reproducible experimental evidence that is coherent with the effects observed in epidemiologic studies, uncertainty still exists concerning the role of correlated pollutants in the associations observed with NO<sub>2</sub>. The limited or inconsistent results from copollutant models evaluating confounding by yCO, PM<sub>2.5</sub>, BC/EC, UFP, or VOCs raises the concern that NO<sub>2</sub> associations could be a result of NO<sub>2</sub> serving as a marker for effects of other traffic-related pollutants or mixtures of pollutants.

---

### 5.3.11.2 Evidence on Other Cardiovascular Effects

There is inconclusive evidence from epidemiologic, controlled human exposure, and animal toxicological studies for other cardiovascular effects from short-term exposure to NO<sub>2</sub>. Epidemiologic studies provide inconsistent evidence for an association between 24-h avg NO<sub>2</sub> and risk of cardiac arrhythmias as examined in patients with ICDs, continuous ECG recordings, out-of-hospital cardiac arrest, and hospital admissions ([Section 5.3.3](#)). Similarly, epidemiologic studies provide inconsistent evidence for a potential association between ambient NO<sub>2</sub> concentrations and risk of hospital admission for cerebrovascular disease and stroke ([Section 5.3.4](#)). Both epidemiologic and controlled human exposure studies provide little to no evidence to indicate that short-term exposure to ambient NO<sub>2</sub> is associated with increased BP or hypertension ([Section 5.3.6](#)). Other

outcomes have an insufficient quantity of studies to evaluate the effects. A small number of epidemiologic studies have found associations between NO<sub>2</sub> concentrations and hospital admissions or ED visits for heart failure (Section 5.3.5) and hospital admission for venous thrombosis and pulmonary embolism (Section 5.3.7).

Various subclinical effects have been investigated that are not clearly associated with a particular clinical cardiovascular event but may be key events in a proposed mode of action for cardiovascular effects other than MI. There is limited evidence from epidemiologic and controlled human exposure studies to suggest that NO<sub>2</sub> exposure results in alterations of cardiac autonomic control. Recent epidemiologic studies generally reported associations between ambient NO<sub>2</sub> concentrations and decreases in indices of HRV (Section 5.3.10.1) and changes in ventricular repolarization (Section 5.3.10.2) among populations with pre-existing or at elevated risk for cardiovascular disease. Experimental studies also evaluated changes in HRV and ventricular repolarization parameters. Although changes were not observed across all endpoints, a recent controlled human exposure study reported decreased HF<sub>n</sub> in healthy exercising adults exposed to NO<sub>2</sub>, indicating a potential disruption in the normal cardiac autonomic control (Huang et al., 2012b). However, similar measures of autonomic control in another controlled human exposure study showed statistically nonsignificant increases after exposure to NO<sub>2</sub> (Scaife et al., 2012).

---

### 5.3.11.3 Conclusion

In conclusion, consistent epidemiologic evidence from multiple studies at relevant NO<sub>2</sub> concentrations is suggestive of, but not sufficient to infer, a causal relationship between short-term NO<sub>2</sub> exposure and cardiovascular health effects. The strongest evidence supporting this determination comprises outcomes related to triggering of an MI. However, uncertainty remains regarding exposure measurement error and potential confounding by traffic-related copollutants. Experimental studies provide some evidence that could propose a potential mode of action but do not provide evidence that is coherent with the epidemiologic studies to help rule out chance, confounding, and other biases. Evidence for other cardiovascular effects is inconclusive, including effects on cardiac arrest and arrhythmia, cerebrovascular disease and stroke, increased blood pressure and hypertension, and decompensation of heart failure. Studies of adults consistently demonstrate NO<sub>2</sub>-associated hospital admissions and ED visits for IHD, MI, and angina, as well as all cardiovascular diseases. This is coherent with evidence for NO<sub>2</sub>-related ST segment decrements and mortality from cardiovascular disease. These results have been replicated by different researchers in different locations and have adjusted for numerous potential confounding factors including meteorological factors and time trends. However,

due to limited analysis of potentially correlated pollutants and recognized limitations of copollutant models, uncertainty remains regarding the extent to which NO<sub>2</sub> is independently associated with cardiovascular effects or if NO<sub>2</sub> serves primarily as a marker for the effects of another traffic-related pollutant or mix of pollutants. Thus, the combined evidence from epidemiologic and experimental studies is suggestive of, but not sufficient to infer, a causal relationship between short-term NO<sub>2</sub> exposure and cardiovascular effects.

**Table 5-52 Summary of evidence, which is suggestive of, but not sufficient to infer, a causal relationship between short-term nitrogen dioxide exposure and cardiovascular effects.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
<b>Triggering a myocardial infarction</b>			
Consistent epidemiologic evidence from multiple, high-quality studies at relevant NO <sub>2</sub> concentrations	Increases in hospital admissions and ED visits for IHD and MI in adults in multiple studies, including multicity studies, in diverse locations.	† <a href="#">Larrieu et al. (2007)</a> ; † <a href="#">Stieb et al. (2009)</a> ; <a href="#">Peel et al. (2007)</a> ; <a href="#">von Klot et al. (2005)</a> ; <a href="#">Mann et al. (2002)</a>	Mean 24-h avg: 11.9–37.2 ppb Mean 1-h max: 45.9 ppb
		<a href="#">Figure 5-13</a> ; <a href="#">Section 5.3.2.1</a>	
	Coherence with limited evidence for increased hospital admissions and ED visits for angina in adults in multiple studies, including multicity studies.	† <a href="#">Szyszkowicz (2009)</a> ; <a href="#">Poloniecki et al. (1997)</a> ; <a href="#">von Klot et al. (2005)</a> <a href="#">Section 5.3.2.2</a>	Mean 24-h avg: 12.1–37.2 ppb
	Increases in hospital admissions and ED visits for all CVD in adults in multiple studies, including multicity studies, in diverse locations.	† <a href="#">Larrieu et al. (2007)</a> ; † <a href="#">Ito et al. (2011)</a> ; <a href="#">Peel et al. (2007)</a> ; <a href="#">Tolbert et al. (2007)</a> ; <a href="#">von Klot et al. (2005)</a> ; <a href="#">Ballester et al. (2006)</a> ; <a href="#">Barnett et al. (2006)</a> <a href="#">Section 5.3.8</a>	Mean 24-h avg: 11.9–40.5 ppb Mean 1-h max: 43.2–45.9 ppb
	Coherence with ST-segment depression in adults with pre-existing coronary heart disease in association with 24-h avg and 1-h avg NO <sub>2</sub> .	† <a href="#">Chuang et al. (2008)</a> ; † <a href="#">Delfino et al. (2011)</a> <a href="#">Section 5.3.2.3</a>	Mean 24-h avg: 21.4 ppb; Mean 1-h max: 27.5 ppb
Consistent evidence for increased risk of cardiovascular mortality in adults applying differing model specifications in diverse locations.	† <a href="#">Bellini et al. (2007)</a> ; † <a href="#">Wong et al. (2008)</a> ; † <a href="#">Chen et al. (2012b)</a> ; † <a href="#">Chiusolo et al. (2011)</a> <a href="#">Section 5.3.9</a>	Mean 24-h avg: 13.5–35.4 ppb	

**Table 5-52 (Continued): Summary of evidence, which is suggestive of, but not sufficient to infer, a causal relationship between short-term nitrogen dioxide exposure and cardiovascular effects.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
Uncertainty regarding exposure measurement error	Majority of evidence from time-series studies that rely on central site exposure estimates.		
Uncertainty regarding potential confounding by traffic-related copollutants	<p>Inability to disentangle the effects of traffic-related pollutants because of lack of examination of BC/EC and VOCs, and inconsistent NO<sub>2</sub> associations with adjustment for PM<sub>2.5</sub>, UFP, or CO.</p> <hr/> <p>NO<sub>2</sub> associations with ED visits, hospital admissions, and mortality found with adjustment for other potential confounding factors including meteorological factors and time trends as well as PM<sub>10</sub>, O<sub>3</sub>, or SO<sub>2</sub>.</p>	<p><a href="#">Supplemental Figures S5-2, S5-3, S5-4, and S5-5 (U.S. EPA, 2015b, c, d, e)</a></p>	
<p>Limited evidence for key events in the proposed mode of action</p> <p>Oxidative stress</p>	<p>Limited and supportive evidence of increased oxidative stress in heart tissue in rats with relevant NO<sub>2</sub> exposures (i.e., MDA) and plasma from NO<sub>2</sub>-exposed humans (i.e., LOX-1).</p>	<p><a href="#">†Li et al. (2011a) Section 4.3.2.9, Figure 4-3</a></p>	<p>Rats: 5,320 ppb but not 2,660 ppb NO<sub>2</sub></p>
Inflammation	<p>Limited and supportive toxicological evidence of increased transcription of some inflammatory mediators in vitro (i.e., IL-8, ICAM-1, VCAM-1) and in rats (i.e., ICAM-1, TNF-α).</p>	<p><a href="#">†Channell et al. (2012)</a></p>	<p>Human cells exposed to plasma from healthy adults: 500 ppb NO<sub>2</sub></p>
		<p><a href="#">†Li et al. (2011a)</a></p>	<p>Rats: 2,660 and 5,320 ppb NO<sub>2</sub></p>
	<p>Limited and inconsistent evidence in controlled human exposure studies (i.e., IL-6, IL-8, ICAM-1).</p>	<p><a href="#">†Huang et al. (2012b);</a> <a href="#">†Riedl et al. (2012)</a></p>	<p>Adults: 350, 500 ppb NO<sub>2</sub></p>
	<p>Inconsistent epidemiologic evidence for changes in CRP, IL-6, and TNF-RII.</p>	<p><a href="#">Section 5.3.10.4</a></p>	

**Table 5-52 (Continued): Summary of evidence, which is suggestive of, but not sufficient to infer, a causal relationship between short-term nitrogen dioxide exposure and cardiovascular effects.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
<b>Other cardiovascular effects</b>			
Inconclusive evidence from epidemiologic, controlled human exposure and toxicological studies	Inconsistent epidemiologic evidence for an association between NO <sub>2</sub> and risk of cardiac arrest and arrhythmias, cerebrovascular disease and stroke, and increased blood pressure and hypertension.	<a href="#">Sections 5.3.3, 5.3.4, and 5.3.6</a>	
	Insufficient quantity of studies evaluating decompensation of heart failure and venous thrombosis and pulmonary embolism.	† <a href="#">Stieb et al. (2009)</a> ; † <a href="#">Yang (2008)</a> <a href="#">Section 5.3.5</a> † <a href="#">Dales et al. (2010)</a> <a href="#">Section 5.3.7</a>	
	Inconsistent changes in HRV in controlled human exposure studies.	† <a href="#">Huang et al. (2012b)</a>	Healthy adults: 500 ppb NO <sub>2</sub>
		† <a href="#">Scaife et al. (2012)</a> <a href="#">Section 5.3.10.1</a>	Adults with pre-existing CVD: 400 ppb NO <sub>2</sub>
	Limited epidemiologic evidence for changes in HRV and ventricular repolarization.  Stronger associations observed in groups of individuals with pre-existing cardiovascular disease.	HRV: <a href="#">Timonen et al. (2006)</a> ; † <a href="#">Suh and Zanobetti (2010a)</a> ; † <a href="#">Zanobetti et al. (2010)</a> <a href="#">Section 5.3.10.1</a>  QT interval: <a href="#">Henneberger et al. (2005)</a> <a href="#">Section 5.3.10.2</a>	

avg = average; BC= black carbon; CO = carbon monoxide; CRP = C-reactive protein; CVD = cardiovascular disease; EC = elemental carbon; ED = emergency department; h = hour; HRV = heart rate variability; ICAM-1 = intercellular adhesion molecule 1; IHD = ischemic heart disease; IL = interleukin; LOX-1 = receptor for oxidized low-density lipoprotein; max = maximum; MDA = malondialdehyde; MI = myocardial infarction; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; O<sub>3</sub> = ozone; PM<sub>2.5</sub> = particulate matter with a nominal aerodynamic diameter less than or equal to 2.5 µm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm; ppb = parts per billion; SO<sub>2</sub> = sulfur dioxide; TNF-RII = tumor necrosis factor receptor-II; UFP = ultrafine particles; VCAM-1 = vascular adhesion molecule-1; VOC = volatile organic compound.

<sup>a</sup>Based on aspects considered in judgments of causality and weight of evidence in causal framework in [Tables I](#) and [II](#) of the [Preamble](#).

<sup>b</sup>Describes the key evidence and references, supporting or contradicting, that contribute most heavily to causal determination and, where applicable, to uncertainties or inconsistencies. References to earlier sections indicate where full body of evidence is described.

<sup>c</sup>Describes the NO<sub>2</sub> concentrations with which the evidence is substantiated.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

---

## 5.4 Total Mortality

---

### 5.4.1 Introduction and Summary of the 2008 Integrated Science Assessment for Oxides of Nitrogen

Prior to the 2008 ISA for Oxides of Nitrogen, epidemiologic studies had not been identified that examined whether an association exists between short-term NO<sub>2</sub> exposure and mortality. The 2008 ISA for Oxides of Nitrogen evaluated a collection of studies, including multicity studies, conducted in the U.S., Canada, and Europe, and a meta-analysis ([U.S. EPA, 2008c](#)). All of these studies reported evidence of an association between short-term NO<sub>2</sub> exposure and mortality with estimates ranging from 0.5 to 3.6% for a 20-ppb increase in 24-h avg or 30-ppb increase in 1-h max NO<sub>2</sub> concentrations. A limitation of this collection of studies was that the majority focused specifically on PM and did not conduct extensive analyses to examine the relationship between short-term NO<sub>2</sub> exposure and mortality.

Multicity studies conducted in the U.S. ([HEI, 2003](#)), Canada ([Brook et al., 2007](#); [Burnett et al., 2004](#)), and Europe ([Samoli et al., 2006](#)), as well as a large study conducted in the Netherlands ([Hoek, 2003](#)), consistently reported positive associations between short-term NO<sub>2</sub> exposure and mortality, specifically at lag 1. Associations were robust in copollutant models with PM<sub>10</sub>, SO<sub>2</sub>, or O<sub>3</sub>. These results were confirmed in a meta-analysis that did not include any of the aforementioned multicity studies ([Stieb et al., 2002](#)).

Of the studies evaluated in the 2008 ISA for Oxides of Nitrogen, a limited number provided additional information (i.e., seasonal analyses, examination of cause-specific mortality, examination of effect modifiers) on the NO<sub>2</sub>-mortality relationship. Initial evidence indicated a larger NO<sub>2</sub>-mortality association during the warmer months ([Brook et al., 2007](#); [Burnett et al., 2004](#); [HEI, 2003](#)). Additionally, an examination of total and cause-specific mortality found associations similar in magnitude across mortality outcomes (total, respiratory, and cardiovascular); however, some studies reported stronger NO<sub>2</sub> associations for respiratory mortality ([Biggeri et al., 2005](#); [Simpson et al., 2005b](#)). Potential effect modifiers of the NO<sub>2</sub>-mortality relationship were examined only within the APHEA study, which found that within the European cities, geographic area and smoking prevalence modified the NO<sub>2</sub>-mortality relationship. It is worth noting that additional multicity European studies that focused on PM ([Aga et al., 2003](#); [Katsouyanni et al., 2003](#)) reported that cities with higher NO<sub>2</sub> concentrations also had higher PM risk estimates indicating that NO<sub>2</sub> and PM may be potential effect modifiers of each other.

In summary, the multicity studies evaluated in the 2008 ISA for Oxides of Nitrogen consistently observed positive associations between short-term NO<sub>2</sub> exposure and mortality. These studies indicated that associations were found to occur within the first few days after exposure and are potentially influenced by season. However, uncertainties remained in the NO<sub>2</sub>-mortality relationship, which led to the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) concluding that the evidence “was suggestive but not sufficient to infer a causal relationship.” These uncertainties and data gaps included whether: NO<sub>2</sub> is acting primarily as an indicator for another pollutant or a mix of pollutants; there is evidence for potential copollutant confounding; specific factors modify the NO<sub>2</sub>-mortality relationship; there is seasonal heterogeneity in mortality associations; NO<sub>2</sub> associations are stronger with specific mortality outcomes; and the shape of the NO<sub>2</sub>-mortality concentration-response relationship is linear.

---

#### 5.4.2 Associations between Short-Term Nitrogen Dioxide Exposure and Mortality

Since the completion of the 2008 ISA for Oxides of Nitrogen, the body of epidemiologic literature that has examined the association between short-term NO<sub>2</sub> exposure and mortality has grown. However, similar to the collection of studies evaluated in the 2008 ISA for Oxides of Nitrogen, most of the recent studies did not focus specifically on the NO<sub>2</sub>-mortality relationship but on other pollutants. Of the studies identified, a limited number have been conducted in the U.S., Canada, and Europe, with the majority being conducted in Asia due to the increased focus on examining the effect of air pollution on health in developing countries. Although these studies are informative in evaluation of the relationship between oxides of nitrogen and mortality, the broad implications of these studies in the context of results from studies conducted in the U.S., Canada, and Western Europe are limited. This is because studies conducted in Asia encompass cities with meteorological ([Tsai et al., 2010](#); [Wong et al., 2008](#)), outdoor air pollution (e.g., concentrations, mixtures, and transport of pollutants), and sociodemographic (e.g., disease patterns, age structure, and socioeconomic variables) ([Kan et al., 2010](#)) characteristics that differ from cities in North America and Western Europe, potentially limiting the generalizability of results from these studies to other cities.

Overall, this section evaluates studies that examined the association between short-term NO<sub>2</sub> exposure and mortality and addresses the key uncertainties and data gaps in the NO<sub>2</sub>-mortality relationship identified in the 2008 ISA for Oxides of Nitrogen: potential confounding of NO<sub>2</sub> associations, effect measure modification (i.e., sources of heterogeneity in risk estimates across cities), seasonal heterogeneity in NO<sub>2</sub> associations, and the NO<sub>2</sub>-mortality C-R relationship. Other recent studies of mortality are not the

focus of this evaluation because they were conducted in small single-cities, encompass a short study duration, had insufficient sample size, and/or did not examine potential copollutant confounding. The full list of the studies can be found in [Supplemental Table S5-4 \(U.S. EPA, 2015i\)](#).

---

### **5.4.3 Associations between Short-term Nitrogen Dioxide Exposure and Mortality in All-Year Analyses**

Multicity studies evaluated in the 2008 ISA for Oxides of Nitrogen reported consistent, positive associations between short-term NO<sub>2</sub> exposure and mortality in all-year analyses ([U.S. EPA, 2008c](#)). However, when focusing on specific causes of mortality, some studies reported similar risk estimates across total (nonaccidental), cardiovascular, and respiratory mortality ([Samoli et al., 2006](#); [Burnett et al., 2004](#)), while others indicated larger respiratory mortality risk estimates compared to both total and cardiovascular mortality ([Atkinson et al., 2012](#); [Biggeri et al., 2005](#); [Simpson et al., 2005b](#)). Additional multicity studies focusing on COPD ([Meng et al., 2013](#)) and stroke ([Chen et al., 2013b](#)) mortality further support potential differences in the NO<sub>2</sub>-mortality association by mortality outcome. Although only a small number of multicity studies have been conducted since the completion of the 2008 ISA for Oxides of Nitrogen, these studies build upon and provide additional evidence for an association between short-term NO<sub>2</sub> exposure and total mortality along with potential differences by mortality outcome. Air quality characteristics and study specific details for the studies evaluated in this section are provided in [Table 5-53](#).

**Table 5-53 Air quality characteristics of studies evaluated in the 2008 Integrated Science Assessment for Oxides of Nitrogen and recently published multicity and select single-city studies.**

Study	Location (Years)	Mortality Outcome(s)	Exposure Assignment	Averaging Time	Mean Concentration ppb	Upper Percentile Concentrations ppb
<a href="#">Biggeri et al. (2005)</a>	8 Italian cities (1990–1999)	Total, cardiovascular, respiratory	Average of NO <sub>2</sub> concentrations across all monitors in each city (1–6 monitors). Monitors influenced by local traffic excluded.	24-h avg	30.1–55.0	95th: 45.8–94.0 Max: 62.6–160.7
<a href="#">Brook et al. (2007)</a>	10 Canadian cities (1984–2000)	Total	Average of NO <sub>2</sub> concentrations across all monitors in each city.	24-h avg	NR	NR
<a href="#">Burnett et al. (2004)</a>	12 Canadian cities (1981–1999)	Total, cardiovascular, respiratory	Average of NO <sub>2</sub> concentrations across all monitors in each city.	24-h avg	10.0–26.4	NR
<a href="#">HEI (2003)</a>	58 U.S. cities <sup>a</sup> (1987–1994)	Total	Average of NO <sub>2</sub> concentrations across all monitors in each city.	24-h avg	9.2–39.4	NR
<a href="#">Hoek (2003)</a>	the Netherlands (1986–1994)	Total	15 NO <sub>2</sub> monitors across the study area, mean concentration calculated in each region then weighted by population density in each region.	24-h avg	NR	NR
<a href="#">Samoli et al. (2006)</a>	30 European cities (1990–1997)	Total, cardiovascular, respiratory	Average of NO <sub>2</sub> concentrations across all monitors in each city.	1-h max <sup>b</sup>	24.0–80.5	90th: 33.1–132.5
<a href="#">Simpson et al. (2005b)</a>	4 Australian cities (1996–1999)	Total, cardiovascular, respiratory	Average of NO <sub>2</sub> concentrations across all monitors in each city.	1-h max	16.3–23.7	Max: 96.0–111.5
<a href="#">Stieb et al. (2003)</a>	Meta-analysis, worldwide (years NR)	Total	NA	NR	NR	NR

**Table 5-53 (Continued): Air quality characteristics of studies evaluated in the 2008 Integrated Science Assessment for Oxides of Nitrogen and recently published multicity and select single-city studies.**

Study	Location (Years)	Mortality Outcome(s)	Exposure Assignment	Averaging Time	Mean Concentration ppb	Upper Percentile Concentrations ppb
<a href="#">†Atkinson et al. (2012)</a>	Meta-analysis, Asia (years NR)	Total, cardiovascular, respiratory	NA	NR	NR	NR
<a href="#">†Bellini et al. (2007)</a>	15 Italian cities (1996–2002)	Total, cardiovascular, respiratory	NR	24-h avg	NR	NR
<a href="#">†Berglind et al. (2009)</a>	5 European cities (1992–2002)	Total	Average of NO <sub>2</sub> concentrations across all monitors in each city.	24-h avg	11.0–35.4	NR
<a href="#">†Chen et al. (2012b)</a>	17 Chinese cities (1996–2010 <sup>c</sup> )	Total, cardiovascular, respiratory	Average of NO <sub>2</sub> concentrations across all monitors in each city (2–13 monitors). <sup>e</sup>	24-h avg	13.5–34.8	Max: 55.1–132.1
<a href="#">†Chen et al. (2013b)</a>	8 Chinese cities (1996–2008 <sup>d</sup> )	Stroke	Average of NO <sub>2</sub> concentrations across all monitors in each city (2–12 monitors). <sup>e</sup>	24-h avg	19.7–35.6	NR
<a href="#">†Chiusolo et al. (2011)</a>	10 Italian cities <sup>e</sup> (2001–2005)	Total, cardiovascular, cerebrovascular, respiratory	If more than 1 monitor, average of NO <sub>2</sub> concentrations across all monitors in each city (1–5 monitors).	24-h avg	13.8–35.0	90th: 21.7–48.8
<a href="#">†Kan et al. (2010); Kan et al. (2008)</a>	Shanghai, China (2001–2004)	Total, cardiovascular, respiratory	Average of NO <sub>2</sub> concentrations across 6 monitors.	24-h avg	35.4	75th: 42.1 Max: 134.9
<a href="#">†Faustini et al. (2013)</a>	6 Italian cities (2001–2005)	Respiratory (out-of-hospital)	Average of NO <sub>2</sub> concentrations over all monitors within each city (1–5 monitors). <sup>f</sup>	24-h avg	24.5–35.1	NR
<a href="#">†Ito et al. (2011)</a>	New York, NY (2000–2006)	Cardiovascular	Average of NO <sub>2</sub> concentrations across all monitors.	24-h avg	28.7	NR
<a href="#">†Sacks et al. (2012)</a>	Philadelphia, PA (1992–1995)	Cardiovascular	Central site monitor.	1-h max	47.4	Max: 146.7

**Table 5-53 (Continued): Air quality characteristics of studies evaluated in the 2008 Integrated Science Assessment for Oxides of Nitrogen and recently published multicity and select single-city studies.**

Study	Location (Years)	Mortality Outcome(s)	Exposure Assignment	Averaging Time	Mean Concentration ppb	Upper Percentile Concentrations ppb
<a href="#">†Meng et al. (2013)</a>	4 Chinese cities (1996–2008 <sup>c</sup> )	COPD	Average of NO <sub>2</sub> concentrations across all monitors in each city (7–8 monitors). <sup>d</sup>	24-h avg	30.6–35.4	NR
<a href="#">†Moolgavkar et al. (2013)</a>	72 U.S. cities <sup>e</sup> (1987–2000)	Total	Average of NO <sub>2</sub> concentrations across all monitors in each city.	24-h avg	NR	NR
<a href="#">†Shin et al. (2012)</a>	24 Canadian cities (1984–2004)	Cardiopulmonary	If more than 1 monitor, average of NO <sub>2</sub> concentrations across all monitors in each city (1–8 monitors).	24-h avg	8.7–25.0	NR
<a href="#">†Stieb et al. (2008)</a>	12 Canadian cities (1981–2000)	Total	If more than 1 monitor, average of NO <sub>2</sub> concentrations across all monitors in each city.	3-h max	1981–1990: 24.7–42.6 1991–2000: 16.3–39.2	NR
<a href="#">†Wong et al. (2010); Wong et al. (2008)</a>	4 Asian cities (1996–2004 <sup>h</sup> )	Total cardiovascular respiratory	Average of NO <sub>2</sub> concentrations across all monitors in each city (6–10 monitors).	24-h avg	23.2–34.6	75th: 28.5–41.2 Max: 72.6–131.9

avg = average; COPD = chronic obstructive pulmonary disease; h = hour; max = maximum; NA = not available; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; NY = New York; PA = Pennsylvania; ppb = parts per billion; U.S. = United States.

<sup>a</sup>Of the 90 cities included in the NMMAPS analysis only 58 had NO<sub>2</sub> data.

<sup>b</sup>[Samoli et al. \(2006\)](#) estimated 1-h max concentrations for each city by multiplying 24-h avg concentrations by 1.64.

<sup>c</sup>Study period varied for each city and encompassed 2 to 7 yr. Hong Kong, China was the only city that had air quality data prior to 2000.

<sup>d</sup>These monitors were “mandated to not be in the direct vicinity of traffic or of industrial sources, and not be influenced by local pollution sources, and to avoid buildings, or those housing large emitters, such as coal-, waste-, or oil-burning boilers, furnaces, and incinerators” ([Chen et al., 2013b](#); [Meng et al., 2013](#); [Chen et al., 2012b](#)).

<sup>e</sup>Only 9 cities (Cagliari was excluded) were included in the formal analysis of examining potential factors that could increase the risk of mortality due to short-term NO<sub>2</sub> exposure.


<sup>f</sup>Information on the monitors used in this study were obtained from [Colais et al. \(2012\)](#).

<sup>g</sup>Of the 108 cities included in the analyses using NMMAPS data only 72 had NO<sub>2</sub> data.

<sup>h</sup>The study period varied for each city, Bangkok: 1999–2003, Hong Kong: 1996–2002, and Shanghai and Wuhan: 2001–2004.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

As demonstrated in [Figure 5-22](#) and [Table 5-54](#), multicity studies evaluated in the 2008 ISA for Oxides of Nitrogen and those recently published, consistently provide evidence of positive associations between short-term NO<sub>2</sub> exposure and total (nonaccidental) mortality. In these multicity studies, the associations observed were in analyses that primarily examined all ages, the exceptions being [Chiusolo et al. \(2011\)](#) and [Berglind et al. \(2009\)](#), who both focused on the risk of mortality attributed to air pollution in the population ≥35 years of age. Across these studies, associations between short-term NO<sub>2</sub> exposure and mortality were examined primarily in the total population; however, [Berglind et al. \(2009\)](#) focused on a subset of the population (i.e., MI survivors). The large effect estimate for [Berglind et al. \(2009\)](#) could be attributed to the larger mortality rate for MI survivors: 30-day mortality rate of 14–15% and 1-year mortality rate of 22–24%, compared to populations examined in the other multicity studies ([Berglind et al., 2009](#)).



Note: CI = confidence interval; Black = studies from the 2008 Integrated Science Assessment for Oxides of Nitrogen; Red = recent studies. Results are presented per a 20-ppb increase in 24-h avg nitrogen dioxide concentrations or a 30-ppb increase in 1-h max nitrogen dioxide concentrations.

**Figure 5-22 Summary of multicity studies that examined the association between short-term nitrogen dioxide exposure and total mortality.**

**Table 5-54 Corresponding percentage increase in total mortality for Figure 5-22.**


Study	Location	Age	Lag	Averaging Time	% Increase (95% CI) <sup>a</sup>
<a href="#">Dominici et al. (2003)</a>	58 U.S. cities	All	1	24-h avg	0.5 (0.09, 0.90)
<a href="#">Stieb et al. (2003)</a>	Meta-analysis (worldwide)	All	---	24-h avg	0.8 (0.20, 1.5)
<a href="#">Samoli et al. (2006)</a>	30 European cities	All	0–1	1-h max	1.8 (1.3, 2.2)
<a href="#">Burnett et al. (2004)</a>	12 Canadian cities	All	0–2	24-h avg	2.0 (1.1, 2.9)
<a href="#">Hoek (2003)</a>	the Netherlands	All	0–6	24-h avg	2.6 (1.2, 4.0)
<a href="#">Simpson et al. (2005b)</a>	4 Australian cities	All	0–1	1-h max	3.4 (1.1, 5.7)
<a href="#">Brook et al. (2007)</a>	10 Canadian cities	All	1	24-h avg	3.5 (1.4, 5.5)
<a href="#">Biggeri et al. (2005)</a>	8 Italian cities	All	0–1	1-h max	3.6 (2.3, 5.0)
† <a href="#">Stieb et al. (2008)</a>	12 Canadian cities	All	1	3-h max	1.9 (0.80, 2.9)
† <a href="#">Moolgavkar et al. (2013)</a>	72 U.S. cities	All	1	24-h avg	2.1 (1.8, 2.3)
† <a href="#">Bellini et al. (2007)</a>	15 Italian cities	All	0–1	24-h avg	2.2 (1.0, 3.6)
† <a href="#">Atkinson et al. (2012)</a>	Meta-analysis (Asia)	All	---	24-h avg	3.7 (2.1, 5.4)
† <a href="#">Wong et al. (2008)</a>	4 Asian cities	All	0–1	24-h avg	4.7 (3.2, 6.2)
† <a href="#">Chen et al. (2012b)</a>	17 Chinese cities	All	0–1	24-h avg	6.3 (4.2, 8.4)
† <a href="#">Chiusolo et al. (2011)</a>	10 Italian cities	≥35	0–5	24-h avg	8.1 (3.7, 12.7)
† <a href="#">Berglind et al. (2009)</a>	5 European cities	≥35	0–1	24-h avg	11.6 (–5.9, 32.4)

avg = average; CI = confidence interval; U.S. = United States.

<sup>a</sup>Results are presented for a 20-ppb increase in 24-h avg nitrogen dioxide concentrations or a 30-ppb increase in 1-h max nitrogen dioxide concentrations.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

When focusing on cause-specific mortality, recent multicity studies reported similar patterns of associations to those evaluated in the 2008 ISA for Oxides of Nitrogen with some evidence of larger respiratory mortality risk estimates ([Figure 5-23](#) and [Table 5-55](#)). However, in a study of 15 Italian cities, [Bellini et al. \(2007\)](#) observed smaller cardiovascular and respiratory mortality risk estimates compared to total mortality, which contradicts the results of [Biggeri et al. \(2005\)](#) of which [Bellini et al. \(2007\)](#) is an extension. Additionally, the total mortality results of [Bellini et al. \(2007\)](#) are smaller in magnitude than those observed in [Biggeri et al. \(2005\)](#).



Note: APHEA2 = Air Pollution and Health: A European Approach 2; CAPES =China Air Pollution and Health Effects Study; C = confidence interval; MISA = meta-analysis of the Italian studies on short-term effects of air pollution; NR = not reported; PAPA = Public Health and Air Pollution in Asia; ppb = parts per billion. Black = studies from the 2008 Integrated Science Assessment for Oxides of Nitrogen, red symbols = recent studies. Filled circles = total mortality, crosshatch = cardiovascular mortality, dots = respiratory mortality.

<sup>a</sup> Although the study was not part of the CAPES study, it included four of the cities also included in CAPES;

<sup>b</sup>Study examined individuals  $\geq 35$  years of age while the other studies examined all ages. Results are presented per a 20-ppb increase in 24-h avg nitrogen dioxide concentrations or a 30-ppb increase in 1-h max nitrogen dioxide concentrations.

**Figure 5-23 Percentage increase in total, cardiovascular, and respiratory mortality from multicity studies in relation to ambient nitrogen dioxide concentrations.**

**Table 5-55 Corresponding percentage increase for Figure 5-23.**

Study	Location	Age	Lag	Averaging Time	Mortality	% Increase (95% CI) <sup>a</sup>
<a href="#">Samoli et al. (2006)</a>	30 European cities	All	0-1	1-h max	Total Cardiovascular Respiratory	1.8 (1.3, 2.2) 2.3 (1.7, 3.0) 2.2 (1.0, 3.4)
<a href="#">Burnett et al. (2004)</a>	12 Canadian cities	All	0-2	24-h avg	Total Cardiopulmonary Respiratory	2.0 (1.1, 2.9) 2.0 (0.5, 3.9) 2.1 (-0.3, 3.9)
<a href="#">Simpson et al. (2005b)</a>	4 Australian cities	All	0-1	1-h max	Total Cardiovascular Respiratory	3.4 (1.1, 5.7) 4.3 (0.9, 7.8) 11.4 (3.4, 19.7)
<a href="#">Biggeri et al. (2005)</a>	8 Italian cities	All	0-1	1-h max	Total Cardiovascular Respiratory	3.5 (2.2, 4.9) 5.0 (2.9, 7.1) 5.4 (0.2, 11.0)
† <a href="#">Bellini et al. (2007)</a>	15 Italian cities	All	0-1	24-h avg	Total Cardiovascular Respiratory	2.2 (1.0, 3.6) 1.5 (-1.7, 4.0) 1.4 (-2.4, 6.7)
† <a href="#">Atkinson et al. (2012)</a>	Meta-analysis (Asia)	All	---	24-h avg	Total Cardiovascular Respiratory	3.7 (2.1, 5.4) 4.1 (2.2, 6.0) 6.7 (3.2, 10.3)
† <a href="#">Wong et al. (2008)</a>	4 Asian cities	All	0-1	24-h avg	Total Cardiovascular Respiratory	4.7 (3.2, 6.2) 5.2 (3.4, 7.0) 5.7 (2.6, 8.8)
† <a href="#">Chen et al. (2012b)</a>	17 Chinese cities	All	0-1	24-h avg	Total Cardiovascular	6.3 (4.2, 8.4) 6.9 (3.8, 10.1)
† <a href="#">Chen et al. (2013b)</a>	8 Chinese cities	All	0-1	24-h avg	Stroke	5.6 (3.4, 8.0)
† <a href="#">Chen et al. (2012b)</a>	17 Chinese cities	All	0-1	24-h avg	Respiratory	9.8 (5.5, 14.2)
† <a href="#">Meng et al. (2013)</a>	4 Chinese cities	All	0-1	24-h avg	COPD	7.1 (5.4, 8.9)
† <a href="#">Chiusolo et al. (2011)</a>	10 Italian cities	≥35 yr	0-5	24-h avg	Total Cardiac	8.1 (3.7, 12.7) 10.3 (5.9, 14.8)
			1-5		Respiratory	13.7 (2.9, 25.8)

avg = average; CI = confidence interval; COPD = chronic obstructive pulmonary disease; h = hour; max = maximum; yr = years.

<sup>a</sup>Results are presented for a 20-ppb increase in 24-h avg nitrogen dioxide concentrations or a 30-ppb increase in 1-h max nitrogen dioxide concentrations.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

---

#### 5.4.4 Potential Confounding of the Nitrogen Dioxide-Mortality Relationship

A key uncertainty of the NO<sub>2</sub>-mortality relationship identified in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) was whether NO<sub>2</sub> acts primarily as a surrogate of another unmeasured pollutant. As such, although the multicity studies evaluated in the 2008 ISA for Oxides of Nitrogen reported consistent evidence of an association between short-term NO<sub>2</sub> exposure and mortality that persisted in copollutant models with PM<sub>10</sub>, SO<sub>2</sub>, or O<sub>3</sub>, these studies often concluded that the observed mortality effects could not be attributed solely to NO<sub>2</sub>. Copollutant analyses conducted in recent studies further attempted to identify whether NO<sub>2</sub> has an independent effect on mortality. Additionally, recent studies have examined whether the extent of temporal adjustment employed adequately controls for the potential confounding effects of season on the NO<sub>2</sub>-mortality relationship.

##### Copollutant Confounding

In the examination of the potential confounding effects of copollutants on the NO<sub>2</sub>-mortality relationship, it is informative to evaluate whether NO<sub>2</sub> risk estimates remain robust in copollutant models, specifically with PM<sub>2.5</sub> and traffic-related pollutants (e.g., EC, CO), and whether NO<sub>2</sub> modifies the effect of other pollutants. Recent multicity studies examine the NO<sub>2</sub>-mortality relationship by taking into consideration both of these aspects in different study designs and in different study locations (i.e., U.S., Canada, Europe, and Asia). However, copollutant analyses in these studies did not include traffic-related pollutants, complicating the overall interpretation of results regarding whether there is an independent effect of short-term NO<sub>2</sub> exposures on mortality.

In a study of 108 U.S. cities using data from the NMMAPS for 1987–2000 (of which 72 had NO<sub>2</sub> data), [Moolgavkar et al. \(2013\)](#) used a subsampling approach where a random sample of 4 cities was removed from the 108 cities over 5,000 bootstrap cycles to examine associations between short-term air pollution concentrations and mortality. This approach was used instead of the two-stage Bayesian hierarchical approach employed in the original NMMAPS analysis, which assumes that city-specific risk estimates are normally distributed around a national mean ([Dominici et al., 2003](#)). In a single-pollutant model using 100 degrees of freedom (~7 *df*/yr, which is consistent with NMMAPS) to control for temporal trends, [Moolgavkar et al. \(2013\)](#) reported a 2.1% (95% CI: 1.8, 2.3) increase in total (nonaccidental) mortality at lag 1 day for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations. The single-pollutant result is larger in magnitude than that observed in ([Dominici et al., 2003](#)), which only included 58 cities in the NO<sub>2</sub> analysis ([Figure 5-22](#)). In a copollutant analysis with PM<sub>10</sub>, the NO<sub>2</sub>-mortality risk estimate was relatively unchanged (1.9% [95% CI: 1.3, 2.4]), and similar to the copollutant results in ([Dominici et al., 2003](#)).

[Stieb et al. \(2008\)](#) reported results consistent with [Moolgavkar et al. \(2013\)](#) in a study that focused on the development of a new air quality health index in Canada. Focusing on Lag Day 1 and models using 10 *df* per year, [Stieb et al. \(2008\)](#) examined whether copollutants confounded the single-pollutant results in both copollutant and multipollutant models with CO, O<sub>3</sub>, PM<sub>10</sub>, PM<sub>2.5</sub>, and SO<sub>2</sub>. However, the study did not clearly identify which results pertained to which model. As stated previously in this ISA, multipollutant models are difficult to interpret due to the multicollinearity often observed between pollutants and as a result are not used to assess whether there is evidence of copollutant confounding. In models using all available data and limited to days with PM<sub>10</sub> data the results of the copollutant and multipollutant analyses conducted by [Stieb et al. \(2008\)](#) indicate that the NO<sub>2</sub>-mortality relationship remain relatively unchanged when adjusted for other pollutants, including some traffic-related pollutants (quantitative results not presented).

Additional studies conducted in Europe and Asia also provide evidence indicating that NO<sub>2</sub>-mortality associations remain robust in copollutant models; however, these studies also did not focus on traffic-related pollutants. [Chiusolo et al. \(2011\)](#) conducted a multicity study of 10 Italian cities using a time-stratified, case-crossover approach as part of the Italian Epi Air multicenter study “Air Pollution and Health: Epidemiological Surveillance and Primary Prevention.” The authors reported consistent, positive associations for total and cause-specific mortality (i.e., cardiac, cerebrovascular, and respiratory), ranging from an 8.1 to 13.7% increase for a 20-ppb increase in 24-hour NO<sub>2</sub> concentrations using an unconstrained distributed lag of 0–5 days (lag 1–5 days was used for respiratory mortality). In copollutant models, NO<sub>2</sub> risk estimates remained robust in models with PM<sub>10</sub> in all-year analyses and with O<sub>3</sub> in analyses restricted to the summer season (i.e., April–September) ([Table 5-56](#)).

**Table 5-56 Percentage increase in total and cause-specific mortality for a 20-ppb increase in 24-hour average nitrogen dioxide concentrations in single- and copollutant models with particulate matter in all-year analyses or ozone in summer season analyses.**

Mortality	Season	Model	% Increase (95% CI)
All natural	All-year	NO <sub>2</sub> (lag 0–5)	8.1 (3.7, 12.7)
		With PM <sub>10</sub> (lag 0–5)	7.5 (1.9, 13.5)
	April–September	NO <sub>2</sub> (lag 0–5)	17.8 (12.3, 23.6)
		With O <sub>3</sub> (lag 0–5)	18.2 (13.1, 23.6)
Cardiac	All-year	NO <sub>2</sub> (lag 0–5)	10.3 (5.9, 14.8)
		With PM <sub>10</sub> (lag 0–5)	10.1 (4.0, 16.4)
	April–September	NO <sub>2</sub> (lag 0–5)	19.2 (11.4, 27.4)
		With O <sub>3</sub> (lag 0–5)	18.8 (10.7, 27.5)
Cerebrovascular	All-year	NO <sub>2</sub> (lag 0–5)	9.1 (–0.5, 19.7)
		With PM <sub>10</sub> (lag 0–5)	9.9 (–2.6, 24.1)
	April–September	NO <sub>2</sub> (lag 0–5)	33.0 (19.2, 48.3)
		With O <sub>3</sub> (lag 0–5)	30.2 (13.9, 48.8)
Respiratory	All-year	NO <sub>2</sub> (lag 1–5)	13.7 (2.9, 25.8)
		With PM <sub>10</sub> (lag 0–5)	13.4 (2.9, 24.8)
	April–September	NO <sub>2</sub> (lag 1–5)	41.3 (16.2, 71.7)
		With O <sub>3</sub> (lag 0–5)	43.4 (14.6, 79.5)

CI = confidence interval; NO<sub>2</sub> = nitrogen dioxide; O<sub>3</sub> = ozone; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm.

Concentrations converted from µg/m<sup>3</sup> to ppb using the conversion factor of 0.532, assuming standard temperature (25°C) and pressure (1 atm).

Source: Reproduced from Environmental Health Perspectives, ([Chiusolo et al., 2011](#)).

The Public Health and Air Pollution in Asia (PAPA) study as well as CAPES collectively found that the NO<sub>2</sub>-mortality association remains robust in copollutant models with a nontraffic-related pollutant in analyses conducted in Asian cities. The PAPA study examined the effect of air pollution on mortality in four cities, one in Thailand (i.e., Bangkok) and three in China (i.e., Hong Kong, Shanghai, and Wuhan) ([Wong et al., 2010](#); [Wong et al., 2008](#)). In these study locations, PM<sub>10</sub> and SO<sub>2</sub> concentrations are much higher than those reported in the U.S.; however, NO<sub>2</sub> and O<sub>3</sub> concentrations are

fairly similar ([Wong et al., 2010](#); [Wong et al., 2008](#)). Copollutant models were only analyzed in the individual cities; a combined four-city analysis was not conducted. In models using lag 0–1 days NO<sub>2</sub> concentrations in the Chinese cities, NO<sub>2</sub> mortality risk estimates were relatively unchanged in copollutant models (quantitative results not presented). However, in Bangkok, the NO<sub>2</sub>-mortality risk estimate was attenuated in models with PM<sub>10</sub>.

The results from the Chinese cities in the PAPA study are consistent with those found in CAPES ([Chen et al., 2012b](#)). In a two-stage Bayesian hierarchical model, where the first stage followed the PAPA protocol, [Chen et al. \(2012b\)](#) reported a 6.3% increase (95% CI: 4.2, 8.4) in total mortality, 6.9% increase (95% CI: 3.8, 10.1) for cardiovascular mortality, and 9.8% increase (95% CI: 5.5, 14.2) for respiratory mortality for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations at lag 0–1 days. Although NO<sub>2</sub> was moderately correlated with both PM<sub>10</sub> and SO<sub>2</sub>, 0.66 and 0.65, respectively, NO<sub>2</sub>-mortality associations, although attenuated, remained positive across total, cardiovascular, and respiratory mortality with the percentage increase in mortality ranging from 4.6–6.7% in copollutant models with PM<sub>10</sub> and 5.2–7.0% in models with SO<sub>2</sub> for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations.

In addition to examining whether copollutants confound the NO<sub>2</sub>-mortality relationship, studies also conducted analyses to examine if there was any indication that NO<sub>2</sub> modifies the PM<sub>10</sub>-mortality relationship. The Air Pollution and Health: A European and North American Approach study, although it focused specifically on examining the PM<sub>10</sub>-mortality relationship, also conducted an analysis to identify whether NO<sub>2</sub> modifies the PM<sub>10</sub>-mortality relationship. In both the European and U.S. data sets, as mean NO<sub>2</sub> concentrations and the NO<sub>2</sub>/PM<sub>10</sub> ratio increased, there was evidence that the risk of PM<sub>10</sub> mortality increased. These results are consistent with [Katsouyanni et al. \(2003\)](#) and [Katsouyanni et al. \(2001\)](#), who reported higher PM<sub>10</sub> risk estimates in cities with higher NO<sub>2</sub> concentrations, suggesting that NO<sub>2</sub> and PM<sub>10</sub> may be effect modifiers of each other.

## Temporal Confounding

Recent studies have also examined whether the NO<sub>2</sub>-mortality relationship is subject to temporal confounding. These studies have focused on examining the effect of increasing the number of *df* employed per year to control for temporal trends on NO<sub>2</sub>-mortality risk estimates. Using the entire data set, which encompassed the years 1981–2000, [Stieb et al. \(2008\)](#) examined the effect of using an alternative number of *df* to adjust for seasonal cycles on NO<sub>2</sub>-mortality risk estimates. In analyses of single-day lags from 0 to 2 days in single-pollutant models, the authors reported comparable risk estimates for each individual lag day when using 6, 8, 10, 12, and 14 *df* per year. Similar to [Stieb et al.](#)

(2008), the PAPA study also examined the impact of alternative approaches to controlling for temporal trends on mortality risk estimates. In models using 4, 6, 8, 10, or 12 *df* per year, Wong et al. (2010) also reported relatively similar results across the *df* per year specified, with some evidence for a slight attenuation of the NO<sub>2</sub>-mortality association in Wuhan, China as the *df* per year increased.

Unlike Stieb et al. (2008) and Wong et al. (2010), who conducted a systematic analysis of the influence of increasing the *df* per year to control for temporal trends on the NO<sub>2</sub>-mortality relationship, Moolgavkar et al. (2013) only compared models that used 50 *df* (~3.5 *df* per year) or 100 *df* (~7 *df* per year) in the statistical model. However, similar to both Stieb et al. (2008) and Wong et al. (2010), Moolgavkar et al. (2013) reported similar results regardless of the number of *df* used, 2.0% (95% CI: 1.8, 2.3) for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations at lag 1 day in the 50 *df* model and 2.1% (95% CI: 1.8, 2.3) in the 100 *df* model.

---

#### 5.4.5 Modification of the Nitrogen Dioxide-Mortality Relationship

To date, a limited number of studies have examined potential effect measure modifiers of the NO<sub>2</sub>-mortality relationship. In the 2008 ISA for Oxides of Nitrogen (U.S. EPA, 2008c), Samoli et al. (2006) provided evidence of regional heterogeneity in NO<sub>2</sub>-mortality associations and higher NO<sub>2</sub>-mortality risk estimates in cities with a lower prevalence of smoking as part of the APHEA-2 study. Recent multicity studies conducted in Italy (Chiusolo et al., 2011), Chile (Cakmak et al., 2011b), and Asia (Chen et al., 2012b) conducted extensive analyses of potential effect measure modifiers of the NO<sub>2</sub>-mortality relationship and identified specific factors that may characterize populations potentially at increased risk of NO<sub>2</sub>-related mortality (Chapter 7). These studies presented evidence indicating that older adults (≥65 years of age), females, individuals with pre-existing cardiovascular or respiratory diseases, and individuals of lower SES, specifically lower income and educational attainment, are at greater risk. Despite these findings, demographic as well as socioeconomic differences between countries may complicate the interpretation of results across these studies, and subsequently the ability to make generalizations across locations regarding the factors that may modify the NO<sub>2</sub>-mortality association.

---

#### 5.4.6 Potential Seasonal Differences in the Nitrogen Dioxide-Mortality Relationship

Studies evaluated in the 2008 ISA for Oxides of Nitrogen indicated seasonal differences in the NO<sub>2</sub>-mortality relationship with evidence of larger associations in the warm or summer season. Recent multicity studies conducted in Canada ([Shin et al., 2012](#); [Stieb et al., 2008](#)) and Italy ([Chiusolo et al., 2011](#); [Bellini et al., 2007](#)) further support these previous findings but also raise additional questions in light of the seasonal patterns in NO<sub>2</sub> concentrations observed in the U.S. and Canada (i.e., higher concentrations in the winter months compared with the summer months) and the higher personal-ambient relationship in the summer compared with the winter ([Section 2.5.4](#)). Additionally, limited information indicates higher correlation between personal and ambient measures in the warm season ([Section 3.4.2](#)), which could be a factor in larger NO<sub>2</sub> risk estimates in the warm season.

In the 12 Canadian city study, [Stieb et al. \(2008\)](#) reported that NO<sub>2</sub>-mortality risk estimates were larger in the warm season (April–September) compared with the cool season (October–March) (quantitative results not presented). These results are consistent with those reported by [Shin et al. \(2012\)](#) in a study that examined year-to-year changes in the association between short-term NO<sub>2</sub> exposure and mortality (i.e., cardiopulmonary and noncardiopulmonary) across 24 Canadian cities during 1984–2004. In seasonal analyses, NO<sub>2</sub> associations with cardiopulmonary mortality at lag 0–2 days were observed to be stronger in the warm season (April–September) compared with the cold season (October–March). [Shin et al. \(2012\)](#) suggest that the larger NO<sub>2</sub> mortality effects in the warm season could be due to the role of NO<sub>2</sub> in the atmospheric reactions that form O<sub>3</sub>, and subsequently suggests that the relationship between NO<sub>2</sub> and O<sub>3</sub> does not allow for a clear assessment of the independent effects of NO<sub>2</sub>. However, in Canada, as well as the U.S., NO<sub>2</sub> concentrations are higher in the cold season compared to the warm season. Additionally, NO<sub>2</sub> and O<sub>3</sub> are not well correlated during the summer ( $r$  ranging from 0.0 to 0.40), which makes it less likely O<sub>3</sub> is a confounder of the NO<sub>2</sub>-mortality relationship ([Section 3.4.4.1](#)).

To date, U.S.-based multicity studies have not examined whether the seasonal patterns of NO<sub>2</sub>-mortality associations observed in Canadian multicity studies are similar in the U.S. However, a few single-city U.S.-based studies that focused on cardiovascular mortality inform upon whether there is evidence of seasonal differences in NO<sub>2</sub>-total mortality associations ([Sacks et al., 2012](#); [Ito et al., 2011](#)). In a study conducted in New York City that examined the association between short-term exposure to air pollution and cardiovascular mortality, [Ito et al. \(2011\)](#) reported similar effect estimates in all-year [1.8% (95% CI: 0.17, 3.3) for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations at lag

1 day] and seasonal [warm: 1.8% (95% CI: -0.4, 3.9); cold: 2.3% (95% CI: 0.0, 4.7)] analyses. The study did not conduct copollutant analyses and the NO<sub>2</sub>-mortality pattern of associations was similar to that observed for PM<sub>2.5</sub> and EC.

[Sacks et al. \(2012\)](#) also examined potential seasonal differences in the NO<sub>2</sub>-cardiovascular mortality association in a study conducted in Philadelphia, PA that examined the influence of various approaches to control for seasonality and the potential confounding effects of weather on the air pollution-cardiovascular mortality relationship. Across models, the authors found that either: NO<sub>2</sub>-mortality associations were similar between warm and cold seasons; or that associations were slightly larger in magnitude during the warm season. These results suggest that the modeling approach employed may influence the NO<sub>2</sub>-mortality associations observed, specifically with regard to whether there is evidence of seasonal differences in associations, but the various approaches did not influence the direction of the observed association.

Multicity studies conducted in Italy provide evidence consistent with that observed in the Canadian multicity studies. In MISA-2, [Bellini et al. \(2007\)](#) reported larger NO<sub>2</sub>-mortality risk estimates in the summer (April–September) compared with the winter (October–March) for total (6.4 versus 0.9% for a 20-ppb increase in 24-h avg NO<sub>2</sub> concentrations at lag 0–1 days), respiratory (9.1 versus -0.04%), and cardiovascular (7.3 versus -0.2%) mortality. In an analysis of 10 Italian cities, [Chiusolo et al. \(2011\)](#) supported the results of [Bellini et al. \(2007\)](#) by indicating larger NO<sub>2</sub>-mortality risk estimates in the warm season compared with all-year ([Table 5-56](#)) for total (nonaccidental) mortality and cause-specific mortality (i.e., cardiac, cerebrovascular, respiratory).

The evidence for increased NO<sub>2</sub>-mortality associations in the warm season, as presented in the Canadian and Italian multicity studies ([Shin et al., 2012](#); [Stieb et al., 2008](#); [Brook et al., 2007](#); [Burnett et al., 2004](#)), differs from the seasonal patterns observed in a study conducted in Shanghai as part of the PAPA study ([Kan et al., 2010](#); [Kan et al., 2008](#)). The authors reported evidence of increased NO<sub>2</sub>-mortality risk estimates in the cold season compared with the warm for total (nonaccidental) mortality (cold: 4.7 versus Warm: 1.7% for a 20-ppb increase in 24-h avg NO<sub>2</sub> at lag 0–1 days), cardiovascular (cold: 4.8 versus Warm: 1.1%), and respiratory mortality (cold: 10.4 versus Warm: -5.1%). Across all of the gaseous pollutants examined, mortality risk estimates were double the size or larger in the cool season, whereas PM<sub>10</sub> mortality risk estimates were similar across seasons except for respiratory mortality (larger in the cool season). The authors speculate these seasonal differences could be due to seasonal exposure differences specific to Shanghai (i.e., limited time spent outdoors and increased air conditioning use in the warm season because of high temperature and humidity and heavy rain, versus more time spent

outdoors and open windows in the cool season) ([Kan et al., 2010](#); [Kan et al., 2008](#)). The results of ([Kan et al., 2010](#); [Kan et al., 2008](#)) highlight the complexity of clearly identifying seasonal patterns in NO<sub>2</sub>-mortality associations across locations with drastically different seasonal weather patterns.


---

#### 5.4.7 Nitrogen Dioxide-Mortality Concentration-Response Relationship and Related Issues

##### Lag Structure of Associations

The 2008 ISA for Oxides of Nitrogen found consistent evidence across studies indicating that NO<sub>2</sub>-mortality effects occur within the first few days after exposure, with multiple studies demonstrating the largest effect occurring the day after exposure (i.e., lag 1 day) ([U.S. EPA, 2008c](#)). Recent multicity studies have conducted additional analyses examining multiday lags, which further inform the lag structure of associations between short-term NO<sub>2</sub> exposure and mortality.

In the analysis of 10 Italian cities, [Chiusolo et al. \(2011\)](#) examined the lag structure of associations between mortality and short-term NO<sub>2</sub> exposure through both single-day and multiday lag analyses. Multiday analyses consisted of a priori defined lags (i.e., 0–1, 2–5, and 0–5 days) examined using an unconstrained distributed lag model. In addition to examining single-day lags of 0 to 5 days, the authors also explored the pattern of associations observed over each individual day using a constrained polynomial distributed lag model. The individual lag days of a constrained distributed lag model are not directly interpretable; however, this analysis allowed [Chiusolo et al. \(2011\)](#) to visually display the potential latency of the NO<sub>2</sub> effect on mortality. Collectively, the single- and multi-day lag analyses support an immediate effect of NO<sub>2</sub> on mortality but also provide evidence for a prolonged effect extending out to 5 days for all mortality outcomes ([Figure 5-24](#)).




Source: Reproduced from Environmental Health Perspectives, ([Chiusolo et al., 2011](#)).

**Figure 5-24 Percentage increase in total and cause-specific mortality associated with short-term increases in ambient nitrogen dioxide concentration at single day lags, individual lag days of a constrained polynomial distributed lag model, and multiday lags of an unconstrained distributed lag model.**

[Chen et al. \(2012b\)](#) also conducted an extensive analysis of the lag structure of associations for the NO<sub>2</sub>-mortality relationship as part of CAPES. Multiday lags were examined by averaging multiple single lag days and using a constrained polynomial distributed lag model of 0–4 days. [Chen et al. \(2012b\)](#) reported the largest effect at single day lags of 0 and 1 and the average of lags 0–1 days indicating an immediate effect of NO<sub>2</sub> on mortality ([Figure 5-25](#)). However, the similar or larger magnitude results for lag 0–4 day avg and the distributed lag model provide some evidence for a delayed NO<sub>2</sub> effect on total, cardiovascular, and respiratory mortality, which is consistent with the results of [Chiusolo et al. \(2011\)](#) ([Figure 5-24](#)). These results were further supported by studies of cause-specific mortality. [Chen et al. \(2013b\)](#) as part of CAPES, in a subset of eight Chinese cities, reported the largest magnitude of an NO<sub>2</sub> effect on stroke mortality

at lag 0–1 days, but the association remained positive and statistically significant in an analysis of lag 0–4 days (Section 5.3.9). In an analysis of COPD mortality in four Chinese cities, [Meng et al. \(2013\)](#) also provided evidence of associations larger in magnitude for multiday averages, suggesting a prolonged effect, with the largest association at lag 0–4 and slightly smaller associations for a lag of 0–1 days (Section 5.2.8). These results are consistent with [Faustini et al. \(2013\)](#) in a study of out-of-hospital respiratory mortality in six Italian cities that found upon examining both single- and multi-day lags the strongest associations with NO<sub>2</sub> were for lags of 2–5 and 0–5 days.



DLM = polynomial distributed lag model, representing the cumulative effects of NO<sub>2</sub>. Percentage increase (mean and 95% CI) of daily mortality associated with a 10-µg/m<sup>3</sup> (5.3-ppb) increase of nitrogen dioxide concentrations, using different lag structures. Multiday average lag 01 corresponds to 2-day moving average, and lag 04 corresponds to 5-day moving average of nitrogen dioxide concentration of the current and previous 4 days.

Source: Reprinted with permission of Elsevier, ([Chen et al., 2012b](#)).

**Figure 5-25 Percentage increase in total and cause-specific mortality associated with short-term increases in ambient nitrogen dioxide concentration in single- and multi-day lag models in a multicity study in China.**


Additional studies that examined associations between NO<sub>2</sub> and mortality at single-day lags or multiday averages provide evidence that is consistent with those studies evaluated in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), which demonstrated strong associations between NO<sub>2</sub> and mortality at lag 1. In the analysis of 12 Canadian cities,

[Stieb et al. \(2008\)](#) found the strongest association between short-term NO<sub>2</sub> exposure and mortality at lag 1 when examining single-day lags of 0–2 days. [Wong et al. \(2008\)](#) and [Wong et al. \(2010\)](#) examined single and multiday lags in each individual city in the PAPA study. In the three Chinese cities, similar to [Stieb et al. \(2008\)](#), the authors reported evidence of immediate effects of NO<sub>2</sub> on mortality; with the strongest association occurring for a 0–1 day lag. However, in Bangkok, the lag structure of associations was different and more in line with those observed in [Chiusolo et al. \(2011\)](#) and [Chen et al. \(2012b\)](#), with the strongest association occurring at a lag of 0–4 days.

### **Concentration-Response Relationship**

The studies evaluated in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) that examined the association between short-term NO<sub>2</sub> exposure and mortality did not conduct formal analyses of the C-R relationship. Recent studies published since the completion of the 2008 ISA for Oxides of Nitrogen have examined the NO<sub>2</sub>-mortality C-R relationship in both multi- and single-city analyses, focusing on the shape of the C-R curve and whether a threshold exists.

Using a subsampling approach, [Moolgavkar et al. \(2013\)](#) examined the shape of the C-R relationship between short-term air pollution exposures and mortality in the NMMAPS data set by applying a nonlinear function (i.e., natural splines with 6 *df*) to each pollutant. This analysis provides support for a linear relationship between short-term NO<sub>2</sub> exposures and mortality ([Figure 5-26](#)). Although [Moolgavkar et al. \(2013\)](#) stated that the C-R relationship for NO<sub>2</sub> “suggest(s) nonlinearity and threshold-like behavior,” the widening of the confidence intervals at the tails of the distribution prevents a clear interpretation of the shape of the curve where the data density is low. Notably, the confidence intervals approach zero at the low end of the NO<sub>2</sub> distribution due to the way the model is structured.



Note: NO<sub>2</sub> = nitrogen dioxide in parts per billion; RR = relative risk. Pointwise means and 95% confidence intervals adjusted for size of the bootstrap sample.


Source: Reproduced from *Environmental Health Perspectives*, (Moolgavkar et al., 2013).

**Figure 5-26 Flexible ambient concentration-response relationship between short-term nitrogen dioxide concentrations and mortality at Lag Day 1.**

The evidence for a linear C-R relationship between short-term NO<sub>2</sub> exposure and mortality was further supported by [Stieb et al. \(2008\)](#) in a pooled analysis of 12 Canadian cities. The authors examined three functional forms (i.e., linear, quadratic, and cubic polynomial) and assessed the model fit using the sum of the Akaike Information Criterion. [Stieb et al. \(2008\)](#) indicated that the linear function was the best fit of the NO<sub>2</sub>-mortality relationship (quantitative results not presented).

Multicity studies conducted in Asia examined the NO<sub>2</sub>-mortality C-R relationship through either a combined analysis using data from all cities or by examining the C-R relationship in individual cities. [Chen et al. \(2012b\)](#) examined the shape of the NO<sub>2</sub>-mortality C-R curve across all cities as part of CAPES for total, cardiovascular, and respiratory mortality using 24-h avg NO<sub>2</sub> concentrations at lag 0–1 days. To limit the influence of extreme NO<sub>2</sub> concentrations on the shape of the C-R curve, concentrations greater than 120 µg/m<sup>3</sup> (62.4 ppb), which represented only 3% of the data, were excluded. The authors used a cubic spline with two knots at different concentrations for each of the mortality outcomes [40 µg/m<sup>3</sup> (20.8 ppb) and 70 µg/m<sup>3</sup> (36.4 ppb) for total

mortality, 50  $\mu\text{g}/\text{m}^3$  (26.0 ppb) and 70  $\mu\text{g}/\text{m}^3$  (36.4 ppb) for cardiovascular mortality, and 40  $\mu\text{g}/\text{m}^3$  (20.8 ppb) and 60  $\mu\text{g}/\text{m}^3$  (31.2 ppb) for respiratory mortality]. [Chen et al. \(2012b\)](#) found evidence of a linear relationship between short-term  $\text{NO}_2$  exposure and total and cause-specific mortality ([Figure 5-27](#)), which was confirmed by the lack of a statistically significant difference in the deviance between the spline and linear fit models. These results are further supported by examinations of the C-R relationship for the cause-specific mortality outcomes of stroke [([Chen et al., 2013b](#)); [Section 5.3.9](#)] and COPD [[Meng et al. \(2013\)](#); [Section 5.2.8](#)], which also provided evidence of a linear relationship.




Note:  $\text{NO}_2$  = nitrogen dioxide.  $\text{NO}_2$  concentrations on the x-axis are in the unit of  $\mu\text{g}/\text{m}^3$ .

Source: Reprinted with permission of Elsevier, ([Chen et al., 2012b](#)).

**Figure 5-27** China Air Pollution and Health Effects Study concentration-response curve for the association between total and cause-specific mortality and 24-hour average nitrogen dioxide concentrations at lag 0–1 days.

The four-city PAPA study ([Wong et al., 2010](#); [Wong et al., 2008](#)) also examined the NO<sub>2</sub>-mortality C-R relationship but only focused on the shape of the C-R curve in each individual city. The C-R curve for the NO<sub>2</sub>-mortality relationship was assessed by applying a natural spline smoother with 3 *df* to NO<sub>2</sub> concentrations. To examine whether the NO<sub>2</sub>-mortality relationship deviates from linearity, the deviance between the smoothed (nonlinear) pollutant model and the unsmoothed (linear) pollutant model was examined. The C-R curves in the three Chinese cities further support the results from [Stieb et al. \(2008\)](#) and [Chen et al. \(2012b\)](#) by indicating a linear relationship between short-term NO<sub>2</sub> concentrations and mortality ([Figure 5-28](#)). Specifically, the evidence for linearity was strongest between the 25th and 75th percentiles of the NO<sub>2</sub> concentrations in each city with some uncertainty in the shape of the C-R curve at lower concentrations where the data density is low, generally below the 25th percentile. The results of the analysis for Bangkok, which provides evidence for nonlinearity, are consistent with what has been observed in examinations of city-specific C-R curves for other air pollutants (e.g., PM<sub>10</sub>, O<sub>3</sub>). That is, the heterogeneity in city-specific risk estimates can translate into heterogeneity in the shape of the C-R curve, which has often been hypothesized to be due to city-specific exposure characteristics and demographics. The results from the Bangkok analysis highlight the difficulty in interpreting a combined C-R curve across cities, when there is evidence for city-to-city differences in the association between short-term NO<sub>2</sub> exposure and mortality.



Note:  $\mu\text{g}/\text{m}^3$  = micrograms per cubic meter;  $\text{NO}_2$  = nitrogen dioxide. Thin vertical lines represent interquartile range of  $\text{NO}_2$  concentrations in each city. The thick line was included by [Wong et al. \(2008\)](#) to depict where the World Health Organization 1-year averaging time standard for  $\text{NO}_2$  of  $40 \mu\text{g}/\text{m}^3$  (20.8 ppb) could be found along the distribution of  $\text{NO}_2$  concentrations in each city.

Source: Reproduced from Environmental Health Perspectives, ([Wong et al., 2008](#)).

**Figure 5-28** Concentration-response curve for association between total mortality and 24-hour average nitrogen dioxide concentrations at lag 0–1 days in the four cities of the Public Health and Air Pollution in Asia study.

---

## 5.4.8 Summary and Causal Determination

Recent multicity studies evaluated since the completion of the 2008 ISA for Oxides of Nitrogen continue to provide consistent evidence of positive associations between short-term NO<sub>2</sub> exposures and total mortality. Although the body of evidence is still consistent, key uncertainties and data gaps still remain; thus, the evidence for short-term NO<sub>2</sub> exposures and total mortality is suggestive of, but not sufficient to infer, a causal relationship. This conclusion is the same as that reached in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)). Recent multicity studies evaluated have further informed key uncertainties and data gaps in the NO<sub>2</sub>-mortality relationship identified in the 2008 ISA for Oxides of Nitrogen including confounding, modification of the NO<sub>2</sub>-mortality relationship, potential seasonal differences in NO<sub>2</sub>-mortality associations, and the shape of the NO<sub>2</sub>-mortality C-R relationship. However, questions remain regarding whether NO<sub>2</sub> is independently associated with mortality, specifically due to the lack of copollutant model analyses with traffic-related pollutants. This section describes the evidence for total mortality with respect to the causal determination for short-term NO<sub>2</sub> exposure, using the framework described in [Table II](#) of the [Preamble](#). The key evidence, as it relates to the causal framework, is summarized in [Table 5-57](#).

Collectively, the evidence from recent multicity studies of short-term NO<sub>2</sub> exposures and mortality consistently demonstrate the NO<sub>2</sub>-mortality association is robust in copollutant models with PM<sub>10</sub>, O<sub>3</sub>, or SO<sub>2</sub>. However, NO<sub>2</sub> is often highly correlated with other traffic-related pollutants complicating the ability to disentangle the independent effects of NO<sub>2</sub> from those of other measured or unmeasured pollutants associated with traffic ([Section 3.4.4](#) and [Figure 3-6](#)), adding uncertainty to the interpretation of the association between NO<sub>2</sub> and total mortality. Studies that focused on PM<sub>10</sub> and examined whether NO<sub>2</sub> modified the PM<sub>10</sub>-mortality relationship reported that PM<sub>10</sub> risk estimates increased as NO<sub>2</sub> concentrations increased or the ratio of NO<sub>2</sub>/PM<sub>10</sub> increased. These results suggest that NO<sub>2</sub> and PM<sub>10</sub> may be effect modifiers of each other. This is consistent with the conclusions of the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)). In addition to copollutant models, recent studies examined the influence of the extent of temporal adjustment on NO<sub>2</sub>-mortality risk estimates and reported similar results across a range of degrees of freedom per year.

An examination of factors that may contribute to increased risk of NO<sub>2</sub>-related mortality, as discussed in [Chapter 7](#), indicate that older adults (≥65 years of age), females, individuals with pre-existing cardiovascular or respiratory diseases, and individuals of lower SES, specifically lower income and educational attainment, are at greater risk. Studies that examined whether there are seasonal differences in the NO<sub>2</sub>-mortality relationship found greater effects in the warm or summer months in multicity studies

conducted in Canada and Europe. However, these results are contradicted by a study conducted in Asia where larger effects were observed in the cold season. These between-study differences in seasonal associations are more than likely a reflection of the different seasonal weather patterns observed between countries ([Kan et al., 2010](#); [Kan et al., 2008](#)).

Those studies that examined the lag structure of associations for the NO<sub>2</sub>-mortality relationship observed that there continues to be evidence of an immediate effect (i.e., lag 0 to 1 day), which is consistent with studies evaluated in the 2008 ISA for Oxides of Nitrogen. Recent studies also provided evidence for a prolonged effect on mortality in distributed lag models with lags ranging from 0–4 to 0–5 days ([Chen et al., 2012b](#); [Chiusolo et al., 2011](#)). Multicity studies examined the shape of the C-R relationship and whether a threshold exists in both a multi- and single-city setting. These studies used different statistical approaches and consistently demonstrated a linear relationship with no evidence of a threshold within the range of NO<sub>2</sub> concentrations currently found in the U.S. However, consistent with observations from C-R analyses conducted for other criteria pollutants [e.g., PM<sub>10</sub> ([U.S. EPA, 2009a](#)) and O<sub>3</sub> ([U.S. EPA, 2013e](#))], an examination of the C-R relationship in individual cities, specifically in China, demonstrated heterogeneity in the shape of the curve across cities ([Wong et al., 2010](#); [Wong et al., 2008](#)).

Overall, recent epidemiologic studies build upon and support the conclusions of the 2008 ISA for Oxides of Nitrogen for total mortality. However, the biological mechanisms that could lead to mortality as a result of short-term NO<sub>2</sub> exposures have not been clearly characterized. This is evident when evaluating the underlying health effects (i.e., cardiovascular effects in [Section 5.3](#) and respiratory effects in [Section 5.2](#)) that could lead to cardiovascular (~35% of total mortality) and respiratory (~9% of total mortality) mortality, the causes of total mortality most thoroughly evaluated ([Hoyert and Xu, 2012](#)).

Epidemiologic studies that examined the relationship between short-term NO<sub>2</sub> exposure and cardiovascular effects found consistent evidence for myocardial infarction, but epidemiologic and experimental evidence for other cardiovascular endpoints is inconclusive. However, important uncertainties remain especially in disentangling whether there is an independent effect of NO<sub>2</sub> on cardiovascular effects, which is the same uncertainty in total mortality studies. Overall this evidence provides limited coherence and biological plausibility for NO<sub>2</sub>-related cardiovascular mortality. For respiratory effects, there is causal evidence for NO<sub>2</sub>-related asthma exacerbation supported by controlled human exposure studies demonstrating increased airway responsiveness in response to short-term NO<sub>2</sub> exposures ([Section 5.2.2.1](#)) as well as

epidemiologic studies reporting associations with asthma-related hospital admissions, ED visits, and symptoms (Section 5.2.2.4). However, the biological mechanism that explains the continuum of effects that could lead to respiratory-related mortality also remains unclear. Additionally, studies that examine the association between short-term NO<sub>2</sub> exposures and mortality rely on central site monitors, which may contribute to exposure measurement error and underestimate NO<sub>2</sub> effects if the temporal variation in ambient NO<sub>2</sub> concentrations reflects variation in people’s NO<sub>2</sub> exposure (Section 3.4.4.1). In conclusion, inference from the consistently positive associations observed across various multicity studies is limited by the uncertainty as to whether NO<sub>2</sub> is independently associated with total mortality as well as the uncertainty in the biological mechanism that could lead to NO<sub>2</sub>-induced mortality. Thus, the evidence is suggestive of, but not sufficient to infer, a causal relationship between short-term NO<sub>2</sub> exposure and total mortality.

**Table 5-57 Summary of evidence, which is suggestive of, but not sufficient to infer, a causal relationship between short-term nitrogen dioxide exposure and total mortality.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
Consistent epidemiologic evidence from multiple, high-quality studies at relevant NO <sub>2</sub> concentrations	Increases in mortality in multicity studies conducted in the U.S., Canada, Europe, and Asia.	<a href="#">Section 5.4.3</a> <a href="#">Table 5-54</a>	Mean 24-h avg: 9.2–55.0 ppb Mean 1-h max: 16.3–80.5 ppb Mean 3-h max: 16.3–42.6 ppb. <a href="#">Table 5-53</a>
Uncertainty regarding potential confounding by traffic-related copollutants	NO <sub>2</sub> associations were relatively unchanged in copollutant models with PM <sub>10</sub> , SO <sub>2</sub> , or O <sub>3</sub> , but confounding by highly correlated traffic-related pollutants (e.g., EC, CO) or PM <sub>2.5</sub> not examined. Unclear whether NO <sub>2</sub> is independently associated with total mortality.	† <a href="#">Moolgavkar et al. (2013)</a> ; † <a href="#">Chen et al. (2012b)</a> , † <a href="#">Chiusolo et al. (2011)</a> ; † <a href="#">Wong et al. (2010)</a> ; † <a href="#">Stieb et al. (2008)</a> ; † <a href="#">Wong et al. (2008)</a>  <a href="#">Section 3.4.4</a> , <a href="#">Figure 3-6</a> ; <a href="#">Section 5.4.4</a>	
	NO <sub>2</sub> and PM <sub>10</sub> may be effect modifiers of each other.	† <a href="#">Katsouyanni et al. (2009)</a> ; <a href="#">Katsouyanni et al. (2003)</a> ; <a href="#">Katsouyanni et al. (2001)</a>	

**Table 5-57 (Continued): Summary of evidence, which is suggestive of, but not sufficient to infer, a causal relationship between short-term nitrogen dioxide exposure and total mortality.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
Uncertainty regarding exposure measurement error	Studies that examine the association between short-term NO <sub>2</sub> exposures and mortality rely on central site monitors.	Sections <a href="#">3.4.5.1</a> and <a href="#">3.5</a>	
Uncertainty due to limited coherence and biological plausibility with cardiovascular morbidity evidence	Consistent epidemiologic evidence for myocardial infarction. Inconclusive epidemiologic and experimental evidence for other cardiovascular endpoints.	Section <a href="#">5.3.11</a> <a href="#">Table 5-52</a>	
Uncertainty due to limited coherence and biological plausibility with respiratory morbidity evidence	Consistent evidence for asthma exacerbation from experimental studies demonstrating increased airway responsiveness and epidemiologic studies. Uncertainty as to the biological mechanism that explains the continuum of effects leading to NO <sub>2</sub> -related cardiovascular mortality and respiratory mortality, which comprise 35% and ~8% of total mortality, respectively. <sup>d</sup>	Section <a href="#">5.2.9</a> <a href="#">Table 5-39</a>	

avg = average; CO = carbon monoxide; EC = elemental carbon; max = maximum; NO<sub>2</sub> = nitrogen dioxide; O<sub>3</sub> = ozone; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 μm; ppb = parts per billion; SO<sub>2</sub> = sulfur dioxide.

<sup>a</sup>Based on aspects considered in judgments of causality and weight of evidence in causal framework in [Tables I](#) and [II](#) of the [Preamble](#).

<sup>b</sup>Describes the key evidence and references, supporting or contradicting, contributing most heavily to causal determination and, where applicable, to uncertainties or inconsistencies. References to earlier sections indicate where full body of evidence is described.

<sup>c</sup>Describes the NO<sub>2</sub> concentrations with which the evidence is substantiated (for experimental studies, below 5,000 ppb).

<sup>d</sup>Statistics taken from [American Heart Association \(2011\)](#).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

---

# CHAPTER 6    INTEGRATED HEALTH EFFECTS OF LONG-TERM EXPOSURE TO OXIDES OF NITROGEN

---

## 6.1    Scope and Issues Considered in Health Effects Assessment

---

### 6.1.1    Scope of Chapter

---

This chapter summarizes, integrates, and evaluates the evidence for a broad spectrum of health effects associated with long-term exposure (i.e., more than 1 month to years) to oxides of nitrogen. As in the preceding chapter on short-term exposure, key considerations in the evaluation include exposure measurement error, effects of other correlated pollutants, and mode of action information to support biological plausibility. This chapter comprises evaluations of the epidemiologic and toxicological evidence for the effects of long-term exposure to oxides of nitrogen on health outcomes related to respiratory effects ([Section 6.2](#)), cardiovascular effects and diabetes ([Section 6.3](#)), reproductive and developmental effects ([Section 6.4](#)), and mortality ([Section 6.5](#)). [Chapter 6](#) concludes with a discussion of the evidence for cancer effects ([Section 6.6](#)). To characterize the weight of evidence for reproductive and developmental effects in a cohesive manner, results from both short-term (i.e., up to 1 month) and long-term exposure studies are included in this chapter. These results are identified according to exposure duration in the text and tables throughout [Section 6.4](#).

Individual sections for broad health categories (e.g., respiratory effects) begin with a summary of conclusions from the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) followed by an evaluation of recent (i.e., published since the completion of the 2008 ISA for Oxides of Nitrogen) studies that builds upon evidence from previous reviews. Within each of these sections, results are organized into smaller outcome groups (e.g., asthma development) that are made up of a continuum of clinical to subclinical events and outcomes. The discussion of individual events and outcomes is then organized by specific scientific discipline (i.e., epidemiology, toxicology). This organization permits a clear description of the extent of coherence and biological plausibility for the effects of oxides of nitrogen on a group of related outcomes, and in turn, provides a transparent characterization of the weight of evidence in drawing conclusions.

Sections for each of the broad health categories (e.g., respiratory effects, cardiovascular effects and diabetes) conclude with an integrated assessment of evidence and conclusions

regarding causality. A determination of causality was made for a broad health category (e.g., respiratory effects) or smaller group of related outcomes (e.g., birth outcomes) by evaluating the evidence for each category or group independently with the causal framework (described in the [Preamble](#)). Findings for mortality informed multiple causal determinations. Findings for cause-specific mortality (i.e., respiratory, cardiovascular) were used to assess the continuum of effects and inform the causal determinations for respiratory and cardiovascular effects. A separate causal determination was made for total mortality ([Section 6.5](#)), based primarily on the evidence for nonaccidental causes of mortality combined but also based on the extent of biological plausibility provided by evidence for the spectrum of cardiovascular and respiratory effects that are underlying causes of mortality. Judgments of causality were made by evaluating the evidence for the full range of concentrations in animal toxicological and epidemiologic studies defined in this ISA to be relevant to ambient exposure (i.e., up to 5,000 ppb NO<sub>2</sub>; [Section 1.2](#)). Experimental studies that examined higher concentrations were evaluated mainly to inform judgments about plausible modes of action.

---

## 6.1.2 Evidence Evaluation and Integration to Form Causal Determinations

As was done for relationships of health effects with short-term exposure, judgments regarding causality were made by evaluating evidence for the consistency of findings across multiple studies, the coherence of findings across related endpoints and across disciplines, and the extent to which chance, confounding (i.e., bias due to a correlation with NO<sub>2</sub> exposures or ambient concentrations and relationship with the outcome), and other biases could be ruled out with reasonable confidence. This evaluation involved integrating various lines of evidence and a consideration of the strength of inference from individual studies (detailed in the [Appendix](#) to the ISA).

Epidemiologic studies of long-term NO<sub>2</sub> exposure generally rely on differences in exposure between subjects. For example, studies may base exposure contrasts on differences in residential location (spatial differences) or time periods that vary in long-term ambient NO<sub>2</sub> concentrations. For the assessment of potential confounding, long-term exposure epidemiologic studies were evaluated for the extent to which they considered other factors associated with health outcomes and correlated with exposures to oxides of nitrogen. These potential confounding factors can include socioeconomic status (SES), diet, smoking or exposure to environmental tobacco smoke, medication use, and copollutant exposures ([Appendix](#)). Epidemiologic studies varied in the extent to which they considered potential confounding. Because no single study examined all potential confounding factors and not all potential confounding factors were examined in the collective body of evidence, residual confounding by unmeasured factors is possible.

Residual confounding is also possible by poorly measured factors. The evidence was evaluated based on factors well documented in the literature to be associated with NO<sub>2</sub> exposure and health outcomes. Other considerations in drawing inferences about the independent effects of NO<sub>2</sub> were the limitations of multivariable models, including copollutant models, to examine potential confounding ([Section 5.1.2.1](#)). Specific to copollutant confounding, the magnitude of correlations between NO<sub>2</sub> and copollutants was assessed, and emphasis was placed on particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm (PM<sub>2.5</sub>) and traffic-related pollutants (e.g., BC/EC, carbon monoxide [CO]). The potential for differential measurement error for NO<sub>2</sub> and copollutants also was considered.

This ISA presents epidemiologic effect estimates for associations with health outcomes scaled to the same increment of oxides of nitrogen to increase comparability among studies.<sup>1</sup> For long-term exposure metrics, effect estimates are scaled to a 10-ppb increase in NO<sub>2</sub> or NO and a 20-ppb increase in NO<sub>x</sub>. These increments were derived by calculating the U.S. nationwide percentile distributions for annual average concentrations ([Table 2-2](#)) and then calculating the approximate difference between the median (a typical pollution year) and the 95th percentile (a more polluted year) concentrations among monitors in the State and Local Air Monitoring Stations network. Long-term averages of ambient oxides of nitrogen are lower in concentration than short-term averages, less variable across time, and do not differ widely among multimonth averages, annual averages, or multiyear averages [[Supplemental Table S6-1](#); ([U.S. EPA, 2015j](#))]. Thus, all long-term exposure metrics were scaled to the same increment. Effect estimates that were reported in terms of μg/m<sup>3</sup> were converted to ppb and standardized for NO<sub>2</sub> and NO but not NO<sub>x</sub>. Because the proportions of NO<sub>2</sub> and NO are unknown for the various NO<sub>x</sub> metrics, concentrations could not be converted from μg/m<sup>3</sup> to ppb. And data are not available to calculate the percentiles of NO<sub>x</sub> concentrations in μg/m<sup>3</sup> at a national scale for the U.S. or other countries. Therefore, the ISA presents effect estimates based on μg/m<sup>3</sup> of NO<sub>x</sub> as they are reported in individual studies.

To form causal determinations, evidence was integrated across a spectrum of related endpoints, including cause-specific mortality, and across disciplines to assess the extent to which chance, confounding, and other biases could be ruled out with reasonable confidence. Animal toxicological studies can provide direct evidence for health effects related to NO<sub>2</sub> exposures. Coherence between toxicological and epidemiologic findings can address uncertainties such as whether epidemiologic associations with health outcomes plausibly reflect an independent effect of ambient NO<sub>2</sub> exposure or could be confounded by other factors. Experimental studies also can provide biological plausibility

---

<sup>1</sup> This is in contrast with reported effect estimates that are scaled to various changes in concentration such as interquartile range for the study period or an arbitrary unit such as 5 ppb.

by identifying key events in the modes of action for health effects. Thus, integration of evidence was used to inform uncertainties for any particular outcome or discipline due to factors such as publication bias, selection bias, exposure measurement error, or confounding by copollutant exposures. The subsequent sections assess strength of inference from studies and integrate evidence across multiple lines of evidence to characterize relationships between oxides of nitrogen and various health effects.

---

## 6.2 Respiratory Effects

---

### 6.2.1 Introduction

The 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) examined the epidemiologic and toxicological evidence on long-term exposure to NO<sub>2</sub> and respiratory effects and concluded that the evidence was suggestive of, but not sufficient to infer, a causal relationship. The key supporting evidence comprised epidemiologic associations linking higher NO<sub>2</sub> exposure with decrements in lung function and partially irreversible decrements in lung development in children. However, several sources of uncertainty were acknowledged, including confounding by traffic-related copollutants. For example, the southern California Children's Health Study (CHS) decrements in lung development in children not only in association with higher ambient NO<sub>2</sub> concentrations but also with EC, proximity to traffic (<500 m), and PM<sub>2.5</sub> ([Gauderman et al., 2004](#)). Because of the high correlation of long-term averages of NO<sub>2</sub> with such copollutants, an independent effect of NO<sub>2</sub> could not be discerned in the evidence base as a whole. Animal toxicological studies demonstrated that long-term exposure to NO<sub>2</sub> resulted in permanent morphologic changes to the lung, particularly in the centriacinar region and bronchiolar epithelium. However, such effects were indicative of emphysema-like disease and were not related to the epidemiologic associations observed between NO<sub>2</sub> and decreases in lung function or development in children. Another source of uncertainty was the inconsistent cross-sectional evidence for associations between long-term exposure to NO<sub>2</sub> and increases in asthma prevalence. Epidemiologic studies conducted in both the U.S. and Europe also reported inconsistent results regarding an association between long-term exposure to NO<sub>2</sub> and respiratory symptoms.

This section evaluates the current body of evidence examining the relationship between long-term exposure to NO<sub>2</sub> and respiratory effects. The strongest evidence is that for asthma development in children, particularly from recent longitudinal epidemiologic studies, and is presented first. Evidence for respiratory disease severity, development of

allergic disease, altered lung function and development, altered lung morphology, respiratory infections, and COPD is discussed thereafter. No animal toxicological studies evaluating respiratory effects of long-term NO<sub>2</sub> exposure have been published since the release of the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), but previous studies are evaluated to inform the biological plausibility for the array of respiratory effects examined.

---

## 6.2.2 Development of Asthma or Chronic Bronchitis


Asthma is a chronic disease characterized by inflammation, variable airflow obstruction, airway hyperresponsiveness (AHR), and in some cases, airway remodeling. To characterize the evidence for a relationship between long-term NO<sub>2</sub> exposure and asthma development, this section evaluates asthma incidence in children in longitudinal cohort studies. This section also evaluates evidence for airway responsiveness, allergic responses, and pulmonary inflammation, which are key events in the proposed mode of action linking long-term NO<sub>2</sub> exposure and asthma development ([Figure 4-2](#)). A few studies examined chronic bronchitis alone or as part of a composite index with asthma.

---

### 6.2.2.1 Asthma or Chronic Bronchitis in Children

Recent prospective and retrospective longitudinal cohort studies comprise a strong evidence base that generally demonstrates a positive relationship between long-term NO<sub>2</sub> exposure and asthma incidence in children ([Figure 6-1](#)). Unless stated otherwise, associations were observed with annual average NO<sub>2</sub> concentrations. The consistency is supported by a pooled analysis ([Macintyre et al., 2014a](#)) and many meta-analyses ([Anderson et al., 2013](#); [Gasana et al., 2012](#); [Gowers et al., 2012](#); [Takenoue et al., 2012](#); [Bråbäck and Forsberg, 2009](#)). However, some meta-analyses included children and adults as well as both cross-sectional and prospective studies. Longitudinal studies in children were conducted in North America, Europe, and Asia (detailed in [Table 6-1](#)). Most studies used physician-diagnosed asthma as the indicator for asthma incidence. Cross-sectional studies of asthma prevalence were reviewed and are discussed to inform understanding of potential copollutant confounding and other policy-relevant issues [Tables AX6 3-15, AX6 3-16, and AX6 3-17 of the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) describe previous studies]. However, longitudinal studies were emphasized because they can better characterize the temporality between exposure and incidence of a health effect. Namely, the prospective designs distinguished between onset of asthma and the exacerbation of asthma by defining asthma incidence as diagnosis of asthma by a physician in the time since the previous follow-up period. As described in the sections

that follow, other strengths of the longitudinal studies are follow-up of children from birth to ages 7 to 12 years or from ages 8 to 18 years. The reliability of asthma diagnosis improves in children ages 5 years and older. Additionally, several exposure assessment methods were used across studies, and many studies aimed to estimate exposure for individual study participants.



Note: avg = average; IDW = inverse distance weighted; LUR = land use regression; yr = year(s). Black = study from the 2008 Integrated Science Assessment for Oxides of Nitrogen; red = recent studies. Circles = nitrogen dioxide; triangles = nitric oxide; diamond = sum of nitrogen dioxide and nitric oxide. All effect estimates are standardized to 10 ppb, with the exception of [Gruzieva et al. \(2013\)](#) who examined NO<sub>x</sub> in µg/m<sup>3</sup> and [Ofstedal et al. \(2009a\)](#) who did not report increments for the effect estimates for the birth to age 4 years or birth to age 10 years exposure periods. See [Table 6-1](#) for study details and quantitative results.

**Figure 6-1 Associations of long-term exposure to oxides of nitrogen with asthma incidence in longitudinal cohort studies of children.**

**Table 6-1 Longitudinal studies of long-term exposure to oxides of nitrogen and asthma incidence in children.**

Study <sup>a</sup>	Exposure Assessment	Copollutant Correlation	Statistical Methods	Comments	Effect Estimates (95% CI) <sup>b</sup>
<b>Vancouver, Canada</b>					
<p>†<a href="#">Carlsten et al. (2011c)</a>                      n = 184 children followed from birth to age 7 yr                      Cohort with high risk of asthma: 1 parent/sibling with asthma or 2 parents/siblings with other allergic disease.                      Related publications: <a href="#">Carlsten et al. (2011a)</a>, <a href="#">Carlsten et al. (2011b)</a>, <a href="#">Henderson et al. (2007)</a>, <a href="#">Marshall et al. (2008)</a></p>	<p>LUR model                      Annual avg at birth residence.                      Estimates for 1995 generated by temporally adjusting high resolution (10 m) 2003 annual averages.                      LOOCV (in sample): Mean error = 0; SD = 2.75 (15%).                      R<sup>2</sup> for comparisons with measurements at central sites and by mobile monitoring = 0.69, 0.44 (<a href="#">Henderson et al., 2007</a>).                      Mean (SD): 17.3 (13.1) ppb</p>	<p>Pearson r:                      NO<sub>2</sub>-PM<sub>2.5</sub> = 0.7                      NO<sub>2</sub>-BC = 0.5                      NO<sub>2</sub>-NO = 0.8                      NO-PM<sub>2.5</sub> = 0.5                      NO-BC = 0.3                      LUR models for PM<sub>2.5</sub> and BC showed poorer predictive accuracy.</p>	<p>Multiple logistic regression adjusted for maternal education, history of asthma in mother, father or siblings, atopic status at age 1 yr.</p>	<p>63% follow-up participation at age 7 yr.                      Key characteristics of children followed did not differ from those in the original cohort.</p>	<p>OR for NO<sub>2</sub> among all children:                      2.9 (0.8, 10.9)                      Association observed with PM<sub>2.5</sub> with wide CI; no association observed with BC.                      OR for NO among 13 children with both allergist diagnosis of asthma and bronchial hyperactivity:                      1.2 (0.9, 1.7)</p>

**Table 6-1 (Continued): Longitudinal studies of long-term exposure to oxides of nitrogen and asthma incidence in children.**

Study <sup>a</sup>	Exposure Assessment	Copollutant Correlation	Statistical Methods	Comments	Effect Estimates (95% CI) <sup>b</sup>
<b>Children, Allergy, Milieu, Stockholm, Epidemiology Survey (BAMSE), Stockholm, Sweden</b>					
<p>†<a href="#">Gruzieva et al. (2013)</a>                      n = 3,633 children followed from birth (1994–1996) to age 12 yr.                      Related publications:  <a href="#">Gruzieva et al. (2012)</a>,  <a href="#">Nordling et al. (2008)</a>,  <a href="#">Wickman et al. (2002)</a></p>	<p>Dispersion model                      Annual avg NO<sub>x</sub> at all residences from birth to age 12 yr (1994–2008).                      Time and activity patterns used to estimate exposure.                      Model validated against measurements at central site monitors. <i>R</i> = 0.74 for correlation of NO<sub>2</sub> at monitors and traffic-related NO<sub>2</sub> estimated from NO<sub>x</sub>.</p>	<p><i>r</i> = 0.96 for NO<sub>x</sub>-PM<sub>10</sub></p>	<p>Multinomial regression/generalized estimating equation adjusted for municipality, SES, year house was built, mother or father with doctor diagnosis of asthma and asthma medication.</p>	<p>Associations were stronger for the oldest children and for nonallergic asthma.                      Follow-up participation: 96% yr 1, 94% yr 2, 91% yr 4, 84% yr 8, and 82% yr 12.                      Study population and the original cohort had similar characteristics.</p>	<p>OR for NO<sub>x</sub> during the first yr of life and development of incident asthma at 12 yr of age.                      1.87 (1.0, 3.44) per 46.8 µg/m<sup>3</sup> NO<sub>x</sub></p>
<b>Maternal-Infant Smoking Study of East Boston, MA</b>					
<p>†<a href="#">Clougherty et al. (2007)</a>                      n = 413 children followed from birth (1987–1993).                      End of follow-up NR.                      N = 255 lifetime residents.                      Median age of asthma diagnosis 5 yr.</p>	<p>LUR model                      Annual avg for various time windows and avg from birth to diagnosis for all residences during a given period.                      Model developed based on monthly measurements 1987–2004. No information on validation.                      Mean (SD) for year of diagnosis: 27.5 (4.3) ppb</p>	<p>NR</p>	<p>Regression model adjusted for maternal asthma, education, and smoking before and after pregnancy, child's sex and age.</p>	<p>Association limited to group with high exposure to violence.</p>	<p>OR for NO<sub>2</sub> in the yr of diagnosis in group with high exposure to violence:                      3.12 (1.36, 7.15)</p>

**Table 6-1 (Continued): Longitudinal studies of long-term exposure to oxides of nitrogen and asthma incidence in children.**

Study <sup>a</sup>	Exposure Assessment	Copollutant Correlation	Statistical Methods	Comments	Effect Estimates (95% CI) <sup>b</sup>
<b>Southwest British Columbia, Canada</b>					
<p>†<a href="#">Clark et al. (2010)</a>                      n = 2,801 children followed from birth (1999–2000) to age 3–4 yr.                      All births in southwest British Columbia eligible.                      Related publications: <a href="#">Henderson et al. (2007)</a>, <a href="#">Marshall et al. (2008)</a></p>	<p>LUR model and IDW of central site monitors                      Annual avg for first yr of life. LUR estimates with postal code resolution.                      IDW of 3 closest monitors within 50 km.                      LUR model LOOCV (in sample): Mean error = 0.0; SD = 2.75 (15%). <math>R^2</math> with measurements at central sites and sites that vary in traffic = 0.69, 0.44 (<a href="#">Henderson et al., 2007</a>).                      Poorer predictability of variability due to local traffic.                      Mean (SD):                      16.3 (12.3) ppb</p>	<p>Correlations among pollutants were generally high. Quantitative results reported only for O<sub>3</sub>.  <math>R = -0.9</math> to <math>-0.7</math>.</p>	<p>Conditional logistic regression adjusted for native status, breast-feeding, maternal smoking, income quartile, maternal age, birth weight, and gestational length.</p>	<p>To address the lower reliability of asthma diagnosis in young children, asthma was defined as hospital admission or at least two outpatient diagnoses.</p>	<p>OR for IDW:                      1.24 (1.14, 1.34)                      OR for LUR:                      1.26 (1.08, 1.48)                      Associations observed with CO, BC, and proximity to point sources. Traffic-related pollutants associated with the highest risks.                      ORs were smaller for PM<sub>2.5</sub> than for NO<sub>2</sub> for both LUR and IDW.                      Associations also observed with PM<sub>10</sub>, SO<sub>2</sub>.</p>

**Table 6-1 (Continued): Longitudinal studies of long-term exposure to oxides of nitrogen and asthma incidence in children.**

Study <sup>a</sup>	Exposure Assessment	Copollutant Correlation	Statistical Methods	Comments	Effect Estimates (95% CI) <sup>b</sup>
<b>Prevention and Incidence of Asthma and Mite Allergy (PIAMA), the Netherlands</b>					
<p>†<a href="#">Gehring et al. (2010)</a>                      n = 3,863 children followed from birth to age 8 yr                      Related publications:  <a href="#">Wijga et al. (2014)</a>,  <a href="#">Eeftens et al. (2011)</a>,  <a href="#">Hoek et al. (2008)</a>,  <a href="#">Brauer et al. (2007)</a>,  <a href="#">Brauer et al. (2003)</a>,  <a href="#">Brauer et al. (2002)</a></p>	<p>LUR model                      Annual avg at birth residence.                      Developed from 40 sites: 16 urban/suburban, 12 regional, 12 traffic.                      5–10% of population lived near major roads.                      LOOCV (in sample): <math>R^2 = 0.68</math>.                      Good agreement among measured and modeled <math>\text{NO}_2</math> concentrations for 2007 and 1999–2000 at the same locations.                      Mean (10th–90th percentile): 13.5 (7.8–18.5) ppb</p>	<p><math>\text{NO}_2</math>-<math>\text{PM}_{2.5}</math>: <math>r = 0.93</math>  <math>\text{NO}_2</math>-soot: <math>r = 0.96</math>  <math>\text{PM}_{2.5}</math>-soot: <math>r = 0.97</math></p>	<p>Generalized estimating equations adjusted for sex, study arm, use of mite-impermeable mattress covers, maternal and paternal allergies, maternal and paternal education, maternal prenatal smoking, breastfeeding, presence of a gas stove in the child's home, having older siblings, and any smoking at home.</p>	<p>Follow-up participation: 94.4% yr 1, 82% yr 8.                      Characteristics of the original cohort and studied groups are similar.</p>	<p>OR: 1.32 (0.93, 1.85) with adjustment for study region                      OR: 1.36 (1.09, 1.67) without adjustment for study region                      Similar ORs for <math>\text{PM}_{2.5}</math> and soot.</p>
<b>Gene and Environmental Prospective Study in Italy (GASPII), Rome, Italy</b>					
<p>†<a href="#">Ranzi et al. (2014)</a>                      n = 486 children followed from birth (2003–2004) to age 7 yr                      Related publication:  <a href="#">Cesaroni et al. (2012)</a></p>	<p>LUR model                      Annual avg at birth residence, current residence, lifetime avg.  <math>\text{NO}_2</math> measured simultaneously at 78 locations in winter, spring, and fall 2007.                      LOOCV (in sample): <math>R^2 = 0.66</math>.                      Mean (10th–90th percentile) at age 7 yr: 20.0 (15.5–25.4) ppb.</p>	<p><math>\text{NO}_2</math>-<math>\text{O}_3</math>:                      Spearman <math>r = -0.34</math>.</p>	<p>Logistic regression adjusted for sex, age, breastfeeding at 3 mo, day care attendance, presence of any pets in the home, siblings, maternal and paternal smoking, maternal prenatal smoking, maternal and paternal education, presence of molds or dampness at home, familial asthma or allergies.</p>	<p>Follow-up participation: 99–71% from age 6 mo to 7 yr.</p>	<p>OR for lifetime avg: 1.17 (0.63, 2.20)                      OR adjusted for <math>\text{O}_3</math>: 1.11 (0.54, 2.25)</p>

**Table 6-1 (Continued): Longitudinal studies of long-term exposure to oxides of nitrogen and asthma incidence in children.**

Study <sup>a</sup>	Exposure Assessment	Copollutant Correlation	Statistical Methods	Comments	Effect Estimates (95% CI) <sup>b</sup>
<b>Oslo, Norway</b>					
<p>†<a href="#">Ofstedal et al. (2009a)</a>                      n = 2,329 children followed from birth (1992–1993) to age 9–10 yr.                      Related publications: <a href="#">(Ofstedal et al., 2009b)</a>, <a href="#">Laupsa and Slordal (2003)</a>, <a href="#">Walker et al. (1999)</a>, <a href="#">Gronskoi et al. (1993)</a></p>	<p>Dispersion model                      Annual avg at residence in first yr of life, birth to asthma diagnosis, and yr before diagnosis.                      Modeled estimates well correlated with measurements from 10 central site monitors.                      R = 0.76.                      Mean (25th–75th percentile) for first yr of life:                      20.9 (13.2–28.1) ppb</p>	<p>NO<sub>2</sub>-PM<sub>2.5</sub> &amp; NO<sub>2</sub>-PM<sub>10</sub>:                      r = 0.79–0.91.</p>	<p>Cox proportional hazard regression and logistic regression adjusted for sex, parental atopy, maternal smoking in pregnancy, paternal education, and maternal marital status at the child's birth.</p>		<p>RR for NO<sub>2</sub> in first yr of life and asthma onset at any age:                      0.87 (0.76, 1.00)                      Average NO<sub>2</sub> before diagnosis not associated with asthma diagnosed at any age or after age 4 yr.</p>
<b>Chiba prefecture, Japan</b>					
<p><a href="#">Shima et al. (2002)</a>                      n = 1,910 children in eight communities followed from 1st grade (age 6 yr) to 6th grade. Enrolled 1989–1992.</p>	<p>Central site monitors                      10-yr avg (1988–1997).                      Almost all children's homes and schools were about 1 km from sites.                      Range across communities:                      7.3–31.4 ppb</p>	<p>NR</p>	<p>Logistic regression adjusted for sex, history of allergic diseases, respiratory diseases prior to age 2 yr, parental history of allergic diseases, maternal smoking habits, type of heater used in winter in the home, and construction elements of the house.</p>	<p>67% follow-up participation. Lower follow-up among urban children than rural because of more frequent changes in residence. Exposure data not calculated for 944 children due to missing residential data for 3-yr period before enrollment (missing questionnaire).</p>	<p>OR: 1.71 (1.04, 2.79)</p>

**Table 6-1 (Continued): Longitudinal studies of long-term exposure to oxides of nitrogen and asthma incidence in children.**

Study <sup>a</sup>	Exposure Assessment	Copollutant Correlation	Statistical Methods	Comments	Effect Estimates (95% CI) <sup>b</sup>
<b>Children's Health Study (CHS), southern California</b>					
<p>†<a href="#">Jerrett et al. (2008)</a> n = 217 children followed from ages 10 to 18 yr. Enrolled in 1993 or 1996 from 11 southern California communities. Asthma assessed over 8 yr of follow-up.</p>	<p>Residential outdoor monitors. Season and annual avg estimated from Palmes tubes outside home for 2 weeks summer and winter. Mean (SD) annual avg NO<sub>2</sub> range across 11 communities: 9.6 (2.5)–51.3 (4.4) ppb</p>	<p>No quantitative data. Correlations of residential NO<sub>2</sub> with measures of traffic proximity or modeled pollutant concentrations reported to be moderate to high.</p>	<p>Random-effects Cox proportional hazards model adjusted for median household income, proportion of respondents with low education, percentage of males unemployed, percentage living in poverty, temperature, and humidity.</p>	<p>Within-community effects (deviation of individual from mean) similar to between-community effects (community mean). Suggests influence of both regional and local pollution. Smaller range in NO<sub>2</sub> within communities than between communities.</p>	<p>HR: 1.51 (1.12, 2.05)</p>
<p>†<a href="#">McConnell et al. (2010a)</a> n = 2,497 children ages 4.8–9.0 yr followed for 3 yr. Enrolled 2002–2003 in 13 southern California communities. Related publications: <a href="#">Wu et al. (2005)</a>, <a href="#">Peters et al. (1999)</a>, <a href="#">Benson (1984)</a></p>	<p>NO<sub>2</sub>: central site, 1 per community NO<sub>x</sub>: dispersion model for home and school. Annual avg, time period Within-community variability of personal NO<sub>2</sub> estimates: ± 20–40%. Lower for EC, PM<sub>10</sub>, PM<sub>2.5</sub>, and CO (<a href="#">Wu et al., 2005</a>). For different CHS cohort, residential NO<sub>2</sub> and freeway-related NO<sub>2</sub> from dispersion model correlated with <math>r = 0.56</math> (<a href="#">Gauderman et al., 2005</a>). Residential and modeled NO<sub>2</sub> may have some level of independence. Mean (range): 20.4 (8.7–23.6) ppb</p>	<p>NR</p>	<p>Multilevel Cox proportional hazards model adjusted for sociodemographic characteristics, exposure to cigarette and wildfire smoke, health insurance, housing characteristics, history of allergy, and parental asthma.</p>	<p>74% follow-up participation. Lower follow-up among Hispanic children and children with lower SES. NO<sub>2</sub> association was similar after adjusting for these factors. Risk for NO<sub>x</sub> was higher in children with high parental stress compared to low parental stress (<a href="#">Shankardass et al., 2009</a>).</p>	<p>HR for central site NO<sub>2</sub>: 1.39 (1.07, 1.80) HR for modeled NO<sub>x</sub> from freeways: 1.67 (1.32, 2.12) near homes 1.88 (1.10, 3.19) near schools. OR for PM<sub>2.5</sub> central site (per 3.5 µg/m<sup>3</sup>): 1.66 (0.91, 3.05)</p>

**Table 6-1 (Continued): Longitudinal studies of long-term exposure to oxides of nitrogen and asthma incidence in children.**

Study <sup>a</sup>	Exposure Assessment	Copollutant Correlation	Statistical Methods	Comments	Effect Estimates (95% CI) <sup>b</sup>
<b>Genes-environment &amp; admixture in Latino Americans and the study of African Americans, asthma, genes, &amp; environments</b>					
† <a href="#">Nishimura et al. (2013)</a> n = 4,320, ages 8–21 yr Multicity study: Chicago, IL; Bronx, NY; Houston, TX; San Francisco Bay Area, CA; Puerto Rico.	IDW of central site monitors Average for first yr and first 3 yr of life. IDW estimates based on 4 closest monitors within 50 km of home. Mean (SD) across cities: 9.9 (2.9) to 32.1 (5.7)	NR	Logistic regression adjusted for age, sex, ethnicity, and composite SES. Sensitivity analysis conducted with: maternal prenatal smoking, smoking in the household ages 0–2 yr, and maternal language of preference.	Associations varied among cities. Cities varied in racial/ethnic make-up of study population, air pollution concentrations.	OR for first yr of life, all cities combined: 1.37 (1.08, 1.73) OR for PM <sub>2.5</sub> (per 1 µg/m <sup>3</sup> ): 1.03 (0.90, 1.18)

BAMSE = Children, Allergy, Milieu, Stockholm, Epidemiology Survey; BC = black carbon; CHS = Children’s Health Study; CI = confidence interval; CO = carbon monoxide; EC = elemental carbon; GASPII = Gene and Environmental Prospective Study in Italy; HR = hazard ratio; IDW = inverse distance weighting; LOOCV = leave-one-out cross validation, LUR = land use regression; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; NR = not reported; OR = odds ratio; PIAMA = Prevention and Incidence of Asthma and Mite Allergy; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm; RR = risk ratio, relative risk; SD = standard deviation; SES = socioeconomic status.


<sup>a</sup>Studies are presented in the order of appearance in the text.

<sup>b</sup>Results are presented for a 10 ppb change in NO<sub>2</sub> unless otherwise specified.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

The majority of studies administered an annual questionnaire that asked parents whether a doctor has ever diagnosed the child as having asthma. Asthma incidence was defined as a diagnosis at follow-up, with no diagnosis at any previous time of evaluation. The use of questionnaires to determine asthma incidence is a best practice ([Burr, 1992](#); [Ferris, 1978](#)) and adds to the strength of inference from the available studies. [Carlsten et al. \(2011a\)](#) is particularly noteworthy for having a pediatric allergist apply uniform criteria to assess asthma in children when they were 7 years old. NO<sub>2</sub> also was associated with a composite measure of doctor-diagnosed asthma or asthmatic/spastic/obstructive bronchitis ([Krämer et al., 2009](#)), which could represent conditions other than asthma. Among children age 12 years, [Gruzieva et al. \(2013\)](#) found an association of NO<sub>x</sub> estimated from a dispersion model with asthma incidence defined as at least 4 episodes of wheeze in the last 12 months, or at least one episode in combination with prescription of inhaled corticosteroids. Although wheeze may not necessarily indicate an asthma diagnosis, a prescription for corticosteroids likely would have resulted from a physician making a diagnosis of asthma. An uncertainty in this study is whether the NO<sub>x</sub> exposure estimate represents NO<sub>2</sub> exposure equally among subjects. Further, the very high correlations that have been observed for dispersion model estimates of NO<sub>x</sub> with PM<sub>2.5</sub> as well as traffic-related copollutants such as CO and EC ([Table 6-1](#)) produces large uncertainty in attributing associations to NO<sub>x</sub> specifically.

Transient wheezing is common in infants and often resolves as the child ages ([Martinez et al., 1995](#)). Thus, asthma diagnosis in infants and young children may have lower reliability. As a child progresses in age, the reliability of diagnosis of asthma would be expected to improve as would the strength of inference regarding associations with NO<sub>2</sub> exposure. Although a few studies indicated asthma assessment in young children ([Clark et al., 2010](#); [Clougherty et al., 2007](#)), a strength of the evidence base is the many studies that followed children to age 7 to 18 years to ascertain asthma ([Figure 6-1](#) and [Table 6-1](#)). Consistent with reliability of asthma diagnosis increasing with age, [Gehring et al. \(2010\)](#) observed associations of NO<sub>2</sub> that were greater in magnitude at later age evaluation and with longer follow-up time. Results from models with air pollution-age interaction terms indicated small age-related differences, but larger odds ratios (ORs) were observed at ages 6–8 years ([Figure 6-2](#)). [Gruzieva et al. \(2013\)](#) found an association with asthma incidence at age 12 years but not at earlier ages. However, the association was with NO<sub>x</sub>. In contrast, a few studies did not observe associations of NO<sub>2</sub> with asthma diagnosed at any age examined ([Ranzi et al., 2014](#); [Ofstedal et al., 2009a](#)).



Note: mo. = months. Blank circle = nitrogen dioxide (NO<sub>2</sub>); gray circle = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm; black circle = soot. Results are not adjusted for study region. Study region is a key determinant of air pollutant concentrations in the land use regression models used to estimate exposures, and adjustment may partly remove the influence of the pollutant. Odds ratios were calculated for an interquartile range increase in air pollutant (5.5 ppb for NO<sub>2</sub>).

Source: Reprinted with permission of American Thoracic Society, [Gehring et al. \(2010\)](#).

**Figure 6-2 Overall and age-specific associations between annual average air pollutant concentrations at the birth residence and asthma during the first 8 years of life.**

Early-life influences have been implicated in the potential development of asthma as discussed in recent reviews ([Kim et al., 2013](#); [Kudo et al., 2013a](#)). Infancy could be considered an important period for asthma development given the immaturity of the respiratory system; however, because lung development occurs throughout childhood ([Section 7.5.1](#)), other periods during childhood also may be important. Across studies, no single critical time window of NO<sub>2</sub> exposure is identified. Associations were observed for NO<sub>2</sub> in the birth year ([Carlsten et al., 2011c](#)). Other studies found larger magnitudes of association with NO<sub>2</sub> exposure in the first 3 years of life ([Nishimura et al., 2013](#)) or year of diagnosis ([Clougherty et al., 2007](#)). [Gruzieva et al. \(2013\)](#) observed that asthma was associated with NO<sub>x</sub> for the first year of life but not with average NO<sub>x</sub> concentrations since the date of the previous follow-up or during the preceding 12 months. Both of the latter exposure periods were periods of lower exposure. Often, the various early life exposure periods that are evaluated are highly correlated with one another, making it difficult to interpret the results or identify a single exposure window of concern. Exposure measurement error also may vary across time periods due to changes in time-activity patterns, for example.

Confidence in the evidence base also is based on the high follow-up participation reported in many studies. The range across studies was 63 to 82%. The high follow-up participation increases the likelihood that the results are representative of the original study population. No study indicated that results could have been unduly influenced by selective drop-out due to exposure or asthma status. An uncertainty in the evidence base is whether there is a monotonic concentration-dependent increase in NO<sub>2</sub>-related asthma risk. Analysis of the concentration–response relationship is limited and does not clearly indicate a concentration-dependent increase. [Shima et al. \(2002\)](#) observed a linear relationship for NO<sub>2</sub>-related asthma across communities in Japan, with higher asthma incidence observed in communities with higher 10-year average NO<sub>2</sub> concentrations. Analyzing individual subjects, [Carlsten et al. \(2011c\)](#) observed higher risk estimates in the second and third tertiles of NO<sub>2</sub>, but the very wide and overlapping CIs ([Table 6-1](#)) do not strongly demonstrate a linear relationship. These studies did not conduct analysis to evaluate whether there is a threshold effect.

As described in [Section 3.4.5.2](#), misrepresenting the differences between subjects in long-term NO<sub>2</sub> exposure due to the high variability in ambient concentrations observed in many locations can bias health effects associations. Thus, a key issue in evaluating the strength of inference about NO<sub>2</sub>-related asthma development from epidemiologic studies is the extent to which the NO<sub>2</sub> exposure assessment method used in a study captured the variability in exposure among study subjects. The set of studies examining asthma among children used a variety of exposure assessment techniques including land use regression (LUR) models, monitors outside each subject’s home, a single or nearest community monitoring site, monitoring site measurements combined by inverse distance weighting (IDW), and dispersion models ([Table 6-1](#)). These studies of asthma incidence demonstrate various levels of effort to design exposure assessments that might characterize exposure for individual subjects. However, the exposure assessment of many studies of asthma development provide a strong basis for drawing inferences about the relationship between long-term NO<sub>2</sub> exposure and asthma development in children. Such judgments are based on how well studies considered the strengths and limitations of the exposure assessment method as described in [Section 3.4.5.2](#).

Because children spend a large portion of time near their home, NO<sub>2</sub> concentrations at home have the potential to represent exposure well. Many recent longitudinal studies found increased risk of asthma incidence in association with ambient NO<sub>2</sub> concentrations estimated outside each subject’s home using LUR models ([Table 6-1](#)), including a pooled analysis of six birth cohort studies (5,115 children) ([Macintyre et al., 2014a](#)). Annual average NO<sub>2</sub> assigned to each child’s birth address by LUR was associated with asthma (up to ages 7–8 years) with an odds ratio (OR) of 1.48 (95% CI: 1.06, 2.06) per 10-ppb increase in NO<sub>2</sub>. Many LUR models were developed based on a large number of sites that

varied in urbanicity and traffic to represent the range locations in the study area, measurements of multiple seasons, and various traffic indicators ([Cesaroni et al., 2012](#); [Clougherty et al., 2007](#); [Henderson et al., 2007](#); [Brauer et al., 2003](#)).

Some individual studies demonstrated LUR models to have good accuracy with respect to predicting the spatial pattern of ambient NO<sub>2</sub> concentrations in the study area. As shown in [Table 6-1](#), leave-one-out cross validation (LOOCV) indicated good to excellent predictive accuracy ([Ranzi et al., 2014](#); [Carlsten et al., 2011c](#); [Gehring et al., 2010](#)). For example, in the Netherlands cohort, the LOOCV for the LUR model had an  $R^2$  of 0.68 ([Eeftens et al., 2011](#); [Gehring et al., 2010](#)). In many studies, the LUR model was developed with NO<sub>2</sub> measurements taken during a different time period as the exposure period examined in relation to asthma. The Netherlands study demonstrated the temporal validity of the LUR model. There was good agreement among LUR-predicted NO<sub>2</sub> concentrations and NO<sub>2</sub> measurement at the same sites in 1999–2000 and 2007 ([Eeftens et al., 2011](#); [Gehring et al., 2010](#)). NO<sub>2</sub> exposures for the Italian cohort also were estimated with an LUR model shown to have good predictive accuracy [LOOCV  $R^2 = 0.67$ ; ([Ranzi et al., 2014](#); [Cesaroni et al., 2012](#))], and no association with asthma was observed. Most of the LOOCV procedures were based on removing one measurement from the sample of sites used to develop the LUR model. This in-sample validation may not represent how well the model can predict NO<sub>2</sub> concentrations at other sites not used in the model. For the Vancouver, Canada cohort, LOOCV was performed with NO<sub>2</sub> measured at nonLUR sites. The model had better predictive accuracy for central site monitors than sites with low or high traffic [ $R^2 = 0.69$  versus 0.44; ([Carlsten et al., 2011c](#); [Henderson et al., 2007](#))].

Unlike the aforementioned LUR studies, [Clark et al. \(2010\)](#) assigned NO<sub>2</sub> exposure at the postal code or block levels, which have the potential for greater exposure measurement error than estimates outside the home ([Section 3.4.5.2](#)). [Clark et al. \(2010\)](#) did not provide information on whether the block-level estimates adequately represented the variation in NO<sub>2</sub> concentrations in the study area or between-subject differences in ambient NO<sub>2</sub> exposure. Information on model validation was not reported for the East Boston cohort either ([Clougherty et al., 2007](#)). Thus, these studies have weaker inference compared to the other LUR studies. However, the well-validated NO<sub>2</sub> exposure estimates in [Gehring et al. \(2010\)](#) and [Carlsten et al. \(2011c\)](#) provide a good basis for inferring a relationship between NO<sub>2</sub> exposure and asthma development in children.

Adding to the LUR studies are studies that related asthma incidence to NO<sub>2</sub> measurements spatially aligned with subjects' homes and/or schools. The spatial alignment of monitors to children's residences and/or schools increases confidence in the NO<sub>2</sub> metrics to capture between-subject variation in NO<sub>2</sub> exposures. Although NO<sub>2</sub>

measurements from central site monitors have well-known limitations in capturing the spatial heterogeneity in concentrations within an area ([Section 3.4.5.2](#)), [Shima et al. \(2002\)](#) reduced the potential for exposure measurement error by estimating NO<sub>2</sub> exposure from sites located 1 km (for a majority of subjects) to 2 km from a subject's home and/or school. Such estimates may better capture the spatial heterogeneity in ambient NO<sub>2</sub> concentrations compared to concentrations from a single site in the community or averaged across monitoring sites.

In a CHS cohort, asthma incidence was associated with annual average NO<sub>2</sub> exposure estimated from two 2-week passive sampling periods outside children's homes ([Jerrett et al., 2008](#)). However, the NO<sub>2</sub> monitoring for some children occurred after asthma diagnosis, and information was not reported on the extent of temporal mismatch. While long-term trends in NO<sub>2</sub> concentrations tend to be similar within a community, it is not known what percentage of the cohort moved to different communities during follow-up. In a separate CHS cohort, asthma incidence was associated with NO<sub>2</sub> measured at one central site per community ([McConnell et al., 2010a](#)). In the study area, NO<sub>2</sub> concentrations show high within-community variability ([Table 6-1](#)). Thus, it is unknown how well the central site measurements represent between-subject variation in exposure. [Jerrett et al. \(2008\)](#) modeled the effects of the within- and between-community variation in NO<sub>2</sub>. This approach allowed examination of the potentially different contributions of local NO<sub>2</sub> and regional NO<sub>2</sub> to the associations with asthma. Both within-community variation and between-community variation in NO<sub>2</sub> were associated with the development of asthma. The study did not examine whether associations for NO<sub>2</sub> are independent of traffic-related copollutants or PM<sub>2.5</sub>; thus, the results provide evidence that both regional and local pollution contributed to the observed associations.

In contrast with [Shima et al. \(2002\)](#), other studies assigned NO<sub>2</sub> exposure based on central site measurements with coarser spatial resolution by combining concentrations across monitors by inverse distance weighting (IDW) ([Nishimura et al., 2013](#); [Clark et al., 2010](#)). IDW is used to account for spatial variability in that greater weight is placed on measurements in closer proximity to subjects. However, the representativeness of IDW estimates to the fine-scale spatial pattern of NO<sub>2</sub> concentrations may vary across locations, depending on the presence of localized sources between measurement sites ([Section 3.2.1.1](#)). Studies in the U.S. and British Columbia, Canada aimed to characterize NO<sub>2</sub> exposure for individual subjects or at the postal code level by combining NO<sub>2</sub> concentrations across the three or four closest ambient monitors within 50 km by IDW ([Nishimura et al., 2013](#); [Clark et al., 2010](#)). These studies did not provide information to assess the extent to which the IDW estimates based on a 50-km buffer captured local sources in the study areas or represented between-subject variation in NO<sub>2</sub> exposure, and thus the studies have uncertainty regarding associations with asthma incidence. For the

British Columbia, Canada cohort, [Clark et al. \(2010\)](#) found similar ORs for asthma incidence in relation to NO<sub>2</sub> exposures estimated by LUR and IDW; however, both methods estimated exposures at the postal code level and may have similar uncertainty in representing subjects' exposures. In the British Columbia, Canada study area, NO<sub>2</sub> concentrations estimated by LUR and IDW for the postal code spatial scale agreed well with concentrations at central site monitors ([Marshall et al., 2008](#)), but it is unclear whether the LUR or IDW estimates represent NO<sub>2</sub> variability at smaller spatial scales.

Dispersion models have the potential to produce uncertain exposure estimates due to inaccuracies in estimating within-community conditions that result from simplifying assumptions of the NO<sub>x</sub> reaction model and meteorological conditions ([Section 3.4.5.2](#)). However, these limitations do not necessarily apply across locations. [Ofstedal et al. \(2009a\)](#) did not observe an increased risk of asthma development in children in relation to long-term NO<sub>2</sub> exposure. However, there is indication that the NO<sub>2</sub> exposure metrics captured some spatial variability in NO<sub>2</sub> within the study area. There was high correlation ( $r = 0.76$ ; [Table 6-1](#)) in NO<sub>2</sub> concentrations estimated by dispersion model and measured at 10 central site monitors in the city.

The ability to distinguish among the effects of correlated factors is important in making inferences about the effects of NO<sub>2</sub> on asthma development. The longitudinal studies of children observed associations with NO<sub>2</sub> after adjusting for various confounding factors such as sociodemographic and housing characteristics, cigarette smoking exposure, history of asthma and parental asthma, and education. A key concern for NO<sub>2</sub> is potential confounding by PM<sub>2.5</sub> and traffic-related pollutants such as CO, EC, and ultrafine particles (UFP). No studies of NO<sub>2</sub> and asthma development examined copollutant models with traffic-related copollutants or with PM<sub>2.5</sub>. In Japan, [Hasunuma et al. \(2014\)](#) linked a reduction in ambient NO<sub>2</sub> concentrations from 1997 to 2009 to a reduction in the prevalence of asthma. While these results support an association of asthma with NO<sub>2</sub>, key copollutants were not examined. The limited information available on the potential for confounding by key copollutants is the correlations reported with NO<sub>2</sub> and associations for copollutants. [Hwang et al. \(2005\)](#) did not analyze copollutant models with traffic-related copollutants but observed that the association for NO<sub>x</sub> with asthma prevalence remained relatively unchanged with adjustment for either sulfur dioxide (SO<sub>2</sub>), PM<sub>10</sub>, or O<sub>3</sub>. The cross-sectional design, lack of analysis of NO<sub>2</sub>, and use of central site measurements limits inferences from the copollutant model results from this study.

For key copollutants, the level of detail on correlations varies across studies. In some cases, the correlations are not reported or a statement of moderate to high correlation is reported without quantitative results ([Table 6-1](#)). No data were reported for the correlations of NO<sub>2</sub> with CO or UFP. For PM<sub>2.5</sub>, correlations range from about 0.7 to

0.93. The strong correlations often observed make it difficult to distinguish whether there is an independent effect for NO<sub>2</sub>. For the Vancouver cohort, residential estimates of BC and NO<sub>2</sub> were moderately correlated ( $r = 0.5$ ) ([Carlsten et al., 2011c](#)). However, the lower predictive accuracy for the LUR model for BC may result in differential exposure error and misrepresent the correlation with NO<sub>2</sub>. Thus, the moderate correlation may not reflect the true potential for confounding.

PM<sub>2.5</sub> was evaluated in several of the studies relating NO<sub>2</sub> exposure to asthma incidence in children ([Table 6-1](#)). [McConnell et al. \(2010a\)](#), assigning exposure from a single community central site, observed a smaller risk estimate for PM<sub>2.5</sub> than for NO<sub>2</sub> and a wider CI. They did not report a correlation between NO<sub>2</sub> and PM<sub>2.5</sub>. The association for NO<sub>2</sub> was attenuated with adjustment for dispersion model estimates of residential NO<sub>x</sub>, which was nearly perfectly correlated with traffic-related copollutants such as EC and CO. NO<sub>x</sub> results were not altered by NO<sub>2</sub> or PM<sub>2.5</sub> adjustment. These results may reflect differences in exposure measurement error for central site NO<sub>2</sub> and residential estimates of NO<sub>x</sub> or may indicate that NO<sub>x</sub> represents NO<sub>2</sub> as well as other traffic-related pollutants. [Carlsten et al. \(2011c\)](#) reported a correlation between NO<sub>2</sub> and PM<sub>2.5</sub> of  $r = 0.7$ ; and NO<sub>2</sub> and BC of  $r = 0.5$ . A larger OR but wider 95% CI was observed for PM<sub>2.5</sub> than NO<sub>2</sub>, and no risk for BC. However, the LUR models for PM<sub>2.5</sub> and BC were demonstrated to have poor predictive accuracy. [Nishimura et al. \(2013\)](#) did not report correlations between pollutants and observed a smaller OR for PM<sub>2.5</sub> than NO<sub>2</sub>, both of which were estimated by IDW. [Gehring et al. \(2010\)](#) reported a correlation between NO<sub>2</sub> and PM<sub>2.5</sub> of 0.93 and observed similar ORs for NO<sub>2</sub> and PM<sub>2.5</sub>. Both pollutants were estimated by LUR models that were shown to have similar predictive accuracy. [Clark et al. \(2010\)](#) reported high correlations between NO<sub>2</sub> and the other pollutants but did not provide quantitative data. Based on exposure assessment by LUR and IDW at the postal code level, [Clark et al. \(2010\)](#) observed PM<sub>2.5</sub> effect estimates that were smaller than those for NO<sub>2</sub> with wider 95% CIs. Thus, stronger effect estimates with smaller CIs were generally observed for NO<sub>2</sub> than for PM<sub>2.5</sub>. However, for BC estimated by LUR, the odds ratio was larger than that for NO<sub>2</sub>. Risk estimates were not always larger for NO<sub>2</sub> compared with BC. Potential differential exposure measurement error in many studies between NO<sub>2</sub> and PM<sub>2.5</sub> or BC may limit inferences that can be drawn about confounding by comparing the magnitude of associations with asthma.

Long-term exposure to ambient NO<sub>2</sub> is consistently associated with the development of asthma in children as examined in several longitudinal studies. Associations are observed with various periods of exposure, including the first year of life, the year prior to asthma diagnosis, and cumulative exposure. Strengths of the evidence base include the general timing of asthma diagnosis, which lends confidence that the NO<sub>2</sub> exposure preceded asthma development. Further, physician-diagnosed asthma, whether by parental report or

clinical assessment, along with the assessment of children older than age 5 years provides reliability in the outcome to represent asthma development. Also providing a good basis for inferring associations of NO<sub>2</sub> with asthma incidence, some studies estimated residential NO<sub>2</sub> from LUR models that were demonstrated to predict well the variability in NO<sub>2</sub> in study locations or examined NO<sub>2</sub> measured at locations 1–2 km of subjects' school or home ([Table 6-1](#)). A key uncertainty that remains when examining the epidemiologic evidence alone is the inability to determine whether NO<sub>2</sub> exposure has an independent effect from that of other pollutants in the ambient mixture. The strong correlations reported between NO<sub>2</sub> and PM<sub>2.5</sub>, the paucity of data on correlations with other traffic-related pollutants such as CO and EC/BC, and the lack of examination of potential confounding by traffic-related copollutants introduces uncertainty of the extent to which NO<sub>2</sub> has an independent effect or serves primarily as a surrogate for other highly correlated pollutants based on just epidemiologic results.

---

#### 6.2.2.2 Asthma or Chronic Bronchitis in Adults

Since the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), recent longitudinal studies have examined asthma and chronic bronchitis in adults in relation to long-term exposure to NO<sub>2</sub> and observed positive associations. In the European Community Respiratory Health Survey (ECRHS) cohort, this relationship in adults was examined using various definitions of asthma or chronic bronchitis and exposure assessment approaches.

Home outdoor NO<sub>2</sub> was associated with chronic bronchitis defined as productive (phlegm-producing) chronic cough more than 3 months each year ([Sunyer et al., 2006](#)). The follow-up time period was 8.9 years. Indoor kitchen and outdoor (at the kitchen window) residential NO<sub>2</sub> was measured using Palmes tubes during a 14-day period in 1,634 households of ECRHS subjects who did not change residences during the follow-up. This was repeated in 659 households (45%) 6 months later. A linear concentration–response relationship with NO<sub>2</sub> was observed only in females. NO<sub>2</sub> was associated with chronic bronchitis after adjustment for traffic intensity at the residence.

New onset asthma was related to NO<sub>2</sub> exposure in the ECRHS adult cohort as ascertained by a positive response to the question “Have you ever had asthma?” ([Jacquemin et al., 2009b](#)) and a continuous asthma score ([Jacquemin et al., 2009a](#)). Asthma incidence was defined as reporting asthma in the follow-up (1999 to 2001) but not at baseline (1991 to 1993). Outdoor NO<sub>2</sub> estimates developed from NO<sub>x</sub> emissions were linked to subjects' home addresses. For “ever having asthma,” the adjusted OR was 1.96 (95% CI: 1.04,

3.70) per 10-ppb increase in NO<sub>2</sub>. The OR for asthma incidence based on the ratio of the mean asthma score was 1.48 (95% CI: 1.18, 1.85) per 10-ppb increase in NO<sub>2</sub>.

In a preliminary examination of a smaller group of the ECRHS cohort, the prospective Respiratory Health in Northern Europe cohort study, [Modig et al. \(2009\)](#) used dispersion models and two definitions of asthma for 3,824 adults (ages 20–44 years at baseline): (1) the cumulative number of onset cases of asthma and (2) incident cases of asthma. Asthma was defined as no asthma attacks during the last 12 months and no current use of asthma medication at the start of the study but having asthma or ever being diagnosed with asthma at follow-up. NO<sub>2</sub> concentrations estimated at the home were associated with risk of developing asthma. The OR was 2.04 (95% CI: 1.14, 3.65) for the cumulative number of onset cases of asthma and 2.25 (95% CI: 1.00, 5.07) for the incident definition of cases per 10-ppb increase in NO<sub>2</sub> concentration. The OR for asthma increased across NO<sub>2</sub> tertiles, indicating a concentration-dependent relationship. With the first tertile as the reference, the OR was higher for the third tertile (OR<sub>onset</sub> 1.58 [95% CI: 0.96, 2.6]; OR<sub>incident</sub> 2.06 [95% CI: 0.98, 4.32]) than for the second tertile (OR<sub>onset</sub> 1.17 [95% CI: 0.70, 1.94]; OR<sub>incident</sub> 1.77 [95% CI: 0.86, 3.64]).

[Castro-Giner et al. \(2009\)](#) prospectively examined asthma incidence and prevalence in the large (2,577 subjects at follow-up) ECRHS cohort from 13 European cities. In the longitudinal analysis, for the 120 subjects who developed asthma during the follow-up period, NO<sub>2</sub> was associated with new-onset asthma with an OR of 2.20 (95% CI: 1.17, 4.10) per 10-ppb increase. For asthma prevalence, an association was indicated among subjects who changed homes rather than subjects who lived in the same home during follow-up (movers OR: 2.53 [95% CI: 1.16, 5.56]; nonmovers OR: 1.04 [95% CI: 0.66, 1.64]). However, for new-onset asthma, evidence for association was stronger among nonmovers than movers [nonmovers OR: 2.39 (95% CI: 1.10, 5.22); movers OR: 2.09 (95% CI: 0.70, 6.12)].

In a meta-analysis, [Cai et al. \(2014\)](#) cross-sectionally assessed the associations of outdoor air pollution on the prevalence of chronic bronchitis symptoms in adults in five cohort studies participating in the European Study of Cohorts for Air Pollution Effects (ESCAPE) project. Annual average NO<sub>2</sub>, NO<sub>x</sub>, as well as PM<sub>10</sub>, PM<sub>2.5</sub>, PM<sub>absorbance</sub>, and PM<sub>coarse</sub> from 2008–2011 were assigned to home addresses by LUR. Symptoms examined were chronic bronchitis (cough and phlegm for ≥3 months of the year for ≥2 years), chronic cough (with/without phlegm), and chronic phlegm (with/without cough). Overall, there were no associations with any air pollutant or traffic exposure.

In summary, among adults, long-term NO<sub>2</sub> exposure generally is associated with asthma incidence and chronic bronchitis. The longitudinal design of the studies lends strength to the interpretation of results. Studies aimed to produce individual estimates of exposure at

the residence, and in most cases, NO<sub>2</sub> exposures estimated from dispersion models were demonstrated to be well correlated with measured concentrations in the study locations ( $R^2 = 0.60\text{--}0.79$ ). However, the strength of inference is limited because findings are based on one cohort, and none of the studies in adults considered confounding by PM<sub>2.5</sub> or traffic-related pollutants.

---

### 6.2.2.3 Subclinical Effects Underlying Development of Asthma or Chronic Bronchitis

Animal toxicological studies demonstrate that long-term NO<sub>2</sub> exposure enhances both responsiveness of airways and the development of allergic responses. Some animal toxicological studies and epidemiological studies of long-term exposure show increases in pulmonary inflammation and oxidative stress. Thus, there is some evidence that suggests a mechanistic basis for the development of asthma in relation to NO<sub>2</sub> exposure.

#### Airway Responsiveness

Animal toxicological studies have demonstrated that NO<sub>2</sub> exposure enhances responsiveness of airways to nonspecific and specific challenges. A subchronic-duration study demonstrated concentration-dependent increases in airway responsiveness to histamine in NO<sub>2</sub>-exposed guinea pigs ([Kobayashi and Miura, 1995](#)). In this study, one experiment demonstrated AHR after 6 weeks of exposure to 4,000 ppb, but not 60 or 500 ppb NO<sub>2</sub>. In another experiment, AHR was observed in guinea pigs exposed to 4,000 ppb NO<sub>2</sub> for 6 weeks; 2,000 ppb for 6 and 12 weeks; and 1,000 ppb for 12 weeks. Specific airways resistance in the absence of a challenge agent was increased in guinea pigs exposed to 2,000 and 4,000 ppb NO<sub>2</sub> for 12 weeks. AHR occurring with increased airway resistance suggests the involvement of airway remodeling. Another subchronic-duration exposure study found delayed bronchial responses, measured as increased respiration rate, in guinea pigs sensitized and challenged with *C. albicans* and exposed to NO<sub>2</sub> [4,760 ppb, 4 h/day, 5 days/week, 6 weeks ([Kitabatake et al., 1995](#))]. However, NO<sub>2</sub> exposure (4,000 ppb, 2 h/day, 3 months) failed to alter airway responsiveness to a nonspecific challenge in rabbits sensitized at birth with house dust mite antigen ([Douglas et al., 1995](#)). Overall, results are consistent with those in rodents with short-term exposure to NO<sub>2</sub> ([Section 4.3.2.5](#)). In addition, they are supported by findings for effects underlying development of AHR, including inflammation, and allergic sensitization ([Section 4.3.2](#)).

## **Development of Allergic Responses**

Toxicological studies provide some evidence that is coherent with the development of allergic responses seen in some of the epidemiologic studies ([Section 6.2.4](#)). One subchronic-duration study showed that exposure to 4,000 ppb NO<sub>2</sub> for 12 weeks led to enhanced immunoglobulin E (IgE)-mediated release of histamine from mast cells isolated from guinea pigs ([Fujimaki and Nohara, 1994](#)). This response was not found in mast cells from rats similarly exposed in the same study. Furthermore, two short-term studies provide evidence that exposure to NO<sub>2</sub> leads to T-derived lymphocyte helper 2 (Th2) skewing and/or allergic sensitization in healthy human adults exposed repeatedly to 2,000 ppb NO<sub>2</sub> and in naïve animals exposed repeatedly to 3,000 ppb NO<sub>2</sub>, as discussed in [Sections 4.3.2.6](#) and [5.2.7.4](#) ([Pathmanathan et al., 2003](#); [Ohashi et al., 1994](#)). Findings of increased histamine release from mast cells, increased nasal eosinophils, and increased Th2 cytokines seen in humans and animal models exposed to NO<sub>2</sub> provide support for the epidemiologic evidence relating NO<sub>2</sub> exposure to asthma development and the findings in some of the epidemiologic studies for the association of NO<sub>2</sub> exposure with the development of allergic responses.

## **Pulmonary Inflammation and Oxidative Stress**

Inflammation and oxidative stress are identified as key events in the proposed mode of action for development of asthma ([Figure 4-2](#)). Long-term NO<sub>2</sub> exposure has been shown to induce pulmonary inflammation or oxidative stress in toxicological and epidemiologic studies, but results are not entirely consistent. Similarly, there is some evidence for a relationship of short-term exposure to NO<sub>2</sub> with pulmonary inflammation and oxidative stress ([Section 5.2.7.4](#)) to describe a potential pathophysiologic basis for development of asthma in response to repeated NO<sub>2</sub> exposures.

### ***Epidemiologic Evidence in Children***

In the CHS cohort of 1,211 schoolchildren from eight southern California communities, annual average NO<sub>2</sub> was associated with a longitudinal increase in exhaled nitric oxide (eNO; using a flow rate of 50 mL/sec) in 2006–2007 and 2007–2008 ([Berhane et al., 2014](#)). This association was observed with adjustment for short-term NO<sub>2</sub> assessed from central monitoring sites and was independent of asthma status. Based on prior findings in CHS ([Bastain et al., 2011](#)) that elevated eNO is associated with increased risk of new onset asthma, an effect of long-term exposure to NO<sub>2</sub> on increases in eNO over time is consistent with a role for NO<sub>2</sub> in asthma pathogenesis. However, NO<sub>2</sub> exposure was estimated from a single monitor in each of the study communities, and confounding by PM<sub>2.5</sub> or traffic-related pollutants was not examined.

Using LUR models to estimate annual average NO<sub>2</sub> exposure, [Liu et al. \(2014a\)](#) observed null associations with eNO among all children (n = 1,985, age 10 years, ESCAPE) and those without asthma (n = 1,793) in both the single and copollutant (PM<sub>10</sub>) models. NO<sub>2</sub> was positively associated with eNO in the 192 children with asthma.

Using a cross-sectional prevalence design, [Dales et al. \(2008\)](#) examined the relationship of eNO and NO<sub>2</sub> in a cohort of 2,402 healthy school children. NO<sub>2</sub> was estimated for each child's residential postal code. Quantitative results were not reported; the study authors only indicate that NO<sub>2</sub> showed positive but statistically nonsignificant associations with eNO. An eNO-roadway density association persisted after adjustment for air pollutant concentrations (NO<sub>2</sub>, SO<sub>2</sub>, and PM<sub>2.5</sub>) within the previous 24 and 48 hours of the eNO measure, indicating that the association with roadway density was unlikely to be confounded by an unmeasured short-term exposure effect.

The short-term evidence base provides support for the development of asthma in relation to long-term NO<sub>2</sub> exposure. Epidemiologic studies indicate associations between short-term NO<sub>2</sub> exposure and increases in oxidative stress and pulmonary inflammation in the general population of children and in healthy adults ([Section 5.2.7.4](#)).

### ***Toxicological Evidence***

Similar to studies of short-term NO<sub>2</sub> exposure ([Section 5.2.7.4](#)), some animal toxicological studies of long-term exposure show increases in pulmonary inflammation, oxidative stress, and injury. Details from these studies, all of which were reviewed in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), are presented in [Table 6-2](#).

Many studies investigating NO<sub>2</sub>-induced injury and oxidative stress in the airway measured changes in lipids, which are necessary for both lung function and defense. [Sagai et al. \(1982\)](#) reported that rats exposed to 40, 400, or 4,000 ppb NO<sub>2</sub> for 9 or 18 months had increased ethane exhalation and that exposure to 40 ppb for 9 months resulted in increased lipid peroxidation. [Arner and Rhoades \(1973\)](#) showed that rats exposed to 2,900 ppb NO<sub>2</sub> for 9 months had decreased lipid content leading to increased surface tension of the lung surfactant and altered lung mechanics.

Histopathological assessment of lung tissue showed that long-term exposure to NO<sub>2</sub> resulted in alveolar macrophage (AM) accumulation and areas of hyperinflation ([Gregory et al., 1983](#)). [Kumae and Arakawa \(2006\)](#) exposed rats to 200, 500, or 2,000 ppb NO<sub>2</sub> prenatally (embryonic group) or postnatally during the weanling period (5 weeks old, weanling group) and assayed bronchoalveolar lavage (BAL) fluid at 8 and 12 weeks of age. In the embryonic group, exposure to 500 ppb NO<sub>2</sub> resulted in increases in lymphocytes at 8 weeks and increases in macrophages and neutrophils at 12 weeks. No changes in differential cell counts were observed in the weanling group at 8 weeks of age,

but at 12 weeks of age, macrophages and lymphocytes were increased with exposures at and above 500 ppb and neutrophils were increased at 2,000 ppb. The embryonic group also had increased tumor necrosis factor alpha (TNF- $\alpha$ ) and interferon gamma (IFN- $\gamma$ ) at 8 weeks but not at 12 weeks. In the weanling group, TNF- $\alpha$  was increased at both 8 and 12 weeks, and IFN- $\gamma$  was increased only at 12 weeks.

Long-term NO<sub>2</sub> exposure can modify oxidant balance in the airway. However, similar to short-term exposures ([Section 5.2.2.5](#)), long-term ambient-relevant NO<sub>2</sub> exposures do not consistently induce effects on antioxidant levels or enzyme activity across species.

Long-term NO<sub>2</sub> exposure has increased, decreased, and unaltered activity of enzymes involved in the glutathione cycle ([Sagai et al., 1984](#); [Gregory et al., 1983](#); [Ayaz and Csallany, 1978](#)). [Sagai et al. \(1984\)](#) reported increased nonprotein sulfhydryl levels and decreased glutathione S-transferase (GST) activity in adult male rats after 9 and 18 months of exposure to 400 ppb NO<sub>2</sub> and decreased glutathione peroxidase (GPx) activity and increased glucose-6-phosphate dehydrogenase activity after exposure to 4,000 ppb NO<sub>2</sub>. There were no changes in the activity of 6-phosphogluconate dehydrogenase, superoxide dismutase (SOD), or disulfide reductase after exposure to 400 ppb NO<sub>2</sub>. [Gregory et al. \(1983\)](#) reported increased GPx activity in BAL fluid after 6 weeks of exposure to 5,000 ppb NO<sub>2</sub>; however, at 15 weeks, enzyme activity returned to control levels although slight changes in pathology were reported. [Ayaz and Csallany \(1978\)](#) showed that continuous exposure to 1,000 ppb NO<sub>2</sub> for 17 months decreased GPx activity in Vitamin E-deficient mice but increased GPx activity in Vitamin E-supplemented mice.

**Table 6-2 Characteristics of animal toxicological studies of long-term nitrogen dioxide exposure and respiratory effects.**

Study	Species (Strain); Sample Size; Sex; Age	Exposure Details	Endpoints Examined
<a href="#">Arner and Rhoades (1973)</a>	Rats (Long-Evans); n = NR; M; age NR	2,900 ppb for 5 days/week for 9 mo	Histopathologic evaluation and morphometry
<a href="#">Ayaz and Csallany (1978)</a>	Mice (C57BL/6J); n = 120; F; age NR	500 ppb or 1,000 ppb continuously for 17 mo	Morphometry
<a href="#">Blair et al. (1969)</a>	Mice (strain NR); n = 4/group; sex & age NR	500 ppb for 6, 18, or 24 h/day, 7 days/week for 3–12 mo	Histopathologic evaluation
<a href="#">Chang et al. (1986)</a>	Rat (Fisher 344); n = 8/group; M; 1-day or 6 weeks	(1) 500 ppb continuously with two, daily 1-h spikes of 1,500 ppb, 5 days/week for 6 weeks (2) 2,000 ppb continuously for 7 days/week for 6 weeks; Two 1-h spikes daily to 6,000 ppb (6-week rats only)	Histopathologic evaluation and lung morphometry
<a href="#">Crapo et al. (1984)</a>	Rat (CD, Fisher 344); n = NR; M; 6 week	2,000 ppb for 23 h/day; two daily 30-min spikes of 6,000 ppb	Morphometric analysis of proximal alveolar and distal alveolar regions
<a href="#">Ehrlich and Henry (1968)</a>	Mice (Swiss albino); n = ≥30/group, n = 4–8/group; F; age NR	(1) 500 ppb continuously (2) 500 ppb for 6 h/day (3) 500 ppb for 18 h/day (1–3) for 1 to 12 mo; challenged with <i>Klebsiella pneumoniae</i> after exposure	Mortality, hematology, serum LDH, body weight, bacterial clearance
<a href="#">Fujimaki and Nohara (1994)</a>	Rats (Wistar); n = 10/group; M; 8 weeks Guinea pigs (Hartley); n = 10/group; sex NR; 8 weeks	1,000, 2,000, or 4,000 ppb continuously for 12 weeks	Mast cell counts and histamine release
<a href="#">Furiosi et al. (1973)</a>	Monkey ( <i>Macaca speciosa</i> ), n = 4–5/group; M/F; maturing Rat (Sprague-Dawley); n = 15–25/group; M; weanling	(1) 2,000 ppb NO <sub>2</sub> continuously (2) 330 µg/m <sup>3</sup> NaCl continuously (3) 2,000 ppb NO <sub>2</sub> + 330 µg/m <sup>3</sup> NaCl continuously (1–3) for 14 mo	Histopathologic evaluation, hematology
<a href="#">Greene and Schneider (1978)</a>	Baboons; n = 6; M/F; 3 to 4 yr	2,000 ppb 8 h/day, 5 days/week for 6 mo	Immunologic and histopathologic evaluation

**Table 6-2 (Continued): Characteristics of animal toxicological studies of long-term nitrogen dioxide exposure and respiratory effects.**

Study	Species (Strain); Sample Size; Sex; Age	Exposure Details	Endpoints Examined
<a href="#">Gregory et al. (1983)</a>	Rat (Fischer 344); n = 4–6/group; sex NR; 14–16 weeks	(1) 1,000 ppb (2) 5,000 ppb (3) 1,000 ppb with two daily, 1.5-h spikes of 5,000 ppb (1–3) 7 h/day for 5 days/week for up to 15 weeks	Histopathological evaluation, BAL fluid analysis (LDH, ALKP, glutathione peroxidase), antioxidant enzymes in lung homogenates
<a href="#">Hayashi et al. (1987)</a>	Rat (Wistar); n = 18–160/group; M; age NR	500 ppb or 5,000 ppb continuously for up to 19 mo	Morphological changes, histology
<a href="#">Henry et al. (1970)</a>	Squirrel monkeys; n = 37; M; age NR	5,000 ppb continuously for 2 mo; challenge with <i>Klebsiella pneumoniae</i> or influenza after exposure	Infection resistance, mortality, peripheral blood markers, and respiratory function
<a href="#">Kumae and Arakawa (2006)</a>	Rats (Brown-Norway); n = 5–47/group; F; age NR	200, 500, or 2,000 ppb pre- and post-natal for up to 12 postnatal weeks	Immunologic evaluation (alveolar macrophage activity) and BAL fluid cell counts and cytokines
<a href="#">Kubota et al. (1987)</a>	Rat (JCL Wistar); n = 3–4/group; M; 2 mo	40, 400, or 4,000 ppb continuously for 9, 18, and 27 mo	Serological examination and lung morphometry
<a href="#">Lafuma et al. (1987)</a>	Hamster (Golden Syrian); n = 7–9/group; M; age NR	2,000 ppb NO <sub>2</sub> for 8 h/day for 5 days/week for 2 mo	Lung histopathology and morphometry, lung mechanics, serum elastase activity, and protease inhibitor capacity
<a href="#">Mercer et al. (1995)</a>	Rats (Fischer 344); n = 5/group; M; 7 weeks	500 ppb continuously with 2 daily, 1-h peaks of 1,500 ppb for 9 weeks	Histopathologic evaluation and morphometry
<a href="#">Miller et al. (1987)</a>	Mice (CD-1); n = 18–21/ group; F; 4–6 weeks	(1) 200 ppb (2) 200 ppb daily continuously for 7 days/week with 2 daily, 1-h peaks of 780 ppb 5 days/week (1–2) 16, 32, or 52 weeks	Histopathologic evaluation, pulmonary function, and antibacterial host defenses
<a href="#">Sagai et al. (1982)</a>	Rats (JCL, Wistar); n = 6–12/group; M; 8 weeks	10,000 ppb continuously for 2 weeks	Antioxidant levels, enzyme activity, lipid peroxidation
<a href="#">Sagai et al. (1984)</a>	Rats (JCL Wistar); n = 4–6/group; M; 8 weeks	40, 400, or 4,000 ppb continuously for 9, 18, or 27 mo	Histopathologic evaluation and morphometry
<a href="#">Sherwin and Richters (1982)</a>	Mice (Swiss Webster); n = 30/group; M; young adults	340 ppb for 6 h/day for 5 days/week for 6 weeks	Type II pneumocytes in the lungs and alveolar wall area

**Table 6-2 (Continued): Characteristics of animal toxicological studies of long-term nitrogen dioxide exposure and respiratory effects.**

Study	Species (Strain); Sample Size; Sex; Age	Exposure Details	Endpoints Examined
<a href="#">Stevens et al. (1988)</a>	Rat (Fischer 344); n = 1 or 6/group; M; neonate, young adult	500, 1,000, or 2,000 ppb continuously with two daily, 1-h spikes at 1,500, 3,000, or 6,000 ppb for 5 days/week for 6 weeks	Pulmonary function
<a href="#">Tepper et al. (1993)</a>	Rats (Fischer 344); n = 11–16/group; M; 60 days	500 ppb continuously 7 days/week with two daily, 2-h spikes of 1,500 ppb, 5 days/week for up to 78 weeks	Pulmonary function and lung disease
<a href="#">Wagner et al. (1965)</a>	Dog (mongrels); n = 6–10/group; M; age NR Rabbit; n = 4–8/group; M; age NR Guinea pig (English); 15–31/group; M; age NR Rat (Sherman); n = 20–40/group; M; age NR Mice (HLA, C57Bl/6J, CAF/Jax); n = 60–110/group; M; age NR	1,000 or 5,000 ppb continuously for 10–18 months	Pulmonary function and histopathology

ALKP = alkaline phosphatase; BAL = bronchoalveolar lavage; F = female; LDH = lactate dehydrogenase; M = Male; NaCl = sodium chloride; NO<sub>2</sub> = nitrogen dioxide; NR = not reported.

#### 6.2.2.4 Summary of Development of Asthma or Chronic Bronchitis

The recent evidence base adds several longitudinal studies that consistently find a positive association of various NO<sub>2</sub> exposure measures with asthma incidence in children at several ages. Many studies observe associations with individual, residential ambient NO<sub>2</sub> exposure estimated by LUR that were demonstrated to well predict ambient NO<sub>2</sub> concentrations in the study locations. Another study observed an association with NO<sub>2</sub> measured at sites 1–2 km from the subjects' school or home. Asthma incidence was also associated with neighborhood-level ambient NO<sub>2</sub> concentrations estimated by IDW or measured at a single community central site monitor. For the latter, studies did not report information on the representativeness of the neighborhood-level exposure estimates. In adults, positive associations are also observed; however, this evidence base is limited primarily to one adult cohort in Europe. None of the studies of children or adults examined whether there was evidence for an association of NO<sub>2</sub> with health effects independent from PM<sub>2.5</sub> or traffic-related pollutants such as EC/BC, CO, or UFP.

Toxicological and controlled human exposure studies reduce some of the uncertainty in the epidemiologic evidence by providing biological plausibility for a relationship between long-term NO<sub>2</sub> exposure and asthma development. In the pathophysiology of asthma, recurrent pulmonary inflammation, allergic sensitization, and subsequent development of AHR play important roles ([Section 4.3.5](#) and [Figure 4-2](#)). Long-term-exposure toxicological studies demonstrate NO<sub>2</sub>-induced AHR, and experimental studies of repeated short-term exposures provide evidence for NO<sub>2</sub>-induced development of allergic responses in healthy adults and animal models as well as increases in neutrophils in healthy adults. In one study of guinea pigs, NO<sub>2</sub>-induced (1,000–4,000 ppb) increases in AHR was accompanied by an increase in specific airways resistance, suggesting that airway remodeling may contribute to the development of AHR [[Kobayashi and Miura, 1995](#)]; [Section 4.3.2.5](#)]. Mechanistic studies indicate that inflammatory mediators and structural changes occurring due to airway remodeling can alter the contractility of airway smooth muscle. There also is some evidence for pulmonary oxidative stress induced by short-term NO<sub>2</sub> exposure in healthy adults ([Section 5.2.7.4](#)) and long-term exposure in rodents ([Section 6.2.2.3](#)), although results overall are not consistent. Epidemiologic evidence points to associations between short-term increases in ambient NO<sub>2</sub> concentrations and increases in pulmonary inflammation in healthy children and adults ([Section 5.2.7.4](#)), but such evidence is limited and inconsistent for long-term NO<sub>2</sub> exposure. The positive relationship between NO<sub>2</sub> exposures and asthma in longitudinal epidemiologic studies and the small body of evidence indicating NO<sub>2</sub> effects on inflammation, allergic sensitization, and AHR, which are key events in the proposed mode of action for the development of asthma, indicate that long-term NO<sub>2</sub> exposure could have an independent role in asthma development.

---

### **6.2.3 Severity of Asthma, Chronic Bronchitis, and Chronic Obstructive Pulmonary Disease: Respiratory Symptoms and Hospital Admissions**

In the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), there was inconsistent evidence for an association between long-term exposure to NO<sub>2</sub> and respiratory disease severity assessed as occurrence of respiratory symptoms. There was a single longitudinal study, and for the many cross-sectional studies, there was uncertainty related to the temporality of exposure and occurrence of symptoms. There are several recent longitudinal studies of respiratory disease severity, which are the focus of this evaluation. Studies that evaluated indoor NO<sub>2</sub> concentrations are discussed first, followed by studies of outdoor NO<sub>2</sub> concentrations. Cross-sectional studies were reviewed, and results generally do not differ from those in longitudinal studies ([Annesi-Maesano et al., 2012a](#); [Ghosh et al., 2012b](#); [Dong et al., 2011](#); [Mi et al., 2006](#); [Pattenden et al., 2006](#); [Nicolai et al., 2003](#); [Brauer et al., 2002](#); [Gehring et al., 2002](#); [Zemp et al., 1999](#)). Previous

cross-sectional studies are summarized in Annex Table AX6.3-17 of the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008a](#)). A key consideration in evaluating respiratory disease severity is whether the study design or statistical methods accounted for the potential effects of short-term exposure.


---

### 6.2.3.1 Indoor Nitrogen Dioxide and Respiratory Symptoms in Children and Adults

Effects of indoor NO<sub>2</sub> may not be confounded by all of the same copollutants as outdoor NO<sub>2</sub>, although there could be confounding by other indoor pollutants such as those emitted from heating sources. Coherence between associations of respiratory disease severity for indoor and ambient NO<sub>2</sub> exposure metrics can aid in drawing inferences about the effects of ambient NO<sub>2</sub> exposure. For long-term NO<sub>2</sub> exposures, the recent indoor prospective study of school-aged children ([Belanger et al., 2013](#)) and the adult indoor prospective study ([Hansel et al., 2013](#)) provide evidence that supports a relationship between long-term NO<sub>2</sub> exposure and respiratory disease severity.

[Belanger et al. \(2013\)](#) observed positive associations of asthma severity score, wheeze, nighttime symptoms, and rescue medication use with indoor residential NO<sub>2</sub> where the mean monitoring length was 33 [standard deviation (SD): 7] days. [Figure 6-3](#) illustrates the concentration–response relationships between indoor NO<sub>2</sub> and asthma-related effects with threshold functions for each outcome. In adjusted models with quintiles of NO<sub>2</sub> exposure, concentrations >14.3 ppb compared with the reference level (≤6 ppb, designated as the threshold value) were associated with elevated risk of a one-level increase in asthma severity score (OR: 1.43 [95% CI: 1.08, 1.88]). These same exposures were also associated with increased risks of wheeze (OR: 1.53 [95% CI: 1.16, 2.02]), night symptoms (OR: 1.59 [95% CI: 1.24, 2.01]), and rescue medication use (OR: 1.74 [95% CI: 1.34, 2.26]). Every fivefold increase in NO<sub>2</sub> exposure >6 ppb was associated with increases in asthma-related outcomes ([Table 6-3](#)).

Recent studies of infants are consistent with previous results ([Samet et al., 1993](#)) that showed no association between 2-week avg exposure to NO<sub>2</sub> and the incidence and duration of respiratory illness. [Raaschou-Nielsen et al. \(2010b\)](#) and [Sonnenschein-Van der Voort et al. \(2012\)](#) found no associations between indoor NO<sub>2</sub> exposure and wheezing in infants.



**Figure 6-3** Concentration–response relationships between asthma-related effects and indoor nitrogen dioxide illustrated with constrained, natural spline and threshold functions in hierarchical ordered logistic regression models.

**Table 6-3 Longitudinal studies of long-term nitrogen dioxide exposure and respiratory symptoms in children.**

Study <sup>a</sup>	Exposure Assessment	Pollutant Correlation	Statistical Methods	Comments	Results (95% CI) <sup>b</sup>
<b>Study of Traffic, Air Quality, and Respiratory Health, Connecticut and Western Massachusetts</b>					
<p>†<a href="#">Belanger et al. (2013)</a>                      n = 1,642 children with asthma, ages 5–10 yr.                      Followed for 1 yr during 2006–2009.</p>	<p>Indoor residential.                      Repeated measurements with Palmes tubes in bedrooms and dayroom for 4 weeks for 4 seasons.</p>	<p>No other pollutants examined.</p>	<p>Hierarchical ordered logistic regression adjusted for age, sex, atopy, season of monitoring, race/ethnicity, mother’s education, smoking in the home, and all five variables for combined specific sensitization and exposure to indoor allergens. Also adjusted for maintenance medication use because it was also associated with SES.</p>	<p>Asthma severity score consisted of symptoms and medication use based on the Global Initiative for Asthma (<a href="#">NHLBI, 2002</a>).</p>	<p>OR per fivefold increase in NO<sub>2</sub> exposure above 6 ppb                      Asthma severity score: 1.37 (1.01, 1.89)                      Wheeze: 1.49 (1.09, 2.03)                      Night symptoms: 1.52 (1.16, 2.00)                      Rescue medication use: 1.78 (1.33, 2.38)</p>

**Table 6-3 (Continued): Longitudinal studies of long-term nitrogen dioxide exposure and respiratory symptoms in children.**

Study <sup>a</sup>	Exposure Assessment	Pollutant Correlation	Statistical Methods	Comments	Results (95% CI) <sup>b</sup>
<b>Children's Health Study (CHS), southern California</b>					
<p><a href="#">McConnell et al. (2003)</a>                      n = 475 children with asthma or bronchitic symptoms, ages 9–10 yr (4th grade) and 12–13 yr (7th grade).                      Followed 1996–1999.                      Completed two or more yearly follow-up questionnaires.</p>	<p>Central site—1 in each of 12 communities.                      Within community: yearly deviation in each community from overall 4-yr mean.                      Between communities: 4-yr average across communities.                      Mean (SD) 4-yr avg across communities: 19.4 (11.3) ppb.</p>	<p>Within-community correlations differed in that NO<sub>2</sub> could be distinguished from most other major pollutants except OC and I ACID.                      EC: 0.54                      OC: 0.67                      PM<sub>2.5</sub>: 0.54                      O<sub>3</sub>: 0.59                      PM<sub>10</sub>: 0.20                      PM<sub>10-2.5</sub>: -0.22                      I ACID: 0.65                      O ACID: 0.48</p>	<p>Three-stage regression adjusted for age, maternal smoking history, child's sex, maternal and child's race.                      Within-community estimates were adjusted for between-community effects of the pollutant and vice versa.</p>	<p>Overall participation rate was high (82%).</p>	<p>OR within community 1.97 (1.22, 3.18)                      OR between communities 1.22 (1.00, 1.49)                      Copollutant model results:                      Within community                      NO<sub>2</sub> with EC: 1.05<sup>c</sup>                      NO<sub>2</sub> with OC: 1.04 NS                      NO<sub>2</sub> with PM<sub>2.5</sub>: 1.05 NS                      NO<sub>2</sub> with O<sub>3</sub>: 1.06 NS                      NO<sub>2</sub> with PM<sub>10</sub>: 1.07<sup>c</sup>                      NO<sub>2</sub> with PM<sub>10-2.5</sub>: 1.08<sup>d</sup>                      NO<sub>2</sub> with I ACID: 1.09<sup>d</sup>                      NO<sub>2</sub> with O ACID: 1.07<sup>c</sup>                      Between communities                      NO<sub>2</sub> with EC: 1.01 NS                      NO<sub>2</sub> with OC: 1.01 NS                      NO<sub>2</sub> with PM<sub>2.5</sub>: 1.01 NS                      NO<sub>2</sub> with O<sub>3</sub>: 1.02<sup>c</sup>                      NO<sub>2</sub> with PM<sub>10</sub>: 1.01 NS                      NO<sub>2</sub> with PM<sub>10-2.5</sub>: 1.02<sup>c</sup>                      NO<sub>2</sub> with I ACID: 1.02 NS                      NO<sub>2</sub> with O ACID: 1.02 NS</p>

**Table 6-3 (Continued): Longitudinal studies of long-term nitrogen dioxide exposure and respiratory symptoms in children.**

Study <sup>a</sup>	Exposure Assessment	Pollutant Correlation	Statistical Methods	Comments	Results (95% CI) <sup>b</sup>
<b>Prevention and Incidence of Asthma and Mite Allergy (PIAMA), the Netherlands</b>					
† <a href="#">Gehring et al. (2010)</a> n = 3,863 children followed from birth to age 8 yr	LUR model Annual avg at birth residence.	NO <sub>2</sub> -PM <sub>2.5</sub> : 0.93 NO <sub>2</sub> -soot: 0.96	GEE adjusted for sex, study arm (intervention or natural history), use of mite-impermeable mattress covers, allergies of mother and father, maternal and paternal education, maternal prenatal smoking, breastfeeding, presence of a gas stove in the child's home, presence of older siblings, smoking, signs of dampness and pets in the child's home, day care attendance, and Dutch nationality.	NO <sub>2</sub> not associated with atopic eczema, allergic sensitization, or bronchial hyperresponsiveness. No copollutant models.	OR for asthma symptoms: 1.17 (0.98, 1.39) without adjustment for study region. OR for wheeze: 1.27 (1.07, 1.50) without adjustment for study region.
<b>Children, Allergy, Milieu, Stockholm, Epidemiology Survey (BAMSE), Stockholm, Sweden</b>					
† <a href="#">Gruzieva et al. (2013)</a> n = 3,633 children followed from birth (1994–1996) to age 12 yr. Related publications: <a href="#">Melén et al. (2008)</a> <a href="#">Nordling et al. (2008)</a>	Dispersion model Annual avg NO <sub>x</sub> at all residences from birth to age 12 yr (1994–2008).	NO <sub>x</sub> -PM <sub>10</sub> for first yr of life: 0.96	Multinomial regression/GEE adjusted for municipality, SES, yr the house was built, and heredity.		OR for wheeze at 12 yr of age, 3 or more episodes: 1.35 (0.79, 2.29) per 20 ppb NO <sub>x</sub> . No association of NO <sub>x</sub> after the first yr of life with asthma symptoms.

BAMSE = Children, Allergy, Milieu, Stockholm, Epidemiology Survey; CHS = Children's Health Study; CI = confidence interval; EC = elemental carbon; GEE = generalized estimating equations; I ACID = inorganic acid; LUR = land use regression; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; NR = not reported; NS = not statistically significant; O ACID = organic acid; O<sub>3</sub> = Ozone; OC = organic carbon; OR = odds ratio; PIAMA = Prevention and Incidence of Asthma and Mite Allergy; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm; PM<sub>10-2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm and greater than a nominal mean of 2.5 µm; SD = standard deviation; SES = socioeconomic status.

<sup>a</sup>Studies are presented in the order of appearance in the text.

<sup>b</sup>Results are presented per 10-ppb increase in NO<sub>2</sub> unless otherwise specified.

<sup>c</sup>p < 0.01.

<sup>d</sup>p < 0.05.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

[Hansel et al. \(2013\)](#) investigated indoor NO<sub>2</sub> and PM<sub>2.5</sub> concentrations in relation to respiratory effects among former smokers with COPD in Baltimore, MD. Pollutants and symptoms were measured at baseline, 3 months, and 6 months. Pollutants were measured in the bedroom and the main living area, rooms where participants reported spending the most time. No interaction was indicated between PM<sub>2.5</sub> and NO<sub>2</sub>, and increasing NO<sub>2</sub> concentrations in the main living area were independently associated with increased dyspnea and increased rescue medication use with adjustment for PM<sub>2.5</sub>. Higher bedroom NO<sub>2</sub> concentrations were associated with increased risk of nocturnal awakenings (OR: 1.59 [95% CI: 1.05, 2.42] per 10-ppb increase) and severe exacerbations (OR: 1.65 [95% CI: 1.02, 2.64]). NO<sub>2</sub> concentrations were not associated with lung function. There was indication of outdoor NO<sub>2</sub> concentrations contributing to indoor NO<sub>2</sub>. Among the 26 subjects who lived within 4.8 km of a central monitoring site, outdoor NO<sub>2</sub> concentrations explained 25% of the variance in indoor NO<sub>2</sub> concentrations.

---


### 6.2.3.2 Outdoor Nitrogen Dioxide and Respiratory Symptoms in Children

A number of studies ([Table 6-3](#)) observed an association between various respiratory symptoms in children and long-term exposure to outdoor NO<sub>2</sub>. [McConnell et al. \(2003\)](#) examined children with asthma for bronchitic symptoms, including daily cough for 3 months in a row, congestion or phlegm 3 months in a row, or bronchitis. Thus, while these symptoms may have started with acute exacerbation of asthma, they were likely to represent chronic indolent symptoms. In copollutant models, the effects of yearly variation in NO<sub>2</sub>, ascertained from a central monitoring site in each community, were only modestly reduced by adjusting for either PM<sub>2.5</sub> or a traffic-related copollutant such as EC or organic carbon (OC; [Figure 6-4](#) and [Table 6-3](#)).

[Gehring et al. \(2010\)](#) examined a composite of asthma symptoms (one or more attacks of wheeze, shortness of breath, prescription of inhalation steroids) and wheeze (transient, late onset, persistent) and observed positive associations with LUR modeled NO<sub>2</sub> exposures. [Gruzieva et al. \(2013\)](#) examined wheeze, categorized as either one or more episodes or three or more episodes in the past year and observed an association with NO<sub>x</sub> concentrations from a dispersion model.

[Hwang and Lee \(2010\)](#) provide information on the potential for copollutant confounding of NO<sub>2</sub> associations with respiratory symptoms but based on a cross-sectional analysis. The associations between NO<sub>2</sub> and respiratory symptoms in children with asthma did not appreciably change in copollutant models with PM<sub>2.5</sub> (ORs for NO<sub>2</sub> adjusted for PM<sub>2.5</sub>: 2.25 [95% CI: 1.17, 4.33] for bronchitis; 1.60 [95% CI: 0.76, 3.34] for chronic phlegm;

1.30 [95% CI: 0.53, 3.12] for chronic cough; 2.21 [95% CI: 1.23, 3.97] for bronchitic symptoms per 10-ppb increase in NO<sub>2</sub>).



Notes: EC = elemental carbon; I ACID = inorganic acid; NO<sub>2</sub> = nitrogen dioxide; O<sub>3</sub> = ozone; O ACID = organic acid; OC = organic carbon; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 μm; PM<sub>10-2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 μm and greater than a nominal mean of 2.5 μm; ppb = parts per billion.  
 Source: Reprinted with permission of the American Thoracic Society, [McConnell et al. \(2003\)](#).

**Figure 6-4 Within-community odds ratios for bronchitis symptoms associated with nitrogen dioxide adjusted for a copollutant in the 12 communities of the Children’s Health Study.**

### Outdoor Nitrogen Dioxide and Respiratory Symptoms in Adults with Asthma

The relationship between long-term NO<sub>2</sub> exposure and respiratory symptoms in adults was examined in many prospective studies of asthma incidence in adults discussed in [Section 6.2.2.2. Jacquemin et al. \(2009b\)](#) reported that associations between NO<sub>2</sub> and all of the examined asthma symptoms at ECHRS II were positive. The strongest was for waking with a feeling of chest tightness in the last 12 months. Symptoms in the last 12 months at ECRHS II among people without asthma at baseline were also associated with NO<sub>2</sub>. NO<sub>2</sub> exposures estimated from dispersion models were demonstrated to be moderately correlated with measured concentrations in the study locations ( $R^2 = 0.60$ ).

In the cross-sectional Swiss Study on Air Pollution and Lung Disease in Adults (SAPALDIA), [Zemp et al. \(1999\)](#) report an association between NO<sub>2</sub> and prevalence of respiratory symptoms in adults. [Bentayeb et al. \(2010\)](#) reported cross-sectional associations to be weakly positive for cough and phlegm in adults (≥65 years old, in Bordeaux, France) in relation to NO<sub>2</sub> exposure.

### **Outdoor Nitrogen Dioxide and Asthma Hospital Admissions in Adults**

Recent studies represent the first evaluation of the association between long-term NO<sub>2</sub> exposure and hospital admissions for asthma. The Danish Diet, Cancer and Health cohort examined asthma hospital admissions [International Classification of Diseases (ICD)-10: J45–46] in adults ages 50–65 years at baseline ([Andersen et al., 2012a](#)). Associations between NO<sub>2</sub> concentration estimated by the Danish Air geographic information system (GIS) dispersion modelling system and hospital admission were found in the full cohort [hazard ratio (HR) per–10 ppb NO<sub>2</sub>: 1.44 [95% CI: 1.14, 1.84]]. NO<sub>2</sub> was estimated to have a similar effect on the first asthma hospital admission (HR: 1.36 [95% CI: 1.03, 1.80]), but people with a previous asthma hospital admission were at greater risk for re-admission (HR: 3.05 [95% CI: 1.57, 5.90]). NO<sub>2</sub> was associated with a much larger risk of asthma hospital admission among people with previous admission for COPD (HR: 2.34 [95% CI: 1.25, 4.40]). Some of the observed effects could possibly be ascribed to the short-term effects of increases in air pollution on the days prior to asthma admission. The 35-year avg, 15-year avg, and 1-year avg NO<sub>2</sub> preceding admission were highly correlated ( $r = 0.88, 0.92$ ) and were more strongly associated with asthma hospital admission than was 1-year avg NO<sub>2</sub> at baseline. The authors indicated that they could not discern whether the results reflected the importance of more recent exposures or the better performance of the dispersion model in more recent years. The NO<sub>2</sub> exposure estimates may be less certain for earlier time periods because of uncertainty in emission factors and traffic counts that are used as inputs to the dispersion model.

An ecological time-series study ([Delamater et al., 2012](#)) and a cross-sectional study ([Meng et al., 2010](#)) provide inconsistent results with regard to asthma-related emergency department (ED) visits or hospital admissions. A time-series study observed that monthly NO<sub>2</sub> concentrations were associated with monthly asthma hospital admission rates in Los Angeles, CA, but NO<sub>2</sub> concentrations were averaged over the county ([Delamater et al., 2012](#)). A cross-sectional study in the San Joaquin Valley, CA examined more spatially resolved estimates of NO<sub>2</sub> exposure for subjects, ages 1 to 65+ years, who reported physician-diagnosed asthma. Annual average NO<sub>2</sub> concentrations were assigned to subjects from the closest air monitoring station within 8 km of the residential ZIP code, but data on duration of residence were not available. No quantitative results were shown

for NO<sub>2</sub>, but NO<sub>2</sub> was reported not to be associated with asthma-related ED visits or hospital admissions ([Meng et al., 2010](#)).

---

### 6.2.3.3 Summary of Severity of Asthma, Chronic Bronchitis, and Chronic Obstructive Pulmonary Disease

Longitudinal studies observe associations between long-term ambient NO<sub>2</sub> exposure metrics and an array of respiratory symptoms in school-age children. Results in infants are inconsistent. Transient symptoms are common in infants; thus, symptoms in infants may not have strong implications for development of respiratory disease. For children, ambient NO<sub>2</sub> exposure was assessed using outdoor residential measurements, an LUR that estimated exposure at subjects' homes, and central site measurements. The [McConnell et al. \(2003\)](#) study is unique in that it is the only prospective study examining bronchitic symptoms in children with asthma. The study authors report stronger associations for NO<sub>2</sub> variation within communities (within-community associations are less prone to confounding by time-fixed personal covariates) than for NO<sub>2</sub> variation between communities.

Further supporting a relationship with NO<sub>2</sub>, indoor NO<sub>2</sub> was associated with asthma symptoms and medication use in children with asthma ([Belanger et al., 2013](#)) and respiratory symptoms in former smokers with COPD ([Hansel et al., 2013](#)). The effect estimates for indoor NO<sub>2</sub> were generally larger than those reported in the studies of outdoor NO<sub>2</sub>, and [Belanger et al. \(2013\)](#) provided evidence for a concentration-dependent increase in NO<sub>2</sub>-related symptoms. These indoor NO<sub>2</sub> exposures may be part of a different mix of air pollutants than is NO<sub>2</sub> in the ambient air and support an independent effect of NO<sub>2</sub>.

An uncertainty in the evidence base is the potential influence of short-term NO<sub>2</sub> exposure. While many studies aimed to characterize chronic symptoms, they did not examine whether associations were independent of short-term NO<sub>2</sub> exposure. Another uncertainty is the potential confounding by other traffic-related pollutants. Long-term averages of NO<sub>2</sub> showed a correlation of 0.54 for ambient EC and 0.96 for soot; no data are available for CO ([Table 6-3](#)). For PM<sub>2.5</sub>, the correlations are 0.54 for central site measurements and 0.93 ([Gehring et al., 2010](#); [McConnell et al., 2003](#)). In limited analysis, NO<sub>2</sub> associations with symptoms persisted with adjustment for EC or PM<sub>2.5</sub> as measured at central sites and was somewhat attenuated with adjustment for OC. The weaker NO<sub>2</sub>-copollutant correlations and copollutant model results are based on central site measurements and could reflect differential exposure measurement error. The collective evidence from this group of prospective studies is supportive of a relationship of long-term exposure to NO<sub>2</sub> and increased respiratory symptoms using various

indicators in children with asthma, but evidence identifying an independent association of long-term NO<sub>2</sub> exposure is limited.

---

## 6.2.4 Development of Allergic Disease

---

### 6.2.4.1 Epidemiologic Studies of Children or Adults

Recent cross-sectional studies report results for various aspects of allergic responses in relation to long-term exposure to NO<sub>2</sub>. Allergic sensitization indicators included measures of IgE, allergic rhinitis, skin prick test, and reporting of respiratory allergy/hay fever. Various age groups were examined, including children less than 6 years old, children aged about 10 years, and adults. As described in [Section 6.2.2.3](#), the few available experimental studies support an effect of long-term or repeated short-term NO<sub>2</sub> exposure on development of allergic responses.

In a nationally representative sample of the U.S. population, [Weir et al. \(2013\)](#) linked annual average concentrations of NO<sub>2</sub> to allergen-specific IgE data for participants aged 6 years and older in the 2005–2006 National Health and Nutrition Examination Survey using both monitor-based (within 32.2 km) air pollution estimates and the Community Multiscale Air Quality model (36 km) and observed that increased concentrations of NO<sub>2</sub> were associated with positive IgE to any allergen.

In the German Infant Nutritional Intervention (GINI) and Lifestyle-Related Factors on the Immune System and the Development of Allergies in Childhood (LISA) cohorts, analysis of individual-based exposure to NO<sub>2</sub> derived from LUR and allergic disease outcomes during the first 6 years of life ([Morgenstern et al., 2008](#)) indicated associations with eczema. Some associations with allergen-specific IgE and hay fever were positive but imprecise with wide 95% CIs. Previous analyses of these cohorts did not indicate associations with runny nose and sneezing at age 2 years ([Morgenstern et al., 2007](#); [Gehring et al., 2002](#)). A longitudinal study of the LISA and GINI cohorts ([Fuertes et al., 2013](#)) found no evidence that NO<sub>2</sub> exposure in the birth year increases the prevalence of allergic rhinitis or increases risk of aeroallergen sensitization as determined by allergen-specific IgE in children examined at age 10 years. Air pollution concentrations decreased in the study areas during this time.

[Annesi-Maesano et al. \(2007\)](#) related lifetime prevalence of allergic conditions in 5,338 schoolchildren (ages 10.4 ± 0.7 years) attending 108 randomly chosen schools in six French cities to NO<sub>2</sub> concentrations in school yards and at central site monitors. The

authors used a 5-day avg NO<sub>2</sub> concentration to represent long-term exposure to NO<sub>2</sub>. NO<sub>2</sub> was positively associated with flexural dermatitis and skin prick test to indoor allergens but not with allergic rhinitis or atopic dermatitis. In the same study population, [Annesi-Maesano et al. \(2012a\)](#) also evaluated a 5-day mean concentration for indoor classroom NO<sub>2</sub>, categorized into tertiles independent of the city (low <9.7 ppb, medium >9.7 to <12.9 ppb, high >12.9 ppb NO<sub>2</sub>). Between-school and within-school variability of the measured indoor pollutants were estimated using linear mixed models for longitudinal data. Among children with atopy (n = 1,719), high NO<sub>2</sub> was related to previous-year allergic asthma but not allergic rhinitis.

Similar to NO<sub>2</sub>, NO<sub>x</sub> is inconsistently associated with development of allergic responses. [Nordling et al. \(2008\)](#) reported that exposure to dispersion-modeled NO<sub>x</sub> from traffic during the first year of life was associated with sensitization (measured as specific IgE) to inhalant allergens, especially pollen (OR: 1.24 [95% CI: 1.04, 1.49] per 10-ppb increase in NO<sub>2</sub>). In the Children, Allergy, Milieu, Stockholm, Epidemiology Survey (BAMSE) cohort, NO<sub>x</sub> assessed from a dispersion model was not associated with risk of allergic sensitization in children at age 4 years ([Gruzieva et al., 2012](#)).

Cross-sectional studies also do not consistently link long-term NO<sub>2</sub> exposure to allergic conditions in children or adults. Among 30,139 Chinese children aged 3 to 12 years, [Dong et al. \(2011\)](#) observed positive associations between 3-year avg of NO<sub>2</sub> and allergic rhinitis in the 26,004 children without allergic predisposition (n = 26,004), mainly among males. Among children with an allergic predisposition, associations were detected in males and females. In school children in Taiwan, [Hwang et al. \(2006\)](#) observed that a 10-ppb increase in NO<sub>2</sub> was associated with a higher prevalence of allergic rhinitis, with an OR of 1.11 (95% CI: 1.08, 1.15). [Parker et al. \(2009\)](#) evaluated respiratory allergy/hay fever in the 1999–2005 U.S. National Health Interview Survey of approximately 70,000 children and observed no associations with NO<sub>2</sub>. In 2,644 adults aged 18–70 years living in Nottingham, U.K., [Pujades-Rodriguez et al. \(2009\)](#) found generally null associations between NO<sub>2</sub> concentration and skin test positivity, total IgE, and questionnaire-reported eczema or hay fever. Total IgE levels were not related to NO<sub>2</sub> concentrations in 369 adults with asthma in five French centers as part of the Epidemiological Study on the Genetics and Environment of Asthma ([Rage et al., 2009](#)) but were related to O<sub>3</sub> concentrations.

---

#### 6.2.4.2 Summary of Development of Allergic Responses

A few available experimental studies demonstrate the effects of repeated short- or long-term NO<sub>2</sub> exposure on development of an allergic phenotype in healthy adults and

animal models ([Section 6.2.2.3](#)). These findings not only suggest the possibility that recurrent or chronic exposure to NO<sub>2</sub> may lead to the development of asthma but also support a role for NO<sub>2</sub> exposure in the development of allergic conditions. Long-term NO<sub>2</sub> exposure has been linked to indicators of allergic sensitization such as allergen-specific IgE or skin prick test in a few cross-sectional studies of children around age 10 years but not the longitudinal study. Results also are inconsistent for outcomes such as allergic rhinitis or hay fever. In children 6 years and younger and in adults, indicators of allergic responses are not related to NO<sub>2</sub> exposure. NO<sub>2</sub> metrics aimed at characterizing individual exposures, such as 5-day measurements in school yards and residential estimates from LUR, produced inconsistent results. Thus, the evidence base for a relationship between long-term NO<sub>2</sub> exposure and allergic responses is limited.

---


## 6.2.5 Lung Function and Lung Development

The 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) characterized longitudinal studies as showing a relationship between NO<sub>2</sub> concentrations and decrements in lung function and lung development in children. A key uncertainty in these studies was the high correlation of NO<sub>2</sub> concentrations with other traffic-related pollutants and the potential for confounding. Recent longitudinal epidemiologic studies add to the evidence base linking long-term NO<sub>2</sub> exposure to decrements in lung function and lung development as assessed by supervised spirometry. As with severity of respiratory disease, a key consideration in evaluating the evidence for relationships of lung function and lung development with long-term exposure is whether studies accounted for the effects of short-term exposure.

---

### 6.2.5.1 Lung Function and Development in Children

The key longitudinal epidemiologic studies continue to show associations between long-term NO<sub>2</sub> exposure and decrements in lung function, especially as children reach adolescence ([Figure 6-5](#) and [Table 6-4](#)). Lung function continues to increase through early adulthood with growth and development, then declines with aging ([Stanojevic et al., 2008](#); [Zeman and Bennett, 2006](#); [Thurlbeck, 1982](#)). Thus, the relationship between long-term NO<sub>2</sub> exposure and decreased lung function over time in school-age children into early adulthood is an indicator of decreased lung development.



Note: avg = average; CI = confidence interval; FEF<sub>25-75</sub> = forced expiratory flow between 25 and 75% of forced vital capacity; FEV<sub>1</sub> = forced expiratory volume in 1 second; FVC = forced vital capacity; LUR = land use regression; MMEF = maximum (or maximal) midexpiratory flow; mL = milliliters; mL/sec = milliliters per second; mo = month; PEF = peak expiratory flow; yr = year(s). Black = study from the 2008 Integrated Science Assessment for Oxides of Nitrogen; red = recent studies. Circles = nitrogen dioxide (NO<sub>2</sub>); Diamonds = sum of NO<sub>2</sub> and nitric oxide (NO<sub>x</sub>). Effect estimates are standardized to a 10-ppb increase in NO<sub>2</sub> and a 20-ppb increase in NO<sub>x</sub> concentration. Effect estimates from [Schultz et al. \(2012\)](#) are not standardized because NO<sub>x</sub> is examined in µg/m<sup>3</sup>.

**Figure 6-5 Associations of oxides of nitrogen with lung function or lung development from longitudinal studies of children.**

**Table 6-4 Longitudinal studies of long-term nitrogen dioxide exposure and lung function and lung development in children.**

Study <sup>a</sup>	Exposure Assessment	Pollutant Correlation	Statistical Methods	Comments	Results (95% CI) <sup>b</sup>
<b>Children's Health Study (CHS), southern California</b>					
<a href="#">Gauderman et al. (2004)</a> n = 1,759 children followed ages 10–18 yr). Follow-up began in 1993.	Central site monitors, 1 in each of 12 communities. 8-yr avg. Monitoring conducted 1994–2000. Range in mean NO <sub>2</sub> across communities: 34.6 ppb.	NO <sub>2</sub> -EC: 0.94 NO <sub>2</sub> -acid vapor: 0.87 NO <sub>2</sub> -PM <sub>2.5</sub> : 0.79 NO <sub>2</sub> -PM <sub>10</sub> : 0.67 NO <sub>2</sub> -OC: 0.64	Two-stage linear regression adjusted for log height, BMI, BMI squared, race, Hispanic ethnicity, doctor-diagnosed asthma, any tobacco smoking by the child in the preceding yr, exposure to environmental tobacco smoke, and exercise; or respiratory tract illness on the day of the test and indicator variables for the field technician and the spirometer.	Follow-up participation: n = 1,414 in 1995, 1,252 in 1997, 1,031 in 1999, and 747 in 2001 (10% loss per yr). Children who moved away from recruitment community were classified as lost to follow-up. Model fit no better in copollutant than in single-pollutant models. No quantitative data shown. Adjustment for 3-day avg NO <sub>2</sub> before each lung function test did not alter association for long-term NO <sub>2</sub> .	Change over 8-yr period: FVC: -27.5 (-54.7, -0.2) mL FEV <sub>1</sub> : -29.3 (-47.5, -11.1) mL MMEF: -61.0 (-109.1, -12.8) mL/sec
<a href="#">Gauderman et al. (2007)</a> n = 3,677 children, mean age 10 yr (SD 0.44) 12 CHS communities	Central site monitors, 1 in each of 12 communities. 8-yr avg. Monitoring conducted 1994–2000. Range in mean NO <sub>2</sub> across communities: 34.6 ppb.	NR	Regression models adjusted for local traffic exposure, height, height squared, BMI, BMI squared, present asthma status, exercise or respiratory illness on the day of the test, any tobacco smoking by the child in the previous yr, and indicator variables for field technician.	NO <sub>2</sub> and distance to freeways were independently associated with decrements in lung development. Compared with living >1,500 away from a freeway, living within 500 m of a freeway was associated with a mean percent-predicted FEV <sub>1</sub> of 97.0% (94.6, 99.4) and MMEF of 93.4% (89.1, 97.7).	Change in FEV <sub>1</sub> over 8-yr period: -32 mL/sec 95% CI NR.

**Table 6-4 (Continued): Longitudinal studies of long-term nitrogen dioxide exposure and lung function and lung development in children.**

Study <sup>a</sup>	Exposure Assessment	Pollutant Correlation	Statistical Methods	Comments	Results (95% CI) <sup>b</sup>
<p><a href="#">†Breton et al. (2011)</a> 1993 cohort 1: n = 1,759 1996 cohort 2: n = 2,004 Both cohorts followed from age 10 to 18 yr.</p>	<p>Central site monitors, 1 in each of 12 communities. Annual avg. Monitoring conducted 1994–2000. Range in mean NO<sub>2</sub> across communities: 34.6 ppb.</p>	<p>NO<sub>2</sub>-PM<sub>2.5</sub> = 0.79 NO<sub>2</sub>-O<sub>3</sub> = -0.11</p>	<p>Hierarchical mixed effects models adjusted for height, height squared, BMI, BMI squared, current asthma status, exercise or respiratory illness on the day of the test, any tobacco smoking by the child in the last yr, glutathione S-transferase mu 1 genotype, and indicator variables for the field technician.</p>	<p>Main purpose was to determine whether sequence variation in genes in the glutathione synthesis pathway alters susceptibility to air pollution effects on lung function.  Haplotype “0100000” was associated with a 39.6-mL, 29.1-mL, and 51.0-mL/sec reduction in FEV<sub>1</sub>, FVC, and MMEF, respectively, over 8-yr follow-up.</p>	<p>FEV<sub>1</sub>: -29.8 (-50.0, -9.7) mL FVC: -29.8 (-54.7, -5.0) mL MMEF: -54.4 (-90.8, -18.0) mL/sec</p>
<p><a href="#">†Urman et al. (2014)</a> n = 1,811 children, mean age 11 yr. 82% of the active 2002 cohort from 8 CHS communities.</p>	<p>LUR model for near-roadway NO<sub>2</sub> and NO<sub>x</sub>. Central site monitor for NO<sub>2</sub>. LUR: annual avg at residence. Central site: 6-yr avg LUR model developed from 900 monitoring sites in CHS communities (<a href="#">Franklin et al., 2012</a>). 10-fold cross-validation R<sup>2</sup> for NO<sub>2</sub> = 69% in basin (higher pollution) and 72% out of basin (lower pollution) Quantitative data on mean NO<sub>2</sub> or NO<sub>x</sub> NR.</p>	<p>Central site concentrations: NO<sub>2</sub>-PM<sub>2.5</sub>: 0.60 NO<sub>2</sub>-PM<sub>10</sub>: 0.06 Near-roadway NO, NO<sub>2</sub>, and NO<sub>x</sub> (within communities): &gt;0.90</p>	<p>Linear regression models for near-roadway NO<sub>2</sub> and NO<sub>x</sub> with fixed effects for study community. Mixed model for central site pollutants with random intercept for community and adjusted for near-roadway NO<sub>2</sub>, NO, or NO<sub>x</sub>. Adjusted for log height, height squared, BMI, BMI squared, sex, age, sex x age interaction, race, Hispanic ethnicity, respiratory illness at time of test, and field technician and study community.</p>	<p>NO<sub>2</sub> was associated with FEV<sub>1</sub> but not FVC. Lung function deficits of 2–3% were associated with PM<sub>2.5</sub>, PM<sub>10</sub>, and O<sub>3</sub>. Associations with central site NO<sub>2</sub> and near-roadway NO<sub>x</sub> were independent in copollutant models. Associations for near-roadway NO<sub>x</sub> were not modified by central site pollutant concentrations.</p>	<p>Near-roadway NO<sub>x</sub>: FVC: -1.7% (-2.9, -0.55) FEV<sub>1</sub>: -1.2% (-2.4, -0.01) Associations observed in all communities and also for NO<sub>2</sub> and NO. Residential proximity to a freeway was associated with a reduction in FVC.</p>

**Table 6-4 (Continued): Longitudinal studies of long-term nitrogen dioxide exposure and lung function and lung development in children.**

Study <sup>a</sup>	Exposure Assessment	Pollutant Correlation	Statistical Methods	Comments	Results (95% CI) <sup>b</sup>
<b>Children, Allergy, Milieu, Stockholm, Epidemiology Survey (BAMSE), Stockholm, Sweden</b>					
<p>†<a href="#">Schultz et al. (2012)</a>                      n = 1,924 children followed from birth to age 8 yr.                      Related Publications: <a href="#">Nordling et al. (2008)</a></p>	<p>Dispersion model NO<sub>x</sub>                      Time-weighted average exposures for various time windows estimated based on lifetime residential, day care, and school addresses.                      Short-term average concentrations assessed from central sites.</p>	<p>NR</p>	<p>Linear regression adjusted for sex, age, height, municipality, and heredity for asthma and/or allergy. Additional adjustments for temperature, relative humidity, O<sub>3</sub>, and PM<sub>10</sub> levels during 3–7 days before each child's pulmonary function test showed little effect on the estimates for long-term avg NO<sub>x</sub>.</p>	<p>Specific adjustment for short-term NO<sub>x</sub> was not discussed.                      OR for NO<sub>x</sub> in first yr of life                      FEV<sub>1</sub> 80% of predicted: 2.1 (0.6, 8.1)                      FEV<sub>1</sub> 85% of predicted: 3.4 (1.6, 7.4)</p>	<p>FEV<sub>1</sub> per 47 µg/m<sup>3</sup> increase in NO<sub>x</sub> in first yr of life:                      –34.9                      (–80.1, 10.4) mL                      Group sensitized against any common inhalant or food allergens, and those with asthma at 8 yr:                      –98.9 (–169, –28.4) mL                      No clear association with NO<sub>x</sub> exposure after infancy.</p>
<b>Prevention and Incidence of Asthma and Mite Allergy (PIAMA), the Netherlands</b>					
<p>†<a href="#">Eenhuizen et al. (2013)</a>                      n = 880 children, age 4 yr</p>	<p>LUR model                      Annual avg NO<sub>2</sub> at birth residence.                      Mean: 10.4 ppb.                      Daily average NO<sub>2</sub> concentrations on the day Rint measurement obtained from central sites.</p>	<p>For birth address:                      NO<sub>2</sub>-PM<sub>2.5</sub>: 0.93                      NO<sub>2</sub>-soot: 0.96                      NO<sub>2</sub> on test day and long-term NO<sub>2</sub>: 0.55                      NO<sub>2</sub> on the day before the test and long-term NO<sub>2</sub>: 0.57</p>	<p>Multiple linear regression adjusted for sex, age at examination (days), height, weight, maternal prenatal smoking, any smoking in the child's home, use of gas for cooking, parental allergy, dampness in the home, education of the parents, season, temperature, and humidity on the day of the Rint measurement.</p>	<p>First report of an association in 4-yr old children. Rint at age 4 yr predicted asthma and wheeze at age 8 yr. Long-term average PM<sub>2.5</sub> and soot associated with Rint. A monotonic increase of Rint with increasing NO<sub>2</sub> concentration was seen, with no threshold identified.</p>	<p>Change in Rint:                      0.05 (0.001, 0.11) kPaxs/L</p>

**Table 6-4 (Continued): Longitudinal studies of long-term nitrogen dioxide exposure and lung function and lung development in children.**

Study <sup>a</sup>	Exposure Assessment	Pollutant Correlation	Statistical Methods	Comments	Results (95% CI) <sup>b</sup>
<b>Manchester Asthma and Allergy Study (MAAS), Manchester, U.K.</b>					
<p>†<a href="#">Mølter et al. (2013)</a>            †<a href="#">Mølter et al. (2010a)</a>            †<a href="#">Mølter et al. (2010b)</a>            †<a href="#">Mølter et al. (2012)</a>            n = 1,185.            Followed from birth (1995–1997) to age 11 yr.</p>	<p>Personal            4- or 6-yr avg            Estimated from Microenvironmental Exposure Model that incorporated children's time-activity patterns and LUR modeled concentrations.            The modeled estimates agreed well with measured NO<sub>2</sub> concentrations.            Mean (SD) NO<sub>2</sub>:            14.76 (6.6) ppb</p>	<p>NO<sub>2</sub>-PM<sub>10</sub>            Pearson <i>r</i> = 0.59 to 0.89.</p>	<p>GEE adjusted for age, atopy, asthma or wheeze, presence of a gas cooker in the home, hospital admission for infection in first two yr or life, pubertal stage of development, 3-day avg PM<sub>10</sub>.            Also considered sex, BMI, ethnicity, parental atopy, parental smoking, day care attendance during first 2 yr of life, family history of asthma, dog or cat in the home, visible signs of dampness or mold in the home, duration of breast feeding, and paternal income.</p>		<p>Change in percent predicted FEV<sub>1</sub> during age 5–11 yr:            -15.6 (-26.1, -5.3)            Based on the average predicted FEV<sub>1</sub> in cohort of 1.65 L, change equals total decrease in FEV<sub>1</sub> of 263 mL.            Change in percent predicted post-bronchodilator FEV<sub>1</sub> during age 5–11 yr:            -19.8 (-32.5, -7.1).            Equivalent to total 413 mL decrease.</p>
<b>Mexico City, Mexico</b>					
<p><a href="#">Rojas-Martinez et al. (2007a)</a>  <a href="#">Rojas-Martinez et al. (2007b)</a>            n = 3,170 children followed ages 8–11 yr (1996–1999).            Recruited from 31 schools.</p>	<p>Central site NO<sub>2</sub>            6-mo avg            Closest site to school, Within 2–10 km.            Mean (SD) NO<sub>2</sub> across communities:            27.2 (10.9) to 42.6 (13.2)</p>	<p>24-h avg NO<sub>2</sub> and 8-h avg O<sub>3</sub>: 0.166            24-h avg NO<sub>2</sub> and 24-h avg PM<sub>10</sub>: 0.250</p>	<p>General linear mixed models adjusted for age, BMI, height, height by age, weekday time spent in outdoor activities, and environmental tobacco smoke.</p>	<p>NO<sub>2</sub>, O<sub>3</sub>, and PM<sub>10</sub> were associated with decrements in lung development after adjusting for short-term averages (day before lung function measurement) for the pollutants.</p>	<p>Girls            FVC: -40 (-46, -34) mL            FEV<sub>1</sub>: -27 (-33, -22) mL            FEF<sub>25–75%</sub>:            7 (-8, 18) mL/sec            Boys            FVC: -38 (-44, -31) mL            FEV<sub>1</sub>: -22 (-28, -16) mL            FEF<sub>25–75%</sub>:            3 (-10, 16) mL/sec</p>

**Table 6-4 (Continued): Longitudinal studies of long-term nitrogen dioxide exposure and lung function and lung development in children.**

Study <sup>a</sup>	Exposure Assessment	Pollutant Correlation	Statistical Methods	Comments	Results (95% CI) <sup>b</sup>
<b>Oslo, Norway</b>					
<a href="#">Ofstedal et al. (2008)</a> n = 2,307 children followed from birth (1992–1993) to age 9–10 yr. Related Publications: <a href="#">Slørdal et al. (2003)</a>	Dispersion model NO <sub>2</sub> Annual avg at residence in first yr of life and lifetime avg. Modeled estimates well correlated with measurements from 10 central site monitors. <i>r</i> = 0.76. Mean NO <sub>2</sub> : 16 ppb in the first yr of life 11.86 ppb for lifetime avg	NO <sub>2</sub> and PM <sub>2.5</sub> or PM <sub>10</sub> <i>r</i> = 0.83–0.95	Multiple linear regression adjusted for sex, height, age, BMI, birth weight, temperature lagged 1–3 days before the lung function test, current asthma, indicator for participation in the Oslo Birth Cohort study, maternal smoking in early lifetime, parental ethnicity, education, and smoking.	NO <sub>2</sub> associations stronger in girls. In models that included both short- and long-term NO <sub>2</sub> exposures, only the association with long-term NO <sub>2</sub> remained.	NO <sub>2</sub> in first yr of life among all children: FEV <sub>1</sub> : –6.0 (–18.0, 6.2) mL FVC: –1.4 (–14.6, 11.8) mL PEF: –57.9 (–92.5, –22.3) mL/sec FEF <sub>50%</sub> : –37.3 (–71.2, –3.5) mL/sec

Avg = average, BAMSE = Children, Allergy, Milieu, Stockholm, Epidemiology Survey; BMI = body mass index; CHS = Children’s Health Study; CI = confidence interval; EC = elemental carbon; FEF = forced expiratory flow; FEF<sub>50%</sub> = forced expiratory flow at 50% of forced vital capacity. FEF<sub>25–75%</sub> = forced expiratory flow between 25 and 75% of forced vital capacity; FEV<sub>1</sub> = forced expiratory volume in 1 second; FVC = forced vital capacity; GEE = generalized estimating equations; kPaxs/L = kilopascal times seconds per liter; LUR = land use regression; MAAS = Manchester Asthma and Allergy Study; MMEF = maximum (or maximal) midexpiratory flow; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; NR = not reported; O<sub>3</sub> = ozone; OC = organic carbon; PEF = peak expiratory flow; PIAMA = Prevention and Incidence of Asthma and Mite Allergy; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 μm; SD = standard deviation.

<sup>a</sup>Studies are presented in the order of appearance in the text.

<sup>b</sup>Results are presented for a 10-ppb change in NO<sub>2</sub> and 20-ppb change in NO<sub>x</sub> unless otherwise specified.

†Studies published since the 2008 ISA for Oxides of Nitrogen.


The CHS has examined three separate cohorts for pollutant effects on lung function and development [1993 cohort in [Gauderman et al. \(2004\)](#), 1993 and 1996 cohorts in [Gauderman et al. \(2007\)](#) and [Breton et al. \(2011\)](#), and 2002 cohort in [Urman et al. \(2014\)](#)]. The results of [Breton et al. \(2011\)](#) are consistent with earlier results from [Gauderman et al. \(2004\)](#). Both [Gauderman et al. \(2007\)](#) and [Urman et al. \(2014\)](#) observed that associations with NO<sub>2</sub> assessed from central sites persisted with adjustment for distance to freeway or near-roadway NO<sub>x</sub>, and [Urman et al. \(2014\)](#) observed that the association with near-roadway NO<sub>x</sub> was not modified by PM<sub>2.5</sub> measured at a central site. Inference from these copollutant model results are limited because of the potential for differential exposure measurement error.

[Urman et al. \(2014\)](#) examined lung function in 1,811 children (82% of the active cohort) from eight communities in the CHS cohort established in 2002–2003. NO<sub>2</sub> was assessed from a single central site monitor in each of the study communities. LUR models were developed from 900 monitoring sites in the CHS communities ([Franklin et al., 2012](#)) to estimate near-roadway NO<sub>x</sub>, NO<sub>2</sub>, and NO at children's homes. LUR models for NO<sub>x</sub> used estimates from a dispersion model. For FEV<sub>1</sub>, there was little change in the association of near-roadway NO<sub>x</sub> after adjusting for PM<sub>2.5</sub> measured at the central site. NO<sub>x</sub> associations also persisted with adjustment for PM<sub>10</sub> or O<sub>3</sub>. Central site NO<sub>2</sub> remained associated with FEV<sub>1</sub> after adjustment for near-roadway NO<sub>x</sub>. Near-roadway NO<sub>2</sub> also was associated with decrements in lung function. Near-roadway NO<sub>x</sub> was associated with lung function decrements in children with and without asthma, suggesting that traffic-related pollution may affect all children. The association for within-community near-roadway NO<sub>x</sub> was somewhat less than that for between-community regional NO<sub>x</sub>, although the two effect estimates were based on increments of pollution that may not be directly comparable.

[Gauderman et al. \(2007\)](#) reported results of an 8-year follow-up on 3,677 children who participated in the CHS. Throughout the 8-year follow-up, around an 11% loss of study participants per year was observed. The FEV<sub>1</sub> reduction was –31.5 mL (95% CI not reported) for an increase in NO<sub>2</sub> of 10 ppb. Children living <500 m from a freeway (n = 440) had deficits in lung development over the 8-year follow-up compared to children who lived at least 1,500 m from a freeway. When examined in the same model, both distance to freeway and NO<sub>2</sub> measured at community central sites were associated with decrements in lung development. There was no evidence that the association for NO<sub>2</sub> differed according to distance to freeway or vice versa. Acid vapor, EC, PM<sub>10</sub>, and PM<sub>2.5</sub>, but not O<sub>3</sub>, were associated with reduced lung development.

[Gauderman et al. \(2004\)](#) examined the 1993 CHS cohort of 1,759 children aged 10 to 18 years and report that although the average increase in FEV<sub>1</sub> over time was larger in

boys than in girls, the associations of lung development with NO<sub>2</sub> measured at central site monitor did not differ between the sexes. As depicted by the regression line in [Figure 6-6](#), for both sexes combined, the average difference in FEV<sub>1</sub> growth over the 8-year period between the communities with the lowest and highest 8-year avg NO<sub>2</sub> concentration (34.6 ppb difference) was -101.4 mL (95% CI: -165, -38.4). [Gauderman et al. \(2004\)](#) further indicated that NO<sub>2</sub> exposure over the 8-year follow-up was associated with clinically relevant decrements in attained lung function at the age of 18 years ([Figure 6-7](#)). Clinical relevance was defined as FEV<sub>1</sub> less than 80% of the predicted value for height, BMI, sex, race/ethnicity, and asthma status. Across the 12 communities, higher NO<sub>2</sub> was associated with an increase in the percentage of children with FEV<sub>1</sub> less than 80% predicted.




Note: FEV<sub>1</sub> = forced expiratory volume in 1 second; NO<sub>2</sub> = nitrogen dioxide; ppb = parts per billion.

Source: Reprinted with permission of the Massachusetts Medical Society, [Gauderman et al. \(2004\)](#).

**Figure 6-6** Community-specific average growth in forced expiratory volume in 1 second (mL) among girls and boys from 1993 to 2001, plotted against average nitrogen dioxide concentrations from 1994 through 2000.

Several recent studies examined lung function in cohorts other than the CHS. In 1,924 school-age children in the Swedish birth cohort BAMSE [Schultz et al. \(2012\)](#) observed that NO<sub>x</sub> exposure during the first year of life was associated with a deficit in FEV<sub>1</sub>. The ORs of having a deficit of 80% and 85% of predicted FEV<sub>1</sub> were 2.1 (95% CI: 0.6, 8.1), and 3.4 (95% CI: 1.6, 7.4), respectively, for a 47 µg/m<sup>3</sup> increase in NO<sub>x</sub>. Authors did not account for the influence of short-term NO<sub>x</sub> exposure but did observe the association for long-term PM<sub>10</sub> to persist after accounting for short-term PM<sub>10</sub>.



Note: AL = Alpine; AT = Atascadero; FEV<sub>1</sub> = forced expiratory volume in 1 second; LE = Lake Elsinore; LA = Lake Arrowhead; LN = Lancaster; LM = Lompoc; LB = Long Beach; ML = Mira Loma; NO<sub>2</sub> = nitrogen dioxide; P = p value; ppb = parts per billion; R = correlation coefficient; RV = Riverside; SD = San Dimas; SM = Santa Maria; and UP = Upland.

Source: Reprinted with permission of the Massachusetts Medical Society, [Gauderman et al. \(2004\)](#).

**Figure 6-7** Community-specific proportion of 18-year-olds with a forced expiratory volume in 1 second below 80% of the predicted value, plotted against the average concentrations of nitrogen dioxide from 1994 through 2000.

Limited data are available on NO<sub>2</sub>-related lung function changes in young children, such as those age 4 years or younger because of the difficulties of lung function examinations in this age group. [Eenhuizen et al. \(2013\)](#) measured interrupter resistance (Rint), an indicator of airway resistance, in 4-year-old children participating in the Prevention and Incidence of Asthma and Mite Allergy (PIAMA) Dutch birth cohort study. Of the original invited 1,808 children, a total of 880 children were in the final analysis. The children with valid Rint data did not have different characteristics than the population recruited for the study. Long-term average concentrations of NO<sub>2</sub>, PM<sub>2.5</sub>, and soot at the residential address at birth were assessed using LUR models as discussed in [Section 6.2.2.1](#), and daily average air pollution concentrations on the day of clinical examination were obtained. Positive associations were observed between long-term average NO<sub>2</sub> concentrations and Rint. Such findings are supported by the study showing NO<sub>2</sub>-induced increased airway resistance in guinea pigs ([Section 6.2.2.3](#)). The findings also support a relationship between NO<sub>2</sub> and asthma, given that Rint at age 4 years was a predictor of asthma and wheeze at age 8 years. A monotonic increase in Rint with increasing NO<sub>2</sub> concentration, with no suggestion of a threshold, was observed. Short-term exposure was not associated with interrupter resistance. NO<sub>2</sub> concentrations on the test day and the day before the test were moderately correlated with long-term concentrations. This is the first report of an association in 4-year-old children. NO<sub>2</sub> was highly correlated with PM<sub>2.5</sub> and soot (quantitative data not reported), and an independent association could not be discerned for any of the examined pollutants.

The long-term effects of PM<sub>10</sub> and NO<sub>2</sub> exposure on specific airway resistance (sRaw) and FEV<sub>1</sub> before and after bronchodilator treatment was examined within the Manchester Asthma and Allergy Study (MAAS) birth cohort ([Mölter et al., 2013](#)). At age 11 years, the cohort size was 813. A Microenvironmental Exposure Model incorporated an LUR model and children's time-activity patterns to produce total person exposure estimates. The model was validated, and there was good agreement between modeled and measured total personal NO<sub>2</sub> concentrations for short-term averaging times ([Mölter et al., 2012](#)). Higher lifetime exposure to NO<sub>2</sub> was associated with a smaller increase in percent predicted FEV<sub>1</sub> over time, both before (16.0% [95% CI: -26.0, -0.5] for a 10-ppb increase in NO<sub>2</sub>) and after bronchodilator treatment (23% [95% CI: -37.0, -9.0]).

As part of ESCAPE, [Gehring et al. \(2013\)](#) analyzed data from birth cohort studies conducted in Germany, Sweden, the Netherlands, and the U.K. that measured lung function at 6 to 8 years of age. The five birth cohorts [BAMSE, MAAS, German Infant Nutritional Intervention South (GINI SOUTH), GINI/LISA, and PIAMA] are discussed in [Section 6.2.2.1](#). Annual average exposures to NO<sub>2</sub>, NO<sub>x</sub>, PM<sub>2.5</sub>, PM<sub>10</sub>, PM coarse, and PM absorbance at the birth address and current address were estimated by LUR models, except for the BAMSE cohort, for which a dispersion model was used. Associations of

lung function with estimated air pollution concentrations and traffic indicators were examined for each cohort using linear regression analysis, and then combined by random effects meta-analysis. Across the five cohorts, annual mean (SD) for NO<sub>2</sub> ranged from 7.44 (2.87) to 12.6 (1.91) ppb. Long-term associations were adjusted for short-term changes in pollutants measured at central sites. NO<sub>2</sub> and NO<sub>x</sub> estimated for the current address were associated with decrements in both FEV<sub>1</sub> and forced vital capacity (FVC) as were PM<sub>2.5</sub> and PM<sub>2.5</sub> absorbance. NO<sub>2</sub> and PM<sub>2.5</sub> at the current address also were associated with peak expiratory flow (PEF). For the five cohorts combined, NO<sub>2</sub> at the birth address was associated with a smaller decrease in lung function than was NO<sub>2</sub> for the current address. Short-term (7-day avg) exposure to NO<sub>2</sub> also was associated with lung function decrements. Traffic intensity on the nearest street and traffic load on major roads within a 100-m buffer were associated with deficits in lung function, although the effect estimates had wide confidence intervals, indicating imprecise associations. Annual average concentrations of NO<sub>2</sub>, NO<sub>x</sub>, PM<sub>2.5</sub>, and PM<sub>10</sub> at the current address were associated with clinically relevant lung function decrements (FEV<sub>1</sub> < 85% predicted). In copollutant models with NO<sub>2</sub> and PM<sub>2.5</sub>, effect estimates for both pollutants were reduced, but the relative impact on NO<sub>2</sub> and PM<sub>2.5</sub> differed among lung function indices. Associations for FEV<sub>1</sub> and PEF were reduced more for NO<sub>2</sub> than for PM<sub>2.5</sub>. In contrast, the association for FVC was reduced more for PM<sub>2.5</sub> than for NO<sub>2</sub>. Thus, the results do not clearly discern an independent effect for either PM<sub>2.5</sub> or NO<sub>2</sub>.

In Mexico City, Mexico, [Rojas-Martinez et al. \(2007b\)](#) and [Rojas-Martinez et al. \(2007a\)](#) evaluated lung development in a prospective cohort of children aged 8 years at baseline. Long-term NO<sub>2</sub> exposures were assigned from the closest central monitoring site located within 2 km of schools. An unspecified number of children were lost to follow-up during the study, mainly because they moved to another area of the city or to another city altogether. Information was obtained from a total of 3,170 children. A 10-ppb increase in NO<sub>2</sub> was associated with an annual deficit in FEV<sub>1</sub> of 27 (95% CI: 22, 33) mL in girls and 22 (95% CI: 16, 28) mL in boys. The negative association for NO<sub>2</sub> persisted in copollutant models with O<sub>3</sub> or PM<sub>10</sub>. A deficit in lung development was observed for NO<sub>2</sub> after adjusting for the short-term associations with NO<sub>2</sub> (previous-day concentrations).

A cohort study in Oslo, Norway, examined associations of short- and long-term NO<sub>2</sub> and other pollutant exposures on PEF and forced expiratory flow at 25% of forced vital capacity and 50% of forced vital capacity in 2,307 children ages 9–10 years ([Oftedal et al., 2008](#)). In models that included both short- and long-term NO<sub>2</sub> exposures estimated from dispersion models, only the association with long-term NO<sub>2</sub> remained. Adjusting for a contextual socioeconomic factor diminished the association with NO<sub>2</sub>.

In summary, epidemiologic findings consistently indicate associations of long-term NO<sub>2</sub> exposure with decrements in lung function and lung development in school children. However examination of potential for confounding by PM<sub>2.5</sub> and traffic-related copollutants is limited, and it is unclear whether NO<sub>2</sub> exposure has an independent effect.

---

### 6.2.5.2 Lung Function in Adults

Both longitudinal and cross-sectional ([Forbes et al., 2009b](#); [Sekine et al., 2004](#)) studies are inconsistent in showing associations between long-term NO<sub>2</sub> exposure and lung function. In the ECRHS cohort [Götschi et al. \(2008\)](#), FEV<sub>1</sub> and FVC were assessed at baseline and after 9 years of follow-up from 21 European centers (followed-up sample N = 5,610). Quantitative results were not reported; NO<sub>2</sub> was reported only to show no statistically significant association with average lung function. This is in contrast to the results from [Ackermann-Lieblich et al. \(1997\)](#) (SAPALDIA) and [Schikowski et al. \(2005\)](#) [Study on the Influence of Air Pollution on Lung, Inflammation, and Aging (SALIA)], which examined far more homogenous populations than the ECRHS cohort.

A recent study ([Boogaard et al., 2013](#)) evaluated the impact on lung function of a reduction in outdoor pollution concentrations resulting from restricting old heavy-duty vehicles in all inner cities and other related policies. At 12 locations in the Netherlands, NO<sub>2</sub> was measured on the street where participants lived within 500 m of subjects' homes. Respiratory health was measured in 2008 and 2010, during which air pollution concentrations decreased. The study population included both children and adults, but 84% was above age 30 years at baseline. The participation rate was around 10%. Over the two time periods, 585 subjects were re-evaluated for spirometry. Reductions in concentrations of NO<sub>2</sub> and NO<sub>x</sub> as well as soot, copper (Cu), and iron (Fe) were associated with increases in FVC. Airway resistance decreased with a decline in PM<sub>10</sub> and PM<sub>2.5</sub>, although these associations were somewhat less consistent. No associations were found with eNO. Results were driven largely by the small group of residents living at the one urban street where traffic flow as well as air pollution were drastically reduced.

In a Nottingham, U.K. cohort of adults aged 18–70 years, lung function changes were evaluated in a cross-sectional analysis of 2,599 subjects at baseline and a longitudinal analysis of 1,329 subjects followed up 9 years later ([Pujades-Rodriguez et al., 2009](#)). There were no substantial cross-sectional associations between home proximity to the roadside and NO<sub>2</sub> concentration with lung function or any other outcome. Also, neither exposure was associated with a decline in FEV<sub>1</sub> over time. Insufficient contrast in NO<sub>2</sub> exposure (interquartile range: 18.1–19.1 ppb) may be a factor in the inability to detect any associations for NO<sub>2</sub> in this study population.

---

### 6.2.5.3 Toxicological Studies of Lung Function

The 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) reported inconsistent evidence of changes in lung function in animals after long-term ambient-relevant NO<sub>2</sub> exposures. No recent studies are available. [Arner and Rhoades \(1973\)](#) exposed rats to 2,900 ppb NO<sub>2</sub> continuously for 5 days/week for 9 months and reported changes in lipid composition in the airway that could be related to observed functional consequences, including decreased lung volume and compliance and increased surface tension, although these changes have not been consistently observed in animal studies.

[Tepper et al. \(1993\)](#) exposed rats to a background concentration of 500 ppb NO<sub>2</sub> for 16 h/day followed by a 6 hour peak of 1,500 ppb and 2 hours of downtime for up to 78 weeks. Frequency of breath was substantially slower in these animals and was paralleled by a trend toward increased tidal volume, expiratory resistance, and inspiratory and expiratory time, although changes were not statistically significant. [Mercer et al. \(1995\)](#) and [Miller et al. \(1987\)](#) examined similar exposures in rats and mice, respectively, and also reported that NO<sub>2</sub> exposure did not alter lung function, although mice tended to have slightly decreased vital capacity from 16 to 52 weeks of exposure.

Inconsistent effects were also described in studies of long-term NO<sub>2</sub> exposure in the range of 6–8 weeks. [Stevens et al. \(1988\)](#) exposed 1-day- and 7-week-old rats to 500, 1,000, and 2,000 ppb NO<sub>2</sub> continuously with two daily peaks at three times the baseline concentration (1,500, 3,000, and 6,000 ppb) for 1–7 weeks and observed different results among age groups. Rats exposed from 1 day of age had increased lung compliance after 3 weeks of exposure that returned to control levels by 6 weeks (1,000 ppb with 3,000 ppb peaks). In rats exposed from 7 weeks of age, compliance was decreased after 6 weeks of exposure at 1,000 and 2,000 ppb NO<sub>2</sub>. In an 8-week study, [Lafuma et al. \(1987\)](#), reported increased lung volumes in animals exposed to 2,000 ppb (8 h/day, 5 days/week), but vital capacity and compliance were not affected.

---

### 6.2.5.4 Summary of Lung Function

Recent longitudinal studies continue to indicate associations between early-life NO<sub>2</sub> exposure and decrements in lung function and lung development in school-aged children. An association also was observed in young children aged 4 years. A linear concentration–response relationship was observed in one study. Such associations also are observed in cross-sectional studies ([Gao et al., 2013](#); [Svendsen et al., 2012](#); [Lee et al., 2011d](#); [Rosenlund et al., 2009b](#); [Tager et al., 2005](#); [Sekine et al., 2004](#); [Moseler et al., 1994](#)). A meta-analysis across five birth cohorts in Europe using LUR exposure estimates reported results consistent with the rest of the evidence base. Evidence in adults is more

limited and inconsistent. In children, much of the evidence is for FEV<sub>1</sub>, which reflects the mechanical properties of the airways. There is less evidence for FVC, which represents lung volume. As examined in two longitudinal studies, short-term NO<sub>2</sub> exposures did not explain the association between long-term NO<sub>2</sub> exposure and lung function. Associations were observed in various locations using varied exposure assessment methods, lung function measurements, and time of follow-up with children. Many studies demonstrated that LUR models used to estimate individual-level residential NO<sub>2</sub> exposure were able to well predict measured NO<sub>2</sub> concentrations in the study area.

An important uncertainty in the evidence base is whether NO<sub>2</sub> exposure has an independent effect on lung function or lung development. Results for NO<sub>2</sub> were inconsistent with PM<sub>2.5</sub> adjustment. In copollutant models with PM<sub>2.5</sub>, NO<sub>2</sub> remained associated with FVC but not FEV<sub>1</sub> or PEF. NO<sub>x</sub> association persisted with adjustment for PM<sub>2.5</sub>, but there likely is differential measurement error for NO<sub>x</sub> exposure estimated for individual children and PM<sub>2.5</sub> measured at central sites. Confounding by traffic-related pollutants is unexamined, and high copollutant correlations often are observed. Animal studies do not address this uncertainty in the epidemiologic evidence as they demonstrate inconsistent effects of long-term NO<sub>2</sub> exposure on lung function. However, age may be an influential factor on the effect of NO<sub>2</sub> on lung function that has not been adequately addressed by the existing body of toxicological evidence.

---

## 6.2.6 Changes in Lung Morphology

While no recent studies are available, the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) reported that animal toxicological studies demonstrate morphological changes to the respiratory tract resulting from exposure to NO<sub>2</sub> but variable responses to concentrations below 5,000 ppb. Study characteristics are presented in [Table 6-2](#). [Wagner et al. \(1965\)](#) exposed dogs, rabbits, guinea pigs, rats, hamsters, and mice to 1,000 or 5,000 ppb NO<sub>2</sub> for up to 18 months and found enlarged air space and edema and areas of mild to moderately thickened septae with chronic inflammatory cells. However, some of these observations were also made in control animals and were not considered to be statistically significant in any species. Importantly, this study demonstrated differences in sensitivity to NO<sub>2</sub> across species. [Furiosi et al. \(1973\)](#) exposed monkeys and rats to 2,000 ppb NO<sub>2</sub> continuously for 14 months and also found species-specific responses; monkeys experienced hypertrophy of the bronchiolar epithelium that was most notable in the respiratory bronchioles in addition to development of a cuboidal phenotype in the squamous proximal bronchiolar epithelium. In rats, these effects were more occasional under identical exposure conditions.

The majority of other morphologic studies employed rodent models to evaluate effects of NO<sub>2</sub> exposure. [Chang et al. \(1986\)](#) compared responses in mature and juvenile rats to an urban exposure pattern of NO<sub>2</sub> for 6 weeks (500 ppb continuously with two daily peaks at 1,500 ppb). Mature rats were more sensitive to NO<sub>2</sub> exposure and exhibited increased surface density of the alveolar basement membrane and decreased air space in the proximal alveolar regions. This was accompanied by an increase in lung volume attributable to Type II cell hyperplasia and increases in fibroblasts, alveolar macrophages, and extracellular matrix. In the juvenile rats, effects of exposure were limited to thinning of Type II cells that were spread over more surface area compared to controls. [Mercer et al. \(1995\)](#) found more subtle effects in rats with NO<sub>2</sub> exposure; frequency of fenestrae was increased in the alveolar epithelium. However, there were no changes found in the extracellular matrix or interstitial cells. Also, lungs did not appear to have differences in alveolar septal thickness, parenchymal cell populations, or cellular size and surface area after 9 weeks of exposure. [Crapo et al. \(1984\)](#) conducted a 6-week study in rats with a similar exposure pattern at higher concentrations (2,000 ppb NO<sub>2</sub> for 23 h/day with two 30-minute peaks of 6,000 ppb) and reported hypertrophy and hyperproliferation of the alveolar epithelium. In another study, rats were exposed to a similar urban exposure pattern in addition to a single high concentration for up to 15 weeks; these animals had subpleural alveolar macrophage accumulation and areas of focal hyperinflation, although the mean linear intercept (MLI), a measure of free distance in the air space, was not changed ([Gregory et al., 1983](#)). Conversely, [Lafuma et al. \(1987\)](#) reported that hamsters exposed to 2,000 ppb NO<sub>2</sub> for 8 h/day, 5 days/week for 8 weeks had increased MLI and decreased internal surface area, but no lesions were found in the bronchiole or bronchiolar epithelium, alveolar ducts, or alveolar epithelium.

[Kubota et al. \(1987\)](#) assessed pathology of the airway in rats exposed continuously for 27 months to 40, 400, or 4,000 ppb NO<sub>2</sub>. At the highest exposure, rats had increased bronchial epithelial proliferation after 9 and 18 months, and by 27 months, proliferation and edema resulted in fibrosis. Exposure to 400 ppb produced similar morphological changes in the bronchial epithelium that was not apparent until 27 months. Exposure to 40 ppb NO<sub>2</sub> did not result in morphological changes that could be identified by microscopic techniques. Studies conducted at similar concentrations and durations, 500 ppb NO<sub>2</sub> for up to 19 months reported analogous effects. [Blair et al. \(1969\)](#) described an increase in alveolar size after 3 months of exposure with loss of cilia in respiratory bronchioles, which persisted at 12 months. After 4 months of exposure, [Hayashi et al. \(1987\)](#) reported Type II cell hypertrophy and interstitial edema leading to thickened alveolar septa at 6 months and fibrous pleural thickening at 9 months. Similarly, exposure to 500 ppb for 7 months resulted in interstitial edema and Type II cell hyperplasia in rats, and additional injury at 1,000 ppb included loss of cilia in the terminal bronchioles ([Yamamoto and Takahashi, 1984](#)). Type II cell hyperplasia was also documented by

[Sherwin and Richters \(1982\)](#) as was an increase in the MLI. These studies demonstrate that long-term exposure to NO<sub>2</sub> can result in changes in lung morphology including Type II cell hyperplasia, loss of cilia in the bronchiolar region, change in phenotype of bronchiolar epithelium, fibrosis, and enlarged airspace, some of which are permanent, while others may be transient.

---

## 6.2.7 Respiratory Infection

Toxicological studies, as reviewed in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), demonstrated NO<sub>2</sub>-induced mortality from infection in experiment animals as well as changes in host defense mechanisms. Epidemiologic investigation of the relationship between long-term NO<sub>2</sub> exposure and respiratory infection is limited, particularly in longitudinal studies.

---

### 6.2.7.1 Epidemiologic Studies of Respiratory Infection

NO<sub>2</sub> exposure is inconsistently associated with respiratory infection in infants and young children up to 3 years of age ([Aguilera et al., 2013](#); [Sunyer et al., 2004](#)). In a multicity longitudinal study, [Sunyer et al. \(2004\)](#) observed no associations between 2-week indoor NO<sub>2</sub> exposure and lower respiratory tract infections during the first year of life. In analyzing infections during the first year of life, authors used the 2-week NO<sub>2</sub> measurement to represent long-term exposure. [Aguilera et al. \(2013\)](#) observed an association between increased NO<sub>2</sub> exposure estimated by LUR and increased risk of upper and lower respiratory tract infections in infants.

In a population-based case-control study in Hamilton, Ontario, Canada, [Neupane et al. \(2010\)](#) examined hospital admission for community-acquired pneumonia in 345 adults aged 65 years or more. Control participants (n = 494) aged 65 years or more were randomly selected by telephone calls from the same community as cases from July 2003 to April 2005. Annual average NO<sub>2</sub> exposures were estimated by three methods: central site monitors, LUR models, and IDW. Participants had to present to the emergency room with at least two signs and symptoms for pneumonia and have a new opacity on a chest radiograph interpreted by a radiologist as being compatible with pneumonia. NO<sub>2</sub> and PM<sub>2.5</sub> were associated with hospital admission for community-acquired pneumonia, but SO<sub>2</sub> was not. NO<sub>2</sub> exposure estimated by all three methods were associated with pneumonia (ORs per 10 ppb increase: 3.20 [95% CI: 1.37, 7.45] for IDW; 1.97 [95% CI: 1.21, 3.19] for bicubic spline; 1.93 [95% CI: 1.00, 3.74] for LUR). There was no mention of adjustment for short-term exposure effects, and it is not clear what the relative impacts

on respiratory infections are for short-term versus long-term exposure. Associations are observed between short-term NO<sub>2</sub> exposure and hospital admissions for pneumonia (Table 5-25), but quantitative comparisons with long-term NO<sub>2</sub> exposure effect estimates may not be informative given the differences in exposure assessment methods and distribution of NO<sub>2</sub> concentrations.

Parent report of physician-diagnosed pneumonia, croup, and otitis media during early childhood was examined in 10 European birth cohorts: BAMSE (Sweden), Gene and Environmental Prospective Study in Italy [GASPII (Italy)], Gene and Environmental Prospective Study in Italy plus environmental and genetic influences (GINIplus), Lifestyle-Related factors on the Immune System and the Development of Allergies in Childhood plus the influence of traffic emissions and genetics [LISAplus (Germany)], MAAS (U.K.), PIAMA (the Netherlands), and four Infancia y Medio Ambiente cohorts [Spain; (MacIntyre et al., 2014b)]. Annual average NO<sub>2</sub> exposure was estimated using LUR models and assigned to children based on their residential address at birth. Identical protocols were used to develop LUR models for each study area. There was a complete outcome (at least one), exposure (a minimum of NO<sub>2</sub> and NO<sub>x</sub>), and potential confounder information for 16,059 children across all 10 cohorts. For pneumonia, the meta-analysis produced a combined adjusted OR of 1.64 (95% CI: 1.02, 1.65) per 10-ppb increase in NO<sub>2</sub>. NO<sub>2</sub> was associated with otitis media but not croup. NO<sub>2</sub> measurements to build the LUR models were made 2008–2011, but children in the study cohorts were born as early as 1994. To address this temporal mismatch, a sensitivity analyses was conducted using data from central site monitors to back-extrapolate LUR estimates and produced results generally consistent with the main findings. NO<sub>2</sub> associations with pneumonia were attenuated and had wide 95% CIs with adjustment PM<sub>2.5</sub> or PM<sub>2.5</sub> absorbance. ORs (95% CI) for NO<sub>2</sub> in copollutant models, respectively, were: 1.32 (0.72, 2.42) and 1.36 (0.57, 3.28). Correlations between NO<sub>2</sub> and PM<sub>2.5</sub> ranged between 0.42 and 0.80, and correlations between NO<sub>2</sub> and PM<sub>2.5</sub> absorbance ranged between 0.40 and 0.93.

---

### 6.2.7.2 Toxicological Studies of Respiratory Infection

Long-term NO<sub>2</sub> exposure has been shown to increase susceptibility of experimental animals to infection. In Henry et al. (1970), squirrel monkeys exposed to 5,000 ppb NO<sub>2</sub> for 2 months and then exposed to *Klebsiella pneumoniae* or influenza had increased markers of infection, white blood cell counts and erythrocyte sedimentation rate (ESR), 3 days post-infection. Furthermore, two of the seven monkeys exposed to NO<sub>2</sub> died at 3 and 10 days post-infection. When influenza virus was given 24 hours prior to NO<sub>2</sub> exposure and after NO<sub>2</sub> exposure, tidal volume and respiratory rate increased and the ESR increased. One of the three exposed monkeys died 5 days post-infection. Ehrlich and

[Henry \(1968\)](#) and [Ehrlich \(1980\)](#) also studied the effects of NO<sub>2</sub> on *Klebsiella pneumoniae* infection in mice. Exposures were either continuous or intermittent (6 or 18 h/day) at a concentration of 500 ppb NO<sub>2</sub>, and bacterial challenge was administered at 1, 3, 6, 9, and 12 months. Continuous exposure to NO<sub>2</sub> for 3 months or longer increased mortality rates after infection, whereas intermittent exposures increased mortality at 6, 9, and 12 months. Likewise, [Miller et al. \(1987\)](#) showed increased mortality in mice exposed to a base of 200 ppb NO<sub>2</sub> with two daily 1-hour peaks of 800 ppb and subsequent challenge with *Streptococcus zooepidemicus* at 16, 32, and 52 weeks.

---

### 6.2.7.3 Subclinical Effects Underlying Respiratory Infection

Impaired host defense mechanisms can increase susceptibility to bacterial and viral infection, and toxicological studies in experimental animals demonstrate that ambient-relevant NO<sub>2</sub> exposures for periods greater than 6 weeks can modulate lung host defense including alter characteristics of AMs. Characteristics of these studies, which were also reviewed in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), are presented in [Table 6-2](#).

Alveolar macrophages play a critical role in removing pathogens from the airways, and impaired function can increase susceptibility to infection and injury. [Chang et al. \(1986\)](#) showed that exposure to 500 ppb NO<sub>2</sub> continuously with 1,500 ppb 1-hour peaks twice daily for 6 weeks increased the number of AMs in the alveoli and their cellular volume. [Gregory et al. \(1983\)](#) reported similar findings and observed AM accumulation in lung sections by light microscopy after exposure to 5,000 ppb NO<sub>2</sub> or a base of 1,000 ppb NO<sub>2</sub> with 5,000 ppb spikes twice each day for 15 weeks.

[Greene and Schneider \(1978\)](#) investigated the function of AMs isolated from antigen-sensitized baboons exposed to 2,000 ppb NO<sub>2</sub> for 8 h/day, 5 days/week for 6 months and found that AMs had diminished response to migration inhibitory factor obtained from antigen-stimulated lymphocytes. However, sample size in this study was small: 3 exposed to NO<sub>2</sub> and antigen, 1 exposed to NO<sub>2</sub> alone, 1 exposed to antigen alone, and 1 air control. Other studies have not reported on this endpoint.

In addition to AMs, mast cells play an important role in host defense and inflammatory processes. [Fujimaki and Nohara \(1994\)](#) exposed both rats and guinea pigs to 1,000, 2,000, or 4,000 ppb NO<sub>2</sub> continuously for 12 weeks. Although the number of mast cells in the airway increased after exposure to 2,000 and 4,000 ppb, these changes were not statistically significant. Histamine, released by mast cells, was reduced in rats at 2,000 ppb NO<sub>2</sub> and increased in guinea pigs at 4,000 ppb. This observation suggests species differences in response to NO<sub>2</sub> exposure.

---

#### 6.2.7.4 Summary of Respiratory Infection

In the small body of epidemiologic studies, long-term NO<sub>2</sub> exposure estimated for subjects' homes by LUR was associated with respiratory infections in school children and pneumonia hospital admissions in adults, ages 65 years or older. Results are inconsistent in infants. Particularly for hospital admissions, it is not clear whether the association observed for long-term NO<sub>2</sub> exposure is independent of an association with short-term exposure. As examined in school children, associations for long-term NO<sub>2</sub> exposure were positive with adjustment for PM<sub>2.5</sub> or PM<sub>2.5</sub> absorbance, but the 95% CIs were very wide. Thus, an independent association for NO<sub>2</sub> is not clearly indicated. A small body of toxicological studies provide support for an independent effect of NO<sub>2</sub> exposure on respiratory infections, showing that mice and monkeys exposed to 500 or 5,000 ppb NO<sub>2</sub> for periods greater than 6 weeks have increased infection-induced mortality and AM numbers in the airways.

---

#### 6.2.8 Chronic Obstructive Pulmonary Disease

Recent epidemiologic studies examined associations between long-term NO<sub>2</sub> exposure and effects related to COPD, including the study of indoor NO<sub>2</sub> and respiratory symptoms in adults with COPD ([Hansel et al., 2013](#)), described in [Section 6.2.3.1](#). Few studies examined COPD development, and results are inconsistent. In a longitudinal cohort study, [Andersen et al. \(2011\)](#) estimated outdoor annual average NO<sub>2</sub> and NO<sub>x</sub> since 1971 by a validated LUR model for residential locations and calculated time-weighted averages for 15-, 25- and 35-year periods ([Raaschou-Nielsen et al., 2000](#)). No other pollutants were considered. COPD hospital admissions were ascertained from 1976, and incidence of COPD was defined as first hospital admission between 1993–1997 and June 2006. COPD incidence was associated with the 35- and 25-year mean concentration of NO<sub>2</sub> (HR: 1.28; [95% CI: 1.07, 1.54] and 1.22 [95% CI: 1.03, 1.45] per 10-ppb increase) and 35-year mean concentration of NO<sub>x</sub> (1.16 [95% CI: 1.04, 1.31] per 20-ppb increase). Weaker positive associations were observed with 25-year mean NO<sub>x</sub>, 15-year mean NO<sub>2</sub> and NO<sub>x</sub>, and baseline residence traffic proxies (major road within 50 m, traffic load within 200 m). The associations with NO<sub>2</sub> were stronger than those with NO<sub>x</sub>. The association was stronger in people with diabetes and asthma compared to the rest of the cohort, but no difference in association was observed by smoking or occupational exposure. COPD incidence was most strongly associated with 35-year avg NO<sub>2</sub>, suggesting that long-duration, possibly lifetime exposure may be associated with development of COPD.

[Gan et al. \(2013\)](#) evaluated a population-based cohort in Canada that included a 5-year exposure period and a 4-year follow-up period. All residents aged 45–85 years of Metropolitan Vancouver, Canada, during the exposure period and did not have known COPD at baseline were included in this study (n = 467,994). Five-year average residential exposures to NO<sub>2</sub> and NO were estimated using LUR models, incorporating changes in exposure over time due to changes in residences. COPD incidence was ascertained from a hospital admissions database and defined as admission during the follow-up period. Mortality also was studied and is discussed in [Section 6.5.2](#). The association of 5-year NO<sub>2</sub> with COPD hospital admission was null. The exposure period examined in this study was shorter than that in [Andersen et al. \(2011\)](#) (i.e., 25–35 years).

In the ECRHS cohort, the association of NO<sub>x</sub> with prevalence of COPD and related symptoms was investigated by two methods for assessing exposure to power plant-specific emissions of NO<sub>x</sub> ([Amster et al., 2014](#)). NO<sub>x</sub> exposures (8-year avg) related to power plant emissions were estimated for subjects' residences (n = 2,244) based on kriging ambient concentrations from 20 central site monitors downwind of the power plant (source approach), and peak emission events (event approach) were defined as 30-minute concentrations that exceeded 125 ppb NO<sub>2</sub>. Neither source-based nor event-based power plant NO<sub>x</sub> emissions were associated with COPD prevalence. Respiratory symptoms were associated with source-based NO<sub>x</sub> but not event-based NO<sub>x</sub>.

In a cross-sectional study, [Wood et al. \(2009\)](#) examined respiratory phenotype (PiZZ type) in alpha 1-antitrypsin deficiency ( $\alpha$ -ATD) from the U.K.  $\alpha$ -ATD registry. This deficiency leads to exacerbated responses to inflammatory stimuli. In total, 304 PiZZ subjects underwent full lung-function testing and quantitative high-resolution computed tomography to identify the presence and severity of COPD emphysema. Annual average NO<sub>2</sub> was estimated for subjects' homes with dispersion models. NO<sub>2</sub> was associated with improved gas transfer and less severe emphysema. Similar associations were observed with SO<sub>2</sub> and particles. In contrast, O<sub>3</sub> was associated with worse gas transfer and more severe emphysema, albeit accounting for only a small proportion of the lung function variability. NO<sub>2</sub> was negatively correlated with O<sub>3</sub>, which might explain NO<sub>2</sub> associations with gas transfer and emphysema severity. No information was provided on how well the dispersion model captured the spatial pattern of long-term NO<sub>2</sub> concentrations.

---

### 6.2.9 Summary and Causal Determination

There is likely to be a causal relationship between long-term NO<sub>2</sub> exposure and respiratory effects, based strongly on evidence integrated across disciplines for a relationship with asthma development. There is more uncertainty in relationships with

lung function and partially irreversible decrements in lung development in children, respiratory disease severity, chronic bronchitis/asthma incidence in adults, COPD hospital admissions, and respiratory infection.

The conclusion of a “likely to be causal relationship” represents a change from the “suggestive of, but not sufficient to infer, a causal relationship” determined in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)). The main difference in the evidence base is several recent longitudinal studies that indicate associations between asthma incidence in children and long-term NO<sub>2</sub> exposures estimated for at or near children’s homes or schools and biological plausibility from previous experimental studies. In contrast, the 2008 ISA for Oxides of Nitrogen reported inconsistent findings from a limited number of cross-sectional studies that examined asthma prevalence. An additional uncertainty identified in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) was the potential for NO<sub>2</sub> to serve primarily as a surrogate for another traffic-related pollutant or mixture. Because of the high correlations among traffic-related pollutants and limited examination of copollutant confounding, the independent effects of long-term NO<sub>2</sub> exposure could not be clearly discerned in the last review. While this uncertainty continues to apply to the epidemiologic evidence across the respiratory effects examined, coherence of epidemiologic evidence for asthma incidence with the limited previous toxicological evidence for both AHR and development of allergic responses, which are key events in the proposed mode of action for asthma development, provides support for an independent effect of long-term exposure to NO<sub>2</sub> on development of asthma. The key evidence supporting the “likely to a causal relationship” is detailed in [Table 6-5](#) using the framework described in [Table II](#) of the [Preamble](#) to this ISA.

---

### 6.2.9.1 Evidence on Development of Asthma

Multiple longitudinal studies demonstrate associations between higher ambient NO<sub>2</sub> concentrations measured in the first year of life, in the year of diagnosis, or over a lifetime and asthma incidence in children. Results are consistent across locations based on various study designs and cohorts ([Table 6-1](#)). Consistency across studies in the use of questionnaires to ascertain parent report of physician-diagnosed asthma, a best practice ([Burr, 1992](#); [Ferris, 1978](#)), adds to the strength of inference about associations with NO<sub>2</sub>.

A pooled analysis across six birth cohorts relating NO<sub>2</sub> with ever asthma (OR: 1.48 [95% CI: 1.06, 2.04] per 10 ppb increase) ([Macintyre et al., 2014a](#)) is consistent with results from individual studies. A strength of several studies is NO<sub>2</sub> exposures estimated at or near children’s homes or schools from central sites 1 km away or from LUR models that were demonstrated to represent well the spatial variability in the study areas. LUR

models were developed with traffic metrics assessed at various buffers [e.g., 100 m ([Gehring et al., 2010](#)), 500 m ([Clougherty et al., 2007](#))]. Associations were observed across a range of ambient NO<sub>2</sub> concentrations [([Carlsten et al., 2011c](#); [Gehring et al., 2010](#); [Jerrett et al., 2008](#); [Clougherty et al., 2007](#)); [Table 6-1](#)]. In limited analysis of the concentration-response relationship, results did not consistently indicate a linear relationship in the range of ambient NO<sub>2</sub> concentrations examined ([Carlsten et al., 2011c](#); [Shima et al., 2002](#)). These studies did not conduct analyses to evaluate whether there is a threshold for effects. Limited supporting evidence for incidence of asthma or chronic bronchitis incidence in adults is provided in the ECRHS cohort in relation to NO<sub>2</sub> measurements outside subjects' homes ([Sunyer et al., 2007](#)) and estimated by dispersion models that were validated against ambient measurements.

Epidemiologic studies of asthma development in children have not clearly characterized potential confounding by PM<sub>2.5</sub> or traffic-related pollutants [e.g., CO, BC/EC, volatile organic compounds (VOCs)]. In the longitudinal studies, correlations with PM<sub>2.5</sub> and BC were often high (e.g.,  $r = 0.7-0.96$ ), and no studies of asthma incidence evaluated copollutant models to address copollutant confounding, making it difficult to evaluate the independent effect of NO<sub>2</sub>. Across studies that examined both NO<sub>2</sub> and PM<sub>2.5</sub>, PM<sub>2.5</sub> concentrations were associated with asthma development ([Nishimura et al., 2013](#); [Clark et al., 2010](#); [McConnell et al., 2010a](#)). Effect estimates were smaller in magnitude for PM<sub>2.5</sub> compared to NO<sub>2</sub>, but because of the potential for differential exposure measurement error, comparisons of effect estimates may not be meaningful.

The uncertainty in the epidemiologic evidence base is partly reduced by the biological plausibility provided by findings from experimental studies that demonstrate NO<sub>2</sub>-induced effects on key events in the mode of action proposed for the development of asthma ([Figure 4-2](#)). Though not consistently demonstrated, AHR was induced in guinea pigs after 6–12 weeks of exposure to NO<sub>2</sub> [1,000–4,000 ppb; ([Kobayashi and Miura, 1995](#))], and there is some evidence that airway remodeling was involved. Experimental studies also indicate that short-term exposure repeated over several days and long-term NO<sub>2</sub> exposure can induce Th2 skewing/allergic sensitization by showing increased Th2 cytokines, airway eosinophils, and IgE-mediated responses ([Sections 4.3.5](#) and [6.2.2.3](#)). Epidemiologic evidence for NO<sub>2</sub>-related pulmonary inflammation is inconsistent ([Section 6.2.2.3](#)), but reported in a recent longitudinal study ([Berhane et al., 2014](#)). The association was independent of short-term changes in NO<sub>2</sub> concentrations, and elevated eNO was associated with increased risk of new onset asthma in the cohort. Recurrent pulmonary inflammation and oxidative stress are identified as key early events in the proposed mode of action for asthma development ([Figure 4-2](#)). While the effects of long-term NO<sub>2</sub> exposure on oxidative stress in toxicological studies are variable and transient ([Section 6.2.2.3](#)), some evidence supports a relationship between short-term

NO<sub>2</sub> exposure and increased pulmonary inflammation. Evidence from controlled human exposure studies indicates that repeated NO<sub>2</sub> exposure increases neutrophils in healthy adults, and epidemiologic evidence also points to associations between ambient NO<sub>2</sub> concentrations and increases in pulmonary inflammation in healthy children and adults ([Section 5.2.2.5](#)). Findings for short-term NO<sub>2</sub> exposure support an effect on asthma development by describing a potential role for repeated exposures to lead to recurrent inflammation and allergic responses.

The limited evidence base for NO<sub>2</sub>-related development of AHR and allergic responses and increases in pulmonary inflammation combined with the consistent epidemiologic evidence for NO<sub>2</sub>-related development of asthma in children are coherent and indicate a biologically plausible sequence of events by which long-term NO<sub>2</sub> exposure could lead to asthma development.

---

#### **6.2.9.2 Evidence on Lung Function**

Another line of evidence indicating a relationship between long-term NO<sub>2</sub> exposure and respiratory effects includes multiple, longitudinal epidemiologic studies observing associations between long-term NO<sub>2</sub> exposure and decrements in lung function and partially irreversible decrements in lung development in children. Expanding on evidence reviewed in the 2008 ISA, recent studies consistently demonstrate associations with individual-level NO<sub>2</sub> exposure estimates based on time-activity patterns and/or LUR ([Urman et al., 2014](#); [Eenhuizen et al., 2013](#); [Mölter et al., 2013](#)). Associations are also observed with NO<sub>2</sub> assessed from central sites. [Gauderman et al. \(2004\)](#) found an NO<sub>2</sub> concentration-dependent decrement in lung development but based on comparisons among communities not individual subjects.

Potential confounding of long-term NO<sub>2</sub>-related decrements in lung function and lung development by traffic-related copollutants has not been evaluated, although an association was observed with adjustment for O<sub>3</sub> or PM<sub>10</sub>. Toxicological studies do not clearly support epidemiologic findings. NO<sub>2</sub>-induced changes in lung function were inconsistently demonstrated in animal models [([Tepper et al., 1993](#); [Stevens et al., 1988](#); [Lafuma et al., 1987](#)); [Section 6.2.5.3](#)]. Long-term NO<sub>2</sub> exposure was observed to alter lung morphology in adult experimental animals but not juvenile animals ([Section 6.2.6](#)), but the changes observed do not appear to contribute to altered lung function or explain the effects observed in epidemiologic studies. Thus, it remains unclear whether NO<sub>2</sub> exposure has an independent effect on lung function or lung development.

---

### 6.2.9.3 Evidence on Respiratory Disease Severity

Several longitudinal studies consistently demonstrate increases in respiratory symptoms in children with asthma in relation to increased ambient NO<sub>2</sub> concentrations (Section 6.2.3 and Table 6-3). Associations were observed with NO<sub>2</sub> estimated from central sites and NO<sub>2</sub> estimated for children's homes using LUR. Studies did not examine whether associations of long-term NO<sub>2</sub> were independent of short-term exposure; however, [McConnell et al. \(2003\)](#) assessed chronic symptoms as a daily cough for 3 months or congestion/phlegm for 3 months. Limited information from longitudinal studies of indoor NO<sub>2</sub> support an association with respiratory symptoms in children with asthma and adults with COPD ([Belanger et al., 2013](#); [Hansel et al., 2013](#)). Findings for indoor NO<sub>2</sub> exposure provide support for an independent relationship between NO<sub>2</sub> and respiratory effects because NO<sub>2</sub> may exist as part of a different air pollutant mixture indoors than in the ambient air (Section 5.2.9.6). In limited analysis of copollutant models, associations of NO<sub>2</sub> with respiratory symptoms in children persisted with adjustment for PM<sub>2.5</sub> or the traffic-related pollutants EC or OC. Potentially limiting inference from these results, pollutants were measured from central sites, and correlations with NO<sub>2</sub> were high for PM<sub>2.5</sub> and EC (0.75 and 0.92, respectively).

---

### 6.2.9.4 Evidence on Respiratory Infection

In the limited body of epidemiologic studies, findings do not consistently indicate associations between long-term NO<sub>2</sub> exposure and respiratory infection. Findings in infants are inconsistent, and associations with pneumonia hospital admissions in adults could be due to short-term exposure. An evaluation of 10 European birth cohorts demonstrated associations of residential estimates of NO<sub>2</sub> exposure with parental report of physician-diagnosed pneumonia and otitis media ([MacIntyre et al., 2014b](#)). Adjustment for PM<sub>2.5</sub> or PM<sub>2.5</sub> absorbance produced associations for NO<sub>2</sub> with wide 95% CIs, limiting inferences about independent NO<sub>2</sub> associations (Section 6.2.7.2). The strongest toxicological evidence for long-term NO<sub>2</sub> exposure leading to respiratory effects is that for respiratory infection (Section 6.2.7.2). Exposure to 200–5,000 ppb NO<sub>2</sub> for 1 month up to 1 year increased mortality in rodents and squirrel monkeys following bacterial challenge ([Miller et al., 1987](#); [Henry et al., 1970](#)) and altered AM numbers and morphology ([Gregory et al., 1983](#); [Aranyi et al., 1976](#)). The latter are identified as key events in the proposed mode of action linking NO<sub>2</sub> exposure to respiratory infection.

---

### 6.2.9.5 Analysis of Potential Confounding by Traffic-Related Copollutants

Potential confounding of long-term NO<sub>2</sub> associations with respiratory effects by traffic-related copollutants has been examined to a limited extent, particularly in longitudinal analyses of asthma incidence. In longitudinal studies of children, copollutant models were analyzed for chronic bronchitic symptoms ([McConnell et al., 2003](#)) and lung function and respiratory infection ([MacIntyre et al., 2014b](#); [Gehring et al., 2013](#)). NO<sub>2</sub> associations varied with adjustment for EC, OC, PM<sub>2.5</sub> absorbance, or PM<sub>2.5</sub>, from not changing or being modestly reduced to being attenuated. In some cases, copollutants were moderately correlated with NO<sub>2</sub> ( $r = 0.37$ – $0.46$  for PM<sub>2.5</sub>,  $0.52$  for PM<sub>2.5</sub> absorbance,  $0.58$  for OC). However, high correlations often were reported ( $r = 0.72$ – $0.80$  for PM<sub>2.5</sub> or  $0.75$ – $0.92$  for PM<sub>2.5</sub> absorbance or EC). Although some studies indicate an independent association for long-term NO<sub>2</sub> exposure with some respiratory effects, inconsistency in the evidence and limited analysis of the array of potential confounding traffic-related copollutants make it difficult to disentangle the independent effect of NO<sub>2</sub> from other traffic-related pollutants or mixtures in the epidemiologic studies.

---

### 6.2.9.6 Conclusion

Taken together, recent epidemiologic studies and previous experimental studies provide evidence that there is likely to be a causal relationship between long-term NO<sub>2</sub> exposure and respiratory effects ([Table 6-5](#)). This conclusion is based on the evidence for asthma development. Evidence for other respiratory effects such as respiratory disease severity, lung function changes, and respiratory infection is more uncertain because the combined epidemiologic and/or experimental evidence does not clearly demonstrate an independent effect of long-term NO<sub>2</sub> exposure. Recent epidemiologic studies consistently indicate increases in asthma incidence in children particularly in association with NO<sub>2</sub> exposures estimated at or near children's homes or schools. Potential confounding by copollutants of greatest concern, PM<sub>2.5</sub> and traffic-related copollutants, largely is unexamined. Experimental evidence indicating AHR induced by long-term NO<sub>2</sub> exposure and development of an allergic phenotype with repeated short-term or long-term NO<sub>2</sub> exposure provides biological plausibility by characterizing a potential mode of action by which long-term NO<sub>2</sub> exposure may lead to asthma development. However, because this experimental evidence is limited, there remains some uncertainty regarding an independent effect of long-term NO<sub>2</sub> exposure on asthma development. Thus, the combined consistent epidemiologic evidence and consistent but limited experimental evidence for development of asthma is sufficient to conclude that there is likely to be a causal relationship between long-term NO<sub>2</sub> exposure and respiratory effects.

**Table 6-5 Summary of key evidence for a likely to be a causal relationship between long-term nitrogen dioxide exposure and respiratory effects.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
<b>Asthma Development</b>			
Consistent epidemiologic evidence from multiple, high-quality studies with relevant NO <sub>2</sub> concentrations	Consistent evidence for increases in asthma incidence in diverse cohorts of children in U.S., Europe, Canada, and Asia. Asthma ascertainment by parental report of doctor diagnosis.	† <a href="#">Carlsten et al. (2011c)</a> , † <a href="#">Clougherty et al. (2007)</a> , † <a href="#">Gehring et al. (2010)</a> , † <a href="#">Jerrett et al. (2008)</a> , <a href="#">Shima et al. (2002)</a> Weak evidence: † <a href="#">Ranzi et al. (2014)</a> <a href="#">Section 6.2.2.1, Table 6-1, Figure 6-1</a>	Means across studies of LUR model: 13.5, 17.3, 27.5 ppb 75th percentile: 15.1, 15.4 ppb, Max: 69.4 ppb Range in mean residential NO <sub>2</sub> across communities: 9.6 to 51.3 ppb Range in mean central site NO <sub>2</sub> across communities: 7.3–31.4 ppb
	Supporting evidence for asthma incidence or chronic bronchitis in the ECHRS cohort of adults.	† <a href="#">Jacquemin et al. (2009b)</a> , † <a href="#">Modig et al. (2009)</a> , <a href="#">Sunyer et al. (2006)</a> <a href="#">Section 6.2.2.2</a>	
Consistent evidence for NO <sub>2</sub> metrics with lower potential for exposure measurement error	NO <sub>2</sub> estimated for children's homes with well-validated LUR models or by monitoring at or near children's homes/schools.	† <a href="#">Carlsten et al. (2011c)</a> , † <a href="#">Gehring et al. (2010)</a> , † <a href="#">Jerrett et al. (2008)</a> , <a href="#">Shima et al. (2002)</a> <a href="#">Section 6.2.2.1</a>	
Uncertainty regarding potential confounding by PM <sub>2.5</sub> or traffic-related copollutants	Correlations with PM <sub>2.5</sub> and EC often were high ( $r = 0.7-0.96$ ). Copollutant models not analyzed. Associations found with adjustment for SES, family history of asthma, smoking exposure, gas stove in home	† <a href="#">McConnell et al. (2010a)</a> <a href="#">Table 6-1</a>	
Some evidence for key events in the proposed mode of action Allergic responses	Increased IgE-mediated histamine release in mast cells from rodents.	<a href="#">Fujimaki and Nohara (1994)</a> <a href="#">Section 6.2.4.1</a>	4,000 ppb for 12 weeks
	Experimental findings for development of Th2 phenotype with short-term NO <sub>2</sub> .	<a href="#">Pathmanathan et al. (2003)</a> , <a href="#">Ohashi et al. (1994)</a> <a href="#">Section 5.2.7.4</a>	2,000 ppb over 4 consecutive days; 3,000 ppb for 2 weeks
	Inconsistent epidemiologic evidence	<a href="#">Section 6.2.4.1</a>	

**Table 6-5 (Continued): Summary of key evidence for a likely to be a causal relationship between long-term nitrogen dioxide exposure and respiratory effects.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
Airway hyperresponsiveness	Increased airway responsiveness with short-term exposure in experimental studies of healthy adults and guinea pigs	Humans: <a href="#">Section 5.2.7.1</a> Guinea pigs: <a href="#">Kobayashi and Shinozaki (1990)</a>	Humans: 1,000–2,000 ppb for 3 h but not below Guinea pigs: 4,000 ppb for 7 days
	Limited evidence in guinea pigs with long-term exposure; increased airway resistance suggests airway remodeling.	<a href="#">Kobayashi and Miura (1995)</a>	1,000–4,000 ppb for 6–12 weeks
Inflammation	Increases in lymphocytes, PMNs, in rats with long-term exposure.	<a href="#">Kumae and Arakawa (2006)</a> , <a href="#">Blomberg et al. (1999)</a>	500 or 2,000 ppb; prenatal or postnatal exposure up to 12 weeks of age for 4 days
	Increases in PMNs in healthy adults with repeated short-term exposure.	<a href="#">Section 6.2.2.3</a> , <a href="#">Section 5.2.7.4</a>	
	Inconsistent epidemiologic evidence with exposure assessment by LUR and central site.	† <a href="#">Berhane et al. (2014)</a> , † <a href="#">Liu et al. (2014a)</a> <a href="#">Section 6.2.2.3</a>	
	Limited epidemiologic evidence in healthy children and adults with short-term exposures assessed in subjects' locations and associations adjusted for BC/EC, OC, PNC, or PM <sub>2.5</sub> .	† <a href="#">Strak et al. (2012)</a> , † <a href="#">Steenhof et al. (2013)</a> , † <a href="#">Lin et al. (2011)</a> <a href="#">Section 5.2.7.4</a>	Max for 5-h avg: 96 ppb Means for 24-h avg across seasons: 24.3–45.3 ppb
Oxidative stress	Varying and transient effects on antioxidant levels and enzyme activity.	<a href="#">Ayaz and Csallany (1978)</a> , <a href="#">Gregory et al. (1983)</a> , <a href="#">Sagai et al. (1984)</a> <a href="#">Section 6.2.2.3</a>	400, 1,000, 5,000 ppb for 6 weeks to 18 mo

**Table 6-5 (Continued): Summary of key evidence for a likely to be a causal relationship between long-term nitrogen dioxide exposure and respiratory effects.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
<b>Severity of Asthma</b>			
Consistent epidemiologic evidence but uncertainty regarding NO <sub>2</sub> independent effects	Consistent evidence for increases in respiratory symptoms in children with asthma. Exposure assessment by central site measurements and LUR model.	<a href="#">McConnell et al. (2003)</a> , † <a href="#">Gehring et al. (2010)</a> <a href="#">Table 6-3</a> <a href="#">Section 6.2.3.2</a>	Residential NO <sub>2</sub> by LUR model: Mean: 13.5 ppb 10th–90th percentile: 7.8–18.5 ppb Central site: Mean, Max 4-yr avg for 12 communities: 19.4, 38.0 ppb
	Associations with respiratory symptoms remain robust with adjustment for a traffic-related copollutant: PM <sub>2.5</sub> , EC, or OC. But, analysis is limited and based on central site exposure assessment.	<a href="#">McConnell et al. (2003)</a> , † <a href="#">Hwang and Lee (2010)</a> <a href="#">Table 6-3</a>	
	In limited analysis, associations with respiratory symptoms remain robust with adjustment for O <sub>3</sub> , SO <sub>2</sub> , PM <sub>10-2.5</sub> , or PM <sub>10</sub> .	<a href="#">McConnell et al. (2003)</a> , † <a href="#">Hwang and Lee (2010)</a>	
	Evidence for associations between indoor NO <sub>2</sub> and respiratory symptoms in children with asthma ages 5–10 yr; inconsistent evidence in younger children and infants.	† <a href="#">Belanger et al. (2013)</a> <a href="#">Section 6.2.3.1</a>	Mean daily indoor NO <sub>2</sub> : 10.6 ppb 75th: 12.5 ppb
<b>Lung Function and Development</b>			
Consistent epidemiologic evidence from multiple, high-quality studies but uncertainty regarding NO <sub>2</sub> independent effects	Epidemiologic evidence for decrements in lung function and partially irreversible decrements in lung development in children.	<a href="#">Gauderman et al. (2004)</a> , <a href="#">Rojas-Martinez et al. (2007a)</a> , † <a href="#">Mölter et al. (2013)</a> , † <a href="#">Gehring et al. (2013)</a> , † <a href="#">Urman et al. (2014)</a> , † <a href="#">Eenhuizen et al. (2013)</a> <a href="#">Section 6.2.5.1</a>	NO <sub>2</sub> by LUR model: Means across communities: 7.4–12.6 ppb Overall study mean: 13.5 ppb, 75th: 15.4 ppb Central site NO <sub>2</sub> mean across communities: 27.2–42.6 ppb
	In limited analysis, associations are inconsistent with adjustment for PM <sub>2.5</sub> but robust with adjustment for PM <sub>10</sub> or O <sub>3</sub> . Residential NO <sub>2</sub> -PM <sub>2.5</sub> correlations vary across cohorts. Pearson $r = 0.31-0.76$ .	† <a href="#">Gehring et al. (2013)</a> , <a href="#">Rojas-Martinez et al. (2007b)</a>	

**Table 6-5 (Continued): Summary of key evidence for a likely to be a causal relationship between long-term nitrogen dioxide exposure and respiratory effects.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
Uncertain relevance of toxicological evidence	Changes in lung morphology including increases in edema, hypertrophy of lung epithelium, fibrotic changes in adult not juvenile animals. Uncertain relevance to epidemiologic findings.	<a href="#">Kubota et al. (1987)</a> , <a href="#">Hayashi et al. (1987)</a> Section <a href="#">6.2.6</a>	500 ppb for 19 mo, 4,000 ppb for 9–27 mo
<b>Respiratory Infection</b>			
Consistent toxicological evidence	Increased mortality of mice and monkeys with NO <sub>2</sub> exposure and challenge with bacterial or viral infection.	<a href="#">Henry et al. (1970)</a> , <a href="#">Ehrlich and Henry (1968)</a> , <a href="#">Ehrlich (1980)</a> , <a href="#">Miller et al. (1987)</a> Section <a href="#">6.2.7.2</a>	500 ppb for 3 mo, 5,000 ppb for 2 mo, 200 ppb base plus daily spike of 800 ppb for 16–52 weeks
Limited and inconsistent epidemiologic evidence	Associations with physician-diagnosed pneumonia and otitis media in multicounty European cohort study but not consistently in other studies.	† <a href="#">Macintyre et al. (2014a)</a> Section <a href="#">6.2.7.1</a>	Range in mean across 10 birth cohorts: 7.5–23.7 ppb
Limited evidence for key events in proposed mode of action	Increased AM infiltration to lung tissue or increased lymphocytes in BAL fluid of experimental animals.	<a href="#">Gregory et al. (1983)</a> Section <a href="#">6.2.7.3</a>	5,000 ppb for 15 weeks
<b>COPD</b>			
Limited and inconsistent epidemiologic evidence	Inconsistent evidence for hospital admissions for COPD in adults. Unclear whether independent of short-term exposure effects.	† <a href="#">Andersen et al. (2011)</a> , † <a href="#">Gan et al. (2013)</a> Section <a href="#">6.2.8</a>	

AM = alveolar macrophage; BAL = bronchoalveolar lavage; BC = black carbon; COPD = chronic obstructive pulmonary disease; EC = elemental carbon; ECHRS = European Community Respiratory Health Survey; IgE = immunoglobulin E; LUR = land use regression; NO<sub>2</sub> = nitrogen dioxide; O<sub>3</sub> = ozone; OC = organic carbon; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm; PM<sub>10-2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm and greater than a nominal mean of 2.5 µm; PMN = polymorphonuclear cell(s), polymorphonuclear leukocyte; PNC = particle number concentration; SES = socioeconomic status; SO<sub>2</sub> = sulfur dioxide; Th2 = T-derived lymphocyte helper 2.

<sup>a</sup>Based on aspects considered in judgments of causality and weight of evidence in causal framework in [Tables I](#) and [II](#) of the [Preamble](#).

<sup>b</sup>Describes the key evidence and references, supporting or contradicting, contributing most heavily to causal determination and, where applicable, to uncertainties or inconsistencies. References to earlier sections indicate where full body of evidence is characterized.

<sup>c</sup>Describes the NO<sub>2</sub> concentrations with which the evidence is substantiated (for experimental studies, ≤ 5,000 ppb).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

---

## 6.3 Cardiovascular Effects and Diabetes

---

### 6.3.1 Introduction

The 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) concluded that “the available epidemiologic and toxicological evidence was inadequate to infer the presence or absence of a causal relationship” between cardiovascular effects and long-term NO<sub>2</sub> exposure. This section updates the previous review with the inclusion of recent studies on the cardiovascular effects of NO<sub>2</sub> and NO<sub>x</sub> exposure in humans, animals, and cells. Additionally, recent evidence on the relationship between diabetes and exposure to NO<sub>2</sub> and NO<sub>x</sub> is discussed; there were no studies available on this relationship at the time of the last review. Data from individual studies related to cardiovascular health effects and diabetes can be found in summary tables in each section, and an integrated summary of the evidence is presented in [Section 6.3.9](#).

At the completion of the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) one epidemiologic study of the association of cardiovascular disease (CVD) with long-term exposure to NO<sub>2</sub> was available for review. [Miller et al. \(2007\)](#) studied 65,893 post-menopausal women (50–79 years old) without previous CVD from 36 U.S. metropolitan areas. Exposures to air pollution were estimated by assigning the annual (2000) mean air pollutant concentration measured at the monitor nearest to the subject’s five-digit residential ZIP code centroid. In single-pollutant models, PM<sub>2.5</sub> showed the strongest associations with the CVD events [myocardial infarction (MI), revascularization, angina, congestive heart failure, coronary heart disease (CHD) death], followed by SO<sub>2</sub>. The association of NO<sub>2</sub> with overall CVD events was 1.04 (95% CI: 0.96, 1.12) per 10-ppb increase, and NO<sub>2</sub> was not associated with CVD events when the data set was restricted to those study participants with nonmissing exposure data. Previous animal toxicological studies were limited to examination of changes in heart rate, vagal response, and alterations in specific hematological parameters [e.g., hematocrit, hemoglobin, erythrocytes; ([U.S. EPA, 2008c, 1993a](#))].

Large, prospective studies with consideration of potential confounding and other sources of bias have become available since the completion of the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), and are emphasized in this section (see [Appendix](#) for study evaluation guidelines). The exposure assessment method was also an important consideration in the evaluation of long-term exposure and cardiovascular effects and diabetes, given the spatial variability typically observed in ambient NO<sub>2</sub> concentrations

([Section 2.5.3](#)). Exposure assessment was evaluated drawing upon discussions in [Section 3.2](#) and [Section 3.4.5](#). A select number of recent studies employed exposure assessment methods to account for the spatial variability of NO<sub>2</sub>. For example, LUR model predictions generally have been found to correlate well with outdoor NO<sub>2</sub> measurements ([Section 3.2.2.1](#)). For long-term NO<sub>2</sub> exposure, exposure assessment was evaluated by the extent to which the method represented the spatial variability in NO<sub>2</sub> concentrations in a given study. For modeled estimates, such information includes statistics indicating the correlation between predicted and measured NO<sub>2</sub> concentrations.

Several recent epidemiologic studies report positive associations of NO<sub>2</sub> and NO<sub>x</sub> exposure with heart disease, stroke, hypertension, and diabetes. The body of evidence is generally consistent for heart disease and includes several large, longitudinal studies with consideration of multiple potential confounding factors including age, sex, BMI, smoking, and pre-existing conditions ([Table 6-6](#)). There is also a consistent body of evidence for diabetes comprising large, longitudinal studies that consider multiple potential confounding factors including age, sex, BMI, smoking, and pre-existing conditions ([Table 6-10](#)). Some of these studies employed validated exposure assessment methods such as LUR, which were demonstrated to capture the spatial variability of NO<sub>2</sub> concentration. The extent to which the studies inform the independent effect of NO<sub>2</sub> exposure through their consideration of copollutants of greatest concern (i.e., CO, BC, PM<sub>2.5</sub>) and noise is discussed in this section. A small number of experimental animal studies examining the effect of NO<sub>2</sub> on oxidative stress and the progression of vascular disease provide limited support for the biological plausibility of the cardiovascular effects observed in the epidemiologic studies.

---

### 6.3.2 Heart Disease

Several studies published since the 2008 ISA for Oxides of Nitrogen examine the association of long-term NO<sub>2</sub> exposure and heart disease. Although the evidence from the epidemiologic studies is not entirely consistent, several prospective studies and/or studies with exposure assessment strategies designed to capture the spatial variability of NO<sub>2</sub> report positive associations. Most studies adjust for a wide array of potential confounders such as age, sex, BMI, smoking, and pre-existing conditions ([Table 6-6](#)), but uncertainty remains on the extent to which the findings can be explained by correlated copollutant exposures and noise.

[Cesaroni et al. \(2014\)](#) reported an increased risk of incident coronary events of 1.06 (95% CI: 0.96, 1.16) per 10-ppb increase in NO<sub>2</sub>. This large study of 11 cohorts from 5 countries used LUR to assign exposure at each participant's residence. Authors

reported good performance of exposure models based on their comparison of predicted estimates and concentrations measured at 40 sites ( $R^2 \geq 0.61$ ). A study of pulmonary patients in Toronto, Canada ([Beckerman et al., 2012](#)) reported an increased risk of 1.17 (95% CI 1.01, 1.36) per 10-ppb increase in NO<sub>2</sub> with ischemic heart disease (IHD) prevalence after adjustment for individual covariates as well as simultaneous adjustment for O<sub>3</sub> and PM<sub>2.5</sub>. In this study, LUR was also used to estimate NO<sub>2</sub> concentrations, which were assigned at the post code centroid level (typically one block area or specific building in this study area). In another prospectively designed study, [Gan et al. \(2011\)](#) examined the association of long-term exposure to BC, PM<sub>2.5</sub>, NO<sub>2</sub>, and NO with CHD hospital admission and mortality among participants (45–85 year-olds) residing in Vancouver, Canada enrolled in the universal health insurance system. In this study, LUR was used to predict NO<sub>2</sub> concentrations at a resolution of 10 m. These predicted concentrations were adjusted using factors derived from regulatory monitoring data and then linked to each participant's postal code of residence (typically one block or specific building in this study area). After adjustment for potential confounders, NO<sub>2</sub> and NO were inversely associated with CHD hospitalization (HR: 0.93 [95% CI: 0.89, 0.98] and HR: 0.96 [95% CI: 0.92, 0.98] per 10 ppb, respectively); however, positive associations of NO<sub>2</sub> and NO with CHD mortality were observed ([Section 6.5.2](#)).

**Table 6-6 Epidemiologic studies of long-term exposure to oxides of nitrogen and heart disease.**

Study	Cohort, Location, Study Period	Exposure Assessment and Concentration (ppb)	Effect Estimates (95% CI) <sup>a</sup>
<a href="#">†Cesaroni et al. (2014)</a>	ESCAPE Project, 11 cohorts 5 countries in Europe 2008–2012	LUR model Annual avg NO <sub>2</sub> , NO <sub>x</sub> Model developed from 40 monitoring sites and linked to geocoded addresses. NO <sub>2</sub> means and ranges across cohorts: 4.2 (3.2–5.8) to 31.9 (22.3–40.9)	Coronary events NO <sub>2</sub> HR: 1.06 (0.96, 1.16) NO <sub>x</sub> HR: 1.01 (0.98, 1.05) per 20 µg/m <sup>3</sup> NO <sub>x</sub> Covariate adjustment: marital status, education, occupation, smoking status duration and intensity, SES. Copollutant adjustment: none
<a href="#">†Gan et al. (2011)</a>	Population-based cohort Vancouver, Canada 1999–2002 n = 452,735	LUR model 5-yr avg (NO <sub>2</sub> and NO, 1995–1998) and 4 yr avg (1999–2002; 10-m spatial resolution). Concentrations assigned to postal code centroids (typically ~1 city block in urban areas and larger in less populated areas). NO <sub>2</sub> : Mean 16.3, IQR 4.5 NO: Mean 26.1, IQR 10.8	CHD hospital admission (ICD-9 410–414) NO <sub>2</sub> RR: 0.93 (0.89, 0.98) NO RR: 0.96 (0.92, 0.98) per 10 ppb NO <sub>2</sub> and NO Covariates: age, sex, pre-existing diabetes, COPD, hypertension, SES. Copollutant adjustment: none
<a href="#">†Beckerman et al. (2012)</a>	Cohort of pulmonary patients Toronto, Canada 1992–1999 n = 2,414	LUR model Average of fall 2002 and spring 2004 NO <sub>2</sub> exposures assigned at the postal code centroid (typically 1 block, or single building and larger in less populated areas). Cross-validation showed mean 4% difference between modeled and measured NO <sub>2</sub> . NO <sub>2</sub> : Median 22.9, IQR 4.0	IHD prevalence (ICD-9 412–414)—old MI, angina or other IHD RR: 1.24 (1.01, 1.40) Covariate adjustment: sex, age, pack-yr smoking, BMI, deprivation index, diabetes. RR 1.17 (1.01, 1.36) after adjustment for covariates above plus O <sub>3</sub> and PM <sub>2.5</sub> (in same model).
<a href="#">†Rosenlund et al. (2009a)</a>	SHEEP Study Stockholm, Sweden 1985–1996 n = 24,347 cases, 276,926 controls	Dispersion model 5-yr avg NO <sub>2</sub> Modeling of traffic-related emissions. 25-m resolution inner city, 100-m urban, 500-m regional/countryside. Concentrations assigned to residential address. 5th–95th: 15.9 cases Median: 6.9 cases, 6.3 controls	First nonfatal MI OR: 0.93 (0.78, 1.12) Covariates: age, sex, calendar yr, SES. Copollutant adjustment: none

**Table 6-6 (Continued): Epidemiologic studies of long-term exposure to oxides of nitrogen and heart disease.**

Study	Cohort, Location, Study Period	Exposure Assessment and Concentration (ppb)	Effect Estimates (95% CI) <sup>a</sup>
<a href="#">†Hart et al. (2013)</a>	NHS cohort 11 States in the U.S. 1990–2008 n = 121,700	Dispersion model Annual avg (2000) NO <sub>2</sub> Assigned to residential address. Main results were for traffic proximity. Concentrations NR	Incident MI HR: 1.22 (0.99, 1.50) per 1-ppb increase in NO <sub>2</sub> between addresses Covariate adjustment: BMI, physical activity, healthy diet score, alcohol, hypercholesterolemia, high blood pressure, diabetes, family history of MI, smoking status, mental health status, father's occupation, marital status, husband's education, education level, employment, median income/home value. Copolutant adjustment: none
<a href="#">†Lipsett et al. (2011)</a>	CTS cohort California, U.S. Jun 1996–Dec 2005 n = 124,614	Central site monitor concentrations combined by IDW Gridded pollutant surface (250-m spatial resolution) created and concentrations linked to geocoded residential address. Defined representative range of 3–5 km (neighborhood and regional monitors, respectively) for NO <sub>x</sub> and NO <sub>2</sub> to account for spatial variability of pollutant. NO <sub>2</sub> : Mean: 33.6, IQR: 10.3 NO <sub>x</sub> : Mean: 95.6, IQR: 58.3	MI incidence NO <sub>2</sub> HR: 1.06 (0.88, 1.23) NO <sub>x</sub> HR: 1.00 (0.95, 1.05) Covariate adjustment: age, race, smoking second-hand smoke, BMI, lifetime physical activity, nutritional factors, alcohol, marital status, menopausal status, hormone therapy, hypertension medication and aspirin, family history of MI/stroke. Copolutant adjustment: none
<a href="#">†Atkinson et al. (2013)</a>	General practice patient national cohort U.K. 2003 n = 836,557	Dispersion model Annual average NO <sub>2</sub> (2002) Model incorporated all known emissions sources (1 × 1 km resolution). Concentrations linked to residential post code centroids that typically include 13 residential addresses. Mean: 12.0, IQR: 5.7	MI incidence HR: 0.97 (0.90, 1.04) Arrhythmia incidence HR: 0.98 (0.91, 1.04) Heart failure incidence HR: 1.11 (1.02, 1.21) Covariates: age, sex, smoking, BMI, diabetes, hypertension, index of multiple deprivation. Copolutant adjustment: none
<a href="#">†de Kluizenaar et al. (2013)</a>	Eindhoven, the Netherlands 1991–2003 n = 18,213	Dispersion model Annual avg NO <sub>2</sub> 1 × 1 km resolution, linked to residential address. 5th–95th percentile range: 7.5	CBVD and IHD: 1.16 (0.95, 1.45) Covariates: age, sex, BMI, smoking, education, exercise, marital status, alcohol use, work situation, financial difficulties 1.18 (0.93, 1.48) after adjustment for the covariates above plus noise

**Table 6-6 (Continued): Epidemiologic studies of long-term exposure to oxides of nitrogen and heart disease.**

Study	Cohort, Location, Study Period	Exposure Assessment and Concentration (ppb)	Effect Estimates (95% CI) <sup>a</sup>
<a href="#">†Dong et al. (2013a)</a>	33 communities in 11 districts of 3 cities in Liaoning Province, China 2006–2008 n = 24,845	Central site monitor Communities were 1 km of a monitor (selected to maximize intra- and inter-city gradients). District-specific 3-yr avg NO <sub>2</sub> Mean: 18.7, Median: 17.5, IQR: 4.8	Self-reported CVD OR: 1.04 (0.60, 1.87) Copolutant adjustment: none
<a href="#">Miller et al. (2007)</a>	WHI cohort 36 U.S. cities 1994–1998	Central site monitor Annual avg (2000) NO <sub>2</sub> Nearest monitor to residence ZIP code centroid (overall effect based on intra- and inter-city gradients). Concentrations NR	Incident CVD events HR: 1.04 (0.96, 1.12) Covariates: age, ethnicity, education, household income, smoking, diabetes, hypertension, systolic blood pressure, BMI, hypercholesterolemia. Copolutant adjustment: none

BMI = body mass index; CBVD = cerebrovascular disease; CHD = coronary heart disease; CI = confidence interval; COPD = chronic obstructive pulmonary disease; CTS = California Teachers Study; CVD = cardiovascular disease; Dec = December; ESCAPE = European Study of Cohorts for Air Pollution Effects; HR = hazard ratio; ICD = international Classification of Diseases; IDW = inverse distance weighting; IHD = ischemic heart disease; IQR = interquartile range; LUR = land use regression; MI = myocardial infarction; NHS = Nurses Health Study; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; NR = not reported; O<sub>3</sub> = ozone; OR = odds ratio; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm; RR = risk ratio(s), relative risk; SES = socioeconomic status; SHEEP = Stockholm Heart Epidemiology Program; WHI = Women's Health Initiative.

<sup>a</sup>Effect estimates are reported per 10-ppb increase in NO<sub>2</sub> or NO and 20-ppb increase in NO<sub>x</sub> unless otherwise specified. NO<sub>x</sub> results that are originally reported in μg/m<sup>3</sup> are not standardized if the molecular weight needed to convert to ppb is not reported.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

Several other studies characterized NO<sub>2</sub> exposure using IDW estimates of concentration from central site monitors or dispersion models that captured a range of spatial resolutions. Uncertainties associated with these models are described in detail in [Sections 3.2.2](#) and [3.2.3](#). Briefly, estimates derived from IDW monitor concentrations may not capture the true variability in NO<sub>2</sub> concentration from local sources if the monitor coverage is not adequately dense. Biases in dispersion model output can occur in either direction and depend on the complexity of the topography, meteorology, and sources that are modelled. Two studies addressed these potential uncertainties by demonstrating that dispersion models well represented the spatial pattern of NO<sub>2</sub> concentrations in the study communities. Dispersion model estimates were shown to agree well with NO<sub>2</sub> concentrations measured at sites in the communities ([Atkinson et al., 2013](#); [Rosenlund et al., 2009a](#)).

[Lipsett et al. \(2011\)](#) determined the association of incident MI with long-term exposure to NO<sub>2</sub>, NO<sub>x</sub>, other gases (CO, O<sub>3</sub>, SO<sub>2</sub>), and PM in a prospective study. These authors followed a cohort of California public school teachers aged 20–80 years old (n = 124,614). Each participant's geocoded residential address was linked to a pollutant

surface with a spatial resolution of 250 m, which was determined by IDW interpolation of NO<sub>2</sub> concentrations measured at central site monitors within 3 km of a home. Those living outside the radial range for which the monitor was intended to provide representative data were excluded from the analysis. The authors observed a positive association between NO<sub>2</sub> and incident MI (HR: 1.06 [95% CI: 0.88, 1.23] per 10 ppb). In a study of women enrolled in the Nurses' Health Study (NHS), [Hart et al. \(2013\)](#) reported an increased risk of incident MI associated with living consistently near sources of traffic. Although the main analyses in this study was for distance to roadway, the authors used a dispersion model to predict the change in NO<sub>2</sub> concentration among those who moved from one address to another. They observed an increased risk of incident MI in association with current NO<sub>2</sub> compared with NO<sub>2</sub> concentration at the previous address ([Table 6-6](#)).

[Rosenlund et al. \(2009a\)](#) conducted a case-control study of first MI using the registry of hospital discharges and deaths for Stockholm County, Sweden and randomly selected population-based controls. Predicted 5-year avg NO<sub>2</sub> concentrations were determined and linked to each participant's geocoded address using dispersion models. The resolution of the predicted concentrations corresponded to 500 m in the countryside, 100 m in urban areas, and 25 m in the inner city. Five-year average NO<sub>2</sub> concentration was associated with fatal MI (OR: 1.14 [95% CI: 1.09, 1.19] per 10 ppb) but not with nonfatal MI (OR: 0.93 [95% CI: 0.78, 1.12] per 10 ppb). CO and PM<sub>10</sub> were also associated with fatal cases of MI in this population. [Atkinson et al. \(2013\)](#) examined the association of incident cardiovascular disease with NO<sub>2</sub>. These authors studied patients (aged 40–89 years) registered with 205 general practices across the U.K. Predicted annual average NO<sub>2</sub> concentrations within 1 × 1 km grids, estimated using dispersion models, were assigned to participants based on their residential postal code. Cardiovascular disease outcomes included in the analysis were MI, arrhythmias, and heart failures. The authors reported a positive association between NO<sub>2</sub> and heart failure in fully adjusted models (HR: 1.11 [95% CI: 1.02, 1.21] per 10 ppb). Incident MI and arrhythmia were not associated with NO<sub>2</sub> concentration in this analysis. A similar pattern of findings was observed for the associations between PM and these outcomes (associations with CHD and MI were null while the association of PM<sub>10</sub> with heart failure was positive).

[de Kloizenaar et al. \(2013\)](#) assigned NO<sub>2</sub> exposure to participants' residential addresses, based on dispersion modelling with a 1 × 1 km resolution, reported an association of NO<sub>2</sub> with CHD and cerebrovascular disease hospital admissions that was robust to adjustment for individual-level covariates and noise (HR 1.18 [95% CI: 0.93, 1.48] per 10 ppb increase in NO<sub>2</sub>). As discussed above, the only study available for inclusion in the previous assessment was ([Miller et al., 2007](#)), which compared annual average concentration assigned at the ZIP code centroid level to study participants across 36 U.S.

cities. This study reported a null association between NO<sub>2</sub> and incident CVD events. [Dong et al. \(2013a\)](#) reported a small, imprecise increase in the prevalence of self-reported CVD comparing 3-year avg concentrations for communities within 1 km of an air monitoring station across 3 cities in Liaoning, China (OR: 1.04 [95% CI: 0.60, 1.87] per 10 ppb increase NO<sub>2</sub>).

Overall, several epidemiologic studies, including some large studies with prospective designs; adjustment for known risk factors for cardiovascular disease such as age, sex, BMI, and smoking; and NO<sub>2</sub> exposures estimated at or near homes with well-validated LUR models ([Cesaroni et al., 2014](#); [Beckerman et al., 2012](#)), provide evidence for associations between long-term exposure to NO<sub>2</sub> and risk of heart disease. Although positive associations between MI and CHD were not observed consistently across studies, with some reporting null or inverse associations with CHD or MI morbidity, others reported increased risk of mortality due to CHD or MI ([Gan et al., 2011](#); [Rosenlund et al., 2009a](#)), and a positive association with heart failure was reported by [Atkinson et al. \(2013\)](#). The few studies that examined confounding by PM<sub>2.5</sub> ([Beckerman et al., 2012](#)) or noise ([de Kluizenaar et al., 2013](#)) provide showed that NO<sub>2</sub> estimates are robust to adjustment for these factors. However, PM<sub>2.5</sub> confounding was analyzed with O<sub>3</sub> in a multipollutant model, which is prone to produce unreliable results. In general, the epidemiologic studies were not designed to distinguish the independent effect of NO<sub>2</sub> from the effects of other traffic-related pollutants (e.g., BC, EC, CO), noise, or stress.

---

### 6.3.3 Cerebrovascular Disease and Stroke

Several studies published since the 2008 ISA for Oxides of Nitrogen examine the association of long-term NO<sub>2</sub> exposure and stroke ([Table 6-7](#)). Evidence from epidemiologic studies is not consistent, and there is uncertainty in the extent to which the findings can be explained by noise or exposures to traffic-related copollutants.

A hospital-based, case-control study in Edmonton, Canada reported a positive association of NO<sub>2</sub> exposure with ischemic stroke (OR: 1.06 [95% CI: 0.88, 1.28] per 10 ppb increase) and a stronger positive association with hemorrhagic stroke (OR: 1.14 [95% CI 0.85, 1.54]) but not with transient ischemic attack [OR: 0.90 (95% CI: 0.74, 1.10); ([Johnson et al., 2013](#))]. This was the only study of stroke to use LUR to estimate NO<sub>2</sub> concentration at the participants' residences, but no information was reported on how well the model predicted NO<sub>2</sub> concentrations in the study area. Findings were similar in an ecological analysis of annual incidence of stroke also conducted in Edmonton, Canada. Positive, imprecise associations with hemorrhagic and nonhemorrhagic stroke incidence were observed with IDW average NO<sub>2</sub> concentration assigned based on

residential postal code ([Johnson et al., 2010a](#)). Associations of stroke with CO and traffic density were also observed in this study.

**Table 6-7 Epidemiologic studies of long-term exposure to oxides of nitrogen and cerebrovascular disease or stroke.**

Study	Cohort, Location, Study Period	Exposure Assessment and Concentration (ppb)	Effect Estimates (95% CI) <sup>a</sup>
<a href="#">†Johnson et al. (2013)</a>	Edmonton, Canada Jan 2007–Dec 2009 n = 4,696 cases, 37,723 controls	LUR model NO <sub>2</sub> concentrations matched to residential postal code (spatial resolution <50 m). No information reported on model validation. Means: 15.4 for cases, 15.2 for controls	Stroke hospital admissions: All stroke: 1.02 (0.88, 1.17) IS: 1.06 (0.88, 1.28) TIA: 0.90 (0.74, 1.10) HS: 1.14 (0.85, 1.54) Covariate adjustment: age, sex, SES. Copollutant adjustment: none
<a href="#">†Johnson et al. (2010a)</a>	Edmonton, Canada Jan 2003–Dec 2007	Central site monitor concentrations combined by IDW 5-yr avg NO <sub>2</sub> Concentrations assigned at postal code centroid level. Mean: 15.7, IQR: 2.2	Ecological analysis of stroke incidence rates: HS ED visits Q1 RR 1.0 (reference) Q2 RR: 0.88 (0.68, 1.14) Q3 RR: 1.03 (0.79, 1.20) Q4 RR: 1.13 (0.90, 1.43) Q5 RR: 1.14 (0.92, 1.52) nonHS ED visits Q1 RR 1.0 (reference) Q2 RR: 1.0 (0.85, 1.18) Q3 RR: 1.05 (0.92, 1.20) Q4 RR: 1.02 (0.87, 1.18) Q5 RR: 1.08 (0.91, 1.27) Covariate adjustment: age, sex, household income. Copollutant adjustment: none
<a href="#">†Sørensen et al. (2014)</a>	Diet, Cancer, and Health cohort Copenhagen or Aarhus, Denmark 1993/1997–Jun 2006 n = 57,053	LUR and dispersion model combined Annual avg NO <sub>2</sub> Concentrations linked to geocoded residential address. r = 0.67 for modeled and measured NO <sub>2</sub> in high-traffic street canyon. Median: 8.1, 10th: 6.3, 90th: 12.4, IQR: 3.0	Noise-adjusted IS incidence NO <sub>2</sub> (at the time of diagnosis) IRR: 1.04 (0.85, 1.24) NO <sub>x</sub> IRR: 0.97 (0.92, 1.03) per 20 µg/m <sup>3</sup> NO <sub>x</sub> Covariate adjustment: age, sex, education, municipality, SES, smoking status and intensity, intake of fruits, vegetables, alcohol, and coffee, physical activity, BMI, calendar yr. Copollutant adjustment: none

**Table 6-7 (Continued): Epidemiologic studies of long-term exposure to oxides of nitrogen and cerebrovascular disease or stroke.**

Study	Cohort, Location, Study Period	Exposure Assessment and Concentration (ppb)	Effect Estimates (95% CI) <sup>a</sup>
<a href="#">†Andersen et al. (2012b)</a>	Diet, Cancer, and Health cohort Copenhagen or Aarhus, Denmark 1993/1997–Jun 2006 n = 57,053	LUR and dispersion model combined Annual avg NO <sub>2</sub> Concentrations linked to geocoded residential address. r = 0.67 for modeled and measured NO <sub>2</sub> in high-traffic street canyon. Median: 8.1, 10th: 6.3, 90th: 12.4, IQR: 3.0	IS incidence NO <sub>2</sub> HR: 1.19 (0.88, 1.61) HS incidence NO <sub>2</sub> HR: 0.80 (0.53, 1.23) Covariate adjustment: smoking status, duration, intensity; ETS; sex; BMI; education; sports activity; alcohol, fruit, fat consumption; hypertension; hypercholesterolemia. Copolutant adjustment: none
<a href="#">†de Kluizenaar et al. (2013)</a>	Eindhoven, the Netherlands 1991–2003 n = 18,213	Dispersion model Annual avg NO <sub>2</sub> 1 × 1 km resolution, linked to residential address. 5th–95th percentile range: 7.5	IHD or CBVD hospital admissions HR: 1.16 (0.95, 1.45) Covariate adjustment: age, sex, BMI, smoking, education, marital status, exercise, alcohol use, work situation, financial difficulty. Copolutant adjustment: none HR: 1.18 (0.93, 1.48) after adjustment for covariates above plus noise
<a href="#">†Lipsett et al. (2011)</a>	CTS cohort California, U.S. Jun 1996–Dec 2005 n = 133,479	Central site monitor concentrations combined by IDW Gridded pollutant surface (250-m spatial resolution) created and concentrations linked to geocoded residential address. Defined representative range of 3–5 km (neighborhood and regional monitors, respectively) for NO <sub>x</sub> and NO <sub>2</sub> to account for spatial variability of pollutant. NO <sub>2</sub> : Mean: 33.6, IQR: 10.3 NO <sub>x</sub> : Mean: 95.6, IQR: 58.3	Stroke incidence NO <sub>x</sub> HR: 1.01 (0.98, 1.05) NO <sub>2</sub> HR: 1.02 (0.90, 1.16) Covariate adjustment: age, race, smoking, second-hand smoke, BMI, lifetime physical activity, nutritional factors, alcohol, marital status, menopausal status, hormone therapy, hypertension, medication and aspirin, family history of MI/stroke. Copolutant adjustment: none
<a href="#">†Atkinson et al. (2013)</a>	General practice patient national cohort U.K. 2003 n = 836,557	Dispersion model Annual average NO <sub>2</sub> (2002) Model incorporated all known emissions sources (1 × 1 km resolution). Concentrations linked to residential post code centroids that typically include 13 residential addresses. Mean: 12.0, IQR: 5.7	Stroke incidence HR: 0.98 (0.91, 1.06) Covariates: age, sex, smoking BMI, diabetes, hypertension, index of multiple deprivation. Copolutant adjustment: none

**Table 6-7 (Continued): Epidemiologic studies of long-term exposure to oxides of nitrogen and cerebrovascular disease or stroke.**

Study	Cohort, Location, Study Period	Exposure Assessment and Concentration (ppb)	Effect Estimates (95% CI) <sup>a</sup>
<a href="#">†Dong et al. (2013a)</a>	33 communities in 11 districts of 3 cities in Liaoning Province, China 2006–2008 n = 24,845	Central site monitor Communities were 1 km of a monitor (selected to maximize intra- and inter-city gradients). District-specific 3-yr avg NO <sub>2</sub> Mean: 18.7, Median: 17.5, IQR: 4.8	Self-reported stroke: OR: 1.27 (0.92, 1.76) Sex-specific results also presented. Covariate adjustment: age, gender, education, occupation, family income, BMI, hypertension, family history of stroke, family history of CVD, smoking status, drinking, diet, exercise. Copolutant adjustment: none

BMI = body mass index; CI = confidence interval; CTS = California Teachers Study; CBVD = cerebrovascular disease; CVD = cardiovascular disease; Dec = December; ED = emergency department; ETS = environmental tobacco smoke; HR = hazard ratio; HS = hemorrhagic stroke; IDW = inverse distance weighting; IHD = ischemic heart disease; IQR = interquartile range; IS = ischemic stroke; LUR = land use regression; MI = myocardial infarction; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; nonHS = nonhemorrhagic stroke; OR = odds ratio; Q1 = 1st quintile; Q2 = 2nd quintile; Q3 = 3rd quintile; Q4 = 4th quintile; Q5 = 5th quintile; RR = risk ratio(s), relative risk; SD = standard deviation; SES = socioeconomic status; TIA = transient ischemic attack.

<sup>a</sup>Effect estimates are reported per 10-ppb increase in NO<sub>2</sub> or NO and 20-ppb increase in NO<sub>x</sub> unless otherwise specified. NO<sub>x</sub> results that are originally reported in µg/m<sup>3</sup> are not standardized if the molecular weight needed to convert to ppb is not reported.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

[Andersen et al. \(2012b\)](#) conducted a study of long-term traffic-related NO<sub>2</sub> exposure and incident stroke using data from a large cohort study of residents of Copenhagen, Denmark enrolled in the Danish Diet, Cancer, and Health Study. The Danish GIS-based air pollution and human exposure dispersion modelling system was used to predict NO<sub>2</sub> concentrations for geocoded residential address histories up to approximately 35 years in duration. The authors reported an increase in ischemic stroke incidence (HR 1.19 [95% CI: 0.88, 1.61]) but not hemorrhagic stroke incidence (HR: 0.80 [95% CI: 0.53, 1.23]). In an analysis of the same data set that adjusted for traffic-related road noise as a potential confounder, [Sørensen et al. \(2014\)](#) reported a substantially attenuated risk estimate between NO<sub>2</sub> concentration at the time of diagnosis and ischemic stroke [incidence rate ratios (IRR: 1.04 [95% CI: 0.85, 1.24]). The association for the combined effect of the highest tertile of noise and the highest tertile of NO<sub>2</sub> was increased (IRR: 1.28 [95% CI: 1.09, 1.52]), and the association with fatal strokes persisted after adjustment for noise. A study of IHD and cerebrovascular diseases combined reported that associations with NO<sub>2</sub> were robust to adjustment for noise and other individual-level covariates (HR: 1.18 [95% CI 0.9, 1.48] per 10 ppb increase) ([de Kluienaar et al., 2013](#)).

[Lipsett et al. \(2011\)](#) analyzed the association of incident stroke with long-term exposure to NO<sub>2</sub>, NO<sub>x</sub>, other gases (CO, O<sub>3</sub>, SO<sub>2</sub>), and PM. These authors analyzed data from a cohort of California public school teachers and assigned exposure by linking IDW NO<sub>2</sub> concentrations from monitors within 3 km of participants' geocoded addresses. An association with incident stroke that was close to the null value (HR: 1.02 [95% CI: 0.90,

1.16] per 10-ppb increase in NO<sub>2</sub>) was observed. Estimates for the association of other pollutants (PM<sub>10</sub>, PM<sub>2.5</sub>, SO<sub>2</sub>, and O<sub>3</sub>) with incident stroke were increased.

[Atkinson et al. \(2013\)](#) examined the association of incident cardiovascular disease with NO<sub>2</sub>. These authors studied patients (aged 40–89 years) registered with 205 general practices across the U.K. Predicted annual average NO<sub>2</sub> concentrations within 1 × 1 km grids, estimated using dispersion models, were assigned to participants based on their residential postal code. Incident stroke was not associated with NO<sub>2</sub> concentration in this analysis. An increase in NO<sub>2</sub> concentration for communities within 1 km of an air monitoring station was associated with self-reported stroke prevalence in a multicity study in China (OR 1.27 [95% CI: 0.92, 1.76] per 10 ppb increase) ([Dong et al., 2013a](#)). [Oudin et al. \(2011\)](#) reported no association between long-term NO<sub>x</sub> exposure and ischemic stroke in a population- and registry-based, case-control study conducted in Scania, Sweden. Exposure was characterized using dispersion models to estimate outdoor NO<sub>x</sub> concentrations within 500 × 500 m grids and linking those predicted concentrations to geocoded residential addresses. Although no association of NO<sub>x</sub> exposure with stroke was observed, modification of the association of diabetes and stroke by long-term NO<sub>x</sub> exposure was reported in this study.

Although several studies report an increased risk between NO<sub>2</sub> exposure and stroke and/or cerebrovascular disease, estimates are generally imprecise ([de Kluizenaar et al., 2013](#); [Dong et al., 2013a](#); [Johnson et al., 2013](#); [Andersen et al., 2012b](#); [Johnson et al., 2010a](#)). Some studies reported weak or null associations ([Atkinson et al., 2013](#); [Lipsett et al., 2011](#)). The positive associations observed for stroke were not consistent across stroke subtype. [Johnson et al. \(2013\)](#) observed a larger increased risk for hemorrhagic compared to ischemic stroke in a LUR study, while [Andersen et al. \(2012b\)](#) observed an increase for ischemic not hemorrhagic stroke in the Danish Diet, Cancer, and Health Study. The association with ischemic stroke observed by [Andersen et al. \(2012b\)](#) was diminished after further adjustment for noise, although an interaction between the highest tertile of NO<sub>2</sub> and highest tertile of noise was observed ([Sørensen et al., 2014](#)). Evidence from epidemiologic studies is not consistent; one study used LUR to estimate NO<sub>2</sub> exposures at homes but did not report information on how well the model captured the fine-scale variability of NO<sub>2</sub> concentrations. Further, there is uncertainty in the extent to which findings can be explained by noise or exposures to traffic-related copollutants.

---

### 6.3.4 Hypertension

There were no studies of the effect of long-term NO<sub>2</sub> or NO<sub>x</sub> exposure on hypertension in the 2008 ISA for Oxides of Nitrogen. Several recent studies of both children and adults

add to the evidence base ([Table 6-8](#)). Overall, findings from studies of both adults and children are inconsistent. Further, the independent effect of NO<sub>2</sub> is not distinguished from the effect of noise and other traffic pollutants in the epidemiologic studies reporting positive associations.

[Coogan et al. \(2012\)](#) examined the association of long-term NO<sub>x</sub> exposure with incident hypertension among black women residing in Los Angeles, CA. An LUR model was used to estimate exposure at each participant's residential address, and a cross-validation  $R^2$  of 0.92 indicated that the model predicted well the pattern of NO<sub>x</sub> concentrations in the study area. These authors reported an increased risk of 1.24 (95% CI: 1.05, 1.45) per 20-ppb increase in NO<sub>x</sub> after adjustment for a wide array of potential confounders including traffic-related noise exposure. Slight attenuation in the effect estimate for NO<sub>x</sub> was reported after adjustment for PM<sub>2.5</sub>. Although the correlation between NO<sub>x</sub> and PM<sub>2.5</sub> was low ( $r = 0.27$ ), PM<sub>2.5</sub> concentration was estimated using kriging of central site monitor measurements and may be subject to differential exposure measurement error. Further, correlations between NO<sub>x</sub> and other traffic-related copollutants were not reported.

In a cross-sectional study, [Foraster et al. \(2014\)](#) reported that NO<sub>2</sub> was associated with an increase in systolic blood pressure that was attenuated to varying degrees depending on the method of adjustment for medication use but not with hypertension. In this study, LUR was used to estimate NO<sub>2</sub> exposure among participants (35–83 years) of a large population-based cohort study. A cross-validation  $R^2$  of 0.63 indicated good agreement between modeled and measured concentrations. Both short-term exposure to NO<sub>2</sub> and noise were adjusted for in the analysis, in addition to an array of other potential confounders. Associations with systolic blood pressure were stronger among those with cardiovascular disease, those living alone, and those living in areas with high traffic load and traffic noise. In a large study involving Danish adults (50–64 year old), [Sørensen et al. \(2012\)](#) reported an inverse association between NO<sub>2</sub> and both systolic and diastolic blood pressure at baseline while largely null findings were reported for self-reported incident hypertension. A validated dispersion model was used in this study to predict annual and 5-year avg NO<sub>2</sub> concentration and to assign exposure based on residential address history [ $r = 0.90$  for measured and predicted 1/2-year avg NO<sub>2</sub> concentration in greater Copenhagen, Denmark area; ([Sørensen et al., 2012](#))]. [Dong et al. \(2013b\)](#) reported imprecise associations of prevalent hypertension and increased blood pressure with average NO<sub>2</sub> concentration from monitoring stations located within 1 km of the community where study participants resided. Stronger associations of hypertension with PM<sub>10</sub>, SO<sub>2</sub>, and O<sub>3</sub> were reported in this study.

**Table 6-8 Epidemiologic studies of long-term exposure to oxides of nitrogen and hypertension and blood pressure.**

Study	Cohort, Location, Study Period	Exposure Assessment and Concentrations (ppb)	Effect Estimates (95% CI) <sup>a</sup>
<b>Studies of Adults</b>			
<a href="#">†Coogan et al. (2012)</a>	BWHS cohort Los Angeles, CA 2006 n = 3,236	LUR model Annual avg NO <sub>x</sub> Model incorporated traffic, land use, population, and physical geography to estimate exposure at the participants' residences. Summer and winter field measurements taken at 183 sites in Los Angeles, CA. Cross-validation with 16 sites, R <sup>2</sup> = 0.92 Mean: 43.3, Median: 41.6, IQR: 12.4	Hypertension IRR: 1.24 (1.05, 1.45) Covariate adjustment: age, BMI, yr of education, income, number of people in the household, smoking, drinks per week, h/week of physical activity, neighborhood SES score, noise. Copollutant adjustment: none IRR: 1.19 (1.00, 1.40) after adjustment for covariates above and PM <sub>2.5</sub>
<a href="#">†Foraster et al. (2014)</a>	REGICOR cohort Girona, Spain 2007–2009 n = 3,836	LUR model Annual avg NO <sub>2</sub> Primary model inputs were air sampler height and traffic-related variables. NO <sub>2</sub> concentrations estimated at participant's geocoded address. Cross-validation R <sup>2</sup> = 0.61 Median: 14.1, IQR: 6.22	Systolic BP change (mm Hg) Participants taking BP-lowering medications: 2.24 (–2.58, 7.06) Participants not taking BP-lowering medications: 2.52 (0.26, 4.80) Covariates: age, age squared, sex, living alone, education, diabetes, BMI, smoking, alcohol consumption, deprivation, daily NO <sub>2</sub> , temperature, nighttime railway and traffic noise. Copollutant adjustment: none
<a href="#">†Sørensen et al. (2012)</a>	Diet, Cancer, and Health cohort Copenhagen and Aarhus, Denmark 2000–2002 n = 45,271	LUR and dispersion model combined Annual and 5-yr avg NO <sub>x</sub> Model sums local air pollution from street traffic based on traffic location and density. NO <sub>x</sub> , NO <sub>2</sub> , and NO concentrations predicted at each participant's residence. 1-yr avg (µg/m <sup>3</sup> ) Baseline: Median 20.2, IQR 72.5 Follow-up: Median 20.0, IQR 71.1 5-yr avg Baseline: Median 19.6, IQR 73.2 Follow-up: Median 19.3, IQR: 71.4	Systolic BP change (mm Hg) per doubling NO <sub>x</sub> 1-yr period: –0.53 (–0.88, –0.19) 5-yr period: –0.84 (–0.84, –0.16) OR for hypertension 5-yr period: 0.96 (0.91, 1.00) Covariates: traffic noise, short term NO <sub>x</sub> , temperature, relative humidity, season, age, sex, calendar yr, center of enrollment, length of school attendance, BMI, smoking status, alcohol intake, intake of fruit and vegetables, sport during leisure time. Copollutant adjustment: none

**Table 6-8 (Continued): Epidemiologic studies of long-term exposure to oxides of nitrogen and hypertension and blood pressure.**

Study	Cohort, Location, Study Period	Exposure Assessment and Concentrations (ppb)	Effect Estimates (95% CI) <sup>a</sup>
<a href="#">†Dong et al. (2013b)</a>	33 communities in 11 districts of 3 cities in Liaoning Province, China 2006–2008 n = 24,845	Central site monitor Communities were 1 km of a monitor (selected to maximize intra- and inter-city gradients). District-specific 3-yr avg NO <sub>2</sub> Mean: 18.7, Median: 17.5, IQR: 4.8	BP change (mm Hg) Diastolic: 0.46 (–0.10, 1.03) Systolic: 0.48 (–0.44, 1.42) Estimated change in the prevalence of hypertension OR: 1.20 (1.00, 1.46) Covariate adjustment: smoking status, duration, intensity; ETS; sex; BMI; education; sports activity; alcohol, fruit, fat consumption; hypertension; hypercholesterolemia. Copollutant adjustment: none
<b>Studies of Children</b>			
<a href="#">†Liu et al. (2014b)</a>	GINIplus and LISIplus cohorts Germany Oct 2008–Nov 2009 n = 2,368	LUR model Annual avg NO <sub>2</sub> NO <sub>2</sub> measurements taken during three 2-week periods (warm, cold, and intermediate seasons) at 40 sites. Exposure estimated for each participant's residence. Cross-validation R <sup>2</sup> : 0.67 for Munich Mean: 12.4, Median: 18.8, IQR: 3.4	BP change (mm Hg) Systolic: 0.32 (–1.32, 1.96) Diastolic: –0.18 (–1.41, 1.05) Covariate adjustment: cohort study, area, sex, age, BMI, physical activity, maternal smoking during pregnancy, parental education, parental history of hypertension, 7-day avg NO <sub>2</sub> , 7-day temperature. Additionally adjusted for road-traffic noise (n = 605) Systolic: –0.70 (–3.43, 2.02) Diastolic: –2.58 (–4.89, –0.23) Copollutant adjustment: none
<a href="#">†Bilenko et al. (2015)</a>	PIAMA birth cohort the Netherlands Feb 2009–Feb 2010 n = 1,432	LUR model Annual avg NO <sub>2</sub> NO <sub>2</sub> measurements taken during three 2-week periods (warm, cold, and intermediate seasons) at 80 sites. Exposure estimated at each participant's residence. Median: 11.6, IQR: 4.1	BP change (mm Hg) Diastolic: 0.80 (–0.43, 2.03) Systolic: –0.07 (–1.69, 1.55) Covariate adjustment: age, sex, height, BMI, cuff size, gestational age at birth, birthweight, weight gain during first yr of life, breast feeding, maternal smoking during pregnancy, parental smoking in child's home, physical activity, puberty development scale, maternal education, maternal hypertension during pregnancy, pneumonia, and/or otitis media during first 2 yr of life, ambient temperature, room temperature. Copollutant adjustment: none

**Table 6-8 (Continued): Epidemiologic studies of long-term exposure to oxides of nitrogen and hypertension and blood pressure.**

Study	Cohort, Location, Study Period	Exposure Assessment and Concentrations (ppb)	Effect Estimates (95% CI) <sup>a</sup>
† <a href="#">Clark et al. (2012)</a>	RANCH study U.K. 2001–2003 n = 719 children, ages (9–10 yr) in 11 schools	LUR and dispersion model combined Annual avg NO <sub>2</sub> Concentrations estimated at 20 × 20 m resolution at each school.	No associations reported with systolic or diastolic blood pressure. Covariate adjustment: age, gender, employment status, crowding, home ownership, mother’s educational level, long-standing illness, language spoken at home, parental support for school work, classroom window glazing type, and noise. Copolutant adjustment: none

BMI = body mass index; BP = blood pressure; BWHS = Black Women’s Health Study; CI = confidence interval; ETS = environmental tobacco smoke; Feb = February; GINIplus = German Infant Nutritional Intervention plus environmental and genetic influences; IQR = interquartile range; IRR = incidence rate ratios; LISApplus = Lifestyle-Related factors on the Immune System and the Development of Allergies in Childhood plus the influence of traffic emissions and genetics; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; RANCH = Road Traffic and Aircraft Noise Exposure and Children’s Cognition and Health; LUR = land use regression model; OR = odds ratio; PIAMA = Prevention and Incidence of Asthma and Mite Allergy; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm; REGICOR = Registre Gironí del Cor; SES = socioeconomic status.

<sup>a</sup>Effect estimates are reported per 10-ppb increase in NO<sub>2</sub> or NO and 20-ppb increase in NO<sub>x</sub> unless otherwise specified. NO<sub>x</sub> results that are originally reported in µg/m<sup>3</sup> are not standardized if the molecular weight needed to convert to ppb is not reported.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

Additional studies examined the association of NO<sub>2</sub> with blood pressure in children. [Liu et al. \(2014b\)](#) reported an association with increased diastolic blood pressure that was diminished after adjustment for traffic-related noise exposure. [Bilenko et al. \(2015\)](#), however, reported an association between NO<sub>2</sub> and diastolic blood pressure that was robust to adjustment for noise. A study designed to evaluate the effect of aircraft noise on cognition among school children (9–10 years old) reported no association between NO<sub>2</sub> and blood pressure after adjustment for noise ([Clark et al., 2012](#)). All studies used LUR models to assign NO<sub>2</sub> exposure at participants’ residential addresses, but only [Liu et al. \(2014b\)](#) reported on model performance (cross-validation R<sup>2</sup> = 0.67).

Overall, findings from studies of adults and studies of children report weak, inconsistent results for the association between NO<sub>2</sub> and hypertension and increased blood pressure, although one prospective study using LUR to estimate exposure and adjusting for cardiovascular disease risk factors reported an association of NO<sub>x</sub> with hypertension ([Coogan et al., 2012](#)). Uncertainties remain regarding the independent effect of NO<sub>2</sub> on hypertension and blood pressure, specifically whether confounding by correlated traffic-related pollutants or noise can explain the positive associations observed.

---

### 6.3.5 Cardiovascular Mortality

Results of studies of long-term exposure to NO<sub>2</sub> and cardiovascular diseases are coherent with findings reporting associations of long-term NO<sub>2</sub> exposure with total and cardiovascular mortality. Positive associations with total mortality, as well as deaths due to cardiovascular disease have been observed in cohort studies conducted in the U.S. and Europe ([Figure 6-9](#), [Table 6-16](#), and [Section 6.5.2](#)). Specifically, the strongest evidence comes from a number of recent studies that have observed positive associations between exposure to NO<sub>2</sub> and NO<sub>x</sub> and IHD mortality ([Cesaroni et al., 2013](#); [Chen et al., 2013a](#); [Lipsett et al., 2011](#); [Yorifuji et al., 2010](#)), mortality due to coronary heart disease ([Gan et al., 2011](#); [Rosenlund et al., 2008b](#)), and circulatory mortality ([Yorifuji et al., 2010](#); [Jerrett et al., 2009](#)). Coherence for the effect of long-term exposure and cardiovascular effects is also provided by the evidence from studies of short-term cardiovascular mortality and morbidity ([Section 5.3](#)).

---

### 6.3.6 Markers of Cardiovascular Disease or Mortality

Some recent epidemiologic and toxicological studies ([Table 6-9](#)) have investigated the effects of long-term NO<sub>2</sub> exposure on risk factors and markers of cardiovascular disease risk or mortality, such as arterial stiffness, subclinical atherosclerosis, circulating lipids, and heart rate variability (HRV). Previous information was limited. The 1993 AQCD for Oxides of Nitrogen ([U.S. EPA, 1993a](#)) reported a significant reduction in heart rate in rats exposed to 1,200 and 4,000 ppb NO<sub>2</sub> for 1 month but not after lower concentrations or longer durations of exposure ([Suzuki et al., 1981](#)). There were no changes in vagal responses in rats exposed to 400 ppb NO<sub>2</sub> for 4 weeks ([Tsubone and Suzuki, 1984](#)).

Several recent cross-sectional analyses of long-term exposure to NO<sub>2</sub> evaluated vascular markers of cardiovascular disease. [Rivera et al. \(2013\)](#) estimated NO<sub>2</sub> concentrations with LUR models whose performance in predicting measured concentrations varied among study areas (Cross-validation R<sup>2</sup> = 0.32–0.61). Increases in carotid intima-media thickness (cIMT) observed in crude models were attenuated in fully adjusted models while a positive association between NO<sub>2</sub> and high ankle brachial index (ABI >1.3) remained. A study of vascular damage in healthy young adults also used LUR to estimate NO<sub>2</sub> exposure but did not report information on model validation ([Lenters et al., 2010](#)). Increases in pulse wave velocity and augmentation index, but not cIMT, were observed in association with NO<sub>2</sub> exposure. In a study that combined central site concentrations by IDW to estimate residential exposure to NO<sub>2</sub> during childhood lifestages, no association was observed with cIMT among young adults ([Breton et al., 2012](#)).

The effects of NO<sub>2</sub> in relation to autonomic function in a random selection of Swiss cohort study participants were examined by [Felber Dietrich et al. \(2008\)](#). Measures of HRV were linked to annual NO<sub>2</sub> concentration at each participant's residential address estimated by dispersion model predictions supplemented with land use and meteorological data. The model demonstrated good predictability of outdoor home NO<sub>2</sub> concentrations, which were measured for some study participants ( $R^2 = 0.77-0.86$  across areas). Annual average NO<sub>2</sub> concentration was associated with decreased standard deviation of beat-to-beat (NN) intervals, an index of total HRV, nighttime low-frequency component of HRV (LF), and LF/high frequency (HF) component of HRV ratio in women. No associations with other parameters of HRV were observed in these data.

A recent toxicological study by [Seilkop et al. \(2012\)](#) reported changes in markers that are characteristic of vascular disease development and progression. Mice were exposed for 50 days to various multipollutant atmospheres (diesel or gasoline exhaust, wood smoke, or simulated "downwind" coal emissions) comprising varying concentrations of NO<sub>2</sub> (0–3,670 ppb) and other pollutants. A data mining technique known as multiple additive regression trees analysis was employed to identify associations between the 45 different exposure component categories, including NO<sub>2</sub>, and various indicators of cardiovascular disease stability and progression [e.g., endothelin-1 (ET-1), matrix metalloproteinase (MMP)-3, MMP-7, MMP-9, tissue inhibitor of metalloproteinase-2 (TIMP-2)]. The results demonstrated that NO<sub>2</sub> was one of the strongest predictors of responses. More specifically, NO<sub>2</sub> ranked among the top three predictors for ET-1 and TIMP-2; however, the study design did not allow for the independent effects of NO<sub>2</sub> to be evaluated.

In another study, [Takano et al. \(2004\)](#) reported that obese rats (Otsuka Long-Evans Tokushima Fatty) had elevated levels of triglycerides and decreased high-density lipoprotein (HDL) and HDL/total cholesterol levels after long-term exposure to 160 ppb NO<sub>2</sub> compared to control rats breathing clean air. HDL levels were also decreased after 800 ppb NO<sub>2</sub> exposure in the obese strain and in the nonobese rats (Long-Evans Tokushima). The authors suggested that obese animals were at greater risk of dyslipidemia following NO<sub>2</sub> exposure.

Overall, a limited number of epidemiologic and toxicological studies have evaluated long-term NO<sub>2</sub> exposure on markers of cardiovascular disease or mortality. There is some evidence for increased arterial stiffness, increased markers for cardiovascular disease stability and progression, dyslipidemia, decreased HRV, and reduced HR; however, these effects have only been reported in one study each. Findings from several studies of cIMT are inconsistent. Further, an independent effect of NO<sub>2</sub> is not clearly distinguished in the available body of epidemiologic and toxicological evidence.

**Table 6-9 Characteristics of toxicological studies of long-term nitrogen dioxide exposure and cardiovascular effects.**

Study	Species (Strain); Sample size; Sex; Age	Exposure Details	Endpoints Examined
<a href="#">de Burbure et al. (2007)</a>	Rats (Wistar); n = 8/group; M 8 weeks	High (6 µg/day) or low (1.3 µg/day) selenium; (1) 1,000 ppb, 28 days, 6 h/day, 5 days/week (Se <sup>+</sup> /Se <sup>-</sup> ); (2) 5,000 ppb, 5 days, 6 h/day	GPx in plasma and RBC lysate; SOD activity in RBC lysate; GST activity in RBC lysate; TBARS in plasma. Endpoints examined immediately and 48 h after exposure.
<a href="#">Fenters et al. (1973)</a>	Squirrel monkeys; adult; n = 4; M; age NR	1,000 ppb NO <sub>2</sub> continuously for 16 mo; challenged with influenza virus	Hemoglobin and hematocrit levels measured throughout the study.
<a href="#">Furiosi et al. (1973)</a>	Monkeys ( <i>Macaca speciosa</i> ); n = 4; M/F; adult Rats (Sprague-Dawley); n = 8; M; 4 weeks	(1) 2,000 ppb NO <sub>2</sub> continuously for 14 mo	Erythrocyte, hematocrit, and hemoglobin levels measured throughout the study.
<a href="#">†Seilkop et al. (2012)</a>	Mice (ApoE <sup>-/-</sup> ); n = 8-10; M; 10 weeks	260, 745, and 3,670 ppb (along with dilutions of 1/3 and 1/10) NO <sub>2</sub> 6 h/day, 7 days/week for 50 days; co-exposure with 700 other components; fed a high-fat diet	ET-1, VEGF, MMP-3, MMP-7, MMP-9, TIMP-2, HO-1, TBARS in proximal aorta 18-h after exposure.
<a href="#">Suzuki et al. (1981)</a>	Rats (strain NR); n = 6; sex and age NR	400, 1,200, and 4,000 ppb NO <sub>2</sub> ; 1, 2, and 3 mo	Heart rate and hemoglobin levels measured after 1, 2, and 3 mo exposures.
<a href="#">Takano et al. (2004)</a>	Rats (OLETF and LETO); n = 10-14; M; 4 weeks	160, 800, or 4,000 ppb NO <sub>2</sub> continuously for 32 weeks	BW, triglyceride, HDL, total cholesterol, HDL/total cholesterol, and sugar measured 8 weeks after exposure.
<a href="#">Tsubone and Suzuki (1984)</a>	Rats (Wistar); n = 6; M; 9-13 weeks	400 and 4,000 ppb NO <sub>2</sub> continuously for 1 and 4 weeks, respectively. Immediately after exposure, animals injected with 5 µg/kg BW phenyl diguanide	Heart rate measured 10 sec after injection.
<a href="#">Wagner et al. (1965)</a>	Dogs; n = 6-10/group; M; adult	1,000 or 5,000 ppb NO <sub>2</sub> continuously for 18 mo	Hemoglobin and hematocrit levels measured quarterly throughout exposure.

BW = body weight; ET-1 = endothelin-1; GPx = glutathione peroxidase; GST = glutathione s-transferase; HDL = high density lipoprotein; HO-1 = heme oxygenase-1; LETO = Long-Evans Tokushima; MMP = matrix metalloproteinase; NO<sub>2</sub> = nitrogen dioxide; NR = not reported; OLETF = Otsuka Long-Evans Tokushima Fatty; RBC = red blood cell; SOD = superoxide dismutase; TBARS = thiobarbituric acid reactive substances; TIMP-2 = tissue inhibitor of metalloproteinase-2; VEGF = vascular endothelial growth factor.

†Study published since the 2008 ISA for Oxides of Nitrogen.

---

### 6.3.7 Diabetes

There were no epidemiologic studies examining the association of NO<sub>2</sub> exposure with diabetes or insulin deficiency in the 2008 ISA for Oxides of Nitrogen. Recent large prospective studies using exposure assessment methods designed to achieve high spatial resolution, provide some evidence of an association ([Table 6-10](#)). However, studies overall have not distinguished an independent effect of NO<sub>2</sub> on diabetes.

[Coogan et al. \(2012\)](#) examined the association of long-term NO<sub>x</sub> exposure with incident diabetes among black women residing in Los Angeles, CA. An LUR model was applied to estimate exposure at each participant's residential address, and a cross-validation  $R^2$  of 0.92 indicated that the model predicted well the pattern of NO<sub>x</sub> concentrations in the study area. An increased risk of 1.43 (95% CI: 1.12, 1.84) per 20-ppb increase in NO<sub>x</sub> was observed after adjustment for a wide array of potential confounders including traffic-related noise exposure. PM<sub>2.5</sub> and NO<sub>x</sub> concentrations were poorly correlated ( $r = 0.27$ ), and negligible attenuation in the NO<sub>x</sub> effect estimate was reported after adjustment for PM<sub>2.5</sub>. However, PM<sub>2.5</sub> concentrations were estimated using kriging of central site monitor measurements and may be subject to differential exposure measurement error. Further, correlations between NO<sub>x</sub> and NO<sub>2</sub> or other traffic-related copollutants were not reported. An increased risk of Type II diabetes in association with LUR estimates of NO<sub>2</sub> was reported among older adult women living in the Ruhr district of West Germany (HR: 1.55 [95% CI: 1.20, 1.99] per 10-ppb increase in NO<sub>2</sub>; [Kramer et al., 2010](#)). In this study, nondiabetic women (age 54–55) were followed over 16 years (1990–2006), and alternate NO<sub>2</sub> exposure assessment methods (mean monitor concentration and emission inventory-based methods) were compared. Relative risks determined by these alternative methods were smaller and less precise compared to those obtained using LUR models, which showed good predictability of NO<sub>2</sub> concentrations measured at central site monitors ( $r = 0.66$ ). Although diabetes status was self-reported in this study, a validation study comparing self-reported diabetes from the questionnaire to answers obtained during a clinical exam interview indicated 99% concordance. In an analysis of a subgroup ( $n = 363$ ) of these women, [Teichert et al. \(2013\)](#) observed positive associations of NO<sub>2</sub> and NO<sub>x</sub> exposure (estimated for the period 10–20 years prior to the baseline exam) with impaired glucose metabolism (IGM). Risk estimates were robust to adjustment for an array of biomarkers of subclinical inflammation.

**Table 6-10 Epidemiologic studies of long-term exposure to oxides of nitrogen and diabetes or diabetes-related effects.**

Study	Cohort, Location, Study Period	Exposure Assessment and Concentrations (ppb)	Effect Estimates (95% CI) <sup>a</sup>
<a href="#">†Coogan et al. (2012)</a>	BWHS cohort Los Angeles, CA 1995–2005 n = 3,236	LUR model Annual avg NO <sub>x</sub> Model incorporated traffic, land use, population, and physical geography to estimate exposure at the participants' residences. Summer and winter field measurements taken at 183 sites in Los Angeles, CA. Cross-validation with 16 sites, R <sup>2</sup> = 0.92 Mean: 43.3, Median: 41.6, IQR: 12.4	Diabetes IRR: 1.20 (1.06, 1.36) Covariate adjustment: age, BMI, yr of education, income, number of people in the household, smoking, drinks per week, h/week of physical activity, neighborhood SES, family history of diabetes. IRR: 1.19 (1.04, 1.35) adjusted for above covariates plus PM <sub>2.5</sub>
<a href="#">†Kramer et al. (2010)</a>	SALIA cohort Ruhr district, West Germany 1990–2006 n = 1,755 Older adult women, ages 54–55 yr at enrollment	LUR model, nearest central site monitor, emissions inventory Annual avg for LUR and emissions inventory, 5-yr avg (1986–1990) for central site LUR model estimated NO <sub>2</sub> at participant's residence (r = 0.66 for correlation with concentrations at central site monitors). Emission inventory estimated traffic-related NO <sub>2</sub> at 1 × 1 km grid. Central site monitors covered 8 × 8 km grid to capture broad scale variability in NO <sub>2</sub> . LUR: Median, 18.3, IQR: 8.0 Central site monitor: Median: 22.2, IQR: 13.2 Emissions inventory: Median: 6.4, IQR: 10.1	Diabetes LUR HR: 1.55 (1.20, 1.99) Central site monitor HR: 1.25 (1.02, 1.53) Emission inventory HR: 1.15 (1.04, 1.27) Covariate adjustment: age, BMI, heating with fossil fuels, workplace exposure to dust/fumes, extreme temperature, smoking, and education. Copolutant adjustment: none
<a href="#">†Teichert et al. (2013)</a>	SALIA cohort Ruhr district, West Germany 2003–2009 Subgroup, n = 363 Older adult women ages 54–55 yr at enrollment	LUR for NO <sub>2</sub> and NO <sub>x</sub> , nearest central site monitor for NO <sub>2</sub> Annual avg NO <sub>2</sub> and 10 to 20-yr avg NO <sub>2</sub> and NO <sub>x</sub> for LUR, 5-yr avg (2003–2007) for central site NO <sub>2</sub> LUR model estimated NO <sub>2</sub> at participant's residences (40 sites, cross-validation R <sup>2</sup> = 0.84). 10 to 20-yr avg NO <sub>2</sub> and NO <sub>x</sub> prior to disease estimated by back-extrapolation. LUR estimates multiplied by ratio of concentration at baseline to follow-up period. Central site monitors covered 8 × 8 km grid to capture broad scale variability in NO <sub>2</sub> . NO <sub>2</sub> Group with IGM: Mean: 21.1, SD: 5.8 Group without IGM: Mean: 20.1, SD: 4.1 NO <sub>x</sub> (µg/m <sup>3</sup> ) Group with IGM: Mean: 74.1, SD: 31.2 Group without IGM: Mean: 69.3, SD: 30.0	IGM for LUR exposure estimates NO <sub>2</sub> OR: 1.63 (1.06, 2.51) NO <sub>x</sub> OR: 1.41 (1.01, 1.97) per 43.2 µg/m <sup>3</sup> NO <sub>x</sub> Covariate adjustment: age, BMI, smoking status, passive smoking, education, exposure to indoor mold, and season of blood sampling. Copolutant adjustment: none

**Table 6-10 (Continued): Epidemiologic studies of long-term exposure to oxides of nitrogen and diabetes or diabetes-related effects.**

Study	Cohort, Location, Study Period	Exposure Assessment and Concentrations (ppb)	Effect Estimates (95% CI) <sup>a</sup>
<a href="#">†Eze et al. (2014)</a>	SAPALDIA cohort Switzerland 1991–2002 n = 6,372	LUR model and dispersion model combined 10-yr avg NO <sub>2</sub> Dispersion model (200 × 200 m resolution) incorporated LUR to reduce underestimation at background sites. Annual NO <sub>2</sub> combined with residential history to estimate 10-yr avg exposure. Ratio of model predictions and measurements at central sites < 0.04. Mean: 15.0, IQR: 6.1	Diabetes prevalence OR: 1.43 (1.08, 1.88) Covariate adjustments: age, sex, educational level, neighborhood SEI, lifestyle, BMI, noise, hypertension, hs-CRP, and dyslipidemia. OR: 1.08 (0.72, 1.62) adjusted for above covariates plus PM <sub>10</sub>
<a href="#">†Brook et al. (2008)</a>	Patients who attended 2 respiratory clinics Hamilton and Toronto, Canada 2002–2004 n = 7,634	LUR model NO <sub>2</sub> measured at ~250 sites selected using a location-allocation model, and concentrations estimated at participants' residences. Difference between predicted and measured NO <sub>2</sub> : 1–7% for Hamilton, < 4% for Toronto Hamilton Female: Median: 15.3, IQR: 3 Male: Median: 15.2, IQR: 3.2 Toronto Female: Median: 22.9, IQR: 3.9 Male: Median: 23, IQR: 20.8	Diabetes mellitus Female OR: 1.48 (1.00, 2.16) Male OR: 0.90 (0.60, 1.34) Both sexes combined OR: 1.16 (0.82, 1.61) Covariate adjustment: age, BMI, and neighborhood income. Copollutant adjustment: none
<a href="#">†Dijkema et al. (2011b)</a>	Westfriesland, the Netherlands (semirural) 2007 n = 8,018	LUR model NO <sub>2</sub> concentration estimate at residential address at the time of recruitment. Cross-validation R <sup>2</sup> = 0.82 Ranges for quartiles Q1 4.7–7.5, Q2: 7.5–8.1, Q3: 8.1–8.8, Q4: 8.8–19.1	Type II diabetes prevalence Q1 OR: 1.00 (reference) Q2 OR: 1.03 (0.82, 1.31) Q3 OR: 1.25 (0.99, 1.56) Q4 OR: 0.8 (0.63, 1.02) Covariate adjustment: average monthly income, age, sex.
<a href="#">†Andersen et al. (2012c)</a>	Diet, Cancer, and Health cohort Copenhagen and Aarhus, Denmark Jan 1995–Jun 2006 n = 57,053	Dispersion model Model sums local air pollution from street traffic based on traffic location and density. AirGIS used to predict the NO <sub>2</sub> concentrations at each participant's residence. r = 0.77 between predicted and measured 6-mo avg NO <sub>2</sub> . 1971–end of follow-up: Median: 7.7, IQR: 2.6 1991–end of follow-up: Median: 8.1, IQR: 3.0	Diabetes from 1971–end of follow-up All diabetes HR: 1.00 (0.89, 1.12) Confirmed diabetes HR: 1.16 (1.00, 1.34) Diabetes from 1991–end of follow-up All diabetes HR: 1.04 (0.93, 1.16) Confirmed diabetes HR: 1.16 (1.04, 1.30) Covariate adjustment: sex, BMI, waist-to-hip ratio, smoking status, smoking duration, smoking intensity, environmental tobacco smoke, educational level, physical/sports activity in leisure time, alcohol, fruit, fat consumption, calendar yr. Copollutant adjustment: none Confirmed diabetes defined as exclusion of cases identified solely by glucose blood test.

**Table 6-10 (Continued): Epidemiologic studies of long-term exposure to oxides of nitrogen and diabetes or diabetes-related effects.**

Study	Cohort, Location, Study Period	Exposure Assessment and Concentrations (ppb)	Effect Estimates (95% CI) <sup>a</sup>
† <a href="#">Thiering et al. (2013)</a>	GINIplus and LISIplus cohorts Germany Oct 2008–Nov 2009 n = 397	LUR model Annual average NO <sub>2</sub> NO <sub>2</sub> measurements taken during three 2-week periods (warm, cold, and intermediate seasons) at 40 sites, and concentrations estimated at each participant's residence. Cross-validation R <sup>2</sup> : 0.67 for Munich Mean: 11.5, SD: 2.8	Insulin resistance percentage difference: 29.77 (6.85, 57.43) Covariate adjustment: sex, age, BMI, birth weight, study center, parental education, study, study design, puberty status, exposure to smoke. Copollutant adjustment: none

BMI = body mass index; BWHS = Black Women's Health Study; CI = confidence interval; GINIplus = German Infant Nutritional Intervention plus environmental and genetic influences; HOMA = homeostatic model assessment; HR = hazard ratio; hs-CRP = high sensitivity C-reactive protein; IGM = impaired glucose metabolism; IQR = interquartile range; IRR = incidence rate ratios; LISIplus = Lifestyle-Related Factors on the Immune System and the Development of Allergies in Childhood plus the influence of traffic emissions and genetics; LUR = land use regression model; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; OR = odds ratio; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 µm; Q1 = 1st quartile; Q2 = 2nd quartile; Q3 = 3rd quartile; Q4 = 4th quartile; SALIA = Study on the Influence of Air Pollution on Lung, Inflammation, and Aging; SAPALDIA = Swiss study on Air Pollution and Lung Disease in adults; SD = standard deviation; SEI = socioeconomic index; SES = socioeconomic status.

<sup>a</sup>Effect estimates are reported per 10-ppb increase in NO<sub>2</sub> or NO and 20-ppb increase in NO<sub>x</sub> unless otherwise specified. NO<sub>x</sub> results that are originally reported in µg/m<sup>3</sup> are not standardized if the molecular weight needed to convert to ppb is not reported.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

In a large study of prevalent diabetes ascertained by self-report among randomly selected adults (ages 18–65 years), which also used LUR, [Eze et al. \(2014\)](#) reported a positive association (OR: 1.43 [95% CI: 1.08, 1.88] per 10 ppb increase in NO<sub>2</sub>). Noise was included among the array of potential confounders for which the final model was adjusted. The association of NO<sub>2</sub> with diabetes was attenuated after adjustment for PM<sub>10</sub> in a copollutant model (OR: 1.08 [95% CI: 0.72, 1.62] per 10-ppb increase in NO<sub>2</sub>). In another study of diabetes prevalence using LUR, [Brook et al. \(2008\)](#) reported an increased risk in the prevalence of diabetes mellitus (Types I and II) of 1.48 (95% CI: 1.00, 2.16) per 10-ppb increase in NO<sub>2</sub> among female respiratory patients in two Canadian cities. NO<sub>2</sub> exposure was not associated with diabetes in male patients, however. Prevalent diabetes was not associated with NO<sub>2</sub> exposure estimated by LUR in a semirural population in the Netherlands ([Dijkema et al., 2011b](#)). All of these studies demonstrated that LUR models well predicted measured NO<sub>2</sub> concentrations in the study areas.

A large prospective study examined the association of NO<sub>2</sub> exposure with diabetes incidence among participants of the Danish Diet, Cancer, and Health Cohort ([Andersen et al., 2012c](#)). A validated dispersion model [ $r \geq 0.75$  between measured and predicted 6-month avg NO<sub>2</sub> concentration; ([Hertel et al., 2014](#))] was used to assign mean NO<sub>2</sub> concentration since 1971 based on residential address history. No association between NO<sub>2</sub> exposure and diabetes was observed in fully adjusted models (HR: 1.00 [95% CI: 0.89, 1.12] per

10-ppb increase in NO<sub>2</sub>); however, after restricting the analyses to confirmed cases of diabetes, a positive association was observed (HR: 1.16 [95% CI: 1.04, 1.30] per 10-ppb increase in NO<sub>2</sub>). Long-term exposure to traffic noise was not associated with a higher risk of diabetes in this population ([Sørensen et al., 2013](#)). Another study designed to evaluate the association of long-term exposure to aircraft noise with diabetes found that, although associations with metabolic outcomes such as waist circumference were observed, no association of Type II diabetes or BMI with noise was present. ([Eriksson et al., 2014](#)).

A study in children examined the association of NO<sub>2</sub> concentration with insulin resistance, which plays a key role in the development of Type II diabetes mellitus. Among 10-year-old children (n = 397), [Thiering et al. \(2013\)](#) reported that a 10-ppb increase in NO<sub>2</sub> was associated with a 30% increase (95% CI: 6.9, 57.4) in the homeostatic model assessment (HOMA) of insulin resistance, a metric derived from blood glucose and serum insulin measurements. Additionally, two recent studies reported contrasting findings regarding the associations between short-term NO<sub>2</sub> exposure and measures of insulin resistance. In contrast with results from [Thiering et al. \(2013\)](#), [Kelishadi et al. \(2009\)](#) reported a lack of an association between 24-h avg NO<sub>2</sub> and insulin resistance in a study of 374 Iranian children aged 10–18 years. Coherent with the results of studies examining long-term exposure and diabetes in adults, a panel study of older adults in Korea observed a 1.33 μU/mL (95% CI: 0.54, 2.11) increase in insulin resistance and a 0.52 mean (95% CI: 0.24, 0.77) increase in the HOMA of insulin resistance [fasting insulin × (fasting glucose ÷ 22.5)] per 20-ppb increase in 24-h avg NO<sub>2</sub> at lag 7 ([Kim and Hong, 2012](#)). The association was stronger in participants with a history of diabetes mellitus but still present for those without. Both of the short-term exposure studies relied on central site monitoring for exposure estimation, and neither evaluated potential confounding by other traffic-related pollutants.

Generally consistent associations of NO<sub>2</sub> ([Teichert et al., 2013](#); [Andersen et al., 2012c](#); [Kramer et al., 2010](#)) as well as NO<sub>x</sub> ([Coogan et al., 2012](#)) with diabetes or impaired insulin metabolism are reported in prospective studies using LUR to assign exposure. Associations of NO<sub>2</sub> with prevalent diabetes among females and respiratory patients are reported in some ([Eze et al., 2014](#); [Brook et al., 2008](#)) but not all studies ([Dijkema et al., 2011b](#)). All of studies estimating exposure with LUR models indicated that the modeled estimates agreed well with measured concentrations in the study areas ([Table 6-10](#)). Findings regarding the potential for noise exposure to confound observed associations of NO<sub>2</sub> and NO<sub>x</sub> with diabetes are limited, as is coherence with short-term exposure studies of insulin resistance. Overall, studies have not distinguished an independent effect of NO<sub>2</sub> from other traffic-related exposures on diabetes.

---

### 6.3.8 Subclinical Effects Underlying Cardiovascular Disease and Diabetes

Inflammation and oxidative stress have been shown to play a role in the progression of chronic heart disease and diabetes. Although studies of inflammation and oxidative stress were not generally available for review in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), a number of null findings related to changes in hematological parameters were reported. Hematocrit and hemoglobin levels were unchanged in squirrel monkeys ([Fenters et al., 1973](#)), rats ([Suzuki et al., 1981](#)), or dogs exposed to  $\leq 5,000$  ppb NO<sub>2</sub> ([Wagner et al., 1965](#)). However, [Furiosi et al. \(1973\)](#) reported polycythemia due to reduced mean corpuscular volume and an increased trend in the ratio of neutrophil to lymphocytes in the blood of NO<sub>2</sub>-exposed monkeys and similar increases in erythrocyte counts in NO<sub>2</sub>-exposed rats.

A limited number of studies published since the 2008 ISA for Oxides of Nitrogen have evaluated markers of inflammation and oxidative stress. [Forbes et al. \(2009a\)](#) examined the association of annual average NO<sub>2</sub> concentrations with C-reactive protein (CRP) and fibrinogen among a population in England. Multilevel linear regression models were used to determine pooled estimates across three cross-sectional surveys conducted during different years. Each participant's postal code of residence was linked to a predicted annual average NO<sub>2</sub> concentration derived from dispersion models. NO<sub>2</sub> was not associated with increased CRP or fibrinogen in these data nor were PM<sub>10</sub>, SO<sub>2</sub>, or O<sub>3</sub>. A study conducted among men and women (ages 45–70 years) in Stockholm, Sweden reported an association of 30-year avg traffic-related NO<sub>2</sub> concentrations estimated using dispersion models with increases in interleukin-6 (IL-6) and CRP but not with TNF- $\alpha$ , fibrinogen, or PAI-1 ([Panasevich et al., 2009](#)). Associations between several metrics of SO<sub>2</sub> exposure and increased IL-6 and CRP were observed in this study. In another analysis from this study, long-term exposure to NO<sub>2</sub> interacted with IL-6 and TNF polymorphisms on an additive scale with regard to increased MI risk ([Panasevich et al., 2013](#)). In a study of COPD patients, annual average NO<sub>2</sub> concentration was associated with increases in interleukin-8 (IL-8) but not with the other markers studied including CRP, TNF- $\alpha$ , IL-6, fibrinogen, and hepatocyte growth factor ([Dadvand et al., 2014b](#)).

[de Burbure et al. \(2007\)](#) examined oxidative stress markers in rats on a low selenium (Se-L) or supplemented selenium (Se-S) diet exposed to 1,000 ppb NO<sub>2</sub> for 28 days. Blood Se levels decreased significantly in both groups immediately after the 28-day exposure and continued to decrease in the Se-S diet rats following a 48-hour recovery period. GPx, of which Se is an integral component, also decreased immediately and 48 hours after exposure only in the plasma of Se-S diet rats. However, GPx levels increased in red blood cells (RBC) of Se-L diet rats immediately after the 28-day exposure and increased in both groups 48 hours later. RBC SOD activity increased in

both groups immediately after the exposure and decreased in Se-L diet rats 48 hours later. GST was increased for both groups immediately after the 28-day exposure and continued to increase after the 48-hour recovery period, potentially compensating for the transient increase in thiobarbituric acid reactive substances (TBARS) immediately after exposure.

As discussed in [Section 6.3.6](#), [Seilkop et al. \(2012\)](#) examined the effects of NO<sub>2</sub> exposure, in a multipollutant context, on markers of oxidative stress [heme oxygenase-1 (HO-1) expression and TBARS, indicator of lipid peroxidation] in ApoE<sup>-/-</sup> mice fed a high-fat diet. Mice were exposed to various atmospheres (diesel or gasoline exhaust, wood smoke, or simulated “downwind” coal emissions) with varying concentrations of NO<sub>2</sub> (0–745 ppb) for 50 days. Associations between the oxidative stress indicators and the 45 different exposure component categories were determined using a data mining technique known as multiple additive regression trees analysis. The results demonstrated NO<sub>2</sub> was among one of the strongest predictors of response for TBARS but not HO-1.

Overall, a limited number of epidemiologic and toxicological studies have evaluated long-term NO<sub>2</sub> exposure on inflammation and oxidative stress with some, but not all, studies reporting positive associations. In general, findings of the epidemiologic studies do not separate the effect of NO<sub>2</sub> from copollutants, and the few animal toxicological studies do not clearly demonstrate an effect of NO<sub>2</sub> exposure.

---

### 6.3.9 Summary and Causal Determination

Overall, the evidence is suggestive of, but not sufficient to infer, a causal relationship between long-term exposure to NO<sub>2</sub> and cardiovascular health effects and diabetes. This conclusion is based heavily on recent epidemiologic studies reporting associations of NO<sub>2</sub> with heart disease and diabetes. While well-conducted studies of NO<sub>x</sub> are also available, these studies are less informative regarding the independent effect of NO<sub>2</sub> exposure on cardiovascular effects and diabetes. The current conclusion represents a change from the conclusion drawn in the 2008 ISA for Oxides of Nitrogen, which stated that the evidence was inadequate to infer the presence or absence of a causal relationship ([U.S. EPA, 2008c](#)). Previously, [Miller et al. \(2007\)](#) reported a positive association between long-term NO<sub>2</sub> exposure and cardiovascular events among post-menopausal women but did not distinguish an independent effect of NO<sub>2</sub>. Toxicological evidence reported no changes in hematocrit or hemoglobin and increased erythrocyte count and did not demonstrate that long-term NO<sub>2</sub> exposure induces cardiovascular effects. In contrast, although not with entire consistency, several recent studies report positive associations of NO<sub>2</sub> exposure with heart disease and diabetes. As in the 2008 ISA, uncertainty remains as to whether NO<sub>2</sub> exposure has an independent effect of other traffic-related pollutants and

noise for both cardiovascular effects and diabetes. Evidence from experimental studies is limited and inconsistent and does not clearly support biological plausibility. The key evidence as it relates to the causal determination is detailed in [Table 6-11](#) using the framework described in [Table II](#) of the [Preamble](#) to the ISA.

Evidence from recent, large and well-conducted prospective epidemiologic studies generally supports an association of long-term exposure to NO<sub>2</sub> with heart disease. Studies were prospective in design and did not report evidence that findings were likely to be biased by selective participation or missing data. Additionally, these studies adjusted for a wide array of cardiovascular risk factors and used exposure assessment methods that captured the fine scale variability in NO<sub>2</sub> concentration. The evidence for the association of long-term NO<sub>2</sub> exposure with stroke and hypertension is less consistent. The strongest evidence for heart disease comes from a large multicohort prospective study ([Cesaroni et al., 2014](#)) with supporting evidence from cross-sectional study of CHD hospital admissions ([Beckerman et al., 2012](#)). Both of these studies demonstrated LUR modeled estimates to agree well with measured NO<sub>2</sub> concentrations in the study areas. Consistent findings from multiple epidemiologic studies of cardiovascular mortality support these morbidity findings ([Section 6.5.2](#)). Studies using dispersion models or IDW for exposure assessments were less consistent, with some reporting positive associations ([Lipsett et al., 2011](#)) and others reporting null associations with heart disease ([Atkinson et al., 2013](#); [Rosenlund et al., 2009a](#)). IDW and dispersion modeling may not adequately capture the spatial variability in NO<sub>2</sub> concentrations ([Section 3.2.3](#)) and produce biased exposure estimates and health effect estimates. However, in the null studies, dispersion model estimates were shown to represent well the spatial pattern of measured NO<sub>2</sub> concentrations in the study areas. Epidemiologic studies have not adequately accounted for confounding by PM<sub>2.5</sub>, noise, or traffic-related copollutants, and there is limited coherence and biological plausibility for NO<sub>2</sub>-related development of heart disease. Epidemiologic evidence does not consistently link long-term NO<sub>2</sub> exposures to markers of cardiovascular risk [e.g., increased high ABI ([Rivera et al., 2013](#)), arterial stiffness ([Lenters et al., 2010](#)), cIMT, and markers of inflammation [CRP and IL-6; ([Panasevich et al., 2009](#))]. Experimental studies also do not clearly demonstrate an independent effect of NO<sub>2</sub> exposure on heart disease development. Long-term NO<sub>2</sub> exposure induced dyslipidemia in rats ([Takano et al., 2004](#)), but short-term or long-term NO<sub>2</sub> exposure did not consistently increase inflammation or oxidative stress in controlled human exposure or animal toxicological studies ([Channell et al., 2012](#); [Huang et al., 2012b](#); [Riedl et al., 2012](#); [Li et al., 2011a](#); [de Burbure et al., 2007](#)). Further, these are early events in the proposed mode of action and not specific to development of heart disease.

Evidence from recent, large and well-conducted prospective epidemiologic studies generally supports the association of long-term exposure to NO<sub>2</sub> with diabetes. Several large prospective studies also using LUR report increased risk of diabetes, impaired glucose metabolism, and increased insulin resistance with NO<sub>2</sub> exposure ([Teichert et al., 2013](#); [Thiering et al., 2013](#); [Kramer et al., 2010](#)). These studies indicated that LUR modeled estimates agreed well with measured NO<sub>2</sub> concentrations in the study areas. Several studies reporting positive associations were prospective in design and did not report evidence that findings were likely to be biased by selective participation or missing data. As with heart disease, epidemiologic studies have not adequately accounted for confounding by PM<sub>2.5</sub>, noise, or traffic-related copollutants, and there is limited coherence and biological plausibility for NO<sub>2</sub>-related development of diabetes. Long-term NO<sub>2</sub> exposure induced dyslipidemia in rats ([Takano et al., 2004](#)), but short-term or long-term NO<sub>2</sub> exposure did not consistently increase inflammation or oxidative stress in controlled human exposure or animal toxicological studies ([Channell et al., 2012](#); [Huang et al., 2012b](#); [Riedl et al., 2012](#); [Li et al., 2011a](#); [de Burbure et al., 2007](#)). These are early events and not specific to development of diabetes.

Several epidemiologic studies report positive associations of NO<sub>2</sub> exposure with both heart disease and diabetes, and the annual average or multi-year avg residential exposures were typically considered surrogates for long-term exposure, and residential stability was assumed (or sometimes required for eligibility). Confounding by correlated traffic-related pollutants and noise remains an uncertainty, and experimental studies do not clearly support the biological plausibility of associations observed in the epidemiologic studies. Further, most studies did not disentangle the effects of long-term from short-term exposure. These general limitations introduce some uncertainty with regard to the specific patterns of exposure associated with the observed effects. Overall, the evidence from some epidemiologic studies of heart disease and diabetes but uncertainty about an independent effect of NO<sub>2</sub> is suggestive of, but not sufficient to infer, a causal relationship between long-term NO<sub>2</sub> exposure and cardiovascular effects and diabetes.

**Table 6-11 Summary of evidence, which is suggestive of, but not sufficient to infer, a causal relationship between long-term nitrogen dioxide exposure and cardiovascular effects and diabetes.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
<b>Heart Disease</b>			
Evidence from epidemiologic studies generally supportive but not entirely consistent	Findings from a large multicohort prospective study using validated LUR provides evidence that NO <sub>2</sub> is associated with coronary events.	† <a href="#">Cesaroni et al. (2014)</a> <a href="#">Section 6.3.2</a>	Range of mean annual avg across cohorts: 4.2–31.9 ppb
	Supporting evidence from cross-sectional study of CHD hospital admissions and study of MI incidence using LUR or IDW to estimate NO <sub>2</sub> exposure.	† <a href="#">Beckerman et al. (2012)</a> , † <a href="#">Lipsett et al. (2011)</a>	Median: 22.9 ppb Mean: 33.6 ppb
	Inverse or null associations of NO <sub>2</sub> with CHD or MI reported in some studies.	† <a href="#">Atkinson et al. (2013)</a> , † <a href="#">Rosenlund et al. (2009a)</a> , † <a href="#">Gan et al. (2011)</a>	Annual avg mean: 12.0 ppb 5-yr avg: median: 6.9 (cases), 6.3 (controls) ppb, mean: 16.3 ppb
Limited coherence with evidence for effects on cardiovascular disease risk factors	Associations with some markers of vascular damage observed in some but not all epidemiologic studies.	† <a href="#">Lenters et al. (2010)</a> † <a href="#">Rivera et al. (2013)</a> <a href="#">Section 6.3.6</a>	Means: 19.7 ppb for annual avg, 11.0 ppb for 10-yr avg
Coherence with evidence for cardiovascular mortality	Strongest evidence of mortality from IHD, CHD, and circulatory diseases, including supporting evidence from studies that report weak or null associations with cardiovascular morbidity.	† <a href="#">Rosenlund et al. (2009a)</a> ; † <a href="#">Gan et al. (2011)</a> <a href="#">Section 6.5.2</a>	5-yr avg: median: 6.9 (cases), 6.3 (controls) ppb, mean: 16.3 ppb
Uncertainty regarding potential confounding by traffic-related copollutants and noise	Overall, studies did not adjust for PM <sub>2.5</sub> , BC, EC, or CO. Confounding by noise examined in one study.	<a href="#">Section 6.3.2</a>	
<b>Cerebrovascular Disease and Stroke</b>			
Inconsistent epidemiologic evidence	Some studies of variable quality report increased, typically imprecise, risks of stroke and/or cerebrovascular disease with NO <sub>2</sub> . Inconsistency across stroke subtype.	† <a href="#">Johnson et al. (2013)</a> , † <a href="#">Johnson et al. (2010a)</a> , † <a href="#">Andersen et al. (2012b)</a> , † <a href="#">de Kluizenaar et al. (2013)</a> , † <a href="#">Dong et al. (2013a)</a> <a href="#">Section 6.3.3</a>	Means for annual avg and 3- or 5-yr avg: 15.2–18.7 ppb Median for annual avg: 8.1 ppb
	Other studies reported weak or null associations.	† <a href="#">Atkinson et al. (2013)</a> , † <a href="#">Lipsett et al. (2011)</a>	Means for annual avg: 12.0, 33.6

**Table 6-11 (Continued): Summary of evidence, which is suggestive of, but not sufficient to infer, a causal relationship between long-term nitrogen dioxide exposure and cardiovascular effects and diabetes.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
Uncertainty regarding potential confounding by traffic-related copollutants and noise	Results not consistently robust to adjustment for noise. No studies examined confounding by traffic pollutants.	† <a href="#">Sørensen et al. (2014)</a> , † <a href="#">de Kluizenaar et al. (2013)</a> <a href="#">Section 6.3.3</a>	
<b>Hypertension</b>			
Inconsistent epidemiologic evidence	Cross-sectional association with increased blood pressure but not hypertension.	† <a href="#">Foraster et al. (2014)</a> <a href="#">Section 6.3.4</a>	Median for annual avg: 14.1
Uncertainty regarding potential confounding by traffic-related copollutants and noise	Studies did not adjust for PM <sub>2.5</sub> , BC, EC, or CO. Few studies adjusted for noise.	<a href="#">Section 6.3.4</a>	
	Association observed with NO <sub>x</sub> may not represent effect of NO <sub>2</sub> .	† <a href="#">Coogan et al. (2012)</a>	
<b>Diabetes</b>			
Evidence from epidemiologic studies generally consistent and supportive	Large prospective studies using LUR report increased risk of diabetes incidence, impaired glucose metabolism, and increased insulin resistance with NO <sub>2</sub> exposure.	† <a href="#">Kramer et al. (2010)</a> , † <a href="#">Teichert et al. (2013)</a> , † <a href="#">Thiering et al. (2013)</a> <a href="#">Section 6.3.7</a>	Median for annual avg: 18.3 ppb. Means for annual avg: 11.5–21 ppb
	Supporting evidence that NO <sub>2</sub> exposure is associated with prevalent diabetes.	† <a href="#">Eze et al. (2014)</a> , † <a href="#">Brook et al. (2008)</a> —females only	Means: 15.0 ppb for 10-yr avg, 15, 23 ppb for annual avg
	Association observed among confirmed cases of diabetes but not overall.	† <a href="#">Andersen et al. (2012c)</a>	Medians for multi-yr avg: 7.7, 8.1 ppb
Uncertainty regarding potential confounding by traffic-related copollutants and noise	Consistent but limited evidence that associations are robust to adjustment for noise. Overall, studies did not adjust for PM <sub>2.5</sub> , BC, EC, CO.	† <a href="#">Eze et al. (2014)</a> ; † <a href="#">Sørensen et al. (2013)</a> ; † <a href="#">Eriksson et al. (2014)</a> <a href="#">Section 6.3.7</a>	
	Associations observed with NO <sub>x</sub> may not represent effect of NO <sub>2</sub> .	† <a href="#">Coogan et al. (2012)</a>	
Limited toxicological evidence for NO <sub>2</sub> independent effect	Dyslipidemia—increased triglycerides and decreased HDL—in rats.	<a href="#">Takano et al. (2004)</a> <a href="#">Section 6.3.8</a>	160 ppb for 32 weeks

**Table 6-11 (Continued): Summary of evidence, which is suggestive of, but not sufficient to infer, a causal relationship between long-term nitrogen dioxide exposure and cardiovascular effects and diabetes.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
<b>Limited Evidence for Key Events in the Proposed Mode of Action for Cardiovascular Effects and Diabetes</b>			
Oxidative stress	Some, but not entirely consistent evidence of increased oxidative stress in rats (i.e., MDA, TBARS) with short-term and long-term NO <sub>2</sub> exposures and in plasma from NO <sub>2</sub> -exposed humans (i.e., LOX-1).	<a href="#">de Burbure et al. (2007)</a> , † <a href="#">Li et al. (2011a)</a> , † <a href="#">Channell et al. (2012)</a> <a href="#">Section 4.3.2.9</a> , <a href="#">Figure 4-3</a>	Rats: 1,000 ppb for 28 days, 5,320 ppb but not 2,660 ppb for 7 days Human cells exposed to plasma from healthy adults: 500 ppb for 2 h
Inflammation	Limited and supportive toxicological evidence of increased transcription of some inflammatory mediators in vitro (i.e., IL-8, ICAM-1, VCAM-1) and in rats (i.e., ICAM-1, TNF-α) after short-term NO <sub>2</sub> exposure.	† <a href="#">Channell et al. (2012)</a> † <a href="#">Li et al. (2011a)</a> <a href="#">Section 4.3.2.9</a> , <a href="#">Figure 4-3</a>	Human cells exposed to plasma from healthy adults: 500 ppb for 2 h Rats: 2,660 and 5,320 ppb for 7 days
	Limited and inconclusive evidence in controlled human exposure studies (i.e., IL-6, IL-8, ICAM-1).	† <a href="#">Huang et al. (2012b)</a> , † <a href="#">Riedl et al. (2012)</a>	350 and 500 ppb for 2 h
	Inconsistent epidemiologic evidence for increases in CRP and IL-6 in adults.	<a href="#">Section 6.3.8</a>	
Dyslipidemia (for heart disease)	Increased triglycerides and decreased HDL—in rats.	<a href="#">Takano et al. (2004)</a> <a href="#">Section 6.3.8</a>	160 ppb for 32 weeks

BC = black carbon; CHD = coronary heart disease; CO = carbon monoxide; CRP = C-reactive protein; EC = elemental carbon; HDL = high-density lipoprotein; ICAM = intercellular adhesion molecule 1; IDW = inverse distance weighting; IGM = impaired glucose metabolism; IHD = ischemic heart disease; IL-6 = interleukin-6; IL-8 = interleukin-8; LOX-1 = lectin-like oxidized low density lipoprotein receptor 1; LUR = land use regression; MDA = malondialdehyde; MI = myocardial infarction; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; NR = not reported; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm; TBARS = thiobarbituric acid reactive substances; TNF-α = tumor necrosis factor alpha; VCAM-1 = vascular cell adhesion molecule 1.

<sup>a</sup>Based on aspects considered in judgments of causality and weight of evidence in causal framework in [Tables I](#) and [II](#) of the [Preamble](#).

<sup>b</sup>Describes the key evidence and references, supporting or contradicting, contributing most heavily to causal determination and, where applicable, to uncertainties or inconsistencies. References to earlier sections indicate where full body of evidence is characterized.

<sup>c</sup>Describes the NO<sub>2</sub> concentrations with which the evidence is substantiated (for experimental studies, ≤ 5,000 ppb).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

---

## 6.4 Reproductive and Developmental Effects

---

### 6.4.1 Introduction

The body of literature characterizing reproductive and developmental effects associated with exposure to NO<sub>2</sub> is large and has grown considerably since the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), with much of the research focused on birth outcomes. Well-designed studies with consideration of potential confounding and other sources of bias are emphasized in this section (see [Appendix](#) for study evaluation guidelines). Due to the growth in the quantity of literature, as well as in the breadth of the health endpoints evaluated, the reproductive and developmental effects are divided into three separate categories: (1) Fertility, Reproduction, and Pregnancy (i.e., the ability to achieve and maintain a healthy pregnancy, with emphasis on the health of potential parents); (2) Birth Outcomes [i.e., measures of birth weight and fetal growth, preterm birth (PTB), birth defects, and infant mortality, with emphasis on the perinatal health of the child]; and (3) Developmental Effects (i.e., effect on development through puberty/adolescence). Separate causal determinations are made for each of these categories. Among the epidemiologic studies of birth outcomes, various measures of birth weight and fetal growth, such as low birth weight (LBW), small for gestational age (SGA), intrauterine growth restriction (IUGR), and preterm birth (<37-week gestation) have received more attention in air pollution research, while congenital malformations are less studied. There is some examination of effects on fertility and pregnancy conditions; however, studies on any particular endpoint remain limited. In toxicological studies, outcomes analogous to fetal growth and birth weight in humans include litter size and birth weight. Nervous system outcomes after early life exposures to NO<sub>2</sub> are examined in the toxicological and epidemiologic literature.

A major issue in studying environmental exposures and reproductive and developmental effects (including infant mortality) is selecting the relevant exposure period because the biological mechanisms leading to these outcomes and the critical periods of exposure are poorly understood. Exposures proximate to death may be most relevant if exposure causes an acute effect. However, exposure occurring in gestation or early life might affect critical growth and development. For some developmental effects, results may be observable later in the first year of life, or cumulative exposure during the first year of life may be the most important determinant. To account for this, many epidemiologic studies evaluate multiple exposure periods including long-term exposure periods, such as

the entirety of pregnancy; and individual trimesters or months of pregnancy or short-term (days to weeks) exposure periods, such as the days and weeks immediately preceding birth. Due to the shorter length of gestation in rodents (about 18–24 days, on average), animal toxicological studies investigating the effects of NO<sub>2</sub> on pregnancy generally utilize short-term exposure periods, which cover an entire gestation. Thus, a study in humans that uses the entire pregnancy as the exposure period is considered to have a long-term exposure period (about 40 weeks, on average), while a toxicological study conducted with rats that also uses the entire pregnancy as the exposure period (about 18–24 days, on average) is defined as a short-term exposure. In order to characterize the weight of evidence for the effects of NO<sub>2</sub> on reproductive and developmental effects in a consistent, cohesive, and integrated manner, results from both short-term and long-term exposure periods are included in this section and are identified accordingly in the text and tables throughout this section.

Although the biological mechanisms are not fully understood, several hypotheses have been proposed for the effects of NO<sub>2</sub> on reproductive and developmental outcomes; these include oxidative stress, systemic inflammation, vascular dysfunction, and impaired immune function. The study of these outcomes can be difficult given the need for detailed exposure data and potential residential movement of mothers during pregnancy. Air pollution epidemiologic studies reviewed in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) examined impacts on birth-related endpoints, including intrauterine, perinatal, post-neonatal, and infant deaths; premature births; intrauterine growth restriction; very low birth weight (weight <1,500 g) and low birth weight (weight <2,500 g); and birth defects. However, in the limited number of studies included in the 2008 ISA for Oxides of Nitrogen, no associations were found between NO<sub>2</sub> and birth outcomes, with the possible exception of birth defects. Overall, the evidence evaluated in the 2008 ISA for Oxides of Nitrogen was inconsistent and lacked coherence and plausibility, and was determined to be inadequate to infer the presence or absence of a causal relationship.

Several recent articles reviewed methodological issues relating to the study of outdoor air pollution and adverse birth outcomes ([Chen et al., 2010a](#); [Woodruff et al., 2009](#); [Ritz and Wilhelm, 2008](#); [Slama et al., 2008](#)). Some of the key challenges to interpretation of these study results include the difficulty in assessing exposure as most studies use existing monitoring networks to estimate individual exposure to ambient air pollution; the inability to control for potential confounders such as other risk factors that affect birth outcomes (e.g., smoking); evaluating the exposure window (e.g., trimester) of importance; and limited evidence on the physiological mechanism of these effects ([Ritz and Wilhelm, 2008](#); [Slama et al., 2008](#)). Recently, an international collaboration was formed to better understand the relationships between air pollution and adverse birth

outcomes and to examine some of these methodological issues through standardized parallel analyses in data sets from different countries ([Woodruff et al., 2010](#)). Initial results from this collaboration have examined PM and birth weight ([Parker et al., 2011](#)); work on NO<sub>2</sub> has not yet been performed. The exposure assessment method was an important consideration in the evaluation of long-term exposure and reproductive and developmental outcomes, given the spatial variability typically observed in ambient NO<sub>2</sub> concentrations ([Section 2.5.3](#)). Exposure assessment was evaluated drawing upon discussions in [Section 3.2](#) and [Section 3.4.5](#). Many recent studies employed exposure assessment methods to account for the spatial variability of NO<sub>2</sub>. For example, LUR model predictions generally have been found to correlate well with outdoor NO<sub>2</sub> measurements ([Section 3.2.2.1](#)). For long-term NO<sub>2</sub> exposure, exposure assessment was evaluated by the extent to which the method represented the spatial variability in NO<sub>2</sub> concentrations in a given study. For modeled estimates, such information includes statistics indicating the correlation between predicted and measured NO<sub>2</sub> concentrations.

Overall, the number of studies examining the relationship of NO<sub>2</sub> exposure with reproductive and developmental effects has increased tremendously, yet evidence for an independent effect of NO<sub>2</sub> exposure remains relatively uncertain. Although a previous animal study ([Shalamberidze and Tsereteli, 1971a, b](#)) found that exposure to NO<sub>2</sub> during pregnancy led to some abnormal birth outcomes in rats, epidemiologic studies to date have reported inconsistent results for the association of ambient NO<sub>2</sub> concentrations and a range of reproductive and developmental effects, though the evidence has been generally supportive for some outcomes such as fetal growth.

---

## 6.4.2 Fertility, Reproduction, and Pregnancy

---

### 6.4.2.1 Effects on Sperm

A limited amount of research has been conducted to examine the association between NO<sub>2</sub> and male reproductive outcomes, specifically semen quality. To date, the epidemiologic studies have considered various exposure durations before semen collection that encompass either the entire period of spermatogenesis (i.e., 90 days) or key periods of sperm development that correspond to epididymal storage, development of sperm motility, and spermatogenesis.

An occupational study of male motorway company employees reported that men with the highest NO<sub>2</sub> exposures in the workplace (near-road environment, ~160 ppb) had lower sperm motility, but no difference in sperm count, compared to men with lower exposures

[~80 ppb; ([Boggia et al., 2009](#))]. Two epidemiologic studies evaluated the relationship between sperm quality and ambient concentrations of NO<sub>2</sub> based on ambient and personal monitoring ([Rubes et al., 2010](#)) or statistical models ([Sokol et al., 2006](#)) and observed no associations; while a cross-sectional study observed associations between NO<sub>2</sub> measured at central site monitors and some semen quality parameters ([Zhou et al., 2014](#)). No recent toxicological studies have examined the effect of NO<sub>2</sub> exposure on semen quality. [Kripke and Sherwin \(1984\)](#) found no statistically significant effects on spermatogenesis, or on germinal and interstitial cells of the testes of a small group of LEW/f mai rats (n = 6) after 21 days of exposure to a single concentration of NO<sub>2</sub>, 1,000 ppb 7 h/day, 5 days/week ([Table 6-13](#)). Overall, there is little and inconsistent epidemiologic evidence and no toxicological evidence of effects of NO<sub>2</sub> exposure on sperm or semen quality.

---

#### 6.4.2.2 Effects on Reproduction

Several recent studies have examined the association between exposure to NO<sub>2</sub> during pregnancy and the ability to reproduce. Gametes (i.e., ova and sperm) may be even more at risk, especially outside of the human body, as occurs with assisted reproduction. Smokers require twice the number of in vitro fertilization (IVF) attempts to conceive as nonsmokers ([Feichtinger et al., 1997](#)), suggesting that a preconception exposure can be harmful to pregnancy. A recent study estimated daily concentrations of criteria pollutants at addresses of women undergoing their first IVF cycle and at their IVF labs from 2000 to 2007 in the northeastern U.S. ([Legro et al., 2010](#)). Increasing NO<sub>2</sub> concentration estimated at the patient's address during ovulation induction (short-term exposure, ~12 days) was associated with a decreased chance of live birth (OR: 0.80 [95% CI: 0.71, 0.91] per 10-ppb increase). Similar risks were observed when the exposure period was the daily concentration averaged over the days from oocyte retrieval through embryo transfer, and the days from embryo transfer through the pregnancy test (14 days). The authors also observed a decreased odds of live birth when exposed from embryo transfer to live birth [long-term exposure, ~200 days; OR: 0.76 [95% CI: 0.56, 1.02] per 10-ppb increase). After adjusting for O<sub>3</sub> in a copollutant model, NO<sub>2</sub> continued to be associated with IVF failure. The results of this study suggest that both short- and long-term exposure to NO<sub>2</sub> during ovulation and gestation was detrimental and reduced the likelihood of a live birth. In a more general population, increased NO<sub>2</sub> exposure in the 30 days before initiation of unprotected intercourse also was associated with reduced fecundability [fecundability ratio per 10 ppb: 0.50 [95% CI: 0.32, 0.76]] ([Slama et al., 2013](#)). Similarly, in a cross-sectional study of fertility rates, [Nieuwenhuijsen et al. \(2014\)](#) observed lower fertility in census tracts with higher NO<sub>2</sub> and NO<sub>x</sub> concentrations estimated at the level of the census tract. Importantly, census tract associations may not

reflect associations for individuals. Further, none of these studies examined confounding by traffic-related copollutants.

In contrast, NO<sub>2</sub> exposure has not been shown to induce effects on fertility in animals. A breeding study found that exposures of rats to 67 or 1,300 ppb NO<sub>2</sub> 12 h/day for 3 months ([Table 6-13](#)) produced no change in the number of dams that became pregnant after mating with an unexposed male ([Shalamberidze and Tsereteli, 1971a, b](#)). At the higher dose, NO<sub>2</sub> exposure impaired estrous cyclicity (cycle prolongation, increased duration of diestrus, decreased number of normal and total estrus cycles), and the exposed females had a decreased number of ovarian primordial follicles.

---

### 6.4.2.3 Effects on Pregnancy

#### Epidemiologic Evidence

Evidence suggests that exposure to air pollutants may affect maternal and fetal health during pregnancy. Systemic inflammation has been proposed as a potential biological mechanism through which air pollution could result in adverse pregnancy outcomes ([Slama et al., 2008](#); [Kannan et al., 2006](#)). Recent studies have investigated the relationship between CRP, a marker for systemic inflammation, measured in maternal blood during early pregnancy and in umbilical cord blood (as a measure of fetal health) and NO<sub>2</sub> concentrations. [van den Hooven et al. \(2012a\)](#) observed generally null associations between exposure to NO<sub>2</sub> and maternal CRP levels but did observe a positive, linear relationship between quartiles of NO<sub>2</sub> exposure and fetal CRP levels. This association was evident when exposure was measured 1, 2, and 4 weeks prior to delivery but was strongest when exposure to NO<sub>2</sub> was measured over the entire pregnancy. Similarly, [Lee et al. \(2011c\)](#) observed generally null associations between short-term exposure (i.e., 1 to 29 days) to NO<sub>2</sub> and elevated maternal CRP levels.

Pregnancy-associated hypertension is a leading cause of perinatal and maternal mortality and morbidity. A large body of research has linked changes in blood pressure to ambient air pollution; however, evidence is inconsistent for NO<sub>2</sub> ([Sections 5.3.6 and 6.3.4](#)). A few recent studies have examined whether increases in NO<sub>2</sub> concentrations are associated with blood pressure changes in women who are pregnant. The results of these studies are not consistent. [Hampel et al. \(2011\)](#) observed that increases in NO<sub>2</sub> concentrations measured at central site monitors were associated with decreases in systolic blood pressure but found no clear associations between NO<sub>2</sub> concentrations and diastolic blood pressure. [Lee et al. \(2012b\)](#) observed associations between exposure to NO<sub>2</sub> estimated for the maternal ZIP code using kriging interpolation and changes in blood pressure that

were null for the entire population and when the population was restricted to nonsmokers. [van den Hooven et al. \(2011\)](#) observed small increases in systolic blood pressure associated with increases in NO<sub>2</sub> concentrations estimated from a GIS spatiotemporal model across all three trimesters of pregnancy but did not observe a similar association with diastolic blood pressure. [Mobasher et al. \(2013\)](#) observed a positive association between exposure to NO<sub>2</sub> (estimated with IDW and spatial mapping) during the first trimester and hypertensive disorders of pregnancy, though the association was imprecise and was reduced when exposure was averaged over the second and third trimesters. The same pattern was observed when analyses were restricted to nonobese women, but among obese women, the effect estimate was below 1.00 for each trimester. [Xu et al. \(2014\)](#) observed positive associations between NO<sub>2</sub> concentrations measured at central site monitors during the entire pregnancy and first trimester and hypertensive disorders of pregnancy. Associations remained positive after adjustment for CO or PM<sub>2.5</sub>; however, differential exposure measurement error may limit inference regarding a potential independent association for NO<sub>2</sub>.

New-onset gestational hypertension can contribute to pre-eclampsia, a common pregnancy complication diagnosed after 20 weeks of pregnancy. [Wu et al. \(2009\)](#) observed a 45% increase (95% CI: 23, 64) in the risk of pre-eclampsia associated with a 20-ppb increase in NO<sub>x</sub> averaged over the entire pregnancy. When NO<sub>x</sub> was examined as categories, the association was consistent with a linear concentration-response relationship. Similarly, NO<sub>2</sub> concentrations during pregnancy were associated with an increased risk of pre-eclampsia among a cohort of Australian women ([Pereira et al., 2013](#)), with the strongest association observed when exposure was limited to the third trimester. [Malmqvist et al. \(2013\)](#) also observed a positive association between NO<sub>x</sub> concentrations in the third trimester of pregnancy and pre-eclampsia consistent with a linear concentration-response relationship in a Swedish cohort. [Dadvand et al. \(2013\)](#) observed increases in odds of pre-eclampsia, particularly late-onset pre-eclampsia, with increased NO<sub>2</sub> exposure during the third and first trimesters, and with entire pregnancy exposures. A number of other studies, of similar quality and using similar study designs, did not observe positive associations for NO<sub>2</sub> exposure and risks of pregnancy-induced hypertension or pre-eclampsia across different exposure periods including exposure over entire pregnancy ([Nahidi et al., 2014](#); [van den Hooven et al., 2011](#)) and the first trimester exposure ([Olsson et al., 2013](#)]. NO<sub>2</sub> exposure estimated at each subject's residential address using LUR or dispersion models that were demonstrated to predict well the ambient NO<sub>2</sub> measurements in the study areas showed both positive [cross-validation R<sup>2</sup> = 0.68; ([Pereira et al., 2013](#))] and null [ $r = 0.77$  for correlations between modeled and measured NO<sub>2</sub> ([van den Hooven et al., 2011](#))] associations with pre-eclampsia. A meta-analysis of pre-eclampsia studies reported a combined OR for NO<sub>2</sub> of 1.23 (95% CI: 1.04, 1.42), though there was a large amount of heterogeneity between studies

particularly in outcome definition; removal of an influential study produced an OR of 1.11 (95% CI: 1.04, 1.17) with no observed heterogeneity ([Pedersen et al., 2014](#)). None of the studies of pre-eclampsia examined confounding by PM<sub>2.5</sub> or traffic-related copollutants.

Other pregnancy complications that have recently been evaluated and found to be associated with NO<sub>2</sub> include gestational diabetes ([Malmqvist et al., 2013](#)) and markers of placental growth and function ([van den Hooven et al., 2012b](#)). Overall, the evidence for the effects of NO<sub>2</sub> on pregnancy outcomes is inconsistent. Key studies examining the association between exposure to NO<sub>2</sub> and pregnancy-related effects can be found in [Table 6-12](#). [Supplemental Table S6-2 \(U.S. EPA, 2013g\)](#) provides an overview of all of the epidemiologic studies of pregnancy-related health effects.

### **Toxicological Evidence**

Evidence from animal toxicological studies ([Table 6-13](#)) does not clearly indicate that NO<sub>2</sub> exposure affects pregnancy. NO<sub>2</sub> exposure of rats to 1,500 or 3,000 ppb over the duration of pregnancy did not alter dam weight gain over pregnancy, assessed as a percentage of body weight at conception or Gestational Day (GD) 0 ([Di Giovanni et al., 1994](#)). Fetal lethality in toxicological studies is measured by counting pup loss or resorption sites. This directly affects litter size, i.e., number of live pups born. Rat dams that received 1,300 ppb NO<sub>2</sub> 12 h/day for 3 months before pregnancy had decreased litter size ([Shalamberidze and Tsereteli, 1971a, b](#)). However, litter size was not affected in rat dams exposed to 1,500 or 3,000 ppb NO<sub>2</sub> exposure over the duration of pregnancy ([Di Giovanni et al., 1994](#))

**Table 6-12 Key epidemiologic studies of oxides of nitrogen and reproductive and developmental effects.**

Study	Location Sample Size	Exposure Assessment and Concentrations (ppb)	Selected Effect Estimates (95% CI) <sup>a</sup>
<b>Fertility, Reproduction, and Pregnancy</b>			
<a href="#">†Legro et al. (2010)</a>	Northeastern U.S. n = 7,403	Central site monitors combined by kriging 3.6- to 199-day avg NO <sub>2</sub> Means: ~19 for each exposure window evaluated	Odds of live birth following IVF Medication start to oocyte retrieval: 0.80 (0.71, 0.91) Oocyte retrieval to embryo transfer: 0.87 (0.79, 0.96) Embryo transfer to pregnancy test (14 days): 0.76 (0.66, 0.86) Embryo transfer to live birth: 0.76 (0.56, 1.02)
<a href="#">†Slama et al. (2013)</a>	Teplice, Czech Republic n = 1,916	Central site monitor Within 12 km of residence 1- and 2-mo avg NO <sub>2</sub> Median for 1-mo avg: 19	Fecundity ratio 30 days before unprotected intercourse (Lag 1): 0.50 (0.32, 0.76) 30 days before Lag 1 (Lag 2): 1.10 (0.69, 1.80) Lag 1 + Lag 2: 0.52 (0.28, 0.94) Month post-outcome: 1.17 (0.76, 1.85)
<a href="#">†Wu et al. (2009)</a>	southern California, U.S. n = 81,186	Dispersion model Pregnancy- and trimester-avg NO <sub>x</sub> r = 0.91 for NO <sub>x</sub> and PM <sub>2.5</sub> Means: EP 7.2, T1 7.5, T2 7.3, T3: 7.1	Pre-eclampsia EP: 1.44 (1.23, 1.68)
<a href="#">†Pereira et al. (2013)</a>	Perth, Australia n = 23,452	LUR model Pregnancy- and trimester-avg NO <sub>2</sub> NO <sub>2</sub> estimated at home address. No information on model validation. Means: EP: 23.0, T1 23.3, T2 23.3, T3 22.5	Pre-eclampsia T1: 1.04 (0.94, 1.16) T2: 1.02 (0.91, 1.15) T3: 1.17 (1.04, 1.32) EP: 1.22 (1.02, 1.49)
<a href="#">†Malmqvist et al. (2013)</a>	Sweden N = 81,110	Dispersion model Trimester-avg NO <sub>x</sub> Median for T1: 7.5 NO <sub>x</sub> estimated at home address. Dispersion model had a spatial resolution of 500 × 500 m.	Pre-eclampsia, T3 exposure Q1: reference Q2: 1.28 (1.13, 1.46) Q3: 1.33 (1.17, 1.52) Q4: 1.51 (1.32, 1.73) Gestational diabetes, T3 exposure Q1: reference Q2: 1.19 (0.99, 1.44) Q3: 1.52 (1.28, 1.82) Q4: 1.69 (1.41, 2.03)

**Table 6-12 (Continued): Key epidemiologic studies of oxides of nitrogen and reproductive and developmental effects.**

Study	Location Sample Size	Exposure Assessment and Concentrations (ppb)	Selected Effect Estimates (95% CI) <sup>a</sup>
<a href="#">†Dadvand et al. (2013)</a>	Barcelona, Spain n = 8,398	LUR model Pregnancy- and trimester-avg NO <sub>2</sub> NO <sub>2</sub> estimated at home address. Cross-validation R <sup>2</sup> = 0.68. Means: EP 30, T1 30, T2 31, T3 31	Pre-eclampsia T1: 1.07 (0.94, 1.22) T2: 1.03 (0.90, 1.19) T3: 1.11 (0.99, 1.23) EP: 1.09 (0.94, 1.27)
<b>Birth Outcomes</b>			
<a href="#">†Aguilera et al. (2010)</a>	Catalonia, Spain n = 562	LUR model Trimester avg NO <sub>2</sub> NO <sub>2</sub> estimated at home address. Root mean squared error for cross-validation = 0.85 ppb Means: T1 17.3, T2 16.9, T3 17.1	Fetal length (% change) T1: -2.04 (-7.01, 2.95) T2: -1.69 (-7.05, 3.69) T3: 0.33 (-4.06, 4.72) Head circumference (% change) T1: 0.25 (-5.42, 5.91) T2: 1.70 (-3.69, 7.07) T3: 0.23 (-4.32, 4.77) Abdominal circumference (% change) T1: -2.82 (-8.24, 2.59) T2: -0.13 (-5.64, 5.38) T3: 0.74 (-3.92, 5.40) Biparietal diameter (% change) T1: 3.87 (-2.04, 9.75) T2: 4.90 (-0.34, 10.11) T3: 1.48 (-3.41, 6.35) Estimated fetal weight (% change) T1: -2.22 (-7.39, 2.98) T2: 0.46 (-5.82, 6.72) T3: 0.91 (-3.65, 5.45)
<a href="#">†Iñiguez et al. (2012)</a>	Valencia, Spain n = 818	LUR model Trimester-avg NO <sub>2</sub> NO <sub>2</sub> estimated at home address. No information on model validation Median: 20.2 for EP	Fetal length (ratio) T1: 0.97 (0.92, 1.02) T2: 0.96 (0.92, 1.00) T3: 0.97 (0.92, 1.02) Abdominal circumference (ratio) T1: 0.96 (0.92, 0.99) T2: 0.98 (0.94, 1.02) T3: 0.98 (0.94, 1.03) Biparietal diameter (ratio) T1: 0.96 (0.92, 1.00) T2: 0.97 (0.92, 1.01) T3: 0.98 (94, 1.02) Estimated fetal weight (ratio) T1: 0.96 (0.92, 1.00) T2: 0.98 (0.94, 1.02) T3: 0.97 (0.93, 1.02)

**Table 6-12 (Continued): Key epidemiologic studies of oxides of nitrogen and reproductive and developmental effects.**

Study	Location Sample Size	Exposure Assessment and Concentrations (ppb)	Selected Effect Estimates (95% CI) <sup>a</sup>
<a href="#">†van den Hooven et al. (2012c)</a>	Rotterdam, the Netherlands n = 7,772	Dispersion model, GIS-based techniques, and central site monitors combined Pregnancy- and trimester-avg NO <sub>2</sub> Pearson r = 0.77 for modeled and measured annual avg NO <sub>2</sub> at 18 sites Mean: 21.2, Median: 21.1, 75th: 22.4, Max: 30.3	Head circumference (mm), T3 Q1: reference Q2: -0.40 (-1.00, 0.20) Q3: -0.81 (-1.42, -0.20) Q4: -1.28 (-1.96, -0.61) Length (mm), T3 Q1: reference Q2: -0.02 (-0.17, 0.13) Q3: -0.09 (-0.24, 0.06) Q4: -0.33 (-0.50, -0.16) SGA, EP Q1: reference Q2: 0.93 (0.66, 1.31) Q3: 1.25 (0.90, 1.73) Q4: 1.35 (0.94, 1.94)
<a href="#">†Hansen et al. (2008)</a>	Brisbane, Australia n = 15,623	Nearest central site monitor 1-mo avg NO <sub>2</sub> Homes within 2–14 km of 1 of 17 monitors Mean: 9.8 for city 1992–2003	Head circumference (mm) M1: 0.54 (-1.88, 2.94) M2: -0.16 (-2.54, 2.20) M3: -0.60 (-3.18, 2.00) M4: -0.30 (-2.30, 1.68) Biparietal diameter (mm) M1: 0.14 (-0.62, 0.88) M2: -0.20 (-0.88, 0.50) M3: -0.12 (-0.82, 0.58) M4: -0.16 (-0.74, 0.42) Abdominal circumference (mm) M1: 0.48 (-1.98, 2.94) M2: 0.98 (-1.40, 3.34) M3: 0.20 (-2.12, 2.52) M4: 0.30 (-1.80, 2.40) Femur length (mm) M1: 0.06 (-0.50, 0.62) M2: -0.18 (-0.78, 0.44) M3: 0.02 (-0.52, 0.56) M4: -0.26 (-0.80, 0.26)
<a href="#">†Ritz et al. (2014)</a>	Los Angeles, CA LUR: n = 501 Central site monitors: n = 98	LUR model Trimester-avg NO <sub>2</sub> NO <sub>2</sub> estimated at home address. Cross-validation R <sup>2</sup> = 0.87 Mean: 22.7	Biparietal diameter (mm) GW 0–19: -0.41 (-1.07, 0.23) GW 19–29: 0.39 (-0.25, 1.02) GW 29–37: -0.50 (-1.23, 0.23)
		Central site monitors Measurements combined by IDW Means: T1 37.3 T2 37.6 T3 39.3	GW 0–19: -4.45 (-10.55, 1.55) GW 19–29: 4.92 (0.03, 9.83) GW 29–37: -8.33 (-13.83, -2.83)

**Table 6-12 (Continued): Key epidemiologic studies of oxides of nitrogen and reproductive and developmental effects.**

Study	Location Sample Size	Exposure Assessment and Concentrations (ppb)	Selected Effect Estimates (95% CI) <sup>a</sup>
<a href="#">†Estarlich et al. (2011)</a>	Asturias, Gipuzkoa, Sabadell, Valencia, Spain n = 2,337	LUR model Pregnancy-avg NO <sub>2</sub> NO <sub>2</sub> estimated at home address. No information on model validation Means: Overall 15.5, Urban 15.9, Rural: 8.7	Birth length (cm) EP: -1.69 (-0.34, -0.02) Head circumference (cm) EP: -0.01 (0.13, 0.11)
<a href="#">†Ballester et al. (2010)</a>	Valencia, Spain n = 785	LUR model and central site monitors combined Pregnancy-avg NO <sub>2</sub> NO <sub>2</sub> estimated at home address. No information on model validation. Mean: 19.6	Head circumference (cm) -0.11 (-0.25, 0.03) Birth length (cm) -0.09 (-0.27, 0.10) SGA—weight 1.59 (0.89, 2.84) SGA—length 1.48 (0.628, 3.49)
<a href="#">†Hansen et al. (2007)</a>	Brisbane, Australia n = 26,617	Central site monitors Trimester-avg NO <sub>2</sub> Measurements averaged across city City-wide concentrations 1999–2003: Median 7.8, 75th: 11.4, Max: 24.2	Head circumference (cm) T1: 0.05 (-0.05, 0.17) T2: 0.08 (-0.02, 0.19) T3: 0.00 (-0.10, 0.10) Crown-heel length (cm) T1: 0.24 (0.05, 0.42) T2: 0.07 (-0.10, 0.24) T3: -0.15 (-0.25, -0.05)
<a href="#">†Darrow et al. (2011b)</a>	Atlanta, GA n = 406,627	Central site monitors Pregnancy-, trimester-, and first 28-day avg of 1-h max NO <sub>2</sub> Population-weighted average of all monitors in city Mean: 23.6 for first 28-day avg	Birth weight (g) Entire pregnancy: -18.4 (-28.0, -9.0) First 28 days: 0.8 (-3.6, 5.2) T3 All subjects: -9.0 (-17.0, -1.2) Non-Hispanic white: -9.2 (-18.6, 0.2) Non-Hispanic black: -7.8 (-17.4, 1.6) Hispanic: -11.6 (-24.8, 1.4)
<a href="#">†Bell et al. (2007)</a>	Connecticut and Massachusetts, U.S. n = 358,504	Central site monitors Pregnancy-avg Measurements averaged across county Mean: 17.4	Birth weight (g), EP exposure All subjects: -18.5 (-22.5, -14.6) Black mothers: -26.5 (-37.5, -15.6) White mothers: -17.3 (-21.7 -13.1) LBW: 1.06 (1.00, 1.11)

**Table 6-12 (Continued): Key epidemiologic studies of oxides of nitrogen and reproductive and developmental effects.**

Study	Location Sample Size	Exposure Assessment and Concentrations (ppb)	Selected Effect Estimates (95% CI) <sup>a</sup>
<b>Postnatal Development</b>			
<a href="#">†van Kempen et al. (2012)</a>	the Netherlands n = 485	LUR model—school Annual avg NO <sub>2</sub> Concurrent exposure. Cross-validation R <sup>2</sup> = 0.85. Mean: 16.5	Change in score, adjusted for traffic noise Memory: -0.30 (-0.55, 0.04) Measures of attention SRTT, reaction time (msec): -2.23 (-22.1, 17.7) SAT block, # errors: -0.02 (-0.42, 0.38) SAT block, reaction time (msec): 13.9 (-16.7, 43.9) SAT switch, # errors: -1.19 (-3.62, 1.26) SAT switch, reaction time (msec): 21.5 (-45.2, 88.2) Locomotion: 0.08 (-0.08, 0.25)
		LUR model—home Annual avg NO <sub>2</sub> Concurrent exposure. Cross-validation R <sup>2</sup> = 0.85. Mean: 16.4	Change in score, adjusted for traffic noise Memory: 0.17 (-0.08, 0.42) Measures of attention SRTT, reaction time (msec): -2.11 (-21.0, 16.7) SAT block, # errors: -0.04 (-0.40, 0.32) SAT block, reaction time (msec): 15.9 (-11.3, 43.0) SAT switch, # errors: -1.23 (-3.32, 0.87) SAT switch, reaction time (msec): -20.2 (-74.9, 34.5) Locomotion: 0.06 (-0.08, 0.21)
<a href="#">†Clark et al. (2012)</a>	U.K. n = 719	LUR model and dispersion model combined—school Annual avg NO <sub>2</sub> Concurrent exposure. No information on model validation. Mean: 22.7	Change in score, adjusted for traffic noise Reading comprehension: 0.08 (-0.17, 0.34) Information recall: 0.28 (-0.62, 1.17) Working memory: 0.06 (-5.55, 5.66) Physiological distress: 0.47 (-0.62, 1.57)
<a href="#">†Freire et al. (2010)</a>	Spain n = 210	LUR model—home Annual avg NO <sub>2</sub> Concurrent exposure. Cross-validation R <sup>2</sup> = 0.64. Mean: 11.1	Change in score in group with NO <sub>2</sub> >13.2 ppb compared with group with NO <sub>2</sub> <8.2 ppb General cognitive index: -4.2 (-14, 5.6) Verbal: -3.09 (-13.31, 7.13) Quantitative: -6.71 (-17.91, 4.49) Memory: -5.52 (-16.18, 5.13) Executive function: -4.93 (-14.90, 5.05) Gross motor function: -8.6 (-19, 1.7) Fine motor skills: 0.91 (-10.22, 12.05)

**Table 6-12 (Continued): Key epidemiologic studies of oxides of nitrogen and reproductive and developmental effects.**

Study	Location Sample Size	Exposure Assessment and Concentrations (ppb)	Selected Effect Estimates (95% CI) <sup>a</sup>
† <a href="#">Guxens et al. (2014)</a>	n = 9,482	LUR model—home Annual avg NO <sub>2</sub> Prenatal exposure. Exposure estimated by back-extrapolation using central site measurements. Cross-validation R <sup>2</sup> = 0.49–0.87 across cities.	Change in cognitive or motor function score
	Ruhr, Germany	Median: NR	Mental development: -3.61 (-8.53, 1.32) Motor function: -5.04 (-11, 0.49)
	Heraklion, Greece	Median: 6.1	Mental development: 1.90 (-2.33, 6.13) Motor function: -0.83 (-5.39, 3.74)
	Asturias, Spain	Median: NR	Mental development: -1.39 (-3.12, 0.34) Motor function: -2.03 (-3.82, -0.24)
	Gipuzkoa, Spain	Median: NR	Mental development: -1.11 (-6.65, 4.44) Motor function: 0.17 (-1.73, 5.34)
	Valencia, Spain	Median: NR	General cognition: -1.35 (-3.74, 1.03) Motor function: -3.72 (-6.37, -1.07)
	Sabadell, Spain	Median: 23.4	General cognition: -0.15 (-2.42, 2.12) Motor function: 0.71 (-1.71, -3.14)
	Granada, Spain	Median: NR	General cognition: 3.18 (-0.26, 6.62) Motor function: 1.80 (-1.73, 5.34)
	Rotterdam, the Netherlands	Median: NR	Motor function: -0.17 (-1.60, 1.26)
	Poitiers, France	Median: NR	Motor function: -0.64 (-6.75, 5.47)
Nancy, France	Median: NR	Motor function: -2.84 (-5.64, -0.04)	
Rome, Italy	Median: NR	Motor function: -1.97 (-4.44, 0.49)	
† <a href="#">Guxens et al. (2012)</a>	Valencia, Sabadell, Asturias, Gipuzkoa, Spain n = 1,889	LUR model—home Pregnancy-avg NO <sub>2</sub> Exposure estimated by back-extrapolation using central site measurements. Cross-validation R <sup>2</sup> = 0.75, 0.77. Means: Overall 15.7, Valencia 19.6, Sabadell 17.1, Asturias 12.3, Gipuzkoa: 10.7	Change in mental development index <sup>b</sup> Location All regions: -0.95 (-3.90, 1.89) Gipuzkoa: -5.15 (-8.04, -2.27) Asturias: 0.17 (-2.71, 3.04) Sabadell: 1.98 (-1.69, 5.66) Valencia: -0.43 (-2.86, 2.01) Maternal fruit and vegetable intake ≤405 g/day: -4.13 (-7.06, -1.21) >405 g/day: 0.25 (-3.63, 4.12) Maternal Vitamin D circulation Low: -2.49 (-6.87, 1.89) Medium: -0.55 (-3.48, 2.39) High: -0.11 (-2.72, 2.49)

**Table 6-12 (Continued): Key epidemiologic studies of oxides of nitrogen and reproductive and developmental effects.**

Study	Location Sample Size	Exposure Assessment and Concentrations (ppb)	Selected Effect Estimates (95% CI) <sup>a</sup>
† <a href="#">Becerra et al. (2013)</a>	Los Angeles County, CA n = 83,385	LUR model—home Pregnancy- and trimester-avg NO <sub>2</sub> Monthly exposure estimated using central site measurements. Cross-validation R <sup>2</sup> = 0.87. Mean: 28.0	Odds ratio for autism EP: 1.05 (0.98, 1.12) T1: 1.03 (0.98, 1.08) T2: 1.03 (0.98, 1.08) T3: 1.04 (0.98, 1.09)
		Central site monitor Nearest central site monitor to birth residence. Mean: 30.8	EP: 1.04 (0.98, 1.10) T1: 1.04 (0.99, 1.08) T2: 1.01 (0.97, 1.06) T3: 1.02 (0.97, 1.07)
† <a href="#">Volk et al. (2013)</a>	California, U.S. n = 524	Dispersion model Pregnancy- and first yr-avg NO <sub>x</sub> . Exposure estimated within 5 km of child's home. r ~ 0.99 for correlation with EC and CO. Q1: ≤9.7 Q2: 9.7–16.9 Q3: 16.9–31.8 Q4: ≥31.8	Odds ratio for autism relative to Q1 First yr of life Q2: 0.91 (0.56, 1.47) Q3: 1.00 (0.62, 1.62) Q4: 3.10 (1.76, 5.57) EP Q2: 1.26 (0.77, 2.06) Q3: 1.09 (0.67, 1.79) Q4: 1.98 (1.20, 3.31)
		Central site monitors Measurements from sites within 50 km of homes, combined by IDW	Odds ratio for autism First yr of life: 1.67 (1.25, 2.23) EP: 1.52 (1.16, 2.00)

avg = average; CA = California; CI = confidence interval; cm = centimeter; EC = elemental carbon; EP = entire pregnancy; GIS = geographic information system; GW = gestational week; IDW = inverse distance weighting; IVF = in vitro fertilization; LBW = low birth weight; LUR = land use regression; M1 = Month 1; M2 = Month 2; M3 = Month 3; M4 = Month 4; msec = milliseconds; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; NR = not reported; Q1 = 1st quartile; Q2 = 2nd quartile; Q3 = 3rd quartile; Q4 = 4th quartile; SAT = switching attention test; SGA = small for gestational age; SRTT = simple reaction time test; T1 = 1st trimester; T2 = 2nd trimester; T3 = 3rd trimester.

<sup>a</sup>Relative risk per 10-ppb change in NO<sub>2</sub> or 20-ppb change in NO<sub>x</sub>, unless otherwise noted.

<sup>b</sup>Per doubling in NO<sub>2</sub> concentration.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

## 6.4.3 Birth Outcomes

### 6.4.3.1 Fetal Growth

Fetal growth is influenced by maternal, placental, and fetal factors. The biological mechanisms by which air pollutants may influence the developing fetus remain largely unknown. LBW has often been used as an outcome measure because it is easily available

and accurately recorded on birth certificates. However, LBW may result from either short gestation or inadequate growth in utero. Most of the studies investigating air pollution exposure and LBW limited their analyses to term infants to focus on inadequate growth. A number of studies were identified that specifically addressed growth restriction in utero by identifying infants who failed to meet specific growth standards. Usually, these infants had birth weight less than the 10th percentile for gestational age, using an external standard.

A limitation of environmental studies that use birth weight as a proxy measure of fetal growth is that patterns of fetal growth during pregnancy cannot be assessed. This is particularly important when investigating pollutant exposures during early pregnancy as birth weight is recorded many months after the exposure period. The insult of air pollution may have a transient effect on fetal growth, where growth is hindered at one point in time but catches up at a later point. For example, maternal smoking during pregnancy can alter the growth rate of individual body segments of the fetus at variable developmental stages, as the fetus experiences selective growth restriction and augmentation ([Lampl and Jeanty, 2003](#)).

The terms SGA, which is defined as a birth weight <10th percentile for gestational age (and often sex and/or race), and IUGR are often used interchangeably. However, this definition of SGA does have limitations. For example, using it for IUGR may overestimate the percentage of “growth-restricted” neonates as it is unlikely that 10% of neonates have growth restriction ([Wollmann, 1998](#)). On the other hand, when the 10th percentile is based on the distribution of live births at a population level, the percentage of SGA among PTB is most likely underestimated ([Hutcheon and Platt, 2008](#)). Nevertheless, SGA represents a statistical description of a small neonate, whereas the term IUGR is reserved for those with clinical evidence of abnormal growth. Thus, all IUGR neonates will be SGA, but not all SGA neonates will be IUGR ([Wollmann, 1998](#)). In the following section, the terms SGA and IUGR are referred to as each cited study used the terms.

The 2008 ISA for Oxides of Nitrogen reviewed three studies that evaluated the relationship between exposure to NO<sub>2</sub> and fetal growth ([Mannes et al., 2005](#); [Salam et al., 2005](#); [Liu et al., 2003](#)) and concluded that they “did not consistently report associations between NO<sub>2</sub> exposure and intrauterine growth retardation” ([U.S. EPA, 2008c](#)). In recent years, a number of studies have examined various metrics of fetal growth restriction. Several of these recent studies have used anthropometric measurements (e.g., head circumference, abdominal circumference) measured via ultrasound at different periods of pregnancy in order to evaluate patterns of fetal growth during pregnancy and to detect growth restriction that may occur early in pregnancy, but which may no longer be

detectable at birth. In a mother and child cohort study conducted in Spain, ultrasound measurements were recorded at 12, 20, and 32 weeks of gestation, and these anthropometric measurements were recorded again at birth ([Iñiguez et al., 2012](#); [Aguilera et al., 2010](#)). [Aguilera et al. \(2010\)](#) observed that exposure to NO<sub>2</sub> early in pregnancy was associated with impaired growth in head circumference from Weeks 12 to 20 of gestation and abdominal circumference and estimated fetal weight from Weeks 20 to 32. Similarly, [Iñiguez et al. \(2012\)](#) reported decreased fetal length and decreased biparietal diameter measured by ultrasound in association with exposure to NO<sub>2</sub> during Weeks 12–20 of gestation. Decreased birth length and head circumference measured at birth were also associated with exposure to NO<sub>2</sub> during this same period. Examining fetal growth characteristics assessed by ultrasound during each trimester of pregnancy, [van den Hooven et al. \(2012c\)](#) observed decreases in head circumference and fetal length in the second and third trimesters associated with exposure to NO<sub>2</sub>. [Hansen et al. \(2008\)](#) used ultrasound measurements during Weeks 13–26 of pregnancy and did not observe associations between exposure to relatively low concentrations of NO<sub>2</sub> (mean: 9.8 ppb) and head circumference, biparietal diameter, abdominal circumference, or fetal length. [Ritz et al. \(2014\)](#) used multiple ultrasound measures to examine fetal growth parameters across gestation and observed that higher exposure to NO<sub>2</sub> during Gestational Weeks 29–37 was associated with decrements in biparietal diameter at 37 weeks; no consistent associations were found for head circumference, femur length, or abdominal circumference.

Several studies made use of anthropometric measurements made immediately after birth to evaluate fetal growth. [Estarlich et al. \(2011\)](#), [Ballester et al. \(2010\)](#), and [Hansen et al. \(2007\)](#) observed decreases in body length associated with exposure to NO<sub>2</sub>. This association persisted when NO<sub>2</sub> exposure was estimated for each trimester of pregnancy in the study by [Estarlich et al. \(2011\)](#). [Ballester et al. \(2010\)](#) observed the strongest association with NO<sub>2</sub> exposure during the first trimester, while [Hansen et al. \(2007\)](#) reported that the association was strongest for NO<sub>2</sub> exposure measured at the end of the pregnancy.

When using SGA as an indicator of fetal growth restriction, several studies observed associations with exposure to NO<sub>2</sub>, NO<sub>x</sub>, or NO ([Sathyanarayana et al., 2013](#); [Le et al., 2012](#); [Pereira et al., 2012](#); [Malmqvist et al., 2011](#); [Ballester et al., 2010](#); [Rich et al., 2009](#); [Brauer et al., 2008](#); [Mannes et al., 2005](#)). These associations were most often observed for exposure to NO<sub>2</sub> during the second trimester ([Pereira et al., 2012](#); [Ballester et al., 2010](#); [Rich et al., 2009](#); [Mannes et al., 2005](#)). [Gehring et al. \(2011a\)](#), [Hansen et al. \(2007\)](#), [Olsson et al. \(2013\)](#), [Kashima et al. \(2011\)](#), and [Hannam et al. \(2014\)](#) did not observe an increased risk of SGA associated with exposure to NO<sub>2</sub>. All of the studies that used IUGR as an indicator of fetal growth restriction observed an association with

exposure to NO<sub>2</sub>, and this association was strongest for exposures at the beginning of pregnancy [i.e., first month or first trimester; ([Liu et al., 2007](#); [Salam et al., 2005](#); [Liu et al., 2003](#))].

When evaluating the association between fetal growth and exposure to NO<sub>2</sub>, many studies estimated NO<sub>2</sub> exposure at the maternal residence using LUR models ([Iñiguez et al., 2012](#); [Pereira et al., 2012](#); [Estarlich et al., 2011](#); [Gehring et al., 2011a](#); [Aguilera et al., 2010](#); [Ballester et al., 2010](#); [Brauer et al., 2008](#)) and dispersion models ([van den Hooven et al., 2012c](#)). Generally, the results of studies that relied on estimates of NO<sub>2</sub> from LUR models were not substantially different from those that estimated exposure to NO<sub>2</sub> using concentrations measured at central site monitors. Given the differences among the study designs, it cannot be concluded that the inconsistencies are related to exposure assessment method or length of follow-up periods. However, in a study that assigned exposure to NO<sub>2</sub> using both a LUR model and IDW of measured NO<sub>2</sub> concentration from monitors, [Brauer et al. \(2008\)](#) found higher risks for SGA using the monitoring data (OR: 1.28 [95% CI: 1.18, 1.36]) compared to the risks observed with the NO<sub>2</sub> estimates from the LUR model (OR 0.94 [95% CI: 0.80, 1.10]). In general, epidemiologic studies that estimate long-term NO<sub>2</sub> exposure from central site monitors can carry uncertainty because the exposure error resulting from spatial misalignment between subjects and monitor locations can overestimate or underestimate associations with health effects ([Section 3.4.5.2](#)). While many studies did not report on the extent to which exposures estimated from central site monitors or models represented the spatial pattern in ambient NO<sub>2</sub> concentrations, some studies demonstrated that their LUR or dispersion models had good accuracy in predicting ambient NO<sub>2</sub> concentrations in the study areas ([van den Hooven et al., 2012c](#); [Aguilera et al., 2010](#)).

Several studies incorporated data on activity patterns in order to decrease potential error in residential exposure estimates. [Aguilera et al. \(2010\)](#) and [Estarlich et al. \(2011\)](#) only analyzed subjects who spent 15 or more hours per day at home or subjects who spent less than 2 hours a day in an outdoor environment other than at their primary residence and found stronger associations between measures of decreased fetal growth and exposure to NO<sub>2</sub>. In contrast, when [Gehring et al. \(2011a\)](#) limited their analyses to participants who did not move during pregnancy or did not have paid employment outside of the home, there were no consistent associations between SGA and exposure to NO<sub>2</sub>.

In summary, there is generally consistent evidence for an association between exposure to NO<sub>2</sub> and fetal growth restriction, including recent evidence from studies that used fetal anthropometric measurements made via ultrasound and anthropometric measurements made immediately after birth. Some studies demonstrated the validity of models used to estimate residential exposure for individual subjects. These are consistent with the studies

of the clinical measurement of IUGR and the statistical definition of SGA. Key studies can be found in [Table 6-12. Supplemental Table S6-3 \(U.S. EPA, 2013h\)](#) provides an overview of all of the epidemiologic studies of fetal growth effects. The evidence is less certain when it comes to assessing the time period of pregnancy when exposure to NO<sub>2</sub> is associated with the highest risks. Some studies find the highest risks associated with NO<sub>2</sub> when NO<sub>2</sub> is measured in early pregnancy, while in other studies, the time period associated with the greatest risk is toward the end of pregnancy. Others find the greatest risk when exposure is assigned for the entire pregnancy period. A major uncertainty is whether NO<sub>2</sub> exposure has an independent effect on fetal growth restriction because epidemiologic studies did not examine the potential for confounding by traffic-related copollutants, toxicological investigation of these outcomes is lacking.

---

#### 6.4.3.2 Preterm Birth

PTB is a syndrome ([Romero et al., 2006](#)) that is characterized by multiple etiologies. It is, therefore, unusual to be able to identify an exact cause for each PTB. In addition, PTB is not an adverse outcome in itself but an important determinant of health status (i.e., neonatal morbidity and mortality). Although some overlap exists for common risk factors, different etiologic entities related to distinct risk factor profiles and leading to different neonatal and post-neonatal complications are attributed to PTB and measures of fetal growth. Although both restricted fetal growth and PTB can result in LBW, prematurity does not have to result in LBW or growth-restricted babies.

A major issue in studying environmental exposures and PTB is selecting the relevant exposure period because the biological mechanisms leading to PTB and the critical periods of vulnerability are poorly understood ([Bobak, 2000](#)). Short-term exposures proximate to birth may be most relevant if exposure causes an acute effect. However, exposure occurring in early gestation might affect placentation, with results observable later in pregnancy, or cumulative exposure during pregnancy may be the most important determinant. The studies reviewed have dealt with this issue in different ways. Many have considered several exposure metrics based on different periods of exposure. Often the time periods used are the first month (or first trimester) of pregnancy and the last month (or 6 weeks) prior to delivery. Using a time interval prior to delivery introduces an additional problem because cases and controls are not in the same stage of development when they are compared. For example, a preterm infant delivered at 36 weeks is a 32-week fetus 4 weeks prior to birth, while an infant born at term (40 weeks) is a 36-week fetus 4 weeks prior to birth.

Recently, investigators have examined the association of PTB with both short-term (i.e., hours, days, or weeks) and long-term (i.e., months or years) exposure periods. Time-series studies have been used to examine the association between air pollution concentrations during the days immediately preceding birth. An advantage of these time-series studies is that this approach can remove the influence of covariates that do not vary across individuals over a short period of time. Retrospective cohort and case-control studies have been used to examine long-term exposure periods, often averaging air pollution concentrations over months or trimesters of pregnancy.

Studies of PTB fail to show consistency in the periods during pregnancy when pollutants are associated with an effect. For example, while some studies find the strongest effects associated with exposures early in pregnancy, others report effects when the exposure is limited to the second or third trimester. Many studies of PTB compare exposure in quartiles, using the lowest quartile as the reference (or control) group. No studies use a truly unexposed control group. If exposure in the lowest quartile confers risk, then it may be difficult to demonstrate additional risk associated with a higher quartile. Thus, negative studies must be interpreted with caution.

Preterm birth occurs both naturally (idiopathic PTB) and as a result of medical intervention (iatrogenic PTB). [Ritz et al. \(2000\)](#) excluded all births by Cesarean section to limit their studies to idiopathic PTB. No other studies attempted to distinguish the type of PTB, although air pollution exposure may be associated with only one type. This is a source of potential effect misclassification. One study examined preterm premature rupture of membranes, observing positive ORs with NO<sub>2</sub> exposure ([Dadvand et al., 2014a](#)).

A number of recent studies evaluated the association between exposure to NO<sub>2</sub> and PTB, and the results generally are inconsistent. The body of literature that observed an association between NO<sub>2</sub> or NO<sub>x</sub> and PTB ([Gehring et al., 2014](#); [Trasande et al., 2013](#); [Le et al., 2012](#); [Olsson et al., 2012](#); [Wu et al., 2011a](#); [Llop et al., 2010](#); [Darrow et al., 2009](#); [Wu et al., 2009](#); [Jiang et al., 2007](#); [Leem et al., 2006](#); [Maroziene and Grazuleviciene, 2002](#); [Bobak, 2000](#)) is generally the same (in both the quantity and quality of studies) to the one that finds no consistent pattern in the association between NO<sub>2</sub> and PTB ([Hannam et al., 2014](#); [Olsson et al., 2013](#); [Gehring et al., 2011a](#); [Gehring et al., 2011b](#); [Kashima et al., 2011](#); [Basu et al., 2010](#); [Brauer et al., 2008](#); [Jalaludin et al., 2007](#); [Ritz et al., 2007](#); [Hansen et al., 2006](#); [Liu et al., 2003](#); [Ritz et al., 2000](#)). Among the studies that observe an association between exposure to NO<sub>2</sub> and PTB, the association seems to be strongest for exposure to NO<sub>2</sub> late in pregnancy, including the third trimester ([Llop et al., 2010](#); [Leem et al., 2006](#); [Bobak, 2000](#)), the last 8 weeks of pregnancy ([Jiang](#)

[et al., 2007](#)), the last 6 weeks of pregnancy ([Darrow et al., 2009](#)), month of birth ([Trasande et al., 2013](#)), or the last week of pregnancy ([Olsson et al., 2012](#)).

Several studies examined very preterm birth (VPTB, <30 weeks gestation). Some observed positive associations with NO<sub>2</sub> for VPTB when none were observed for PTB ([Brauer et al., 2008](#)), or observed stronger associations for NO<sub>2</sub> or NO<sub>x</sub> with VPTB compared to those for PTB ([Wu et al., 2011a](#); [Wu et al., 2009](#)).

Several studies of PTB estimated NO<sub>2</sub> concentrations for subjects' homes or postal codes with LUR models ([Gehring et al., 2014](#); [Gehring et al., 2011a](#); [Gehring et al., 2011b](#); [Kashima et al., 2011](#); [Wu et al., 2011a](#); [Llop et al., 2010](#); [Brauer et al., 2008](#)) or dispersion models ([Wu et al., 2011a](#)). Results for an association between PTB and exposure to NO<sub>2</sub> were inconsistent among studies that demonstrated that LUR models predicted well ambient NO<sub>2</sub> concentrations in the study areas (cross-validation R<sup>2</sup> = 0.63–0.87). In general, epidemiologic studies that estimate long-term NO<sub>2</sub> exposure from central site monitors can carry uncertainty because the exposure error resulting from spatial misalignment between subjects and monitor locations can overestimate or underestimate associations with health effects ([Section 3.4.5.2](#)). Studies did not report on the extent to which exposures estimated from central site monitors represented the spatial pattern in ambient NO<sub>2</sub> concentrations. The results of studies that used NO<sub>2</sub> concentrations from central site monitors were similarly inconsistent as those that estimated residential NO<sub>2</sub> exposure. [Brauer et al. \(2008\)](#) assigned exposure to NO<sub>2</sub> using both a LUR model and IDW of NO<sub>2</sub> concentration from monitors and found comparable risk estimates per 10 ppb for VPTB using the monitoring data (OR: 1.24, [95% CI: 0.80, 1.88]) and NO<sub>2</sub> estimates from the LUR model (OR: 1.16 [95% CI: 0.93, 1.61]). However, both LUR and IDW estimated exposures for subjects' postal code and may have similar exposure error. In summary, the evidence for an association between NO<sub>2</sub> exposure and PTB is inconsistent [[Supplemental Table S6-4 \(U.S. EPA, 2013i\)](#)]. Given the differences among the study designs, it cannot be concluded that the inconsistencies are related to exposure assessment method or length of follow-up periods.

---

### 6.4.3.3 Birth Weight

With birth weight routinely collected in vital statistics and being a powerful predictor of infant mortality, it is the most studied outcome within air pollution-birth outcome research. Air pollution researchers have analyzed birth weight as a continuous variable and/or as a dichotomized variable in the form of LBW [<2,500 g (5 lbs., 8 oz.)].

Birth weight is primarily determined by gestational age and intrauterine growth but also depends on maternal, placental, and fetal factors as well as on environmental influences.

In both developed and developing countries, LBW is the most important predictor for neonatal mortality and is an important determinant of post-neonatal mortality and morbidity. Studies report that infants who are smallest at birth have a higher incidence of diseases and disabilities that continue into adulthood ([Hack and Fanaroff, 1999](#)).

A number of recent studies evaluated the association between exposure to NO<sub>2</sub> and birth weight, and the results generally are inconsistent. When examining birth weight as a continuous variable, several studies observed decreases in birth weight associated with increases in NO<sub>2</sub> exposure ([Gehring et al., 2014](#); [Laurent et al., 2014](#); [Savitz et al., 2014](#); [Darrow et al., 2011b](#); [Estarlich et al., 2011](#); [Ballester et al., 2010](#); [Morello-Frosch et al., 2010](#); [Bell et al., 2007](#)). Generally, these studies observed the largest decreases in birth weight when exposure to NO<sub>2</sub> was averaged over the entire pregnancy. There are also a number of studies that examined birth weight as a continuous variable that found no consistent decreases in birth weight associated with increases in NO<sub>2</sub> exposure averaged over the entire pregnancy or specific trimesters of pregnancy ([Hannam et al., 2014](#); [Sellier et al., 2014](#); [Pedersen et al., 2013](#); [Geer et al., 2012](#); [Rahmalia et al., 2012](#); [Gehring et al., 2011a](#); [Gehring et al., 2011b](#); [Kashima et al., 2011](#); [Lepeule et al., 2010](#); [Aguilera et al., 2009](#); [Hansen et al., 2007](#); [Salam et al., 2005](#); [Gouveia et al., 2004](#)). With LBW examined as the risk of having a baby weighing less than 2,500 g, the study results remain inconsistent, with some study authors observing an association between LBW and exposure to NO<sub>2</sub> ([Dadvand et al., 2014c](#); [Ebisu and Bell, 2012](#); [Ghosh et al., 2012a](#); [Wilhelm et al., 2012](#); [Morello-Frosch et al., 2010](#); [Brauer et al., 2008](#); [Bell et al., 2007](#); [Lee et al., 2003](#)), while others reporting no consistent association ([Pedersen et al., 2013](#); [Kashima et al., 2011](#); [Slama et al., 2007](#); [Salam et al., 2005](#); [Wilhelm and Ritz, 2005](#); [Gouveia et al., 2004](#); [Liu et al., 2003](#); [Marozienne and Grazuleviciene, 2002](#); [Bobak, 2000](#)). One study observed decreases in effect estimates for both LBW and change in birth weight with increases in NO<sub>2</sub> exposure ([Laurent et al., 2013](#)). Generally, the studies that observed the largest risks for LBW averaged exposure to NO<sub>2</sub> over the entire pregnancy.

Some studies incorporated data on activity patterns in order to reduce potential error in residential exposure estimates. [Estarlich et al. \(2011\)](#) only analyzed subjects who spent 15 or more hours per day at home or subjects who spent less than 2 hours a day in an outdoor environment other than at their primary residence and found stronger associations between birth weight and NO<sub>2</sub> exposure. These sensitivity analyses did not consistently change the associations observed by [Aguilera et al. \(2009\)](#). When [Gehring et al. \(2011a\)](#) limited their analyses to participants who did not move during pregnancy, or did not have paid employment outside of the home, they continued to observe no consistent associations between birth weight and exposure to NO<sub>2</sub>.

Several birth weight studies estimated NO<sub>2</sub> concentrations for subjects' homes or postal code with LUR models, kriging of monitored concentrations ([Ghosh et al., 2012a](#); [Wilhelm et al., 2012](#); [Estarlich et al., 2011](#); [Gehring et al., 2011a](#); [Gehring et al., 2011b](#); [Kashima et al., 2011](#); [Ballester et al., 2010](#); [Lepeule et al., 2010](#); [Aguilera et al., 2009](#); [Brauer et al., 2008](#); [Slama et al., 2007](#)), or dispersion models ([Rahmalia et al., 2012](#); [van den Hooven et al., 2012b](#); [Madsen et al., 2010](#)). Results for an association with birth weight are inconsistent among studies that demonstrated that LUR models predicted well ambient NO<sub>2</sub> concentrations in the study areas (cross-validation R<sup>2</sup> = 0.63–0.87) or that dispersion model estimates correlated well with monitored concentrations. In general, epidemiologic studies that estimate long-term NO<sub>2</sub> exposure from central site monitors can carry uncertainty because the exposure error resulting from spatial misalignment between subjects and monitor locations can overestimate or underestimate associations with health effects ([Section 3.4.5.2](#)). Studies did not report on the extent to which exposures estimated from central site monitors represented the spatial pattern in ambient NO<sub>2</sub> concentrations, and their results were similarly inconsistent as studies that estimated residential NO<sub>2</sub> exposure. Some studies compared the use of central site monitor data to assign exposure to LUR or kriging, and concluded that while the monitoring data may include larger errors in estimated exposure, these errors had little impact on the association between exposure to NO<sub>2</sub> and birth weight calculated using two exposure assessment methods that different in spatial resolution ([Lepeule et al., 2010](#); [Madsen et al., 2010](#)). Given the differences among the study designs, it cannot be concluded that the inconsistencies are related to exposure assessment method or length of follow-up periods.

In summary, epidemiologic evidence for an association between NO<sub>2</sub> exposure and birth weight is generally inconsistent, with some studies observing an association, while other studies observe no consistent pattern of association [[Table 6-12](#) for key studies and [Supplemental Table S6-5 \(U.S. EPA, 2013j\)](#) for all studies]. Further, supporting evidence from toxicological studies is limited. Albino rats exposed to 1,300 ppb NO<sub>2</sub> 12 h/day for 3 months prior to breeding ([Table 6-13](#)) produced pups with statistically significant decreased birth weights ([Shalamberidze and Tsereteli, 1971a, b](#)). Statistically significant body-weight decrements continued to be observed at postnatal day (PND) 4 and PND12.

---

#### 6.4.3.4 Birth Defects

Despite the growing body of literature evaluating the association between ambient air pollution and various adverse birth outcomes, relatively few studies have investigated the effect of temporal variations in ambient air pollution on birth defects. Heart defects and oral clefts have been the focus of the majority of these recent studies, given their higher prevalence than other birth defects and associated mortality.

A recent study investigated the association between NO or NO<sub>2</sub> and cardiac birth defects ([Padula et al., 2013a](#)) and other noncardiac birth defects ([Padula et al., 2013b](#)) in the San Joaquin Valley in California. The authors observed no associations between heart defects and NO or NO<sub>2</sub> but did observe an association between neural tube defects and both NO and NO<sub>2</sub>. In a further analysis of noncardiac/nonneural tube defects, [Padula et al. \(2013c\)](#) observed no associations between NO or NO<sub>2</sub> and any of the defects studied. A nine-state cardiac birth defect case-control study observed associations between NO<sub>2</sub> and coarctation of the aorta, pulmonary valve stenosis, and left ventricular outflow tract obstructions ([Stingone et al., 2014](#)). A Barcelona, Spain-based case-control study of 18 congenital anomaly groups found coarctation of the aorta and digestive system defects associated with increases in NO<sub>2</sub> ([Schembari et al., 2014](#)). Two studies examining trisomy risk observed no correlations/associations with NO<sub>2</sub>, and a correlation between NO and Trisomy 21 ([Chung et al., 2014](#); [Jurewicz et al., 2014](#)). In general, studies of birth defects have focused on cardiac defects, and the results from these studies are not entirely consistent. This inconsistency could be due to the absence of true associations between NO<sub>2</sub> and risks of cardiovascular malformations; it could also be due to differences in populations, pollution concentrations, outcome definitions, or analytical approaches. Also, the lack of consistency of associations between NO<sub>2</sub> and cardiovascular malformations might be due to issues relating to statistical power or measurement error. A recent meta-analysis of air pollution and congenital anomalies observed elevated summary effects for NO<sub>2</sub> and coarctation of the aorta (OR: 1.17 [95% CI: 1.00, 1.36] per 10-ppb NO<sub>2</sub>), tetralogy of Fallot (OR: 1.20 [95% CI: 1.02, 1.42]), and atrial septal defects (1.10 [95% CI: 0.91, 1.33]) ([Vrijheid et al., 2011](#)). Ventral septal defects exhibited an elevated summary estimate, but there also was high heterogeneity between studies. Another meta-analysis found association only between coarctation of the aorta and NO<sub>2</sub> ([Chen et al., 2014a](#)). These authors note that heterogeneity in the results of these studies may be due to inherent differences in study location, study design, and/or analytic methods, and comment that these studies have not employed some recent advances in exposure assessment used in other areas of air pollution research that may help refine or reduce this heterogeneity. Further, none of the birth defect studies of NO<sub>2</sub>, including meta-analyses, examined confounding by PM<sub>2.5</sub> or traffic-related pollutants. These studies are characterized in [Supplemental Table S6-6 \(U.S. EPA, 2013k\)](#).

---

#### **6.4.3.5 Early Life Mortality**

An important question regarding the association between NO<sub>2</sub> and infant mortality is the critical window of exposure during development for which infants are at risk. Several age intervals have been explored: neonatal (<1 month); post-neonatal (1 month to 1 year);

and an overall interval for infants that includes both the neonatal and post-neonatal periods (<1 year). During the neonatal and post-neonatal periods, the developing lung is highly sensitive to environmental toxicants. The lung is not well developed at birth, with 80% of alveoli being formed postnatally. The studies below reflect a variety of study designs, exposure periods, regions, and included many relevant potential confounders except for traffic-related copollutants. As discussed below, a handful of studies have examined the effect of ambient air pollution on neonatal and post-neonatal mortality, with the former the least studied. These studies varied somewhat with regard to the outcomes and exposure periods examined and study designs employed. Because it is unknown whether early life mortality follows similar biological pathways or modes of action to adult mortality, studies on adult mortality are discussed in [Section 6.5](#).

Overall, the evidence for an association between exposure to NO<sub>2</sub> and infant mortality is inconsistent. Recent epidemiologic studies examined the association between long-term exposure to NO<sub>2</sub> measured at central site monitors and stillbirths, with one study observing an association ([Faiz et al., 2012](#)) and another observing associations near the null value ([Hwang et al., 2011](#)). [Faiz et al. \(2013\)](#) observed positive ORs for stillbirth with NO<sub>2</sub> exposures 2 days before birth. A case-control study of spontaneous abortion before 14 weeks of gestation found a positive OR for NO<sub>2</sub> exposure ([Moridi et al., 2014](#)). [Hou et al. \(2014\)](#) also found positive ORs for fetal loss before 14 weeks of gestation with NO<sub>2</sub> exposure; however, these estimates have large confidence intervals and may not be reliable. [Enkhmaa et al. \(2014\)](#) found high correlations between air pollutants and fetal loss before 20 weeks in Mongolia including NO<sub>2</sub>, but these results were unadjusted for other factors or copollutants. One study investigated the association between short-term exposure to NO<sub>2</sub> and mortality during the neonatal period ([Lin et al., 2004a](#)) and did not observe a positive association. More studies examined the association between exposure to NO<sub>2</sub> and mortality during the post-neonatal period. [Son et al. \(2008\)](#), [Tsai et al. \(2006\)](#), and [Yang et al. \(2006\)](#) examined the association between short-term exposure to NO<sub>2</sub> and post-neonatal mortality, while [Ritz et al. \(2006\)](#) investigated the association between long-term exposure to NO<sub>2</sub> and post-neonatal mortality; none observed a consistent, positive association. Finally, two studies examined the association between NO<sub>2</sub> and sudden infant death syndrome. [Dales et al. \(2004\)](#) and [Ritz et al. \(2006\)](#) observed positive associations with short-term and long-term exposure to NO<sub>2</sub>, respectively. [Supplemental Table S6-8 \(U.S. EPA, 2013m\)](#) provides a brief overview of the epidemiologic studies of infant mortality.

Toxicological evidence for NO<sub>2</sub>-related infant mortality is similarly inconsistent. [Tabacova et al. \(1985\)](#) exposed rodent dams to 50, 500, or 5,300 ppb NO<sub>2</sub> (6 h/day, 7 days/week, GD 0–21; [Table 6-13](#)). Statistically significant decreased pup viability was seen at PND21 with 5,300 ppb NO<sub>2</sub>. Another study in which male pups received prenatal

exposure to NO<sub>2</sub> via a different daily exposure duration (dam continuous exposure to 1,500 or 3,000 ppb, GD 0–20) showed no statistically significant effects on pup postnatal mortality to PND21 ([Di Giovanni et al., 1994](#)).

---

## 6.4.4 Postnatal Development

The role of prenatal air pollution exposure has assumed increasing importance over time for effects on postnatal development. Ambient air pollution exposures of pregnant women have been associated with negative birth outcomes. Additionally, the prenatal and early postnatal periods are critical periods for extensive growth and development, and air pollution exposures during this period have been linked to health effects in the first years of life. Thus, air pollution-related effects in both the developing fetus and infant have implications for effects on postnatal development. This evaluation of the relationship of postnatal developmental with NO<sub>2</sub> exposure consists primarily of neurodevelopmental outcomes and limited toxicological information on physical development. Studies examining the effects of NO<sub>2</sub> exposure on development of the respiratory system ([Sections 6.2.5](#) and [6.2.6](#)) inform the evaluation of the relationship between long-term NO<sub>2</sub> exposure and respiratory effects ([Section 6.2.9](#)).

---

### 6.4.4.1 Neurodevelopmental Effects

Epidemiologic studies of neurodevelopment in children were not available for the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), but several have been published since then. As described in the sections that follow, associations with NO<sub>2</sub> are inconsistent for cognitive function, which was most extensively examined, and for attention-related behaviors, motor function, psychological distress, and autism, which were examined in a few studies each. [Table 6-12](#) details the key studies, and [Supplemental Table S6-7 \(U.S. EPA, 2013I\)](#) provides an overview of all of the epidemiologic studies of neurodevelopmental effects. Strengths of the studies overall are assessment of neurodevelopment with widely used, structured neuropsychological tests, spatial alignment of ambient NO<sub>2</sub> concentrations to subjects' school or home locations, and examination of potential confounding by multiple SES indicators. While some studies considered birth outcomes and traffic noise exposure as potential confounding factors, smoking and stress were inconsistent or not considered. Further, in most studies, NO<sub>2</sub> was the only air pollutant examined, and uncertainty remains regarding potential confounding by copollutants that are well-characterized risk factors for decrements in neurodevelopmental function such as lead, PM<sub>2.5</sub>, or PM components such as polycyclic aromatic hydrocarbons.

## Cognitive Function

NO<sub>2</sub> is not consistently associated with cognition in children. Among children age 4 years, indoor home NO<sub>2</sub> at age 3 months was associated with multiple measures of cognitive function, from a general cognition index to memory, verbal, and quantitative skills ([Morales et al., 2009](#)). These associations were limited to children with a GST Pi 1 valine (Val) –105 allele [isoleucine (Ile)/Val or Val/Val versus Ile/Ile genotype], which is associated with lower oxidative metabolism. In contrast with indoor NO<sub>2</sub>, ambient NO<sub>2</sub> assessed concurrently with cognitive function or for the prenatal period was not clearly associated with cognitive function in school children or infants ([Guxens et al., 2014](#); [Clark et al., 2012](#); [Guxens et al., 2012](#); [van Kempen et al., 2012](#); [Freire et al., 2010](#); [Wang et al., 2009a](#)). Within studies, results were inconsistent among the multiple indices of cognitive function examined. Results also were inconsistent across studies, including those for indices of memory, which was examined in most studies. As was done in the 2013 ISA for Lead ([U.S. EPA, 2013c](#)), evidence is evaluated separately for cognition in school children and infants.

A common strength of the studies conducted in school children is the assessment of NO<sub>2</sub> exposures for home or school locations using well-validated LUR models ([Section 3.2.2.1](#)). [van Kempen et al. \(2012\)](#) is particularly noteworthy for assessing exposures outside both home and school and examining potential confounding by traffic noise. The LUR model well predicted ambient NO<sub>2</sub> concentrations in the study area ( $R^2$  for cross-validation = 0.85). School, not home, NO<sub>2</sub> was associated with memory with adjustment for noise ([Table 6-12](#)). Neither school nor home NO<sub>2</sub> was associated with the ability to process information. A similar study found school-based aircraft noise, but not NO<sub>2</sub>, to be associated with cognitive function ([Clark et al., 2012](#)). NO<sub>2</sub> estimated for home locations also was inconsistently associated with cognitive function. Another study of concurrent NO<sub>2</sub> exposure observed that higher home outdoor NO<sub>2</sub> was associated with poorer cognitive function, but the wide 95% CIs call into question the reliability of findings ([Freire et al., 2010](#)). Associations for prenatal residential NO<sub>2</sub> exposure were similarly inconsistent among cohorts in three cities in Spain, with negative, null, and positive associations observed with cognition [([Guxens et al., 2014](#)); [Table 6-12](#)]. Across studies, NO<sub>2</sub> exposures were estimated from LUR models that varied in performance across locations; however, the inconsistency in findings does not appear to be related to model performance. In [Freire et al. \(2010\)](#), the cross-validation  $R^2$  was 0.64 for urban and nonurban areas combined. There was indication that the model was better for nonurban areas, where 84% of subjects lived. Additionally, NO<sub>2</sub> was not associated with decrements in cognitive function in cities in Spain where LUR models predicted ambient NO<sub>2</sub> concentrations well [cross-validation  $R^2 = 0.75, 0.77$ ; ([Guxens et al., 2012](#); [Estarlich et al., 2011](#))]. [Wang et al. \(2009a\)](#) also produced inconsistent findings but has weaker

implications because of its ecological comparison of school locations that differed in ambient NO<sub>2</sub> concentrations not direct analysis of NO<sub>2</sub>.

The Bayley Scales of Infant Development is a widely used and reliable test for infant development. The mental development index is a measure of sensory acuity, memory, and early language skills. However, the Bayley Scales of Infant Development scores are not necessarily correlated with development of children at older ages, and the tests at age 1 year or younger do not assess many outcomes that are analogous to those assessed at 2 and 3 years old. Across studies, mental development in infants ages 6 to 24 months was not associated with trimester-specific prenatal NO<sub>2</sub> exposure or NO<sub>2</sub> exposure from birth to age 6 months ([Lin et al., 2014](#)) and was inconsistently associated with NO<sub>2</sub> averaged over pregnancy ([Guxens et al., 2014](#); [Kim et al., 2014](#); [Guxens et al., 2012](#)). In an analysis of cohorts across multiple European countries, associations were found in locations where the LUR model better predicted ambient NO<sub>2</sub> [cross-validation  $R^2 = 0.69\text{--}0.84$  versus 0.45 or 0.51; ([Beelen et al., 2013](#); [Estarlich et al., 2011](#))]. Associations for four cohorts in Spain differed between publications [([Guxens et al., 2014](#); [Guxens et al., 2012](#)); [Table 6-12](#)]. Other than sample sizes and possibly different pregnancy addresses used to estimate NO<sub>2</sub> exposure, an explanation for divergent results is not clear ([Guxens et al., 2014](#); [Estarlich et al., 2011](#)). Mental development of infants also was inconsistently associated with NO<sub>2</sub> exposure assessed by averaging concentrations across central site monitors within a city ([Lin et al., 2014](#)) or combining concentrations by IDW ([Kim et al., 2014](#)). [Kim et al. \(2014\)](#) illustrated the uncertainty of the IDW method in capturing the spatial heterogeneity in ambient NO<sub>2</sub> concentrations in their study area by indicating a moderate or weak correlation ( $r = 0.42, 0.21$ ) between ambient NO<sub>2</sub> concentrations estimated by IDW and measured outside homes in a subset of subjects. Another uncertainty in these studies is the lack of examination of potential confounding by benzene ([Guxens et al., 2012](#)) or PM<sub>10</sub> ([Kim et al., 2014](#)), which showed a similar pattern of association as did NO<sub>2</sub> and were highly or moderately correlated with NO<sub>2</sub> ( $r = 0.70$  and  $0.40$ , respectively).

### **Attention-Related Behaviors**

The few studies of attention-related behaviors produced contrasting results for associations with NO<sub>2</sub>. [Morales et al. \(2009\)](#) observed that exposure to gas appliances and higher indoor NO<sub>2</sub> at age 3 months were associated with elevated odds ratios for symptoms of Attention Deficit Hyperactivity Disorder at age 4 years. The association was attributable mainly to inattention, as hyperactivity was not associated with NO<sub>2</sub>. As was observed for cognitive function, associations were limited to children with a GST Pi 1 Val-105 allele. In contrast, outdoor school and home NO<sub>2</sub> concentrations (with or without adjustment for road traffic and aircraft noise) were not associated with poorer

performance on multiple tests of sustained and switching attention ([van Kempen et al., 2012](#)). There was some evidence of an NO<sub>2</sub>-road traffic noise interaction, as home outdoor NO<sub>2</sub> was associated with poorer attention switching among children in the highest noise category. Home NO<sub>2</sub> and road traffic noise were moderately correlated ( $r = 0.30$ ). The ecological study did not find attention performance test results to differ consistently with respect to school locations ([Wang et al., 2009a](#)).

## Motor Function

Evidence does not strongly indicate that NO<sub>2</sub> exposure affects motor function of children. Whereas higher indoor home NO<sub>2</sub> exposure at age 3 months was associated with poorer motor function in 4-year olds ([Morales et al., 2009](#)), findings are inconsistent for ambient NO<sub>2</sub> exposure. A combined analysis of multiple European cohorts found that NO<sub>2</sub> exposure ascertained for the birth address by LUR was associated with poorer motor function overall, but associations were limited to half of the individual cohorts ([Guxens et al., 2014](#)). PM<sub>2.5</sub>, PM<sub>2.5</sub> absorbance (an indicator of EC), PM<sub>10</sub>, and coarse PM were not associated with motor function in all of the same cohorts as NO<sub>2</sub>. Thus, confounding by these copollutants does not seem to fully explain the NO<sub>2</sub> associations. There was no clear pattern of association by gross or fine motor function or by age at which motor function was assessed. NO<sub>2</sub> was associated with poorer motor function among children ages 1–6 years in some locations but not others. The inconsistency in findings does not appear to depend on the adequacy of the LUR models to represent ambient NO<sub>2</sub> concentrations in the study area. LUR models showed a similar range in performance [cross-validation  $R^2 = 0.31$  to  $0.87$ ; ([Beelen et al., 2013](#); [Estarlich et al., 2011](#))] in locations where associations were observed and not observed. A limitation of the LUR models is that they were constructed based on ambient concentrations measured after the birth of some subjects. When the analysis was restricted to subjects whose birth dates coincided with the period of ambient monitoring, the effect estimate decreased; however, there was evidence of association between NO<sub>2</sub> and motor function for the combined cohorts ([Table 6-12](#)).

Results also are inconsistent for concurrent exposure. Among children ages 9–11 years, neither concurrent NO<sub>2</sub> nor noise exposure, alone or combined, at school or home, was associated with fine motor function ([van Kempen et al., 2012](#)). Among children age 4 years, higher concurrent outdoor home NO<sub>2</sub> exposure was associated with poorer gross motor function but not fine motor skills ([Freire et al., 2010](#)). Children attending schools with higher ambient NO<sub>2</sub> had poorer motor function compared to children attending schools with lower NO<sub>2</sub> ([Wang et al., 2009a](#)); however, attributing the findings to NO<sub>2</sub> versus another factor that differed between schools is not possible. Like home- or school-based exposure estimates, NO<sub>2</sub> exposure assessed from central sites was not

clearly associated with motor function in infants. Prenatal and lifetime exposure was inconsistently associated with motor function at 6 months of age, and no associations were observed in infants ages 12 to 24 months ([Kim et al., 2014](#); [Lin et al., 2014](#)).

Limited evidence from toxicological studies also shows mixed effects of NO<sub>2</sub> exposure on motor function. [Tabacova et al. \(1985\)](#) found deficits in motor function and postural gait in rat pups exposed gestationally to 50, 500, or 5,300 ppb NO<sub>2</sub> ([Table 6-13](#); 6 h/day, 7 days/week, GD 0–20). In the open field test, female and male animals exhibited retarded locomotor development, with stronger effects earlier in life (testing done until 3 months of age). On PND9, reductions were noted in horizontal motility and head raising with prolonged periods of immobility, hypotonia, tremor, and equilibrium deficits. Gait deficits including hindlimb dragging, crawling in lieu of walking, pivoting, and impaired body raising ability were observed out to PND14 even in animals in the lowest dose group. [Tabacova et al. \(1985\)](#) also found deficits in righting reflex and the auditory startle reflex. In a separate study, prenatal exposure to 1,500 or 3,000 ppb NO<sub>2</sub> [[Di Giovanni et al., 1994](#)]; dam exposure GD 0–20] did not have a statistically significant effect on motor function in 10- to 15-day-old male pups as measured by infrared sensors.

### **Psychological Distress**

The two available studies produced equivocal evidence for the effects of NO<sub>2</sub> exposure on psychological distress. Among children ages 9–10 years, an index of emotional, social, and conduct problems was not associated with concurrent NO<sub>2</sub> or with aircraft or road traffic noise at school, either alone or after mutual adjustment ([Clark et al., 2012](#)). In rats, [Di Giovanni et al. \(1994\)](#) reported that 3,000 ppb continuous NO<sub>2</sub> exposure of dams during GD 0–21 resulted in decreased pup vocalization, an indicator of emotionality, in males removed from the nest at PND5, PND10, or PND15.

### **Autism**

Autism is a neurodevelopmental disorder characterized by impaired social interaction, verbal and nonverbal communication deficits, and repetitive or stereotypic behavior. Although the causes of autism are not fully understood, genetic conditions, family history, and older parental age have been implicated as risk factors. Case-control studies in California, U.S. observed that higher NO<sub>2</sub> concentrations during the prenatal period and during the first year of life were associated with higher odds ratios for autism in children ages 24–71 months ([Becerra et al., 2013](#); [Volk et al., 2013](#)). In both studies, cases were identified from regional referral centers contracted by the Department of Developmental Services. Controls were selected as birth certificate records not having a matching record of autism with the referral centers. Controls were matched to cases by

age, sex, and wide geographic area. However, matching by area of residence was based only on birth addresses. These studies also observed stronger associations for autism among children with mothers with less than a high school education compared with higher education ([Becerra et al., 2013](#)) and children with the CC MET genotype compared with CC/GG genotype ([Volk et al., 2014](#)). The CC MET genotype is associated with decreased MET protein in the brain and has been associated with autism risk.

Between studies, inference about NO<sub>2</sub> is stronger in ([Becerra et al., 2013](#)). Residential NO<sub>2</sub> exposure was assessed using a well-validated LUR model [cross-validation  $R^2 = 0.87$ ; ([Su et al., 2009a](#))]. In contrast, [Volk et al. \(2013\)](#) examined central site ambient NO<sub>2</sub> concentrations and NO<sub>x</sub> estimated with a dispersion model. There are large uncertainties with these exposure measures. Central site NO<sub>2</sub> concentrations were assigned from a site 5 km from homes, if available, or by IDW over a 50-km area. The authors did not report what proportion of subjects were assigned NO<sub>2</sub> exposures at the 5-km or 50-km scale, but neither scale may adequately capture the spatial heterogeneity in NO<sub>2</sub> concentrations ([Section 3.2.3](#)). Inference is poor for NO<sub>x</sub> as it was nearly perfectly correlated ( $r \sim 0.99$ ) with EC and CO. In each study, PM<sub>2.5</sub> also was associated with autism, and ([Becerra et al., 2013](#)) found that NO<sub>2</sub> associations were robust to adjustment for PM<sub>2.5</sub> as well as the traffic-related copollutant CO. NO<sub>2</sub> associations also were robust to adjustment for O<sub>3</sub> or PM<sub>10</sub>. However, the reliability of the copollutant model results is uncertain as copollutant concentrations were assessed from central sites, and exposure measurement error likely varies between central site copollutant concentrations and residential estimates of NO<sub>2</sub>.

### **Neuronal Degeneration and Nervous System Oxidative Stress**

A recent study found that short-term NO<sub>2</sub> exposure induced neuronal degeneration and oxidative stress in the brains of adult male Wistar rats. Seven-day (6 h/day) exposure to 2,500–5,320 ppb NO<sub>2</sub> ([Li et al., 2012a](#)) had no effect on body weight; however, concentration-dependent reductions in brain-to-body-weight ratios were observed, with statistically significant differences at 5,320 ppb NO<sub>2</sub>. Histopathological analysis of cerebral cortex demonstrated a concentration-dependent increase in swollen or shrunken nuclei and a concentration-dependent, statistically significant increase in apoptotic cell number in all NO<sub>2</sub>-exposed rats. Statistically significant changes in antioxidant enzyme activities [Cu/zinc (Zn) SOD, MnSOD, and GPx], protein carbonyls, and malondialdehyde were observed in response to 5,320 ppb NO<sub>2</sub>. While rats exposed to 2,500 ppb NO<sub>2</sub> demonstrated a statistically significant increase in the protein level of p-53, rats exposed to the higher concentrations exhibited statistically significant increases in mRNA and protein levels of c-fos, c-jun, p-53, and bax. These results, especially at higher concentrations of NO<sub>2</sub>, are consistent with oxidative stress.

---

#### 6.4.4.2 Physical Development

Limited information from toxicological studies does not clearly indicate that NO<sub>2</sub> exposure affects physical postnatal development. Distinct exposure periods and test endpoints produced disparate results in two studies on postnatal body-weight gain in pups whose dams were exposed to NO<sub>2</sub>. Albino rats with prenatal exposures to 1,300 ppb NO<sub>2</sub> for 12 hours a day during the 3 months prior to breeding showed decrements in postnatal body weight at PND4 and 12 in ([Shalamberidze and Tsereteli, 1971a, b](#)). Continuous NO<sub>2</sub> exposure during gestation [continuous exposure of dam to 1,500 or 3,000 ppb NO<sub>2</sub>, GD 0–20; ([Di Giovanni et al., 1994](#))] produced no statistically significant differences in weight gain at PND1, 11, or 21 in male Wistar rat pups. [Tabacova et al. \(1985\)](#) saw concentration-dependent delays in eye opening and incisor eruption in rodents after maternal exposure to NO<sub>2</sub> during pregnancy (dam exposure: GD 0–21, 5 h/day, 25, 500 or 5,300 ppb NO<sub>2</sub>) ([Table 6-13](#)).

---

#### 6.4.4.3 Summary of Postnatal Development

The collective evidence does not consistently indicate a relationship between NO<sub>2</sub> exposure and effects on postnatal development. Very few outcomes were similar between epidemiologic and toxicological studies. Physical development, examined as postnatal weight gain, eye opening, and incisor eruption in only a few studies of rats, was not clearly affected by prenatal NO<sub>2</sub> exposures in the range of 500 to 5,320 ppb. As examined primarily in epidemiologic studies, prenatal, early life, or concurrent school-age NO<sub>2</sub> exposure was not consistently associated with cognitive function, attention-related behaviors, motor function, or psychological distress in infants or school children. While epidemiologic associations were observed for indoor home NO<sub>2</sub> ([Morales et al., 2009](#)), evidence is equivocal for ambient NO<sub>2</sub>, including exposure metrics spatially aligned with subjects' home and school locations using LUR models that well represented the spatial heterogeneity in the study areas ([Guxens et al., 2014](#); [van Kempen et al., 2012](#); [Freire et al., 2010](#)). In limited examination of children in California, U.S., autism was associated with residential prenatal NO<sub>2</sub> exposure ([Becerra et al., 2013](#)).

In addition to the inconsistent or limited evidence for NO<sub>2</sub>-related neurodevelopmental effects, there is uncertainty regarding confounding by factors spatially correlated with NO<sub>2</sub> at the level of individuals or communities. Studies observed associations with NO<sub>2</sub> with adjustment for SES indicators and birth outcomes. However, analysis of confounding was absent for stress and was very limited for smoking, noise, and traffic-related copollutants. Neurodevelopmental effects were associated with noise, PM<sub>2.5</sub>, and the traffic-related copollutants benzene and CO. There were observations of

NO<sub>2</sub>-associated memory decrements with adjustment for traffic noise and NO<sub>2</sub>-associated autism with adjustment for PM<sub>2.5</sub> or CO. The reliability of the copollutant model results is uncertain because of potential differential exposure measurement error between residential NO<sub>2</sub> and central site copollutant measurements. Other pollutants characterized to be associated with neurodevelopment such as lead or polycyclic aromatic hydrocarbons (U.S. EPA, 2013c, 2009b) were not examined as potential confounding copollutants. Toxicological evidence is far more limited than epidemiologic evidence and is similarly uncertain. Prenatal NO<sub>2</sub> exposure induced psychological distress (Di Giovanni et al., 1994) in rat offspring but showed mixed effects on motor function (Di Giovanni et al., 1994; Tabacova et al., 1985). Further, although some studies showed effects on postnatal development, there is very little information to propose possible modes of action for ambient-relevant NO<sub>2</sub> exposures. In a recent study of adult rats, short-term exposure to 5,320 ppb NO<sub>2</sub> induced increases in the neuronal apoptotic and oxidative stress markers (Li et al., 2012a), which have been linked to cognitive function.

**Table 6-13 Characteristics of toxicological studies of nitrogen dioxide exposure and reproductive and developmental effects.**

Reference	Species (Strain); Sample Size; Sex; Age	Exposure Details	Endpoints Examined
<a href="#">Kripke and Sherwin (1984)</a>	Rats (LEW/f mai); n = 6; M; young adult	1,000 ppb NO <sub>2</sub> for 7 h/day, 5 days/week for 21 days.	Spermatogenesis, germinal cells histology, testicular interstitial cell histology.
<a href="#">Shalamberidze and Tsereteli (1971a)</a> , <a href="#">Shalamberidze and Tsereteli (1971b)</a>	Rats (albino); n = 7; F; pup and adult	67 or 1,300 ppb NO <sub>2</sub> Exposure of dams for 12 h/day for 3 mo before pregnancy.	Litter size, birth weight, postnatal weight gain (body weight).
<a href="#">Tabacova et al. (1985)</a>	Rats (Wistar); n = 20; F; pup to adult	25, 50, 500, or 5,300 ppb NO <sub>2</sub> Exposure of dams for 5 h/day during GD 0–21	Pup viability, physical development (eye opening, incisor eruption); neuromotor (righting reflex, postural gait, geotaxis); hepatic lipid peroxidation; hepatic drug-metabolizing enzyme activity. Progeny followed up to PND60.
<a href="#">Di Giovanni et al. (1994)</a>	Rats (Wistar); n = 7; M; pup and adult	1,500 or 3,000 ppb NO <sub>2</sub> Exposure of dams continuously GD 0–20	Neurobehavior (ultrasonic vocalization), maternal body weight during pregnancy, litter size, postnatal body weight, early life mortality, motor function. Progeny tested for vocalizations on PND5, PND10, and PND15.

F = female; GD = gestational day; h = hour; M = male; mo = month; NO<sub>2</sub> = nitrogen dioxide; PND = postnatal day.

---

## 6.4.5 Summary and Causal Determination

Overall, the evidence is suggestive of, but not sufficient to infer, a causal relationship between exposure to NO<sub>2</sub> and birth outcomes and is inadequate to infer the presence or absence of a causal relationship between exposure to NO<sub>2</sub> and fertility, reproduction and pregnancy as well as postnatal development. Separate conclusions are made for these groups of reproductive and developmental effects because they are likely to have different etiologies and critical exposure patterns over different lifestages. At the time of the 2008 ISA for Oxides of Nitrogen, a limited number of epidemiologic and toxicological studies had assessed the relationship between NO<sub>2</sub> exposure and reproductive and developmental effects. The 2008 ISA concluded that there was not consistent evidence for an association between NO<sub>2</sub> and birth outcomes and that evidence was inadequate to infer the presence or absence of a causal relationship with reproductive and developmental effects overall ([U.S. EPA, 2008c](#)). The change in the causal determination for birth outcomes reflects the larger number of studies that observed associations with fetal growth restriction and the improved outcome assessment (e.g., measurements throughout pregnancy via ultrasound) and exposure assessment (e.g., well-validated LUR models) employed by these studies. The key evidence as it relates to the causal determinations is summarized in [Table 6-14](#) using the framework described in [Table II](#) of the [Preamble](#) to the ISA.

### **Fertility, Reproduction, and Pregnancy**

Relationships of outcomes related to fertility, reproduction, and pregnancy with NO<sub>2</sub> exposure have only recently been evaluated, and thus, the number of studies for any one endpoint is limited. One study ([Legro et al., 2010](#)) observed a decreased odds of live birth associated with higher NO<sub>2</sub> concentrations during ovulation induction and the period after embryo transfer; while another ([Slama et al., 2013](#)) observed decreased fecundability with higher NO<sub>2</sub> exposure near conception. Both studies assessed NO<sub>2</sub> exposure from central site monitors, and neither evaluated confounding by traffic-related copollutants. NO<sub>2</sub>-exposed rats showed impaired estrus cyclicity and a decrease in number of primordial follicles, which could indicate an effect on reproduction. There is inconsistent evidence for an association of NO<sub>2</sub> exposure estimated from well-validated LUR models with pre-eclampsia or reduced placental growth and function. Toxicological studies examined different effects on pregnancy and gave divergent results for NO<sub>2</sub>-related maternal weight gain during pregnancy and reduced litter size. There is generally no evidence for an effect of NO<sub>2</sub> exposure on sperm quality in either epidemiologic or toxicological studies. Collectively, the limited evidence is of

insufficient consistency and is inadequate to infer a causal relationship between NO<sub>2</sub> exposure and effects on fertility, reproduction, and pregnancy.

### **Birth Outcomes**

While the collective evidence for many of the birth outcomes examined is not entirely consistent, there are several well-designed, well-conducted studies that indicate an association between NO<sub>2</sub> and poorer birth outcomes, particularly fetal growth restriction. For example, the Spanish cohort that used anthropometric fetal measurements throughout pregnancy ([Iñiguez et al., 2012](#); [Estarlich et al., 2011](#); [Aguilera et al., 2010](#); [Ballester et al., 2010](#)) observed small, yet consistent associations with impaired fetal growth. Some studies of fetal growth restriction demonstrated that LUR models used to estimate NO<sub>2</sub> exposure predicted well ambient NO<sub>2</sub> concentrations in the study areas. Studies that examined PTB, birth weight, birth defects, and infant mortality had inconsistent results (i.e., positive and null associations). For PTB, many associations very close to the null value. Several different methods for exposure assessment were used in studies of birth outcomes, and results were inconsistent across methods. Generally, studies of birth outcomes did not evaluate confounding by PM<sub>2.5</sub> or other traffic-related pollutants, resulting in uncertainty in an independent effect of NO<sub>2</sub> exposure. NO<sub>2</sub>-related decrements in rat pup birth weight were reported in a toxicology study ([Shalamberidze and Tsereteli, 1971a](#)), which provides limited support for the associations with fetal growth restriction observed in epidemiologic studies. Collectively, the epidemiologic evidence for fetal growth restriction but uncertainty regarding an independent effect of NO<sub>2</sub> exposure is suggestive of, but not sufficient to infer, a causal relationship between NO<sub>2</sub> exposure and effects on birth outcomes.

### **Postnatal Development**

There is inconsistent evidence from both epidemiologic and toxicological studies for a relationship between prenatal and childhood NO<sub>2</sub> exposure and effects on postnatal development. Findings across the several recent epidemiologic studies of neurodevelopment do not consistently support associations of NO<sub>2</sub> with cognitive function, attention-related behaviors, motor function, or psychological distress in children. Many of these studies estimate ambient NO<sub>2</sub> exposures for children's homes or schools using LUR models that predicted well ambient NO<sub>2</sub> concentrations in study areas. NO<sub>2</sub> exposures were related to autism in children in recent epidemiologic studies, but such findings are limited to a few studies. In the small group of epidemiologic studies observing associations with neurodevelopmental effects, examination of confounding by noise, stress, or traffic-related copollutants was absent or unreliable. Toxicological

evidence for effects on neurodevelopment also is limited and mixed. NO<sub>2</sub> exposure impaired vocalization of rat pups in one study but did not affect motor function (e.g., startle and righting reflex, postural gait, impaired walking, head raising) consistently. Toxicological evidence for impaired physical development as well is mixed. Collectively, the evidence is of insufficient consistency or quantity and is inadequate to infer a causal relationship between exposure to NO<sub>2</sub> and effects on postnatal development.

**Table 6-14 Summary of evidence supporting the causal determinations for relationships between long-term nitrogen dioxide exposure and reproductive and developmental effects.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
<b>Fertility, Reproduction, and Pregnancy—Inadequate to Infer a Causal Relationship</b>			
Inconsistent epidemiologic evidence for pre-eclampsia	Inconsistent associations when NO <sub>2</sub> exposure is assessed across entire pregnancy and after adjustment for many potential confounders. Uncertainty regarding potential confounding by traffic-related copollutants.	† <a href="#">Dadvand et al. (2013)</a> , † <a href="#">van den Hooven et al. (2011)</a> , † <a href="#">Pereira et al. (2013)</a> <a href="#">Section 6.4.2.3</a>	Association with mean 31 ppb for trimester avg No association with means 21.2, 23.0, and 30 ppb for pregnancy-avg
Inconsistent epidemiologic and toxicological evidence for other pregnancy-related effects	Limited and inconsistent epidemiologic evidence for associations with pregnancy-induced hypertension and placental growth and function.	† <a href="#">Hampel et al. (2011)</a> , † <a href="#">Lee et al. (2012b)</a> , † <a href="#">Mobasher et al. (2013)</a> , † <a href="#">Xu et al. (2014)</a> , † <a href="#">van den Hooven et al. (2012b)</a> <a href="#">Section 6.4.2.3</a>	Inconsistent associations Mean: 10.9, 11.5 ppb for 7-day avg Means: 18.7–30 ppb for trimester-avg Mean: 21.2 for pregnancy-avg
	No effect in rats on maternal weight gain during pregnancy.	<a href="#">Di Giovanni et al. (1994)</a> <a href="#">Section 6.4.2.3</a>	1,500 and 3,000 ppb for 21 days
Inconsistent epidemiologic evidence for in vitro fertilization failure	Decreased odds of live birth associated with higher NO <sub>2</sub> concentrations during ovulation induction and the period after embryo transfer.	† <a href="#">Legro et al. (2010)</a> , † <a href="#">Slama et al. (2013)</a> <a href="#">Section 6.4.2.2</a>	Mean: 19 ppb for 3.6- to 200-day avg Median: 19 ppb for 1 mo-avg
Lack of supporting epidemiologic and toxicological evidence for effects on sperm	Limited number of toxicological and epidemiologic studies provide no evidence for effects on sperm count or motility, spermatogenesis.	Rats: <a href="#">Kripke and Sherwin (1984)</a> Humans: † <a href="#">Rubes et al. (2010)</a> , <a href="#">Sokol et al. (2006)</a> <a href="#">Section 6.4.2.1</a>	Rats: 1,000 ppb for 21 days Humans: Mean 16.8 ppb for 90-day avg, 30.1 for 24-h avg

**Table 6-14 (Continued): Summary of evidence supporting the causal determinations for relationships between long-term nitrogen dioxide exposure and reproductive and developmental effects.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
Limited evidence for key events in proposed mode of action	Impaired estrus cyclicity and decreased number of primordial follicles in rats.	<a href="#">Shalamberidze and Tsereteli (1971a)</a> <a href="#">Section 6.4.2.2</a>	1,300 ppb for 3 mo before pregnancy
<b>Birth Outcomes—Suggestive of, but Not Sufficient to Infer, a Causal Relationship</b>			
Evidence from multiple epidemiologic studies of fetal growth restriction is generally supportive but not entirely consistent	Strongest evidence from well-conducted Spanish cohort studies that observe associations with fetal growth restriction. Some demonstrate LUR model to predict well ambient NO <sub>2</sub> concentrations. Supported by consistent evidence for SGA and IUGR. Outcomes assessed with anthropometric fetal measurements.	† <a href="#">Aguilera et al. (2010)</a> , † <a href="#">Iñiguez et al. (2012)</a> , † <a href="#">Estarlich et al. (2011)</a> , † <a href="#">Ballester et al. (2010)</a> <a href="#">Section 6.4.3.1</a>	Mean trimester-avg: 7.8–36.1 ppb
Limited and inconsistent epidemiologic evidence for other birth outcomes	Some studies observe an association with PTB, birth weight, birth defects, and infant mortality while other studies observe no consistent pattern of association.	<a href="#">Section 6.4.3.2</a> , <a href="#">Section 6.4.3.3</a> , <a href="#">Section 6.4.3.4</a> , <a href="#">Section 6.4.3.5</a>	Mean trimester-avg (PTB): 8.8–37.6 ppb Mean trimester-avg (birth weight): 6.2–62.7 ppb Mean early pregnancy avg (birth defects): 8.2–28.0 ppb Mean 24-h avg (infant mortality): 20.3–50.3 ppb
Limited and inconsistent toxicological evidence with relevant NO <sub>2</sub> exposures	Mixed evidence for effects on litter size and late embryonic lethality in rats.	<a href="#">Shalamberidze and Tsereteli (1971a)</a> , <a href="#">Di Giovanni et al. (1994)</a> , <a href="#">Tabacova et al. (1985)</a> <a href="#">Section 6.4.3.3</a> and <a href="#">Section 6.4.3.5</a>	1,300 ppb for 3 mo, 500 and 5,300 ppb for 20 days, 1,500 and 3,000 ppb for 21 days
Weak evidence for key events in proposed mode of action Inflammation	Increase in C-reactive protein concentration in human umbilical cord blood but not maternal blood.	† <a href="#">van den Hooven et al. (2012a)</a> <a href="#">Section 6.4.2.3</a>	Mean 1-week avg before delivery: 21.4 ppb

**Table 6-14 (Continued): Summary of evidence supporting the causal determinations for relationships between long-term nitrogen dioxide exposure and reproductive and developmental effects.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
<b>Postnatal Development—Inadequate to Infer a Causal Relationship</b>			
Limited and inconsistent epidemiologic and toxicological evidence for effects on neurodevelopment	Some but not all epidemiologic studies showed associations with cognitive function decrements in infants and schoolchildren.	† <a href="#">van Kempen et al. (2012)</a> , † <a href="#">Morales et al. (2009)</a> , † <a href="#">Guxens et al. (2012)</a> No association: † <a href="#">Clark et al. (2012)</a> , † <a href="#">Freire et al. (2010)</a> , † <a href="#">Guxens et al. (2014)</a> <a href="#">Section 6.4.4.1</a>	Mean concurrent: 16.5, 16.4 ppb Mean prenatal: 15.7 ppb
	Inconsistent evidence NO <sub>2</sub> exposures estimated for children’s homes or schools using LUR models that predict well study area ambient NO <sub>2</sub> concentrations.		
	Uncertainty regarding potential confounding by traffic-related copollutants.		
	More limited and inconsistent epidemiologic evidence for attention-related behaviors, motor function, psychological distress.	<a href="#">Section 6.4.4.1</a>	
	Increased emotionality in rat pups, but effects on motor function inconsistent with prenatal exposure.	<a href="#">Tabacova et al. (1985)</a> , <a href="#">Di Giovanni et al. (1994)</a> <a href="#">Section 6.4.4.1</a>	50–5,300 ppb for 20 days, 1,500 and 3,000 ppb for 21 days
Prenatal NO <sub>2</sub> exposure associated with early childhood autism in California, U.S.	† <a href="#">Becerra et al. (2013)</a> <a href="#">Section 6.4.4.1</a>	Mean: 30.8 ppb	
Limited evidence for key events in proposed mode of action. Increased apoptotic factors and oxidative stress in brain of adult rats.	† <a href="#">Li et al. (2012a)</a> <a href="#">Section 6.4.4.1</a>	2,500 and 5,320 ppb for 7 days	
Limited and inconsistent toxicological evidence for physical development	Delayed postnatal eye opening and incisor eruption but mixed effects on postnatal growth.	<a href="#">Tabacova et al. (1985)</a> , <a href="#">Di Giovanni et al. (1994)</a> <a href="#">Section 6.4.4.2</a>	500 and 5,300 ppb for 20 days, 1,500 and 3,000 ppb for 21 days

avg = average; NO<sub>2</sub> = nitrogen dioxide; PTB = preterm birth; SGA = small for gestational age; IUGR = intrauterine growth restriction.

<sup>a</sup>Based on aspects considered in judgments of causality and weight of evidence in causal framework in [Tables I](#) and [II](#) of the [Preamble](#).

<sup>b</sup>Describes the key evidence and references, supporting or contradicting, contributing most heavily to causal determination and, where applicable, to uncertainties or inconsistencies. References to earlier sections indicate where full body of evidence is characterized.

<sup>c</sup>Describes the NO<sub>2</sub> concentrations with which the evidence is substantiated (for experimental studies, ≤ 5,000 ppb).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

---

## 6.5 Total Mortality

### 6.5.1 Introduction and Review of Evidence from 2008 Integrated Science Assessment for Oxides of Nitrogen

At the time of the 2008 ISA for Oxides of Nitrogen, a limited number of epidemiologic studies had assessed the relationship between long-term exposure to NO<sub>2</sub> and mortality in adults, including cause-specific and total mortality. The 2008 ISA concluded that the evidence was “inadequate to infer the presence or absence of a causal relationship” ([U.S. EPA, 2008c](#)). In this ISA, findings for cause-specific mortality (i.e., respiratory, cardiovascular) are used to assess the continuum of effects and inform the causal determinations for respiratory and cardiovascular effects. The causal determination for total mortality contained herein ([Section 6.5](#)) is based primarily on the evidence for nonaccidental mortality but also is informed by the extent to which evidence for the spectrum of cardiovascular and respiratory effects provides biological plausibility for NO<sub>2</sub>-related total mortality. The exposure assessment method was an important consideration in the evaluation of long-term exposure and mortality, given the spatial variability typically observed in ambient NO<sub>2</sub> concentrations ([Section 2.5.3](#)). Exposure assessment was evaluated drawing upon discussions in [Section 3.2](#) and [Section 3.4.5](#). Several recent studies of long-term exposure to NO<sub>2</sub> and mortality employed exposure assessment methods to account for the spatial variability of NO<sub>2</sub>. For example, LUR model predictions have been found to correlate well with outdoor NO<sub>2</sub> concentration measurements ([Section 3.2.2.1](#)). For long-term NO<sub>2</sub> exposure, exposure assessment was evaluated by the extent to which the method represented the spatial variability in NO<sub>2</sub> concentrations in a given study. [Supplemental Table S6-9 \(U.S. EPA, 2013n\)](#) provides an overview of the epidemiologic studies of long-term exposure to NO<sub>2</sub> or NO<sub>x</sub> and mortality, including details on exposure assessment and mean concentrations from the study locations.

Two seminal studies of long-term exposure to air pollution and mortality among adults have been conducted in the United States; the American Cancer Society (ACS) and the Harvard Six Cities (HSC) cohorts have undergone extensive independent re-analyses and have reported extended results including additional years of follow-up. The initial reports from the ACS ([Pope et al., 1995](#)) and the HSC ([Dockery et al., 1993](#)) studies did not include results for gaseous pollutants. However, as reported in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), in re-analyses of these studies, [Krewski et al. \(2000\)](#) examined the association between gaseous pollutants, including NO<sub>2</sub>, and mortality. [Krewski et al. \(2000\)](#) observed a positive association between long-term exposure to NO<sub>2</sub>

and mortality in the HSC cohort, with effect estimates<sup>1</sup> similar in magnitude to those observed with PM<sub>2.5</sub>. The effect estimates were positive for various causes of mortality but were the strongest for cardiopulmonary and total mortality. In a re-analysis of the ACS cohort data ([Krewski et al., 2000](#)), long-term exposure to NO<sub>2</sub> estimated from central site monitors was not associated with mortality. An extended study of the ACS cohort ([Pope et al., 2002](#)) doubled the follow-up time and tripled the number of deaths compared to the original study but still observed no association between long-term exposure to NO<sub>2</sub> and mortality.

A series of studies ([Lipfert et al., 2006a](#); [Lipfert et al., 2006b](#); [Lipfert et al., 2003](#), [2000](#)) characterized a national cohort of over 70,000 male U.S. military veterans who were diagnosed as having hypertension in the mid-1970s and were followed through 2001. In the earlier studies, the authors reported increased risk of mortality associated with exposure to NO<sub>2</sub>; these excess risks were in the range of 5–9% ([Lipfert et al., 2003](#), [2000](#)). In the later studies, the authors focused on traffic density in this cohort. [Lipfert et al. \(2006b\)](#) and [Lipfert et al. \(2006a\)](#) reported that traffic density was a better predictor of mortality than NO<sub>2</sub>, though they still observed a positive association between mortality and NO<sub>2</sub> exposure. The results from the series of studies characterizing the Veterans cohort are indicative of a traffic-related air pollution effect on mortality, but the study population (lower SES, males with hypertension and a very high smoking rate) was not representative of the general U.S. population.

In another cohort conducted in the U.S. [the California Seventh-Day Adventist cohort (AHSMOG)], [Abbey et al. \(1999\)](#) enrolled young adult, nonsmoking Seventh-Day Adventists throughout California. Generally, NO<sub>2</sub> was not associated with total, cardiopulmonary, or respiratory mortality in either men or women. The authors observed large risk estimates for lung cancer mortality for most of the air pollutants examined, including NO<sub>2</sub>, but the number of lung cancer deaths in this cohort was very small (12 for females and 18 for males out of a total of 5,652 subjects); therefore, it is difficult to interpret these results.

Several studies conducted in European countries have examined the relationship between long-term exposure to traffic-related pollutants (including NO<sub>2</sub> and NO<sub>x</sub>) and mortality among adults. [Hoek et al. \(2002\)](#) observed an association between NO<sub>2</sub> and mortality in the Netherlands Cohort Study on Diet and Cancer (NLCS), though the association with living near a major road was stronger in magnitude. On the other hand, [Gehring et al. \(2006\)](#) observed that NO<sub>2</sub> was generally more strongly associated with mortality than an

---

<sup>1</sup> Quantitative effect estimates from studies reviewed in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) can be found alongside effect estimates from more recent studies in [Figure 6-8](#), [Figure 6-9](#), and [Figure 6-10](#) (and in corresponding [Table 6-15](#), [Table 6-16](#), and [Table 6-17](#) respectively).

indicator for living near a major road in a cohort of women from Germany. Results from the Air Pollution and Chronic Respiratory Diseases survey conducted in France, demonstrated increased risk between long-term exposure to NO<sub>2</sub> and total, cardiopulmonary, and lung cancer mortality ([Filleul et al., 2005](#)). Similarly, [Nafstad et al. \(2004\)](#) observed an association between NO<sub>x</sub> and total mortality, as well as deaths due to respiratory causes, lung cancer, and ischemic heart disease in a cohort of Norwegian men. [Nyberg et al. \(2000\)](#) observed similar results for lung cancer mortality in a case-control study of men in Stockholm, Sweden. [Naess et al. \(2007\)](#) investigated the concentration-response relationships between NO<sub>2</sub> and cause-specific mortality among a cohort from Oslo, Norway, aged 51–90 years. Total mortality, as well as death due to cardiovascular causes, lung cancer, and COPD were associated with NO<sub>2</sub> for both men and women in two different age groups, 51–70 and 71–90 years. [Naess et al. \(2007\)](#) reported that the effects appeared to increase at NO<sub>2</sub> levels higher than 21 ppb in the younger age group (with little evidence of an association below 21 ppb), while a linear effect was observed between 10 and 31 ppb in the older age group.

The results from these studies led to the conclusion that the evidence was inadequate to infer the presence or absence of a causal relationship in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)). The 2008 ISA also noted that potential confounding by copollutants was an important uncertainty when interpreting the evidence for the association between long-term exposure to NO<sub>2</sub> and mortality. Collinearity among criteria pollutants is another uncertainty that needs to be considered; several studies reported moderate-to-high correlations between NO<sub>2</sub> and PM indices (i.e., >0.5). The 2008 ISA acknowledged that NO<sub>2</sub> could be serving primarily a surrogate or marker for traffic-related pollution. These uncertainties do not preclude the possibility of an independent effect of NO<sub>2</sub> or of NO<sub>2</sub> playing a role in interactions among traffic-related pollutants.

---

### 6.5.2 Recent Evidence for Mortality from Long-Term Exposure to Oxides of Nitrogen

Several recent studies provide extended analyses of existing cohort studies of adult populations. Because it is unknown whether early life mortality follows similar biological pathways or modes of action to adult mortality, studies on early life mortality are discussed in [Section 6.4.3](#). In a re-analysis that extended the follow-up period for the ACS cohort to 18 years (1982–2000), [Krewski et al. \(2009\)](#) reported generally null associations between long-term exposure to NO<sub>2</sub> estimated from central site monitors and total and cause-specific mortality, similar to what was reported in the initial reanalysis of this cohort ([Krewski et al., 2000](#)). In an update to the ACS study including cohort

members residing in California, [Jerrett et al. \(2013\)](#) estimated long-term (i.e., 15 years) exposures to NO<sub>2</sub> at the home addresses of each of the cohort members using LUR models that predicted well ambient NO<sub>2</sub> concentrations in the study area (cross-validation R<sup>2</sup> = 0.71). The authors observed positive associations between predicted NO<sub>2</sub> exposures and total, CVD, IHD, stroke, and lung cancer mortality, but not for respiratory mortality. The strongest associations were observed for deaths due to lung cancer and stroke. The associations with CVD and IHD mortality were attenuated in copollutant models that included PM<sub>2.5</sub> (also estimated from an LUR model with similar predictive capacity), while the association with lung cancer was generally unchanged in copollutant models. In an update to the Veterans cohort study, [Lipfert et al. \(2009\)](#) looked at markers for specific emission sources, including NO<sub>x</sub> as a marker of traffic, and their relationship with mortality, using a 26-year follow-up period now available for this cohort. The authors observed an association between long-term exposures to NO<sub>x</sub> estimated from a plume-in-grid model and mortality, and noted that this association was stronger among men living in areas with high traffic density compared to men living in areas with lower traffic density. The authors also demonstrate that traffic-related air pollutants (including NO<sub>x</sub>) are better predictors of mortality than a measure of traffic density in this cohort. Updated results also were reported for the NLCS cohort [the same effect estimates are reported by both [Beelen et al. \(2008b\)](#) and [Brunekreef et al. \(2009\)](#)]. Consistent with previous results from this cohort, the authors observe an association with total mortality. In the updated results, the authors observe the strongest effect between long-term exposure to NO<sub>2</sub> estimated from central site monitors and respiratory mortality; this association is stronger than any observed with the traffic variables and total or cause-specific mortality.

In updates to a cohort of women in Germany ([Gehring et al., 2006](#)), [Schikowski et al. \(2007\)](#) observed a positive association between ambient NO<sub>2</sub> concentrations measured at central site monitors and cardiovascular mortality among older women, though this association was not modified by lung function status (i.e., normal versus impaired lung function). [Heinrich et al. \(2013\)](#) included five additional years of follow-up and twice as many fatalities compared to the original analysis. In the updated analyses, the authors observed positive associations between NO<sub>2</sub> concentrations measured at central site monitors and total and cardiopulmonary mortality. The effect estimates were highest for women living within 50 m of a road with median daily traffic volume of 5,000 cars or greater. The effect estimates for the associations between total and cardiopulmonary mortality and NO<sub>2</sub> were generally lower for the follow-up period compared to the original analysis.

Several recent U.S. cohort studies examined the association between long-term exposures to NO<sub>2</sub> and mortality in occupational cohorts. [Hart et al. \(2011\)](#) examined the association between residential exposure to NO<sub>2</sub> estimated from a spatial smoothing model and

mortality among men in the U.S. trucking industry in the Trucking Industry Particle Study (TriPS). The authors observed an increase in cardiovascular disease mortality and a decrease in COPD mortality associated with NO<sub>2</sub> exposure. The association between NO<sub>2</sub> exposure and total mortality was robust to the inclusion of PM<sub>10</sub> or SO<sub>2</sub> in copollutant models. This association was stronger when the cohort was restricted to truck drivers that maintained local routes, and long haul drivers were excluded. COPD mortality was positively associated with NO<sub>2</sub> exposure in the sensitivity analysis excluding long haul drivers. The associations for other causes of death (i.e., lung cancer, IHD, respiratory disease) were generally positive. Another recent U.S. cohort study, The California Teachers Study ([Lipsett et al., 2011](#)) examined the association between long-term exposure to NO<sub>x</sub> and NO<sub>2</sub> measured at central site monitors and mortality among current and former female public school teachers. The authors observed the strongest associations between IHD mortality and exposure to NO<sub>x</sub> and NO<sub>2</sub>; the associations for other causes of death (i.e., CVD, cerebrovascular, respiratory, lung cancer, and total) were less consistent and generally close to the null value. [Hart et al. \(2013\)](#) examined the association between long-term exposure to NO<sub>2</sub> and total mortality among a cohort of female nurses in the Nurses' Health Study. The authors used spatial modeling to estimate exposure to NO<sub>2</sub> and observed a small increase in the risk of total mortality. In a sensitivity analysis examining women that moved during study follow-up, the authors observed even higher risks among women that moved to areas with higher concentrations of NO<sub>2</sub>.

A number of recent studies examined the association between long-term exposure to NO<sub>2</sub> and mortality in Canadian cities. All three studies estimated long-term NO<sub>2</sub> exposure using well-validated LUR models (predicted versus measured: R<sup>2</sup> = 0.90 for Toronto, Ontario, R<sup>2</sup> = 0.69, 0.44 for Vancouver, British Columbia, 1–7% difference for Hamilton, Ontario, 4% difference for Windsor, Ontario). [Chen et al. \(2013a\)](#) conducted a cohort study in three cities in Ontario and observed that long-term exposure to NO<sub>2</sub> was associated with an increased risk of cardiovascular mortality. The association was stronger when mortality from IHD was evaluated separately. In a single-city study conducted in Toronto, Ontario, [Jerrett et al. \(2009\)](#) examined subjects from a respiratory clinic and observed positive associations with total and circulatory mortality. The associations with respiratory and lung cancer mortality were also positive, though less precise. In a model that included both NO<sub>2</sub> and proximity to traffic, the effect estimate for NO<sub>2</sub> remained robust, and the effect attributable to traffic was attenuated. [Gan et al. \(2013\)](#) and [Gan et al. \(2011\)](#) conducted a single-city, population-based cohort study in Vancouver, British Columbia to evaluate the association between traffic-related pollutants and risk of mortality due to CHD and COPD, respectively. LUR models were used to estimate exposure over a 5-year period, (1994–1998) and the cohort was followed for 4 years (1999–2002). The authors observed the strongest associations (i.e., highest

magnitude) for exposures to NO<sub>2</sub> and CHD mortality; however, these associations were greatly attenuated when PM<sub>2.5</sub> or BC were included in the model. The correlations between NO<sub>2</sub> and PM<sub>2.5</sub> and BC were low to moderate ( $r < 0.5$ ), and LUR models for PM<sub>2.5</sub> and BC showed poorer predictive accuracy. The authors observed positive associations between both NO and NO<sub>2</sub> concentrations and COPD mortality, which were slightly attenuated when PM<sub>2.5</sub> or BC were included in the model.

A recent multicenter European study pooled data from 22 existing cohort studies and used a strictly standardized protocol to investigate the associations between long-term concentrations of NO<sub>2</sub> and NO<sub>x</sub> and total ([Beelen et al., 2014a](#)), respiratory ([Dimakopoulou et al., 2014](#)), and cardiovascular ([Beelen et al., 2014b](#)) mortality. The authors used LUR models to assign exposure and observed generally null associations with total, respiratory, and cardiovascular mortality. For most cohorts, LUR models were shown to predict well ambient NO<sub>2</sub> concentrations (cross-validation  $R^2 = 0.46-0.87$ ). In copollutant models, the total mortality null associations did not change after adjustment for PM<sub>2.5</sub> or PM<sub>10-2.5</sub>.

Several studies examined the association between long-term exposure to NO<sub>2</sub> and mortality in England. [Carey et al. \(2013\)](#) conducted a cohort study using an emissions-based model to assign exposure. Model validation was good (cross-validation  $R^2 = 0.57-0.80$ ), and model estimates for NO<sub>2</sub> were highly correlated with PM<sub>10</sub> and PM<sub>2.5</sub> ( $r = 0.9$ ). The authors observed positive associations with total mortality; these associations were stronger for respiratory and lung cancer deaths, and somewhat attenuated when restricted to cardiovascular deaths. [Tonne and Wilkinson \(2013\)](#) evaluated the association between long-term exposure to NO<sub>2</sub> and NO<sub>x</sub> estimated from a Gaussian dispersion model among survivors of hospital admissions for acute coronary system in England and Wales and observed evidence of a null association after adjustment for PM<sub>2.5</sub>. In a single-city study, [Maheswaran et al. \(2010\)](#) compiled a cohort of stroke survivors and estimated NO<sub>2</sub> exposures from an emissions model across London, U.K. Modeled NO<sub>2</sub> concentrations were well correlated with measurements at 56 sites ( $r = 0.91$ ). The authors observed a nearly 30% increase in total mortality per 10-ppb increase in exposure to NO<sub>2</sub>.


Rome, Italy was the setting for a number of single-city cohort studies. [Cesaroni et al. \(2013\)](#) observed positive associations between long-term exposure to NO<sub>2</sub> estimated from an LUR model and total, cardiovascular, IHD, respiratory, and lung cancer mortality among the adult population in the Rome Longitudinal Study (RoLS). As examined for total mortality, the association was robust to the inclusion of PM<sub>2.5</sub> in the model. The modeled estimates for both NO<sub>2</sub> (cross-validation  $R^2 = 0.61$ ) and PM<sub>2.5</sub> ( $r = 0.83$ ) agreed well with measured concentrations in the study area, but NO<sub>2</sub> and PM<sub>2.5</sub> were highly

correlated ( $r = 0.79$ ). Later, these authors used several different LUR models to predict  $\text{NO}_2$  in Rome, Italy ([Cesaroni et al., 2012](#)) and observed that the modest, positive association between total mortality and  $\text{NO}_2$  concentrations was consistent across all models evaluated. [Rosenlund et al. \(2008b\)](#) conducted a cohort study in Rome, Italy to investigate the effects of long-term exposure to  $\text{NO}_2$  and cardiovascular deaths, including mortality among previous MI survivors. The authors observed a positive association between long-term exposures to  $\text{NO}_2$  estimated from an LUR model and fatal coronary events, though they did not observe an association with mortality among survivors of a first coronary event. Modeled  $\text{NO}_2$  estimates correlated well ( $r = 0.77$ ) with measurements, but exposures were estimated at the level of census blocks.

A Danish study evaluated the association between long-term exposure to  $\text{NO}_2$  (estimated from a dispersion model) and diabetes-related mortality ([Raaschou-Nielsen et al., 2013b](#)). The authors reported a 30% increase in risk of diabetes-related mortality associated with  $\text{NO}_2$  concentrations. In Brisbane, Australia, [Wang et al. \(2009b\)](#) examined the association between long-term exposure to  $\text{NO}_2$  estimated from central site monitors and cardiorespiratory mortality. The relative risk for  $\text{NO}_2$  and cardiorespiratory mortality was near the null value.

A number of studies were conducted in Asian countries to evaluate the association between long-term-exposure to  $\text{NO}_2$  and mortality. In a national study covering 16 provinces in eastern China, [Cao et al. \(2011\)](#) observed positive associations between ambient  $\text{NO}_x$  concentrations from central site monitors and total, cardiovascular, respiratory, and lung cancer mortality. The association between total mortality and  $\text{NO}_x$  was relatively unchanged in a copollutant model with total suspended particles (TSP) but was reduced by half in a copollutant model with  $\text{SO}_2$ . The associations between  $\text{NO}_x$  and cardiovascular, respiratory, and lung cancer mortality were all attenuated in copollutant models including either TSP or  $\text{SO}_2$ . In a single-city study in Shenyang, China, the authors observed a strong, positive association between long-term exposure to  $\text{NO}_2$  estimated from central site monitors and respiratory ([Dong et al., 2012](#)), total, cardiovascular, and cerebrovascular ([Zhang et al., 2011](#)) mortality. In Shizuoka, Japan, [Yorifuji et al. \(2010\)](#) observed positive associations between  $\text{NO}_2$  estimated from an LUR model and total, cardiopulmonary, IHD, and respiratory disease mortality, with the strongest effects observed for IHD mortality. When the analysis was restricted to nonsmokers, a positive association was observed with lung cancer mortality. Similar observations were reported for lung cancer by [Katanoda et al. \(2011\)](#) among a cohort in Tokyo, Japan, and [Liu et al. \(2008\)](#) for a study of women living in Taiwan. In a related study, [Liu et al. \(2009a\)](#) also observed a positive association between long-term exposure to  $\text{NO}_2$  and bladder cancer mortality.

The quantitative results of mortality studies are characterized in [Figure 6-8](#), [Figure 6-9](#), and [Figure 6-10](#); and [Table 6-15](#), [Table 6-16](#), and [Table 6-17](#).



Note: ACS = American Cancer Society; AHSMOG = California Seventh-Day Adventists Cohort; CA = California; CI = confidence interval; ESCAPE = European Study of Cohorts for Air Pollution Effects; HSC = Harvard Six Cities; NLCS = Netherlands Cohort Study on Diet and Cancer; NLCS-AIR = Netherlands Cohort Study on Air Pollution and Mortality; PAARC = Air Pollution and Chronic Respiratory Diseases; RoLS = Rome Longitudinal Study; TriPS = Trucking Industry Particle Study. Black = studies from the 2008 Integrated Science Assessment for Oxides of Nitrogen; Red = recent studies and those not included in 2008 Integrated Science Assessment. Circles = NO<sub>2</sub>; triangles = NO<sub>x</sub>. Studies are presented in descending order of mean concentration.

<sup>a</sup>Hazard ratios are standardized to a 10-ppb increase in NO<sub>2</sub> and a 20-ppb increase in NO<sub>x</sub> concentration.

<sup>b</sup>Effect estimates from studies measuring NO<sub>x</sub> in µg/m<sup>3</sup> are not standardized.

**Figure 6-8 Association between long-term exposure to oxides of nitrogen and total mortality.**

**Table 6-15 Corresponding risk estimates for Figure 6-8.**

Study	Location	Notes	Hazard Ratio (95% CI) <sup>a</sup>
<a href="#">Abbey et al. (1999)</a>	U.S.	Men Women	1.02 (0.95, 1.08) 0.99 (0.94, 1.05)
† <a href="#">Lipsett et al. (2011)</a>	California, U.S.	Women, NO <sub>2</sub> Women, NO <sub>x</sub>	0.97 (0.94, 1.05) 1.02 (0.98, 1.06)
<a href="#">Krewski et al. (2000)</a>	U.S.		0.99 (0.99, 1.00)
† <a href="#">Cao et al. (2011)</a>	China	NO <sub>x</sub>	1.02 (1.00, 1.03) <sup>b</sup>
<a href="#">Filleul et al. (2005)</a>	France	24 areas 18 areas	0.98 (0.96, 1.00) 1.22 (1.10, 1.34)
† <a href="#">Zhang et al. (2011)</a>	China		5.39 (4.94, 5.94)
† <a href="#">Cesaroni et al. (2012)</a>	Italy		1.07 (1.05, 1.11)
† <a href="#">Cesaroni et al. (2013)</a>	Italy		1.06 (1.04, 1.06)
† <a href="#">Tonne and Wilkinson (2013)</a>	England and Wales, U.K.	NO <sub>x</sub>	1.03 (1.01, 1.05) <sup>b</sup>
<a href="#">Lipfert et al. (2000)</a>	U.S.		1.07 (1.04, 1.10)
† <a href="#">Maheswaran et al. (2010)</a>	England, U.K.	Stroke survivors	1.59 (1.22, 2.09)
<a href="#">Pope et al. (2002)</a>	U.S.		1.00 (0.98, 1.02)
<a href="#">Lipfert et al. (2006b)</a>	U.S.		1.03 (0.98, 1.02)
† <a href="#">Brunekreef et al. (2009)</a>	the Netherlands	Full cohort Case cohort	1.05 (1.00, 1.10) 0.92 (0.79, 1.06)
<a href="#">Gehring et al. (2006)</a>	Germany	1-yr avg 5-yr avg	1.20 (1.02, 1.41) 1.23 (1.02, 1.47)
† <a href="#">Heinrich et al. (2013)</a>	Germany		1.21 (1.08, 1.36)
<a href="#">Hoek et al. (2002)</a>	the Netherlands		1.15 (0.89, 1.49)
† <a href="#">Jerrett et al. (2009)</a>	Canada		1.48 (1.00, 2.16)
<a href="#">Lipfert et al. (2006a)</a>	U.S.		1.04 (0.97, 1.13)
† <a href="#">Hart et al. (2011)</a>	U.S.	Full cohort Excluding long haul drivers	1.10 (1.06, 1.15) 1.19 (1.13, 1.26)
† <a href="#">Hart et al. (2013)</a>	U.S.	Female nurses	1.03 (1.00, 1.06)
† <a href="#">Yorifuji et al. (2010)</a>	Japan		1.04 (0.93, 1.32)
† <a href="#">Jerrett et al. (2013)</a>	U.S.		1.08 (1.02, 1.14)

**Table 6-15 (Continued): Corresponding risk estimates for Figure 6-8.**


Study	Location	Notes	Hazard Ratio (95% CI) <sup>a</sup>
<a href="#">†Carey et al. (2013)</a>	England, U.K.		1.11 (1.05, 1.15)
<a href="#">Nafstad et al. (2004)</a>	Norway		1.16 (1.12, 1.22)
<a href="#">†Tonne and Wilkinson (2013)</a>	England and Wales, U.K.		1.12 (1.06, 1.20)
<a href="#">Krewski et al. (2000)</a>	U.S.	NO <sub>x</sub>	1.15 (1.04, 1.27)
<a href="#">†Lipfert et al. (2009)</a>	U.S.		1.04 (1.03, 1.05)
<a href="#">†Beelen et al. (2014a)</a>	Europe	Pooled analysis, NO <sub>2</sub> Pooled analysis, NO <sub>x</sub>	1.02 (0.98, 1.06) 1.02 (1.00, 1.04) <sup>b</sup>

avg = average; CI = confidence interval; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>

<sup>a</sup>Effect estimates are standardized to a 10-ppb increase in NO<sub>2</sub> and a 20-ppb increase in NO<sub>x</sub> concentration, unless otherwise specified.

<sup>b</sup>Effect estimates for NO<sub>x</sub> based on µg/m<sup>3</sup> are not standardized. Effect estimate in [Cao et al. \(2011\)](#) and [Tonne and Wilkinson \(2013\)](#) is per 10 µg/m<sup>3</sup> increase and in [Beelen et al. \(2014a\)](#) is per 20 µg/m<sup>3</sup> increase.

†Studies published since the 2008 ISA for Oxides of Nitrogen.



Note: ACS = American Cancer Society; AHSMOG = California Seventh-Day Adventists Cohort; CA = California; CHD = coronary heart disease; CI = confidence interval; ESCAPE = European Study of Cohorts for Air Pollution Effects; HSC = Harvard Six Cities; IHD = ischemic heart disease; NLCS = Netherlands Cohort Study on Diet and Cancer; NLCS-AIR = Netherlands Cohort Study on Air Pollution and Mortality; PAARC = Air Pollution and Chronic Respiratory Diseases; RoLS = Rome Longitudinal Study; SALIA = Study on the Influence of Air Pollution on Lung, Inflammation, and Aging; TRIPS = Trucking Industry Particle Study. Black = studies from the 2008 Integrated Science Assessment for Oxides of Nitrogen, red = recent studies and those not included in the 2008 Integrated Science Assessment. Circles = NO<sub>2</sub>; triangles = NO<sub>x</sub>; squares = NO. Studies are presented in descending order of mean concentration (in parts per billion [ppb]).

<sup>a</sup>Hazard ratios are standardized to a 10-ppb increase in NO<sub>2</sub> and NO, and a 20-ppb increase in NO<sub>x</sub> concentration.

<sup>b</sup>Effect estimates from studies measuring NO<sub>x</sub> in µg/m<sup>3</sup> are not standardized.

**Figure 6-9 Associations between long-term exposure to oxides of nitrogen and cardiovascular mortality.**

**Table 6-16 Corresponding risk estimates for Figure 6-9.**

Study	Location	Notes	Hazard Ratio (95% CI) <sup>a</sup>
<b>Cardiovascular Disease</b>			
<a href="#">Naess et al. (2007)</a>	Norway	Women	1.06 (1.00, 1.12)
† <a href="#">Lipsett et al. (2011)</a>	California, U.S.	Women, NO <sub>2</sub>	0.98 (0.88, 1.09) 1.05 (0.99, 1.12)
† <a href="#">Cao et al. (2011)<sup>b</sup></a>	China	NO <sub>x</sub>	1.02 (1.01, 1.04)
† <a href="#">Schikowski et al. (2007)</a>	Germany		1.86 (1.26, 2.74)
† <a href="#">Zhang et al. (2011)</a>	China		5.43 (4.82, 6.16)
† <a href="#">Cesaroni et al. (2013)</a>	Italy		1.06 (1.04, 1.08)
† <a href="#">Brunekreef et al. (2009)</a>	the Netherlands	Full cohort Case cohort	1.04 (0.96, 1.13) 0.92 (0.77, 1.10)
† <a href="#">Hart et al. (2011)</a>	U.S.	Full cohort Excluding long haul drivers	1.09 (1.01, 1.17) 1.14 (1.03, 1.25)
† <a href="#">Jerrett et al. (2013)</a>	U.S.		1.12 (1.02, 1.22)
† <a href="#">Chen et al. (2013a)</a>	Canada		1.17 (1.10, 1.23)
† <a href="#">Carey et al. (2013)</a>	England		1.05 (1.00, 1.13)
† <a href="#">Beelen et al. (2014b)</a>	Europe	Pooled analysis, NO <sub>2</sub>	1.02 (0.94, 1.12) 1.02 (0.99, 1.06) <sup>c</sup>
<b>Cardiopulmonary Disease</b>			
<a href="#">Abbey et al. (1999)</a>	U.S.	Men Women	1.01 (0.93, 1.09) 1.02 (0.95, 1.09)
<a href="#">Krewski et al. (2000)</a>	U.S.		1.01 (1.00, 1.02)
<a href="#">Filleul et al. (2005)</a>	France	24 areas 18 areas	1.00 (0.96, 1.04) 1.16 (0.93, 1.45)
<a href="#">Gehring et al. (2006)</a>	Germany	1-yr avg 5-yr avg	1.70 (1.28, 2.26) 1.92 (1.35, 2.71)
† <a href="#">Heinrich et al. (2013)</a>	Germany		1.67 (1.36, 2.05)
† <a href="#">Wang et al. (2009b)</a>	Australia		0.95 (0.74, 1.22)
<a href="#">Hoek et al. (2002)</a>	the Netherlands		1.45 (0.99, 2.13)
† <a href="#">Yorifuji et al. (2010)</a>	Japan		1.32 (1.12, 1.54)
<a href="#">Krewski et al. (2000)</a>	U.S.		1.17 (1.03, 1.34)

**Table 6-16 (Continued): Corresponding risk estimates for Figure 6-9.**

Study	Location	Notes	Hazard Ratio (95% CI) <sup>a</sup>
<b>CHD</b>			
† <a href="#">Rosenlund et al. (2008b)</a>	Italy	Out of hospital	1.16 (1.04, 1.26)
		In hospital	1.10 (0.94, 1.30)
		Following nonfatal coronary event	0.91 (0.80, 1.04)
† <a href="#">Gan et al. (2011)</a>	Canada	NO <sub>2</sub>	1.09 (1.02, 1.19)
		NO	1.09 (1.03, 1.15)
† <a href="#">Carey et al. (2013)</a>	England		0.98 (0.90, 1.07)
<b>IHD</b>			
† <a href="#">Lipsett et al. (2011)</a>	California, U.S.	Women, NO <sub>2</sub>	1.07 (0.92, 1.24)
		Women, NO <sub>x</sub>	1.09 (1.00, 1.19)
<a href="#">Krewski et al. (2000)</a>	U.S.		1.02 (1.00, 1.03)
† <a href="#">Cesaroni et al. (2013)</a>	Italy		1.10 (1.06, 1.14)
† <a href="#">Hart et al. (2011)</a>	U.S.	Full cohort	1.01 (0.92, 1.11)
		Excluding long haul drivers	1.07 (0.95, 1.21)
† <a href="#">Yorifuji et al. (2010)</a>	Japan		1.57 (1.04, 2.36)
† <a href="#">Jerrett et al. (2013)</a>	U.S.		1.17 (1.04, 1.31)
<a href="#">Nafstad et al. (2004)</a>	Norway	NO <sub>x</sub>	1.08 (1.03, 1.12) <sup>b</sup>
† <a href="#">Chen et al. (2013a)</a>	Canada		1.19 (1.08, 1.30)
† <a href="#">Carey et al. (2013)</a>	England	MI only	1.00 (0.88, 1.13)
† <a href="#">Beelen et al. (2014b)</a>	Europe	Pooled analysis, all IHD; NO <sub>2</sub>	1.00 (0.84, 1.18)
		Pooled analysis all IHD; NO <sub>x</sub>	1.02 (0.95, 1.09) <sup>b</sup>
		Pooled analysis, MI only; NO <sub>2</sub>	0.96 (0.79, 1.18)
		Pooled analysis, MI only; NO <sub>x</sub>	0.99 (0.90, 1.07) <sup>b</sup>
<b>Circulatory Disease</b>			
† <a href="#">Jerrett et al. (2009)</a>	Canada		2.53 (1.27, 5.11)
† <a href="#">Yorifuji et al. (2010)</a>	Japan		1.30 (1.06, 1.59)
<b>Cerebrovascular Disease</b>			
† <a href="#">Lipsett et al. (2011)</a>	California, U.S.	Women, NO <sub>2</sub>	0.86 (0.71, 1.06)
		Women, NO <sub>x</sub>	1.01 (0.90, 1.14)
† <a href="#">Zhang et al. (2011)</a>	China		5.35 (4.67, 6.11)
† <a href="#">Cesaroni et al. (2013)</a>	Italy		1.02 (0.98, 1.06)
† <a href="#">Yorifuji et al. (2010)</a>	Japan		1.18 (0.89, 1.57)
<a href="#">Nafstad et al. (2004)</a>	Norway	NO <sub>x</sub>	1.04 (0.94, 1.15) <sup>b</sup>

**Table 6-16 (Continued): Corresponding risk estimates for Figure 6-9.**


Study	Location	Notes	Hazard Ratio (95% CI) <sup>a</sup>
<a href="#">†Chen et al. (2013a)</a>	Canada		0.92 (0.81, 1.10)
<a href="#">†Beelen et al. (2014b)</a>	Europe	Pooled analysis, NO <sub>2</sub> Pooled analysis, NO <sub>x</sub>	1.02 (0.87, 1.20) 1.00 (0.93, 1.08) <sup>b</sup>
<b>Stroke</b>			
<a href="#">†Jerrett et al. (2013)</a>	U.S.		1.20 (1.04, 1.39)
<a href="#">†Carey et al. (2013)</a>	England		1.00 (0.91, 1.09)
<b>Heart Failure</b>			
<a href="#">†Carey et al. (2013)</a>	England		1.09 (0.91, 1.32)
<b>Diabetes</b>			
<a href="#">†Raaschou-Nielsen et al. (2013b)</a>	Denmark		1.66 (0.96, 2.89)

avg = average; CHD = coronary heart disease; CI = confidence interval; IHD = ischemic heart disease; MI = myocardial infarction; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>.

<sup>a</sup>Effect estimates are standardized to a 10-ppb increase in NO<sub>2</sub> and NO, or a 20-ppb increase in NO<sub>x</sub> concentration.

<sup>b</sup>Effect estimates for NO<sub>x</sub> based on µg/m<sup>3</sup> are not standardized. Effect estimate in [Cao et al. \(2011\)](#) and [Nafstad et al. \(2004\)](#) is per 10 µg/m<sup>3</sup> increase. Effect estimate in [Beelen et al. \(2014b\)](#) is per 20 µg/m<sup>3</sup> increase.

†Studies published since the 2008 ISA for Oxides of Nitrogen.



Note: ACS = American Cancer Society; AHSMOG = California Seventh-Day Adventists Cohort; CA = California; CI = confidence interval; COPD = chronic obstructive pulmonary disease; ESCAPE = European Study of Cohorts for Air Pollution Effects; HSC = Harvard Six Cities; NLCS-AIR = Netherlands Cohort Study of Air Pollution and Mortality; PAARC = Air Pollution and Chronic Respiratory Diseases; RoLS = Rome Longitudinal Study; TriPS = Traffic Industry Particle Study; yr = year. Black = studies from the 2008 Integrated Science Assessment for Oxides of Nitrogen. Red = studies not included in 2008 Integrated Science Assessment; Circles = NO<sub>2</sub>; triangles = NO<sub>x</sub>; squares = NO. Studies are presented in descending order of mean concentration (in parts per billion [ppb]).

<sup>a</sup>Hazard ratios are standardized to a 10-ppb increase in NO<sub>2</sub> or NO and a 20-ppb increase in NO<sub>x</sub> concentration.

<sup>b</sup>Effect estimates from studies measuring NO<sub>x</sub> in µg/m<sup>3</sup> are not standardized.

**Figure 6-10 Associations between long-term exposure to oxides of nitrogen and respiratory mortality.**

**Table 6-17 Corresponding risk estimates for Figure 6-10.**

Study	Location	Notes	Hazard Ratio (95% CI) <sup>a</sup>
<b>Respiratory</b>			
<a href="#">Abbey et al. (1999)</a>	U.S.	Men Women	0.93 (0.82, 1.07) 0.98 (0.87, 1.11)
† <a href="#">Lipsett et al. (2011)</a>	California, U.S.	Women, NO <sub>2</sub> Women, NO <sub>x</sub>	0.93 (0.76, 1.15) 0.94 (0.83, 1.07)
† <a href="#">Cao et al. (2011)</a>	China	NO <sub>x</sub>	1.03 (1.00, 1.06) <sup>b</sup>
† <a href="#">Dong et al. (2012)</a>	China		6.1 (5.2, 7.2)
† <a href="#">Cesaroni et al. (2013)</a>	Italy		1.06 (1.00, 1.12)
† <a href="#">Brunekreef et al. (2009)</a>	the Netherlands	Full cohort Case cohort	1.22 (1.00, 1.48) 1.16 (0.83, 1.62)
† <a href="#">Heinrich et al. (2013)</a>	Germany		1.15 (0.67, 2.00)
† <a href="#">Jerrett et al. (2009)</a>	Canada		1.16 (0.37, 2.71)
† <a href="#">Hart et al. (2011)</a>	U.S.	Full cohort Excluding long haul drivers	1.07 (0.91, 1.27) 1.26 (1.01, 1.56)
† <a href="#">Yorifuji et al. (2010)</a>	Japan		1.39 (1.04, 1.83)
† <a href="#">Jerrett et al. (2013)</a>	U.S.		1.00 (0.83, 1.20)
† <a href="#">Carey et al. (2013)</a>	England		1.28 (1.18, 1.38)
<a href="#">Nafstad et al. (2004)</a>	Norway	NO <sub>x</sub>	1.32 (1.12, 1.54) <sup>b</sup>
† <a href="#">Dimakopoulou et al. (2014)</a>	Europe	Pooled analysis, NO <sub>2</sub> Pooled analysis, NO <sub>x</sub>	0.94 (0.80, 1.10) 0.99 (0.90, 1.09) <sup>b</sup>
† <a href="#">Katanoda et al. (2011)</a>	Japan	All subjects Men Women	1.16 (1.12, 1.21) 1.11 (1.05, 1.18) 1.25 (1.18, 1.33)
<b>COPD</b>			
<a href="#">Naess et al. (2007)</a>	Norway	Men Women	1.18 (1.04, 1.33) 1.05 (0.93, 1.18)
† <a href="#">Gan et al. (2013)</a>	Canada	NO <sub>2</sub> NO	1.09 (0.91, 1.32) 1.06 (0.97, 1.15)
† <a href="#">Hart et al. (2011)</a>	U.S.	Full cohort Excluding long haul drivers	0.97 (0.79, 1.19) 1.01 (0.82, 1.44)

**Table 6-17 (Continued): Corresponding risk estimates for Figure 6-10.**

Study	Location	Notes	Hazard Ratio (95% CI) <sup>a</sup>
<a href="#">†Yorifuji et al. (2010)</a>	Japan		1.22 (0.63, 2.31)
<a href="#">†Carey et al. (2013)</a>	England		1.13 (0.98, 1.28)
<b>Lung Cancer</b>			
<a href="#">Abbey et al. (1999)</a>	U.S.	Men Women	1.35 (0.96, 1.90) 1.69 (1.07, 2.65)
<a href="#">†Lipsett et al. (2011)</a>	California, U.S.	Women, NO <sub>2</sub> Women, NO <sub>x</sub>	1.00 (0.76, 1.32) 0.98 (0.90, 1.07)
<a href="#">Naess et al. (2007)</a>	Norway	Men Women	1.06 (0.97, 1.15) 1.20 (1.09, 1.32)
<a href="#">Krewski et al. (2000)</a>	U.S.		0.99 (0.97, 1.01)
<a href="#">†Cao et al. (2011)</a>	China	NO <sub>x</sub>	1.03 (0.99, 1.07) <sup>b</sup>
<a href="#">Filleul et al. (2005)</a>	France	24 areas 18 areas	0.94 (0.89, 1.02) 1.12 (0.77, 1.61)
<a href="#">†Cesaroni et al. (2013)</a>	Italy		1.08 (1.04, 1.14)
<a href="#">†Brunekreef et al. (2009)</a>	the Netherlands	Full cohort Case cohort	0.94 (0.81, 1.09) 0.87 (0.66, 1.14)
<a href="#">†Heinrich et al. (2013)</a>	Germany		1.56 (0.91, 2.69)
<a href="#">†Hart et al. (2011)</a>	U.S.	Full cohort Excluding long haul drivers	1.07 (0.96, 1.19) 1.09 (0.95, 1.25)
<a href="#">Nyberg et al. (2000)</a>	Sweden	30-yr exposure 10-yr exposure	1.10 (0.87, 1.36) 1.20 (0.94, 1.48)
<a href="#">†Yorifuji et al. (2010)</a>	Japan		0.91 (0.63, 1.34)
<a href="#">†Jerrett et al. (2013)</a>	U.S.		1.29 (1.05, 1.59)
<a href="#">†Carey et al. (2013)</a>	England		1.20 (1.09, 1.32)
<a href="#">Nafstad et al. (2004)</a>	Norway	NO <sub>x</sub>	1.11 (1.03, 1.19) <sup>b</sup>
<a href="#">Krewski et al. (2000)</a>	U.S.		1.09 (0.76, 1.57)
<a href="#">†Katanoda et al. (2011)</a>	Japan	All subjects Men Women	1.17 (1.10, 1.26) 1.18 (1.11, 1.26) 1.13 (1.01, 1.27)

CI = confidence interval; COPD = chronic obstructive pulmonary disease; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>.

<sup>a</sup>Effect estimates are standardized to a 10-ppb increase in NO<sub>2</sub> and NO or a 20-ppb increase in NO<sub>x</sub> concentration, unless otherwise specified.

<sup>b</sup>Effect estimates for NO<sub>x</sub> based on µg/m<sup>3</sup> are not standardized. Effect estimate in [Cao et al. \(2011\)](#) and [Nafstad et al. \(2004\)](#) is per 10 µg/m<sup>3</sup> increase. Effect estimate in [Dimakopoulou et al. \(2014\)](#) is per 20 µg/m<sup>3</sup> increase.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

---

### 6.5.3 Summary and Causal Determination

Collectively, the evidence is suggestive of, but not sufficient to infer, a causal relationship between long-term exposure to NO<sub>2</sub> and mortality among adults.<sup>1</sup> The strongest evidence comes from cohort studies conducted in the U.S., Canada, and Europe, which generally show positive associations with total mortality, as well as deaths due to respiratory and cardiovascular disease ([Chen et al., 2013a](#); [Gan et al., 2013](#); [Hart et al., 2013](#); [Heinrich et al., 2013](#); [Jerrett et al., 2013](#); [Gan et al., 2011](#); [Hart et al., 2011](#); [Lipsett et al., 2011](#); [Brunekreef et al., 2009](#); [Jerrett et al., 2009](#); [Beelen et al., 2008b](#); [Schikowski et al., 2007](#); [Krewski et al., 2000](#)). The results from these studies are coherent with studies that have observed associations between long-term exposure to NO<sub>2</sub> and respiratory hospital admissions ([Andersen et al., 2012a](#); [Andersen et al., 2011](#)) and cardiovascular effects ([Hart et al., 2011](#); [Lipsett et al., 2011](#)). The evidence for short- and long-term respiratory and cardiovascular morbidity provides limited biological plausibility for mortality. In the 2008 ISA for Oxides of Nitrogen, a limited number of epidemiologic studies assessed the relationship between long-term exposure to NO<sub>2</sub> and mortality in adults. The 2008 ISA concluded that the scarce amount of evidence was “inadequate to infer the presence or absence of a causal relationship” ([U.S. EPA, 2008c](#)). The stronger conclusion in this ISA is based on evidence in recent studies for an association between long-term exposure to NO<sub>2</sub> and mortality from extended analyses of existing cohorts as well as original results from new cohorts in the U.S., Europe, and Asia. The key evidence as it relates to the causal determination is summarized in [Table 6-18](#) using the framework described in [Table II](#) of the [Preamble](#).

Many of the studies evaluating the associations between long-term exposure to NO<sub>2</sub> and mortality used concentrations measured at central site monitors to assign exposure. Many recent studies employed exposure assessment methods such as LUR or dispersion modeling to account for the spatial variability of NO<sub>2</sub> and estimate exposure at subjects’ homes. There was no distinguishable pattern or trend in the results of this body of evidence that could be attributed to the use of central site monitors, LUR, or dispersion models to assign exposure. However, demonstrations in many studies that LUR or dispersion modeled estimates of NO<sub>2</sub> exposures well predicted NO<sub>2</sub> concentrations in the study areas lend confidence in the results for associations with mortality. While the results were generally consistent across studies, there were several well-designed, well-conducted studies that did not observe an association between long-term exposure to NO<sub>2</sub> and mortality ([Beelen et al., 2014a](#); [Beelen et al., 2014b](#); [Dimakopoulou et al., 2014](#);

---

<sup>1</sup> For early life mortality, see [Section 6.4.3](#).

[Krewski et al., 2009](#); [Pope et al., 2002](#); [Abbey et al., 1999](#)). Many of these studies not observing associations also estimated NO<sub>2</sub> exposure with well-validated models.

Recent studies examined the potential for copollutant confounding by PM<sub>2.5</sub>, the traffic-related pollutant BC, or measures of traffic proximity or density in copollutant models ([Beelen et al., 2014a](#); [Jerrett et al., 2013](#); [Hart et al., 2011](#)). These recent studies address a previously identified data gap. The NO<sub>2</sub> results from these models were generally attenuated with the adjustment for PM<sub>2.5</sub> or BC, though analysis of confounding is limited and not all key traffic-related copollutants (i.e., CO) were evaluated. It remains difficult to disentangle the independent effect of NO<sub>2</sub> from the potential effect of the traffic-related pollution mixture or other components of that mixture. Further, the evidence does not demonstrate that long-term NO<sub>2</sub> exposure has an independent effect on the cardiovascular and respiratory morbidity outcomes that are major underlying causes of mortality. In conclusion the generally supporting epidemiologic evidence but uncertainty regarding an independent NO<sub>2</sub> effect is suggestive of, but not sufficient to infer, a causal relationship between long-term exposure to NO<sub>2</sub> and total mortality.

**Table 6-18 Summary of evidence, which is suggestive of, but not sufficient to infer, a causal relationship between long-term nitrogen dioxide exposure and total mortality.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
High-quality epidemiologic studies are generally supportive but not entirely consistent	Positive association with cardiovascular mortality in the HSC cohort and total mortality a subset of the ACS cohort, with effect estimates similar in magnitude to those observed with PM <sub>2.5</sub> , even after adjustment for common potential confounders.	<a href="#">Krewski et al. (2000)</a>	Means across cities (1980): 6.1–21.9 ppb
	Updated results from the NLCS report a positive association with total mortality, effects for respiratory mortality stronger than any observed with traffic variables and total or other cause-specific mortality.	† <a href="#">Jerrett et al. (2013)</a> <a href="#">Sections 6.5.1</a> and <a href="#">6.5.2</a>	Mean (1988–2002): 12.3 ppb
	Updated results from German women’s cohort report positive associations with total and cardiopulmonary mortality.	† <a href="#">Beelen et al. (2008b)</a> , † <a href="#">Brunekreef et al. (2009)</a>	Mean: 2.8–31.7 ppb for annual avg. Median: 20.2 ppb for 10-yr avg
	Recent cohort studies in the U.S. observe increases in total mortality and mortality due to cardiovascular disease in separate cohorts of men and women.	† <a href="#">Heinrich et al. (2013)</a> , † <a href="#">Schikowski et al. (2007)</a>	Mean: 20.7 ppb for 15-yr avg. Median: 24.4 ppb for 5-yr avg
	Positive associations with total, cardiovascular, respiratory, and lung cancer mortality in Canadian cities. NO <sub>2</sub> exposure estimated with well-validated LUR models.	† <a href="#">Hart et al. (2011)</a> † <a href="#">Lipsett et al. (2011)</a> † <a href="#">Hart et al. (2013)</a>	Mean (1985–2000): 14.2 ppb Mean (1996–2005): 33.6 ppb; max: 67.2 ppb Median (2000): 13.9 ppb
Some studies show no association	No association in several re-analyses of the ACS cohort.	† <a href="#">Chen et al. (2013a)</a> , † <a href="#">Jerrett et al. (2009)</a> , † <a href="#">Gan et al. (2011)</a> , † <a href="#">Gan et al. (2013)</a> <a href="#">Krewski et al. (2000)</a> , <a href="#">Pope et al. (2002)</a> , † <a href="#">Krewski et al. (2009)</a> <a href="#">Sections 6.5.1</a> and <a href="#">6.5.2</a>	Mean (1982–1998): 21.4–27.9 ppb Mean (1982–1998): 27.9 ppb; max 51.1 ppb
	No association in a multi-country European study of 22 existing cohorts for total, cardiovascular, or respiratory mortality. NO <sub>2</sub> exposure estimated with well-validated LUR models.	† <a href="#">Beelen et al. (2014a)</a> , † <a href="#">Dimakopoulou et al. (2014)</a> , † <a href="#">Beelen et al. (2014b)</a>	Mean across cities: 12.1–21.7 ppb for annual avg. Median: 22.9 ppb for annual avg Mean: 17.0, 17.1 ppb for 5-yr avg
	No association with total, cardiopulmonary, or respiratory mortality in the AHSMOG.	<a href="#">Abbey et al. (1999)</a>	Mean (1973–1992): 36.8 ppb

**Table 6-18 (Continued): Summary of evidence, which is suggestive of, but not sufficient to infer, a causal relationship between long-term nitrogen dioxide exposure and total mortality.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
Uncertainty remains regarding independent effects of NO <sub>2</sub>	Associations with mortality generally attenuated with adjustment for PM <sub>2.5</sub> or BC. Analysis is limited and does not include many traffic-related copollutants (i.e., CO). When reported, correlations with copollutants were highly variable (low to high).	† <a href="#">Jerrett et al. (2013)</a> , † <a href="#">Gan et al. (2011)</a> , † <a href="#">Gan et al. (2013)</a> <a href="#">Section 6.5.2</a>	
Limited coherence with evidence for respiratory and cardiovascular morbidity	Limited evidence for COPD hospital admissions in adults but uncertainty in independent NO <sub>2</sub> effect.	† <a href="#">Andersen et al. (2011)</a> , † <a href="#">Andersen et al. (2012a)</a> <a href="#">Section 6.2.8</a>	35-yr mean: 9.0 ppb 25-yr mean: 9.5 ppb
	Some inconsistencies reported for cardiovascular morbidity. Coherent evidence for MI and heart failure, but uncertainty in independent NO <sub>2</sub> effect.	† <a href="#">Lipsett et al. (2011)</a> , † <a href="#">Atkinson et al. (2013)</a> <a href="#">Section 6.3.2</a>	Mean: 33.6 ppb for multi-yr avg, 12.0 ppb for annual avg

ACS = American Cancer Society; AHSMOG = Adventist Health Study of Smog; BC = black carbon; CO = carbon monoxide; COPD = chronic obstructive pulmonary disease; HSC = Harvard Six Cities; LUR = land use regression; MI = myocardial infarction; NLCS = Netherlands Cohort Study on Diet and Cancer; NO<sub>2</sub> = nitrogen dioxide; ppb = parts per billion; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 µm.

<sup>a</sup>Based on aspects considered in judgments of causality and weight of evidence in causal framework in [Tables I](#) and [II](#) of the [Preamble](#).

<sup>b</sup>Describes the key evidence and references, supporting or contradicting, contributing most heavily to causal determination and, where applicable, to uncertainties or inconsistencies. References to earlier sections indicate where full body of evidence is characterized.

<sup>c</sup>Describes the NO<sub>2</sub> concentrations with which the evidence is substantiated (for experimental studies, ≤ 5,000 ppb).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

## 6.6 Cancer

### 6.6.1 Introduction

The 1993 AQCD for Oxides of Nitrogen and the 2008 ISA for Oxides of Nitrogen reported that there was no clear evidence that NO<sub>2</sub> or other oxides of nitrogen act as a direct carcinogen. The U.S. Department of Health and Human Services and the International Agency for Research on Cancer have not classified oxides of nitrogen for potential carcinogenicity. The American Conference of Industrial Hygienists has classified NO<sub>2</sub> as A4 (not classifiable for humans or animals). The 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) included a few epidemiologic studies of oxides of nitrogen and cancer, both examining lung cancer incidence and reporting positive associations. Several additional epidemiologic studies examined lung cancer and a few

studies each examined leukemia, bladder cancer, breast cancer, and prostate cancer. These are all described in more detail in [Supplemental Table S6-10 \(U.S. EPA, 2013o\)](#), which includes information on the exposure assessment and duration, as well as effect estimates. For the evaluation of long-term exposure and cancer, important considerations were the exposure assessment method and potential confounding by PM<sub>2.5</sub>, diesel exhaust, polycyclic aromatic hydrocarbons, and other traffic-related copollutants. Ambient NO<sub>2</sub> concentrations typically show spatial variability ([Section 2.5.3](#)), and PM<sub>2.5</sub> and traffic-related copollutants also show associations with cancer. Exposure assessment was evaluated drawing upon discussions in [Sections 3.2](#) and [3.4.5](#). Several recent studies of cancer employed exposure assessment methods to account for the spatial variability of NO<sub>2</sub>. For example, LUR model predictions have been found to correlate well with outdoor NO<sub>2</sub> concentration measurements ([Section 3.2.2.1](#)). For long-term NO<sub>2</sub> exposure, exposure assessment was evaluated by the extent to which the method represented the spatial variability in NO<sub>2</sub> concentrations in a given study.

---

## 6.6.2 Lung Cancer

### 6.6.2.1 Epidemiologic Studies

#### Lung Cancer Incidence

The two previous studies in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) reported positive associations between NO<sub>2</sub> or NO<sub>x</sub> and lung cancer incidence ([Nafstad et al., 2003](#); [Nyberg et al., 2000](#)). [Nyberg et al. \(2000\)](#) reported an association between NO<sub>2</sub> and lung cancer at the highest 10-year avg concentrations of NO<sub>2</sub> with a 20-year lag. NO<sub>2</sub> exposure was estimated from NO<sub>x</sub> emissions and a geostatistical model. The association was relatively unchanged after adjustment for SO<sub>2</sub>, which was not observed to be associated with lung cancer (Pearson r with NO<sub>2</sub> exposure = 0.64). [Nafstad et al. \(2003\)](#) performed a study with 24 years of follow-up and reported a positive association between NO<sub>x</sub> concentrations and lung cancer incidence during the early years of the study, but the authors report more recent years had weaker associations (results were not provided). Neither of the previous studies examined PM<sub>2.5</sub>, diesel exhaust, polycyclic aromatic hydrocarbons, or other traffic-related pollutants or reported information on whether the exposure assessment methods captured the spatial variability in the study areas.

Evidence from recent studies is inconsistent regarding an association between long-term NO<sub>2</sub> exposure and lung cancer incidence, including results for NO<sub>2</sub> exposures estimated using well-validated LUR models. A meta-analytical study combined individual

estimates from 17 cohort studies across nine countries in Europe ([Raaschou-Nielsen et al., 2013a](#)). Positive associations for NO<sub>2</sub> and lung cancer became null after adjusting for smoking-related covariates, fruit intake, and area-level SES. No associations were observed for PM<sub>2.5</sub>, PM<sub>2.5</sub> absorbance, and PM<sub>10-2.5</sub>, but PM<sub>10</sub> was positively associated with lung cancer. LUR models for all of the examined pollutants were demonstrated to predict well ambient concentrations in the study areas (cross-validation R<sup>2</sup> = 0.60–0.80). A smaller study in Toronto, Canada reported a positive association between NO<sub>2</sub> concentrations and lung cancer only when using a population-based control group ([Villeneuve et al., 2014](#)). The association was present when using NO<sub>2</sub> concentration at the time of the interview, from 10 years prior, and from a time-weighted average. Cross-validation of the LUR model indicated a small difference (4%) between model predictions and measured concentrations. There was no association in analyses adjusted for personal (e.g., age, smoking, BMI) and neighborhood SES (e.g., neighborhood unemployment rate) covariates using both hospital-based and population-based controls. The traffic-related pollutant benzene also was associated with lung cancer incidence, and confounding by benzene was not evaluated (r = 0.67 for correlation with NO<sub>2</sub>).

NO<sub>2</sub> exposure was not consistently associated with lung cancer incidence in studies with more uncertain exposure estimates. In a Netherlands cohort, 5-yr and 10-yr avg NO<sub>2</sub> exposure was estimated for subjects' homes using LUR models, but information was not reported on model validation. Over 11 years of follow-up, no associations were observed in analyses using case-cohort and full cohort approaches. ([Brunekreef et al., 2009](#); [Beelen et al., 2008a](#)). NO<sub>2</sub> was highly correlated (r > 0.75) with PM<sub>2.5</sub>, PM<sub>2.5</sub> absorbance, and black smoke (BS), which also were not associated with lung cancer incidence. In Canada, 20-yr avg NO<sub>2</sub> exposure estimated from a spatiotemporal model was associated with lung cancer incidence ([Hystad et al., 2013](#)). However, national model was used to estimate exposure at the level of the postal code, and the model showed considerable variation with measured concentrations (cross-validation R<sup>2</sup> = 0.38). An association was present for adenocarcinomas but not squamous cell carcinoma. Confidence intervals for estimates of small cell and large cell carcinomas were wide. PM<sub>2.5</sub> demonstrated some associations with lung cancer incidence, especially in the third and fourth, but not fifth, quintiles of exposures. Copollutant models were not examined for NO<sub>2</sub> and PM<sub>2.5</sub> because of the high correlation between the pollutants. Odds of lung cancer increased in association with NO<sub>2</sub> concentrations when the analysis was limited to the closest monitor within 50 km, but it is unclear whether the 50 km distance adequately represents the spatial variability in NO<sub>2</sub> exposure. In stratified analyses, associations appeared to be greater among men; results were null for women. No differences were apparent by education or smoking status.

NO<sub>2</sub> exposure estimated from central site monitors was not associated with lung cancer incidence. A case-control study of molecular changes and genetic susceptibility used

multiple statistical techniques to evaluate the associations between air pollutants and lung cancer incidence ([Papathomas et al., 2011](#)). A high risk group was identified as having combined high PM<sub>10</sub> and NO<sub>2</sub> exposures and residence in main roads; however, NO<sub>2</sub> exposure examined individually was not associated with lung cancer incidence. The same was true of PM<sub>10</sub>. In another statistical model, PM<sub>10</sub> but not NO<sub>2</sub> was chosen as a predictor. An ecologic study in Taiwan observed no associations for NO<sub>2</sub> concentrations with all lung cancer cases combined, adenocarcinomas, or squamous cell carcinomas ([Tseng et al., 2012](#)). No association was observed for CO, but other traffic-related pollutants were not examined. A positive association was observed in the highest quartile of NO for adenocarcinomas but not for squamous cell carcinomas.

Similar to a previous study, recent analyses reported an association between increased NO<sub>x</sub> concentrations and lung cancer incidence. In Danish cohorts, the increased incidence with NO<sub>x</sub> exposure persisted in some models of specific cancer types, such as squamous cell carcinomas ([Raaschou-Nielsen et al., 2010a](#)). For associations stratified by sex, length of education, and smoking status, the precision decreased (i.e., wider 95% CI), and no differences were observed between the groups. One of the Danish cohorts was used in another study where the follow-up period was extended 5 years to include more cases ([Raaschou-Nielsen et al., 2011b](#)). Increased incidence rate of lung cancer was observed in the highest quartile of NO<sub>x</sub> concentrations, and risk was greater in the group with 8 years or more of schooling, the group with lower fruit intake, nonsmokers, and females. In these studies, residential NO<sub>x</sub> exposure was estimated from a model with emissions and geographical data as inputs. The modeled NO<sub>x</sub> estimates correlated well with measured concentrations on a busy street ( $r = 0.88$ ), but they also were nearly perfectly correlated with traffic-related copollutants (e.g.,  $r = 0.93$  for particle number concentration). Therefore, an independent NO<sub>x</sub> effect is not discernable.

### **Lung Cancer Mortality**

Compared to lung cancer incidence, long-term NO<sub>2</sub> exposure was more consistently associated with lung cancer mortality. Positive associations were observed in many but not all studies with NO<sub>2</sub> exposure estimated at or near subjects' homes with well-validated models or nearby central site monitors. As with lung cancer incidence, an independent association with lung cancer mortality is uncertain. In most studies, PM<sub>2.5</sub> was highly correlated with NO<sub>2</sub> ( $r = 0.79$ – $0.95$ ), was estimated with models with similar predictive capacity, and also associated with lung cancer mortality. Further, important copollutants such as diesel exhaust particles or VOCs were not examined. In the ACS Cancer Prevention Study II cohort, lung cancer mortality was positively associated with NO<sub>2</sub> exposure estimated by an LUR model that predicted well ambient NO<sub>2</sub> concentrations in the study area (cross-validation  $R^2 = 0.71$ ) ([Jerrett et al., 2013](#)). NO<sub>2</sub>

was moderately correlated with PM<sub>2.5</sub> and O<sub>3</sub> (Pearson  $r = 0.55$ ). The positive association with NO<sub>2</sub> was robust to adjustment with PM<sub>2.5</sub> or O<sub>3</sub>. In a U.S. study of men employed by the trucking industry in 1985, no association was observed with lung cancer mortality ascertained from the National Death Index through 2000 ([Hart et al., 2011](#)). NO<sub>2</sub> exposure was estimated for subjects' homes using a well-validated spatial smoothing model (cross-validation  $R^2 = 0.88$ ). There was no association after long-haul drivers who are away from the home at least one night per week were excluded from the analyses. Similar results were observed for PM<sub>10</sub> and SO<sub>2</sub>.

Long-term NO<sub>2</sub> exposure also was associated with lung cancer mortality in studies conducted across Europe. These studies also estimated NO<sub>2</sub> exposure with well-validated LUR, emissions-based, or dispersion models (cross-validation  $R^2 = 0.57$ – $0.80$  across locations or  $r = 0.30$ – $0.87$  for correlation with measured NO<sub>2</sub> across seasons). In England, lung cancer mortality was ascertained from a large nationally representative database ([Carey et al., 2013](#)). In Rome, Italy, the association demonstrated a linear relationship ([Cesaroni et al., 2013](#)). A study in Oslo, Norway linked lung cancer mortality ascertained for a 4-year period to NO<sub>2</sub> averaged over this follow-up period ([Naess et al., 2007](#)). The association was positive only among women. In a nonparametric smooth analysis that combined the sexes, the increase in log odds for lung cancer appears to begin around 21.3 ppb for the 51–70 year age group while the increase appears to occur at lower concentrations among those aged 71–90 years. A study in Japan estimated NO<sub>2</sub> exposure with an LUR model that did not perform as well as the aforementioned studies (cross-validation  $R^2 = 0.54$ ). Among individuals ages 65–84 years at enrollment and followed for about 6 years, NO<sub>2</sub> was not associated with lung cancer mortality ([Yorifuji et al., 2010](#)). With additional years of follow-up, associations for lung cancer mortality were observed for NO<sub>2</sub> exposure estimated for the year of mortality, averaged 1 to 3 years before death, and averaged over follow-up ([Yorifuji et al., 2013](#)). In this Japanese cohort, no effect measure modification was indicated by smoking status, age, sex, BMI, diabetes, hypertension, or financial ability.

A few studies estimated NO<sub>2</sub> exposure from central site monitors located in close proximity to subjects. A multi-region study in Japan followed individuals for 10 years and reported region-specific results ([Katanoda et al., 2011](#)). NO<sub>2</sub> was inconsistently associated with lung cancer mortality between two regions where distance to the monitor was less than 1 km. The region where the association was observed had the highest NO<sub>2</sub> concentration (data on association by region only presented in figures). A study in France monitored NO<sub>2</sub> in study areas that were 0.5 to 2.3 km wide ([Filleul et al., 2005](#)). NO<sub>2</sub> was associated with lung cancer mortality only after exclusion of areas with a strong influence of heavy traffic (i.e., monitoring sites reporting a high ratio of NO to NO<sub>2</sub>). The small area around most monitors and the exclusion of high-traffic areas suggest that the

monitor may fairly well represent NO<sub>2</sub> concentrations across the study area. BS, which was highly correlated with NO<sub>2</sub> ( $r = 0.72$ ), was not associated with lung cancer mortality.

Associations with lung cancer mortality generally were not observed in studies with more uncertainty in NO<sub>2</sub> exposure estimates. No association was reported with NO<sub>x</sub> in a national study of urban areas in China (Cao et al., 2011). NO<sub>2</sub> was not associated with lung cancer mortality in the NCLS with follow-up of at least 10 years (Brunekreef et al., 2009; Beelen et al., 2008b). NO<sub>2</sub> exposure was estimated for subjects' homes by LUR, but no information was reported on model validation. No association was observed with PM<sub>2.5</sub> or BS. Lung cancer mortality was not associated with NO<sub>2</sub> exposure estimated from central site monitors in the ACS cohort (Krewski et al., 2009) or in a cohort of women in Germany (Heinrich et al., 2013). Neither study indicated the extent to which the concentrations averaged over the metropolitan statistical area (ACS) or assigned from the nearest monitor which in most cases was within 5 km (German cohort) represented the spatial variability in NO<sub>2</sub> concentrations in the study area. Such information is lacking also in a study in Taiwan, which used a case-control design (Liu et al., 2008). The highest tertile of NO<sub>2</sub> concentration was positively associated with lung cancer mortality. Lung cancer mortality was not associated with SO<sub>2</sub>, PM<sub>10</sub>, or O<sub>3</sub> but was associated with CO as well as an exposure index combining the highest tertile of CO and NO<sub>2</sub>.

---

### 6.6.2.2 Animal Toxicological Studies

#### Lung Tumors with Co-exposure with Known Carcinogens or Copollutants

The 1993 AQCD for Oxides of Nitrogen and the 2008 ISA for Oxides of Nitrogen reported a lack of evidence that NO<sub>2</sub> acts as a direct carcinogen but noted a possible role for NO<sub>2</sub> to act as a tumor promoter in the lung with co-exposure with known carcinogens or diesel exhaust particles. Toxicological studies of NO<sub>2</sub> and carcinogenicity and genotoxicity are described in Table 6-19. There also is some evidence of hyperplasia of respiratory epithelium with NO<sub>2</sub> exposure, which is consistent with a role for NO<sub>2</sub> in tumor promotion (Section 6.2.6). Continuous exposure to 4,000 ppb NO<sub>2</sub> for 17 months after injection with the carcinogen N-bis(2-hydroxy-propyl) nitrosamine (BHPN) led to a statistically nonsignificant fivefold increase in the number of rats that developed adenomas or adenocarcinomas of the lungs compared to clean air exposure (Ichinose et al., 1991). The number of rats with tumors following BHPN exposure and BHPN plus NO<sub>2</sub> co-exposure did not differ statistically. Another study by the same lab (Ichinose and Sagai, 1992) showed statistically significant increases in rats with lung tumors with combined 13-month exposure to 400 ppb NO<sub>2</sub> and 50 ppb O<sub>3</sub> after BHPN injection (5 rats). BHPN injection alone did not induce tumors, and the increase with O<sub>3</sub> exposure

alone (3 rats) or NO<sub>2</sub> plus H<sub>2</sub>SO<sub>4</sub> exposure (3 rats) was not statistically significant. Rats were not exposed to NO<sub>2</sub> alone.

Higher than ambient-relevant NO<sub>2</sub> exposure (6,000 ppb, 8 months) combined with diesel exhaust particle extract-coated carbon black particles (DEPcCBP) increased the number of F344 rats with lung tumors (alveolar adenomas) for the animals ([Ohyama et al., 1999](#)). DEPcCBP exposure occurred by intratracheal (IT) installation once per week for 4 weeks and did not induce tumors when given alone.

### **Lung Tumors in Animals with Spontaneously High Tumor Rates**

The 2008 ISA for Oxides of Nitrogen described increased tumors in rodents with spontaneously high tumor rates with higher than ambient-relevant NO<sub>2</sub> exposure but not clearly with relevant exposure concentrations. In AKR/cum mice, 250 ppb NO<sub>2</sub> exposure for up to 26 weeks decreased progression of spontaneous T cell lymphoma and increased survival rates ([Richters and Damji, 1990](#)). A similar duration of exposure (6 months, 6 h/day, 5 days/week) to 1,000 or 5,000 ppb NO<sub>2</sub> had no effect on pulmonary adenomas in A/J mice, but 10,000 ppb NO<sub>2</sub> induced a small, but statistically significant increase in pulmonary adenomas [increased tumor multiplicity; ([Adkins et al., 1986](#))]. In CAF1/Jax mice, continuous exposure to 5,000 ppb NO<sub>2</sub> produced statistically significant increases in the number of mice with pulmonary tumors when compared with controls after 12 months but not after 14 or 16 months ([Wagner et al., 1965](#)).

### **Facilitation of Lung Cancer Metastases**

The 2008 ISA for Oxides of Nitrogen summarized a group of experiments by one lab that focused on the role of NO<sub>2</sub> in facilitation of metastases, or more accurately, colonization of the lung by tumor cells. [Richters and Kuraitis \(1981\)](#), [Richters et al. \(1985\)](#), and [Richters and Kuraitis \(1983\)](#) exposed mice to 300–800 ppb NO<sub>2</sub> for 10 or 12 weeks, then injected mice intravenously (i.v.) with the B16 melanoma cell line. Lung tumors were then counted, with results of some of the experiments showing significantly increased numbers of tumors.

### **Genotoxicity in Airway Cells**

Ex vivo exposure of human nasal epithelial mucosa cells cultured at the air-liquid interface starting at 10 ppb NO<sub>2</sub> ([Koehler et al., 2013](#); [Koehler et al., 2010](#)) or 100 ppb NO<sub>2</sub> ([Koehler et al., 2011](#)) produced increased deoxyribonucleic acid (DNA) fragmentation measured with the single cell gel electrophoresis (comet) assay as early as

30 minutes after exposure. Percentage of DNA content in the tail as detected with the comet assay decreased with increasing exposure duration [0.5, 1, 2, and 3-hour exposure; (Koehler et al., 2013)]. NO<sub>2</sub> exposure induced micronuclei formation in some but not all studies but did not affect cell proliferation.

**Table 6-19 Characteristics of toxicological studies of carcinogenicity and genotoxicity with exposure to nitrogen dioxide.**

Reference	Species (Strain); Sample Size; Sex; Age	Exposure Details	Endpoints Examined
<a href="#">Ichinose et al. (1991)</a>	Rats (Wistar); n = 30; M; adult	40, 400, or 4,000 ppb NO <sub>2</sub> for 17 mo. Followed injection with carcinogen BHPN.	Incidence of BHPN-induced lung tumors (adenoma or adenocarcinomas)
<a href="#">Ichinose and Sagai (1992)</a>	Rats (Wistar); n = 36; M; adult	(1) 400 ppb NO <sub>2</sub> + 50 ppb O <sub>3</sub> (2) 400 ppb NO <sub>2</sub> + 1 mg/m <sup>3</sup> H <sub>2</sub> SO <sub>4</sub> (1-2) Exposure 11 h/day for 13 mo, followed by 11 mo of clean air exposure. Followed injection with carcinogen BHPN.	Incidence of BHPN-induced lung tumors (adenoma or adenocarcinomas)
<a href="#">Ohyama et al. (1999)</a>	Rats (F344); n = 26; M; adult	6,000 ppb NO <sub>2</sub> for 16 h/day for 8 mo, followed by 8 mo of clean air exposure. Co-exposure to DEPcCBP. IT installation 1 day/week for 4 weeks.	Lung tumor incidence (alveolar adenomas)
<a href="#">Richters and Damji (1990)</a>	Mice (AKR/cum); n = 50; F; adult	250 ppb NO <sub>2</sub> for 7 h/day, 5 days/week for up to 26 weeks.	Tumor progression and survival rate
<a href="#">Adkins et al. (1986)</a>	Mice (A/J, spontaneously high tumor rates); n = 30; F; adult	1,000, 5,000, or 10,000 ppb NO <sub>2</sub> for 6 h/day, 5 days/week for 6 mo.	Lung tumor multiplicity (pulmonary adenomas)
<a href="#">Wagner et al. (1965)</a>	Mice (CAF1/Jax); n = 20; M; adult	5,000 ppb NO <sub>2</sub> continuously for 16 mo.	Lung tumor multiplicity measured at 12, 14, and 16 mo.
<a href="#">Richters and Kuraitis (1981)</a>	Mice (Swiss Webster); n = 24; M; adult Mice (C57BL/6J); n = 90; m; adult	400 or 800 ppb NO <sub>2</sub> for 8 h/day, 5 days/week for 10 weeks (Swiss mice) or 12 weeks (C57BL/6J mice). Both strains then infused i.v. with B16 melanoma cells that are known to metastasize to the lung.	Facilitation of lung tumor metastasis (incidence of lung tumors) 3 weeks after infusion of melanoma cells
<a href="#">Richters et al. (1985)</a>	Mice (C57BL/6J); n = 48; M; adult	400 ppb NO <sub>2</sub> continuously for 12 weeks. All animals infused i.v. with B16 melanoma cells that are known to metastasize to the lung.	Facilitation of lung tumor metastasis (incidence of lung tumors) 3 weeks after infusion of melanoma cells

**Table 6-19 (Continued): Characteristics of animal toxicological studies of carcinogenicity and genotoxicity with exposure to nitrogen dioxide.**

Reference	Species (Strain); Sample Size; Sex; Age	Exposure Details	Endpoints Examined
<a href="#">Richters and Kuraitis (1983)</a>	Mice (C57BL/6J); n = 25, 51, 23; M; adult	300, 400, or 500 ppb NO <sub>2</sub> for 7 h/day, 5 days/week for 10 weeks. All animals then infused i.v. with B16 melanoma cells that are known to metastasize to the lung.	Facilitation of lung tumor metastasis (incidence of lung tumors) 3 weeks after infusion of melanoma cells
<a href="#">†Koehler et al. (2013)</a>	Human cells	10 ppb NO <sub>2</sub> for 0, 0.5, 1, 2 and 3 h. Ex vivo cell culture at the air-liquid interface, primary human nasal epithelia cells from n = 10 donors.	Comet assay, micronucleus formation, proliferation assay, apoptosis, necrosis, cytotoxicity
<a href="#">†Koehler et al. (2010)</a>	Human cells	10, 100, or 1,000 ppb NO <sub>2</sub> for 0 or 0.5 h. Ex vivo cell culture at the air-liquid interface, primary human nasal epithelia cells from n = 10 donors.	Comet assay, micronucleus formation, proliferation assay, cytotoxicity
<a href="#">†Koehler et al. (2011)</a>	Human cells	100 ppb NO <sub>2</sub> for 0, 0.5, 1, 2, and 3 h. Ex vivo cell culture at the air-liquid interface, primary human nasal epithelia cells from n = 10 donors.	Comet assay, micronucleus formation, proliferation assay, apoptosis, necrosis, cytotoxicity

BHPN = N-bis(2-hydroxypropyl) nitrosamine; DEPCcCBP = diesel exhaust particle extract-coated carbon black particles; IT = intratracheal; i.v. = intravenously; NO<sub>2</sub> = nitrogen dioxide; O<sub>3</sub> = ozone.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

### 6.6.2.3 Summary of Lung Cancer

Multiple epidemiologic studies examined the associations of long-term average NO<sub>2</sub> or NO<sub>x</sub> concentrations with lung cancer incidence or mortality. Positive associations were reported in multiple studies, but many studies reported no associations. The evidence is more consistent for association of NO<sub>2</sub> exposure with lung cancer mortality. The inconsistency in the evidence does not appear to be related to the length of exposure period examined, length of follow-up period, or the method of exposure assessment. Studies using central site monitors for exposure estimates can carry uncertainty because the exposure error resulting from spatial misalignment between subjects and monitor locations can overestimate or underestimate associations with health effects (Section 3.4.5.2). However, a few studies estimated NO<sub>2</sub> exposure from central sites located near (e.g., within 1 km) subjects and/or in areas not influenced by heavy traffic, and associations with lung cancer mortality were observed in some locations ([Katanoda et al., 2011](#); [Filleul et al., 2005](#)). Several studies estimated long-term NO<sub>2</sub> exposure at

subjects' homes with well-validated LUR or dispersion models. Predicted NO<sub>2</sub> concentrations were demonstrated to correlate well with measured NO<sub>2</sub> concentrations in the study areas. These studies did not observe associations with lung cancer incidence ([Villeneuve et al., 2014](#); [Raaschou-Nielsen et al., 2013a](#)), but many observed associations with lung cancer mortality ([Carey et al., 2013](#); [Cesaroni et al., 2013](#); [Jerrett et al., 2013](#); [Naess et al., 2007](#)). Most of these studies controlled for confounders, such as smoking and age, but evaluation of confounding by important copollutants such as PM<sub>2.5</sub>, diesel exhaust particles, polycyclic aromatic hydrocarbons, volatile organic compounds, and other traffic-related pollutants generally is absent. Evidence from toxicological evidence studies does little to address the uncertainty in epidemiologic studies. NO<sub>2</sub> exposure is not shown to independently induce lung tumors, and there is inconsistent evidence that ambient-relevant NO<sub>2</sub> exposures promote lung tumors when given in conjunction with a known carcinogen. There is some evidence that NO<sub>2</sub> exposure may facilitate metastases of tumors to the lung and induce some genotoxic effects in nasal cells.

---

### 6.6.3 Leukemia Incidence and Mortality

Leukemia was not examined in studies available for the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), but was examined in recent studies. Studies in children examining estimates of prenatal NO<sub>2</sub> exposure at the residence with well-validated LUR models did not consistently observe associations with leukemia incidence. Another uncertainty relates to the lack of examination of PM<sub>2.5</sub>, diesel exhaust, polycyclic aromatic hydrocarbons, or other traffic-related pollutants to assess potential confounding by key copollutants. Among children in Los Angeles County, CA, NO<sub>2</sub>, NO, and NO<sub>x</sub> concentrations averaged over the prenatal period were associated with incidence of acute lymphoblastic leukemia between ages 0 and 5 years ([Ghosh et al., 2013](#)). The cross-validation R<sup>2</sup> of the LUR models exceeded 0.87. A positive association was observed for second trimester-average NO<sub>2</sub> but not for the first or third trimesters. None of the oxides of nitrogen was associated with acute myeloid leukemia, which comprised 13% of leukemia cases in the study population. A similar case-control study in Italy observed no association between prenatal NO<sub>2</sub> exposure and leukemia incidence ([Badaloni et al., 2013](#)). This was true in analyses limited to children aged 0–4 years and children who never moved. Controls were randomly selected from the population and matched to cases by age, sex, and region of residence. Although the analysis was based on all leukemia, acute lymphoblastic leukemia comprised 87% of cases. The authors also reported that LUR models were validated. No association was observed with PM<sub>2.5</sub> either, which was highly correlated with PM<sub>2.5</sub> ( $r = 0.78$ ).

Other studies in children reported associations between NO<sub>2</sub> and leukemia incidence or mortality but have more uncertainty regarding the exposure estimates. Information was not reported on whether a smoothed map of NO<sub>2</sub> concentrations with a 4 km<sup>2</sup> resolution ([Amigou et al., 2011](#)), or concentrations from one central site in a municipality ([Weng et al., 2008](#)) adequately represented the spatial variability of concentrations in the study areas. Another uncertainty is the examination of exposure around the time of diagnosis. Information was not reported on the extent to which recent exposure represented exposure during development of leukemia.

A study in Denmark examined adults and reported no association between NO<sub>x</sub> and leukemia incidence ([Raaschou-Nielsen et al., 2011a](#)). NO<sub>x</sub> exposure was estimated for subjects' residences from a dispersion model. Modeled estimates agreed well with measured concentrations (r = 0.90) and also were highly correlated with other traffic-related pollutants (e.g., r = 0.93 with particle number concentration).

---

#### 6.6.4 Bladder Cancer Incidence and Mortality

Similar to leukemia, recent studies provide information on potential associations of oxides of nitrogen and bladder cancer not available for the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)). Similar to leukemia, a study of adults in Denmark observed no association of bladder cancer incidence and estimates of residential NO<sub>x</sub> exposure ([Raaschou-Nielsen et al., 2011a](#)).

A study performed in Taiwan examined mortality records, comparing individuals (matched on sex, year of birth, and year of death) with and without mortality due to bladder cancer ([Liu et al., 2009a](#)). Increased odds of bladder cancer mortality was associated with increased NO<sub>2</sub> concentrations. This trend was also observed for SO<sub>2</sub>. The highest tertile of PM<sub>10</sub> concentration was also associated with bladder cancer mortality, but no association was observed for CO or O<sub>3</sub> concentrations. Elevated ORs also were observed for an index combining higher tertiles of NO<sub>2</sub> and SO<sub>2</sub> concentrations (relative to the first tertile of ≤4.32 ppb NO<sub>2</sub> and ≤20.99 ppb SO<sub>2</sub>). Although the point estimates for NO<sub>2</sub> and SO<sub>2</sub> combined are higher than those observed for NO<sub>2</sub> or SO<sub>2</sub> alone [[Supplemental Table S6-10; U.S. EPA, 2013o](#)], the 95% CIs overlap. Therefore, it is unclear whether NO<sub>2</sub> and SO<sub>2</sub> combined contribute to higher odds of mortality than either pollutant on its own. More importantly, an independent association for NO<sub>2</sub> is not discernable as confounding by PM<sub>2.5</sub> or traffic-related copollutants was not examined. An additional uncertainty is the extent to which concurrent NO<sub>2</sub> concentrations at one central site monitor in each municipality adequately represent exposure contrasts between subjects.

---

### 6.6.5 Breast Cancer Incidence

Recent studies also examined associations of NO<sub>2</sub> or NO<sub>x</sub> with breast cancer but have uncertainty in inference from their results. A Canadian study of post-menopausal breast cancer incidence using a hospital-based case-control study design estimated NO<sub>2</sub> exposure at residential addresses from LUR models and from concentrations at central site monitors combined by IDW ([Crouse et al., 2010](#)). Modeled estimates of NO<sub>2</sub> agreed better with concentrations at sites left out of the model ( $r = 0.90$ ) than with concentrations at 9 central site monitors ( $R^2 = 0.56$ ). For NO<sub>2</sub> estimated from central sites and LUR, ORs were elevated for annual average NO<sub>2</sub> around the time of diagnosis and 10-years prior. However, the wide 95% CIs produce uncertainty in the association for annual average NO<sub>2</sub> 10 years before diagnosis, a period more relevant for cancer development. Exposure was estimated for the current residential address, and to improve correspondence to past exposure, sensitivity analyses were limited to subjects who were residents of the same address for at least 10 years prior to the study. ORs remained elevated, but 95% CIs were wide. Another uncertainty is potential bias in results due to the selection of controls, which were hospital based and limit the generalizability of the study.

As with leukemia and bladder cancer, a study in Denmark observed no association between NO<sub>x</sub> and breast cancer incidence ([Raaschou-Nielsen et al., 2011a](#)). This study, unlike the one performed in Canada, included all breast cancer cases instead of limiting to post-menopausal cases. In an ecologic study of the U.S. by [Wei et al. \(2012\)](#), states with the higher NO<sub>x</sub> emissions had higher breast cancer incidence rates ( $r = 0.89$ ). Similar correlations were observed for emissions of the traffic-related pollutants CO and VOCs as well as PM<sub>10</sub> and SO<sub>2</sub>. This study is limited by its ecologic nature and the lack of individual-level data. There is no control for potential confounding factors.

---

### 6.6.6 Prostate Cancer Incidence

Studies of prostate cancer were not available for the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)). However, a recent study indicates an association with NO<sub>2</sub> exposure among men in Montreal, Canada ([Parent et al., 2013](#)). Cases were recruited through pathology departments. Population-based controls were identified through electoral lists and frequency matched by 5-year age groups. NO<sub>2</sub> exposure was estimated for the period around diagnosis with an LUR model that predicted well NO<sub>2</sub> concentrations at sites left out of the model ( $r = 0.90$ ). Prostate cancer also was associated with NO<sub>2</sub> exposures estimated by back-extrapolation for 10 and 20 years before diagnosis. Multiple sensitivity analyses were performed, including the addition of smoking and alcohol consumption as confounders, exclusion of proxy subjects, exclusion of subjects without a prostate cancer

screening in the past 5 years, exclusion of subjects at their residence for less than 10 years, and comparisons of subjects with geocoding to their exact address or to a centroid of their postal code. ORs were positive, although the wide 95% CIs in some cases indicated uncertainty in the associations. A key uncertainty in this study is confounding by PM<sub>2.5</sub> and traffic-related copollutants. NO<sub>2</sub> was the only pollutant examined. As with other cancers, prostate cancer was not associated with NO<sub>x</sub> among men in Denmark ([Raaschou-Nielsen et al., 2011a](#)).

---

## 6.6.7 Other Cancer Incidences and Mortality

A few recent studies examined incidence or mortality of an array of cancers, including cervical, brain, buccal cavity/pharynx, esophageal, stomach, colon, rectal, liver, pancreatic, laryngeal, uterine, ovarian, kidney, melanoma, non-Hodgkin lymphoma, and myeloma. An array of tumor types were examined, including central nervous system tumors, intracranial and intraspinal embryonal tumors, primitive neuroectodermal tumor, other gliomas, neuroblastoma, retinoblastoma, unilateral retinoblastoma, Wilms tumor, hepatoblastoma, rhabdomyosarcomas, germ cell tumors, extracranial and extragonadal germ cell tumors, and teratoma). A few positive associations were observed between NO<sub>x</sub> and cervical or brain cancer in adults ([Raaschou-Nielsen et al., 2011a](#)) or NO<sub>x</sub> and retinoblastoma in children ([Ghosh et al., 2013](#)). However, most associations were null, including those for NO<sub>2</sub> exposure. Both of these studies estimated NO<sub>x</sub> or NO<sub>2</sub> exposure with well-validated models. A study in Canada observed a positive association between daily NO<sub>2</sub> concentrations and mortality from all types of cancer combined ([Goldberg et al., 2013](#)). No association was reported for CO or PM<sub>2.5</sub>; however, the biological relevance of daily exposure to mortality from all types of cancer combined is not clear.

---

## 6.6.8 Genotoxicity

### 6.6.8.1 Toxicological Studies

Results from toxicological studies do not clearly indicate that NO<sub>2</sub> exposure induces mutations or genotoxic effects. Few studies examined ambient-relevant NO<sub>2</sub> exposures, and findings are mixed even for higher than ambient-relevant exposures. Of the *in vivo* assays reported in the 2008 ISA for Oxides of Nitrogen [([U.S. EPA, 2008a](#)), Annex Tables AX4-11, AX4-12, and AX4-13], two studies observed mutations or chromosomal abnormalities in rat lung cells (50,000–560,000 ppb NO<sub>2</sub> >12 days; 27,000 ppb NO<sub>2</sub>, 3 hours). No genotoxicity was seen in tests employing *Drosophila* recessive lethals

(500,000–7,000,000 ppb NO<sub>2</sub>, 1 hour), *Drosophila* wing spot test (50,000–280,000 ppb NO<sub>2</sub>, 2 days), or mouse bone marrow micronuclei (20,000 ppb, 23 hours). In vitro exposures to NO<sub>2</sub> yielded positive findings in a majority of the tests in rodent (2,000–3,000 ppb NO<sub>2</sub>, 10 minutes) and human cell lines, bacteria (5,000–90,000 ppb NO<sub>2</sub>, 30 minutes), and plants (5,000 ppb NO<sub>2</sub>, 24 hours).

Evidence for genotoxicity is equally inconclusive in limited examination of ambient-relevant NO<sub>2</sub> exposures. NO<sub>2</sub> exposures of 100–5,000 ppb (6 hours) did not induce chromosomal aberrations in mouse spermatocytes or lymphocytes [(U.S. EPA, 2008a), Annex Table AX4-12]. A recent study observed that male rats exposed to 2,660 or 5,320 ppb NO<sub>2</sub> for 6 h/day for 7 days had increases in DNA damage in the liver, lung, and kidney, increases in micronuclei formation in bone marrow, and increases in DNA-protein cross-links in the brain and liver (Han et al., 2013). Exposure to 5,320 ppb NO<sub>2</sub> also induced DNA damage in the spleen and heart.

The 2008 ISA for Oxides of Nitrogen discussed the possibility that NO<sub>2</sub> could produce cancer via nitrosamine formation (U.S. EPA, 2008c). N-nitroso compounds can be generated endogenously in the human body from NO<sub>2</sub> via processes that generate nitrite (NO<sub>2</sub><sup>-</sup>) or nitrate. Further, NO<sub>2</sub> is known to react with amines to produce nitrosamines, known animal carcinogens. Such reactions have not been demonstrated with ambient-relevant exposures. Peroxyacetyl nitrate (PAN) is an oxide of nitrogen produced by reactions involving ultraviolet, NO<sub>2</sub>, and hydrocarbons (Section 2.2). PAN is weakly mutagenic in the lungs of the highly susceptible big Blue (R) mice and in *Salmonella* and produces a unique signature mutation (DeMarini et al., 2000). But, such effects were observed with PAN exposures more than five order of magnitude above typical ambient concentrations (Section 2.4.1).

---

### 6.6.8.2 Epidemiologic Studies

Similar to toxicological evidence, a recent epidemiologic study observed mixed evidence for associations between NO<sub>2</sub> exposure and genotoxicity in children in Italy living near chipboard industries (Marcon et al., 2014). NO<sub>2</sub> was measured 3 km from the industries, and residential exposure was estimated by kriging. NO<sub>2</sub> exposure was not associated with results of comet assays (i.e., tail length, moment, or intensity) but was associated with some results of micronucleus assays. A 10-ppb increase in NO<sub>2</sub> concentration was associated with a 1.16% (95% CI: 0.6, 1.7) change in binucleated cells and an increased risk ratio of nuclear buds of 3.72 (95% CI: 1.67, 7.73). Formaldehyde was associated with nuclear buds and comet tail intensity and moment but not with binucleated cells. Potential confounding of NO<sub>2</sub> associations was not examined.

---

### 6.6.9 Summary and Causal Determination

The evidence for long-term NO<sub>2</sub> exposure and cancer is suggestive of, but not sufficient to infer, a causal relationship. This conclusion is based primarily on some, but not entirely consistent, epidemiologic and toxicological evidence for lung cancer. There is not toxicological evidence that NO<sub>2</sub> at ambient-relevant exposure concentrations is a direct carcinogen. A few recent epidemiologic studies each indicate associations of NO<sub>2</sub> exposure with leukemia, prostate cancer, and bladder cancer mortality. However, none of these epidemiologic studies examined potential confounding by key traffic-related pollutants, and biological plausibility from toxicological studies is lacking.

The current conclusion represents a change from the “inadequate to infer the presence or absence of a causal relationship” determination made in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)). At that time, there was some toxicological evidence that NO<sub>2</sub> exposure may act as a tumor promotor, and a few epidemiologic studies indicating associations between long-term NO<sub>2</sub> exposure and lung cancer incidence. The change to “suggestive, but not sufficient, to infer a causal relationship” in this ISA is based on the positive associations observed in some epidemiologic studies between NO<sub>2</sub> exposure and lung cancer incidence and mortality studies and the limited coherence provided by some toxicological studies. The key evidence as it relates to the causal determination is summarized in [Table 6-20](#) using the framework described in [Table II](#) of the [Preamble](#).

Epidemiologic studies of lung cancer incidence have mixed results, with some studies reporting no associations and others reporting positive associations. Evidence is inconsistent particularly among studies that estimated subjects’ residential NO<sub>2</sub> exposure with well-validated models. Although epidemiologic findings for NO<sub>2</sub>-related lung cancer mortality are not entirely consistent, more studies reported positive associations. Many studies of lung cancer mortality estimated NO<sub>2</sub> exposure with LUR or dispersion models that were shown to predict well ambient NO<sub>2</sub> concentrations in the study areas. Most of these studies included large sample sizes and aimed to account for many potential confounders, including age, SES, and smoking exposures. A major limitation of the epidemiologic evidence is that investigation into potential confounding by PM<sub>2.5</sub>, diesel exhaust, polycyclic aromatic hydrocarbons, and VOCs is largely absent. In fact, in many epidemiologic studies, NO<sub>2</sub> was the only pollutant examined. The uncertainty as to whether NO<sub>2</sub> exposure independently is related to lung cancer also exists in the toxicological evidence. Toxicological data provide no clear evidence of NO<sub>2</sub> acting as a complete carcinogen, and agencies that classify carcinogens including the Department of Health and Human Services, the International Agency for Research on Cancer, and the EPA have not classified oxides of nitrogen for potential carcinogenicity. The American Conference of Industrial Hygienists has classified NO<sub>2</sub> as A4 (not classifiable for humans).

or animals). Genotoxic and mutagenic studies with NO<sub>2</sub> have mixed results. However, some studies showed that NO<sub>2</sub> may act as a tumor promoter at the site of contact. Co-exposure to a known carcinogen (nitrosamine), exposure of rodents with spontaneously high tumor rates, or exposure of rodents injected with metastatic cancer cells ambient-relevant NO<sub>2</sub> exposures increased lung tumor burden or the number of rodents with lung tumors. A role in tumor promotion may be possible due to an effect of NO<sub>2</sub> on producing cellular damage, inducing respiratory epithelial hyperplasia ([Section 6.2.6](#)), or promoting regenerative cell proliferation.

In conclusion, while some studies observed no associations, some epidemiologic findings point to lung cancer incidence and mortality in association with NO<sub>2</sub> exposure estimated using well-validated models. Epidemiologic studies largely did not examine confounding by key traffic-related copollutants, and toxicological studies provide no clear evidence of NO<sub>2</sub> acting as a complete carcinogen. However, some toxicological studies in tumor-prone rodents or with co-exposure with a known carcinogen indicate that ambient-relevant NO<sub>2</sub> exposures can increase lung tumor incidence. The evidence from some epidemiologic studies for lung cancer incidence and mortality combined with some toxicological evidence for lung tumor promotion is suggestive of, but not sufficient to infer, a causal relationship between long-term exposure to NO<sub>2</sub> and cancer.

**Table 6-20 Summary of evidence, which is suggestive of, but not sufficient to infer, a causal relationship between long-term nitrogen dioxide exposure and cancer.**

Rationale for Causal Determination <sup>a</sup>	Key Evidence <sup>b</sup>	Key References <sup>b</sup>	NO <sub>2</sub> Concentrations Associated with Effects <sup>c</sup>
<b>Lung Cancer</b>			
Evidence from epidemiologic studies generally supportive but not consistent	Positive associations with lung cancer incidence or mortality in multiple studies conducted in the U.S., Canada, and Europe. Lack of examination of PM <sub>2.5</sub> or traffic-related copollutants.	<a href="#">Nyberg et al. (2000)</a> , † <a href="#">Cesaroni et al. (2013)</a> , <a href="#">Filleul et al. (2005)</a> , † <a href="#">Carey et al. (2013)</a> , † <a href="#">Jerrett et al. (2013)</a> , † <a href="#">Hystad et al. (2013)</a> Section <a href="#">6.6.2</a>	Means: 12, 23.2 ppb for annual avg, 12.3, 15.4 ppb for multi-yr avg, 6.4–32.4 ppb across cities in multicity study
	No associations with lung cancer incidence or mortality in multiple studies conducted in the U.S. and Europe.	† <a href="#">Raaschou-Nielsen et al. (2013a)</a> , † <a href="#">Brunekreef et al. (2009)</a> , † <a href="#">Papathomas et al. (2011)</a> , † <a href="#">Beelen et al. (2008b)</a> , † <a href="#">Hart et al. (2011)</a>	Means: 14.2 ppb for 15-yr avg, 19.6 ppb for 20-yr avg, 2.8–31.8 ppb for annual avg across cities in multicity study
Lack of toxicological evidence for direct effect on carcinogenesis but limited evidence for tumor promotion with ambient-relevant exposures	NO <sub>2</sub> exposure alone does not induce lung tumors. Mixed evidence for tumor promotion with co-exposure to known carcinogen. Limited evidence for facilitation of metastasis.	<a href="#">Adkins et al. (1986)</a> , <a href="#">Richters and Damji (1990)</a> , <a href="#">Wagner et al. (1965)</a> , <a href="#">Richters and Kuraitis (1981)</a> , <a href="#">Richters and Kuraitis (1983)</a> , <a href="#">Ichinose et al. (1991)</a> Section <a href="#">6.6.2.2</a>	Tumor promotion with nitrosamine exposure: inconsistent 250–5,000 ppb for 6–17 mo. Facilitation of metastases: 300–800 ppb for 10 or 12 weeks
Limited evidence for key events in proposed mode of action	Finding of mutagenicity and micronucleus formation in ex vivo culture of primary human nasal epithelial cells exposed to NO <sub>2</sub> .	† <a href="#">Koehler et al. (2013)</a> , † <a href="#">Koehler et al. (2011)</a> , † <a href="#">Koehler et al. (2010)</a> Section <a href="#">6.6.2.2</a>	10, 100, 1,000, 10,000 ppb
<b>Cancers of Sites Outside the Lung</b>			
Limited epidemiologic evidence and uncertainty regarding independent effect of NO <sub>2</sub>	Positive associations with leukemia, bladder cancer, and prostate cancer. Lack of examination of PM <sub>2.5</sub> or traffic-related copollutants.	† <a href="#">Liu et al. (2009a)</a> , † <a href="#">Parent et al. (2013)</a> , † <a href="#">Ghosh et al. (2013)</a> Sections <a href="#">6.6.3</a> , <a href="#">6.6.4</a> , <a href="#">6.6.6</a>	Means or medians: 17–24 ppb for annual avg
Weak evidence for key events in proposed mode of action	No mutagenicity or genotoxicity in animal models with ambient-relevant exposure. Mixed evidence with higher exposure.	2008 NO <sub>x</sub> ISA Annex Tables AX4-11, AX 4-12, and AX4-13 ( <a href="#">U.S. EPA, 2008a</a> )	

h = hours; min = minutes; mo = months; NO<sub>2</sub> = nitrogen dioxide; ppb = parts per billion; yr = yr.

<sup>a</sup>Based on aspects considered in judgments of causality and weight of evidence in causal framework in [Tables I](#) and [II](#) of the [Preamble](#).

<sup>b</sup>Describes the key evidence and references, supporting and contradicting, contributing most heavily to causal determination and, where applicable, to uncertainties or inconsistencies. References to earlier sections indicate where the full body of evidence is described.

<sup>c</sup>Describes the NO<sub>2</sub> concentrations with which the evidence is substantiated (for experimental studies, ≤ 5,000 ppb).

†Studies published since the 2008 ISA for Oxides of Nitrogen.

---

# CHAPTER 7      POPULATIONS AND LIFESTAGES POTENTIALLY AT RISK FOR HEALTH EFFECTS RELATED TO NITROGEN DIOXIDE EXPOSURE

---

## 7.1      Introduction

This chapter aims to characterize populations and lifestyles that may be at increased risk for detrimental health effects in response to ambient NO<sub>2</sub> exposure, using the approach developed for the 2013 ISAs for Ozone and Lead ([U.S. EPA, 2013c, e](#)). The NAAQS are intended to protect public health with an adequate margin of safety. Protection is provided for both the population as a whole and those potentially at increased risk for health effects in response to exposure to a criteria air pollutant ([Preface](#) to the ISA). The scientific literature has used a variety of terms to describe populations at increased risk of an air pollutant-related health effect or factors that increase people's risk. These terms include susceptible, vulnerable, sensitive, and at-risk, with recent literature introducing the term response-modifying factor ([Vinikoor-Imler et al., 2014](#)) ([Preamble](#) to the ISA). Due to the inconsistency in definitions for these terms across the scientific literature and the lack of a consensus on terminology in the scientific community, as detailed in the [Preamble](#), recent ISAs have used the broadly applicable term “at-risk” population or lifestyle. Thus, this chapter identifies, evaluates, and characterizes at-risk factors to address the main question of what populations and lifestyles are at increased risk of an NO<sub>2</sub>-related health effect. Some factors may reduce risk, and these are acknowledged in this evaluation. However, for the purposes of identifying those populations or lifestyles at greater risk to inform decisions on the NAAQS, the focus of this chapter is on characterizing those factors that may increase risk.

Individuals, and ultimately populations, could be at increased risk of an air pollutant-related health effect for various reasons. As discussed in the [Preamble](#), risk may be modified by intrinsic or extrinsic factors, differences in internal dose, or differences in exposure to air pollutant concentrations. The objective of this chapter is to identify, evaluate, and characterize the evidence for factors that potentially increase the risk of health effects related to exposure to NO<sub>2</sub>, regardless of whether the change in risk is due to intrinsic factors, extrinsic factors, increased internal dose, increased exposure, or a combination. It is important to note that although risk of an NO<sub>2</sub>-related health effect is evaluated for each factor individually, it is likely that portions of the population are at increased risk of an NO<sub>2</sub>-related health effect due to a combination of co-occurring factors (e.g., residential location and SES). However, information on the interaction

among factors remains limited. Thus, the following sections characterize the overall confidence for a particular factor to result in increased risk for NO<sub>2</sub>-related health effects.

---

## 7.2 Approach to Evaluating and Characterizing the Evidence for At-Risk Factors

The systematic approach used to evaluate factors that may increase the risk of a population or specific lifestage to an air pollutant-related health effect is described in more detail in the [Preamble](#). The evaluation emphasizes relevant health studies discussed in [Chapter 5](#) and [Chapter 6](#) of this ISA building on the evidence presented in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) and the 1993 Air Quality Criteria for Oxides of Nitrogen ([U.S. EPA, 1993a](#)). Based on the approach developed for the ISAs for Ozone and Lead ([U.S. EPA, 2013c, e](#)), evidence is integrated across scientific disciplines, across health effects, and where available, with information on exposure and dosimetry ([Chapters 3](#) and [4](#)). Conclusions are drawn based on the overall confidence that a specific factor may characterize a population or lifestage at increased risk of an NO<sub>2</sub>-related health effect.

As discussed in the [Preamble](#), this evaluation focuses on health effect studies that conduct stratified analyses to compare populations or lifestages exposed to similar air pollutant concentrations within the same study design. For the evaluation of these studies, important considerations include whether the stratified analyses were planned a priori or were post hoc analyses, whether the study conducted multiple comparisons, and whether there were small sample sizes in individual strata. These study design issues can increase the probability of finding associations by chance or reduce power to detect associations in subgroup analyses. Experimental studies that examine health effects exclusively in human subjects or animal models with a particular factor, such as pre-existing disease, are also important lines of evidence to evaluate because they inform judgments of the coherence and biological plausibility of effects observed in epidemiologic studies, as well as the independent effect of NO<sub>2</sub> exposure. Additionally, studies examining whether factors may result in differential exposure to NO<sub>2</sub> are included. Excluded from this evaluation are a small group of studies that examined potential at-risk populations or lifestages based on NO<sub>x</sub> exposures because they do not directly inform understanding of whether a population is at increased risk of an NO<sub>2</sub>-related health effect ([Section 1.1](#)).

The objective of this chapter is not to detail individual study results but to integrate information in preceding chapters and describe the basis for characterizing the evidence for each factor to increase risk of NO<sub>2</sub>-related health effects as adequate, suggestive, inadequate, or no effect ([Table 7-1](#)). Classifications are based on the cumulative evidence

available for each factor, regardless of whether the risk is due to increased exposure, internal dose, biological effect, or a combination of reasons. The classification provides a consistent basis for evaluating the evidence for an at-risk population or lifestage and for describing the overall confidence in the evidence. The classifications are not direct assessments of causation but rather build on causal determinations to inform decisions on whether a NAAQS provides an adequate margin of safety across groups in the population. Thus, for NO<sub>2</sub>, judgments about at-risk factors emphasize evidence for asthma exacerbation and asthma development, which are the basis for concluding that relationships of short-term (Section 5.2.9) and long-term (Section 6.2.9) NO<sub>2</sub> exposure with respiratory effects, respectively, are causal and likely to be causal. These are the health effects for which there is the strongest evidence for NO<sub>2</sub> exposure having effects independent of traffic-related copollutants. The factors that are evaluated in this chapter include pre-existing diseases and conditions (Section 7.3), genetic factors (Section 7.4), sociodemographic factors (Section 7.5), and behavioral and other factors (Section 7.6). Section 7.7 summarizes the evidence for each factor to increase risk of NO<sub>2</sub>-related health effects.

**Table 7-1 Characterization of evidence for factors potentially increasing the risk for nitrogen dioxide-related health effects.**

<b>Classification</b>	<b>Health Effects</b>
Adequate evidence	There is substantial, consistent evidence within a discipline to conclude that a factor results in a population or lifestage being at increased risk of air pollutant-related health effect(s) relative to some reference population or lifestage. Where applicable, this evidence includes coherence across disciplines. Evidence includes multiple high-quality studies.
Suggestive evidence	The collective evidence suggests that a factor results in a population or lifestage being at increased risk of air pollutant-related health effect(s) relative to some reference population or lifestage, but the evidence is limited due to some inconsistency within a discipline or, where applicable, a lack of coherence across disciplines.
Inadequate evidence	The collective evidence is inadequate to determine whether a factor results in a population or lifestage being at increased risk of air pollutant-related health effect(s) relative to some reference population or lifestage. The available studies are of insufficient quantity, quality, consistency, and/or statistical power to permit a conclusion to be drawn.
Evidence of no effect	There is substantial, consistent evidence within a discipline to conclude that a factor does not result in a population or lifestage being at increased risk of air pollutant-related health effect(s) relative to some reference population or lifestage. Where applicable, the evidence includes coherence across disciplines. Evidence includes multiple high-quality studies.

---

## 7.3 Pre-Existing Disease/Conditions

Individuals with pre-existing disease may be considered at greater risk for some air pollution-related health effects because they may be in a compromised biological state depending on the disease and severity. The 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) concluded that those with pre-existing pulmonary conditions were likely to be at greater risk for NO<sub>2</sub>-related health effects, especially individuals with asthma. Among recent studies evaluating effect measure modification by pre-existing disease, the largest group examined asthma ([Section 7.3.1](#)). Several studies are available on other diseases: COPD ([Section 7.3.2](#)), CVD ([Section 7.3.3](#)), diabetes ([Section 7.3.4](#)), and obesity ([Section 7.3.5](#)). [Table 7-2](#) presents the prevalence of these diseases according to the Centers for Disease Control's National Center for Health Statistics ([Blackwell et al., 2014](#)), including the proportion of adults with a current diagnosis categorized by age and geographic region. The large proportions of the U.S. population affected by many chronic diseases, including various cardiovascular diseases, indicate the potential importance of characterizing the risk of NO<sub>2</sub>-related health effects for affected populations.

**Table 7-2 Prevalence of selected respiratory, cardiovascular, and metabolic diseases and disorders among adults by age and region in the United States in 2012.**

Chronic Disease/Condition	Adults (18+)	Age (%) <sup>a</sup>				Region (%) <sup>b</sup>			
	n (in thousands)	18-44	45-64	65-74	75+	North-east	Midwest	South	West
All (n, in thousands)	234,921	111,034	82,038	23,760	18,089	42,760	53,378	85,578	53,205
<b>Selected respiratory diseases</b>									
Asthma <sup>c</sup>	18,719	8.1	8.4	7.8	6.0	9.2	8.1	7.3	7.8
COPD	6,790	0.5	3.8	6.9	8.6	2.2	3.2	3.0	2.1
<b>Selected cardiovascular diseases/conditions</b>									
All heart disease	26,561	3.8	12.1	24.4	36.9	10.0	11.6	11.6	9.3
Coronary heart disease	15,281	0.9	7.1	16.2	25.8	5.3	6.5	7.0	5.1
Hypertension	59,830	8.3	33.7	52.3	59.2	21.4	24.1	26.6	21.5
Stroke	6,370	0.6	2.8	6.3	10.7	1.8	2.5	3.0	2.5
<b>Selected metabolic disorders/conditions</b>									
Diabetes	21,319	2.4	12.7	21.1	19.8	7.6	8.4	10.0	7.3
Obesity (BMI ≥ 30 kg/m <sup>2</sup> )	64,117	26.0	33.7	29.7	18.0	25.1	29.9	29.9	25.2
Overweight (BMI 25-30 kg/m <sup>2</sup> )	78,455	31.4	36.8	40.7	38.6	34.3	34.1	34.2	35.3

BMI = body mass index; COPD = chronic obstructive pulmonary disease.

<sup>a</sup>Percentage of individual adults within each age group with disease, based on n (at the top of each age column).

<sup>b</sup>Percentage of individual adults within each geographic region with disease, based on n (at the top of each region column).

<sup>c</sup>Asthma prevalence is reported for "still has asthma."

Source: [Blackwell et al. \(2014\)](#); National Center for Health Statistics: Data from Tables 1 and 2; Tables 3 and 4; Tables 7 and 8; and Tables 28 and 29 of the Centers for Disease Control and Prevention report.

### 7.3.1 Asthma

Approximately 8.0% of adults and 9.3% of children (age <18 years) in the U.S. currently have asthma ([Blackwell et al., 2014](#); [Bloom et al., 2013](#)), and it is the leading chronic illness affecting children. This ISA concludes that there is a causal relationship between short-term NO<sub>2</sub> exposure and respiratory effects, based primarily on evidence for effects on asthma exacerbation ([Section 5.2.9](#)). The evidence demonstrating NO<sub>2</sub>-induced

asthma exacerbation was the basis for the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) concluding that individuals with pre-existing pulmonary conditions, particularly those with asthma, are likely at greater risk of NO<sub>2</sub>-related health effects. The current evaluation includes controlled human exposure and epidemiologic studies that compared NO<sub>2</sub>-related health effects between groups with or without asthma ([Tables 7-3](#) and [7-4](#)). As a whole, results of these comparisons are variable; however, controlled human exposure studies provide compelling evidence that people with asthma are at greater risk for NO<sub>2</sub>-related respiratory effects than people without asthma.

Information is sparse to determine whether NO<sub>2</sub> exposure or internal dose differs between people with and without asthma. Epidemiologic studies comparing NO<sub>2</sub>-related health effects between children with and without asthma did not have measures of NO<sub>2</sub> exposure for individual children; such measures were not required because the study designs relied on temporal variation in short-term NO<sub>2</sub> exposure. People with asthma tend to have oronasal breathing; however, the implications on differential uptake of NO<sub>2</sub> in the respiratory tract have not been examined ([Section 4.2.2.3](#)). Based on limited study, some data suggest that children with asthma spend less time outdoors on high air pollution days ([Mansfield et al., 2006](#)); other data point to children with asthma spending more time outdoors in general but with less vigorous activity in summer ([Avol et al., 1998](#)). These limited data on outdoor activity also do not clearly indicate whether people with asthma could have higher NO<sub>2</sub> exposure or internal dose than people without asthma. Nor are the data conclusive in indicating whether epidemiologic studies are subject to greater exposure measurement error for people with asthma and thus less likely to detect differences in NO<sub>2</sub>-related health effects.

Controlled human exposure studies demonstrating NO<sub>2</sub>-induced increases in airway responsiveness in adults with asthma provide key evidence for an independent, causal relationship between NO<sub>2</sub> exposure and respiratory effects ([Section 5.2.9](#)). This evidence also demonstrates greater sensitivity of adults with asthma to short-term NO<sub>2</sub> exposure compared to adults without asthma. A meta-analysis conducted by [Folinsbee \(1992\)](#) demonstrates that NO<sub>2</sub> exposures in the range of 100–300 ppb increased airway responsiveness in adults with asthma ([Table 7-3](#)). The meta-analysis combined groups that varied with respect to respiratory symptoms and medication use at the time of assessment but similarly had high prevalence (50–100%) of atopic asthma. Additionally, in many studies, these participants were characterized as having mild asthma. Few studies of healthy adults examined airway responsiveness for NO<sub>2</sub> exposures below 300 ppb, and results indicate increased airway responsiveness in healthy adults only for NO<sub>2</sub> exposures >1,000 ppb. In comparison to airway responsiveness, there is inconsistent evidence for the effects of short-term NO<sub>2</sub> exposure on lung function in adults with asthma in the absence of a bronchoconstricting agent, and the limited evidence is inconclusive in

demonstrating differences in response between healthy adults and those with asthma [(Vagaggini et al., 1996; Jörres et al., 1995; Linn et al., 1985b); Table 7-3].

Epidemiologic evidence does not clearly show differences in NO<sub>2</sub>-related health effects between children with and without asthma (Table 7-4). Evidence is inconsistent in studies that explicitly noted a priori comparisons (Patel et al., 2010; Barraza-Villarreal et al., 2008; Holguin et al., 2007) as well as studies judged to have strong exposure assessment, such as those monitoring NO<sub>2</sub> at or near children's schools (Lin et al., 2011; Flamant-Hulin et al., 2010; Holguin et al., 2007). Some of these studies had large numbers of children with asthma for comparison. Effect measure modification by asthma also is inconsistent for cardiovascular and metabolic effects (Table 7-4), although inference is weak because of uncertainty as to whether NO<sub>2</sub> exposure has independent relationships with these effects (Section 6.3.9). A notable difference between epidemiologic and controlled human exposure studies comparing people with and without asthma is that the epidemiologic studies examined a more diverse set of respiratory outcomes and asthma phenotypes. Asthma is a heterogeneous disease as demonstrated in Section 5.2.2. One limitation of epidemiologic studies that may obscure potential differences among people with and without asthma is that these studies commonly analyze all people with asthma together, even though there are varying phenotypes and triggers of asthma as indicated by varying atopy and asthma medication use.

Several lines of evidence indicate that people with asthma are at increased risk for NO<sub>2</sub>-related health effects. The causal relationship determined for short-term NO<sub>2</sub> exposure and respiratory effects is based on the evidence for asthma exacerbation (Section 5.2.9). Controlled human exposure studies demonstrate that NO<sub>2</sub> has an independent effect on increasing airway responsiveness in adults with asthma and show increased sensitivity of adults with asthma compared to healthy adults. Epidemiologic studies do not clearly demonstrate differences between populations with and without asthma. The study populations represent an array of asthma phenotypes, and limited epidemiologic evidence indicates larger NO<sub>2</sub>-related respiratory effects in children with asthma not using asthma medication. Thus, the epidemiologic results are not necessarily incoherent with experimental findings from populations of mostly mild, atopic asthma. Information is insufficient to determine whether the increased risk for people with asthma is attributable to higher NO<sub>2</sub> exposure or internal dose. There is clear evidence for an effect of NO<sub>2</sub> exposure on asthma exacerbation and for increased sensitivity of adults with asthma to NO<sub>2</sub>-induced increases in airway responsiveness in controlled human exposure studies. Therefore, evidence is adequate to conclude that people with asthma are at increased risk for NO<sub>2</sub>-related health effects.

**Table 7-3 Controlled human exposure studies evaluating pre-existing asthma.**

Factor Evaluated	Reference Category	Direction of Effect Modification or Effect <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Asthma-related outcomes and short-term exposure</b>						
Asthma n = 33 ≤300 ppb NO <sub>2</sub>	Healthy n = 36 <1,000 ppb NO <sub>2</sub>	↑	Airway responsiveness	n = 355	Range: 100 ppb NO <sub>2</sub> for 1 h to 7,500 ppb NO <sub>2</sub> for 2 h of exposure; Exposures at rest	<a href="#">Folinsbee (1992)</a>
Asthma n = 12	Healthy n = 8	—	Airway inflammation	n = 20 Ages 21–37 yr	1,000 ppb NO <sub>2</sub> for 3 h; Exercise 10 min on/10 min off at individual's maximum workload	<a href="#">Jörres et al. (1995)</a>
		↑	Lung function decrement			
Asthma n = 4	Healthy n = 7	—	Lung function decrement	n = 11 Mean age 31.5 yr	300 ppb NO <sub>2</sub> for 1 h; Exercise at $\dot{V}_E = 25$ L/min	<a href="#">Vagaggini et al. (1996)</a>
Asthma n = 23	Healthy n = 25	—	Airway resistance	n = 48 Ages 18–36 yr	4,000 ppb NO <sub>2</sub> for 75 min; Two 15-min periods of exercise at $\dot{V}_E = 25$ L/min and 50 L/min	<a href="#">Linn et al. (1985b)</a>
Atopic asthma	None	—	Lung function decrement, allergen response	n = 11 Mean age 31.2 yr	(1) 200 ppb NO <sub>2</sub> for 6 h (2) 200 ppb NO <sub>2</sub> and 100 ppb O <sub>3</sub> for 6 h (3) 400 ppb NO <sub>2</sub> for 3 h (4) 400 ppb NO <sub>2</sub> and 200 ppb O <sub>3</sub> for 3 h (1–4) Exercise 10 min on/40 min off at $\dot{V}_E = 32$ L/min	<a href="#">Jenkins et al. (1999)</a>
Asthma	None	—	Lung function decrement	n = 41 Mean age 31 yr	200 ppb NO <sub>2</sub> for 2 h; Exercise 15 min on/15 min off at $\dot{V}_E = \sim 2$ times resting	<a href="#">Kleinman et al. (1983)</a>
Asthma	None	↑	Lung function decrement	n = 15 Mean age 33 yr	300 ppb NO <sub>2</sub> for 30 min Exercise 10 min on/20 min off at $\dot{V}_E > 3$ times resting	<a href="#">Bauer et al. (1986)</a>
Asthma	None	—	Airway resistance	n = 11 Ages 7–55 yr	250 ppb NO <sub>2</sub> for 30 min; Exercise 10 min on/20 min off at $\dot{V}_E$ 3 times resting	<a href="#">Jörres and Magnussen (1991)</a>

NO<sub>2</sub> = nitrogen dioxide; O<sub>3</sub> = ozone;  $\dot{V}_E$  = minute ventilation.

<sup>a</sup>Up facing arrow indicates that the effect of NO<sub>2</sub> is greater (e.g., larger lung function decrement, larger increase in airway inflammation) in the group with the factor evaluated than in the reference group. Down facing arrow indicates that the effect of NO<sub>2</sub> is smaller in the group with the factor evaluated than in the reference group. A dash indicates no difference in NO<sub>2</sub>-related health effect between groups. In some studies, only a population with pre-existing disease was examined; therefore, the arrow or dash represents the direction of the effect in that population after exposure to NO<sub>2</sub> relative to exposure to filtered air.

**Table 7-4 Epidemiologic studies evaluating pre-existing asthma.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Asthma-related outcomes and short-term exposure</b>						
Asthma n = 57	No asthma n = 192	↑	Asthma symptoms	n = 249 Ages 14–20 yr	New York, NY, 2003–2005	<a href="#">Patel et al. (2010)</a> †
Asthma n = 50, 89% with atopy	No asthma n = 158, 72% with atopy	↓	Pulmonary inflammation, lung function decrement	n = 208 Ages 7.9–11 yr	Mexico City, 2003–2005	<a href="#">Barraza-Villarreal et al. (2008)</a> †
Asthma n = 8	No asthma n = 30	—	Pulmonary inflammation	n = 38 Ages 9–12 yr	Beijing, China, 2008	<a href="#">Lin et al. (2011)</a> †
Asthma n = 100	No asthma n = 100	—	Pulmonary inflammation	n = 200 Ages 6–12 yr	Ciudad Juarez, Mexico, 2001–2002	<a href="#">Holguin et al. (2007)</a> †
Asthma n = 34	No asthma n = 70	—	Pulmonary inflammation	n = 104 Mean age 10.3 yr	Clermont-Ferrand, France	<a href="#">Flamant-Hulin et al. (2010)</a> †
Asthma n = 169	No asthma n = 2,071	↓	Pulmonary inflammation	n = 2,240 Ages 5–7 yr	southern California, 2004–2005	<a href="#">Berhane et al. (2011)</a> †
<b>Nonasthma outcomes and long-term exposure</b>						
Asthma n = 50	No asthma n = 1,934	↑	Incident stroke	n = 1,984 Ages 50–65 yr at baseline	Copenhagen, Aarhus counties, Denmark, 1993–2006	<a href="#">Andersen et al. (2012b)</a> †
		↑	Fatal stroke			
Asthma n = 1,273	No asthma n = 50,545	—	Diabetes	n = 51,818 Ages 50–65 yr at baseline	Copenhagen, Aarhus counties, Denmark, 1993–2006	<a href="#">Andersen et al. (2012c)</a> †

<sup>a</sup>Up facing arrow indicates that the effect of nitrogen dioxide (NO<sub>2</sub>) is greater (e.g., larger lung function decrement, larger increase in pulmonary inflammation) in the group with the factor evaluated than in the reference group. Down facing arrow indicates that the effect of NO<sub>2</sub> is smaller in the group with the factor evaluated than in the reference group. A dash indicates no difference in NO<sub>2</sub>-related health effect between groups.

†Studies published since the 2008 ISA for Oxides of Nitrogen

### 7.3.2 Chronic Obstructive Pulmonary Disease

Chronic lower respiratory disease, including COPD, was ranked as the third leading cause of death in the U.S. in 2011 ([Hoyert and Xu, 2012](#)). COPD comprises chronic bronchitis and emphysema and affects approximately 6.8 million adults in the U.S., respectively ([Table 7-2](#)). Given that people with COPD have compromised respiratory

function and systemic inflammation, they could be at increased risk for an array of NO<sub>2</sub>-related health effects. Evidence for differential NO<sub>2</sub>-related respiratory or cardiovascular effects between adults with COPD and those without COPD is weak ([Tables 7-5](#) and [7-6](#)). Information on potential NO<sub>2</sub> exposure or dosimetry differences is lacking. Similar total personal NO<sub>2</sub> exposure was measured in adults with COPD and adults with prior myocardial infarction (MI), but no comparison was made to healthy adults ([Suh and Zanobetti, 2010b](#)).

Compared with asthma exacerbation, there is greater uncertainty regarding a relationship between short-term NO<sub>2</sub> exposure and COPD exacerbation ([Section 5.2.4](#)). This is illustrated by the lack of consistent evidence from controlled human exposure studies for changes in lung function or pulmonary inflammation in adults with COPD following NO<sub>2</sub> exposure ([Gong et al., 2005](#); [Linn et al., 1985a](#)). Only a few studies compared adults with COPD and healthy adults, and not all indicated larger NO<sub>2</sub>-induced decrements in lung function in adults with COPD ([Table 7-5](#)). Among adults with COPD, NO<sub>2</sub> exposures of 300 ppb for 1 or 4 hours induced decreases in lung function of 4.8, 8.2 ([Morrow et al., 1992](#)) or 10% ([Vagaggini et al., 1996](#)) relative to air control exposures. In contrast, in healthy adults, NO<sub>2</sub> did not have any effect on lung function or resulted in increased lung function. However, adults with COPD were older than healthy adults and/or had a higher prevalence of smoking, which could have influenced results ([Table 7-5](#)). For example, in one study, smokers had larger NO<sub>2</sub>-induced decrements in lung function independently of COPD ([Morrow et al., 1992](#)).

COPD was not observed to modify associations between long-term NO<sub>2</sub> exposure and diabetes ([Eze et al., 2014](#); [Andersen et al., 2012c](#)), but some epidemiologic studies show larger associations of short-term or long-term NO<sub>2</sub> exposure with various cardiovascular effects among adults with COPD ([Table 7-6](#)). Inference is limited from studies of cardiovascular effects due to lack of comparison to healthy groups in the short-term exposure studies ([Suh and Zanobetti, 2010b](#); [Peel et al., 2007](#)) and uncertainty regarding an independent relationship with cardiovascular effects for both short-term and long-term NO<sub>2</sub> exposure ([Sections 5.3.11](#) and [6.3.9](#)).

In conclusion, some but not all epidemiologic evidence points to larger NO<sub>2</sub>-related cardiovascular effects in adults with COPD, and there is uncertainty as to whether the findings reflect an independent effect of NO<sub>2</sub>. NO<sub>2</sub> exposure and internal dose differences for people with COPD are unknown. Controlled human exposure studies do not clearly demonstrate that NO<sub>2</sub> exposure induces respiratory effects in adults with COPD, and the limited findings for larger lung function decrements in adults with COPD relative to healthy adults may be influenced by differences between groups in age or smoking. The limited and inconsistent evidence from controlled human exposure studies for

NO<sub>2</sub>-related changes in lung function is inadequate to determine whether people with COPD are at increased risk for NO<sub>2</sub>-related health effects.

**Table 7-5 Controlled human exposure studies evaluating pre-existing chronic obstructive pulmonary disease.**

Factor Evaluated	Reference Category	Direction of Effect Modification or Effect <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Nonasthma outcomes and short-term exposure</b>						
COPD n = 20	Healthy n = 20	↑	Lung function decrement	n = 40 Mean age 59.9 yr	300 ppb NO <sub>2</sub> for 4 h; Three 7 min periods of exercise at $\dot{V}_E = \sim 4$ times resting	<a href="#">Morrow et al. (1992)</a>
		—	Symptoms, respiratory conductance			
COPD n = 7	Healthy n = 7	↑	Lung function decrement	n = 14 Mean age COPD: 58 yr Healthy: 34 yr	300 ppb NO <sub>2</sub> for 1 h; Exercise at $\dot{V}_E = 25$ L/min	<a href="#">Vagaggini et al. (1996)</a>
		—	Sputum cell counts, symptoms			
COPD n = 18	Healthy n = 6	—	Lung function decrement, heart rate, blood pressure, symptoms	n = 24 Mean age COPD: 72 yr Healthy: 68 yr	(1) 400 ppb NO <sub>2</sub> for 2 h (2) 200 µg/m <sup>3</sup> CAPs for 2 h (3) 400 ppb NO <sub>2</sub> and 200 µg/m <sup>3</sup> CAPs for 2 h (1–3) Exercise 15 min on/15 min off at $\dot{V}_E = \sim 2$ times resting	<a href="#">Gong et al. (2005)</a>
COPD	None	—	Lung function decrement, heart rate, symptoms	n = 22 Mean age 60.8 yr	500, 1,000, or 2,000 NO <sub>2</sub> ppb for 1 h; Exercise 15 min on/15 min off $\dot{V}_E = 16$ L/min	<a href="#">Linn et al. (1985a)</a>

CAPs = concentrated ambient particles; COPD = chronic obstructive pulmonary disease; NO<sub>2</sub> = nitrogen dioxide;  $\dot{V}_E$  = minute ventilation.

<sup>a</sup>Up facing arrow indicates that the effect of NO<sub>2</sub> is greater (e.g., larger lung function decrement, larger increase in symptoms) in the group with the factor evaluated than in the reference group. Down facing arrow indicates that the effect of NO<sub>2</sub> is smaller in the group with the factor evaluated than in the reference group. A dash indicates no difference in NO<sub>2</sub>-related health effect between groups. In some studies, only a population with pre-existing disease was examined; therefore, the arrow or dash represents the direction of the effect in that population after exposure to NO<sub>2</sub> relative to exposure to filtered air.

**Table 7-6 Epidemiologic studies evaluating pre-existing chronic obstructive pulmonary disease.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Nonasthma outcomes and short-term exposure</b>						
COPD n = 18	Recent MI n = 12	↑	HRV pNN50 decrement	n = 30 Ages NR	Atlanta, GA, 1999–2000	<a href="#">Suh and Zanobetti (2010b)</a> †
		—	HRV r-MSSD decrement			
COPD n = 8% ED visits	No COPD n = 92% ED visits	↑	Cardiovascular-related ED visits	n = 103,551 ED visits for CVD; 31 participating hospitals	Atlanta, GA, 1993–2000	<a href="#">Peel et al. (2007)</a>
<b>Nonasthma outcomes and long-term exposure</b>						
COPD n = 121	No COPD n = 1,863	—	Incident stroke	n = 1,984 Ages 50–65 yr at baseline	Copenhagen, Aarhus counties, Denmark, 1993–2006	<a href="#">Andersen et al. (2012b)</a> †
COPD n = 6	No COPD n = 136	↑	Fatal stroke	n = 142 Ages 50–65 yr at baseline		
COPD n = 2,058	No COPD n = 49,760	—	Diabetes	n = 51,818 Ages 50–65 yr at baseline	Copenhagen, Aarhus counties, Denmark, 1993–2006	<a href="#">Andersen et al. (2012c)</a> †
COPD n = 1,268	No COPD n = 5,124	—	Diabetes	n = 6,392 Ages 29–73 yr	Switzerland, 2002	<a href="#">Eze et al. (2014)</a> †

COPD = chronic obstructive pulmonary disease; CVD = cardiovascular disease; HRV = heart rate variability; MI = myocardial infarction; NR = not reported.

<sup>a</sup>Up facing arrow indicates that the effect of nitrogen dioxide (NO<sub>2</sub>) is greater (e.g., larger decrement in HRV, larger increase in ED visits) in the group with the factor evaluated than in the reference group. Down facing arrow indicates that the effect of NO<sub>2</sub> is smaller in the group with the factor evaluated than in the reference group. A dash indicates no difference in NO<sub>2</sub>-related health effect between groups.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

### 7.3.3 Cardiovascular Disease

Cardiovascular disease is the primary cause of death in the U.S., and approximately 11% of adults report a diagnosis of heart disease. In addition, hypertension has been diagnosed in roughly 24% of the adult U.S. population ([Blackwell et al., 2014](#)). For both short-term ([Section 5.3.11](#)) and long-term ([Section 6.3.9](#)) NO<sub>2</sub> exposure, the collective body of evidence is suggestive, but not sufficient, to infer a causal relationship with cardiovascular effects. These conclusions are primarily based on the uncertainty in

distinguishing an independent relationship for NO<sub>2</sub> with cardiovascular effects. In addition to this uncertainty, the evidence base does not consistently show that pre-existing CVD increases the risk for health effects related to short-term or long-term NO<sub>2</sub> exposure ([Table 7-7](#)). NO<sub>2</sub> exposure or dose differences for people with CVD are not characterized. [Suh and Zanobetti \(2010b\)](#) found that total personal NO<sub>2</sub> exposure was similar for adults with prior MI and adults with COPD but made no comparison to healthy adults.

For short-term exposure, NO<sub>2</sub>-related mortality was higher among individuals with CVD ([Chiusolo et al., 2011](#)); however, the majority of evidence, which is for cardiovascular hospital admissions and ED visits, is inconsistent ([Table 7-7](#)). The strongest evidence for a relationship between short-term NO<sub>2</sub> exposure and cardiovascular effects is for MI ([Section 5.4.8](#)), and most studies show no difference in the association in groups with hypertension ([Tsai et al., 2012](#); [Peel et al., 2007](#); [D'Ippoliti et al., 2003](#)), arrhythmia ([Tsai et al., 2012](#); [Mann et al., 2002](#)), or congestive heart failure ([Tsai et al., 2012](#); [D'Ippoliti et al., 2003](#)). Many studies of long-term NO<sub>2</sub> exposure compared groups with and without hypertension and found no difference in the association with diabetes ([Eze et al., 2014](#); [Andersen et al., 2012c](#)) and no consistent difference in the association with stroke ([Andersen et al., 2012b](#)). For blood pressure examined as an outcome, associations with long-term NO<sub>2</sub> exposure were larger in groups with pre-existing CVD ([Foraster et al., 2014](#)).

Among studies examining subclinical cardiovascular effects such as changes in HRV, interleukin (IL)-6, or arrhythmic events recorded on electrocardiograms, most did not observe that associations with short- or long-term NO<sub>2</sub> exposure differed between groups with or without pre-existing CVD, whether defined as any CVD, ischemic heart disease (IHD), or hypertension ([Panasevich et al., 2009](#); [Felber Dietrich et al., 2008](#); [Ljungman et al., 2008](#)). Risk factors for CVD, including higher systemic inflammation and hypercholesterolemia, do not consistently modify NO<sub>2</sub>-related cardiovascular effects ([Andersen et al., 2012b](#); [Huang et al., 2012a](#)). Experimental studies ([Table 7-8](#)) also do not clearly support NO<sub>2</sub>-induced subclinical cardiovascular effects in adults with CVD ([Scaife et al., 2012](#)) or a mouse model of CVD ([Campen et al., 2010](#)).

For associations with short-term and long-term NO<sub>2</sub> exposure, people with and without pre-existing CVD have been compared with respect to an array of cardiovascular diseases, events, and subclinical effects. Studies are also diverse in the conditions by which they define pre-existing CVD. No consistent difference in NO<sub>2</sub>-related cardiovascular effects is demonstrated between groups with and without pre-existing CVD, and it is unclear whether people with CVD differ in NO<sub>2</sub> exposure or internal dose. Additionally, there is limited experimental evidence supporting the biological plausibility

of NO<sub>2</sub>-related health effects in response to pre-existing cardiovascular conditions. In conclusion, the large evidence base lacks sufficient consistency in demonstrating that pre-existing CVD modifies NO<sub>2</sub>-related cardiovascular effects, and an independent effect of NO<sub>2</sub> is uncertain overall. Therefore, the evidence is inadequate to determine whether people with CVD are at increased risk for NO<sub>2</sub>-related health effects.

**Table 7-7 Epidemiologic studies evaluating pre-existing cardiovascular disease.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Nonasthma outcomes and short-term exposure</b>						
Hypertension n = 30% visits	No hypertension n = 70% visits	↑	Arrhythmia ED visits	n = 103,551 ED visits for CVD; 31 participating hospitals	Atlanta, GA, 1993–2000	<a href="#">Peel et al. (2007)</a>
		—	ED visits for IHD or CHF			
Hypertension n = 40% visits	No hypertension n = 60% visits	—	Hospital admission for MI	n = 27,563 hospital admissions	Taipei, Taiwan 1999–2009	<a href="#">Tsai et al. (2012)</a> †
CHF n = 15% visits	No CHF n = 85% visits	—				
Cardiac arrhythmia n = 11% visits	No cardiac arrhythmia n = 89% visits	—				
Hypertension n = 1,648	No hypertension n = 4,883	—	First hospital admission for acute MI	n = 6,531 hospital records	Rome, Italy, 1995–1997	<a href="#">D'Ippoliti et al. (2003)</a>
Heart conduction disorder n = 414	No heart conduction disorder n = 6,117	↑				
Cardiac dysrhythmia n = 1,296	No cardiac dysrhythmia n = 5,235	—				
Heart failure n = 703	No heart failure n = 5,828	—				

**Table 7-7 (Continued): Epidemiologic studies evaluating pre-existing cardiovascular disease.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
Secondary diagnosis of arrhythmia n = 34.5% admissions	No secondary diagnosis of arrhythmia n = 65.5% admissions	—	Hospital admission for IHD	n = 54,863 hospital admissions	southern California, 1988–1995	<a href="#">Mann et al. (2002)</a>
Secondary diagnosis of CHF n = 14.1% admissions	No secondary diagnosis of CHF n = 85.9% admissions	↑				
Pre-existing heart disease n = 525 with stroke	No pre-existing heart disease n = 2,214 with stroke	↑	Hospital admission for ischemic stroke	n = 5,927 hospital admissions	Edmonton, Canada, 2003–2009	<a href="#">Villeneuve et al. (2012)†</a>
		—	Hospital admission for hemorrhagic stroke			
IHD n = 56	No IHD n = 32	—	Ventricular tachy-arrhythmia	n = 88 with implantable cardioverter defibrillators Ages 28–85 yr	Gothenburg, Stockholm, Sweden, 2001–2006	<a href="#">Ljungman et al. (2008)†</a>
Pre-existing CVD n = 1.2–14%	No pre-existing CVD n = 86–98.8%	↑	Total mortality	n = 276,205 natural deaths	10 cities, Italy 12% of population 2001–2005	<a href="#">Chiusolo et al. (2011)†</a>
<b>Nonasthma outcomes and long-term exposure</b>						
Hypertension n = 575	No hypertension n = 1,409	—	Incident stroke	n = 1,984 Ages 50–65 yr at baseline	Copenhagen, Aarhus counties, Denmark, 1993–2006	<a href="#">Andersen et al. (2012b)†</a>
Hypertension n = 38	No hypertension n = 104	—	Fatal stroke	n = 142 Ages 50–65 yr at baseline		
Hypercholesterolemia n = 230	No hypercholesterolemia n = 1,754	—	Incident stroke (confirmed by hospital admission)	n = 1,984 Ages 50–65 yr at baseline	Copenhagen, Aarhus counties, Denmark, 1993–2006	<a href="#">Andersen et al. (2012b)†</a>
Hypercholesterolemia n = 19	No hypercholesterolemia n = 123	—	Fatal stroke (confirmed by hospital admission)	n = 142 Ages 50–65 yr at baseline		
Pre-existing CVD n = 269	No pre-existing CVD n = 3,431	↑	Systolic/diastolic blood pressure	n = 3,700 Ages 35–83 yr	Girona, Spain	<a href="#">Foraster et al. (2014)†</a>

**Table 7-7 (Continued): Epidemiologic studies evaluating pre-existing cardiovascular disease.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
Hypertension n = 867	No hypertension n = 669	—	Blood IL-6 levels	n = 1,536 Ages 45–70 yr	Stockholm county, Sweden, 1992–1994	<a href="#">Panasevich et al. (2009)</a> †
Hypertension n = 19.4%	No hypertension n = 80.6%	—	Diabetes	n = 6,392 Ages 29–73 yr	Switzerland, 2002	<a href="#">Eze et al. (2014)</a> †

CHF = congestive heart failure; CVD = cardiovascular disease; ED = emergency department; IHD = ischemic heart disease; MI = myocardial infarction.

<sup>a</sup>Up facing arrow indicates that the effect of nitrogen dioxide (NO<sub>2</sub>) is greater (e.g., larger increase in hospital admission, larger risk of mortality) in the group with the factor evaluated than in the reference group. Down facing arrow indicates that the effect of NO<sub>2</sub> is smaller in the group with the factor evaluated than in the reference group. A dash indicates no difference in NO<sub>2</sub>-related health effect between groups.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

**Table 7-8 Controlled human exposure and toxicological studies informing risk due to pre-existing cardiovascular disease.**

Factor Evaluated	Reference Category	Direction of Effect <sup>a</sup>	Outcome	Study Population/ Animal Model	Study Details	Study
<b>Nonasthma outcomes and short-term exposure</b>						
Stable CHD or impaired left ventricular systolic function	None	—	Heart rate, HRV decrement	n = 18 humans Mean age 68 yr	400 ppb NO <sub>2</sub> for 1 h	<a href="#">Scaife et al. (2012)</a> †
Atherosclerosis	None	↑	Oxidative stress in heart tissue	n = 5–10 mice/group, ApoE <sup>-/-</sup>	200 or 2,000 ppb NO <sub>2</sub> , 6 h/day, 7 days High fat diet	<a href="#">Campen et al. (2010)</a> †

CHD = coronary heart disease; HRV = heart rate variability; NO<sub>2</sub> = nitrogen dioxide.

<sup>a</sup>These studies only examined subjects with cardiovascular disease and have no reference group. A dash indicates that NO<sub>2</sub> was not observed to induce an effect in the group with cardiovascular disease evaluated relative to clean air exposure. An up-facing arrow indicates that NO<sub>2</sub> induced an effect on the outcome (e.g., cause a decrement in HRV) in the group with cardiovascular disease.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

### 7.3.4 Diabetes

Diabetes mellitus is a group of diseases characterized by high blood glucose levels that result from defects in the body's ability to produce and/or use insulin. High blood glucose levels can damage blood vessels, increasing the risk of people with diabetes for heart

disease or stroke. Diabetes and cardiovascular disease are also linked by common risk factors such as hypertension and obesity. These relationships support the potential for diabetes to influence the risk of cardiovascular disease. Diabetes has been examined as a modifier of NO<sub>2</sub>-related health effects in adults, and the large number of affected adults [21 million or 8.6% with diagnosis in the U.S. in 2012 ([Blackwell et al., 2014](#))] underscores the potential public health impact of elevated risk from diabetes. However, diabetes has not consistently been observed to modify epidemiologic associations of NO<sub>2</sub> exposure with cardiovascular effects, and no consistent pattern is observed for short-term or long-term exposure or for any particular outcome ([Table 7-9](#)). No difference by diabetes was observed in studies of short-term NO<sub>2</sub> exposure with hospital admissions or ED visits for IHD or MI ([Tsai et al., 2012](#); [Filho et al., 2008](#)) or of long-term NO<sub>2</sub> exposure with stroke ([Andersen et al., 2012b](#)). Diabetes also did not clearly modify associations of short-term or long-term NO<sub>2</sub> exposure with the subclinical effects of heart rate variability, ventricular tachyarrhythmia, blood pressure, and blood IL-6 levels ([Foraster et al., 2014](#); [Huang et al., 2012a](#); [Panasevich et al., 2009](#); [Ljungman et al., 2008](#)). Associations of short-term and long-term NO<sub>2</sub> exposure with total mortality also did not consistently differ between people with and without diabetes ([Faustini et al., 2013](#); [Chiusolo et al., 2011](#); [Maheswaran et al., 2010](#)). It is unknown whether people with diabetes differ with respect to NO<sub>2</sub> exposure or dosimetry. In conclusion, there is inconsistent evidence that diabetes modifies NO<sub>2</sub>-related cardiovascular effects. This finding along with uncertainty in an independent effect of NO<sub>2</sub> on cardiovascular outcomes ([Sections 5.3.11](#) and [6.3.9](#)) makes the evidence inadequate to determine whether people with diabetes are at increased risk for NO<sub>2</sub>-related health effects.

**Table 7-9 Epidemiologic studies evaluating pre-existing diabetes.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Nonasthma outcomes and short-term exposure</b>						
Diabetes n = 11.3% admission	No diabetes n = 88.7% admission	—	Respiratory hospital admission	n = 100,690 hospital admissions	6 cities, Italy, 2001–2005	<a href="#">Faustini et al. (2013)†</a>
Diabetes 29.6% admission	No diabetes 70.4% admission	—	Hospital admission for MI	n = 27,563 hospital admissions	Taipei, Taiwan 1999–2009	<a href="#">Tsai et al. (2012)†</a>
Diabetes n = 700 ED visits	No diabetes n = 44,300 ED visits	↑	ED visits for hypertension and cardiac ischemic disease	n = 45,000 ED visits	Sao Paulo Hospital, January 2001–July 2003	<a href="#">Filho et al. (2008)†</a>
Diabetes n = 9	No diabetes n = 31	↓	HRV decrement	n = 40 with CVD Mean age 66 yr	Beijing, China, summer 2007 and summer 2008	<a href="#">Huang et al. (2012a)†</a>
Diabetes n = 12	No diabetes n = 76	—	Ventricular tachy-arrhythmia	n = 88 with implantable cardioverter defibrillators Ages 28–85 yr	Gothenburg, Stockholm, Sweden, 2001–2006	<a href="#">Ljungman et al. (2008)†</a>
Diabetes n = 30,260	No diabetes n = 245,945	↑	Total mortality	n = 276,205 natural deaths	6 cities, Italy, 2001–2005	<a href="#">Chiusolo et al. (2011)†</a>
<b>Nonasthma outcomes and long-term exposure</b>						
Diabetes n = 97	No diabetes n = 1,887	—	Incident stroke	n = 1,984 Ages 50–65 yr at baseline	Copenhagen, Aarhus counties, Denmark, 1993–2006	<a href="#">Andersen et al. (2012b)†</a>
Diabetes n = 9	No diabetes n = 133	—	Fatal stroke	n = 142 Ages 50–65 yr at baseline		
Diabetes n = 580	No diabetes n = 3,120	—	Systolic blood pressure	n = 3,700 Ages 35–83 yr	Girona, Spain	<a href="#">Foraster et al. (2014)†</a>
		↓	Diastolic blood pressure			
Diabetes n = 121	No diabetes n = 1,415	—	Relative IL-6 level	n = 1,536 Ages 45–70 yr	Stockholm county, Sweden 1992–1994	<a href="#">Panasevich et al. (2009)†</a>

**Table 7-9 (Continued): Epidemiologic studies evaluating pre-existing diabetes.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
Diabetes n = 315	No diabetes n = 1,541	↓	Total mortality	n = 3,320 Mean age 70 yr	London, England Follow-up: 1995–2005 NO <sub>2</sub> assessed for 2002	<a href="#">Maheswaran et al. (2010)</a> †
Diabetes n = 1,045	No diabetes n = 12,399	—	Lung cancer mortality	n = 13,444 Ages >65 yr	Shizuoka, Japan 1999–2006	<a href="#">Yorifuji et al. (2010)</a> †

CVD = cardiovascular disease; ED = emergency department; HRV = heart rate variability; IL = interleukin; MI = myocardial infarction.

<sup>a</sup>Up facing arrow indicates that the effect of nitrogen dioxide (NO<sub>2</sub>) is greater (e.g., larger risk of ED visit, larger decrement in HRV) in the group with the factor evaluated than in the reference group. Down facing arrow indicates that the effect of NO<sub>2</sub> is smaller in the group with the factor evaluated than in the reference group. A dash indicates no difference in effects between groups.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

### 7.3.5 Obesity

Obesity can be defined as a BMI of 30 kg/m<sup>2</sup> or greater. It is a public health issue of increasing importance as obesity rates have continually increased over several decades in the U.S. among adults and children ([Blackwell et al., 2014](#)). Obesity or high BMI has been examined as a modifier of NO<sub>2</sub>-related health effects only in adults. Among U.S. adults, prevalence of both obesity and being overweight (BMI of 25–30 kg/m<sup>2</sup>) are high (28 and 34.5%, respectively). Being obese or overweight could increase the risk of NO<sub>2</sub>-related health effects through multiple mechanisms including persistent, low-grade inflammation. Poor diet and chronic diseases often occur with obesity and could be part of the pathway by which obesity increases the risk of NO<sub>2</sub>-related health effects or could act in combination with obesity to increase risk.

The 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) did not evaluate obesity as a potential factor that could increase the risk of NO<sub>2</sub>-related health effects. Recent studies have examined obesity or BMI as a potential effect measure modifier, but overall the evidence is inconsistent as to whether obesity leads to increased risk of NO<sub>2</sub>-related health effects. And while activity and breathing patterns differ in obese individuals, it is not known whether these factors contribute to differences in NO<sub>2</sub> exposure or dosimetry. Most studies examined whether obesity increases the risk of NO<sub>2</sub>-related cardiovascular and metabolic effects, which is expected given the evidence that obesity is a risk factor for both cardiovascular disease and diabetes. A study in rats provides evidence that long-term NO<sub>2</sub> exposure has larger effects on dyslipidemia, a known risk factor for

cardiovascular disease, in obese rats compared to nonobese rats [([Takano et al., 2004](#)); [Table 7-10](#)]. However, differences between obese and nonobese strains were limited to 160 ppb NO<sub>2</sub> and not observed at higher NO<sub>2</sub> exposures.

The epidemiologic evidence is not coherent with the results in rats. There is some indication of larger NO<sub>2</sub>-associated cardiovascular or diabetes-related mortality in obese groups ([Raaschou-Nielsen et al., 2012](#)). However, most studies did not provide evidence that associations between long-term NO<sub>2</sub> exposure and cardiovascular disease or diabetes differed between obese and nonobese groups [([Eze et al., 2014](#); [Atkinson et al., 2013](#); [Hart et al., 2013](#); [Mobasher et al., 2013](#); [Andersen et al., 2012c](#); [Andersen et al., 2012b](#)); [Table 7-11](#)]. Most studies used a similar definition of obese: BMI > 30 kg/m<sup>2</sup>. High BMI also did not tend to modify associations of short-term and long-term NO<sub>2</sub> exposure with subclinical cardiovascular effects ([Dadvand et al., 2014b](#); [Huang et al., 2012a](#); [Baja et al., 2010](#); [Ljungman et al., 2008](#)). The limited number of studies that examined NO<sub>2</sub> associations with mortality from respiratory causes or lung cancer also did not provide any evidence of increased risk for obese individuals ([Dimakopoulou et al., 2014](#); [Yorifuji et al., 2010](#)).

In conclusion, obesity increased NO<sub>2</sub>-related cardiovascular effects in a single study in rats, but a larger body of epidemiologic evidence largely shows no difference between obese and nonobese adults. Obesity also does not tend to modify associations of long-term NO<sub>2</sub> exposure with mortality or diabetes. In addition to the limited evidence indicating that obese people may be at increased risk of NO<sub>2</sub>-related health effects, uncertainty remains in the overall body of evidence regarding the independent effects of NO<sub>2</sub> on cardiovascular effects, diabetes ([Section 6.3.9](#)), and mortality ([Section 6.5.3](#)). Further, information on potential NO<sub>2</sub> exposure or dosimetry differences by obesity is lacking. Therefore, the evidence is inadequate to determine whether obese individuals are at increased risk for NO<sub>2</sub>-related health effects.

**Table 7-10 Toxicological study evaluating pre-existing obesity.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Animal Model	Study Details	Study
<b>Nonasthma outcomes and long-term exposure</b>						
Obesity n = 9–13	No obesity n = 10–14	↑	Triglycerides, HDL, total cholesterol, blood sugar	Rats (OLETF and LETO diabetes models) n = 10–14 males/group	160, 800, or 4,000 ppb NO <sub>2</sub> ; continuously for 32 weeks	<a href="#">Takano et al. (2004)</a>

HDL = high density lipoprotein; NO<sub>2</sub> = nitrogen dioxide.

<sup>a</sup>Up facing arrow indicates that the effect of NO<sub>2</sub> is greater (e.g., larger increase in triglycerides) in the group with the factor evaluated than in the reference group.

**Table 7-11 Epidemiologic studies evaluating pre-existing obesity.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Nonasthma outcomes and short-term exposure</b>						
High BMI (≥27) n = 29 or 30	Low BMI (<27) n = 69	—	Ventricular arrhythmia	n = 98 with implantable cardioverter defibrillators Ages 28–85 yr	Gothenburg, Stockholm, Sweden, 2001–2006	<a href="#">Ljungman et al. (2008)</a> †
High BMI (≥25) n = 16	Low BMI (<25) n = 24	—	HRV decrement	n = 40 nonsmoking adults with CVD Mean age 66 yr	Beijing, China, summer 2007 and summer 2008	<a href="#">Huang et al. (2012a)</a> †
High BMI (≥30) n = 27.6%	Low BMI (<30) n = 72.4%	↑	Change in ventricular repolarization	n = 580 males Mean age 75 yr	Boston, MA area, Follow-up: 2000–2008	<a href="#">Baja et al. (2010)</a> †
<b>Nonasthma outcomes and long-term exposure</b>						
High BMI (≥30) <sup>b</sup>	Low BMI (<30) <sup>b</sup>	—	Incidence MI	n = 84,562 Ages 30–55 yr at enrollment	U.S., 1990–2008	<a href="#">Hart et al. (2013)</a> †
High BMI (>30) n = 109,104	Low BMI (25–30) n = 243,556	—	Heart failure	n = 836,557 Ages 40–89 yr at baseline	England, 2003–2007	<a href="#">Atkinson et al. (2013)</a> †
High BMI (≥30) n = 84	Low BMI (<30) n = 158	—	C-reactive protein	n = 242 adults with clinically stable COPD Mean age 68 yr	Barcelona, Spain, 2004–2006	<a href="#">Dadvand et al. (2014b)</a> †
		—	TNF-α			
		—	IL-6			
		↓	IL-8			
		—	Fibrinogen			
		—	Hepatocyte growth factor			
High BMI (≥30) n = 366	Low BMI (<30) n = 1,618	—	Incident stroke	n = 1,984 Ages 50–65 yr at baseline	Copenhagen, Aarhus counties, Denmark, 1993–2006	<a href="#">Andersen et al. (2012b)</a> †
High BMI (≥30) n = 19	Low BMI (<30) n = 123	—	Fatal stroke	n = 142 Ages 50–65 yr at baseline		

**Table 7-11 (Continued): Epidemiologic studies evaluating pre-existing obesity.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
High/very high BMI (≥25) n = 28,937	Low BMI (<25) n = 22,881	—	Diabetes	n = 51,818 Ages 50–65 yr at baseline	Copenhagen, Aarhus counties, Denmark, 1993–2006	<a href="#">Andersen et al. (2012c)</a> †
High waist-to-hip ratio (>0.90 M, >0.85 F) n = 26,183	Low waist-to-hip ratio (≤0.90 M, ≤0.85 F) n = 25,635	↑				
High BMI <sup>b</sup> (>30)	Low BMI <sup>b</sup> (≤30)	—	Diabetes	n = 6,392 Ages 29–73 yr	Switzerland, 2002	<a href="#">Eze et al. (2014)</a> †
High BMI (>30) n = 68	Low BMI (<30) n = 213	—	Hypertensive disorders of pregnancy	n = 298 predominantly Hispanic women	Los Angeles, CA, 1996–2008	<a href="#">Mobasher et al. (2013)</a> †
High BMI <sup>b</sup> (>30)	Low BMI <sup>b</sup> (<30)	↓	Respiratory mortality	n = 307,553 Mean age across 16 cohorts 41.9–73.0 yr at baseline	Europe Follow-up: 1985–2007 NO <sub>2</sub> exposure assessed for 2008–2011	<a href="#">Dimakopoulou et al. (2014)</a> †
High BMI (>25) n = 1,950	Low BMI (<18.5) n = 1,010	—	CVD mortality	n = 9,941, 256 deaths Ages 35–103 yr	Shenyang, China Follow-up: 1998–2009 NO <sub>2</sub> exposure assessed for 1998–2009	<a href="#">Zhang et al. (2011)</a> †
High BMI (>30) n = 96,076 person-yr	Low BMI (<25) n = 298,503 person-yr	↑	Diabetes-related mortality	n = 52,061 Ages 50–64 yr	Denmark Follow-up: 1971–2009 NO <sub>2</sub> exposure assessed for 1971–2009	<a href="#">Raaschou-Nielsen et al. (2012)</a> †
High BMI (>21.8) <sup>b</sup>	Low BMI (<21.8) <sup>b</sup>	—	Lung cancer mortality	n = 13,444 Ages >65 yr	Shizuoka, Japan, 1999–2006	<a href="#">Yorifuji et al. (2010)</a> †

BMI = body mass index; CA = California; CVD = cardiovascular disease; COPD = chronic obstructive pulmonary disease; F = female; HRV = heart rate variability; M = male; MI = myocardial infarction; NO<sub>2</sub> = nitrogen dioxide; TNF = tumor necrosis factor; IL = interleukin.

<sup>a</sup>Up facing arrow indicates that the effect of NO<sub>2</sub> is greater (e.g., larger change in ventricular repolarization) in the group with the factor evaluated than in the reference group. Down facing arrow indicates that the effect of NO<sub>2</sub> is smaller in the group with the evaluated factor than in the reference group. A dash indicates no difference in NO<sub>2</sub>-related health effect between groups.

<sup>b</sup>Sample size not reported.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

---

## 7.4 Genetic Factors

Genetic variation in the human population is known to contribute to numerous diseases and differential physiologic responses. The 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) concluded that “it remains plausible that there are genetic factors that can influence health responses to NO<sub>2</sub>, though the few available studies did not provide specific support.” Since then, many studies have examined whether specific genetic polymorphisms increase the risk of NO<sub>2</sub>-related health effects. A strength of these studies is that they use a targeted approach, focusing on specific genes that potentially are involved in signaling pathways mediating biological responses to NO<sub>2</sub>. For example, NO<sub>2</sub> exposure can lead to the formation of oxidation products ([Section 4.3.2.1](#)) and also modulate immune function ([Section 4.3.2.6](#)), and studies examined variants for genes encoding antioxidant enzymes [e.g., glutathione S-transferases (GSTs)] and mediators of immune response [e.g., tumor necrosis factor-alpha (TNF- $\alpha$ )]. A potential limitation for drawing conclusions is the large number of genetic variants examined within studies, which increases the probability of finding associations by chance alone. Thus, consistency in findings across genetic variants is considered. Further, the functional or biological consequence of some of the gene variants is unknown, and some variants may be surrogates for another linked gene or a group of related genes. Thus, where available, the variant effect is described ([Table 7-12](#)) and considered in conclusions.

Several studies examined gene variants for modification of NO<sub>2</sub>-asthma relationships, and oxidative stress is described as a key process underlying asthma exacerbation and development attributed to NO<sub>2</sub> exposure ([Section 4.3.2.1](#)). However, studies that examined functional variants of GST Mu 1 or GST Pi 1 estimated similar ([Castro-Giner et al., 2009](#)) or lower ([Romieu et al., 2006](#)) effects of short-term or long-term NO<sub>2</sub> exposure on asthma symptoms or asthma prevalence in groups with variants encoding enzymes with null or reduced oxidative metabolizing activity ([Table 7-12](#)). These variants are common in the population, and NO<sub>2</sub>-related health effects were compared between groups with fairly similar numbers of people ([Table 7-12](#)). However, it is not clear that either study planned comparisons a priori. Another limitation of the study that observed no difference is the uncertain temporal sequence of current exposure and current asthma status ([Castro-Giner et al., 2009](#)).

The beta-2-adrenergic receptor (ADRB2) is an encoded G protein-coupled receptor that plays an important role in the regulation of airway smooth muscle tone and is the pharmacological target of beta-agonist asthma medications ([Hizawa, 2011](#)). NO<sub>2</sub> exposure has been shown to increase airway responsiveness in adults with asthma

([Section 5.2.2.1](#)), providing a plausible role for variants in ADRB2 in modifying the risk of NO<sub>2</sub>-associated asthma. Higher methylation of the ADRB2 promoter, which is associated with reduced expression of the receptor, was observed to increase the risk of asthma severity in children associated with indoor residential NO<sub>2</sub> exposure ([Fu et al., 2012](#)). There is mixed evidence for beta-agonist medication use in modifying NO<sub>2</sub>-associated respiratory effects ([Section 5.2.2.2](#)), and it is not known whether the response to beta-agonists is influenced by genetic variants in ADRB2.

Similar to variants with known functional differences, no clear evidence exists that genetic variants with unknown functional differences increase NO<sub>2</sub>-related risk of asthma. As examined in a single study that estimated long-term NO<sub>2</sub> exposure at subjects' homes, a variant in the antioxidant enzyme NADPH-quinone oxidoreductase (NQO1) increased associations with asthma prevalence in adults. However, NQO1 was one among many variants examined. No modification was observed by variants in ADRB2 or the immune response genes TNF- $\alpha$  and toll-like receptor (TLR)4 [([Castro-Giner et al., 2009](#)); [Table 7-12](#)], which are known to have a role in oxidant-induced inflammation and asthma pathogenesis.

Inflammation and oxidative stress are also linked to cardiovascular and metabolic effects ([Section 4.3.2.9](#)). However, gene variants associated with increased inflammatory mediators in the blood did not modify associations of long-term NO<sub>2</sub> exposure with myocardial infarction ([Panasevich et al., 2013](#)). Genetic variants with the potential for elevated oxidative stress did increase NO<sub>2</sub>-related subclinical cardiovascular and metabolic effects [([Kim and Hong, 2012](#); [Baja et al., 2010](#)); [Table 7-12](#)]. A strength of ([Baja et al. \(2010\)](#)) is that, rather than performing multiple comparisons of individual variants, they analyzed the sum of gene variants with increased oxidative stress potential as a cumulative index of oxidative stress potential. Despite some positive findings, independent relationships between short-term NO<sub>2</sub> exposure and cardiovascular and metabolic effects are uncertain. Thus, it is not clear the extent to which the findings for modification by gene variants can be attributed to NO<sub>2</sub> specifically. Genetic variants in oxidative metabolism enzymes with unknown functional differences did not clearly modify associations of long-term NO<sub>2</sub> exposure with decrements in lung development in children. Associations were larger for some variants in glutathione metabolism pathway genes, such as glutathione synthetase [GSS; ([Breton et al., 2011](#))]. However, the results were not consistent across the multiple gene variants of glutathione examined [glutathione reductase (GSR), glutamate-cysteine ligase, modifier subunit (GCLM), glutamate-cysteine ligase, catalytic subunit (GCLC)] or NQO1 (rs10517).

There is evidence for independent relationships of short-term and long-term NO<sub>2</sub> exposure, respectively, with exacerbation ([Section 5.2.9](#)) and development

(Section 6.2.9) of asthma, and antioxidant modulation, immune-mediated inflammation, and airway responsiveness are described as key events in the underlying modes of action (Section 4.3.5). Evidence in rodents and humans that dietary antioxidants modify NO<sub>2</sub>-induced pulmonary oxidative stress (Section 7.6.1) would suggest a role for variants in oxidative metabolism genes in modifying the effects of NO<sub>2</sub> on asthma exacerbation or development. However, gene variants with greater potential for oxidative stress were not observed to modify associations of short-term NO<sub>2</sub> exposure with asthma-related effects. Variants in antioxidant and immune-related genes did modify some associations of long-term NO<sub>2</sub> exposure with asthma, but results are inconsistent for any particular gene variant or outcome and are based on multiple comparisons and post hoc analyses. While gene variants for antioxidant enzymes and inflammatory cytokines modified cardiovascular and metabolic effects, the findings were limited to subclinical outcomes and did not include myocardial infarction. Overall, the findings for effect measure modification by genetic variants are inconsistent for asthma-related effects, and the interpretation of the results for cardiovascular and metabolic effects is complicated by the uncertainty as to whether the results can be attributed specifically to NO<sub>2</sub> exposure. Also unknown is whether the gene variants alter oxidant species or inflammatory mediators in response to NO<sub>2</sub> exposure. Additionally, because it currently is uncertain whether a particular gene variant examined in isolation can clearly represent an at-risk population, evidence for effect measure modification may provide insight only on biological pathways mediating a health effect. For all of these reasons, the evidence is inadequate to determine whether genetic variants, particularly for antioxidant enzymes and immune responses, increase the risk for NO<sub>2</sub>-related health effects.

**Table 7-12 Epidemiologic studies evaluating genetic factors.**

Factor Evaluated/Gene Function	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population and other Details	Study
<b>Asthma-related outcomes and functional gene variants</b>					
GSTM1 null, n = 58 Null oxidant metabolizing capacity	GSTM1 positive, n = 93	↓	Asthma symptoms and medication use	Mexico City, Mexico n = 151 children with asthma Ages NR Short-term exposure	<a href="#">Romieu et al. (2006)</a>
GSTP1 Val105Val, n = 54 (rsID 947894) Reduced oxidant metabolizing capacity	Ile105Ile, n = 97	↓			
GSTM1 null n = 49% Null oxidant metabolizing capacity	GSTM1 positive, n = 51%	—	Asthma prevalence	Umea and Uppsala, Sweden; Ipswich and Norwich, U.K.; Albacete, Barcelona, Huelva, Galdakao, and Oviedo, Spain; Erfurt, Germany; Paris, Grenoble, France; Antwerp, Belgium n = 2,920 Mean age 43 yr Long-term exposure	<a href="#">Castro-Giner et al. (2009)†</a>
GSTP1 Val105Val (rsID 1695) n = 32% Reduced oxidant metabolizing capacity	GSTP1 Ile105Ile or Ile105Val n = 68%	—			
TNF-α 308 GA/AA (rs1800629) n = 16% Increased expression	TNF-α 308 GG n = 84%	—			
ADRB2 <sup>b</sup> Intermediate or high methylation levels Reduced expression	ADRB2 <sup>b</sup> Low methylation levels	↑	Asthma severity	CT and Springfield, Worcester, MA n = 182 Ages 5–12 yr, followed for 1 yr Long-term exposure	<a href="#">Fu et al. (2012)†</a>

**Table 7-12 (Continued): Epidemiologic studies evaluating genetic factors.**

Factor Evaluated/Gene Function	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population and other Details	Study
<b>Asthma-related outcomes and gene variants with unknown functional difference</b>					
NQO1 CC (rs2917666) n = 32%	NQO1 GC or GG, n = 68%	↑	Asthma prevalence	Multiple European countries (see above) n = 2,920 Mean age 43 yr Long-term exposure	<a href="#">Castro-Giner et al. (2009)</a> †
TLR4 GG (rs11536889) n = 14%	TLR4 GC or CC n = 86%	↑			
ADRB2 rs1042713 G/G rs1042714 C/C rs1042718 C/C rs1042719 G/G n = 18–40%	G/A or A/A C/G or G/G C/A or A/A G/C or C/C n = 60–82%	—			
<b>Nonasthma outcomes and functional gene variants</b>					
TNF-α 308 GA/AA Increased expression n = 17%	TNF-α 308 GG n = 83%	—	MI	Stockholm County, Sweden n = 2,698 Ages 45–70 yr Long-term exposure	<a href="#">Panasevich et al. (2013)</a> †
IL-6 174 CC n = 48%	IL-6 174 GG n = 52%	—			
IL-6 598 AA n = 47%	IL-6 598 GG n = 53%	—			
≥4 variants with increased oxidative stress potential <sup>b</sup> (GSTT1, GSTP1, GSTM1, HMOX, NQO1, HFE)	<4 variants with increased oxidative stress potential <sup>b</sup>	↑	Heart rate-corrected QT interval (ventricular repolarization)	Boston, MA area n = 580 males Mean age 75 yr Short-term exposure	<a href="#">Baja et al. (2010)</a> †

**Table 7-12 (Continued): Epidemiologic studies evaluating genetic factors.**

Factor Evaluated/Gene Function	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population and other Details	Study
GSTM1 null, n = 299	GSTM1 positive, n = 225	↑	Fasting glucose	Seoul, Korea n = 560	<a href="#">Kim and Hong (2012)</a> †
Null oxidant metabolizing capacity		↑	Insulin level	Ages 60–87 yr Short-term exposure	
GSTT1 null, n = 270	GSTT1 positive, n = 254	↑	Fasting glucose	Seoul, Korea n = 560	<a href="#">Kim and Hong (2012)</a> †
Null oxidant metabolizing capacity		↑	Insulin level	Ages 60–87 yr Short-term exposure	
GSTP1 Val105Val or Ile105Val (rs1695), n = 179	GSTP1 Ile105Ile, n = 359	↑	Fasting glucose		
Reduced oxidant metabolizing capacity (Val/Val)		–	Insulin level		
GSTP1 Val105Val or Ile105Val n = 198	GSTP1 Ile/Ile n = 152	↑	Cognitive function decrement	Menorca, Spain n = 350 children followed from birth to age 4 yr Long-term exposure	<a href="#">Morales et al. (2009)</a> †
Reduced oxidant metabolizing capacity					
<b>Nonasthma outcomes and gene variants with unknown functional difference</b>					
GSS haplotype 0100000, n = 1,010 (rs1801310)	Other haplotypes, n = 1,096	↑	Lung development decrement	Alpine, Atascadero, Lake Elsinore, Lake Arrowhead, Lancaster, Lompoc, Long Beach, Mira Loma, Riverside, San Dimas, Santa Maria, Upland, CA	<a href="#">Breton et al. (2011)</a> †
Unknown function					
GSR, various SNPs n = 3–21%	Other haplotypes n = 3–21%	–			
Unknown function				n = 2,106 children followed ages 10–18 yr Long-term exposure	
GCLM, various SNPs, n = 6–35%	Other haplotypes, n = 6–35%	–			
Unknown function					
GCLC, various SNPs, n = 4–54%	Other haplotypes, n = 4–54%	–			
Unknown function					

**Table 7-12 (Continued): Epidemiologic studies evaluating genetic factors.**

Factor Evaluated/Gene Function	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population and other Details	Study
MET Tyrosine receptor kinase CC (rs1858830) n = 102	MET Tyrosine receptor kinase CG/GG n = 305	↑	Autism	Multiple unspecified locations, CA n = 252 with autism, 156 without Ages 2–5 yr Long-term exposure	<a href="#">Volk et al. (2014)</a> †

ADRB2 = beta-2 adrenergic receptor; CA = California; GCLC = glutamate-cysteine ligase catalytic subunit; GCLM = glutamate-cysteine ligase; modifier subunit; GSR = glutathione reductase; GSS = glutathione synthetase; GSTM1 = glutathione S-transferase mu1; GSTP1 = glutathione s-transferase Pi 1; GSTT1 = glutathione S-transferase theta 1; HFE = hemochromatosis; HMOX = heme oxygenase; IL = interleukin; MI = myocardial infarction; NQO1 = NAD(P)H:quinone oxidoreductase 1; NR = not reported; TLR = toll-like receptor; TNF = tumor necrosis factor.

<sup>a</sup>Up facing arrow indicates that the effect of nitrogen dioxide (NO<sub>2</sub>) is greater (e.g., larger increase in symptoms) in the group with the factor evaluated than in the reference group. Down facing arrow indicates that the effect of NO<sub>2</sub> is smaller (e.g., smaller increase in symptoms) in the group with the factor evaluated than in the reference group. A dash indicates no difference in NO<sub>2</sub>-related health effect between groups.

<sup>b</sup>Sample size not reported.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

## 7.5 Sociodemographic Factors

### 7.5.1 Lifestage

Lifestage refers to a distinguishable time frame in an individual’s life characterized by unique and relatively stable behavioral and/or physiological characteristics that are associated with development and growth (U.S. EPA, 2014b). The 2008 ISA for Oxides of Nitrogen (U.S. EPA, 2008c) cited supporting evidence for increased risk of health effects related to NO<sub>2</sub> exposure among children and older adults. Differential health effects of NO<sub>2</sub> across lifestages theoretically could be due to several factors:

- The human respiratory system is not fully developed until 18–20 years of age, and therefore, it is plausible to consider children to have an intrinsic risk for respiratory effects due to potential perturbations in normal lung development.
- Older adults (typically considered those 65 years of age or greater) have weakened immune function, impaired healing, decrements in pulmonary and cardiovascular function, and greater prevalence of chronic disease (Table 7-2).
- Exposure/internal dose of NO<sub>2</sub> may vary across lifestages due to varying ventilation and time-activity patterns.

Studies in this ISA add to the evidence presented in the 2008 ISA indicating increased risk of NO<sub>2</sub>-related health effects for children and older adults. Further, this evaluation of lifestage as a factor that may increase risk for NO<sub>2</sub>-related health effects draws upon information about time-activity patterns and ventilation patterns among different lifestages to assess the potential for differences in NO<sub>2</sub> exposure or internal dose among lifestages.

---

### 7.5.1.1 Children

According to the 2010 census, 24% of the U.S. population is less than 18 years of age, with 6.5% less than age 6 years ([Howden and Meyer, 2011](#)). The large proportion of children in the U.S. underscores the public health impact of characterizing the risk of NO<sub>2</sub>-related health effects for children.

NO<sub>2</sub> exposure or internal dose differences in children are not well characterized. However, children and adults differ with respect to time-activity patterns, which are determinants of inter-individual variability in NO<sub>2</sub> exposure [([Mölter et al., 2012](#); [Kousa et al., 2001](#)); [Section 3.4.3.1](#)] and which potentially could lead to differences in NO<sub>2</sub> exposure and internal dose. The National Human Activity Pattern Survey showed that children spend more time outdoors compared with adults ([Klepeis et al., 1996](#)), and a longitudinal study in California showed a larger proportion of children reported spending over 30 minutes performing moderate or vigorous outdoor physical activity ([Wu et al., 2011b](#)). However, other than school or work, there was little variation among groups in time spent in various microenvironments ([Wu et al., 2011b](#); [Klepeis et al., 1996](#)). Although a recent meta-analysis suggested a weaker association between ambient NO<sub>2</sub> concentrations and personal NO<sub>2</sub> exposure of children ([Meng et al., 2012a](#)), some studies found ambient NO<sub>2</sub>-related respiratory effects in children for whom there were moderate personal-ambient correlations [*r* values of 0.43 and 0.63; ([Delfino et al., 2006](#); [Linn et al., 1996](#))]. Such personal-ambient NO<sub>2</sub> relationships are consistent with children spending greater amounts of time outdoors and could be an explanation for larger risk of NO<sub>2</sub>-related health effects for children. A recent analysis found children more likely than adults to take part in vigorous activity or aerobic exercise [indoors and outdoors; ([Wu et al., 2011b](#))]. Higher activity along with higher ventilation rates relative to lung volume and higher propensity for oronasal breathing could potentially result in greater NO<sub>2</sub> penetration to the lower respiratory tract of children; however, this has not been examined for NO<sub>2</sub> ([Section 4.2.2.3](#)).

Epidemiologic evidence across diverse locations (U.S., Canada, Europe, Asia, Australia) consistently demonstrates that short-term increases in ambient NO<sub>2</sub> concentration are

associated with larger increases in asthma-related hospital admissions, ED visits, or outpatient visits among children than adults [([Son et al., 2013](#); [Sinclair et al., 2010](#); [Ko et al., 2007b](#); [Villeneuve et al., 2007](#); [Hinwood et al., 2006](#); [Peel et al., 2005](#); [Atkinson et al., 1999a](#); [Anderson et al., 1998](#)); [Table 7-13](#)]. A few of these studies specified the aim to compare lifestages a priori ([Ko et al., 2007b](#); [Villeneuve et al., 2007](#); [Anderson et al., 1998](#)). Most results are based on comparisons between children ages 0–14 years and people ages 15–64 years, and these show NO<sub>2</sub>-associated increases in asthma hospital admissions that are 1.8 to 3.4-fold greater in children ([Son et al., 2013](#); [Ko et al., 2007b](#); [Atkinson et al., 1999a](#); [Anderson et al., 1998](#)). Not all results demonstrated increased risk for children, with some studies of asthma hospital admissions, outpatient visits, and medication sales showing no difference in association with NO<sub>2</sub> between children and adults or no association in either group ([Burra et al., 2009](#); [Laurent et al., 2009](#); [Migliaretti et al., 2005](#); [Petroeschovsky et al., 2001](#)). Except for [Petroeschovsky et al. \(2001\)](#), these studies had similar sample sizes as those observing increased risk for children ([Table 7-13](#)). A few results point to larger NO<sub>2</sub>-related increases in asthma hospital admissions or ED visits among younger children (e.g., age 0–4 years, 2–4 years) than older children ages 5–14 years ([Samoli et al., 2011](#); [Villeneuve et al., 2007](#)); however, inference from these findings is limited because of the questionable reliability of asthma diagnosis in children below the age of 5 years ([Section 5.2.2.4](#)).

The single available toxicological study does not indicate greater NO<sub>2</sub>-related lung injury, inflammation, or lung host defense among juvenile than mature rodents. The most pronounced effects, including mortality, occurred with 10,000-ppb NO<sub>2</sub> exposure, above that considered in this ISA to be ambient relevant [([Azoulay-Dupuis et al., 1983](#)); [Table 7-14](#)]. Because the endpoints examined in the rodents largely were related to pneumonia and emphysema and are not specific to asthma-related effects, they are not considered to be in conflict with epidemiologic evidence.

Risk may vary among children according to the time window of exposure because there are differences in lung development over the course of childhood. Across epidemiologic studies, asthma development was associated with long-term NO<sub>2</sub> exposures assessed for various time windows, including birth, the first year of life, year of asthma diagnosis, and lifetime exposure ([Section 6.2.2.1](#)). In limited comparisons of time periods in both epidemiologic and toxicological studies, no single critical time window of exposure was identified for the effects of short-term or long-term NO<sub>2</sub> exposure on outcomes related to asthma exacerbation or development ([Tables 7-13](#) and [7-14](#)). In epidemiologic studies, critical time windows were assessed from longitudinal studies that permitted within-subject comparisons as children were followed over time. In cohorts of children diagnosed with asthma at a median age of 2 or 5 years, NO<sub>2</sub> in the first year of life was associated with similar or lower risk of asthma compared with NO<sub>2</sub> assessed for later in

childhood [average of ages 1–3 years or average in year of diagnosis; ([Nishimura et al., 2013](#); [Clougherty et al., 2007](#))]. The young age of diagnosis in most of these children limits inference about critical time windows of NO<sub>2</sub> exposure. In the Children’s Health Study (CHS) cohorts, both exposures and respiratory outcomes were examined at various ages during follow-up from ages 5 or 10 years to 18 years. The heterogeneity among studies in exposure assessment methods, statistical methods, and examination of incidence or prevalence of outcomes is not amenable to quantitative comparisons. However, NO<sub>2</sub> exposure was associated with asthma and respiratory symptoms in childhood (ages 9–13 or 10 years) and into adolescence [ages 13–16 years or 10–18 years; ([Jerrett et al., 2008](#); [McConnell et al., 2006](#); [Gauderman et al., 2005](#); [McConnell et al., 2003](#); [McConnell et al., 1999](#))], also pointing to risk of NO<sub>2</sub>-associated respiratory effects throughout childhood.

In conclusion, epidemiologic evidence generally demonstrates that NO<sub>2</sub>-related asthma exacerbation is greater in children compared to adults. In a few cases, no difference was observed by age for NO<sub>2</sub>-associated asthma outpatient visits and medication use. However, there is sufficient consistency for asthma hospital admissions and ED visits and for similar age comparisons (ages 0–14 years vs. 15–64 years). Limited toxicological results suggest greater NO<sub>2</sub>-induced pulmonary injury and impaired host defense in mature compared to juvenile animals, but most of the endpoints examined are related to pneumonia and emphysema rather than asthma, and results are not considered to contradict epidemiologic evidence. Neither epidemiologic nor toxicological evidence clearly identifies a single critical time window of exposure in childhood (e.g., infancy, later childhood) for asthma-related effects attributable to NO<sub>2</sub> exposure. Children have different time-activity and ventilation patterns than adults, but it is not clear whether these contribute to higher NO<sub>2</sub> exposure or internal dose or increased risk for NO<sub>2</sub>-related asthma exacerbation in children. Overall, the consistent epidemiologic evidence for larger NO<sub>2</sub>-related asthma exacerbation is adequate to conclude that children are at increased risk for NO<sub>2</sub>-related health effects.

**Table 7-13 Epidemiologic studies evaluating childhood lifestage.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Asthma-related outcomes and short-term NO<sub>2</sub> exposure: age of health effect</b>						
Childhood Ages 0–14 yr n = 23,596	Adulthood Ages 15–65 yr n = 21,204	↑	Asthma hospital admission	n = 69,176 admissions; 15 hospitals	Hong Kong, 2000–2005	<a href="#">Ko et al. (2007b)</a> †
Childhood Ages 0–14 yr n = mean 8.7/day	Adulthood Ages 15–64 yr n = mean 4.3/day	↑	Asthma hospital admission	n = 5.7–36.3 mean daily admissions across cities	8 cities, South Korea, 2003–2008	<a href="#">Son et al. (2013)</a> †
Childhood Ages 0–14 yr n = mean 19.5/day	Adulthood Ages 15–64 yr n = mean 13.1/day	↑	Asthma hospital admission	n = mean 35.1 admissions per day	London, U.K., 1987–1992	<a href="#">Anderson et al. (1998)</a>
Childhood Ages 0–14 yr <sup>b</sup>	Younger adulthood Ages 15–64 yr <sup>b</sup>	↓	Asthma hospital admission	n = 202,472 admissions for asthma, heart diseases, nonrespiratory diseases	Turin, Italy, 1997–1999	<a href="#">Migliaretti et al. (2005)</a>
Childhood Ages 0–14 yr n = mean 5.6/day	All ages n = mean 8.8/day	↑	Asthma hospital admission	n = 8.8 mean asthma admissions per day	Perth, Australia, 1992–1998	<a href="#">Hinwood et al. (2006)</a>
Childhood Ages 0–14 yr n = mean 2.6/day	Adulthood Ages 15–64 yr n = mean 1.7/day	–	Asthma hospital admission	n = 13,246 asthma admissions	Brisbane, Australia, 1987–1994	<a href="#">Petroeschevsky et al. (2001)</a>
Childhood Ages 0–4 yr n = median 1/day	Childhood Ages 5–14 yr n = median 0/day	↑	Asthma hospital admission	n = 3,601 asthma admissions, 3 children's hospitals	Athens, Greece, 2001–2004	<a href="#">Samoli et al. (2011)</a> †
Childhood Ages 5–14 yr n = 13,145	Childhood Ages 15–44 yr n = 24,916	↑	Asthma ED visits	n = 57,192 ED visits, 5 hospitals	Edmonton, Canada, 1992–2002	<a href="#">Villeneuve et al. (2007)</a> †
Childhood Ages 2–18 yr <sup>b</sup>	Adulthood Ages ≥19 yr <sup>b</sup>	↑	Asthma ED visits	n = mean 39.0 asthma visits/day, 31 hospitals	Atlanta, GA, 1993–2000	<a href="#">Peel et al. (2005)</a>

**Table 7-13 (Continued): Epidemiologic studies evaluating childhood lifestage.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
Childhood Ages 0–14 yr n = mean 12.0/day	Adulthood Ages 15–64 yr n = mean 11.4/day	↑	Asthma ED visits	n = 28,435 asthma visits, 12 hospitals	London, U.K., 1992–1994	<a href="#">Atkinson et al. (1999a)</a>
Childhood Ages NR n = 28,487	Adulthood Ages NR n = 19,085	↑	Asthma outpatient visits	n = 47,572 asthma visits	Atlanta, GA, 1998–2002	<a href="#">Sinclair et al. (2010)†</a>
Childhood Ages 1–17 yr n = 1,146,215	Adulthood Ages 18–64 yr n = 1,558,071	–	Asthma outpatient visits	n = 2,704,286 Asthma visits, Ontario Health Insurance Plan Ages 1–64 yr	Toronto, Canada, 1992–2001	<a href="#">Burra et al. (2009)†</a>
Childhood Ages 0–19 yr n = 7,774	Adulthood Ages 20–39 yr n = 7,347	–	Asthma medication sales	n = 261,063 Ages 0–39 yr	Strasbourg, France, 2004	<a href="#">Laurent et al. (2009)†</a>
<b>Asthma-related outcomes and long-term exposure: time window of childhood exposure</b>						
Exposure in yr of diagnosis	Exposure in first yr of life	↑	Asthma incidence Median age of diagnosis: 5 yr	n = 417 children	Boston, MA, Follow-up: prenatally (1987–1993) to 1997	<a href="#">Clougherty et al. (2007)†</a>
Exposure in first yr of life	Exposure in first 3 yr of life	–	Asthma prevalence Median age of diagnosis: 2 yr	n = 4,320 children enrolled between ages of 8 and 21 yr	5 U.S. cities, 1996–2001	<a href="#">Nishimura et al. (2013)†</a>

ED = emergency department; NR = not reported.

<sup>a</sup>Up facing arrow indicates that the effect of nitrogen dioxide (NO<sub>2</sub>) is greater (e.g., larger increase in hospital admission) in the group with the factor evaluated than in the reference group. Down facing arrow indicates that the effect of NO<sub>2</sub> is smaller in the group with the factor evaluated than in the reference group. A dash indicates no difference in NO<sub>2</sub>-related health effect between groups.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

**Table 7-14 Toxicological studies evaluating childhood lifestage.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Animal Model	Study Details	Study
<b>Asthma-related outcomes and short-term exposure: time window of childhood exposure</b>						
Prenatal/weanling exposure	Weanling exposure	↓	Eosinophils, neutrophils, lymphocytes	Rats (Brown Norway, model of allergic disease)	Prenatal/weanling exposure: Breeding pairs mated in 200, 500, or 2,000 ppb NO <sub>2</sub> . Litters continuously exposed to age 8 and 12 weeks Weanling exposure: 5 week old rats exposed to 200, 500, or 2,000 ppb NO <sub>2</sub> continuously to age 8 and 12 weeks	<a href="#">Kumae and Arakawa (2006)</a>
		↑	Alveolar macrophage activity	n = 5-7/group Females		
<b>Nonasthma outcomes and short-term exposure: age of health effect</b>						
Juvenile age	Adult age	—	Mortality	Rats (Wistar) n = 5-8/group	2,000 ppb NO <sub>2</sub> for 3 days at ages 5, 10, 21, 45, 55, and 60 days	<a href="#">Azoulay-Dupuis et al. (1983)</a>
Juvenile age	Adult age	—		Guinea pigs (Hartley) n = 5-8/group		
Juvenile age	Adult age	—	Inflammatory cells in bronchial	Rats (Wistar) n = 5-8/group	2,000 ppb NO <sub>2</sub> for 3 days at 5, 10, 21, 45, 55, and 60 days of age	
Juvenile age	Adult age	↓	airway, alveolar edema	Guinea pigs (Hartley) n = 5-8/group		

NO<sub>2</sub> = nitrogen dioxide.

<sup>a</sup>Up facing arrow indicates that the effect of NO<sub>2</sub> is greater (e.g., greater increase in alveolar macrophage activity) in the group with the factor evaluated than in the reference group. Down facing arrow indicates that the effect of NO<sub>2</sub> is smaller in the group with the factor evaluated than in the reference group. A dash indicates no difference in NO<sub>2</sub>-related health effect between groups.

### 7.5.1.2 Older Adults

According to the 2012 National Population Projections issued by the U.S. Census Bureau, 13% of the U.S. population was age 65 years or older in 2010, and by 2030, this fraction is estimated to grow to 20% ([Ortman et al., 2014](#)). Thus, this lifestage represents a substantial proportion of the U.S. population that is potentially at increased risk for health effects related to NO<sub>2</sub> exposure.

It is not clear whether NO<sub>2</sub> exposure or uptake in the respiratory tract differs between older adults and younger adults. The National Human Activity Pattern Survey indicated that older adults spend more time outdoors at home but less time outdoors in other locations or in vehicles ([Klepeis et al., 1996](#)). A recent study in California did not consistently indicate differences in time spent in particular microenvironments or time engaged in vigorous or outdoor activity ([Wu et al., 2011b](#)).

In contrast with exposure or dose information, epidemiologic evidence points to greater risk of NO<sub>2</sub>-related health effects in older adults (ages 65 years and older) compared with younger adults. The 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) indicated that older adults may be at increased risk for NO<sub>2</sub>-related respiratory effects and mortality, and recent epidemiologic findings add to this body of evidence ([Table 7-15](#)).

Comparisons of older and younger adults with respect to NO<sub>2</sub>-related asthma exacerbation are limited and generally show larger (one to threefold) effects in adults ages 65 years or older than among individuals ages 15–64 years or 15–65 years ([Ko et al., 2007b](#); [Villeneuve et al., 2007](#); [Migliaretti et al., 2005](#); [Anderson et al., 1998](#)). Some of these studies specified the aim to compare lifestages a priori ([Ko et al., 2007b](#); [Villeneuve et al., 2007](#); [Anderson et al., 1998](#)). A few studies showed no increased risk in older adults [[Son et al., 2013](#); [Hinwood et al., 2006](#)]; [Table 7-15](#)], and it is not clear that the sample sizes differed from those in studies observing increased risk for older adults. Results for all respiratory hospital admissions combined also tend to show larger associations with NO<sub>2</sub> among older adults ages 65 years or older ([Arbex et al., 2009](#); [Wong et al., 2009](#); [Hinwood et al., 2006](#); [Atkinson et al., 1999a](#)). Controlled human exposure studies of older adults did not examine asthma-related effects or draw comparisons with younger adults. Examination of older adults was limited to healthy adults, and the sparse evidence shows only statistically nonsignificant decrements in lung function following NO<sub>2</sub> exposure [[Gong et al., 2005](#); [Morrow et al., 1992](#)]; [Table 7-16](#)].

For nonrespiratory effects, associations of short-term NO<sub>2</sub> with total mortality in most studies were larger in adults ages 65 or older than in younger adults ([Table 7-15](#)), with evidence pointing to elevated risk among the oldest adults ages greater than 75 or 85 years ([Chen et al., 2012b](#); [Cakmak et al., 2011b](#); [Chiusolo et al., 2011](#)). Studies of long-term NO<sub>2</sub> exposure do not provide strong evidence of elevated risk of health effects among older adults, with inconsistent effect measure modification observed for total or cause-specific mortality ([Dimakopoulou et al., 2014](#); [Carey et al., 2013](#); [Cesaroni et al., 2013](#); [Zhang et al., 2011](#); [Maheswaran et al., 2010](#); [Yorifuji et al., 2010](#)) and generally no difference by age group observed for associations with cardiovascular effects or diabetes ([Eze et al., 2014](#); [Atkinson et al., 2013](#); [Rivera et al., 2013](#); [Wichmann et al., 2013](#); [Andersen et al., 2012b](#); [Rosenlund et al., 2009a](#); [Ljungman et al., 2008](#); [Min et al., 2008](#)). The age to define older adults varied among mortality and cardiovascular effect studies

from 50 to 75 years. Further, it is uncertain the extent to which the findings in older adults for mortality or cardiovascular effects can be attributable to NO<sub>2</sub> because of uncertainty in whether relationships of NO<sub>2</sub> exposure with these health effects are independent of highly correlated copollutants ([Sections 5.3.11, 5.4.8, 6.3.9, and 6.5.3](#)). In particular, older adults consistently have increased risk for mortality associated with short-term PM<sub>2.5</sub> exposure ([U.S. EPA, 2009a](#)). Differences in confounding among lifestages are not well characterized for NO<sub>2</sub>. As examined in a few studies of asthma hospital admissions, adjustment for total suspended particles eliminated the NO<sub>2</sub> association in older adults but not younger adults or children ([Migliaretti et al., 2005](#)), whereas the NO<sub>2</sub> association in older adults persisted with adjustment for black smoke ([Anderson et al., 1998](#)). Other issues limiting inference are the lack of examination of copollutants and exposure assessment based on measurements from central site monitors.

Although NO<sub>2</sub> exposure or dosimetry differences in older adults are not characterized, there is generally supportive evidence for larger NO<sub>2</sub>-related risk of hospital admissions and ED visits for asthma in older adults compared to younger adults. Most of these studies compared adults ages 64–65 years or older with individuals ages 15 to 64 or 65 years. Controlled human exposure studies do not indicate increased risk in older adults, but the limited evidence is based on healthy adults not those with asthma. Thus, the evidence from controlled human exposure studies is not considered to conflict with epidemiologic evidence. As described in [Section 5.2.9](#), a relationship between NO<sub>2</sub> exposure and respiratory effects in healthy populations is not clearly demonstrated. Older adults have larger NO<sub>2</sub>-related increases in total mortality but not cardiovascular effects; however, inferences about the risk for older adults from this evidence is limited because of uncertainties regarding the independent effect of NO<sub>2</sub> on nonasthma outcomes. Overall, the consistent epidemiologic evidence for larger NO<sub>2</sub>-related asthma hospital admissions and ED visits is adequate to conclude that older adults are at increased risk for NO<sub>2</sub>-related health effects.

**Table 7-15 Epidemiologic studies evaluating older adult lifestage.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Asthma-related outcomes and short-term exposure</b>						
Older adulthood Ages >65 yr n = 24,916	Younger adulthood Ages 15–65 yr n = 21,204	↑	Asthma hospital admission	n = 69,176 admissions, 15 hospitals	Hong Kong, 2000–2005	<a href="#">Ko et al. (2007b)</a> †
Older adulthood Ages ≥65 yr n = mean 2.6/day	Younger adulthood Ages 15–64 yr n = mean 13.1/day	↑	Asthma hospital admission	n = mean 35.1 admissions per day	London, U.K., 1987–1992	<a href="#">Anderson et al. (1998)</a>
Older adulthood Ages >64 yr <sup>b</sup>	Younger adulthood Ages 15–64 yr <sup>b</sup>	↑	Asthma hospital admission	n = 202,472 admissions for asthma, heart diseases, nonrespiratory diseases	Turin, Italy, 1997–1999	<a href="#">Migliaretti et al. (2005)</a>
Older adulthood Ages ≥65 yr <sup>b</sup>	All ages <sup>b</sup>	–	Asthma hospital admission	n = 8.8 mean asthma admissions per day	Perth, Australia, 1992–1998	<a href="#">Hinwood et al. (2006)</a>
Older adulthood Ages >65 yr n = 4,705	Younger adulthood Ages 15–64 yr n = 32,815	↑	Asthma ED visits	n = 57,912 visits, 5 hospitals	Edmonton, Canada, 1992–2002	<a href="#">Villeneuve et al. (2007)</a> †
Older adulthood Ages ≥65 yr n = mean 3/day	Younger adulthood Ages 15–64 yr n = mean 4.3/day	–	Asthma and allergic disease hospital admission	n = 5.7–36.3 mean daily admissions across cities	8 South Korean cities, 2003–2008	<a href="#">Son et al. (2013)</a> †

**Table 7-15 (Continued): Epidemiologic studies evaluating older adult lifestage.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Nonasthma outcomes and short-term exposure</b>						
Older adulthood Ages ≥65 yr <sup>b</sup>	All ages <sup>b</sup>	—	COPD hospital admission	n = 91.5–270.3 mean daily admissions across conditions, 14 hospitals	Hong Kong, 1996–2002	<a href="#">Wong et al. (2009)</a> †
		↑	COPD hospital admission with influenza			
		—	Acute respiratory disease hospital admission			
		↑	Cardiovascular hospital admission			
Older adulthood Ages >64 yr, n = 789	Younger adulthood Ages 40–64 yr, n = 980	↑	COPD ED visits	n = 1,769 COPD ED visits, 40 hospitals	Sao Paulo, Brazil, 2001–2003	<a href="#">Arbex et al. (2009)</a> †
Older adulthood Ages ≥65 yr <sup>b</sup>	Younger adulthood, childhood Ages 5–64 yr <sup>b</sup>	↑	Total mortality	n = 11–119 mean daily deaths across cities	17 Chinese cities	<a href="#">Chen et al. (2012b)</a> †
Older adulthood Ages ≥65 yr, n = 187,608	Younger adulthood, childhood Ages <65 yr, n = 91,253	↑	Total mortality	n = 7.29–15.8 mean daily deaths across locations	Santiago Province, Chile (7 urban centers), 1997–2007	<a href="#">Cakmak et al. (2011b)</a> †
Older adulthood Ages ≥85 yr n = 90,070	Younger adulthood Ages 35–64 yr n = 181,031	↑	Total mortality	n = 276,205 natural deaths	10 Italian cities, 2001–2005	<a href="#">Chiusolo et al. (2011)</a> †
Older adulthood Ages 65–74 yr n = 52,689	Younger adulthood Ages 35–64 yr n = 35,803	↓				

**Table 7-15 (Continued): Epidemiologic studies evaluating older adult lifestage.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Nonasthma outcomes and long-term exposure</b>						
Older adulthood Ages ≥75 yr <sup>b</sup>	Younger adulthood Ages <60 yr <sup>b</sup>	↓	Total mortality, cardiovascular mortality	n = 1,265,058 Ages ≥30 yr	Rome, Italy, 2001–2010	<a href="#">Cesaroni et al. (2013)</a> †
		–	Lung cancer mortality			
Older adulthood Ages ≥75 yr <sup>b</sup>	Younger adulthood Ages 65–75 yr <sup>b</sup>	–	Lung cancer or cardiopulmonary mortality	n = 13,444 Ages >65 yr	Shizuoka, Japan, 1999–2006	<a href="#">Yorifuji et al. (2010)</a> †
Older adulthood Ages ≥60 yr n = 365,368	Younger adulthood Ages 40–60 yr n = 470,239	↑	Total mortality	n = 835,607 deaths Ages 40–89 yr	England Follow-up: 2003–2007 NO <sub>2</sub> exposure assessed for 2002	<a href="#">Carey et al. (2013)</a> †
Older adulthood Ages >60 yr n = 4,061	Younger adulthood Ages ≤60 yr n = 5,880	–	Cardiovascular mortality	n = 9,941, 256 deaths Ages 35–103 yr	Shenyang, China Follow-up: 1998–2009 NO <sub>2</sub> exposure assessed for 1998–2009	<a href="#">Zhang et al. (2011)</a> †
Older adulthood Ages ≥60 yr <sup>b</sup>	Younger adulthood Ages <60 yr <sup>b</sup>	↑	Respiratory mortality	n = 307,553 Mean age across 16 cohorts 41.9–73.0 yr at baseline	Europe Follow-up: 1985–2007 NO <sub>2</sub> exposure assessed for 2008–2011	<a href="#">Dimakopoulou et al. (2014)</a> †
Older adulthood Ages >70 yr n = 1,329	Younger adulthood Ages ≤70 yr n = 527	↓	Total mortality	n = 3,320 Mean age 70 yr	London, England Follow-up: 1995–2005 NO <sub>2</sub> exposure assessed for 2002	<a href="#">Maheswaran et al. (2010)</a> †
Older adulthood Ages >50 yr n = 635	Younger adulthood Ages 20–50 yr n = 242	↑	HRV decrement in low frequency domain	n = 1,349 healthy subjects Mean age 44 yr	Taein Island, South Korea, 2003–2004	<a href="#">Min et al. (2008)</a> †

**Table 7-15 (Continued): Epidemiologic studies evaluating older adult lifestage.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
Older adulthood Ages >75 yr n = 1,995	Younger adulthood Ages <60 yr, n = 1,252	—	Out-of-hospital cardiac arrest	n = 4,657 events	Copenhagen, Denmark, 2000–2010	<a href="#">Wichmann et al. (2013)†</a>
	Younger adulthood Ages 60–75 yr, n = 1,410	↑				
Older adulthood Ages ≥65 yr n = 50	Younger adulthood Ages <65 yr n = 60	—	Ventricular arrhythmia	n = 211 with implantable cardioverter defibrillators Ages 28–85 yr	Gothenburg, Stockholm, Sweden, 2001–2006	<a href="#">Ljungman et al. (2008)†</a>
Older adulthood Ages ≥65 yr n = 137,184	Younger adulthood Ages <65 yr n = 417,156	—	MI	n = 43,275 cases, 511,065 controls Ages 15–79 yr	Stockholm County, Sweden, 1985–1996	<a href="#">Rosenlund et al. (2009a)†</a>
Older adulthood Ages 65–89 yr <sup>b</sup>	Younger adulthood Ages 40–64 yr <sup>b</sup>	—	Heart failure	n = 836,557 Ages 40–89 yr at baseline	England, 2003–2007	<a href="#">Atkinson et al. (2013)†</a>
Older adulthood Ages ≥56 yr n = 1,297	Younger adulthood Ages <56 yr n = 687	—	Incidence stroke	n = 1,984 Ages 50–65 yr at baseline	Copenhagen, Aarhus counties, Denmark, 1993–2006	<a href="#">Andersen et al. (2012b)†</a>
Older adulthood Ages ≥56 yr, n = 106	Younger adulthood Ages <56 yr, n = 36	—	Fatal stroke	n = 142 Ages 50–65 yr at baseline		
Older adulthood Ages ≥60 yr Female <sup>b</sup>	Younger adulthood Ages <60 yr Female <sup>b</sup>	—	Intima media thickness cca	n = 2,780 Median age 58 yr	Girona Province, Spain, 2007–2010	<a href="#">Rivera et al. (2013)†</a>
		↓	Intima media thickness 6seg			
Male <sup>b</sup>	Male <sup>b</sup>	↑	Intima media thickness cca			
		—	Intima media thickness 6seg			

**Table 7-15 (Continued): Epidemiologic studies evaluating older adult lifestage.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
Older adulthood Ages ≥65 yr n = 2,234	Younger adulthood Ages 55–65 yr n = 3,913	—	Prevalent hypertension	n = 24,845 Mean age 45.59 yr	Shenyang, Anshan and Jinzhou, China, 2006–2008	<a href="#">Dong et al. (2013b)</a> †
Older adulthood Ages >50 yr <sup>b</sup>	Younger adulthood Ages ≤50 yr <sup>b</sup>	—	Diabetes	n = 6,392 Ages 29–73 yr	Switzerland, 2002	<a href="#">Eze et al. (2014)</a> †

COPD = chronic obstructive pulmonary disease; ED = emergency department; HRV = heart rate variability; MI = myocardial infarction.

<sup>a</sup>Up facing arrow indicates that the effect of nitrogen dioxide (NO<sub>2</sub>) is greater (e.g., larger risk of hospital admission, larger decrement in HRV) in the group with the factor evaluated than in the reference group. Down facing arrow indicates that the effect of NO<sub>2</sub> is smaller in the group with the factor evaluated than in the reference group. A dash indicates no difference in NO<sub>2</sub>-related health effect between groups.

<sup>b</sup>Sample size not reported.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

**Table 7-16 Controlled human exposure studies informing risk for older adult lifestage.**

Factor Evaluated	Reference Category	Direction of Effect <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Nonasthma outcomes and short-term exposure</b>						
Older adulthood	None	—	Lung function decrement	n = 20 (10 males, 10 females) Mean age 61 yr	300 ppb NO <sub>2</sub> for 4 h with exercise	<a href="#">Morrow et al. (1992)</a>
Older adulthood	None	—	Lung function decrement, pulmonary inflammation	n = 6 (2 males, 4 females) Mean age 68 yr	400 ppb NO <sub>2</sub> for 2 h with exercise	<a href="#">Gong et al. (2005)</a>

NO<sub>2</sub> = nitrogen dioxide.

<sup>a</sup>These studies only examined older adults and have no reference group. A dash indicates that NO<sub>2</sub> was not observed to induce an effect in the older adults relative to clean air exposure.

---

## 7.5.2 Socioeconomic Status

SES is a composite measure that usually consists of economic status measured by income, social status measured by education, and work status measured by occupation. Persons with lower SES generally have been found to have a higher prevalence of pre-existing diseases, potential inequities in access to resources such as healthcare, and possibly increased nutritional deficiencies. Neighborhoods comprising low SES populations are characterized as having fewer resources and more psychosocial stressors and air pollution sources ([Diez Roux and Mair, 2010](#); [O'Neill et al., 2003](#)); thus, community-level SES may influence health. Any or a combination of these factors could link low SES to increased risk for NO<sub>2</sub>-related health effects. According to the U.S. Census Bureau's American Community Survey, 15.8% (approximately 48.8 million) of Americans were of poverty status in 2013 as defined by household income, which is one metric used to define SES ([Bishaw and Fontenot, 2014](#)). Across the indicators of SES examined (e.g., education level, employment status, insurance status, social deprivation, access to health care), there is some evidence for higher NO<sub>2</sub> exposure and larger risk of NO<sub>2</sub>-related health effects among low SES groups in the population, but these relationships are not uniformly observed ([Table 7-17](#)). A challenge in synthesizing findings across studies is the array of SES indicators examined. Further, many studies were conducted outside of the U.S., and because demographics, bureaucracy, and the local economy vary among countries, relationships of SES metrics to extent of deprivation or inequities also may vary among countries. In addition, the studies examined SES for individual subjects (e.g., household income) and for communities (e.g., mean income of census tract). Because individual- and community-level SES indicators have been shown to have independent influences on health, these indicators were evaluated separately as modifiers of NO<sub>2</sub> exposure and NO<sub>2</sub>-related health effects.

Several studies relate higher NO<sub>2</sub> exposure with indicators of low SES, but the relationship varies across communities, levels of SES, and indicators of SES. Results from studies conducted in the U.S., Canada, and Europe point to a relationship between higher ambient NO<sub>2</sub> exposure among populations of low SES as determined by household income, job class (e.g., unskilled, professional, skilled manual labor), or education. Higher ambient NO<sub>2</sub> concentrations have been measured in communities in Montreal, Canada and Los Angeles, CA with high proportions of nonwhite residents and low SES residents ([Su et al., 2012](#); [Molitor et al., 2011](#); [Crouse et al., 2009b](#); [Su et al., 2009c](#)). While many of these studies examined community-level correlations based on census block or tract SES and NO<sub>2</sub> modeled at the neighborhood scale ([Clark et al., 2014](#); [Deguen and Zmirou-Navier, 2010](#); [Namdeo and Stringer, 2008](#); [Kruize et al., 2007](#); [Chaix et al., 2006](#); [Mitchell, 2005](#)), studies with data from individuals also found relationships between higher residential or personal NO<sub>2</sub> exposure and lower SES ([Llop](#)

[et al., 2011](#); [Deguen and Zmirou-Navier, 2010](#)). A U.S.-wide analysis of census blocks suggests inequities in NO<sub>2</sub> exposure in the low SES communities by age, with higher exposures indicated for children and older adults ([Clark et al., 2014](#)).

While most results indicate higher NO<sub>2</sub> exposure in low SES groups, some indicate that the relationship between NO<sub>2</sub> exposure and SES varies in strength and direction. In some cases, a nonlinear relationship is observed with either no difference in NO<sub>2</sub> concentrations among communities in the higher end of the income distribution [e.g., top 50%; ([Kruize et al., 2007](#))] or higher NO<sub>2</sub> concentrations in some affluent communities in the downtown core of a city ([Crouse et al., 2009b](#)). Other studies find that the relationship varies across communities ([Stroh et al., 2005](#)) and among particular SES indicators [e.g., education but not occupation, country of birth but not education; ([Stroh et al., 2005](#); [Rotko et al., 2001](#))]. The relationship between NO<sub>2</sub> exposure and SES also may weaken over time as was forecasted for Leeds, U.K. Over the period 1993–2005, increased prevalence of vehicles with more efficient emissions controls and surcharges for using congested roads were predicted to reduce the discrepancy in NO<sub>2</sub> exposures between groups with high and low deprivation index [combining unemployment, noncar ownership, nonhome ownership, and household overcrowding; ([Mitchell, 2005](#))]. [O'Neill et al. \(2003\)](#) noted that several factors might alter the relationship between NO<sub>2</sub> exposure and SES, including changing development, migration, and transportation patterns all of which could result in individuals of high SES having high NO<sub>2</sub> exposures.

There is also the possibility that a multitude of factors may interact to influence the risk of NO<sub>2</sub>-related health effects in populations of low SES. The hypothesis of “double jeopardy” describes interactions between higher air pollution exposure and social inequities in health, whereby risk of health effects may be increased for low SES and/or nonwhite populations because of increased exposure as well as increased psychosocial stress or less access to health services ([O'Neill et al., 2003](#)). An index combining risk factors such as air pollution concentrations, including NO<sub>2</sub>, with nonwhite population and low SES population has been constructed for communities in a few California cities ([Su et al., 2012](#); [2009c](#)). However, health effects have not been examined in relation to such indices comprising NO<sub>2</sub>, and for the studies evaluated in this ISA, the risk for certain SES or nonwhite populations resulting from multiple stressors has not been characterized.

While there is strong evidence for relationships between short-term and long-term NO<sub>2</sub> exposure and asthma exacerbation ([Section 5.2.9](#)) and development ([Section 6.2.9](#)), evidence does not clearly indicate differences among groups of varying SES ([Table 7-17](#)). All of these studies described their analyses of SES as a priori objectives. U.S. studies observed higher risk of NO<sub>2</sub>-related asthma exacerbation and incidence in groups made up of low SES children as defined by high psychosocial stress due to

exposure to community violence ([Clougherty et al., 2007](#)) or having no health insurance ([Grineski et al., 2010](#)). A study in Asia did not observe differences in NO<sub>2</sub>-related asthma outpatient visits by insurance status ([Kim et al., 2007](#)). Census tract- or block-level income or a composite SES index did not modify associations of short-term NO<sub>2</sub> exposure with asthma hospital admissions, physician visits, or medication sales among all ages ([Burra et al., 2009](#); [Laurent et al., 2009](#); [Lin et al., 2004b](#)).

There is limited analysis of interactions between SES and other factors in modifying risk of NO<sub>2</sub>-related asthma hospital admissions, but the results are not conclusive regarding the potential risk due to multiple co-occurring factors within a population. For children, the association did not differ between Hispanic and white children, except in the group without health insurance ([Grineski et al., 2010](#)). In another study, associations did not differ between low- and high-income census tracts among children, adults, males, or females ([Burra et al., 2009](#)).

Several studies in various countries found larger associations for short-term and long-term NO<sub>2</sub> exposures with total mortality in low SES compared to high SES groups as indicated by education, income, or employment [([Carey et al., 2013](#); [Cesaroni et al., 2013](#); [Chen et al., 2012b](#); [Cakmak et al., 2011b](#); [Chiusolo et al., 2011](#)); [Table 7-17](#)]. The increased risk for low SES was observed with both individual- and community-level SES indicators. Despite the consistency of results, the extent to which the findings can be attributed specifically to NO<sub>2</sub> is uncertain because potential confounding of relationships between NO<sub>2</sub> exposure and total mortality by traffic-related copollutants has not been adequately assessed ([Sections 5.4.8](#) and [6.5.3](#)).

Evidence that SES modifies associations of long-term NO<sub>2</sub> exposure with cardiovascular effects, diabetes, reproductive effects, developmental effects, or cancer is unclear ([Table 7-17](#)). However, independent relationships of NO<sub>2</sub> exposure with these health effects are uncertain ([Sections 6.3.9](#), [6.4.5](#), and [6.6.9](#)). Most studies found no difference among SES groups ([Eze et al., 2014](#); [Andersen et al., 2012c](#); [Guxens et al., 2012](#); [Pereira et al., 2012](#); [Zhang et al., 2011](#); [Lenters et al., 2010](#); [Yorifuji et al., 2010](#); [Rosenlund et al., 2009a](#)) or inconsistent effect measure modification among the outcomes examined ([Foraster et al., 2014](#); [Andersen et al., 2012b](#)). A few studies found larger associations among lower SES groups ([Becerra et al., 2013](#); [Morello-Frosch et al., 2010](#)), but just as many observed weaker NO<sub>2</sub>-related effects among lower SES groups ([Atkinson et al., 2013](#); [Rivera et al., 2013](#)). A diverse set of SES indicators was examined, and results are inconsistent even among studies examining education or income. Results are inconsistent for both individual- and community-level SES indicators.

Interpreting the evidence for exposure or effect measure modification by SES is challenging given the diversity of individual- and community-level SES indicators

examined across studies, array of countries where studies were conducted, and uncertainty in the independent effect of NO<sub>2</sub> on many of the health outcomes examined. Evidence indicates higher NO<sub>2</sub> exposure among low SES communities, although elevated concentrations are also reported for some high SES communities. Associations between short-term NO<sub>2</sub> exposure and asthma exacerbation do not consistently vary by SES, and results for cardiovascular effects, diabetes, reproductive effects, developmental effects, and cancer also are inconsistent. No clear pattern of effect measure modification is observed for individual- or community-level SES indicators. Evidence consistently demonstrates larger associations between NO<sub>2</sub> exposure and total mortality among low SES groups, but uncertainty remains in attributing the findings specifically to NO<sub>2</sub>. The mortality evidence combined with the evidence for higher NO<sub>2</sub> exposure is suggestive that low SES populations are at increased risk for NO<sub>2</sub>-related health effects.

**Table 7-17 Epidemiologic studies evaluating socioeconomic status.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Asthma-related outcomes and individual-level SES indicators</b>						
No insurance n = 205	Insurance n = 2,508 Private n = 2,015 Medicaid	↑	Asthma hospital admission	n = 4,728 asthma admissions Ages <14 yr	Phoenix, AZ, 2001–2003 Short-term exposure	<a href="#">Grineski et al. (2010)</a> †
Lowest quintile income-based insurance premiums n = 24%	Highest quintile income-based insurance premiums n = 17%	–	Asthma emergency outpatient visit	n = 254 mean visits per day Prior asthma diagnosis required	Seoul, Korea, 2002 Short-term exposure	<a href="#">Kim et al. (2007)</a>
High exposure to violence <sup>b</sup>	Low exposure to violence <sup>b</sup>	↑	Asthma incidence	n = 417 children followed from prenatal period	Boston, MA, 1987–1993, Follow-up to 1997 Long-term exposure	<a href="#">Clougherty et al. (2007)</a> †
<b>Asthma-related outcomes and area-level SES indicators</b>						
Low income census tracts <sup>b</sup>	High income census tracts <sup>b</sup>	–	Asthma hospital admission	n = 3,822 admissions Ages 6–12 yr	Vancouver, Canada (13 subdivisions), 1987–1998 Short-term exposure	<a href="#">Lin et al. (2004b)</a>

**Table 7-17 (Continued): Epidemiologic studies evaluating socioeconomic status.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
Lowest quintile for census tract income n = 610,121	Highest quintile for census tract income n = 527,385	—	Asthma physician visits	n = 2,704,286 asthma visits, Ontario Health Insurance Plan Ages 1–64 yr	Toronto, Canada, 1992–2001 Short-term exposure	<a href="#">Burra et al. (2009)†</a>
Lowest stratum SES census blocks: composite of income, job, education, housing n = 43,674	Highest stratum SES census blocks n = 49,111	—	Asthma medication sales	n = 261,063 Ages 0–39 yr	Strasbourg, France, 2004 Short-term exposure	<a href="#">Laurent et al. (2009)†</a>
<b>Nonasthma outcomes and individual-level SES indicators</b>						
Low education (illiterate/primary school) <sup>b</sup>	High education (middle school and above) <sup>b</sup>	↑	Total mortality	n = 11–119 mean daily deaths across cities	17 Chinese cities Short-term exposure	<a href="#">Chen et al. (2012b)†</a>
Blue collar work, Low-level white collar work n = 57.9%	High-level white collar work n = 42.1%	—	MI	n = 43,275 cases, 511,065 controls	Stockholm county, Sweden, 1985–1996 Long-term exposure	<a href="#">Rosenlund et al. (2009a)†</a>
Low income (<mean of controls) n = 44.4%	High income (>mean of controls) n = 55.6%	—				
Low education (<high school) n = 58.5%	High education (≥high school) n = 41.5%	—				
Low or medium education n = 65%	High education n = 35%	—	Atherosclerosis (carotid intima-media thickness)	n = 745 Ages 26–30 yr	Utrecht, the Netherlands, 1999–2000 Long-term exposure	<a href="#">Lenters et al. (2010)†</a>
Primary or secondary school n = 2,234	Higher education/technician n = 526	↓	Atherosclerosis (carotid intima-media thickness)	n = 2,780 Median age 58 yr	Girona Province, Spain, 2007–2010 Long-term exposure	<a href="#">Rivera et al. (2013)†</a>

**Table 7-17 (Continued): Epidemiologic studies evaluating socioeconomic status.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
Low or medium education (<10 yr) n = 1,628	High education (≥10 yr) n = 356	—	Incident stroke	n = 1,984 Ages 50–65 yr at baseline	Copenhagen, Aarhus counties, Denmark, 1993–2006 Long-term exposure	<a href="#">Andersen et al. (2012b)</a> †
Low or medium education (<10 yr) n = 110	High education (≥10 yr) n = 32	↑	Fatal stroke	n = 142 Ages 50–65 yr at baseline		
Low or medium education (<10 yr) n = 40,956	High education (≥10 yr) n = 10,862	—	Diabetes	n = 51,818 Ages 50–65 yr at baseline	Copenhagen, Aarhus counties, Denmark, 1993–2006 Long-term exposure	<a href="#">Andersen et al. (2012c)</a> †
Low or medium education (primary or secondary) n = 4,586	High education (college or university) n = 1,806	—	Diabetes	n = 6,392 Ages 29–73 yr	Switzerland, 2002 Long-term exposure	<a href="#">Eze et al. (2014)</a> †
Illiterate/primary education n = 1,540	Secondary/university education n = 2,160	—	Systolic blood pressure	n = 3,700 Ages 35–83 yr	Girona Province, Spain Long-term exposure	<a href="#">Foraster et al. (2014)</a> †
		↑	Diastolic blood pressure			
Low income (<200 mo) n = 1,817	High income (≥800 mo) n = 2,618	—	Cardiovascular mortality	n = 9,941, 256 deaths Ages 35–103 yr	Shenyang, China Follow-up: 1998–2009 NO <sub>2</sub> assessed for 1998–2009 Long-term exposure	<a href="#">Zhang et al. (2011)</a> †
Low education n = 5,970	High education n = 3,971	—				
Low education (<8 yr) n = 33%	High education (<10 yr) n = 21%	—	Diabetes-related mortality	n = 52,061 Ages 50–64 yr	Denmark Follow-up: 1971–2009 NO <sub>2</sub> exposure assessed for 1971–2009 Long-term exposure	<a href="#">Raaschou-Nielsen et al. (2012)</a> †
Financially incapable (self-reported) n = 4,054	Financially capable (self-reported) n = 7,340	—	Lung cancer mortality	n = 13,444 Ages >65 yr	Shizuoka, Japan, 1999–2006 Long-term exposure	<a href="#">Yorifuji et al. (2010)</a> †

**Table 7-17 (Continued): Epidemiologic studies evaluating socioeconomic status.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
Low parental social class (semi-skilled/unskilled occupation ≤primary education) n = 33%	High parental social class (managers/technician occupation university degree education) n = 41%	—	Mental development decrement in infants at age 14 mo	n = 1,889 children followed from prenatal period	4 Spanish cities, 2003–2008 Long-term exposure	<a href="#">Guxens et al. (2012)†</a>
Low maternal education (<high school) n = 1,725	High maternal education (>high school) n = 3,926	↑	Autistic disorder in children	n = 7,603 children with autism, 10 controls per case	Los Angeles, CA, 1998–2009 Long-term exposure	<a href="#">Becerra et al. (2013)†</a>
<b>Nonasthma outcomes and both individual-level and area-level SES indicators</b>						
Low education (<primary school) census area <sup>b</sup>	High education (university diploma) census area <sup>b</sup>	↑	Total mortality	n = 7.29–15.8 mean daily deaths across locations	Santiago Province, Chile 7 urban centers 1997–2007 Short-term exposure	<a href="#">Cakmak et al. (2011b)†</a>
Low income census area <sup>b</sup>	High income census area <sup>b</sup>	↑				
Un-employed <sup>b</sup>	White collar worker <sup>b</sup>	↑				
<b>Nonasthma outcomes and area-level SES indicators</b>						
Low income census tracts <20th percentile n = 33,565	Middle income census tracts 20th–80th percentile n = 93,040	↑	Total mortality	n = 276,205 natural deaths Ages >35 yr SES available for 44% of study population	10 Italian cities, 2001–2005 Short-term exposure	<a href="#">Chiusolo et al. (2011)†</a>
Low or middle income census tracts n = 126,605	High income census tracts >80th percentile n = 38,681	—				

**Table 7-17 (Continued): Epidemiologic studies evaluating socioeconomic status.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
Low socio-economic position census block <sup>b</sup>	High or medium socio-economic position census block <sup>b</sup>	↑	Mortality—total, cardiovascular, IHD, lung cancer	n = 1,265,058 Ages ≥30 yr	Rome, Italy, 2001–2010 Long-term exposure	<a href="#">Cesaroni et al. (2013)†</a>
Lowest quintile for area-level income n = 12.5%	Lowest quintile for area-level income n = 24.7%	↑	Total mortality	n = 835,607 Ages 40–89 yr	England Follow-up: 2003–2007 NO <sub>2</sub> exposure assessed for 2002 Long-term exposure	<a href="#">Carey et al. (2013)†</a>
Lowest deprivation index area n = 20%	Highest deprivation index area n = 20%	↓	Heart failure	n = 836,557, Ages 40–89 yr at baseline	England, 2003–2007 Long-term exposure	<a href="#">Atkinson et al. (2013)†</a>
Lowest tertile for area-level SES n = 7,556	Highest tertile for area-level SES n = 7,941	—	Small for gestational age or intrauterine growth restriction	n = 23,452 women/infants	Perth, Western Australia, 2000–2006 Long-term exposure	<a href="#">Pereira et al. (2012)†</a>
High neighborhood level poverty <sup>b</sup>	Low neighborhood level poverty <sup>b</sup>	↑	Low birth weight	n = 3,545,177 births	California, 1996–2006 Long-term exposure	<a href="#">Morello-Frosch et al. (2010)†</a>

AZ = Arizona; CA = California; IHD = ischemic heart disease; MI = myocardial infarction; NO<sub>2</sub> = nitrogen dioxide; SES = socioeconomic status.

<sup>a</sup>Up facing arrow indicates that the effect of NO<sub>2</sub> is greater (e.g., larger risk of hospital admission) in the group with the factor evaluated than in the reference group. Down facing arrow indicates that the effect of NO<sub>2</sub> is smaller in the group with the factor evaluated than in the reference group. A dash indicates no difference in NO<sub>2</sub>-related health effect between groups.

<sup>b</sup>Sample size not reported.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

### 7.5.3 Race/Ethnicity

In the 2010 U.S. census, 63.7% of the U.S. population identified themselves as non-Hispanic white; 12.6% reported their race as non-Hispanic black; and 16.3% reported being Hispanic ([Humes et al., 2011](#)). Race and ethnicity are complex factors that are often closely correlated with other factors including particular genetics, diet, and SES. Therefore, race and ethnicity may influence any potential differences in NO<sub>2</sub>-related health effects through both intrinsic and extrinsic mechanisms.

Information characterizing racial/ethnic differences in NO<sub>2</sub> exposure is sparse but suggests higher exposure among nonwhite people independent of SES. For U.S. urban areas, the population-weighted mean annual average NO<sub>2</sub> for nonwhites was estimated to be 4.6 ppb (38%) higher than for whites ([Clark et al., 2014](#)). This difference was observed across the distribution of census block household income. However, NO<sub>2</sub> was estimated from a national scale land use regression model and may reflect census block differences other than race or in combination with race.

In contrast with exposure, NO<sub>2</sub>-related health effects do not clearly differ between nonwhite and white populations ([Table 7-18](#)). This was shown in a study of asthma ED visits among children that specifically aimed to analyze racial/ethnic differences ([Grineski et al., 2010](#)). Interestingly, there was a difference between Hispanic and white children who had no health insurance ([Section 7.5.2](#)), as well as larger risk of NO<sub>2</sub>-related asthma ED visit for black children compared to Hispanic children. Racial and ethnic differences in NO<sub>2</sub>-related health effects also are not consistently found for birth outcomes, although the implications of these findings are weak because an independent relationship between NO<sub>2</sub> exposure and birth outcomes is not certain. Some studies estimated larger effects on birth weight or gestational age among babies of black or Hispanic mothers ([Rich et al., 2009](#); [Bell et al., 2007](#)); whereas others estimated larger effects for babies of white mothers ([Morello-Frosch et al., 2010](#)), or no difference among races ([Darrow et al., 2011b](#); [Madsen et al., 2010](#)).

There is some indication that NO<sub>2</sub> exposure may be higher among nonwhite compared to white populations, but information on NO<sub>2</sub> exposure at the individual level is lacking. NO<sub>2</sub>-related health effects do not consistently differ among racial and ethnic groups, particularly, for asthma exacerbation, which is concluded to have an independent relationship with short-term NO<sub>2</sub> exposure ([Section 5.2.9](#)). Additionally, it is unclear whether higher NO<sub>2</sub> exposure in combination with higher prevalence of potential at-risk factors impact the health of nonwhite populations ([Section 7.5.2](#)). Overall, the evidence for potential differences in the risk of NO<sub>2</sub>-related health effects by race and ethnicity is inconsistent and largely based on birth outcomes, for which an independent relationship with NO<sub>2</sub> exposure is uncertain. Therefore, the evidence is inadequate to determine whether race or ethnicity increases the risk for NO<sub>2</sub>-related health effects.

**Table 7-18 Epidemiologic studies evaluating race/ethnicity.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Asthma-related outcomes and short-term exposure</b>						
Black race n = 635	White race n = 2,227	—	Asthma hospital admission	n = 4,316 asthma admissions Ages <14 yr	Phoenix, AZ, 2001–2003	<a href="#">Grineski et al. (2010)</a> †
Black race n = 635	Hispanic race n = 1,454	↑				
Hispanic race n = 1,454	White race n = 2,227	—				
<b>Nonasthma outcomes and long-term exposure</b>						
Black maternal race n = 10.7%	White maternal race n = 83.4%	↑	Birth weight decrement	n = 358,504 births	CT; MA 1999–2002	<a href="#">Bell et al. (2007)</a>
Hispanic maternal race n = 14.3%	White maternal race n = 45.2%	—	Birth weight decrement	n = 406,627 full-term, singleton births	Atlanta, GA, 1994–2004	<a href="#">Darrow et al. (2011b)</a> †
Non-Hispanic black maternal race n = 40.5%		—				
Non-Western ethnicity n = 24.3%	Western ethnicity n = 75.7%	—	Birth weight decrement	n = 25,229 full-term, singleton births	Oslo, Norway	<a href="#">Madsen et al. (2010)</a> †
Hispanic maternal race n = 51.5%	Non-Hispanic white maternal race n = 32.2%	↓	Birth weight decrement	n = 3,545,177 singleton births, 37–44 week gestation	California, 1996–2006	<a href="#">Morello-Frosch et al. (2010)</a> †
Non-Hispanic black maternal race n = 5.8%		↓				

**Table 7-18 (Continued): Epidemiologic studies evaluating race/ethnicity.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
Hispanic maternal race n = 31%	White or African-American maternal race n = 69%	↑	Very small for gestational age	n = 178,198 singleton births, 37–42 week gestation, birth weight >500 g	New Jersey, 1999–2003	<a href="#">Rich et al. (2009)†</a>

AZ = Arizona; CT = Connecticut; MA = Massachusetts.

<sup>a</sup>Up facing arrow indicates that the effect of nitrogen dioxide (NO<sub>2</sub>) is greater (e.g., larger risk of hospital admission, larger decrement in birth weight) in the group with the factor evaluated than in the reference group. Down facing arrow indicates that the effect of NO<sub>2</sub> is smaller in the group with the factor evaluated than in the reference group. A dash indicates no difference in NO<sub>2</sub>-related health effect between groups.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

## 7.5.4 Sex

A vast number of health conditions and diseases have been shown to differ by sex, with some indication that there may be differences by sex in the relationship between air pollution and health effects. The 2010 U.S. census indicates an approximately equal distribution of males and females in the U.S.: 49.2% male and 50.8% female ([Howden and Meyer, 2011](#)). However, the distribution varies by age with a greater prevalence of females above 65 years of age compared to males. Thus, the public health implications of potential sex-based differences in air pollution-related health effects may vary among age groups within the population.

Comparisons of NO<sub>2</sub> internal dose are lacking, and limited evidence from a large (n = 1,634) multi-European country study indicates no difference in NO<sub>2</sub> exposure between males and females as shown by similar 2-week average residential outdoor NO<sub>2</sub> concentrations ([Sunyer et al., 2006](#)). With respect to NO<sub>2</sub>-related health effects, studies of asthma exacerbation and asthma development do not show that associations with short-term and long-term NO<sub>2</sub> exposure are consistently higher for either male or female children ([Table 7-19](#)). Evidence equally points to increased risk for females ([Clark et al., 2010](#); [Kim et al., 2004](#); [Lin et al., 2004b](#)), increased risk for males ([Carlsten et al., 2011c](#); [Mann et al., 2010](#)), and no difference between sexes ([Sarnat et al., 2012](#); [Liu et al., 2009b](#)). Few studies indicated that comparisons were planned a priori ([Mann et al., 2010](#); [Lin et al., 2004b](#)). However, because the proportion of sexes tended to be approximately equal, many studies had fairly large numbers of male and females to compare. Differences between males and females also were inconsistent in studies that estimated NO<sub>2</sub> exposure at subjects' schools ([Sarnat et al., 2012](#)) or at homes using land use

regression models that were shown to predict ambient NO<sub>2</sub> concentration in the study areas well [([Carlsten et al., 2011c](#); [Clark et al., 2010](#)); [Section 6.2.2.1](#)].

Inconsistent evidence for differences by sex is also observed for associations of short-term and long-term NO<sub>2</sub> exposures with respiratory infections, bronchitis, or respiratory symptoms in children ([Zemek et al., 2010](#); [Lin et al., 2005](#)). In contrast, associations of long-term NO<sub>2</sub> exposure with lung function decrements ([Rosenlund et al., 2009b](#); [Oftedal et al., 2008](#); [Rojas-Martinez et al., 2007a](#); [Peters et al., 1999](#)) are consistently larger in female than male children. This effect measure modification is not explained by lower baseline lung function in females. While many studies measured NO<sub>2</sub> concentrations near (2 km) subjects' schools or estimated concentrations at or near homes using well-validated models [([Rosenlund et al., 2009b](#); [Oftedal et al., 2008](#); [Rojas-Martinez et al., 2007a](#)); [Section 6.2.5.1](#)], there is uncertainty about potential confounding by other traffic-related pollutants ([Section 6.2.9](#)). Thus, the extent to which the larger NO<sub>2</sub>-related decreases in lung function among females reflect an independent effect of NO<sub>2</sub> exposure is unclear.

Beyond respiratory effects, the majority of studies observed no difference between males and females in associations of long-term NO<sub>2</sub> exposure with an array of cardiovascular effects, diabetes, total mortality, cause-specific mortality, or lung cancer incidence as described in [Table 7-19](#) ([Beelen et al., 2014b](#); [Eze et al., 2014](#); [Atkinson et al., 2013](#); [Cesaroni et al., 2013](#); [Dong et al., 2013a](#); [Johnson et al., 2013](#); [Andersen et al., 2012c](#); [Raaschou-Nielsen et al., 2012](#); [Raaschou-Nielsen et al., 2011b](#); [Zhang et al., 2011](#); [Raaschou-Nielsen et al., 2010a](#); [Yorifuji et al., 2010](#); [Rosenlund et al., 2009a](#); [Abbey et al., 1999](#)). In most cases, no difference between males and females was observed for NO<sub>2</sub> associations with subclinical effects such as changes in blood pressure, atherosclerosis, HRV, systemic inflammation, or insulin resistance ([Bilenko et al., 2015](#); [Foraster et al., 2014](#); [Atkinson et al., 2013](#); [Dong et al., 2013b](#); [Rivera et al., 2013](#); [Thiering et al., 2013](#); [Lenters et al., 2010](#); [Panasevich et al., 2009](#); [Felber Dietrich et al., 2008](#)). In the relatively small group of studies that found differences between males and females, most observed greater risk among females for associations of short-term NO<sub>2</sub> exposure with cardiac arrest or mortality ([Wichmann et al., 2013](#); [Cakmak et al., 2011b](#); [Kan et al., 2008](#)). Similar to the evidence for lung function, there is uncertainty as to whether NO<sub>2</sub> exposure has an effect on cardiovascular outcomes or mortality independent of other traffic-related pollutants ([Sections 6.3.9](#) and [6.5.3](#)). Thus, the extent to which the greater risk for females or lack of modification of NO<sub>2</sub>-related cardiovascular effects or mortality by sex can be attributable to NO<sub>2</sub> versus correlated copollutants is not clear.

The collective body of evidence does not clearly indicate that NO<sub>2</sub> exposure or NO<sub>2</sub>-related health effects differ between males and females. Differences between males

and females are not consistently observed for associations of short-term and long-term NO<sub>2</sub> exposure with asthma exacerbation and asthma development, the health effects for which evidence most strongly indicates independent relationships with NO<sub>2</sub> exposure (Sections 5.2.9 and 6.2.9). Nonrespiratory health effects related to long-term NO<sub>2</sub> exposure mostly do not differ between males and females, but lung function decrements related to long-term NO<sub>2</sub> exposure and mortality and cardiovascular effects related to short-term NO<sub>2</sub> exposure are increased consistently among females. Because it is uncertain whether NO<sub>2</sub> exposure has an independent effect on these health outcomes, the evidence is suggestive that females are at increased risk for NO<sub>2</sub>-related health effects.

**Table 7-19 Epidemiologic studies evaluating sex.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Asthma-related outcomes and short-term exposure</b>						
Female n = 1,454	Male n = 2,368	↑	Asthma hospital admission	n = 3,822 admissions Ages 6–12 yr	Vancouver, Canada, 1987–1998	<a href="#">Lin et al. (2004b)</a>
Female n = 20	Male n = 38	—	Pulmonary inflammation	n = 58 children with asthma Ages 6–12 yr	Ciudad Juarez, Mexico and El Paso, TX	<a href="#">Sarnat et al. (2012)†</a>
Female n = 68	Male n = 114	—	Lung function decrement, Pulmonary inflammation	n = 182 children with asthma Ages 9–14 yr	Windsor, Canada, 2005	<a href="#">Liu et al. (2009b)†</a>
Female n = 43.5%	Male n = 56.5%	↓	Wheeze	n = 315 children with asthma Ages 6–11 yr	Fresno, CA, 2000–2005	<a href="#">Mann et al. (2010)†</a>

**Table 7-19 (Continued): Epidemiologic studies evaluating sex.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Asthma-related outcomes and long-term exposure</b>						
Female n = 52.6%	Male n = 47.4%	↑	Asthma prevalence and incidence	n = 1,109 children Grades 3–5	San Francisco, CA, 2001	<a href="#">Kim et al. (2004)</a>
Female n = 89	Male n = 97	↓	Asthma incidence	n = 184 children followed from birth to age 7 yr	Vancouver, Canada	<a href="#">Carlsten et al. (2011c)†</a>
Female n = 7,560	Male n = 13,332	↑	Asthma incidence	n = 20,892 children followed from birth to age 5 yr	Southwestern British Columbia, Canada	<a href="#">Clark et al. (2010)†</a>
<b>Nonasthma outcomes and short-term exposure</b>						
Female n = 2,137	Male n = 2,077	↑	Respiratory hospital admission	n = 4,214 respiratory admissions	Windsor, Canada, 1995–2000	<a href="#">Luginaah et al. (2005)</a>
Female n = 2,784	Male n = 3,998	–	Respiratory infection hospital admission	n = 6,782 admissions in children Ages 0–14 yr	Toronto, Canada, 1998–2001	<a href="#">Lin et al. (2005)</a>
Female n = 8,055	Male n = 6,472	↑	Otitis media ED visits	n = 14,527 ED visits Ages 1–3 yr	Edmonton, Canada, 1992–2002	<a href="#">Zemek et al. (2010)†</a>
Female n = 24	Male n = 16	↑	HRV	n = 40 nonsmoking adults with CVD Mean age 65.6 yr	Beijing, China, summer 2007 and summer 2008	<a href="#">Huang et al. (2012a)†</a>
Female n = 1,846	Male n = 2,811	↑	Out-of-hospital cardiac arrest	n = 4,657 events	Copenhagen, Denmark, 2000–2010	<a href="#">Wichmann et al. (2013)†</a>
Female n = 51.9%	Male n = 48.1%	↓	Total mortality	n = 276,205 natural deaths Ages >35 yr	10 cities, Italy, 2001–2005	<a href="#">Chiusolo et al. (2011)†</a>
Female <sup>b</sup>	Male <sup>b</sup>	↑	Total mortality	n = 7.29–15.8 mean daily deaths across locations	Santiago Province, Chile (7 urban centers), 1997–2007	<a href="#">Cakmak et al. (2011b)†</a>

**Table 7-19 (Continued): Epidemiologic studies evaluating sex.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
Female Mean daily deaths = 56.5	Male Mean daily deaths = 62.5%	↑	Total mortality	n = 173,911 deaths	Shanghai, China, 2001–2004	<a href="#">Kan et al. (2008)†</a>
<b>Nonasthma outcomes and long-term exposure</b>						
Female n = 49%	Male n = 51%	↑	Lung function decrement	n = 2,307 Ages 9–10 yr	Oslo, Norway, 2001–2002	<a href="#">Ofteidal et al. (2008)</a>
Female n = 942–1,161	Male n = 890–1,160	↑	Lung development decrement	n = 3,170 healthy children Age 8 yr	Mexico City, Mexico, 1996–1999	<a href="#">Rojas-Martinez et al. (2007a)</a>
Female n = 648	Male n = 711	↑	Lung function decrement	n = 1,760 Ages 9–14 yr	Rome, Italy, 2000–2001	<a href="#">Rosenlund et al. (2009b)†</a>
Female <sup>b</sup>	Male <sup>b</sup>	↑	Lung function decrement	n = 3,293 Grades 4, 7, 10	Southern California, 1986–1990	<a href="#">Peters et al. (1999)</a>
Female n = 52.6%	Male n = 47.4%	—	Bronchitis	n = 1,109 Grades 3–5	San Francisco, CA, 2001	<a href="#">Kim et al. (2004)</a>
Female n = 832	Male n = 924	—	Respiratory symptoms	n = 1,756 full-term infants Assessed at ages 1 and 2 yr	3 German cities, 1995–1999	<a href="#">Gehring et al. (2002)</a>
Female n = 49.4%	Male n = 50.6%	—	MI	n = 43,275 cases, 511,065 control	Stockholm county, Sweden, 1985–1996	<a href="#">Rosenlund et al. (2009a)†</a>
Female n = 508	Male n = 1,028	—	Blood IL-6 level	n = 1,536 Ages 45–70 yr	Stockholm county, Sweden, 1992–1994	<a href="#">Panasevich et al. (2009)†</a>
Female n = 395	Male n = 350	—	Mean carotid artery intima media thickness	n = 745 Ages 26–30 yr	Utrecht, the Netherlands, 1999–2000	<a href="#">Lenters et al. (2010)†</a>
Female n = 53.6%	Male n = 46.4%	—	Atherosclerosis (carotid intima media thickness)	n = 2,780 Median age 58 yr	Girona Province, Spain, 2007–2010	<a href="#">Rivera et al. (2013)†</a>
Female n = 1,980	Male n = 1,720	—	Systolic/diastolic blood pressure	n = 3,700 Ages 35–83 yr	Girona, Spain	<a href="#">Foraster et al. (2014)†</a>

**Table 7-19 (Continued): Epidemiologic studies evaluating sex.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
Female n = 431,388	Male n = 405,169	—	Heart failure	n = 836,557 Ages 40–89 at baseline	England, 2003–2007	<a href="#">Atkinson et al. (2013)</a> †
Female n = 573	Male n = 574	—	Systolic/diastolic blood pressure	n = 1,147 Age 12 yr	the Netherlands	<a href="#">Bilenko et al. (2015)</a> †
Female n = 12,184	Male n = 12,661	—	Incident CVD	n = 24,845 Mean age 41.7 yr	Shenyang, Anshan and Jinzhou, China, 2009	<a href="#">Dong et al. (2013a)</a> †
		—	Incident stroke			
Female n = 12,184	Male n = 12,661	—	Incidence hypertension	n = 24,845 Mean age 45.59 yr	Shenyang, Anshan and Jinzhou, China, 2009–2010	<a href="#">Dong et al. (2013b)</a> †
		—	Absolute increase in arterial blood pressure			
Female n = 829	Male n = 1,155	—	Incident stroke	n = 1,984 Ages 50–65 yr at baseline	Copenhagen, Aarhus counties, Denmark, 1993–2006	<a href="#">Andersen et al. (2012b)</a> †
Female n = 63	Male n = 79	—	Fatal stroke	n = 142 Ages 50–65 yr at baseline		
Female n = 18,085	Male n = 29,030	—	Stroke	n = 4,696 cases and 37,723 controls Ages ≥20 yr	Edmonton, Alberta, Canada, 2007–2009	<a href="#">Johnson et al. (2013)</a> †
Female n = 725	Male n = 683	—	HRV decrement (SDNN)	n = 1,408 Ages ≥50 yr	Switzerland Follow-up: 1991 to 2001–2003	<a href="#">Felber Dietrich et al. (2008)</a> †
Female with CVD n = 115	Male with CVD n = 121	—				
Female without CVD n = 610	Male without CVD n = 562	↑				
Female n = 27,273	Male n = 24,545		Diabetes	n = 51,818 Ages 50–65 yr at baseline	Copenhagen, Aarhus counties, Denmark, 1993–2006	<a href="#">Andersen et al. (2012c)</a> †
Female n = 51.3%	Male n = 48.7%	—	Diabetes	n = 6,392 Ages 29–73 yr	Switzerland, 2002	<a href="#">Eze et al. (2014)</a> †

**Table 7-19 (Continued): Epidemiologic studies evaluating sex.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
Female n = 222	Male n = 175	—	Insulin resistance	n = 397 Age 10 yr	Munich and Wesel, Germany	<a href="#">Thiering et al. (2013)</a> †
Female n = 47.7–77.5% across cohorts	Male n = 22.5–52.3% across cohorts	—	Respiratory mortality	n = 307,553 Mean age across 16 cohorts 41.9–73.0 yr at baseline	Europe Follow-up: 1985–2007 NO <sub>2</sub> exposure assessed for 2008–2011	<a href="#">Dimakopoulou et al. (2014)</a> †
Female n = 51.47%	Male n = 48.53%	—	CVD mortality	n = 9,941, 256 deaths Ages 35–103 yr	Shenyang, China Follow-up: 1998–2009 NO <sub>2</sub> exposure assessed for 1998–2009	<a href="#">Zhang et al. (2011)</a> †
Female n = 63%	Male n = 37%	—	CVD mortality	n = 367,383 Mean age 41.1–70.3 yr across 22 cohorts	Europe Follow-up: 1985–2007 NO <sub>2</sub> exposure assessed for 2008–2011	<a href="#">Beelen et al. (2014b)</a> †
Female n = 52.5%	Male n = 47.5%	—	Diabetes-related mortality	n = 52,061 Ages 50–64 yr	Denmark Follow-up: 1971–2009 NO <sub>2</sub> exposure assessed for 1971–2009	<a href="#">Raaschou-Nielsen et al. (2012)</a> †
Female n = 430,891	Male n = 404,716	↑	Total mortality	n = 835,607 deaths Ages 40–89 yr	England Follow-up: 2003–2007 NO <sub>2</sub> exposure assessed for 2002	<a href="#">Carey et al. (2013)</a> †
Female <sup>b</sup>	Male <sup>b</sup>	—	Mortality (total, CVD, IHD, lung cancer)	n = 1,265,058 Ages ≥30 yr	Rome, Italy, 2001–2010	<a href="#">Cesaroni et al. (2013)</a> †
Female n = 111 deaths	Male n = 407 deaths	—	Lung cancer mortality	n = 63,520 Ages >40 yr	3 prefectures, Japan, 1983–1985	<a href="#">Katanoda et al. (2011)</a> †
		↑	Respiratory mortality			

**Table 7-19 (Continued): Epidemiologic studies evaluating sex.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
Female n = 203– 7,840 deaths	Male n = 233– 4,531 deaths	↑	Lung cancer mortality	n = 138,977, 518 deaths Ages 51–90 yr	Oslo, Norway, 1992–1998	<a href="#">Naess et al. (2007)</a>
		–	CVD mortality			
		↓	COPD mortality			
Female n = 4,060	Male n = 2,278	↑	Lung cancer mortality	n = 6,338 nonsmoking, non-Hispanic adults Ages 27–95 yr	California, Follow-up: 1977–1992 NO <sub>2</sub> exposure assessed for 1973–1992	<a href="#">Abbey et al. (1999)</a>
		–	Total mortality			
		–	Cardiopulmonary mortality			
		–	Respiratory mortality			
Female n = 49%	Male n = 51%	–	Lung cancer mortality	n = 13,444 Ages >65 yr	Shizuoka, Japan, 1999–2006	<a href="#">Yorifuji et al. (2010)†</a>
Female n = 1,206	Male n = 2,275	–	Lung cancer incidence	n = 3,481 Ages 20–93 yr at enrollment	Copenhagen, Aarhus counties, Denmark, 1970–1997	<a href="#">Raaschou-Nielsen et al. (2010a)†</a>
Female n = 27,788	Male n = 25,182	–	Lung cancer incidence	n = 52,970 Ages 50–64 yr	Copenhagen, Aarhus counties, Denmark, 1993–1997	<a href="#">Raaschou-Nielsen et al. (2011b)†</a>

CA = California; COPD = chronic obstructive pulmonary disease; CVD = cardiovascular disease; ED = emergency department; HRV = heart rate variability; IHD = ischemic heart disease; IL = interleukin; MI = myocardial infarction; NO<sub>2</sub> = nitrogen dioxide.

<sup>a</sup>Up facing arrow indicates that the effect of NO<sub>2</sub> is greater (e.g., larger risk of hospital admission, larger decrement in HRV) in the group with the factor evaluated than in the reference group. Down facing arrow indicates that the effect of NO<sub>2</sub> is smaller in the group with the factor evaluated than in the reference group. A dash indicates no difference in NO<sub>2</sub>-related health effect between groups.

<sup>b</sup>Sample size not reported.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

---

## 7.5.5 Residence in Urban Areas

A majority (81%) of the U.S. population lives in urban areas, and U.S. census data indicate that the urban population grew 12% from 2000 to 2010. Higher ambient NO<sub>2</sub> concentrations in urban than suburban areas and the large numbers of people potentially having higher exposures highlight the public health impact of potential differences in NO<sub>2</sub>-related health effects in urban residents. Higher ambient NO<sub>2</sub> concentrations have been described for downtown versus suburban areas [14.9 ppb vs. 11.7 ppb; ([Rotko et al., 2001](#))]. Higher ambient NO<sub>2</sub> concentrations also were related to building characteristics such as high-rise building versus single family home and older versus newer construction (before or after 1970). Proximity to roads has been shown to be a determinant of personal NO<sub>2</sub> exposure ([Section 7.5.6](#)), and the higher road density in urban areas and proximity to major roads also may result in higher exposure of urban residents. The topography of urban communities also may contribute to higher NO<sub>2</sub> exposure among residents because the presence of street canyons enhances mixing at elevations closer to the street canyon-urban boundary layer interface, resulting in higher NO<sub>2</sub> concentrations at lower elevations ([Section 2.5.3](#)). This may have implications for higher NO<sub>2</sub> exposures for pedestrians, outdoor workers, and those living on lower floors of buildings. Multiple lines of evidence indicate that residing in urban areas may lead to increased exposure to NO<sub>2</sub>.

Although the potential for higher exposure of urban residents to NO<sub>2</sub> is well characterized, epidemiologic comparisons of NO<sub>2</sub>-related health effects between urban and nonurban residents are limited and use variable definitions of urban and nonurban residence ([Table 7-20](#)). The single study examining asthma exacerbation, which specified comparisons a priori, did not observe that associations of short-term increases in NO<sub>2</sub> with changes in lung function differed between urban and suburban children with asthma ([Ranzi et al., 2004](#)). Associations of NO<sub>2</sub> exposure with nonasthma outcomes did not differ by urban residence ([Atkinson et al., 2013](#); [Steenenberg et al., 2001](#)). However, there is uncertainty regarding the extent to which NO<sub>2</sub> exposure is independently related to respiratory effects in healthy populations ([Section 5.2.9](#)) or to cardiovascular effects ([Section 6.3.9](#)).

Evidence indicates the potential for higher ambient NO<sub>2</sub> exposure among urban residents, but the limited epidemiologic evidence does not provide a strong basis for inferring whether urban residence leads to increased risk for NO<sub>2</sub>-related health effects. Overall, the limited epidemiologic evidence on urban residence is inconsistent and is based on variable definitions of urban and nonurban residence and health effects not conclusively linked to NO<sub>2</sub> exposure. As a result, the evidence is inadequate to determine whether residence in urban areas increases the risk for NO<sub>2</sub>-related health effects.

**Table 7-20 Epidemiologic studies evaluating urban residence.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Asthma-related outcomes and short-term exposure</b>						
Urban-industrial residence n = 67	Rural residence n = 51	—	Lung function variability	n = 118 children with asthma or respiratory symptoms Ages 6–11 yr	Urban & rural areas Emilia-Romagna, Italy, 1999	<a href="#">Ranzi et al. (2004)</a>
<b>Nonasthma outcomes and short-term and long-term exposure</b>						
Urban residence n = 38	Suburban residence n = 44	↑	Lung function decrement	n = 82 Ages 8–13 yr	Utrecht, Bilthoven, the Netherlands Short-term exposure	<a href="#">Steerenberg et al. (2001)</a>
Residence in London n = 91,992	Residence in North/South UK (excluding London) n = 744,565	—	Heart failure	n = 836,557 Ages 40–89 yr at baseline	UK, 2003–2007 Long-term exposure	<a href="#">Atkinson et al. (2013)†</a>

UK = United Kingdom.

<sup>a</sup>Up facing arrow indicates that the effect of nitrogen dioxide (NO<sub>2</sub>) is greater (e.g., larger decrement in lung function) in the group with the factor evaluated than in the reference group. Down facing arrow indicates that the effect of NO<sub>2</sub> is smaller (e.g., smaller decrement in lung function) in the group with the factor evaluated than in the reference group. A dash indicates no difference in NO<sub>2</sub>-related health effect between groups.

†Study published since the 2008 ISA for Oxides of Nitrogen


## 7.5.6 Proximity to Roadways

A zone of elevated NO<sub>2</sub> concentrations (on average 30% and up to 100%) typically extends to within 200–500 m of roads with heavy traffic ([Section 2.5.3](#)). Thus, individuals spending a substantial amount of time on or near high-traffic roadways, including those living or working near highways and commuting on roadways, are likely to be exposed to elevated NO<sub>2</sub> concentrations.

Large proportions of the U.S. population potentially have elevated NO<sub>2</sub> exposures as a result of living within 200 to 500 m of roadways. Seventeen percent of U.S. homes are located within 91 m of a highway with four or more lanes, a railroad, or an airport ([U.S. Census Bureau, 2009](#)). Specific to road traffic, [Rowangould \(2013\)](#) found that over 19% of the U.S. population lives within 100 m of roads with an annual average daily traffic

(AADT) of 25,000 vehicles, and 1.3% lives near roads with AADT greater than 200,000. The proportion is much larger in certain parts of the country, mostly coinciding with urban areas. For example in Los Angeles, CA, primary and secondary roads run through neighborhoods with population density as high as 15,000–18,000 people per km<sup>2</sup> [(U.S. Census Bureau, 2014, 2013a); Figure 7-1]. Among California residents, 40% lives within 100 m of roads with AADT of 25,000 (Rowangould, 2013).

Though far from generalizable across populations, there are examples indicating that residence near a busy roadway may be associated with higher NO<sub>2</sub> exposure. In the southern California CHS cohort, closer proximity to a freeway showed a range of correlations with residential NO<sub>2</sub> measurements, with values of –0.73 to –0.90 in some communities (Gauderman et al., 2005). In a cohort of pregnant women who spent on average 60% of time home indoors, traffic intensity within 250 and 500 m of homes was moderately correlated with personal NO<sub>2</sub> exposures [ $r = 0.3, 0.4$ , respectively; (Schembari et al., 2013)]. However, the strongest correlation was not observed for traffic intensity in closest proximity to homes ( $r = 0.2$  for traffic intensity within a 100-m buffer). Such results may be explained by the atmospheric chemistry of NO<sub>2</sub>. Depending on atmospheric stability, NO<sub>2</sub> concentrations can dilute with distance from the road or extend beyond 1 km of the roadway (Section 2.5.3) and may be higher after some of the NO reacts photochemically to become NO<sub>2</sub>.



Source: National Center for Environmental Assessment analysis of U.S. census data ([U.S. Census Bureau, 2014, 2013a](#)).

**Figure 7-1** Map of population density in Los Angeles, CA, in relation to primary and secondary roads.

Exposure in transport is found to be an important determinant of total personal NO<sub>2</sub> exposure ([Son et al., 2004](#); [Lee et al., 2000](#)), although time in transport makes up a relatively small proportion of people’s activities. Such findings have implications for people who commute on roadways as well as for professional drivers. Among the populace working outside the home, 15.6% spend 45 minutes or more commuting to

work each day ([U.S. Census Bureau, 2007](#)). Average one-way commuting times for the U.S. labor force working outside the home are 19.3 minutes for bicyclists, 11.5 minutes for walkers, and 25.9 minutes for all other modes of transportation. The potential of higher NO<sub>2</sub> exposure of people who commute on roadways and professional drivers is supported by many observations of in-vehicle NO<sub>2</sub> concentrations approaching roadside concentrations ([Figure 3-2](#)) and some evidence of higher personal NO<sub>2</sub> exposure during transport than in outdoor or indoor environments ([Delgado-Saborit, 2012](#)). The relationship of health effects with NO<sub>2</sub> exposure during commute or while driving for work is not well characterized. In the CHS cohort, longer commuting time to school was associated with increased wheeze but not asthma onset; commute-time NO<sub>2</sub> exposures were not measured ([McConnell et al., 2010b](#)).

Children are characterized to be at increased risk for NO<sub>2</sub>-related health effects ([Section 7.5.1.1](#)), and time spent near major roads could potentially be a source of higher NO<sub>2</sub> exposure contributing to health effects. Attendance at schools or daycare near major roads may be an important determinant of NO<sub>2</sub> exposure, and ambient NO<sub>2</sub> concentrations at schools have been associated with respiratory effects in children with asthma ([Sections 5.2.2.2](#) and [5.2.2.5](#)). Seven percent of U.S. schools serving 3,152,000 school children are located within 100 m of a major roadway, and 15% of U.S. schools serving 6,357,000 school children are located within 250 m of a major roadway [not specifically defined in terms of AADT, number of lanes, or other criteria; ([Kingsley et al., 2014](#))]. In California, 2.3% of public schools serving 150,323 children were estimated to be located within 150 m of high-traffic roads [ $\geq 50,000$  vehicles per day; ([Green et al., 2004](#))]. Also in California, 1,534 daycare facilities serving 57,173 (7% of those in daycare) children were within 200 m of roadways with AADT of  $\geq 50,000$ , and 4,479 facilities serving 171,818 (21%) children were within 200 m of roadways with AADT of 25,000–49,999 ([Houston et al., 2006](#)). Though neither of these analyses assessed NO<sub>2</sub> exposures, they identify the large numbers of children potentially exposed to higher NO<sub>2</sub> concentrations in locations where they spend several hours per day.

There is some indication that traffic exposures differ among sociodemographic groups. In California, schools or daycare in close proximity to high-traffic roadways had a higher percentage of nonwhite students ([Green et al., 2004](#)) or tended to be located in areas with higher percentages of nonwhite residents ([Houston et al., 2006](#)). Analyses of U.S. census blocks or tracts indicate associations of higher traffic or road density or proximity to roadways with higher proportion of nonwhite residents ([Rowangould, 2013](#); [Tian et al., 2013](#)). In some ([Rowangould, 2013](#); [Green et al., 2004](#)) but not all ([Tian et al., 2013](#)) cases, closer proximity to roadways or higher traffic density was associated with lower SES at the school or census block level. In analyses not considering proximity or density of traffic, higher NO<sub>2</sub> exposures are suggested for nonwhite ([Section 7.5.3](#)) or low SES

([Section 7.5.2](#)) populations. However, it is not understood whether observations of higher NO<sub>2</sub> exposures in certain sociodemographic groups are related to disparities in traffic exposure.

Large proportions of the U.S. population live or attend school near roads or travel on roads, and some evidence indicates higher NO<sub>2</sub> exposure with proximity to roads. Traffic proximity may be more prevalent among nonwhite and low SES groups, but the influence of traffic proximity on differential NO<sub>2</sub> exposure in these groups is unclear. While traffic proximity ([HEI, 2010](#)) and NO<sub>2</sub> exposure near traffic ([Section 5.2.9.3](#)) are linked to asthma exacerbation or prevalence, studies have not examined whether NO<sub>2</sub>-related risk of asthma differs for populations living near traffic ([Table 7-21](#)). Closer residential proximity to freeway was associated with larger NO<sub>2</sub>-related decrements in lung development among children ([Gauderman et al., 2007](#)), but NO<sub>2</sub> concentrations as measured at central sites were weakly correlated with traffic counts near homes, and an independent effect of NO<sub>2</sub> exposure on lung development is uncertain. Additionally, results are inconclusive for cardiovascular effects and leukemia ([Foraster et al., 2014](#); [Hart et al., 2013](#); [Amigou et al., 2011](#)). The insufficient quantity and consistency of evidence, based on health effects for which independent relationships with NO<sub>2</sub> exposure are uncertain, is inadequate to determine whether populations in close proximity to roadways are at increased risk for NO<sub>2</sub>-related health effects.

**Table 7-21 Epidemiologic studies evaluating proximity to roadways.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Nonasthma outcomes and long-term exposure</b>						
Residence <500 m from freeway n = 440	Residence 1,000–1,500 m from freeway <sup>b</sup>	↑	Lung development decrement (change over time)	n = 3,677 children followed ages 10–18 yr	Alpine, Lake Elsinore, Lake Arrowhead, Atascadero, Lancaster, San Dimas, Long Beach, Mira Loma, Lompoc, Riverside, Santa Maria, Upland, CA Follow-up: 1993/1996 to 2001/2004	<a href="#">Gauderman et al. (2007)</a>
Near road n = 539 MI cases	Far from road (>50 m from road with	↑	Incident MI	n = 84,562 Ages 30–55 yr at enrollment	U.S., 1990–2008	<a href="#">Hart et al. (2013)</a> †
Moved near road n = 48 MI cases	>2 lanes or >150 m from highway) n = 2,841 MI cases	↑				
Moved away from road n = 603 MI cases		–				
Traffic intensity of nearest road >median	Traffic intensity of nearest road ≤median	–	Systolic blood pressure	n = 3,700 Ages 35–83 yr	Girona, Spain	<a href="#">Foraster et al. (2014)</a> †
		–	Diastolic blood pressure			
Traffic load at 500 m >median	Traffic load at 500 m ≤median	↑	Systolic blood pressure			
		–	Diastolic blood pressure			
Residence <500 m of main roads n = 48	Residence ≥500 m from all road types n = 954	–	Leukemia	n = 763 cases, 1,681 controls Ages <15 yr	France, 2003–2004	<a href="#">Amigou et al. (2011)</a> †

CA = California; MI = myocardial infarction.

<sup>a</sup>Up facing arrow indicates that the effect of nitrogen dioxide (NO<sub>2</sub>) is greater (e.g., larger decrement in development, larger risk of MI) in the group with the factor evaluated than in the reference group. Down facing arrow indicates that the effect of NO<sub>2</sub> is smaller in the group with the factor evaluated than in the reference group. A dash indicates no difference in NO<sub>2</sub>-related health effect between groups.

<sup>b</sup>Sample size not reported.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

---

## 7.6 Behavioral and Other Factors

---

### 7.6.1 Diet

Diet is an important influence on health and thus, plausibly could influence air pollutant-related health effects. The 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)) did not discuss whether diet influences the risk of NO<sub>2</sub>-related health effects; however, evidence from previous experimental studies indicates reduced or greater respiratory effects in humans and rodents with supplementation of or deficiencies in antioxidant vitamins, respectively ([Table 7-22](#)). It is not clear that diet would affect NO<sub>2</sub> exposure, although the two may be linked through a common relationship with SES. However, NO<sub>2</sub> reactions in the epithelial lining fluid of the respiratory tract form oxidation products ([Section 4.3.2.1](#)), and dietary antioxidants could affect the availability of such oxidation products to initiate subsequent events in the mode of action for NO<sub>2</sub>-related health effects. Increased risk of NO<sub>2</sub>-related health effects due to dietary deficiencies in antioxidants could have a large public health impact. Among U.S. adults, 37.7% and 22.6% report consuming fruits and vegetables, respectively, less than once a day ([CDC, 2013](#)), which could result in lower levels of Vitamins C and E.

The strongest evidence for diet modifying NO<sub>2</sub>-related health effects comes from a controlled human exposure study that demonstrated that healthy adults with diets supplemented with Vitamin C had less airway responsiveness following 2,000 ppb NO<sub>2</sub> for 1 hour compared to adults with a normal diet ([Mohsenin, 1987b](#)). Airway responsiveness is a hallmark of asthma exacerbation ([Figure 4-1](#)). The evidence that higher antioxidant vitamin intake reduces NO<sub>2</sub>-induced airway responsiveness is supported by experimental evidence in humans and rodents that higher dietary Vitamin E and/or C reduces NO<sub>2</sub>-induced pulmonary inflammation and modulates the oxidant/antioxidant balance [([Mohsenin, 1991](#); [Hatch et al., 1986](#); [Elsayed and Mustafa, 1982](#); [Sevanian et al., 1982b](#); [Selgrade et al., 1981](#); [Ayaz and Csallany, 1978](#)); [Table 7-22](#)]. Pulmonary inflammation and formation of oxidation products are early events in the mode of action for NO<sub>2</sub> effects on asthma exacerbation ([Figure 4-1](#) and [Section 4.3.5](#)). Despite the consistency and coherence of evidence, findings are limited, particularly for changes that are indicative of health effects. The changes in NO<sub>2</sub>-induced lipid peroxidation, antioxidant levels, and antioxidant enzyme activity observed in relation to vitamin deficiencies or supplementation may or may not lead to health effects.

Epidemiologic studies have not examined whether diet modifies NO<sub>2</sub>-related respiratory effects. Limited information indicates that associations of long-term NO<sub>2</sub> exposure with mental development in infants are larger in groups with low fruit intake (maternal prenatal or concurrent, respectively) than groups with high fruit intake [([Guxens et al., 2012](#)); [Table 7-23](#)]. Fruits are a source of antioxidants; thus, the results for modification by fruit intake are consistent with those for dietary antioxidant vitamins. However, because evidence for NO<sub>2</sub>-related neurodevelopmental effects is overall inconclusive ([Section 6.4.5](#)), the available epidemiologic evidence cannot adequately inform whether diet deficiencies increase the risk for NO<sub>2</sub>-related health effects.

Experimental studies in humans and animals provide evidence that dietary intake of Vitamin C or E modifies airway responsiveness, pulmonary inflammation, and oxidant balance following NO<sub>2</sub> exposure, with high vitamin intake reducing these effects and low intake increasing effects. Epidemiologic evidence is available only for health effects for which relationships with NO<sub>2</sub> are uncertain. Oxidative stress, pulmonary inflammation, and airway responsiveness are key events in the mode of action for asthma exacerbation ([Figure 4-1](#)); thus, a biologically plausible mechanism exists for dietary antioxidants to reduce the risk of NO<sub>2</sub>-related health effects. Despite this biological plausibility, most findings are for changes in oxidant/antioxidant balance rather than changes clearly indicative of health effects, such as airway responsiveness. Thus, the findings for dietary deficiencies may further support a role for oxidative stress in the biological pathways that mediate the effects of NO<sub>2</sub> exposure on asthma exacerbation. Therefore, there is suggestive evidence that low dietary antioxidant intake increases the risk for NO<sub>2</sub>-related health effects.

**Table 7-22 Controlled human exposure and toxicological studies evaluating diet.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population/ Animal Model	Study Details	Study
<b>Asthma-related outcomes and short-term exposure</b>						
Vitamin C supplemented diet 3 days n = 11	Normal diet n = 11	↓	Airway responsiveness	Humans n = 8 male, 3 female Ages 18–37 yr	2,000 ppb NO <sub>2</sub> for 1 h, randomized, double-blind	<a href="#">Mohsenin (1987b)</a>
<b>Nonspecific outcomes and short-term exposure</b>						
Vitamin C and E supplemented diet 4 weeks n = 10	Normal diet n = 9	↓	Lipid peroxidation in lavage fluid	Humans n = 10 male, 9 female Ages 21–33 yr	4,000 ppb NO <sub>2</sub> for 3 h	<a href="#">Mohsenin (1991)</a>
Vitamin C supplemented diet n = 4–5	Vitamin C normal diet n = 9	↑	Pulmonary inflammation	Guinea pigs (Hartley) n = 2–6 males/group	400, 1,000, 3,000, or 5,000 ppb NO <sub>2</sub> for 3 days	<a href="#">Selgrade et al. (1981)</a>
Vitamin C deficient diet n = 5–8	Vitamin C supplemented diet n = 15	↑	Pulmonary inflammation, Antioxidant reduction	Guinea pigs (Hartley) n = 3–15 males/group	4,800 ppb NO <sub>2</sub> for 3 h	<a href="#">Hatch et al. (1986)</a>
Vitamin E deficient diet, birth–adolescence n = 6–7	Vitamin E supplemented diet n = 6–8	↑	Lipid peroxidation, Pulmonary inflammation	Rats (Sprague-Dawley) n = 6–8/group	3,000 ppb NO <sub>2</sub> for 1 week	<a href="#">Sevanian et al. (1982b)</a>
Vitamin E deficient diet, birth–adolescence n = 6	Vitamin E supplemented diet n = 6	↑	Lipid peroxidation, Induction of antioxidant enzymes	Rats (Sprague-Dawley) n = 6/group	3,000 ppb NO <sub>2</sub> for 1 week	<a href="#">Elsayed and Mustafa (1982)</a>
<b>Nonspecific outcomes and long-term exposure</b>						
Vitamin E deficient diet n = 6–10	Vitamin E supplemented diet n = 6–10	↑	Glutathione peroxidase activity reduction	Mice (C57BL/6J) n = 120 females	500 or 1,000 ppb NO <sub>2</sub> for 17 mo	<a href="#">Ayaz and Csallany (1978)</a>

NO<sub>2</sub> = nitrogen dioxide.

<sup>a</sup>Up facing arrow indicates that the effect of NO<sub>2</sub> is greater (e.g., larger increase in airway responsiveness, larger increase in lipid peroxidation) in the group with the factor evaluated than in the reference group.

**Table 7-23 Epidemiologic studies evaluating diet.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Nonasthma outcomes and long-term exposure</b>						
Low healthy eating index (≤109) <sup>b</sup>	High healthy eating index (>109) <sup>b</sup>	—	MI incidence	n = 84,562 Ages 30–55 yr at enrollment	U.S., 1990–2008	<a href="#">Hart et al. (2013)</a> †
Low maternal fruit intake in 1st trimester (≤405 g per day) n = 33.5%	Medium/high maternal fruit intake in 1st trimester (405 g per day) n = 66.5%	↑	Decrement in mental development score in infants at age 14 mo	n = 1,889 children followed from prenatal period	Valencia, Sabadell, Gipuzkoa, and Asturias, Spain 2003–2008	<a href="#">Guxens et al. (2012)</a> †

MI = myocardial infarction.

<sup>a</sup>Up facing arrow indicates that the effect of nitrogen dioxide (NO<sub>2</sub>) is greater (e.g., larger decrement in mental development score) in the group with the factor evaluated than in the reference group. A dash indicates no difference in NO<sub>2</sub>-related health effect between groups.

<sup>b</sup>Sample size not reported.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

## 7.6.2 Smoking

In the 2012 National Health Interview Survey, 18.1% of U.S. adults reported being current smokers, and 21.3% reported being a former smoker ([Blackwell et al., 2014](#)). Smoking is a well-documented risk factor for many diseases, but it is unclear whether smoking exacerbates health effects associated with air pollutant exposures, including NO<sub>2</sub>. Information on NO<sub>2</sub> exposure or internal dose differences between smokers and nonsmokers also is lacking.

Although many controlled human exposure studies report smoking status, comparisons between smokers and nonsmokers are infrequent due to small sample size. In addition to being limited, the available evidence is based on nonasthma outcomes. Among healthy adults, NO<sub>2</sub> exposure induced a larger decrement in lung function in smokers than in nonsmokers [([Morrow et al., 1992](#)); [Table 7-24](#)]. There is a lack of epidemiologic studies to draw direct coherence with this experimental evidence for respiratory effects. As examined primarily for cardiovascular or diabetes morbidity and mortality, most associations with long-term NO<sub>2</sub> do not differ between smokers and nonsmokers

([Dadvand et al., 2014b](#); [Atkinson et al., 2013](#); [Hart et al., 2013](#); [Rivera et al., 2013](#); [Andersen et al., 2012b](#); [Zhang et al., 2011](#); [Lenters et al., 2010](#); [Panasevich et al., 2009](#)) or are larger among nonsmokers [([Carey et al., 2013](#); [Andersen et al., 2012c](#); [Raaschou-Nielsen et al., 2012](#); [Maheswaran et al., 2010](#)); [Table 7-25](#)]. A similar lack of difference between smokers and nonsmokers was observed for NO<sub>2</sub> associations with lung cancer incidence ([Raaschou-Nielsen et al., 2011b](#); [Raaschou-Nielsen et al., 2010a](#)), although the association with lung cancer mortality was larger in smokers when limited to males ([Katanoda et al., 2011](#)).

A controlled human exposure study demonstrated larger NO<sub>2</sub>-induced decrements in lung function among smokers compared to nonsmokers, but there is no information from experimental or epidemiologic studies on asthma-related effects. Most epidemiologic comparisons of smokers and nonsmokers are for NO<sub>2</sub>-related cardiovascular effects, diabetes, or mortality and do not indicate differences between the groups. Many studies similarly defined smoking as current or former smoking, providing a basis for comparisons across studies. Although there is lack of evidence for differences in risk for NO<sub>2</sub>-related health effects by smoking status, there is also uncertainty as to whether NO<sub>2</sub> has an independent relationship with cardiovascular effects, diabetes ([Section 6.3.9](#)), and mortality ([Section 6.5.3](#)), the health effects for which smoking status was examined. Therefore, the evidence is inadequate to determine whether smoking increases the risk of NO<sub>2</sub>-related health effects.

**Table 7-24 Controlled human exposure study evaluating smoking.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Nonasthma outcomes and short-term exposure</b>						
Current or former smoking n = 7	Never smoking n = 13	—	Lung function decrement	n = 20 healthy adults (10 males, 10 females) Mean age 61 yr	300 ppb NO <sub>2</sub> for 4 h with exercise	<a href="#">Morrow et al. (1992)</a>

NO<sub>2</sub> = nitrogen dioxide.

<sup>a</sup>A dash indicates no difference in NO<sub>2</sub>-related health effects in the group with the factor evaluated and the reference group.

**Table 7-25 Epidemiologic studies evaluating smoking status.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Nonasthma outcomes and short-term exposure</b>						
Current or former smoking n = 74%	Never smoking n = 28.4%	↓	Change in ventricular repolarization	n = 580 males Mean age 75 yr	Boston, MA, Follow-up: 2000–2008	<a href="#">Baja et al. (2010)</a> †
<b>Nonasthma outcomes and long-term exposure</b>						
Current or former smoking <sup>b</sup>	Never smoking <sup>b</sup>	–	Incident MI	n = 84,562 Ages 30–55 yr at enrollment	U.S., 1990–2008	<a href="#">Hart et al. (2013)</a> †
Current or former smoking n = 313,487	Never smoking n = 396,647	–	Heart failure	n = 836,557 Ages 40–89 yr in 2003	England, 2003–2007	<a href="#">Atkinson et al. (2013)</a> †
Current or former smoking n = 1,503	Never smoking n = 481	–	Incident stroke	n = 1,984 Ages 50–65 yr at baseline	Copenhagen, Aarhus counties, Denmark, 1993–2006	<a href="#">Andersen et al. (2012b)</a> †
Current or former smoking n = 118	Never smoking n = 24	–	Fatal stroke	n = 142 Ages 50–65 yr at baseline		
Current or former smoking n = 33,380	Never smoking n = 18,438	↓	Diabetes	n = 51,818 Ages 50–65 yr at baseline	Copenhagen, Aarhus counties, Denmark, 1993–2006	<a href="#">Andersen et al. (2012c)</a> †
Current or former smoking n = 45%	Never smoking n = 55%	–	Atherosclerosis (carotid intima media thickness)	n = 745 Ages 26–30 yr	Utrecht, the Netherlands, 1999–2000	<a href="#">Lenters et al. (2010)</a> †
Current or former smoking n = 45.5%	Never smoking n = 54.5%	–	Atherosclerosis (carotid intima media thickness)	n = 2,780 Median age 58 yr	Girona Province, Spain, 2007–2010	<a href="#">Rivera et al. (2013)</a> †

**Table 7-25 (Continued): Epidemiologic studies evaluating smoking status.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
Current smoking n = 90	Former smoking n = 152	↓	C-reactive protein	n = 242 adults with clinically stable COPD Mean age 68 yr	Barcelona, Spain, 2004–2006	<a href="#">Dadvand et al. (2014b)</a> †
		–	TNF-α			
		–	IL-6			
		–	IL-8			
		↓	Fibrinogen			
–	Hepatocyte growth factor					
Current or former smoking n = 917	Never smoking n = 619	–	Blood IL-6 level	n = 1,536 Ages 45–70 yr	Stockholm county, Sweden, 1992–1994	<a href="#">Panasevich et al. (2009)</a> †
Current or former smoking n = 25.5–65% across cohorts	Never smoking n = 35–74.5% across cohorts	↑	Respiratory mortality	n = 307,553 Mean age across 16 cohorts 41.9–73.0 yr at baseline	Europe Follow-up: 1985–2007 NO <sub>2</sub> exposure assessed for 2008–2011	<a href="#">Dimakopoulou et al. (2014)</a> †
Current or former smoking n = 2,850	Never smoking n = 4,359	–	CVD mortality	n = 9,941, 256 deaths Ages 35–103 yr	Shenyang, China Follow-up: 1998–2009 NO <sub>2</sub> exposure assessed for 1998–2009	<a href="#">Zhang et al. (2011)</a> †
Current or former smoking n = 64%	Never smoking n = 36%	↓	Diabetes-related mortality	n = 52,061 Ages 50–64 yr	Denmark Follow-up: 1971–2009. NO <sub>2</sub> exposure assessed for 1971–2009	<a href="#">Raaschou-Nielsen et al. (2012)</a> †
Current smoking n = 608	Never or former smoking n = 1,248	↓	Total mortality	n = 3,320 Mean age 70 yr	London, England Follow-up: 1995–2005 NO <sub>2</sub> assessed for 2002	<a href="#">Maheswaran et al. (2010)</a> †

**Table 7-25 (Continued): Epidemiologic studies evaluating smoking status.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
Current or former smoking n = 322,766	Never smoking n = 386,591	↓	Total mortality	n = 835,607 deaths Ages 40–89 yr	England Follow-up: 2003–2007 NO <sub>2</sub> exposure assessed for 2002	<a href="#">Carey et al. (2013)†</a>
Current smoking, male n = 292 deaths	Former smoking, male n = 90 deaths	↑	Lung cancer mortality	n = 63,520 Ages >40 yr	3 prefectures, Japan 1983–1985	<a href="#">Katanoda et al. (2011)†</a>
Current or former smoking n = 3,713	No smoking n = 9,135	↓	Lung cancer or cardiopulmonary mortality	n = 13,444 Ages >65 yr	Shizuoka, Japan, 1999–2006	<a href="#">Yorifuji et al. (2010)†</a>
Current or former smoking n = 3,372	No smoking n = 109	—	Lung cancer incidence	n = 3,481 Ages 20–93 yr at baseline	Copenhagen, Aarhus counties, Denmark, 1970–1997	<a href="#">Raaschou-Nielsen et al. (2010a)†</a>
Current or former smoking n = 19,253	No smoking n = 33,717	—	Lung cancer incidence	n = 52,970 Ages 50–64 yr	Copenhagen, Aarhus counties, Denmark, 1993–1997	<a href="#">Raaschou-Nielsen et al. (2011b)†</a>

CVD = cardiovascular mortality; IL = interleukin; MI = myocardial infarction; NO<sub>2</sub> = nitrogen dioxide; TNF = tumor necrosis factor.

<sup>a</sup>Up facing arrow indicates that the effect of NO<sub>2</sub> is greater (e.g., larger risk of hypertension) in the group with the factor evaluated than in the reference group. Down facing arrow indicates that the effect of NO<sub>2</sub> is smaller in the group with the factor evaluated than in the reference group. A dash indicates no difference in NO<sub>2</sub>-related health effect between groups.

<sup>b</sup>Sample size not reported.

†Studies published since the 2008 ISA for Oxides of Nitrogen

---

### 7.6.3 Physical Activity

Physical activity outdoors could lead to higher NO<sub>2</sub> exposure ([Section 3.4.3.1](#)) and uptake in the respiratory tract. There is some evidence indicating that during physical activity, increased respiratory rate and oronasal breathing can increase the deposition of NO<sub>2</sub> in the lower respiratory tract ([Section 4.2.2.3](#)). Thus, physical activity could have implications for increasing the risk of NO<sub>2</sub>-related health effects. However, the role of concurrent physical activity in modifying NO<sub>2</sub>-related health effects has not been characterized. Rather, physical activity has been examined as an indicator of active versus sedentary lifestyle or fitness. Further, outdoor activity has not been assessed. The influence of general activity or fitness on NO<sub>2</sub> exposure and internal dose are not known.

Epidemiologic studies did not examine physical activity or exercise as a modifier of asthma-related effects but of cardiovascular effects, diabetes, and mortality, for which independent relationships with NO<sub>2</sub> are uncertain ([Sections 6.3.9](#) and [6.5.3](#)). These studies have inconsistent results with respect to whether physical activity increases the risk for NO<sub>2</sub>-related health effects ([Table 7-26](#)). Associations between long-term NO<sub>2</sub> exposure and mortality from diabetes was higher in the group not engaging in exercise ([Raaschou-Nielsen et al., 2012](#)), but risk of diabetes was similar or lower among those with low levels of physical activity ([Eze et al., 2014](#); [Andersen et al., 2012c](#)). Similarly, NO<sub>2</sub>-related cardiovascular mortality was greater in the group with no exercise ([Zhang et al., 2011](#)), but associations with other cardiovascular effects were similar between groups with low or high physical activity ([Hart et al., 2013](#); [Panasevich et al., 2009](#)).

Contributing to the uncertainty in the evidence base is the heterogeneity across studies in how physical activity was defined, for example, the frequency or intensity of activity. Overall, the inconsistent evidence based on health effects for which independent relationships with NO<sub>2</sub> exposure are uncertain is inadequate to determine whether low or high physical activity increases the risk for NO<sub>2</sub>-related health effects.

**Table 7-26 Epidemiologic studies evaluating physical activity.**

Factor Evaluated	Reference Category	Direction of Effect Modification <sup>a</sup>	Outcome	Study Population	Study Details	Study
<b>Nonasthma outcomes and long-term exposure</b>						
Low physical activity (<18 METS/week) <sup>b</sup>	High physical activity (≥18 METS/week) <sup>b</sup>	—	Incident MI	n = 84,562 Ages 30–55 yr at baseline	U.S., 1990–2008	<a href="#">Hart et al. (2013)†</a>
Physical inactivity n = 23,536	Physical activity or playing sports in leisure time n = 28,282	↓	Diabetes	n = 51,818 Ages 50–65 yr at baseline	Copenhagen, Aarhus counties, Denmark, 1993–2006	<a href="#">Andersen et al. (2012c)†</a>
Low physical activity (<0.5 h/week) n = 38%	Physical activity (≥2 h/week) n = 28%	—	Diabetes	n = 6,392 Ages 29–73 yr	Switzerland, 2002	<a href="#">Eze et al. (2014)†</a>
Physical inactivity (inactive leisure time) n = 543	Physical activity n = 993	—	Blood IL-6 level	n = 1,536 Ages 45–70 yr	Stockholm county, Sweden, 1992–1994	<a href="#">Panasevich et al. (2009)†</a>
No Exercise n = 45.7%	Exercise n = 54.3%	↑	Diabetes-related mortality	n = 52,061 Ages 50–64 yr	Denmark Follow-up and NO <sub>2</sub> exposure assessed for 1971–2009	<a href="#">Raaschou-Nielsen et al. (2012)†</a>
No Exercise n = 5,795	Exercise n = 4,146	↑	CVD mortality	n = 9,941, 256 deaths Ages 35–103 yr	Shenyang, China Follow-up and NO <sub>2</sub> exposure assessed for 1998–2009	<a href="#">Zhang et al. (2011)†</a>

CVD = cardiovascular disease; IL = interleukin; METS = metabolic equivalents; MI = myocardial infarction; NO<sub>2</sub> = nitrogen dioxide.

<sup>a</sup>Up facing arrow indicates that the effect of NO<sub>2</sub> is greater (e.g., larger risk of mortality) in the group with the factor evaluated than in the reference group. Down facing arrow indicates that the effect of NO<sub>2</sub> is smaller in the group with the factor evaluated than in the reference group. A dash indicates no difference in NO<sub>2</sub>-related health effect between groups.

<sup>b</sup>Sample size not reported.

†Studies published since the 2008 ISA for Oxides of Nitrogen.

## 7.7 Conclusions

This chapter evaluates factors that may characterize populations and lifestages at increased risk for health effects related to NO<sub>2</sub> exposure ([Table 7-27](#)). The evidence for each factor was classified based on judgments of the consistency, coherence, and

biological plausibility of evidence integrated across epidemiologic, controlled human exposure, and toxicological studies as detailed in [Table 7-1](#). The evaluation also drew upon information presented in preceding chapters on exposure, dosimetry, modes of action, and independent relationships of NO<sub>2</sub> exposure with health effects.

Consistent with observations made in the 2008 ISA for Oxides of Nitrogen ([U.S. EPA, 2008c](#)), there is adequate evidence to conclude that people with asthma, children, and older adults are at increased risk for NO<sub>2</sub>-related health effects. Not only does evidence consistently indicate increased risk for these groups, but the evidence is based on findings for short-term NO<sub>2</sub> exposure and outcomes related to asthma exacerbation. Asthma exacerbation is the basis for concluding a causal relationship exists between short-term NO<sub>2</sub> exposure and respiratory effects ([Section 5.2.9](#)). In addition to the strong evidence for a relationship between short-term NO<sub>2</sub> exposure and asthma exacerbation, the conclusion that people with asthma are at increased risk of NO<sub>2</sub>-related health effects is supported by results from a meta-analysis of controlled human exposure studies demonstrating that NO<sub>2</sub> exposure increases airway responsiveness, a key feature of asthma exacerbation, at lower concentrations in people with asthma compared to healthy individuals. Epidemiologic evidence does not consistently demonstrate differences in NO<sub>2</sub>-related respiratory effects in people with asthma. It is important to note that there is evidence of heterogeneity in asthma severity and triggers within study populations; thus, the epidemiologic evidence is not considered to be in conflict with experimental evidence. Children and older adults consistently have larger magnitude associations between NO<sub>2</sub> exposure and asthma hospital admissions and ED visits, compared to adults or the general population. There is not clear evidence from controlled human exposure studies that NO<sub>2</sub> induces respiratory effects in older adults, but examination is limited and based on healthy adults, not adults with asthma. Time-activity patterns and ventilation rates differ among age groups, but it is not understood whether these factors contribute to increased NO<sub>2</sub> exposure, internal dose, or risk of NO<sub>2</sub>-related health effects for children and older adults.

**Table 7-27 Summary of evidence for potential increased nitrogen dioxide exposure and increased risk of nitrogen dioxide-related health effects.**

Evidence Classification	Factor Evaluated	Rationale for Classification
Adequate evidence	Asthma ( <a href="#">Section 7.3.1</a> ) Lifestage ( <a href="#">Section 7.5.1.1</a> ): Children ( <a href="#">Section 7.5.1.2</a> ): Older adults	<ul style="list-style-type: none"> <li>• Each factor: consistent evidence for increased risk for NO<sub>2</sub>-related asthma exacerbation.</li> <li>• Asthma: evidence from controlled human exposure studies.</li> <li>• Lifestage: different time-activity patterns and ventilation patterns but unclear implications for differences in NO<sub>2</sub> exposure or internal dose.</li> </ul>
Suggestive evidence	SES ( <a href="#">Section 7.5.2</a> ): Low SES Sex ( <a href="#">Section 7.5.4</a> ): Females Diet ( <a href="#">Section 7.6.1</a> ): Reduced antioxidant intake	<ul style="list-style-type: none"> <li>• Each factor: limited and generally supporting evidence for differences in NO<sub>2</sub>-related health effects.</li> <li>• SES and females: findings based primarily on mortality for SES and exposure and lung function for females. Uncertainty in independent relationships with NO<sub>2</sub> exposure provides limited basis for inferences about differential risk.</li> <li>• Reduced dietary antioxidant vitamin intake: consistent evidence from experimental studies for modification of NO<sub>2</sub>-related respiratory effects, but changes in oxidant balance may not necessarily indicate health effects.</li> </ul>
Inadequate evidence	COPD ( <a href="#">Section 7.3.2</a> ) Cardiovascular disease ( <a href="#">Section 7.3.3</a> ) Diabetes ( <a href="#">Section 7.3.4</a> ) Genetic factors ( <a href="#">Section 7.4</a> ) Obesity ( <a href="#">Section 7.3.5</a> ) Smoking ( <a href="#">Section 7.6.2</a> ) Physical activity ( <a href="#">Section 7.6.3</a> ) Race/ethnicity ( <a href="#">Section 7.5.3</a> ) Residence in urban areas ( <a href="#">Section 7.5.5</a> ) Proximity to roadways ( <a href="#">Section 7.5.6</a> )	<ul style="list-style-type: none"> <li>• Epidemiologic findings inconsistently show differences in NO<sub>2</sub>-related health effects, show no difference, or are limited in quantity.</li> <li>• Findings based primarily on cardiovascular effects, diabetes, birth outcomes, and mortality. Uncertainty in independent relationships with NO<sub>2</sub> provides limited basis for inferences about differential risk.</li> <li>• Indication of higher NO<sub>2</sub> exposure among nonwhite populations, urban residents, and people spending time or living near roadways, but insufficient information to assess increased risk of NO<sub>2</sub>-related health effects.</li> </ul>
Evidence of no effect	None	

COPD = chronic obstructive pulmonary disease; NO<sub>2</sub> = nitrogen dioxide; SES = socioeconomic status.

There is suggestive evidence that people with low antioxidant diets, people of low SES, and females are at increased risk for NO<sub>2</sub>-related health effects because of some uncertainties in the evidence bases. While experimental studies indicate that dietary intake of Vitamin C or E modifies NO<sub>2</sub>-related effects on airway responsiveness, much of the evidence is for effects on oxidant balance, which are not necessarily indicative of health effects. Evidence indicates that low SES populations have higher NO<sub>2</sub> exposure and larger NO<sub>2</sub>-related risk of mortality. For females, limited epidemiologic evidence points to larger NO<sub>2</sub>-related decrements in lung function. However, for low SES populations and females, the evidence is based on health effects for which independent relationships with NO<sub>2</sub> exposure are uncertain ([Sections 5.4.8](#) and [6.2.9](#)).

There is inadequate evidence to determine whether pre-existing cardiovascular disease, diabetes, COPD, genetic variants, obesity, smoking, or physically active lifestyle increases the risk for NO<sub>2</sub>-related health effects. Studies show either inconsistent or no modification of NO<sub>2</sub>-related health effects by these factors, and information is based primarily on cardiovascular effects ([Section 5.3.11](#) and [6.3.9](#)) and mortality ([Sections 5.4.8](#) and [6.5.3](#)) for which independent relationships with NO<sub>2</sub> are uncertain. Evidence also is inadequate to determine whether race/ethnicity, urban residence, or proximity to roadways increase the risk for NO<sub>2</sub>-related health effects. While nonwhite populations, urban residents, and people with close proximity to roadways (i.e., living, attending school, working, or commuting on or near roadways) may have increased exposure to NO<sub>2</sub>, there is limited or inconsistent evidence for larger NO<sub>2</sub>-related health effects in these populations. Further, inferences about the potential differential risk for these populations are limited by evidence that is based on cardiovascular effects ([Section 6.3.9](#)) and birth outcomes ([Section 6.4.5](#)), for which independent effects of NO<sub>2</sub> exposure are uncertain. Additionally, it is important to note that many factors may be acting in combination to influence risk, which may lead to a different public health impact than is reflected when evaluating any one factor in isolation. However, at this time information remains limited as to the impact of multiple factors and how they affect the risk for NO<sub>2</sub>-related health effects.

In conclusion, evidence is adequate to conclude that people with asthma, children, and older adults are at increased risk for NO<sub>2</sub>-related health effects. The large proportions of the U.S. that encompass each of these groups and lifestages (i.e., 8% adults and 9.3% children with asthma, 24% childhood lifestage, 13% older adult lifestage) underscores the potential public health impact of NO<sub>2</sub>-related health effects.

---

## APPENDIX: EVALUATION OF STUDIES ON HEALTH EFFECTS OF OXIDES OF NITROGEN

This appendix describes the approach used in the Integrated Science Assessment (ISA) for Oxides of Nitrogen to evaluate strength of inference from health effect studies. As described in the [Preamble](#) to the ISA ([Section 5.a](#)), causal determinations were informed by the integration of evidence across scientific disciplines (e.g., exposure, animal toxicology, epidemiology) and related outcomes and judgments of the strength of inference from individual studies. [Table A-1](#) describes aspects considered in evaluating the strength of inference from controlled human exposure, animal toxicological, and epidemiologic studies. This evaluation was applied to studies included in this ISA from previous assessments and those published since the 2008 ISA for Oxides of Nitrogen. The aspects found in [Table A-1](#) are consistent with current best practices employed in other approaches for reporting or evaluating health science data.<sup>1</sup> Additionally, the aspects are compatible with guidelines published by the United States Environmental Protection Agency related to cancer, neurotoxicity, reproductive toxicity, and developmental toxicity ([U.S. EPA, 2005, 1998b, 1996b, 1991](#)).

These aspects were not used as a checklist or strict criteria to define the quality of a study, and judgments on strength of inference were made without considering the results of a study. The presence or absence of particular features in a study did not necessarily define a less informative study or exclude a study from consideration in the ISA. Further, these aspects were not criteria for a particular determination of causality in the five-level hierarchy. As described in the [Preamble](#), causal determinations were based on judgments of the overall strengths and limitations of the collective body of available studies and the coherence of evidence across scientific disciplines and related outcomes. [Table A-1](#) is not intended to be a complete list of aspects that affect the strength of inference from a study, but they comprise the major aspects considered in this ISA to evaluate studies. Where possible, study considerations, for example, exposure assessment and confounding (i.e., bias due to a relationship with the outcome and correlation with exposures to oxides of nitrogen), are framed to be specific to oxides of nitrogen. Thus, judgments of the strength of inference from a study can vary depending on the specific pollutant being assessed.

---

<sup>1</sup> For example, NTP OHAT approach ([Rooney et al., 2014](#)), IRIS Preamble ([U.S. EPA, 2013p](#)), ToxRTTool ([Klimisch et al., 1997](#)), STROBE guidelines ([von Elm et al., 2007](#)), and ARRIVE guidelines ([Kilkenny et al., 2010](#)).

**Table A-1 Scientific considerations for evaluating the strength of inference from studies on the health effects of oxides of nitrogen.**

Study Aspect:
Study Design
Controlled Human Exposure
<p>Inference is stronger for studies that clearly describe the primary and any secondary aims of the study or specific hypotheses being tested. Study subjects should be randomly exposed without knowledge of the exposure condition. Preference is given to balanced crossover (repeated measures) or parallel design studies that include control (e.g., clean filtered air) exposures. In crossover studies, there should be sufficient and specified time between exposure days to avoid carryover effects from prior exposure days. In parallel design studies, all study groups should be matched for individual characteristics such as age, sex, race, anthropometric properties, and health status. In studies evaluating effects of disease, appropriately matched healthy controls are desired for interpretative purposes.</p>
Animal Toxicology
<p>Inference is stronger for studies that clearly describe the primary and any secondary aims of the study or specific hypotheses being tested. Studies should include appropriately matched control exposures (e.g., clean filtered air, time matched). Studies should use methods to limit differences in baseline characteristics of control and exposure groups. Studies should randomize assignment to exposure groups and, where possible, conceal allocation to research personnel. Experimental procedures and conditions as well as animal care (e.g., housing, husbandry) should be identical between groups. Blinding of research personnel to the study group may not be possible due to animal welfare and experimental considerations; however, differences in the monitoring or handling of animals in all groups by research personnel should be minimized.</p>
Epidemiology
<p>Inference is stronger for studies that clearly describe the primary and any secondary aims of the study or specific hypotheses being tested.</p> <p>For short-term exposure, time-series, case crossover, and panel studies are emphasized over cross-sectional studies because they examine temporal correlations and are less prone to confounding by factors that differ between individuals (e.g., SES, age). Panel studies with scripted exposures, in particular, can have strong inference because they have consistent, well-defined exposure durations across subjects, measure pollutants at the location of exposures, and measure outcomes at consistent, well-defined lags after exposures. Studies with large sample sizes and conducted over multiple years are considered to produce more reliable results. If other quality parameters are equal, multicity studies carry more weight than single-city studies because they tend to have larger sample sizes and lower potential for publication bias.</p> <p>For long-term exposure, inference is considered to be stronger for prospective cohort studies and case-control studies nested within a cohort (e.g., for rare diseases) than cross-sectional, other case-control, or ecologic studies. Cohort studies can better inform the temporality of exposure and effect. Other designs can have uncertainty related to the appropriateness of the control group or validity of inference about individuals from group-level data. Study design limitations can bias health effect associations in either direction.</p>

**Study Aspect:****Study Population/Test Model****Controlled Human Exposure**

In general, the subjects recruited into study groups should be similarly matched for age, sex, race, anthropometric properties, and health status. In studies evaluating effects of specific subject characteristics (e.g., disease, genetic polymorphism), appropriately matched healthy controls are preferred. Relevant characteristics and health status should be reported for each experimental group. Criteria for including and excluding subjects should be clearly indicated. For the examination of populations with an underlying health condition (e.g., asthma), independent, clinical assessment of the health condition is ideal, but self-report of physician diagnosis generally is considered to be reliable for respiratory diseases as well as cardiovascular diseases and events.<sup>a</sup> The loss or withdrawal of recruited subjects during the course of a study should be reported. Specific rationale for excluding subject(s) from any portion of a protocol should be explained.

**Animal Toxicology**

Ideally, studies should report species, strain, substrain, genetic background, age, sex, and weight. However, differences among studies in these parameters do not necessarily exclude comparisons from being made across studies. Unless data indicate otherwise, all animal species and strains are considered appropriate for evaluating effects of NO<sub>2</sub> or NO exposure. It is preferred that investigators test for effects in both sexes and multiple lifestages and report the result for each group separately. All animals used in a study should be accounted for, and rationale for exclusion of animals or data should be specified.

**Epidemiology**

There is greater confidence in results from studies with a population that is recruited from and representative of the target population. Studies with high participation and low drop-out over time that is not dependent on exposure or health status are considered to have low potential for selection bias. Clearly specified criteria for including and excluding subjects can aid in assessing selection bias. For populations with an underlying health condition, independent, clinical assessment of the health condition is valuable, but self-report of physician diagnosis generally is considered to be reliable for respiratory diseases as well as cardiovascular diseases and events.<sup>a</sup> Comparisons of groups with and without an underlying health condition are more informative if groups are from the same source population. Selection bias can influence results in either direction or may not affect the validity of results but rather reduce the generalizability of findings to the target population.

**Pollutant****Controlled Human Exposure**

The focus is on studies testing NO<sub>2</sub> exposure.

**Animal Toxicology**

The focus is on studies testing NO<sub>2</sub> exposure.

**Epidemiology**

Most of the available health effect studies examine NO<sub>2</sub>; fewer examine NO or NO<sub>x</sub>. Studies that compare health effect associations among these species are informative. Typically, one species is examined, and studies of NO<sub>2</sub> are emphasized. It is not clear that ambient-relevant NO exposures induce detrimental health effects (Section 4.2.3). The relationship of NO<sub>x</sub> to NO<sub>2</sub> varies with distance from roads, and thus, may vary among subjects. Hence, the extent to which associations with NO<sub>x</sub> reflect those for NO<sub>2</sub> versus other pollutants from traffic is uncertain.

---

**Study Aspect:**

---

**Exposure Assessment or Assignment**

---

**Controlled Human Exposure**

---

Studies should well characterize pollutant concentration, temperature, and relative humidity and/or have measures in place to adequately control the exposure conditions for subject safety. For this assessment, the focus is on studies that use NO<sub>2</sub> or NO concentrations less than or equal to 5,000 ppb ([Section 1.2](#)). Studies that use higher exposure concentrations may provide information relevant to mode of action, dosimetry, or at-risk human populations. Preference is given to balanced crossover or parallel design studies that include control exposures (e.g., clean filtered air). Study subjects should be randomly exposed without knowledge of the exposure condition. Method of exposure (e.g., chamber, facemask) should be specified and activity level of subjects during exposures should be well characterized.

---

**Animal Toxicology**

---

Studies should characterize pollutant concentration, temperature, and relative humidity and have measures in place to adequately control the exposure conditions. The focus is on inhalation exposure. Noninhalation exposure experiments may provide information relevant to mode of action. In vitro studies generally are not included; however, such studies may be included, particularly if conducted in airway cells, if they provide mechanistic insight or examine similar effects as in vivo. All studies should include exposure control groups (e.g., clean filtered air). For this assessment, the focus is on studies that use NO<sub>2</sub> or NO concentrations less than or equal to 5,000 ppb ([Section 1.2](#)). Studies that use higher exposure concentrations may provide information relevant to mode of action, dosimetry, interspecies variation, or at-risk human populations.

---

**Epidemiology**

---

Of primary relevance are relationships of health effects with the ambient component of exposure to oxides of nitrogen. However, information about ambient exposure rarely is available for individual subjects; most often, inference is based on ambient concentrations. Studies that compare exposure assessment methods are considered to be particularly informative. Inference is strong when the duration or lag of the exposure metric corresponds with the time course for physiological changes in the outcome (e.g., up to a few days for symptoms) or latency of disease (e.g., several years for cancer).

Given the spatial heterogeneity in ambient oxides of nitrogen and variable relationships between personal exposures and ambient concentrations ([Section 3.4.2](#)), validated methods that capture the extent of variability for the particular study design (temporal for short-term exposure studies versus spatial contrasts for long-term exposure studies) and location carry greater weight. Central site measurements, whether averaged across multiple monitors or assigned from the nearest or single available monitor, have well-recognized limitations in capturing variation in oxides of nitrogen. Inference from central site measurements can be adequate if correlated with personal exposures, closely located to study subjects, highly correlated across monitors within a location, used in locations with well-distributed sources, or combined with time-activity information.

In studies of short-term exposure, metrics that may capture temporal variation in ambient oxides of nitrogen and provide a good basis for inference include concentrations in subjects' microenvironments (e.g., outdoor home, school, in-vehicle) and individual-level outdoor concentrations combined with time-activity data. Results for total personal and indoor NO<sub>2</sub> exposure are other lines of evidence that inform judgments about causality of NO<sub>2</sub> because inference is based on an individual's microenvironmental exposures and the potential for copollutant confounding may be lower or different than that for ambient concentrations. Results for total personal exposure can inform understanding of the effects of ambient exposure when well correlated with ambient concentrations. For long-term exposures, LUR models validated to well represent spatial variation in ambient NO<sub>2</sub> in the study area can provide good estimates of individual exposure. Less weight is placed on NO<sub>x</sub> from dispersion models because NO<sub>x</sub> estimates often show near perfect correlations ( $r = 0.94\text{--}0.99$ ) with EC, PM<sub>2.5</sub>, and CO, and the effects of NO<sub>x</sub> cannot be distinguished from traffic-related copollutants. Dispersion models may not well account for all sources of NO<sub>2</sub> or NO<sub>x</sub> or the emissions and transformation chemistry in an urban location, and thus, poorly estimate neighborhood-scale variability ([Section 3.2.2.2](#)).

Exposure measurement error often attenuates health effect estimates or decreases the precision of the association (i.e., wider 95% CIs), particularly associations based on temporal variation in short-term exposure ([Section 3.4.5](#)). However, exposure measurement error can bias estimates away from the null, particularly for long-term exposures.

---

---

**Study Aspect:**

---

**Outcome Assessment/Evaluation**

---

**Controlled Human Exposure**

---

Endpoints should be assessed in the same manner for control and exposure groups (e.g., time after exposure, methods, endpoint evaluator) using valid, reliable methods. Blinding of endpoint evaluators is ideal, especially for qualitative endpoints (e.g., histopathology). For each experiment and each experimental group, including controls, precise details of all procedures carried out should be provided including how, when, and where. Time of the endpoint evaluations is a key consideration that will vary depending on the endpoint evaluated. Endpoints should be assessed at time points that are appropriate for the research questions.

**Animal Toxicology**

---

Endpoints should be assessed in the same manner for control and exposure groups (e.g., time after exposure, methods, endpoint evaluator) using valid, reliable methods. Blinding of endpoint evaluators is ideal, especially for qualitative endpoints (e.g., histopathology). For each experiment and each experimental group, including controls, precise details of all procedures carried out should be provided including how, when, and where. Time of the endpoint evaluations is a key consideration that will vary depending on the endpoint evaluated. Endpoints should be assessed at time points that are appropriate for the research questions.

**Epidemiology**

---

Inference is stronger when outcomes are assessed or reported without knowledge of exposure status. Knowledge of exposure status could produce artifactual associations. There is greater confidence when outcomes assessed by interview, self-report, clinical examination, or analysis of biological indicators are defined by consistent criteria and collected by validated, reliable methods. Independent clinical assessment is valuable for outcomes such as lung function or incidence of disease, but report of physician diagnosis has shown good reliability.<sup>a</sup> Outcomes assessed at time intervals that correspond with the time course for physiological changes (e.g., up to a few days for symptoms) are emphasized. When health effects of long-term exposure are assessed by acute events such as symptoms or hospital admissions, inference is strengthened when results are adjusted for short-term exposure. Validated questionnaires for subjective outcomes such as symptoms are regarded to be reliable,<sup>b</sup> particularly when collected frequently and not subject to long recall. For biological samples, the chemical stability of the substance of interest and the sensitivity and precision of the analytical method is considered.

If not based on knowledge of exposure status, errors in outcome assessment tend to bias results toward the null.

---

**Study Aspect:**

**Potential Copollutant Confounding**

**Controlled Human Exposure**

Exposure should be well characterized to evaluate independent effects of NO<sub>2</sub> or NO.

**Animal Toxicology**

Exposure should be well characterized to evaluate independent effects of NO<sub>2</sub> or NO.

**Epidemiology**

Confounding can occur by copollutants that are highly correlated with oxides of nitrogen and have similar modes of action and health effects. Not accounting for copollutant confounding can produce artifactual associations; thus, studies that examine copollutant confounding carry greater weight. The predominant method is copollutant modeling, which is especially informative when measurement error is comparable for copollutants and correlations are not high. Interaction and joint effect models are examined to a lesser extent. Copollutant confounding also can be assessed by evaluating correlations between oxides of nitrogen and copollutants and comparing health associations between oxides of nitrogen and copollutants in single-pollutant models if exposure measurement error is comparable among pollutants. Studies that examine only oxides of nitrogen are considered to poorly inform the potential for copollutant confounding.

Among copollutants, those of primary concern are traffic-related pollutants, which include CO, PM<sub>2.5</sub>, BC/EC, OC, UFP, metal PM components such as copper, zinc, and iron, as well as VOCs such as benzene, acetaldehyde, toluene, ethylbenzene, and xylene. Short-term and long-term metrics for these pollutants often show moderate to high correlations with oxides of nitrogen (Figure 3-6). Many traffic-related pollutants also are hypothesized to have common modes of action.<sup>c</sup> Common key events include formation of secondary oxidation products, inflammation, and, for respiratory effects, increases in airway responsiveness. Traffic-related pollutants also show relationships with many of the health effects evaluated in this ISA<sup>d</sup> except as follows: for long-term exposure, there is uncertainty regarding confounding by UFP because of the short atmospheric lifetime; and for long-term exposure, CO is not considered to be an important confounding copollutant for mortality or lung cancer.<sup>d</sup>

There generally is less concern of confounding by PM<sub>10</sub>, SO<sub>2</sub>, and O<sub>3</sub> because they show varying and often lower correlations with NO<sub>2</sub> (Figure 3-6). O<sub>3</sub> generally is negatively or weakly positively correlated with NO<sub>2</sub> but may be a confounder where moderate positive correlations are observed. O<sub>3</sub> and SO<sub>2</sub> in particular show similarities with NO<sub>2</sub> in mode of action. PM<sub>10</sub>, SO<sub>2</sub>, and O<sub>3</sub> show relationships with the health effects evaluated in this ISA<sup>d</sup> except as follows: for short-term exposure, SO<sub>2</sub> is not considered to be a strong confounding copollutant for cardiovascular effects; and for long-term exposure, neither O<sub>3</sub> nor SO<sub>2</sub> is considered to be a strong confounder for any health effect.

**Study Aspect:****Other Potential Confounding Factors<sup>e</sup>****Controlled Human Exposure**

Preference is given to studies using experimental and control groups that are matched for individual level characteristics (e.g., body weight, smoking history, age) and time-varying factors (e.g., seasonal and diurnal patterns).

**Animal Toxicology**

Preference is given to studies using experimental and control groups that are matched for individual level characteristics (e.g., body weight, litter size, food and water consumption) and time-varying factors (e.g., seasonal and diurnal patterns).

**Epidemiology**

Factors are considered to be potential confounders if demonstrated in the scientific literature to be related to health effects and correlated with oxides of nitrogen and/or traffic indicators. Not accounting for confounders can produce artifactual associations; thus, studies that statistically adjust for multiple factors or control for them in the study design are emphasized. Less weight is placed on studies that adjust for factors that mediate the relationship between oxides of nitrogen and health effects, which can bias results toward the null. In the absence of information linking health risk factors to oxides of nitrogen or traffic indicators, a factor may be evaluated as a potential effect measure modifier, but uncertainty is noted as to its role as a confounder. Confounders vary according to study design, exposure duration, and health effects and include the following.

For time-series and panel studies of short-term exposure:

- Respiratory Effects—meteorology, day of week, season, medication use, allergen exposure (potential effect modifier)
- Cardiovascular Effects—meteorology, day of week, season, medication use
- Total Mortality—meteorology, day of week, season, long-term temporal trends

For studies of long-term exposure:

- Respiratory Effects—socioeconomic status, race, age, medication use, smoking, stress
- Cardiovascular Effects, Diabetes, Reproductive Effects, and Developmental Effects—socioeconomic status, race, age, medication use, smoking, stress, noise
- Total Mortality—socioeconomic status, race, age, medication use, smoking, comorbid health conditions
- Cancer—socioeconomic status, race, age, occupational exposure

---

**Study Aspect:**

---

**Statistical Methodology**

---

**Controlled Human Exposure**

---

Statistical methods should be clearly described and appropriate for the study design and research question (e.g., correction for multiple comparisons). Generally, statistical significance is considered in the evaluation of findings of controlled human exposure studies. Detection of statistical significance is influenced by a variety of factors including, but not limited to, the size of the study, exposure and outcome measurement error, and statistical model specifications. Sample size is not a criterion for excluding a study; ideally, the sample size should provide adequate power to detect hypothesized effects (e.g., sample sizes less than three are considered less informative). Because statistical tests have limitations, consideration is given to both trends in data and reproducibility of results.

**Animal Toxicology**

---

Statistical methods should be clearly described and appropriate for the study design and research question (e.g., correction for multiple comparisons). Generally, statistical significance is considered in the evaluations of findings of animal toxicology studies. Detection of statistical significance is influenced by a variety of factors including, but not limited to, the size of the study, exposure and outcome measurement error, and statistical model specifications. Sample size is not a criterion for excluding a study; ideally, the sample size should provide adequate power to detect hypothesized effects (e.g., sample sizes less than three are considered less informative). Because statistical tests have limitations, consideration is given to both trends in data and reproducibility of results.

**Epidemiology**

---

Multivariable regression models that include potential confounding factors are emphasized. However, multipollutant models (more than two pollutants) are considered to produce too much uncertainty from copollutant collinearity to be informative. Models with interaction terms can help evaluate potential confounding as well as effect modification. Sensitivity analyses with alternate specifications for potential confounding inform the stability of findings and aid in judging the strength of inference of results. In the case of multiple comparisons, consistency in the pattern of association can increase confidence that the associations were not found by chance alone. Statistical methods that are appropriate for the power of the study carry greater weight. For example, categorical analyses with small sample sizes can be prone to bias results toward or away from the null. Statistical tests such as t-tests and chi-squared tests are not considered sensitive enough for adequate inferences regarding pollutant-health effect associations. For all methods, the effect estimate and precision of the estimate (i.e., width of 95% CI) are important considerations rather than statistical significance.

---

BC = black carbon; CI = confidence interval; CO = carbon monoxide; EC = elemental carbon; ISA = Integrated Science Assessment; LUR = land use regression; NO = nitric oxide; NO<sub>2</sub> = nitrogen dioxide; NO<sub>x</sub> = sum of NO and NO<sub>2</sub>; O<sub>3</sub> = ozone; OC = organic carbon; PM<sub>2.5</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 2.5 μm; PM<sub>10</sub> = particulate matter with a nominal mean aerodynamic diameter less than or equal to 10 μm; ppb = parts per billion; SES = socioeconomic status; SO<sub>2</sub> = sulfur dioxide; UFP = ultrafine particles; VOC = volatile organic compound.

<sup>a</sup>Toren et al. (1993); Murgia et al. (2014); Weakley et al. (2013); Yang et al. (2011); Heckbert et al. (2004); Barr et al. (2002); Muhajarine et al. (1997).

<sup>b</sup>Burney et al. (1989).

<sup>c</sup>Information on modes of action for NO<sub>2</sub> is described in Section 4.3. The characterization of similar modes of action for many traffic-related pollutants is based on information described in the most recently completed ISAs (U.S. EPA, 2013e, 2010b, 2009a, 2008d) and the Health Effects Institute's 2010 review of traffic-related air pollution (HEI, 2010).

<sup>d</sup>Judgments regarding potential confounding by other criteria pollutants are based on studies evaluated in this ISA, causal determinations made in the most recently completed ISAs (U.S. EPA, 2013e, 2010b, 2009a, 2008d), as well as recent reviews published by the Health Effects Institute (HEI Review Panel on Ultrafine Particles, 2013; HEI, 2010). Judgments regarding potential confounding by the PM components EC/BC, OC, metals, and UFP as well as VOCs should not be inferred as conclusions regarding causality of their relationships with health effects. Their consideration as potential confounders is based on associations with oxides of nitrogen and health effects observed in the studies examined in this ISA and reviews conducted by the Health Effects Institute. Judgments regarding potential confounding by PM<sub>10</sub> should not be inferred as conclusions regarding causality specifically for that size fraction. The 2009 ISA for Particulate Matter evaluated PM<sub>10</sub> studies but did not form individual causal determinations for that size fraction because PM<sub>10</sub> comprises both fine and thoracic coarse particles.

<sup>e</sup>Many factors evaluated as potential confounders can be effect measure modifiers (e.g., season, comorbid health condition) or mediators of health effects related to oxides of nitrogen (comorbid health condition).

---

## REFERENCES

- [AAP](#) (American Academy of Pediatrics). (2004). Ambient air pollution: Health hazards to children. *Pediatrics* 114: 1699-1707. <http://dx.doi.org/10.1542/peds.2004-2166>
- [Abbey, DE; Nishino, N; McDonnell, WF; Burchette, RJ; Knutsen, SF; Beeson, WL; Yang, JX.](#) (1999). Long-term inhalable particles and other air pollutants related to mortality in nonsmokers. *Am J Respir Crit Care Med* 159: 373-382. <http://dx.doi.org/10.1164/ajrccm.159.2.9806020>
- [Ackermann-Lieblich, U; Leuenberger, P; Schwartz, J; Schindler, C; Monn, C; Bolognini, G; Bongard, JP; Brändli, O; Domenighetti, G; Elsasser, S; Grize, L; Karrer, W; Keller, R; Keller-Wossidlo, H; Künzli, N; Martin, BW; Medici, TC; Perruchoud, AP; Schöni, MH; Tschopp, JM; Villiger, B; Wüthrich, B; Zellweger, JP; Zemp, E.](#) (1997). Lung function and long term exposure to air pollutants in Switzerland. *Am J Respir Crit Care Med* 155: 122-129. <http://dx.doi.org/10.1164/ajrccm.155.1.9001300>
- [Adamkiewicz, G; Ebelt, S; Syring, M; Slater, J; Speizer, FE; Schwartz, J; Suh, H; Gold, DR.](#) (2004). Association between air pollution exposure and exhaled nitric oxide in an elderly population. *Thorax* 59: 204-209. <http://dx.doi.org/10.1136/thorax.2003.006445>
- [Adamkiewicz, G; Hsu, HH; Vallarino, J; Melly, SJ; Spengler, JD; Levy, JI.](#) (2010). Nitrogen dioxide concentrations in neighborhoods adjacent to a commercial airport: A land use regression modeling study. *Environ Health* 9: 73. <http://dx.doi.org/10.1186/1476-069X-9-73>
- [Adams, WC; Brookes, KA; Schelegle, ES.](#) (1987). Effects of NO<sub>2</sub> alone and in combination with O<sub>3</sub> on young men and women. *J Appl Physiol* 62: 1698-1704.
- [Adgent, MA; Squadrito, GL; Ballinger, CA; Krzywanski, DM; Lancaster, JR, Jr; Postlethwait, EM.](#) (2012). Desferrioxamine inhibits protein tyrosine nitration: Mechanisms and implications. *Free Radic Biol Med* 53: 951-961. <http://dx.doi.org/10.1016/j.freeradbiomed.2012.06.003>
- [Adkins, B, Jr; Van Stee, EW; Simmons, JE; Eustis, SL.](#) (1986). Oncogenic response of strain A/J mice to inhaled chemicals. *J Toxicol Environ Health* 17: 311-322. <http://dx.doi.org/10.1080/15287398609530825>
- [Aga, E; Samoli, E; Touloumi, G; Anderson, HR; Cadum, E; Forsberg, B; Goodman, P; Goren, A; Kotesovec, F; Kriz, B; Macarol-Hiti, M; Medina, S; Paldy, A; Schindler, C; Sunyer, J; Tittanen, P; Wojtyniak, B; Zmirou, D; Schwartz, J; Katsouyanni, K.](#) (2003). Short-term effects of ambient particles on mortality in the elderly: Results from 28 cities in the APHEA2 project. *Eur Respir J* 21: 28s-33s. <http://dx.doi.org/10.1183/09031936.03.00402803>
- [Agarwal, R; Awasthi, A; Singh, N; Gupta, PK; Mittal, SK.](#) (2012). Effects of exposure to rice-crop residue burning smoke on pulmonary functions and Oxygen Saturation level of human beings in Patiala (India). *Sci Total Environ* 429: 161-166. <http://dx.doi.org/10.1016/j.scitotenv.2012.03.074>
- [Aguilera, I; Garcia-Esteban, R; Iñiguez, C; Nieuwenhuijsen, MJ; Rodríguez, À; Paez, M; Ballester, F; Sunyer, J.](#) (2010). Prenatal exposure to traffic-related air pollution and ultrasound measures of fetal growth in the INMA Sabadell cohort. *Environ Health Perspect* 118: 705-711. <http://dx.doi.org/10.1289/ehp.0901228>
- [Aguilera, I; Guxens, M; Garcia-Esteban, R; Corbella, T; Nieuwenhuijsen, MJ; Foradada, CM; Sunyer, J.](#) (2009). Association between GIS-based exposure to urban air pollution during pregnancy and birth weight in the INMA Sabadell cohort. *Environ Health Perspect* 117: 1322-1327. <http://dx.doi.org/10.1289/ehp.0800256>
- [Aguilera, I; Pedersen, M; Garcia-Esteban, R; Ballester, F; Basterrechea, M; Esplugues, A; Fernández-Somoano, A; Lertxundi, A; Tardón, A; Sunyer, J.](#) (2013). Early-life exposure to outdoor air pollution and respiratory health, ear infections, and eczema in infants from the INMA study. *Environ Health Perspect* 121: 387-392. <http://dx.doi.org/10.1289/ehp.1205281>
- [Aguilera, I; Sunyer, J; Fernández-Patier, R; Hoek, G; Aguirre-Alfaro, A; Meliefste, K; Bomboi-Mingarro, MT; Nieuwenhuijsen, MJ; Herce-Garraleta, D; Brunekreef, B.](#) (2008). Estimation of outdoor NO<sub>x</sub>, NO<sub>2</sub>, and BTEX exposure in a cohort of pregnant women using land use regression modeling. *Environ Sci Technol* 42: 815-821. <http://dx.doi.org/10.1021/es0715492>

- [Ahmad, T; Mabalirajan, U; Sharma, A; Aich, J; Makhija, L; Ghosh, B; Agrawal, A.](#) (2011). Simvastatin improves epithelial dysfunction and airway hyperresponsiveness: From asymmetric dimethyl-arginine to asthma. *Am J Respir Cell Mol Biol* 44: 531-539. <http://dx.doi.org/10.1165/rcmb.2010-0041OC>
- [Ahmed, T; Dougherty, R; Sackner, MA.](#) (1983a). Effect of 0.1 ppm NO<sub>2</sub> on pulmonary functions and non-specific bronchial reactivity of normals and asthmatics [final report]. (CR-83/11/BI). Warren, MI: General Motors Research Laboratories.
- [Ahmed, T; Dougherty, R; Sackner, MA.](#) (1983b). Effect of NO<sub>2</sub> exposure on specific bronchial reactivity in subjects with allergic bronchial asthma [final report]. (CR-83/07/BI). Warren, MI: General Motors Research Laboratories.
- [Ainslie, B; Steyn, DG; Su, J; Buzzelli, M; Brauer, M; Larson, T; Rucker, M.](#) (2008). A source area model incorporating simplified atmospheric dispersion and advection at fine scale for population air pollutant exposure assessment. *Atmos Environ* 42: 2394-2404. <http://dx.doi.org/10.1016/j.atmosenv.2007.12.021>
- [Al-Hegelan, M; Tighe, RM; Castillo, C; Hollingsworth, JW.](#) (2011). Ambient ozone and pulmonary innate immunity [Review]. *Immunol Res* 49: 173-191. <http://dx.doi.org/10.1007/s12026-010-8180-z>
- [Alarie, Y.](#) (1973). Sensory irritation by airborne chemicals [Review]. *CRC Crit Rev Toxicol* 2: 299-363. <http://dx.doi.org/10.3109/10408447309082020>
- [Alberg, T; Nilsen, A; Hansen, JS; Nygaard, UC; Løvik, M.](#) (2011). Nitrogen dioxide: No influence on allergic sensitization in an intranasal mouse model with ovalbumin and diesel exhaust particles. *Inhal Toxicol* 23: 268-276. <http://dx.doi.org/10.3109/08958378.2011.566898>
- [Alexanderson, C; Olin, AC; Dahlman-Höglund, A; Finizia, C; Torén, K.](#) (2012). Nasal nitric oxide in a random sample of adults and its relationship to sensitization, cat allergen, rhinitis, and ambient nitric oxide. *Am J Rhinol Allergy* 26: e99-e103. <http://dx.doi.org/10.2500/ajra.2012.26.3777>
- [Allen, RW; Amram, O; Wheeler, AJ; Brauer, M.](#) (2011). The transferability of NO and NO<sub>2</sub> land use regression models between cities and pollutants. *Atmos Environ* 45: 369-378. <http://dx.doi.org/10.1016/j.atmosenv.2010.10.002>
- [Allen, RW; Davies, H; Cohen, MA; Mallach, G; Kaufman, JD; Adar, SD.](#) (2009). The spatial relationship between traffic-generated air pollution and noise in 2 US cities. *Environ Res* 109: 334-342. <http://dx.doi.org/10.1016/j.envres.2008.12.006>
- [Alm, S; Mukala, K; Pasanen, P; Tiittanen, P; Ruuskanen, J; Tuomisto, J; Jantunen, MJ.](#) (1998). Personal NO<sub>2</sub> exposures of preschool children in Helsinki. *J Expo Anal Environ Epidemiol* 8: 79-100.
- [Altuğ, H; Gaga, EO; Döğeroğlu, T; Brunekreef, B; Hoek, G; Van Doorn, W.](#) (2014). Effects of ambient air pollution on respiratory tract complaints and airway inflammation in primary school children. *Sci Total Environ* 479-480: 201-209. <http://dx.doi.org/10.1016/j.scitotenv.2014.01.127>
- [Alving, K; Weitzberg, E; Lundberg, JM.](#) (1993). Increased amount of nitric oxide in exhaled air of asthmatics. *Eur Respir J* 6: 1368-1370.
- [American Heart Association.](#) (2011). Cardiovascular disease statistics. Available online at <http://web.archive.org/web/20110410093532/http://www.americanheart.org/presenter.jhtml?identifier=4478> (accessed April 12, 2011).
- [Amigou, A; Sermage-Faure, C; Orsi, L; Leverger, G; Baruchel, A; Bertrand, Y; Nelken, B; Robert, A; Michel, G; Margueritte, G; Perel, Y; Mechinaud, F; Bordigoni, P; Hémon, D; Clavel, J.](#) (2011). Road traffic and childhood leukemia: The ESCALE Study (SFCE). *Environ Health Perspect* 119: 566-572. <http://dx.doi.org/10.1289/ehp.1002429>
- [Amoruso, MA; Witz, G; Goldstein, BD.](#) (1981). Decreased superoxide anion radical production by rat alveolar macrophages following inhalation of ozone or nitrogen dioxide. *Life Sci* 28: 2215-2221. [http://dx.doi.org/10.1016/0024-3205\(81\)90572-5](http://dx.doi.org/10.1016/0024-3205(81)90572-5)
- [Amster, ED; Haim, M; Dubnov, J; Broday, DM.](#) (2014). Contribution of nitrogen oxide and sulfur dioxide exposure from power plant emissions on respiratory symptom and disease prevalence. *Environ Pollut* 186: 20-28. <http://dx.doi.org/10.1016/j.envpol.2013.10.032>

- [Andersen, ZJ; Bønnelykke, K; Hvidberg, M; Jensen, SS; Ketzel, M; Loft, S; Sørensen, M; Tjønneland, A; Overvad, K; Raaschou-Nielsen, O.](#) (2012a). Long-term exposure to air pollution and asthma hospitalisations in older adults: A cohort study. *Thorax* 67: 6-11. <http://dx.doi.org/10.1136/thoraxjnl-2011-200711>
- [Andersen, ZJ; Hvidberg, M; Jensen, SS; Ketzel, M; Loft, S; Sørensen, M; Tjønneland, A; Overvad, K; Raaschou-Nielsen, O.](#) (2011). Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution: A cohort study. *Am J Respir Crit Care Med* 183: 455-461. <http://dx.doi.org/10.1164/rccm.201006-0937OC>
- [Andersen, ZJ; Kristiansen, LC; Andersen, KK; Olsen, TS; Hvidberg, M; Jensen, SS; Ketzel, M; Loft, S; Sørensen, M; Tjønneland, A; Overvad, K; Raaschou-Nielsen, O.](#) (2012b). Stroke and long-term exposure to outdoor air pollution from nitrogen dioxide: A cohort study. *Stroke* 43: 320-325. <http://dx.doi.org/10.1161/STROKEAHA.111.629246>
- [Andersen, ZJ; Loft, S; Ketzel, M; Stage, M; Scheike, T; Hermansen, MN; Bisgaard, H.](#) (2008a). Ambient air pollution triggers wheezing symptoms in infants. *Thorax* 63: 710-716. <http://dx.doi.org/10.1136/thx.2007.085480>
- [Andersen, ZJ; Olsen, TS; Andersen, KK; Loft, S; Ketzel, M; Raaschou-Nielsen, O.](#) (2010). Association between short-term exposure to ultrafine particles and hospital admissions for stroke in Copenhagen, Denmark. *Eur Heart J* 31: 2034-2040. <http://dx.doi.org/10.1093/eurheartj/ehq188>
- [Andersen, ZJ; Raaschou-Nielsen, O; Ketzel, M; Jensen, SS; Hvidberg, M; Loft, S; Tjønneland, A; Overvad, K; Sørensen, M.](#) (2012c). Diabetes incidence and long-term exposure to air pollution: A cohort study. *Diabetes Care* 35: 92-98. <http://dx.doi.org/10.2337/dc11-1155>
- [Andersen, ZJ; Wahlin, P; Raaschou-Nielsen, O; Ketzel, M; Scheike, T; Loft, S.](#) (2008b). Size distribution and total number concentration of ultrafine and accumulation mode particles and hospital admissions in children and the elderly in Copenhagen, Denmark. *Occup Environ Med* 65: 458-466. <http://dx.doi.org/10.1136/oem.2007.033290>
- [Andersen, ZJ; Wahlin, P; Raaschou-Nielsen, O; Scheike, T; Loft, S.](#) (2007). Ambient particle source apportionment and daily hospital admissions among children and elderly in Copenhagen. *J Expo Sci Environ Epidemiol* 17: 625-636. <http://dx.doi.org/10.1038/sj.jes.7500546>
- [Anderson, HR; Armstrong, B; Hajat, S; Harrison, R; Monk, V; Poloniecki, J; Timmis, A; Wilkinson, P.](#) (2010). Air pollution and activation of implantable cardioverter defibrillators in London. *Epidemiology* 21: 405-413. <http://dx.doi.org/10.1097/EDE.0b013e3181d61600>
- [Anderson, HR; Favarato, G; Atkinson, RW.](#) (2013). Long-term exposure to air pollution and the incidence of asthma: Meta-analysis of cohort studies. *Air Qual Atmos Health* 6: 47-56. <http://dx.doi.org/10.1007/s11869-011-0144-5>
- [Anderson, HR; Ponce de Leon, A; Bland, JM; Bower, JS; Emberlin, J; Strachen, DP.](#) (1998). Air pollution, pollens, and daily admissions for asthma in London 1987-92. *Thorax* 53: 842-848. <http://dx.doi.org/10.1136/thx.53.10.842>
- [Anderson, JT; Zeng, M; Li, Q; Stapley, R; Moore, DR; Chenna, B; Fineberg, N; Zmijewski, J; Eltoum, IE; Siegal, GP; Gaggar, A; Barnes, S; Velu, SE; Thannickal, VJ; Abraham, E; Patel, RP; Lancaster, J. R.; Chaplin, DD; Dransfield, MT; Deshane, JS.](#) (2011). Elevated levels of NO are localized to distal airways in asthma. *Free Radic Biol Med* 50: 1679-1688. <http://dx.doi.org/10.1016/j.freeradbiomed.2011.03.015>
- [Annesi-Maesano, I; Hulin, M; Lavaud, F; Raheison, C; Kopferschmitt, C; de Blay, F; Charpin, DA; Denis, C.](#) (2012a). Poor air quality in classrooms related to asthma and rhinitis in primary schoolchildren of the French 6 Cities Study. *Thorax* 67: 682-688. <http://dx.doi.org/10.1136/thoraxjnl-2011-200391>
- [Annesi-Maesano, I; Moreau, D; Caillaud, D; Lavaud, F; Le Moulec, Y; Taytard, A; Pauli, G; Charpin, D.](#) (2007). Residential proximity fine particles related to allergic sensitisation and asthma in primary school children. *Respir Med* 101: 1721-1729. <http://dx.doi.org/10.1016/j.rmed.2007.02.022>
- [Annesi-Maesano, I; Rouve, S; Desqueyroux, H; Jankovski, R; Klossek, JM; Thibaudon, M; Demoly, P; Didier, A.](#) (2012b). Grass pollen counts, air pollution levels and allergic rhinitis severity. *Int Arch Allergy Immunol* 158: 397-404. <http://dx.doi.org/10.1159/000332964>

- [Arain, MA; Blair, R; Finkelstein, N; Brook, J; Jerrett, M.](#) (2009). Meteorological influences on the spatial and temporal variability of NO<sub>2</sub> in Toronto and Hamilton. *Can Geogr* 53: 165-190. <http://dx.doi.org/10.1111/j.1541-0064.2009.00252.x>
- [Aranyi, C; Fenters, J; Erhlich, R; Gardner, D.](#) (1976). Scanning electron microscopy of alveolar macrophages after exposure to oxygen, nitrogen dioxide, and ozone [Abstract]. *Environ Health Perspect* 16: 180.
- [Arbex, MA; de Souza Conceição, GM; Cendon, SP; Arbex, FF; Lopes, AC; Moysés, EP; Santiago, SL; Saldiva, PHN; Pereira, LAA; Braga, ALF.](#) (2009). Urban air pollution and chronic obstructive pulmonary disease-related emergency department visits. *J Epidemiol Community Health* 63: 777-783. <http://dx.doi.org/10.1136/jech.2008.078360>
- [Arhami, M; Polidori, A; Delfino, RJ; Tjoa, T; Sioutas, C.](#) (2009). Associations between personal, indoor, and residential outdoor pollutant concentrations: Implications for exposure assessment to size-fractionated particulate matter. *J Air Waste Manag Assoc* 59: 392-404. <http://dx.doi.org/10.3155/1047-3289.59.4.392>
- [Arner, EC; Rhoades, RA.](#) (1973). Long-term nitrogen dioxide exposure: Effects on lung lipids and mechanical properties. *Arch Environ Health* 26: 156-160. <http://dx.doi.org/10.1080/00039896.1973.10666244>
- [Arnold, JR; Hartsell, BE; Luke, WT; Ullah, SMR; Dasgupta, PK; Huey, LG; Tate, P.](#) (2007). Field test of four methods for gas-phase ambient nitric acid. *Atmos Environ* 41: 4210-4226. <http://dx.doi.org/10.1016/j.atmosenv.2006.07.058>
- [Asgharian, B; Price, OT; Schroeter, JD; Kimbell, JS; Jones, L; Singal, M.](#) (2011). Derivation of mass transfer coefficients for transient uptake and tissue disposition of soluble and reactive vapors in lung airways. *Ann Biomed Eng* 39: 1788-1804. <http://dx.doi.org/10.1007/s10439-011-0274-9>
- [Atari, DO; Luginaah, I; Xu, X; Fung, K.](#) (2008). Spatial variability of ambient nitrogen dioxide and sulfur dioxide in Sarnia, "Chemical Valley," Ontario, Canada. *J Toxicol Environ Health A* 71: 1572-1581. <http://dx.doi.org/10.1080/15287390802414158>
- [Atari, DO; Luginaah, IN; Fung, K.](#) (2009). The relationship between odour annoyance scores and modelled ambient air pollution in Sarnia, "Chemical Valley", Ontario. *Int J Environ Res Public Health* 6: 2655-2675. <http://dx.doi.org/10.3390/ijerph6102655>
- [Ather, JL; Alcorn, JF; Brown, AL; Guala, AS; Suratt, BT; Janssen-Heininger, YM; Poynter, ME.](#) (2010). Distinct functions of airway epithelial nuclear factor-kappaB activity regulate nitrogen dioxide-induced acute lung injury. *Am J Respir Cell Mol Biol* 43: 443-451. <http://dx.doi.org/10.1165/rcmb.2008-0416OC>
- [Atkinson, RW; Anderson, HR; Strachan, DP; Bland, JM; Bremner, SA; Ponce de Leon, A.](#) (1999a). Short-term associations between outdoor air pollution and visits to accident and emergency departments in London for respiratory complaints. *Eur Respir J* 13: 257-265.
- [Atkinson, RW; Bremner, SA; Anderson, HR; Strachan, DP; Bland, JM; Ponce de Leon, A.](#) (1999b). Short-term associations between emergency hospital admissions for respiratory and cardiovascular disease and outdoor air pollution in London. *Arch Environ Health* 54: 398-411. <http://dx.doi.org/10.1080/00039899909603371>
- [Atkinson, RW; Carey, IM; Kent, AJ; van Staa, TP; Anderson, HR; Cook, DG.](#) (2013). Long-term exposure to outdoor air pollution and incidence of cardiovascular diseases. *Epidemiology* 24: 44-53. <http://dx.doi.org/10.1097/EDE.0b013e318276ccb8>
- [Atkinson, RW; Cohen, A; Mehta, S; Anderson, HR.](#) (2012). Systematic review and meta-analysis of epidemiological time-series studies on outdoor air pollution and health in Asia. *Air Qual Atmos Health* 5: 383-391. <http://dx.doi.org/10.1007/s11869-010-0123-2>
- [ATS](#) (American Thoracic Society). (2000a). Guidelines for methacholine and exercise challenge testing-1999. *Am J Respir Crit Care Med* 161: 309-329. <http://dx.doi.org/10.1164/ajrccm.161.1.ats11-99>
- [ATS](#) (American Thoracic Society). (2000b). What constitutes an adverse health effect of air pollution? *Am J Respir Crit Care Med* 161: 665-673. <http://dx.doi.org/10.1164/ajrccm.161.2.ats4-00>

- ATS/ERS (American Thoracic Society and European Respiratory Society). (2005). ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. *Am J Respir Crit Care Med* 171: 912-930. <http://dx.doi.org/10.1164/rccm.200406-710ST>
- ATSDR (Agency for Toxic Substances and Disease Registry). (2006). A study of ambient air contaminants and asthma in New York City: Part A and B. Atlanta, GA: U.S. Department of Health and Human Services. [http://permanent.access.gpo.gov/ips88357/ASTHMA\\_BRONX\\_FINAL\\_REPORT.pdf](http://permanent.access.gpo.gov/ips88357/ASTHMA_BRONX_FINAL_REPORT.pdf)
- Augusto, O; Bonini, MG; Amanso, AM; Linares, E; Santos, CC; De Menezes, SL. (2002). Nitrogen dioxide and carbonate radical anion: Two emerging radicals in biology [Review]. *Free Radic Biol Med* 32: 841-859. [http://dx.doi.org/10.1016/S0891-5849\(02\)00786-4](http://dx.doi.org/10.1016/S0891-5849(02)00786-4)
- Avol, EL; Linn, WS; Peng, RC; Valencia, G; Little, D; Hackney, JD. (1988). Laboratory study of asthmatic volunteers exposed to nitrogen dioxide and to ambient air pollution. *Am Ind Hyg Assoc J* 49: 143-149. <http://dx.doi.org/10.1080/15298668891379530>
- Avol, EL; Linn, WS; Peng, RC; Whynot, JD; Shamoo, DA; Little, DE; Smith, MN; Hackney, JD. (1989). Experimental exposures of young asthmatic volunteers to 0.3 ppm nitrogen dioxide and to ambient air pollution. *Toxicol Ind Health* 5: 1025-1034.
- Avol, EL; Navidi, WC; Rappaport, EB; Peters, JM. (1998). Acute effects of ambient ozone on asthmatic, wheezy, and healthy children. (82). Topsfield, MA: Health Effects Institute; Flagship Press.
- Ayaz, KL; Csallany, AS. (1978). Long-term NO<sub>2</sub> exposure of mice in the presence and absence of vitamin E. II. Effect of glutathione peroxidase. *Arch Environ Occup Health* 33: 292-296. <http://dx.doi.org/10.1080/00039896.1978.10667350>
- Azadniv, M; Utell, MJ; Morrow, PE; Gibb, FR; Nichols, J; Roberts, NJ, Jr; Speers, DM; Torres, A; Tsai, Y; Abraham, MK; Voter, KZ; Frampton, MW. (1998). Effects of nitrogen dioxide exposure on human host defense. *Inhal Toxicol* 10: 585-601. <http://dx.doi.org/10.1080/089583798197556>
- Azoulay-Dupuis, E; Torres, M; Soler, P; Moreau, J. (1983). Pulmonary NO<sub>2</sub> toxicity in neonate and adult guinea pigs and rats. *Environ Res* 30: 322-339. [http://dx.doi.org/10.1016/0013-9351\(83\)90218-9](http://dx.doi.org/10.1016/0013-9351(83)90218-9)
- Babior, BM; Takeuchi, C; Ruedi, J; Gutierrez, A; Wentworth, P. (2003). Investigating antibody-catalyzed ozone generation by human neutrophils. *PNAS* 100: 3031-3034. <http://dx.doi.org/10.1073/pnas.0530251100>
- Baccarelli, A; Zanobetti, A; Martinelli, I; Grillo, P; Hou, L; Lanzani, G; Mannucci, PM; Bertazzi, PA; Schwartz, J. (2007). Air pollution, smoking, and plasma homocysteine. *Environ Health Perspect* 115: 176-181. <http://dx.doi.org/10.1289/ehp.9517>
- Badaloni, C; Ranucci, A; Cesaroni, G; Zanini, G; Vienneau, D; Al-Aidrous, F; De Hoogh, K; Magnani, C; Forastiere, F; Group, SS. (2013). Air pollution and childhood leukaemia: a nationwide case-control study in Italy. *Occup Environ Med* 70: 876-883. <http://dx.doi.org/10.1136/oemed-2013-101604>
- Bagheri Lankarani, N; Kreis, I; Griffiths, DA. (2010). Air pollution effects on peak expiratory flow rate in children. *Iran J Allergy Asthma Immunol* 9: 117-126. <http://dx.doi.org/09.02/ijaai.117126>
- Baja, ES; Schwartz, JD; Wellenius, GA; Coull, BA; Zanobetti, A; Vokonas, PS; Suh, HH. (2010). Traffic-related air pollution and QT interval: Modification by diabetes, obesity, and oxidative stress gene polymorphisms in the Normative Aging Study. *Environ Health Perspect* 118: 840-846. <http://dx.doi.org/10.1289/ehp.0901396>
- Baldauf, R; Thoma, E; Hays, M; Shores, R; Kinsey, J; Gullett, B; Kimbrough, S; Isakov, V; Long, T; Snow, R; Khlystov, A; Weinstein, J; Chen, FL; Seila, R; Olson, D; Gilmour, I; Cho, SH; Watkins, N; Rowley, P; Bang, J. (2008a). Traffic and meteorological impacts on near-road air quality: Summary of methods and trends from the Raleigh near-road study. *J Air Waste Manag Assoc* 58: 865-878. <http://dx.doi.org/10.3155/1047-3289.58.7.865>
- Baldauf, R; Thoma, E; Khlystov, A; Isakov, V; Bowker, G; Long, T; Snow, R. (2008b). Impacts of noise barriers on near-road air quality. *Atmos Environ* 42: 7502-7507. <http://dx.doi.org/10.1016/j.atmosenv.2008.05.051>

- [Baldauf, R; Watkins, N; Heist, D; Bailey, C; Rowley, P; Shores, R.](#) (2009). Near-road air quality monitoring: Factors affecting network design and interpretation of data. *Air Qual Atmos Health* 2: 1-9. <http://dx.doi.org/10.1007/s11869-009-0028-0>
- [Ballester, F; Estarlich, M; Iñiguez, C; Llop, S; Ramón, R; Esplugues, A; Lacasaña, M; Rebagliato, M.](#) (2010). Air pollution exposure during pregnancy and reduced birth size: A prospective birth cohort study in Valencia, Spain. *Environ Health* 9: 6. <http://dx.doi.org/10.1186/1476-069X-9-6>
- [Ballester, F; Rodriguez, P; Iniguez, C; Saez, M; Daponte, A; Galan, I; Taracido, M; Arribas, F; Bellido, J; Cirarda, FB; Canada, A; Guillen, JJ; Guillen-Grima, F; Lopez, E; Perez-Hoyos, S; Lertxundi, A; Toro, S.](#) (2006). Air pollution and cardiovascular admissions association in Spain: Results within the EMECAS project. *J Epidemiol Community Health* 60: 328-336. <http://dx.doi.org/10.1136/jech.2005.037978>
- [Ballester, F; Tenías, JM; Pérez-Hoyos, S.](#) (2001). Air pollution and emergency hospital admissions for cardiovascular diseases in Valencia, Spain. *J Epidemiol Community Health* 55: 57-65. <http://dx.doi.org/10.1136/jech.55.1.57>
- [Barck, C; Lundahl, J; Halldén, G; Bylin, G.](#) (2005a). Brief exposures to NO<sub>2</sub> augment the allergic inflammation in asthmatics. *Environ Res* 97: 58-66. <http://dx.doi.org/10.1016/j.envres.2004.02.009>
- [Barck, C; Lundahl, J; Holmström, M; Bylin, G.](#) (2005b). Does nitrogen dioxide affect inflammatory markers after nasal allergen challenge? *Am J Rhinol* 19: 560-566.
- [Barck, C; Sandstrom, T; Lundahl, J; Hallden, G; Svartengren, M; Strand, V; Rak, S; Bylin, G.](#) (2002). Ambient level of NO<sub>2</sub> augments the inflammatory response to inhaled allergen in asthmatics. *Respir Med* 96: 907-917. <http://dx.doi.org/10.1053/rmed.2002.1374>
- [Barclay, JL; Miller, BG; Dick, S; Dennekamp, M; Ford, I; Hillis, GS; Ayres, JG; Seaton, A.](#) (2009). A panel study of air pollution in subjects with heart failure: negative results in treated patients. *Occup Environ Med* 66: 325-334. <http://dx.doi.org/10.1136/oem.2008.039032>
- [Barnes, PJ; Liew, FY.](#) (1995). Nitric oxide and asthmatic inflammation [Review]. *Immunol Today* 16: 128-130. [http://dx.doi.org/10.1016/0167-5699\(95\)80128-6](http://dx.doi.org/10.1016/0167-5699(95)80128-6)
- [Barnett, AG; Williams, GM; Schwartz, J; Best, TL; Neller, AH; Petroeschovsky, AL; Simpson, RW.](#) (2006). The effects of air pollution on hospitalizations for cardiovascular disease in elderly people in Australian and New Zealand cities. *Environ Health Perspect* 114: 1018-1023. <http://dx.doi.org/10.1289/ehp.8674>
- [Barr, RG; Herbstman, J; Speizer, FE; Camargo, CA, Jr.](#) (2002). Validation of self-reported chronic obstructive pulmonary disease in a cohort study of nurses. *Am J Epidemiol* 155: 965-971. <http://dx.doi.org/10.1093/aje/155.10.965>
- [Barraza-Villarreal, A; Sunyer, J; Hernandez-Cadena, L; Escamilla-Núñez, MC; Sienra-Monge, JJ; Ramírez-Aguilar, M; Cortez-Lugo, M; Holguin, F; Diaz-Sánchez, D; Olin, AC; Romieu, I.](#) (2008). Air pollution, airway inflammation, and lung function in a cohort study of Mexico City schoolchildren. *Environ Health Perspect* 116: 832-838. <http://dx.doi.org/10.1289/ehp.10926>
- [Bartell, SM; Longhurst, J; Tjoa, T; Sioutas, C; Delfino, RJ.](#) (2013). Particulate air pollution, ambulatory heart rate variability, and cardiac arrhythmia in retirement community residents with coronary artery disease. *Environ Health Perspect* 121: 1135-1141. <http://dx.doi.org/10.1289/ehp.1205914>
- [Barth, PJ; Müller, B.](#) (1999). Effects of nitrogen dioxide exposure on Clara cell proliferation and morphology. *Pathol Res Pract* 195: 487-493. [http://dx.doi.org/10.1016/S0344-0338\(99\)80052-1](http://dx.doi.org/10.1016/S0344-0338(99)80052-1)
- [Barth, PJ; Muller, B; Wagner, U; Bittinger, A.](#) (1995). Quantitative analysis of parenchymal and vascular alterations in NO<sub>2</sub>-induced lung injury in rats. *Eur Respir J* 8: 1115-1121. <http://dx.doi.org/10.1183/09031936.95.08071115>
- [Bartolomei, V; Sörgel, M; Gligorovski, S; Alvarez, EG; Gandolfo, A; Streckowski, R; Quivet, E; Held, A; Zetzsch, C; Wortham, H.](#) (2014). Formation of indoor nitrous acid (HONO) by light-induced NO<sub>2</sub> heterogeneous reactions with white wall paint. *Environ Sci Pollut Res Int* 21: 9259-9269. <http://dx.doi.org/10.1007/s11356-014-2836-5>

- [Basagaña, X; Aguilera, I; Rivera, M; Agis, D; Foraster, M; Marrugat, J; Elosua, R; Künzli, N.](#) (2013). Measurement error in epidemiologic studies of air pollution based on land-use regression models. *Am J Epidemiol* 178: 1342-1346. <http://dx.doi.org/10.1093/aje/kwt127>
- [Basagaña, X; Rivera, M; Aguilera, I; Agis, D; Bouso, L; Elosua, R; Foraster, M; de Nazelle, A; Nieuwenhuijsen, M; Vila, J; Künzli, N.](#) (2012). Effect of the number of measurement sites on land use regression models in estimating local air pollution. *Atmos Environ* 54: 634-642. <http://dx.doi.org/10.1016/j.atmosenv.2012.01.064>
- [Bastacky, J; Lee, CY; Goerke, J; Koushafar, H; Yager, D; Kenaga, L; Speed, TP; Chen, Y; Clements, JA.](#) (1995). Alveolar lining layer is thin and continuous: Low-temperature scanning electron microscopy of rat lung. *J Appl Physiol* 79: 1615-1628.
- [Bastain, T; Islam, T; Berhane, K; Mcconnell, R; Rappaport, E; Salam, M; Linn, W; Avol, E; Zhang, Y; Gilliland, F.](#) (2011). Exhaled nitric oxide, susceptibility and new-onset asthma in the Children's Health Study. *Eur Respir J* 37: 523-531. <http://dx.doi.org/10.1183/09031936.00021210>
- [Basu, R; Malig, B; Ostro, B.](#) (2010). High ambient temperature and the risk of preterm delivery. *Am J Epidemiol* 172: 1108-1117. <http://dx.doi.org/10.1093/aje/kwq170>
- [Bates, DV; Macklem, PT; Christie, RV.](#) (1971). *Respiratory function in disease: An introduction to the integrated study of the lung* (2nd ed.). Philadelphia, PA: W.B. Saunders Company.
- [Bateson, TF; Coull, BA; Hubbell, B; Ito, K; Jerrett, M; Lumley, T; Thomas, D; Vedal, S; Ross, M.](#) (2007). Panel discussion review: Session three - issues involved in interpretation of epidemiologic analyses - statistical modeling. *J Expo Sci Environ Epidemiol* 17: S90-S96. <http://dx.doi.org/10.1038/sj.jes.7500631>
- [Bauer, MA; Utell, MJ; Morrow, PE; Speers, DM; Gibb, FR.](#) (1986). Inhalation of 0.30 ppm nitrogen dioxide potentiates exercise-induced bronchospasm in asthmatics. *Am Rev Respir Dis* 134: 1203-1208.
- [Bautista, AP; Eisenlohr, CP; Lanz, MJ.](#) (2011). Nasal nitric oxide and nasal eosinophils decrease with levocetirizine in subjects with perennial allergic rhinitis. *Am J Rhinol Allergy* 25: 383-387. <http://dx.doi.org/10.2500/ajra.2011.25.3668>
- [Baxter, LK; Duvall, RM; Sacks, J.](#) (2013). Examining the effects of air pollution composition on within region differences in PM(2.5) mortality risk estimates. *J Expo Sci Environ Epidemiol* 23: 457-465. <http://dx.doi.org/10.1038/jes.2012.114>
- [Beaupré, A; Orehek, J.](#) (1982). Factors influencing the bronchodilator effect of a deep inspiration in asthmatic patients with provoked bronchoconstriction. *Thorax* 37: 124-128. <http://dx.doi.org/10.1136/thx.37.2.124>
- [Beaven, MA.](#) (2009). Our perception of the mast cell from Paul Ehrlich to now. *Eur J Immunol* 39: 11-25. <http://dx.doi.org/10.1002/eji.200838899>
- [Becerra, TA; Wilhelm, M; Olsen, J; Cockburn, M; Ritz, B.](#) (2013). Ambient air pollution and autism in Los Angeles County, California. *Environ Health Perspect* 121: 380-386. <http://dx.doi.org/10.1289/ehp.1205827>
- [Beckerman, B; Jerrett, M; Brook, JR; Verma, DK; Arain, MA; Finkelstein, MM.](#) (2008). Correlation of nitrogen dioxide with other traffic pollutants near a major expressway. *Atmos Environ* 42: 275-290. <http://dx.doi.org/10.1016/j.atmosenv.2007.09.042>
- [Beckerman, BS; Jerrett, M; Finkelstein, M; Kanaroglou, P; Brook, JR; Arain, MA; Sears, MR; Stieb, D; Balmes, J; Chapman, K.](#) (2012). The association between chronic exposure to traffic-related air pollution and ischemic heart disease. *J Toxicol Environ Health A* 75: 402-411. <http://dx.doi.org/10.1080/15287394.2012.670899>
- [Beckerman, BS; Jerrett, M; Martin, RV; van Donkelaar, A; Ross, Z, ev; Burnett, RT.](#) (2013a). Application of the deletion/substitution/addition algorithm to selecting land use regression models for interpolating air pollution measurements in California. *Atmos Environ* 77: 172-177. <http://dx.doi.org/10.1016/j.atmosenv.2013.04.024>
- [Beckerman, BS; Jerrett, M; Serre, M; Martin, RV; Lee, S; van Donkelaar, A; Ross, Z, ev; Su, J; Burnett, RT.](#) (2013b). A hybrid approach to estimating national scale spatiotemporal variability of PM2.5 in the contiguous United States. *Environ Sci Technol* 47: 7233-7241. <http://dx.doi.org/10.1021/es400039u>

- Bequemin, MM; Bertholon, JF; Bouchikhi, A; Malarbet, JL; Roy, M. (1999). Oronasal ventilation partitioning in adults and children: Effect on aerosol deposition in airways. *Radiat Prot Dosimetry* 81: 221-228.
- Beelen, R; Hoek, G; Houthuijs, D; van den Brandt, PA; Goldbohm, RA; Fischer, P; Schouten, LJ; Armstrong, B; Brunekreef, B. (2009). The joint association of air pollution and noise from road traffic with cardiovascular mortality in a cohort study. *Occup Environ Med* 66: 243-250. <http://dx.doi.org/10.1136/oem.2008.042358>
- Beelen, R; Hoek, G; van den Brandt, PA; Goldbohm, RA; Fischer, P; Schouten, LJ; Armstrong, B; Brunekreef, B. (2008a). Long-term exposure to traffic-related air pollution and lung cancer risk. *Epidemiology* 19: 702-710. <http://dx.doi.org/10.1097/EDE.0b013e318181b3ca>
- Beelen, R; Hoek, G; van den Brandt, PA; Goldbohm, RA; Fischer, P; Schouten, LJ; Jerrett, M; Hughes, E; Armstrong, B; Brunekreef, B. (2008b). Long-term effects of traffic-related air pollution on mortality in a Dutch cohort (NLCS-AIR study). *Environ Health Perspect* 116: 196-202. <http://dx.doi.org/10.1289/ehp.10767>
- Beelen, R; Hoek, G; Vienneau, D; Eeftens, M; Dimakopoulou, K; Pedeli, X; Tsai, MY, i; Kuenzli, N; Schikowski, T; Marcon, A; Eriksen, KT; Raaschou-Nielsen, O, le; Stephanou, E; Patelarou, E; Lanki, T; Yli-Toumi, T; Declercq, C; Falq, G; Stempfelet, M; Birk, M; Cyrus, J; von Klot, S; Nador, G; Varro, MJ; Dedele, A; Grazuleviciene, R; Moelter, A; Lindley, S; Madsen, C; Cesaroni, G; Ranzi, A; Badaloni, C; Hoffmann, B; Nonnemacher, M; Kraemer, U; Kuhlbusch, T; Cirach, M; de Nazelle, A; Nieuwenhuijsen, M; Bellander, T, om; Korek, M; Olsson, D; Stromgren, M; Dons, E, vi; Jerrett, M; Fischer, P; Wang, M; Brunekreef, B; de Hoogh, K. (2013). Development of NO<sub>2</sub> and NO<sub>x</sub> land use regression models for estimating air pollution exposure in 36 study areas in Europe - The ESCAPE project. *Atmos Environ* 72: 10-23. <http://dx.doi.org/10.1016/j.atmosenv.2013.02.037>
- Beelen, R; Raaschou-Nielsen, O; Stafoggia, M; Andersen, ZJ; Weinmayr, G; Hoffmann, B; Wolf, K; Samoli, E; Fischer, P; Nieuwenhuijsen, M; Vineis, P; Xun, WW; Katsouyanni, K; Dimakopoulou, K; Oudin, A; Forsberg, B; Modig, L; Havulinna, AS; Lanki, T; Turunen, A; Oftedal, B; Nystad, W; Nafstad, P; De Faire, U; Pedersen, NL; Ostenson, CG; Fratiglioni, L; Penell, J; Korek, M; Pershagen, G; Eriksen, KT; Overvad, K; Ellermann, T; Eeftens, M; Peeters, PH; Meliefste, K; Wang, M; Bueno-De-Mesquita, B; Sugiri, D; Krämer, U; Heinrich, J; de Hoogh, K; Key, T; Peters, A; Hampel, R; Concin, H; Nagel, G; Ineichen, A; Schaffner, E; Probst-Hensch, N; Künzli, N; Schindler, C; Schikowski, T; Adam, M; Phuleria, H; Vilier, A; Clavel-Chapelon, F; Declercq, C; Grioni, S; Krogh, V; Tsai, MY; Ricceri, F; Sacerdote, C; Galassi, C; Migliore, E; Ranzi, A; Cesaroni, G; Badaloni, C; Forastiere, F; Tamayo, I; Amiano, P; Dorronsoro, M; Katsoulis, M; Trichopoulou, A; Brunekreef, B; Hoek, G. (2014a). Effects of long-term exposure to air pollution on natural-cause mortality: an analysis of 22 European cohorts within the multicentre ESCAPE project. *Lancet* 383: 785-795. [http://dx.doi.org/10.1016/S0140-6736\(13\)62158-3](http://dx.doi.org/10.1016/S0140-6736(13)62158-3)
- Beelen, R; Stafoggia, M; Raaschou-Nielsen, O; Andersen, ZJ; Xun, WW; Katsouyanni, K; Dimakopoulou, K; Brunekreef, B; Weinmayr, G; Hoffmann, B; Wolf, K; Samoli, E; Houthuijs, D; Nieuwenhuijsen, M; Oudin, A; Forsberg, B; Olsson, D; Salomaa, V; Lanki, T; Yli-Tuomi, T; Oftedal, B; Aamodt, G; Nafstad, P; De Faire, U; Pedersen, NL; Ostenson, CG; Fratiglioni, L; Penell, J; Korek, M; Pyko, A; Eriksen, KT; Tjønneland, A; Becker, T; Eeftens, M; Bots, M; Meliefste, K; Wang, M; Bueno-De-Mesquita, B; Sugiri, D; Krämer, U; Heinrich, J; de Hoogh, K; Key, T; Peters, A; Cyrus, J; Concin, H; Nagel, G; Ineichen, A; Schaffner, E; Probst-Hensch, N; Dratva, J; Ducret-Stich, R; Vilier, A; Clavel-Chapelon, F; Stempfelet, M; Grioni, S; Krogh, V; Tsai, MY; Marcon, A; Ricceri, F; Sacerdote, C; Galassi, C; Migliore, E; Ranzi, A; Cesaroni, G; Badaloni, C; Forastiere, F; Tamayo, I; Amiano, P; Dorronsoro, M; Katsoulis, M; Trichopoulou, A; Vineis, P; Hoek, G. (2014b). Long-term exposure to air pollution and cardiovascular mortality: An analysis of 22 European cohorts. *Epidemiology* 25: 368-378. <http://dx.doi.org/10.1097/EDE.0000000000000076>
- Beelen, R; Voogt, M; Duyzer, J; Zandveld, P; Hoek, G. (2010). Comparison of the performances of land use regression modelling and dispersion modelling in estimating small-scale variations in long-term air pollution concentrations in a Dutch urban area. *Atmos Environ* 44: 4614-4621. <http://dx.doi.org/10.1016/j.atmosenv.2010.08.005>
- Beevers, SD; Carslaw, DC. (2005). The impact of congestion charging on vehicle emissions in London. *Atmos Environ* 39: 1-5. <http://dx.doi.org/10.1016/j.atmosenv.2004.10.001>

- [Beevers, SD; Kitwiroon, N; Williams, ML; Carslaw, DC.](#) (2012). One way coupling of CMAQ and a road source dispersion model for fine scale air pollution predictions. *Atmos Environ* 59: 47-58. <http://dx.doi.org/10.1016/j.atmosenv.2012.05.034>
- [Beevers, SD; Kitwiroon, N; Williams, ML; Kelly, FJ; Ross Anderson, H; Carslaw, DC.](#) (2013). Air pollution dispersion models for human exposure predictions in London. *J Expo Sci Environ Epidemiol* 23: 647-653. <http://dx.doi.org/10.1038/jes.2013.6>
- [Belanger, K; Holford, TR; Gent, JF; Hill, ME; Kezik, JM; Leaderer, BP.](#) (2013). Household levels of nitrogen dioxide and pediatric asthma severity. *Epidemiology* 24: 320-330. <http://dx.doi.org/10.1097/EDE.0b013e318280e2ac>
- [Bell, ML; Dominici, F; Samet, JM.](#) (2005). A meta-analysis of time-series studies of ozone and mortality with comparison to the national morbidity, mortality, and air pollution study. *Epidemiology* 16: 436-445. <http://dx.doi.org/10.1097/01.ede.0000165817.40152.85>
- [Bell, ML; Ebisu, K; Belanger, K.](#) (2007). Ambient air pollution and low birth weight in Connecticut and Massachusetts. *Environ Health Perspect* 115: 1118-1124. <http://dx.doi.org/10.1289/ehp.9759>
- [Bell, ML; Levy, JK; Lin, Z.](#) (2008). The effect of sandstorms and air pollution on cause-specific hospital admissions in Taipei, Taiwan. *Occup Environ Med* 65: 104-111. <http://dx.doi.org/10.1136/oem.2006.031500>
- [Bell, S; Ashenden, TW.](#) (1997). Spatial and temporal variation in nitrogen dioxide pollution adjacent to rural roads. *Water Air Soil Pollut* 95: 87-98. <http://dx.doi.org/10.1023/A:1026478127687>
- [Bellander, T; Wichmann, J; Lind, T.](#) (2012). Individual exposure to NO<sub>2</sub> in relation to spatial and temporal exposure indices in Stockholm, Sweden: The INDEX study. *PLoS ONE* 7: e39536. <http://dx.doi.org/10.1371/journal.pone.0039536>
- [Bellini, P; Baccini, M; Biggeri, A; Terracini, B.](#) (2007). The meta-analysis of the Italian studies on short-term effects of air pollution (MISA): Old and new issues on the interpretation of the statistical evidences. *Environmetrics* 18: 219-229. <http://dx.doi.org/10.1002/env.836>
- [Belvisi, MG; Stretton, CD; Miura, M; Verleden, GM; Tadjkarimi, S; Yacoub, MH; Barnes, PJ.](#) (1992). Inhibitory NANC nerves in human tracheal smooth muscle: A quest for the neurotransmitter. *J Appl Physiol* 73: 2505-2510.
- [Bennett, WD; Zeman, KL; Jarabek, AM.](#) (2008). Nasal contribution to breathing and fine particle deposition in children versus adults. *J Toxicol Environ Health A* 71: 227-237. <http://dx.doi.org/10.1080/15287390701598200>
- [Benson, PE.](#) (1984). CALINE4 - a dispersion model for predicting air pollutant concentrations near roadways. (FHWA/CA/TL-84/15). Sacramento, California: California Department of Transportation, Office of Transportation Laboratory. <https://ntrl.ntis.gov/NTRL/dashboard/searchResults.xhtml?searchQuery=PB85211498>
- [Benson, PE.](#) (1992). A review of the development and application of the CALINE3 and CALINE4 models. *Atmos Environ* 26: 379-390. [http://dx.doi.org/10.1016/0957-1272\(92\)90013-I](http://dx.doi.org/10.1016/0957-1272(92)90013-I)
- [Bentayeb, M; Helmer, C; Raherison, C; Dartigues, JF; Tessier, JF; Annesi-Maesano, I.](#) (2010). Bronchitis-like symptoms and proximity air pollution in French elderly. *Respir Med* 104: 880-888. <http://dx.doi.org/10.1016/j.rmed.2010.01.004>
- [Bentayeb, M; Stempfelet, M; Wagner, V; Zins, M; Bonenfant, S; Songeur, C; Sanchez, O; Rosso, A; Brulfert, G; Rios, I; Chaxel, E; Virga, J; Armengaud, A; Rossello, P; Riviere, E; Bernard, M; Vasbien, F; Deprost, R.](#) (2014). Retrospective modeling outdoor air pollution at a fine spatial scale in France, 1989-2008. *Atmos Environ* 92: 267-279. <http://dx.doi.org/10.1016/j.atmosenv.2014.04.019>
- [Berglund, N; Bellander, T; Forastiere, F; von Klot, S; Aalto, P; Elosua, R; Kulmala, M; Lanki, T; Löwel, H; Peters, A; Picciotto, S; Salomaa, V; Stafoggia, M; Sunyer, J; Nyberg, F.](#) (2009). Ambient air pollution and daily mortality among survivors of myocardial infarction. *Epidemiology* 20: 110-118. <http://dx.doi.org/10.1097/EDE.0b013e3181878b50>

- [Berhane, K; Zhang, Y; Linn, WS; Rappaport, EB; Bastain, TM; Salam, MT; Islam, T; Lurmann, F; Gilliland, FD.](#) (2011). The effect of ambient air pollution on exhaled nitric oxide in the Children's Health Study. *Eur Respir J* 37: 1029-1036. <http://dx.doi.org/10.1183/09031936.00081410>
- [Berhane, K; Zhang, Y; Salam, MT; Eckel, SP; Linn, WS; Rappaport, EB; Bastain, TM; Lurmann, F; Gilliland, FD.](#) (2014). Longitudinal effects of air pollution on exhaled nitric oxide: the Children's Health Study. *Occup Environ Med* 71: 507-513. <http://dx.doi.org/10.1136/oemed-2013-101874>
- [Berkowicz, R; Ketznel, M; Jensen, SS; Hvidberg, M; Raaschou-Nielsen, O.](#) (2008). Evaluation and application of OSPM for traffic pollution assessment for a large number of street locations. *Environ Modell Softw* 23: 296-303. <http://dx.doi.org/10.1016/j.envsoft.2007.04.007>
- [Bernhard, W; Haslam, PL; Floros, J.](#) (2004). From birds to humans: New concepts on airways relative to alveolar surfactant [Review]. *Am J Respir Cell Mol Biol* 30: 6-11. <http://dx.doi.org/10.1165/rcmb.2003-0158TR>
- [Berrocal, VJ; Gelfand, AE; Holland, DM.](#) (2010a). A bivariate space-time downscaler under space and time misalignment. *Ann Appl Stat* 4: 1942-1975. <http://dx.doi.org/10.1214/10-AOAS351>
- [Berrocal, VJ; Gelfand, AE; Holland, DM.](#) (2010b). A spatio-temporal downscaler for output from numerical models. *J Agric Biol Environ Stat* 15: 176-197. <http://dx.doi.org/10.1007/s13253-009-0004-z>
- [Berrocal, VJ; Gelfand, AE; Holland, DM.](#) (2012). Space-time data fusion under error in computer model output: An application to modeling air quality. *Biometrics* 68: 837-848. <http://dx.doi.org/10.1111/j.1541-0420.2011.01725.x>
- [Bevelander, M; Mayette, J; Whittaker, LA; Paveglio, SA; Jones, CC; Robbins, J; Hemenway, D; Akira, S; Uematsu, S; Poynter, ME.](#) (2007). Nitrogen dioxide promotes allergic sensitization to inhaled antigen. *J Immunol* 179: 3680-3688.
- [Bhaskar, KR; O'Sullivan, DD; Seltzer, J; Rossing, TH; Drazen, JM; Reid, LM.](#) (1985). Density gradient study of bronchial mucus aspirates from healthy volunteers (smokers and nonsmokers) and from patients with tracheostomy. *Exp Lung Res* 9: 289-308. <http://dx.doi.org/10.3109/01902148509057529>
- [Bhaskaran, K; Hajat, S; Armstrong, B; Haines, A; Herrett, E; Wilkinson, P; Smeeth, L.](#) (2011). The effects of hourly differences in air pollution on the risk of myocardial infarction: case crossover analysis of the MINAP database. *B M J* 343: d5531. <http://dx.doi.org/10.1136/bmj.d5531>
- [Bidani, A; Postlethwait, EM.](#) (1998). Kinetic determinants of inhaled reactive gas absorption. In *MP Hlastala; HT Robertson (Eds.), Complexity in structure and function of the lung* (pp. 243-296). New York, NY: Marcell Dekker Inc.
- [Biggeri, A; Baccini, M; Bellini, P; Terracini, B.](#) (2005). Meta-analysis of the Italian studies of short-term effects of air pollution (MISA), 1990-1999. *Int J Occup Environ Health* 11: 107-122. <http://dx.doi.org/10.1179/oeht.2005.11.1.107>
- [Bignal, KL; Ashmore, MR; Headley, AD; Stewart, K; Weigert, K.](#) (2007). Ecological impacts of air pollution from road transport on local vegetation. *Appl Geochem* 22: 1265-1271. <http://dx.doi.org/10.1016/j.apgeochem.2007.03.017>
- [Bilenko, N; Rossem, LV; Brunekreef, B; Beelen, R; Eeftens, M; Hoek, G; Houthuijs, D; de Jongste, JC; Kempen, EV; Koppelman, GH; Meliefste, K; Oldenwening, M; Smit, HA; Wijga, AH; Gehring, U.](#) (2015). Traffic-related air pollution and noise and children's blood pressure: results from the PIAMA birth cohort study. *Euro J Prev Cardio* 22: 4-12. <http://dx.doi.org/10.1177/2047487313505821>
- [Bind, MA; Baccarelli, A; Zanobetti, A; Tarantini, L; Suh, H; Vokonas, P; Schwartz, J.](#) (2012). Air pollution and markers of coagulation, inflammation, and endothelial function: Associations and epigenetic-environment interactions in an elderly cohort. *Epidemiology* 23: 332-340. <http://dx.doi.org/10.1097/EDE.0b013e31824523f0>
- [Bishaw, A; Fontenot, K.](#) (2014). Poverty: 2012 and 2013 - American community survey briefs. (ACSB/13-01). Suitland, MD: U.S. Census Bureau. <https://www.census.gov/content/dam/Census/library/publications/2014/acs/acsbr13-01.pdf>

- Blackwell, DL; Lucas, JW; Clarke, TC. (2014). Summary health statistics for U.S. adults: National health interview survey, 2012. In Vital and health statistics. Hyattsville, MD: National Center for Health Statistics, U.S Department of Health and Human Services. [http://www.cdc.gov/nchs/data/series/sr\\_10/sr10\\_260.pdf](http://www.cdc.gov/nchs/data/series/sr_10/sr10_260.pdf)
- Blair, WH; Henry, MC; Ehrlich, R. (1969). Chronic toxicity of nitrogen dioxide: II. Effect on histopathology of lung tissue. Arch Environ Health 18: 186-192. <http://dx.doi.org/10.1080/00039896.1969.10665391>
- Blomberg, A; Krishna, MT; Bocchino, V; Biscione, GL; Shute, JK; Kelly, FJ; Frew, AJ; Holgate, ST; Sandstrom, T. (1997). The inflammatory effects of 2 ppm NO<sub>2</sub> on the airways of healthy subjects. Am J Respir Crit Care Med 156: 418-424. <http://dx.doi.org/10.1164/ajrccm.156.2.9612042>
- Blomberg, A; Krishna, MT; Helleday, R; Söderberg, M; Ledin, MC; Kelly, FJ; Frew, AJ; Holgate, ST; Sandström, T. (1999). Persistent airway inflammation but accommodated antioxidant and lung function responses after repeated daily exposure to nitrogen dioxide. Am J Respir Crit Care Med 159: 536-543. <http://dx.doi.org/10.1164/ajrccm.159.2.9711068>
- Blood, AB; Schroeder, HJ; Terry, MH; Merrill-Henry, J; Bragg, SL; Vrancken, K; Liu, T; Herring, JL; Sowers, LC; Wilson, SM; Power, GG. (2011). Inhaled nitrite reverses hemolysis-induced pulmonary vasoconstriction in newborn lambs without blood participation. Circulation 123: 605-612. <http://dx.doi.org/10.1161/CIRCULATIONAHA.110.001073>
- Bloom, B; Jones, LI; Freeman, G. (2013). Summary health statistics for U.S. children: National health interview survey, 2012. In Vital and health statistics. Hyattsville, MD: National Center for Health Statistics, U.S Department of Health and Human Services. [http://www.cdc.gov/nchs/data/series/sr\\_10/sr10\\_258.pdf](http://www.cdc.gov/nchs/data/series/sr_10/sr10_258.pdf)
- Blount, RJ; Djawe, K; Daly, KR; Jarlsberg, LG; Fong, S; Balmes, J; Miller, RF; Walzer, PD; Huang, L. (2013). Ambient air pollution associated with suppressed serologic responses to *Pneumocystis jirovecii* in a prospective cohort of HIV-infected patients with *Pneumocystis pneumonia*. PLoS ONE 8: e80795. <http://dx.doi.org/10.1371/journal.pone.0080795>
- Bobak, M. (2000). Outdoor air pollution, low birth weight, and prematurity. Environ Health Perspect 108: 173-176. <http://dx.doi.org/10.2307/3454517>
- Boersma, KF; Eskes, HJ; Brinksma, EJ. (2004). Error analysis for tropospheric NO<sub>2</sub> retrieval from space. J Geophys Res 109: D04311. <http://dx.doi.org/10.1029/2003JD003962>
- Boezen, M; Schouten, J; Rijcken, B; Vonk, J; Gerritsen, J; Van Der Zee, S; Hoek, G; Brunekreef, B; Postma, D. (1998). Peak expiratory flow variability, bronchial responsiveness, and susceptibility to ambient air pollution in adults. Am J Respir Crit Care Med 158: 1848-1854. <http://dx.doi.org/10.1164/ajrccm.158.6.9804072>
- Boggia, B; Carbone, U; Farinero, E; Zarrilli, S; Lombardi, G; Colao, A; De Rosa, N; De Rosa, M. (2009). Effects of working posture and exposure to traffic pollutants on sperm quality. J Endocrinol Invest 32: 430-434. <http://dx.doi.org/10.1007/BF03346481>
- Bonacci, G; Baker, PR; Salvatore, S. R.; Shores, D; Khoo, NK; Koenitzer, J. R.; Vitturi, DA; Woodcock, S. R.; Golin-Bisello, F; Cole, MP; Watkins, S; St Croix, C; Batthyany, CI; Freeman, BA; Schopfer, FJ. (2012). Conjugated linoleic acid is a preferential substrate for fatty acid nitration. J Biol Chem 287: 44071-44082. <http://dx.doi.org/10.1074/jbc.M112.401356>
- Bonacci, G; Schopfer, FJ; Batthyany, CI; Rudolph, TK; Rudolph, V; Khoo, NK; Kelley, EE; Freeman, BA. (2011). Electrophilic fatty acids regulate matrix metalloproteinase activity and expression. J Biol Chem 286: 16074-16081. <http://dx.doi.org/10.1074/jbc.M111.225029>
- Boogaard, H; Fischer, PH; Janssen, NA; Kos, GP; Weijers, EP; Cassee, FR; van der Zee, SC; de Hartog, JJ; Meliefste, K; Wang, M; Brunekreef, B; Hoek, G. (2013). Respiratory effects of a reduction in outdoor air pollution concentrations. Epidemiology 24: 753-761. <http://dx.doi.org/10.1097/EDE.0b013e31829e1639>
- Borland, CDR; Dunningham, H; Bottrill, F; Vuylsteke, A; Yilmaz, C; Dane, DM; Hsia, CCW. (2010). Significant blood resistance to nitric oxide transfer in the lung. J Appl Physiol 108: 1052-1060. <http://dx.doi.org/10.1152/jappphysiol.00904.2009>

- [Bråbäck, L; Forsberg, B.](#) (2009). Does traffic exhaust contribute to the development of asthma and allergic sensitization in children: Findings from recent cohort studies [Review]. *Environ Health* 8: 17. <http://dx.doi.org/10.1186/1476-069X-8-17>
- [Brahmajothi, MV; Mason, SN; Whorton, AR; McMahon, TJ; Auten, RL.](#) (2010). Transport rather than diffusion-dependent route for nitric oxide gas activity in alveolar epithelium. *Free Radic Biol Med* 49: 294-300. <http://dx.doi.org/10.1016/j.freeradbiomed.2010.04.020>
- [Brauer, M; Hoek, G; Smit, HA; de Jongste, JC; Gerritsen, J; Postma, DS; Kerkhof, M; Brunekreef, B.](#) (2007). Air pollution and development of asthma, allergy and infections in a birth cohort. *Eur Respir J* 29: 879-888. <http://dx.doi.org/10.1183/09031936.00083406>
- [Brauer, M; Hoek, G; van Vliet, P; Meliefste, K; Fischer, P; Gehring, U; Heinrich, J; Cyrus, J; Bellander, T; Lewne, M; Brunekreef, B.](#) (2003). Estimating long-term average particulate air pollution concentrations: Application of traffic indicators and geographic information systems. *Epidemiology* 14: 228-239. <http://dx.doi.org/10.1097/00001648-200303000-00019>
- [Brauer, M; Hoek, G; Van Vliet, P; Meliefste, K; Fischer, PH; Wijga, A; Koopman, LP; Neijens, HJ; Gerritsen, J; Kerkhof, M; Heinrich, J; Bellander, T; Brunekreef, B.](#) (2002). Air pollution from traffic and the development of respiratory infections and asthmatic and allergic symptoms in children. *Am J Respir Crit Care Med* 166: 1092-1098. <http://dx.doi.org/10.1164/rccm.200108-007OC>
- [Brauer, M; Koutrakis, P; Keeler, GJ; Spengler, JD.](#) (1991). Indoor and outdoor concentrations of inorganic acidic aerosols and gases. *J Air Waste Manag Assoc* 41: 171-181. <http://dx.doi.org/10.1080/10473289.1991.10466834>
- [Brauer, M; Lencar, C; Tamburic, L; Koehoorn, M; Demers, P; Karr, C.](#) (2008). A cohort study of traffic-related air pollution impacts on birth outcomes. *Environ Health Perspect* 116: 680-686. <http://dx.doi.org/10.1289/ehp.10952>
- [Brauer, M; Ryan, PB; Suh, HH; Koutrakis, P; Spengler, JD; Leslie, NP; Billick, IH.](#) (1990). Measurements of nitrous acid inside two research houses. *Environ Sci Technol* 24: 1521-1527. <http://dx.doi.org/10.1021/es00080a011>
- [Breton, CV; Salam, MT; Vora, H; Gauderman, WJ; Gilliland, FD.](#) (2011). Genetic variation in the glutathione synthesis pathway, air pollution, and children's lung function growth. *Am J Respir Crit Care Med* 183: 243-248. <http://dx.doi.org/10.1164/rccm.201006-0849OC>
- [Breton, CV; Wang, X; Mack, WJ; Berhane, K; Lopez, M; Islam, TS; Feng, M; Lurmann, F; McConnell, R; Hodis, HN; Künzli, N; Avol, E.](#) (2012). Childhood air pollutant exposure and carotid artery intima-media thickness in young adults. *Circulation* 126: 1614-1620. <http://dx.doi.org/10.1161/CIRCULATIONAHA.112.096164>
- [Britten, RE; Hanna, SR.](#) (2003). Flow and dispersion in urban areas. *Annu Rev Fluid Mech* 35: 469-496. <http://dx.doi.org/10.1146/annurev.fluid.35.101101.161147>
- [Brixey, LA; Heist, DK; Richmond-Bryant, J; Bowker, GE; Perry, SG; Wiener, RW.](#) (2009). The effect of a tall tower on flow and dispersion through a model urban neighborhood: Part 2: Pollutant dispersion. *J Environ Monit* 11: 2171-2179. <http://dx.doi.org/10.1039/B907137g>
- [Brochu, P; Brodeur, J; Krishnan, K.](#) (2011). Derivation of physiological inhalation rates in children, adults, and elderly based on nighttime and daytime respiratory parameters. *Inhal Toxicol* 23: 74-94. <http://dx.doi.org/10.3109/08958378.2010.543439>
- [Brody, DJ; Zhang, X; Kit, BK; Dillon, CF.](#) (2013). Reference values and factors associated with exhaled nitric oxide: U.S. youth and adults. *Respir Med* 107: 1682-1691. <http://dx.doi.org/10.1016/j.rmed.2013.07.006>
- [Brook, JR; Burnett, RT; Dann, TF; Cakmak, S; Goldberg, MS; Fan, X; Wheeler, AJ.](#) (2007). Further interpretation of the acute effect of nitrogen dioxide observed in Canadian time-series studies. *J Expo Sci Environ Epidemiol* 17: S36-S44. <http://dx.doi.org/10.1038/sj.jes.7500626>

- [Brook, RD; Jerreft, M; Brook, JR; Bard, RL; Finkelstein, MM.](#) (2008). The relationship between diabetes mellitus and traffic-related air pollution. *J Occup Environ Med* 50: 32-38. <http://dx.doi.org/10.1097/JOM.0b013e31815dba70>
- [Brown, JS.](#) (2015). Nitrogen dioxide exposure and airway responsiveness in individuals with asthma. *Inhal Toxicol* 27: 1-14. <http://dx.doi.org/10.3109/08958378.2014.979960>
- [Brown, KW; Sarnat, JA; Suh, HH; Coull, BA; Koutrakis, P.](#) (2009). Factors influencing relationships between personal and ambient concentrations of gaseous and particulate pollutants. *Sci Total Environ* 407: 3754-3765. <http://dx.doi.org/10.1016/j.scitotenv.2009.02.016>
- [Brown, SS; Dubé, WP; Karamchandani, P; Yarwood, G; Peischl, J; Ryerson, TB; Neuman, JA; Nowak, JB; Holloway, JS; Washenfelder, RA; Brock, CA; Frost, GJ; Trainer, M; Parrish, DD; Fehsenfeld, FC; Ravishankara, AR.](#) (2012). Effects of NO<sub>x</sub> control and plume mixing on nighttime chemical processing of plumes from coal-fired power plants. *J Geophys Res* 117: D07304. <http://dx.doi.org/10.1029/2011JD016954>
- [Brown, SS; Stutz, J.](#) (2012). Nighttime radical observations and chemistry. *Chem Soc Rev* 41: 6405-6447. <http://dx.doi.org/10.1039/c2cs35181a>
- [Brunekreef, B; Beelen, R; Hoek, G; Schouten, L; Bausch-Goldbohm, S; Fischer, P; Armstrong, B; Hughes, E; Jerrett, M; van den Brandt, P.](#) (2009). Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: The NLCs-AIR Study. (139). Boston, MA: Health Effects Institute. <http://www.n65.nl/NCLS-AIR-Study-2009.pdf>
- [Brusasco, V; Crimi, E; Gianiorio, P; Lantero, S; Rossi, GA.](#) (1990). Allergen-induced increase in airway responsiveness and inflammation in mild asthma. *J Appl Physiol* 69: 2209-2214.
- [Brüske, I.](#) (2014). Email from Dr. Irene Brüske to Molini Patel, cc Dr. Regina Hampel, Dr. Kathrin Wolf. WG: question re: 2010 Inhalational toxicology paper (With attachments). Available online
- [Brüske, I; Hampel, R; Baumgärtner, Z; Ruckerl, R; Greven, S; Koenig, W; Peters, A; Schneider, A.](#) (2011). Ambient air pollution and lipoprotein-associated phospholipase A2 in survivors of myocardial infarction. *Environ Health Perspect* 119: 921-926. <http://dx.doi.org/10.1289/ehp.1002681>
- [Bruske, I; Hampel, R; Socher, MM; Ruckerl, R; Schneider, A; Heinrich, J; Oberdorster, G; Wichmann, HE; Peters, A.](#) (2010). Impact of ambient air pollution on the differential white blood cell count in patients with chronic pulmonary disease. *Inhal Toxicol* 22: 245-252. <http://dx.doi.org/10.3109/08958370903207274>
- [Bryan, NS.](#) (2006). Nitrite in nitric oxide biology: Cause or consequence? A systems-based review [Review]. *Free Radic Biol Med* 41: 691-701. <http://dx.doi.org/10.1016/j.freeradbiomed.2006.05.019>
- [Bryan, NS; Fernandez, BO; Bauer, SM; Garcia-Saura, MF; Milsom, AB; Rassaf, T; Maloney, RE; Bharti, A; Rodriguez, J; Feelisch, M.](#) (2005). Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues. *Nat Chem Biol* 1: 290-297. <http://dx.doi.org/10.1038/nchembio734>
- [Bucsela, EJ; Krotkov, NA; Celarier, EA; Lamsal, LN; Swartz, WH; Bhartia, PK; Boersma, KF; Veeffkind, JP; Gleason, JF; Pickering, KE.](#) (2013). A new stratospheric and tropospheric NO<sub>2</sub> retrieval algorithm for nadir-viewing satellite instruments: Applications to OMI. *Atmos Meas Tech Disc* 6: 1361-1407. <http://dx.doi.org/10.5194/amtd-6-1361-2013>
- [Burke, JM; Zufall, MJ; Ozkaynak, H.](#) (2001). A population exposure model for particulate matter: Case study results for PM<sub>2.5</sub> in Philadelphia, PA. *J Expo Anal Environ Epidemiol* 11: 470-489.
- [Burling, IR; Yokelson, RJ; Griffith, DWT; Johnson, TJ; Veres, P; Roberts, JM; Warneke, C; Urbanski, SP; Reardon, J; Weise, DR; Hao, WM; De Gouw, J.](#) (2010). Laboratory measurements of trace gas emissions from biomass burning of fuel types from the southeastern and southwestern United States. *Atmos Chem Phys* 10: 11115-11130. <http://dx.doi.org/10.5194/acp-10-11115-2010>
- [Burnett, RT; Brook, J; Dann, T; Delocla, C; Philips, O; Cakmak, S; Vincent, R; Goldberg, MS; Krewski, D.](#) (2000). Association between particulate- and gas-phase components of urban air pollution and daily mortality in eight Canadian cities. *Inhal Toxicol* 12: 15-39. <http://dx.doi.org/10.1080/08958370050164851>

- [Burnett, RT; Smith-Doiron, M; Stieb, D; Cakmak, S; Brook, JR.](#) (1999). Effects of particulate and gaseous air pollution on cardiorespiratory hospitalizations. *Arch Environ Health* 54: 130-139. <http://dx.doi.org/10.1080/00039899909602248>
- [Burnett, RT; Smith-Doiron, M; Stieb, D; Raizenne, ME; Brook, JR; Dales, RE; Leech, JA; Cakmak, S; Krewski, D.](#) (2001). Association between ozone and hospitalization for acute respiratory diseases in children less than 2 years of age. *Am J Epidemiol* 153: 444-452. <http://dx.doi.org/10.1093/aje/153.5.444>
- [Burnett, RT; Stieb, D; Brook, JR; Cakmak, S; Dales, R; Raizenne, M; Vincent, R; Dann, T.](#) (2004). Associations between short-term changes in nitrogen dioxide and mortality in Canadian cities. *Arch Environ Occup Health* 59: 228-236. <http://dx.doi.org/10.3200/AEOH.59.5.228-236>
- [Burney, PG; Laitinen, LA; Perdrizet, S; Huckauf, H; Tattersfield, AE; Chinn, S; Poisson, N; Heeren, A; Britton, JR; Jones, T.](#) (1989). Validity and repeatability of the IUATLD (1984) Bronchial Symptoms Questionnaire: an international comparison. *Eur Respir J* 2: 940-945.
- [Burr, ML.](#) (1992). Diagnosing asthma by questionnaire in epidemiological surveys [Editorial]. *Clin Exp Allergy* 22: 509-510. <http://dx.doi.org/10.1111/j.1365-2222.1992.tb00158.x>
- [Burra, TA; Moineddin, R; Agha, MM; Glazier, RH.](#) (2009). Social disadvantage, air pollution, and asthma physician visits in Toronto, Canada. *Environ Res* 109: 567-574. <http://dx.doi.org/10.1016/j.envres.2009.03.004>
- [Butland, BK; Armstrong, B; Atkinson, RW; Wilkinson, P; Heal, MR; Doherty, RM; Vieno, M.](#) (2013). Measurement error in time-series analysis: a simulation study comparing modelled and monitored data. *BMC Med Res Methodol* 13: 136. <http://dx.doi.org/10.1186/1471-2288-13-136>
- [Button, B; Cai, LH; Ehre, C; Kesimer, M; Hill, DB; Sheehan, JK; Boucher, RC; Rubinstein, M.](#) (2012). A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. *Science* 337: 937-941. <http://dx.doi.org/10.1126/science.1223012>
- [Buzica, D; Gerboles, M; Plaisance, H.](#) (2008). The equivalence of diffusive samplers to reference methods for monitoring O<sub>3</sub>, benzene and NO<sub>2</sub> in ambient air. *J Environ Monit* 10: 1052-1059. <http://dx.doi.org/10.1039/b802260g>
- [Bylin, G.](#) (1993). Health risk evaluation of nitrogen oxide: Controlled studies on humans. *Scand J Work Environ Health* 19: 37-43.
- [Bylin, G; Hedenstierna, G; Lindvall, T; Sundin, B.](#) (1988). Ambient nitrogen dioxide concentrations increase bronchial responsiveness in subjects with mild asthma. *Eur Respir J* 1: 606-612.
- [Bylin, G; Lindvall, T; Rehn, T; Sundin, B.](#) (1985). Effects of short-term exposure to ambient nitrogen dioxide concentrations on human bronchial reactivity and lung function. *Eur Respir J* 66: 205-217.
- [Byun, D; Schere, KL.](#) (2006). Review of the governing equations, computational algorithms, and other components of the models-3 community multiscale air quality (CMAQ) modeling system [Review]. *Appl Mech Rev* 59: 51-77. <http://dx.doi.org/10.1115/1.2128636>
- [CAA. Clean Air Act, as amended by Pub. L. No. 101-549, section 108: Air quality criteria and control techniques, 42 USC 7408, 42 USC](#) (1990a). <http://www.law.cornell.edu/uscode/text/42/7408>
- [CAA](#) (Clean Air Act). (1990b). Clean Air Act, as amended by Pub. L. No. 101-549, section 109: National primary and secondary ambient air quality standards, 42 USC 7409. <http://www.epa.gov/air/caa/title1.html#ia>
- [CAA. Clean Air Act, section 302: Definitions, 42 USC 7602, 42 USC](#) (2005). <http://www.gpo.gov/fdsys/pkg/USCODE-2005-title42/pdf/USCODE-2005-title42-chap85-subchapIII-sec7602.pdf>
- [Cahill, TA; Cahill, TM; Barnes, DE; Spada, NJ; Miller, R.](#) (2011). Inorganic and organic aerosols downwind of California's Roseville railyard. *Aerosol Sci Technol* 45: 1049-1059. <http://dx.doi.org/10.1080/02786826.2011.580796>

- [Cai, Y; Schikowski, T; Adam, M; Buschka, A; Carsin, AE; Jacquemin, B; Marcon, A; Sanchez, M; Vierkötter, A; Al-Kanaani, Z; Beelen, R; Birk, M; Brunekreef, B; Cirach, M; Clavel-Chapelon, F; Declercq, C; de Hoogh, K; de Nazelle, A; Ducret-Stich, RE; Valeria Ferretti, V; Forsberg, B; Gerbase, MW; Hardy, R; Heinrich, J; Hoek, G; Jarvis, D; Keidel, D; Kuh, D; Nieuwenhuijsen, MJ; Ragettli, MS; Ranzi, A; Rochat, T; Schindler, C; Sugiri, D; Temam, S; Tsai, MY; Varraso, R; Kauffmann, F; Krämer, U; Sunyer, J; Künzli, N; Probst-Hensch, N; Hansell, AL.](#) (2014). Cross-sectional associations between air pollution and chronic bronchitis: an ESCAPE meta-analysis across five cohorts [Review]. *Thorax* 69: 1005-1014. <http://dx.doi.org/10.1136/thoraxjnl-2013-204352>
- [Cakmak, S; Dales, R; Leech, J; Liu, L.](#) (2011a). The influence of air pollution on cardiovascular and pulmonary function and exercise capacity: Canadian Health Measures Survey (CHMS). *Environ Res* 111: 1309-1312. <http://dx.doi.org/10.1016/j.envres.2011.09.016>
- [Cakmak, S; Dales, RE; Judek, S.](#) (2006). Respiratory health effects of air pollution gases: Modification by education and income. *Arch Environ Occup Health* 61: 5-10. <http://dx.doi.org/10.3200/AEOH.61.1.5-10>
- [Cakmak, S; Dales, RE; Rubio, MA; Vidal, CB.](#) (2011b). The risk of dying on days of higher air pollution among the socially disadvantaged elderly. *Environ Res* 111: 388-393. <http://dx.doi.org/10.1016/j.envres.2011.01.003>
- [Cakmak, S; Dales, RE; Vida, CB.](#) (2009). Components of particulate air pollution and mortality in Chile. *Int J Occup Environ Health* 15: 152-158. <http://dx.doi.org/10.1179/107735209799195844>
- [Campen, MJ; Lund, AK; Doyle-Eisele, ML; Mcdonald, JD; Knuckles, TL; Rohr, AC; Knipping, EM; Mauderly, JL.](#) (2010). A comparison of vascular effects from complex and individual air pollutants indicates a role for monoxide gases and volatile hydrocarbons. *Environ Health Perspect* 118: 921-927. <http://dx.doi.org/10.1289/ehp.0901207>
- [Cano Garcinuno, A; Mora Gandarillas, I.](#) (2013). Early patterns of wheezing in asthmatic and nonasthmatic children. *Eur Respir J* 42: 1020-1028. <http://dx.doi.org/10.1183/09031936.00148712>
- [Canova, C; Torresan, S; Simonato, L; Scapellato, ML; Tessari, R; Visentin, A; Lotti, M; Maestrelli, P.](#) (2010). Carbon monoxide pollution is associated with decreased lung function in asthmatic adults. *Eur Respir J* 35: 266-272. <http://dx.doi.org/10.1183/09031936.00043709>
- [Cao, G; Jang, M.](#) (2008). Secondary organic aerosol formation from toluene photooxidation under various NO<sub>x</sub> conditions and particle acidity. *Atmos Chem Phys Discuss* 8: 14467-14495. <http://dx.doi.org/10.5194/acpd-8-14467-2008>
- [Cao, G; Jang, M.](#) (2010). An SOA model for toluene oxidation in the presence of inorganic aerosols. *Environ Sci Technol* 44: 727-733. <http://dx.doi.org/10.1021/es901682r>
- [Cao, J; Yang, C; Li, J; Chen, R; Chen, B; Gu, B; Kan, H.](#) (2011). Association between long-term exposure to outdoor air pollution and mortality in China: A cohort study. *J Hazard Mater* 186: 1594-1600. <http://dx.doi.org/10.1016/j.jhazmat.2010.12.036>
- [Cape, JN; Tang, YS; van Dijk, N; Love, L; Sutton, MA; Palmer, SCF.](#) (2004). Concentrations of ammonia and nitrogen dioxide at roadside verges, and their contribution to nitrogen deposition. *Environ Pollut* 132: 469-478. <http://dx.doi.org/10.1016/j.envpol.2004.05.009>
- [Cardinale, F; Tesse, R; Fucilli, C; Loffredo, MS; Iacoviello, G; Chinellato, I; Armenio, L.](#) (2007). Correlation between exhaled nitric oxide and dietary consumption of fats and antioxidants in children with asthma [Letter]. *J Allergy Clin Immunol* 119: 1268-1270. <http://dx.doi.org/10.1016/j.jaci.2007.01.028>
- [Carey, IM; Atkinson, RW; Kent, AJ; van Staa, T; Cook, DG; Anderson, HR.](#) (2013). Mortality associations with long-term exposure to outdoor air pollution in a national English cohort. *Am J Respir Crit Care Med* 187: 1226-1233. <http://dx.doi.org/10.1164/rccm.201210-1758OC>
- [Carlsen, HK; Forsberg, B; Meister, K; Gíslason, T; Oudin, A.](#) (2013). Ozone is associated with cardiopulmonary and stroke emergency hospital visits in Reykjavík, Iceland 2003-2009. *Environ Health* 12: 28. <http://dx.doi.org/10.1186/1476-069X-12-28>

- Carlsen, HK; Zoëga, H; Valdimarsdóttir, U; Gíslason, T; Hrafnkelsson, B. (2012). Hydrogen sulfide and particle matter levels associated with increased dispensing of anti-asthma drugs in Iceland's capital. *Environ Res* 113: 33-39. <http://dx.doi.org/10.1016/j.envres.2011.10.010>
- Carlsten, C; Brauer, M; Dimich-Ward, H; Dybuncio, A; Becker, AB; Chan-Yeung, M. (2011a). Combined exposure to dog and indoor pollution: Incident asthma in a high-risk birth cohort. *Eur Respir J* 37: 324-330. <http://dx.doi.org/10.1183/09031936.00187609>
- Carlsten, C; Dybuncio, A; Becker, A; Chan-Yeung, M; Brauer, M. (2011b). GSTP1 polymorphism modifies risk for incident asthma associated with nitrogen dioxide in a high-risk birth cohort [Letter]. *Occup Environ Med* In Press: In Press. <http://dx.doi.org/10.1136/oem.2010.063560>
- Carlsten, C; Dybuncio, A; Becker, A; Chan-Yeung, M; Brauer, M. (2011c). Traffic-related air pollution and incident asthma in a high-risk birth cohort. *Occup Environ Med* 68: 291-295. <http://dx.doi.org/10.1136/oem.2010.055152>
- Carraro, S; Gottardi, G; Bonetto, G; Baraldi, E. (2007). Exhaled nitric oxide in children with asthma and sinusitis [Review]. *PAI* 18: 28-30. <http://dx.doi.org/10.1111/j.1399-3038.2007.00629.x>
- Carlsaw, DC; Beevers, SD; Ropkins, K; Bell, MC. (2006). Detecting and quantifying aircraft and other on-airport contributions to ambient nitrogen oxides in the vicinity of a large international airport. *Atmos Environ* 40: 5424-5434. <http://dx.doi.org/10.1016/j.atmosenv.2006.04.062>
- Carlsaw, DC; Williams, ML; Barratt, B, en. (2012a). A short-term intervention study - Impact of airport closure due to the eruption of Eyjafjallajökull on near-field air quality. *Atmos Environ* 54: 328-336. <http://dx.doi.org/10.1016/j.atmosenv.2012.02.020>
- Carlsaw, N; Mota, T; Jenkin, ME; Barley, MH; Mcfiggans, G. (2012b). A significant role for nitrate and peroxide groups on indoor secondary organic aerosol. *Environ Sci Technol* 46: 9290-9298. <http://dx.doi.org/10.1021/es301350x>
- CASAC (Clean Air Scientific Advisory Committee). (2009). Comments and recommendations concerning EPA's proposed rule for the revision of the National Ambient Air Quality Standards (NAAQS) for nitrogen dioxide (unsigned) [EPA Report]. (EPA-CASAC-09-014). Washington, D.C.: U.S. Environmental Protection Agency.
- Castro-Giner, F; Künzli, N; Jacquemin, B; Forsberg, B; de Cid, R; Sunyer, J; Jarvis, D; Briggs, D; Vienneau, D; Norback, D; González, JR; Guerra, S; Janson, C; Antó, JM; Wjst, M; Heinrich, J; Estivill, X; Kogevinas, M. (2009). Traffic-related air pollution, oxidative stress genes, and asthma (ECHRS). *Environ Health Perspect* 117: 1919-1924. <http://dx.doi.org/10.1289/ehp.0900589>
- Castro, HA; Cunha, MF; Mendonça, GA; Junger, WL; Cunha-Cruz, J; Leon, AP. (2009). Effect of air pollution on lung function in schoolchildren in Rio de Janeiro, Brazil. *Rev Saude Publica* 43: 26-34. <http://dx.doi.org/10.1590/S0034-89102009000100004>
- Cattaneo, A; Tecce, N; Derudi, M; Gelosa, S; Nano, G; Cavallo, DM. (2014). Assessment of modeled indoor air concentrations of particulate matter, gaseous pollutants, and volatile organic compounds emitted from candles. *Hum Ecol Risk Assess* 20: 962-979. <http://dx.doi.org/10.1080/10807039.2013.821902>
- Cavanagh, DG; Morris, JB. (1987). Mucus protection and airway peroxidation following nitrogen dioxide exposure in the rat. *J Toxicol Environ Health* 22: 313-328. <http://dx.doi.org/10.1080/15287398709531074>
- CDC (Centers for Disease Control and Prevention). (2004). The health consequences of smoking: A report of the Surgeon General. Washington, DC: U.S. Department of Health and Human Services. [http://www.cdc.gov/tobacco/data\\_statistics/sgr/2004/index.htm](http://www.cdc.gov/tobacco/data_statistics/sgr/2004/index.htm)
- CDC (Centers for Disease Control and Prevention). (2013). State indicator report on fruits and vegetables. Atlanta, GA. <http://www.cdc.gov/nutrition/downloads/State-Indicator-Report-Fruits-Vegetables-2013.pdf>
- Centro di Ricerche Ambientali (Centro di Ricerche Ambientali di Padova). (2006). Radiello(R) manual. Padova, Italy: Fondazione Salvatore Maugeri Clinica del Lavoro e Della Riabilitazione I.R.C.C.S., Centro di Ricerche Ambientali. <http://www.radiello.com/english/Radiello%27s%20manual%2001-06.pdf>

- [Cesaroni, G; Badaloni, C; Gariazzo, C; Stafoggia, M; Sozzi, R; Davoli, M; Forastiere, F.](#) (2013). Long-term exposure to urban air pollution and mortality in a cohort of more than a million adults in Rome. *Environ Health Perspect* 121: 324-331. <http://dx.doi.org/10.1289/ehp.1205862>
- [Cesaroni, G; Badaloni, C; Porta, D; Forastiere, F; Perucci, CA.](#) (2008). Comparison between various indices of exposure to traffic-related air pollution and their impact on respiratory health in adults. *Occup Environ Med* 65: 683-690. <http://dx.doi.org/10.1136/oem.2007.037846>
- [Cesaroni, G; Forastiere, F; Stafoggia, M; Andersen, ZJ; Badaloni, C; Beelen, R; Caracciolo, B; de Faire, U; Erbel, R; Eriksen, KT; Fratiglioni, L; Galassi, C; Hampel, R; Heier, M; Hennig, F; Hilding, A; Hoffmann, B; Houthuijs, D; Jöckel, KH; Korek, M; Lanki, T; Leander, K; Magnusson, PK; Migliore, E; Ostenson, CG; Overvad, K; Pedersen, NL; J, JP; Penell, J; Pershagen, G; Pyko, A; Raaschou-Nielsen, O; Ranzi, A; Ricceri, F; Sacerdote, C; Salomaa, V; Swart, W; Turunen, AW; Vineis, P; Weinmayr, G; Wolf, K; de Hoogh, K; Hoek, G; Brunekreef, B; Peters, A.](#) (2014). Long term exposure to ambient air pollution and incidence of acute coronary events: prospective cohort study and meta-analysis in 11 European cohorts from the ESCAPE Project. *B M J (Online)* 348: f7412.
- [Cesaroni, G; Porta, D; Badaloni, C; Stafoggia, M; Eeftens, M; Meliefste, K; Forastiere, F.](#) (2012). Nitrogen dioxide levels estimated from land use regression models several years apart and association with mortality in a large cohort study. *Environ Health* 11: 48. <http://dx.doi.org/10.1186/1476-069X-11-48>
- [Chadha, TS; Birch, S; Sackner, MA.](#) (1987). Oronasal distribution of ventilation during exercise in normal subjects and patients with asthma and rhinitis. *Chest* 92: 1037-1041. <http://dx.doi.org/10.1378/chest.92.6.1037>
- [Chaix, B; Gustafsson, S; Jerrett, M; Kristersson, H; Lithman, T; Boalt, A; Merlo, J.](#) (2006). Children's exposure to nitrogen dioxide in Sweden: Investigating environmental injustice in an egalitarian country. *J Epidemiol Community Health* 60: 234-241. <http://dx.doi.org/10.1136/jech.2005.038190>
- [Chakraborty, S; Balakotiah, V; Bidani, A.](#) (2004). Diffusing capacity reexamined: Relative roles of diffusion and chemical reaction in red cell uptake of O<sub>2</sub>, CO, CO<sub>2</sub>, and NO. *J Appl Physiol* 97: 2284-2302. <http://dx.doi.org/10.1152/jappphysiol.00469.2004>
- [Chambers, DC; Ayres, JG.](#) (2001). Effects of nitrogen dioxide exposure and ascorbic acid supplementation on exhaled nitric oxide in healthy human subjects. *Thorax* 56: 774-778. <http://dx.doi.org/10.1136/thorax.56.10.774>
- [Chan, CC; Chuang, KJ; Chen, WJ; Chang, WT; Lee, CT; Peng, CM.](#) (2008). Increasing cardiopulmonary emergency visits by long-range transported Asian dust storms in Taiwan. *Environ Res* 106: 393-400. <http://dx.doi.org/10.1016/j.envres.2007.09.006>
- [Chaney, AM; Cryer, DJ; Nicholl, EJ; Seakins, PW.](#) (2011). NO and NO(2) interconversion downwind of two different line sources in suburban environments. *Atmos Environ* 45: 5863-5871. <http://dx.doi.org/10.1016/j.atmosenv.2011.06.070>
- [Chang, CC; Tsai, SS; Ho, SC; Yang, CY.](#) (2005). Air pollution and hospital admissions for cardiovascular disease in Taipei, Taiwan. *Environ Res* 98: 114-119. <http://dx.doi.org/10.1016/j.envres.2004.07.005>
- [Chang, JC; Franzese, P; Chayantrakom, K; Hanna, SR.](#) (2003). Evaluations of CALPUFF, HPAC, and VLSTRACK with two mesoscale field datasets. *J Appl Meteorol* 42: 453-466. [http://dx.doi.org/10.1175/1520-0450\(2003\)042<0453:EOCHAV>2.0.CO;2](http://dx.doi.org/10.1175/1520-0450(2003)042<0453:EOCHAV>2.0.CO;2)
- [Chang, LY; Graham, JA; Miller, FJ; Ospital, JJ; Crapo, JD.](#) (1986). Effects of subchronic inhalation of low concentrations of nitrogen dioxide: I. The proximal alveolar region of juvenile and adult rats. *Toxicol Appl Pharmacol* 83: 46-61. [http://dx.doi.org/10.1016/0041-008X\(86\)90321-2](http://dx.doi.org/10.1016/0041-008X(86)90321-2)
- [Chang, YK; Wu, CC; Lee, LT; Lin, RS; Yu, YH; Chen, YC.](#) (2012). The short-term effects of air pollution on adolescent lung function in Taiwan. *Chemosphere* 87: 26-30. <http://dx.doi.org/10.1016/j.chemosphere.2011.11.048>

- [Channell, MM; Paffett, ML; Devlin, RB; Madden, MC; Campen, MJ.](#) (2012). Circulating factors induce coronary endothelial cell activation following exposure to inhaled diesel exhaust and nitrogen dioxide in humans: Evidence from a novel translational in vitro model. *Toxicol Sci* 127: 179-186. <http://dx.doi.org/10.1093/toxsci/kfs084>
- [Chase, MW, Jr.](#) (1998). NIST-JANAF thermochemical tables, monograph 9 (Fourth Edition ed.). Washington DC: American Chemical Society. <http://www.nist.gov/srd/monogr.cfm>
- [Chatzidiakou, L; Mumovic, D; Summerfield, AJ; Hong, SM; Altamirano-Medina, H.](#) (2014). A Victorian school and a low carbon designed school: Comparison of indoor air quality, energy performance, and student health. *Indoor Built Environ* 23: 417-432. <http://dx.doi.org/10.1177/1420326X14532388>
- [Chen, BY; Chan, CC; Lee, CT; Cheng, TJ; Huang, WC; Jhou, JC; Han, YY; Chen, CC; Guo, YL.](#) (2012a). The association of ambient air pollution with airway inflammation in schoolchildren. *Am J Epidemiol* 175: 764-774. <http://dx.doi.org/10.1093/aje/kwr380>
- [Chen, EK; Zmirou-Navier, D; Padilla, C; Deguen, S.](#) (2014a). Effects of air pollution on the risk of congenital anomalies: a systematic review and meta-analysis [Review]. *Int J Environ Res Public Health* 11: 7642-7668. <http://dx.doi.org/10.3390/ijerph110807642>
- [Chen, G; Li, J; Ying, Q; Sherman, S; Perkins, N; Rajeshwari, S; Mendola, P.](#) (2014b). Evaluation of observation-fused regional air quality model results for population air pollution exposure estimation. *Sci Total Environ* 485-486: 563-574. <http://dx.doi.org/10.1016/j.scitotenv.2014.03.107>
- [Chen, G; Song, G; Jiang, L; Zhang, Y; Zhao, N; Chen, B; Kan, H.](#) (2008). Short-term effects of ambient gaseous pollutants and particulate matter on daily mortality in Shanghai, China. *J Occup Health* 50: 41-47. <http://dx.doi.org/10.1539/joh.50.41>
- [Chen, H; Goldberg, MS; Burnett, RT; Jerrett, M; Wheeler, AJ; Villeneuve, PJ.](#) (2013a). Long-term exposure to traffic-related air pollution and cardiovascular mortality. *Epidemiology* 24: 35-43. <http://dx.doi.org/10.1097/EDE.0b013e318276c005>
- [Chen, L; Bell, EM; Caton, AR; Druschel, CM; Lin, S.](#) (2010a). Residential mobility during pregnancy and the potential for ambient air pollution exposure misclassification. *Environ Res* 110: 162-168. <http://dx.doi.org/10.1016/j.envres.2009.11.001>
- [Chen, L; Villeneuve, PJ; Rowe, BH; Liu, L; Stieb, DM.](#) (2014c). The Air Quality Health Index as a predictor of emergency department visits for ischemic stroke in Edmonton, Canada. *J Expo Sci Environ Epidemiol* 24: 358-364. <http://dx.doi.org/10.1038/jes.2013.82>
- [Chen, R; Chu, C; Tan, J; Cao, J; Song, W; Xu, X; Jiang, C; Ma, W; Yang, C; Chen, B; Gui, Y; Kan, H.](#) (2010b). Ambient air pollution and hospital admission in Shanghai, China. *J Hazard Mater* 181: 234-240. <http://dx.doi.org/10.1016/j.jhazmat.2010.05.002>
- [Chen, R; Samoli, E; Wong, CM; Huang, W; Wang, Z; Chen, B; Kan, H.](#) (2012b). Associations between short-term exposure to nitrogen dioxide and mortality in 17 Chinese cities: The China Air Pollution and Health Effects Study (CAPES). *Environ Int* 45: 32-38. <http://dx.doi.org/10.1016/j.envint.2012.04.008>
- [Chen, R; Zhang, Y; Yang, C; Zhao, Z; Xu, X; Kan, H.](#) (2013b). Acute effect of ambient air pollution on stroke mortality in the china air pollution and health effects study. *Stroke* 44: 954-960. <http://dx.doi.org/10.1161/STROKEAHA.111.673442>
- [Chen, SY; Su, TC; Lin, YL; Chan, CC.](#) (2012c). Short-term effects of air pollution on pulse pressure among nonsmoking adults. *Epidemiology* 23: 341-348. <http://dx.doi.org/10.1097/EDE.0b013e3182452f1d>
- [Cheng, MF; Tsai, SS; Yang, CY.](#) (2009a). Air pollution and hospital admissions for myocardial infarction in a tropical city: Kaohsiung, Taiwan. *J Toxicol Environ Health A* 72: 1135-1140. <http://dx.doi.org/10.1080/15287390903091756>
- [Cheng, WC; Liu, CH; Leung, DYC.](#) (2008). Computational formulation for the evaluation of street canyon ventilation and pollutant removal performance. *Atmos Environ* 42: 9041-9051. <http://dx.doi.org/10.1016/j.atmosenv.2008.09.045>

- Cheng, WC; Liu, CH; Leung, DYC. (2009b). On the correlation of air and pollutant exchange for street canyons in combined wind-buoyancy-driven flow. *Atmos Environ* 43: 3682-3690. <http://dx.doi.org/10.1016/j.atmosenv.2009.04.054>
- Chetta, A; Foresi, A; Del Donno, M; Consigli, GF; Bertorelli, G; Pesci, A; Barbee, RA; Olivieri, D. (1996). Bronchial responsiveness to distilled water and methacholine and its relationship to inflammation and remodeling of the airways in asthma. *Am J Respir Crit Care Med* 153: 910-917. <http://dx.doi.org/10.1164/ajrccm.153.3.8630572>
- Cheung, D; Dick, EC; Timmers, MC; de Klerk, EP; Spaan, WJ; Sterk, PJ. (1995). Rhinovirus inhalation causes long-lasting excessive airway narrowing in response to methacholine in asthmatic subjects in vivo. *Am J Respir Crit Care Med* 152: 1490-1496. <http://dx.doi.org/10.1164/ajrccm.152.5.7582282>
- Chimentì, L; Morici, G; Paterno, A; Bonanno, A; Vultaggio, M; Bellia, V; Bonsignore, MR. (2009). Environmental conditions, air pollutants, and airway cells in runners: A longitudinal field study. *J Sports Sci* 27: 925-935. <http://dx.doi.org/10.1080/02640410902946493>
- Chiusolo, M; Cadum, E; Stafoggia, M; Galassi, C; Berti, G; Faustini, A; Bisanti, L; Vigotti, MA; Dessì, MP; Cernigliaro, A; Mallone, S; Pacelli, B; Minerba, S; Simonato, L; Forastiere, F. (2011). Short term effects of nitrogen dioxide on mortality and susceptibility factors in 10 Italian cities: The EpiAir Study. *Environ Health Perspect* 119: 1233-1238. <http://dx.doi.org/10.1289/ehp.1002904>
- Choi, JH; Xu, QS; Park, SY; Kim, JH; Hwang, SS; Lee, KH; Lee, HJ; Hong, YC. (2007). Seasonal variation of effect of air pollution on blood pressure. *J Epidemiol Community Health* 61: 314-318. <http://dx.doi.org/10.1136/jech.2006.049205>
- Choi, Y; Kim, H; Tong, D; Lee, P. (2012). Summertime weekly cycles of observed and modeled NO<sub>x</sub> and O<sub>3</sub> concentrations as a function of satellite-derived ozone production sensitivity and land use types over the Continental United States. *Atmos Chem Phys* 12: 6291-6307. <http://dx.doi.org/10.5194/acp-12-6291-2012>
- Chuang, KJ; Chan, CC; Su, TC; Lee, CT; Tang, CS. (2007a). The effect of urban air pollution on inflammation, oxidative stress, coagulation, and autonomic dysfunction in young adults. *Am J Respir Crit Care Med* 176: 370-376. <http://dx.doi.org/10.1164/rccm.200611-1627OC>
- Chuang, KJ; Chan, CC; Su, TC; Lin, LY; Lee, CT. (2007b). Associations between particulate sulfate and organic carbon exposures and heart rate variability in patients with or at risk for cardiovascular diseases. *J Occup Environ Med* 49: 610-617. <http://dx.doi.org/10.1097/JOM.0b013e318058205b>
- Chuang, KJ; Coull, BA; Zanobetti, A; Suh, H; Schwartz, J; Stone, PH; Litonjua, A; Speizer, FE; Gold, DR. (2008). Particulate air pollution as a risk factor for ST-segment depression in patients with coronary artery disease. *Circulation* 118: 1314-1320. <http://dx.doi.org/10.1161/CIRCULATIONAHA.108.765669>
- Chuang, KJ; Yan, YH; Cheng, TJ. (2010). Effect of air pollution on blood pressure, blood lipids, and blood sugar: A population-based approach. *J Occup Environ Med* 52: 258-262. <http://dx.doi.org/10.1097/JOM.0b013e3181ceff7a>
- Chung, MK; Lao, TT; Ting, YH; Wong, TW; Leung, TY. (2014). Seasonality of fetal trisomy 21 - Have ambient air pollutants played a role? *J Matern Fetal Neonatal Med* 28: 552-557. <http://dx.doi.org/10.3109/14767058.2014.924104>
- Cimorelli, AJ; Perry, SG; Venkatram, A; Weil, JC; Paine, R; Wilson, RB; Lee, RF; Peters, WD; Brode, RW. (2005). AERMOD: A dispersion model for industrial source applications. Part I: General model formulation and boundary layer characterization. *J Appl Meteorol* 44: 682-693. <http://dx.doi.org/10.1175/JAM2227.1>
- Ckless, K; Hodgkins, SR; Ather, JL; Martin, R; Poynter, ME. (2011). Epithelial, dendritic, and CD4(+) T cell regulation of and by reactive oxygen and nitrogen species in allergic sensitization [Review]. *Biochim Biophys Acta* 1810: 10251034. <http://dx.doi.org/10.1016/j.bbagen.2011.03.005>
- Ckless, K; Lampert, A; Reiss, J; Kasahara, D; Poynter, ME; Irvin, CG; Lundblad, LKA; Norton, R; van der Vliet, A; Janssen-Heininger, YMW. (2008). Inhibition of arginase activity enhances inflammation in mice with allergic airway disease, in association with increases in protein S-nitrosylation and tyrosine nitration. *J Immunol* 181: 4255-4264.

- [Clapp, L; Jenkin, M.](#) (2001). Analysis of the relationship between ambient levels of O<sub>3</sub>, NO<sub>2</sub> and NO as a function of NO<sub>x</sub> in the UK. *Atmos Environ* 35: 6391-6405. [http://dx.doi.org/10.1016/S1352-2310\(01\)00378-8](http://dx.doi.org/10.1016/S1352-2310(01)00378-8)
- [Clark, C; Crombie, R; Head, J; van Kamp, I; van Kempen, E; Stansfeld, SA.](#) (2012). Does traffic-related air pollution explain associations of aircraft and road traffic noise exposure on children's health and cognition? A secondary analysis of the United Kingdom sample from the RANCH project. *Am J Epidemiol* 176: 327-337. <http://dx.doi.org/10.1093/aje/kws012>
- [Clark, LP; Millet, DB; Marshall, JD.](#) (2014). National patterns in environmental injustice and inequality: Outdoor NO<sub>2</sub> air pollution in the United States. *PLoS ONE* 9: e94431. <http://dx.doi.org/10.1371/journal.pone.0094431>
- [Clark, NA; Demers, PA; Karr, CJ; Koehoorn, M; Lencar, C; Tamburic, L; Brauer, M.](#) (2010). Effect of early life exposure to air pollution on development of childhood asthma. *Environ Health Perspect* 118: 284-290. <http://dx.doi.org/10.1289/ehp.0900916>
- [Clary-Meinesz, C; Mouroux, J; Huitorel, P; Cosson, J; Schoevaert, D; Blaive, B.](#) (1997). Ciliary beat frequency in human bronchi and bronchioles. *Chest* 111: 692-697. <http://dx.doi.org/10.1378/chest.111.3.692>
- [Clements, AL; Jia, Y; Denbleyker, A; McDonald-Buller, E; Fraser, MP; Allen, DT; Collins, DR; Michel, E; Pudota, J; Sullivan, D; Zhu, Y.](#) (2009). Air pollutant concentrations near three Texas roadways, part II: Chemical characterization and transformation of pollutants. *Atmos Environ* 43: 4523-4534. <http://dx.doi.org/10.1016/j.atmosenv.2009.06.044>
- [Cleveland, WS; Graedel, TE; Kleiner, B; Warner, JL.](#) (1974). Sunday and workday variations in photochemical air pollutants in New Jersey and New York. *Science* 186: 1037-1038. <http://dx.doi.org/10.1126/science.186.4168.1037>
- [Clougherty, JE; Kheirbek, I; Eisl, HM; Ross, Z; Pezeshki, G; Gorczynski, JE; Johnson, S; Markowitz, S; Kass, D; Matte, T.](#) (2013). Intra-urban spatial variability in wintertime street-level concentrations of multiple combustion-related air pollutants: The New York City Community Air Survey (NYCCAS). *J Expo Sci Environ Epidemiol* 23: 232-240. <http://dx.doi.org/10.1038/jes.2012.125>
- [Clougherty, JE; Levy, JI; Kubzansky, LD; Ryan, PB; Suglia, SF; Canner, MJ; Wright, RJ.](#) (2007). Synergistic effects of traffic-related air pollution and exposure to violence on urban asthma etiology. *Environ Health Perspect* 115: 1140-1146. <http://dx.doi.org/10.1289/ehp.9863>
- [Cockcroft, DW.](#) (2010). Direct challenge tests. Airway hyperresponsiveness in asthma: Its measurement and clinical significance [Review]. *Chest* 138: 18S-24S. <http://dx.doi.org/10.1378/chest.10-0088>
- [Cockcroft, DW; Berscheid, BA; Murdock, KY.](#) (1983). Unimodal distribution of bronchial responsiveness to inhaled histamine in a random human population. *Chest* 83: 751-754. <http://dx.doi.org/10.1378/chest.83.5.751>
- [Cockcroft, DW; Davis, BE.](#) (2006a). Airway hyperresponsiveness as a determinant of the early asthmatic response to inhaled allergen [Review]. *J Asthma* 43: 175-178. <http://dx.doi.org/10.1080/02770900600566348>
- [Cockcroft, DW; Davis, BE.](#) (2006b). The bronchoprotective effect of inhaling methacholine by using total lung capacity inspirations has a marked influence on the interpretation of the test result [Review]. *J Allergy Clin Immunol* 117: 1244-1248. <http://dx.doi.org/10.1016/j.jaci.2006.02.038>
- [Cockcroft, DW; Davis, BE.](#) (2006c). Mechanisms of airway hyperresponsiveness [Review]. *J Allergy Clin Immunol* 118: 551-559. <http://dx.doi.org/10.1016/j.jaci.2006.07.012>
- [Cockcroft, DW; Davis, BE; Todd, DC; Smycniuk, AJ.](#) (2005). Methacholine challenge: Comparison of two methods. *Chest* 127: 839-844. <http://dx.doi.org/10.1378/chest.127.3.839>
- [Cohan, A; Wu, J; Dabdub, D.](#) (2011). High-resolution pollutant transport in the San Pedro Bay of California. *Atmos Pollut Res* 2: 237-246. <http://dx.doi.org/10.5094/APR.2011.030>

- Cohen, MA; Adar, SD; Allen, RW; Avol, E; Curl, CL; Gould, T; Hardie, D; Ho, A; Kinney, P; Larson, TV; Sampson, P; Sheppard, L; Stukovsky, KD; Swan, SS; Liu, LJ; Kaufman, JD. (2009). Approach to estimating participant pollutant exposures in the multi-ethnic study of atherosclerosis and air pollution (MESA Air). *Environ Sci Technol* 43: 4687-4693. <http://dx.doi.org/10.1021/es8030837>
- Colais, P; Faustini, A; Stafoggia, M; Berti, G; Bisanti, L; Cadum, E; Cernigliaro, A; Mallone, S; Pacelli, B; Serinelli, M; Simonato, L; Vigotti, MA; Forastiere, F. (2012). Particulate air pollution and hospital admissions for cardiac diseases in potentially sensitive subgroups. *Epidemiology* 23: 473-481. <http://dx.doi.org/10.1097/EDE.0b013e31824d5a85>
- Comhair, SAA; Erzurum, SC. (2010). Redox control of asthma: Molecular mechanisms and therapeutic opportunities [Review]. *Antioxid Redox Signal* 12: 93-124. <http://dx.doi.org/10.1089/ARS.2008.2425>
- Connell, DP; Withum, JA; Winter, SE; Statnick, RM; Bilonick, RA. (2005). The Steubenville Comprehensive Air Monitoring Program (SCAMP): Associations among fine particulate matter, co-pollutants, and meteorological conditions. *J Air Waste Manag Assoc* 55: 481-496. <http://dx.doi.org/10.1080/10473289.2005.10464631>
- Connor, LM; Ballinger, CA; Albrecht, TB; Postlethwait, EM. (2004). Interfacial phospholipids inhibit ozone reactive absorption-mediated cytotoxicity in vitro. *Am J Physiol* 286: L1169-L1178. <http://dx.doi.org/10.1152/ajplung.00397.2003>
- Connor, LM; Bidani, A; Goerke, J; Clements, JA; Postlethwait, EM. (2001). NO<sub>2</sub> interfacial transfer is reduced by phospholipid monolayers. *J Appl Physiol* 91: 2024-2034.
- Coogan, PF; White, LF; Jerrett, M; Brook, RD; Su, JG; Seto, E; Burnett, R; Palmer, JR; Rosenberg, L. (2012). Air pollution and incidence of hypertension and diabetes mellitus in black women living in Los Angeles. *Circulation* 125: 767-772. <http://dx.doi.org/10.1161/CIRCULATIONAHA.111.052753>
- Corbett, JJ; Fischbeck, PS; Pandis, SN. (1999). Global nitrogen and sulfur inventories for oceangoing ships. *J Geophys Res Atmos* 104: 3457-3470. <http://dx.doi.org/10.1029/1998JD100040>
- Correia-Deur, J; Claudio, L; Imazawa, AT; Eluf-Neto, J. (2012). Variations in peak expiratory flow measurements associated to air pollution and allergic sensitization in children in Sao Paulo, Brazil. *Am J Ind Med* 55: 1087-1098. <http://dx.doi.org/10.1002/ajim.22060>
- Cosby, K; Partovi, KS; Crawford, JH; Patel, RP; Reiter, CD; Martyr, S; Yang, BK; Waclawiw, MA; Zalos, G; Xu, X; Huang, KT; Shields, H; Kim-Shapiro, DB; Schechter, AN; Cannon, RO; Gladwin, MT. (2003). Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. *Nat Med* 9: 1498-1505. <http://dx.doi.org/10.1038/nm954>
- Cowie, CT; Rose, N; Gillett, R; Walter, S; Marks, GB. (2012). Redistribution of traffic related air pollution associated with a new road tunnel. *Environ Sci Technol* 46: 2918-2927. <http://dx.doi.org/10.1021/es202686r>
- Crapo, JD; Barry, BE; Chang, LY; Mercer, RR. (1984). Alterations in lung structure caused by inhalation of oxidants. *J Toxicol Environ Health* 13: 301-321. <http://dx.doi.org/10.1080/15287398409530500>
- Crooks, J; Isakov, V. (2013). A wavelet-based approach to blending observations with deterministic computer models to resolve the intraurban air pollution field. *J Air Waste Manag Assoc* 63: 1369-1385. <http://dx.doi.org/10.1080/10962247.2012.758061>
- Crosley, DR. (1996). NO<sub>y</sub> blue ribbon panel. *J Geophys Res* 101: 2049-2052. <http://dx.doi.org/10.1029/95JD02276>
- Crouse, DL; Goldberg, MS; Ross, NA. (2009a). A prediction-based approach to modelling temporal and spatial variability of traffic-related air pollution in Montreal, Canada. *Atmos Environ* 43: 5075-5084. <http://dx.doi.org/10.1016/j.atmosenv.2009.06.040>
- Crouse, DL; Goldberg, MS; Ross, NA; Chen, H; Labrèche, F. (2010). Postmenopausal breast cancer is associated with exposure to traffic-related air pollution in Montreal, Canada: A casecontrol study. *Environ Health Perspect* 118: 1578-1583. <http://dx.doi.org/10.1289/ehp.1002221>

- [Crouse, DL; Ross, NA; Goldberg, MS.](#) (2009b). Double burden of deprivation and high concentrations of ambient air pollution at the neighbourhood scale in Montreal, Canada. *Soc Sci Med* 69: 971-981. <http://dx.doi.org/10.1016/j.socscimed.2009.07.010>
- [Cui, H; Yao, R; Xu, X; Xin, C; Yang, J.](#) (2011). A tracer experiment study to evaluate the CALPUFF real time application in a near-field complex terrain setting. *Atmos Environ* 45: 7525-7532. <http://dx.doi.org/10.1016/j.atmosenv.2011.08.041>
- [Cuinica, LG; Abreu, I; Esteves da Silva, J.](#) (2014). Effect of air pollutant NO<sub>2</sub> on *Betula pendula*, *Ostrya carpinifolia* and *Carpinus betulus* pollen fertility and human allergenicity. *Environ Pollut* 186: 50-55. <http://dx.doi.org/10.1016/j.envpol.2013.12.001>
- [D'Ippoliti, D; Forastiere, F; Ancona, C; Agabiti, N; Fusco, D; Michelozzi, P; Perucci, CA.](#) (2003). Air pollution and myocardial infarction in Rome: a case-crossover analysis. *Epidemiology* 14: 528-535. <http://dx.doi.org/10.1097/01.ede.0000082046.22919.72>
- [Dadvand, P; Basagaña, X; Figueras, F; Martinez, D; Beelen, R; Cirach, M; de Nazelle, A; Hoek, G; Ostro, B; Nieuwenhuijsen, MJ.](#) (2014a). Air pollution and preterm premature rupture of membranes: a spatiotemporal analysis. *Am J Epidemiol* 179: 200-207. <http://dx.doi.org/10.1093/aje/kwt240>
- [Dadvand, P; Figueras, F; Basagaña, X; Beelen, R; Martinez, D; Cirach, M; Schembari, A; Hoek, G; Brunekreef, B; Nieuwenhuijsen, MJ.](#) (2013). Ambient air pollution and preeclampsia: A spatiotemporal analysis. *Environ Health Perspect* 121: 1365-1371. <http://dx.doi.org/10.1289/ehp.1206430>
- [Dadvand, P; Nieuwenhuijsen, MJ; Agustí, A; de Batlle, J; Benet, M; Beelen, R; Cirach, M; Martinez, D; Hoek, G; Basagaña, X; Ferrer, A; Ferrer, J; Rodriguez-Roisin, R; Sauleda, J; Guerra, S; Antó, JM; Garcia-Aymerich, J.](#) (2014b). Air pollution and biomarkers of systemic inflammation and tissue repair in COPD patients. *Eur Respir J* 44: 603-613. <http://dx.doi.org/10.1183/09031936.00168813>
- [Dadvand, P; Ostro, B; Figueras, F; Foraster, M; Basagaña, X; Valentín, A; Martinez, D; Beelen, R; Cirach, M; Hoek, G; Jerrett, M; Brunekreef, B; Nieuwenhuijsen, MJ.](#) (2014c). Residential proximity to major roads and term low birth weight: The roles of air pollution, heat, noise, and road-adjacent trees. *Epidemiology* 25: 518-525. <http://dx.doi.org/10.1097/EDE.000000000000107>
- [Daiber, A; Muenzel, T.](#) (2012). Increased circulating levels of 3-nitrotyrosine autoantibodies marker for or maker of cardiovascular disease? [Editorial]. *Circulation* 126: 2371-2373. <http://dx.doi.org/10.1161/CIRCULATIONAHA.112.143214>
- [Dales, R; Burnett, RT; Smith-Doiron, M; Stieb, DM; Brook, JR.](#) (2004). Air pollution and sudden infant death syndrome. *Pediatrics* 113: e628-e631.
- [Dales, R; Chen, L; Frescura, AM; Liu, L; Villeneuve, PJ.](#) (2009a). Acute effects of outdoor air pollution on forced expiratory volume in 1 s: A panel study of schoolchildren with asthma. *Eur Respir J* 34: 316-323. <http://dx.doi.org/10.1183/09031936.00138908>
- [Dales, R; Kauri, LM; Cakmak, S; Mahmud, M; Weichenthal, SA; Van Ryswyk, K; Kumarathasan, P; Thomson, E; Vincent, R; Broad, G; Liu, L.](#) (2013). Acute changes in lung function associated with proximity to a steel plant: A randomized study. *Environ Int* 55: 15-19. <http://dx.doi.org/10.1016/j.envint.2013.01.014>
- [Dales, R; Wheeler, A; Mahmud, M; Frescura, AM; Smith-Doiron, M; Nethery, E; Liu, L.](#) (2008). The influence of living near roadways on spirometry and exhaled nitric oxide in elementary schoolchildren. *Environ Health Perspect* 116: 1423-1427. <http://dx.doi.org/10.1289/ehp.10943>
- [Dales, RE; Cakmak, S; Doiron, MS.](#) (2006). Gaseous air pollutants and hospitalization for respiratory disease in the neonatal period. *Environ Health Perspect* 114: 1751-1754.
- [Dales, RE; Cakmak, S; Vidal, CB.](#) (2009b). Air pollution and hospitalization for headache in Chile. *Am J Epidemiol* 170: 1057-1066. <http://dx.doi.org/10.1093/aje/kwp217>
- [Dales, RE; Cakmak, S; Vidal, CB.](#) (2010). Air pollution and hospitalization for venous thromboembolic disease in Chile. *J Thromb Haemost* 8: 669-674. <http://dx.doi.org/10.1111/j.1538-7836.2010.03760.x>

- [Dall'Osto, M; Thorpe, A; Beddows, DCS; Harrison, RM; Barlow, JF; Dunbar, T; Williams, PI; Coe, H.](#) (2011). Remarkable dynamics of nanoparticles in the urban atmosphere. *Atmos Chem Phys* 11: 6623-6637. <http://dx.doi.org/10.5194/acp-11-6623-2011>
- [Dallmann, TR; Harley, RA.](#) (2010). Evaluation of mobile source emission trends in the United States. *J Geophys Res* 115: D14305. <http://dx.doi.org/10.1029/2010JD013862>
- [Darrow, LA; Klein, M; Flanders, WD; Waller, LA; Correa, A; Marcus, M; Mulholland, JA; Russell, AG; Tolbert, PE.](#) (2009). Ambient air pollution and preterm birth: A time-series analysis. *Epidemiology* 20: 689-698. <http://dx.doi.org/10.1097/EDE.0b013e3181a7128f>
- [Darrow, LA; Klein, M; Sarnat, JA; Mulholland, JA; Strickland, MJ; Sarnat, SE; Russell, AG; Tolbert, PE.](#) (2011a). The use of alternative pollutant metrics in time-series studies of ambient air pollution and respiratory emergency department visits. *J Expo Sci Environ Epidemiol* 21: 10-19. <http://dx.doi.org/10.1038/jes.2009.49>
- [Darrow, LA; Klein, M; Strickland, MJ; Mulholland, JA; Tolbert, PE.](#) (2011b). Ambient air pollution and birth weight in full-term infants in Atlanta, 1994-2004. *Environ Health Perspect* 119: 731-737. <http://dx.doi.org/10.1289/ehp.1002785>
- [Davies, HW; Vlaanderen, JJ; Henderson, SB; Brauer, M.](#) (2009). Correlation between co-exposures to noise and air pollution from traffic sources. *Occup Environ Med* 66: 347-350. <http://dx.doi.org/10.1136/oem.2008.041764>
- [Davies, RJ; Rusznak, C; Calderón, MA; Wang, JH; Abdelaziz, MM; Devalia, JL.](#) (1997). Allergen-irritant interaction and the role of corticosteroids [Review]. *Allergy* 52: 59-65. <http://dx.doi.org/10.1111/j.1398-9995.1997.tb04873.x>
- [Davis, JK; Davidson, M; Schoeb, TR.](#) (1991). Murine respiratory mycoplasmosis: A model to study effects of oxidants (pp. 1-29; discussion 31-43). Health Effects Institute. <http://pubs.healtheffects.org/view.php?id=65>
- [Davis, JK; Davidson, MK; Schoeb, TR; Lindsey, JR.](#) (1992). Decreased intrapulmonary killing of *Mycoplasma pulmonis* after short-term exposure to NO<sub>2</sub> is associated with damaged alveolar macrophages. *Am Rev Respir Dis* 145: 406-411. [http://dx.doi.org/10.1164/ajrccm/145.2\\_Pt\\_1.406](http://dx.doi.org/10.1164/ajrccm/145.2_Pt_1.406)
- [Dawson, SV; Schenker, MB.](#) (1979). Health effects of inhalation of ambient concentrations of nitrogen dioxide [Editorial]. *Am Rev Respir Dis* 120: 281-292.
- [de Burbure, CY; Heilier, JF; Nève, J; Becker, A; Albrecht, C; Borm, PJA; Gromadzinska, J; Wasowicz, W; Ryzdzynski, K; Bernard, AM.](#) (2007). Lung permeability, antioxidant status, and NO<sub>2</sub> inhalation: A selenium supplementation study in rats. *J Toxicol Environ Health A* 70: 284-294. <http://dx.doi.org/10.1080/15287390600884875>
- [de Gouw, JA; Warneke, C; Parrish, DD; Holloway, JS; Trainer, M; Fehsenfeld, FC.](#) (2003). Emission sources and ocean uptake of acetonitrile (CH<sub>3</sub>CN) in the atmosphere. *J Geophys Res* 108: 4329. <http://dx.doi.org/10.1029/2002JD002897>
- [de Kluizenaar, Y; van Lenthe, FJ; Visschedijk, AJ; Zandveld, PY; Miedema, HM; Mackenbach, JP.](#) (2013). Road traffic noise, air pollution components and cardiovascular events. *Noise Health* 15: 388-397. <http://dx.doi.org/10.4103/1463-1741.121230>
- [De Santis, F; Allegrini, I; Fazio, MC; Pasella, D.](#) (1996). Characterization of indoor air quality in the Church of San Luigi Dei Francesi, Rome, Italy. *Int J Environ Anal Chem* 64: 71-81. <http://dx.doi.org/10.1080/03067319608028336>
- [de Winter-Sorkina, R; Cassee, FR.](#) (2002). From concentration to dose: Factors influencing airborne particulate matter deposition in humans and rats (pp. 1-36). (RIVM Report 650010031). Bilthoven, Netherlands: National Institute for Public Health and the Environment. [http://www.rivm.nl/en/Documents\\_and\\_publications/Scientific/Reports/2003/februari/From\\_concentration\\_to\\_dose\\_factors\\_influencing\\_airborne\\_particulate\\_matter\\_deposition\\_in\\_humans\\_and\\_rats?sp=cml2bXE9ZmFsc2U7c2VhemNoYmFzZT01MDI5MDtyaXZtcT1mYWxzZTs=&pagenr=5030](http://www.rivm.nl/en/Documents_and_publications/Scientific/Reports/2003/februari/From_concentration_to_dose_factors_influencing_airborne_particulate_matter_deposition_in_humans_and_rats?sp=cml2bXE9ZmFsc2U7c2VhemNoYmFzZT01MDI5MDtyaXZtcT1mYWxzZTs=&pagenr=5030)

- Debry, E; Mallet, V. (2014). Ensemble forecasting with machine learning algorithms for ozone, nitrogen dioxide and PM10 on the Prev'Air platform. *Atmos Environ* 91: 71-84. <http://dx.doi.org/10.1016/j.atmosenv.2014.03.049>
- DeCastro, BR; Sax, AN; Chillrud, SN; Kinney, PL; Spengler, JD. (2007). Modeling time-location patterns of inner-city high school students in New York and Los Angeles using a longitudinal approach with generalized estimating equations. *J Expo Sci Environ Epidemiol* 17: 233-247. <http://dx.doi.org/10.1038/sj.jes.7500504>
- Deguen, S; Zmirou-Navier, D. (2010). Social inequalities resulting from health risks related to ambient air quality--A European review [Review]. *Eur J Public Health* 20: 27-35. <http://dx.doi.org/10.1093/eurpub/ckp220>
- Delamater, PL; Finley, AO; Banerjee, S. (2012). An analysis of asthma hospitalizations, air pollution, and weather conditions in Los Angeles County, California. *Sci Total Environ* 425: 110-118. <http://dx.doi.org/10.1016/j.scitotenv.2012.02.015>
- Delfino, RJ. (2006). Think globally, breathe locally [Editorial]. *Thorax* 61: 184-185. <http://dx.doi.org/10.1136/thx.2005.047894>
- Delfino, RJ; Gillen, DL; Tjoa, T; Staimer, N; Polidori, A; Arhami, M; Sioutas, C; Longhurst, J. (2011). Electrocardiographic ST-segment depression and exposure to traffic-related aerosols in elderly subjects with coronary artery disease. *Environ Health Perspect* 119: 196-202. <http://dx.doi.org/10.1289/ehp.1002372>
- Delfino, RJ; Gone, H; Linn, WS; Pellizzari, ED; Hu, Y. (2003). Asthma symptoms in Hispanic children and daily ambient exposures to toxic and criteria air pollutants. *Environ Health Perspect* 111: 647-656.
- Delfino, RJ; Staimer, N; Gillen, D; Tjoa, T; Sioutas, C; Fung, K; George, SC; Kleinman, MT. (2006). Personal and ambient air pollution is associated with increased exhaled nitric oxide in children with asthma. *Environ Health Perspect* 114: 1736-1743.
- Delfino, RJ; Staimer, N; Tjoa, T; Arhami, M; Polidori, A; Gillen, DL; George, SC; Shafer, MM; Schauer, JJ; Sioutas, C. (2010). Associations of primary and secondary organic aerosols with airway and systemic inflammation in an elderly panel cohort. *Epidemiology* 21: 892-902. <http://dx.doi.org/10.1097/EDE.0b013e3181f20e6c>
- Delfino, RJ; Staimer, N; Tjoa, T; Gillen, D; Kleinman, MT; Sioutas, C; Cooper, D. (2008a). Personal and ambient air pollution exposures and lung function decrements in children with asthma. *Environ Health Perspect* 116: 550-558. <http://dx.doi.org/10.1289/ehp.10911>
- Delfino, RJ; Staimer, N; Tjoa, T; Gillen, DL; Polidori, A; Arhami, M; Kleinman, MT; Vaziri, ND; Longhurst, J; Sioutas, C. (2009). Air pollution exposures and circulating biomarkers of effect in a susceptible population: Clues to potential causal component mixtures and mechanisms. *Environ Health Perspect* 117: 1232-1238. <http://dx.doi.org/10.1289/ehp.0800194>
- Delfino, RJ; Staimer, N; Tjoa, T; Gillen, DL; Schauer, JJ; Shafer, MM. (2013). Airway inflammation and oxidative potential of air pollutant particles in a pediatric asthma panel. *J Expo Sci Environ Epidemiol* 23: 466-473. <http://dx.doi.org/10.1038/jes.2013.25>
- Delfino, RJ; Staimer, N; Tjoa, T; Polidori, A; Arhami, M; Gillen, DL; Kleinman, MT; Vaziri, ND; Longhurst, J; Zaldivar, F; Sioutas, C. (2008b). Circulating biomarkers of inflammation, antioxidant activity, and platelet activation are associated with primary combustion aerosols in subjects with coronary artery disease. *Environ Health Perspect* 116: 898-906. <http://dx.doi.org/10.1289/ehp.11189>
- Delfino, RJ; Zeiger, RS; Seltzer, JM; Street, DH; McLaren, CE. (2002). Association of asthma symptoms with peak particulate air pollution and effect modification by anti-inflammatory medication use. *Environ Health Perspect* 110: A607-A617.
- Delgado-Saborit, JM. (2012). Use of real-time sensors to characterise human exposures to combustion related pollutants. *J Environ Monit* 14: 1824-1837. <http://dx.doi.org/10.1039/c2em10996d>

- [DeMarini, DM; Shelton, ML; Kohan, MJ; Hudgens, EE; Kleindienst, TE; Ball, LM; Walsh, D; de Boer, JG; Lewis-Bevan, L; Rabinowitz, J. R.; Claxton, LD; Lewtas, J.](#) (2000). Mutagenicity in lung of Big Blue(R) mice and induction of tandem-base substitutions in Salmonella by the air pollutant peroxyacetyl nitrate (PAN): Predicted formation of intrastrand cross-links. *Mutat Res-Fundam Mol Mech Mutagen* 457: 41-55. [http://dx.doi.org/10.1016/S0027-5107\(00\)00121-4](http://dx.doi.org/10.1016/S0027-5107(00)00121-4)
- [Denman, KL; Brasseur, G; Chidthaisong, A; Ciais, P; Cox, PM; Dickinson, RE; Hauglustaine, D; Heinze, C; Holland, E; Jacob, D; Lohmann, U; Ramachandran, S; da Silva Dias, PL; Wofsy, SC; Zhang, X.](#) (2007). Couplings between changes in the climate system and biogeochemistry. In *Climate change 2007: The physical science basis* (pp. 499-587). New York, NY: Cambridge University Press. [http://www.ipcc.ch/publications\\_and\\_data/publications\\_ipcc\\_fourth\\_assessment\\_report\\_wg1\\_report\\_the\\_physical\\_science\\_basis.htm](http://www.ipcc.ch/publications_and_data/publications_ipcc_fourth_assessment_report_wg1_report_the_physical_science_basis.htm)
- [Dennekamp, M; Akram, M; Abramson, MJ; Tonkin, A; Sim, MR; Fridman, M; Erbas, B.](#) (2010). Outdoor air pollution as a trigger for out-of-hospital cardiac arrests. *Epidemiology* 21: 494-500. <http://dx.doi.org/10.1097/EDE.0b013e3181e093db>
- [Desqueyroux, H; Pujet, JC; Prosper, M; Le Moullec, Y; Momas, I.](#) (2002). Effects of air pollution on adults with chronic obstructive pulmonary disease. *Arch Environ Occup Health* 57: 554-560. <http://dx.doi.org/10.1080/00039890209602088>
- [Devalia, JL; Rusznak, C; Herdman, MJ; Trigg, CJ; Tarraf, H; Davies, RJ.](#) (1994). Effect of nitrogen-dioxide and sulfur-dioxide on airway response of mild asthmatic-patients to allergen inhalation. *Lancet* 344: 1668-1671. [http://dx.doi.org/10.1016/S0140-6736\(94\)90458-8](http://dx.doi.org/10.1016/S0140-6736(94)90458-8)
- [Devlin, RB; Horstman, DP; Gerrity, TR; Becker, S; Madden, MC.](#) (1999). Inflammatory response in humans exposed to 2.0 PPM nitrogen dioxide. *Inhal Toxicol* 11: 89-109. <http://dx.doi.org/10.1080/089583799197195>
- [Di Giovanni, V; Cagiano, R; Carratù, MR; De Salvia, MA; Giustino, A; Cuomo, V.](#) (1994). Alterations in the ontogeny of rat pup ultrasonic vocalization produced by prenatal exposure to nitrogen dioxide. *Psychopharmacology* 116: 423-427.
- [di Sabatino, S; Kastner-Klein, P; Berkowicz, R; Britter, RE; Fedorovich.](#) (2003). The modelling of turbulence from traffic in urban dispersion models Part I: Theoretical considerations. *Environ Fluid Mech* 3: 129-143. <http://dx.doi.org/10.1023/A:1022063608237>
- [Diette, GB; Hansel, NN; Buckley, TJ; Curtin-Brosnan, J; Eggleston, PA; Matsui, EC; McCormack, MC; Williams, DL; Breysse, PN.](#) (2007). Home indoor pollutant exposures among inner-city children with and without asthma. *Environ Health Perspect* 115: 1665-1669. <http://dx.doi.org/10.1289/ehp.10088>
- [Diez Roux, AV; Mair, C.](#) (2010). Neighborhoods and health. *Ann N Y Acad Sci* 1186: 125-145. <http://dx.doi.org/10.1111/j.1749-6632.2009.05333.x>
- [Dijkema, MB; Gehring, U; van Strien, RT; van der Zee, SC; Fischer, P; Hoek, G; Brunekreef, B.](#) (2011a). A comparison of different approaches to estimate small-scale spatial variation in outdoor NO concentrations. *Environ Health Perspect* 119: 670-675. <http://dx.doi.org/10.1289/ehp.0901818>
- [Dijkema, MBA; Mallant, SF; Gehring, U; van den Hurk, K; Alsema, M; van Strien, RT; Fischer, PH; Nijpels, G; Stehouwer, CDA; Hoek, G; Dekker, JM; Brunekreef, B.](#) (2011b). Long-term exposure to traffic-related air pollution and type 2 diabetes prevalence in a cross-sectional screening-study in the Netherlands. *Environ Health* 10: 76. <http://dx.doi.org/10.1186/1476-069X-10-76>
- [Dimakopoulou, K; Samoli, E; Beelen, R; Stafoggia, M; Andersen, ZJ; Hoffmann, B; Fischer, P; Nieuwenhuijsen, M; Vineis, P; Xun, W; Hoek, G; Raaschou-Nielsen, O; Oudin, A; Forsberg, B; Modig, L; Jousilahti, P; Lanki, T; Turunen, A; Oftedal, B; Nafstad, P; Schwarze, PE; Penell, J; Fratiglioni, L; Andersson, N; Pedersen, N; Korek, M; De Faire, U; Eriksen, KT; Tjønneland, A; Becker, T; Wang, M; Bueno-De-Mesquita, B; Tsai, MY; Eeftens, M; Peeters, PH; Meliefste, K; Marcon, A; Krämer, U; Kuhlbusch, TA; Vossoughi, M; Key, T; de Hoogh, K; Hampel, R; Peters, A; Heinrich, J; Weinmayr, G; Concini, H; Nagel, G; Ineichen, A; Jacquemin, B; Stempfelet, M; Vilier, A; Ricceri, F; Sacerdote, C; Pedeli, X; Katsoulis, M; Trichopoulou, A; Brunekreef, B; Katsouyanni, K.](#) (2014). Air pollution and nonmalignant respiratory mortality in 16 cohorts within the ESCAPE project. *Am J Respir Crit Care Med* 189: 684-696. <http://dx.doi.org/10.1164/rccm.201310-1777OC>

- [Dimeo, MJ; Glenn, MG; Holtzman, MJ; Sheller, JR; Nadel, JA; Boushey, HA.](#) (1981). Threshold concentration of ozone causing an increase in bronchial reactivity in humans and adaptation with repeated exposures. *Am Rev Respir Dis* 124: 245-248.
- [Dimitriou, K; Kassomenos, P.](#) (2014). Local and regional sources of fine and coarse particulate matter based on traffic and background monitoring. *Theor Appl Climatol* 116: 413-433. <http://dx.doi.org/10.1007/s00704-013-0961-6>
- [Dimitroulopoulou, C; Ashmore, MR; Hill, MTR; Byrne, MA; Kinnersley, R.](#) (2006). INDAIR: A probabilistic model of indoor air pollution in UK homes. *Atmos Environ* 40: 6362-6379. <http://dx.doi.org/10.1016/j.atmosenv.2006.05.047>
- [Dionisio, KL; Baxter, LK; Chang, HH.](#) (2014). An empirical assessment of exposure measurement error and effect attenuation in bipollutant epidemiologic models. *Environ Health Perspect* 122: 1216-1224. <http://dx.doi.org/10.1289/ehp.1307772>
- [Dionisio, KL; Isakov, V; Baxter, LK; Sarnat, JA; Sarnat, SE; Burke, J; Rosenbaum, A; Graham, SE; Cook, R; Mulholland, J; Oezkaynak, H.](#) (2013). Development and evaluation of alternative approaches for exposure assessment of multiple air pollutants in Atlanta, Georgia. *J Expo Sci Environ Epidemiol* 23: 581-592. <http://dx.doi.org/10.1038/jes.2013.59>
- [Dockery, DW; Pope, CA, III; Xu, X; Spengler, JD; Ware, JH; Fay, ME; Ferris, BG, Jr; Speizer, FE.](#) (1993). An association between air pollution and mortality in six US cities. *N Engl J Med* 329: 1753-1759. <http://dx.doi.org/10.1056/NEJM199312093292401>
- [Dominici, F; McDermott, A; Daniels, M; Zeger, SL; Samet, JM.](#) (2003). Mortality among residents of 90 cities [HEI]. In *Revised analyses of time-series studies of air pollution and health* (pp. 9-24). Boston, MA: Health Effects Institute. <http://pubs.healtheffects.org/view.php?id=4>
- [Dong, G; Qian, Z; Wang, J; Chen, W; Ma, W; Trevathan, E; Xaverius, PK; DeClue, R; Wiese, A; Langston, M; Liu, MM; Wang, D; Ren, W.](#) (2013a). Associations between ambient air pollution and prevalence of stroke and cardiovascular diseases in 33 Chinese communities. *Atmos Environ* 77: 968-973. <http://dx.doi.org/10.1016/j.atmosenv.2013.06.034>
- [Dong, GH; Chen, T; Liu, MM; Wang, D; Ma, YN; Ren, WH; Lee, YL; Zhao, YD; He, QC.](#) (2011). Gender differences and effect of air pollution on asthma in children with and without allergic predisposition: Northeast Chinese children health study. *PLoS ONE* 6: e22470. <http://dx.doi.org/10.1371/journal.pone.0022470>
- [Dong, GH; Qian, ZM; Xaverius, PK; Trevathan, E; Maalouf, S; Parker, J; Yang, L; Liu, MM; Wang, D; Ren, WH; Ma, W; Wang, J; Zelicoff, A; Fu, Q; Simckes, M.](#) (2013b). Association between long-term air pollution and increased blood pressure and hypertension in China. *Hypertension* 61: 578-584. <http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.00003>
- [Dong, GH; Zhang, P; Sun, B; Zhang, L; Chen, X; Ma, N; Yu, F; Guo, H; Huang, H; Lee, YL; Tang, N; Chen, J.](#) (2012). Long-term exposure to ambient air pollution and respiratory disease mortality in Shenyang, China: A 12-year population-based retrospective cohort study. *Respiration* 84: 360-368. <http://dx.doi.org/10.1159/000332930>
- [Dons, E; Van Poppel, M; Int Panis, L; De Prins, S; Berghmans, P; Koppen, G; Matheussen, C.](#) (2014). Land use regression models as a tool for short, medium and long term exposure to traffic related air pollution. *Sci Total Environ* 476-477: 378-386. <http://dx.doi.org/10.1016/j.scitotenv.2014.01.025>
- [Douglas, GJ; Price, JF; Page, CP.](#) (1995). The effect of prolonged exposure to NO<sub>2</sub> from birth on airways responsiveness in rabbits sensitized at birth. *Eur Respir J* 8: 246-252. <http://dx.doi.org/10.1183/09031936.95.08020246>
- [Dowell, AR; Kilburn, KH; Pratt, PC.](#) (1971). Short-term exposure to nitrogen dioxide: Effects on pulmonary ultrastructure, compliance, and the surfactant system. *Arch Intern Med* 128: 74-80. <http://dx.doi.org/10.1001/archinte.1971.00310190078009>
- [Drahl, C.](#) (2009). Probing for in-body ozone. *Chem Eng News* 87: 40-42. <http://dx.doi.org/10.1021/cen-v087n025.p040>

- Drechsler-Parks, DM. (1995). Cardiac output effects of O<sub>3</sub> and NO<sub>2</sub> exposure in healthy older adults. *Toxicol Ind Health* 11: 99-109. <http://dx.doi.org/10.1177/074823379501100109>
- Dressel, H; Müller, F; Fischer, R; Römmelt, H; Hohlfeld, JM; Behr, J; Huber, RM; Nowak, D; Jörres, RA. (2010). Independent information of nonspecific biomarkers in exhaled breath condensate. *Respiration* 80: 401-409. <http://dx.doi.org/10.1159/000319945>
- Dryden, DM; Spooner, CH; Stickland, MK; Vandermeer, B; Tjosvold, L; Bialy, L; Wong, K; Rowe, BH. (2010). Exercise-induced bronchoconstriction and asthma. (AHRQ Publication No. 10-E001). Rockville, MD: Agency for Healthcare Research and Quality. <http://www.ahrq.gov/research/findings/evidence-based-reports/eibeia-evidence-report.pdf>
- Du, X; Fu, L; Ge, W; Zhang, S; Wang, H. (2011). Exposure of taxi drivers and office workers to traffic-related pollutants in Beijing: A note. *Transport Res Transport Environ* 16: 78-81. <http://dx.doi.org/10.1016/j.trd.2010.08.002>
- Duan, X; Buckpitt, AR; Pinkerton, KE; Ji, C; Plopper, CG. (1996). Ozone-induced alterations in glutathione in lung subcompartments of rats and monkeys. *Am J Respir Cell Mol Biol* 14: 70-75. <http://dx.doi.org/10.1165/ajrcmb.14.1.8534488>
- Duan, X; Buckpitt, AR; Plopper, CG. (1993). Variation in antioxidant enzyme activities in anatomic subcompartments within rat and rhesus monkey lung. *Toxicol Appl Pharmacol* 123: 73-82. <http://dx.doi.org/10.1006/taap.1993.1223>
- Ducret-Stich, RE; Tsai, MY; Ragettli, MS; Ineichen, A; Kuenzli, N; Phuleria, HC. (2013). Role of highway traffic on spatial and temporal distributions of air pollutants in a Swiss Alpine valley. *Sci Total Environ* 456-457: 50-60. <http://dx.doi.org/10.1016/j.scitotenv.2013.03.065>
- Dunlea, EJ; Herndon, SC; Nelson, DD; Volkamer, RM; San Martini, F; Sheehy, PM; Zahniser, MS; Shorter, JH; Wormhoudt, JC; Lamb, BK; Allwine, EJ; Gaffney, JS; Marley, NA; Grutter, M; Marquez, C; Blanco, S; Cardenas, B; Retama, A; Ramon Villegas, CR; Kolb, CE; Molina, LT; Molina, MJ. (2007). Evaluation of nitrogen dioxide chemiluminescence monitors in a polluted urban environment. *Atmos Chem Phys* 7: 2691-2704.
- Dupuy, PM; Shore, SA; Drazen, JM; Frostell, C; Hill, WA; Zapol, WM. (1992). Bronchodilator action of inhaled nitric oxide in guinea pigs. *J Clin Invest* 90: 421-428. <http://dx.doi.org/10.1172/JCI115877>
- Durant, JL; Ash, CA; Wood, EC; Herndon, SC; Jayne, JT; Knighton, WB; Canagaratna, MR; Trull, JB; Brugge, D; Zamore, W; Kolb, CE. (2010). Short-term variation in near-highway air pollutant gradients on a winter morning. *Atmos Chem Phys* 10: 8341-8352. <http://dx.doi.org/10.5194/acp-10-8341-2010>
- Düring, I; Bächlin, W; Ketzler, M; Baum, A; Friedrich, U; Würzler, S. (2011). A new simplified NO/NO<sub>2</sub> conversion model under consideration of direct NO<sub>2</sub>-emissions. *Meteor Z* 20: 67-73. <http://dx.doi.org/10.1127/0941-2948/2011/0491>
- Ebisu, K; Bell, ML. (2012). Airborne PM<sub>2.5</sub> chemical components and low birth weight in the Northeastern and Mid-Atlantic regions of the United States. *Environ Health Perspect* 120: 1746-1752. <http://dx.doi.org/10.1289/ehp.1104763>
- Eder, B; Yu, S. (2005). A performance evaluation of the 2004 release of Models-3 CMAQ. *Atmos Environ* 40: 4811-4824. <http://dx.doi.org/10.1016/j.atmosenv.2005.08.045>
- Eeftens, M; Beelen, R; Fischer, P; Brunekreef, B; Meliefste, K; Hoek, G. (2011). Stability of measured and modelled spatial contrasts in NO<sub>2</sub> over time. *Occup Environ Med* 68: 765-770. <http://dx.doi.org/10.1136/oem.2010.061135>

- [Eeftens, M; Tsai, MY; Ampe, C; Anwander, B; Beelen, R; Bellander, T; Cesaroni, G; Cirach, M; Cyrus, J; de Hoogh, K; De Nazelle, A; de Vocht, F; Declercq, C; Dedele, A; Eriksen, K; Galassi, C; Grazuleviciene, R; Grivas, G; Heinrich, J; Hoffmann, B; Lakovides, M; Ineichen, A; Katsouyanni, K; Korek, M; Kraemer, U; Kuhlbusch, T; Lanki, T; Madsen, C; Meliefste, K; Moelter, A; Mosler, G; Nieuwenhuijsen, M; Oldenwening, M; Pennanen, A; Probst-Hensch, N; Quass, U; Raaschou-Nielsen, O. Ie; Ranzi, A; Stephanou, E; Sugiri, D; Udvardy, O; Vaskoevi, E. va; Weinmayr, G; Brunekreef, B; Hoek, G.](#) (2012). Spatial variation of PM2.5, PM10, PM2.5 absorbance and PMcoarse concentrations between and within 20 European study areas and the relationship with NO2 - Results of the ESCAPE project. *Atmos Environ* 62: 303-317. <http://dx.doi.org/10.1016/j.atmosenv.2012.08.038>
- [Eenhuizen, E; Gehring, U; Wijga, AH; Smit, HA; Fischer, PH; Brauer, M; Koppelman, GH; Kerkhof, M; de Jongste, JC; Brunekreef, B; Hoek, G.](#) (2013). Traffic related air pollution is related to interrupter resistance in four-year old children. *Eur Respir J* 41: 1257-1263. <http://dx.doi.org/10.1183/09031936.00020812>
- [Ehrlich, R.](#) (1980). Interaction between environmental pollutants and respiratory infections. *Environ Health Perspect* 35: 89-99.
- [Ehrlich, R; Findlay, JC; Fenters, JD; Gardner, DE.](#) (1977). Health effects of short-term inhalation of nitrogen dioxide and ozone mixtures. *Environ Res* 14: 223-231. [http://dx.doi.org/10.1016/0013-9351\(77\)90034-2](http://dx.doi.org/10.1016/0013-9351(77)90034-2)
- [Ehrlich, R; Findlay, JC; Gardner, DE.](#) (1979). Effects of repeated exposures to peak concentrations of nitrogen dioxide and ozone on resistance to streptococcal pneumonia. *J Toxicol Environ Health* 5: 631-642. <http://dx.doi.org/10.1080/15287397909529775>
- [Ehrlich, R; Henry, MC.](#) (1968). Chronic toxicity of nitrogen dioxide: I: Effect on resistance to bacterial pneumonia. *Arch Environ Health* 17: 860-865. <http://dx.doi.org/10.1080/00039896.1968.10665342>
- [EIONET](#) (European Environment Information and Observation Network). (2014). European topic centre on air pollution and climate change mitigation: AirBase- the European air quality database. Available online at <http://acm.eionet.europa.eu/databases/airbase>
- [Elsayed, NM; Mustafa, MG.](#) (1982). Dietary antioxidants and the biochemical response to oxidant inhalation: I: Influence of dietary vitamin E on the biochemical effects of nitrogen dioxide exposure in rat lung. *Toxicol Appl Pharmacol* 66: 319-328. [http://dx.doi.org/10.1016/0041-008X\(82\)90298-8](http://dx.doi.org/10.1016/0041-008X(82)90298-8)
- [Enami, S; Hoffmann, MR; Colussi, AJ.](#) (2009). Absorption of inhaled NO(2) [Letter]. *J Phys Chem B* 113: 7977-7981. <http://dx.doi.org/10.1021/jp902667x>
- [England, C; Corcoran, WH.](#) (1974). Kinetics and mechanisms of the gas-phase reaction of water vapor and nitrogen dioxide. *Ind Eng Chem Fundam* 13: 373-384. <http://dx.doi.org/10.1021/i160052a014>
- [Enkhmaa, D; Warburton, N; Javzandulam, B; Uyanga, J; Khishigsuren, Y; Lodoysamba, S; Enkhtur, S; Warburton, D.](#) (2014). Seasonal ambient air pollution correlates strongly with spontaneous abortion in Mongolia. *BMC Pregnancy Childbirth* 14: 146. <http://dx.doi.org/10.1186/1471-2393-14-146>
- [Ensor, KB; Raun, LH; Persse, D.](#) (2013). A case-crossover analysis of out-of-hospital cardiac arrest and air pollution. *Circulation* 127: 1192-1199. <http://dx.doi.org/10.1161/CIRCULATIONAHA.113.000027>
- [Eriksson, C; Hilding, A; Pyko, A; Bluhm, G; Pershagen, G; Ostenson, CG.](#) (2014). Long-term aircraft noise exposure and body mass index, waist circumference, and type 2 diabetes: A prospective study. *Environ Health Perspect* 122: 687-694. <http://dx.doi.org/10.1289/ehp.1307115>
- [Erjefält, JS; Greiff, L; Andersson, M; Matsson, E; Petersen, H; Linden, M; Ansari, T; Jeffery, PK; Persson, CG.](#) (1999). Allergen-induced eosinophil cytotoxicity is a primary mechanism for granule protein release in human upper airways. *Am J Respir Crit Care Med* 160: 304-312. <http://dx.doi.org/10.1164/ajrccm.160.1.9809048>
- [Escamilla-Núñez, MC; Barraza-Villarreal, A; Hernandez-Cadena, L; Moreno-Macias, H; Ramirez-Aguilar, M; Sienra-Monge, JJ; Cortez-Lugo, M; Texcalac, JL; del Rio-Navarro, B; Romieu, I.](#) (2008). Traffic-related air pollution and respiratory symptoms among asthmatic children, resident in Mexico City: The EVA cohort study. *Respir Res* 9: 74. <http://dx.doi.org/10.1186/1465-9921-9-74>

- [Esplugues, A; Ballester, F; Estarlich, M; Llop, S; Fuentes-Leonarte, V; Mantilla, E; Vioque, J; Iñiguez, C.](#) (2011). Outdoor, but not indoor, nitrogen dioxide exposure is associated with persistent cough during the first year of life. *Sci Total Environ* 409: 4667-4673. <http://dx.doi.org/10.1016/j.scitotenv.2011.08.007>
- [Esposito, S; Galeone, C; Lelii, M; Longhi, B; Ascolese, B; Senatore, L; Prada, E; Montinaro, V; Malerba, S; Patria, MF; Principi, N.](#) (2014). Impact of air pollution on respiratory diseases in children with recurrent wheezing or asthma. *BMC Pulm Med* 14: 130. <http://dx.doi.org/10.1186/1471-2466-14-130>
- [Estarlich, M; Ballester, F; Aguilera, I; Fernández-Somoano, A; Lertxundi, A; Llop, S; Freire, C; Tardón, A; Basterrechea, M; Sunyer, J; Iñiguez, C.](#) (2011). Residential exposure to outdoor air pollution during pregnancy and anthropometric measures at birth in a multicenter cohort in Spain. *Environ Health Perspect* 119: 1333-1338. <http://dx.doi.org/10.1289/ehp.1002918>
- [Eze, IC; Schaffner, E; Fischer, E; Schikowski, T; Adam, M; Imboden, M; Tsai, M; Carballo, D; von Eckardstein, A; Künzli, N; Schindler, C; Probst-Hensch, N.](#) (2014). Long-term air pollution exposure and diabetes in a population-based Swiss cohort. *Environ Int* 70: 95-105. <http://dx.doi.org/10.1016/j.envint.2014.05.014>
- [Ezratty, V; Guillosoy, G; Neukirch, C; Dehoux, M; Koscielny, S; Bonay, M; Cabanes, PA; Samet, JM; Mure, P; Ropert, L; Tokarek, S; Lambrozo, J; Aubier, M.](#) (2014). Repeated nitrogen dioxide exposures and eosinophilic airway inflammation in asthmatics: a randomized crossover study. *Environ Health Perspect* 122: 850-855. <http://dx.doi.org/10.1289/ehp.1307240>
- [Faiz, AS; Rhoads, GG; Demissie, K; Kruse, L; Lin, Y; Rich, DQ.](#) (2012). Ambient air pollution and the risk of stillbirth. *Am J Epidemiol* 176: 308-316. <http://dx.doi.org/10.1093/aje/kws029>
- [Faiz, AS; Rhoads, GG; Demissie, K; Lin, Y; Kruse, L; Rich, DQ.](#) (2013). Does ambient air pollution trigger stillbirth? *Epidemiology* 24: 538-544. <http://dx.doi.org/10.1097/EDE.0b013e3182949ce5>
- [Faustini, A; Stafoggia, M; Berti, G; Bisanti, L; Chiusolo, M; Cernigliaro, A; Mallone, S; Primerano, R; Scarnato, C; Simonato, L; Vigotti, MA; Forastiere, F.](#) (2011). The relationship between ambient particulate matter and respiratory mortality: A multi-city study in Italy. *Eur Respir J* 38: 538-547. <http://dx.doi.org/10.1183/09031936.00093710>
- [Faustini, A; Stafoggia, M; Colais, P; Berti, G; Bisanti, L; Cadum, E; Cernigliaro, A; Mallone, S; Scarnato, C; Forastiere, F.](#) (2013). Air pollution and multiple acute respiratory outcomes. *Eur Respir J* 42: 304-313. <http://dx.doi.org/10.1183/09031936.00128712>
- [Fehrenbach, H; Zimmermann, G; Starke, E; Bratu, VA; Conrad, D; Yildirim, AO; Fehrenbach, A.](#) (2007). Nitrogen dioxide induces apoptosis and proliferation but not emphysema in rat lungs. *Thorax* 62: 438-446. <http://dx.doi.org/10.1136/thx.2006.062364>
- [Fehsenfeld, FC; Dickerson, RR; Hubler, G; Luke, WT; Nunnermacker, LJ; Williams, EJ; Roberts, JM; Calvert, JG; Curran, CM; Delany, AC; Eubank, CS; Fahey, DW; Fried, A; Gandrud, BW; Langford, AO; Murphy, PC; Norton, RB; Pickering, KE; Ridley, BA.](#) (1987). A ground-based intercomparison of NO, NO<sub>x</sub>, and NO<sub>y</sub> measurement techniques. *J Geophys Res* 92: 14,710-714,722. <http://dx.doi.org/10.1029/JD092iD12p14710>
- [Feichtinger, W; Papalambrou, K; Poehl, M; Krischker, U; Neumann, K.](#) (1997). Smoking and in vitro fertilization: A meta-analysis. *J Assist Reprod Genet* 14: 596-599. <http://dx.doi.org/10.1023/A:1022584802711>
- [Felber Dietrich, D; Gemperli, A; Gaspoz, JM; Schindler, C; Liu, LJ; Gold, DR; Schwartz, J; Rochat, T; Barthélémy, JC; Pons, M; Roche, F; Probst Hensch, NM; Bridevaux, PO; Gerbase, MW; Neu, U; Ackermann-Lieblich, U.](#) (2008). Differences in heart rate variability associated with long-term exposure to NO<sub>2</sub>. *Environ Health Perspect* 116: 1357-1361. <http://dx.doi.org/10.1289/ehp.11377>
- [Fenters, JD; Findlay, JC; Port, CD; Ehrlich, R; Coffin, DL.](#) (1973). Chronic exposure to nitrogen dioxide: Immunologic, physiologic, and pathologic effects in virus-challenged squirrel monkeys. *Arch Environ Health* 27: 85-89. <http://dx.doi.org/10.1080/00039896.1973.10666324>
- [Feo Brito, F; Mur Gimeno, P; Martinez, C; Tobias, A; Suarez, L; Guerra, F; Borja, JM; Alonso, AM.](#) (2007). Air pollution and seasonal asthma during the pollen season: A cohort study in Puertollano and Ciudad Real (Spain). *Allergy* 62: 1152-1157. <http://dx.doi.org/10.1111/j.1398-9995.2007.01438.x>

- [Ferin, J; Leach, LJ.](#) (1975). The effects of selected air pollutants on clearance of titanite oxide particles from the lungs of rats. *Inhaled Particles 4 Pt 1*: 333-341.
- [Fernández-Somoano, A; Estarlich, M; Ballester, F; Fernández-Patier, R; Aguirre-Alfaro, A; Herce-Garraleta, MD; Tardón, A.](#) (2011). Outdoor NO<sub>2</sub> and benzene exposure in the INMA (Environment and Childhood) Asturias cohort (Spain). *Atmos Environ* 45: 5240-5246. <http://dx.doi.org/10.1016/j.atmosenv.2011.02.010>
- [Fernando, HJS.](#) (2010). Fluid dynamics of urban atmospheres in complex terrain. *Annu Rev Fluid Mech* 42: 365-389. <http://dx.doi.org/10.1146/annurev-fluid-121108-145459>
- [Ferris, BG.](#) (1978). Epidemiology standardization project II: Recommended respiratory disease questionnaires for use with adults and children in epidemiological research. *Am J Respir Crit Care Med* 118: 7-53.
- [Filho, MAP; Pereira, LAA; Arbex, FF; Arbex, M; Conceição, GM; Santos, UP; Lopes, AC; Saldiva, PHN; Braga, ALF; Cendon, S.](#) (2008). Effect of air pollution on diabetes and cardiovascular diseases in São Paulo, Brazil. *Braz J Med Biol Res* 41: 526-532. <http://dx.doi.org/10.1590/S0100-879X2008005000020>
- [Filleul, L; Rondeau, V; Vandentorren, S; Le Moual, N; Cantagrel, A; Annesi-Maesano, I; Charpin, D; Declercq, C; Neukirch, F; Paris, C; Vervloet, D; Brochard, P; Tessier, JF; Kauffmann, F; Baldi, I.](#) (2005). Twenty five year mortality and air pollution: Results from the French PAARC survey. *Occup Environ Med* 62: 453-460. <http://dx.doi.org/10.1136/oem.2004.014746>
- [Finegold, JA; Asaria, P; Francis, DP.](#) (2013). Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United Nations. *Int J Cardiol* 168: 934-945. <http://dx.doi.org/10.1016/j.ijcard.2012.10.046>
- [Finlayson-Pitts, BJ; Sweetman, LL; Weissbart, B.](#) (1987). A Fourier transform infrared spectrometry study of the reactions of phosphatidylcholines with gaseous N<sub>2</sub>O<sub>5</sub> and NO<sub>2</sub>. *Toxicol Appl Pharmacol* 89: 438-448. [http://dx.doi.org/10.1016/0041-008X\(87\)90163-3](http://dx.doi.org/10.1016/0041-008X(87)90163-3)
- [Finlayson-Pitts, BJ; Wingen, LM; Sumner, AL; Syomin, D; Ramazan, KA.](#) (2003). The heterogeneous hydrolysis of NO<sub>2</sub> in laboratory systems and in outdoor and indoor atmospheres: An integrated mechanism. *Phys Chem Chem Phys* 5: 223-242. <http://dx.doi.org/10.1039/b208564j>
- [Finn, D; Clawson, KL; Carter, RG; Rich, JD; Eckman, RM; Perry, SG; Isakov, V; Heist, DK.](#) (2010). Tracer studies to characterize the effects of roadside noise barriers on near-road pollutant dispersion under varying atmospheric stability conditions. *Atmos Environ* 44: 204-214. <http://dx.doi.org/10.1016/j.atmosenv.2009.10.012>
- [Fischer, EV; Jacob, DJ; Yantosca, RM; Sulprizio, MP; Millet, DB; Mao, J; Paulot, F; Singh, HB; Roiger, A; Ries, L; Talbot, RW; Dzepina, K; Pandey Deolal, S.](#) (2014). Atmospheric peroxyacetyl nitrate (PAN): a global budget and source attribution. *Atmos Chem Phys* 14: 2679-2698. <http://dx.doi.org/10.5194/acp-14-2679-2014>
- [Flamant-Hulin, M; Caillaud, D; Sacco, P; Pénard-Morand, C; Annesi-Maesano, I.](#) (2010). Air pollution and increased levels of fractional exhaled nitric oxide in children with no history of airway damage. *J Toxicol Environ Health A* 73: 272-283. <http://dx.doi.org/10.1080/15287390903249206>
- [Foley, KM; Roselle, SJ; Appel, KW; Bhave, PV; Pleim, JE; Otte, TL; Mathur, R; Sarwar, G; Young, JO; Gilliam, RC; Nolte, CG; Kelly, JT; Gilliland, AB; Bash, JO.](#) (2010). Incremental testing of the Community Multiscale Air Quality (CMAQ) modeling system version 4.7. *Geoscientific Model Development* 3: 205-226.
- [Folinsbee, LJ.](#) (1992). Does nitrogen dioxide exposure increase airways responsiveness? *Toxicol Ind Health* 8: 273-283.
- [Folinsbee, LJ; Horvath, SM; Bedi, JF; Delehunt, JC.](#) (1978). Effect of 0.62 ppm NO<sub>2</sub> on cardiopulmonary function in young male nonsmokers. *Environ Res* 15: 199-205. [http://dx.doi.org/10.1016/0013-9351\(78\)90096-8](http://dx.doi.org/10.1016/0013-9351(78)90096-8)
- [Foraster, M; Basagaña, X; Aguilera, I; Rivera, M; Agis, D; Bouso, L; Deltell, A; Marrugat, J; Ramos, R; Sunyer, J; Vila, J; Elosua, R; Künzli, N.](#) (2014). Association of long-term exposure to traffic-related air pollution with blood pressure and hypertension in an adult population-based cohort in Spain (the REGICOR Study). *Environ Health Perspect* 122: 404-411. <http://dx.doi.org/10.1289/ehp.1306497>

- Forbes, LJ; Patel, MD; Rudnicka, AR; Cook, DG; Bush, T; Stedman, JR; Whincup, PH; Strachan, DP; Anderson, HR. (2009a). Chronic exposure to outdoor air pollution and diagnosed cardiovascular disease: meta-analysis of three large cross-sectional surveys. *Environ Health* 8: 30. <http://dx.doi.org/10.1186/1476-069X-8-30>
- Forbes, L.J.L; Kapetanakis, V; Rudnicka, AR; Cook, DG; Bush, T; Stedman, JR; Whincup, PH; Strachan, DP; Anderson, HR. (2009b). Chronic exposure to outdoor air pollution and lung function in adults. *Thorax* 64: 657-663. <http://dx.doi.org/10.1136/thx.2008.109389>
- Ford, E; Hughes, MN; Wardman, P. (2002). Kinetics of the reactions of nitrogen dioxide with glutathione, cysteine, and uric acid at physiological pH. *Free Radic Biol Med* 32: 1314-1323. [http://dx.doi.org/10.1016/S0891-5849\(02\)00850-X](http://dx.doi.org/10.1016/S0891-5849(02)00850-X)
- Forsberg, B; Stjernberg, N; Linne, R; Segerstedt, B; Wall, S. (1998). Daily air pollution levels and acute asthma in southern Sweden. *Eur Respir J* 12: 900-905.
- Förstermann, U; Sessa, WC. (2012). Nitric oxide synthases: Regulation and function [Review]. *Eur Heart J* 33: 829-837. <http://dx.doi.org/10.1093/eurheartj/ehr304>
- Fox, GA. (1991). Practical causal inference for ecoepidemiologists. *J Toxicol Environ Health A* 33: 359-373. <http://dx.doi.org/10.1080/15287399109531535>
- Fraenkel, DJ; Bardin, PG; Sanderson, G; Lampe, F; Johnston, SL; Holgate, ST. (1995). Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects. *Am J Respir Crit Care Med* 151: 879-886. [http://dx.doi.org/10.1164/ajrccm/151.3\\_Pt\\_1.879](http://dx.doi.org/10.1164/ajrccm/151.3_Pt_1.879)
- Frampton, MW; Boscia, J; Roberts, NJ, Jr; Azadniv, M; Torres, A; Cox, C; Morrow, PE; Nichols, J; Chalupa, D; Frasier, LM; Gibb, FR; Speers, DM; Tsai, Y; Utell, MJ. (2002). Nitrogen dioxide exposure: Effects on airway and blood cells. *Am J Physiol* 282: L155-L165.
- Frampton, MW; Morrow, PE; Cox, C; Gibb, FR; Speers, DM; Utell, MJ. (1991). Effects of nitrogen dioxide exposure on pulmonary function and airway reactivity in normal humans. *Am Rev Respir Dis* 143: 522-527. <http://dx.doi.org/10.1164/ajrccm/143.3.522>
- Frampton, MW; Smeglin, AM; Roberts, NJ, Jr; Finkelstein, JN; Morrow, PE; Utell, MJ. (1989). Nitrogen dioxide exposure in vivo and human alveolar macrophage inactivation of influenza virus in vitro. *Environ Res* 48: 179-192. [http://dx.doi.org/10.1016/S0013-9351\(89\)80033-7](http://dx.doi.org/10.1016/S0013-9351(89)80033-7)
- Franck, U; Leitte, AM; Suppan, P. (2014). Multiple exposures to airborne pollutants and hospital admissions due to diseases of the circulatory system in Santiago de Chile. *Sci Total Environ* 468-469: 746-756. <http://dx.doi.org/10.1016/j.scitotenv.2013.08.088>
- Franklin, M; Vora, H; Avol, E; McConnell, R; Lurmann, F; Liu, F; Penfold, B; Berhane, K; Gilliland, F; Gauderman, WJ. (2012). Predictors of intra-community variation in air quality. *J Expo Sci Environ Epidemiol* 22: 135-147. <http://dx.doi.org/10.1038/jes.2011.45>
- Freeman, G; Furiosi, NJ; Haydon, GB. (1966). Effects of continuous exposure of 0.8 ppm NO<sub>2</sub> on respiration of rats. *Arch Environ Health* 13: 454-456. <http://dx.doi.org/10.1080/00039896.1966.10664595>
- Freire, C; Ramos, R; Puertas, R; Lopez-Espinosa, MJ; Julvez, J; Aguilera, I; Cruz, F; Fernandez, MF; Sunyer, J; Olea, N. (2010). Association of traffic-related air pollution with cognitive development in children. *J Epidemiol Community Health* 64: 223-228. <http://dx.doi.org/10.1136/jech.2008.084574>
- Fruin, S; Westerdahl, D; Sax, T; Sioutas, C; Fine, PM. (2008). Measurements and predictors of on-road ultrafine particle concentrations and associated pollutants in Los Angeles. *Atmos Environ* 42: 207-219. <http://dx.doi.org/10.1016/j.atmosenv.2007.09.057>
- Fu, A; Leaderer, BP; Gent, JF; Leaderer, D; Zhu, Y. (2012). An environmental epigenetic study of ADRB2 5'-UTR methylation and childhood asthma severity. *Clin Exp Allergy* 42: 1575-1581. <http://dx.doi.org/10.1111/j.1365-2222.2012.04055.x>
- Fuchs, H; Dubé, WP; Lerner, BM; Wagner, NL; Williams, EJ; Brown, SS. (2009). A sensitive and versatile detector for atmospheric NO<sub>2</sub> and NO<sub>x</sub> based on blue diode laser cavity ring-down spectroscopy. *Environ Sci Technol* 43: 7831-7836. <http://dx.doi.org/10.1021/es902067h>

- Fuentes, M. (2009). Statistical issues in health impact assessment at the state and local levels. *Air Qual Atmos Health* 2: 47-55. <http://dx.doi.org/10.1007/s11869-009-0033-3>
- Fuentes, M; Raftery, AE. (2005). Model evaluation and spatial interpolation by Bayesian combination of observations with outputs from numerical models. *Biometrics* 61: 36-45. <http://dx.doi.org/10.1111/j.0006-341X.2005.030821.x>
- Fuertes, E; Standl, M; Cyrus, J; Berdel, D; von Berg, A; Bauer, CP; Krämer, U; Sugiri, D; Lehmann, I; Koletzko, S; Carlsten, C; Brauer, M; Heinrich, J. (2013). A longitudinal analysis of associations between traffic-related air pollution with asthma, allergies and sensitization in the GINIplus and LISApplus birth cohorts. *Peer J* 1: e193. <http://dx.doi.org/10.7717/peerj.193>
- Fujimaki, H; Nohara, O. (1994). Changes in the response of lung mast cells isolated from rats and guinea pigs exposed to nitrogen dioxide. *Inhal Toxicol* 6: 515-520. <http://dx.doi.org/10.3109/08958379409040508>
- Fujita, EM; Campbell, DE; Zielinska, B; Arnott, WP; Chow, JC. (2011). Concentrations of air toxics in motor vehicle-dominated environments (pp. 3-77). (ISSN 1041-5505
- 156). Boston, MA: Health Effects Institute.
- Fukuto, J; Carrington, SJ; Tantillo, DJ; Harrison, JG; Ignarro, LJ; Freeman, BA; Chen, A; Wink, DA. (2012). Small molecule signaling agents: The integrated chemistry and biochemistry of nitrogen oxides, oxides of carbon, dioxygen, hydrogen sulfide, and their derived species [Review]. *Chem Res Toxicol* 25: 769-793. <http://dx.doi.org/10.1021/tx2005234>
- Fung, KY; Khan, S; Krewski, D; Chen, Y. (2006). Association between air pollution and multiple respiratory hospitalizations among the elderly in Vancouver, Canada. *Inhal Toxicol* 18: 1005-1011. <http://dx.doi.org/10.1080/08958370600904538>
- Fung, KY; Luginaah, I; Gorey, KM; Webster, G. (2005). Air pollution and daily hospital admissions for cardiovascular diseases in Windsor, Ontario. *Can J Public Health* 96: 29-33.
- Furiosi, NJ; Crane, SC; Freeman, G. (1973). Mixed sodium chloride aerosol and nitrogen dioxide in air: Biological effects on monkeys and rats. *Arch Environ Occup Health* 27: 405-408.
- Gair, AJ; Penkett, SA; Oyola, P. (1991). Development of a simple passive technique for the determination of nitrogen-dioxide in remote continental locations. *Atmos Environ* 25A: 1927-1939.
- Gan, W; Koehoorn, M; Davies, H; Demers, P; Tamburic, L; Brauer, M. (2011). Long-term exposure to traffic-related air pollution and the risk of coronary heart disease hospitalization and mortality. *Environ Health Perspect* 119: 501-507. <http://dx.doi.org/10.1289/ehp.1002511>
- Gan, WQ; Davies, HW; Koehoorn, M; Brauer, M. (2012a). Association of long-term exposure to community noise and traffic-related air pollution with coronary heart disease mortality. *Am J Epidemiol* 175: 898-906. <http://dx.doi.org/10.1093/aje/kwr424>
- Gan, WQ; Fitzgerald, JM; Carlsten, C; Sadatsafavi, M; Brauer, M. (2013). Associations of ambient air pollution with chronic obstructive pulmonary disease hospitalization and mortality. *Am J Respir Crit Care Med* 187: 721-727. <http://dx.doi.org/10.1164/rccm.201211-2004OC>
- Gan, WQ; Mclean, K; Brauer, M; Chiarello, SA; Davies, HW. (2012b). Modeling population exposure to community noise and air pollution in a large metropolitan area. *Environ Res* 116: 11-16. <http://dx.doi.org/10.1016/j.envres.2012.04.001>
- Gao, Y; Chan, EY; Li, LP; He, QQ; Wong, TW. (2013). Chronic effects of ambient air pollution on lung function among Chinese children. *Arch Dis Child* 98: 128-135. <http://dx.doi.org/10.1136/archdischild-2011-301541>
- Gardner, DE; Miller, FJ; Blommer, EJ; Coffin, DL. (1979). Influence of exposure mode on the toxicity of NO<sub>2</sub>. *Environ Health Perspect* 30: 23-29.
- Gasana, J; Dillikar, D; Mendy, A; Forno, E; Ramos Vieira, E. (2012). Motor vehicle air pollution and asthma in children: A meta-analysis. *Environ Res* 117: 36-45. <http://dx.doi.org/10.1016/j.envres.2012.05.001>

- [Gass, K; Klein, M; Chang, HH; Flanders, WD; Strickland, MJ.](#) (2014). Classification and regression trees for epidemiologic research: an air pollution example. *Environ Health* 13: 17. <http://dx.doi.org/10.1186/1476-069X-13-17>
- [Gaston, B; Sears, S; Woods, J; Hunt, J; Ponaman, M; McMahon, T; Stamler, J.](#) (1998). Bronchodilator S-nitrosothiol deficiency in asthmatic respiratory failure. *Lancet* 351: 1317-1319. [http://dx.doi.org/10.1016/S0140-6736\(97\)07485-0](http://dx.doi.org/10.1016/S0140-6736(97)07485-0)
- [Gauderman, WJ; Avol, E; Gilliland, F; Vora, H; Thomas, D; Berhane, K; McConnell, R; Kuenzli, N; Lurmann, F; Rappaport, E; Margolis, H; Bates, D; Peters, J.](#) (2004). The effect of air pollution on lung development from 10 to 18 years of age. *N Engl J Med* 351: 1057-1067. <http://dx.doi.org/10.1056/NEJMoa040610>
- [Gauderman, WJ; Avol, E; Lurmann, F; Kuenzli, N; Gilliland, F; Peters, J; McConnell, R.](#) (2005). Childhood asthma and exposure to traffic and nitrogen dioxide. *Epidemiology* 16: 737-743. <http://dx.doi.org/10.1097/01.ede.0000181308.51440.75>
- [Gauderman, WJ; Vora, H; McConnell, R; Berhane, K; Gilliland, F; Thomas, D; Lurmann, F; Avol, E; Kunzli, N; Jerrett, M; Peters, J.](#) (2007). Effect of exposure to traffic on lung development from 10 to 18 years of age: A cohort study. *Lancet* 369: 571-577. [http://dx.doi.org/10.1016/S0140-6736\(07\)60037-3](http://dx.doi.org/10.1016/S0140-6736(07)60037-3)
- [Gauvin, S; Le Moulec, Y; Bremont, F; Momas, I; Balducci, F; Ciognard, F; Poilve, MP; Zmirou, D.](#) (2001). Relationships between nitrogen dioxide personal exposure and ambient air monitoring measurements among children in three French metropolitan areas: VESTA study. *Arch Environ Occup Health* 56: 336-341. <http://dx.doi.org/10.1080/00039890109604465>
- [Gee, GC; Payne-Sturges, DC.](#) (2004). Environmental health disparities: A framework integrating psychosocial and environmental concepts [Review]. *Environ Health Perspect* 112: 1645-1653. <http://dx.doi.org/10.1289/ehp.7074>
- [Geer, LA; Weedon, J; Bell, ML.](#) (2012). Ambient air pollution and term birth weight in Texas from 1998 to 2004. *J Air Waste Manag Assoc* 62: 1285-1295. <http://dx.doi.org/10.1080/10962247.2012.707632>
- [Gehring, U; Cyrus, J; Sedlmeir, G; Brunekreef, B; Bellander, T; Fischer, P; Bauer, CP; Reinhardt, D; Wichmann, HE; Heinrich, J.](#) (2002). Traffic-related air pollution and respiratory health during the first 2 yrs of life. *Eur Respir J* 19: 690-698. <http://dx.doi.org/10.1183/09031936.02.01182001>
- [Gehring, U; Gruzieva, O; Agius, RM; Beelen, R; Custovic, A; Cyrus, J; Eeftens, M; Flexeder, C; Fuertes, E; Heinrich, J; Hoffmann, B; de Jongste, JC; Kerkhof, M; Klümper, C; Korek, M; Mölter, A; Schultz, ES; Simpson, A; Sugiri, D; Svartengren, M; von Berg, A; Wijga, AH; Pershagen, G; Brunekreef, B.](#) (2013). Air pollution exposure and lung function in children: the ESCAPE project. *Environ Health Perspect* 121: 1357-1364. <http://dx.doi.org/10.1289/ehp.1306770>
- [Gehring, U; Heinrich, J; Kramer, U; Grote, V; Hochadel, M; Sugiri, D; Kraft, M; Rauchfuss, K; Eberwein, HG; Wichmann, HE.](#) (2006). Long-term exposure to ambient air pollution and cardiopulmonary mortality in women. *Epidemiology* 17: 545-551. <http://dx.doi.org/10.1097/01.ede.0000224541.38258.87>
- [Gehring, U; Tamburic, L; Sbihi, H; Davies, HW; Brauer, M.](#) (2014). Impact of noise and air pollution on pregnancy outcomes. *Epidemiology* 25: 351-358. <http://dx.doi.org/10.1097/EDE.0000000000000073>
- [Gehring, U; van Eijsden, M; Dijkema, MB; van der Wal, MF; Fischer, P; Brunekreef, B.](#) (2011a). Traffic-related air pollution and pregnancy outcomes in the Dutch ABCD birth cohort study. *Occup Environ Med* 68: 36-43. <http://dx.doi.org/10.1136/oem.2009.053132>
- [Gehring, U; Wijga, AH; Brauer, M; Fischer, P; de Jongste, JC; Kerkhof, M; Oldenwening, M; Smit, HA; Brunekreef, B.](#) (2010). Traffic-related air pollution and the development of asthma and allergies during the first 8 years of life. *Am J Respir Crit Care Med* 181: 596-603. <http://dx.doi.org/10.1164/rccm.200906-0858OC>
- [Gehring, U; Wijga, AH; Fischer, P; de Jongste, JC; Kerkhof, M; Koppelman, GH; Smit, HA; Brunekreef, B.](#) (2011b). Traffic-related air pollution, preterm birth and term birth weight in the PIAMA birth cohort study. *Environ Res* 111: 125-135. <http://dx.doi.org/10.1016/j.envres.2010.10.004>

- Gelb, AF; Barnes, PJ; George, SC; Ricciardolo, FL; Dimaria, G; Zamel, N. (2012). Review of exhaled nitric oxide in chronic obstructive pulmonary disease [Review]. *J Breath Res* 6: 047101. <http://dx.doi.org/10.1088/1752-7155/6/4/047101>
- Gent, JF; Koutrakis, P; Belanger, K; Triche, E; Holford, TR; Bracken, MB; Leaderer, BP. (2009). Symptoms and medication use in children with asthma and traffic-related sources of fine particle pollution. *Environ Health Perspect* 117: 1168-1174. <http://dx.doi.org/10.1289/ehp.0800335>
- Geyh, AS; Xue, J; Ozkaynak, H; Spengler, JD. (2000). The Harvard Southern California chronic ozone exposure study: Assessing ozone exposure of grade-school-age children in two southern California communities. *Environ Health Perspect* 108: 265-270.
- Ghannam, K; El-Fadel, M. (2013). A framework for emissions source apportionment in industrial areas: MM5/CALPUFF in a near-field application. *J Air Waste Manag Assoc* 63: 190-204. <http://dx.doi.org/10.1080/10962247.2012.739982>
- Ghosh, JK; Heck, JE; Cockburn, M; Su, J; Jerrett, M; Ritz, B. (2013). Prenatal exposure to traffic-related air pollution and risk of early childhood cancers. *Am J Epidemiol* 178: 1233-1239. <http://dx.doi.org/10.1093/aje/kwt129>
- Ghosh, JKC; Wilhelm, M; Su, J; Goldberg, D; Cockburn, M; Jerrett, M; Ritz, B. (2012a). Assessing the influence of traffic-related air pollution on risk of term low birth weight on the basis of land-use-based regression models and measures of air toxics. *Am J Epidemiol* 175: 1262-1274. <http://dx.doi.org/10.1093/aje/kwr469>
- Ghosh, R; Joad, J; Benes, I; Dostal, M; Sram, RJ; Hertz-Picciotto, I. (2012b). Ambient nitrogen oxides exposure and early childhood respiratory illnesses. *Environ Int* 39: 96-102. <http://dx.doi.org/10.1016/j.envint.2011.10.001>
- Gibson, MD; Kundu, S; Satish, M. (2013). Dispersion model evaluation of PM2.5, NOX and SO2 from point and major line sources in Nova Scotia, Canada using AERMOD Gaussian plume air dispersion model. *Atmos Pollut Res* 4: 157-167. <http://dx.doi.org/10.5094/APR.2013.016>
- Gilbert, NL; Goldberg, MS; Brook, JR; Jerrett, M. (2007). The influence of highway traffic on ambient nitrogen dioxide concentrations beyond the immediate vicinity of highways. *Atmos Environ* 41: 2670-2673. <http://dx.doi.org/10.1016/j.atmosenv.2006.12.007>
- Gilbert, NL; Woodhouse, S; Stieb, DM; Brook, JR. (2003). Ambient nitrogen dioxide and distance from a major highway. *Sci Total Environ* 312: 43-46. [http://dx.doi.org/10.1016/S0048-9697\(03\)00228-6](http://dx.doi.org/10.1016/S0048-9697(03)00228-6)
- Gilbraith, N; Powers, SE. (2013). Residential demand response reduces air pollutant emissions on peak electricity demand days in New York City. *Energy Policy* 59: 459-469. <http://dx.doi.org/10.1016/j.enpol.2013.03.056>
- Gillespie-Bennett, J; Pierse, N; Wickens, K; Crane, J; Howden-Chapman, P. (2011). The respiratory health effects of nitrogen dioxide in children with asthma. *Eur Respir J* 38: 303-309. <http://dx.doi.org/10.1183/09031936.00115409>
- Gilmour, MI; Park, P; Selgrade, MK. (1996). Increased immune and inflammatory responses to dust mite antigen in rats exposed to 5 ppm NO2. *Fundam Appl Toxicol* 31: 65-70. <http://dx.doi.org/10.1006/faat.1996.0076>
- Gladwin, MT; Schechter, AN; Kim-Shapiro, DB; Patel, RP; Hogg, N; Shiva, S; Cannon, RO, III; Kelm, M; Wink, DA; Espey, MG; Oldfield, EH; Pluta, RM; Freeman, BA; Lancaster, JR; Feelisch, M; Lundberg, JO. (2005). The emerging biology of the nitrite anion. *Nat Chem Biol* 1: 308-314. <http://dx.doi.org/10.1038/nchembio1105-308>
- Goggins, WB; Chan, EY; Yang, CY. (2013). Weather, pollution, and acute myocardial infarction in Hong Kong and Taiwan. *Int J Cardiol* 168: 243-249. <http://dx.doi.org/10.1016/j.ijcard.2012.09.087>
- Goings, SAJ; Kulle, TJ; Bascom, R; Sauder, LR; Green, DJ; Hebel, JR; Clements, ML. (1989). Effect of nitrogen dioxide exposure on susceptibility to influenza A virus infection in healthy adults. *Am Rev Respir Dis* 139: 1075-1081. <http://dx.doi.org/10.1164/ajrcem/139.5.1075>

- [Goldberg, MS; Burnett, RT; Stieb, DM; Brophy, JM; Daskalopoulou, SS; Valois, MF; Brook, JR.](#) (2013). Associations between ambient air pollution and daily mortality among elderly persons in Montreal, Quebec. *Sci Total Environ* 463-464: 931942. <http://dx.doi.org/10.1016/j.scitotenv.2013.06.095>
- [Goldberg, MS; Giannetti, N; Burnett, RT; Mayo, NE; Valois, MF; Brophy, JM.](#) (2008). A panel study in congestive heart failure to estimate the short-term effects from personal factors and environmental conditions on oxygen saturation and pulse rate. *Occup Environ Med* 65: 659-666. <http://dx.doi.org/10.1136/oem.2007.034934>
- [Goldman, GT.](#) (2013). Email from Gretchen Tanner Goldman to Dr Richmond-Bryant; Response to Data Request. Available online at <http://www.regulations.gov/#!documentDetail;D=EPA-HQ-ORD-2013-0232-0019>
- [Goldman, GT; Mulholland, JA; Russell, AG; Gass, K; Strickland, MJ; Tolbert, PE.](#) (2012). Characterization of ambient air pollution measurement error in a time-series health study using a geostatistical simulation approach. *Atmos Environ* 57: 101-108. <http://dx.doi.org/10.1016/j.atmosenv.2012.04.045>
- [Goldman, GT; Mulholland, JA; Russell, AG; Srivastava, A; Strickland, MJ; Klein, M; Waller, LA; Tolbert, PE; Edgerton, ES.](#) (2010). Ambient air pollutant measurement error: characterization and impacts in a time-series epidemiologic study in Atlanta. *Environ Sci Technol* 44: 7692-7698. <http://dx.doi.org/10.1021/es101386r>
- [Goldman, GT; Mulholland, JA; Russell, AG; Strickland, MJ; Klein, M; Waller, LA; Tolbert, PE.](#) (2011). Impact of exposure measurement error in air pollution epidemiology: Effect of error type in time-series studies. *Environ Health* 10: 61. <http://dx.doi.org/10.1186/1476-069X-10-61>
- [Goldstein, BD; Hamburger, SJ; Falk, GW; Amoruso, MA.](#) (1977). Effect of ozone and nitrogen dioxide on the agglutination of rat alveolar macrophages by concanavalin A. *Life Sci* 21: 1637-1644. [http://dx.doi.org/10.1016/0024-3205\(77\)90242-9](http://dx.doi.org/10.1016/0024-3205(77)90242-9)
- [Goldstein, E; Eagle, MC; Hoeprich, PD.](#) (1973). Effect of nitrogen dioxide on pulmonary bacterial defense mechanisms. *Arch Environ Health* 26: 202-204. <http://dx.doi.org/10.1080/00039896.1973.10666256>
- [Goldstein, E; Warshauer, D; Lippert, W; Tarkington, B.](#) (1974). Ozone and nitrogen dioxide exposure: Murine pulmonary defense mechanisms. *Arch Environ Health* 28: 85-90. <http://dx.doi.org/10.1080/00039896.1974.10666444>
- [Goldstein, S; Lind, J; Merenyi, G.](#) (2004). Reaction of organic peroxy radicals with NO<sub>2</sub> and NO in aqueous solution: Intermediacy of organic peroxyxynitrate and peroxyxynitrite species. *J Phys Chem A* 108: 1719-1725. <http://dx.doi.org/10.1021/jp037431z>
- [Gong, H; Linn, WS; Clark, KW; Anderson, KR; Geller, MD; Sioutas, C.](#) (2005). Respiratory responses to exposures with fine particulates and nitrogen dioxide in the elderly with and without COPD. *Inhal Toxicol* 17: 123-132. <http://dx.doi.org/10.1080/08958370590904481>
- [Gonzales, M; Myers, O; Smith, L; Olvera, HA; Mukerjee, S; Li, WW; Pingitore, N; Amaya, M; Burchiel, S; Berwick, M.](#) (2012). Evaluation of land use regression models for NO<sub>2</sub> in El Paso, Texas, USA. *Sci Total Environ* 432: 135-142. <http://dx.doi.org/10.1016/j.scitotenv.2012.05.062>
- [Gonzales, M; Qualls, C; Hudgens, E; Neas, L.](#) (2005). Characterization of a spatial gradient of nitrogen dioxide across a United States-Mexico border city during winter. *Sci Total Environ* 337: 163-173. <http://dx.doi.org/10.1016/j.scitotenv.2004.07.010>
- [Goodman, JE; Chandalia, JK; Thakali, S; Seeley, M.](#) (2009). Meta-analysis of nitrogen dioxide exposure and airway hyper-responsiveness in asthmatics. *Crit Rev Toxicol* 39: 719-742. <http://dx.doi.org/10.3109/10408440903283641>
- [Gordon, M; Staebler, RM; Liggio, J; Li, SM; Wentzell, J; Lu, G; Lee, P; Brook, JR.](#) (2012). Measured and modeled variation in pollutant concentration near roadways. *Atmos Environ* 57: 138-145. <http://dx.doi.org/10.1016/j.atmosenv.2012.04.022>

- [Götschi, T; Sunyer, J; Chinn, S; de Marco, R; Forsberg, B; Gauderman, JW; Garcia-Esteban, R; Heinrich, J; Jacquemin, B; Jarvis, D; Ponzio, M; Villani, S; Künzli, N.](#) (2008). Air pollution and lung function in the European Community Respiratory Health Survey. *Int J Epidemiol* 37: 1349-1358. <http://dx.doi.org/10.1093/ije/dyn136>
- [Gouveia, N; Bremner, SA; Novaes, HMD.](#) (2004). Association between ambient air pollution and birth weight in São Paulo, Brazil. *J Epidemiol Community Health* 58: 11-17. <http://dx.doi.org/10.1136/jech.58.1.11>
- [Gowers, AM; Cullinan, P; Ayres, JG; Anderson, HR; Strachan, DP; Holgate, ST; Mills, IC; Maynard, RL.](#) (2012). Does outdoor air pollution induce new cases of asthma? Biological plausibility and evidence; a review [Review]. *Respirology* 17: 887-898. <http://dx.doi.org/10.1111/j.1440-1843.2012.02195.x>
- [Graham, JA; Gardner, DE; Blommer, EJ; House, DE; Menache, MG; Miller, FJ.](#) (1987). Influence of exposure patterns of nitrogen dioxide and modifications by ozone on susceptibility to bacterial infectious disease in mice. *J Toxicol Environ Health* 21: 113-125. <http://dx.doi.org/10.1080/15287398709531006>
- [Gray, EL; Patton, FM; Goldberg, SB; Kaplan, E.](#) (1954). Toxicity of the oxides of nitrogen. II. Acute inhalation toxicity of nitrogen dioxide, red fuming nitric acid, and white fuming nitric acid. *AMA Arch Ind Health* 10: 418-422.
- [Green, RS; Smorodinsky, S; Kim, JJ; McLaughlin, R; Ostro, B.](#) (2004). Proximity of California public schools to busy roads. *Environ Health Perspect* 112: 61-66. <http://dx.doi.org/10.1289/ehp.6566>
- [Greene, ND; Schneider, SL.](#) (1978). Effects of NO<sub>2</sub> on the response of baboon alveolar macrophages to migration inhibitory factor. *J Toxicol Environ Health* 4: 869-880. <http://dx.doi.org/10.1080/15287397809529708>
- [Greenwald, R; Sarnat, SE; Raysoni, AU; Li, WW; Johnson, BA; Stock, TH; Holguin, F; Sosa, T; Sarnat, JA.](#) (2013). Associations between source-indicative pollution metrics and increases in pulmonary inflammation and reduced lung function in a panel of asthmatic children. *Air Qual Atmos Health* 6: 487-499. <http://dx.doi.org/10.1007/s11869-012-0186-3>
- [Gregory, RE; Pickrell, JA; Hahn, FF; Hobbs, CH.](#) (1983). Pulmonary effects of intermittent subacute exposure to low-level nitrogen dioxide. *J Toxicol Environ Health* 11: 405-414. <http://dx.doi.org/10.1080/15287398309530354>
- [Griffiths, PT; Badger, CL; Cox, RA; Folkers, M; Henk, HH; Mentel, TF.](#) (2009). Reactive uptake of N<sub>2</sub>O<sub>5</sub> by aerosols containing dicarboxylic acids. Effect of particle phase, composition, and nitrate content. *J Phys Chem A* 113: 5082-5090. <http://dx.doi.org/10.1021/jp8096814>
- [Grineski, SE; Staniswalis, JG; Peng, Y; Atkinson-Palombo, C.](#) (2010). Children's asthma hospitalizations and relative risk due to nitrogen dioxide (NO<sub>2</sub>): Effect modification by race, ethnicity, and insurance status. *Environ Res* 110: 178-188. <http://dx.doi.org/10.1016/j.envres.2009.10.012>
- [Griscavage, JM; Hobbs, AJ; Ignarro, LJ.](#) (1995). Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds [Review]. In LJ Ignarro; F Murad (Eds.), *Nitric oxide: Biochemistry, molecular biology, and therapeutic implications* (pp. 215-234). San Diego, CA: Academic Press. [http://dx.doi.org/10.1016/S1054-3589\(08\)61088-1](http://dx.doi.org/10.1016/S1054-3589(08)61088-1)
- [Gronski, KE; Walker, SE; Gram, F.](#) (1993). Evaluation of a model for hourly spatial concentration distributions. *Atmos Environ* 27: 105-120. [http://dx.doi.org/10.1016/0957-1272\(93\)90050-G](http://dx.doi.org/10.1016/0957-1272(93)90050-G)
- [Gruzieva, O; Bellander, T; Eneroth, K; Kull, I; Melén, E; Nordling, E; van Hage, M; Wickman, M; Moskalenko, V; Hulchiy, O; Pershagen, G.](#) (2012). Traffic-related air pollution and development of allergic sensitization in children during the first 8 years of life. *J Allergy Clin Immunol* 129: 240-246. <http://dx.doi.org/10.1016/j.jaci.2011.11.001>
- [Gruzieva, O; Bergström, A; Hulchiy, O; Kull, I; Lind, T; Melén, E; Moskalenko, V; Pershagen, G; Bellander, T.](#) (2013). Exposure to air pollution from traffic and childhood asthma until 12 years of age. *Epidemiology* 24: 54-61. <http://dx.doi.org/10.1097/EDE.0b013e318276c1ea>

- Gryparis, A; Coull, BA; Schwartz, J. (2007). Controlling for confounding in the presence of measurement error in hierarchical models: A Bayesian approach. *J Expo Sci Environ Epidemiol* 17: S20-S28. <http://dx.doi.org/10.1038/sj.jes.7500624>
- Gu, Z; Zhang, Y; Lei, K. (2010). Large eddy simulation of flow in a street canyon with tree planting under various atmospheric instability conditions. *Sci China Tech Sci* 53: 1928-1937. <http://dx.doi.org/10.1007/s11431-010-3243-x>
- Guo, Y; Jia, Y; Pan, X; Liu, L; Wichmann, HE. (2009). The association between fine particulate air pollution and hospital emergency room visits for cardiovascular diseases in Beijing, China. *Sci Total Environ* 407: 4826-4830. <http://dx.doi.org/10.1016/j.scitotenv.2009.05.022>
- Guo, Y; Tong, S; Li, S; Barnett, AG; Yu, W; Zhang, Y; Pan, X. (2010). Gaseous air pollution and emergency hospital visits for hypertension in Beijing, China: a time-stratified case-crossover study. *Environ Health* 9: 57. <http://dx.doi.org/10.1186/1476-069X-9-57>
- Gushchin, IS; Petyaev, IM; Tsinkalovsky, OR. (1990). Kinetics of oxygen metabolism indices in the course of histamine secretion from rat mast cells. *Agents and Actions* 30: 85-88. <http://dx.doi.org/10.1007/BF01969005>
- Guxens, M; Aguilera, I; Ballester, F; Estarlich, M; Fernández-Somoano, A; Lertxundi, A; Lertxundi, N; Mendez, MA; Tardón, A; Vrijheid, M; Sunyer, J. (2012). Prenatal exposure to residential air pollution and infant mental development: Modulation by antioxidants and detoxification factors. *Environ Health Perspect* 120: 144-149. <http://dx.doi.org/10.1289/ehp.1103469>
- Guxens, M; Garcia-Esteban, R; Giorgis-Allemand, L; Forns, J; Badaloni, C; Ballester, F; Beelen, R; Cesaroni, G; Chatzi, L; de Agostini, M; de Nazelle, A; Eeftens, M; Fernandez, MF; Fernández-Somoano, A; Forastiere, F; Gehring, U; Ghassabian, A; Heude, B; Jaddoe, VW; Klümper, C; Kogevinas, M; Krämer, U; Larroque, B; Lertxundi, A; Lertxundi, N; Murcia, M; Navel, V; Nieuwenhuijsen, M; Porta, D; Ramos, R; Roumeliotaki, T; Slama, R; Sørensen, M; Stephanou, EG; Sugiri, D; Tardón, A; Tiemeier, H; Tiesler, CM; Verhulst, FC; Vrijkotte, T; Wilhelm, M; Brunekreef, B; Pershagen, G; Sunyer, J. (2014). Air pollution during pregnancy and childhood cognitive and psychomotor development: Six European birth cohorts. *Epidemiology* 25: 636-647. <http://dx.doi.org/10.1097/EDE.0000000000000133>
- Hack, M; Fanaroff, AA. (1999). Outcomes of children of extremely low birth weight and gestational age in the 1990s [Review]. *Early Hum Dev* 53: 193-218. [http://dx.doi.org/10.1016/S0378-3782\(98\)00052-8](http://dx.doi.org/10.1016/S0378-3782(98)00052-8)
- Hackney, JD; Thiede, FC; Linn, WS; Pedersen, EE; Spier, CE; Law, DC; Fischer, DA. (1978). Experimental studies on human health effects of air pollutants. IV. Short-term physiological and clinical effects of nitrogen dioxide exposure. *Arch Environ Health* 33: 176-181. <http://dx.doi.org/10.1080/00039896.1978.10667330>
- Hagenbjork-Gustafsson, A; Eriksson, K; Forsberg, B. (2009). Field evaluation of the Ogawa Diffusive Sampler for NO(2)/NO(x) in a cold climate [Abstract]. *Epidemiology* 20: S161. <http://dx.doi.org/10.1097/01.ede.0000362548.83420.d7>
- Hagler, GSW; Tang, W; Freeman, MJ; Heist, DK; Perry, SG; Vette, AF. (2011). Model evaluation of roadside barrier impact on near-road air pollution. *Atmos Environ* 45: 2522-2530. <http://dx.doi.org/10.1016/j.atmosenv.2011.02.030>
- Halonen, JI; Lanki, T; Yli-Tuomi, T; Tiittanen, P; Kulmala, M; Pekkanen. (2009). Particulate air pollution and acute cardiorespiratory hospital admissions and mortality among the elderly. *Epidemiology* 20: 143-153. <http://dx.doi.org/10.1097/EDE.0b013e31818c7237>
- Hameed, S; Pinto, JP; Stewart, RW. (1979). Sensitivity of the predicted CO-OH-CH4 perturbation to tropospheric NOx concentrations. *J Geophys Res Oceans* 84: 763-768. <http://dx.doi.org/10.1029/JC084iC02p00763>
- Hamid, Q; Springall, DR; Riveros-Moreno, V; Chanez, P; Howarth, P; Redington, A; Bousquet, J; Godard, P; Holgate, S; Polak, JM. (1993). Induction of nitric oxide synthase in asthma. *Lancet* 342: 1510-1513. [http://dx.doi.org/10.1016/S0140-6736\(05\)80083-2](http://dx.doi.org/10.1016/S0140-6736(05)80083-2)

- [Hampel, R; Lepeule, J; Schneider, A; Bottagisi, S; Charles, MA; Ducimetière, P; Peters, A; Slama, R.](#) (2011). Short-term impact of ambient air pollution and air temperature on blood pressure among pregnant women. *Epidemiology* 22: 671-679. <http://dx.doi.org/10.1097/EDE.0b013e318226e8d6>
- [Han, M; Guo, Z; Li, G; Sang, N.](#) (2013). Nitrogen dioxide inhalation induces genotoxicity in rats. *Chemosphere* 90: 2737-2742. <http://dx.doi.org/10.1016/j.chemosphere.2012.11.057>
- [Hannam, K; McNamee, R; Baker, P; Sibley, C; Agius, R.](#) (2014). Air pollution exposure and adverse pregnancy outcomes in a large UK birth cohort: use of a novel spatio-temporal modelling technique. *Scand J Work Environ Health* 40: 518-530. <http://dx.doi.org/10.5271/sjweh.3423>
- [Hansel, NN; Breyse, PN; McCormack, MC; Matsui, EC; Curtin-Brosnan, J; Williams, DAL; Moore, JL; Cuhran, JL; Diette, GB.](#) (2008). A longitudinal study of indoor nitrogen dioxide levels and respiratory symptoms in inner-city children with asthma. *Environ Health Perspect* 116: 1428-1432. <http://dx.doi.org/10.1289/ehp.11349>
- [Hansel, NN; McCormack, MC; Belli, AJ; Matsui, EC; Peng, RD; Aloe, C; Paulin, L; Williams, DL; Diette, GB; Breyse, PN.](#) (2013). In-home air pollution is linked to respiratory morbidity in former smokers with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 187: 1085-1090. <http://dx.doi.org/10.1164/rccm.201211-1987OC>
- [Hansen, C; Neller, A; Williams, G; Simpson, R.](#) (2006). Maternal exposure to low levels of ambient air pollution and preterm birth in Brisbane, Australia. *BJOG* 113: 935-941. <http://dx.doi.org/10.1111/j.1471-0528.2006.01010.x>
- [Hansen, C; Neller, A; Williams, G; Simpson, R.](#) (2007). Low levels of ambient air pollution during pregnancy and fetal growth among term neonates in Brisbane, Australia. *Environ Res* 103: 383-389. <http://dx.doi.org/10.1016/j.envres.2006.06.010>
- [Hansen, CA; Barnett, AG; Pritchard, G.](#) (2008). The effect of ambient air pollution during early pregnancy on fetal ultrasonic measurements during mid-pregnancy. *Environ Health Perspect* 116: 362-369. <http://dx.doi.org/10.1289/ehp.10720>
- [Hansen, DA; Edgerton, ES; Hartsell, BE; Jansen, JJ; Kandasamy, N; Hidy, GM; Blanchard, CL.](#) (2003). The southeastern aerosol research and characterization study: Part I - overview. *J Air Waste Manag Assoc* 53: 1460-1471. <http://dx.doi.org/10.1080/10473289.2003.10466318>
- [Harre, ESM; Price, PD; Ayrey, RB; Toop, LJ; Martin, IR; Town, GI.](#) (1997). Respiratory effects of air pollution in chronic obstructive pulmonary disease: A three month prospective study. *Thorax* 52: 1040-1044. <http://dx.doi.org/10.1136/thx.52.12.1040>
- [Harrison, MAJ; Barra, S; Borghesi, D; Vione, D; Arsene, C; Olariu, RI.](#) (2005). Nitrated phenols in the atmosphere: a review [Review]. *Atmos Environ* 39: 231-248. <http://dx.doi.org/10.1016/j.atmosenv.2004.09.044>
- [Hart, J; Yanosky, J; Puett, R; Ryan, L; Dockery, D; Smith, T; Garshick, E; Laden, F.](#) (2009). Spatial modeling of PM10 and NO2 in the continental United States, 1985-2000. *Environ Health Perspect* 117: 1690-1696. <http://dx.doi.org/10.1289/ehp.0900840>
- [Hart, JE; Garshick, E; Dockery, DW; Smith, TJ; Ryan, L; Laden, F.](#) (2011). Long-term ambient multi-pollutant exposures and mortality. *Am J Respir Crit Care Med* 183: 73-78. <http://dx.doi.org/10.1164/rccm.200912-1903OC>
- [Hart, JE; Rimm, EB; Rexrode, KM; Laden, F.](#) (2013). Changes in traffic exposure and the risk of incident myocardial infarction and all-cause mortality. *Epidemiology* 24: 734-742. <http://dx.doi.org/10.1097/EDE.0b013e31829d5dae>
- [Hasunuma, H; Ishimaru, Y; Yoda, Y; Shima, M.](#) (2014). Decline of ambient air pollution levels due to measures to control automobile emissions and effects on the prevalence of respiratory and allergic disorders among children in Japan. *Environ Res* 131: 111-118. <http://dx.doi.org/10.1016/j.envres.2014.03.007>
- [Hatch, GE.](#) (1992). Comparative biochemistry of airway lining fluid. In RA Parent (Ed.), *Comparative biology of the normal lung*, Vol 1: Treatise on pulmonary toxicology (pp. 617-632). Boca Raton, FL: CRC Press, Inc.

- Hatch, GE; Slade, R; Selgrade, MK; Stead, AG. (1986). Nitrogen dioxide exposure and lung antioxidants in ascorbic acid-deficient guinea pigs. *Toxicol Appl Pharmacol* 82: 351-359. [http://dx.doi.org/10.1016/0041-008X\(86\)90212-7](http://dx.doi.org/10.1016/0041-008X(86)90212-7)
- Hatzopoulou, M; Weichenthal, S; Barreau, G; Goldberg, M; Farrell, W; Crouse, D; Ross, N. (2013). A web-based route planning tool to reduce cyclists' exposures to traffic pollution: A case study in Montreal, Canada. *Environ Res* 123: 58-61. <http://dx.doi.org/10.1016/j.envres.2013.03.004>
- Hayashi, Y; Kohno, T; Ohwada, H. (1987). Morphological effects of nitrogen dioxide on the rat lung. *Environ Health Perspect* 73: 135-145.
- Hazucha, MJ; Folinsbee, LJ; Seal, E; Bromberg, PA. (1994). Lung function response of healthy women after sequential exposures to NO<sub>2</sub> and O<sub>3</sub>. *Am J Respir Crit Care Med* 150: 642-647. <http://dx.doi.org/10.1164/ajrcm.150.3.8087332>
- Hazucha, MJ; Ginsberg, JF; McDonnell, WF; Haak, ED, Jr; Pimmel, RL; Salaam, SA; House, DE; Bromberg, PA. (1983). Effects of 0.1 ppm nitrogen dioxide on airways of normal and asthmatic subjects. *J Appl Physiol Respir Environ Exerc Physiol* 54: 730-739.
- He, M; Dhaniyala, S. (2011). A dispersion model for traffic produced turbulence in a two-way traffic scenario. *Environ Fluid Mech* 11: 627-640. <http://dx.doi.org/10.1007/s10652-011-9215-2>
- Heal, MR. (2008). The effect of absorbent grid preparation method on precision and accuracy of ambient nitrogen dioxide measurements using Palmes passive diffusion tubes. *J Environ Monit* 10: 1363-1369. <http://dx.doi.org/10.1039/b811230d>
- Heckbert, SR; Kooperberg, C; Safford, MM; Psaty, BM; Hsia, J; McTiernan, A; Gaziano, JM; Frishman, WH; Curb, JD. (2004). Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. *Am J Epidemiol* 160: 1152-1158. <http://dx.doi.org/10.1093/aje/kwh314>
- HEI (Health Effects Institute). (2003). Revised analyses of time-series studies of air pollution and health [HEI]. (HEI Special Report). Boston, MA: Health Effects Institute (HEI). <http://pubs.healtheffects.org/view.php?id=4>
- HEI (Health Effects Institute). (2010). Traffic-related air pollution: A critical review of the literature on emissions, exposure, and health effects. (Special Report 17). Boston, MA: Health Effects Institute (HEI). <http://pubs.healtheffects.org/view.php?id=334>
- HEI (Health Effects Institute). (2012). Effects of short-term exposure to air pollution on hospital admissions of young children for acute lower respiratory infections in Ho Chi Minh City, Vietnam (pp. 5-72; discussion 73-83). (Research Report 169). Boston, MA: Health Effects Institute, HEI Collaborative Working Group on Air Pollution, Poverty, and Health in Ho Chi Minh City. <http://pubs.healtheffects.org/view.php?id=380>
- HEI Review Panel on Ultrafine Particles. (2013). Understanding the health effects of ambient ultrafine particles. (HEI Perspectives 3). Boston, MA: Health Effects Institute. <http://pubs.healtheffects.org/view.php?id=394>
- Heinrich, J; Thiering, E; Rzehak, P; Krämer, U; Hochadel, M; Rauchfuss, KM; Gehring, U; Wichmann, HE. (2013). Long-term exposure to NO<sub>2</sub> and PM<sub>10</sub> and all-cause and cause-specific mortality in a prospective cohort of women. *Occup Environ Med* 70: 179-186. <http://dx.doi.org/10.1136/oemed-2012-100876>
- Heist, DK; Brixey, LA; Richmond-Bryant, J; Bowker, GE; Perry, SG; Wiener, RW. (2009a). The effect of a tall tower on flow and dispersion through a model urban neighborhood: Part 1. Flow characteristics. *J Environ Monit* 11: 2163-2170. <http://dx.doi.org/10.1039/B907135k>
- Heist, DK; Perry, SG; Brixey, LA. (2009b). A wind tunnel study of the effect of roadway configurations on the dispersion of traffic-related pollution. *Atmos Environ* 43: 5101-5111. <http://dx.doi.org/10.1016/j.atmosenv.2009.06.034>
- Held, T; Chang, DPY; Niemeier, DA. (2003). UCD 2001: An improved model to simulate pollutant dispersion from roadways. *Atmos Environ* 37: 5325-5336. <http://dx.doi.org/10.1016/j.atmosenv.2003.09.015>

- [Helleday, R; Huberman, D; Blomberg, A; Stjernberg, N; Sandstrom, T.](#) (1995). Nitrogen dioxide exposure impairs the frequency of the mucociliary activity in healthy subjects. *Eur Respir J* 8: 1664-1668. <http://dx.doi.org/10.1183/09031936.95.08101664>
- [Helleday, R; Sandstrom, T; Stjernberg, N.](#) (1994). Differences in bronchoalveolar cell response to nitrogen dioxide exposure between smokers and nonsmokers. *Eur Respir J* 7: 1213-1220. <http://dx.doi.org/10.1183/09031936.94.07071213>
- [Heller, H; Korbmacher, N; Gäbler, R; Brandt, S; Breitbach, T; Juergens, U; Grohé, C; Schuster, KD.](#) (2004). Pulmonary 15NO uptake in interstitial lung disease. *Nitric Oxide* 10: 229-232. <http://dx.doi.org/10.1016/j.niox.2004.06.001>
- [Henderson, SB; Beckerman, B; Jerrett, M; Brauer, M.](#) (2007). Application of land use regression to estimate long-term concentrations of traffic-related nitrogen oxides and fine particulate matter. *Environ Sci Technol* 41: 2422-2428. <http://dx.doi.org/10.1021/es0606780>
- [Hendrick, EM; Tino, VR; Hanna, SR; Egan, BA.](#) (2013). Evaluation of NO<sub>2</sub> predictions by the plume volume molar ratio method (PVMRM) and ozone limiting method (OLM) in AERMOD using new field observations. *J Air Waste Manag Assoc* 63: 844-854. <http://dx.doi.org/10.1080/10962247.2013.798599>
- [Henneberger, A; Zareba, W; Ibald-Mulli, A; Rückerl, R; Cyrus, J; Couderc, JP; Mykins, B; Woelke, G; Wichmann, HE; Peters, A.](#) (2005). Repolarization changes induced by air pollution in ischemic heart disease patients. *Environ Health Perspect* 113: 440-446. <http://dx.doi.org/10.1289/ehp.7579>
- [Henry, MC; Findlay, J; Spangler, J; Ehrlich, R.](#) (1970). Chronic toxicity of NO<sub>2</sub> in squirrel monkeys: III. Effect on resistance to bacterial and viral infection. *Arch Environ Health* 20: 566-570. <http://dx.doi.org/10.1080/00039896.1970.10665663>
- [Hernández-Cadena, L; Holguin, F; Barraza-Villarreal, A; Del Río-Navarro, BE; Sienra-Monge, JJ; Romieu, I.](#) (2009). Increased levels of outdoor air pollutants are associated with reduced bronchodilation in children with asthma. *Chest* 136: 1529-1536. <http://dx.doi.org/10.1378/chest.08-1463>
- [Hertel, O; Jensen, SS; Ketzel, M; Becker, T; Peel, RG; Orby, PV; Skjoth, CA; Ellermann, T; Raaschou-Nielsen, O; Sorensen, M; Brauner, EV; Andersen, ZJ; Loft, S; Schlunssen, V; Bonlokke, JH; Sigsgaard, T.](#) (2014). Utilizing monitoring data and spatial analysis tools for exposure assessment of atmospheric pollutants in Denmark [Chapter 6]. In LL McConnell; J Dachs; CJ Hapeman (Eds.), *Occurrence, fate and impact fo atmospheric pollutants on environmental and human health* (pp. 95-122). Washington, D.C.: American Chemical Society. <http://pubs.acs.org/doi/abs/10.1021/bk-2013-1149.ch006>
- [Hesterberg, TW; Bunn, WB; McClellan, RO; Hamade, AK; Long, CM; Valberg, PA.](#) (2009). Critical review of the human data on short-term nitrogen dioxide (NO<sub>2</sub>) exposures: Evidence for NO<sub>2</sub> no-effect levels [Review]. *Crit Rev Toxicol* 39: 743-781. <http://dx.doi.org/10.3109/10408440903294945>
- [HEW](#) (U.S. Department of Health, Education and Welfare). (1964). *Smoking and health: Report of the advisory committee to the surgeon general of the public health service*. Washington, DC: U.S. Department of Health, Education, and Welfare. <http://profiles.nlm.nih.gov/ps/retrieve/ResourceMetadata/NNBBMQ>
- [Higdon, A; Diers, AR; Oh, J; Landar, A; Darley-USmar, VM.](#) (2012). Cell signalling by reactive lipid species: New concepts and molecular mechanisms [Review]. *Biochem J* 442: 453-464. <http://dx.doi.org/10.1042/BJ20111752>
- [Higgins, BG; Francis, HC; Yates, C; Warburton, CJ; Fletcher, AM; Pickering, CAC; Woodcock, AA.](#) (2000). Environmental exposure to air pollution and allergens and peak flow changes. *Eur Respir J* 16: 66.
- [Higgins, BG; Francis, HC; Yates, CJ; Warburton, CJ; Fletcher, AM; Reid, JA; Pickering, CAC; Woodcock, AA.](#) (1995). Effects of air pollution on symptoms and peak expiratory flow measurements in subjects with obstructive airways disease. *Thorax* 50: 149-155. <http://dx.doi.org/10.1136/thx.50.2.149>
- [Hildebrandt, K; Rückerl, R; Koenig, W; Schneider, A; Pitz, M; Heinrich, J; Marder, V; Frampton, M; Oberdörster, G; Wichmann, HE; Peters, A.](#) (2009). Short-term effects of air pollution: A panel study of blood markers in patients with chronic pulmonary disease. *Part Fibre Toxicol* 6: 25. <http://dx.doi.org/10.1186/1743-8977-6-25>

- [Hill, AB.](#) (1965). The environment and disease: Association or causation? *Proc R Soc Med* 58: 295-300.
- [Hill, BG; Dranka, BP; Bailey, SM; Lancaster, JR; Darley-Usmar, VM.](#) (2010). What part of NO don't you understand? Some answers to the cardinal questions in nitric oxide biology [Review]. *J Biol Chem* 285: 19699-19704. <http://dx.doi.org/10.1074/jbc.R110.101618>
- [Hiltermann, TJN; Stolk, J; van der Zee, SC; Brunekreef, B; de Bruijne, CR; Fischer, PH; Ameling, CB; Sterk, PJ; Hiemstra, PS; van Bree, L.](#) (1998). Asthma severity and susceptibility to air pollution. *Eur Respir J* 11: 686-693.
- [Hinwood, AL; De Klerk, N; Rodriguez, C; Jacoby, P; Runnion, T; Rye, P; Landau, L; Murray, F; Feldwick, M; Spickett, J.](#) (2006). The relationship between changes in daily air pollution and hospitalizations in Perth, Australia 1992-1998: A case-crossover study. *Int J Environ Health Res* 16: 27-46. <http://dx.doi.org/10.1080/09603120500397680>
- [Hizawa, N.](#) (2011). Pharmacogenetics of  $\beta_2$ -agonists [Review]. *Allergol Int* 60: 239-246. <http://dx.doi.org/10.2332/allergolint.11-RAI-0317>
- [Hodgkins, SR; Ather, JL; Paveglio, SA; Allard, JL; LeClair, LA; Suratt, BT; Boyson, JE; Poynter, ME.](#) (2010). NO<sub>2</sub> inhalation induces maturation of pulmonary CD11c<sup>+</sup> cells that promote antigenspecific CD4<sup>+</sup> T cell polarization. *Respir Res* 11: 102. <http://dx.doi.org/10.1186/1465-9921-11-102>
- [Hoek, G.](#) (2003). Daily mortality and air pollution in The Netherlands [HEI]. In Revised analyses of time-series studies of air pollution and health (pp. 133-141). Boston, MA: Health Effects Institute. <http://pubs.healtheffects.org/getfile.php?u=21>
- [Hoek, G; Beelen, R; de Hoogh, K; Vienneau, D; Gulliver, J; Fischer, P; Briggs, D.](#) (2008). A review of land-use regression models to assess spatial variation of outdoor air pollution [Review]. *Atmos Environ* 42: 7561-7578. <http://dx.doi.org/10.1016/j.atmosenv.2008.05.057>
- [Hoek, G; Brunekreef, B; Goldbohm, S; Fischer, P; van den Brandt, PA.](#) (2002). Association between mortality and indicators of traffic-related air pollution in the Netherlands: A cohort study. *Lancet* 360: 1203-1209. [http://dx.doi.org/10.1016/s0140-6736\(02\)11280-3](http://dx.doi.org/10.1016/s0140-6736(02)11280-3)
- [Hogman, M; Frostell, C; Arnberg, H; Hedenstierna, G.](#) (1993). Inhalation of nitric oxide modulates methacholine-induced bronchoconstriction in the rabbit. *Eur Respir J* 6: 177-180.
- [Hohlfeld, JM.](#) (2002). The role of surfactant in asthma. *Respir Res* 3: 4. <http://dx.doi.org/10.1186/rr176>
- [Holguin, F; Flores, S; Ross, Z; Cortez, M; Molina, M; Molina, L; Rincon, C; Jerrett, M; Berhane, K; Granados, A; Romieu, I.](#) (2007). Traffic-related exposures, airway function, inflammation, and respiratory symptoms in children. *Am J Respir Crit Care Med* 176: 1236-1242. <http://dx.doi.org/10.1164/rccm.200611-1616OC>
- [Hong, JH; Lee, JH; Park, SS.](#) (2007). Application of an in-situ measurement system to determine HONO levels in an indoor environment. *Journal of Korean Society for Atmospheric Environment* 23: 191-202. <http://dx.doi.org/10.5572/KOSAE.2007.23.2.191>
- [Hooftman, RN; Kuper, CF; Appelman, LM.](#) (1988). Comparative sensitivity of histo-pathology and specific lung parameters in the detection of lung injury. *J Appl Toxicol* 8: 59-65. <http://dx.doi.org/10.1002/jat.2550080110>
- [Horowitz, LW; Fiore, AM; Milly, GP; Cohen, RC; Perring, A; Wooldridge, PJ; Hess, PG; Emmons, LK; Lamarque, JF.](#) (2007). Observational constraints on the chemistry of isoprene nitrates over the eastern United States. *J Geophys Res Atmos* 112: D12S08. <http://dx.doi.org/10.1029/2006JD007747>
- [Hou, HY; Wang, D; Zou, XP; Yang, ZH; Li, TC; Chen, YQ.](#) (2014). Does ambient air pollutants increase the risk of fetal loss? A case-control study. *Arch Gynecol Obstet* 289: 285-291. <http://dx.doi.org/10.1007/s00404-013-2962-1>
- [Houston, D; Ong, P; Wu, J; Winer, A.](#) (2006). Proximity of licensed child care facilities to near-roadway vehicle pollution. *Am J Public Health* 96: 1611-1617. <http://dx.doi.org/10.2105/AJPH.2005.077727>
- [Howden, LM; Meyer, JA.](#) (2011). Age and sex composition: 2010. (2010 Census Briefs, C2010BR-03). Washington, DC: U.S. Department of Commerce, Economics and Statistics Administration, U.S. Census Bureau. <http://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf>

- [Hoyert, DL; Xu, J.](#) (2012). Deaths: Preliminary data for 2011. National Vital Statistics Reports 61: 1-51.
- [Hsieh, YL; Yang, YH; Wu, TN; Yang, CY.](#) (2010). Air pollution and hospital admissions for myocardial infarction in a subtropical city: Taipei, Taiwan. *J Toxicol Environ Health A* 73: 757-765. <http://dx.doi.org/10.1080/15287391003684789>
- [Hu, S; Fruin, S; Kozawa, K; Mara, S; Paulson, SE; Winer, AM.](#) (2009). A wide area of air pollutant impact downwind of a freeway during pre-sunrise hours. *Atmos Environ* 43: 2541-2549. <http://dx.doi.org/10.1016/j.atmosenv.2009.02.033>
- [Huang, W; Zhu, T; Pan, X; Hu, M; Lu, SE; Lin, Y; Wang, T; Zhang, Y; Tang, X.](#) (2012a). Air pollution and autonomic and vascular dysfunction in patients with cardiovascular disease: Interactions of systemic inflammation, overweight, and gender. *Am J Epidemiol* 176: 117-126. <http://dx.doi.org/10.1093/aje/kwr511>
- [Huang, YC; Rappold, AG; Graff, DW; Ghio, AJ; Devlin, RB.](#) (2012b). Synergistic effects of exposure to concentrated ambient fine pollution particles and nitrogen dioxide in humans. *Inhal Toxicol* 24: 790-797. <http://dx.doi.org/10.3109/08958378.2012.718809>
- [Hubbard, AK; Symanowicz, PT; Thibodeau, M; Thrall, RS; Schramm, CM; Cloutier, MM; Morris, JB.](#) (2002). Effect of nitrogen dioxide on ovalbumin-induced allergic airway disease in a murine model. *J Toxicol Environ Health A* 65: 1999-2005. <http://dx.doi.org/10.1080/00984100290071397>
- [Hudman, RC; Russell, AR; Valin, LC; Cohen, RC.](#) (2010). Interannual variability in soil nitric oxide emissions over the United States as viewed from space. *Atmos Chem Phys* 10: 9943-9952. <http://dx.doi.org/10.5194/acp-10-9943-2010>
- [Huie, RE.](#) (1994). The reaction kinetics of NO<sub>2</sub> [Review]. *Toxicology* 89: 193-216. [http://dx.doi.org/10.1016/0300-483X\(94\)90098-1](http://dx.doi.org/10.1016/0300-483X(94)90098-1)
- [Humes, KR; Jones, NA; Ramirez, RR.](#) (2011). Overview of race and Hispanic origin: 2010. (2010 Census Briefs, C2010BR-02). Washington, DC: U.S. Department of Commerce, Economics and Statistics Administration, U.S. Census Bureau. <http://www.census.gov/prod/cen2010/briefs/c2010br-02.pdf>
- [Husar, RB; Patterson, DE; Husar, JD; Gillani, NV; Wilson, WE, Jr.](#) (1978). Sulfur budget of a power plant plume. *Atmos Environ* 12: 549-568. [http://dx.doi.org/10.1016/0004-6981\(78\)90236-6](http://dx.doi.org/10.1016/0004-6981(78)90236-6)
- [Hutcheon, JA; Platt, RW.](#) (2008). The missing data problem in birth weight percentiles and thresholds for "small-for-gestational-age". *Am J Epidemiol* 167: 786-792. <http://dx.doi.org/10.1093/aje/kwm327>
- [Hwang, BF; Jaakkola, JJK; Lee, YL; Lin, YC; Guo, YLL.](#) (2006). Relation between air pollution and allergic rhinitis in Taiwanese schoolchildren. *Respir Res* 7: 23. <http://dx.doi.org/10.1186/1465-9921-7-23>
- [Hwang, BF; Lee, YL.](#) (2010). Air pollution and prevalence of bronchitic symptoms among children in Taiwan. *Chest* 138: 956-964. <http://dx.doi.org/10.1378/chest.09-2600>
- [Hwang, BF; Lee, YL; Jaakkola, JJ.](#) (2011). Air pollution and stillbirth: A population-based case-control study in Taiwan. *Environ Health Perspect* 119: 1345-1349. <http://dx.doi.org/10.1289/ehp.1003056>
- [Hwang, BF; Lee, YL; Lin, YC; Jaakkola, JJK; Guo, YL.](#) (2005). Traffic related air pollution as a determinant of asthma among Taiwanese school children. *Thorax* 60: 467-473. <http://dx.doi.org/10.1136/thx.2004.033977>
- [Hystad, P; Demers, PA; Johnson, KC; Carpiano, RM; Brauer, M.](#) (2013). Long-term residential exposure to air pollution and lung cancer risk. *Epidemiology* 24: 762-772. <http://dx.doi.org/10.1097/EDE.0b013e3182949ae7>
- [Hystad, P; Setton, E; Cervantes, A; Poplawski, K; Deschenes, S; Brauer, M; van Donkelaar, A; Lamsal, L; Martin, R; Jerrett, M; Demers, P.](#) (2011). Creating national air pollution models for population exposure assessment in Canada. *Environ Health Perspect* 119: 1123-1129. <http://dx.doi.org/10.1289/ehp.1002976>
- [IARC](#) (International Agency for Research on Cancer). (2006). IARC monographs on the evaluation of carcinogenic risks to humans: Preamble. Lyon, France: World Health Organization. <http://monographs.iarc.fr/ENG/Preamble/>

- Ichinose, T; Arakawa, K; Shimojo, N; Sagai, M. (1988). Biochemical effects of combined gases of nitrogen dioxide and ozone: II. Species differences in lipid peroxides and antioxidative protective enzymes in the lungs. *Toxicol Lett* 42: 167-176.
- Ichinose, T; Fujii, K; Sagai, M. (1991). Experimental studies on tumor promotion by nitrogen dioxide. *Toxicology* 67: 211-225. [http://dx.doi.org/10.1016/0300-483X\(91\)90144-P](http://dx.doi.org/10.1016/0300-483X(91)90144-P)
- Ichinose, T; Sagai, M. (1989). Biochemical effects of combined gases of nitrogen dioxide and ozone III Synergistic effects on lipid peroxidation and antioxidative protective systems in the lungs of rats and guinea pigs. *Toxicology* 59: 259-270. [http://dx.doi.org/10.1016/0300-483X\(89\)90196-0](http://dx.doi.org/10.1016/0300-483X(89)90196-0)
- Ichinose, T; Sagai, M. (1992). Combined exposure to NO<sub>2</sub>, O<sub>3</sub> and H<sub>2</sub>SO<sub>4</sub>-aerosol and lung tumor formation in rats. *Toxicology* 74: 173-184. [http://dx.doi.org/10.1016/0300-483X\(92\)90137-4](http://dx.doi.org/10.1016/0300-483X(92)90137-4)
- Illing, JW; Miller, FJ; Gardner, DE. (1980). Decreased resistance to infection in exercised mice exposed to NO<sub>2</sub> and O<sub>3</sub>. *J Toxicol Environ Health* 6: 843-851. <http://dx.doi.org/10.1080/15287398009529902>
- Iniñiguez, C; Ballester, F; Amoros, R; Estarlich, M; Murcia, M; Esplugues, A; Rebagliato, M. (2009). The impact of outdoor NO<sub>2</sub> exposure on fetal growth assessed by ultrasounds during pregnancy [Abstract]. *Epidemiology* 20: S78. <http://dx.doi.org/10.1097/01.ede.0000362944.07976.ba>
- Iniñiguez, C; Ballester, F; Estarlich, M; Esplugues, A; Murcia, M; Llop, S; Plana, A; Amorós, R; Rebagliato, M. (2012). Prenatal exposure to traffic-related air pollution and fetal growth in a cohort of pregnant women. *Occup Environ Med* 69: 736-744. <http://dx.doi.org/10.1136/oemed-2011-100550>
- Iniñiguez, C; Ballester, F; Estarlich, M; Llop, S; Fernandez-Patier, R; Aguirre-Alfaro, A; Esplugues, A. (2009). Estimation of personal NO<sub>2</sub> exposure in a cohort of pregnant women. *Sci Total Environ* 407: 6093-6099. <http://dx.doi.org/10.1016/j.scitotenv.2009.08.006>
- Ioannidis, JPA. (2008). Why most discovered true associations are inflated [Review]. *Epidemiology* 19: 640-648. <http://dx.doi.org/10.1097/EDE.0b013e31818131e7>
- IOM (Institute of Medicine). (2008). Improving the presumptive disability decision-making process for veterans. In JM Samet; CC Bodurov (Eds.). Washington, DC: National Academies Press. <http://dx.doi.org/10.17226/11908>
- IPCC (Intergovernmental Panel on Climate Change). (2007). Climate change 2007: Impacts, adaptation and vulnerability. Cambridge, UK: Cambridge University Press. [https://www.ipcc.ch/publications\\_and\\_data/publications\\_ipcc\\_fourth\\_assessment\\_report\\_wg2\\_report\\_impacts\\_adaptation\\_and\\_vulnerability.htm](https://www.ipcc.ch/publications_and_data/publications_ipcc_fourth_assessment_report_wg2_report_impacts_adaptation_and_vulnerability.htm)
- Isaacs, K; McCurdy, T; Glen, G; Nysewander, M; Errickson, A; Forbes, S; Graham, S; McCurdy, L; Smith, L; Tulve, N; Vallero, D. (2013). Statistical properties of longitudinal time-activity data for use in human exposure modeling. *J Expo Sci Environ Epidemiol* 23: 328-336. <http://dx.doi.org/10.1038/jes.2012.94>
- Isakov, V; Touma, JS; Burke, J; Lobdell, DT; Palma, T; Rosenbaum, A; Ozkaynak, H. (2009). Combining regional- and local-scale air quality models with exposure models for use in environmental health studies. *J Air Waste Manag Assoc* 59: 461-472.
- Iskandar, A; Andersen, ZJ; Bønnelykke, K; Ellermann, T; Andersen, KK; Bisgaard, H. (2012). Coarse and fine particles but not ultrafine particles in urban air trigger hospital admission for asthma in children. *Thorax* 67: 252-257. <http://dx.doi.org/10.1136/thoraxjnl-2011-200324>
- Ito, K; Mathes, R; Ross, Z; Nádas, A; Thurston, G; Matte, T. (2011). Fine particulate matter constituents associated with cardiovascular hospitalizations and mortality in New York City. *Environ Health Perspect* 119: 467-473. <http://dx.doi.org/10.1289/ehp.1002667>
- Ito, K; Thurston, GD; Silverman, RA. (2007). Characterization of PM<sub>2.5</sub>, gaseous pollutants, and meteorological interactions in the context of time-series health effects models. *J Expo Sci Environ Epidemiol* 17: S45-S60. <http://dx.doi.org/10.1038/sj.jes.7500627>
- Ivy, D; Mulholland, JA; Russell, AG. (2008). Development of ambient air quality population-weighted metrics for use in time-series health studies. *J Air Waste Manag Assoc* 58: 711-720. <http://dx.doi.org/10.3155/1047-3289.58.5.711>

- [Jackson, AC; Murphy, MM; Rassulo, J; Celli, BR; Ingram, RH.](#) (2004). Deep breath reversal and exponential return of methacholine-induced obstruction in asthmatic and nonasthmatic subjects. *J Appl Physiol* 96: 137-142. <http://dx.doi.org/10.1152/jappphysiol.00504.2003>
- [Jackson, LP.](#) (2009). [Letter from EPA Administrator Lisa P. Jackson to Dr. Jonathan M. Samet. Subject: Changes to the NAAQS review process]. Available online at [http://yosemite.epa.gov/sab/sabproduct.nsf/WebCASAC/Jackson%2005-21-09/\\$File/NAAQS%20Letter%20to%20CASAC%20Chair-May%202009.pdf](http://yosemite.epa.gov/sab/sabproduct.nsf/WebCASAC/Jackson%2005-21-09/$File/NAAQS%20Letter%20to%20CASAC%20Chair-May%202009.pdf)
- [Jacob, DJ.](#) (1999). Introduction to atmospheric chemistry. Princeton, NJ: Princeton University Press.
- [Jacobson, MZ.](#) (2002). Atmospheric pollution: History, science, and regulation. New York: Cambridge University Press. <http://www.cambridge.org/us/academic/subjects/earth-and-environmental-science/atmospheric-science-and-meteorology/atmospheric-pollution-history-science-and-regulation>
- [Jacquemin, B; Sunyer, J; Forsberg, B; Aguilera, I; Bouso, L; Briggs, D; de Marco, R; García-Esteban, R; Heinrich, J; Jarvis, D; Maldonado, JA; Payo, F; Rage, E; Vienneau, D; Künzli, N.](#) (2009a). Association between modelled traffic-related air pollution and asthma score in the ECRHS. *Eur Respir J* 34: 834-842. <http://dx.doi.org/10.1183/09031936.00138208>
- [Jacquemin, B; Sunyer, J; Forsberg, B; Aguilera, I; Briggs, D; García-Esteban, R; Götschi, T; Heinrich, J; Järholm, B; Jarvis, D; Vienneau, D; Künzli, N.](#) (2009b). Home outdoor NO<sub>2</sub> and new onset of self-reported asthma in adults. *Epidemiology* 20: 119-126. <http://dx.doi.org/10.1097/EDE.0b013e3181886e76>
- [Jaegle, L; Steinberger, L; Martin, RV; Chance, K.](#) (2005). Global partitioning of NO<sub>x</sub> sources using satellite observations: Relative roles of fossil fuel combustion, biomass burning and soil emissions. *Faraday Discuss* 130: 407-423. <http://dx.doi.org/10.1039/b502128f>
- [Jaffe, DH; Singer, ME; Rimm, AA.](#) (2003). Air pollution and emergency department visits for asthma among Ohio Medicaid recipients, 1991-1996. *Environ Res* 91: 21-28. [http://dx.doi.org/10.1016/S0013-9351\(02\)00004-X](http://dx.doi.org/10.1016/S0013-9351(02)00004-X)
- [Jain, B; Rubinstein, I; Robbins, RA; Leise, KL; Sisson, JH.](#) (1993). Modulation of airway epithelial cell ciliary beat frequency by nitric oxide. *Biochem Biophys Res Commun* 191: 83-88. <http://dx.doi.org/10.1006/bbrc.1993.1187>
- [Jakab, GJ.](#) (1987). Modulation of pulmonary defense mechanisms by acute exposures to nitrogen dioxide. *Experientia*, Suppl 51: 235-242.
- [Jakab, GJ.](#) (1988). Modulation of pulmonary defense mechanisms against viral and bacterial infections by acute exposures to nitrogen dioxide (pp. 1-38). (HEI Research Report no. 20). Cambridge, MA: Health Effects Institute. <http://pubs.healtheffects.org/view.php?id=238>
- [Jalaludin, B; Khalaj, B; Sheppard, V; Morgan, G.](#) (2008). Air pollution and ED visits for asthma in Australian children: A case-crossover analysis. *Int Arch Occup Environ Health* 81: 967-974. <http://dx.doi.org/10.1007/s00420-007-0290-0>
- [Jalaludin, B; Mannes, T; Morgan, G; Lincoln, D; Sheppard, V; Corbett, S.](#) (2007). Impact of ambient air pollution on gestational age is modified by season in Sydney, Australia. *Environ Health* 6: 16. <http://dx.doi.org/10.1186/1476-069X-6-16>
- [Jalaludin, B; Morgan, G; Lincoln, D; Sheppard, V; Simpson, R; Corbett, S.](#) (2006). Associations between ambient air pollution and daily emergency department attendances for cardiovascular disease in the elderly (65+ years), Sydney, Australia. *J Expo Sci Environ Epidemiol* 16: 225-237. <http://dx.doi.org/10.1038/sj.jea.7500451>
- [Jalaludin, BB; O'Toole, BI; Leeder, SR.](#) (2004). Acute effects of urban ambient air pollution on respiratory symptoms, asthma medication use, and doctor visits for asthma in a cohort of Australian children. *Environ Res* 95: 32-42. [http://dx.doi.org/10.1016/S0013-9351\(03\)00038-0](http://dx.doi.org/10.1016/S0013-9351(03)00038-0)
- [Janssen, S; Dumont, G; Fierens, F; Deutsch, F; Maiheu, B; Celis, D; Trimpeneers, E; Mensink, C.](#) (2012). Land use to characterize spatial representativeness of air quality monitoring stations and its relevance for model validation. *Atmos Environ* 59: 492-500. <http://dx.doi.org/10.1016/j.atmosenv.2012.05.028>

- [Jarvis, DL; Leaderer, BP; Chinn, S; Burney, PG.](#) (2005). Indoor nitrous acid and respiratory symptoms and lung function in adults. *Thorax* 60: 474-479. <http://dx.doi.org/10.1136/thx.2004.032177>
- [Jenkins, HS; Devalia, JL; Mister, RL; Bevan, AM; Rusznak, C; Davies, RJ.](#) (1999). The effect of exposure to ozone and nitrogen dioxide on the airway response of atopic asthmatics to inhaled allergen: Dose- and time-dependent effects. *Am J Respir Crit Care Med* 160: 33-39. <http://dx.doi.org/10.1164/ajrccm.160.1.9808119>
- [Jensen, SS; Larson, T; Deepti, KC; Kaufman, JD.](#) (2009). Modeling traffic air pollution in street canyons in New York City for intra-urban exposure assessment in the US Multi-Ethnic Study of atherosclerosis and air pollution. *Atmos Environ* 43: 4544-4556. <http://dx.doi.org/10.1016/j.atmosenv.2009.06.042>
- [Jerrett, M; Arain, MA; Kanaroglou, P; Beckerman, B; Crouse, D; Gilbert, NL; Brook, JR; Finkelstein, N; Finkelstein, MM.](#) (2007). Modeling the intraurban variability of ambient traffic pollution in Toronto, Canada. *J Toxicol Environ Health A* 70: 200-212. <http://dx.doi.org/10.1080/15287390600883018>
- [Jerrett, M; Burnett, RT; Beckerman, BS; Turner, MC; Krewski, D; Thurston, G; Martin, RV; van Donkelaar, A; Hughes, E; Shi, Y; Gapstur, SM; Thun, MJ; Pope, CA, III.](#) (2013). Spatial analysis of air pollution and mortality in California. *Am J Respir Crit Care Med* 188: 593-599. <http://dx.doi.org/10.1164/rccm.201303-0609OC>
- [Jerrett, M; Finkelstein, MM; Brook, JR; Arain, MA; Kanaroglou, P; Stieb, DM; Gilbert, NL; Verma, D; Finkelstein, N; Chapman, KR; Sears, MR.](#) (2009). A cohort study of traffic-related air pollution and mortality in Toronto, Ontario, Canada. *Environ Health Perspect* 117: 772-777. <http://dx.doi.org/10.1289/ehp.11533>
- [Jerrett, M; Shankardass, K; Berhane, K; Gauderman, WJ; Künzli, N; Avol, E; Gilliland, F; Lurmann, F; Molitor, JN; Molitor, JT; Thomas, DC; Peters, J; McConnell, R.](#) (2008). Traffic-related air pollution and asthma onset in children: A prospective cohort study with individual exposure measurement. *Environ Health Perspect* 116: 1433-1438. <http://dx.doi.org/10.1289/ehp.10968>
- [Jevtić, M; Dragić, N; Bijelović, S; Popović, M.](#) (2014). Cardiovascular diseases and air pollution in Novi Sad, Serbia. *Int J Occup Med Environ Health* 27: 153-164. <http://dx.doi.org/10.2478/s13382-014-0239-y>
- [Ji, Y; Gao, Y; Li, G; An, T.](#) (2012). Theoretical study of the reaction mechanism and kinetics of low-molecular-weight atmospheric aldehydes (C1C4) with NO<sub>2</sub>. *Atmos Environ* 54: 288-295. <http://dx.doi.org/10.1016/j.atmosenv.2012.02.040>
- [Jia, X; Song, X; Shima, M; Tamura, K; Deng, F; Guo, X.](#) (2011). Acute effect of ambient ozone on heart rate variability in healthy elderly subjects. *J Expo Sci Environ Epidemiol* 21: 541-547. <http://dx.doi.org/10.1038/jes.2011.18>
- [Jiang, LL; Zhang, YH; Song, GX; Chen, GH; Chen, BH; Zhao, NQ; Kan, HD.](#) (2007). A time series analysis of outdoor air pollution and preterm birth in Shanghai, China. *Biomed Environ Sci* 20: 426-431.
- [Jilma, B; Kastner, J; Mensik, C; Vondrovec, B; Hildebrandt, J; Krejcy, K; Wagner, OF; Eichler, H.](#) (1996). Sex differences in concentrations of exhaled nitric oxide and plasma nitrate. *Life Sci* 58: 469-476. [http://dx.doi.org/10.1016/0024-3205\(95\)02311-9](http://dx.doi.org/10.1016/0024-3205(95)02311-9)
- [Johnson, JY; Rowe, BH; Villeneuve, PJ.](#) (2010a). Ecological analysis of long-term exposure to ambient air pollution and the incidence of stroke in Edmonton, Alberta, Canada. *Stroke* 41: 1319-1325. <http://dx.doi.org/10.1161/STROKEAHA.110.580571>
- [Johnson, JYM; Rowe, BH; Allen, RW; Peters, PA; Villeneuve, PJ.](#) (2013). A case-control study of medium-term exposure to ambient nitrogen dioxide pollution and hospitalization for stroke. *BMC Public Health* 13: 368. <http://dx.doi.org/10.1186/1471-2458-13-368>
- [Johnson, M; Isakov, V; Touma, JS; Mukerjee, S; Özkaynak, H.](#) (2010b). Evaluation of land-use regression models used to predict air quality concentrations in an urban area. *Atmos Environ* 44: 3660-3668. <http://dx.doi.org/10.1016/j.atmosenv.2010.06.041>
- [Jones, SL; Kittelson, J; Cowan, JO; Flannery, EM; Hancox, RJ; McLachlan, CR; Taylor, DR.](#) (2001). The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. *Am J Respir Crit Care Med* 164: 738-743. <http://dx.doi.org/10.1164/ajrccm.164.5.2012125>

- [Jörres, R; Magnussen, H.](#) (1990). Airways response of asthmatics after a 30 min exposure, at resting ventilation, to 0.25 ppm NO<sub>2</sub> or 0.5 ppm SO<sub>2</sub>. *Eur Respir J* 3: 132-137.
- [Jörres, R; Magnussen, H.](#) (1991). Effect of 0.25 ppm nitrogen dioxide on the airway response to methacholine in asymptomatic asthmatic patients. *Lung* 169: 77-85. <http://dx.doi.org/10.1007/BF02714145>
- [Jörres, R; Nowak, D; Grimminger, F; Seeger, W; Oldigs, M; Magnussen, H.](#) (1995). The effect of 1 ppm nitrogen dioxide on bronchoalveolar lavage cells and inflammatory mediators in normal and asthmatic subjects. *Eur Respir J* 8: 416-424. <http://dx.doi.org/10.1183/09031936.95.08030416>
- [Joyce, PL; von Glasow, R; Simpson, WR.](#) (2014). The fate of NO<sub>x</sub> emissions due to nocturnal oxidation at high latitudes: 1-D simulations and sensitivity experiments. *Atmos Chem Phys* 14: 7601-7616. <http://dx.doi.org/10.5194/acp-14-7601-2014>
- [Jurewicz, J; Radwan, M; Sobala, W; Polańska, K; Radwan, P; Jakubowski, L; Ułańska, A; Hanke, W.](#) (2014). The relationship between exposure to air pollution and sperm disomy. *Environ Mol Mutagen* 56: 50-59. <http://dx.doi.org/10.1002/em.21883>
- [Just, J; Segala, C; Sahraoui, F; Priol, G; Grimfeld, A; Neukirch, F.](#) (2002). Short-term health effects of particulate and photochemical air pollution in asthmatic children. *Eur Respir J* 20: 899-906. <http://dx.doi.org/10.1183/09031936.02.00236902>
- [Kan, H; Chen, B; Zhao, N; London, SJ; Song, G; Chen, G; Zhang, Y; Jiang, L.](#) (2010). Part 1. A time-series study of ambient air pollution and daily mortality in Shanghai, China. In *Public Health and Air Pollution in Asia (PAPA): Coordinated studies of short-term exposure to air pollution and daily mortality in four cities* (pp. 17-78). Boston, MA: Health Effects Institute. <http://pubs.healtheffects.org/view.php?id=348>
- [Kan, H; London, SJ; Chen, G; Zhang, Y; Song, G; Zhao, N; Jiang, L; Chen, B.](#) (2008). Season, sex, age, and education as modifiers of the effects of outdoor air pollution on daily mortality in Shanghai, China: The Public Health and Air Pollution in Asia (PAPA) Study. *Environ Health Perspect* 116: 1183-1188. <http://dx.doi.org/10.1289/ehp.10851>
- [Kannan, S; Misra, DP; Dvorch, JT; Krishnakumar, A.](#) (2006). Exposures to airborne particulate matter and adverse perinatal outcomes: A biologically plausible mechanistic framework for exploring potential effect modification by nutrition. *Environ Health Perspect* 114: 1636-1642. <http://dx.doi.org/10.1289/ehp.9081>
- [Karakatsani, A; Analitis, A; Perifanou, D; Ayres, JG; Harrison, RM; Kotronarou, A; Kavouras, IG; Pekkanen, J; Hämeri, K; Kos, GP; de Hartog, JJ; Hoek, G; Katsouyanni, K.](#) (2012). Particulate matter air pollution and respiratory symptoms in individuals having either asthma or chronic obstructive pulmonary disease: A European multicentre panel study. *Environ Health* 11: 75. <http://dx.doi.org/10.1186/1476-069X-11-75>
- [Karner, AA; Eisinger, DS; Niemeier, DA.](#) (2010). Near-roadway air quality: Synthesizing the findings from real-world data. *Environ Sci Technol* 44: 5334-5344. <http://dx.doi.org/10.1021/es100008x>
- [Karr, C; Lumley, T; Shepherd, K; Davis, R; Larson, T; Ritz, B; Kaufman, J.](#) (2006). A case-crossover study of wintertime ambient air pollution and infant bronchiolitis. *Environ Health Perspect* 114: 277-281. <http://dx.doi.org/10.1289/ehp.8313>
- [Karr, CJ; Rudra, CB; Miller, KA; Gould, TR; Larson, T; Sathyanarayana, S; Koenig, JQ.](#) (2009). Infant exposure to fine particulate matter and traffic and risk of hospitalization for RSV bronchiolitis in a region with lower ambient air pollution. *Environ Res* 109: 321-327. <http://dx.doi.org/10.1016/j.envres.2008.11.006>
- [Kashima, S; Naruse, H; Yorifuji, T; Ohki, S; Murakoshi, T; Takao, S; Tsuda, T; Doi, H.](#) (2011). Residential proximity to heavy traffic and birth weight in Shizuoka, Japan. *Environ Res* 111: 377-387. <http://dx.doi.org/10.1016/j.envres.2011.02.005>
- [Kastner-Klein, P; Fedorovich, E; Ketzel, M; R, B; Britter, R.](#) (2003). The modelling of turbulence from traffic in urban dispersion models part II: Evaluation against laboratory and full-scale concentration measurements in street canyons. *Environ Fluid Mech* 3: 145-172. <http://dx.doi.org/10.1023/A:1022049224166>
- [Kastner-Klein, P; Fedorovich, E; Rotach, MW.](#) (2001). A wind tunnel study of organised and turbulent air motions in urban street canyons. *J Wind Eng Ind Aerod* 89: 849-861. [http://dx.doi.org/10.1016/S0167-6105\(01\)00074-5](http://dx.doi.org/10.1016/S0167-6105(01)00074-5)

- [Katanoda, K; Sobue, T; Satoh, H; Tajima, K; Suzuki, T; Nakatsuka, H; Takezaki, T; Nakayama, T; Nitta, H; Tanabe, K; Tominaga, S.](#) (2011). An association between long-term exposure to ambient air pollution and mortality from lung cancer and respiratory diseases in Japan. *J Epidemiol* 21: 132-143. <http://dx.doi.org/10.2188/jea.JE20100098>
- [Katsouyanni, K; Samet, JM; Anderson, HR; Atkinson, R; Le Tertre, A; Medina, S; Samoli, E; Touloumi, G; Burnett, RT; Krewski, D; Ramsay, T; Dominici, F; Peng, RD; Schwartz, J; Zanobetti, A.](#) (2009). Air pollution and health: A European and North American approach (APHENA) (pp. 5-90). (ISSN 1041-5505 Research Report 142). Boston, MA: Health Effects Institute. <http://pubs.healtheffects.org/view.php?id=327>
- [Katsouyanni, K; Touloumi, G; Samoli, E; Gryparis, A; Le Tertre, A; Monopolis, Y; Rossi, G; Zmirou, D; Ballester, F; Boumghar, A; Anderson, HR; Wojtyniak, B; Paldy, A; Braunstein, R; Pekkanen, J; Schindler, C; Schwartz, J.](#) (2001). Confounding and effect modification in the short-term effects of ambient particles on total mortality: Results from 29 European cities within the APHEA2 project. *Epidemiology* 12: 521-531.
- [Katsouyanni, K; Touloumi, G; Samoli, E; Petasakis, Y; Analitis, A; Le Tertre, A; Rossi, G; Zmirou, D; Ballester, F; Boumghar, A; Anderson, HR; Wojtyniak, B; Paldy, A; Braunstein, R; Pekkanen, J; Schindler, C; Schwartz, J.](#) (2003). Sensitivity analysis of various models of short-term effects of ambient particles on total mortality in 29 cities in APHEA2. In *Revised Analyses of Time-series Studies of Air Pollution and Health* (pp. 157-164). Boston, MA: Health Effects Institute.
- [Kebabian, PL; Wood, EC; Herndon, SC; Freedman, A.](#) (2008). A practical alternative to chemiluminescence-based detection of nitrogen dioxide: Cavity attenuated phase shift spectroscopy. *Environ Sci Technol* 42: 6040-6045. <http://dx.doi.org/10.1021/es703204j>
- [Kehrl, HR; Peden, DB; Ball, B; Folinsbee, LJ; Horstman, D.](#) (1999). Increased specific airway reactivity of persons with mild allergic asthma after 7.6 hours of exposure to 0.16 ppm ozone. *J Allergy Clin Immunol* 104: 1198-1204. [http://dx.doi.org/10.1016/S0091-6749\(99\)70013-8](http://dx.doi.org/10.1016/S0091-6749(99)70013-8)
- [Kelishadi, R; Mirghaffari, N; Poursafa, P; Gidding, SS.](#) (2009). Lifestyle and environmental factors associated with inflammation, oxidative stress and insulin resistance in children. *Atherosclerosis* 203: 311-319. <http://dx.doi.org/10.1016/j.atherosclerosis.2008.06.022>
- [Keller, JP; Olives, C; Kim, SY; Sheppard, L; Sampson, PD; Szpiro, AA; Oron, AP; Lindström, J; Vedal, S; Kaufman, JD.](#) (2015). A unified spatiotemporal modeling approach for predicting concentrations of multiple air pollutants in the multi-ethnic study of atherosclerosis and air pollution. *Environ Health Perspect* 123: 301-309. <http://dx.doi.org/10.1289/ehp.1408145>
- [Kelly, FJ; Blomberg, A; Frew, A; Holgate, ST; Sandstrom, T.](#) (1996a). Antioxidant kinetics in lung lavage fluid following exposure of humans to nitrogen dioxide. *Am J Respir Crit Care Med* 154: 1700-1705. <http://dx.doi.org/10.1164/ajrccm.154.6.8970358>
- [Kelly, FJ; Cotgrove, M; Mudway, IS.](#) (1996b). Respiratory tract lining fluid antioxidants: the first line of defence against gaseous pollutants. *Cent Eur J Public Health* 4: 11-14.
- [Kelly, FJ; Tetley, TD.](#) (1997). Nitrogen dioxide depletes uric acid and ascorbic acid but not glutathione from lung lining fluid. *Biochemistry* 325: 95-99.
- [Kettle, AJ; Clark, BM; Winterbourn, CC.](#) (2004). Superoxide converts indigo carmine to isatin sulfonic acid: Implications for the hypothesis that neutrophils produce ozone. *J Biol Chem* 279: 18521-18525. <http://dx.doi.org/10.1074/jbc.M400334200>
- [Khafaie, MA; Salvi, SS; Ojha, A; Khafaie, B; Gore, SS; Yajnik, CS.](#) (2013). Systemic inflammation (C-reactive protein) in type 2 diabetic patients is associated with ambient air pollution in Pune City, India. *Diabetes Care* 36: 625-630. <http://dx.doi.org/10.2337/dc12-0388>
- [Kharitonov, SA; Barnes, PJ.](#) (2000). Clinical aspects of exhaled nitric oxide [Review]. *Eur Respir J* 16: 781-792.
- [Kharitonov, SA; Walker, L; Barnes, PJ.](#) (2005). Repeatability of standardised nasal nitric oxide measurements in healthy and asthmatic adults and children. *Respir Med* 99: 1105-1114. <http://dx.doi.org/10.1016/j.rmed.2005.02.019>

- Kheirbek, I; Ito, K; Neitzel, R; Kim, J; Johnson, S; Ross, Z; Eisl, H; Matte, T. (2014). Spatial Variation in Environmental Noise and Air Pollution in New York City. *J Urban Health* 91: 415-431. <http://dx.doi.org/10.1007/s11524-013-9857-0>
- Khoder, MI. (2002). Nitrous acid concentrations in homes and offices in residential areas in Greater Cairo. *J Environ Monit* 4: 573-578. <http://dx.doi.org/10.1039/b201818g>
- Khoo, NK; Rudolph, V; Cole, MP; Golin-Bisello, F; Schopfer, FJ; Woodcock, SR; Batthyany, C; Freeman, BA. (2010). Activation of vascular endothelial nitric oxide synthase and heme oxygenase-1 expression by electrophilic nitro-fatty acids. *Free Radic Biol Med* 48: 230-239. <http://dx.doi.org/10.1016/j.freeradbiomed.2009.10.046>
- Kikugawa, K; Kogi, K. (1987). Oxidation products of linoleate and linolenate exposed to nitrogen dioxide. *Chem Pharm Bull (Tokyo)* 35: 344-349. <http://dx.doi.org/10.1248/cpb.35.344>
- Kikuya, M; Hozawa, A; Ohokubo, T; Tsuji, I; Michimata, M; Matsubara, M; Ota, M; Nagai, K; Araki, T; Satoh, H; Ito, S; Hisamichi, S; Imai, Y. (2000). Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. *Hypertension* 36: 901-906. <http://dx.doi.org/10.1161/01.HYP.36.5.901>
- Kilkenny, C; Browne, WJ; Cuthill, IC; Emerson, M; Altman, DG. (2010). Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research [Review]. *PLoS Biol* 8: e1000412. <http://dx.doi.org/10.1371/journal.pbio.1000412>
- Kim, D; Sass-Kortsak, A; Purdham, JT; Dales, RE; Brook, JR. (2006a). Associations between personal exposures and fixed-site ambient measurements of fine particulate matter, nitrogen dioxide, and carbon monoxide in Toronto, Canada. *J Expo Sci Environ Epidemiol* 16: 172-183. <http://dx.doi.org/10.1038/sj.jea.7500446>
- Kim, E; Park, H; Hong, YC; Ha, M; Kim, Y; Kim, BN; Kim, Y; Roh, YM; Lee, BE; Ryu, JM; Kim, BM; Ha, EH. (2014). Prenatal exposure to PM10 and NO2 and children's neurodevelopment from birth to 24 months of age: Mothers and Children's Environmental Health (MOCEH) study. *Sci Total Environ* 481: 439-445. <http://dx.doi.org/10.1016/j.scitotenv.2014.01.107>
- Kim, JH; Hong, YC. (2012). GSTM1, GSTT1, and GSTP1 polymorphisms and associations between air pollutants and markers of insulin resistance in elderly Koreans. *Environ Health Perspect* 120: 1378-1384. <http://dx.doi.org/10.1289/ehp.1104406>
- Kim, JJ; Smorodinsky, S; Lipsett, M; Singer, BC; Hodgson, AT; Ostro, B. (2004). Traffic-related air pollution near busy roads: the East Bay children's Respiratory Health Study. *Am J Respir Crit Care Med* 170: 520-526. <http://dx.doi.org/10.1164/rccm.200403-281OC>
- Kim, S; Kim, Y; Lee, MR; Kim, J; Jung, A; Park, JS; Jang, AS; Park, SW; Uh, ST; Choi, JS; Kim, YH; Buckley, T; Park, CS. (2012). Winter season temperature drops and sulfur dioxide levels affect on exacerbation of refractory asthma in South Korea: a time-trend controlled case-crossover study using soonchunhyang asthma cohort data. *J Asthma* 49: 679-687. <http://dx.doi.org/10.3109/02770903.2012.702839>
- Kim, SW; Heckel, A; McKeen, SA; Frost, GJ; Hsie, E, -Y; Trainer, MK; Richter, A; Burrows, JP; Peckham, SE; Grell, GA. (2006b). Satellite-observed U.S. power plant NOx emission reductions and their impact on air quality. *Geophys Res Lett* 33: L22812. <http://dx.doi.org/10.1029/2006GL027749>
- Kim, SW; McKeen, SA; Frost, GJ; Lee, SH; Trainer, M; Richter, A; Angevine, WM; Atlas, E; Bianco, L; Boersma, KF; Brioude, J; Burrows, JP; de Gouw, J; Fried, A; Gleason, J; Hilboll, A; Mellqvist, J; Peischl, J; Richter, D; Rivera, C; Ryerson, T; Te Lintel Hekkert, S; Walega, J; Warneke, C; Weibring, P; Williams, E. (2011). Evaluations of NOx and highly reactive VOC emission inventories in Texas and their implications for ozone plume simulations during the Texas Air Quality Study 2006. *Atmos Chem Phys* 11: 11361-11386. <http://dx.doi.org/10.5194/acp-11-11361-2011>
- Kim, SY; O'Neill, MS; Lee, JT; Cho, Y; Kim, J; Kim, H. (2007). Air pollution, socioeconomic position, and emergency hospital visits for asthma in Seoul, Korea. *Int Arch Occup Environ Health* 80: 701-710. <http://dx.doi.org/10.1007/s00420-007-0182-3>
- Kim, YM; Kim, YS; Jeon, SG; Kim, YK. (2013). Immunopathogenesis of allergic asthma: more than the Th2 hypothesis. *Allergy Asthma Immunol Res* 5: 189-196. <http://dx.doi.org/10.4168/air.2013.5.4.189>

- [Kimbrough, ES; Baldauf, RW; Watkins, N.](#) (2013). Seasonal and diurnal analysis of NO<sub>2</sub> concentrations from a long-duration study conducted in Las Vegas, Nevada. *J Air Waste Manag Assoc* 63: 934-942. <http://dx.doi.org/10.1080/10962247.2013.795919>
- [Kingsley, SL; Eliot, MN; Carlson, L; Finn, J; Macintosh, DL; Suh, HH; Wellenius, GA.](#) (2014). Proximity of US schools to major roadways: a nationwide assessment. *J Expo Sci Environ Epidemiol* 24: 253-259. <http://dx.doi.org/10.1038/jes.2014.5>
- [Kinsella, J; Carter, R; Reid, WH; Campbell, D; Clark, CJ.](#) (1991). Increased airways reactivity after smoke inhalation. *Lancet* 337: 595-597.
- [Kirsch, M; Korth, HG; Sustmann, R; De Groot, H.](#) (2002). The pathobiochemistry of nitrogen dioxide [Review]. *Biol Chem* 383: 389-399. <http://dx.doi.org/10.1515/BC.2002.043>
- [Kitabatake, M; Yamamoto, H; Yuan, PF; Manjurul, H; Murase, S; Yamauchi, T.](#) (1995). Effects of exposure to NO<sub>2</sub> or SO<sub>2</sub> on bronchopulmonary reaction induced by *Candida albicans* in guinea pigs. *J Toxicol Environ Health* 45: 75-82. <http://dx.doi.org/10.1080/15287399509531981>
- [Kjaergaard, SK; Rasmussen, TR.](#) (1996). Clinical studies of effects of nitrogen oxides in healthy and asthmatic subjects. *Cent Eur J Public Health* 4: 23-26.
- [Klapmeyer, ME; Marr, LC.](#) (2012). CO<sub>2</sub>, NO<sub>x</sub>, and particle emissions from aircraft and support activities at a regional airport. *Environ Sci Technol* 46: 10974-10981. <http://dx.doi.org/10.1021/es302346x>
- [Kleeberger, SR; Zhang, LY; Jakab, GJ.](#) (1997). Differential susceptibility to oxidant exposure in inbred strains of mice: Nitrogen dioxide versus ozone. *Inhal Toxicol* 9: 601-621. <http://dx.doi.org/10.1080/089583797198006>
- [Kleffmann, J; Tapia, GV; Bejan, I; Kurtenbach, R; Wiesen, P.](#) (2013). NO<sub>2</sub> measurement techniques: Pitfalls and new developments. In I Barnes; KJ Rudzin'ski (Eds.), *Disposal of dangerous chemicals in urban areas and mega cities*. New York, NY: Springer. [http://dx.doi.org/10.1007/978-94-007-5034-0\\_2](http://dx.doi.org/10.1007/978-94-007-5034-0_2)
- [Kleinman, MT; Bailey, RM; Linn, WS; Anderson, KR; Whynot, JD; Shamoo, DA; Hackney, JD.](#) (1983). Effects of 0.2 ppm nitrogen dioxide on pulmonary function and response to bronchoprovocation in asthmatics. *J Toxicol Environ Health* 12: 815-826. <http://dx.doi.org/10.1080/15287398309530472>
- [Kleinman, MT; Mautz, WJ.](#) (1991). The effects of exercise on dose and dose distribution of inhaled automotive pollutants. (Research Report no. 45). Cambridge, MA: Health Effects Institute. <http://pubs.healtheffects.org/view.php?id=45>
- [Klepeis, NE; Nelson, WC; Ott, WR; Robinson, JP; Tsang, AM; Switzer, P; Behar, JV; Hern, SC; Engelmann, WH.](#) (2001). The National Human Activity Pattern Survey (NHAPS): A resource for assessing exposure to environmental pollutants. *J Expo Anal Environ Epidemiol* 11: 231-252. <http://dx.doi.org/10.1038/sj.jea.7500165>
- [Klepeis, NE; Tsang, AM; Behar, JV.](#) (1996). Analysis of the national human activity pattern survey (NHAPS) respondents from a standpoint of exposure assessment [EPA Report]. (EPA/600/R-96/074). Washington, DC: U.S. Environmental Protection Agency. [http://exposurescience.org/pub/reports/NHAPS\\_Report1.pdf#...Local](http://exposurescience.org/pub/reports/NHAPS_Report1.pdf#...Local) SettingsTemporary Internet FilesContent.Outlook3JQ221FPB\_Approaches\_Population\_Tables.docx
- [Klimisch, HJ; Andreae, M; Tillmann, U.](#) (1997). A systematic approach for evaluating the quality of experimental toxicological and ecotoxicological data. *Regul Toxicol Pharmacol* 25: 1-5. <http://dx.doi.org/10.1006/rtph.1996.1076>
- [Kloek, J; Mortaz, E; van Ark, I; Lilly, CM; Nijkamp, FP; Folkerts, G.](#) (2010). Glutathione prevents the early asthmatic reaction and airway hyperresponsiveness in guinea pigs. *J Physiol Pharmacol* 61: 67-72.
- [Knuckles, TL; Buntz, JG; Paffett, M; Channell, M; Harmon, M; Cherng, T; Lucas, SN; McDonald, JD; Kanagy, NL; Campen, MJ.](#) (2011). Formation of vascular S-nitrosothiols and plasma nitrates/nitrites following inhalation of diesel emissions. *J Toxicol Environ Health A* 74: 828-837. <http://dx.doi.org/10.1080/15287394.2011.570225>

- Ko, FW; Tam, W; Wong, TW; Chan, DP; Tung, AH; Lai, CKW; Hui, DSC. (2007a). Temporal relationship between air pollutants and hospital admissions for chronic obstructive pulmonary disease in Hong Kong. *Thorax* 62: 780-785. <http://dx.doi.org/10.1136/thx.2006.076166>
- Ko, FWS; Tam, W; Wong, TW; Lai, CKW; Wong, GWK; Leung, TF; Ng, SSS; Hui, DSC. (2007b). Effects of air pollution on asthma hospitalization rates in different age groups in Hong Kong. *Clin Exp Allergy* 37: 1312-1319. <http://dx.doi.org/10.1111/j.1365-2222.2007.02791.x>
- Kobayashi, T; Miura, T. (1995). Concentration- and time-dependent increase in specific airway resistance after induction of airway hyperresponsiveness by subchronic exposure of guinea pigs to nitrogen dioxide. *Fundam Appl Toxicol* 25: 154-158. <http://dx.doi.org/10.1006/faat.1995.1049>
- Kobayashi, T; Shinozaki, Y. (1990). Effect of subacute exposure to nitrogen dioxide on the airway responsiveness of guinea pig. *Agents Actions Suppl* 31: 71-74.
- Kodama, Y; Arashidani, K; Tokui, N; Kawamoto, T; Matsuno, K; Kunugita, N; Minakawa, N. (2002). Environmental NO<sub>2</sub> concentration and exposure in daily life along main roads in Tokyo. *Environ Res* 89: 236-244. <http://dx.doi.org/10.1006/enrs.2002.4350>
- Koehler, C; Ginzkey, C; Friehs, G; Hackenberg, S; Froelich, K; Scherzed, A; Burghartz, M; Kessler, M; Kleinsasser, N. (2010). Aspects of nitrogen dioxide toxicity in environmental urban concentrations in human nasal epithelium. *Toxicol Appl Pharmacol* 245: 219-225. <http://dx.doi.org/10.1016/j.taap.2010.03.003>
- Koehler, C; Ginzkey, C; Friehs, G; Hackenberg, S; Froelich, K; Scherzed, A; Burghartz, M; Kessler, M; Kleinsasser, N. (2011). Ex vivo toxicity of nitrogen dioxide in human nasal epithelium at the WHO defined 1-h limit value. *Toxicol Lett* 207: 89-95. <http://dx.doi.org/10.1016/j.toxlet.2011.08.004>
- Koehler, C; Thielen, S; Ginzkey, C; Hackenberg, S; Scherzed, A; Burghartz, M; Paulus, M; Hagen, R; Kleinsasser, NH. (2013). Nitrogen dioxide is genotoxic in urban concentrations. *Inhal Toxicol* 25: 341-347. <http://dx.doi.org/10.3109/08958378.2013.788104>
- Koenig, JQ; Covert, DS; Marshall, SG; Van Belle, G; Pierson, WE. (1987). The effects of ozone and nitrogen dioxide on pulmonary function in healthy and in asthmatic adolescents. *Am J Respir Crit Care Med* 136: 1152-1157. <http://dx.doi.org/10.1164/ajrccm/136.5.1152>
- Kornartit, C; Sokhi, RS; Burton, MA; Ravindra, K. (2010). Activity pattern and personal exposure to nitrogen dioxide in indoor and outdoor microenvironments. *Environ Int* 36: 36-45. <http://dx.doi.org/10.1016/j.envint.2009.09.004>
- Kousa, A; Monn, C; Rotko, T; Alm, S; Oblesby, L; Jantunen, MJ. (2001). Personal exposures to NO<sub>2</sub> in the EXPOLIS-study: Relation to residential indoor, outdoor and workplace concentrations in Basel, Helsinki and Prague. *Atmos Environ* 35: 3405-3412.
- Koutrakis, P; Suh, HH; Sarnat, JA; Brown, KW; Coull, BA; Schwartz, J. (2005). Characterization of particulate and gas exposures of sensitive subpopulations living in Baltimore and Boston (pp. 1-65; discussion 67-75). (ISSN 1041-5505131). Boston, MA: Health Effects Institute. <http://pubs.healtheffects.org/view.php?id=91>
- Kramer, U; Herder, C; Sugiri, D; Strassburger, K; Schikowski, T; Ranft, U; Rathmann, W. (2010). Traffic-related air pollution and incident type 2 diabetes: Results from the SALIA cohort study. *Environ Health Perspect* 118: 1273-1279. <http://dx.doi.org/10.1289/ehp.0901689>
- Krämer, U; Sugiri, D; Ranft, U; Krutmann, J; von Berg, A; Berdel, D; Behrendt, H; Kuhlbusch, T; Hochadel, M; Wichmann, HE; Heinrich, J. (2009). Eczema, respiratory allergies, and traffic-related air pollution in birth cohorts from small-town areas. *J Dermatol Sci* 56: 99-105. <http://dx.doi.org/10.1016/j.jdermsci.2009.07.014>
- Krewski, D; Burnett, RT; Goldberg, MS; Hoover, K; Siemiatycki, J; Jerrett, M; Abrahamowicz, M; White, WH. (2000). Reanalysis of the Harvard Six Cities study and the American Cancer Society study of particulate air pollution and mortality. Cambridge, MA: Health Effects Institute. <http://pubs.healtheffects.org/view.php?id=6>

- [Krewski, D; Jerrett, M; Burnett, RT; Ma, R; Hughes, E; Shi, Y; Turner, MC; Pope AC, I; Thurston, G; Calle, EE; Thun, MJ; Beckerman, B; Deluca, P; Finkelstein, N; Ito, K; Moore, DK; Newbold, KB; Ramsay, T; Ross, Z; Shin, H; Tempalski, B.](#) (2009). Extended follow-up and spatial analysis of the American Cancer Society study linking particulate air pollution and mortality (pp. 5-114; discussion 115-136). (ISSN 1041-5505, HEI Research Report 140). Boston, MA: Health Effects Institute. <http://pubs.healtheffects.org/view.php?id=315>
- [Kripke, BJ; Sherwin, RP.](#) (1984). Nitrogen dioxide exposure--influence on rat testes. *Anesth Analg* 63: 526-528.
- [Krishna, MT; Holgate, ST.](#) (1999). Inflammatory mechanisms underlying potentiation of effects of inhaled aeroallergens in response to nitrogen dioxide in allergic airways disease [Review]. *Clin Exp Allergy* 29: 150-154. <http://dx.doi.org/10.1046/j.1365-2222.1999.00512.x>
- [Kruize, H; Driessen, PP; Glasbergen, P; van Egmond, KN.](#) (2007). Environmental equity and the role of public policy: Experiences in the Rijnmond region. *Environ Manage* 40: 578-595. <http://dx.doi.org/10.1007/s00267-005-0378-9>
- [Kruize, H; Hanninen, O; Breugelmans, O; Lebret, E; Jantunen, M.](#) (2003). Description and demonstration of the EXPOLIS simulation model: two examples of modeling population exposure to particulate matter. *J Expo Anal Environ Epidemiol* 13: 87-99. <http://dx.doi.org/10.1038/sj.jea.7500258>
- [Kubota, K; Murakami, M; Takenaka, S; Kawai, K; Kyono, H.](#) (1987). Effects of long-term nitrogen dioxide exposure on rat lung: Morphological observations. *Environ Health Perspect* 73: 157-169.
- [Kudo, M; Ishigatsubo, Y; Aoki, I.](#) (2013a). Pathology of asthma [Review]. *FMICB* 4: 1-16. <http://dx.doi.org/10.3389/fmicb.2013.00263>
- [Kudo, M; Khalifeh Soltani, SM; Sakuma, SA; McKleroy, W; Lee, TH; Woodruff, PG; Lee, JW; Huang, K; Chen, C; Arjomandi, M; Huang, X; Atabai, K.](#) (2013b). Mfge8 suppresses airway hyperresponsiveness in asthma by regulating smooth muscle contraction. *PNAS* 110: 660-665. <http://dx.doi.org/10.1073/pnas.1216673110>
- [Kulle, TJ; Clements, ML.](#) (1988). Susceptibility to virus infection with exposure to nitrogen dioxide (pp. 5-21). (ISSN 1041-5505). Cambridge, MA: Health Effects Institute. <http://pubs.healtheffects.org/view.php?id=243>
- [Kumae, T; Arakawa, H.](#) (2006). Comparison of effects of in vivo nitrogen dioxide exposure starting from different periods on alveolar macrophage activity, assessed by a chemiluminescence technique in Brown-Norway rats. *Luminescence* 21: 226-232. <http://dx.doi.org/10.1002/bio.911>
- [Kunimoto, M; Mochitate, K; Kaya, K; Miura, T; Kubota, K.](#) (1984). Effects of nitrogen dioxide on red blood cells of rats: Alterations of cell membrane components and populational changes of red blood cells during in vivo exposure to NO<sub>2</sub>. *Environ Res* 33: 361-369.
- [La Rovere, MT; Pinna, GD; Maestri, R; Mortara, A; Capomolla, S; Febo, O; Ferrari, R; Franchini, M; Gnemmi, M; Opasich, C; Riccardi, PG; Traversi, E; Cobelli, F.](#) (2003). Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. *Circulation* 107: 565-570.
- [LaFranchi, BW; Goldstein, AH; Cohen, RC.](#) (2011). Observations of the temperature dependent response of ozone to NO<sub>x</sub> reductions in the Sacramento, CA urban plume. *Atmos Chem Phys* 11: 6945-6960. <http://dx.doi.org/10.5194/acp-11-6945-2011>
- [Lafuma, C; Harf, A; Lange, F; Bozzi, L; Poncy, JL; Bignon, J.](#) (1987). Effect of low-level NO<sub>2</sub> chronic exposure on elastase-induced emphysema. *Environ Res* 43: 75-84. [http://dx.doi.org/10.1016/S0013-9351\(87\)80059-2](http://dx.doi.org/10.1016/S0013-9351(87)80059-2)
- [Lagorio, S; Forastiere, F; Pistelli, R; Iavarone, I; Michelozzi, P; Fano, V; Marconi, A; Ziemacki, G; Ostro, BD.](#) (2006). Air pollution and lung function among susceptible adult subjects: A panel study. *Environ Health* 5: 11. <http://dx.doi.org/10.1186/1476-069X-5-11>
- [Lampl, M; Jeanty, P.](#) (2003). Timing is everything: A reconsideration of fetal growth velocity patterns identifies the importance of individual and sex differences. *Am J Hum Biol* 15: 667-680. <http://dx.doi.org/10.1002/ajhb.10204>

- [Lamsal, LN; Martin, RV; Van Donkelaar, A; Celarier, EA; Bucsela, EJ; Boersma, KF; Dirksen, R; Luo, C; Wang, Y.](#) (2010). Indirect validation of tropospheric nitrogen dioxide retrieved from the OMI satellite instrument: Insight into the seasonal variation of nitrogen oxides at northern midlatitudes. *J Geophys Res* 115: D05302. <http://dx.doi.org/10.1029/2009JD013351>
- [Lamsal, LN; Martin, RV; Van Donkelaar, A; Steinbacher, M; Celarier, EA; Bucsela, E; Dunlea, EJ; Pinto, JP.](#) (2008). Ground-level nitrogen dioxide concentrations inferred from the satellite-borne ozone monitoring instrument. *J Geophys Res* 113: D16308. <http://dx.doi.org/10.1029/2007JD009235>
- [Langrish, JP; Lundbäck, M; Barath, S; Söderberg, S; Mills, NL; Newby, DE; Sandström, T; Blomberg, A.](#) (2010). Exposure to nitrogen dioxide is not associated with vascular dysfunction in man. *Inhal Toxicol* 22: 192-198. <http://dx.doi.org/10.3109/08958370903144105>
- [Larrieu, S; Jusot, JF; Blanchard, M; Prouvost, H; Declercq, C; Fabre, P; Pascal, L; Le Tertre, A; Wagner, V; Rivière, S; Chardon, B; Borelli, D; Cassadou, S; Eilstein, D; Lefranc, A.](#) (2007). Short term effects of air pollution on hospitalizations for cardiovascular diseases in eight French cities: The PSAS program. *Sci Total Environ* 387: 105-112. <http://dx.doi.org/10.1016/j.scitotenv.2007.07.025>
- [Last, JA; Warren, DL.](#) (1987). Synergistic interaction between nitrogen dioxide and respirable aerosols of sulfuric acid or sodium chloride on rat lungs. *Toxicol Appl Pharmacol* 90: 34-42. [http://dx.doi.org/10.1016/0041-008X\(87\)90303-6](http://dx.doi.org/10.1016/0041-008X(87)90303-6)
- [Laumbach, RJ; Rich, DQ; Gandhi, S; Amorosa, L; Schneider, S; Zhang, J; Ohman-Strickland, P; Gong, J; Lelyanov, O; Kipen, HM.](#) (2010). Acute changes in heart rate variability in subjects with diabetes following a highway traffic exposure. *J Occup Environ Med* 52: 324-331. <http://dx.doi.org/10.1097/JOM.0b013e3181d241fa>
- [Laupsa, H; Slordal, LH.](#) (2003). Applying model calculations to estimate urban air quality with respect to the requirements of the EU directives on NO<sub>2</sub>, PM<sub>10</sub> and C<sub>6</sub>H<sub>6</sub>. *Int J Environ Pollut* 20: 309-320.
- [Laurent, O; Hu, J; Li, L; Cockburn, M; Escobedo, L; Kleeman, MJ; Wu, J.](#) (2014). Sources and contents of air pollution affecting term low birth weight in Los Angeles County, California, 2001-2008. *Environ Res* 134: 488-495. <http://dx.doi.org/10.1016/j.envres.2014.05.003>
- [Laurent, O; Pedrono, G; Filleul, L; Segala, C; Lefranc, A; Schillinger, C; Riviere, E; Bard, D.](#) (2009). Influence of socioeconomic deprivation on the relation between air pollution and beta-agonist sales for asthma. *Chest* 135: 717-723. <http://dx.doi.org/10.1378/chest.08-1604>
- [Laurent, O; Wu, J; Li, L; Chung, J; Bartell, S.](#) (2013). Investigating the association between birth weight and complementary air pollution metrics: a cohort study. *Environ Health* 12: 18. <http://dx.doi.org/10.1186/1476-069X-12-18>
- [Le, HQ; Batterman, SA; Wirth, JJ; Wahl, RL; Hoggatt, KJ; Sadeghnejad, A; Hultin, ML; Depa, M.](#) (2012). Air pollutant exposure and preterm and term small-for-gestational-age births in Detroit, Michigan: Long-term trends and associations. *Environ Int* 44: 7-17. <http://dx.doi.org/10.1016/j.envint.2012.01.003>
- [Leaderer, BP; Naeher, L; Jankun, T; Balenger, K; Holford, TR; Toth, C; Sullivan, J; Wolfson, JM; Koutrakis, P.](#) (1999). Indoor, outdoor, and regional summer and winter concentrations of PM<sub>10</sub>, PM<sub>2.5</sub>, SO<sub>4</sub><sup>2-</sup>, H<sup>+</sup>, NH<sub>4</sub><sup>+</sup>, NO<sub>3</sub><sup>-</sup>, NH<sub>3</sub>, and nitrous acid in homes with and without kerosene space heaters. *Environ Health Perspect* 107: 223-231.
- [Lee, BE; Ha, EH; Park, HS; Kim, YJ; Hong, YC; Kim, H; Lee, JT.](#) (2003). Exposure to air pollution during different gestational phases contributes to risks of low birth weight. *Hum Reprod* 18: 638-643. <http://dx.doi.org/10.1093/humrep/deg102>
- [Lee, BH; Wood, EC; Zahniser, MS; Mcmanus, JB; Nelson, DD; Herndon, SC; Santoni, GW; Wofsy, SC; Munger, JW.](#) (2011a). Simultaneous measurements of atmospheric HONO and NO<sub>2</sub> via absorption spectroscopy using tunable mid-infrared continuous-wave quantum cascade lasers. *Appl Phys B* 102: 417-423. <http://dx.doi.org/10.1007/s00340-010-4266-5>
- [Lee, BJ; Jeung, YJ; Lee, JY; Choi, DC.](#) (2011b). Increased S-nitrosothiol levels in nonasthmatic eosinophilic bronchitis compared with cough variant asthma. *Int Arch Allergy Immunol* 156: 99-103. <http://dx.doi.org/10.1159/000321919>

- [Lee, H; Gu, M; Kim, YJ; Hwang, J; Jung, U.](#) (2012a). First-time remote sensing of NO<sub>2</sub> vertical distributions in an urban street canyon using Topographic Target Light scattering Differential Optical Absorption Spectroscopy (ToTaL-DOAS). *Atmos Environ* 54: 519-528. <http://dx.doi.org/10.1016/j.atmosenv.2012.02.065>
- [Lee, K; Xue, J; Geyh, AS; Ozkaynak, H; Leaderer, BP; Weschler, CJ; Spengler, JD.](#) (2002). Nitrous acid, nitrogen dioxide, and ozone concentrations in residential environments. *Environ Health Perspect* 110: 145-150.
- [Lee, K; Yang, W; Bofinger, ND.](#) (2000). Impact of microenvironmental nitrogen dioxide concentrations on personal exposures in Australia. *J Air Waste Manag Assoc* 50: 1739-1744.
- [Lee, K; Yeom, J; Yoon, C; Yang, W; Son, BS; Jeon, JM; Yu, SD; Park, CH.](#) (2013). Seasonal and geographic effects on predicting personal exposure to nitrogen dioxide by time-weighted microenvironmental model. *Atmos Environ* 67: 143-148. <http://dx.doi.org/10.1016/j.atmosenv.2012.11.010>
- [Lee, PC; Talbott, EO; Roberts, JM; Catov, JM; Bilonick, RA; Stone, RA; Sharma, RK; Ritz, B.](#) (2012b). Ambient air pollution exposure and blood pressure changes during pregnancy. *Environ Res* 117: 46-53. <http://dx.doi.org/10.1016/j.envres.2012.05.011>
- [Lee, PC; Talbott, EO; Roberts, JM; Catov, JM; Sharma, RK; Ritz, B.](#) (2011c). Particulate air pollution exposure and C-reactive protein during early pregnancy. *Epidemiology* 22: 524-531. <http://dx.doi.org/10.1097/EDE.0b013e31821c6c58>
- [Lee, YL; Wang, WH; Lu, CW; Lin, YH; Hwang, BF.](#) (2011d). Effects of ambient air pollution on pulmonary function among schoolchildren. *Int J Hyg Environ Health* 214: 369-375. <http://dx.doi.org/10.1016/j.ijheh.2011.05.004>
- [Leem, JH; Kaplan, BM; Shim, YK; Pohl, HR; Gotway, CA; Bullard, SM; Rogers, JF; Smith, MM; Tylenda, CA.](#) (2006). Exposures to air pollutants during pregnancy and preterm delivery. *Environ Health Perspect* 114: 905-910. <http://dx.doi.org/10.1289/ehp.8733>
- [Legro, RS; Sauer, MV; Mottla, GL; Richter, KS; Li, X; Dodson, WC; Liao, D.](#) (2010). Effect of air quality on assisted human reproduction. *Hum Reprod* 25: 1317-1324. <http://dx.doi.org/10.1093/humrep/deq021>
- [Lehnert, BE; Archuleta, DC; Ellis, T; Session, WS; Lehnert, NM; Gurley, LR; Stavert, DM.](#) (1994). Lung injury following exposure of rats to relatively high mass concentrations of nitrogen dioxide. *Toxicology* 89: 239-277. [http://dx.doi.org/10.1016/0300-483X\(94\)90100-7](http://dx.doi.org/10.1016/0300-483X(94)90100-7)
- [Lenters, V; Uiterwaal, CS; Beelen, R; Bots, ML; Fischer, P; Brunekreef, B; Hoek, G.](#) (2010). Long-term exposure to air pollution and vascular damage in young adults. *Epidemiology* 21: 512-520. <http://dx.doi.org/10.1097/EDE.0b013e3181dec3a7>
- [Lepeule, J.](#) (2014). Email from Johanna Lepeule to Molini Patel. Re: question re: in press EHP paper (With attachments). Available online
- [Lepeule, J; Bind, MA; Baccarelli, AA; Koutrakis, P; Tarantini, L; Litonjua, A; Sparrow, D; Vokonas, P; Schwartz, JD.](#) (2014). Epigenetic influences on associations between air pollutants and lung function in elderly men: the normative aging study. *Environ Health Perspect* 122: 566-572. <http://dx.doi.org/10.1289/ehp.1206458>
- [Lepeule, J; Caïni, F; Bottagisi, S; Galineau, J; Hulin, A; Marquis, N; Bohet, A; Siroux, V; Kaminski, M; Charles, MA; Slama, R.](#) (2010). Maternal exposure to nitrogen dioxide during pregnancy and offspring birth weight: Comparison of two exposure models. *Environ Health Perspect* 118: 1483-1489. <http://dx.doi.org/10.1289/ehp.0901509>
- [Levy, D; Sheppard, L; Checkoway, H; Kaufman, J; Lumley, T; Koenig, J; Siscovick, D.](#) (2001). A case-crossover analysis of particulate matter air pollution and out-of-hospital primary cardiac arrest. *Epidemiology* 12: 193-199.
- [Levy, I; Mihele, C; Lu, G; Narayan, J; Hilker, N; Brook, JR.](#) (2014). Elucidating multipollutant exposure across a complex metropolitan area by systematic deployment of a mobile laboratory. *Atmos Chem Phys* 14: 7173-7193. <http://dx.doi.org/10.5194/acp-14-7173-2014>

- [Levy, JL; Baxter, LK; Clougherty, JE.](#) (2006). The air quality impacts of road closures associated with the 2004 Democratic National Convention in Boston. *Environ Health* 5: 16. <http://dx.doi.org/10.1186/1476-069X-5-16>
- [Li, H; Chen, L; Guo, Z; Sang, N; Li, G.](#) (2012a). In vivo screening to determine neurological hazards of nitrogen dioxide (NO<sub>2</sub>) using Wistar rats. *J Hazard Mater* 225-226: 46-53. <http://dx.doi.org/10.1016/j.jhazmat.2012.04.063>
- [Li, H; Han, M; Guo, L; Li, G; Sang, N.](#) (2011a). Oxidative stress, endothelial dysfunction and inflammatory response in rat heart to NO inhalation exposure. *Chemosphere* 82: 1589-1596. <http://dx.doi.org/10.1016/j.chemosphere.2010.11.055>
- [Li, H; Li, QD; Wang, MS; Li, FJ; Li, QH; Ma, XJ; Wang, D.](#) (2013). Smoking and air pollution exposure and lung cancer mortality in Zhaoyuan County. *Int J Hyg Environ Health* 216: 63-70. <http://dx.doi.org/10.1016/j.ijheh.2012.06.003>
- [Li, L; Wu, J; Wilhelm, M; Ritz, B.](#) (2012b). Use of generalized additive models and cokriging of spatial residuals to improve land-use regression estimates of nitrogen oxides in Southern California. *Atmos Environ* 55: 220-228. <http://dx.doi.org/10.1016/j.atmosenv.2012.03.035>
- [Li, S; Batterman, S; Wasilevich, E; Wahl, R; Wirth, J; Su, FC; Mukherjee, B.](#) (2011b). Association of daily asthma emergency department visits and hospital admissions with ambient air pollutants among the pediatric Medicaid population in Detroit: Time-series and time-stratified case-crossover analyses with threshold effects. *Environ Res* 111: 1137-1147. <http://dx.doi.org/10.1016/j.envres.2011.06.002>
- [Li, X; Liu, C; Leung, D.](#) (2005). Development of a model for the determination of air exchange rates for street canyons. *Atmos Environ* 39: 7285-7296. <http://dx.doi.org/10.1016/j.atmosenv.2005.09.007>
- [Liard, R; Zureik, M; Le Moullec, Y; Soussan, D; Glorian, M; Grimfeld, A; Neukirch, F.](#) (1999). Use of personal passive samplers for measurement of NO<sub>2</sub>, NO, and O<sub>3</sub> levels in panel studies. *Environ Res* 81: 339-348. <http://dx.doi.org/10.1006/enrs.1999.3993>
- [Lima, ES; Bonini, MG; Augusto, O; Barbeiro, HV; Souza, HP; Abdalla, DS.](#) (2005). Nitrate lipids decompose to nitric oxide and lipid radicals and cause vasorelaxation. *Free Radic Biol Med* 39: 532-539. <http://dx.doi.org/10.1016/j.freeradbiomed.2005.04.005>
- [Lin, CA; Pereira, LAA; Nishioka, DC; Conceicao, GMS; Graga, ALF; Saldiva, PHN.](#) (2004a). Air pollution and neonatal deaths in Sao Paulo, Brazil. *Braz J Med Biol Res* 37: 765-770. <http://dx.doi.org/10.1590/S0100-879X2004000500019>
- [Lin, CC; Yang, SK; Lin, KC; Ho, WC; Hsieh, WS; Shu, BC; Chen, PC.](#) (2014). Multilevel analysis of air pollution and early childhood neurobehavioral development. *Int J Environ Res Public Health* 11: 6827-6841. <http://dx.doi.org/10.3390/ijerph110706827>
- [Lin, M; Chen, Y; Villeneuve, PJ; Burnett, RT; Lemyre, L; Hertzman, C; McGrail, KM; Krewski, D.](#) (2004b). Gaseous air pollutants and asthma hospitalization of children with low household income in Vancouver, British Columbia, Canada. *Am J Epidemiol* 159: 294-303. <http://dx.doi.org/10.1093/aje/kwh043>
- [Lin, M; Fiore, AM; Horowitz, LW; Cooper, OR; Naik, V; Holloway, J; Johnson, BJ; Middlebrook, AM; Oltmans, SJ; Pollack, IB; Ryerson, TB; Warner, JX; Wiedinmyer, C; Wilson, J; Wyman, B.](#) (2012). Transport of Asian ozone pollution into surface air over the western United States in spring. *J Geophys Res* 117: D00V07. <http://dx.doi.org/10.1029/2011JD016961>
- [Lin, M; Stieb, DM; Chen, Y.](#) (2005). Coarse particulate matter and hospitalization for respiratory infections in children younger than 15 years in Toronto: A case-crossover analysis. *Pediatrics* 116: 235-240. <http://dx.doi.org/10.1542/peds.2004-2012>
- [Lin, W; Huang, W; Zhu, T; Hu, M; Brunekreef, B; Zhang, Y; Liu, X; Cheng, H; Gehring, U; Li, C; Tang, X.](#) (2011). Acute respiratory inflammation in children and black carbon in ambient air before and during the 2008 Beijing Olympics. *Environ Health Perspect* 119: 1507-1512. <http://dx.doi.org/10.1289/ehp.1103461>
- [Linaker, CH; Chauhan, AJ; Inskip, HM; Holgate, ST; Coggon, D.](#) (2000). Personal exposures of children to nitrogen dioxide relative to concentrations in outdoor air. *Occup Environ Med* 57: 472-476.

- [Linares, C; Diaz, J.](#) (2010). Short-term effect of concentrations of fine particulate matter on hospital admissions due to cardiovascular and respiratory causes among the over-75 age group in Madrid, Spain. *Public Health* 124: 28-36. <http://dx.doi.org/10.1016/j.puhe.2009.11.007>
- [Lindström, J; Szpiro, AA; Sampson, PD; Oron, AP; Richards, M; Larson, TV; Sheppard, L.](#) (2013). A flexible spatio-temporal model for air pollution with spatial and spatio-temporal covariates. *Environ Ecol Stat* 21: 411-433. <http://dx.doi.org/10.1007/s10651-013-0261-4>
- [Linhares, D; Jacinto, T; Pereira, AM; Fonseca, JA.](#) (2011). Effects of atopy and rhinitis on exhaled nitric oxide values - a systematic review. *Clin Transl Allergy* 1: 8. <http://dx.doi.org/10.1186/2045-7022-1-8>
- [Link, MS; Luttmann-Gibson, H; Schwartz, J; Mittleman, MA; Wessler, B; Gold, DR; Dockery, DW; Laden, F.](#) (2013). Acute exposure to air pollution triggers atrial fibrillation. *J Am Coll Cardiol* 62: 816-825. <http://dx.doi.org/10.1016/j.jacc.2013.05.043>
- [Linn, WS; Shamoo, DA; Anderson, KR; Peng, RC; Avol, EL; Hackney, JD; Gong, H, Jr.](#) (1996). Short-term air pollution exposures and responses in Los Angeles area schoolchildren. *J Expo Anal Environ Epidemiol* 6: 449-472.
- [Linn, WS; Shamoo, DA; Spier, CE; Valencia, LM; Anzar, UT; Venet, TG; Avol, EL; Hackney, JD.](#) (1985a). Controlled exposure of volunteers with chronic obstructive pulmonary disease to nitrogen dioxide. *Arch Environ Health* 40: 313-317. <http://dx.doi.org/10.1080/00039896.1985.10545939>
- [Linn, WS; Solomon, JC; Trim, SC; Spier, CE; Shamoo, DA; Venet, TG; Avol, EL; Hackney, JD.](#) (1985b). Effects of exposure to 4 ppm nitrogen dioxide in healthy and asthmatic volunteers. *Arch Environ Occup Health* 40: 234-239.
- [Linn, WS; Szlachcic, Y; Gong, H, Jr; Kinney, PL; Berhane, KT.](#) (2000). Air pollution and daily hospital admissions in metropolitan Los Angeles. *Environ Health Perspect* 108: 427-434.
- [Lipfert, FW; Baty, JD; Miller, JP; Wyzga, RE.](#) (2006a). PM<sub>2.5</sub> constituents and related air quality variables as predictors of survival in a cohort of U.S. military veterans. *Inhal Toxicol* 18: 645-657. <http://dx.doi.org/10.1080/08958370600742946>
- [Lipfert, FW; Perry, HM, Jr; Miller, JP; Baty, JD; Wyzga, RE; Carmody, SE.](#) (2000). The Washington University-EPRI veterans' cohort mortality study: Preliminary results. *Inhal Toxicol* 12: 41-73. <http://dx.doi.org/10.1080/713856640>
- [Lipfert, FW; Perry, HM, Jr; Miller, JP; Baty, JD; Wyzga, RE; Carmody, SE.](#) (2003). Air pollution, blood pressure, and their long-term associations with mortality. *Inhal Toxicol* 15: 493-512. <http://dx.doi.org/10.1080/08958370304463>
- [Lipfert, FW; Wyzga, RE; Baty, JD; Miller, JP.](#) (2006b). Traffic density as a surrogate measure of environmental exposures in studies of air pollution health effects: Long-term mortality in a cohort of US veterans. *Atmos Environ* 40: 154-169. <http://dx.doi.org/10.1016/j.atmosenv.2005.09.027>
- [Lipfert, FW; Wyzga, RE; Baty, JD; Miller, JP.](#) (2009). Air pollution and survival within the Washington University-EPRI veterans cohort: Risks based on modeled estimates of ambient levels of hazardous and criteria air pollutants. *J Air Waste Manag Assoc* 59: 473-489. <http://dx.doi.org/10.3155/1047-3289.59.4.473>
- [Lipsett, MJ; Ostro, BD; Reynolds, P; Goldberg, D; Hertz, A; Jerrett, M; Smith, DF; Garcia, C; Chang, ET; Bernstein, L.](#) (2011). Long-term exposure to air pollution and cardiorespiratory disease in the California teachers study cohort. *Am J Respir Crit Care Med* 184: 828-835. <http://dx.doi.org/10.1164/rccm.201012-2082OC>
- [Liu, C; Flexeder, C; Fuertes, E; Cyrus, J; Bauer, CP; Koletzko, S; Hoffmann, B; von Berg, A; Heinrich, J; Groups, fitGaLS.](#) (2014a). Effects of air pollution on exhaled nitric oxide in children: Results from the GINIplus and LISAPlus studies. *Int J Hyg Environ Health* 217: 483-491. <http://dx.doi.org/10.1016/j.ijheh.2013.09.006>

- [Liu, C; Fuertes, E; Tiesler, CMT; Birk, M; Babisch, W; Bauer, CP; Koletzko, S; von Berg, A; Hoffmann, B; Heinrich, J. \(2014b\). The associations between traffic-related air pollution and noise with blood pressure in children: Results from the GINIplus and LISApplus studies. \*Int J Hyg Environ Health\* 217: 499-505. <http://dx.doi.org/10.1016/j.ijheh.2013.09.008>](#)
- [Liu, CC; Tsai, SS; Chiu, HF; Wu, TN; Chen, CC; Yang, CY. \(2009a\). Ambient exposure to criteria air pollutants and risk of death from bladder cancer in Taiwan. \*Inhal Toxicol\* 21: 48-54. <http://dx.doi.org/10.1080/08958370802207326>](#)
- [Liu, CC; Tsai, SS; Chiu, HF; Wu, TN; Yang, CY. \(2008\). Ambient exposure to criteria air pollutants and female lung cancer in Taiwan. \*Inhal Toxicol\* 20: 311-317. <http://dx.doi.org/10.1080/08958370701866107>](#)
- [Liu, CH; Leung, DYC; Barth, MC. \(2005\). On the prediction of air and pollutant exchange rates in street canyons of different aspect ratios using large-eddy simulation. \*Atmos Environ\* 39: 1567-1574. <http://dx.doi.org/10.1016/j.atmosenv.2004.08.036>](#)
- [Liu, L. \(2013\). Email from Dr. Liu to Dr. Patel; Response to data request. Available online at <http://www.regulations.gov/#!documentDetail;D=EPA-HQ-ORD-2013-0232-0013>](#)
- [Liu, L; Kauri, LM; Mahmud, M; Weichenthal, S; Cakmak, S; Shutt, R; You, H; Thomson, E; Vincent, R; Kumarathasan, P; Broad, G; Dales, R. \(2014c\). Exposure to air pollution near a steel plant and effects on cardiovascular physiology: A randomized crossover study. \*Int J Hyg Environ Health\* 217: 279-286. <http://dx.doi.org/10.1016/j.ijheh.2013.06.007>](#)
- [Liu, L; Poon, R; Chen, L; Frescura, AM; Montuschi, P; Ciabattini, G; Wheeler, A; Dales, R. \(2009b\). Acute effects of air pollution on pulmonary function, airway inflammation, and oxidative stress in asthmatic children. \*Environ Health Perspect\* 117: 668-674. <http://dx.doi.org/10.1289/ehp11813>](#)
- [Liu, S; Krewski, D; Shi, Y; Chen, Y; Burnett, R. \(2007\). Association between maternal exposure to ambient air pollutants during pregnancy and fetal growth restriction. \*J Expo Sci Environ Epidemiol\* 17: 426-432. <http://dx.doi.org/10.1038/sj.jes.7500503>](#)
- [Liu, S; Krewski, D; Shi, Y; Chen, Y; Burnett, RT. \(2003\). Association between gaseous ambient air pollutants and adverse pregnancy outcomes in Vancouver, Canada. \*Environ Health Perspect\* 111: 1773-1778.](#)
- [Ljungman, P; Bellander, T; Schneider, A; Breitner, S; Forastiere, F; Hampel, R; Illig, T; Jacquemin, B; Katsouyanni, K; von Klot, S; Koenig, W; Lanki, T; Nyberg, F; Pekkanen, J; Pistelli, R; Pitsavos, C; Rosenqvist, M; Sunyer, J; Peters, A. \(2009\). Modification of the interleukin-6 response to air pollution by interleukin-6 and fibrinogen polymorphisms. \*Environ Health Perspect\* 117: 1373-1379. <http://dx.doi.org/10.1289/ehp.0800370>](#)
- [Ljungman, PL; Wilker, EH; Rice, MB; Schwartz, J; Gold, DR; Koutrakis, P; Vita, JA; Mitchell, GF; Vasan, RS; Benjamin, EJ; Mittleman, MA; Hamburg, NM. \(2014\). Short-term exposure to air pollution and digital vascular function. \*Am J Epidemiol\* 180: 482-489. <http://dx.doi.org/10.1093/aje/kwu161>](#)
- [Ljungman, PLS; Berglind, N; Holmgren, C; Gadler, F; Edvardsson, N; Pershagen, G; Rosenqvist, M; Sjögren, B; Bellander, T. \(2008\). Rapid effects of air pollution on ventricular arrhythmias. \*Eur Heart J\* 29: 2894-2901. <http://dx.doi.org/10.1093/eurheartj/ehn463>](#)
- [Llop, S; Ballester, F; Estarlich, M; Esplugues, A; Rebagliato, M; Iniguez, C. \(2010\). Preterm birth and exposure to air pollutants during pregnancy. \*Environ Res\* 110: 778-785. <http://dx.doi.org/10.1016/j.envres.2010.09.009>](#)
- [Llop, S; Ballester, F; Estarlich, M; Iniguez, C; Ramón, R; Gonzalez, MC; Murcia, M; Esplugues, A; Rebagliato, M. \(2011\). Social factors associated with nitrogen dioxide \(NO<sub>2</sub>\) exposure during pregnancy: The INMA-Valencia project in Spain. \*Soc Sci Med\* 72: 890-898. <http://dx.doi.org/10.1016/j.socscimed.2010.12.018>](#)
- [Llorca, J; Salas, A; Prieto-Salceda, D; Chinchon-Bengochea, V; Delgado-Rodriguez, M. \(2005\). Nitrogen dioxide increases cardiorespiratory admissions in Torrelavega \(Spain\). \*J Environ Health\* 68: 30-35.](#)
- [Loupa, G; Rapsomanikis, S. \(2008\). Air pollutant emission rates and concentrations in medieval churches. \*J Atmos Chem\* 60: 169-187. <http://dx.doi.org/10.1007/s10874-008-9116-z>](#)

- [Lovich, MA; Bruno, NK; Plant, CP; Wei, AE; Vasquez, GB; Johnson, BJ; Fine, DH; Gilbert, RJ.](#) (2011). Use of ultra pure nitric oxide generated by the reduction of nitrogen dioxide to reverse pulmonary hypertension in hypoxemic swine. *Nitric Oxide* 24: 204-212. <http://dx.doi.org/10.1016/j.niox.2011.04.006>
- [Lu, C; Deng, Q; Yu, CWF; Sundell, J; Ou, C.](#) (2014). Effects of ambient air pollution on the prevalence of pneumonia in children: Implication for National Ambient Air Quality Standards in China. *Indoor Built Environ* 23: 259-269. <http://dx.doi.org/10.1177/1420326X13504423>
- [Lu, KD; Breyse, PN; Diette, GB; Curtin-Brosnan, J; Aloe, C; Williams, DL; Peng, RD; McCormack, MC; Matsui, EC.](#) (2013). Being overweight increases susceptibility to indoor pollutants among urban children with asthma. *J Allergy Clin Immunol* 131: 1017-1023.e1013. <http://dx.doi.org/10.1016/j.jaci.2012.12.1570>
- [Luginaah, IN; Fung, KY; Gorey, KM; Webster, G; Wills, C.](#) (2005). Association of ambient air pollution with respiratory hospitalization in a government-designated "area of concern": The case of Windsor, Ontario. *Environ Health Perspect* 113: 290-296. <http://dx.doi.org/10.1289/ehp.7300>
- [Lundberg, JO; Carlström, M; Larsen, FJ; Weitzberg, E.](#) (2011). Roles of dietary inorganic nitrate in cardiovascular health and disease [Review]. *Cardiovasc Res* 89: 525-532. <http://dx.doi.org/10.1093/cvr/cvq325>
- [Lundberg, JON; Farkas-Szallasi, T; Weitzberg, E; Rinder, J; Lidholm, J; Änggård, A; Hökfelt, T; Lundberg, JM; Alving, K.](#) (1995). High nitric oxide production in human paranasal sinuses. *Nat Med* 1: 370-373. <http://dx.doi.org/10.1038/nm0495-370>
- [Lundberg, JON; Settergren, G; Gelinder, S; Lundberg, JM; Alving, K; Weitzberg, E.](#) (1996). Inhalation of nasally derived nitric oxide modulates pulmonary function in humans. *Acta Physiol Scand* 158: 343-347. <http://dx.doi.org/10.1046/j.1365-201X.1996.557321000.x>
- [Maantay, JA; Tu, J; Maroko, AR.](#) (2009). Loose-coupling an air dispersion model and a geographic information system (GIS) for studying air pollution and asthma in the Bronx, New York City. *Int J Environ Health Res* 19: 59-79. <http://dx.doi.org/10.1080/09603120802392868>
- [Maarsingh, H; Bossenga, BE; Bos, IS; Volders, HH; Zaagsma, J; Meurs, H.](#) (2009). L-arginine deficiency causes airway hyperresponsiveness after the late asthmatic reaction. *Eur Respir J* 34: 191-199. <http://dx.doi.org/10.1183/09031936.00105408>
- [Maarsingh, H; Zuidhof, AB; Bos, IS; van Duin, M; Boucher, JL; Zaagsma, J; Meurs, H.](#) (2008). Arginase inhibition protects against allergen-induced airway obstruction, hyperresponsiveness, and inflammation. *Am J Respir Crit Care Med* 178: 565-573. <http://dx.doi.org/10.1164/rccm.200710-1588OC>
- [Mabalarajan, U; Ahmad, T; Leishangthem, GD; Dinda, AK; Agrawal, A; Ghosh, B.](#) (2010a). L-arginine reduces mitochondrial dysfunction and airway injury in murine allergic airway inflammation. *Int Immunopharmacol* 10: 1514-1519. <http://dx.doi.org/10.1016/j.intimp.2010.08.025>
- [Mabalarajan, U; Ahmad, T; Leishangthem, GD; Joseph, DA; Dinda, AK; Agrawal, A; Ghosh, B.](#) (2010b). Beneficial effects of high dose of L-arginine on airway hyperresponsiveness and airway inflammation in a murine model of asthma. *J Allergy Clin Immunol* 125: 626-635. <http://dx.doi.org/10.1016/j.jaci.2009.10.065>
- [Macintyre, EA; Brauer, M; Melén, E; Bauer, CP; Bauer, M; Berdel, D; Bergström, A; Brunekreef, B; Chan-Yeung, M; Klümper, C; Fuertes, E; Gehring, U; Gref, A; Heinrich, J; Herbarth, O; Kerkhof, M; Koppelman, GH; Kozyrskyj, AL; Pershagen, G; Postma, DS; Thiering, E; Tiesler, CM; Carlsten, C.](#) (2014a). GSTP1 and TNF gene variants and associations between air pollution and incident childhood asthma: The traffic, asthma and genetics (TAG) study. *Environ Health Perspect* 122: 418-424. <http://dx.doi.org/10.1289/ehp.1307459>
- [MacIntyre, EA; Gehring, U; Mölter, A; Fuertes, E; Klümper, C; Krämer, U; Quass, U; Hoffmann, B; Gascon, M; Brunekreef, B; Koppelman, GH; Beelen, R; Hoek, G; Birk, M; de Jongste, JC; Smit, HA; Cyrys, J; Gruzieva, O; Korek, M; Bergström, A; Agius, RM; de Vocht, F; Simpson, A; Porta, D; Forastiere, F; Badaloni, C; Cesaroni, G; Esplugues, A; Fernández-Somoano, A; Lerxundi, A; Sunyer, J; Cirach, M; Nieuwenhuijsen, MJ; Pershagen, G; Heinrich, J.](#) (2014b). Air pollution and respiratory infections during early childhood: an analysis of 10 European birth cohorts within the ESCAPE Project. *Environ Health Perspect* 122: 107-113. <http://dx.doi.org/10.1289/ehp.1306755>

- [MacIntyre, HL; Evans, MJ](#). (2010). Sensitivity of a global model to the uptake of N<sub>2</sub>O<sub>5</sub> by tropospheric aerosol. *Atmos Chem Phys* 10: 7409-7414. <http://dx.doi.org/10.5194/acp-10-7409-2010>
- [MacNaughton, P; Melly, S; Vallarino, J; Adamkiewicz, G; Spengler, JD](#). (2014). Impact of bicycle route type on exposure to traffic-related air pollution. *Sci Total Environ* 490: 37-43. <http://dx.doi.org/10.1016/j.scitotenv.2014.04.111>
- [Madej, E; Folkes, LK; Wardman, P; Czapski, G; Goldstein, S](#). (2008). Thiyl radicals react with nitric oxide to form S-nitrosothiols with rate constants near the diffusion-controlled limit. *Free Radic Biol Med* 44: 2013-2018. <http://dx.doi.org/10.1016/j.freeradbiomed.2008.02.015>
- [Madsen, C; Durand, KL; Nafstad, P; Schwarze, PE; Rønningen, KS; Håheim, LL](#). (2008). Associations between environmental exposures and serum concentrations of Clara cell protein among elderly men in Oslo, Norway. *Environ Res* 108: 354-360. <http://dx.doi.org/10.1016/j.envres.2008.07.017>
- [Madsen, C; Gehring, U; Walker, SE; Brunekreef, B; Stigum, H; Naess, O; Nafstad, P](#). (2010). Ambient air pollution exposure, residential mobility and term birth weight in Oslo, Norway. *Environ Res* 110: 363-371. <http://dx.doi.org/10.1016/j.envres.2010.02.005>
- [Maestrelli, P; Canova, C; Scapellato, ML; Visentin, A; Tessari, R; Bartolucci, GB; Simonato, L; Lotti, M](#). (2011). Personal exposure to particulate matter is associated with worse health perception in adult asthma. *J Investig Allergol Clin Immunol* 21: 120-128.
- [Magnussen, H; Reuss, G; Jörres, R](#). (1986). Airway response to methacholine during exercise induced refractoriness in asthma. *Thorax* 41: 667-670.
- [Maher, AR; Milsom, AB; Gunaruwan, P; Abozguia, K; Ahmed, I; Weaver, RA; Thomas, P; Ashrafian, H; Born, GVR; James, PE; Frenneaux, MP](#). (2008). Hypoxic modulation of exogenous nitrite-induced vasodilation in humans. *Circulation* 117: 670-677. <http://dx.doi.org/10.1161/CIRCULATIONAHA.107.719591>
- [Maheswaran, R; Pearson, T; Smeeton, NC; Beevers, SD; Campbell, MJ; Wolfe, CD](#). (2010). Impact of outdoor air pollution on survival after stroke: population-based cohort study. *Stroke* 41: 869-877. <http://dx.doi.org/10.1161/STROKEAHA.109.567743>
- [Major, TA; Panmanee, W; Mortensen, JE; Gray, LD; Hoglen, N; Hassett, DJ](#). (2010). Sodium nitrite-mediated killing of the major cystic fibrosis pathogens *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Burkholderia cepacia* under anaerobic planktonic and biofilm conditions. *Antimicrob Agents Chemother* 54: 4671-4677. <http://dx.doi.org/10.1128/AAC.00379-10>
- [Malinowski, A; Janson, C; Holm, L; Nordvall, L; Alving, K](#). (2009). Basal and induced NO formation in the pharyngo-oral tract influences estimates of alveolar NO levels. *J Appl Physiol* 106: 513-519. <http://dx.doi.org/10.1152/jappphysiol.91148.2008>
- [Malm-Erfjält, M; Persson, CG; Erfjält, JS](#). (2001). Degranulation status of airway tissue eosinophils in mouse models of allergic airway inflammation. *Am J Respir Cell Mol Biol* 24: 352-359. <http://dx.doi.org/10.1165/ajrcmb.24.3.4357>
- [Malmqvist, E; Jakobsson, K; Tinnerberg, H; Rignell-Hydbom, A; Rylander, L](#). (2013). Gestational diabetes and preeclampsia in association with air pollution at levels below current air quality guidelines. *Environ Health Perspect* 121: 488-493. <http://dx.doi.org/10.1289/ehp.1205736>
- [Malmqvist, E; Rignell-Hydbom, A; Tinnerberg, H; Björk, J; Strohm, E; Jakobsson, K; Rittner, R; Rylander, L](#). (2011). Maternal exposure to air pollution and birth outcomes. *Environ Health Perspect* 119: 553-558. <http://dx.doi.org/10.1289/ehp.1002564>
- [Mann, JK; Balmes, JR; Bruckner, TA; Mortimer, KM; Margolis, HG; Pratt, B; Hammond, SK; Lurmann, F; Tager, IB](#). (2010). Short-term effects of air pollution on wheeze in asthmatic children in Fresno, California. *Environ Health Perspect* 118: 1497-1502. <http://dx.doi.org/10.1289/ehp.0901292>
- [Mann, JK; Tager, IB; Lurmann, F; Segal, M; Quesenberry, CP, Jr; Lugg, MM; Shan, J; Van den Eeden, SK](#). (2002). Air pollution and hospital admissions for ischemic heart disease in persons with congestive heart failure or arrhythmia. *Environ Health Perspect* 110: 1247-1252.

- Mannes, T; Jalaludin, B; Morgan, G; Lincoln, D; Sheppard, V; Corbett, S. (2005). Impact of ambient air pollution on birth weight in Sydney, Australia. *Occup Environ Med* 62: 524-530. <http://dx.doi.org/10.1136/oem.2004.014282>
- Mansfield, CA; Johnson, FR; Van Houtven, GL. (2006). The missing piece: Valuing averting behavior for children's ozone exposures. *Resource Energ Econ* 28: 215-228. <http://dx.doi.org/10.1016/j.reseneeco.2006.02.002>
- Mar, TF; Norris, GA; Koenig, JQ; Larson, TV. (2000). Associations between air pollution and mortality in Phoenix, 1995-1997. *Environ Health Perspect* 108: 347-353.
- Marcon, A; Fracasso, ME; Marchetti, P; Doria, D; Girardi, P; Guarda, L; Pesce, G; Pironi, V; Ricci, P; de Marco, R. (2014). Outdoor formaldehyde and NO<sub>2</sub> exposures and markers of genotoxicity in children living near chipboard industries. *Environ Health Perspect* 122: 639-645. <http://dx.doi.org/10.1289/ehp.1307259>
- Marozienne, L; Grazuleviciene, R. (2002). Maternal exposure to low-level air pollution and pregnancy outcomes: A population-based study. *Environ Health* 1: 6. <http://dx.doi.org/10.1186/1476-069X-1-6>
- Marr, LC; Harley, RA. (2002). Modeling the effect of weekday-weekend differences in motor vehicle emissions on photochemical air pollution in central California. *Environ Sci Technol* 36: 4099-4106. <http://dx.doi.org/10.1021/es020629x>
- Marshall, HE; Potts, EN; Kelleher, ZT; Stamler, JS; Foster, WM; Auten, RL. (2009). Protection from lipopolysaccharide-induced lung injury by augmentation of airway S-nitrosothiols. *Am J Respir Crit Care Med* 180: 11-18. <http://dx.doi.org/10.1164/rccm.200807-1186OC>
- Marshall, HE; Stamler, JS. (2001). Inhibition of NF-kappa B by S-nitrosylation. *Biochemistry* 40: 1688-1693. <http://dx.doi.org/10.1021/bi002239y>
- Marshall, JD; Nethery, E; Brauer, M. (2008). Within-urban variability in ambient air pollution: Comparison of estimation methods. *Atmos Environ* 42: 1359-1369. <http://dx.doi.org/10.1016/j.atmosenv.2007.08.012>
- Martin, RA; Ather, JL; Lundblad, LKA; Suratt, BT; Boyson, JE; Budd, RC; Alcorn, JF; Flavell, RA; Eisenbarth, SC; Poynter, ME. (2013). Interleukin-1 receptor and caspase-1 are required for the Th17 response in NO<sub>2</sub>-promoted allergic airway disease. *Am J Respir Cell Mol Biol* 48: 655-664. <http://dx.doi.org/10.1165/rcmb.2012-0423OC>
- Martin, RV; Chance, K; Jacob, DJ; Kurosu, TP; Spurr, RJD; Bucsele, E; Gleason, JF; Palmer, PI; Bey, I; Fiore, AM; Li, Q; Yantosca, RM; Koelemeijer, RBA. (2002). An improved retrieval of tropospheric nitrogen dioxide from GOME. *J Geophys Res* 107: 4437. <http://dx.doi.org/10.1029/2001JD001027>
- Martinez, FD; Wright, AL; Taussig, LM; Holberg, CJ; Halonen, M; Morgan, WJ. (1995). Asthma and wheezing in the first six years of life. *N Engl J Med* 332: 133-138. <http://dx.doi.org/10.1056/NEJM199501193320301>
- Martins, P. (2013). Email from Dr. Martins to Dr Patel; Response to data request. Martins, P.
- Martins, PC; Valente, J; Papoila, AL; Caires, I; Araújo-Martins, J; Mata, P; Lopes, M; Torres, S; Rosado-Pinto, J; Borrego, C; Annesi-Maesano, I; Neuparth, N. (2012). Airways changes related to air pollution exposure in wheezing children. *Eur Respir J* 39: 246-253. <http://dx.doi.org/10.1183/09031936.00025111>
- Maruo, YY; Ogawa, S; Ichino, T; Muraio, N; Uchiyama, M. (2003). Measurement of local variations in atmospheric nitrogen dioxide levels in Sapporo, Japan, using a new method with high spatial and high temporal resolution. *Atmos Environ* 37: 1065-1074. [http://dx.doi.org/10.1016/S1352-2310\(02\)00974-3](http://dx.doi.org/10.1016/S1352-2310(02)00974-3)
- Masiol, M; Agostinelli, C; Formenton, G; Tarabotti, E; Pavoni, B. (2014). Thirteen years of air pollution hourly monitoring in a large city: Potential sources, trends, cycles and effects of car-free days. *Sci Total Environ* 494-495: 84-96. <http://dx.doi.org/10.1016/j.scitotenv.2014.06.122>
- Massoli, P; Fortner, EC; Canagaratna, MR; Williams, LR; Zhang, Q; Sun, Y; Schwab, JJ; Trimborn, A; Onasch, TB; Demerjian, KL; Kolb, CE; Worsnop, DR; Jayne, JT. (2012). Pollution gradients and chemical characterization of particulate matter from vehicular traffic near major roadways: Results from the 2009 Queens College air quality study in NYC. *Aerosol Sci Technol* 46: 1201-1218. <http://dx.doi.org/10.1080/02786826.2012.701784>

- [Matalon, S; Shrestha, K; Kirk, M; Waldheuser, S; McDonald, B; Smith, K; Gao, Z; Belaouaj, A; Crouch, EC.](#) (2009). Modification of surfactant protein D by reactive oxygen-nitrogen intermediates is accompanied by loss of aggregating activity, in vitro and in vivo. *FASEB J* 23: 1415-1430. <http://dx.doi.org/10.1096/fj.08-120568>
- [Matsumura, Y.](#) (1970). The effects of ozone, nitrogen dioxide, and sulfur dioxide on the experimentally induced allergic respiratory disorder in guinea pigs: II. The effects of ozone on the absorption and the retention of antigen in the lung. *Am Rev Respir Dis* 102: 438-443.
- [Matte, TD; Ross, Z; Kheirbek, I; Eisl, H; Johnson, S; Gorczynski, JE; Kass, D; Markowitz, S; Pezeshki, G; Clougherty, JE.](#) (2013). Monitoring intraurban spatial patterns of multiple combustion air pollutants in New York City: Design and implementation. *J Expo Sci Environ Epidemiol* 23: 223-231. <http://dx.doi.org/10.1038/jes.2012.126>
- [Mauderly, JL; Cheng, YS; Gillett, NA; Griffith, WC; Henderson, RF; Pickrell, JA; Ulblff, RK.](#) (1990). Influence of preexisting pulmonary emphysema on susceptibility of rats to chronic inhalation exposure to nitrogen dioxide. *Inhal Toxicol* 2: 129-150. <http://dx.doi.org/10.3109/08958379009145250>
- [McAdam, K; Steer, P; Perrotta, K.](#) (2011). Using continuous sampling to examine the distribution of traffic related air pollution in proximity to a major road. *Atmos Environ* 45: 2080-2086. <http://dx.doi.org/10.1016/j.atmosenv.2011.01.050>
- [McClenny, WA; Williams, EJ; Cohen, RC; Stutz, J.](#) (2002). Preparing to measure the effects of the NOx SIP call--methods for ambient air monitoring of NO, NO2, NOy, and individual NOz species. *J Air Waste Manag Assoc* 52: 542-562. <http://dx.doi.org/10.1080/10473289.2002.10470801>
- [McConnell, R; Berhane, K; Gilliland, F; London, SJ; Vora, H; Avol, E; Gauderman, WJ; Margolis, HG; Lurmann, F; Thomas, DC; Peters, JM.](#) (1999). Air pollution and bronchitic symptoms in southern California children with asthma. *Environ Health Perspect* 107: 757-760.
- [McConnell, R; Berhane, K; Gilliland, F; Molitor, J; Thomas, D; Lurmann, F; Avol, E; Gauderman, WJ; Peters, JM.](#) (2003). Prospective study of air pollution and bronchitic symptoms in children with asthma. *Am J Respir Crit Care Med* 168: 790-797. <http://dx.doi.org/10.1164/rccm.200304-466OC>
- [McConnell, R; Berhane, K; Molitor, J; Gilliland, F; Kunzli, N; Thorne, PS; Thomas, D; Gauderman, WJ; Avol, E; Lurmann, F; Rappaport, E; Jerrett, M; Peters, J.](#) (2006). Dog ownership enhances symptomatic responses to air pollution in children with asthma. *Environ Health Perspect* 114: 1910-1915. <http://dx.doi.org/10.1289/ehp.8548>
- [McConnell, R; Islam, T; Shankardass, K; Jerrett, M; Lurmann, F; Gilliland, F; Gauderman, J; Avol, E; Künzli, N; Yao, L; Peters, J; Berhane, K.](#) (2010a). Childhood incident asthma and traffic-related air pollution at home and school. *Environ Health Perspect* 118: 1021-1026. <http://dx.doi.org/10.1289/ehp.0901232>
- [McConnell, R; Liu, FF; Wu, J; Lurmann, F; Peters, J; Berhane, K.](#) (2010b). Asthma and school commuting time. *J Occup Environ Med* 52: 827-829. <http://dx.doi.org/10.1097/JOM.0b013e3181ebf1a9>
- [McCreanor, J; Cullinan, P; Nieuwenhuijsen, MJ; Stewart-Evans, J; Malliarou, E; Jarup, L; Harrington, R; Svartengren, M; Han, IK; Ohman-Strickland, P; Chung, KF; Zhang, J.](#) (2007). Respiratory effects of exposure to diesel traffic in persons with asthma. *N Engl J Med* 357: 2348-2358. <http://dx.doi.org/10.1056/NEJMoa071535>
- [McCurdy, T; Glen, G; Smith, L; Lakkadi, Y.](#) (2000). The National Exposure Research Laboratory's consolidated human activity database. *J Expo Anal Environ Epidemiol* 10: 566-578. <http://dx.doi.org/10.1038/sj.jea.7500114>
- [McDonald, BC; Dallmann, TR; Martin, EW; Harley, RA.](#) (2012). Long-term trends in nitrogen oxide emissions from motor vehicles at national, state, and air basin scales. *J Geophys Res* 117: D00V18. <http://dx.doi.org/10.1029/2012JD018304>
- [McGrath, JJ; Smith, DL.](#) (1984). Respiratory responses to nitrogen dioxide inhalation: Subtitle: Nitrogen dioxide. *J Environ Sci Health, Part A: Environ Sci Eng* 19: 417-431. <http://dx.doi.org/10.1080/10934528409375168>

- [McMeeking, GR; Kreidenweis, SM; Baker, S; Carrico, CM; Chow, JC; Collett, JL, Jr; Hao, WM; Holden, AS; Kirchstetter, TW; Malm, WC; Moosmüller, H; Sullivan, AP; Wold, CE.](#) (2009). Emissions of trace gases and aerosols during the open combustion of biomass in the laboratory. *J Geophys Res Atmos* 114: D19210. <http://dx.doi.org/10.1029/2009jd011836>
- [Mebust, AK; Russell, AR; Hudman, RC; Valin, LC; Cohen, RC.](#) (2011). Characterization of wildfire NO<sub>x</sub> emissions using MODIS fire radiative power and OMI tropospheric NO<sub>2</sub> columns. *Atmos Chem Phys* 11: 5839-5851. <http://dx.doi.org/10.5194/acp-11-5839-2011>
- [Mehta, S; Ngo, LH; Dzung, DV; Cohen, A; Thach, TO; Dan, VX; Tuan, ND; Giang, LT.](#) (2013). Air pollution and admissions for acute lower respiratory infections in young children of Ho Chi Minh City. *Air Qual Atmos Health* 6: 167-179. <http://dx.doi.org/10.1007/s11869-011-0158-z>
- [Melén, E; Nyberg, F; Lindgren, CM; Berglind, N; Zucchelli, M; Nordling, E; Hallberg, J; Svartengren, M; Morgenstern, R; Kere, J; Bellander, T; Wickman, M; Pershagen, G.](#) (2008). Interactions between glutathione S-transferase P1, tumor necrosis factor, and traffic-related air pollution for development of childhood allergic disease. *Environ Health Perspect* 116: 1077-1084. <http://dx.doi.org/10.1289/ehp.11117>
- [Meng, Q; Williams, R; Pinto, JP.](#) (2012a). Determinants of the associations between ambient concentrations and personal exposures to ambient PM<sub>2.5</sub>, NO<sub>2</sub>, and O<sub>3</sub> during DEARS. *Atmos Environ* 63: 109-116. <http://dx.doi.org/10.1016/j.atmosenv.2012.09.019>
- [Meng, QY; Svendsgaard, D; Kotchmar, DJ; Pinto, JP.](#) (2012b). Associations between personal exposures and ambient concentrations of nitrogen dioxide: A quantitative research synthesis. *Atmos Environ* 57: 322-329. <http://dx.doi.org/10.1016/j.atmosenv.2012.04.035>
- [Meng, X; Wang, C; Cao, D; Wong, CM; Kan, H.](#) (2013). Short-term effect of ambient air pollution on COPD mortality in four Chinese cities. *Atmos Environ* 77: 149-154. <http://dx.doi.org/10.1016/j.atmosenv.2013.05.001>
- [Meng, YY; Rull, RP; Wilhelm, M; Lombardi, C; Balmes, J; Ritz, B.](#) (2010). Outdoor air pollution and uncontrolled asthma in the San Joaquin Valley, California. *J Epidemiol Community Health* 64: 142-147. <http://dx.doi.org/10.1136/jech.2008.083576>
- [Mercer, LD; Szpiro, AA; Sheppard, L; Lindström, J; Adar, SD; Allen, RW; Avol, EL; Oron, AP; Larson, T; Liu, LJ; Kaufman, JD.](#) (2011). Comparing universal kriging and land-use regression for predicting concentrations of gaseous oxides of nitrogen (NO<sub>x</sub>) for the Multi-Ethnic Study of Atherosclerosis and Air Pollution (MESA Air). *Atmos Environ* 45: 4412-4420. <http://dx.doi.org/10.1016/j.atmosenv.2011.05.043>
- [Mercer, RR; Costa, DL; Crapo, JD.](#) (1995). Effects of prolonged exposure to low doses of nitric oxide or nitrogen dioxide on the alveolar septa of the adult rat lung. *Lab Invest* 73: 20-28.
- [Mercer, RR; Russell, ML; Roggli, VL; Crapo, JD.](#) (1994). Cell number and distribution in human and rat airways. *Am J Respir Cell Mol Biol* 10: 613-624.
- [Mersch, J; Dyce, BJ; Haverback, BJ; Sherwin, RP.](#) (1973). Diphosphoglycerate content of red blood cells: Measurements in guinea pigs exposed to 04 ppm nitrogen dioxide. *Arch Environ Health* 27: 94-95. <http://dx.doi.org/10.1080/00039896.1973.10666326>
- [Metzger, KB; Klein, M; Flanders, WD; Peel, JL; Mulholland, JA; Langberg, JJ; Tolbert, PE.](#) (2007). Ambient air pollution and cardiac arrhythmias in patients with implantable defibrillators. *Epidemiology* 18: 585-592. <http://dx.doi.org/10.1097/EDE.0b013e318124ff0e>
- [Mi, YH; Norbäck, D; Tao, J; Mi, YL; Ferm, M.](#) (2006). Current asthma and respiratory symptoms among pupils in Shanghai, China: Influence of building ventilation, nitrogen dioxide, ozone, and formaldehyde in classrooms. *Indoor Air* 16: 454-464. <http://dx.doi.org/10.1111/j.1600-0668.2006.00439.x>
- [Migliaretti, G; Cadum, E; Migliore, E; Cavallo, F.](#) (2005). Traffic air pollution and hospital admission for asthma: a case-control approach in a Turin (Italy) population. *Int Arch Occup Environ Health* 78: 164-169. <http://dx.doi.org/10.1007/s00420-004-0569-3>
- [Miller, FJ; Graham, JA; Illing, JW; Gardner, DE.](#) (1980). Extrapulmonary effects of NO<sub>2</sub> as reflected by pentobarbital-induced sleeping time in mice. *Toxicol Lett* 6: 267-274.

- [Miller, FJ; Graham, JA; Raub, JA; Illing, JW; Ménache, MG; House, DE; Gardner, DE.](#) (1987). Evaluating the toxicity of urban patterns of oxidant gases. II. Effects in mice from chronic exposure to nitrogen dioxide. *J Toxicol Environ Health* 21: 99-112. <http://dx.doi.org/10.1080/15287398709531005>
- [Miller, FJ; Overton, JH; Gerrity, TR; Graham, RC.](#) (1988). Interspecies dosimetry of reactive gases. In U Mohr; D Dungworth; R McClellan; G Kimmerle; W Stober; J Lewkowski (Eds.), *Inhalation toxicology: The design and interpretation of inhalation studies and their use in risk assessment* (pp. 139-155). New York, NY: Springer-Verlag.
- [Miller, FJ; Overton, JH, Jr; Jaskot, RH; Menzel, DB.](#) (1985). A model of the regional uptake of gaseous pollutants in the lung: I. The sensitivity of the uptake of ozone in the human lung to lower respiratory tract secretions and exercise. *Toxicol Appl Pharmacol* 79: 11-27. [http://dx.doi.org/10.1016/0041-008X\(85\)90364-3](http://dx.doi.org/10.1016/0041-008X(85)90364-3)
- [Miller, FJ; Overton, JH; Myers, ET; Graham, JA.](#) (1982). Pulmonary dosimetry of nitrogen dioxide in animals and man. In T Schneider; L Grant (Eds.), *Air pollution by nitrogen oxides* (pp. 377-386). Amsterdam: Elsevier Scientific Publishing Company.
- [Miller, KA; Siscovick, DS; Sheppard, L; Shepherd, K; Sullivan, JH; Anderson, GL; Kaufman, JD.](#) (2007). Long-term exposure to air pollution and incidence of cardiovascular events in women. *N Engl J Med* 356: 447-458. <http://dx.doi.org/10.1056/NEJMoa054409>
- [Min, KB; Min, JY; Cho, SI; Paek, D.](#) (2008). The relationship between air pollutants and heart-rate variability among community residents in Korea. *Inhal Toxicol* 20: 435-444. <http://dx.doi.org/10.1080/08958370801903834>
- [Minguillón, MC; Rivas, I; Aguilera, I; Alastuey, A; Moreno, T; Amato, F; Sunyer, J; Querol, X.](#) (2012). Within-city contrasts in PM composition and sources and their relationship with nitrogen oxides. *J Environ Monit* 14: 2718-2728. <http://dx.doi.org/10.1039/c2em30469d>
- [Misra, A; Roorda, MJ; Maclean, HL.](#) (2013). An integrated modelling approach to estimate urban traffic emissions. *Atmos Environ* 73: 81-91. <http://dx.doi.org/10.1016/j.atmosenv.2013.03.013>
- [Mitchell, G.](#) (2005). Forecasting environmental equity: Air quality responses to road user charging in Leeds, UK. *J Environ Manage* 77: 212-226. <http://dx.doi.org/10.1016/j.jenvman.2005.04.013>
- [Miyaniishi, K; Kinouchi, T; Kataoka, K; Kanoh, T; Ohnishi, Y.](#) (1996). In vivo formation of mutagens by intraperitoneal administration of polycyclic aromatic hydrocarbons in animals during exposure to nitrogen dioxide. *Carcinogenesis* 17: 1483-1490.
- [Mobasher, Z; Salam, MT; Goodwin, TM; Lurmann, F; Ingles, SA; Wilson, ML.](#) (2013). Associations between ambient air pollution and hypertensive disorders of pregnancy. *Environ Res* 123: 9-16. <http://dx.doi.org/10.1016/j.envres.2013.01.006>
- [Mochitate, K; Miura, T.](#) (1984). In vivo effect of nitrogen dioxide on the activities of glycolytic enzymes in red blood cells of rats. *Toxicol Lett* 22: 315-321.
- [Mochitate, K; Takahashi, Y; Ohsumi, T; Miura, T.](#) (1986). Activation and increment of alveolar macrophages induced by nitrogen dioxide. *J Toxicol Environ Health* 17: 229-239. <http://dx.doi.org/10.1080/15287398609530819>
- [Modig, L; Torén, K; Janson, C; Jarvholm, B; Forsberg, B.](#) (2009). Vehicle exhaust outside the home and onset of asthma among adults. *Eur Respir J* 33: 1261-1267. <http://dx.doi.org/10.1183/09031936.00101108>
- [Mohsenin, V.](#) (1987a). Airway responses to nitrogen dioxide in asthmatic subjects. *J Toxicol Environ Health* 22: 371-380. <http://dx.doi.org/10.1080/15287398709531080>
- [Mohsenin, V.](#) (1987b). Effect of vitamin C on NO<sub>2</sub>-induced airway hyperresponsiveness in normal subjects: A randomized double-blind experiment. *Am Rev Respir Dis* 136: 1408-1411. <http://dx.doi.org/10.1164/ajrccm/136.6.1408>
- [Mohsenin, V.](#) (1988). Airway responses to 2.0 ppm nitrogen dioxide in normal subjects. *Arch Environ Health* 43: 242-246. <http://dx.doi.org/10.1080/00039896.1988.9934941>

- Mohsenin, V. (1991). Lipid peroxidation and antielastase activity in the lung under oxidant stress: Role of antioxidant defenses. *J Appl Physiol* 70: 1456-1462.
- Molitor, J; Su, JG; Molitor, NT; Rubio, VG; Richardson, S; Hastie, D; Morello-Frosch, R; Jerrett, M. (2011). Identifying vulnerable populations through an examination of the association between multipollutant profiles and poverty. *Environ Sci Technol* 45: 7754-7760. <http://dx.doi.org/10.1021/es104017x>
- Mollner, AK; Valluvadasan, S; Feng, L; Sprague, MK; Okumura, M; Milligan, DB; Bloss, WJ; Sander, SP; Martien, PT; Harley, RA; McCoy, AB; Carter, WRL. (2010). Rate of gas phase association of hydroxyl radical and nitrogen dioxide. *Science* 330: 646-649. <http://dx.doi.org/10.1126/science.1193030>
- Molloy, SB; Cheng, M; Galbally, IE; Keywood, MD; Lawson, SJ; Powell, JC; Gillett, R; Dunne, E; Selleck, PW. (2012). Indoor air quality in typical temperate zone Australian dwellings. *Atmos Environ* 54: 400-407. <http://dx.doi.org/10.1016/j.atmosenv.2012.02.031>
- Mölder, A; Agius, RM; de Vocht, F; Lindley, S; Gerrard, W; Lowe, L; Belgrave, D; Custovic, A; Simpson, A. (2013). Long-term exposure to PM10 and NO2 in association with lung volume and airway resistance in the MAAS birth cohort. *Environ Health Perspect* 121: 1232-1238. <http://dx.doi.org/10.1289/ehp.1205961>
- Mölder, A; Lindley, S; de Vocht, F; Agius, R; Kerry, G; Johnson, K; Ashmore, M; Terry, A; Dimitroulopoulou, S; Simpson, A. (2012). Performance of a microenvironmental model for estimating personal NO2 exposure in children. *Atmos Environ* 51: 225-233. <http://dx.doi.org/10.1016/j.atmosenv.2012.01.030>
- Mölder, A; Lindley, S; de Vocht, F; Simpson, A; Agius, R. (2010a). Modelling air pollution for epidemiologic research--Part I: A novel approach combining land use regression and air dispersion. *Sci Total Environ* 408: 5862-5869. <http://dx.doi.org/10.1016/j.scitotenv.2010.08.027>
- Mölder, A; Lindley, S; de Vocht, F; Simpson, A; Agius, R. (2010b). Modelling air pollution for epidemiologic research--Part II: Predicting temporal variation through land use regression. *Sci Total Environ* 409: 211-217. <http://dx.doi.org/10.1016/j.scitotenv.2010.10.005>
- Monn, C; Carabias, V; Junker, M; Waeber, R; Karrer, M; Wanner, HU. (1997). Small-scale spatial variability of particulate matter <10 µm (PM10) and nitrogen dioxide. *Atmos Environ* 31: 2243-2247.
- Moolgavkar, SH. (2003). Air pollution and daily deaths and hospital admissions in Los Angeles and Cook counties. In *Revised Analyses of the National Morbidity, Mortality, and Air Pollution Study, Part II* (pp. 183-198). Boston, MA: Health Effects Institute.
- Moolgavkar, SH; McClellan, RO; Dewanji, A; Turim, J; Luebeck, EG; Edwards, M. (2013). Time-series analyses of air pollution and mortality in the United States: A subsampling approach. *Environ Health Perspect* 121: 73-78. <http://dx.doi.org/10.1289/ehp.1104507>
- Moon, JS; Kim, YS; Kim, JH; Son, BS; Kim, DS; Yang, W. (2009). Respiratory health effects among schoolchildren and their relationship to air pollutants in Korea. *Int J Environ Health Res* 19: 31-48. <http://dx.doi.org/10.1080/09603120802272201>
- Morales, E; Julvez, J; Torrent, M; de Cid, R; Guxens, M; Bustamante, M; Künzli, N; Sunyer, J. (2009). Association of early-life exposure to household gas appliances and indoor nitrogen dioxide with cognition and attention behavior in preschoolers. *Am J Epidemiol* 169: 1327-1336. <http://dx.doi.org/10.1093/aje/kwp067>
- Morello-Frosch, R; Jesdale, BM; Sadd, JL; Pastor, M. (2010). Ambient air pollution exposure and full-term birth weight in California. *Environ Health* 9: 44. <http://dx.doi.org/10.1186/1476-069X-9-44>
- Morgan, G; Corbett, S; Wlodarczyk, J. (1998). Air pollution and hospital admissions in Sydney, Australia, 1990 to 1994. *Am J Public Health* 88: 1761-1766. <http://dx.doi.org/10.2105/AJPH.88.12.1761>
- Morgenstern, V; Zutavern, A; Cyrys, J; Brockow, I; Gehring, U; Koletzko, S; Bauer, CP; Reinhardt, D; Wichmann, HE; Heinrich, J. (2007). Respiratory health and individual estimated exposure to traffic-related air pollutants in a cohort of young children. *Occup Environ Med* 64: 8-16. <http://dx.doi.org/10.1136/oem.2006.028241>

- [Morgenstern, V; Zutavern, A; Cyrus, J; Brockow, I; Koletzko, S; Krämer, U; Behrendt, H; Herbarth, O; von Berg, A; Bauer, CP; Wichmann, HE; Heinrich, J.](#) (2008). Atopic diseases, allergic sensitization, and exposure to traffic-related air pollution in children. *Am J Respir Crit Care Med* 177: 1331-1337. <http://dx.doi.org/10.1164/rccm.200701-036OC>
- [Moridi, M; Ziaei, S; Kazemnejad, A.](#) (2014). Exposure to ambient air pollutants and spontaneous abortion. *J Obstet Gynaecol Res* 40: 743-748. <http://dx.doi.org/10.1111/jog.12231>
- [Morrow, PE; Utell, MJ.](#) (1989a). Responses of susceptible subpopulations to nitrogen dioxide [HEI] (pp. 1-45). (ISSN 1041-5505 Research Report 23). Cambridge, MA: Health Effects Institute. <http://pubs.healtheffects.org/view.php?id=235>
- [Morrow, PE; Utell, MJ.](#) (1989b). Responses of susceptible subpopulations to nitrogen dioxide: Appendix H. Selected raw data [HEI]. (Research Report 23). Cambridge, MA: Health Effects Institute.
- [Morrow, PE; Utell, MJ; Bauer, MA; Smeglin, AM; Frampton, MW; Cox, C; Speers, DM; Gibb, FR.](#) (1992). Pulmonary performance of elderly normal subjects and subjects with chronic obstructive pulmonary disease exposed to 0.3 ppm nitrogen dioxide. *Am J Respir Crit Care Med* 145: 291-300. [http://dx.doi.org/10.1164/ajrccm/145.2\\_Pt\\_1.291](http://dx.doi.org/10.1164/ajrccm/145.2_Pt_1.291)
- [Mortimer, KM; Neas, LM; Dockery, DW; Redline, S; Tager, IB.](#) (2002). The effect of air pollution on inner-city children with asthma. *Eur Respir J* 19: 699-705. <http://dx.doi.org/10.1183/09031936.02.00247102>
- [Moseler, M; Hendel-Kramer, A; Karmaus, W; Forster, J; Weiss, K; Urbanek, R; Kuehr, J.](#) (1994). Effect of moderate NO<sub>2</sub> air pollution on the lung function of children with asthmatic symptoms. *Environ Res* 67: 109-124. <http://dx.doi.org/10.1006/enrs.1994.1068>
- [Moshhammer, H; Hutter, HP; Hauck, H; Neuberger, M.](#) (2006). Low levels of air pollution induce changes of lung function in a panel of schoolchildren. *Eur Respir J* 27: 1138-1143. <http://dx.doi.org/10.1183/09031936.06.00089605>
- [Muhajarine, N; Mustard, C; Roos, LL; Young, TK; Gelskey, DE.](#) (1997). Comparison of survey and physician claims data for detecting hypertension. *J Clin Epidemiol* 50: 711-718. [http://dx.doi.org/10.1016/S0895-4356\(97\)00019-X](http://dx.doi.org/10.1016/S0895-4356(97)00019-X)
- [Mukala, K; Alm, S; Tiittanen, P; Salonen, RO; Jantunen, M; Pekkanen, J.](#) (2000). Nitrogen dioxide exposure assessment and cough among preschool children. *Arch Environ Health* 55: 431-438.
- [Mukerjee, S; Smith, L; Neas, L; Norris, G.](#) (2012a). Evaluation of land use regression models for nitrogen dioxide and benzene in Four US cities. *ScientificWorldJournal* 2012: 865150. <http://dx.doi.org/10.1100/2012/865150>
- [Mukerjee, S; Smith, LA; Johnson, MM; Neas, LM; Stallings, CA.](#) (2009). Spatial analysis and land use regression of VOCs and NO<sub>2</sub> from school-based urban air monitoring in Detroit/Dearborn, USA. *Sci Total Environ* 407: 4642-4651. <http://dx.doi.org/10.1016/j.scitotenv.2009.04.030>
- [Mukerjee, S; Willis, RD; Walker, JT; Hammond, D; Norris, GA; Smith, LA; Welch, DP; Peters, TM.](#) (2012b). Seasonal effects in land use regression models for nitrogen dioxide, coarse particulate matter, and gaseous ammonia in Cleveland, Ohio. *Atmos Pollut Res* 3: 352-361. <http://dx.doi.org/10.5094/APR.2012.039>
- [Mulholland, JA.](#) (2013). Email from Dr. Mulholland to Dr Richmond-Bryant; Response to Data Request. Available online at <http://www.regulations.gov/#!documentDetail;D=EPA-HQ-ORD-2013-0232-0020>
- [Müller, B; Schäfer, H; Barth, P; von Wichert, P.](#) (1994). Lung surfactant components in bronchoalveolar lavage after inhalation of NO<sub>2</sub> as markers of altered surfactant metabolism. *Lung* 172: 61-72. <http://dx.doi.org/10.1007/BF00185077>
- [Murgia, N; Brisman, J; Claesson, A; Muzi, G; Olin, AC; Torén, K.](#) (2014). Validity of a questionnaire-based diagnosis of chronic obstructive pulmonary disease in a general population-based study. *BMC Pulm Med* 14: 49. <http://dx.doi.org/10.1186/1471-2466-14-49>

- [Murphy, JG; Day, DA; Cleary, PA; Wooldridge, PJ; Millet, DB; Goldstein, AH; Cohen, RC.](#) (2006). The weekend effect within and downwind of Sacramento: Part 2. Observational evidence for chemical and dynamical contributions. *Atmos Chem Phys Discuss* 6: 11971-12019. <http://dx.doi.org/10.5194/acpd-6-11971-2006>
- [Murphy, JG; Day, DA; Cleary, PA; Wooldridge, PJ; Millet, DB; Goldstein, AH; Cohen, RC.](#) (2007). The weekend effect within and downwind of Sacramento - Part 1: Observations of ozone, nitrogen oxides, and VOC reactivity. *Atmos Chem Phys* 7: 5327-5339.
- [Murphy, SD; Ulrich, CE; Frankowitz, SH; Xintaras, C.](#) (1964). Altered function in animals inhaling low concentrations of ozone and nitrogen dioxide. *Am Ind Hyg Assoc J* 25: 246-253. <http://dx.doi.org/10.1080/00028896409342583>
- [Murray, AB; Ferguson, AC; Morrison, B.](#) (1981). Airway responsiveness to histamine as a test for overall severity of asthma in children. *J Allergy Clin Immunol* 68: 119-124. [http://dx.doi.org/10.1016/0091-6749\(81\)90169-X](http://dx.doi.org/10.1016/0091-6749(81)90169-X)
- [Mustafa, MG; Elsayed, NM; von Dohlen, FM; Hassett, CM; Postlethwait, EM; Quinn, CL; Graham, JA; Gardner, DE.](#) (1984). A comparison of biochemical effects of nitrogen dioxide, ozone, and their combination in mouse lung. *Toxicol Appl Pharmacol* 72: 82-90.
- [NAEPP](#) (National Asthma Education and Prevention Program). (2007). Expert panel report 3 (EPR-3): Guidelines for the diagnosis and management of asthma summary report 2007. *J Allergy Clin Immunol* 120: S94-S138. <http://dx.doi.org/10.1016/j.jaci.2007.09.029>
- [Naess, O; Nafstad, P; Aamodt, G; Claussen, B; Rosland, P.](#) (2007). Relation between concentration of air pollution and cause-specific mortality: four-year exposures to nitrogen dioxide and particulate matter pollutants in 470 neighborhoods in Oslo, Norway. *Am J Epidemiol* 165: 435-443. <http://dx.doi.org/10.1093/aje/kwk016>
- [Nafstad, P; Håheim, LL; Oftedal, B; Gram, F; Holme, I; Hjermann, I; Leren, P.](#) (2003). Lung cancer and air pollution: A 27 year follow up of 16 209 Norwegian men. *Thorax* 58: 1071-1076. <http://dx.doi.org/10.1136/thorax.58.12.1071>
- [Nafstad, P; Haheim, LL; Wisloff, T; Gram, F; Oftedal, B; Holme, I; Hjermann, I; Leren, P.](#) (2004). Urban air pollution and mortality in a cohort of Norwegian men. *Environ Health Perspect* 112: 610-615.
- [Nahidi, F; Gholami, R; Rashidi, Y; Majd, HA.](#) (2014). Relationship between air pollution and pre-eclampsia in pregnant women: a case-control study. *East Mediterr Health J* 19: S60-S66.
- [Nakajima, T; Kusumoto, S.](#) (1968). Effect of nitrogen dioxide exposure on the contents of reduced glutathione in mouse lung. *Food Sanitation Research (English)* 6: 17-21.
- [Namdeo, A; Stringer, C.](#) (2008). Investigating the relationship between air pollution, health and social deprivation in Leeds, UK. *Environ Int* 34: 585-591. <http://dx.doi.org/10.1016/j.envint.2007.12.015>
- [NAPAP](#) (National Acid Precipitation Assessment Program). (1991). The experience and legacy of NAPAP: Report of the Oversight Review Board of the National Acid Precipitation Assessment Program. Washington, DC.
- [Neta, P; Huie, RE; Ross, AB.](#) (1988). Rate constants for reactions of inorganic radicals in aqueous solution. *J Phys Chem Ref Data* 17: 1027-1284. <http://dx.doi.org/10.1063/1.555808>
- [Nettesheim, P; Hanna, MG, Jr; Doherty, DG; Newell, RF; Hellman, A.](#) (1970). Effect of chronic exposure to air pollutants on the respiratory tracts of mice: Histopathological findings. In P Nettesheim; MG Hanna, Jr.; JW Deatherage, Jr. (Eds.), *Morphology of experimental respiratory carcinogenesis: proceedings of a biology division, Oak Ridge National Laboratory conference; May; Gatlinburg, TN. Oak Ridge, TN: U.S. Atomic Energy Commission.*
- [Neupane, B; Jerrett, M; Burnett, RT; Marrie, T; Arain, A; Loeb, M.](#) (2010). Long-term exposure to ambient air pollution and risk of hospitalization with community-acquired pneumonia in older adults. *Am J Respir Crit Care Med* 181: 47-53. <http://dx.doi.org/10.1164/rccm.200901-0160OC>

- Ng, AW; Bidani, A; Heming, TA. (2004). Innate host defense of the lung: effects of lung-lining fluid pH [Review]. *Lung* 182: 297-317. <http://dx.doi.org/10.1007/s00408-004-2511-6>
- NHLBI (National Institutes of Health, National Heart Lung and Blood Institute). (2002). Global initiative for asthma: Global strategy for asthma management and prevention. U.S. Department of Health and Human Services. <http://www.ginasthma.org/Guidelines/guidelines-2002-original%3a-workshop-report%2c-global-strategy-for-asthmamanagement-and-prevention.html>
- Nicolai, T; Carr, D; Weiland, SK; Duhme, H; Von Ehrenstein, O; Wagner, C; Von Mutius, E. (2003). Urban traffic and pollutant exposure related to respiratory outcomes and atopy in a large sample of children. *Eur Respir J* 21: 956-963.
- Nieuwenhuijsen, MJ; Basagaña, X; Davdand, P; Martinez, D; Cirach, M; Beelen, R; Jacquemin, B. (2014). Air pollution and human fertility rates. *Environ Int* 70: 9-14. <http://dx.doi.org/10.1016/j.envint.2014.05.005>
- Nishikawa, Y; Murano, K; Mukai, H. (2009). Comparison of sampling resistance for one to three sheets of membrane type passive sampler. *Water Air Soil Pollut* 197: 241-247. <http://dx.doi.org/10.1007/s11270-008-9807-8>
- Nishimura, KK; Galanter, JM; Roth, LA; Oh, SS; Thakur, N; Nguyen, EA; Thyne, S; Farber, HJ; Serebrisky, D; Kumar, R; Brigino-Buenaventura, E; Davis, A; LeNoir, MA; Meade, K; Rodriguez-Cintron, W; Avila, PC; Borrell, LN; Bibbins-Domingo, K; Rodriguez-Santana, JR; Sen, S; Lurmann, F; Balmes, JR; Burchard, EG. (2013). Early-life air pollution and asthma risk in minority children: The GALA II and SAGE II studies. *Am J Respir Crit Care Med* 188: 309-318. <http://dx.doi.org/10.1164/rccm.201302-0264OC>
- Nishino, N; Atkinson, R; Arey, J. (2008). Formation of nitro products from the gas-phase OH radical-initiated reactions of toluene, naphthalene, and biphenyl: effect of NO<sub>2</sub> concentration. *Environ Sci Technol* 42: 9203-9209. <http://dx.doi.org/10.1021/es802046m>
- Nitta, H; Sato, T; Nakai, S; Maeda, K; Aoki, S; Ono, M. (1993). Respiratory health associated with exposure to automobile exhaust: I. Results of cross-sectional studies in 1979, 1982, and 1983. *Arch Environ Health* 48: 53-58. <http://dx.doi.org/10.1080/00039896.1993.9938393>
- Noda, N; Takeno, S; Fukui, T; Hirakawa, K. (2012). Monitoring of oral and nasal exhaled nitric oxide in eosinophilic chronic rhinosinusitis: A prospective study. *Am J Rhinol Allergy* 26: 255-259. <http://dx.doi.org/10.2500/ajra.2012.26.3772>
- Nøjgaard, JK. (2010). Indoor measurements of the sum of the nitrate radical, NO<sub>3</sub>, and nitrogen pentoxide, N<sub>2</sub>O<sub>5</sub> in Denmark. *Chemosphere* 79: 898-904. <http://dx.doi.org/10.1016/j.chemosphere.2010.02.025>
- Nøjgaard, JK; Bilde, M; Stenby, C; Nielsen, OJ; Wolkoff, P. (2006). The effect of nitrogen dioxide on particle formation during ozonolysis of two abundant monoterpenes indoors. *Atmos Environ* 40: 1030-1042. <http://dx.doi.org/10.1016/j.atmosenv.2005.11.029>
- Nordling, E; Berglind, N; Melén, E; Emenius, G; Hallberg, J; Nyberg, F; Pershagen, G; Svartengren, M; Wickman, M; Bellander, T. (2008). Traffic-related air pollution and childhood respiratory symptoms, function and allergies. *Epidemiology* 19: 401-408. <http://dx.doi.org/10.1097/EDE.0b013e31816a1ce3>
- North, ML; Khanna, N; Marsden, PA; Grasemann, H; Scott, JA. (2009). Functionally important role for arginase 1 in the airway hyperresponsiveness of asthma. *Am J Physiol Lung Cell Mol Physiol* 296: L911-L920. <http://dx.doi.org/10.1152/ajplung.00025.2009>
- Novotny, EV; Bechle, MJ; Millet, DB; Marshall, JD. (2011). National satellite-based land-use regression: NO<sub>2</sub> in the United States. *Environ Sci Technol* 45: 4407-4414. <http://dx.doi.org/10.1021/es103578x>
- Nunnermacker, LJ; Imre, D; Daum, PH; Kleinman, L; Lee, YN; Lee, JH; Springston, SR; Newman, L; Weinstein-Lloyd, J; Luke, WT; Banta, R; Alvarez, R; Senff, C; Sillman, S; Holdren, M; Keigley, GW; Zhou, X. (1998). Characterization of the Nashville urban plume on July 3 and July 18, 1995. *J Geophys Res* 103: 28129-28148.

- Nuvolone, D; Balzi, D; Chini, M; Scala, D; Giovannini, F; Barchielli, A. (2011). Short-term association between ambient air pollution and risk of hospitalization for acute myocardial infarction: Results of the cardiovascular risk and air pollution in Tuscany (RISCAT) study. *Am J Epidemiol* 174: 63-71.  
<http://dx.doi.org/10.1093/aje/kwr046>
- Nyberg, F; Gustavsson, P; Jarup, L; Bellander, T; Berglund, N; Jakobsson, R; Pershagen, G. (2000). Urban air pollution and lung cancer in Stockholm. *Epidemiology* 11: 487-495.
- O'Byrne, PM; Gauvreau, GM; Brannan, JD. (2009). Provoked models of asthma: What have we learnt? [Review]. *Clin Exp Allergy* 39: 181-192. <http://dx.doi.org/10.1111/j.1365-2222.2008.03172.x>
- O'Connor, GT; Neas, L; Vaughn, B; Kattan, M; Mitchell, H; Crain, EF; Evans, R, III; Gruchalla, R; Morgan, W; Stout, J; Adams, GK; Lippmann, M. (2008). Acute respiratory health effects of air pollution on children with asthma in US inner cities. *J Allergy Clin Immunol* 121: 1133-1139.e1131.  
<http://dx.doi.org/10.1016/j.jaci.2008.02.020>
- O'Donnell, VB; Eiserich, JP; Chumley, PH; Jablonsky, MJ; Krishna, NR; Kirk, M; Barnes, S; Darley-USmar, VM; Freeman, BA. (1999). Nitration of unsaturated fatty acids by nitric oxide-derived reactive nitrogen species peroxynitrite, nitrous acid, nitrogen dioxide, and nitronium ion. *Chem Res Toxicol* 12: 83-92.  
<http://dx.doi.org/10.1021/tx980207u>
- O'Neill, MS; Jerrett, M; Kawachi, I; Levy, JI; Cohen, AJ; Gouveia, N; Wilkinson, P; Fletcher, T; Cifuentes, L; Schwartz, J. (2003). Health, wealth, and air pollution: Advancing theory and methods [Review]. *Environ Health Perspect* 111: 1861-1870.
- Oda, H; Tsubone, H; Suzuki, A; Ichinose, T; Kubota, K. (1981). Alterations of nitrite and nitrate concentrations in the blood of mice exposed to nitrogen dioxide. *Environ Res* 25: 294-301.
- Odajima, H; Yamazaki, S; Nitta, H. (2008). Decline in peak expiratory flow according to hourly short-term concentration of particulate matter in asthmatic children. *Inhal Toxicol* 20: 1263-1272.  
<http://dx.doi.org/10.1080/08958370802311151>
- Oftedal, B; Brunekreef, B; Nystad, W; Madsen, C; Walker, SE; Nafstad, P. (2008). Residential outdoor air pollution and lung function in schoolchildren. *Epidemiology* 19: 129-137.  
<http://dx.doi.org/10.1097/EDE.0b013e31815c0827>
- Oftedal, B; Nystad, W; Brunekreef, B; Nafstad, P. (2009a). Long-term traffic-related exposures and asthma onset in schoolchildren in Oslo, Norway. *Environ Health Perspect* 117: 839-844.  
<http://dx.doi.org/10.1289/ehp.11491>
- Oftedal, B; Walker, S; Gram, F; McInnes, H; Nafstad, P. (2009b). Modelling long-term averages of local ambient air pollution in Oslo, Norway: evaluation of nitrogen dioxide, PM10 and PM2.5. *Int J Environ Pollut* 36: 110-126. <http://dx.doi.org/10.1504/IJEP.2009.021820>
- Ohashi, Y; Nakai, Y; Sugiura, Y; Ohno, Y; Okamoto, H; Tanaka, A; Kakinoki, Y; Hayashi, M. (1994). Nitrogen dioxide-induced eosinophilia and mucosal injury in the nose of the guinea pig. *Acta Otolaryngol* 114: 547-551.
- Ohshima, K; Ito, T; Kanisawa, M. (1999). The roles of diesel exhaust particle extracts and the promotive effects of NO2 and/or SO2 exposure on rat lung tumorigenesis. *Cancer Lett* 139: 189-197.  
[http://dx.doi.org/10.1016/S0304-3835\(99\)00040-3](http://dx.doi.org/10.1016/S0304-3835(99)00040-3)
- Oiamo, TH; Luginaah, IN; Atari, DO; Gorey, KM. (2011). Air pollution and general practitioner access and utilization: a population based study in Sarnia, 'Chemical Valley,' Ontario. *Environ Health* 10: 71.  
<http://dx.doi.org/10.1186/1476-069X-10-71>
- Oiamo, TH; Luginaah, IN; Buzzelli, M; Tang, K; Xu, X; Brook, JR; Johnson, M. (2012). Assessing the spatial distribution of nitrogen dioxide in London, Ontario. *J Air Waste Manag Assoc* 62: 1335-1345.  
<http://dx.doi.org/10.1080/10962247.2012.715114>
- Olague, EP. (2012). The potential near-source ozone impacts of upstream oil and gas industry emissions. *J Air Waste Manag Assoc* 62: 966-977. <http://dx.doi.org/10.1080/10962247.2012.688923>

- Olague, EP; Kolb, CE; Lefer, B; Rappenglück, B; Zhang, RY; Pinto, JP. (2014). Overview of the SHARP campaign: Motivation, design, and major outcomes. *J Geophys Res* 119: 2597-2610. <http://dx.doi.org/10.1002/2013JD019730>
- Olague, EP; Rappenglück, B; Lefer, B; Stutz, J; Dibb, J; Griffin, R; Brune, WH; Shauck, M; Buhr, M; Jeffries, H; Vizuete, W; Pinto, JP. (2009). Deciphering the role of radical precursors during the Second Texas Air Quality Study. *J Air Waste Manag Assoc* 59: 1258-1277. <http://dx.doi.org/10.3155/1047-3289.59.11.1258>
- Olin, AC; Aldenbratt, A; Ekman, A; Ljungkvist, G; Jungersten, L; Alving, K; Torén, K. (2001). Increased nitric oxide in exhaled air after intake of a nitrate-rich meal. *Respir Med* 95: 153-158. <http://dx.doi.org/10.1053/rmed.2000.1010>
- Olin, AC; Bake, B; Torén, K. (2007). Fraction of exhaled nitric oxide at 50 mL/s: Reference values for adult lifelong never-smokers. *Chest* 131: 1852-1856. <http://dx.doi.org/10.1378/chest.06-2928>
- Olin, AC; Hellgren, J; Karlsson, G; Ljungkvist, G; Nolkranz, K; Torén, K. (1998). Nasal nitric oxide and its relationship to nasal symptoms, smoking and nasal nitrate. *Rhinology* 36: 117-121.
- Olsson, D; Ekström, M; Forsberg, B. (2012). Temporal variation in air pollution concentrations and preterm birth—a population based epidemiological study. *Int J Environ Res Public Health* 9: 272-285. <http://dx.doi.org/10.3390/ijerph9010272>
- Olsson, D; Mogren, I; Forsberg, B. (2013). Air pollution exposure in early pregnancy and adverse pregnancy outcomes: a register-based cohort study. *BMJ Open* 3. <http://dx.doi.org/10.1136/bmjopen-2012-001955>
- Orazzo, F; Nespoli, L; Ito, K; Tassinari, D; Giardina, D; Funis, M; Cecchi, A; Trapani, C; Forgeschi, G; Vignini, M; Nosetti, L; Pigna, S; Zanobetti, A. (2009). Air pollution, aeroallergens, and emergency room visits for acute respiratory diseases and gastroenteric disorders among young children in six Italian cities. *Environ Health Perspect* 117: 1780-1785. <http://dx.doi.org/10.1289/ehp.0900599>
- Orehek, J; Massari, JP; Gayraud, P; Grimaud, C; Charpin, J. (1976). Effect of short-term, low-level nitrogen dioxide exposure on bronchial sensitivity of asthmatic patients. *J Clin Invest* 57: 301-307. <http://dx.doi.org/10.1172/JCI108281>
- Orehek, J; Nicoli, MM; Delpierre, S; Beaupre, A. (1981). Influence of the previous deep inspiration on the spirometric measurement of provoked bronchoconstriction in asthma. *Am Rev Respir Dis* 123: 269-272.
- Ortman, JM; Velkoff, VA; Hogan, H. (2014). An aging nation: The older population in the United States (pp. 1-28). (P25-1140). United States Census Bureau. <http://www.census.gov/library/publications/2014/demo/p25-1140.html>
- Osthoff, HD; Roberts, JM; Ravishankara, AR; Williams, EJ; Lerner, BM; Sommariva, R; Bates, TS; Coffman, D; Quinn, PK; Dibb, JE; Stark, H; Burkholder, JB; Talukdar, RK; Meagher, J; Fehsenfeld, FC; Brown, SS. (2008). High levels of nitryl chloride in the polluted subtropical marine boundary layer. *Nat Geosci* 1: 324-328. <http://dx.doi.org/10.1038/ngeo177>
- Ostro, B; Lipsett, M; Mann, J; Braxton-Owens, H; White, M. (2001). Air pollution and exacerbation of asthma in African-American children in Los Angeles. *Epidemiology* 12: 200-208.
- Oudin, A; Strömberg, U; Jakobsson, K; Stroh, E; Björk, J. (2010). Estimation of short-term effects of air pollution on stroke hospital admissions in southern Sweden. *Neuroepidemiology* 34: 131-142. <http://dx.doi.org/10.1159/000274807>
- Oudin, A; Strömberg, U; Jakobsson, K; Stroh, E; Lindgren, AG; Norrving, B; Pessah-Rasmussen, H; Engström, G; Björk, J. (2011). Hospital admissions for ischemic stroke: does long-term exposure to air pollution interact with major risk factors. *Cerebrovasc Dis* 31: 284-293. <http://dx.doi.org/10.1159/000322600>
- Overton, JH, Jr. (1984). Physicochemical processes and the formulation of dosimetry models. In FJ Miller; DB Menzel (Eds.), *Fundamentals of extrapolation modeling of inhaled toxicants: Ozone and nitrogen dioxide* (pp. 93-114). Washington, DC: Hemisphere Publishing Corporation.
- Ozden, O; Dogeroglu, T. (2008). Field evaluation of a tailor-made new passive sampler for the determination of NO<sub>2</sub> levels in ambient air. *Environ Monit Assess* 142: 243-253. <http://dx.doi.org/10.1007/s10661-007-9921-x>

- Ozkaynak, H; Frey, HC; Burke, J; Pinder, RW. (2009). Analysis of coupled model uncertainties in source-to-dose modeling of human exposures to ambient air pollution: A PM<sub>2.5</sub> case study. *Atmos Environ* 43: 1641-1649. <http://dx.doi.org/10.1016/j.atmosenv.2008.12.008>
- Pacher, P; Beckman, JS; Liaudet, L. (2007). Nitric oxide and peroxynitrite in health and disease [Review]. *Physiol Rev* 87: 315-424. <http://dx.doi.org/10.1152/physrev.00029.2006>
- Pachon, JE; Balachandran, S; Hu, Y; Mulholland, JA; Darrow, LA; Sarnat, JA; Tolbert, PE; Russell, AG. (2012). Development of outcome-based, multipollutant mobile source indicators. *J Air Waste Manag Assoc* 62: 431-442. <http://dx.doi.org/10.1080/10473289.2012.656218>
- Paciorek, CJ. (2010). The importance of scale for spatial-confounding bias and precision of spatial regression estimators. *Stat Sci* 25: 107-125. <http://dx.doi.org/10.1214/10-STS326>
- Pacsi, AP; Alhajeri, NS; Zavala-Araiza, D; Webster, MD; Allen, DT. (2013). Regional air quality impacts of increased natural gas production and use in Texas. *Environ Sci Technol* 47: 3521-3527. <http://dx.doi.org/10.1021/es3044714>
- Padhi, BK; Padhy, PK. (2008). Domestic fuels, indoor air pollution, and children's health. *Ann N Y Acad Sci* 1140: 209-217. <http://dx.doi.org/10.1196/annals.1454.015>
- Padró-Martínez, LT; Patton, AP; Trull, JB; Zamore, W; Brugge, D; Durant, JL. (2012). Mobile monitoring of particle number concentration and other traffic-related air pollutants in a near-highway neighborhood over the course of a year. *Atmos Environ* 61: 253-264. <http://dx.doi.org/10.1016/j.atmosenv.2012.06.088>
- Padula, AM; Tager, IB; Carmichael, SL; Hammond, SK; Lurmann, F; Shaw, GM. (2013a). The association of ambient air pollution and traffic exposures with selected congenital anomalies in the San Joaquin Valley of California. *Am J Epidemiol* 177: 1074-1085. <http://dx.doi.org/10.1093/aje/kws367>
- Padula, AM; Tager, IB; Carmichael, SL; Hammond, SK; Yang, W; Lurmann, F; Shaw, GM. (2013b). Ambient air pollution and traffic exposures and congenital heart defects in the San Joaquin Valley of California. *Paediatr Perinat Epidemiol* 27: 329-339. <http://dx.doi.org/10.1111/ppe.12055>
- Padula, AM; Tager, IB; Carmichael, SL; Hammond, SK; Yang, W; Lurmann, FW; Shaw, GM. (2013c). Traffic-related air pollution and selected birth defects in the San Joaquin Valley of California. *Birth Defects Res A Clin Mol Teratol* 97: 730-735. <http://dx.doi.org/10.1002/bdra.23175>
- Pagani, P; Romano, M; Erroi, A; Ferro, M; Salmona, M. (1994). Biochemical effects of acute and subacute nitrogen dioxide exposure in rat lung and bronchoalveolar lavage fluid. *Arch Environ Contam Toxicol* 27: 426-430. <http://dx.doi.org/10.1007/BF00213182>
- Panasevich, S; Leander, K; Ljungman, P; Bellander, T; de Faire, U; Pershagen, G; Nyberg, F. (2013). Interaction between air pollution exposure and genes in relation to levels of inflammatory markers and risk of myocardial infarction. *BMJ Open* 3: e003058. <http://dx.doi.org/10.1136/bmjopen-2013-003058>
- Panasevich, S; Leander, K; Rosenlund, M; Ljungman, P; Bellander, T; de Faire, U; Pershagen, G; Nyberg, F. (2009). Associations of long- and short-term air pollution exposure with markers of inflammation and coagulation in a population sample. *Occup Environ Med* 66: 747-753. <http://dx.doi.org/10.1136/oem.2008.043471>
- Panteliadis, P; Strak, M; Hoek, G; Weijers, E; van Der Zee, S; Dijkema, M. (2014). Implementation of a low emission zone and evaluation of effects on air quality by long-term monitoring. *Atmos Environ* 86: 113-119. <http://dx.doi.org/10.1016/j.atmosenv.2013.12.035>
- Papathomas, M; Molitor, J; Richardson, S; Riboli, E; Vineis, P. (2011). Examining the joint effect of multiple risk factors using exposure risk profiles: Lung cancer in non-smokers. *Environ Health Perspect* 119: 84-91. <http://dx.doi.org/10.1289/ehp.1002118>
- Parent, ME; Goldberg, MS; Crouse, DL; Ross, NA; Chen, H; Valois, MF; Liautaud, A. (2013). Traffic-related air pollution and prostate cancer risk: A case-control study in Montreal, Canada. *Occup Environ Med* 70: 511-518. <http://dx.doi.org/10.1136/oemed-2012-101211>
- Parenteau, MP; Sawada, MC. (2012). The role of spatial representation in the development of a LUR model for Ottawa, Canada. *Air Qual Atmos Health* 5: 311-323. <http://dx.doi.org/10.1007/s11869-010-0094-3>

- Park, JW; Lim, YH; Kyung, SY; An, CH; Lee, SP; Jeong, SH; Ju, YS. (2005). Effects of ambient particulate matter on peak expiratory flow rates and respiratory symptoms of asthmatics during Asian dust periods in Korea. *Respirology* 10: 470-476. <http://dx.doi.org/10.1111/j.1440-1843.2005.00728.x>
- Park, SK; Auchincloss, AH; O'Neill, MS; Prineas, R; Correa, JC; Keeler, J; Barr, RG; Kaufman, JD; Diez Roux, AV. (2010). Particulate air pollution, metabolic syndrome, and heart rate variability: The Multi-Ethnic Study of Atherosclerosis (MESA). *Environ Health Perspect* 118: 1406-1411. <http://dx.doi.org/10.1289/ehp.0901778>
- Park, SS; Hong, JH; Lee, JH; Kim, YJ; Cho, SY; Kim, SJ. (2008). Investigation of nitrous acid concentration in an indoor environment using an in-situ monitoring system. *Atmos Environ* 42: 6586-6596. <http://dx.doi.org/10.1016/j.atmosenv.2008.05.023>
- Parker, JD; Akinbami, LJ; Woodruff, TJ. (2009). Air pollution and childhood respiratory allergies in the United States. *Environ Health Perspect* 117: 140-147. <http://dx.doi.org/10.1289/ehp.11497>
- Parker, JD; Rich, DQ; Glinianaia, SV; Leem, JH; Wartenberg, D; Bell, ML; Bonzini, M; Brauer, M; Darrow, L; Gehring, U; Gouveia, N; Grillo, P; Ha, E; van den Hooven, EH; Jalaludin, B; Jesdale, BM; Lepeule, J; Morello-Frosch, R; Morgan, GG; Slama, R; Pierik, FH; Pesatori, AC; Sathyanarayana, S; Seo, J; Strickland, M; Tamburic, L; Woodruff, TJ. (2011). The international collaboration on air pollution and pregnancy outcomes: Initial results. *Environ Health Perspect* 119: 1023-1028. <http://dx.doi.org/10.1289/ehp.1002725>
- Parker, RF; Davis, JK; Cassell, GH; White, H; Dziedzic, D; Blalock, DK; Thorp, RB; Simecka, JW. (1989). Short-term exposure to nitrogen dioxide enhances susceptibility to murine respiratory mycoplasmosis and decreases intrapulmonary killing of *Mycoplasma pulmonis*. *Am J Respir Crit Care Med* 140: 502-512. <http://dx.doi.org/10.1164/ajrccm/140.2.502>
- Parrish, DD; Fehsenfeld, FC. (2000). Methods for gas-phase measurements of ozone, ozone precursors and aerosol precursors. *Atmos Environ* 34: 1921-1957. [http://dx.doi.org/10.1016/S1352-2310\(99\)00454-9](http://dx.doi.org/10.1016/S1352-2310(99)00454-9)
- Patel, MM; Chillrud, SN; Correa, JC; Hazi, Y; Feinberg, M; Deepti, KC; Prakash, S; Ross, JM; Levy, D; Kinney, PL. (2010). Traffic-related particulate matter and acute respiratory symptoms among New York City area adolescents. *Environ Health Perspect* 118: 1338-1343. <http://dx.doi.org/10.1289/ehp.0901499>
- Patel, MM; Chillrud, SN; Deepti, KC; Ross, JM; Kinney, PL. (2013). Traffic-related air pollutants and exhaled markers of airway inflammation and oxidative stress in New York City adolescents. *Environ Res* 121: 71-78. <http://dx.doi.org/10.1016/j.envres.2012.10.012>
- Pathmanathan, S; Krishna, MT; Blomberg, A; Helleday, R; Kelly, FJ; Sandström, T; Holgate, ST; Wilson, SJ; Frew, AJ. (2003). Repeated daily exposure to 2 ppm nitrogen dioxide upregulates the expression of IL-5, IL-10, IL-13, and ICAM-1 in the bronchial epithelium of healthy human airways. *Occup Environ Med* 60: 892-896. <http://dx.doi.org/10.1136/oem.60.11.892>
- Pattenden, S; Hoek, G; Braun-Fahrländer, C; Forastiere, F; Kosheleva, A; Neuberger, M; Fletcher, T. (2006). NO<sub>2</sub> and children's respiratory symptoms in the PATY study. *Occup Environ Med* 63: 828-835. <http://dx.doi.org/10.1136/oem.2006.025213>
- Peacock, JL; Anderson, HR; Bremner, SA; Marston, L; Seemungal, TA; Strachan, DP; Wedzicha, JA. (2011). Outdoor air pollution and respiratory health in patients with COPD. *Thorax* 66: 591-596. <http://dx.doi.org/10.1136/thx.2010.155358>
- Peacock, JL; Symonds, P; Jackson, P; Bremner, SA; Scarlett, JF; Strachan, DP; Anderson, HR. (2003). Acute effects of winter air pollution on respiratory function in schoolchildren in southern England. *Occup Environ Med* 60: 82-89. <http://dx.doi.org/10.1136/oem.60.2.82>
- Peacock, M. (2006). Memorandum from Marcus Peacock, Deputy Administrator of the U.S. EPA, to Dr. George Gray, Assistant Administrator of ORD, and Bill Wehrum, Acting Assistant Administrator of OAR: Process for reviewing National Ambient Air Quality Standards. Washington, D.C.: U.S. Environmental Protection Agency.
- Peacock, MC. (2008). Letter from Marcus C. Peacock to Rogene Henderson (regarding CASAC comments on application of new NAAQS process). Available online at <http://www.epa.gov/ttn/naqs/pdfs/PeacocklettertoCASAC090808.pdf>

- [Pedersen, M; Giorgis-Allemand, L; Bernard, C; Aguilera, I; Andersen, AM; Ballester, F; Beelen, RM; Chatzi, L; Cirach, M; Danileviciute, A; Dedele, A; van Eijsden, M; Estarlich, M; Fernández-Somoano, A; Fernández, MF; Forastiere, F; Gehring, U; Grazuleviciene, R; Gruzieva, O; Heude, B; Hoek, G; de Hoogh, K; van Den Hooven, EH; Håberg, SE; Jaddoe, VW; Klümper, C; Korek, M; Krämer, U; Lerchundi, A; Lepeule, J; Nafstad, P; Nystad, W; Patelarou, E; Porta, D; Postma, D; Raaschou-Nielsen, O; Rudnai, P; Sunyer, J; Stephanou, E; Sørensen, M; Thiering, E; Tuffnell, D; Varró, MJ; Vrijkotte, TG; Wijga, A; Wilhelm, M; Wright, J; Nieuwenhuijsen, MJ; Pershagen, G; Brunekreef, B; Kogevinas, M; Slama, R.](#) (2013). Ambient air pollution and low birthweight: a European cohort study (ESCAPE). *Lancet Respir Med* 1: 695-704. [http://dx.doi.org/10.1016/S2213-2600\(13\)70192-9](http://dx.doi.org/10.1016/S2213-2600(13)70192-9)
- [Pedersen, M; Stayner, L; Slama, R; Sørensen, M; Figueras, F; Nieuwenhuijsen, MJ; Raaschou-Nielsen, O; Dadvandy, P.](#) (2014). Ambient air pollution and pregnancy-induced hypertensive disorders: a systematic review and meta-analysis [Review]. *Hypertension* 64: 494-500. <http://dx.doi.org/10.1161/HYPERTENSIONAHA.114.03545>
- [Peel, JL; Klein, M; Flanders, WD; Mulholland, JA; Freed, G; Tolbert, PE.](#) (2011). Ambient air pollution and apnea and bradycardia in high-risk infants on home monitors. *Environ Health Perspect* 119: 1321-1327. <http://dx.doi.org/10.1289/ehp.1002739>
- [Peel, JL; Metzger, KB; Klein, M; Flanders, WD; Mulholland, JA; Tolbert, PE.](#) (2007). Ambient air pollution and cardiovascular emergency department visits in potentially sensitive groups. *Am J Epidemiol* 165: 625-633. <http://dx.doi.org/10.1093/aje/kwk051>
- [Peel, JL; Tolbert, PE; Klein, M; Metzger, KB; Flanders, WD; Todd, K; Mulholland, JA; Ryan, PB; Frumkin, H.](#) (2005). Ambient air pollution and respiratory emergency department visits. *Epidemiology* 16: 164-174. <http://dx.doi.org/10.1097/01.ede.0000152905.42113.db>
- [Pegas, PN; Nunes, T; Alves, CA; Silva, JR; Vieira, SLA; Caseiro, A; Pio, CA.](#) (2012). Indoor and outdoor characterisation of organic and inorganic compounds in city centre and suburban elementary schools of Aveiro, Portugal. *Atmos Environ* 55: 80-89. <http://dx.doi.org/10.1016/j.atmosenv.2012.03.059>
- [Pereira, G; Cook, AG; Hagggar, F; Bower, C; Nassar, N.](#) (2012). Locally derived traffic-related air pollution and fetal growth restriction: A retrospective cohort study. *Occup Environ Med* 69: 815-822. <http://dx.doi.org/10.1136/oemed-2011-100509>
- [Pereira, G; Hagggar, F; Shand, AW; Bower, C; Cook, A; Nassar, N.](#) (2013). Association between pre-eclampsia and locally derived traffic-related air pollution: A retrospective cohort study. *J Epidemiol Community Health* 67: 147-152. <http://dx.doi.org/10.1136/jech-2011-200805>
- [Perring, AE; Pusede, SE; Cohen, RC.](#) (2013). An observational perspective on the atmospheric impacts of alkyl and multifunctional nitrates on ozone and secondary organic aerosol. *Chem Rev* 113: 5848-5870. <http://dx.doi.org/10.1021/cr300520x>
- [Peters, A; Breitner, S; Cyrus, J; Stölzel, M; Pitz, M; Wölke, G; Heinrich, J; Kreyling, W; Küchenhoff, H; Wichmann, H.](#) (2009). The influence of improved air quality on mortality risks in Erfurt, Germany. (137). Boston, MA: Health Effects Institute. <http://pubs.healtheffects.org/view.php?id=299>
- [Peters, JM; Avol, E; Gauderman, WJ; Linn, WS; Navidi, W; London, SJ; Margolis, H; Rappaport, E; Vora, H; Gong, H, Jr; Thomas, DC.](#) (1999). A study of twelve southern California communities with differing levels and types of air pollution: II. Effects on pulmonary function. *Am J Respir Crit Care Med* 159: 768-775. <http://dx.doi.org/10.1164/ajrccm.159.3.9804144>
- [Petroeschovsky, A; Simpson, RW; Thalib, L; Rutherford, S.](#) (2001). Associations between outdoor air pollution and hospital admissions in Brisbane, Australia. *Arch Environ Occup Health* 56: 37-52. <http://dx.doi.org/10.1080/00039890109604053>
- [Pfister, GG; Wiedinmyer, C; Emmons, LK.](#) (2008). Impacts of the fall 2007 California wildfires on surface ozone: Integrating local observations with global model simulations. *Geophys Res Lett* 35: L19814. <http://dx.doi.org/10.1029/2008gl034747>

- [Physick, W; Powell, J; Cope, M; Boast, K; Lee, S.](#) (2011). Measurements of personal exposure to NO<sub>2</sub> and modelling using ambient concentrations and activity data. *Atmos Environ* 45: 2095-2102. <http://dx.doi.org/10.1016/j.atmosenv.2011.01.063>
- [Piechocki-Minguy, A; Plaisance, H; Schadkowski, C; Sagnier, I; Saison, JY; Galloo, JC; Guillermo, R.](#) (2006). A case study of personal exposure to nitrogen dioxide using a new high sensitive diffusive sampler. *Sci Total Environ* 366: 55-64. <http://dx.doi.org/10.1016/j.scitotenv.2005.08.009>
- [Pilotto, LS; Nitschke, M; Smith, BJ; Pisaniello, D; Ruffin, RE; McElroy, HJ; Martin, J; Hiller, JE.](#) (2004). Randomized controlled trial of unflued gas heater replacement on respiratory health of asthmatic schoolchildren. *Int J Epidemiol* 33: 208-214. <http://dx.doi.org/10.1093/ije/dyh018>
- [Pinkston, P; Smeglin, A; Roberts, NJ, Jr; Gibb, FR; Morrow, PE; Utell, MJ.](#) (1988). Effects of in vitro exposure to nitrogen dioxide on human alveolar macrophage release of neutrophil chemotactic factor and interleukin-1. *Environ Res* 47: 48-58. [http://dx.doi.org/10.1016/S0013-9351\(88\)80020-3](http://dx.doi.org/10.1016/S0013-9351(88)80020-3)
- [Pinto, JP; Dibb, J; Lee, BH; Rappenglück, B; Wood, EC; Levy, M; Zhang, RY; Lefer, B; Ren, XR; Stutz, J; Tsai, C; Ackermann, L; Golovko, J; Herndon, SC; Oakes, M; Meng, QY; Munger, JW; Zahniser, M; Zheng, J.](#) (2014). Intercomparison of field measurements of nitrous acid (HONO) during the SHARP campaign. *J Geophys Res Atmos* 119: 5583-5601. <http://dx.doi.org/10.1002/2013JD020287>
- [Pinto, JP; Lefohn, AS; Shadwick, DS.](#) (2004). Spatial variability of PM<sub>2.5</sub> in urban areas in the United States. *J Air Waste Manag Assoc* 54: 440-449.
- [Pirjola, L; Lähde, T; Niemi, JV; Kousa, A; Rönkkö, T; Karjalainen, P; Keskinen, J; Frey, A; Hillamo, R.](#) (2012). Spatial and temporal characterization of traffic emissions in urban microenvironments with a mobile laboratory. *Atmos Environ* 63: 156-167. <http://dx.doi.org/10.1016/j.atmosenv.2012.09.022>
- [Pitard, A; Zeghnoun, A; Courseaux, A; Lamberty, J; Delmas, V; Fossard, JL; Villet, H.](#) (2004). Short-term associations between air pollution and respiratory drug sales. *Environ Res* 95: 43-52. <http://dx.doi.org/10.1016/j.envres.2003.08.006>
- [Pleijel, H; Karlsson, GP; Gerdin, EB.](#) (2004). On the logarithmic relationship between NO<sub>2</sub> concentration and the distance from a highroad. *Sci Total Environ* 332: 261-264. <http://dx.doi.org/10.1016/j.scitotenv.2004.03.020>
- [Plopper, CG; Hatch, GE; Wong, V; Duan, X; Weir, AJ; Tarkington, BK; Devlin, RB; Becker, S; Buckpitt, AR.](#) (1998). Relationship of inhaled ozone concentration to acute tracheobronchial epithelial injury, site-specific ozone dose and glutathione depletion in rhesus monkeys. *Am J Respir Cell Mol Biol* 19: 387-399. <http://dx.doi.org/10.1165/ajrcmb.19.3.3183>
- [Poddubny, VA; Yushketova, NA.](#) (2013). A physicochemical model of sorption processes in NO<sub>2</sub> passive sampling with air humidity effects. *Environ Monit Assess* 185: 3819-3829. <http://dx.doi.org/10.1007/s10661-012-2830-7>
- [Polidori, A; Fine, PM.](#) (2012a). Ambient concentrations of criteria and air toxic pollutants in close proximity to a freeway with heavy-duty diesel traffic. South Coast Air Quality Management District. [www.aqmd.gov/tao/AQ-Reports/I710Fwy\\_Study.pdf](http://www.aqmd.gov/tao/AQ-Reports/I710Fwy_Study.pdf)
- [Polidori, A; Fine, PM.](#) (2012b). Ambient concentrations of criteria and air toxic pollutants in close proximity to a freeway with heavy-duty diesel traffic. Final report. South Coast Air Quality Management District. <http://www.aqmd.gov/docs/default-source/air-quality/air-quality-monitoring-studies/near-roadway-study.pdf?sfvrsn=2>
- [Pollack, IB; Lerner, BM; Ryerson, TB.](#) (2011). Evaluation of ultraviolet light-emitting diodes for detection of atmospheric NO<sub>2</sub> by photolysis - chemiluminescence. *J Atmos Chem* 65: 111-125. <http://dx.doi.org/10.1007/s10874-011-9184-3>

- Pollack, IB; Ryerson, TB; Trainer, M; Parrish, DD; Andrews, AE; Atlas, EL; Blake, DR; Brown, SS; Commane, R; Daube, BC; De Gouw, JA; Dubé, WP; Flynn, J; Frost, GJ; Gilman, JB; Grossberg, N; Holloway, JS; Kofler, J; Kort, EA; Kuster, WC; Lang, PM; Lefer, B; Lueb, RA; Neuman, JA; Nowak, JB; Novelli, PC; Peischl, J; Perring, AE; Roberts, JM; Santoni, G; Schwarz, JP; Spackman, J. R.; Wagner, NL; Warneke, C; Washenfelder, RA; Wofsy, SC; Xiang, B. (2012). Airborne and ground-based observations of a weekend effect in ozone, precursors, and oxidation products in the California South Coast Air Basin. *J Geophys Res* 117: D00V05. <http://dx.doi.org/10.1029/2011JD016772>
- Poloniecki, JD; Atkinson, RW; Ponce de Leon, A; Anderson, HR. (1997). Daily time series for cardiovascular hospital admissions and previous day's air pollution in London, UK. *Occup Environ Med* 54: 535-540. <http://dx.doi.org/10.1136/oem.54.8.535>
- Pönkä, A; Virtanen, M. (1996). Low-level air pollution and hospital admissions for cardiac and cerebrovascular diseases in Helsinki. *Am J Public Health* 86: 1273-1280. <http://dx.doi.org/10.2105/AJPH.86.9.1273>
- Pope, CA, III; Burnett, RT; Thun, MJ; Calle, EE; Krewski, D; Ito, K; Thurston, GD. (2002). Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. *JAMA* 287: 1132-1141. <http://dx.doi.org/10.1001/jama.287.9.1132>
- Pope, CA, III; Thun, MJ; Namboodiri, MM; Dockery, DW; Evans, JS; Speizer, FE; Heath, CW, Jr. (1995). Particulate air pollution as a predictor of mortality in a prospective study of U.S. adults. *Am J Respir Crit Care Med* 151: 669-674. [http://dx.doi.org/10.1164/ajrccm/151.3\\_Pt\\_1.669](http://dx.doi.org/10.1164/ajrccm/151.3_Pt_1.669)
- Posin, C; Clark, K; Jones, MP; Patterson, JV; Buckley, RD; Hackney, JD. (1978). Nitrogen dioxide inhalation and human blood biochemistry. *Arch Environ Occup Health* 33: 318-324. <http://dx.doi.org/10.1080/00039896.1978.10667355>
- Postlethwait, EM; Bidani, A. (1989). Pulmonary disposition of inhaled NO<sub>2</sub>-nitrogen in isolated rat lungs. *Toxicol Appl Pharmacol* 98: 303-312.
- Postlethwait, EM; Bidani, A. (1990). Reactive uptake governs the pulmonary air space removal of inhaled nitrogen dioxide. *J Appl Physiol* 68: 594-603.
- Postlethwait, EM; Bidani, A. (1994). Mechanisms of pulmonary NO<sub>2</sub> absorption [Review]. *Toxicology* 89: 217-237.
- Postlethwait, EM; Bioani, A; Evans, MJ. (1990). The effect of NO<sub>2</sub> exposure on perfusate distribution in isolated rat lungs: Pulmonary versus bronchial circulation. *Toxicol Appl Pharmacol* 106: 456-461. [http://dx.doi.org/10.1016/0041-008X\(90\)90340-Z](http://dx.doi.org/10.1016/0041-008X(90)90340-Z)
- Postlethwait, EM; Langford, SD; Bidani, A. (1991a). Interfacial transfer kinetics of NO<sub>2</sub> into pulmonary epithelial lining fluid. *J Appl Physiol* 71: 1502-1510.
- Postlethwait, EM; Langford, SD; Bidani, A. (1991b). Transfer of NO<sub>2</sub> through pulmonary epithelial lining fluid. *Toxicol Appl Pharmacol* 109: 464-471. [http://dx.doi.org/10.1016/0041-008X\(91\)90009-4](http://dx.doi.org/10.1016/0041-008X(91)90009-4)
- Postlethwait, EM; Langford, SD; Bidani, A. (1992). Kinetics of NO<sub>2</sub> air space absorption in isolated rat lungs. *J Appl Physiol* 73: 1939-1945.
- Postlethwait, EM; Langford, SD; Jacobson, LM; Bidani, A. (1995). NO<sub>2</sub> reactive absorption substrates in rat pulmonary surface lining fluids. *Free Radic Biol Med* 19: 553-563. [http://dx.doi.org/10.1016/0891-5849\(95\)00058-6](http://dx.doi.org/10.1016/0891-5849(95)00058-6)
- Postlethwait, EM; Mustafa, MG. (1981). Fate of inhaled nitrogen dioxide in isolated perfused rat lung. *J Toxicol Environ Health* 7: 861-872. <http://dx.doi.org/10.1080/15287398109530029>
- Postlethwait, EM; Mustafa, MG. (1989). Effect of altered dose rate on NO<sub>2</sub> uptake and transformation in isolated lungs. *J Toxicol Environ Health* 26: 497-507. <http://dx.doi.org/10.1080/15287398909531272>
- Postma, DS; Boezen, HM. (2004). Rationale for the Dutch hypothesis. Allergy and airway hyperresponsiveness as genetic factors and their interaction with environment in the development of asthma and COPD [Review]. *Chest* 126: 96S-104S. [http://dx.doi.org/10.1378/chest.126.2\\_suppl\\_1.96S](http://dx.doi.org/10.1378/chest.126.2_suppl_1.96S)

- [Poynter, ME; Persinger, RL; Irvin, CG; Butnor, KJ; van Hirtum, H; Blay, W; Heintz, NH; Robbins, J; Hemenway, D; Taatjes, DJ; Janssen-Heininger, Y.](#) (2006). Nitrogen dioxide enhances allergic airway inflammation and hyperresponsiveness in the mouse. *Am J Physiol Lung Cell Mol Physiol* 290: L144-L152. <http://dx.doi.org/10.1152/ajplung.00131.2005>
- [Pratt, GC; Parson, K; Shinoda, N; Lindgren, P; Dunlap, S; Yawn, B; Wollan, P; Johnson, J.](#) (2014). Quantifying traffic exposure. *J Expo Sci Environ Epidemiol* 24: 290-296. <http://dx.doi.org/10.1038/jes.2013.51>
- [Proust, B; Lacroix, G; Robidel, F; Marliere, M; Lecomte, A; Vargaftig, BB.](#) (2002). Interference of a short-term exposure to nitrogen dioxide with allergic airways responses to allergenic challenges in BALB/c mice. *Mediators Inflamm* 11: 251-260. <http://dx.doi.org/10.1080/096293502900000113>
- [Prütz, WA; Möning, H; Butler, J; Land, EJ.](#) (1985). Reactions of nitrogen dioxide in aqueous model systems: Oxidation of tyrosine units in peptides and proteins. *Arch Biochem Biophys* 243: 125-134. [http://dx.doi.org/10.1016/0003-9861\(85\)90780-5](http://dx.doi.org/10.1016/0003-9861(85)90780-5)
- [Pryor, WA.](#) (1992). How far does ozone penetrate into the pulmonary air/tissue boundary before it reacts? *Free Radic Biol Med* 12: 83-88. [http://dx.doi.org/10.1016/0891-5849\(92\)90060-T](http://dx.doi.org/10.1016/0891-5849(92)90060-T)
- [Pryor, WA; Houk, KN; Foote, CS; Fukuto, JM; Ignarro, LJ; Squadrito, GL; Davies, KJA.](#) (2006). Free radical biology and medicine: It's a gas, man! [Review]. *Am J Physiol Regul Integr Comp Physiol* 291: R491-R511. <http://dx.doi.org/10.1152/ajpregu.00614.2005>
- [Pryor, WA; Lightsey, JW.](#) (1981). Mechanisms of nitrogen dioxide reactions: Initiation of lipid peroxidation and the production of nitrous acid. *Science* 214: 435-437. <http://dx.doi.org/10.1126/science.214.4519.435>
- [Pujades-Rodriguez, M; Mckeever, T; Lewis, S; Whyatt, D; Britton, J; Venn, A.](#) (2009). Effect of traffic pollution on respiratory and allergic disease in adults: Cross-sectional and longitudinal analyses. *BMC Pulm Med* 9: 42. <http://dx.doi.org/10.1186/1471-2466-9-42>
- [Pun, BK; Seigneur, C; White, W.](#) (2003). Day-of-week behavior of atmospheric ozone in three US cities. *J Air Waste Manag Assoc* 53: 789-801. <http://dx.doi.org/10.1080/10473289.2003.10466231>
- [Purvis, MR; Ehrlich, R.](#) (1963). Effect of atmospheric pollutants on susceptibility to respiratory infection: II Effect of nitrogen dioxide. *J Infect Dis* 113: 72-76.
- [Pusede, SE; Cohen, RC.](#) (2012). On the observed response of ozone to NO<sub>x</sub> and VOC reactivity reductions in San Joaquin Valley California 1995-present. *Atmos Chem Phys* 12: 8323-8339. <http://dx.doi.org/10.5194/acp-12-8323-2012>
- [Qian, Z; Lin, HM; Chinchilli, VM; Lehman, EB; Duan, Y; Craig, TJ; Wilson, WE; Liao, D; Lazarus, SC; Bascom, R.](#) (2009a). Interaction of ambient air pollution with asthma medication on exhaled nitric oxide among asthmatics. *Arch Environ Occup Health* 64: 168-176. <http://dx.doi.org/10.1080/19338240903240616>
- [Qian, Z; Lin, HM; Chinchilli, VM; Lehman, EB; Stewart, WF; Shah, N; Duan, Y; Craig, TJ; Wilson, WE; Liao, D; Lazarus, SC; Bascom, R.](#) (2009b). Associations between air pollution and peak expiratory flow among patients with persistent asthma. *J Toxicol Environ Health A* 72: 39-46. <http://dx.doi.org/10.1080/15287390802445517>
- [Qiu, H; Yu, IT; Wang, X; Tian, L; Tse, LA; Wong, TW.](#) (2013a). Cool and dry weather enhances the effects of air pollution on emergency IHD hospital admissions. *Int J Cardiol* 168: 500-505. <http://dx.doi.org/10.1016/j.ijcard.2012.09.199>
- [Qiu, H; Yu, ITS; Wang, X; Tian, L; Tse, LA; Wong, TW.](#) (2013b). Season and humidity dependence of the effects of air pollution on COPD hospitalizations in Hong Kong. *Atmos Environ* 76: 74-80. <http://dx.doi.org/10.1016/j.atmosenv.2012.07.026>
- [Que, LG; Yang, Z; Stamler, JS; Lugogo, NL; Kraft, M.](#) (2009). S-nitrosoglutathione reductase: An important regulator in human asthma. *Am J Respir Crit Care Med* 180: 226-231. <http://dx.doi.org/10.1164/rccm.200901-0158OC>

- [Quintana, PJE; Dumbauld, JJ; Garnica, L; Chowdhury, MZ; Velascosoltero, J; Mota-Raigoza, A; Flores, D; Rodriguez, E; Panagon, N; Gamble, J; Irby, T; Tran, C; Elder, J; Galaviz, VE; Hoffman, L; Zavala, M; Molina, LT.](#) (2014). Traffic-related air pollution in the community of San Ysidro, CA, in relation to northbound vehicle wait times at the US-Mexico border Port of Entry. *Atmos Environ* 88: 353-361. <http://dx.doi.org/10.1016/j.atmosenv.2014.01.009>
- [Raaschou-Nielsen, O; Andersen, ZJ; Beelen, R; Samoli, E; Stafoggia, M; Weinmayr, G; Hoffmann, B; Fischer, P; Nieuwenhuijsen, MJ; Brunekreef, B; Xun, WW; Katsouyanni, K; Dimakopoulou, K; Sommar, J; Forsberg, B; Modig, L; Oudin, A; Oftedal, B; Schwarze, PE; Nafstad, P; De Faire, U; Pedersen, NL; Östenson, CG; Fratiglioni, L; Penell, J; Korek, M; Pershagen, G; Eriksen, KT; Sørensen, M; Tjønneland, A; Ellermann, T; Eeftens, M; Peeters, PH; Meliefste, K; Wang, M; Bueno-De-mesquita, B; Key, TJ; De Hoogh, K; Concin, H; Nagel, G; Vilier, A; Grioni, S; Krogh, V; Tsai, MY; Ricceri, F; Sacerdote, C; Galassi, C; Migliore, E; Ranzi, A; Cesaroni, G; Badaloni, C; Forastiere, F; Tamayo, I; Amiano, P; Dorronsoro, M; Trichopoulou, A; Bamia, C; Vineis, P; Hoek, G.](#) (2013a). Air pollution and lung cancer incidence in 17 European cohorts: Prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). *Lancet Oncol* 14: 813-822. [http://dx.doi.org/10.1016/S1470-2045\(13\)70279-1](http://dx.doi.org/10.1016/S1470-2045(13)70279-1)
- [Raaschou-Nielsen, O; Andersen, ZJ; Hvidberg, M; Jensen, SS; Ketzel, M; Sorensen, M; Hansen, J; Loft, S; Overvad, K; Tjønneland, A.](#) (2011a). Air pollution from traffic and cancer incidence: A Danish cohort study. *Environ Health* 10: 67. <http://dx.doi.org/10.1186/1476-069X-10-67>
- [Raaschou-Nielsen, O; Andersen, ZJ; Hvidberg, M; Jensen, SS; Ketzel, M; Sørensen, M; Loft, S; Overvad, K; Tjønneland, A.](#) (2011b). Lung cancer incidence and long-term exposure to air pollution from traffic. *Environ Health Perspect* 119: 860-865. <http://dx.doi.org/10.1289/ehp.1002353>
- [Raaschou-Nielsen, O; Andersen, ZJ; Jensen, SS; Ketzel, M; Sørensen, M; Hansen, J; Loft, S; Tjønneland, A; Overvad, K.](#) (2012). Traffic air pollution and mortality from cardiovascular disease and all causes: A Danish cohort study. *Environ Health* 11: 60. <http://dx.doi.org/10.1186/1476-069X-11-60>
- [Raaschou-Nielsen, O; Bak, H; Sørensen, M; Jensen, SS; Ketzel, M; Hvidberg, M; Schnohr, P; Tjønneland, A; Overvad, K; Loft, S.](#) (2010a). Air pollution from traffic and risk for lung cancer in three Danish cohorts. *Cancer Epidemiol Biomarkers Prev* 19: 1284-1291. <http://dx.doi.org/10.1158/1055-9965.EPI-10-0036>
- [Raaschou-Nielsen, O; Hermansen, MN; Loland, L; Buchvald, F; Pipper, CB; Sørensen, M; Loft, S; Bisgaard, H.](#) (2010b). Long-term exposure to indoor air pollution and wheezing symptoms in infants. *Indoor Air* 20: 159-167. <http://dx.doi.org/10.1111/j.1600-0668.2009.00635.x>
- [Raaschou-Nielsen, O; Hertel, O; Vignati, E; Berkowicz, R; Jensen, SS; Larsen, VB; Lohse, C; Olsen, JH.](#) (2000). An air pollution model for use in epidemiological studies: Evaluation with measured levels of nitrogen dioxide and benzene. *J Expo Anal Environ Epidemiol* 10: 4-14. <http://dx.doi.org/10.1038/sj.jea.7500070>
- [Raaschou-Nielsen, O; Sørensen, M; Ketzel, M; Hertel, O; Loft, S; Tjønneland, A; Overvad, K; Andersen, ZJ.](#) (2013b). Long-term exposure to traffic-related air pollution and diabetes-associated mortality: A cohort study. *Diabetologia* 56: 36-46. <http://dx.doi.org/10.1007/s00125-012-2698-7>
- [Raff, JD; Njegic, B; Chang, WL; Gordon, MS; Dabdub, D; Gerber, RB; Finlayson-Pitts, BJ.](#) (2009). Chlorine activation indoors and outdoors via surface-mediated reactions of nitrogen oxides with hydrogen chloride. *PNAS* 106: 13647-13654. <http://dx.doi.org/10.1073/pnas.0904195106>
- [Rage, E; Jacquemin, B; Nadif, R; Oryszczyn, MP; Siroux, V; Aguilera, I; Kauffmann, F; Künzli, N.](#) (2009). Total serum IgE levels are associated with ambient ozone concentration in asthmatic adults. *Allergy* 64: 40-46. <http://dx.doi.org/10.1111/j.1398-9995.2008.01800.x>
- [Ragettli, MS; Tsai, MY; Braun-Fahrländer, C; de Nazelle, A; Schindler, C; Ineichen, A; Ducret-Stich, RE; Perez, L; Probst-Hensch, N; Künzli, N; Phuleria, HC.](#) (2014). Simulation of population-based commuter exposure to NO using different air pollution models. *Int J Environ Res Public Health* 11: 5049-5068. <http://dx.doi.org/10.3390/ijerph110505049>
- [Rahmalia, A; Giorgis-Allemand, L; Lepeule, J; Philippat, C; Galineau, J; Hulin, A; Charles, MA; Slama, R.](#) (2012). Pregnancy exposure to atmospheric pollutants and placental weight: An approach relying on a dispersion model. *Environ Int* 48: 47-55. <http://dx.doi.org/10.1016/j.envint.2012.06.013>

- [Ramos-Bonilla, JP; Breyse, PN; Dominici, F; Geyh, A; Tankersley, CG.](#) (2010). Ambient air pollution alters heart rate regulation in aged mice. *Inhal Toxicol* 22: 330-339. <http://dx.doi.org/10.3109/08958370903349365>
- [Ranzi, A; Gambini, M; Spattini, A; Galassi, C; Sesti, D; Bedeschi, M; Messori, A; Baroni, A; Cavagni, G; Lauriola, P.](#) (2004). Air pollution and respiratory status in asthmatic children: Hints for a locally based preventive strategy AIRE study. *Eur J Epidemiol* 19: 567-576.
- [Ranzi, A; Porta, D; Badaloni, C; Cesaroni, G; Lauriola, P; Davoli, M; Forastiere, F.](#) (2014). Exposure to air pollution and respiratory symptoms during the first 7 years of life in an Italian birth cohort. *Occup Environ Med* 71: 430-436. <http://dx.doi.org/10.1136/oemed-2013-101867>
- [Rao, KS; Gunter, RL; White, JR; Hosker, RP.](#) (2002). Turbulence and dispersion modeling near highways. *Atmos Environ* 36: 4337-4346. [http://dx.doi.org/10.1016/S1352-2310\(02\)00353-9](http://dx.doi.org/10.1016/S1352-2310(02)00353-9)
- [Rao, M; George, LA; Rosenstiel, TN; Shandas, V; Dinno, A.](#) (2014). Assessing the relationship among urban trees, nitrogen dioxide, and respiratory health. *Environ Pollut* 194: 96-104. <http://dx.doi.org/10.1016/j.envpol.2014.07.011>
- [Rasmussen, TR; Kjaergaard, SK; Tarp, U; Pedersen, OF.](#) (1992). Delayed effects of NO<sub>2</sub> exposure on alveolar permeability and glutathione peroxidase in healthy humans. *Am Rev Respir Dis* 146: 654-659. <http://dx.doi.org/10.1164/ajrccm/146.3.654>
- [Rava, M; Varraso, R; Decoster, B; Huyvaert, H; Le Moual, N; Jacquemin, B; Künzli, N; Kauffmann, F; Zerimech, F; Matran, R; Nadif, R.](#) (2012). Plasma and exhaled breath condensate nitrite-nitrate level in relation to environmental exposures in adults in the EGEA study. *Nitric Oxide* 27: 169-175. <http://dx.doi.org/10.1016/j.niox.2012.06.007>
- [Raysoni, AU; Sarnat, JA; Sarnat, SE; Garcia, JH; Holguin, F; Luevano, SF; Li, WW.](#) (2011). Binational school-based monitoring of traffic-related air pollutants in El Paso, Texas (USA) and Ciudad Juarez, Chihuahua (Mexico). *Environ Pollut* 159: 2476-2486. <http://dx.doi.org/10.1016/j.envpol.2011.06.024>
- [Reddel, HK; Taylor, DR; Bateman, ED; Boulet, LP; Boushey, HA; Busse, WW; Casale, TB; Chanez, P; Enright, PL; Gibson, PG; de Jongste, JC; Kerstjens, HA; Lazarus, SC; Levy, ML; O'Byrne, PM; Partridge, MR; Pavord, ID; Sears, MR; Sterk, PJ; Stoloff, SW; Sullivan, SD; Szeffler, SJ; Thomas, MD; Wenzel, SE.](#) (2009). An official American Thoracic Society/European Respiratory Society statement: Asthma control and exacerbations: Standardizing endpoints for clinical asthma trials and clinical practice. *Am J Respir Crit Care Med* 180: 59-99. <http://dx.doi.org/10.1164/rccm.200801-060ST>
- [Reeves, GK; Cox, DR; Darby, SC; Whitley, E.](#) (1998). Some aspects of measurement error in explanatory variables for continuous and binary regression models. *Stat Med* 17: 2157-2177. [http://dx.doi.org/10.1002/\(SICI\)1097-0258\(19981015\)17:19<2157::AID-SIM916>3.0.CO;2-F](http://dx.doi.org/10.1002/(SICI)1097-0258(19981015)17:19<2157::AID-SIM916>3.0.CO;2-F)
- [Ren, C; Fang, S; Wright, RO; Suh, H; Schwartz, J.](#) (2011). Urinary 8-hydroxy-2'-deoxyguanosine as a biomarker of oxidative DNA damage induced by ambient pollution in the Normative Aging Study. *Occup Environ Med* 68: 562-569. <http://dx.doi.org/10.1136/oem.2010.056358>
- [Ren, X; van Duin, D; Cazorla, M; Chen, S; Mao, J; Zhang, L, i; Brune, WH; Flynn, JH; Grossberg, N; Lefer, BL; Rappenglueck, B; Wong, K; Tsai, C; Stutz, J; Dibb, JE; Jobson, BT; Luke, WT; Kelley, P.](#) (2013). Atmospheric oxidation chemistry and ozone production: Results from SHARP 2009 in Houston, Texas. *J Geophys Res Atmos* 118: 5770-5780. <http://dx.doi.org/10.1002/jgrd.50342>
- [Rice, MB; Ljungman, PL; Wilker, EH; Gold, DR; Schwartz, JD; Koutrakis, P; Washko, GR; O'Connor, GT; Mittleman, MA.](#) (2013). Short-term exposure to air pollution and lung function in the Framingham heart study. *Am J Respir Crit Care Med* 188: 1351-1357. <http://dx.doi.org/10.1164/rccm.201308-1414OC>
- [Rich, DQ; Demissie, K; Lu, SE; Kamat, L; Wartenberg, D; Rhoads, GG.](#) (2009). Ambient air pollutant concentrations during pregnancy and the risk of fetal growth restriction. *J Epidemiol Community Health* 63: 488-496. <http://dx.doi.org/10.1136/jech.2008.082792>
- [Rich, DQ; Kipen, HM; Huang, W; Wang, G; Wang, Y; Zhu, P; Ohman-Strickland, P; Hu, M; Philipp, C; Diehl, SR; Lu, SE; Tong, J; Gong, J; Thomas, D; Zhu, T; Zhang, JJ.](#) (2012). Association between changes in air pollution levels during the Beijing Olympics and biomarkers of inflammation and thrombosis in healthy young adults. *JAMA* 307: 2068-2078. <http://dx.doi.org/10.1001/jama.2012.3488>

- [Rich, DQ; Kipen, HM; Zhang, J; Kamat, L; Wilson, AC; Kostis, JB.](#) (2010). Triggering of transmural infarctions, but not nontransmural infarctions, by ambient fine particles. *Environ Health Perspect* 118: 1229-1234. <http://dx.doi.org/10.1289/ehp.0901624>
- [Richmond-Bryant, J; Reff, A.](#) (2012). Air pollution retention within a complex of urban street canyons: A two-city comparison. *Atmos Environ* 49: 24-32. <http://dx.doi.org/10.1016/j.atmosenv.2011.12.036>
- [Richters, A; Damji, KS.](#) (1990). The relationship between inhalation of nitrogen dioxide, the immune system, and progression of a spontaneously occurring lymphoma in AKR mice. *J Environ Pathol Toxicol Oncol* 10: 225-230.
- [Richters, A; Kuraitis, K.](#) (1981). Inhalation of NO<sub>2</sub> and blood borne cancer cell spread to the lungs. *Arch Environ Health* 36: 36-39.
- [Richters, A; Kuraitis, K.](#) (1983). Air pollutants and the facilitation of cancer metastasis. *Environ Health Perspect* 52: 165-168.
- [Richters, A; Richters, V; Alley, WP.](#) (1985). The mortality rate from lung metastases in animals inhaling nitrogen dioxide (NO<sub>2</sub>). *J Surg Oncol* 28: 63-66. <http://dx.doi.org/10.1002/jso.2930280115>
- [Riedel, TP; Wolfe, GM; Danas, KT; Gilman, JB; Kuster, WC; Bon, DM; Vlasenko, A; Li, SM; Williams, EJ; Lerner, BM; Veres, PR; Roberts, JM; Holloway, JS; Lefer, B; Brown, SS; Thornton, JA.](#) (2014). An MCM modeling study of nitryl chloride (ClNO<sub>2</sub>) impacts on oxidation, ozone production and nitrogen oxide partitioning in polluted continental outflow. *Atmos Chem Phys* 14: 3789-3800. <http://dx.doi.org/10.5194/acp-14-3789-2014>
- [Riedl, MA; Diaz-Sanchez, D; Linn, WS; Gong, H, Jr; Clark, KW; Effros, RM; Miller, JW; Cocker, DR; Berhane, KT.](#) (2012). Allergic inflammation in the human lower respiratory tract affected by exposure to diesel exhaust [HEI] (pp. 5-43; discussion 45-64). (ISSN 1041-5505 Research Report 165). Boston, MA: Health Effects Institute. <http://pubs.healtheffects.org/view.php?id=373>
- [Ritz, B; Qiu, J; Lee, PC; Lurmann, F; Penfold, B; Erin Weiss, R; Mcconnell, R; Arora, C; Hobel, C; Wilhelm, M.](#) (2014). Prenatal air pollution exposure and ultrasound measures of fetal growth in Los Angeles, California. *Environ Res* 130: 7-13. <http://dx.doi.org/10.1016/j.envres.2014.01.006>
- [Ritz, B; Wilhelm, M.](#) (2008). Ambient air pollution and adverse birth outcomes: Methodologic issues in an emerging field [Review]. *Basic Clin Pharmacol Toxicol* 102: 182-190. <http://dx.doi.org/10.1111/j.1742-7843.2007.00161.x>
- [Ritz, B; Wilhelm, M; Hoggatt, KJ; Ghosh, JK.](#) (2007). Ambient air pollution and preterm birth in the environment and pregnancy outcomes study at the University of California, Los Angeles. *Am J Epidemiol* 166: 1045-1052. <http://dx.doi.org/10.1093/aje/kwm181>
- [Ritz, B; Wilhelm, M; Zhao, Y.](#) (2006). Air pollution and infant death in southern California, 1989-2000. *Pediatrics* 118: 493-502. <http://dx.doi.org/10.1542/peds.2006-0027>
- [Ritz, B; Yu, F; Chapa, G; Fruin, S.](#) (2000). Effect of air pollution on preterm birth among children born in Southern California between 1989 and 1993. *Epidemiology* 11: 502-511.
- [Rivas, I; Viana, M; Moreno, T; Pandolfi, M; Amato, F; Reche, C; Bouso, L; Alvarez-Pedrerol, M; Alastuey, A; Sunyer, J; Querol, X.](#) (2014). Child exposure to indoor and outdoor air pollutants in schools in Barcelona, Spain. *Environ Int* 69: 200-212. <http://dx.doi.org/10.1016/j.envint.2014.04.009>
- [Rivera, M; Basagaña, X; Aguilera, I; Foraster, M; Agis, D; de Groot, E; Perez, L; Mendez, MA; Bouso, L; Targa, J; Ramos, R; Sala, J; Marrugat, J; Elosua, R; Künzli, N.](#) (2013). Association between long-term exposure to traffic-related air pollution and subclinical atherosclerosis: The REGICOR study. *Environ Health Perspect* 121: 223-230. <http://dx.doi.org/10.1289/ehp.1205146>
- [Roberts, JM; Veres, PR; Vandenboer, TC; Warneke, C; Graus, M; Williams, EJ; Lefer, B; Brock, CA; Bahreini, R; Öztürk, F; Middlebrook, AM; Wagner, NL; Dubé, WP; De Gouw, JA.](#) (2014). New insights into atmospheric sources and sinks of isocyanic acid, HNCO, from recent urban and regional observations. *J Geophys Res Atmos* 119: 1060-1072. <http://dx.doi.org/10.1002/2013JD019931>

- Roberts, S; Martin, MA. (2006). Using supervised principal components analysis to assess multiple pollutant effects. *Environ Health Perspect* 114: 1877-1882. <http://dx.doi.org/10.1289/ehp.9226>
- Robinson, DP; Lloyd, CD; Mckinley, JM. (2013). Increasing the accuracy of nitrogen dioxide (NO<sub>2</sub>) pollution mapping using geographically weighted regression (GWR) and geostatistics. *Int J Appl Earth Obs Geoinf* 21: 374-383. <http://dx.doi.org/10.1016/j.jag.2011.11.001>
- Robison, TW; Duncan, DP; Forman, HJ. (1990). Chemoattractant and leukotriene B<sub>4</sub> production from rat alveolar macrophages exposed to nitrogen dioxide. *Am J Respir Cell Mol Biol* 3: 21-26. <http://dx.doi.org/10.1165/ajrcmb/3.1.21>
- Robison, TW; Forman, HJ. (1993). Dual effect of nitrogen dioxide on rat alveolar macrophage arachidonate metabolism. *Exp Lung Res* 19: 21-36.
- Robison, TW; Murphy, JK; Beyer, LL; Richters, A; Forman, HJ. (1993). Depression of stimulated arachidonate metabolism and superoxide production in rat alveolar macrophages following in vivo exposure to 0.5 ppm NO<sub>2</sub>. *J Toxicol Environ Health* 38: 273-292. <http://dx.doi.org/10.1080/15287399309531718>
- Rodes, CE; Holland, DM. (1981). Variations of NO, NO<sub>2</sub> and O<sub>3</sub> concentrations downwind of a Los Angeles freeway. *Atmos Environ* 15: 243-250. [http://dx.doi.org/10.1016/0004-6981\(81\)90024-X](http://dx.doi.org/10.1016/0004-6981(81)90024-X)
- Rodgers, MO; Davis, DD. (1989). A UV-photofragmentation/laser-induced fluorescence sensor for the atmospheric detection of HONO. *Environ Sci Technol* 23: 1106-1112.
- Rodriguez, C; Tonkin, R; Heyworth, J; Kusel, M; De Klerk, N; Sly, PD; Franklin, P; Runnion, T; Blockley, A; Landau, L; Hinwood, AL. (2007). The relationship between outdoor air quality and respiratory symptoms in young children. *Int J Environ Health Res* 17: 351-360. <http://dx.doi.org/10.1080/09603120701628669>
- Roemer, W; Hoek, G; Brunekreef, B; Haluszka, J; Kalandidi, A; Pekkanen, J. (1998). Daily variations in air pollution and respiratory health in a multicentre study: The PEACE project. *Eur Respir J* 12: 1354-1361.
- Roger, LJ; Horstman, DH; McDonnell, W; Kehrl, H; Ives, PJ; Seal, E; Chapman, R; Massaro, E. (1990). Pulmonary function, airway responsiveness, and respiratory symptoms in asthmatics following exercise in NO<sub>2</sub>. *Toxicol Ind Health* 6: 155-171. <http://dx.doi.org/10.1177/074823379000600110>
- Rojas-Martinez, R; Perez-Padilla, R; Olaiz-Fernandez, G; Mendoza-Alvarado, L; Moreno-Macias, H; Fortoul, T; McDonnell, W; Loomis, D; Romieu, I. (2007a). Lung function growth in children with long-term exposure to air pollutants in Mexico City. *Am J Respir Crit Care Med* 176: 377-384. <http://dx.doi.org/10.1164/rccm.200510-1678OC>
- Rojas-Martinez, R; Perez-Padilla, R; Olaiz-Fernandez, G; Mendoza-Alvarado, L; Moreno-Macias, H; Fortoul, T; McDonnell, W; Loomis, D; Romieu, I. (2007b). Lung function growth in children with long-term exposure to air pollutants in Mexico City. Online data supplement [Supplemental Data]. *Am J Respir Crit Care Med* [176].
- Rombout, PJ; Dormans, JA; Marra, M; Van Esch, GJ. (1986). Influence of exposure regimen on nitrogen dioxide-induced morphological changes in the rat lung. *Environ Res* 41: 466-480.
- Romero, R; Espinoza, J; Kusanovic, JP; Gotsch, F; Hassan, S; Erez, O; Chaiworapongsa, T; Mazor, M. (2006). The preterm parturition syndrome [Review]. *BJOG* 113: 17-42. <http://dx.doi.org/10.1111/j.1471-0528.2006.01120.x>
- Romieu, I; Barraza-Villarreal, A; Escamilla-Nuñez, C; Almstrand, AC; Diaz-Sanchez, D; Sly, PD; Olin, AC. (2008). Exhaled breath malondialdehyde as a marker of effect of exposure to air pollution in children with asthma. *J Allergy Clin Immunol* 121: 903-909. <http://dx.doi.org/10.1016/j.jaci.2007.12.004>
- Romieu, I; Ramirez-Aguilar, M; Sierra-Monge, JJ; Moreno-Macias, H; Del Rio-Navarro, BE; David, G; Marzec, J; Hernandez-Avila, M; London, S. (2006). GSTM1 and GSTP1 and respiratory health in asthmatic children exposed to ozone. *Eur Respir J* 28: 953-959. <http://dx.doi.org/10.1183/09031936.06.00114905>
- Rooney, AA; Boyles, AL; Wolfe, MS; Bucher, JR; Thayer, KA. (2014). Systematic review and evidence integration for literature-based environmental health science assessments. *Environ Health Perspect* 122: 711-718. <http://dx.doi.org/10.1289/ehp.1307972>

- Roorda-Knape, MC; Janssen, NAH; De Hartog, JJ; Van Vliet, PHN; Harssema, H; Brunekreef, B. (1998). Air pollution from traffic in city districts near major motorways. *Atmos Environ* 32: 1921-1930. [http://dx.doi.org/10.1016/S1352-2310\(97\)00496-2](http://dx.doi.org/10.1016/S1352-2310(97)00496-2)
- Rose, N; Cowie, C; Gillett, R; Marks, GB. (2011). Validation of a spatiotemporal land use regression model incorporating fixed site monitors. *Environ Sci Technol* 45: 294-299. <http://dx.doi.org/10.1021/es100683t>
- Rose, RM; Fuglestad, JM; Skornik, WA; Hammer, SM; Wolfthal, SF; Beck, BD; Brain, JD. (1988). The pathophysiology of enhanced susceptibility to murine cytomegalovirus respiratory infection during short-term exposure to 5 ppm nitrogen dioxide. *Am Rev Respir Dis* 137: 912-917. <http://dx.doi.org/10.1164/ajrccm/137.4.912>
- Rose, RM; Pinkston, P; Skornik, WA. (1989a). Altered susceptibility to viral respiratory infection during short-term exposure to nitrogen dioxide. (HEI Research Report no. 24). Cambridge, MA: Health Effects Institute.
- Rose, RM; Pinkston, P; Skornik, WA. (1989b). Altered susceptibility to viral respiratory infection during short-term exposure to nitrogen dioxide. *Res Rep Health Eff Inst* 1-24.
- Rosenlund, M; Bellander, T; Nordquist, T; Alfredsson, L. (2009a). Traffic-generated air pollution and myocardial infarction. *Epidemiology* 20: 265-271. <http://dx.doi.org/10.1097/EDE.0b013e318190ea68>
- Rosenlund, M; Forastiere, F; Porta, D; De Sario, M; Badaloni, C; Perucci, CA. (2009b). Traffic-related air pollution in relation to respiratory symptoms, allergic sensitisation and lung function in schoolchildren. *Thorax* 64: 573-580. <http://dx.doi.org/10.1136/thx.2007.094953>
- Rosenlund, M; Forastiere, F; Stafoggia, M; Porta, D; Perucci, M; Ranzi, A; Nussio, F; Perucci, C. (2008a). Comparison of regression models with land-use and emissions data to predict the spatial distribution of traffic-related air pollution in Rome. *J Expo Sci Environ Epidemiol* 18: 192-199. <http://dx.doi.org/10.1038/sj.jes.7500571>
- Rosenlund, M; Picciotto, S; Forastiere, F; Stafoggia, M; Perucci, CA. (2008b). Traffic-related air pollution in relation to incidence and prognosis of coronary heart disease. *Epidemiology* 19: 121-128. <http://dx.doi.org/10.1097/EDE.0b013e31815c1921>
- Ross, Z; Ito, K; Johnson, S; Yee, M; Pezeshki, G; Clougherty, JE; Savitz, D; Matte, T. (2013). Spatial and temporal estimation of air pollutants in New York City: Exposure assignment for use in a birth outcomes study. *Environ Health* 12. <http://dx.doi.org/10.1186/1476-069X-12-51>
- Ross, Z; Kheirbek, I; Clougherty, JE; Ito, K; Matte, T; Markowitz, S; Eisl, H. (2011). Noise, air pollutants and traffic: Continuous measurement and correlation at a high-traffic location in New York City. *Environ Res* 111: 1054-1063. <http://dx.doi.org/10.1016/j.envres.2011.09.004>
- Rothman, KJ; Greenland, S. (1998). *Modern epidemiology*. In *Modern Epidemiology* (2nd ed.). Philadelphia, PA: Lippincott, Williams, & Wilkins.
- Rotko, T; Kousa, A; Alm, S; Jantunen, M. (2001). Exposures to nitrogen dioxide in EXPOLIS-Helsinki: Microenvironment, behavioral and sociodemographic factors. *J Expo Anal Environ Epidemiol* 11: 216-223. <http://dx.doi.org/10.1038/sj.jea.7500162>
- Roux, D; Frey, C. (2015). CASAC review of the EPAs integrated science assessment for oxides of nitrogen Health criteria (Second external review draft January 2015) [EPA Report]. (EPA-CASAC-15-001). Washington, DC: U.S. Environmental Protection Agency. [http://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/6612DAF24438687B85257EBB0070369C/\\$File/EPA-CASAC-15-001+unsigned.pdf](http://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/6612DAF24438687B85257EBB0070369C/$File/EPA-CASAC-15-001+unsigned.pdf)
- Rowangould, GM. (2013). A census of the US near-roadway population: Public health and environmental justice considerations. *Transport Res Transport Environ* 25: 59-67. <http://dx.doi.org/10.1016/j.trd.2013.08.003>
- Rubenchik, BL; Glavin, AA; Galenko, PM; Kilichko, AA; Olenick, IO; Artemov, KV. (1995). Gaseous nitrogen dioxide increases the endogenous synthesis of carcinogenic N-nitrosodimethylamine in animals. *J Environ Pathol Toxicol Oncol* 14: 111-115.

- [Rubes, J; Rybar, R; Prinosilova, P; Veznik, Z; Chvatalova, I; Solansky, I; Sram, RJ.](#) (2010). Genetic polymorphisms influence the susceptibility of men to sperm DNA damage associated with exposure to air pollution. *Mutat Res* 683: 9-15. <http://dx.doi.org/10.1016/j.mrfmmm.2009.09.010>
- [Rubinstein, I; Bigby, BG; Reiss, TF; Boushey, HA, Jr.](#) (1990). Short-term exposure to 0.3 ppm nitrogen dioxide does not potentiate airway responsiveness to sulfur dioxide in asthmatic subjects. *Am Rev Respir Dis* 141: 381-385. <http://dx.doi.org/10.1164/ajrccm/141.2.381>
- [Rubinstein, I; Reiss, TF; Bigby, BG; Stites, DP; Boushey, HA, Jr.](#) (1991). Effects of 0.60 PPM nitrogen dioxide on circulating and bronchoalveolar lavage lymphocyte phenotypes in healthy subjects. *Environ Res* 55: 18-30.
- [Rudez, G; Janssen, NA; Kilinc, E; Leebeek, FW; Gerlofs-Nijland, ME; Spronk, HM; ten Cate, H; Cassee, FR; de Maat, MP.](#) (2009). Effects of ambient air pollution on hemostasis and inflammation. *Environ Health Perspect* 117: 995-1001. <http://dx.doi.org/10.1289/ehp.0800437>
- [Rudolph, V; Rudolph, TK; Schopfer, FJ; Bonacci, G; Woodcock, SR; Cole, MP; Baker, PR; Ramani, R; Freeman, BA.](#) (2010). Endogenous generation and protective effects of nitro-fatty acids in a murine model of focal cardiac ischaemia and reperfusion. *Cardiovasc Res* 85: 155-166. <http://dx.doi.org/10.1093/cvr/cvp275>
- [Russell, AR; Perring, AE; Valin, LC; Bucsela, EJ; Browne, EC; Wooldridge, PJ; Cohen, RC.](#) (2011). A high spatial resolution retrieval of NO<sub>2</sub> column densities from OMI: method and evaluation. *Atmos Chem Phys* 11: 8543-8554. <http://dx.doi.org/10.5194/acp-11-8543-2011>
- [Ryerson, TB; Andrews, AE; Angevine, WM; Bates, TS; Brock, CA; Cairns, B; Cohen, RC; Cooper, OR; de Gouw, JA; Fehsenfeld, FC; Ferrare, RA; Fischer, ML; Flagan, RC; Goldstein, AH; Hair, JW; Hardesty, RM; Hostetler, CA; Jimenez, JL; Langford, AO; McCauley, E; McKeen, SA; Molina, LT; Nenes, A; Oltmans, SJ; Parrish, DD; Pederson, J. R.; Pierce, RB; Prather, K; Quinn, PK; Seinfeld, JH; Senff, CJ; Sorooshian, A; Stutz, J; Surratt, JD; Trainer, M; Volkamer, R; Williams, EJ; Wofsy, SC.](#) (2013). The 2010 California Research at the Nexus of Air Quality and Climate Change (CalNex) field study. *J Geophys Res Atmos* 118: 5830-5866. <http://dx.doi.org/10.1002/jgrd.50331>
- [Sacks, JD; Ito, K; Wilson, WE; Neas, LM.](#) (2012). Impact of covariate models on the assessment of the air pollution-mortality association in a single- and multipollutant context. *Am J Epidemiol* 176: 622-634. <http://dx.doi.org/10.1093/aje/kws135>
- [Sacks, JD; Stanek, LW; Luben, TJ; Johns, DO; Buckley, BJ; Brown, JS; Ross, M.](#) (2011). Particulate-matter induced health effects: Who is susceptible? [Review]. *Environ Health Perspect* 119: 446-454. <http://dx.doi.org/10.1289/ehp.1002255>
- [Sagai, M; Arakawa, K; Ichinose, T; Shimojo, N.](#) (1987). Biochemical effects on combined gases of nitrogen dioxide and ozone: I. Species differences of lipid peroxides and phospholipids in lungs. *Toxicology* 46: 251-265. [http://dx.doi.org/10.1016/0300-483X\(87\)90207-1](http://dx.doi.org/10.1016/0300-483X(87)90207-1)
- [Sagai, M; Ichinose, T; Kubota, K.](#) (1984). Studies on the biochemical effects of nitrogen dioxide. IV. Relation between the change of lipid peroxidation and the antioxidative protective system in rat lungs upon life span exposure to low levels of NO<sub>2</sub>. *Toxicol Appl Pharmacol* 73: 444-456.
- [Sagai, M; Ichinose, T; Oda, H; Kubota, K.](#) (1982). Studies on biochemical effects of nitrogen dioxide. II. Changes of the protective systems in rat lungs and of lipid peroxidation by acute exposure. *J Toxicol Environ Health* 9: 153-164. <http://dx.doi.org/10.1080/15287398209530150>
- [Sahsuaroglu, T; Su, JG; Brook, J; Burnett, R; Loeb, M; Jerrett, M.](#) (2009). Predicting personal nitrogen dioxide exposure in an elderly population: Integrating residential indoor and outdoor measurements, fixed-site ambient pollution concentrations, modeled pollutant levels, and time-activity patterns. *J Toxicol Environ Health A* 72: 1520-1533. <http://dx.doi.org/10.1080/15287390903129408>
- [Sajani, SZ; Hanninen, O; Marchesi, S; Lauriola, P.](#) (2011). Comparison of different exposure settings in a case-crossover study on air pollution and daily mortality: Counterintuitive results. *J Expo Sci Environ Epidemiol* 21: 385-394. <http://dx.doi.org/10.1038/jes.2010.27>

- Salam, MT; Byun, HM; Lurmann, F; Breton, CV; Wang, X; Eckel, SP; Gilliland, FD. (2012). Genetic and epigenetic variations in inducible nitric oxide synthase promoter, particulate pollution, and exhaled nitric oxide levels in children. *J Allergy Clin Immunol* 129: 232-239.e237. <http://dx.doi.org/10.1016/j.jaci.2011.09.037>
- Salam, MT; Millstein, J; Li, YF; Lurmann, FW; Margolis, HG; Gilliland, FD. (2005). Birth outcomes and prenatal exposure to ozone, carbon monoxide, and particulate matter: Results from the Children's Health Study. *Environ Health Perspect* 113: 1638-1644. <http://dx.doi.org/10.1289/ehp.8111>
- Salonen, RO; Pennanen, AS; Vahteristo, M; Korkeila, P; Alm, S; Randell, JT. (2008). Health risk assessment of indoor air pollution in Finnish ice arenas. *Environ Int* 34: 51-57. <http://dx.doi.org/10.1016/j.envint.2007.06.012>
- Saltzman, BE. (1954). Colorimetric microdetermination of nitrogen dioxide in the atmosphere. *Anal Chem* 26: 1949-1955.
- Samet, JM. (2008). Letter from Dr. Jonathan M. Samet to The Honorable Stephen L. Johnson. Subject: Clean Air Scientific Advisory Committees (CASAC) peer review of draft chapter 8 of EPA's risk and exposure assessment to support the review of the NO<sub>2</sub> primary National Ambient Air Quality Standard. Available online at [http://yosemite.epa.gov/sab/sabproduct.nsf/WebCASAC/Samet-NAAQSLtr-12-16-08/\\$File/Samet-NAAQS-12-16-08.pdf](http://yosemite.epa.gov/sab/sabproduct.nsf/WebCASAC/Samet-NAAQSLtr-12-16-08/$File/Samet-NAAQS-12-16-08.pdf)
- Samet, JM; Lambert, WE; Skipper, BJ; Cushing, AH; Hunt, WC; Young, SA; McLaren, LC; Schwab, M; Spengler, JD. (1993). Nitrogen dioxide and respiratory illness in children. Part I: Health outcomes. (HEI Research Report no. 58). Cambridge, MA: Health Effects Institute.
- Samoli, E; Aga, E; Touloumi, G; Nisiotis, K; Forsberg, B; Lefranc, A; Pekkanen, J; Wojtyniak, B; Schindler, C; Niciu, E; Brunstein, R; Dodic Fikfak, M; Schwartz, J; Katsouyanni, K. (2006). Short-term effects of nitrogen dioxide on mortality: An analysis within the APHEA project. *Eur Respir J* 27: 1129-1137. <http://dx.doi.org/10.1183/09031936.06.00143905>
- Samoli, E; Nastos, PT; Paliatatos, AG; Katsouyanni, K; Priftis, KN. (2011). Acute effects of air pollution on pediatric asthma exacerbation: Evidence of association and effect modification. *Environ Res* 111: 418-424. <http://dx.doi.org/10.1016/j.envres.2011.01.014>
- Sampson, PD; Szpiro, AA; Sheppard, L; Lindstrom, J; Kaufman, JD. (2011). Pragmatic estimation of a spatio-temporal air quality model with irregular monitoring data. *Atmos Environ* 45: 6593-6606. <http://dx.doi.org/10.1016/j.atmosenv.2011.04.073>
- Sánchez Jiménez, A; Heal, MR; Beverland, JJ. (2011). Intercomparison study of NO<sub>x</sub> passive diffusion tubes with chemiluminescence analysers and evaluation of bias factors. *Atmos Environ* 45: 3062-3068. <http://dx.doi.org/10.1016/j.atmosenv.2011.03.011>
- Sánchez Jiménez, A; Heal, MR; Beverland, JJ. (2012). Correlations of particle number concentrations and metals with nitrogen oxides and other traffic-related air pollutants in Glasgow and London. *Atmos Environ* 54: 667-678. <http://dx.doi.org/10.1016/j.atmosenv.2012.01.047>
- Sander, SP; Abbatt, JPD; Barker, JR; Burkholder, JB; Friedl, RR; Golden, DM; Huie, RE; Kolb, CE; Kurylo, MJ; Moortgat, GK; Orkin, VL; Wine, PH. (2011). Section 1. Biomolecular reactions. In *Chemical kinetics and photochemical data for use in atmospheric studies: Evaluation number 17* (JPL Publication 10-6) (pp. 1-1 - 1-34). Pasadena, CA: Jet Propulsion Laboratory.
- Sandström, T; Andersson, MC; Kolmodin-Hedman, B; Stjernberg, N; Angstrom, T. (1990). Bronchoalveolar mastocytosis and lymphocytosis after nitrogen dioxide exposure in man: A time-kinetic study. *Eur Respir J* 3: 138-143.
- Sandström, T; Helleday, R; Bjermer, L; Stjernberg, N. (1992a). Effects of repeated exposure to 4 ppm nitrogen dioxide on bronchoalveolar lymphocyte subsets and macrophages in healthy men. *Eur Respir J* 5: 1092-1096.
- Sandström, T; Ledin, MC; Thomasson, L; Helleday, R; Stjernberg, N. (1992b). Reductions in lymphocyte subpopulations after repeated exposure to 1.5 ppm nitrogen dioxide. *Br J Ind Med* 49: 850-854.

- [Sandström, T; Stjernberg, N; Eklund, A; Ledin, MC; Bjermer, L; Kolmodin-Hedman, B; Lindström, K; Rosenhall, L; Angström, T.](#) (1991). Inflammatory cell response in bronchoalveolar lavage fluid after nitrogen dioxide exposure of healthy subjects: A dose-response study. *Eur Respir J* 4: 332-339.
- [Saragapani, R; Gentry, PR; Covington, TR; Teeguarden, JG; Clewell, HJ, III.](#) (2003). Evaluation of the potential impact of age- and gender-specific lung morphology and ventilation rate on the dosimetry of vapors. *Inhal Toxicol* 15: 987-1016. <http://dx.doi.org/10.1080/08958370390226350>
- [Sarnat, JA; Brown, KW; Schwartz, J; Coull, BA; Koutrakis, P.](#) (2005). Ambient gas concentrations and personal particulate matter exposures: Implications for studying the health effects of particles. *Epidemiology* 16: 385-395. <http://dx.doi.org/10.1097/01.ede.0000155505.04775.33>
- [Sarnat, JA; Koutrakis, P; Suh, HH.](#) (2000). Assessing the relationship between personal particulate and gaseous exposures of senior citizens living in Baltimore, MD. *J Air Waste Manag Assoc* 50: 1184-1198. <http://dx.doi.org/10.1080/10473289.2000.10464165>
- [Sarnat, JA; Sarnat, SE; Flanders, WD; Chang, HH; Mulholland, J; Baxter, L; Isakov, V; Ozkaynak, H.](#) (2013a). Spatiotemporally resolved air exchange rate as a modifier of acute air pollution-related morbidity in Atlanta. *J Expo Sci Environ Epidemiol* 23: 606-615. <http://dx.doi.org/10.1038/jes.2013.32>
- [Sarnat, JA; Schwartz, J; Catalano, PJ; Suh, HH.](#) (2001). Gaseous pollutants in particulate matter epidemiology: Confounders or surrogates? *Environ Health Perspect* 109: 1053-1061.
- [Sarnat, SE; Coull, BA; Ruiz, PA; Koutrakis, P; Suh, HH.](#) (2006). The influences of ambient particle composition and size on particle infiltration in Los Angeles, CA, residences. *J Air Waste Manag Assoc* 56: 186-196. <http://dx.doi.org/10.1080/10473289.2006.10464449>
- [Sarnat, SE; Klein, M; Sarnat, JA; Flanders, WD; Waller, LA; Mulholland, JA; Russell, AG; Tolbert, PE.](#) (2010). An examination of exposure measurement error from air pollutant spatial variability in time-series studies. *J Expo Sci Environ Epidemiol* 20: 135-146. <http://dx.doi.org/10.1038/jes.2009.10>
- [Sarnat, SE; Raysoni, AU; Li, WW; Holguin, F; Johnson, BA; Flores Luevano, S; Garcia, JH; Sarnat, JA.](#) (2012). Air pollution and acute respiratory response in a panel of asthmatic children along the U.S.-Mexico border. *Environ Health Perspect* 120: 437444. <http://dx.doi.org/10.1289/ehp.1003169>
- [Sarnat, SE; Sarnat, JA; Mulholland, J; Isakov, V; Özkaynak, H; Chang, HH; Klein, M; Tolbert, PE.](#) (2013b). Application of alternative spatiotemporal metrics of ambient air pollution exposure in a time-series epidemiological study in Atlanta. *J Expo Sci Environ Epidemiol* 23: 593-605. <http://dx.doi.org/10.1038/jes.2013.41>
- [Sarwar, G; Corsi, R; Kumura, Y; Allen, D; Weschler, CJ.](#) (2002). Hydroxyl radicals in indoor environments. *Atmos Environ* 36: 3973-3988. [http://dx.doi.org/10.1016/S1352-2310\(02\)00278-9](http://dx.doi.org/10.1016/S1352-2310(02)00278-9)
- [Sather, ME; Slonecker, ET; Mathew, J; Daughtrey, H; Williams, DD.](#) (2007). Evaluation of ogawa passive sampling devices as an alternative measurement method for the nitrogen dioxide annual standard in El Paso, Texas. *Environ Monit Assess* 124: 211-221. <http://dx.doi.org/10.1007/s10661-006-9219-4>
- [Sathyanarayana, S; Zhou, C; Rudra, CB; Gould, T; Larson, T; Koenig, J; Karr, CJ.](#) (2013). Prenatal ambient air pollution exposure and small for gestational age birth in the Puget Sound Air Basin. *Air Qual Atmos Health* 6: 455-463. <http://dx.doi.org/10.1007/s11869-012-0182-7>
- [Savitz, DA; Bobb, JF; Carr, JL; Clougherty, JE; Dominici, F; Elston, B; Ito, K; Ross, Z; Yee, M; Matte, TD.](#) (2014). Ambient fine particulate matter, nitrogen dioxide, and term birth weight in New York, New York. *Am J Epidemiol* 179: 457-466. <http://dx.doi.org/10.1093/aje/kwt268>
- [Scaife, A; Barclay, J; Hillis, GS; Srinivasan, J; MacDonald, DW; Ross, JA; Ayres, JG.](#) (2012). Lack of effect of nitrogen dioxide exposure on heart rate variability in patients with stable coronary heart disease and impaired left ventricular systolic function. *Occup Environ Med* 69: 587-591. <http://dx.doi.org/10.1136/oemed-2011-100126>
- [Scarlett, JF; Abbott, KJ; Peacock, JL; Strachan, DP; Anderson, HR.](#) (1996). Acute effects of summer air pollution on respiratory function in primary school children in southern England. *Thorax* 51: 1109-1114. <http://dx.doi.org/10.1136/thx.51.11.1109>

- [Schembari, A; Nieuwenhuijsen, MJ; Salvador, J; de Nazelle, A; Cirach, M; Dadvand, P; Beelen, R; Hoek, G; Basagaña, X; Vrijheid, M.](#) (2014). Traffic-related air pollution and congenital anomalies in Barcelona. *Environ Health Perspect* 122: 317-323. <http://dx.doi.org/10.1289/ehp.1306802>
- [Schembari, A; Triguero-Mas, M; De Nazelle, A; Dadvand, P; Vrijheid, M; Cirach, M; Martinez, D; Figueras, F; Querol, X; Basagaña, X; Eeftens, M; Meliefste, K; Nieuwenhuijsen, MJ.](#) (2013). Personal, indoor and outdoor air pollution levels among pregnant women. *Atmos Environ* 64: 287-295. <http://dx.doi.org/10.1016/j.atmosenv.2012.09.053>
- [Schikowski, T; Sugiri, D; Ranft, U; Gehring, U; Heinrich, J; Wichmann, HE; Kramer, U.](#) (2007). Does respiratory health contribute to the effects of long-term air pollution exposure on cardiovascular mortality? *Respir Res* 8: 20. <http://dx.doi.org/10.1186/1465-9921-8-20>
- [Schikowski, T; Sugiri, D; Ranft, U; Gehring, U; Heinrich, J; Wichmann, HE; Krämer, U.](#) (2005). Long-term air pollution exposure and living close to busy roads are associated with COPD in women. *Respir Res* 22: 152-161. <http://dx.doi.org/10.1186/1465-9921-6-152>
- [Schildcrout, JS; Sheppard, L; Lumley, T; Slaughter, JC; Koenig, JO; Shapiro, GG.](#) (2006). Ambient air pollution and asthma exacerbations in children: An eight-city analysis. *Am J Epidemiol* 164: 505-517. <http://dx.doi.org/10.1093/aje/kwj225>
- [Schindler, C; Künzli, N; Bongard, JP; Leuenberger, P; Karrer, W; Rapp, R; Monn, C; Ackermann-Liebrich, U.](#) (2001). Short-term variation in air pollution and in average lung function among never-smokers. The Swiss Study on Air Pollution and Lung Diseases in Adults (SAPALDIA). *Am J Respir Crit Care Med* 163: 356-361. <http://dx.doi.org/10.1164/ajrccm.163.2.9911116>
- [Schlesinger, RB.](#) (1987a). Effects of intermittent inhalation exposures to mixed atmospheres of NO<sub>2</sub> and H<sub>2</sub>SO<sub>4</sub> on rabbit alveolar macrophages. *J Toxicol Environ Health* 22: 301-312. <http://dx.doi.org/10.1080/15287398709531073>
- [Schlesinger, RB.](#) (1987b). Intermittent inhalation of nitrogen dioxide: Effects on rabbit alveolar macrophages. *J Toxicol Environ Health* 21: 127-139. <http://dx.doi.org/10.1080/15287398709531007>
- [Schlesinger, RB; Driscoll, KE; Gunnison, AF; Zelikoff, JT.](#) (1990). Pulmonary arachidonic acid metabolism following acute exposures to ozone and nitrogen dioxide. *J Toxicol Environ Health* 31: 275-290. <http://dx.doi.org/10.1080/15287399009531456>
- [Schlesinger, RB; Driscoll, KE; Vollmuth, TA.](#) (1987). Effect of repeated exposures to nitrogen dioxide and sulfuric acid mist alone or in combination on mucociliary clearance from the lungs of rabbits. *Environ Res* 44: 294-301. [http://dx.doi.org/10.1016/S0013-9351\(87\)80238-4](http://dx.doi.org/10.1016/S0013-9351(87)80238-4)
- [Schlesinger, RB; Gearhart, JM.](#) (1987). Intermittent exposures to mixed atmospheres of nitrogen dioxide and sulfuric acid: effect on particle clearance from the respiratory region of rabbit lungs. *Toxicology* 44: 309-319. [http://dx.doi.org/10.1016/0300-483X\(87\)90032-1](http://dx.doi.org/10.1016/0300-483X(87)90032-1)
- [Schultz, ES; Gruzieva, O; Bellander, T; Bottai, M; Hallberg, J; Kull, I; Svartengren, M; Melén, E; Pershagen, G.](#) (2012). Traffic-related air pollution and lung function in children at 8 years of age: A birth cohort study. *Am J Respir Crit Care Med* 186: 1286-1291. <http://dx.doi.org/10.1164/rccm.201206-1045OC>
- [Schwartz, J; Coull, BA.](#) (2003). Control for confounding in the presence of measurement error in hierarchical models. *Biostatistics* 4: 539-553. <http://dx.doi.org/10.1093/biostatistics/4.4.539>
- [Schwartz, J; Dockery, DW; Neas, LM; Wypij, D; Ware, JH; Spengler, JD; Koutrakis, P; Speizer, FE; Ferris, BG, Jr.](#) (1994). Acute effects of summer air pollution on respiratory symptom reporting in children. *Am J Respir Crit Care Med* 150: 1234-1242. <http://dx.doi.org/10.1164/ajrccm.150.5.7952546>
- [Schwartz, SE; White, WH.](#) (1983). Kinetics of reactive dissolution of nitrogen oxides into aqueous solution. In SE Schwartz (Ed.), *Trace atmospheric constituents: Properties, transformations, and fates* (pp. 1-116). New York, NY: Wiley.
- [Sedefian, L; Rao, ST; Czapski, U.](#) (1981). Effects of traffic-generated turbulence on near-field dispersion. *Atmos Environ* (1967) 15: 527-536. [http://dx.doi.org/10.1016/0004-6981\(81\)90182-7](http://dx.doi.org/10.1016/0004-6981(81)90182-7)

- See, KC; Christiani, DC. (2013). Normal values and thresholds for the clinical interpretation of exhaled nitric oxide levels in the US general population: Results from the National Health and Nutrition Examination Survey 2007-2010. *Chest* 143: 107-116. <http://dx.doi.org/10.1378/chest.12-0416>
- Segala, C; Fauroux, B; Just, J; Pascual, L; Grimfeld, A; Neukirch, F. (1998). Short-term effect of winter air pollution on respiratory health of asthmatic children in Paris. *Eur Respir J* 11: 677-685.
- Ségala, C; Poizeau, D; Mesbah, M; Willems, S; Maidenberg, M. (2008). Winter air pollution and infant bronchiolitis in Paris. *Environ Res* 106: 96-100. <http://dx.doi.org/10.1016/j.envres.2007.05.003>
- Seilkop, SK; Campen, MJ; Lund, AK; McDonald, JD; Mauderly, JL. (2012). Identification of chemical components of combustion emissions that affect pro-atherosclerotic vascular responses in mice. *Inhal Toxicol* 24: 270-287. <http://dx.doi.org/10.3109/08958378.2012.667455>
- Seinfeld, JH; Pandis, SN. (1998). Atmospheric chemistry and physics: From air pollution to climate change. New York: John Wiley & Sons. <http://dx.doi.org/10.1063/1.882420>
- Sekine, K; Shima, M; Nitta, Y; Adachi, M. (2004). Long term effects of exposure to automobile exhaust on the pulmonary function of female adults in Tokyo, Japan. *Occup Environ Med* 61: 350-357. <http://dx.doi.org/10.1136/oem.2002.005934>
- Sekine, Y; Watts, SF; Rendell, A; Butsugan, M. (2008). Development of highly sensitive passive sampler for nitrogen dioxide using porous polyethylene membrane filter as turbulence limiting diffuser. *Atmos Environ* 42: 4079-4088. <http://dx.doi.org/10.1016/j.atmosenv.2008.01.029>
- Selgrade, MK; Mole, ML; Miller, FJ; Hatch, GE; Gardner, DE; Hu, PC. (1981). Effect of NO<sub>2</sub> inhalation and vitamin C deficiency on protein and lipid accumulation in the lung. *Environ Res* 26: 422-437.
- Sellier, Y; Galineau, J; Hulin, A; Caini, F; Marquis, N; Navel, V; Bottagisi, S; Giorgis-Allemand, L; Jacquier, C; Slama, R; Lepeule, J. (2014). Health effects of ambient air pollution: Do different methods for estimating exposure lead to different results? *Environ Int* 66: 165-173. <http://dx.doi.org/10.1016/j.envint.2014.02.001>
- Štrevičienė, V; Paliulis, D. (2012). Influence of temperature and relative humidity on the performance of nitrogen dioxide diffusive sampler. *Res J of Chem Sci* 2: 89-92.
- Servais, S; Boussouar, A; Molnar, A; Douki, T; Pequignot, JM; Favier, R. (2005). Age-related sensitivity to lung oxidative stress during ozone exposure. *Free Radic Res* 39: 305-316. <http://dx.doi.org/10.1080/10715760400011098>
- Setton, E; Marshall, JD; Brauer, M; Lundquist, KR; Hystad, P; Keller, P; Cloutier-Fisher, D. (2011). The impact of daily mobility on exposure to traffic-related air pollution and health effect estimates. *J Expo Sci Environ Epidemiol* 21: 42-48. <http://dx.doi.org/10.1038/jes.2010.14>
- Sevanian, A; Elsayed, N; Hacker, AD. (1982a). Effects of vitamin E deficiency and nitrogen dioxide exposure on lung lipid peroxidation: Use of lipid epoxides and malonaldehyde as measures of peroxidation. *J Toxicol Environ Health* 10: 743-756. <http://dx.doi.org/10.1080/15287398209530292>
- Sevanian, A; Hacker, AD; Elsayed, N. (1982b). Influence of vitamin E and nitrogen dioxide on lipid peroxidation in rat lung and liver microsomes. *Lipids* 17: 269-277.
- Shalamberidze, OP; Tsereteli, NT. (1971a). Effect of low concentrations of sulfur and nitrogen dioxides on the estrual cycle and reproductive functions of experimental animals. *Gig Sanit* 36: 178-182.
- Shalamberidze, OP; Tsereteli, NT. (1971b). [Effect of small concentrations of sulfur dioxide and nitrogen peroxide on the estrus cycle and reproductive function in experiments on animals]. *Gig Sanit* 36: 13-17.
- Shankardass, K; McConnell, R; Jerrett, M; Milam, J; Richardson, J; Berhane, K. (2009). Parental stress increases the effect of traffic-related air pollution on childhood asthma incidence. *PNAS* 106: 12406-12411. <http://dx.doi.org/10.1073/pnas.0812910106>
- Shao, X; Stein, M; Ching, J. (2007). Statistical comparisons of methods for interpolating the output of a numerical air quality model. *J Stat Plan Inference* 137: 2277-2293. <http://dx.doi.org/10.1016/j.jspi.2006.07.014>

- Sheppard, L. (2005). Acute air pollution effects: Consequences of exposure distribution and measurements. *J Toxicol Environ Health A* 68: 1127-1135. <http://dx.doi.org/10.1080/15287390590935987>
- Sheppard, L; Slaughter, JC; Schildcrout, J; Liu, J, -S; Lumley, T. (2005). Exposure and measurement contributions to estimates of acute air pollution effects. *J Expo Anal Environ Epidemiol* 15: 366-376. <http://dx.doi.org/10.1038/sj.jea.7500413>
- Sherwin, RP; Carlson, DA. (1973). Protein content of lung lavage fluid of guinea pigs exposed to 0.4 ppm nitrogen dioxide. *Arch Environ Health* 27: 90-93.
- Sherwin, RP; Dibble, J; Weiner, J. (1972). Alveolar wall cells of the guinea pig: Increase in response to 2 ppm nitrogen dioxide. *Arch Environ Health* 24: 43-47.
- Sherwin, RP; Richters, V. (1982). Hyperplasia of type 2 pneumocytes following 0.34 ppm nitrogen dioxide exposure: Quantitation by image analysis. *Arch Environ Health* 37: 306-315. <http://dx.doi.org/10.1080/00039896.1982.10667584>
- Sherwood, RL; Lippert, WE; Goldstein, E; Tarkington, B. (1981). Effect of ferrous sulfate aerosols and nitrogen dioxide on murine pulmonary defense. *Arch Environ Occup Health* 36: 130-135.
- Shi, C; Zhang, B. (2008). Tropospheric NO<sub>2</sub> columns over Northeastern North America: Comparison of CMAQ model simulations with GOME satellite measurements. *Adv Atmos Sci* 25: 59-71. <http://dx.doi.org/10.1007/s00376-008-0059-8>
- Shields, KN; Cavallari, JM; Hunt, MJ; Lazo, M; Molina, M; Molina, L; Holguin, F. (2013). Traffic-related air pollution exposures and changes in heart rate variability in Mexico City: A panel study. *Environ Health* 12: 7. <http://dx.doi.org/10.1186/1476-069X-12-7>
- Shima, M; Nitta, Y; Ando, M; Adachi, M. (2002). Effects of air pollution on the prevalence and incidence of asthma in children. *Arch Environ Health* 57: 529-535. <http://dx.doi.org/10.1080/00039890209602084>
- Shin, HH; Stieb, D; Burnett, R; Takahara, G; Jessiman, B. (2012). Tracking national and regional spatial-temporal mortality risk associated with NO<sub>2</sub> concentrations in Canada: A Bayesian hierarchical two-level model. *Risk Anal* 32: 513-530. <http://dx.doi.org/10.1111/j.1539-6924.2011.01684.x>
- Shmool, JLC; Michanowicz, DR; Cambal, L; Tunno, B; Howell, J; Gillooly, S; Roper, C; Tripathy, S; Chubb, LG; Eisl, HM; Gorczynski, JE; Holguin, FE; Shields, KN; Clougherty, JE. (2014). Saturation sampling for spatial variation in multiple air pollutants across an inversion-prone metropolitan area of complex terrain. *Environ Health* 13: 28. <http://dx.doi.org/10.1186/1476-069X-13-28>
- Sies, H. (2004). Ozone in arteriosclerotic plaques: Searching for the "smoking gun". *Angew Chem Int Ed Engl* 43: 3514-3515. <http://dx.doi.org/10.1002/anie.200460118>
- Silbaugh, SA; Mauderly, JL; Macken, CA. (1981). Effects of sulfuric acid and nitrogen dioxide on airway responsiveness of the guinea pig. *J Toxicol Environ Health* 8: 31-45. <http://dx.doi.org/10.1080/15287398109530048>
- Silkoff, PE; Zhang, L; Dutton, S; Langmack, EL; Vedal, S; Murphy, J; Make, B. (2005). Winter air pollution and disease parameters in advanced chronic obstructive pulmonary disease panels residing in Denver, Colorado. *J Allergy Clin Immunol* 115: 337-344. <http://dx.doi.org/10.1016/j.jaci.2004.11.035>
- Silverman, RA; Ito, K; Freese, J; Kaufman, BJ; De Claro, D; Braun, J; Prezant, DJ. (2010). Association of ambient fine particles with out-of-hospital cardiac arrests in New York City. *Am J Epidemiol* 172: 917-923. <http://dx.doi.org/10.1093/aje/kwq217>
- Simoëns, S; Ayrault, M; Wallace, JM. (2007). The flow across a street canyon of variable width- Part 1: Kinematic description. *Atmos Environ* 41: 9002-9017. <http://dx.doi.org/10.1016/j.atmosenv.2007.08.013>
- Simoëns, S; Wallace, JM. (2008). The flow across a street canyon of variable width Part 2: Scalar dispersion from a street level line source. *Atmos Environ* 42: 2489-2503. <http://dx.doi.org/10.1016/j.atmosenv.2007.12.013>

- [Simon, H; Kimura, Y; McGaughey, G; Allen, DT; Brown, SS; Osthoff, HD; Roberts, JM; Byun, D; Lee, D.](#) (2009). Modeling the impact of CINO<sub>2</sub> on ozone formation in the Houston area. *J Geophys Res Atmos* 114: D00F03. <http://dx.doi.org/10.1029/2008jd010732>
- [Simon, PK; Dasgupta, PK.](#) (1995). Continuous automated measurement of the soluble fraction of atmospheric particulate matter. *Anal Chem* 67: 71-78. <http://dx.doi.org/10.1021/ac00097a012>
- [Simpson, R; Williams, G; Petroeschovsky, A; Best, T; Morgan, G; Denison, L; Hinwood, A; Neville, G.](#) (2005a). The short-term effects of air pollution on hospital admissions in four Australian cities. *Aust N Z J Public Health* 29: 213-221.
- [Simpson, R; Williams, G; Petroeschovsky, A; Best, T; Morgan, G; Denison, L; Hinwood, A; Neville, G; Neller, A.](#) (2005b). The short-term effects of air pollution on daily mortality in four Australian cities. *Aust N Z J Public Health* 29: 205-212. <http://dx.doi.org/10.1111/j.1467-842X.2005.tb00758.x>
- [Sinclair, AH; Edgerton, ES; Wyzga, R; Tolsma, D.](#) (2010). A two-time-period comparison of the effects of ambient air pollution on outpatient visits for acute respiratory illnesses. *J Air Waste Manag Assoc* 60: 163-175. <http://dx.doi.org/10.3155/1047-3289.60.2.163>
- [Sinclair, AH; Tolsma, D.](#) (2004). Associations and lags between air pollution and acute respiratory visits in an ambulatory care setting: 25-month results from the Aerosol Research and Inhalation Epidemiological Study. *J Air Waste Manag Assoc* 54: 1212-1218. <http://dx.doi.org/10.1080/10473289.2004.10470979>
- [Singer, BC; Hodgson, AT; Hotchi, T; Kim, JJ.](#) (2004). Passive measurement of nitrogen oxides to assess traffic-related pollutant exposure for the East Bay Children's Respiratory Health Study. *Atmos Environ* 38: 393-403. <http://dx.doi.org/10.1016/j.atmosenv.2003.10.005>
- [Singh, HB; Salas, L; Herlth, D; Kolyer, R; Czech, E; Avery, M; Crawford, JH; Pierce, RB; Sachse, GW; Blake, DR; Cohen, RC; Bertram, TH; Perring, A; Wooldridge, PJ; Dibb, J; Huey, G; Hudman, RC; Turquety, S; Emmons, LK; Flocke, F; Tang, Y; Carmichael, GR; Horowitz, LW.](#) (2007). Reactive nitrogen distribution and partitioning in the North American troposphere and lowermost stratosphere. *J Geophys Res* 112: D12S04. <http://dx.doi.org/10.1029/2006JD007664>
- [Skouloudis, AN; Kassomenos, P.](#) (2014). Combining environment and health information systems for the assessment of atmospheric pollution on human health. *Sci Total Environ* 488: 364-370. <http://dx.doi.org/10.1016/j.scitotenv.2014.02.116>
- [Slade, R; Crissman, K; Norwood, J; Hatch, G.](#) (1993). Comparison of antioxidant substances in bronchoalveolar lavage cells and fluid from humans, guinea pigs, and rats. *Exp Lung Res* 19: 469-484. <http://dx.doi.org/10.3109/01902149309064358>
- [Slama, R; Bottagisi, S; Solansky, I; Lepeule, J; Giorgis-Allemand, L; Sram, R.](#) (2013). Short-term impact of atmospheric pollution on fecundability. *Epidemiology* 24: 871-879. <http://dx.doi.org/10.1097/EDE.0b013e3182a702c5>
- [Slama, R; Darrow, L; Parker, J; Woodruff, TJ; Strickland, M; Nieuwenhuijsen, M; Glinianaia, S; Hoggatt, KJ; Kannan, S; Hurley, F; Kalinka, J; Sram, R; Brauer, M; Wilhelm, M; Heinrich, J; Ritz, B.](#) (2008). Meeting report: Atmospheric pollution and human reproduction. *Environ Health Perspect* 116: 791-798. <http://dx.doi.org/10.1289/ehp.11074>
- [Slama, R; Morgenstern, V; Cyrus, J; Zutavern, A; Herbarth, O; Wichmann, HE; Heinrich, J; Group, LS.](#) (2007). Traffic-related atmospheric pollutants levels during pregnancy and offspring's term birth weight: A study relying on a land-use regression exposure model. *Environ Health Perspect* 115: 1283-1292. <http://dx.doi.org/10.1289/ehp.10047>
- [Slørdal, LH; Walker, SE; Solberg, S.](#) (2003). The urban air dispersion model EPISODE applied in AirQUIS2003: Technical description. (TR 12/2003). Kjeller, Norway: Norwegian Institute for Air Research.
- [Smargiassi, A; Baldwin, M; Pilger, C; Dugandzic, R; Brauer, M.](#) (2005). Small-scale spatial variability of particle concentrations and traffic levels in Montreal: A pilot study. *Sci Total Environ* 338: 243-251. <http://dx.doi.org/10.1016/j.scitotenv.2004.07.013>

- [Smargiassi, A; Goldberg, MS; Wheeler, AJ; Plante, C; Valois, MF; Mallach, G; Kauri, LM; Shutt, R; Bartlett, S; Raphoz, M; Liu, L.](#) (2014). Associations between personal exposure to air pollutants and lung function tests and cardiovascular indices among children with asthma living near an industrial complex and petroleum refineries. *Environ Res* 132: 38-45. <http://dx.doi.org/10.1016/j.envres.2014.03.030>
- [Smith, LA; Mukerjee, S; Chung, KC; Afghani, J.](#) (2011). Spatial analysis and land use regression of VOCs and NO<sub>2</sub> in Dallas, Texas during two seasons. *J Environ Monit* 13: 999-1007. <http://dx.doi.org/10.1039/c0em00724b>
- [Smith, LL.](#) (2004). Oxygen, oxysterols, ouabain, and ozone: A cautionary tale [Review]. *Free Radic Biol Med* 37: 318-324. <http://dx.doi.org/10.1016/j.freeradbiomed.2004.04.024>
- [Snyder, MG; Venkatram, A; Heist, DK; Perry, SG; Petersen, WB; Isakov, V.](#) (2013). RLINE: A line source dispersion model for near-surface releases. *Atmos Environ* 77: 748-756. <http://dx.doi.org/10.1016/j.atmosenv.2013.05.074>
- [Sokol, RZ; Kraft, P; Fowler, IM; Mamet, R; Kim, E; Berhane, KT.](#) (2006). Exposure to environmental ozone alters semen quality. *Environ Health Perspect* 114: 360-365. <http://dx.doi.org/10.1289/ehp.8232>
- [Solomon, C; Christian, DL; Chen, LL; Welch, BS; Kleinman, MT; Dunham, E; Erle, DJ; Balmes, JR.](#) (2000). Effect of serial-day exposure to nitrogen dioxide on airway and blood leukocytes and lymphocyte subsets. *Eur Respir J* 15: 922-928.
- [Son, B; Yang, W; Breysse, P; Chung, T; Lee, Y.](#) (2004). Estimation of occupational and nonoccupational nitrogen dioxide exposure for Korean taxi drivers using a microenvironmental model. *Environ Res* 94: 291-296. <http://dx.doi.org/10.1016/j.envres.2003.08.004>
- [Son, JY; Bell, ML; Lee, JT.](#) (2010). Individual exposure to air pollution and lung function in Korea: Spatial analysis using multiple exposure approaches. *Environ Res* 110: 739-749. <http://dx.doi.org/10.1016/j.envres.2010.08.003>
- [Son, JY; Cho, YS; Lee, JT.](#) (2008). Effects of air pollution on postneonatal infant mortality among firstborn infants in Seoul, Korea: Case-crossover and time-series analyses. *Arch Environ Occup Health* 63: 108-113. <http://dx.doi.org/10.3200/AEOH.63.3.108-113>
- [Son, JY; Lee, JT; Park, YH; Bell, ML.](#) (2013). Short-term effects of air pollution on hospital admissions in Korea. *Epidemiology* 24: 545-554. <http://dx.doi.org/10.1097/EDE.0b013e3182953244>
- [Song, Y; Namkung, W; Nielson, DW; Lee, JW; Finkbeiner, WE; Verkman, AS.](#) (2009). Airway surface liquid depth measured in ex vivo fragments of pig and human trachea: Dependence on Na<sup>+</sup> and Cl<sup>-</sup> channel function. *Am J Physiol Lung Cell Mol Physiol* 297: L1131-L1140. <http://dx.doi.org/10.1152/ajplung.00085.2009>
- [Sonnenschein-Van der Voort, AM; de Kluizenaar, Y; Jaddoe, VW; Gabriele, C; Raat, H; Moll, HA; Hofman, A; Pierik, FH; Miedema, HM; de Jongste, JC; Duijts, L.](#) (2012). Air pollution, fetal and infant tobacco smoke exposure, and wheezing in preschool children: A population-based prospective birth cohort. *Environ Health* 11: 91. <http://dx.doi.org/10.1186/1476-069X-11-91>
- [Sørensen, M; Andersen, ZJ; Nordborg, RB; Becker, T; Tjønneland, A; Overvad, K; Raaschou-Nielsen, O.](#) (2013). Long-term exposure to road traffic noise and incident diabetes: A cohort study. *Environ Health Perspect* 121: 217-222. <http://dx.doi.org/10.1289/ehp.1205503>
- [Sørensen, M; Hoffmann, B; Hvidberg, M; Ketzel, M; Jensen, SS; Andersen, ZJ; Tjønneland, A; Overvad, K; Raaschou-Nielsen, O.](#) (2012). Long-term exposure to traffic-related air pollution associated with blood pressure and self-reported hypertension in a Danish cohort. *Environ Health Perspect* 120: 418-424. <http://dx.doi.org/10.1289/ehp.1103631>
- [Sørensen, M; Lühdorf, P; Ketzel, M; Andersen, ZJ; Tjønneland, A; Overvad, K; Raaschou-Nielsen, O.](#) (2014). Combined effects of road traffic noise and ambient air pollution in relation to risk for stroke? *Environ Res* 133: 49-55. <http://dx.doi.org/10.1016/j.envres.2014.05.011>

- [Soto-Ramos, M; Castro-Rodríguez, JA; Hinojos-Gallardo, LC; Hernández-Saldaña, R; Cisneros-Castolo, M; Carrillo-Rodríguez, V.](#) (2013). Fractional exhaled nitric oxide has a good correlation with asthma control and lung function in Latino children with asthma. *J Asthma* 50: 590-594. <http://dx.doi.org/10.3109/02770903.2013.792349>
- [Sousa, R; Duque, L; Duarte, AJ; Gomes, CR; Ribeiro, H; Cruz, A; Esteves da Silva, JC; Abreu, I.](#) (2012). In vitro exposure of *Acer negundo* pollen to atmospheric levels of SO and NO: Effects on allergenicity and germination. *Environ Sci Technol* 46: 2406-2412. <http://dx.doi.org/10.1021/es2034685>
- [Southwest Research Institute.](#) (2013). Phase 2 of the advanced collaborative emissions study. (SwRI Final Report 03.17124). Alpharetta, GA: Coordinating Research Council, Inc. [http://crcao.org/reports/recentstudies2013/ACES%20Ph2/03-17124\\_CRC%20ACES%20Phase2-%20FINAL%20Report\\_Khalek-R6-SwRI.pdf](http://crcao.org/reports/recentstudies2013/ACES%20Ph2/03-17124_CRC%20ACES%20Phase2-%20FINAL%20Report_Khalek-R6-SwRI.pdf)
- [Spengler, JD; Brauer, M; Samet, JM; Lambert, WE.](#) (1993). Nitrous acid in Albuquerque, New Mexico, homes. *Environ Sci Technol* 27: 841-845. <http://dx.doi.org/10.1021/es00042a005>
- [Spicer, CW; Coutant, RW; Ward, GF; Joseph, DW; Gaynor, AJ; Billick, IH.](#) (1989). Rates and mechanisms of NO<sub>2</sub> removal from indoor air by residential materials. *Environ Int* 15: 643-654. [http://dx.doi.org/10.1016/0160-4120\(89\)90087-1](http://dx.doi.org/10.1016/0160-4120(89)90087-1)
- [Spiegelman, D.](#) (2013). Regression calibration in air pollution epidemiology with exposure estimated by spatio-temporal modeling. *Environmetrics* 24: 521-524. <http://dx.doi.org/10.1002/env.2249>
- [Spiezia, L; Campello, E; Bon, M; Maggiolo, S; Pelizzaro, E; Simioni, P.](#) (2014). Short-term exposure to high levels of air pollution as a risk factor for acute isolated pulmonary embolism. *Thromb Res Suppl* 134: 259-263. <http://dx.doi.org/10.1016/j.thromres.2014.05.011>
- [Spira-Cohen, A.](#) (2013). Email from Dr. Spira-Cohen to Dr. Patel; Response to data request. Available online
- [Spira-Cohen, A; Chen, LC; Kendall, M; Lall, R; Thurston, GD.](#) (2011). Personal exposures to traffic-related air pollution and acute respiratory health among Bronx schoolchildren with asthma. *Environ Health Perspect* 119: 559-565. <http://dx.doi.org/10.1289/ehp.1002653>
- [Squadrito, GL; Postlethwait, EM.](#) (2009). On the hydrophobicity of nitrogen dioxide: Could there be a "lens" effect for NO<sub>2</sub> reaction kinetics. *Nitric Oxide* 21: 104-109. <http://dx.doi.org/10.1016/j.niox.2009.05.008>
- [Squadrito, GL; Postlethwait, EM; Matalon, S.](#) (2010). Elucidating mechanisms of chlorine toxicity: Reaction kinetics, thermodynamics, and physiological implications [Review]. *Am J Physiol Lung Cell Mol Physiol* 299: L289-L300. <http://dx.doi.org/10.1152/ajplung.00077.2010>
- [Staimer, N; Delfino, RJ; Bufalino, C; Fine, PM; Sioutas, C; Kleinman, MT.](#) (2005). A miniaturized active sampler for the assessment of personal exposure to nitrogen dioxide. *Anal Bioanal Chem* 383: 955-962. <http://dx.doi.org/10.1007/s00216-005-0086-6>
- [Stanojevic, S; Wade, A; Stocks, J; Hankinson, J; Coates, AL; Pan, H; Rosenthal, M; Corey, M; Lebecque, P; Cole, TJ.](#) (2008). Reference ranges for spirometry across all ages: A new approach. *Am J Respir Crit Care Med* 177: 253-260. <http://dx.doi.org/10.1164/rccm.200708-1248OC>
- [Stavrakou, T; Müller, JF; Boersma, KF; De Smedt, I; Van Der A, RJ.](#) (2008). Assessing the distribution and growth rates of NO<sub>x</sub> emission sources by inverting a 10-year record of NO<sub>2</sub> satellite columns. *Geophys Res Lett* 35: L10801. <http://dx.doi.org/10.1029/2008GL033521>
- [Steenhof, M; Janssen, NA; Strak, M; Hoek, G; Gosens, I; Mudway, IS; Kelly, FJ; Harrison, RM; Pieters, RH; Cassee, FR; Brunekreef, B.](#) (2014). Air pollution exposure affects circulating white blood cell counts in healthy subjects: The role of particle composition, oxidative potential and gaseous pollutants - the RAPTES project. *Inhal Toxicol* 26: 141-165. <http://dx.doi.org/10.3109/08958378.2013.861884>
- [Steenhof, M; Mudway, IS; Gosens, I; Hoek, G; Godri, KJ; Kelly, FJ; Harrison, RM; Pieters, RH; Cassee, FR; Lebret, E; Brunekreef, BA; Strak, M; Janssen, NA.](#) (2013). Acute nasal pro-inflammatory response to air pollution depends on characteristics other than particle mass concentration or oxidative potential: The RAPTES project. *Occup Environ Med* 70: 341-348. <http://dx.doi.org/10.1136/oemed-2012-100993>

- [Steenenbergh, PA; Bischoff, EWM, A; de Klerk, A; Verlaan, APJ; Jongbloets, LMN; Van Loveren, H; Opperhuizen, A; Zomer, G; Heisterkamp, SH; Hady, M; Spijksma, FTM; Fischer, PH; Dormans, JAM, A; van Amsterdam, JGC.](#) (2003). Acute effect of air pollution on respiratory complaints, exhaled NO and biomarkers in nasal lavages of allergic children during the pollen season. *Int Arch Allergy Immunol* 131: 127-137. <http://dx.doi.org/10.1159/000070928>
- [Steenenbergh, PA; Nierkens, S; Fischer, PH; Van Loveren, H; Opperhuizen, A; Vos, JG; van Amsterdam, JG.](#) (2001). Traffic-related air pollution affects peak expiratory flow, exhaled nitric oxide, and inflammatory nasal markers. *Arch Environ Health* 56: 167-174. <http://dx.doi.org/10.1080/00039890109604069>
- [Steinbacher, M; Zellweger, C; Schwarzenbach, B; Bugmann, S; Buchmann, B; Ordóñez, C; Prevot, ASH; Hueglin, C.](#) (2007). Nitrogen oxides measurements at rural sites in Switzerland: Bias of conventional measurement techniques. *J Geophys Res Atmos* 112: D11307. <http://dx.doi.org/10.1029/2006JD007971>
- [Steinvil, A; Fireman, E; Kordova-Biezuner, L; Cohen, M; Shapira, I; Berliner, S; Rogowski, O.](#) (2009). Environmental air pollution has decremental effects on pulmonary function test parameters up to one week after exposure. *Am J Med Sci* 338: 273-279. <http://dx.doi.org/10.1097/MAJ.0b013e3181adb3ed>
- [Steinvil, A; Kordova-Biezuner, L; Shapira, I; Berliner, S; Rogowski, O.](#) (2008). Short-term exposure to air pollution and inflammation-sensitive biomarkers. *Environ Res* 106: 51-61. <http://dx.doi.org/10.1016/j.envres.2007.08.006>
- [Stenger, MR; Rose, MJ; Joshi, MS; Rogers, LK; Chicoine, LG; Bauer, JA; Nelin, LD.](#) (2010). Inhaled nitric oxide prevents 3-nitrotyrosine formation in the lungs of neonatal mice exposed to >95% oxygen. *Lung* 188: 217-227. <http://dx.doi.org/10.1007/s00408-010-9235-6>
- [Stern, G; Latzin, P; Röösl, M; Fuchs, O; Proietti, E; Kuehni, C; Frey, U.](#) (2013). A prospective study of the impact of air pollution on respiratory symptoms and infections in infants. *Am J Respir Crit Care Med* 187: 1341-1348. <http://dx.doi.org/10.1164/rccm.201211-2008OC>
- [Stevens, MA; Menache, MG; Crapo, JD; Miller, FJ; Graham, JA.](#) (1988). Pulmonary function in juvenile and young adult rats exposed to low-level NO<sub>2</sub> with diurnal spikes. *J Toxicol Environ Health* 23: 229-240. <http://dx.doi.org/10.1080/15287398809531109>
- [Stieb, DM; Burnett, RT; Smith-Doiron, M; Brion, O; Shin, HH; Economou, V.](#) (2008). A new multipollutant, no-threshold air quality health index based on short-term associations observed in daily time-series analyses. *J Air Waste Manag Assoc* 58: 435-450. <http://dx.doi.org/10.3155/1047-3289.58.3.435>
- [Stieb, DM; Judek, S; Burnett, RT.](#) (2002). Meta-analysis of time-series studies of air pollution and mortality: Effects of gases and particles and the influence of cause of death, age, and season. *J Air Waste Manag Assoc* 52: 470-484. <http://dx.doi.org/10.1080/10473289.2002.10470794>
- [Stieb, DM; Judek, S; Burnett, RT.](#) (2003). Meta-analysis of time-series studies of air pollution and mortality: Update in relation to the use of generalized additive models. *J Air Waste Manag Assoc* 53: 258-261. <http://dx.doi.org/10.1080/10473289.2003.10466149>
- [Stieb, DM; Szyszkowicz, M; Rowe, BH; Leech, JA.](#) (2009). Air pollution and emergency department visits for cardiac and respiratory conditions: A multi-city time-series analysis. *Environ Health* 8. <http://dx.doi.org/10.1186/1476-069X-8-25>
- [Stingone, JA; Luben, TJ; Daniels, JL; Fuentes, M; Richardson, DB; Aylsworth, AS; Herring, AH; Anderka, M; Botto, L; Correa, A; Gilboa, SM; Langlois, PH; Mosley, B; Shaw, GM; Siffel, C; Olshan, AF.](#) (2014). Maternal exposure to criteria air pollutants and congenital heart defects in offspring: Results from the national birth defects prevention study. *Environ Health Perspect* 122: 863-872. <http://dx.doi.org/10.1289/ehp.1307289>
- [Strak, M.](#) (2013). [Email from Dr. Strak to Dr. Patel; Response to data request]. Available online
- [Strak, M; Hoek, G; Godri, KJ; Gosens, I; Mudway, IS; van Oerle, R; Spronk, HM; Cassee, FR; Lebrecht, E; Kelly, FJ; Harrison, RM; Brunekreef, B; Steenhof, M; Janssen, NA.](#) (2013a). Composition of PM affects acute vascular inflammatory and coagulative markers - The RAPTES project. *PLoS ONE* 8: e58944. <http://dx.doi.org/10.1371/journal.pone.0058944>

- [Strak, M; Hoek, G; Steenhof, M; Kilinc, E; Godri, KJ; Gosens, I; Mudway, IS; van Oerle, R; Spronk, HM; Cassee, FR; Kelly, FJ; Harrison, RM; Brunekreef, B; Lebret, E; Janssen, NA.](#) (2013b). Components of ambient air pollution affect thrombin generation in healthy humans: The RAPTES project. *Occup Environ Med* 70: 332-340. <http://dx.doi.org/10.1136/oemed-2012-100992>
- [Strak, M; Janssen, NA; Godri, KJ; Gosens, I; Mudway, IS; Cassee, FR; Lebret, E; Kelly, FJ; Harrison, RM; Brunekreef, B; Steenhof, M; Hoek, G.](#) (2012). Respiratory health effects of airborne particulate matter: The role of particle size, composition and oxidative potential - The RAPTES project. *Environ Health Perspect* 120: 1183-1189. <http://dx.doi.org/10.1289/ehp.1104389>
- [Strand, V; Rak, S; Svartengren, M; Bylin, G.](#) (1997). Nitrogen dioxide exposure enhances asthmatic reaction to inhaled allergen in subjects with asthma. *Am J Respir Crit Care Med* 155: 881-887. <http://dx.doi.org/10.1164/ajrccm.155.3.9117021>
- [Strand, V; Salomonsson, P; Lundahl, J; Bylin, G.](#) (1996). Immediate and delayed effects of nitrogen dioxide exposure at an ambient level on bronchial responsiveness to histamine in subjects with asthma. *Eur Respir J* 9: 733-740. <http://dx.doi.org/10.1183/09031936.96.09040733>
- [Strand, V; Svartengren, M; Rak, S; Barck, C; Bylin, G.](#) (1998). Repeated exposure to an ambient level of NO<sub>2</sub> enhances asthmatic response to a nonsymptomatic allergen dose. *Eur Respir J* 12: 6-12. <http://dx.doi.org/10.1183/09031936.98.12010006>
- [Straney, L; Finn, J; Dennekamp, M; Bremner, A; Tonkin, A; Jacobs, I.](#) (2014). Evaluating the impact of air pollution on the incidence of out-of-hospital cardiac arrest in the Perth Metropolitan Region: 2000-2010. *J Epidemiol Community Health* 68: 6-12. <http://dx.doi.org/10.1136/jech-2013-202955>
- [Strickland, MJ; Darrow, LA; Klein, M; Flanders, WD; Sarnat, JA; Waller, LA; Sarnat, SE; Mulholland, JA; Tolbert, PE.](#) (2010). Short-term associations between ambient air pollutants and pediatric asthma emergency department visits. *Am J Respir Crit Care Med* 182: 307-316. <http://dx.doi.org/10.1164/rccm.200908-1201OC>
- [Strickland, MJ; Darrow, LA; Mulholland, JA; Klein, M; Flanders, WD; Winqvist, A; Tolbert, PE.](#) (2011). Implications of different approaches for characterizing ambient air pollutant concentrations within the urban airshed for time-series studies and health benefits analyses. *Environ Health* 10: 36. <http://dx.doi.org/10.1186/1476-069X-10-36>
- [Stroh, E; Oudin, A; Gustafsson, S; Pilesjo, P; Harrie, L; Stromberg, U; Jakobsson, K.](#) (2005). Are associations between socio-economic characteristics and exposure to air pollution a question of study area size? An example from Scania, Sweden. *Int J Health Geogr* 4: 30-42. <http://dx.doi.org/10.1186/1476-072X-4-30>
- [Stull, R.](#) (2000). *Meteorology for scientists and engineers: A technical companion book with Ahrens' Meteorology Today* (2nd ed.). Pacific Grove, CA: Brooks/Cole.
- [Su, JG; Brauer, M; Ainslie, B; Steyn, D; Larson, T; Buzzelli, M.](#) (2008a). An innovative land use regression model incorporating meteorology for exposure analysis. *Sci Total Environ* 390: 520-529. <http://dx.doi.org/10.1016/j.scitotenv.2007.10.032>
- [Su, JG; Brauer, M; Buzzelli, M.](#) (2008b). Estimating urban morphometry at the neighborhood scale for improvement in modeling long-term average air pollution concentrations. *Atmos Environ* 42: 7884-7893. <http://dx.doi.org/10.1016/j.atmosenv.2008.07.023>
- [Su, JG; Jerrett, M; Beckerman, B.](#) (2009a). A distance-decay variable selection strategy for land use regression modeling of ambient air pollution exposures. *Sci Total Environ* 407: 3890-3898. <http://dx.doi.org/10.1016/j.scitotenv.2009.01.061>
- [Su, JG; Jerrett, M; Beckerman, B; Wilhelm, M; Ghosh, JK; Ritz, B.](#) (2009b). Predicting traffic-related air pollution in Los Angeles using a distance decay regression selection strategy. *Environ Res* 109: 657-670. <http://dx.doi.org/10.1016/j.envres.2009.06.001>
- [Su, JG; Jerrett, M; Morello-Frosch, R; Jesdale, BM; Kyle, AD.](#) (2012). Inequalities in cumulative environmental burdens among three urbanized counties in California. *Environ Int* 40: 79-87. <http://dx.doi.org/10.1016/j.envint.2011.11.003>

- Su, JG; Morello-Frosch, R; Jesdale, BM; Kyle, AD; Shamasunder, B; Jerrett, M. (2009c). An index for assessing demographic inequalities in cumulative environmental hazards with application to Los Angeles, California. *Environ Sci Technol* 43: 7626-7634. <http://dx.doi.org/10.1021/es901041p>
- Suh, HH; Zanobetti, A. (2010a). Erratum: Exposure error masks the relationship between traffic-related air pollution and heart rate variability [Erratum]. *J Occup Environ Med* 52: 1138. <http://dx.doi.org/10.1097/JOM.0b013e3181fd2632>
- Suh, HH; Zanobetti, A. (2010b). Exposure error masks the relationship between traffic-related air pollution and heart rate variability. *J Occup Environ Med* 52: 685-692. <http://dx.doi.org/10.1097/JOM.0b013e3181e8071f>
- Sunyer, J; Jarvis, D; Gotschi, T; Garcia-Esteban, R; Jacquemin, B; Aguilera, I; Ackerman, U; de Marco, R; Forsberg, B; Gislason, T; Heinrich, J; Norbäck, D; Villani, S; Künzli, N. (2006). Chronic bronchitis and urban air pollution in an international study. *Occup Environ Med* 63: 836-843. <http://dx.doi.org/10.1136/oem.2006.027995>
- Sunyer, J; Pekkanen, J; Garcia-Esteban, R; Svanes, C; Künzli, N; Janson, C; de Marco, R; Antó, JM; Burney, P. (2007). Asthma score: Predictive ability and risk factors. *Allergy* 62: 142-148. <http://dx.doi.org/10.1111/j.1398-9995.2006.01184.x>
- Sunyer, J; Puig, C; Torrent, M; Garcia-Algar, O; Calico, I; Munoz-Ortiz, L; Barnes, M; Cullinan, P. (2004). Nitrogen dioxide is not associated with respiratory infection during the first year of life. *Int J Epidemiol* 33: 116-120. <http://dx.doi.org/10.1093/ije/dyh037>
- Suzuki, AK; Tsubone, H; Ichinose, T; Oda, H; Kubota, K. (1981). [Effects of subchronic nitrogen dioxide exposure on arterial blood pH<sub>a</sub>, PaCO<sub>2</sub> and PaO<sub>2</sub> in rats]. *Nippon Eiseigaku Zasshi* 36: 816-823. <http://dx.doi.org/10.1265/jjh.36.816>
- Suzuki, T; Ikeda, S; Kanoh, T; Mizoguchi, I. (1986). Decreased phagocytosis and superoxide anion production in alveolar macrophages of rats exposed to nitrogen dioxide. *Arch Environ Contam Toxicol* 15: 733-739. <http://dx.doi.org/10.1007/BF01054920>
- Svensden, ER; Gonzales, M; Mukerjee, S; Smith, L; Ross, M; Walsh, D; Rhoney, S; Andrews, G; Ozkaynak, H; Neas, LM. (2012). GIS-modeled indicators of traffic-related air pollutants and adverse pulmonary health among children in El Paso, Texas. *Am J Epidemiol* 176: S131-S141. <http://dx.doi.org/10.1093/aje/kws274>
- Szpiro, AA; Paciorek, CJ. (2013a). Measurement error in two-stage analyses, with application to air pollution epidemiology. *Environmetrics* 24: 501-517. <http://dx.doi.org/10.1002/env.2233>
- Szpiro, AA; Paciorek, CJ. (2013b). Rejoinder [Editorial]. *Environmetrics* 24: 531-536. <http://dx.doi.org/10.1002/env.2254>
- Szpiro, AA; Paciorek, CJ; Sheppard, L. (2011a). Does more accurate exposure prediction necessarily improve health effect estimates? *Epidemiology* 22: 680-685. <http://dx.doi.org/10.1097/EDE.0b013e3182254cc6>
- Szpiro, AA; Sampson, PD; Sheppard, L; Lumley, T; Adar, SD; Kaufman, JD. (2010). Predicting intra-urban variation in air pollution concentrations with complex spatio-temporal dependencies. *Environmetrics* 21: 606-631. <http://dx.doi.org/10.1002/env.1014>
- Szpiro, AA; Sheppard, L; Lumley, T. (2011b). Efficient measurement error correction with spatially misaligned data. *Biostatistics* 12: 610-623. <http://dx.doi.org/10.1093/biostatistics/kxq083>
- Szyszkowicz, M. (2007). Air pollution and emergency department visits for ischemic heart disease in Montreal, Canada. *Int J Occup Med Environ Health* 20: 167-173. <http://dx.doi.org/10.2478/v10001-007-0015-3>
- Szyszkowicz, M. (2008). Ambient air pollution and daily emergency department visits for ischemic stroke in Edmonton, Canada. *Int J Occup Med Environ Health* 21: 295-300. <http://dx.doi.org/10.2478/v10001-008-0029-5>
- Szyszkowicz, M. (2009). Air pollution and ED visits for chest pain. *Am J Emerg Med* 27: 165-168. <http://dx.doi.org/10.1016/j.ajem.2008.01.010>

- Szyszkowicz, M; Rowe, BH; Brook, RD. (2012). Even low levels of ambient air pollutants are associated with increased emergency department visits for hypertension. *Can J Cardiol* 28: 360-366. <http://dx.doi.org/10.1016/j.cjca.2011.06.011>
- Tabacova, S; Nikiforov, B; Balabaeva, L. (1985). Postnatal effects of maternal exposure to nitrogen dioxide. *Neurotoxicol Teratol* 7: 785-789.
- Tager, IB; Balmes, J; Lurmann, F; Ngo, L; Alcorn, S; Künzli, N. (2005). Chronic exposure to ambient ozone and lung function in young adults. *Epidemiology* 16: 751-759. <http://dx.doi.org/10.1097/01.ede.0000183166.68809.b0>
- Takano, H; Yanagisawa, R; Inoue, KI; Shimada, A; Ichinose, T; Sadakane, K; Yoshino, S; Yamaki, K; Morita, M; Yoshikawa, T. (2004). Nitrogen dioxide air pollution near ambient levels is an atherogenic risk primarily in obese subjects: A brief communication. *Exp Biol Med* 229: 361-364.
- Takenoue, Y; Kaneko, T; Miyamae, T; Mori, M; Yokota, S. (2012). The influence of outdoor NO<sub>2</sub> exposure on asthma in childhood: Meta-analysis [Review]. *Pediatrics International* 54: 762-769. <http://dx.doi.org/10.1111/j.1442-200X.2012.03674.x>
- Tang, MJ; Schuster, G; Crowley, JN. (2014). Heterogeneous reaction of N<sub>2</sub>O<sub>5</sub> with illite and Arizona test dust particles. *Atmos Chem Phys* 14: 245-254. <http://dx.doi.org/10.5194/acp-14-245-2014>
- Tao, Y; Huang, W; Huang, X; Zhong, L; Lu, SE; Li, Y; Dai, L; Zhang, Y; Zhu, T. (2012). Estimated acute effects of ambient ozone and nitrogen dioxide on mortality in the Pearl River Delta of Southern China. *Environ Health Perspect* 120: 393-398. <http://dx.doi.org/10.1289/ehp.1103715>
- Tashkin, DP; Simmons, MS; Chang, P; Liu, H; Coulson, AH. (1993). Effects of smoked substance abuse on nonspecific airway hyperresponsiveness. *Am Rev Respir Dis* 147: 97-103. <http://dx.doi.org/10.1164/ajrccm/147.1.97>
- Taylor, DR. (2012). Advances in the clinical applications of exhaled nitric oxide measurements [Review]. *J Breath Res* 6: 047102. <http://dx.doi.org/10.1088/1752-7155/6/4/047102>
- Teichert, T; Vossoughi, M; Vierkötter, A; Sugiri, D; Schikowski, T; Schulte, T; Roden, M; Luckhaus, C; Herder, C; Krämer, U. (2013). Association between traffic-related air pollution, subclinical inflammation and impaired glucose metabolism: Results from the SALIA study. *PLoS ONE* 8: e83042. <http://dx.doi.org/10.1371/journal.pone.0083042>
- Tepper, JS; Costa, DL; Winsett, DW; Stevens, MA; Doerfler, DL; Watkinson, WP. (1993). Near-lifetime exposure of the rat to a simulated urban profile of nitrogen dioxide: Pulmonary function evaluation. *Fundam Appl Toxicol* 20: 88-96. <http://dx.doi.org/10.1093/toxsci/20.1.88>
- TFESC and NASPE (Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology). (1996). Heart rate variability: Standards of measurement, physiological interpretation and clinical use. *Circulation* 93: 1043-1065. <http://dx.doi.org/10.1161/01.CIR.93.5.1043>
- Thach, TQ; Wong, CM; Chan, KP; Chau, YK; Thomas, GN; Ou, CQ; Yang, L; Peiris, JSM; Lam, TH; Hedley, AJ. (2010). Air pollutants and health outcomes: Assessment of confounding by influenza. *Atmos Environ* 44: 1437-1442. <http://dx.doi.org/10.1016/j.atmosenv.2010.01.036>
- Thaller, EI; Petronella, SA; Hochman, D; Howard, S; Chhikara, RS; Brooks, EG. (2008). Moderate increases in ambient PM<sub>2.5</sub> and ozone are associated with lung function decreases in beach lifeguards. *J Occup Environ Med* 50: 202-211. <http://dx.doi.org/10.1097/JOM.0b013e31816386b4>
- Thiering, E; Cyrus, J; Kratzsch, J; Meisinger, C; Hoffmann, B; Berdel, D; von Berg, A; Koletzko, S; Bauer, CP; Heinrich, J. (2013). Long-term exposure to traffic-related air pollution and insulin resistance in children: Results from the GINIplus and LISApplus birth cohorts. *Diabetologia* 56: 1696-1704. <http://dx.doi.org/10.1007/s00125-013-2925-x>
- Thomas, HV; Mueller, PK; Wright, R. (1967). Response of rat lung mast cells to nitrogen dioxide inhalation. *J Air Pollut Control Assoc* 17: 33-35. <http://dx.doi.org/10.1080/00022470.1967.10468939>

- [Thompson, AM; Zanobetti, A; Silverman, F; Schwartz, J; Coull, B; Urch, B; Speck, M; Brook, JR; Manno, M; Gold, DR.](#) (2010). Baseline repeated measures from controlled human exposure studies: Associations between ambient air pollution exposure and the systemic inflammatory biomarkers IL-6 and fibrinogen. *Environ Health Perspect* 118: 120-124. <http://dx.doi.org/10.1289/ehp.0900550>
- [Thornton, JA; Braban, CF; Abbatt, JPD.](#) (2003). N2O5 hydrolysis on sub-micron organic aerosol: The effect of relative humidity, particle phase, and particle size. *Phys Chem Chem Phys* 5: 4593-4603. <http://dx.doi.org/10.1039/b307498f>
- [Thornton, JA; Kercher, JP; Riedel, TP; Wagner, NL; Cozic, J; Holloway, JS; Dube, WP; Wolfe, GM; Quinn, PK; Middlebrook, AM; Alexander, B; Brown, SS.](#) (2010). A large atomic chlorine source inferred from mid-continental reactive nitrogen chemistry. *Nature* 464: 271-274. <http://dx.doi.org/10.1038/nature08905>
- [Thurlbeck, WM.](#) (1982). Postnatal human lung growth. *Thorax* 37: 564-571. <http://dx.doi.org/10.1136/thx.37.8.564>
- [Tian, N; Xue, J; Barzyk, TM.](#) (2013). Evaluating socioeconomic and racial differences in traffic-related metrics in the United States using a GIS approach. *J Expo Sci Environ Epidemiol* 23: 215-222. <http://dx.doi.org/10.1038/jes.2012.83>
- [Timonen, KL; Pekkanen, J.](#) (1997). Air pollution and respiratory health among children with asthmatic or cough symptoms. *Am J Respir Crit Care Med* 156: 546-552. <http://dx.doi.org/10.1164/ajrccm.156.2.9608044>
- [Timonen, KL; Vanninen, E; de Hartog, J; Ibaldo-Mulli, A; Brunekreef, B; Gold, DR; Henrich, J; Hoek, G; Lanki, T; Peters, A; Tarkiainen, T; Tiittanen, P; Kreyling, W; Pekkanen, J.](#) (2006). Effects of ultrafine and fine particulate and gaseous air pollution on cardiac autonomic control in subjects with coronary artery disease: The ULTRA study. *J Expo Sci Environ Epidemiol* 16: 332-341. <http://dx.doi.org/10.1038/sj.jea.7500460>
- [Tokairin, T; Kitada, T.](#) (2005). Study on the effect of porous fence on air quality and traffic noise level around a double-decked road structure. *Environ Monit Assess* 105: 121-143. <http://dx.doi.org/10.1007/s10661-005-3160-9>
- [Tolbert, P.](#) (2009). Personal communication from Dr. Paige Tolbert, Emory University to Dr. Ellen Kirrane, NCEA with attachment. Available online
- [Tolbert, PE; Mulholland, JA; MacIntosh, DL; Xu, F; Daniels, D; Devine, OJ; Carlin, BP; Klein, M; Dorley, J; Butler, AJ; Nordenberg, DF; Frumkin, H; Ryan, PB; White, MC.](#) (2000). Air quality and pediatric emergency room visits for asthma in Atlanta, Georgia. *Am J Epidemiol* 151: 798-810.
- [Tolbert, PE; Klein, M; Peel, JL; Sarnat, SE; Sarnat, JA.](#) (2007). Multipollutant modeling issues in a study of ambient air quality and emergency department visits in Atlanta. *J Expo Sci Environ Epidemiol* 17: S29-S35. <http://dx.doi.org/10.1038/sj.jes.7500625>
- [Tonne, C; Wilkinson, P.](#) (2013). Long-term exposure to air pollution is associated with survival following acute coronary syndrome. *European Heart Journal (Online)* 34: 1306-1311. <http://dx.doi.org/10.1093/eurheartj/ehs480>
- [Tonnesen, S; Jeffries, HE.](#) (1994). Inhibition of odd oxygen production in the carbon bond four and generic reaction set mechanisms. *Atmos Environ* 28: 1339-1349. [http://dx.doi.org/10.1016/1352-2310\(94\)90281-X](http://dx.doi.org/10.1016/1352-2310(94)90281-X)
- [Tonse, SR; Brown, NJ; Harley, RA; Jin, L.](#) (2008). A process-analysis based study of the ozone weekend effect. *Atmos Environ* 42: 7728-7736. <http://dx.doi.org/10.1016/j.atmosenv.2008.05.061>
- [Toren, K; Brisman, J; Jarvholm, B.](#) (1993). Asthma and asthma-like symptoms in adults assessed by questionnaires: A literature review [Review]. *Chest* 104: 600-608. <http://dx.doi.org/10.1378/chest.104.2.600>
- [Torok, JA; Brahmajothi, MV; Zhu, H; Tinch, BT; Auten, RL; McMahon, TJ.](#) (2012). Transpulmonary flux of S-nitrosothiols and pulmonary vasodilation during nitric oxide inhalation: Role of transport. *Am J Respir Cell Mol Biol* 47: 37-43. <http://dx.doi.org/10.1165/rcmb.2011-0439OC>
- [Trasande, L; Wong, K; Roy, A; Savitz, DA; Thurston, G.](#) (2013). Exploring prenatal outdoor air pollution, birth outcomes and neonatal health care utilization in a nationally representative sample. *J Expo Sci Environ Epidemiol* 23: 315-321. <http://dx.doi.org/10.1038/jes.2012.124>

- [Tsai, DH; Wang, JL; Chuang, KJ; Chan, CC.](#) (2010). Traffic-related air pollution and cardiovascular mortality in central Taiwan. *Sci Total Environ* 408: 1818-1823. <http://dx.doi.org/10.1016/j.scitotenv.2010.01.044>
- [Tsai, SS; Chen, CC; Hsieh, HJ; Chang, CC; Yang, CY.](#) (2006). Air pollution and postneonatal mortality in a tropical city: Kaohsiung, Taiwan. *Inhal Toxicol* 18: 185-189. <http://dx.doi.org/10.1080/08958370500434214>
- [Tsai, SS; Chen, PS; Yang, YH; Liou, SH; Wu, TN; Sung, FC; Yang, CY.](#) (2012). Air pollution and hospital admissions for myocardial infarction: Are there potentially sensitive groups? *J Toxicol Environ Health A* 75: 242-251. <http://dx.doi.org/10.1080/15287394.2012.641202>
- [Tsai, SS; Chiu, HF; Wu, TN; Yang, CY.](#) (2009). Air pollution and emergency room visits for cardiac arrhythmia in a subtropical city: Taipei, Taiwan. *Inhal Toxicol* 21: 1113-1118. <http://dx.doi.org/10.3109/08958370902758939>
- [Tsai, SS; Goggins, WB; Chiu, HF; Yang, CY.](#) (2003). Evidence for an association between air pollution and daily stroke admissions in Kaohsiung, Taiwan. *Stroke* 34: 2612-2616. <http://dx.doi.org/10.1161/01.STR.0000095564.33543.64>
- [Tseng, CY; Huang, YC; Su, SY; Huang, JY; Lai, CH; Lung, CC; Ho, CC; Liaw, YP.](#) (2012). Cell type specificity of female lung cancer associated with sulfur dioxide from air pollutants in Taiwan: An ecological study. *BMC Public Health* 12: 4. <http://dx.doi.org/10.1186/1471-2458-12-4>
- [Tsubone, H; Oda, H; Suzuki, AK; Kubota, K.](#) (1982). Electrocardiographic abnormalities in rats by acute exposure to nitrogen dioxide. *Toxicol Lett* 12: 125-129. [http://dx.doi.org/10.1016/0378-4274\(82\)90174-6](http://dx.doi.org/10.1016/0378-4274(82)90174-6)
- [Tsubone, H; Suzuki, AK.](#) (1984). Reflex cardiopulmonary responses by stimulation to type J receptors in rats exposed to NO<sub>2</sub>. *J Toxicol Environ Health* 13: 905-917. <http://dx.doi.org/10.1080/15287398409530550>
- [Tsuji, H; Larson, MG; Venditti, FJ, Jr; Manders, ES; Evans, JC; Feldman, CL; Levy, D.](#) (1996). Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. *Circulation* 94: 2850-2855. <http://dx.doi.org/10.1161/01.CIR.94.11.2850>
- [Tsuji, H; Venditti, FJ; Manders, ES; Evans, JC; Larson, MG; Feldman, CL; Levy, D.](#) (1994). Reduced heart rate variability and mortality risk in an elderly cohort: The Framingham Heart Study. *Circulation* 90: 878-883. <http://dx.doi.org/10.1161/01.CIR.90.2.878>
- [Tunnicliffe, WS; Burge, PS; Ayres, JG.](#) (1994). Effect of domestic concentrations of nitrogen dioxide on airway responses to inhaled allergen in asthmatic patients. *Lancet* 344: 1733-1736. [http://dx.doi.org/10.1016/s0140-6736\(94\)92886-x](http://dx.doi.org/10.1016/s0140-6736(94)92886-x)
- [Turin, TC; Kita, Y; Rumana, N; Nakamura, Y; Ueda, K; Takashima, N; Sugihara, H; Morita, Y; Ichikawa, M; Hirose, K; Nitta, H; Okayama, A; Miura, K; Ueshima, H.](#) (2012). Short-term exposure to air pollution and incidence of stroke and acute myocardial infarction in a Japanese population. *Neuroepidemiology* 38: 84-92. <http://dx.doi.org/10.1159/000335654>
- [U.S. Census Bureau.](#) (2007). 2007 American community survey [Database]. Washington, DC: U.S. Department of Commerce, U.S. Census Bureau. Retrieved from <http://www.census.gov/programs-surveys/acs/news/data-releases.2007.html>
- [U.S. Census Bureau.](#) (2009). American housing survey for the United States: 2009. Washington, DC: U.S. Government Printing Office. <http://www.census.gov/prod/2011pubs/h150-09.pdf>
- [U.S. Census Bureau.](#) (2013a). 2013 TIGER/Line shapefiles. Suitland, MD: U.S. Census Bureau, Geography Division. <https://www.census.gov/cgi-bin/geo/shapefiles2013/main>
- [U.S. Census Bureau.](#) (2013b). American community survey 2013 1-year estimate. Available online at [http://factfinder2.census.gov/faces/tableservices/jsf/pages/productview.xhtml?pid=ACS\\_13\\_1YR\\_B01003&prodType=table](http://factfinder2.census.gov/faces/tableservices/jsf/pages/productview.xhtml?pid=ACS_13_1YR_B01003&prodType=table)
- [U.S. Census Bureau.](#) (2014). TIGER/Line with selected demographic and economic data. Suitland, MD: U.S. Census Bureau, Geography Division. <https://www.census.gov/geo/maps-data/data/tiger-data.html>

- [U.S. EPA](http://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=20013K3B.txt) (U.S. Environmental Protection Agency). (1971). Air quality criteria for nitrogen oxides [EPA Report]. (AP-84). Washington DC: U.S. Environmental Protection Agency, Air Pollution Control Office. <http://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=20013K3B.txt>
- [U.S. EPA](http://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=20013K3B.txt) (U.S. Environmental Protection Agency). (1982). Air quality criteria for oxides of nitrogen [EPA Report]. (EPA/600/8-82-026). Research Triangle Park, NC: U.S. Environmental Protection Agency, Environmental Criteria and Assessment Office.
- [U.S. EPA](http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=23162) (U.S. Environmental Protection Agency). (1991). Guidelines for developmental toxicity risk assessment. In US Environmental Protection Agency. (EPA/600/FR-91/001). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum. <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=23162>
- [U.S. EPA](http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=40179) (U.S. Environmental Protection Agency). (1993a). Air quality criteria for oxides of nitrogen, vol. 1-3 [EPA Report]. (EPA/600/8-91/049aF-cF). Research Triangle Park, NC: U.S. Environmental Protection Agency, Environmental Criteria and Assessment Office. <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=40179>
- [U.S. EPA](http://www.fedreg.gov) (U.S. Environmental Protection Agency). (1993b). Ambient air quality surveillance: Final rule. Fed Reg 58: 8452-8475.
- [U.S. EPA](http://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=00002UBE.txt) (U.S. Environmental Protection Agency). (1995a). Review of the national ambient air quality standards for nitrogen dioxide: Assessment of scientific and technical information [EPA Report]. (EPA/452/R-95/005). Research Triangle Park, NC: U.S. Environmental Protection Agency, Office of Air Quality, Planning and Standards. <http://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=00002UBE.txt>
- [U.S. EPA](http://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=2001206A.txt) (U.S. Environmental Protection Agency). (1995b). A user's guide for the CALPUFF dispersion model [EPA Report]. (EPA/454/B-95/006). Research Triangle Park, NC: U.S. Environmental Protection Agency, Office of Air Quality, Planning, and Standards. <http://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=2001206A.txt>
- [U.S. EPA](http://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=2001206A.txt) (U.S. Environmental Protection Agency). (1996a). Air quality criteria for ozone and related photochemical oxidants [EPA Report]. (EPA/600/P-93/004AF). Research Triangle Park, NC.
- [U.S. EPA](http://www.epa.gov/raf/publications/guidelines-reproductive-tox-risk-assessment.htm) (U.S. Environmental Protection Agency). (1996b). Guidelines for reproductive toxicity risk assessment. (EPA/630/R-96/009). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum. <http://www.epa.gov/raf/publications/guidelines-reproductive-tox-risk-assessment.htm>
- [U.S. EPA](http://www.epa.gov/raf/publications/guidelines-ecological-risk-assessment.htm) (U.S. Environmental Protection Agency). (1998a). Guidelines for ecological risk assessment [EPA Report]. (EPA/630/R-95/002F). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum. <http://www.epa.gov/raf/publications/guidelines-ecological-risk-assessment.htm>
- [U.S. EPA](http://www.epa.gov/raf/publications/guidelines-neurotoxicity-risk-assessment.htm) (U.S. Environmental Protection Agency). (1998b). Guidelines for neurotoxicity risk assessment [EPA Report]. (EPA/630/R-95/001F). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum. <http://www.epa.gov/raf/publications/guidelines-neurotoxicity-risk-assessment.htm>
- [U.S. EPA](http://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=30003R9Y.txt) (U.S. Environmental Protection Agency). (1999). Science algorithms of the EPA models-3 Community Multiscale Air Quality (CMAQ) modeling system [EPA Report]. (EPA/600/R-99/030). Washington, DC. <http://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=30003R9Y.txt>
- [U.S. EPA](http://www.fedreg.gov) (U.S. Environmental Protection Agency). (2001). Control of air pollution from new motor vehicles: Heavy-duty engine and vehicle standards and highway diesel fuel sulfur control requirements. Fed Reg 66: 5002-5193.
- [U.S. EPA](http://yosemite.epa.gov/sab%5CSABPRODUCT.NSF/7700D7673673CE83852570CA0075458A/$File/epec02009.pdf) (U.S. Environmental Protection Agency). (2002). A framework for assessing and reporting on ecological condition: An SAB report [EPA Report]. (EPA-SAB-EPEC-02-009). Washington, DC. [http://yosemite.epa.gov/sab%5CSABPRODUCT.NSF/7700D7673673CE83852570CA0075458A/\\$File/epec02009.pdf](http://yosemite.epa.gov/sab%5CSABPRODUCT.NSF/7700D7673673CE83852570CA0075458A/$File/epec02009.pdf)
- [U.S. EPA](http://www2.epa.gov/osa/guidelines-carcinogen-risk-assessment) (U.S. Environmental Protection Agency). (2005). Guidelines for carcinogen risk assessment [EPA Report]. (EPA/630/P-03/001F). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum. <http://www2.epa.gov/osa/guidelines-carcinogen-risk-assessment>

- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2006). Air quality criteria for ozone and related photochemical oxidants [EPA Report]. (EPA/600/R-05/004AF). Research Triangle Park, NC: U.S. Environmental Protection Agency, National Center for Environmental Assessment.  
<http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=149923>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2007a). Integrated review plan for the primary national ambient air quality standard for nitrogen dioxide [EPA Report]. Research Triangle Park, NC: U.S. Environmental Protection Agency, National Center for Environmental Assessment.  
[http://www.epa.gov/ttn/naaqs/standards/nox/data/20070823\\_nox\\_review\\_plan\\_final.pdf](http://www.epa.gov/ttn/naaqs/standards/nox/data/20070823_nox_review_plan_final.pdf)
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2007b). Nitrogen dioxide health assessment plan: Scope and methods for exposure and risk assessment. Draft [EPA Report]. Research Triangle Park, NC: U.S. Environmental Protection Agency, Office of Air Quality Planning and Standards.  
[http://www.epa.gov/ttn/naaqs/standards/nox/data/20070927\\_risk\\_exposure\\_scope.pdf](http://www.epa.gov/ttn/naaqs/standards/nox/data/20070927_risk_exposure_scope.pdf)
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2008a). Integrated science assessment for oxides of nitrogen - Health criteria: Annexes [EPA Report]. (EPA/600/R-08/072). Research Triangle Park, NC: U.S. Environmental Protection Agency, National Center for Environmental Assessment.  
<http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=194645>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2008b). Integrated science assessment for oxides of nitrogen and sulfur: Ecological criteria [EPA Report]. (EPA/600/R-08/082F). Research Triangle Park, NC.  
<http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=201485>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2008c). Integrated science assessment for oxides of nitrogen Health criteria (Final report, 2008) [EPA Report]. (EPA/600/R-08/071). Research Triangle Park, NC: U.S. Environmental Protection Agency, National Center for Environmental Assessment.  
<http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=194645>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2008d). Integrated science assessment for sulfur oxides: Health criteria [EPA Report]. (EPA/600/R-08/047F). Research Triangle Park, NC: U.S. Environmental Protection Agency, National Center for Environmental Assessment.  
<http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=198843>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2008e). Risk and exposure assessment to support the review of the NO<sub>2</sub> primary national ambient air quality standard [EPA Report]. (EPA-452/R-08-008a). Research Triangle Park, NC: U.S. Environmental Protection Agency, Office of Air Quality Planning and Standards. [http://www.epa.gov/ttn/naaqs/standards/nox/data/20081121\\_NO2\\_REA\\_final.pdf](http://www.epa.gov/ttn/naaqs/standards/nox/data/20081121_NO2_REA_final.pdf)
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2009a). Integrated science assessment for particulate matter [EPA Report]. (EPA/600/R-08/139F). Research Triangle Park, NC: U.S. Environmental Protection Agency, National Center for Environmental Assessment.  
<http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=216546>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2009b). Integrated science assessment for particulate matter - Annexes with errata [EPA Report]. (EPA/600/R-08/139). Washington, DC: U.S. Environmental Protection Agency, National Center for Environmental Assessment.  
<http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=216546>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2010a). Final regulatory impact analysis (RIA) for the NO<sub>2</sub> National Ambient Air Quality Standards (NAAQS) [EPA Report]. Research Triangle Park, NC.  
<http://www.epa.gov/tneca1/regdata/RIAs/FinalNO2RIAFulldocument.pdf>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2010b). Integrated science assessment for carbon monoxide [EPA Report]. (EPA/600/R-09/019F). Research Triangle Park, NC: U.S. Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment.  
<http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=218686>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2010c). Primary national ambient air quality standards for nitrogen dioxide. Fed Reg 75: 6474-6537.

- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2011a). 2008 National Emissions Inventory data and documentation. Available online at <http://www.epa.gov/ttn/chief/net/2008inventory.html> (accessed February 17, 2011).
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2011b). Exposure factors handbook: 2011 edition (final) [EPA Report]. (EPA/600/R-090/052F). Washington, DC: U.S. Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment.  
<http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=236252>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2012a). Ambient air monitoring reference and equivalent methods: Designation of three new equivalent methods. Fed Reg 77: 32632-32633.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2012b). Near-road NO<sub>2</sub> monitoring technical assistance document [EPA Report]. (EPA-454/B-12-002). Research Triangle Park, NC: U.S. Environmental Protection Agency, Office of Air Quality Planning and Standards.  
<http://nepis.epa.gov/exe/ZyPURL.cgi?Dockey=P100EPRZ.txt>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2012c). Notice of workshop and call for information on integrated science assessment for oxides of nitrogen. Fed Reg 77: 7149-7151.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2013a). 2011 National Emissions Inventory data and documentation. Available online at <http://www.epa.gov/ttnchie1/net/2011inventory.html> (accessed December 1, 2014).
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2013b). Ambient air monitoring reference and equivalent methods: Designation of five new equivalent methods. Fed Reg 78: 67360-67361.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2013c). Integrated science assessment for lead [EPA Report]. (EPA/600/R-10/075F). Research Triangle Park, NC: U.S. Environmental Protection Agency, National Center for Environmental Assessment.  
<http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=255721>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2013d). Integrated science assessment for ozone and related photochemical oxidants. (EPA/600/R-10/076F). Research Triangle Park, NC: U.S. Environmental Protection Agency, National Center for Environmental Assessment.  
<http://cfpub.epa.gov/ncea/isa/recordisplay.cfm?deid=247492>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2013e). Integrated science assessment for ozone and related photochemical oxidants (final report) [EPA Report]. (EPA/600/R-10/076F). Washington, DC: U.S. Environmental Protection Agency, National Center for Environmental Assessment.  
<http://cfpub.epa.gov/ncea/isa/recordisplay.cfm?deid=247492>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2013f). Notice of workshop and call for information on integrated science assessment for oxides of nitrogen and oxides of sulfur. Fed Reg 78: 53452-53454.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2013g). Supplemental table S6-2. Epidemiologic studies of exposure to oxides of nitrogen and pregnancy effects [EPA Report].
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2013h). Supplemental table S6-3. Epidemiologic studies of exposure to oxides of nitrogen and fetal growth [EPA Report].
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2013i). Supplemental table S6-4. Epidemiologic studies exposure to oxides of nitrogen and preterm birth [EPA Report].
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2013j). Supplemental table S6-5. Epidemiologic studies of exposure to oxides of nitrogen and birth weight [EPA Report].
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2013k). Supplemental table S6-6. Epidemiologic studies of exposure to oxides of nitrogen and birth defects [EPA Report].
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2013l). Supplemental table S6-7. Epidemiologic studies of exposure to nitrogen dioxide and neurodevelopmental effects [EPA Report].

- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2013m). Supplemental table S6-8. Epidemiologic studies of exposure to nitrogen dioxide and infant mortality [EPA Report].
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2013n). Supplemental table S6-9. Epidemiologic studies of long-term exposure to oxides of nitrogen and mortality [EPA Report].
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2013o). Supplemental table S6-10. Epidemiologic studies of exposure to oxides of nitrogen and cancer incidence and mortality [EPA Report].
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2013p). Toxicological review of trimethylbenzenes (CASRN 25551-13-7, 95-63-6, 526-73-8, and 108-67-8) in support of summary information on the Integrated Risk Information System (IRIS): revised external review draft [EPA Report]. (EPA/635/R13/171a). Washington, D.C.: U.S. Environmental Protection Agency, National Center for Environmental Assessment.  
<http://yosemite.epa.gov/sab/SABPRODUCT.NSF/b5d8a1ce9b07293485257375007012b7/ee1e280e77586de985257b65005d37e7!OpenDocument>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2014a). Control of air pollution from motor vehicles: Tier 3 motor vehicle emission and fuel standards. Fed Reg 79: 23414-23886.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2014b). Integrated review plan for the primary national ambient air quality standards for nitrogen dioxide [EPA Report]. (EPA-452/R-14/003). Research Triangle Park, NC: U.S. Environmental Protection Agency, National Center for Environmental Assessment.  
<http://www.epa.gov/ttn/naaqs/standards/nox/data/201406finalirpprimaryno2.pdf>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2014c). Notice of workshop and call for information on integrated science assessment for particulate matter. Fed Reg 79: 71764-71766.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2014d). Office of research and development; Ambient air monitoring reference and equivalent methods: Designation of four new equivalent methods. Fed Reg 79: 34734-34735.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2015a). Supplemental figure S5-1 associations of NO<sub>2</sub> with respiratory effects in copollutant models with PM<sub>10</sub> PM<sub>10\_25</sub> SO<sub>2</sub> O<sub>3</sub>.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2015b). Supplemental Figure S5-2. Results of single-pollutant and copollutants models of short-term exposure to NO<sub>2</sub> with and without PM and CVD HA.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2015c). Supplemental Figure S5-3. Results of single-pollutant and copollutants models of short-term exposure to NO<sub>2</sub> with CO and without CO and CVD HA.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2015d). Supplemental Figure S5-4 Results of single-pollutant and copollutants models of short-term exposure to NO<sub>2</sub> or NOX with and without O<sub>3</sub> and hospital admissions CVD.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2015e). Supplemental Figure S5-5 Results of single-pollutant and copollutants models of short-term exposure to NO<sub>2</sub> or NOX with and without SO<sub>2</sub> and hospital admissions CVD.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2015f). Supplemental table S1-1. Epidemiologic studies of health effects not evaluated in the ISA for oxides for nitrogen [EPA Report].
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2015g). Supplemental Table S5-1. Calculation of increments of oxides of nitrogen for standardizing epidemiologic effect estimates - short-term averages.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2015h). Supplemental Table S5-3. Studies of short-term exposure to oxides of nitrogen and respiratory hospital admissions and ED visits [EPA Report].
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2015i). Supplemental Table S5-4. Studies of short-term exposure to oxides of nitrogen and mortality.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2015j). Supplemental Table S6-1 Calculation of increments of oxides of nitrogen for standardizing effect estimates.

- [Unal, A; Hu, Y; Chang, ME; Talat Odman, M; Russell, AG.](#) (2005). Airport related emissions and impacts on air quality: Application to the Atlanta International Airport. *Atmos Environ* 39: 5787-5798. <http://dx.doi.org/10.1016/j.atmosenv.2005.05.051>
- [UNEP](#) (United Nations Environment Programme). (2003). *Ecosystems and human well-being: A framework for assessment*. Washington, DC: Island Press. <https://www.islandpress.org/book/ecosystems-and-human-well-being-0>
- [Urman, R; McConnell, R; Islam, T; Avol, EL; Lurmann, FW; Vora, H; Linn, WS; Rappaport, EB; Gilliland, FD; Gauderman, WJ.](#) (2014). Associations of children's lung function with ambient air pollution: Joint effects of regional and near-roadway pollutants. *Thorax* 69: 540-547. <http://dx.doi.org/10.1136/thoraxjnl-2012-203159>
- [Vagaggini, B; Paggiaro, PL; Giannini, D; Franco, AD; Cianchetti, S; Carnevali, S; Taccola, M; Bacci, E; Bancalari, L; Dente, FL; Giuntini, C.](#) (1996). Effect of short-term NO<sub>2</sub> exposure on induced sputum in normal, asthmatic and COPD subjects. *Eur Respir J* 9: 1852-1857.
- [Valin, LC; Russell, AR; Cohen, RC.](#) (2013). Variations of OH radical in an urban plume inferred from NO<sub>2</sub> column measurements. *Geophys Res Lett* 40: 1856-1860. <http://dx.doi.org/10.1002/grl.50267>
- [Van As, A.](#) (1977). Pulmonary airway clearance mechanisms: A reappraisal [Editorial]. *Am Rev Respir Dis* 115: 721-726.
- [van den Hooven, EH; de Kluizenaar, Y; Pierik, FH; Hofman, A; van Ratingen, SW; Zandveld, PY; Lindemans, J; Russcher, H; Steegers, EA; Miedema, HM; Jaddoe, VW.](#) (2012a). Chronic air pollution exposure during pregnancy and maternal and fetal C-reactive protein levels: The generation R study. *Environ Health Perspect* 120: 746-751. <http://dx.doi.org/10.1289/ehp.1104345>
- [van den Hooven, EH; de Kluizenaar, Y; Pierik, FH; Hofman, A; van Ratingen, SW; Zandveld, PY; Mackenbach, JP; Steegers, EA; Miedema, HM; Jaddoe, VW.](#) (2011). Air pollution, blood pressure, and the risk of hypertensive complications during pregnancy: The generation R study. *Hypertension* 57: 406-412. <http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.164087>
- [van den Hooven, EH; Pierik, FH; de Kluizenaar, Y; Hofman, A; van Ratingen, SW; Zandveld, PY; Russcher, H; Lindemans, J; Miedema, HM; Steegers, EA; Jaddoe, VW.](#) (2012b). Air pollution exposure and markers of placental growth and function: The Generation R Study. *Environ Health Perspect* 120: 1753-1759. <http://dx.doi.org/10.1289/ehp.1204918>
- [van den Hooven, EH; Pierik, FH; de Kluizenaar, Y; Willemsen, SP; Hofman, A; van Ratingen, SW; Zandvel, PYJ; Mackenbach, JP; Steegers, EAP; Miedema, HME; Jaddoe, VWV.](#) (2012c). Air pollution exposure during pregnancy, ultrasound measures of fetal growth, and adverse birth outcomes: A prospective cohort study. *Environ Health Perspect* 120: 150-156. <http://dx.doi.org/10.1289/ehp.1003316>
- [van der Heijden, HHA, CM; Brouwer, ML; Hoekstra, F; van der Pol, P; Merkus, PJF, M.](#) (2014). Reference values of exhaled nitric oxide in healthy children 1-5 years using off-line tidal breathing. *Pediatr Pulmonol* 49: 291-295. <http://dx.doi.org/10.1002/ppul.22796>
- [van der Vliet, A; O'Neill, CA; Cross, CE; Koostra, JM; Volz, WG; Halliwell, B; Louie, S.](#) (1999). Determination of low-molecular-mass antioxidant concentrations in human respiratory tract lining fluids. *Am J Physiol* 276: L289-L296.
- [van der Zee, SC; Hoek, G; Boezen, HM; Schouten, JP; van Wijnen, JH; Brunekreef, B.](#) (1999). Acute effects of urban air pollution on respiratory health of children with and without chronic respiratory symptoms. *Occup Environ Med* 56: 802-813. <http://dx.doi.org/10.1136/oem.56.12.802>
- [van der Zee, SC; Hoek, G; Boezen, MH; Schouten, JP; van Wijnen, JH; Brunekreef, B.](#) (2000). Acute effects of air pollution on respiratory health of 50-70 yr old adults. *Eur Respir J* 15: 700-709.
- [van Kempen, E; Fischer, P; Janssen, N; Houthuijs, D; van Kamp, I; Stansfeld, S; Cassee, F.](#) (2012). Neurobehavioral effects of exposure to traffic-related air pollution and transportation noise in primary schoolchildren. *Environ Res* 115: 18-25. <http://dx.doi.org/10.1016/j.envres.2012.03.002>

- [Van Roosbroeck, S; Li, R; Hoek, G; Lebret, E; Brunekreef, B; Spiegelman, D.](#) (2008). Traffic-related outdoor air pollution and respiratory symptoms in children: The impact of adjustment for exposure measurement error. *Epidemiology* 19: 409-416. <http://dx.doi.org/10.1097/EDE.0b013e3181673bab>
- [Van Schayck, CP; Dompeling, E; Van Herwaarden, CL; Wever, AM; Van Weel, C.](#) (1991). Interacting effects of atopy and bronchial hyperresponsiveness on the annual decline in lung function and the exacerbation rate in asthma. *Am Rev Respir Dis* 144: 1297-1301. <http://dx.doi.org/10.1164/ajrccm/144.6.1297>
- [Van Stee, EW; Sloane, RA; Simmons, JE; Brunemann, KD.](#) (1983). In vivo formation of N-nitrosomorpholine in CD-1 mice exposed by inhalation to nitrogen dioxide and by gavage to morpholine. *J Natl Cancer Inst* 70: 375-379. <http://dx.doi.org/10.1093/jnci/70.2.375>
- [Van Stee, EW; Sloane, RA; Simmons, JE; Moorman, MP; Brunemann, KD.](#) (1995). Endogenous formation of N-nitrosomorpholine in mice from 15NO<sub>2</sub> by inhalation and morpholine by gavage. *Carcinogenesis* 16: 89-92. <http://dx.doi.org/10.1093/carcin/16.1.89>
- [Vardoulakis, S; Lumbrellas, J; Solazzo, E.](#) (2009). Comparative evaluation of nitrogen oxides and ozone passive diffusion tubes for exposure studies. *Atmos Environ* 43: 2509-2517. <http://dx.doi.org/10.1016/j.atmosenv.2009.02.048>
- [Vardoulakis, S; Solazzo, E; Lumbrellas, J.](#) (2011). Intra-urban and street scale variability of BTEX, NO<sub>2</sub> and O<sub>3</sub> in Birmingham, UK: Implications for exposure assessment. *Atmos Environ* 45: 5069-5078. <http://dx.doi.org/10.1016/j.atmosenv.2011.06.038>
- [Velsor, LW; Ballinger, CA; Patel, J; Postlethwait, EM.](#) (2003). Influence of epithelial lining fluid lipids on NO<sub>2</sub>-induced membrane oxidation and nitration. *Free Radic Biol Med* 34: 720-733. [http://dx.doi.org/10.1016/S0891-5849\(02\)01370-9](http://dx.doi.org/10.1016/S0891-5849(02)01370-9)
- [Velsor, LW; Postlethwait, EM.](#) (1997). NO<sub>2</sub>-induced generation of extracellular reactive oxygen is mediated by epithelial lining layer antioxidants. *Am J Physiol* 17: L1265-L1275.
- [Vencloviene, J; Grazuleviciene, R; Babarskiene, R; Dedele, A; Grazulevicius, T.](#) (2011). Short-term nitrogen dioxide exposure and geomagnetic activity interaction: contribution to emergency hospitalization for acute coronary syndrome. *Int J Environ Health Res* 21: 149-160. <http://dx.doi.org/10.1080/09603123.2010.515671>
- [Venkatram, A; Isakov, V; Thoma, E; Baldauf, R.](#) (2007). Analysis of air quality data near roadways using a dispersion model. *Atmos Environ* 41: 9481-9497. <http://dx.doi.org/10.1016/j.atmosenv.2007.08.045>
- [Verbanck, S; Schuermans, D; Noppen, M; Vincken, W; Paiva, M.](#) (2001). Methacholine versus histamine: Paradoxical response of spirometry and ventilation distribution. *J Appl Physiol* 91: 2587-2594.
- [Vette, A; Burke, J; Norris, G; Landis, M; Batterman, S; Breen, M; Isakov, V; Lewis, T; Gilmour, MI; Kamal, A; Hammond, D; Vedantham, R; Bereznicki, S; Tian, N; Croghan, C.](#) (2013). The Near-Road Exposures and Effects of Urban Air Pollutants Study (NEXUS): Study design and methods. *Sci Total Environ* 448: 38-47. <http://dx.doi.org/10.1016/j.scitotenv.2012.10.072>
- [Vichi, F; De Santis, F.](#) (2012). The measurement of the sink properties of triethanolamine (TEA) as a coating for collecting NO<sub>2</sub> by using annular diffusion denuders. *Environ Technol* 33: 1065-1069. <http://dx.doi.org/10.1080/09593330.2011.606848>
- [Vidale, S; Bonanomi, A; Guidotti, M; Arnaboldi, M; Sterzi, R.](#) (2010). Air pollution positively correlates with daily stroke admission and in hospital mortality: A study in the urban area of Como, Italy. *Neurol Sci* 31: 179-182. <http://dx.doi.org/10.1007/s10072-009-0206-8>
- [Vieira, SE; Stein, RT; Ferraro, AA; Pastro, LD; Pedro, SS; Lemos, M; da Silva, ER; Sly, PD; Saldiva, PH.](#) (2012). Urban air pollutants are significant risk factors for asthma and pneumonia in children: The influence of location on the measurement of pollutants. *Arch Bronconeumol* 48: 389-395. <http://dx.doi.org/10.1016/j.arbres.2012.05.005>
- [Villena, G; Bejan, I; Kurtenbach, R; Wiesen, P; Kleffmann, J.](#) (2011). Development of a new Long Path Absorption Photometer (LOPAP) instrument for the sensitive detection of NO<sub>2</sub> in the atmosphere. *Atmos Meas Tech* 4: 1663-1676. <http://dx.doi.org/10.5194/amt-4-1663-2011>

- Villena, G; Bejan, I; Kurtenbach, R; Wiesen, P; Kleffmann, J. (2012). Interferences of commercial NO<sub>2</sub> instruments in the urban atmosphere and in a smog chamber. *Atmos Meas Tech* 5: 149-159. <http://dx.doi.org/10.5194/amt-5-149-2012>
- Villeneuve, PJ; Chen, L; Rowe, BH; Coates, F. (2007). Outdoor air pollution and emergency department visits for asthma among children and adults: A case-crossover study in northern Alberta, Canada. *Environ Health* 6: 40. <http://dx.doi.org/10.1186/1476-069X-6-40>
- Villeneuve, PJ; Chen, L; Stieb, D; Rowe, BH. (2006a). Associations between outdoor air pollution and emergency department visits for stroke in Edmonton, Canada. *Eur J Epidemiol* 21: 689-700. <http://dx.doi.org/10.1007/s10654-006-9050-9>
- Villeneuve, PJ; Doiron, MS; Stieb, D; Dales, R; Burnett, RT; Dugandzic, R. (2006b). Is outdoor air pollution associated with physician visits for allergic rhinitis among the elderly in Toronto, Canada? *Allergy* 61: 750-758. <http://dx.doi.org/10.1111/j.1398-9995.2006.01070.x>
- Villeneuve, PJ; Jerrett, M; Brenner, D; Su, J; Chen, H; McLaughlin, J. R. (2014). A case-control study of long-term exposure to ambient volatile organic compounds and lung cancer in Toronto, Ontario, Canada. *Am J Epidemiol* 179: 443-451. <http://dx.doi.org/10.1093/aje/kwt289>
- Villeneuve, PJ; Johnson, JY; Pasichnyk, D; Lowes, J; Kirkland, S; Rowe, BH. (2012). Short-term effects of ambient air pollution on stroke: Who is most vulnerable? *Sci Total Environ* 430: 193-201. <http://dx.doi.org/10.1016/j.scitotenv.2012.05.002>
- Vinikoor-Imler, LC; Owens, EO; Nichols, JL; Ross, M; Brown, JS; Sacks, JD. (2014). Evaluating potential response-modifying factors for associations between ozone and health outcomes: A weight-of-evidence approach [Review]. *Environ Health Perspect* 122: 1166-1176. <http://dx.doi.org/10.1289/ehp.1307541>
- Vints, AM; Oostveen, E; Eeckhaut, G; Smolders, M; De Backer, WA. (2005). Time-dependent effect of nitrate-rich meals on exhaled nitric oxide in healthy subjects. *Chest* 128: 2465-2470. <http://dx.doi.org/10.1378/chest.128.4.2465>
- Volk, HE; Kerin, T; Lurmann, F; Hertz-Picciotto, I; McConnell, R; Campbell, DB. (2014). Autism spectrum disorder: Interaction of air pollution with the MET receptor tyrosine kinase gene. *Epidemiology* 25: 44-47. <http://dx.doi.org/10.1097/EDE.0000000000000030>
- Volk, HE; Lurmann, F; Penfold, B; Hertz-Picciotto, I; McConnell, R. (2013). Traffic-related air pollution, particulate matter, and autism. *Arch Gen Psychiatry* 70: 71-77. <http://dx.doi.org/10.1001/jamapsychiatry.2013.266>
- Vollmuth, TA; Driscoll, KE; Schlesinger, RB. (1986). Changes in early alveolar particle clearance due to single and repeated nitrogen dioxide exposures in the rabbit. *J Toxicol Environ Health* 19: 255-266. <http://dx.doi.org/10.1080/15287398609530925>
- von Elm, E; Altman, DG; Egger, M; Pocock, SJ; Gøtzsche, PC; Vandenbroucke, JP. (2007). The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies [Review]. *PLoS Med* 4: e296. <http://dx.doi.org/10.1371/journal.pmed.0040296>
- von Klot, S; Peters, A; Aalto, P; Bellander, T; Berglind, N; D'Ippoliti, D; Elosua, R; Hormann, A; Kulmala, M; Lanki, T; Lowel, H; Pekkanen, J; Picciotto, S; Sunyer, J; Forastiere, F. (2005). Ambient air pollution is associated with increased risk of hospital cardiac readmissions of myocardial infarction survivors in five European cities. *Circulation* 112: 3073-3079. <http://dx.doi.org/10.1161/CIRCULATIONAHA.105.548743>
- von Klot, S; Wölke, G; Tuch, T; Heinrich, J; Dockery, DW; Schwartz, J; Kreyling, WG; Wichmann, HE; Peters, A. (2002). Increased asthma medication use in association with ambient fine and ultrafine particles. *Eur Respir J* 20: 691-702. <http://dx.doi.org/10.1183/09031936.02.01402001>
- von Nieding, G; Wagner, HM. (1979). Effects of NO<sub>2</sub> on chronic bronchitis. *Environ Health Perspect* 29: 137-142.

- [Vrijheid, M; Martinez, D; Aguilera, I; Bustamante, M; Ballester, F; Estarlich, M; Fernandez-Somoano, A; Guxens, M; Lertxundi, N; Martinez, MD; Tardon, A; Sunyer, J.](#) (2012). Indoor air pollution from gas cooking and infant neurodevelopment. *Epidemiology* 23: 23-32. <http://dx.doi.org/10.1097/EDE.0b013e31823a4023>
- [Vrijheid, M; Martinez, D; Manzanares, S; Dadvand, P; Schembari, A; Rankin, J; Nieuwenhuijsen, M.](#) (2011). Ambient air pollution and risk of congenital anomalies: A systematic review and meta-analysis [Review]. *Environ Health Perspect* 119: 598-606. <http://dx.doi.org/10.1289/ehp.1002946>
- [Vutukuru, S; Dabdub, D.](#) (2008). Modeling the effects of ship emissions on coastal air quality: A case study of southern California. *Atmos Environ* 42: 3751-3764. <http://dx.doi.org/10.1016/j.atmosenv.2007.12.073>
- [Wagner, HM.](#) (1970). [Absorption of NO and NO<sub>2</sub> in MIK- and MAK-concentrations during inhalation]. [Absorption von NO und NO<sub>2</sub> in MIK- und MAK-konzentrationen bei der inhalation]. *Staub, Reinhaltung der Luft* 30: 380-381.
- [Wagner, WD; Duncan, BR; Wright, PG; Stokinger, HE.](#) (1965). Experimental study of threshold limit of NO<sub>2</sub>. *Arch Environ Health* 10: 455-466. <http://dx.doi.org/10.1080/00039896.1965.10664029>
- [Walker, SE; Slordal, LH; Guerreiro, C; Gram, F; Gronskei, KE.](#) (1999). Air pollution exposure monitoring and estimation. Part II. Model evaluation and population exposure. *J Environ Monit* 1: 321-326. <http://dx.doi.org/10.1039/A902776I>
- [Walters, LJ; May, MS; Johnson, DE; MacMann, RS; Woodward, WA.](#) (1999). Time-variability of NO<sub>x</sub> emissions from Portland cement kilns. *Environ Sci Technol* 33: 700-704. <http://dx.doi.org/10.1021/es980203b>
- [Wang, J; Widlansky, ME.](#) (2009). Lifestyle choices and endothelial function: Risk and relevance [Review]. *Curr Vasc Pharmacol* 7: 209-224. <http://dx.doi.org/10.2174/157016109787455581>
- [Wang, JH; Devalia, JL; Duddle, JM; Hamilton, SA; Davies, RJ.](#) (1995a). Effect of six-hour exposure to nitrogen dioxide on early-phase nasal response to allergen challenge in patients with a history of seasonal allergic rhinitis. *J Allergy Clin Immunol* 96: 669-676.
- [Wang, JH; Devalia, JL; Rusznak, C; Bagnall, A; Sapsford, RJ; Davies, RJ.](#) (1999). Effect of fluticasone propionate aqueous nasal spray on allergen-induced inflammatory changes in the nasal airways of allergic rhinitis following exposure to nitrogen dioxide. *Clin Exp Allergy* 29: 234-240. <http://dx.doi.org/10.1046/j.1365-2222.1999.00440.x>
- [Wang, JH; Duddle, J; Devalia, JL; Davies, RJ.](#) (1995b). Nitrogen dioxide increases eosinophil activation in the early-phase response to nasal allergen provocation. *Int Arch Allergy Immunol* 107: 103-105. <http://dx.doi.org/10.1159/000236944>
- [Wang, M; Beelen, R; Basagana, X; Becker, T; Cesaroni, G; de Hoogh, K; Dedele, A; Declercq, C; Dimakopoulou, K; Eeftens, M; Forastiere, F; Galassi, C; Grazuleviciene, R; Hoffmann, B; Heinrich, J; Iakovides, M; Kunzli, N; Korek, M; Lindley, S; Mølter, A; Mosler, G; Madsen, C; Nieuwenhuijsen, MJ; Phuleria, H; Pedeli, X; Raaschou-Nielsen, O; Ranzi, A; Sugiri, D; Stempfelet, M; Tsai, MY; Lanki, T; Udvardy, O; Varro, MJ; Wolf, K; Weinmayr, G; Yli-Tuomi, T; Hoek, G; Brunekreef, B.](#) (2013a). Evaluation of land use regression models for NO<sub>2</sub> and particulate matter in 20 European study areas: The ESCAPE project. *Environ Sci Technol* 47: 4357-4364. <http://dx.doi.org/10.1021/es305129t>
- [Wang, M; Beelen, R; Bellander, T; Birk, M; Cesaroni, G; Cirach, M; Cyrus, J; de Hoogh, K; Declercq, C; Dimakopoulou, K; Eeftens, M; Eriksen, KT; Forastiere, F; Galassi, C; Grivas, G; Heinrich, J; Hoffmann, B; Ineichen, A; Korek, M; Lanki, T; Lindley, S; Modig, L; Mølter, A; Nafstad, P; Nieuwenhuijsen, MJ; Nystad, W; Olsson, D; Raaschou-Nielsen, O; Ragetti, M; Ranzi, A; Stempfelet, M; Sugiri, D; Tsai, MY; Udvardy, O; Varró, MJ; Vienneau, D; Weinmayr, G; Wolf, K; Yli-Tuomi, T; Hoek, G; Brunekreef, B.](#) (2014). Performance of multi-city land use regression models for nitrogen dioxide and fine particles. *Environ Health Perspect* 122: 843-849. <http://dx.doi.org/10.1289/ehp.1307271>
- [Wang, M; Beelen, R; Eeftens, M; Meliefste, K; Hoek, G; Brunekreef, B.](#) (2012). Systematic evaluation of land use regression models for NO. *Environ Sci Technol* 46: 4481-4489. <http://dx.doi.org/10.1021/es204183v>

- [Wang, R; Henderson, SB; Sbihi, H; Allen, RW; Brauer, M.](#) (2013b). Temporal stability of land use regression models for traffic-related air pollution. *Atmos Environ* 64: 312-319. <http://dx.doi.org/10.1016/j.atmosenv.2012.09.056>
- [Wang, SQ; Zhang, JL; Zeng, XD; Zeng, YM; Wang, SC; Chen, SY.](#) (2009a). Association of traffic-related air pollution with children's neurobehavioral functions in Quanzhou, China. *Environ Health Perspect* 117: 1612-1618. <http://dx.doi.org/10.1289/ehp.0800023>
- [Wang, XY; Hu, W; Tong, S.](#) (2009b). Long-term exposure to gaseous air pollutants and cardio-respiratory mortality in Brisbane, Australia. *Geospat Health* 3: 257-263.
- [Wang, YJ; Zhang, KM.](#) (2009). Modeling near-road air quality using a computational fluid dynamics model, CFD-VIT-RIT. *Environ Sci Technol* 43: 7778-7783. <http://dx.doi.org/10.1021/es9014844>
- [Ward, DJ; Miller, MR; Walters, S; Harrison, RM; Ayres, JG.](#) (2000). Impact of correcting peak flow for nonlinear errors on air pollutant effect estimates from a panel study. *Eur Respir J* 15: 137-140.
- [Ward, DJ; Roberts, KT; Jones, N; Harrison, RM; Ayres, JG; Hussain, S; Walters, S.](#) (2002). Effects of daily variation in outdoor particulates and ambient acid species in normal and asthmatic children. *Thorax* 57: 489-502. <http://dx.doi.org/10.1136/thorax.57.6.489>
- [Wardman, P.](#) (1998). Nitrogen dioxide in biology: Correlating chemical kinetics with biological effects. In ZB Alfassi (Ed.), *N-centered radicals* (pp. 155-179). Chichester, UK: Wiley.
- [Weakley, J; Webber, MP; Ye, F; Zeig-Owens, R; Cohen, HW; Hall, CB; Kelly, K; Prezant, DJ.](#) (2013). Agreement between obstructive airways disease diagnoses from self-report questionnaires and medical records. *Prev Med* 57: 38-42. <http://dx.doi.org/10.1016/j.ypmed.2013.04.001>
- [Wei, Y; Davis, J; Bina, WF.](#) (2012). Ambient air pollution is associated with the increased incidence of breast cancer in US. *Int J Environ Health Res* 22: 12-21. <http://dx.doi.org/10.1080/09603123.2011.588321>
- [Weichenthal, S; Dufresne, A; Infante-Rivard, C; Joseph, L.](#) (2007). Indoor ultrafine particle exposures and home heating systems: A cross-sectional survey of Canadian homes during the winter months. *J Expo Sci Environ Epidemiol* 17: 288-297. <http://dx.doi.org/10.1038/sj.jes.7500534>
- [Weichenthal, S; Kulka, R; Dubeau, A; Martin, C; Wang, D; Dales, R.](#) (2011). Traffic-related air pollution and acute changes in heart rate variability and respiratory function in urban cyclists. *Environ Health Perspect* 119: 1373-1378. <http://dx.doi.org/10.1289/ehp.1003321>
- [Weinmayr, G; Romeo, E; De Sario, M; Weiland, SK; Forastiere, F.](#) (2010). Short-term effects of PM10 and NO2 on respiratory health among children with asthma or asthma-like symptoms: A systematic review and meta-analysis [Review]. *Environ Health Perspect* 118: 449-457. <http://dx.doi.org/10.1289/ehp.0900844>
- [Weir, CH; Yeatts, KB; Sarnat, JA; Vizuete, W; Salo, PM; Jaramillo, R; Cohn, RD; Chu, H; Zeldin, DC; London, SJ.](#) (2013). Nitrogen dioxide and allergic sensitization in the 2005-2006 National Health and Nutrition Examination Survey. *Respir Med* 107: 1763-1772. <http://dx.doi.org/10.1016/j.rmed.2013.08.010>
- [Weitzberg, E; Hezel, M; Lundberg, JO.](#) (2010). Nitrate-nitrite-nitric oxide pathway: Implications for anesthesiology and intensive care [Review]. *Anesthesiology* 113: 1460-1475. <http://dx.doi.org/10.1097/ALN.0b013e3181fcf3cc>
- [Weitzberg, E; Lundberg, JO.](#) (2013). Novel aspects of dietary nitrate and human health [Review]. *Annu Rev Nutr* 33: 129-159. <http://dx.doi.org/10.1146/annurev-nutr-071812-161159>
- [Wellenius, GA; Burger, MR; Coull, BA; Schwartz, J; Suh, HH; Koutrakis, P; Schlaug, G; Gold, DR; Mittleman, MA.](#) (2012). Ambient air pollution and the risk of acute ischemic stroke. *Arch Intern Med* 172: 229-234. <http://dx.doi.org/10.1001/archinternmed.2011.732>
- [Wellenius, GA; Schwartz, J; Mittleman, MA.](#) (2005). Air pollution and hospital admissions for ischemic and hemorrhagic stroke among medicare beneficiaries. *Stroke* 36: 2549-2553. <http://dx.doi.org/10.1161/01.STR.0000189687.78760.47>

- [Wellenius, GA; Yeh, GY; Coull, BA; Suh, HH; Phillips, RS; Mittleman, MA.](#) (2007). Effects of ambient air pollution on functional status in patients with chronic congestive heart failure: A repeated-measures study. *Environ Health* 6. <http://dx.doi.org/10.1186/1476-069X-6-26>
- [Wendt, JK; Symanski, E; Stock, TH; Chan, W; Du, XL.](#) (2014). Association of short-term increases in ambient air pollution and timing of initial asthma diagnosis among Medicaid-enrolled children in a metropolitan area. *Environ Res* 131: 50-58. <http://dx.doi.org/10.1016/j.envres.2014.02.013>
- [Weng, HH; Tsai, SS; Chen, CC; Chiu, HF; Wu, TN; Yang, CY.](#) (2008). Childhood leukemia development and correlation with traffic air pollution in Taiwan using nitrogen dioxide as an air pollutant marker. *J Toxicol Environ Health A* 71: 434-438. <http://dx.doi.org/10.1080/15287390701839042>
- [Wennmalm, A; Benthin, G; Edlund, A; Jungersten, L; Kieler-Jensen, N; Lundin, S; Westfelt, UN; Petersson, AS; Waagstein, F.](#) (1993). Metabolism and excretion of nitric oxide in humans. An experimental and clinical study. *Circ Res* 73: 1121-1127. <http://dx.doi.org/10.1161/01.RES.73.6.1121>
- [Wheeler, AJ; Smith-Doiron, M; Xu, X; Gilbert, NL; Brook, JR.](#) (2008). Intra-urban variability of air pollution in Windsor, Ontario - Measurement and modeling for human exposure assessment. *Environ Res* 106: 7-16. <http://dx.doi.org/10.1016/j.envres.2007.09.004>
- [WHO](#) (World Health Organization). (1948). Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference, New York, 19-22 June, 1946. In *Constitution of the World Health Organization* (pp. 2). Geneva, Switzerland. [http://whqlibdoc.who.int/hist/official\\_records/constitution.pdf](http://whqlibdoc.who.int/hist/official_records/constitution.pdf)
- [Wichmann, J; Folke, F; Torp-Pedersen, C; Lippert, F; Ketzel, M; Ellermann, T; Loft, S.](#) (2013). Out-of-hospital cardiac arrests and outdoor air pollution exposure in Copenhagen, Denmark. *PLoS ONE* 8. <http://dx.doi.org/10.1371/journal.pone.0053684>
- [Wichmann, J; Ketzel, M; Ellermann, T; Loft, S.](#) (2012). Apparent temperature and acute myocardial infarction hospital admissions in Copenhagen, Denmark: A case-crossover study. *Environ Health* 11. <http://dx.doi.org/10.1186/1476-069X-11-19>
- [Wickman, M; Kull, I; Pershagen, G; Nordvall, SL.](#) (2002). The BAMSE project: Presentation of a prospective longitudinal birth cohort study. *PAI* 13: 11-13. <http://dx.doi.org/10.1034/j.1399-3038.13.s.15.10.x>
- [Widdicombe, JH.](#) (2002). Regulation of the depth and composition of airway surface liquid [Review]. *J Anat* 201: 313-318. <http://dx.doi.org/10.1046/j.1469-7580.2002.00098.x>
- [Widdicombe, JH; Widdicombe, JG.](#) (1995). Regulation of human airway surface liquid [Review]. *Respir Physiol* 99: 3-12. [http://dx.doi.org/10.1016/0034-5687\(94\)00095-H](http://dx.doi.org/10.1016/0034-5687(94)00095-H)
- [Wijga, AH; Kerkhof, M; Gehring, U; de Jongste, JC; Postma, DS; Aalberse, R; Wolse, A; Koppelman, GH; van Rossem, L; Oldenwening, M; Brunekreef, B; Smit, HA.](#) (2014). Cohort profile: The Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort. *Int J Epidemiol* 43: 527-535. <http://dx.doi.org/10.1093/ije/dys231>
- [Wilhelm, M; Ghosh, JK; Su, J; Cockburn, M; Jerrett, M; Ritz, B.](#) (2012). Traffic-related air toxics and term low birth weight in Los Angeles County, California. *Environ Health Perspect* 120: 132-138. <http://dx.doi.org/10.1289/ehp.1103408>
- [Wilhelm, M; Ritz, B.](#) (2005). Local variations in CO and particulate air pollution and adverse birth outcomes in Los Angeles County, California, USA. *Environ Health Perspect* 113: 1212-1221. <http://dx.doi.org/10.1289/ehp.7751>
- [Williams, EJ; Lerner, BM; Murphy, PC; Herndon, SC; Zahniser, MS.](#) (2009). Emissions of NO<sub>x</sub>, SO<sub>2</sub>, CO, and HCHO from commercial marine shipping during Texas Air Quality Study (TexAQS) 2006. *J Geophys Res* 114. <http://dx.doi.org/10.1029/2009JD012094>
- [Williams, R; Brook, R; Bard, R; Conner, T; Shin, H; Burnett, R.](#) (2012a). Impact of personal and ambient-level exposures to nitrogen dioxide and particulate matter on cardiovascular function. *Int J Environ Health Res* 22: 71-91. <http://dx.doi.org/10.1080/09603123.2011.588437>

- [Williams, R; Jones, P; Croghan, C; Thornburg, J; Rodes, C.](#) (2012b). The influence of human and environmental exposure factors on personal NO(2) exposures. *J Expo Sci Environ Epidemiol* 22: 109-115. <http://dx.doi.org/10.1038/jes.2011.20>
- [Williams, R; Rappold, A; Case, M; Schmitt, M; Stone, S; Jones, P; Thornburg, J; Devlin, RB.](#) (2012c). Multi-pollutant exposures in an asthmatic cohort. *Atmos Environ* 61: 244-252. <http://dx.doi.org/10.1016/j.atmosenv.2012.07.049>
- [Wilson, JG; Kingham, S; Pearce, J; Sturman, AP.](#) (2005). A review of intraurban variations in particulate air pollution: Implications for epidemiological research [Review]. *Atmos Environ* 39: 6444-6462. <http://dx.doi.org/10.1016/j.atmosenv.2005.07.030>
- [Wilson, WE; Brauer, M.](#) (2006). Estimation of ambient and non-ambient components of particulate matter exposure from a personal monitoring panel study. *J Expo Sci Environ Epidemiol* 16: 264-274. <http://dx.doi.org/10.1038/sj.jes.7500483>
- [Wilson, WE; Mage, DT; Grant, LD.](#) (2000). Estimating separately personal exposure to ambient and nonambient particulate matter for epidemiology and risk assessment: Why and how. *J Air Waste Manag Assoc* 50: 1167-1183. <http://dx.doi.org/10.1080/10473289.2000.10464164>
- [Wilton, D; Szpiro, A; Gould, T; Larson, T.](#) (2010). Improving spatial concentration estimates for nitrogen oxides using a hybrid meteorological dispersion/land use regression model in Los Angeles, CA and Seattle, WA. *Sci Total Environ* 408: 1120-1130. <http://dx.doi.org/10.1016/j.scitotenv.2009.11.033>
- [Winer, AM; Peters, JW; Smith, JP; Pitts, JN.](#) (1974). Response of commercial chemiluminescent nitric oxide-nitrogen dioxide analyzers to other nitrogen-containing compounds. *Environ Sci Technol* 8: 1118-1121. <http://dx.doi.org/10.1021/es60098a004>
- [Winquist, A; Kirrane, E; Klein, M; Strickland, M; Darrow, LA; Sarnat, SE; Gass, K; Mulholland, J; Russell, A; Tolbert, P.](#) (2014). Joint effects of ambient air pollutants on pediatric asthma emergency department visits in Atlanta, 1998-2004. *Epidemiology* 25: 666-673. <http://dx.doi.org/10.1097/EDE.0000000000000146>
- [Witten, A; Solomon, C; Abbritti, E; Arjomandi, M; Zhai, W; Kleinman, M; Balmes, J.](#) (2005). Effects of nitrogen dioxide on allergic airway responses in subjects with asthma. *J Occup Environ Med* 47: 1250-1259. <http://dx.doi.org/10.1097/01.jom.0000177081.62204.8d>
- [Wittkopp, S; Staimer, N; Tjoa, T; Gillen, D; Daher, N; Shafer, M; Schauer, JJ; Sioutas, C; Delfino, RJ.](#) (2013). Mitochondrial genetic background modifies the relationship between traffic-related air pollution exposure and systemic biomarkers of inflammation. *PLoS ONE* 8: e64444. <http://dx.doi.org/10.1371/journal.pone.0064444>
- [Wiwatanadate, P; Liwsrisakun, C.](#) (2011). Acute effects of air pollution on peak expiratory flow rates and symptoms among asthmatic patients in Chiang Mai, Thailand. *Int J Hyg Environ Health* 214: 251-257. <http://dx.doi.org/10.1016/j.ijheh.2011.03.003>
- [Wiwatanadate, P; Trakultivakorn, M.](#) (2010). Air pollution-related peak expiratory flow rates among asthmatic children in Chiang Mai, Thailand. *Inhal Toxicol* 22: 301-308. <http://dx.doi.org/10.3109/08958370903300327>
- [Wollmann, HA.](#) (1998). Intrauterine growth restriction: Definition and etiology. *Horm Res* 49: 1-6. <http://dx.doi.org/10.1159/000053079>
- [Wong, CM; Vichit-Vadakan, N; Kan, H; Qian, Z.](#) (2008). Public Health and Air Pollution in Asia (PAPA): A multicity study of short-term effects of air pollution on mortality. *Environ Health Perspect* 116: 1195-1202. <http://dx.doi.org/10.1289/ehp.11257>
- [Wong, CM; Vichit-Vadakan, N; Vajanapoom, N; Ostro, B; Thach, TQ; Chau, PY; Chan, EK; Chung, RY; Ou, CQ; Yang, L; Peiris, JS; Thomas, GN; Lam, TH; Wong, TW; Hedley, AJ; Kan, H; Chen, B; Zhao, N; London, SJ; Song, G; Chen, G; Zhang, Y; Jiang, L; Qian, Z; He, Q; Lin, HM; Kong, L; Zhou, D; Liang, S; Zhu, Z; Liao, D; Liu, W; Bentley, CM; Dan, J; Wang, B; Yang, N; Xu, S; Gong, J; Wei, H; Sun, H; Qin, Z.](#) (2010). Part 5. Public health and air pollution in Asia (PAPA): A combined analysis of four studies of air pollution and mortality. In *Public Health and Air Pollution in Asia (PAPA): Coordinated studies of short-term exposure to air pollution and daily mortality in four cities* (pp. 377-418). Boston, MA: Health Effects Institute. <http://pubs.healtheffects.org/getfile.php?u=595>

- [Wong, CM; Yang, L; Thach, TQ; Chau, PY; Chan, KP; Thomas, GN; Lam, TH; Wong, TW; Hedley, AJ; Peiris, JS.](#) (2009). Modification by influenza on health effects of air pollution in Hong Kong. *Environ Health Perspect* 117: 248-253. <http://dx.doi.org/10.1289/ehp.11605>
- [Wong, TW; Lau, TS; Yu, TS; Neller, A; Wong, SL; Tam, W; Pang, SW.](#) (1999). Air pollution and hospital admissions for respiratory and cardiovascular diseases in Hong Kong. *Occup Environ Med* 56: 679-683. <http://dx.doi.org/10.1136/oem.56.10.679>
- [Wood, AM; Harrison, RM; Semple, S; Ayres, JG; Stockley, RA.](#) (2009). Outdoor air pollution is associated with disease severity in  $\alpha$ 1-antitrypsin deficiency. *Eur Respir J* 34: 346-353. <http://dx.doi.org/10.1183/09031936.00087908>
- [Woodruff, TJ; Parker, JD; Adams, K; Bell, ML; Gehring, U; Glinianaia, S; Ha, EH; Jalaludin, B; Slama, R.](#) (2010). International collaboration on air pollution and pregnancy outcomes (ICAPPO). *Int J Environ Res Public Health* 7: 2638-2652. <http://dx.doi.org/10.3390/ijerph7062638>
- [Woodruff, TJ; Parker, JD; Darrow, LA; Slama, R; Bell, ML; Choi, H; Glinianaia, S; Hoggatt, KJ; Karr, CJ; Lobdell, DT; Wilhelm, M.](#) (2009). Methodological issues in studies of air pollution and reproductive health. *Environ Res* 109: 311-320. <http://dx.doi.org/10.1016/j.envres.2008.12.012>
- [Wooldridge, PJ; Perring, AE; Bertram, TH; Flocke, FM; Roberts, JM; Singh, HB; Huey, LG; Thornton, JA; Wolfe, GM; Murphy, JG; Fry, JL; Rollins, AW; Lafranchi, BW; Cohen, RC.](#) (2010). Total Peroxy Nitrates (Sigma PNs) in the atmosphere: The Thermal Dissociation-Laser Induced Fluorescence (TD-LIF) technique and comparisons to speciated PAN measurements. *Atmos Meas Tech* 3: 593-607. <http://dx.doi.org/10.5194/amt-3-593-2010>
- [Wu, J; Lurmann, F; Winer, A; Lu, R; Turco, R; Funk, T.](#) (2005). Development of an individual exposure model for application to the Southern California children's health study. *Atmos Environ* 39: 259-273. <http://dx.doi.org/10.1016/j.atmosenv.2004.09.061>
- [Wu, J; Ren, C; Delfino, RJ; Chung, J; Wilhelm, M; Ritz, B.](#) (2009). Association between local traffic-generated air pollution and preeclampsia and preterm delivery in the south coast air basin of California. *Environ Health Perspect* 117: 1773-1779. <http://dx.doi.org/10.1289/ehp.0800334>
- [Wu, J; Wilhelm, M; Chung, J; Ritz, B.](#) (2011a). Comparing exposure assessment methods for traffic-related air pollution in an adverse pregnancy outcome study. *Environ Res* 111: 685-692. <http://dx.doi.org/10.1016/j.envres.2011.03.008>
- [Wu, X; Bennett, DH; Lee, K; Cassady, DL; Ritz, B; Hertz-Picciotto, I.](#) (2011b). Longitudinal variability of time-location/activity patterns of population at different ages: A longitudinal study in California. *Environ Health* 10. <http://dx.doi.org/10.1186/1476-069X-10-80>
- [Wu, XM; Fan, ZT; Ohman-Strickland, P.](#) (2010). Time-location patterns of a population living in an air pollution hotspot. *J Environ Public Health* 2010: 625461. <http://dx.doi.org/10.1155/2010/625461>
- [Xiang, H; Mertz, KJ; Arena, VC; Brink, LL; Xu, X; Bi, Y; Talbott, EO.](#) (2013). Estimation of short-term effects of air pollution on stroke hospital admissions in Wuhan, China. *PLoS ONE* 8: e61168. <http://dx.doi.org/10.1371/journal.pone.0061168>
- [Xu, X; Hu, H; Ha, S; Roth, J.](#) (2014). Ambient air pollution and hypertensive disorder of pregnancy. *J Epidemiol Community Health* 68: 13-20. <http://dx.doi.org/10.1136/jech-2013-202902>
- [Xu, Z; Hu, W; Williams, G; Clements, AC; Kan, H; Tong, S.](#) (2013). Air pollution, temperature and pediatric influenza in Brisbane, Australia. *Environ Int* 59: 384-388. <http://dx.doi.org/10.1016/j.envint.2013.06.022>
- [Xuan, W; Peat, JK; Toelle, BG; Marks, GB; Berry, G; Woolcock, AJ.](#) (2000). Lung function growth and its relation to airway hyperresponsiveness and recent wheeze: Results from a longitudinal population study. *Am J Respir Crit Care Med* 161: 1820-1824. <http://dx.doi.org/10.1164/ajrccm.161.6.9809118>
- [Xue, J; McCurdy, T; Spengler, J; Ozkaynak, H.](#) (2004). Understanding variability in time spent in selected locations for 7-12-year old children. *J Expo Anal Environ Epidemiol* 14: 222-233. <http://dx.doi.org/10.1038/sj.jea.7500319>

- Yadav, AK; Doran, SF; Samal, AA; Sharma, R; Vedagiri, K; Postlethwait, EM; Squadrito, GL; Fanucchi, MV; Roberts, LJ; Patel, RP; Matalon, S. (2011). Mitigation of chlorine gas lung injury in rats by postexposure administration of sodium nitrite. *Am J Physiol Lung Cell Mol Physiol* 300: L362-L369. <http://dx.doi.org/10.1152/ajplung.00278.2010>
- Yaghi, A; Zaman, A; Cox, G; Dolovich, MB. (2012). Ciliary beating is depressed in nasal cilia from chronic obstructive pulmonary disease subjects. *Respir Med* 106: 1139-1147. <http://dx.doi.org/10.1016/j.rmed.2012.04.001>
- Yamamoto, I; Takahashi, M. (1984). Ultrastructural observations of rat lung exposed to nitrogen dioxide for 7 months. *Kitasato Arch Exper Med* 57: 57-65.
- Yamazaki, S; Shima, M; Ando, M; Nitta, H; Watanabe, H; Nishimuta, T. (2011). Effect of hourly concentration of particulate matter on peak expiratory flow in hospitalized children: A panel study. *Environ Health* 10. <http://dx.doi.org/10.1186/1476-069X-10-15>
- Yang, CL; To, T; Foty, RG; Stieb, DM; Dell, SD. (2011). Verifying a questionnaire diagnosis of asthma in children using health claims data. *BMC Pulm Med* 11. <http://dx.doi.org/10.1186/1471-2466-11-52>
- Yang, CY. (2008). Air pollution and hospital admissions for congestive heart failure in a subtropical city: Taipei, Taiwan. *J Toxicol Environ Health A* 71: 1085-1090. <http://dx.doi.org/10.1080/15287390802114428>
- Yang, CY; Chen, YS; Yang, CH; Ho, SC. (2004). Relationship between ambient air pollution and hospital admissions for cardiovascular diseases in Kaohsiung, Taiwan. *J Toxicol Environ Health A* 67: 483-493. <http://dx.doi.org/10.1080/15287390490276502>
- Yang, CY; Hsieh, HJ; Tsai, SS; Wu, TN; Chiu, HF. (2006). Correlation between air pollution and postneonatal mortality in a subtropical city: Taipei, Taiwan. *J Toxicol Environ Health A* 69: 2033-2040. <http://dx.doi.org/10.1080/15287390600746181>
- Yang, Q; Chen, Y; Krewski, D; Burnett, RT; Shi, Y; McGrail, KM. (2005). Effect of short-term exposure to low levels of gaseous pollutants on chronic obstructive pulmonary disease hospitalizations. *Environ Res* 99: 99-105. <http://dx.doi.org/10.1016/j.envres.2004.09.014>
- Yang, Q; Chen, Y; Shi, Y; Burnett, RT; McGrail, KM; Krewski, D. (2003). Association between ozone and respiratory admissions among children and the elderly in Vancouver, Canada. *Inhal Toxicol* 15: 1297-1308. <http://dx.doi.org/10.1080/08958370390241768>
- Yokoyama, E. (1968). Uptake of SO<sub>2</sub> and NO<sub>2</sub> by the isolated upper airways. *Koshu Eisei Kenkyu* 17: 302-306.
- Yorifuji, T; Kashima, S; Tsuda, T; Ishikawa-Takata, K; Ohta, T; Tsuruta, K; Doi, H. (2013). Long-term exposure to traffic-related air pollution and the risk of death from hemorrhagic stroke and lung cancer in Shizuoka, Japan. *Sci Total Environ* 443: 397-402. <http://dx.doi.org/10.1016/j.scitotenv.2012.10.088>
- Yorifuji, T; Kashima, S; Tsuda, T; Takao, S; Suzuki, E; Doi, H; Sugiyama, M; Ishikawa-Takata, K; Ohta, T. (2010). Long-term exposure to traffic-related air pollution and mortality in Shizuoka, Japan. *Occup Environ Med* 67: 111-117. <http://dx.doi.org/10.1136/oem.2008.045542>
- Yuval; Bekhor, S; Broday, DM. (2013). Data-driven nonlinear optimisation of a simple air pollution dispersion model generating high resolution spatiotemporal exposure. *Atmos Environ* 79: 261-270. <http://dx.doi.org/10.1016/j.atmosenv.2013.06.005>
- Zanobetti, A; Gold, DR; Stone, PH; Suh, HH; Schwartz, J; Coull, BA; Speizer, FE. (2010). Reduction in heart rate variability with traffic and air pollution in patients with coronary artery disease. *Environ Health Perspect* 118: 324-330. <http://dx.doi.org/10.1289/ehp.0901003>
- Zanobetti, A; Schwartz, J. (2006). Air pollution and emergency admissions in Boston, MA. *J Epidemiol Community Health* 60: 890-895. <http://dx.doi.org/10.1136/jech.2005.039834>
- Zeger, SL; Thomas, D; Dominici, F; Samet, JM; Schwartz, J; Dockery, D; Cohen, A. (2000). Exposure measurement error in time-series studies of air pollution: Concepts and consequences. *Environ Health Perspect* 108: 419-426.

- [Zeghnoun, A; Beaudou, P; Carrat, F; Delmas, V; Boudhabhay, O; Gayon, F; Guincetre, D; Czernichow, P.](#) (1999). Air pollution and respiratory drug sales in the city of Le Havre, France, 1993-1996. *Environ Res* 81: 224-230. <http://dx.doi.org/10.1006/enrs.1999.3974>
- [Zeman, KL; Bennett, WD.](#) (2006). Growth of the small airways and alveoli from childhood to the adult lung measured by aerosol-derived airway morphometry. *J Appl Physiol* 100: 965-971. <http://dx.doi.org/10.1152/jappphysiol.00409.2005>
- [Zemek, R; Szyszkowicz, M; Rowe, BH.](#) (2010). Air pollution and emergency department visits for otitis media: A case-crossover study in Edmonton, Canada. *Environ Health Perspect* 118: 1631-1636. <http://dx.doi.org/10.1289/ehp.0901675>
- [Zemp, E; Elsasser, S; Schindler, C; Künzli, N; Perruchoud, AP; Domenighetti, G; Medici, T; Ackermann-Liebrich, U; Leuenberger, P; Monn, C; Bolognini, G; Bongard, JP; Brändli, O; Karrer, W; Keller, R; Schöni, MH; Tschopp, JM; Villiger, B; Zellweger, JP.](#) (1999). Long-term ambient air pollution and respiratory symptoms in adults (SAPALDIA study). *Am J Respir Crit Care Med* 159: 1257-1266. <http://dx.doi.org/10.1164/ajrccm.159.4.9807052>
- [Zetterquist, W; Pedroletti, C; Lundberg, JO; Alving, K.](#) (1999). Salivary contribution to exhaled nitric oxide. *Eur Respir J* 13: 327-333. <http://dx.doi.org/10.1034/j.1399-3003.1999.13b18.x>
- [Zhang, J; Villacorta, L; Chang, L; Fan, Z; Hamblin, M; Zhu, T; Chen, CS; Cole, MP; Schopfer, FJ; Deng, CX; Garcia-Barrio, MT; Feng, YH; Freeman, BA; Chen, YE.](#) (2010a). Nitro-oleic acid inhibits angiotensin II-induced hypertension. *Circ Res* 107: 540-548. <http://dx.doi.org/10.1161/CIRCRESAHA.110.218404>
- [Zhang, J; Zhu, T; Kipen, H; Wang, G; Huang, W; Rich, D; Zhu, P; Wang, Y; Lu, SE; Ohman-Strickland, P; Diehl, S; Hu, M; Tong, J; Gong, J; Thomas, D.](#) (2013). Cardiorespiratory biomarker responses in healthy young adults to drastic air quality changes surrounding the 2008 Beijing Olympics. *Res Rep Health Eff Inst* 174: 5-174.
- [Zhang, PF; Dong, GH; Sun, BJ; Zhang, LW; Chen, X; Ma, NN; Yu, F; Guo, HM; Huang, H; Lee, YL; Tang, NJ; Chen, J.](#) (2011). Long-term exposure to ambient air pollution and mortality due to cardiovascular disease and cerebrovascular disease in Shenyang, China. *PLoS ONE* 6. <http://dx.doi.org/10.1371/journal.pone.0020827>
- [Zhang, Y; Ma, C; Xiao, Y; Liu, C; Xu, Q; Wang, Y; Xu, X; Hao, L.](#) (2010b). Dual role of vitamin C utilization in NO<sub>2</sub>-induced oxidative stress in lung tissues of mice. *Bull Environ Contam Toxicol* 84: 662-666. <http://dx.doi.org/10.1007/s00128-010-0021-1>
- [Zhang, Z; Wang, J; Chen, L; Chen, X; Sun, G; Zhong, N; Kan, H; Lu, W.](#) (2014). Impact of haze and air pollution-related hazards on hospital admissions in Guangzhou, China. *Environ Sci Pollut Res Int* 21: 4236-4244. <http://dx.doi.org/10.1007/s11356-013-2374-6>
- [Zheng, S; Wang, M; Wang, S; Tao, Y; Shang, K.](#) (2013). Short-term effects of gaseous pollutants and particulate matter on daily hospital admissions for cardio-cerebrovascular disease in Lanzhou: Evidence from a heavily polluted city in China. *Int J Environ Res Public Health* 10: 462-477. <http://dx.doi.org/10.3390/ijerph10020462>
- [Zhou, N; Cui, Z; Yang, S; Han, X; Chen, G; Zhou, Z; Zhai, C; Ma, M; Li, L; Cai, M; Li, Y; Ao, L; Shu, W; Liu, J; Cao, J.](#) (2014). Air pollution and decreased semen quality: A comparative study of Chongqing urban and rural areas. *Environ Pollut* 187: 145-152. <http://dx.doi.org/10.1016/j.envpol.2013.12.030>
- [Zhou, Y; Levy, JI.](#) (2007). Factors influencing the spatial extent of mobile source air pollution impacts: A meta-analysis [Review]. *BMC Public Health* 7: 89. <http://dx.doi.org/10.1186/1471-2458-7-89>
- [Zhu, DZ; Nussbaum, NJ; Kuhns, HD; Chang, MCO; Sodeman, D; Moosmuller, H; Watson, JG.](#) (2011). Real-world PM, NO(x), CO, and ultrafine particle emission factors for military non-road heavy duty diesel vehicles. *Atmos Environ* 45: 2603-2609. <http://dx.doi.org/10.1016/j.atmosenv.2011.02.032>
- [Zhu, T.](#) (2013). Email from Dr. Zhu to Dr. Patel; Response to data request. Available online
- [Zhu, Y; Fung, DC; Kennedy, N; Hinds, WC; Eiguren-Fernandez, A.](#) (2008). Measurements of ultrafine particles and other vehicular pollutants inside a mobile exposure system on Los Angeles freeways. *J Air Waste Manag Assoc* 58: 424-434.

Zidek, JV; Shaddick, G; Meloche, J; Chatfield, C; White, R. (2007). A framework for predicting personal exposures to environmental hazards. Environ Ecol Stat 14: 411-431. <http://dx.doi.org/10.1007/s10651-007-0028-x>

Zora, JE; Sarnat, SE; Raysoni, AU; Johnson, BA; Li, WW; Greenwald, R; Holguin, F; Stock, TH; Sarnat, JA. (2013). Associations between urban air pollution and pediatric asthma control in El Paso, Texas. Sci Total Environ 448: 56-65. <http://dx.doi.org/10.1016/j.scitotenv.2012.11.067>

Zou, X; Shen, Z; Yuan, T; Yin, S; Cai, J; Chen, L; Wang, W. (2006). Shifted power-law relationship between NO<sub>2</sub> concentration and the distance from a highway: A new dispersion model based on the wind profile model. Atmos Environ 40: 8068-8073. <http://dx.doi.org/10.1016/j.atmosenv.2006.09.012>